objCls,id,name,alternateDrugAvailable,cancerGenome,crossReferences,dosingInformation,history,indication,labelApplications,labelDocumentAvailable,literature,otherPrescribingGuidance,pediatric,pgxRelated,prescribingGenes,relatedAlleles,relatedChemicals,relatedGenes,source,summaryMarkdown.id,summaryMarkdown.html,textMarkdown.id,textMarkdown.html,pediatricMarkdown.id,pediatricMarkdown.html,testing.id,testing.resource,testing.synonyms,testing.term,testing.termId,testing.valid,prescribingMarkdown.id,prescribingMarkdown.html,retirementReason.id,retirementReason.resource,retirementReason.synonyms,retirementReason.term,retirementReason.termId,retirementReason.valid,biomarkerStatus
Label Annotation,PA166269401,Annotation of EMA Label for nateglinide and CYP2C9,False,False,[],False,"[{'id': 1452304760, 'date': '2023-11-21T00:00:00-08:00', 'description': 'Edited to show withdrawn from use in the European Union. Changed Actionable to Criteria not met. Added source information.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15150922, 'title': 'Starlix | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/starlix', 'crossReferences': [{'id': 1452304761, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/starlix', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/starlix'}], 'notes': 'The authorization for Starlix has been withdrawn.', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450600', 'name': 'nateglinide'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",EMA,1451759940.0,"<p>Nateglinide (STARLIX) was withdrawn from use in the European Union.</p>
",1451759941.0,"<p>Excerpts from the nateglinide (STARLIX) EPAR:</p>
<blockquote class=""blockquote"">
<p>Data available from both in vitro and in vivo experiments indicate that nateglinide is predominantly metabolised by CYP2C9 with involvement of CYP3A4 to a smaller extent.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Particular caution is recommended when nateglinide is co-administered with other more potent inhibitors of CYP2C9 (e.g. fluconazole, gemfibrozil or sulfinpyrazone), or in patients known to be poor metabolisers for CYP2C9 substrates.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""nateglinide_2022_04_20_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/nateglinide_2022_04_20_EMA.pdf"">nateglinide EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166340141,Annotation of HCSC Label for amphetamine and CYP2D6,False,False,[],False,"[{'id': 1453075040, 'date': '2025-03-23T09:00:34.435-07:00', 'description': 'Changed to informative PGx based on new definition', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15158822, 'title': 'Drugs@HCSC: Drug Product TEVA-AMPHETAMINE XR (mixed salts amphetamine), Teva Canada Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92362', 'crossReferences': [{'id': 1452488740, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92362', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92362'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448408', 'name': 'amphetamine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452488741.0,"<p>The HCSC-approved product monograph for amphetamine (TEVA-AMPHETAMINE XR) contains information about CYP2D6 and metabolism.</p>
",1452488742.0,"<p>Excerpt from the amphetamine (TEVA-AMPHETAMINE XR) product monograph:</p>
<blockquote class=""blockquote"">
<p>Although the enzymes involved in amphetamine metabolism have not been clearly defined, CYP2D6 is known to be involved with TEVA-AMPHETAMINE XR (mixed salts amphetamine extended-release capsules) formation of 4-hydroxy-amphetamine. Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a possibility.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Amphetamine_2024_05_30_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Amphetamine_2024_05_30_HCSC.pdf"">amphetamine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452488743.0,"<blockquote class=""blockquote"">
<p>TEVA-AMPHETAMINE XR (mixed salts amphetamine extended-release capsules) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in:</p>
<ul>
<li>Children (6 – 12 years of age)</li>
<li>Adolescents (13 – 17 years of age)</li>
<li>Adults (18 years of age or older)</li>
</ul>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166273281,Annotation of EMA Label for nusinersen and SMN2,False,False,[],False,"[{'id': 1452209480, 'date': '2023-08-17T17:28:16.543-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15133282, 'title': 'Nusinersen | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza', 'crossReferences': [{'id': 1451824760, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182882', 'name': 'nusinersen'}]","[{'objCls': 'Gene', 'id': 'PA35967', 'symbol': 'SMN2', 'name': 'survival of motor neuron 2, centromeric'}]",EMA,1451824761.0,"<p>Nusinersen is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide EMA-indicated for the treatment of the treatment of 5q Spinal Muscular Atrophy.</p>
",1451824762.0,"<p>Excerpts from the <em><strong>Nusinersen</strong></em> (<em><strong>Spinraza</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>Nusinersen is an antisense oligonucleotide (ASO) which increases the proportion of exon 7 inclusion
in survival motor neuron 2 (SMN2) messenger ribonucleic acid (mRNA) transcripts by binding to an
intronic splice silencing site (ISS-N1) found in intron 7 of the SMN2 pre-messenger ribonucleic
acid (pre-mRNA). By binding, the ASO displaces splicing factors, which normally suppress splicing.
Displacement of these factors leads to retention of exon 7 in the SMN2 mRNA and hence when SMN2
mRNA is produced, it can be translated into the functional full length SMN protein.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Nusinersen_EMA_2022_07_13.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Nusinersen_EMA_2022_07_13.pdf""><em><strong>Nusinersen</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166273261,"Annotation of EMA Label for ospemifene and CYP2B6, CYP2C9",False,False,[],False,"[{'id': 1452557520, 'date': '2024-08-16T11:32:57.435-07:00', 'description': 'removed Prescribing Info, Actionable PGx level; these are currently not applied to drug-drug interactions', 'type': 'Update', 'version': 0}, {'id': 1452783280, 'date': '2024-12-13T12:03:24.388-08:00', 'description': 'updated label; combined the annotation with the previously separate CYP2B6 annotation; CYP2B6 is mentioned in the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15133262, 'title': 'Ospemifene | European Medicines Agency.', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/senshio', 'crossReferences': [{'id': 1451824040, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/senshio', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/senshio'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182883', 'name': 'ospemifene'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}, {'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",EMA,1451824100.0,"<p>The ospemifene (Senshio) EPAR notes that ospemifene is metabolized by multiple metabolic pathways, mainly involving the enzymes UGT1A3, UGT2B7, UGT1A1 and UGT1A8, and CYP2C9, CYP3A4 and CYP2C19. CYP2C9 poor metabolizers are mentioned in the context of drug-drug interactions, contraindicating co-administration of strong/moderate CYP3A4 inhibitors in patients who are known or suspected CYP2C9 poor metabolizers.</p>
",1451824101.0,"<p>Excerpts from the ospemifene (Senshio) EPAR:</p>
<blockquote class=""blockquote"">
<p>Ospemifene and its major metabolite, 4-hydroxyospemifene, are metabolised by multiple metabolic pathways, the main enzymes involved are UGT1A3, UGT2B7, UGT1A1 and UGT1A8, and CYP2C9, CYP3A4 and CYP2C19.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>In vitro</em>, ospemifene and 4-hydroxyospemifene did not inhibit or induce the activity of CYP450 enzymes at clinically relevant concentrations. <em>In vitro</em>, ospemifene and 4-hydroxyospemifene inhibited glucuronidation via UGT1A3 and UGT1A9 at clinically relevant concentrations. In <em>in vitro</em> studies ospemifene is a weak inhibitor for CYP2B6, CYP2C9, CYP2C19, CYP2C8 and CYP2D6. Furthermore <em>in vitro</em> studies have shown that ospemifene is a weak inducer for CYP2B6 and CYP3A4. In <em>in vitro</em> studies, ospemifene and 4-hydroxyospemifene did not inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporter polypeptide (OATP)1B1, OATP1B3, OCT2, organic anion transporter (OAT)1, OAT3, or bile salt export pump (BSEP) transporters at clinically relevant concentrations. It is unknown if ospemifene is a substrate for BCRP in the intestine. Therefore care should be taken if ospemifene is administered with a BCRP inhibitor.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>CYP2C9 poor metabolizers</em>
Both CYP2C9 and CYP3A4 are involved in the metabolism of ospemifene. Co-administration of ketoconazole, a strong CYP3A4 inhibitor, increased the AUC of ospemifene by 1.4-fold. In CYP2C9 poor metabolizers, co-administration of CYP3A4 inhibitors may increase systemic concentration of ospemifene to a larger extent. Therefore, co-administration of ospemifene with strong/moderate CYP3A4 inhibitors should be avoided in patients who are known or suspected to be CYP2C9 poor metabolizers based on genotyping or previous history/experience with other CYP2C9 substrates.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Ospemifene_2024_12_13_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ospemifene_2024_12_13_EMA.pdf"">ospemifene EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166271261,Annotation of EMA Label for tegafur / gimeracil / oteracil and DPYD,True,False,[],False,[],False,[],True,"[{'id': 15132202, 'title': 'Teysuno | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno', 'crossReferences': [{'id': 1451800324, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]","[{'objCls': 'Haplotype', 'id': 'PA166171120', 'symbol': 'DPYD c.1129-5923C>G, c.1236G>A (HapB3)', 'name': 'c.1129-5923C>G, c.1236G>A (HapB3)'}, {'objCls': 'Haplotype', 'id': 'PA166171118', 'symbol': 'DPYD c.1679T>G (*13)', 'name': 'c.1679T>G (*13)'}, {'objCls': 'Haplotype', 'id': 'PA166171117', 'symbol': 'DPYD c.1905+1G>A (*2A)', 'name': 'c.1905+1G>A (*2A)'}, {'objCls': 'Haplotype', 'id': 'PA166171119', 'symbol': 'DPYD c.2846A>T', 'name': 'c.2846A>T'}]","[{'objCls': 'Chemical', 'id': 'PA166115442', 'name': 'tegafur / gimeracil / oteracil'}]","[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",EMA,1451800320.0,"<p>The EMA-approved label for tegafur/gimeracil/oteracil (Teysuno) notes that patients who have complete dihydropyrimidine dehydrogenase (DPD) deficiency are at high risk of life-threatening or fatal toxicity, and patients who have partial DPD deficiency are at increased risk of severe and potentially life-threatening toxicity. Phenotype and/or genotype testing prior to initiation of treatment with Teysuno is recommended.</p>
",1451800321.0,"<p>Tegafur/gimeracil/oteracil (Teysuno) is a combination drug that includes tegafur, a pro-drug of 5-fluorouracil, that is used for the treatment of various types of neoplasms including metastatic colorectal and advanced gastric cancer. Variants in the DPYD gene (also known as dihydropyrimidine dehydrogenase and DPD) are associated with increased risk for adverse events. See the <a href=""http://www.pharmgkb.org/pathway/PA150653776"">Fluroropyrimidine Pathway</a> and <a href=""http://www.pharmgkb.org/vip/PA145"">DPYD VIP</a> for more information.</p>
<p>Excerpts from the tegafur/gimeracil/oteracil (Teysuno) EPAR:</p>
<blockquote class=""blockquote"">
<p>Patients with complete DPD deficiency are at high risk of life-threatening or fatal toxicity and must not be treated with Teysuno.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with partial DPD deficiency are at increased risk of severe and potentially life-threatening toxicity. A reduced starting dose should be considered to limit this toxicity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Phenotype and/or genotype testing prior to the initiation of treatment with Teysuno is recommended despite uncertainties regarding optimal pre-treatment testing methodologies.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The four DPYD variants c.1905+1G&gt;A (also known as DPYD*2A), c.1679T&gt;G (DPYD*13), c.2846A&gt;T and c.1236G&gt;A/HapB3 can cause complete absence or reduction of DPD enzymatic activity. Other rare variants may also be associated with an increased risk of severe or life-threatening toxicity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Certain homozygous and compound heterozygous mutations in the DPYD gene locus (e.g. combinations of the four variants with at least one allele of c.1905+1G&gt;A or c.1679T&gt;G) are known to cause complete or near complete absence of DPD enzymatic activity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with certain heterozygous DPYD variants (including c.1905+1G&gt;A, c.1679T&gt;G, c.2846A&gt;T and c.1236G&gt;A/HapB3 variants) have increased risk of severe toxicity when treated with fluoropyrimidines.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""tegafur_gimeracil_oteracil_2022_06_09_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/tegafur_gimeracil_oteracil_2022_06_09_EMA.pdf"">tegafur/gimeracil/oteracil EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1451800322.0,"<p>Excerpts from the tegafur/gimeracil/oteracil (Teysuno) drug label:</p>
<blockquote class=""blockquote"">
<p>Patients with complete DPD deficiency are at high risk of life-threatening or fatal toxicity and must not be treated with Teysuno.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with partial DPD deficiency are at increased risk of severe and potentially life-threatening toxicity. A reduced starting dose should be considered to limit this toxicity.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166273501,Annotation of EMA Label for ipilimumab and HLA-A,False,False,[],False,"[{'id': 1452550620, 'date': '2024-08-07T15:18:42.901-07:00', 'description': 'removed Cancer Genome tag', 'type': 'Update', 'version': 0}, {'id': 1452802941, 'date': '2025-01-09T14:59:20.926-08:00', 'description': 'removed CTLA4 gene; added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15133502, 'title': 'Ipilimumab | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy', 'crossReferences': [{'id': 1451827300, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,True,True,[],"[{'objCls': 'Haplotype', 'id': 'PA166123427', 'symbol': 'HLA-A*02:01', 'name': '*02:01'}]","[{'objCls': 'Chemical', 'id': 'PA166182718', 'name': 'ipilimumab'}]","[{'objCls': 'Gene', 'id': 'PA35055', 'symbol': 'HLA-A', 'name': 'major histocompatibility complex, class I, A'}]",EMA,1451827340.0,"<p>Ipilimumab (Yervoy) is an anti-CTLA-4 monoclonal antibody EMA indicated for treatment of various cancers. The product information also has information about HLA-A*02:01 in trials and lack of implication in adverse reactions.</p>
",1451827341.0,"<p>Excerpts from the ipilimumab (Yervoy) EPAR:</p>
<blockquote class=""blockquote"">
<p>Ipilimumab is a fully human anti-CTLA-4 monoclonal antibody (IgG1κ) produced in Chinese hamster
ovary cells by recombinant DNA technology.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Rates of immune-related adverse reactions in HLA-A2*0201 positive patients
who received ipilimumab in MDX010-20 were similar to those observed in the overall clinical
program.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Ipilimumab_EMA_2022_07_18.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ipilimumab_EMA_2022_07_18.pdf"">ipilimumab EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",1452802940.0,"<p>YERVOY as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults, and adolescents 12 years of age and older (see section 4.4).</p>
",1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166272241,Annotation of HCSC Label for upadacitinib and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15132702, 'title': 'Drugs@HCSC: Drug Product upadacitinib', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00064540.PDF', 'crossReferences': [{'id': 1451813660, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00064540.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00064540.PDF'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166189803', 'name': 'upadacitinib'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1451813680.0,"<p>Upadacitinib (Rinvoq) is indicated for moderate to severe active rheumatoid arthritis or active psoriatic arthritis in adults, or refractory moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older. The HCSC labels states that upadacitinib is metabolized by CYP3A4 with a minor contribution from CYP2D6. However, CYP2D6 metabolic phenotype had no effect on upadacitinib pharmacokinetics.</p>
",1451813681.0,"<p>Excerpts from the Upadacitinib (Rinvoq) product monograph:</p>
<blockquote class=""blockquote"">
<p>In vitro metabolism studies indicated that upadacitinib metabolism is mediated by CYP3A4 with a
potential minor contribution from CYP2D6.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In vitro studies indicate that upadacitinib does not inhibit or induce the activity of cytochrome P450
(CYP) enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) or the transporters
P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, and MATE2K at clinically relevant
concentrations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 metabolic phenotype had no effect on upadacitinib pharmacokinetics (based on population pharmacokinetic
analyses), indicating that inhibitors of CYP2D6 have no clinically relevant effect on upadacitinib
exposures.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Upadacitinib_HCSC_2022_06_28.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Upadacitinib_HCSC_2022_06_28.pdf"">Upadacitinib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166272321,"Annotation of HCSC Label for tipiracil / trifluridine and ERBB2, KRAS",False,True,[],False,"[{'id': 1452217620, 'date': '2023-08-27T22:39:06.238-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132782, 'title': 'Drugs@HCSC: Drug Product Tipiracil and Trifluridine', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00058926.PDF', 'crossReferences': [{'id': 1451814520, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00058926.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00058926.PDF'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184566', 'name': 'tipiracil / trifluridine'}]","[{'objCls': 'Gene', 'id': 'PA27844', 'symbol': 'ERBB2', 'name': 'erb-b2 receptor tyrosine kinase 2'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",HCSC,1451814600.0,"<p>The HCSC label for tipiracil / trifluridine (Lonsurf) states that it is indicated for patients who have failed other targeted therapies including those for KRAS negative metastatic colorectal cancer and HER2 positive (ERBB2) metastatic gastric or gastroesophageal junction cancers. Therefore testing was required for those prior therapies.</p>
",1451814601.0,"<p>Excerpts from the trifluridine and tipiracil (LONSURF) product monograph:</p>
<blockquote class=""blockquote"">
<p>Lonsurf® (trifluridine and tipiracil, as tipiracil hydrochloride tablets) is indicated for the treatment
of adult patients with metastatic colorectal cancer who have been previously treated with, or
are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and
irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type,
anti-EGFR agents.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Lonsurf monotherapy is indicated for the treatment of adult patients with metastatic gastric
cancer or adenocarcinoma of the gastroesophageal junction, who have been previously treated
with at least two prior lines of chemotherapy including a fluoropyrimidine, a platinum, and either
a taxane or irinotecan and if appropriate with HER2/neu-targeted therapy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Study TPU-TAS-102-301 (RECOURSE) – Metastatic colorectal cancer ... KRAS status was wild
(49%) or mutant (51%) at study entry.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Study TAS-102-302 (TAGS) – Metastatic gastric cancer ... Patients with HER2/neu-positive tumors must have received prior HER2/neu targeted therapy, if available.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Tipiracil_Trifluridine_HCSC_2022_06_30.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Tipiracil_Trifluridine_HCSC_2022_06_30.pdf"">tipiracil / trifluridine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166271481,Annotation of HCSC Label for escitalopram and CYP2C19,False,False,[],True,"[{'id': 1452021748, 'date': '2023-02-28T13:03:16.834-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452556365, 'date': '2024-08-14T13:51:38.550-07:00', 'description': 'added Dosing Info tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132262, 'title': 'Drugs@HCSC: Drug Product ACH-ESCITALOPRAM (escitalopram), Accord Healthcare Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91896', 'crossReferences': [{'id': 1452488462, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91896', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91896'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",[],"[{'objCls': 'Chemical', 'id': 'PA10074', 'name': 'escitalopram'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1451802520.0,"<p>The product monograph for escitalopram (ACH-ESCITALOPRAM) notes that the metabolism of escitalopram is mainly mediated by CYP2C19. For patients who are known to be poor metabolizers with respect to CYP2C19, an initial dose of 5 mg daily is recommended. Depending on the individual response, the dose may be increased to a maximum of 10 mg.</p>
",1451802521.0,"<p>ACH-Escitalopram (escitalopram oxalate) is indicated for the symptomatic relief of Major Depressive Disorder (MDD).</p>
<p>Excerpts from the escitalopram (ACH-ESCITALOPRAM) product monograph:</p>
<blockquote class=""blockquote"">
<p>It has been observed that poor metabolizers with respect to CYP2C19 have twice as high a plasma concentration of escitalopram as extensive metabolizers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The metabolism of escitalopram is mainly mediated by CYP2C19. For patients who are known to be poor metabolizers with respect to CYP2C19, an initial dose of 5 mg daily is recommended. Depending on the individual response, the dose may be increased to a maximum of 10 mg.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""escitalopram_2022_06_10_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/escitalopram_2022_06_10_HCSC.pdf"">escitalopram product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451802522.0,"<p>For patients who are known to be poor metabolizers with respect to CYP2C19, an initial dose of 5 mg daily is recommended. Depending on the individual response, the dose may be increased to a maximum of 10 mg.</p>
",,,,,,,
Label Annotation,PA166184114,Annotation of Swissmedic Label for capecitabine and DPYD,True,False,[],True,"[{'id': 1452021768, 'date': '2023-02-28T13:06:24.141-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103156, 'title': 'Swissmedic label for capecitabine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=54657', 'crossReferences': [{'id': 1450813255, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=54657', '_url': 'https://amiko.oddb.org/de/fi?gtin=54657'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448771', 'name': 'capecitabine'}]","[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",Swissmedic,1450813623.0,"<p>The Swiss drug label for capecitabine (Xeloda) states that capecitabine is contraindicated in patients with low or no DPYD activity. Patients with partial DPYD deficiency may be given capecitabine at a significantly reduced dose if the benefit of the drug is deemed to outweigh the risks.</p>
",1450813624.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for capecitabine (Xeloda):</p>
<blockquote class=""blockquote"">
<p>Precautionary measures:
Dihydropyrimidine dehydrogenase (DPD) deficiency: Rare cases of unexpected severe toxicity associated with 5-FU (e.g., stomatitis, diarrhea, mucositis, neutropenia, and neurotoxicity) were attributed to a lack of DPD activity. Patients with low or no activity of DPD, an enzyme involved in the degradation of fluorouracil, have an increased risk of severe, life-threatening or fatal adverse effects caused by fluorouracil and are contraindicated to use Xeloda (see &quot;&quot;Contraindications&quot;&quot;). Such patients with certain homozygous or certain mixed heterozygous mutations in the DPYD gene locus that cause complete or almost complete absence of DPD activity are at the highest risk of life-threatening or fatal toxicity and should not be treated with Xeloda. Safety was not confirmed for any dose in patients with complete absence of DPD activity.
Patients with partial DPD deficiency, in whom the benefit of Xeloda is rated higher than the risks (taking into account the possible suitability of an alternative non-fluoropyrimidine-containing chemotherapy regimen), must be treated with extreme caution, initially with a significant dose reduction followed by close monitoring and dose adjustment according to toxicity.
Patients with undetected DPD deficiency treated with Capecitabine may experience life-threatening toxicities manifesting as overdose. In case of an acute toxicity of grade 2-4, treatment must be discontinued immediately. A permanent termination of treatment should be considered based on the clinical assessment of onset, duration and severity of observed toxicities (see &quot;&quot;Overdose&quot;&quot;).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=54657&amp;highlight=DPD-Aktivität"" target=""_blank"">capecitabine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813625.0,"<blockquote class=""blockquote"">
<p>Patients with low or no activity of DPD ... have an increased risk of severe, life-threatening or fatal adverse effects caused by fluorouracil and are contraindicated to use Xeloda</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with partial DPD deficiency, in whom the benefit of Xeloda is rated higher than the risks (taking into account the possible suitability of an alternative non-fluoropyrimidine-containing chemotherapy regimen), must be treated with extreme caution, initially with a significant dose reduction followed by close monitoring and dose adjustment according to toxicity.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184117,Annotation of Swissmedic Label for carbasalate calcium and G6PD,False,False,[],False,"[{'id': 1451900980, 'date': '2022-09-30T09:25:43.108-07:00', 'description': 'fixed typo', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103158, 'title': 'Swissmedic label for carbasalate calcium', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=10368', 'crossReferences': [{'id': 1450813258, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=10368', '_url': 'https://amiko.oddb.org/de/fi?gtin=10368'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184059', 'name': 'carbasalate calcium'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450813637.0,"<p>The Swiss drug label for carbasalate calcium (Alcacyl) states that carbasalate calcium should be used with caution in patients with G6PD deficiency.</p>
",1450813638.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for carbasalate calcium (Alcacyl):</p>
<blockquote class=""blockquote"">
<p>Precautionary Measures:
Caution is required for... Renal and/or hepatic insufficiency, chronic or recurrent stomach or duodenal complaints, bronchial asthma or general tendency to hypersensitivity, nasal mucous membrane polyps, genetically determined glucose-6-phosphate dehydrogenase deficiency, simultaneous therapy with anticoagulant drugs, conditions with increased risk of bleeding (e.g. injuries, dysmenorrhea).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=10368&amp;highlight=Glucose-6-Phosphatdehydrogenase-Mangel"" target=""_blank"">carbasalate calcium drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184126,Annotation of Swissmedic Label for codeine and CYP2D6,True,False,[],False,[],False,[],True,"[{'id': 15103251, 'title': 'Swissmedic label for Benylin with codeine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55818', 'crossReferences': [{'id': 1450815466, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55818', '_url': 'https://amiko.oddb.org/de/fi?gtin=55818'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103168, 'title': 'Swissmedic label for codeine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=19220', 'crossReferences': [{'id': 1450813275, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=19220', '_url': 'https://amiko.oddb.org/de/fi?gtin=19220'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449088', 'name': 'codeine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450813689.0,"<p>The Swiss drug label for codeine (Codein Knoll) states that codeine is contraindicated in patients with a CYP2D6 ultrarapid metabolizer phenotype.CYP2D6 &quot;slow metabolizers&quot; may experience reduced or no analgesia from codeine.</p>
",1450813690.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for codeine (Codein Knoll):</p>
<blockquote class=""blockquote"">
<p>Contraindications:
Codeine is converted into its active metabolite morphine by the hepatic isozymes CYP2D6, some of which are genetic polymorphisms. Patients with an &quot;ultra-fast CYP2D6 metaboliser&quot; phenotype have a high CYP2D6 activity, so that toxic serum levels of morphine can develop even at low doses. These &quot;ultra-fast metabolizers&quot; can show symptoms of overdose, such as dizziness, deep sedation, shortness of breath, nausea and vomiting, to respiratory and cardiac arrest.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Kinetics:
Codeine is converted in the liver to 5-20% morphine by the isoenzymes CYP2D6. Of the CYP2D6 isoenzymes, some genetic polymorphisms exist which express themselves phenotypically at different rates of metabolism. In ultra-fast CYP2D6 metabolizers (Northern and Central Europeans approx. 1-5%, Southern Europeans approx. 7-12%, other ethnic groups up to 29%) a toxic morphine concentration can be reached even at a low codeine dose (see &quot;Contraindications&quot;). In slow-metabolisers (approx. 7-10% of the Caucasian population) the analgesic effect may be reduced or completely eliminated due to the lower morphine formation.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=19220&amp;highlight=genetische"" target=""_blank"">codeine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813691.0,"<blockquote class=""blockquote"">
<p>Contraindications - Codeine is converted into its active metabolite morphine by the hepatic isozymes CYP2D6, some of which are genetic polymorphisms. Patients with an &quot;ultra-fast CYP2D6 metaboliser&quot; phenotype have a high CYP2D6 activity, so that toxic serum levels of morphine can develop even at low doses. These &quot;ultra-fast metabolizers&quot; can show symptoms of overdose, such as dizziness, deep sedation, shortness of breath, nausea and vomiting, to respiratory and cardiac arrest.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184405,Annotation of Swissmedic Label for brexpiprazole and CYP2D6,False,False,[],True,[],False,[],True,"[{'id': 15103261, 'title': 'Swissmedic label for brexpiprazole (REXULTI)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=66475&highlight=Metabolisierer', 'crossReferences': [{'id': 1450815500, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=66475&highlight=Metabolisierer', '_url': 'https://amiko.oddb.org/de/fi?gtin=66475&highlight=Metabolisierer'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}, {'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166160053', 'name': 'brexpiprazole'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815501.0,"<p>The Swiss drug label for brexpiprazole (REXULTI) states that extensive CYP2D6 metabolizers receiving both CYP3A4 and CYP2D6 inhibitors, or slow CYP2D6 metabolizers receiving strong CYP3A4 inhibitors, are expected to have a 4-5-fold increase in brexpiprazole concentrations. Therefore, the dosage of REXULTI in these cases should be reduced to a quarter of the recommended dose.</p>
",1450815502.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the brexpiprazole (REXULTI) label:</p>
<blockquote class=""blockquote"">
<p>Dosage/Application:
Dose adjustments for slow CYP2D6 metabolizers and simultaneous use of CYP inhibitors or inducers: Slow CYP2D6 Metabolisers
Adjusted dose
Known slow CYP2D6 metabolizers: administration of half the usual dose;
Known slow CYP2D6 metabolizers taking moderate/strong CYP3A4 inhibitors: administration of a quarter of the usual dose&quot;</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Interaction:
REXULTI is metabolized primarily by CYP3A4 and CYP2D6. Based on the results of drug interaction studies, it is recommended that individuals receiving strong CYP2D6 or CYP3A4 inhibitors receive a dose adjustment to half the maintenance dose. Based on estimates from population pharmacokinetic analyses, extensive CYP2D6 metabolizers receiving both CYP3A4 and CYP2D6 inhibitors, or slow CYP2D6 metabolizers receiving strong CYP3A4 inhibitors, are expected to have a 4-5-fold increase in brexpiprazole concentrations. Therefore, the dosage of REXULTI in these cases should be reduced to a quarter of the recommended dose (see Dosage/Application).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Slow CYP2D6 Metabolisers: About 8% of Caucasians and 3-8% of Black/Afro-Americans lack the ability to metabolize CYP2D6 substrates. They are classified as slow metabolizers (poor metabolisers, PM) in contrast to extensive metabolizers (EM). Brexiprazole exposure is about 1.8 times higher in CYP2D6 PMs than in EMs. (see Dosage/Application).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=66475&amp;highlight=Metabolisierer"" target=""_blank"">brexpiprazole drug label</a> (in German);</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450815503.0,"<blockquote class=""blockquote"">
<p>Dose adjustments for slow CYP2D6 metabolizers and simultaneous use of CYP inhibitors or inducers: Slow CYP2D6 Metabolisers
Adjusted dose
Known slow CYP2D6 metabolizers: administration of half the usual dose;
Known slow CYP2D6 metabolizers taking moderate/strong CYP3A4 inhibitors: administration of a quarter of the usual dose.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>REXULTI is metabolized primarily by CYP3A4 and CYP2D6. Based on the results of drug interaction studies, it is recommended that individuals receiving strong CYP2D6 or CYP3A4 inhibitors receive a dose adjustment to half the maintenance dose. Based on estimates from population pharmacokinetic analyses, extensive CYP2D6 metabolizers receiving both CYP3A4 and CYP2D6 inhibitors, or slow CYP2D6 metabolizers receiving strong CYP3A4 inhibitors, are expected to have a 4-5-fold increase in brexpiprazole concentrations. Therefore, the dosage of REXULTI in these cases should be reduced to a quarter of the recommended dose (see Dosage/Application).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184116,Annotation of Swissmedic Label for carbamazepine and HLA-B,True,False,[],False,"[{'id': 1452021787, 'date': '2023-02-28T13:07:22.875-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103157, 'title': 'Swissmedic label for carbamazepine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=29789', 'crossReferences': [{'id': 1450813256, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=29789', '_url': 'https://amiko.oddb.org/de/fi?gtin=29789'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165954769', 'symbol': 'HLA-B*15:02', 'name': '*15:02'}]","[{'objCls': 'Chemical', 'id': 'PA448785', 'name': 'carbamazepine'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",Swissmedic,1450813633.0,"<p>The Swiss drug label for carbamazepine (Tegretol) states that patients from certain ancestries should be tested for the presence of the HLA-B*15:02 allele prior to beginning carbamazepine therapy. Patients carrying the HLA-B*15:02 allele should not be treated with carbamazepine unless the benefits greatly outweigh the risks.</p>
",1450813634.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for carbamazepine (Tegretol):</p>
<blockquote class=""blockquote"">
<p>Precautionary Measures:
Association with HLA-B*1502 Allele: Retrospective studies in patients of Han Chinese and Thai descent showed a strong correlation between SJS/TEN skin reactions associated with the use of carbamazepine and the presence of human leukocyte antigen (HLA)-B*1502 allele. The frequency of this allele is 2-12% in the Han Chinese population and about 8% in Thailand. In Asian countries (e.g. Taiwan, Malaysia and Philippines), where the frequency of the HLA-B*1502 allele is higher, SJS is reported more frequently (&quot;&quot;occasionally&quot;&quot; instead of &quot;&quot;rarely&quot;&quot;). The frequency of carriers of this allele is above 15% in the Philippines and in some Malay populations. Allele frequencies of up to 2% and 6% were reported for Korea and India. The frequency of the HLA-B*1502 allele is negligible in the Caucasian population, as are Africans, indigenous peoples of America, Japan and people of Spanish descent (&lt;1%).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients whose ancestry poses a risk should be tested for carriers of the allele HLA-B*1502 before starting treatment with Tegretol. In the event of a positive result, treatment with Tegretol should be discontinued unless the benefit is clearly greater than the risk. Since HLA-B*1502 is also a risk factor in other antiepileptic drugs, this should be included in the risk assessment. Screening for HLA-B*1502 in population groups with low allele frequency is not required. Similarly, screening is not appropriate for patients who have been using Tegretol for some time, as SJS/TEN usually occurs only in the first months of therapy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The identification of carriers of the HLA-B*1502 allele and thus the avoidance of carbamazepine therapy in these patients of Han Chinese descent led to a decrease in the incidence of carbamazepine-induced SJS/TEN.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genetic screening cannot be a substitute for careful patient monitoring, as many patients who carry the HLA-B*1502 allele do not develop SJS/TEN, but patients who do not have a genetic risk may still develop SJS/TEN. The situation is similar for patients who carry the HLA-A*3101 allele and are treated with Tegretol. These patients do not need to develop SJS/TEN, DRESS, AGEP or maculopapular rash. However, patients who are not carriers of HLA-A*3101 may still develop severe adverse skin reactions. The extent to which other factors, such as dose, compliance, co-medication and co-morbidity, promote the occurrence of these serious adverse skin reactions has not yet been investigated.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Other skin reactions: Slight skin reactions, e.g. isolated macular or maculopapular exanthema, are often temporary and not dangerous; they usually remit within a few days or weeks despite continued therapy or after dose reduction. However, because it is difficult to distinguish the signs of mild and transient skin reactions from the first signs of severe skin reactions, they require close monitoring and immediate discontinuation in the event of progression or signs of systemic hypersensitivity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The HLA-B*1502 allele has no effect on the risk of mild dermatological reactions from carbamazepine.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=29789&amp;highlight=HLA-Allele"" target=""_blank"">carbamazepine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450813635.0,"<blockquote class=""blockquote"">
<p>Patients whose ancestry poses a risk should be tested for carriers of the allele HLA-B*1502 before starting treatment with Tegretol. In the event of a positive result, treatment with Tegretol should be discontinued unless the benefit is clearly greater than the risk. Since HLA-B*1502 is also a risk factor in other antiepileptic drugs, this should be included in the risk assessment. Screening for HLA-B*1502 in population groups with low allele frequency is not required. Similarly, screening is not appropriate for patients who have been using Tegretol for some time, as SJS/TEN usually occurs only in the first months of therapy.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166272701,Annotation of EMA Label for rimegepant and CYP2C9,False,False,[],False,"[{'id': 1452215221, 'date': '2023-08-24T15:16:16.430-07:00', 'description': 'removed prescribing information since ""CYP2C9 genotypes did not significantly influence the pharmacokinetics of rimegepant""', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15133042, 'title': 'Rimegepant | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vydura', 'crossReferences': [{'id': 1451817940, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vydura', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vydura'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166225041', 'name': 'rimegepant'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",EMA,,,1451818160.0,"<p>Excerpts from the Rimegepant (<em><strong>VYDURA</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>Biotransformation
Rimegepant is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>No clinically significant differences in the pharmacokinetics of rimegepant were observed based on
age, sex, race/ethnicity, body weight, migraine status, or CYP2C9 genotype.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Rimegepant_EMA_2022_07_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Rimegepant_EMA_2022_07_05.pdf""><em><strong>Rimegepant</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166271541,Annotation of EMA Label for sacituzumab govitecan and UGT1A1,False,False,[],False,"[{'id': 1452555280, 'date': '2024-08-13T13:43:47.903-07:00', 'description': 'added Other Guidance tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132322, 'title': 'Trodelvy | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy', 'crossReferences': [{'id': 1451803680, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]","[{'objCls': 'Haplotype', 'id': 'PA166115842', 'symbol': 'UGT1A1*28', 'name': '*28'}]","[{'objCls': 'Chemical', 'id': 'PA166225061', 'name': 'sacituzumab govitecan'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",EMA,1451803681.0,"<p>The EMA label for sacituzumab govitecan-hziy (TRODELVY) states that patients with known reduced UGT1A1 activity should be closely monitored for adverse reactions.</p>
",1451803682.0,"<p>Excerpts from the <em><strong>sacituzumab govitecan-hziy</strong></em> (<em><strong>TRODELVY</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p><em><strong>Use in patients with reduced UGT1A1 activity</strong></em></p>
</blockquote>
<blockquote class=""blockquote"">
<p>SN-38 (the small molecule moiety of sacituzumab govitecan) is metabolised via uridine diphosphate-glucuronosyl transferase (UGT1A1). Genetic variants of the UGT1A1 gene such as the UGT1A1*28 allele lead to reduced UGT1A1 enzyme activity. Individuals who are homozygous for UGT1A1*28 allele are potentially at increased risk for neutropenia, febrile neutropenia, and anaemia and may be at increased risk for other adverse reactions following initiation of sacituzumab govitecan treatment (see section 4.8). Approximately 20% of the Black population, 10% of the White population,
and 2% of the East Asian population are homozygous for the UGT1A1*28 allele. Decreased function alleles other than UGT1A1*28 may be present in certain populations. Patients with known reduced UGT1A1 activity should be closely monitored for adverse reactions. When unknown, no testing of
UGT1A1 status is required as the management of adverse reactions including the recommended dose modifications will be the same for all patients.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em><strong>Metabolism</strong></em></p>
</blockquote>
<blockquote class=""blockquote"">
<p>No metabolism studies with sacituzumab govitecan have been conducted. SN-38 (the small molecule moiety of sacituzumab govitecan) is metabolised via UGT1A1.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>SN-38 exposure may be elevated in such patients due to decreased hepatic UGT1A1 activity.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Sacituzumab_Govitecan_EPAR_2022_06_14.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Sacituzumab_Govitecan_EPAR_2022_06_14.pdf"">sacituzumab govitecan drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451803683.0,"<blockquote class=""blockquote"">
<p>Use in patients with reduced UGT1A1 activity</p>
</blockquote>
<blockquote class=""blockquote"">
<p>SN-38 (the small molecule moiety of sacituzumab govitecan) is metabolised via uridine diphosphate-glucuronosyl transferase (UGT1A1). Genetic variants of the UGT1A1 gene such as the UGT1A1*28 allele lead to reduced UGT1A1 enzyme activity. Individuals who are homozygous for UGT1A1*28 allele are potentially at increased risk for neutropenia, febrile neutropenia, and anaemia and may be at increased risk for other adverse reactions following initiation of sacituzumab govitecan treatment (see section 4.8). Approximately 20% of the Black population, 10% of the White population,
and 2% of the East Asian population are homozygous for the UGT1A1*28 allele. Decreased function alleles other than UGT1A1*28 may be present in certain populations. Patients with known reduced UGT1A1 activity should be closely monitored for adverse reactions. When unknown, no testing of
UGT1A1 status is required as the management of adverse reactions including the recommended dose modifications will be the same for all patients.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184506,Annotation of Swissmedic Label for dolutegravir / abacavir / lamivudine and HLA-B,False,False,[],False,"[{'id': 1452021842, 'date': '2023-02-28T13:09:00.730-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103263, 'title': 'Swissmedic label for dolutegravir, abacavir und lamivudine (Triumeq)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=63283', 'crossReferences': [{'id': 1450815647, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=63283', '_url': 'https://amiko.oddb.org/de/fi?gtin=63283'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165987830', 'symbol': 'HLA-B*57:01', 'name': '*57:01'}]","[{'objCls': 'Chemical', 'id': 'PA166184505', 'name': 'dolutegravir / abacavir / lamivudine'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",Swissmedic,1450820463.0,"<p>The Swiss drug label for dolutegravir / abacavir / lamivudine (Triumeq) states that patients should be screened for the presence of HLA-B*57:01 prior to starting treatment with abacavir. Triumeq is contraindicated in carriers of the HLA-B*57:01 allele.</p>
",1450820464.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for dolutegravir / abacavir / lamivudine (Triumeq):</p>
<blockquote class=""blockquote"">
<p>Precautions:
Before initiating treatment with abacavir, HLA-B*5701 status should be determined if possible, and before resuming treatment with abacavir in patients with unknown HLA-B*5701 status who have previously tolerated abacavir.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Triumeq is contraindicated in HLA-B*5701 allele carriers or in patients who had suspected Abacavir HSR after treatment with another abacavir-containing drug (e.g. Ziagen, Kivexa, Trizivir), regardless of HLA-B*5701 status.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=63283&amp;highlight=HLA-B*5701-Allel"" target=""_blank"">dolutegravir / abacavir / lamivudine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450820465.0,"<blockquote class=""blockquote"">
<p>Before initiating treatment with abacavir, HLA-B*5701 status should be determined if possible, and before resuming treatment with abacavir in patients with unknown HLA-B*5701 status who have previously tolerated abacavir.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Triumeq is contraindicated in HLA-B*5701 allele carriers or in patients who had suspected Abacavir HSR after treatment with another abacavir-containing drug (e.g. Ziagen, Kivexa, Trizivir), regardless of HLA-B*5701 status.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184122,Annotation of Swissmedic Label for ciprofloxacin and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103164, 'title': 'Swissmedic label for ciprofloxacin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=47795', 'crossReferences': [{'id': 1450813271, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=47795', '_url': 'https://amiko.oddb.org/de/fi?gtin=47795'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449009', 'name': 'ciprofloxacin'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450813658.0,"<p>The Swiss drug label for ciprofloxacin (Ciproxin) states that ciprofloxacin should be used with caution in patients with G6PD deficiency.</p>
",1450813659.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for ciprofloxacin (Ciproxin):</p>
<blockquote class=""blockquote"">
<p>Precautionary measures:
Patients with a deficiency of glucose-6-phosphate dehydrogenase or family history tend to hemolytic reactions to quinolones. Therefore, ciprofloxacin should be used with caution in these patients.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=47795&amp;highlight=Glucose-6-Phosphat-Dehydrogenase"" target=""_blank"">ciprofloxacin drug label</a> (in German).</p>
</blockquote>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184124,Annotation of Swissmedic Label for clomipramine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103166, 'title': 'Swissmedic label for clomipramine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=32934', 'crossReferences': [{'id': 1450813273, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=32934', '_url': 'https://amiko.oddb.org/de/fi?gtin=32934'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449048', 'name': 'clomipramine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450813681.0,"<p>The Swiss drug label for clomipramine (Anafranil) states that patients with reduced CYP2D6 activity may have high plasma concentrations of desmethylclomipramine, a metabolite of clomipramine.</p>
",1450813682.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<blockquote class=""blockquote"">
<p>Kinetics:
CYP2D6 catalyzes the elimination of the active components, clomipramine and N-desmethylclomipramine, by formation of 2- and 8-hydroxyclomipramine. The hydroxylation of clomipramine and desmethylclomipramine is genetically similar to that of debrisoquine. In patients who metabolize debrisoquine slowly, high concentrations of desmethylclomipramine may occur; however, the concentration of clomipramine is less affected.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=32934&amp;highlight=genetisch"" target=""_blank"">clomipramine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184133,Annotation of Swissmedic Label for dexlansoprazole and CYP2C19,False,False,[],False,[],False,[],True,"[{'id': 15103175, 'title': 'Swissmedic label for dexlansoprazole', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=62993', 'crossReferences': [{'id': 1450813284, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=62993', '_url': 'https://amiko.oddb.org/de/fi?gtin=62993'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166110257', 'name': 'dexlansoprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",Swissmedic,1450813716.0,"<p>The Swiss drug label for dexlansoprazole (Dexilant) states that CYP2C19 poor metabolizers have increased exposure to dexlansoprazole compared to normal metabolizers. CYP2C19 metabolizer phenotype can also affect the nature of some drug-drug interactions involving dexlansoprazole.</p>
",1450813717.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for dexlansoprazole (Dexilant):</p>
<blockquote class=""blockquote"">
<p>Interactions:
Drugs metabolized by P450 enzymes: In vitro studies showed that dexilant is unlikely to inhibit the CYP isoforms 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1 or 3A4. Therefore, no clinically relevant drug interactions with drugs metabolized by these CYP enzymes are expected. Additionally, in vivo studies showed that dexilant had no effect on the pharmacokinetics of simultaneously administered single doses of phenytoin (CYP2C9 substrate) or theophylline (CYP1A2 substrate). The CYP1A2 genotypes of the subjects were not determined in the drug interaction study with theophylline. Although in vitro studies showed that dexilant has the potential to inhibit CYP2C19, an in vivo drug interaction study in mainly CYP2C19 extensive and intermediate metabolizers showed that dexilant does not affect the pharmacokinetics of diazepam (CYP2C19 substrate).
Lansoprazole may increase plasma concentrations of drugs metabolized via CYP3A4. Caution should be exercised when combining dexlansoprazole with drugs that are metabolized via this enzyme and have a narrow therapeutic range.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Tacrolimus: Simultaneous administration of dexlansoprazole may increase the plasma concentration of tacrolimus (a CYP3A and P-glycoprotein (P-gp) substrate) especially in transplant patients who are intermediate to poor metabolisers of CYP2C19. Monitoring of tacrolimus plasma concentrations is recommended when simultaneous treatment with dexlansoprazole is initiated or terminated.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Dexlansoprazole is extensively metabolized in the liver to inactive metabolites by oxidation, reduction and subsequent formation of sulfate, glucuronide and glutathione conjugates. Oxidative metabolites are formed by the cytochrome P450 (CYP) enzyme system, including hydroxylation mainly by CYP2C19 and oxidation to sulfone by CYP3A4. CYP2C19 is a polymorphic liver enzyme that has three phenotypes regarding metabolism of CYP2C19 substrates; extensive (*1/*1), intermediate (*1/mutant) and slow (mutant/mutant). The systemic exposure of dexlansoprazole is about four times higher in slow metabolizers than in extensive metabolizers. Dexlansoprazole is the most important component circulating in plasma, regardless of CYP2C19 metaboliser status. In intermediate and extensive CYP2C19 metabolites, the major metabolites in plasma are 5-hydroxy-dexlansoprazole and its glucuronide conjugate, while in slow CYP2C19 metabolites dexlansoprazole-sulfone is the major metabolite in plasma.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=62993&amp;highlight=Genotypen"" target=""_blank"">dexlansoprazole drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184134,Annotation of Swissmedic Label for dextromethorphan and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103176, 'title': 'Swissmedic label for dextromethorphan', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=39639', 'crossReferences': [{'id': 1450813285, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=39639', '_url': 'https://amiko.oddb.org/de/fi?gtin=39639'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449273', 'name': 'dextromethorphan'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450813720.0,"<p>The Swiss drug label for dextromethorphan (Bexin) states that metabolism and elimination of dextromethorphan are delayed in CYP2D6 &quot;slow metabolizers&quot;.</p>
",1450813721.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for dextromethorphan (Bexin):</p>
<blockquote class=""blockquote"">
<p>Precautionary measures:
In patients with CYP2D6 deficiency, metabolism and elimination of dextromethorphan are significantly delayed. Due to a genetic polymorphism, 10 to 15% of the population belong to the so-called slow metabolizers (debrisoquin type).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Kinetics:
Metabolism and elimination of dextromethorphan are strongly delayed in patients with CYP2D6 deficiency. Due to a genetic polymorphism, 10 to 15% of the population belong to the so-called slow metabolizers (debrisoquin type).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=39639&amp;highlight=genetischenPolymorphismus"" target=""_blank"">dextromethorphan drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184442,Annotation of Swissmedic Label for duloxetine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103264, 'title': 'Swissmedic label for duloxetine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=56983', 'crossReferences': [{'id': 1450815648, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=56983', '_url': 'https://amiko.oddb.org/de/fi?gtin=56983'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10066', 'name': 'duloxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815678.0,"<p>The Swiss drug label for duloxetine (Cymbalta) states that CYP2D6 metabolizer status contributes to inter-individual differences in pharmacokinetics.</p>
",1450815679.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for duloxetine (Cymbalta):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Duloxetine is extensively metabolized by oxidative enzymes (CYP1A2 and the polymorphic CYP2D6) and subsequently conjugated. The pharmacokinetics of duloxetine show a large interindividual variability (generally 50-60%), partly due to sex, age, smoking habits and CYP2D6 metabolisation status.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=56983&amp;highlight=polymorphe"" target=""_blank"">duloxetine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184449,Annotation of Swissmedic Label for flucytosine and DPYD,False,False,[],False,[],False,[],True,"[{'id': 15103273, 'title': 'Swissmedic label for flucytosin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=40467', 'crossReferences': [{'id': 1450815657, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=40467', '_url': 'https://amiko.oddb.org/de/fi?gtin=40467'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449654', 'name': 'flucytosine'}]","[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",Swissmedic,1450815739.0,"<p>The Swiss drug label for flucytosine (Ancotil) cautions about risk for toxicity of flucytosine in patients with DPYD deficiency if nucleoside analogues have been given and states that DPYD testing is indicated. It does not discuss testing in patients receiving flucytosine only.</p>
",1450815740.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for flucytosine (Ancotil):</p>
<blockquote class=""blockquote"">
<p>Precautions:
When flucytosine is degraded, a small amount of 5-fluorouracil is formed as a metabolite. The enzyme dihydropyrimidine dehydrogenase (DPD) plays an essential role in the degradation of 5-fluorouracil. Nucleoside analogues such as brivudine and its analogues are potent, irreversible inhibitors of the enzyme DPD and can therefore lead to a strong increase in the plasma concentration of 5-fluorouracil with the consequence of toxic reactions (leukopenia, thrombocytopenia, etc.) with a potentially lethal outcome. A time interval of at least 4 weeks must therefore be observed between treatment with Brivudin or comparable drugs and the start of therapy with Ancotil (see &quot;Contraindications&quot;). If necessary, the determination of DPD enzyme activity is indicated before starting treatment with Ancotil, as patients with genetically reduced DPD activity (approx. 0.1-3.0% of the Caucasian population) are more at risk of such interaction.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=40467&amp;highlight=genetisch"" target=""_blank"">flucytosin drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,,,,,,,,,
Label Annotation,PA166183786,"Annotation of Swissmedic Label for amlodipine / atorvastatin / perindopril arginine and G6PD, SLCO1B1",False,False,[],False,[],False,[],True,"[{'id': 15103029, 'title': 'Swissmedic label for Triveram', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65514', 'crossReferences': [{'id': 1450811179, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65514', '_url': 'https://amiko.oddb.org/de/fi?gtin=65514'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166154579', 'symbol': 'rs4149056', 'name': 'rs4149056'}]","[{'objCls': 'Chemical', 'id': 'PA166183785', 'name': 'amlodipine / atorvastatin / perindopril arginine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}, {'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",Swissmedic,1450811172.0,"<p>The Swiss drug label for amlodipine, atorvastatin and perindopril arginine (Triveram) states that patients with G6PD deficiency may experience hemolytic anemia. Additionally, patients with the SLCO1B1 rs4149056 CC genotype may have higher atorvastatin exposure which may increase the risk of rhabdomyolysis.</p>
",1450811173.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for amlodipine, atorvastatin and perindopril arginine (Triveram):</p>
<div class=""blockquote"">
<p>Undesirable effects...Hemolytic anemia in patients with congenital G-6PDH deficiency</p>
</div>
<div class=""blockquote"">
<p>SLCO1B1 polymorphism...The hepatic uptake of all HMG-CoA reductase inhibitors, including atorvastatin, requires the OATP1B1 transporter. Patients with SLCO1B1 polymorphism are at risk of increased exposure to atorvastatin, which may increase the risk of rhabdomyolysis (see &quot;Warnings and Precautions&quot;). The polymorphism in the OATC1B1 coding gene (SLCO1B1 c.521CC) causes 2.4 times higher atorvastatin exposure (AUC) than that in individuals without this genotype variant (c.521TT). A genetic disorder of hepatic uptake of atorvastatin is also possible in these patients. Possible effects on efficacy are not known.</p>
</div>
<p>For the complete drug label text with G6PD information highlighted, see the following <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65514&amp;highlight=G-6PDH-Mangel"" target=""_blank"">amlodipine, atorvastatin and perindopril arginine drug label</a>, and for SLCO1B1 information highlighted, see the following <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65514&amp;highlight=Polymorphismus"" target=""_blank"">amlodipine, atorvastatin and perindopril arginine drug label</a> (both in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166271561,Annotation of HCSC Label for sacituzumab govitecan and UGT1A1,True,False,[],False,"[{'id': 1452555300, 'date': '2024-08-13T13:48:15.428-07:00', 'description': 'added Alternate Drug, Other Guidance tags', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132342, 'title': 'Drugs@HCSC: Drug Product TRODELVY (sacituzumab govitecan), Gilead Sciences Canada, Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=100997', 'crossReferences': [{'id': 1451803820, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=100997', '_url': 'https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=100997'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]","[{'objCls': 'Haplotype', 'id': 'PA166115842', 'symbol': 'UGT1A1*28', 'name': '*28'}]","[{'objCls': 'Chemical', 'id': 'PA166225061', 'name': 'sacituzumab govitecan'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",HCSC,1451803821.0,"<p>The HCSC label for sacituzumab govitecan-hziy (TRODELVY) states that patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia; and may be at increased risk for other adverse reactions when treated with TRODELVY, and close monitoring are recommended for patients with known reduced UGT1A1 activity for adverse reactions.</p>
",1451803822.0,"<p>Excerpts from the <em><strong>sacituzumab govitecan-hziy</strong></em> (<em><strong>TRODELVY</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>Individuals who are homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are potentially at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions following initiation of TRODELVY treatment.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Approximately 20% of the Black or African American population, 10% of the White population, and 2% of the East Asian population are homozygous for the UGT1A1*28 allele. Decreased function alleles other than UGT1A1*28 may be present in certain populations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Eighty-nine percent (586/660) of patients who received TRODELVY (up to 10 mg/kg on Days 1 and 8 of a 21-day cycle) had retrospective UGT1A1 genotype results available. The incidence of Grade 3 to 4 neutropenia was 57% (40/70) in patients homozygous for the UGT1A1*28 allele, 47% (115/246) in patients heterozygous for the UGT1A1*28 allele, and 45% (117/261) in patients homozygous for the wild-type allele.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 enzyme activity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>SN-38 (the small molecule moiety of sacituzumab govitecan) is metabolized via UGT1A1. The glucuronide metabolite of SN-38 (SN-38G) was detectable in the serum of patients.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>SN-38 exposure may be elevated in such patients due to decreased hepatic UGT1A1 activity.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Sacituzumab_Govitecan_HCSC_2022_06_14.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Sacituzumab_Govitecan_HCSC_2022_06_14.pdf""><em><strong>sacituzumab govitecan-hziy</strong></em>_ product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451803823.0,"<blockquote class=""blockquote"">
<p>Individuals who are homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are potentially at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions following initiation of TRODELVY treatment.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 enzyme activity.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166272821,Annotation of EMA Label for siponimod and CYP2C9,True,False,[],True,"[{'id': 1452592307, 'date': '2024-09-17T11:51:04.206-07:00', 'description': 'added Alternate Drug tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132942, 'title': 'Siponimod | European Medicines Agency.', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/mayzent', 'crossReferences': [{'id': 1451817800, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/mayzent', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/mayzent'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]","[{'objCls': 'Haplotype', 'id': 'PA165816542', 'symbol': 'CYP2C9*1', 'name': '*1'}, {'objCls': 'Haplotype', 'id': 'PA165816552', 'symbol': 'CYP2C9*11', 'name': '*11'}, {'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}, {'objCls': 'Haplotype', 'id': 'PA165816546', 'symbol': 'CYP2C9*5', 'name': '*5'}, {'objCls': 'Haplotype', 'id': 'PA165816547', 'symbol': 'CYP2C9*6', 'name': '*6'}, {'objCls': 'Haplotype', 'id': 'PA165816549', 'symbol': 'CYP2C9*8', 'name': '*8'}]","[{'objCls': 'Chemical', 'id': 'PA166182736', 'name': 'siponimod'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",EMA,1451818940.0,"<p>Siponimod is contraindicated for individuals with CYP2C9*3/*3 genotype and does adjustments are provided for some genotypes, other genotypes are discussed but no dosing advice given.</p>
",1451818941.0,"<p>Excerpts from the <em><strong>Siponimod</strong></em> (<em><strong>Mayzent</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>CYP2C9 genotype
The CYP2C9 genotype influences siponimod CL/F. Two population pharmacokinetic analyses indicated that CYP2C9*1*1 and *1*2 subjects behave as extensive metabolisers, *2*2 and *1*3 subjects as intermediate metabolisers and *2*3 and *3*3 subjects as poor metabolisers. Compared to CYP2C9*1*1 subjects, individuals with the CYP2C9*2*2, *1*3, *2*3 and *3*3 genotypes have 20%, 35-38%, 45-48% and 74% smaller CL/F values, respectively. Siponimod exposure is therefore approximately 25%, 61%, 91% and 284% higher in CYP2C9*2*2, *1*3, *2*3 and *3*3 subjects, respectively, as compared to *1*1 subjects (see Table 4) (see sections 4.2 and 4.4).
There are other less frequent occurring polymorphisms for CYP2C9. The pharmacokinetics of siponimod have not been evaluated in such subjects. Some polymorphisms such as *5, *6, *8 and *11 are associated with decreased or loss of enzyme function. It is estimated that CYP2C9 *5, *6, *8 and *11 alleles have a combined frequency of approximately 10% in populations with African ancestry, 2% in Latinos/Hispanics and &lt;0.4% in Caucasians and Asians.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Before initiation of treatment, patients must be genotyped for CYP2C9 to determine their CYP2C9 metaboliser status</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In patients with a CYP2C9*3*3 genotype, siponimod should not be used</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In patients with a CYP2C9*2*3 or *1*3 genotype, the recommended maintenance dose is 1 mg</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Siponimod_EMA_2022_07_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Siponimod_EMA_2022_07_05.pdf""><em><strong>Siponimod</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1451818942.0,"<blockquote class=""blockquote"">
<p>Before initiation of treatment, patients must be genotyped for CYP2C9 to determine their CYP2C9 metaboliser status</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In patients with a CYP2C9*3*3 genotype, siponimod should not be used</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In patients with a CYP2C9*2*3 or *1*3 genotype, the recommended maintenance dose is 1 mg</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C9 genotype
Before initiation of treatment with siponimod, patients should be genotyped for CYP2C9 to determine their CYP2C9 metaboliser status (see section 4.2). Patients homozygous for CYP2C9*3 (CYP2C9*3*3 genotype: approximately 0.3 to 0.4% of the population) should not be treated with siponimod. Use of siponimod in these patients results in substantially elevated siponimod plasma levels. The recommended maintenance dose is 1 mg daily in patients with a CYP2C9*2*3 genotype (1.4-1.7% of the population) and in patients with a *1*3 genotype (9-12% of the population) to avoid increased exposure to siponimod.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166272841,Annotation of EMA Label for sodium oxybate and ALDH5A1,True,False,[],False,"[{'id': 1452556520, 'date': '2024-08-14T16:09:58.222-07:00', 'description': 'added Alternate Drug tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132922, 'title': 'Sodium Oxybate | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/xyrem', 'crossReferences': [{'id': 1451817780, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/xyrem', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/xyrem'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA24702', 'symbol': 'ALDH5A1', 'name': 'aldehyde dehydrogenase 5 family member A1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166236501', 'name': 'sodium oxybate'}]","[{'objCls': 'Gene', 'id': 'PA24702', 'symbol': 'ALDH5A1', 'name': 'aldehyde dehydrogenase 5 family member A1'}]",EMA,1451819040.0,"<p>Sodium oxybate is EMA indicated for treatment of narcolepsy with cataplexy in adult patients, adolescents and children from the age of 7 years. It is contraindicated in patients with succinic semialdehyde dehydrogenase deficiency, a rare metabolic disorder caused by homozygous or compound heterozygous mutation in the ALDH5A1 gene <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/271980"" target=""_blank"">see OMIM:271980</a>.</p>
",1451819041.0,"<p>Excerpts from the <em><strong>Sodium Oxybate</strong></em> (<em><strong>Xyrem</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>Contraindications</p>
<p>Patients with succinic semialdehyde dehydrogenase deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Animal studies indicate that metabolism is the major elimination pathway for sodium oxybate, producing carbon dioxide and water via the tricarboxylic acid (Krebs) cycle and secondarily by beta-oxidation. The primary pathway involves a cytosolic NADP+-linked enzyme, GHB dehydrogenase, that catalyses the conversion of sodium oxybate to succinic semialdehyde, which is then biotransformed to succinic acid by the enzyme succinic semialdehyde dehydrogenase</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Sodium_Oxybate_EMA_2022_07_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Sodium_Oxybate_EMA_2022_07_05.pdf""><em><strong>Sodium Oxybate</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451819042.0,"<blockquote class=""blockquote"">
<p>Contraindications</p>
<p>Patients with succinic semialdehyde dehydrogenase deficiency.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166273101,Annotation of EMA Label for pitolisant and CYP2D6,False,False,[],True,[],False,[],True,"[{'id': 15133102, 'title': 'Pitolisant | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade', 'crossReferences': [{'id': 1451819780, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166185163', 'name': 'pitolisant'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1451822360.0,"<p>Pitolisant is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA). There is information about dosage adjustments in CYP2D6 poor metabolizers and CYP2D6 rapid metabolizers. CYP2D6 genotypes are not specified.</p>
",1451822361.0,"<p>Excerpts from the <em><strong>pitolisant</strong></em> (<em><strong>Ozawade</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>CYP2D6 metabolizers phenotype (If known)
By comparison to CYP2D6 extensive metabolizers, higher systemic exposure (up to 3 fold) is observed in CYP2D6 poor metabolizers and lower exposure (by 0.8-fold) is observed in CYP2D6 ultra-rapid metabolizers. No differences in systemic exposure is observed between CYP2D6 extensive and intermediate metabolizers.
In the up-titration scheme, dose increment should take into account the higher exposure in CYP2D6 poor metabolizers, and a dosage adjustment in patients with known poor CYP2D6 metabolizer genotype could be considered depending on individual response and tolerance (see section 5.2). Furthermore, no dose recommendation can currently be given for CYP2D6 ultra-rapid metabolizers taking a CYP3A inducer, because the PK is currently unknown in this subpopulation.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In subjects that are CYP2D6 intermediate, extensive (normal) or ultra-rapid metabolizers, CYP2D6 is the main enzyme involved in the biotransformation of pitolisant, CYP3A is involved to a lesser extent. In subjects that are CYP2D6 poor metabolizers or are CYP2D6 intermediate, extensive or ultra-rapid metabolizers taking CYP3A inducers, CYP3A is significantly involved in the biotransformation of pitolisant and CYP2D6 is involved to a lesser extent.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 inhibitors will most likely have an effect on the pharmacokinetics of pitolisant in subjects that are CYP2D6 intermediate, extensive metabolizers or ultra-rapid metabolizers and taking no CYP3A inducers, but not in subjects that are CYP2D6 poor metabolizers or intermediate, extensive metabolizers or CYP2D6 ultra-rapid metabolizers and taking CYP3A inducers. A dosage adjustment during the combination could eventually be considered depending on individual response and tolerance.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP3A inducers will most likely have an effect on the pharmacokinetics of pitolisant in CYP2D6 poor metabolizers and CYP2D6 ultra-rapid metabolizers and their effect in these populations is currently unknown. A clinical monitoring should be made when both active substances are combined and, eventually a dosage adjustment during the combination and one week after the inducer treatment.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the [<em><strong>Pitolisant</strong></em> EPAR PDF]<a download=""Pitolisant_EMA_2022_07_07.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Pitolisant_EMA_2022_07_07.pdf"">xxx</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451822362.0,"<blockquote class=""blockquote"">
<p>CYP2D6 metabolizers phenotype (If known)
By comparison to CYP2D6 extensive metabolizers, higher systemic exposure (up to 3 fold) is observed in CYP2D6 poor metabolizers and lower exposure (by 0.8-fold) is observed in CYP2D6 ultra-rapid metabolizers. No differences in systemic exposure is observed between CYP2D6 extensive and intermediate metabolizers.
In the up-titration scheme, dose increment should take into account the higher exposure in CYP2D6 poor metabolizers, and a dosage adjustment in patients with known poor CYP2D6 metabolizer genotype could be considered depending on individual response and tolerance (see section 5.2). Furthermore, no dose recommendation can currently be given for CYP2D6 ultra-rapid metabolizers taking a CYP3A inducer, because the PK is currently unknown in this subpopulation.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184157,Annotation of Swissmedic Label for ofloxacin and G6PD,False,False,[],False,"[{'id': 1452021985, 'date': '2023-02-28T14:32:14.952-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103056, 'title': 'Swissmedic label for ofloxacin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=47386', 'crossReferences': [{'id': 1450812017, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=47386', '_url': 'https://amiko.oddb.org/de/fi?gtin=47386'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450684', 'name': 'ofloxacin'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450813897.0,"<p>The Swiss drug label for ofloxacin (Tarivid) states that ofloxacin should be used with caution in patients with G6PD deficiency due to increased risk of hemolytic reactions.</p>
",1450813898.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for ofloxacin (Tarivid):</p>
<blockquote class=""blockquote"">
<p>Precautionary measures:
Patients with latent or diagnosed glucose-6-phosphate dehydrogenase deficiency (G-6 PDH deficiency) may be predisposed to hemolytic reactions in quinolone therapy. Tarivid should therefore be used with caution in these patients.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=47386&amp;highlight=G-6-PDH-Mangel"" target=""_blank"">ofloxacin drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813899.0,"<blockquote class=""blockquote"">
<p>Patients with latent or diagnosed glucose-6-phosphate dehydrogenase deficiency (G-6 PDH deficiency) may be predisposed to hemolytic reactions in quinolone therapy. Tarivid should therefore be used with caution in these patients.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184173,Annotation of Swissmedic Label for oxcarbazepine and HLA-B,True,False,[],False,"[{'id': 1452021987, 'date': '2023-02-28T14:32:36.900-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103062, 'title': 'Swissmedic label for oxcarbazepin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=57883', 'crossReferences': [{'id': 1450812023, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=57883', '_url': 'https://amiko.oddb.org/de/fi?gtin=57883'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165954769', 'symbol': 'HLA-B*15:02', 'name': '*15:02'}]","[{'objCls': 'Chemical', 'id': 'PA450732', 'name': 'oxcarbazepine'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",Swissmedic,1450814011.0,"<p>The Swiss label for oxcarbazepine (Apydan® extent) states that patients who have an increased risk of SJS/TEN should be tested for the presence of the allele HLA-B*1502 before starting treatment with Apydan extent. &quot;In case of a positive result, Apydan extent should not be used unless the benefit is clearly greater than the risk. It should be considered that HLA-B*1502 is also a risk factor for other antiepileptic drugs&quot;.</p>
",1450814012.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for oxcarbazepine (Apydan® extent):</p>
<blockquote class=""blockquote"">
<p>Precautionary measures:
Association with HLA-B*1502 Allele: Retrospective studies in patients of Han Chinese or Thai descent showed a strong correlation between SJS/TEN skin reactions associated with the use of carbamazepine and the presence of human leukocyte antigen (HLA)- B*1502 allele. Since the chemical structure of oxcarbazepine is similar to that of carbamazepine, oxcarbazepine is thought to increase the risk of SJS/TEN skin reactions in patients with HLA-B*1502. Some data also describe such an association for oxcarbazepine.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The prevalence of carriers of this allele is around 20% in the Philippines, 13.5% in Vietnam, 2-12% in the Han Chinese population, a good 8% in Thailand and 2-6% in Korea and India. In the Caucasian population, however, the prevalence of the HLA-B*1502 allele is negligible (&lt;1%), as are Africans, Japanese, the American indigenous population and people of Spanish descent.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The prevalence of homozygous allele carriers is given. The proportion of heterozygotes (and thus of persons with a potentially increased risk of skin reactions) is almost twice as high.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients who have an increased risk due to their ancestry should be tested for the presence of the allele HLA-B*1502 before starting treatment with Apydan extent. In case of a positive result, Apydan extent should not be used unless the benefit is clearly greater than the risk. It should be considered that HLA-B*1502 is also a risk factor for other antiepileptic drugs. Screening for HLA-B*1502 in population groups with low prevalence is not required. Similarly, screening is not appropriate for patients who have been using oxcarbazepine for some time, as SJS/TEN usually occurs only in the first few months of therapy..</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=57883&amp;highlight=HLA-Allele"" target=""_blank"">oxcarbazepine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450814013.0,"<blockquote class=""blockquote"">
<p>Patients who have an increased risk due to their ancestry should be tested for the presence of the allele HLA-B*1502 before starting treatment with Apydan extent. In case of a positive result, Apydan extent should not be used unless the benefit is clearly greater than the risk. It should be considered that HLA-B*1502 is also a risk factor for other antiepileptic drugs. Screening for HLA-B*1502 in population groups with low prevalence is not required. Similarly, screening is not appropriate for patients who have been using oxcarbazepine for some time, as SJS/TEN usually occurs only in the first few months of therapy.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184120,Annotation of Swissmedic Label for quinine and G6PD,True,False,[],False,"[{'id': 1452022000, 'date': '2023-02-28T14:35:24.783-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103162, 'title': 'Swissmedic label for quinine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=56490', 'crossReferences': [{'id': 1450813269, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=56490', '_url': 'https://amiko.oddb.org/de/fi?gtin=56490'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451213', 'name': 'quinine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450813650.0,"<p>The Swiss drug label for quinine (Chininsulfat 250 Hänseler) states that quinine is contraindicated in patients with G6PD deficiency.</p>
",1450813651.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for quinine (Chininsulfat 250 Hänseler):</p>
<blockquote class=""blockquote"">
<p>Contraindications
Chininsulfat 250 Hänseler must not be used in cases of glucose-6-phosphate dehydrogenase deficiency (symptom: haemolytic anaemia) and myasthenia gravis, nor in cases of tinnitus and optic neuritis (previous damage to the optic nerve) and anamnesis with black water fever.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=56490&amp;highlight=Glucose-6-Phosphat-Dehydrogenasemangel"" target=""_blank"">quinine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813652.0,"<blockquote class=""blockquote"">
<p>Chininsulfat 250 Hänseler must not be used in cases of glucose-6-phosphate dehydrogenase deficiency (symptom: haemolytic anaemia)...</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184403,Annotation of Swissmedic Label for rasburicase and G6PD,True,False,[],False,"[{'id': 1452022020, 'date': '2023-02-28T14:36:05.715-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103082, 'title': 'Swissmedic label for rasburicase', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55789', 'crossReferences': [{'id': 1450812043, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55789', '_url': 'https://amiko.oddb.org/de/fi?gtin=55789'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA10176', 'name': 'rasburicase'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450815444.0,"<p>The Swiss drug label for rasburicase (Fasturtec) states that rasburicase is contraindicated in patients with G6PD deficiency due to risk of hemolytic anaemia.</p>
",1450815445.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the rasburicase (Fasturtec) label:</p>
<blockquote class=""blockquote"">
<p>Contraindications:
G6PD deficiency and other metabolic disorders in cell metabolism known to trigger hemolytic anaemia. Hydrogen peroxide is a by-product of the conversion of uric acid to allantoin. To prevent possible hemolytic anaemia caused by hydrogen peroxide, Rasburicase is therefore contraindicated in patients with these disorders.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Unwanted effects:
Occasionally: haemolysis, haemolytic anemia, methaemoglobinemia. Since the enzymatic degradation of uric acid to allantoin produces hydrogen peroxide, haemolytic anaemia or methaemoglobinemia has been observed in certain risk groups, in particular in patients with G6PD deficiency.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=55789&amp;highlight=G6PD-Mangel"" target=""_blank"">rasburicase drug label</a> (in German);</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450815446.0,"<blockquote class=""blockquote"">
<p>G6PD deficiency and other metabolic disorders in cell metabolism known to trigger hemolytic anaemia. Hydrogen peroxide is a by-product of the conversion of uric acid to allantoin. To prevent possible hemolytic anaemia caused by hydrogen peroxide, Rasburicase is therefore contraindicated in patients with these disorders.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184450,Annotation of Swissmedic Label for fluorouracil and DPYD,False,False,[],False,[],False,[],True,"[{'id': 15103274, 'title': 'Swissmedic label for fluorouracil (Efudix)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=36464', 'crossReferences': [{'id': 1450815658, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=36464', '_url': 'https://amiko.oddb.org/de/fi?gtin=36464'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA128406956', 'name': 'fluorouracil'}]","[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",Swissmedic,1450815742.0,"<p>The Swiss drug label for fluorouracil (Efudix) requires DPYD testing in patients receiving fluorouracil who have also been treated with brivudine or other nucleoside analogues.</p>
",1450815743.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for fluorouracil (Efudix):</p>
<blockquote class=""blockquote"">
<p>Interactions:
Efudix should not be used together with brivudine and analogues, irreversible inhibitors of dihydropyrimidine dehydrogenase (DPD), as enzyme inhibition leads to accumulation and increased toxicity of fluorouracil (see &quot;Contraindications&quot; and &quot;Warnings and Precautions&quot;). A time interval of at least 4 weeks must be observed between treatment with Brivudin or analogues and the start of therapy with Efudix. In patients who have recently received brivudine or analogs, as an additional precaution, DPD enzyme activity should be determined before starting treatment with Efudix.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=36464&amp;highlight=DPD-Enzymaktivität"" target=""_blank"">fluoruracil drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166184452,Annotation of Swissmedic Label for fluoxetine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103276, 'title': 'Swissmedic label for fluoxetine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=46347', 'crossReferences': [{'id': 1450815660, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=46347', '_url': 'https://amiko.oddb.org/de/fi?gtin=46347'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449673', 'name': 'fluoxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815752.0,"<p>The Swiss drug label for fluoxetine (Fluctine) states that the sum of fluoxetine and active metabolites is comparable between CYP2D6 extensive and poor metabolizers.</p>
",1450815753.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for drug fluoxetine (Fluctine):</p>
<blockquote class=""blockquote"">
<p>Kinetic:
In about 3 to 10% of the healthy population, a genetic defect leads to a reduction in the activity of cytochrome-450 isozyme 2D6. Such individuals are referred to as &quot;poor metabolizers&quot; of substances such as debrisoquine, dextromethorphan and tricyclic antidepressants. Many substances, including most antidepressants such as fluoxetine and other selective serotonin uptake inhibitors, are metabolized by this isoenzyme; therefore, the pharmacological properties and relative proportions of metabolites are altered in poor metabolizers. However, in the case of fluoxetine and its metabolites, the sum of the plasma concentrations of the 4 active enantiomers is comparable between &quot;poor&quot; and &quot;fast metabolizing&quot;.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=46347&amp;highlight=genetischen"" target=""_blank"">fluoxetine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184461,Annotation of Swissmedic Label for hydroxychloroquine and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103285, 'title': 'Swissmedic label for hydroxychloroquine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=53831', 'crossReferences': [{'id': 1450815670, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=53831', '_url': 'https://amiko.oddb.org/de/fi?gtin=53831'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164777036', 'name': 'hydroxychloroquine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450820146.0,"<p>The Swiss drug label for hydroxychloroquine (Plaquenil) states that this drug is contraindicated in patients with G6PD deficiency.</p>
",1450820147.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for hydroxychloroquine (Plaquenil):</p>
<blockquote class=""blockquote"">
<p>Contraindications:
Plaquenil is contraindicated in hypersensitivity to 4-aminoquinoline, porphyria, hemolytic anemia and glucose-6-phosphate dehydrogenase deficiency.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=53831&amp;highlight=Glucose-6-phosphat-dehydrogenase-Mangel"" target=""_blank"">hydroxychloroquine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166183900,Annotation of Swissmedic Label for moclobemide and CYP2C19,False,False,[],False,[],False,[],True,"[{'id': 15103047, 'title': 'Swissmedic label for moclobemid', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=50085', 'crossReferences': [{'id': 1450812008, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=50085', '_url': 'https://amiko.oddb.org/de/fi?gtin=50085'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA452615', 'name': 'moclobemide'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",Swissmedic,1450812216.0,"<p>The Swiss drug label for moclobemid (Aurorix) states that the metabolism of moclobemide may be affected in genetically induced or drug-induced slow metabolisers. Caution is recommended when using moclobemide with drugs that are metabolized by CYP2C19 as moclobemide inhibits this enzyme.</p>
",1450812217.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the moclobemid (Aurorix) label:</p>
<blockquote class=""blockquote"">
<p>Interaction:
Caution is recommended when using moclobemide with drugs metabolized by CYP2C19 as moclobemide inhibits this enzyme. The plasma concentrations of these drugs (such as proton pump inhibitors (e.g. omeprazole), fluoxetine and fluvoxamine) may increase with concomitant use of moclobemide. Accordingly, moclobemide inhibits the metabolism of omeprazole in CYP2C19-extensive metabolizers and may lead to a doubling of omeprazole exposure.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Moclobemide is partially metabolized by the polymorphic isozymes CYP450 2C19 (mephenytoin polymorphism) and CYP450 2D6 (debrisoquine polymorphism). Therefore, the metabolism of moclobemide may be affected in genetically induced or drug-induced slow metabolisers. Two studies conducted to investigate the influence of these effects show that, due to the variety of alternative metabolic pathways, moclobemide is therapeutically only relevant for mephenytoin polymorphism (CYP450 2C19) and dose adjustment may be necessary.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=50085&amp;highlight=CYP2C19"" target=""_blank"">moclobemide drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166183910,Annotation of Swissmedic Label for nebivolol and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103051, 'title': 'Swissmedic label for Nebivolol und Thiazide', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=59262', 'crossReferences': [{'id': 1450812012, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=59262', '_url': 'https://amiko.oddb.org/de/fi?gtin=59262'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103050, 'title': 'Swissmedic label for nebivolol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=54489', 'crossReferences': [{'id': 1450812011, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=54489', '_url': 'https://amiko.oddb.org/de/fi?gtin=54489'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA151958426', 'name': 'nebivolol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450812274.0,"<p>The Swiss drug label for nebivolol (Nebilet) states that nebivolol is metabolized by CYP2D6. However, the active metabolites achieve a similar effect in the rapidly and slowly metabolizing patients.</p>
",1450812275.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the nebivolol (Nebilet) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Nebivolol is metabolized via alicyclic and aromatic hydroxylation, N-dealkylation and glucuroinization, partly to active metabolites. Although the aromatic hydroxylation is part of the CYP2D6-dependent genetic oxidative polymorphism (about 10% of the population), the active metabolites achieve a similar effect in the rapidly and slowly metabolizing patients.</p>
</blockquote>
<p>Excerpts from the Nebivolol und Thiazide (Nebilet Plus) label:</p>
<blockquote class=""blockquote"">
<p>Metabolism:
Nebivolol is partly metabolized to active metabolites by alicyclic and aromatic hydroxylation, N-dealkylation and glucuronidation. Aromatic hydroxylation is partially catalyzed by the isoenzyme CYP2D6, which has a genetic polymorphism (about 10% of the population are slow metabolizers). Since hydroxymetabolites are active, treatment with nebivolol leads to a similar effect in rapidly and slowly metabolizing patients.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=54489&amp;highlight=CYP2D6"" target=""_blank"">nebivolol drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184221,Annotation of Swissmedic Label for palonosetron and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103066, 'title': 'Swissmedic label for palonosetron', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=57042', 'crossReferences': [{'id': 1450812027, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=57042', '_url': 'https://amiko.oddb.org/de/fi?gtin=57042'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10352', 'name': 'palonosetron'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450814358.0,"<p>The Swiss drug label for palonosetron (Aloxi) states that the CYP2D6 genetic polymorphism does not significantly influence the overall body clearance of palonosetron compared to healthy individuals and no dose adjustment is necessary.</p>
",1450814359.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for palonosetron (Aloxi):</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics
Genetic polymorphism: The genetic polymorphism CYP2D6 does not significantly influence the overall body clearance of palonosetron compared to healthy individuals. For this reason, dose adjustment is not necessary.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=57042&amp;highlight=Genetischer"" target=""_blank"">palonosetron drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184268,Annotation of Swissmedic Label for pazopanib and HLA-B,False,False,[],False,[],False,[],True,"[{'id': 15103072, 'title': 'Swissmedic label for pazopanib', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=60326', 'crossReferences': [{'id': 1450812033, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=60326', '_url': 'https://amiko.oddb.org/de/fi?gtin=60326'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165954769', 'symbol': 'HLA-B*15:02', 'name': '*15:02'}]","[{'objCls': 'Chemical', 'id': 'PA165291492', 'name': 'pazopanib'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",Swissmedic,1450814683.0,"<p>The Swiss drug label for pazopanib (Votrient) states that patients who carry the HLA-B*57:01 allele may have a higher risk of votrient-induced ALT elevation.</p>
",1450814684.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for pazopanib (Votrient):</p>
<blockquote class=""blockquote"">
<p>Precautions:
During the use of Votrient, cases of severe liver failure (including fatal courses) were reported. In patients with severe liver dysfunction, Votrient is contraindicated (see &quot;Contraindications&quot;). Caution and close monitoring are required when administering Votrient to patients with mild to moderate liver dysfunction. During treatment with Votrient, the intake of drugs or substances with known hepatotoxicity should be avoided. In patients with moderate liver dysfunction, a reduced dose of 200 mg Votrient once daily is recommended (see &quot;Dosage/Application&quot;). There is not enough data available for patients with a mild liver dysfunction to make a dose adjustment recommendation. In clinical studies with Votrient, an increase in serum transaminases (ALAT, ASAT) and bilirubin was observed (see &quot;Adverse effects&quot;). In the majority of cases, an isolated increase in ALAT and ASAT without simultaneous increase in alkaline phosphatase or bilirubin was reported. Patients over 60 years of age may have a higher risk of increasing ALAT to &gt;3× ULN. Patients who carry the HLA-B*57:01 allele also have a higher risk of votrient-induced ALT elevation. In all patients receiving Votrient, liver function must be monitored regardless of genotype or age (see &quot;Properties/Effects&quot;). The vast majority (92.5%) of all transaminase increases of any degree occurred in the first 18 weeks. The classification was based on the Common Terminology Criteria for Adverse Events of the National Cancer Institute (NCI CTCAE), version 3.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Properties / Effects:
Pharmacogenomics:Pharmacogenetic meta-analysis of the data from 31 clinical trials in Votrient administered as monotherapy or in combination with other agents showed an increase in ALT to &gt;5× ULN (grade 3 according to NCI CTC) in 19% of HLA-B*57:01 allele carriers and 10% of non-users. In this data set, 133 of the 2235 patients (6%) were carriers of the HLA-B*57:01 allele (see &quot;Warnings and Precautions&quot;).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=60326&amp;highlight=Genotyp"" target=""_blank"">pazopanib drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184395,Annotation of Swissmedic Label for propafenone and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103079, 'title': 'Swissmedic label for propafenone', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=45118', 'crossReferences': [{'id': 1450812040, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=45118', '_url': 'https://amiko.oddb.org/de/fi?gtin=45118'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451131', 'name': 'propafenone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815423.0,"<p>The Swiss drug label for propafenone (Rytmonorm) states that propafenone may be metabolized more slowly in patients with CYP2D6 variants where the 5-hydroxy metabolite is not produced or is produced minimally.</p>
",1450815424.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the propafenone (Rytmonorm) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
There are two genetically determined metabolic patterns. In over 90% of patients, propafenone is metabolized rapidly and extensively with an elimination half-life of 2 to 10 hours. These patients metabolize propafenone to two active metabolites: 5-hydroxy-propafenone produced via CYP2D6 and N-depropylpropafenone (norpropafenone), which is produced via CYP3A4 and CYP1A2. In less than 10% of patients, propafenone is metabolized more slowly because the 5-hydroxy metabolite is not produced or is produced minimally.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Interaction:
Elevated propafenone plasma levels may occur with simultaneous use of propafenone and SSRIs such as fluoxetine and paroxetine. The simultaneous use of propafenone hydrochloride and fluoxetine in extensive metabolizers increased the Cmax and AUC of S-propafenone by 39% and 50%, respectively, and that of R-propafenone by 71% and 50%, respectively. In order to achieve the desired therapeutic effect, lower doses of propafenone may be sufficient.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=45118&amp;highlight=Metabolisierern"" target=""_blank"">propafenone drug label</a> (in German);</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184388,"Annotation of Swissmedic Label for losartan and CYP2C9, CYP3A4",False,False,[],False,[],False,[],True,"[{'id': 15103248, 'title': 'Swissmedic label for losartan (Cosaar)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=52904', 'crossReferences': [{'id': 1450815342, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=52904', '_url': 'https://amiko.oddb.org/de/fi?gtin=52904'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103249, 'title': 'Swissmedic label for losartan and diuretics (Cosaar Plus)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=53629', 'crossReferences': [{'id': 1450815343, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=53629', '_url': 'https://amiko.oddb.org/de/fi?gtin=53629'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450268', 'name': 'losartan'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",Swissmedic,1450815388.0,"<p>The Swiss drug label for losartan (Cosaar) gives information on CYP2C9 and CYP3A4 involvement in formation of active metabolites of losartan.</p>
",1450815389.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for losartan (Cosaar):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Approximately 14% of a perorally administered dose of losartan is converted to an active metabolite. In vitro studies show that cytochrome P450 2C9 and 3A4 are involved in the conversion of losartan into its metabolites. In 1% of the patients a lower conversion was observed due to a genetically determined enzyme defect (less than 1% of the dose compared to 14% of the dose in normal patients). After oral administration of 14C-labelled losartan, the radioactivity circulating in plasma is mainly due to losartan and its active metabolites.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=52904&amp;highlight=genetisch"" target=""_blank"">losartan drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184390,Annotation of Swissmedic Label for sulfamethoxazole / trimethoprim and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103098, 'title': 'Swissmedic label for Sulfamethoxazol und Trimethoprim', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=48306', 'crossReferences': [{'id': 1450812059, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=48306', '_url': 'https://amiko.oddb.org/de/fi?gtin=48306'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10715', 'name': 'sulfamethoxazole / trimethoprim'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450815397.0,"<p>The Swiss drug label for sulfamethoxazole and trimethoprim (Bactrim) cautions about use of the drug in patients with G6PD deficiency.</p>
",1450815398.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for sulfamethoxazole and trimethoprim (Bactrim):</p>
<blockquote class=""blockquote"">
<p>Precautions
In patients with G6PD deficiency and in patients with certain haemoglobinopathies (Hb-Zurich, Hb-Cologne) cyanosis may occur due to sulf- or methaemoglobinemia. In patients with glucose-6-phosphate dehydrogenase deficiency, hemolysis may be induced in sensitive patients regardless of the dose (see &quot;Contraindications&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pregnancy
Congenital G6PD deficiency may lead to neonatal hemolysis.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=48306&amp;highlight=G6PD-Mangel"" target=""_blank"">sulfamethoxazole and trimethoprim drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166278401,"Annotation of HCSC Label for bupivacaine, meloxicam and CYB5R3, G6PD",False,False,[],False,"[{'id': 1452531061, 'date': '2024-07-18T18:00:19.951-07:00', 'description': 'retired because drug product was cancelled pre-market', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15135682, 'title': 'Drugs@HCSC: Drug Product ZYNRELEF (bupivacaine and meloxicam), Heron Therapeutics, Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101509', 'crossReferences': [{'id': 1452531044, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101509', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101509'}], 'notes': 'Current status: Cancelled Pre Market', 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA135057240', 'name': 'bupivacaine'}, {'objCls': 'Chemical', 'id': 'PA450353', 'name': 'meloxicam'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1451881080.0,"<p>The HCSC-approved drug label for bupivacaine and meloxicam (ZYNRELEF) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.</p>
<p><strong>Please note that as of July 2024, the drug label for bupivacaine and meloxicam (ZYNRELEF) has a Current status: Cancelled Pre Market in the HCSC database. As a result, this label annotation has been retired.</strong></p>
",1451881081.0,"<p>Excerpt from the bupivacaine and meloxicam (ZYNRELEF) product monograph:</p>
<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
<p>NOTE: While the CYB5R3 gene is not explicitly stated in the drug label, variants in this gene are associated with congenital methemoglobinemia I and II <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/250800"" target=""_blank"">OMIM 250800</a>.</p>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Bupivacaine_2022_09_13_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Bupivacaine_2022_09_13_HCSC.pdf"">bupivacaine and meloxicam product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452531060.0,"<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
",1451832060.0,Retirement Reason,[],Other,retirement:1451832060,True,
Label Annotation,PA166396961,Annotation of HCSC Label for chloroprocaine and BCHE,False,False,[],False,[],False,[],True,"[{'id': 15177642, 'title': 'Drugs@HCSC: Drug Product CLOROTEKAL (chloroprocaine), B. Braun Melsungen AG', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103981', 'crossReferences': [{'id': 1453095520, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103981', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103981'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448946', 'name': 'chloroprocaine'}]","[{'objCls': 'Gene', 'id': 'PA25294', 'symbol': 'BCHE', 'name': 'butyrylcholinesterase'}]",HCSC,1453095521.0,"<p>The product monograph for chloroprocaine (CLOROTEKAL) states that patients with pseudocholinesterase deficiency may experience prolonged activity of chloroprocaine, potentially increasing the risk of serious adverse reactions.</p>
",1453095522.0,"<p>Excerpts from the chloroprocaine (CLOROTEKAL) product monograph:</p>
<blockquote class=""blockquote"">
<p>Chloroprocaine is rapidly metabolized in plasma by hydrolysis of the ester linkage by pseudocholinesterase. The hydrolysis of chloroprocaine results in the production of ßdiethylaminoethanol and 2-chloro-4-aminobenzoic acid, which inhibits the action of the sulfonamides (see 9.4 Drug-Drug Interactions).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Genetic Polymorphism:</strong> Patients with pseudocholinesterase deficiency may experience prolonged activity of chloroprocaine, potentially increasing the risk of serious adverse reactions.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Chloroprocaine_2025_04_08_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Chloroprocaine_2025_04_08_HCSC.pdf"">chloroprocaine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166281761,Annotation of HCSC Label for paliperidone and CYP2D6,False,False,[],False,"[{'id': 1452725201, 'date': '2024-12-04T14:19:42.163-08:00', 'description': 'added label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171582, 'title': 'Drugs@HCSC: Drug Product INVEGA (paliperidone), Janssen Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78559', 'crossReferences': [{'id': 1452725200, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78559', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78559'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA163518919', 'name': 'paliperidone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1451926120.0,"<p>The HCSC product monograph for paliperidone states that no dose adjustment is needed based on CYP2D6 metabolizer status.</p>
",1451926121.0,"<p>Excerpts from the Paliperidone (<em><strong>INVEGA</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>A population pharmacokinetic analysis to evaluate the influence of predicted CYP2D6 phenotype on exposure indicated that no adjustment in the paliperidone dose on the basis of predicted phenotype is warranted.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Paliperidone_HCSC_2022_10_31.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Paliperidone_HCSC_2022_10_31.pdf""><em><strong>Paliperidone</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166284541,"Annotation of EMA Label for encorafenib and HRAS, KRAS, NRAS",True,True,[],False,"[{'id': 1452304540, 'date': '2023-11-21T00:00:00-08:00', 'description': 'Attached source information.', 'type': 'Update', 'version': 0}, {'id': 1452556305, 'date': '2024-08-14T13:34:06.194-07:00', 'description': 'added Alternate Drug, Other Guidance tags', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102950, 'title': 'Braftovi | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi', 'crossReferences': [{'id': 1450417076, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166179872', 'name': 'encorafenib'}]","[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",EMA,1451955742.0,"<p>The product information for encorafenib states that, based on its mechanism of action, it may promote malignancies associated with activation of RAS through mutation or other mechanisms.</p>
",1451955743.0,"<p>Excerpts from the encorafenib (<em><strong>Braftovi</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>Based on its mechanism of action, encorafenib may promote malignancies associated with activation
of RAS through mutation or other mechanisms. Patients receiving encorafenib should undergo a head
and neck examination, chest/abdomen computerised tomography (CT) scan, anal and pelvic
examinations (for women) and complete blood cell counts prior to initiation, during and at the end of
treatment as clinically appropriate. It should be considered to permanently discontinue encorafenib in
patients who develop RAS mutation-positive non-cutaneous malignancies. Benefits and risks should
be carefully considered before administering encorafenib to patients with a prior or concurrent cancer
associated with RAS mutation.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Encorafenib_EMA_2022_12_01.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Encorafenib_EMA_2022_12_01.pdf""><em><strong>Encorafenib</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451955744.0,"<p>Excerpts from the encorafenib (<em><strong>Braftovi</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>Based on its mechanism of action, encorafenib may promote malignancies associated with activation
of RAS through mutation or other mechanisms. Patients receiving encorafenib should undergo a head
and neck examination, chest/abdomen computerised tomography (CT) scan, anal and pelvic
examinations (for women) and complete blood cell counts prior to initiation, during and at the end of
treatment as clinically appropriate. It should be considered to permanently discontinue encorafenib in
patients who develop RAS mutation-positive non-cutaneous malignancies. Benefits and risks should
be carefully considered before administering encorafenib to patients with a prior or concurrent cancer
associated with RAS mutation.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166397721,"Annotation of FDA Label for relugolix / estradiol / norethindrone acetate and F5, PROC, PROS1, SERPINC1",True,False,[],False,[],False,[],True,"[{'id': 15177762, 'title': 'Drugs@FDA: Drug Product Myfembree (relugolix, estradiol hemihydrate, and norethindrone acetate), Sumitomo Pharma America, Inc - NDA214846/SUPPL-8, 07/17/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214846', 'crossReferences': [{'id': 1453099561, 'resource': 'FDA Application', 'resourceId': 'NDA214846/SUPPL-8', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214846'}], 'objCls': 'Literature', 'pubDate': '2024-07-17T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]","[{'objCls': 'Variant', 'id': 'PA166153554', 'symbol': 'rs6025', 'name': 'rs6025'}]","[{'objCls': 'Chemical', 'id': 'PA166397682', 'name': 'relugolix / estradiol / norethindrone acetate'}]","[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",FDA,1453099580.0,"<p>The FDA-approved drug label for relugolix/estradiol/norethindrone acetate (MYFEMBREE) states that women who are known to have inherited or acquired hypercoagulopathies should not use the drug. Specific inherited hypercoagulophathies were not mentioned on the label, but include protein C (PROC) deficiency, protein S (PROS1) deficiency, antithrombin-III (SERPINC1) deficiency, or Factor V Leiden (F5).</p>
",1453099581.0,"<p>Excerpt from the relugolix/estradiol/norethindrone acetate (MYFEMBREE) label:</p>
<blockquote class=""blockquote"">
<p>MYFEMBREE is contraindicated in women:</p>
<ul>
<li>With a high risk of arterial, venous thrombotic, or thromboembolic disorders [see Boxed Warning and Warnings and Precautions (5.1)]. Examples include women over 35 years of age who smoke and women who are known to have [...] inherited or acquired hypercoagulopathies</li>
</ul>
</blockquote>
<p>Specific inherited hypercoagulophathies were not mentioned on the label, but include protein C (PROC) deficiency, protein S (PROS1) deficiency, antithrombin-III (SERPINC1) deficiency, or Factor V Leiden (F5).</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Relugolix_estradiol_norethindroneacetate_2025_04_11_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Relugolix_estradiol_norethindroneacetate_2025_04_11_FDA.pdf"">relugolix/estradiol/norethindrone acetate drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1453099582.0,"<blockquote class=""blockquote"">
<p>MYFEMBREE is contraindicated in women:</p>
<ul>
<li>With a high risk of arterial, venous thrombotic, or thromboembolic disorders [...]. Examples include [...] women who are known to have [...] inherited or acquired hypercoagulopathies</li>
</ul>
</blockquote>
",,,,,,,
Label Annotation,PA166284681,Annotation of EMA Label for pembrolizumab and BRAF,False,True,[],False,"[{'id': 1452214400, 'date': '2023-08-23T12:57:02.571-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452304560, 'date': '2023-11-21T00:00:00-08:00', 'description': 'Attached source information.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102997, 'title': 'Keytruda | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda', 'crossReferences': [{'id': 1450663652, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166157522', 'symbol': 'rs113488022', 'name': 'rs113488022'}]","[{'objCls': 'Chemical', 'id': 'PA166124615', 'name': 'pembrolizumab'}]","[{'objCls': 'Gene', 'id': 'PA25408', 'symbol': 'BRAF', 'name': 'B-Raf proto-oncogene, serine/threonine kinase'}]",EMA,1451957260.0,"<p>Pembrolizumab is an anti-PD-L1 (CD274) antibody EMA indicated for a number of cancers including melanoma. In the section on clinical trials and melanoma, the participants BRAF V600E status is discussed.</p>
",1451957261.0,"<p>Excerpts from the Pembrolizumab (<em><strong>KEYTRUDA</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>KEYNOTE-006: Controlled study in melanoma patients... Patients with BRAF V600E mutant melanoma were not required to have received prior BRAF inhibitor therapy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>BRAF mutations were reported in 302 (36%) patients. Among patients with BRAF mutant tumours,
139 (46%) were previously treated with a BRAF inhibitor.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Pembrolizumab_EMA_2022_07_11.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Pembrolizumab_EMA_2022_07_11.pdf""><em><strong>Pembrolizumab</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166283161,"Annotation of HCSC Label for niraparib and BRCA1, BRCA2",False,True,[],False,"[{'id': 1452230780, 'date': '2023-09-07T15:40:50.518-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452231381, 'date': '2023-09-08T10:47:25.401-07:00', 'description': 'Added table 17 to show PFS in BRCAmut and non-BRCAmut study subjects. Added Actionable tag.', 'type': 'Update', 'version': 0}, {'id': 1452537741, 'date': '2024-07-24T12:55:20.314-07:00', 'description': 'Added label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161802, 'title': 'Drugs@HCSC: Drug Product Zejula (niraparib), GlaxoSmithKline Inc', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97986', 'crossReferences': [{'id': 1452537740, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97986', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97986'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166131610', 'name': 'niraparib'}]","[{'objCls': 'Gene', 'id': 'PA25411', 'symbol': 'BRCA1', 'name': 'BRCA1 DNA repair associated'}, {'objCls': 'Gene', 'id': 'PA25412', 'symbol': 'BRCA2', 'name': 'BRCA2 DNA repair associated'}]",HCSC,1451940820.0,"<p>THE HCSC label for niraparib (ZEJULA) discusses BRCA1 and BRCA2 variant status in the context of trials and mechanism of action but testing is not required as part of the indication.</p>
",1451940821.0,"<p>Excerpts from the <em><strong>Niraparib</strong></em> (<em><strong>ZEJULA</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>Niraparib reduced tumour growth in mouse xenograft
models of human cancer cell lines with defective BRCA1/2 function and in patient-derived xenograft
tumour models with homologous recombination deficiency that had either mutated or wild type
BRCA1/2, and in tumours that are BRCA wild-type and without detectable homologous recombination
deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The study demonstrated a statistically significant improvement in PFS for patients randomized to
ZEJULA as compared with placebo in the gBRCAmut cohort and the non-gBRCAmut cohort (Table 17,
and Figure 3 and Figure 4).The study demonstrated a statistically significant improvement in PFS for patients randomized to
ZEJULA as compared with placebo in the gBRCAmut cohort and the non-gBRCAmut cohort (Table 17,
and Figure 3 and Figure 4).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Table 17  Efficacy Results - Study 1 (IRC Assessment, Intent-To-Treat Population)</p>
</blockquote>
<table class=""table"">
<thead>
<tr>
<th></th>
<th>gBRCAmut Cohort<br/>ZEJULA (N=138)</th>
<th>gBRCAmut Cohort<br/>Placebo (N=65)</th>
<th>non-gBRCAmut Cohort<br/>ZEJULA (N=234)</th>
<th>non-gBRCAmut Cohort<br/>Placebo (N=116)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFS Median in months (95% CI)</td>
<td>21.0 (12.9, NR)</td>
<td>5.5(3.8, 7.2)</td>
<td>9.3(7.2, 11.2)</td>
<td>3.9 (3.7, 5.5)</td>
</tr>
<tr>
<td>Hazard Ratio (HR)(95% CI)</td>
<td>0.26 (0.17, 0.41)</td>
<td></td>
<td>0.45 (0.34, 0.61)</td>
<td></td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.0001</td>
<td></td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Niraparib_HCSC_2022_11_15.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Niraparib_HCSC_2022_11_15.pdf""><em><strong>Niraparib</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166397701,"Annotation of HCSC Label for relugolix / estradiol / norethindrone acetate and F5, PROC, PROS1, SERPINC1",True,False,[],False,[],False,[],True,"[{'id': 15177742, 'title': 'Drugs@HCSC: Drug Product MYFEMBREE (relugolix, estradiol, norethindrone acetate), Sumitomo Pharma Switzerland GmbH', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00072888.PDF', 'crossReferences': [{'id': 1453099520, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00072888.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00072888.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]","[{'objCls': 'Variant', 'id': 'PA166153554', 'symbol': 'rs6025', 'name': 'rs6025'}]","[{'objCls': 'Chemical', 'id': 'PA166397682', 'name': 'relugolix / estradiol / norethindrone acetate'}]","[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",HCSC,1453099521.0,"<p>The product monograph for relugolix/estradiol/norethindrone acetate (MYFEMBREE) states that patients with a blood clotting disorder such as protein C (PROC) deficiency, protein S (PROS1) deficiency, antithrombin-III (SERPINC1) deficiency, or Factor V Leiden (F5) should not use the drug.</p>
",1453099522.0,"<p>Excerpts from the relugolix/estradiol/norethindrone acetate (MYFEMBREE) product monograph:</p>
<blockquote class=""blockquote"">
<p>MYFEMBREE is contraindicated in patients who [...] have inherited or acquired hypercoagulopathies.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Do not use MYFEMBREE if [...] you have a blood clotting disorder. Examples such as protein C deficiency, protein S deficiency, antithrombin-III deficiency, or Factor V Leiden.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Relugolix_estradiol_norethindroneacetate_2025_04_11_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Relugolix_estradiol_norethindroneacetate_2025_04_11_HCSC.pdf"">relugolix/estradiol/norethindrone acetate product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1453099523.0,"<blockquote class=""blockquote"">
<p>MYFEMBREE is contraindicated in patients who [...] have inherited or acquired hypercoagulopathies.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Do not use MYFEMBREE if [...] you have a blood clotting disorder. Examples such as protein C deficiency, protein S deficiency, antithrombin-III deficiency, or Factor V Leiden.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166284761,Annotation of HCSC Label for cabotegravir / rilpivirine and UGT1A1,False,False,[],False,"[{'id': 1452206441, 'date': '2023-08-14T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15139082, 'title': 'Drugs@HCSC: Drug Product CABENUVA (cabotefravir/rilpivirine), ViiV Healthcare ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98709', 'crossReferences': [{'id': 1451958760, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98709', '_url': 'https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98709'}], 'objCls': 'Literature', 'pubDate': '2022-06-01T00:00:00-07:00', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166251381', 'name': 'cabotegravir / rilpivirine'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",HCSC,1451958780.0,"<p>Cabotegravir / rilpivirine (CABENUVA) is an injectable extended-release combination of antiviral drugs for the treatment of HIV. The HCSC label for cabotegravir / rilpivirine describes that cabotegravir is primarily metabolized by UGT1A1 but states that no dose adjustment is required in subjects with UGT1A1 polymorphisms.</p>
",1451958781.0,"<p>Excerpts from the cabotegravir/rilpivirine (CABENUVA) product monograph:</p>
<blockquote class=""blockquote"">
<p>In a meta-analysis of healthy and HIV-infected subjects, HIV-infected subjects with UGT1A1 genotypes conferring poor cabotegravir metabolism had a 1.2-fold increase in mean steady-state cabotegravir AUC, Cmax, and Ctau following cabotegravir long-acting injection vs. 1.38-fold mean increase following oral cabotegravir administration. This was similar to 1.3- to 1.5-fold mean increase in steady-state cabotegravir, cabotegravir AUC, Cmax, and Ctau observed following oral cabotegravir in healthy and HIV infected subjects combined. Polymorphisms in UGT1A9 were not associated with differences in the pharmacokinetics of cabotegravir, therefore, no dose adjustment is required in subjects with either UGT1A1 or UTG1A9 polymorphisms.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""cabotegravir_rilpivirine_2022_12_08_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/cabotegravir_rilpivirine_2022_12_08_HCSC.pdf"">cabotegravir/rilpivirine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166398041,Annotation of HCSC Label for cariprazine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15177942, 'title': 'Drugs@HCSC: Drug Product VRAYLAR (cariprazine), AbbVie Corporation', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101585', 'crossReferences': [{'id': 1453104120, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101585', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101585'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177476', 'name': 'cariprazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1453104140.0,"<p>Cariprazine (VRAYLAR) is an atypical antipsychotic used for the treatment of schizophrenia and bipolar disorder. The product monograph notes that CYP2D6 poor metabolizer status does not have a statistically significant effect on cariprazine exposure.</p>
",1453104141.0,"<p>Excerpts from the cariprazine (VRAYLAR) product monograph:</p>
<blockquote class=""blockquote"">
<p>Cariprazine is extensively metabolized by CYP3A4 and, to a lesser extent, by CYP2D6 to DCAR. DCAR is then further metabolized into DDCAR by CYP3A4 and, to a lesser extent, CYP2D6. DDCAR is then metabolized by CYP3A4 to a hydroxylated metabolite.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Based on the final population PK analysis, there were no statistically significant differences in cariprazine, DCAR, DDCAR, and TOTAL cariprazine exposures between extensive and poor metabolizers of CYP2D6.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Cariprazine_2025_04_15_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Cariprazine_2025_04_15_HCSC.pdf"">cariprazine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166284241,Annotation of HCSC Label for fosphenytoin and HLA-B,True,False,[],False,"[{'id': 1452556460, 'date': '2024-08-14T15:24:34.550-07:00', 'description': 'added Alternate Drug tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15163882, 'title': 'Drugs@HCSC: Drug Product CEREBYX (fosphenytoin), Searchlight Pharma Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00067688.PDF', 'crossReferences': [{'id': 1452556420, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00067688.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00067688.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165954769', 'symbol': 'HLA-B*15:02', 'name': '*15:02'}]","[{'objCls': 'Chemical', 'id': 'PA164746820', 'name': 'fosphenytoin'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",HCSC,1451953200.0,"<p>The HCSC product monograph states that fosphenytoin should be avoided in patients with a positive test for the HLA-B*1502 allele and discusses some of the limitations of this test.</p>
",1451953201.0,"<p>Excerpts from the Fosphenytoin (<em><strong>CEREBYX</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>Until further information is available, the use of CEREBYX* and other anti-epileptic
drugs associated with SJS/TEN should also be avoided in patients who test positive for the HLA-B*1502 allele</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In studies that included small samples of patients of Asian ancestry a strong association
was found between the risk of developing SJS/TEN and the presence of HLA-B*1502, an
inherited allelic variant of the HLA-B gene.
The HLA-B*1502 allele is found almost exclusively in individuals with ancestry across broad
areas of Asia†. Results of these studies suggest that the presence of the HLA-B *1502 allele may be one of the risk factors for phenytoin-associated SJS/TEN in patients with Asian ancestry.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>HLA-B*1502 genotyping as a screening tool has important limitations and must never
substitute for appropriate clinical vigilance and patient management. Many HLA-B*1502-
positive Asian patients treated with CEREBYX* will not develop SJS/TEN, and these reactions
can still occur infrequently in HLA-B*1502-negative patients of any ethnicity. The role of other
possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug
(AED) dose, compliance, concomitant medications, co-morbidities, and the level of
dermatologic monitoring have not been studied.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Fosphenytoin_HCSC_2022_11_30.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Fosphenytoin_HCSC_2022_11_30.pdf""><em><strong>Fosphenytoin</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451953202.0,"<blockquote class=""blockquote"">
<p>Until further information is available, the use of CEREBYX* and other anti-epileptic
drugs associated with SJS/TEN should also be avoided in patients who test positive for the HLA-B*1502 allele</p>
</blockquote>
",,,,,,,
Label Annotation,PA166224081,Annotation of HCSC Label for oxcarbazepine and HLA-A,False,False,[],False,"[{'id': 1452540041, 'date': '2024-07-26T09:31:03.961-07:00', 'description': 'updated label, added Pediatric tag and info, changed PGx level to Actionable', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162122, 'title': 'Drugs@HCSC: Drug Product APO-OXCARBAZEPINE (oxcarbazepine), APOTEX INC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76987', 'crossReferences': [{'id': 1452540020, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76987', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76987'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165954030', 'symbol': 'HLA-A*31:01', 'name': '*31:01'}]","[{'objCls': 'Chemical', 'id': 'PA450732', 'name': 'oxcarbazepine'}]","[{'objCls': 'Gene', 'id': 'PA35055', 'symbol': 'HLA-A', 'name': 'major histocompatibility complex, class I, A'}]",HCSC,1451267000.0,"<p>The product monograph for oxcarbazepine states that HLA-A*3101 may be a risk factor for the development of cutaneous adverse drug reactions such as SJS, TEN, DRESS, AGEP and maculopapular rash. However, there are insufficient data on patients treated with oxcarbazepine to support a recommendation for testing the presence of HLA-A*3101 allele in patients prior to initiating treatment with oxcarbazepine.</p>
",1451267001.0,"<p>Excerpts from the oxcarbazepine (APO-OXCARBAZEPINE) product monograph:</p>
<blockquote class=""blockquote"">
<p>HLA-A*3101 may be a risk factor for the development of cutaneous adverse drug reactions such as SJS, TEN, DRESS, AGEP and maculopapular rash.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The frequency of the HLA-A*3101 allele, an inherited allelic variant of the HLA-A gene, varies widely between ethnic populations and its frequency is about 2 to 5% in European populations and about 10% in the Japanese population. The frequency of this allele is estimated to be less than 5% in the majority of Australian, Asian, African and North American populations with some exceptions within 5 to 12%. Prevalence above 15% has been estimated in some ethnic groups in South America (Argentina and Brazil), North America (US Navajo and Sioux, and Mexico Sonora Seri) and Southern India (Tamil Nadu) and between 10% to 15% in other native ethnicities in these same regions.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>HLA-A*3101 is associated with an increased risk of carbamazepine-induced cutaneous adverse drug reactions including SJS, TEN, DRESS, or less severe AGEP and maculopapular rash. However, there are insufficient data on patients treated with oxcarbazepine to support a recommendation for testing the presence of HLA-A*3101 allele in patients prior to initiating treatment with oxcarbazepine. Moreover, genetic screening is generally not recommended for any current oxcarbazepine users, as the risk of SJS/TEN, AGEP, DRESS and maculopapular rash is largely confined to the first few months of therapy, regardless of HLA-A*3101 status.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>HLA-B*1502 and HLA-A*3101 genotyping as screening tools have important limitations and must never substitute for appropriate clinical vigilance and patient management. [...] Similarly, many patients positive for HLA-A*3101 and treated with oxcarbazepine will not develop SJS, TEN, DRESS, AGEP or maculopapular rash and patients negative for HLA-A*3101 of any ethnicity can still develop these severe cutaneous adverse reactions. The role of other possible factors in the development of, and morbidity from, these severe cutaneous adverse reactions, such as antiepileptic drug (AED) dose, compliance, concomitant medications, co-morbidities, and the level of dermatologic monitoring have not been studied.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In addition, it should be kept in mind that oxcarbazepine treated patients who will experience SJS/TEN have this reaction within the first few months of treatment. This information may be taken into consideration when deciding whether to screen genetically at-risk patients currently on oxcarbazepine.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Oxcarbazepine_2024_07_26_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Oxcarbazepine_2024_07_26_HCSC.pdf"">oxcarbazepine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452540040.0,"<blockquote class=""blockquote"">
<p>APO-OXCARBAZEPINE (oxcarbazepine) is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children ages 6 to 16.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166284561,"Annotation of HCSC Label for encorafenib and HRAS, KRAS, NRAS",True,True,[],False,"[{'id': 1452556361, 'date': '2024-08-14T13:48:24.418-07:00', 'description': 'updated label, added Alternate Drug, Other Guidance tags', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15163862, 'title': 'Drugs@HCSC: Drug Product BRAFTOVI (encorafenib), Pfizer Canada ULC', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00074711.PDF', 'crossReferences': [{'id': 1452556360, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00074711.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00074711.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166179872', 'name': 'encorafenib'}]","[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",HCSC,1451955840.0,"<p>The product monograph for encorafenib states that, based on its mechanism of action, it may promote malignancies associated with activation of RAS through mutation or other mechanisms.</p>
",1451955841.0,"<p>Excerpt from the encorafenib  (BRAFTOVI) product monograph:</p>
<blockquote class=""blockquote"">
<p>Based on its mechanism of action, BRAFTOVI may promote malignancies associated with activation of RAS through mutation or other mechanisms. Monitor patients receiving BRAFTOVI for signs and symptoms of non-cutaneous malignancies. Permanently discontinue BRAFTOVI in patients who develop RAS mutation-positive non-cutaneous malignancies (see 4.2 DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Encorafenib_2024_08_14_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Encorafenib_2024_08_14_HCSC.pdf"">encorafenib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451955842.0,"<p>Excerpt from the encorafenib  (BRAFTOVI) product monograph:</p>
<blockquote class=""blockquote"">
<p>Based on its mechanism of action, BRAFTOVI may promote malignancies associated with activation of RAS through mutation or other mechanisms. Monitor patients receiving BRAFTOVI for signs and symptoms of non-cutaneous malignancies. Permanently discontinue BRAFTOVI in patients who develop RAS mutation-positive non-cutaneous malignancies (see 4.2 DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166272361,Annotation of HCSC Label for tafamidis and TTR,False,False,[],False,"[{'id': 1452215362, 'date': '2023-08-24T15:59:59.693-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132804, 'title': 'Drugs@HCSC: Drug Product Tafamidis', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00062087.PDF', 'crossReferences': [{'id': 1451814563, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00062087.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00062087.PDF'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184562', 'name': 'tafamidis'}]","[{'objCls': 'Gene', 'id': 'PA37069', 'symbol': 'TTR', 'name': 'transthyretin'}]",HCSC,1451814680.0,"<p>Tafamidis is used to prevent <a href=""/gene/PA37069"">TTR</a> protein from breaking up and forming amyloid fibrils in the heart of patients with transthyretin amyloid cardiomyopathy (ATTR-CM).</p>
",1451814681.0,"<p>Excerpts from the Tafamidis (VYNDAMAX) product monograph:</p>
<blockquote class=""blockquote"">
<p>How does VYNDAMAX work?
VYNDAMAX is used to treat a disease called transthyretin amyloid cardiomyopathy (also known as ATTR-CM). In ATTR-CM, a protein called transthyretin (TTR) breaks up and may form fibrils called amyloid. Amyloid can build up between cells in your heart preventing your heart from working normally. This can cause heart-related symptoms and problems. VYNDAMAX is used to prevent the TTR protein from breaking up and slows the deposit of amyloid fibrils in the heart.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>VYNDAMAX (tafamidis) is indicated for:
the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis (ATTR-CM), wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Mechanism of Action
Tafamidis is a selective stabilizer of TTR. Tafamidis binds to TTR at the thyroxine binding sites, stabilizing the tetramer and slowing dissociation into monomers, the rate-limiting step in the amyloidogenic process.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Tafamidis_HCSC_2022_06_30.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Tafamidis_HCSC_2022_06_30.pdf"">Tafamidis product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166278561,Annotation of HCSC Label for sodium oxybate and ALDH5A1,True,False,[],False,"[{'id': 1452533202, 'date': '2024-07-21T23:34:59.167-07:00', 'description': 'Added Prescribing section, tags and label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161222, 'title': 'Drugs@HCSC: Drug Product Xyrem (sodium oxybate), Jazz Pharmaceuticals Ireland Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75367', 'crossReferences': [{'id': 1452533200, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75367', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75367'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA24702', 'symbol': 'ALDH5A1', 'name': 'aldehyde dehydrogenase 5 family member A1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166236501', 'name': 'sodium oxybate'}]","[{'objCls': 'Gene', 'id': 'PA24702', 'symbol': 'ALDH5A1', 'name': 'aldehyde dehydrogenase 5 family member A1'}]",HCSC,1451887740.0,"<p>Sodium oxybate is HCSC indicated for the treatment of cataplexy in patients with narcolepsy. It is contraindicated in patients with succinic semialdehyde dehydrogenase deficiency, a rare metabolic disorder caused by homozygous or compound heterozygous mutation in the ALDH5A1 gene <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/271980"" target=""_blank"">see OMIM:271980</a>.</p>
",1451887741.0,"<p>Excerpts from the Sodium Oxybate) (<em><strong>Xyrem</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>Xyrem is contraindicated in patients with succinic semialdehyde dehydrogenase deficiency. This
rare disorder is an inborn error of metabolism variably characterized by mental retardation,
hypotonia, and ataxia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Metabolism: Animal studies indicate that metabolism is the major elimination pathway for
sodium oxybate, producing carbon dioxide and water via the tricarboxylic acid (Krebs) cycle and
secondarily by beta-oxidation. The primary pathway involves a cytosolic NADP+-linked
enzyme, GHB dehydrogenase, that catalyses the conversion of sodium oxybate to succinic
semialdehyde, which is then biotransformed to succinic acid by the enzyme succinic
semialdehyde dehydrogenase.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""SodiumOxybate_HCSC_2022_09_20.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/SodiumOxybate_HCSC_2022_09_20.pdf""><em><strong>Sodium Oxybate</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452533201.0,"<p>Excerpt from the Sodium Oxybate) (<em><strong>Xyrem</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>Xyrem is contraindicated in patients with succinic semialdehyde dehydrogenase deficiency. This
rare disorder is an inborn error of metabolism variably characterized by mental retardation,
hypotonia, and ataxia.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166273302,Annotation of EMA Label for nivolumab and BRAF,False,True,[],False,"[{'id': 1452209440, 'date': '2023-08-17T17:21:14.100-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15133302, 'title': 'Nivolumab | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo', 'crossReferences': [{'id': 1451824800, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166157522', 'symbol': 'rs113488022', 'name': 'rs113488022'}]","[{'objCls': 'Chemical', 'id': 'PA166129522', 'name': 'nivolumab'}]","[{'objCls': 'Gene', 'id': 'PA25408', 'symbol': 'BRAF', 'name': 'B-Raf proto-oncogene, serine/threonine kinase'}]",EMA,1451824864.0,"<p>Nivolumab is EMA indicated for several types of cancers. The product information discusses trials that included BRAF mutation positive melanoma but testing is not discussed or required as part of the indication.</p>
",1451824865.0,"<p>Excerpts from the nivolumab (OPDIVO) EPAR:</p>
<blockquote class=""blockquote"">
<p>Efficacy by BRAF status: Objective responses to nivolumab (according to the definition of the
co-primary endpoint) were observed in patients with or without BRAF mutation-positive melanoma.
The ORRs in the BRAF mutation-positive subgroup were 17% (95% CI: 8.4, 29.0) for nivolumab and
11% (95% CI: 2.4, 29.2) for chemotherapy, and in the BRAF wild-type subgroup were
30% (95% CI: 24.0, 36.7) and 9% (95% CI: 4.6, 16.7), respectively.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Nivolumab_EMA_2022_07_13.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Nivolumab_EMA_2022_07_13.pdf"">nivolumab EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166281741,Annotation of HCSC Label for pitolisant and CYP2D6,False,False,[],True,"[{'id': 1452598682, 'date': '2024-09-19T13:57:36.676-07:00', 'description': 'updated label, added Pediatric tag and info, added Other Guidance tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15166002, 'title': 'Drugs@HCSC: Drug Product WAKIX (pitolisant), Endo Ventures Ltd.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100561', 'crossReferences': [{'id': 1452598680, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100561', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100561'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,True,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166185163', 'name': 'pitolisant'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1451926060.0,"<p>The HCSC product monograph for pitolisant recommends dose limitation and close monitoring for CYP2D6 poor metabolizers. It does not give testing information about which variants to test for.</p>
",1451926061.0,"<p>Excerpts from the pitolisant (WAKIX) product monograph:</p>
<blockquote class=""blockquote"">
<p>Greater exposures of pitolisant are expected in patients: [...]</p>
<ul>
<li>who are CYP2D6 poor metabolizers
[...]
Follow recommended dosage adjustments and monitor closely.</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Genetic Polymorphism: For patients who are poor CYP2D6 metabolizers, the total daily dose of WAKIX should not exceed 50% of the recommended maximum for the pertinent age / weight. Monitor these patients closely (see 10.3 Pharmacokinetics).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The extent of QTc prolongation with WAKIX is expected to be higher in patients who are poor metabolizers of CYP2D6 substrates and in patients with hepatic or renal impairment due to higher concentrations of pitolisant. Monitor CYP2D6 poor metabolizers and patients with hepatic or renal impairment for increased QTc. Dosage modification is recommended in CYP2D6 poor metabolizers [...]</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Genetic Polymorphism:</strong> Up to 10% of the population may be CYP2D6 poor metabolizers.
In a study comparing CYP2D6 poor metabolizers (n = 3) to CYP2D6 normal metabolizers (n = 5), Cmax and AUC0-24 of pitolisant after a single dose of WAKIX were 2.7-fold greater and 3.2-fold greater, respectively, in poor metabolizers than normal metabolizers. Following seven days of administration, Cmax and AUC0-24 were 2.1-fold greater and 2.4-fold greater, respectively, in poor metabolizers than normal metabolizers (see 4.2 Recommended Dose and Dosage Adjustment).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Pitolisant_2024_09_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Pitolisant_2024_09_19_HCSC.pdf"">pitolisant product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452598681.0,"<blockquote class=""blockquote"">
<p><strong>Pediatrics (≥ 6 years of age):</strong> Based on the data submitted and reviewed by Health Canada, the safety and efficacy of WAKIX in pediatric patients (6 years of age and older) has been established. Therefore, Health Canada has authorized an indication for pediatric use in patients 6 years of age and older, and weighing at least 30 kg (see 4.2 Recommended Dose and Dosage Adjustment; 7.1.3 Pediatrics).</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451926062.0,"<blockquote class=""blockquote"">
<p>Genetic Polymorphism: For patients who are poor CYP2D6 metabolizers, the total daily dose of WAKIX should not exceed 50% of the recommended maximum for the pertinent age / weight. Monitor these patients closely (see 10.3 Pharmacokinetics).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166273481,Annotation of EMA Label for isatuximab and CD38,False,True,[],False,"[{'id': 1452210001, 'date': '2023-08-18T11:58:35.674-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15133482, 'title': 'Isatuximab | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa', 'crossReferences': [{'id': 1451827220, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166224941', 'name': 'isatuximab'}]","[{'objCls': 'Gene', 'id': 'PA26214', 'symbol': 'CD38', 'name': 'CD38 molecule'}]",EMA,1451827280.0,"<p>Isatuximab is a monoclonal antibody, directed at <a href=""/gene/PA26214"">CD38</a>, and EMA indicated for treatment of multiple myeloma. The FDA table lists various chromosomal abnormalities (del(17p), t(4;14) and t(14;16)) that were observed during the clinical trials for isatuximab, these are also listed in the EMA product information however no alternative dosing or recommended action occurred.</p>
",1451827281.0,"<p>Excerpts from the <em><strong>Isatuximab</strong></em> (<em><strong>SARCLISA</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>Isatuximab is an IgG1-derived monoclonal antibody that binds to a specific extracellular epitope of
CD38 receptor. CD38 is a transmembrane glycoprotein that is highly expressed on multiple myeloma
cells.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Overall, 19.5% of patients (15.6% in the isatuximab arm and 23.5% in the comparator arm) had high-risk
chromosomal abnormalities at study entry; del(17p), t(4;14) and t(14;16) were present in 12.1%
(9.1% in the isatuximab arm and 15.0% in the comparator arm), 8.5% (7.8% in the isatuximab arm
and 9.2% in the comparator arm) and 1.6% (0.6% in the isatuximab arm and 2.6% in the comparator
arm) of patients, respectively.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Isatuximab_EMA_2022_07_18.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Isatuximab_EMA_2022_07_18.pdf""><em><strong>Isatuximab</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166284001,Annotation of EMA Label for enfortumab vedotin and NECTIN4,False,True,[],False,"[{'id': 1452209220, 'date': '2023-08-17T14:00:42.194-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}, {'id': 1452304941, 'date': '2023-11-21T00:00:00-08:00', 'description': 'Attached source information.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15151002, 'title': 'Padcev | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/padcev', 'crossReferences': [{'id': 1452304940, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/padcev', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/padcev'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166190121', 'name': 'enfortumab vedotin'}]","[{'objCls': 'Gene', 'id': 'PA134991624', 'symbol': 'NECTIN4', 'name': 'nectin cell adhesion molecule 4'}]",EMA,1451952160.0,"<p>Enfortumab vedotin is EMA indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor. Enfortumab vedotin is an antibody drug conjugate (ADC) targeting Nectin-4, an adhesion protein located on the surface of the urothelial cancer cells.</p>
",1451952161.0,"<p>Excerpts from the Enfortumab vedotin (<em><strong>Padcev</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>Enfortumab vedotin is an antibody drug conjugate (ADC) targeting Nectin-4, an adhesion protein located on the surface of the urothelial cancer cells.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Skin reactions are associated with enfortumab vedotin as a result of enfortumab vedotin binding to Nectin-4 expressed in the skin.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Nonclinical data suggest that the anticancer activity of enfortumab vedotin is due to the binding of the ADC to Nectin-4-expressing cells, followed by internalisation of the ADC-Nectin-4 complex, and the release of MMAE via proteolytic cleavage. Release of MMAE disrupts the microtubule network within the cell, subsequently inducing cell cycle arrest and apoptotic cell death. MMAE released from enfortumab vedotin targeted cells can diffuse into nearby Nectin-4 low-expressing cells resulting in cytotoxic cell death.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""EnfortumabVedotin_EMA_2022_11_29.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/EnfortumabVedotin_EMA_2022_11_29.pdf""><em><strong>Enfortumab vedotin</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166284021,Annotation of HCSC Label for enfortumab vedotin and NECTIN4,False,True,[],False,"[{'id': 1452209241, 'date': '2023-08-17T14:11:40.020-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}, {'id': 1452782481, 'date': '2024-12-12T17:40:24.857-08:00', 'description': 'added label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171962, 'title': 'Drugs@HCSC: Drug Product PADCEV (enfortumab vedotin), Seagen Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101108', 'crossReferences': [{'id': 1452782480, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101108', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101108'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166190121', 'name': 'enfortumab vedotin'}]","[{'objCls': 'Gene', 'id': 'PA134991624', 'symbol': 'NECTIN4', 'name': 'nectin cell adhesion molecule 4'}]",HCSC,1451952200.0,"<p>Enfortumab vedotin is an antibody-drug conjugate directed against Nectin-4, an adhesion protein located on the surface of
most urothelial cancer cells. PADCEV (enfortumab vedotin for injection) is HCSC indicated for the treatment of adult patients with
unresectable locally advanced or metastatic urothelial cancer (mUC) who have previously received a
platinum-containing chemotherapy and programmed death receptor-1 (PD-1) or programmed deathligand
1 (PD-L1) inhibitor therapy.</p>
",1451952201.0,"<p>Excerpts from the Enfortumab vedotin (<em><strong>PADCEV</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>Enfortumab vedotin is an ADC directed against Nectin-4, an adhesion protein located on the surface of
most urothelial cancer cells. It is comprised of a fully human IgG1-kappa antibody conjugated to the
microtubule-disrupting agent, MMAE, via a protease-cleavable linker. Nonclinical data suggest that the
anticancer activity of enfortumab vedotin is due to the binding of the ADC to Nectin-4-expressing cells,
followed by internalization of the ADC-Nectin-4 complex, and the release of MMAE via proteolytic
cleavage. Release of MMAE disrupts the microtubule network within the cell, subsequently inducing
cell cycle arrest and apoptotic cell death.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Skin reactions are anticipated on-target events, as Nectin-4 is expressed in the skin.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""enfortumabVedotin_HCSC_2022_11_30.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/enfortumabVedotin_HCSC_2022_11_30.pdf""><em><strong>Enfortumab vedotin</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166284261,Annotation of HCSC Label for fosphenytoin and CYP2C9,False,False,[],False,"[{'id': 1452721940, 'date': '2024-12-02T14:26:03.210-08:00', 'description': 'added label document, changed PGx level to Informative', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15163882, 'title': 'Drugs@HCSC: Drug Product CEREBYX (fosphenytoin), Searchlight Pharma Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00067688.PDF', 'crossReferences': [{'id': 1452556420, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00067688.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00067688.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164746820', 'name': 'fosphenytoin'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",HCSC,1451953220.0,"<p>The fosphenytoin HCSC product monograph discusses CYP2C9 and its role in metabolism but does not have information on variants or metabolizer phenotypes.</p>
",1451953221.0,"<p>Excerpts from the Fosphenytoin (<em><strong>CEREBYX</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>CYP2C9 plays the major role in the metabolism of phenytoin</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Fosphenytoin_HCSC_2022_11_30.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Fosphenytoin_HCSC_2022_11_30.pdf""><em><strong>Fosphenytoin</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166278202,"Annotation of EMA Label for azacitidine and KRAS, NRAS, PTPN11",False,True,[],False,"[{'id': 1452206103, 'date': '2023-08-14T09:35:17.652-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15135482, 'title': 'Azacitidine (Vidaza)| European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vidaza', 'crossReferences': [{'id': 1451876925, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vidaza', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vidaza'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451996', 'name': 'azacitidine'}]","[{'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA33986', 'symbol': 'PTPN11', 'name': 'protein tyrosine phosphatase non-receptor type 11'}]",EMA,1451876922.0,"<p>The EPAR for azacitidine includes mention of the genes PTPN11, NRAS, and KRAS when discussing the clinical studies of Juvenile Myelomonocytic Leukemia but not CBL, which is listed in the FDA table.</p>
",1451876923.0,"<p>Excerpts from the Azacitidine (<em><strong>Vidaza</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>In the JMML study arm, 18 patients (13 PTPN11, 3 NRAS, 1 KRAS somatic mutations and 1 clinical diagnosis of neurofibromatosis type 1 NF-1) were enrolled.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Azacitidine_EMA_2022_09_06.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Azacitidine_EMA_2022_09_06.pdf""><em><strong>Azacitidine</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166229921,Annotation of HCSC Label for amifampridine and NAT2,False,False,[],True,[],False,[],True,"[{'id': 15116502, 'title': 'Drugs@HCSC: Drug Product RUZURGI (amifampridine), Médunik Canada', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99254', 'crossReferences': [{'id': 1451338900, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99254', '_url': 'https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99254'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166185150', 'name': 'amifampridine'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",HCSC,1451338928.0,"<p>The product monograph for amifampridine (RUZURGI) states that exposure is increased in patients who are N-acetyltransferase (NAT2) slow acetylators and that it should be initiated at the lowest recommended starting dose possible and patients should be monitored for adverse reactions. Information is not given on what genetic variants to test.</p>
",1451338929.0,"<p>RUZURGI (amifampridine) is indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older.</p>
<p>Excerpts from the amifampridine (RUZURGI) drug label:</p>
<blockquote class=""blockquote"">
<p>Metabolism: Amifampridine is primarily metabolized by N-acetyltransferase 2 (NAT2) to the inactive 3-N-acetyl amifampridine metabolite (3-AC). Metabolism of amifampridine by N-acetyltransferase1 (NAT1) can also occur but at a slower rate. Amifampridine is not metabolized by any of the cytochrome P450 family of enzymes.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genetic Polymorphism: Genetic variants in the N-acetyltransferase gene 2 (NAT2) affect the rate and extent of amifampridine metabolism. In healthy subjects, “slow acetylators” (i.e., carriers of two slow function alleles) had higher average plasma amifampridine concentrations than “intermediate acetylators” (i.e., carriers of one slow and one rapid function allele), and “rapid acetylators” (i.e., carriers of two rapid function alleles).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Subjects classified as slow acetylators based on genotyping for variants of the N-acetyltransferase 2 (NAT2) gene were more likely to experience adverse reactions during RUZURGI treatment than intermediate or rapid acetylators</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The effects of RUZURGI have not been studied under controlled conditions in patients or volunteers with any degree of hepatic impairment. Since RUZURGI is extensively metabolized/acetylated by N-acetyltransferase 2 (NAT2), hepatic impairment can cause an increase in exposure. Therefore, initiate RUZURGI in patients with mild and moderate hepatic impairment using the lowest recommended initial single and total daily doses. Additional caution and monitoring of adverse reactions is recommended for patients with severe hepatic impairment</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""amifampridine_03_24_21_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/amifampridine_03_24_21_HCSC.pdf"">amifampridine product monograph.</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451338930.0,"<p>Excerpts from the amifampridine (RUZURGI) drug label:</p>
<blockquote class=""blockquote"">
<p>RUZURGI is extensively metabolized/acetylated by N-acetyltransferase 2 (NAT2). Therefore, RUZURGI should be initiated at the lowest recommended starting dose possible in patients who are known NAT2 slow acetylators.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The recommended starting dosage in patients weighing less than 45 kg who are known NAT2 slow acetylators is 5 mg daily taken orally in divided doses, 2 to 3 times per day. The recommended starting dose of RUZURGI in patients weighing 45 kg or more who are known NAT2 slow acetylators is 10 mg daily taken orally in divided doses (2 to 3 times per day).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Exposure of RUZURGI is increased in patients who are N-acetyltransferase (NAT2) slow acetylators. Therefore, initiate RUZURGI in patients who are known NAT2 slow acetylators at the lowest recommended starting dose and monitor for adverse reactions. Dose titration should be based on clinical response and tolerability.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166273462,Annotation of EMA Label for lenvatinib,False,True,[],False,"[{'id': 1452210160, 'date': '2023-08-18T14:57:26.412-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15133462, 'title': 'Lenvatinib (kisplyx) | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx', 'crossReferences': [{'id': 1451827180, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15133442, 'title': 'Lenvatinib (lenvima) | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima', 'crossReferences': [{'id': 1451827200, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166153472', 'name': 'lenvatinib'}]",[],EMA,1451827203.0,"<p>The EMA product information for lenvatinib for renal cell carcinoma (Kisplyx) or thyroid cancer (Lenvima) does not have information about microsatelite or mismatch repair that is in the FDA label for lenvatinib or listed in the FDA biomarker table.</p>
",1451827204.0,"<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Lenvatinib_Kisplyx_EMA_2022_07_18.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lenvatinib_Kisplyx_EMA_2022_07_18.pdf""><em><strong>Lenvatinib Kisplyx</strong></em> EPAR PDF</a> or the <a download=""Lenvatinib_Lenvima_EMA_2022_07_18.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lenvatinib_Lenvima_EMA_2022_07_18.pdf""><em><strong>Lenvatinib Lenvima</strong></em> EPAR PDF</a> or the</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166184172,Annotation of Swissmedic Label for Opium derivatives and expectorants and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103061, 'title': 'Swissmedic label for Opium-Derivate und Expektoranzien (Codicalm Sirup)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=60540', 'crossReferences': [{'id': 1450812022, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=60540', '_url': 'https://amiko.oddb.org/de/fi?gtin=60540'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164712951', 'name': 'Opium derivatives and expectorants'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450814006.0,"<p>The Swiss label for opium derivatives und expectorants (Codicalm Sirup) states that codeine metabolism is mediated by CYP2D6 and CYP2D6 &quot;ultra-fast metabolizers&quot; may show symptoms of overdose, such as dizziness, deep sedation, shortness of breath, nausea and vomiting, to respiratory and cardiac arrest.</p>
",1450814007.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for opium derivatives und expectorants (Codicalm Sirup):</p>
<blockquote class=""blockquote"">
<p>Contraindications:
Codeine is converted into its active metabolite morphine by the hepatic isozymes CYP2D6, some of which are genetic polymorphisms. Patients with an &quot;ultra-fast CYP2D6 metaboliser&quot; phenotype have a high CYP2D6 activity, so that toxic serum levels of morphine can develop even at low doses. These &quot;ultra-fast metabolizers&quot; can show symptoms of overdose, such as dizziness, deep sedation, shortness of breath, nausea and vomiting, to respiratory and cardiac arrest.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Precautionary measures:
Due to the genetic variability of CYP2D6, even therapeutic doses of codeine can lead to increased production of the active metabolite morphine with the clinical signs of morphine poisoning (see &quot;Overdose&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Kinetics of Special Patient Groups:
Due to their genetic variation, about 7% of the Caucasian population have no functioning CYP2D6 enzyme and are referred to as slow metabolizers. In these individuals, the effect of codeine may be less pronounced due to the lack of formation of morphine.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In contrast, ultrafast metabolizers have one or more duplications of their CYP2D6-encoding genes and therefore a significantly increased CYP2D6 activity. In these individuals, the plasma concentrations of morphine can be increased and thus also the risk of morphine-induced side effects. This should be considered in particular if the patient also has impaired renal function, which may lead to an increased concentration of the active metabolite morphine-6-glucuronide. It has been estimated that about 1-5.5% of the Caucasian population are ultrafast metabolizers. The prevalence of polymorphism encoding ultrafast metabolic capacity may be higher in the African and Mediterranean populations.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=60540&amp;highlight=genetische"" target=""_blank"">opium derivatives und expectorants drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184112,"Annotation of Swissmedic Label for azathioprine and NUDT15, TPMT",False,False,[],True,[],False,[],True,"[{'id': 15103153, 'title': 'Swissmedic label for azathioprine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=31887', 'crossReferences': [{'id': 1450813249, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=31887', '_url': 'https://amiko.oddb.org/de/fi?gtin=31887'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448515', 'name': 'azathioprine'}]","[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",Swissmedic,1450813605.0,"<p>The Swiss drug label for azathioprine (Imurek) states that a dose reduction is generally required for patients carrying NUDT15 variants and notes that patients with TPMT deficiency are sensitive to the myelosuppressive effect of azathioprine.</p>
",1450813606.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for azathioprine (Imurek):</p>
<blockquote class=""blockquote"">
<p>Dosage/Usage:
Patients with the NU:DT15 variant: Patients with congenital mutant NUDT15 gene have an increased risk of severe azathioprine toxicity. These patients generally require a dose reduction, especially in patients who carry a homozygous NUDT15 variant. Close monitoring of blood values is required in all cases (see &quot;Warnings and Precautions&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Precautionary Measures:
&quot;There are patients with a congenital deficiency of the enzyme thiopurine methyltransferase (TPMT) who are unusually sensitive to the myelosuppressive effect of azathioprine. These tend to develop rapid myelosuppression after treatment with Imurek. This side effect may also occur with simultaneous administration of a drug that inhibits TPMT (such as olsalazine, mesalazine or sulfasalazine) (see &quot;&quot;Interactions&quot;&quot;). Although some laboratories offer tests to determine TPMT activity, no evidence has been provided that these tests can detect all patients at risk of severe toxicity. Therefore, close monitoring of blood levels continues to be necessary.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with the NUDT15 variant: Patients with congenital mutant NUDT15 gene have an increased risk of severe azathioprine toxicity such as early leukopenia and alopecia at conventional doses of thiopurine therapy. In these patients, dose reduction is generally required, especially in patients who are homozygous carriers of the NUDT15 variant (see &quot;&quot;Dosage and use&quot;&quot;). The incidence of NUDT15 c.415C&gt;T is subject to ethnic variability of approximately 10 % in East Asians, 4 % in Hispanic populations, 0.2 % in Europeans and 0 % in Africans. Close monitoring of blood values is required in all cases.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=31887&amp;highlight=Genotypisierung"" target=""_blank"">azathioprine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813607.0,"<blockquote class=""blockquote"">
<p>Patients with the NUDT15 variant: Patients with congenital mutant NUDT15 gene have an increased risk of severe azathioprine toxicity. These patients generally require a dose reduction, especially in patients who carry a homozygous NUDT15 variant.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184125,Annotation of Swissmedic Label for clopidogrel and CYP2C19,False,False,[],True,"[{'id': 1450826893, 'date': '2019-11-05T09:29:51.147-08:00', 'description': 'Added CYP2C19*4 to annotation', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103167, 'title': 'Swissmedic label for clopidogrel', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=54509', 'crossReferences': [{'id': 1450813274, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=54509', '_url': 'https://amiko.oddb.org/de/fi?gtin=54509'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]","[{'objCls': 'Haplotype', 'id': 'PA165980634', 'symbol': 'CYP2C19*1', 'name': '*1'}, {'objCls': 'Haplotype', 'id': 'PA165980635', 'symbol': 'CYP2C19*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165980636', 'symbol': 'CYP2C19*3', 'name': '*3'}, {'objCls': 'Haplotype', 'id': 'PA165980637', 'symbol': 'CYP2C19*4', 'name': '*4'}, {'objCls': 'Haplotype', 'id': 'PA165980638', 'symbol': 'CYP2C19*5', 'name': '*5'}, {'objCls': 'Haplotype', 'id': 'PA165816522', 'symbol': 'CYP2C19*6', 'name': '*6'}, {'objCls': 'Haplotype', 'id': 'PA165816523', 'symbol': 'CYP2C19*7', 'name': '*7'}, {'objCls': 'Haplotype', 'id': 'PA165816524', 'symbol': 'CYP2C19*8', 'name': '*8'}]","[{'objCls': 'Chemical', 'id': 'PA449053', 'name': 'clopidogrel'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",Swissmedic,1450813685.0,"<p>The Swiss drug label for clopidogrel (Plavix) states that clopidogrel has a reduced efficacy in CYP2C19 &quot;slow metatoblizers&quot; and a dose increase should be considered for these patients.</p>
",1450813686.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for clopidogrel (Plavix):</p>
<blockquote class=""blockquote"">
<p>Precautionary Measures:
Patients with a genetic reduction of CYP2C19 (Poor Metaboliser) produce 70% less active metabolite than patients with normal CYP2C19 function. They also show reduced inhibition of platelet aggregation and an increased incidence of cardiovascular events, including myocardial infarction and stent thrombosis. Pharmacogenetic studies can identify genotypes associated with variability in CYP2C19 activity. These studies can help to determine the treatment strategy. The use of higher doses of clopidogrel in slow metabolizers should be considered (see &quot;Dosage/Application: Pharmacogenetics&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dosage/Usage:
Pharmacogenetics: The weak metabolism by CYP2C19 is associated with a reduced antiplatelet effect of clopidogrel. A higher dosage (initial dose 600 mg, followed by 150 mg/day) in slow metabolisers increases the antiplatelet effect. The use of higher doses of clopidogrel in slow metabolisers should be considered. An appropriate dose for this patient population has not yet been determined in clinical outcome studies.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Kinetics:
Pharmacogenetics: CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo clopidogrel intermediate. The pharmacokinetics of the active metabolite and the antiplatelet effect (measured with ex vivo platelet aggregation assays) differ depending on the CYP2C19 genotype. The CYP2C19*1 allele corresponds to fully functional metabolism, while the CYP2C19*2 and CYP2C19*3 alleles correspond to nonfunctional metabolism. The CYP2C19*2 and CYP2C19*3 alleles make up the majority of alleles with reduced function in Caucasian (85%) and Asian (99%) slow metabolizers. Other alleles associated with absent or decreased metabolism are less common and affect in particular CYP2C19*4, *5, *6, *7, and *8. A patient with slow metaboliser status carries two loss-of-function alleles as defined above. The published frequencies for the slow CYP2C19 metaboliser genotype are about 2% for Caucasians, 4% for blacks, and 14% for Chinese.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacogenetic studies are available to determine the CYP2C19 genotype of patients.
Properties and effects:
As the active metabolite is formed by CYP450 enzymes (some of which are subject to genetic polymorphism or may be inhibited by other drugs), not all patients will have sufficient platelet aggregation inhibition (see &quot;Interactions&quot;; &quot;Warnings and Precautions&quot;): Pharmacogenetics&quot;).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=54509&amp;highlight=Pharmakogenetik"" target=""_blank"">clopidogrel drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813687.0,"<blockquote class=""blockquote"">
<p>The weak metabolism by CYP2C19 is associated with a reduced antiplatelet effect of clopidogrel. A higher dosage (initial dose 600 mg, followed by 150 mg/day) in slow metabolisers increases the antiplatelet effect. The use of higher doses of clopidogrel in slow metabolisers should be considered. An appropriate dose for this patient population has not yet been determined in clinical outcome studies.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166182952,Annotation of EMA Label for irinotecan and UGT1A1,False,False,[],True,"[{'id': 1452016860, 'date': '2023-02-22T21:56:11.477-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452489342, 'date': '2024-05-31T15:34:25.952-07:00', 'description': 'added Dosing Info tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102953, 'title': 'Onivyde | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde', 'crossReferences': [{'id': 1450417116, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]","[{'objCls': 'Haplotype', 'id': 'PA166115842', 'symbol': 'UGT1A1*28', 'name': '*28'}]","[{'objCls': 'Chemical', 'id': 'PA450085', 'name': 'irinotecan'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",EMA,1450417113.0,"<p>The EMA European Public Assessment Report (EPAR) for irinotecan (ONIVYDE) states that a reduced starting dose of 50 mg/m2 should be considered for patients with the UGT1A1*28/*28 genotype, with a dose increase to 70 mg/m2 if tolerated in subsequent cycles. Individuals with the UGT1A1*28/*28 genotype are at increased risk for neutropenia.</p>
",1450417114.0,"<p>Excerpts from the irinotecan (ONIVYDE) EPAR:</p>
<div class=""blockquote"">
<p>A reduced starting dose of ONIVYDE (liposomal irinotecan) of 50 mg/m2 should be considered for patients known to be homozygous for the UGT1A1*28 allele...A dose increase of ONIVYDE to 70 mg/m2 should be considered if tolerated in subsequent cycles.</p>
</div>
<div class=""blockquote"">
<p>Individuals who are 7/7 homozygous for the UGT1A1*28 allele are at increased risk for neutropenia from non-liposomal irinotecan. In the clinical study evaluating ONIVYDE+5-FU/LV, the frequency of = Grade 3 neutropenia in these patients (2 of 7 (28.6%)) was similar to the frequency in patients not homozygous for the UGT1A1*28 allele who received a starting dose of ONIVYDE of 70 mg/m2 (30 of 110 (27.3%))...</p>
</div>
<div class=""blockquote"">
<p>UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1*28 polymorphism. In the population pharmacokinetic analysis in patients with ONIVYDE using the results of a subset with UGT1A1*28 genotypic testing, in which the analysis adjusted for the lower dose administered to patients homozygous for the UGT1A1*28 allele, patients homozygous (N=14) and non-homozygous (N=244) for this allele had total SN-38 average steady-state concentrations of 1.06 and 0.95 ng/ml, respectively.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Irinotecan_06_21_19_EMA.pdf"">irinotecan EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450417115.0,"<p>&quot;A reduced starting dose of ONIVYDE (liposomal irinotecan) of 50 mg/m2 should be considered for patients known to be homozygous for the UGT1A1*28 allele...A dose increase of ONIVYDE to 70 mg/m2 should be considered if tolerated in subsequent cycles.&quot;</p>
",,,,,,,
Label Annotation,PA166182925,Annotation of EMA Label for amifampridine phosphate and NAT2,False,False,[],False,[],False,[],True,"[{'id': 15102949, 'title': 'Firdapse (previously Zenas) | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse-previously-zenas', 'crossReferences': [{'id': 1450416861, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse-previously-zenas', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse-previously-zenas'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182002', 'name': 'amifampridine phosphate'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",EMA,1450416691.0,"<p>The EMA European Public Assessment Report (EPAR) for amifampridine (FIRDAPSE) states that exposure to the drug is influenced by the acetylation activity of NAT enzymes and the NAT2 genotype, and that slow acetylators experienced more adverse reactions as compared to fast acetylators.</p>
",1450416692.0,"<p>Excerpts from the amifampridine (FIRDAPSE) EPAR:</p>
<div class=""blockquote"">
<p>The pharmacokinetics and systemic exposure to amifampridine is notably influenced by the overall metabolic acetylation activity of the polymorphic N-acetyl-transferase (NAT) enzymes (acetylator phenotype) and NAT2 genotype, which is subject to genetic variation...as shown in the healthy volunteer study. In this study, slow acetylators experienced more adverse reactions than the fast acetylators. The safety profile in this study is consistent with adverse reactions observed with patients on FIRDAPSE.</p>
</div>
<div class=""blockquote"">
<p>In a study of healthy volunteers, systemic exposure of amifampridine was notably influenced by the overall metabolic acetylation activity of NAT enzymes and NAT2 genotype. The NAT genes are highly polymorphic and result in phenotypes with variable acetylation activity rates ranging from slow to fast...Statistically significant differences in amifampridine PK parameters...was observed between fast and slow acetylators at all dose levels.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Amifampridine_06_18_19_EMA.pdf"">amifampridine EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,1451832060.0,Retirement Reason,[],Other,retirement:1451832060,True,
Label Annotation,PA166183181,Annotation of EMA Label for lesinurad and CYP2C9,False,False,[],False,"[{'id': 1452556480, 'date': '2024-08-14T15:57:35.632-07:00', 'description': 'added Other Guidance tag', 'type': 'Update', 'version': 0}, {'id': 1452694340, 'date': '2024-11-08T11:54:36.770-08:00', 'description': 'add notice of withdrawal of marketing authorization', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102956, 'title': 'Zurampic | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic', 'crossReferences': [{'id': 1450604481, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic'}], 'notes': 'Marketing authorization withdrawn on January 31, 2020.', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]","[{'objCls': 'Haplotype', 'id': 'PA165816542', 'symbol': 'CYP2C9*1', 'name': '*1'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA166160006', 'name': 'lesinurad'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",EMA,1450604477.0,"<p>The EMA European Public Assessment Report (EPAR) for lesinurad (Zurampic) states that patients who are known CYP2C9 poor metabolizers should be treated with caution due to an increased risk for renal-related adverse effects.</p>
<p><strong>Note: The marketing authorization for lesinurad (Zurampic) in the European Union was withdrawn on July 31, 2020.</strong></p>
",1450604478.0,"<p>Excerpts from the lesinurad (Zurampic) EPAR:</p>
<blockquote class=""blockquote"">
<p>Patients known to be CYP2C9 poor metabolisers should be treated with caution, as the potential risk of renal-related adverse effects may be increased...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Approximately half of an oral dose of lesinurad is cleared via CYP2C9 metabolism. The effect of CYP2C9 genotype on the pharmacokinetics of lesinurad was studied in 8 healthy subjects and 59 patients with gout following daily dosing of lesinurad ranging from 200 mg to 600 mg in the absence or presence of a xanthine oxidase inhibitor. At the 400 mg dose, when compared with extensive CYP2C9 metabolisers (CYP2C9 *1/*1 (N=41)), increased lesinurad exposures were observed in intermediate CYP2C9 metabolisers (CYP2C9 *1/*3 (N=4), approximately 22% increase in AUC) and in poor CYP2C9 metabolisers (CYP2C9 *3/*3 (N=1), approximately 111% increase in AUC) accompanied with higher lesinurad renal excretion. However, individual values were well within the range observed in the extensive metaboliser subjects.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Lesinurad_06_25_19_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lesinurad_06_25_19_EMA.pdf"">lesinurad EPAR PDF</a></p>
<p><strong>Note: On July 31, 2020, the European Commission issued a notification that the marketing authorization for lesinurad (Zurampic) in the European Union had been withdrawn. The withdrawal was at the request of the marketing authorisation holder, Grunenthal GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450604480.0,"<p>&quot;Patients known to be CYP2C9 poor metabolisers should be treated with caution, as the potential risk of renal-related adverse effects may be increased...&quot;</p>
",,,,,,,
Label Annotation,PA166184121,Annotation of Swissmedic Label for chloroquine and G6PD,True,False,[],False,"[{'id': 1452021820, 'date': '2023-02-28T13:07:59.801-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103163, 'title': 'Swissmedic label for chloroquine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=18889&highlight', 'crossReferences': [{'id': 1450813270, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=18889&highlight', '_url': 'https://amiko.oddb.org/de/fi?gtin=18889&highlight'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448948', 'name': 'chloroquine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450813654.0,"<p>The Swiss drug label for chloroquine (Nivaquine) states that chloroquine is contraindicated in patients with G6PD deficiency.</p>
",1450813655.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<blockquote class=""blockquote"">
<p>Contraindications:
Hypersensitivity to 4-aminoquinolines; glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) (symptoms: haemolytic anaemia, favism); diseases of the haematopoietic organs, central nervous system; pre-existing retinopathies; myasthenia gravis.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Undesired Effects:
Frequency not known: In patients with G6PD deficiency, cases of haemolytic anaemia have been observed in combination with other drugs that may potentially lead to haemolysis (see paragraph &quot;Contraindications&quot;).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=18889&amp;highlight=G6PD-Mangel"" target=""_blank"">chloroquine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813656.0,"<blockquote class=""blockquote"">
<p>Contraindications... glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) (symptoms: haemolytic anaemia, favism)</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184429,Annotation of Swissmedic Label for ezetimibe / simvastatin and SLCO1B1,False,False,[],True,"[{'id': 1452021847, 'date': '2023-02-28T13:10:57.662-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103091, 'title': 'Swissmedic label for Simvastatin und Ezetimib', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=56953', 'crossReferences': [{'id': 1450812052, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=56953', '_url': 'https://amiko.oddb.org/de/fi?gtin=56953'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]","[{'objCls': 'Variant', 'id': 'PA166154579', 'symbol': 'rs4149056', 'name': 'rs4149056'}]","[{'objCls': 'Chemical', 'id': 'PA166184495', 'name': 'ezetimibe / simvastatin'}]","[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",Swissmedic,1450815594.0,"<p>The Swiss drug label for ezetimibe/simvastatin (Inegy) states that patients with SLCO1B1 c.521T&gt;C polymorphism are at risk of increased exposure to simvastatin acid, which may lead to an increased risk of rhabdomyolysis.  &quot;Genotyping for the presence of the C allele should be considered as part of the benefit-risk assessment in individual patients before prescribing simvastatin 80 mg, and high doses should be avoided in identified carriers of the CC genotype.&quot;</p>
",1450815595.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the simvastatin (Inegy) label:</p>
<blockquote class=""blockquote"">
<p>Precautions:
Reduced function of transport proteins:
The decreased function of the hepatic OATP transport protein may increase the systemic exposure to simvastatin acid, as well as the risk for myopathy and rhabdomyolysis. Decreased function may result from inhibition by interacting drugs (e.g., ciclosporin) or may occur in patients carrying the SLCO1B1 c.521T&gt;C genotype.
Patients carrying the allele c.521T&gt;C of the SLCO1B1 gene encoding a less active OATP1B1 protein have increased systemic exposure to simvastatin acid and increased risk of myopathy. The risk of myopathy caused by high-dose simvastatin (80 mg) is generally 1% without genetic testing. Based on the results of the SEARCH study, carriers of the homozygous C allele (also called CC) treated with 80 mg have a 15% risk of myopathy within one year, while carriers of the heterozygous C allele (CT) have a 1.5% risk. Patients with the most common genotype (TT) have a risk of 0.3% (see &quot;Pharmacokinetics&quot;). Where available, genotyping for the presence of the C allele should be considered as part of the benefit-risk assessment in individual patients before prescribing simvastatin 80 mg, and high doses should be avoided in identified carriers of the CC genotype. However, the absence of this gene in genotyping does not exclude the possibility of myopathy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
race: ezetimibe
The meta-analysis of the pharmacokinetic studies showed no pharmacokinetic differences between blacks and Caucasians.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>SLCO1B1 Polymorphism: simvastatin:
Carriers of the c.521T&gt;C allele of the SLCO1B1 gene have a lower OATP1B1 activity. The average bioavailability (AUC) of the most important active metabolite, simvastatinic acid, is 120% for heterozygous carriers (CT) of the C allele and 221% for homozygous carriers (CC), relative to those of patients with the most common genotype (TT). The C allele has a frequency of 18% in the European population. Patients with SLCO1B1 polymorphism are at risk of increased exposure to simvastatin acid, which may lead to an increased risk of rhabdomyolysis (see &quot;Warnings and Precautions&quot;, Myopathy/Rhabdomyolysis).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=49742&amp;highlight=Allel"" target=""_blank"">zocor drug label</a> (in German); <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=56953&amp;highlight=genotypischer"" target=""_blank"">Inegy drug label</a> (in German)</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1450815596.0,"<blockquote class=""blockquote"">
<p>Where available, genotyping for the presence of the C allele should be considered as part of the benefit-risk assessment in individual patients before prescribing simvastatin 80 mg, and high doses should be avoided in identified carriers of the CC genotype. However, the absence of this gene in genotyping does not exclude the possibility of myopathy.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184502,Annotation of Swissmedic Label for lamivudine / abacavir and HLA-B,False,False,[],False,"[{'id': 1451178088, 'date': '2020-06-18T11:02:32.870-07:00', 'description': 'Fixed format of block quotes in prescribing.', 'type': 'Update', 'version': 0}, {'id': 1452021980, 'date': '2023-02-28T14:30:55.048-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103242, 'title': 'Swissmedic label for lamivudine and abacavir (Kivexa)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=56977', 'crossReferences': [{'id': 1450815333, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=56977', '_url': 'https://amiko.oddb.org/de/fi?gtin=56977'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165987830', 'symbol': 'HLA-B*57:01', 'name': '*57:01'}]","[{'objCls': 'Chemical', 'id': 'PA166184501', 'name': 'lamivudine / abacavir'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",Swissmedic,1450820446.0,"<p>The Swiss drug label for lamivudine / abacavir (Kivexa) states that patients should be screened for the presence of HLA-B*57:01 prior to starting treatment with abacavir. Kivexa is contraindicated in carriers of the HLA-B*57:01 allele.</p>
",1450820447.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for lamivudine / abacavir (Kivexa):</p>
<blockquote class=""blockquote"">
<p>Precautions:
Before initiating treatment with abacavir, HLA-B*5701 status should be determined if possible, and before resuming treatment with abacavir in patients with unknown HLA-B*5701 status who have previously tolerated abacavir.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Kivexa is contraindicated in HLA-B*5701 allele carriers or in patients who had suspected Abacavir HSR after treatment with another abacavir-containing drug (e.g. Ziagen, Trizivir, Triumeq), regardless of HLA-B*5701 status.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=56977&amp;highlight=HLA-B*5701-Allel"" target=""_blank"">lamivudine / abacavir drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450820448.0,"<blockquote class=""blockquote"">
<p>Before initiating treatment with abacavir, HLA-B*5701 status should be determined if possible, and before resuming treatment with abacavir in patients with unknown HLA-B*5701 status who have previously tolerated abacavir.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Kivexa is contraindicated in HLA-B*5701 allele carriers or in patients who had suspected Abacavir HSR after treatment with another abacavir-containing drug (e.g. Ziagen, Trizivir, Triumeq), regardless of HLA-B*5701 status.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184113,Annotation of Swissmedic Label for bisoprolol fumarate / perindopril arginine and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103154, 'title': 'Swissmedic label for bisoprolol fumarate / perindopril arginine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65904', 'crossReferences': [{'id': 1450813250, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65904', '_url': 'https://amiko.oddb.org/de/fi?gtin=65904'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184057', 'name': 'bisoprolol fumarate / perindopril arginine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450813611.0,"<p>The Swiss drug label for bisoprolol fumarate/perindopril arginine (Cosyrel) states that patients with G6PD deficiency may experience hemolytic anemia as a result of bisoprolol fumarate/perindopril arginine treatment.</p>
",1450813612.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for bisoprolol fumarate/perindopril arginine (Cosyrel):</p>
<blockquote class=""blockquote"">
<p>Undesired effects:
Very rare: Agranulocytosis, pancytopenia, leukopenia, neutropenia, thrombocytopenia (see &quot;Warnings and Precautions&quot;), haemolytic anaemia in patients with congenital G-6PDH deficiency.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65904&amp;highlight=G-6PDH-Mangel"" target=""_blank"">bisoprolol fumarate/perindopril arginine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184132,Annotation of Swissmedic Label for dasabuvir and IFNL3,False,False,[],False,[],False,[],True,"[{'id': 15103173, 'title': 'Swissmedic label for dasabuvir', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65302', 'crossReferences': [{'id': 1450813282, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65302', '_url': 'https://amiko.oddb.org/de/fi?gtin=65302'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166163411', 'name': 'dasabuvir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",Swissmedic,1450813713.0,"<p>The Swiss drug label for dasabuvir (Exviera) states that patients with an IFNL3 (IL28B) CC genotype have an increased sustained viral response than patients with the CC genotype.</p>
",1450813714.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for dasabuvir (Exviera):</p>
<blockquote class=""blockquote"">
<p>Properties/Effects:
Host factors: Response to pegIFN/RBV pretreatment, sex, ethnicity, age, IL28B allele, body mass index at baseline, depression or bipolar disorder in history, fibrosis stage.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In the group Exviera and Viekirax without ribavirin, patients with IL28B not CC genotype showed a statistically lower SVR12 rate than patients with IL28B CC genotype. A lower SVR12 rate was also shown in this group in patients with fibrosis stage F2 or higher.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>All studies report prevalence of IL28B non-CC genotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Example: The TURQUOISE III study is a multicenter, unblinded, single-arm Phase 3b study evaluating the efficacy and safety of 12-week treatment with Exviera and Viekirax in adult patients with HCV-GT1b infection and compensated cirrhosis who were either not previously treated or had previously received pegIFN/RBV treatment. The treated patients (N = 60) had a median age of 60.5 years (range: 26 to 78) and were 45% untreated and 55% pretreated with pegIFN/RBV (including 12 with non-response or partial response, 3 with recurrent disease and 18 other patients with less well described pegIFN/RBV failure). Other characteristics: 25.0% were =65 years, 61.7% male, 11.7% black and 5.0% Hispanic or Latin American, and 28% had a body mass index of at least 30 kg/m2, 21.7% a platelet count below 90×109 per liter, 16.7% an albumin concentration below 35 g/l, 91.7% an HCV RNA baseline of at least 800,000 IU per milliliter, 83.3% an IL28B non-CC genotype.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65302&amp;highlight=ethnische"" target=""_blank"">dasabuvir drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184443,Annotation of Swissmedic Label for efavirenz and CYP2B6,False,False,[],False,[],False,[],True,"[{'id': 15103265, 'title': 'Swissmedic label for efavirenz', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=56000', 'crossReferences': [{'id': 1450815649, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=56000', '_url': 'https://amiko.oddb.org/de/fi?gtin=56000'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103268, 'title': 'Swissmedic label for emtricitabin, tenofovir disoproxil und efavirenz (Atripla)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=60011', 'crossReferences': [{'id': 1450815652, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=60011', '_url': 'https://amiko.oddb.org/de/fi?gtin=60011'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165818750', 'symbol': 'CYP2B6*1', 'name': '*1'}, {'objCls': 'Haplotype', 'id': 'PA165818762', 'symbol': 'CYP2B6*6', 'name': '*6'}, {'objCls': 'Variant', 'id': 'PA166155409', 'symbol': 'rs3745274', 'name': 'rs3745274'}]","[{'objCls': 'Chemical', 'id': 'PA449441', 'name': 'efavirenz'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}]",Swissmedic,1450815684.0,"<p>The Swiss drug label for efavirenz (Stocrin) states that patients with elevated efavirenz concentrations, such as patients with CYP2B6 genotypes *1/*6 and *6/*6, have a higher risk of prolonging the QTc interval.</p>
",1450815685.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for efavirenz (Stocrin):</p>
<blockquote class=""blockquote"">
<p>Properties/Effects:
Patients with elevated efavirenz concentrations, such as patients with CYP2B6 genotypes *1/*6 and *6/*6, have a higher risk of prolonging the QTc interval.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Kinetics:
Patients with the homozygous genetic variant G516T of the CYP2B6 isozyme may have increased efavirenz plasma levels. The clinical implications are unknown, but more frequent and severe adverse effects cannot be ruled out.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=56000&amp;highlight=Genotypen"" target=""_blank"">efavirenz drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184446,Annotation of Swissmedic Label for escitalopram and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103269, 'title': 'Swissmedic label for escitalopram', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55961', 'crossReferences': [{'id': 1450815653, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55961', '_url': 'https://amiko.oddb.org/de/fi?gtin=55961'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10074', 'name': 'escitalopram'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815729.0,"<p>The Swiss drug label for escitalopram (Cipralex) states that no significant changes in plasma levels were measured in poor CYP2D6 metabolizers.</p>
",1450815730.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for escitalopram (Cipralex):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Polymorphism: In poor metabolisers with respect to CYP2C19, twice as high plasma levels of escitalopram were measured as in good metabolisers. No significant changes in plasma levels were measured in poor CYP2D6 metabolizers.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=55961&amp;highlight=Metabolisierer"" target=""_blank"">escitalopram drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184447,Annotation of Swissmedic Label for fesoterodine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103271, 'title': 'Swissmedic label for fesoterodin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=58743', 'crossReferences': [{'id': 1450815655, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=58743', '_url': 'https://amiko.oddb.org/de/fi?gtin=58743'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958376', 'name': 'fesoterodine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815732.0,"<p>The Swiss drug label for fesoterodine (Toviaz) cautions the increased likelihood of side effects in CYP2D6 poor metabolizers.</p>
",1450815733.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for fesoterodine (Toviaz) :</p>
<blockquote class=""blockquote"">
<p>Precautions:
In clinical studies, poor metabolizers for the enzyme CYP2D6 appeared to have more anticholinergic side effects than patients with normal metabolism of fesoterodine. In the event of unusually strong side effects, the possibility of reduced metabolism should therefore be considered. Comedication with CYP3A4 inhibitors should be avoided in patients with severe side effects.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=58743&amp;highlight=Metabolizer"" target=""_blank"">fesoteridine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184451,Annotation of Swissmedic Label for fluorouracil and TYMS,False,False,[],False,[],False,[],True,"[{'id': 15103275, 'title': 'Swissmedic label for fluorouracil (Fluorouracil Labatec)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65688', 'crossReferences': [{'id': 1450815659, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65688', '_url': 'https://amiko.oddb.org/de/fi?gtin=65688'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166155331', 'symbol': 'rs45445694', 'name': 'rs45445694'}]","[{'objCls': 'Chemical', 'id': 'PA128406956', 'name': 'fluorouracil'}]","[{'objCls': 'Gene', 'id': 'PA359', 'symbol': 'TYMS', 'name': 'thymidylate synthetase'}]",Swissmedic,1450815749.0,"<p>The Swiss drug label for fluorouracil (Fluorouracil Labatec) cautions about increased toxicity in patients with the 2R/2R and 2R/3R genotypes in the TYMS gene promoter relative to that of 3R/3R individuals.</p>
",1450815750.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for fluorouracil (Fluorouracil Labatec):</p>
<blockquote class=""blockquote"">
<p>Precautions:
There is also a correlation between the toxicity of fluorouracil and the polymorphism of thymidylate synthase (TYMS). The expression of TYMS is caused by the promoter of the TYMS gene. There are variants with a doubling (2R), tripling (3R) or a multiple of a 28-base pair subunit in the promoter region. The toxicity of fluorouracil is inversely proportional to the number of repeats (R). In patients of homozygous genotype 2R/2R the probability of grade 3-4 toxicity is 20 times higher and in patients of heterozygous genotype 2R/3R 6 times higher than in patients of homozygous genotype 3R/3R.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65688&amp;highlight=Genotyp"" target=""_blank"">fluorouracil drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184455,Annotation of Swissmedic Label for gefitinib and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103280, 'title': 'Swissmedic label for gefitinib', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=56154', 'crossReferences': [{'id': 1450815664, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=56154', '_url': 'https://amiko.oddb.org/de/fi?gtin=56154'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA131301952', 'name': 'gefitinib'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815763.0,"<p>The Swiss drug label for gefitinib (Iressa) states that CYP2D6 poor metabolizers had increased exposure compared to CYP2D6 extensive metabolizers.</p>
",1450815764.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for gefitinib (Iressa):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
CYP2D6 polymorphism: Slow metabolizers did not produce measurable concentrations of O-desmethyl gefitinib. Mean gefitinib exposure was twice as high in the slow metabolizer group as in the rapid metabolizer group.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=56154&amp;highlight=Metabolisierer"" target=""_blank"">gefitinib drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184457,Annotation of Swissmedic Label for gliclazide and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103282, 'title': 'Swissmedic label for gliclazid', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55234', 'crossReferences': [{'id': 1450815666, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55234', '_url': 'https://amiko.oddb.org/de/fi?gtin=55234'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10892', 'name': 'gliclazide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450819198.0,"<p>The Swiss drug label for gliclazide (Diamicron) states that caution should be used when treating patients with G6PD deficiency with gliclazide as they are at increased risk for hemolytic anemia.</p>
",1450819199.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for drug (trade name):</p>
<blockquote class=""blockquote"">
<p>Precautions:
In patients with glucose-6-phosphate dehydrogenase deficiency (G6PD), treatment with blood sugar-lowering sulfonamides may cause hemolytic anemia. Since Gliclazide belongs to the chemical class of blood sugar-lowering sulfonamides, it should be used cautiously in patients with G6PD deficiency and treatment alternatives to blood sugar-lowering sulfonamides should be considered.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=55234&amp;highlight=G6PD"" target=""_blank"">gliclazide drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184374,Annotation of Swissmedic Label for ibrutinib and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103235, 'title': 'Swissmedic label for ibrutinib', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65173', 'crossReferences': [{'id': 1450815053, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65173', '_url': 'https://amiko.oddb.org/de/fi?gtin=65173'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166121346', 'name': 'ibrutinib'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815310.0,"<p>The Swiss drug label for ibrutinib (IMBRUVICA) states that no precautions are required in patients with different CYP2D6 genotypes.</p>
",1450815311.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for ibrutinib (IMBRUVICA):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
In vitro studies have shown that CYP2D6 is less than 2 % involved in the oxidative metabolism of ibrutinib. In the human mass balance study, subjects genotyped as poor CYP2D6 metabolizers also showed a pharmacokinetic profile comparable to that of extensive metabolizers. Therefore, no precautions are required in patients with different CYP2D6 genotypes.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65173&amp;highlight=genotypisiert&amp;anchor=section14"" target=""_blank"">ibrutinib drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184383,"Annotation of Swissmedic Label for lapatinib and HLA-DQA1, HLA-DRB1",False,False,[],False,[],False,[],True,"[{'id': 15103244, 'title': 'Swissmedic label for lapatinib', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=57937', 'crossReferences': [{'id': 1450815335, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=57937', '_url': 'https://amiko.oddb.org/de/fi?gtin=57937'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165951292', 'symbol': 'HLA-DQA1*02:01', 'name': '*02:01'}, {'objCls': 'Haplotype', 'id': 'PA165951644', 'symbol': 'HLA-DRB1*07:01', 'name': '*07:01'}]","[{'objCls': 'Chemical', 'id': 'PA152241907', 'name': 'lapatinib'}]","[{'objCls': 'Gene', 'id': 'PA35066', 'symbol': 'HLA-DQA1', 'name': 'major histocompatibility complex, class II, DQ alpha 1'}, {'objCls': 'Gene', 'id': 'PA35072', 'symbol': 'HLA-DRB1', 'name': 'major histocompatibility complex, class II, DR beta 1'}]",Swissmedic,1450815372.0,"<p>The Swiss drug label for lapatinib (Tyverb) cautions for increased risk of drug induced liver injury in carriers of the HLA alleles DQA1*02:01 and DRB1*07:01.</p>
",1450815373.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for lapatinib (Tyverb):</p>
<blockquote class=""blockquote"">
<p>Precautions:
Carriers of the HLA alleles DQA1*02:01 and DRB1*07:01 have an increased risk of lapatinib-associated hepatotoxicity. In a large-scale randomized clinical study of lapatinib monotherapy (n = 1,194), the overall risk of high-grade liver damage (ALT above five times the upper normal range limit, NCI-CTCAE grade 3) was 2% (1:50); carriers of alleles DQA1*02:01 and DRB1*07:01 were 8% (1:12) and non-carriers 0.5% (1:200). In Caucasian, Asian, African and Latin American populations, HLA risk alleles are common (15 to 25%), but less common in Japanese populations (1%). In severe liver dysfunction, Tyverb should be discontinued and then not resumed.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=57937"" target=""_blank"">lapatinib drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184427,"Annotation of Swissmedic Label for ezetimibe / rosuvastatin and ABCG2, SLCO1B1",False,False,[],True,"[{'id': 1452021846, 'date': '2023-02-28T13:10:35.592-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452555241, 'date': '2024-08-13T13:25:33.400-07:00', 'description': 'added Dosing Info tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103088, 'title': 'Swissmedic label for Rosuvastatin und Ezetimib', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=66835', 'crossReferences': [{'id': 1450812049, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=66835', '_url': 'https://amiko.oddb.org/de/fi?gtin=66835'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA390', 'symbol': 'ABCG2', 'name': 'ATP binding cassette subfamily G member 2 (JR blood group)'}, {'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]","[{'objCls': 'Variant', 'id': 'PA166156544', 'symbol': 'rs2231142', 'name': 'rs2231142'}, {'objCls': 'Variant', 'id': 'PA166154579', 'symbol': 'rs4149056', 'name': 'rs4149056'}]","[{'objCls': 'Chemical', 'id': 'PA166184498', 'name': 'ezetimibe / rosuvastatin'}]","[{'objCls': 'Gene', 'id': 'PA390', 'symbol': 'ABCG2', 'name': 'ATP binding cassette subfamily G member 2 (JR blood group)'}, {'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",Swissmedic,1450815584.0,"<p>The Swiss drug label for ezetimibe/rosuvastatin (Ezetimib-Rosuvastatin-Mepha Kapseln) states that genetic polymorphisms in SLCO1B1 and ABCG2  may lead to an increase in rosuvastatin exposure, a reduction in the dosage is recommended.</p>
",1450815585.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the rosuvastatin (Ezetimib-Rosuvastatin-Mepha) label:</p>
<blockquote class=""blockquote"">
<p>Dosage:
Genetic polymorphisms: Specific types of genetic polymorphisms are known that may lead to an increase in rosuvastatin exposure (see &quot;Pharmacokinetics&quot;). In patients in whom such a polymorphism is known, a reduction in the dosage of ezetimib-rosuvastatin mepha is recommended.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Genetic polymorphisms: The availability of HMG-CoA reductase inhibitors such as rosuvastatin depends, among other things, on the transport proteins OATP1B1 and BCRP. Patients with different sequence variations of the SLCO1B1 gene (OATP1B1) and/or the ABCG2 gene (BCRP) are at risk of increased exposure to rosvastatin. The genotype variants SLCO1B1 c.521CC and ABCG2 c.421AA are associated with approximately 1.7-fold higher exposure to rosuvastatin (AUC) and 2.4-fold higher exposure, respectively, than the variants SLCO1B1 c.521TT and ABCG2 c.421CC.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=66835&amp;highlight=Genetische"" target=""_blank"">Ezetimib-Rosuvastatin-Mepha drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450815586.0,"<blockquote class=""blockquote"">
<p>Dosage: Specific types of genetic polymorphisms are known that may lead to an increase in rosuvastatin exposure (see &quot;Pharmacokinetics&quot;). In patients in whom such a polymorphism is known, a reduction in the dosage of ezetimib-rosuvastatin mepha is recommended.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166398581,"Annotation of HCSC Label for clomipramine and CYP2C19, CYP2D6",False,False,[],False,[],False,[],True,"[{'id': 15177962, 'title': 'Drugs@HCSC: Drug Product ANAFRANIL (clomipramine), Apotex Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4382', 'crossReferences': [{'id': 1453105862, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4382', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4382'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449048', 'name': 'clomipramine'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1453106226.0,"<p>The product monograph for clomipramine (ANAFRANIL) notes that CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants  such as clomipramine when given usual doses and recommends dosage adjustments for CYP2D6 and CYP2C19 poor metabolizers in the context of drug-drug interactions.</p>
",1453106227.0,"<p>Excerpts from the clomipramine (ANAFRANIL) product monograph:</p>
<blockquote class=""blockquote"">
<p>The primary route of clomipramine metabolism is demethylation to form the active metabolite, N-desmethylclomipramine, which can be formed by several P450 enzymes, primarily CYP3A4, CYP2C19 and CYP1A2.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Drugs Metabolized by P450 2D6 –</strong> The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8- fold increase in plasma AUC of the TCA).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Genetic Polymorphism:</strong> TCAs including clomipramine are primarily metabolised by the hepatic cytochrome P450 isozymes CYP2D6 and CYP2C19, which are polymorphic in the population. Patients known to be poor CYP2D6 or CYP2C19 metabolisers may have higher plasma levels of clomipramine (see 9.2 Drug Interactions Overview). Dosage adjustments should be considered (see 4.2 Recommended Dose and Dosage Adjustment, Concomitant use with inhibitors of cytochrome P450 enzymes; CYP3A and CYP2C inducers).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>To help avoid side effects and ensure proper use, talk to your healthcare professional before you take ANAFRANIL. Talk about any health conditions or problems you may have, including if you:</strong> [...]</p>
<ul>
<li>have been told you have enzymes that do not work well (such as “CYP2D6 poor metabolizer” or “CYP2C19 poor metabolizer”).</li>
</ul>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Clomipramine_2025_04_16_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Clomipramine_2025_04_16_HCSC.pdf"">clomipramine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1453106228.0,"<blockquote class=""blockquote"">
<p>Patients known to be poor CYP2D6 or CYP2C19 metabolisers may have higher plasma levels of clomipramine (see 9.2 Drug Interactions Overview). Dosage adjustments should be considered (see 4.2 Recommended Dose and Dosage Adjustment, Concomitant use with inhibitors of cytochrome P450 enzymes; CYP3A and CYP2C inducers).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184155,Annotation of Swissmedic Label for nitrofurantoin and G6PD,True,False,[],False,[],False,[],True,"[{'id': 15103053, 'title': 'Swissmedic label for nitrofurantoin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=35941', 'crossReferences': [{'id': 1450812014, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=35941', '_url': 'https://amiko.oddb.org/de/fi?gtin=35941'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450640', 'name': 'nitrofurantoin'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450813890.0,"<p>The Swiss drug label for nitrofurantoin (Uvamin retard) states that breastfeeding of infants suspected or known to suffer from erythrocyte enzyme deficiency (including G6PD deficiency) should be avoided as traces of nitrofurantoin are found in breast milk.</p>
",1450813891.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for nitrofurantoin (Uvamin® retard):</p>
<blockquote class=""blockquote"">
<p>Pregnancy:
Breastfeeding of infants suspected or known to suffer from erythrocyte enzyme deficiency (including G6PD deficiency) should be avoided as traces of nitrofurantoin are found in breast milk.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Adverse effect:
Rarely: Agranulocytosis, eosinophilia, leukopenia, granulocytopenia, hemolytic anemia, glucose-6-phosphate dehydrogenase deficiency, thrombocytopenia and megaloblastic anemia. Aplastic anemia. Blood levels generally normalized after treatment discontinuation.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=35941&amp;highlight=Glucose-6-phosphat-Dehydrogenase-Mangel"" target=""_blank"">nitrofurantoin drug label</a> (in German).</p>
</blockquote>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813892.0,"<blockquote class=""blockquote"">
<p>Breastfeeding of infants suspected or known to suffer from erythrocyte enzyme deficiency (including G6PD deficiency) should be avoided as traces of nitrofurantoin are found in breast milk.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184500,Annotation of Swissmedic Label for simvastatin and SLCO1B1,False,False,[],False,"[{'id': 1452022043, 'date': '2023-02-28T14:36:57.168-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103090, 'title': 'Swissmedic label for simvastatin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=49742', 'crossReferences': [{'id': 1450812051, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=49742', '_url': 'https://amiko.oddb.org/de/fi?gtin=49742'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]","[{'objCls': 'Variant', 'id': 'PA166154579', 'symbol': 'rs4149056', 'name': 'rs4149056'}]","[{'objCls': 'Chemical', 'id': 'PA451363', 'name': 'simvastatin'}]","[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",Swissmedic,1450820427.0,"<p>The Swiss drug label for simvastatin (Zocor® 20 mg/40 mg/80 mg) states that patients with SLCO1B1 c.521T&gt;C polymorphism are at risk of increased exposure to simvastatin acid, which may lead to an increased risk of rhabdomyolysis.  &quot;Genotyping for the presence of the C allele should be considered as part of the benefit-risk assessment in individual patients before prescribing simvastatin 80 mg, and high doses should be avoided in identified carriers of the CC genotype.&quot;</p>
",1450820428.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the simvastatin (Zocor) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
SLCO1B1 Polymorphism: Carriers of the c.521T&gt;C allele of the SLCO1B1 gene have a lower OATP1B1 activity. The average bioavailability (AUC) of the most important active metabolite, simvastatinic acid, is 120% for heterozygous carriers (CT) of the C allele and 221% for homozygous carriers (CC), relative to those of patients with the most common genotype (TT). The C allele has a frequency of 18% in the European population. Patients with SLCO1B1 polymorphism are at risk of increased exposure to simvastatin acid, which may lead to an increased risk of rhabdomyolysis (see &quot;Warnings and Precautions, Myopathy/Rhabdomyolysis&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Precautions:
In a clinical study in which patients at high risk of cardiovascular disease were treated with simvastatin 40 mg per day (mean follow-up 3.9 years), the incidence of myopathy was approximately 0.05% in non-Chinese patients (n=7367) compared to 0.24% in Chinese patients (n=5468). Since the Chinese were the only Asian population included in this clinical trial, simvastatin should be prescribed with caution in Asian patients and the lowest necessary dose should be used.
Reduced function of transport proteins:
The decreased function of the hepatic OATP transport protein may increase the systemic exposure to simvastatin acid, as well as the risk for myopathy and rhabdomyolysis. Decreased function may result from inhibition by interacting drugs (e.g., ciclosporin) or may occur in patients carrying the SLCO1B1 c.521T&gt;C genotype.
Patients carrying the allele c.521T&gt;C of the SLCO1B1 gene encoding a less active OATP1B1 protein have increased systemic exposure to simvastatin acid and increased risk of myopathy. The risk of myopathy caused by high-dose simvastatin (80 mg) is generally 1% without genetic testing. Based on the results of the SEARCH study, carriers of the homozygous C allele (also called CC) treated with 80 mg have a 15% risk of myopathy within one year, while carriers of the heterozygous C allele (CT) have a 1.5% risk. Patients with the most common genotype (TT) have a risk of 0.3% (see &quot;Pharmacokinetics&quot;). Where available, genotyping for the presence of the C allele should be considered as part of the benefit-risk assessment in individual patients before prescribing simvastatin 80 mg, and high doses should be avoided in identified carriers of the CC genotype. However, the absence of this gene in genotyping does not exclude the possibility of myopathy.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=49742&amp;highlight=Allel"" target=""_blank"">zocor drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1450820429.0,"<blockquote class=""blockquote"">
<p>Where available, genotyping for the presence of the C allele should be considered as part of the benefit-risk assessment in individual patients before prescribing simvastatin 80 mg, and high doses should be avoided in identified carriers of the CC genotype. However, the absence of this gene in genotyping does not exclude the possibility of myopathy.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166119827,Annotation of EMA Label for dextromethorphan / quinidine and CYP2D6,False,False,[],False,"[{'id': 1184175111, 'date': '2014-05-02T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452218620, 'date': '2023-08-28T10:44:02.932-07:00', 'description': 'changed level to informative PGx, remove prescribing info tag', 'type': 'Update', 'version': 0}, {'id': 1453106700, 'date': '2025-04-16T14:36:47.953-07:00', 'description': 'changed PGx level to ""informative"" due to possibility of subtherapeutic concentrations in CYP2D6 UMs', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102908, 'title': 'Nuedexta | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/nuedexta', 'crossReferences': [{'id': 1450416962, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/nuedexta', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/nuedexta'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166175998', 'name': 'dextromethorphan / quinidine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1447982111.0,"<p>The EMA European Public Assessment Report (EPAR) for dextromethorphan and quinidine (Nuedexta) does not require dose adjustment based on CYP2D6 genotype. Efficacy is not expected to be affected in CYP2D6 poor metabolizers, however adverse reactions to quinidine are possible. Dextromethorphan is rapidly metabolized in CYP2D6 ultrarapid metabolizers, and may result in subtherapeutic concentrations. <strong>Please note that as of February 2016 dextromethorphan and quinidine (Nuedexta) has been <a rel=""noopener noreferrer"" href=""https://www.ema.europa.eu/en/medicines/human/EPAR/nuedexta"" target=""_blank"">withdrawn</a> from use in the European Union.</strong></p>
",1447982110.0,"<p><strong>Please note that as of February 2016 dextromethorphan and quinidine (Nuedexta) has been <a rel=""noopener noreferrer"" href=""https://www.ema.europa.eu/en/medicines/human/EPAR/nuedexta"" target=""_blank"">withdrawn</a> from use in the European Union.</strong></p>
<p>Excerpts from the dextromethorphan and quinidine (Nuedexta) EPAR:</p>
<div class=""blockquote"">
<p>Dose adjustment is not required in patients with a non-functional CYPD2D6 enzyme, referred to as poor metabolisers (PMs). Dose adjustment is not required in patients with increased CYP2D6 activity, referred to as ultra-rapid metabolisers (UMs), see section 5.2. In the event of inadequate clinical response, see recommended dose titration schedule.</p>
</div>
<div class=""blockquote"">
<p>The quinidine component is intended to inhibit CYP2D6 so that higher exposure to dextromethorphan can be achieved compared to when dextromethorphan is given alone. Approximately 7-8% of individuals of Caucasian descent, 3-6% of Black African descent, 2-3% of Arab descent and 1-2% of Asian descent generally lack the capacity to metabolize CYP2D6 substrates and are classified as Poor Metabolizer (PMs). The quinidine component is not expected to contribute to the effectiveness of NUEDEXTA in PMs, but adverse reactions of the quinidine component are still possible.</p>
</div>
<div class=""blockquote"">
<p>Approximately 1-10% of individuals of Caucasian descent, 5-30% of Black African descent, 12-40% of Arab descent and 1% of Asian descent exhibit increased metabolic activity for CYP2D6 substrates and are classified as Ultra-rapid Metabolizer (UMs). In such UM patients, dextromethorphan is rapidly metabolised, leading to lower, potentially subtherapeutic concentrations.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Dextromethorphan_quinidine_EMA_EPAR_May_02_2014.pdf"">dextromethorphan and quinidine EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184160,Annotation of Swissmedic Label for ondansetron and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103059, 'title': 'Swissmedic label for ondansetron', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=50710', 'crossReferences': [{'id': 1450812020, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=50710', '_url': 'https://amiko.oddb.org/de/fi?gtin=50710'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450705', 'name': 'ondansetron'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450813910.0,"<p>The Swiss label for ondansetron (Zofran®/- Zydis®) states that CYP3A4, CYP2D6 and CYP1A2 are involved in ondansetron metabolism. However, the overall rate of ondansetron elimination will hardly be affected by the absence of one enzyme (e.g. genetic CYP2D6 deficiency).</p>
",1450813911.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for ondansetron (Zofran®/- Zydis®):</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
In vitro studies have shown that ondansetron is a substrate of hepatic cytochrome P-450 enzymes in humans, including CYP1A2, CYP2D6 and CYP3A4. CYP3A4 is most important for the total turnover of ondansetron. Since the ondansetron metabolism can take place via several metabolic enzymes, it is to be expected that inhibition or the absence of one enzyme (e.g. genetic CYP2D6 deficiency) will be compensated by other enzymes and that the overall rate of ondansetron elimination will hardly be affected.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Interactions:
Ondansetron is subject to metabolism by several hepatic cytochrome P-450 enzymes: CYP3A4, CYP2D6 and CYP1A2. Since the ondansetron metabolism can therefore take place via several metabolic enzymes, it is to be expected that an inhibition or reduced activity of one of these enzymes (e.g. genetic CYP2D6 deficiency) will under normal circumstances be compensated by other enzymes and only lead to a small or no significant change in the overall clearance of ondansetron or the dose requirement.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=50710&amp;highlight=genetischer"" target=""_blank"">ondansetron drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184177,Annotation of Swissmedic Label for oxycodone and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103063, 'title': 'Swissmedic label for oxycodon', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=54871', 'crossReferences': [{'id': 1450812024, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=54871', '_url': 'https://amiko.oddb.org/de/fi?gtin=54871'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103064, 'title': 'Swissmedic label for oxycodon, kombinationen', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=58683', 'crossReferences': [{'id': 1450812025, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=58683', '_url': 'https://amiko.oddb.org/de/fi?gtin=58683'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450741', 'name': 'oxycodone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450814047.0,"<p>The Swiss label for oxycodone (Oxycontin or Targin) states that genetic polymorphisms of CYP2D6 can alter the efficacy of oxycodone or lead to undesired effects.</p>
",1450814048.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for oxycodone (Oxycontin):</p>
<blockquote class=""blockquote"">
<p>Dosage/applications:
Genetic polymorphisms:Genetic polymorphisms of CYP2D6 can alter the efficacy of oxycodone or lead to undesired effects (see section &quot;Pharmacokinetics&quot;).</p>
</blockquote>
<p>Excerpt from the drug label for oxycodone (Targin):</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Genetic polymorphisms: With slow CYP2D6 metabolisers (7-8% of all Caucasians) a weaker analgesic effect is possible. Ultra-fast CYP2D6 metabolizers (2-4% of all Caucasians) may have a higher analgesic effect and an increased risk of adverse effects.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=54871&amp;highlight=Genetische"" target=""_blank"">oxycodone drug label</a> (in German)</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184220,Annotation of Swissmedic Label for paliperidone and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103065, 'title': 'Swissmedic label for paliperidon', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=66054', 'crossReferences': [{'id': 1450812026, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=66054', '_url': 'https://amiko.oddb.org/de/fi?gtin=66054'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA163518919', 'name': 'paliperidone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450814355.0,"<p>The Swiss label for paliperidon (Trevicta) states that no discernible difference between extensive metabolisers and slow metabolisers of CYP2D6 substrates with respect to apparent clearance of paliperidone after application of oral paliperidone.</p>
",1450814356.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for paliperidone (Trevicta):</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
In vivo, four metabolic pathways were identified, none of which accounted for more than 10% of the dose: Dealkylation, hydroxylation, dehydrogenation and benzisoxazole cleavage. Although in vitro studies indicate a possible involvement of CYP2D6 and CYP3A4 in the conversion of paliperidone, there is no evidence of a significant role of these isoenzymes in the metabolism of paliperidone in vivo. Population pharmacokinetic analyses showed no discernible difference between extensive metabolisers and slow metabolisers of CYP2D6 substrates with respect to apparente clearance of paliperidone after application of oral paliperidone. In vitro studies with human liver microsomes show that paliperidone does not significantly inhibit the metabolism of drugs converted by cytochrome P-450 isozymes such as CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4 and CYP3A5.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=66054&amp;highlight=Metabolisierern"" target=""_blank"">paliperidone drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184286,Annotation of Swissmedic Label for perindopril and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103073, 'title': 'Swissmedic label for perindopril', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=57617', 'crossReferences': [{'id': 1450812034, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=57617', '_url': 'https://amiko.oddb.org/de/fi?gtin=57617'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450877', 'name': 'perindopril'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450814794.0,"<p>The Swiss drug label for perindopril (COVERSUM N 5 mg/10 mg) states that patients with congenital G6PD deficiency may have risk for haemolytic anaemia.</p>
",1450814795.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for perindopril (COVERSUM N 5 mg/10 mg):</p>
<blockquote class=""blockquote"">
<p>Unwanted effects:
Very rare: Agranulocytosis or pancytopenia, reduction of haemoglobin and haematocrit, leukopenia, neutropenia, haemolytic anaemia in patients with congenital G6PD deficiency, thrombocytopenia or anaemia.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=57617&amp;highlight=G6PD-Mangel"" target=""_blank"">peridopril drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184393,Annotation of Swissmedic Label for pitavastatin and SLCO1B1,False,False,[],False,[],False,[],True,"[{'id': 15103076, 'title': 'Swissmedic label for pitavastatin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=62329', 'crossReferences': [{'id': 1450812037, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=62329', '_url': 'https://amiko.oddb.org/de/fi?gtin=62329'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA142650384', 'name': 'pitavastatin'}]","[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",Swissmedic,1450815417.0,"<p>The Swiss drug label for pitavastatin (Livazo) states that genetic variation in SLCO1B1 gene may impact pitavastatin concentration.</p>
",1450815418.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the pitavastatin (Livazo) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Pitavastatin is actively transported by various hepatic transporters, including OATP1B1 and OATP1B3, into the hepatocytes (the site of action and metabolism). The AUC in plasma is variable with about factor 4 between the highest and the lowest value. Studies with SLCO1B1 (the gene coding for OATP1B1) suggest that a polymorphism of this gene contributes greatly to AUC variability. Pitavastatin is not a substrate of p-glycoprotein.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=62329&amp;highlight=Polymorphismus"" target=""_blank"">pitavastatin drug label</a> (in German);</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184396,Annotation of Swissmedic Label for rabeprazole and CYP2C19,False,False,[],False,[],False,[],True,"[{'id': 15103080, 'title': 'Swissmedic label for rabeprazole', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55090', 'crossReferences': [{'id': 1450812041, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55090', '_url': 'https://amiko.oddb.org/de/fi?gtin=55090'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451216', 'name': 'rabeprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",Swissmedic,1450815426.0,"<p>The Swiss drug label for rabeprazole (Pariet) states that CYP2C19 slow metabolizers may have higher concentration (AUC) as compared to extensive metabolizers.</p>
",1450815427.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the rabeprazole (Pariet) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
CYP2C19 Polymorphism: After repeated administration of 20 mg rabbeprazole daily for one week, CYP2C19 slow metabolizers had an AUC that was approximately 1,9× higher and a t that was 1,6× higher than the corresponding parameters in extensive metabolizers. C, on the other hand, increased by only 40%.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=55090&amp;highlight=Polymorphismus"" target=""_blank"">rabeprazole drug label</a> (in German);</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184421,Annotation of Swissmedic Label for risperidone and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103086, 'title': 'Swissmedic label for risperidone', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=52316', 'crossReferences': [{'id': 1450812047, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=52316', '_url': 'https://amiko.oddb.org/de/fi?gtin=52316'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451257', 'name': 'risperidone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815537.0,"<p>The Swiss label for risperidone (Risperdal) states that CYP2D6 plays a role in risperidone metabolism. However, no clinically relevant differences were observed in slow and fast metabolizers.</p>
",1450815538.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the risperidone (Risperdal) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Risperdal is completely resorbed after oral administration and reaches maximum plasma concentration within 1 to 2 hours, in older patients within 2 to 3 hours. Since its absorption is not affected by food, Risperidone can be taken with or independently of meals. Absolute bioavailability is 66% for rapid metabolizers and 82% for slow metabolizers. CYP 2D has a genetic (debrisoquine/dextromethorphan) polymorphism. Rapid metabolizers rapidly convert risperidone to 9-hydroxy-risperidone, while slow metabolizers do so more slowly. Fast metabolizers therefore have lower risperidone and higher 9-hydroxy-risperidone concentrations in plasma than slow metabolizers. Since risperidone and 9-hydroxy-risperidone have approximately the same antipsychotic activity, the sum of their concentrations is decisive. For this reason, no clinically relevant differences were observed in slow and fast metabolizers.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=52316&amp;highlight=Metabolisierer"" target=""_blank"">risperidone drug label</a> (in German);</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184389,Annotation of Swissmedic Label for sulfadiazine and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103096, 'title': 'Swissmedic label for Sulfadiazin-Silber', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=38607', 'crossReferences': [{'id': 1450812057, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=38607', '_url': 'https://amiko.oddb.org/de/fi?gtin=38607'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103097, 'title': 'Swissmedic label for Sulfadiazin-Silber, Kombinationen', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=51722', 'crossReferences': [{'id': 1450812058, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=51722', '_url': 'https://amiko.oddb.org/de/fi?gtin=51722'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451539', 'name': 'sulfadiazine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450815393.0,"<p>The Swiss drug labels for sulfadiazin-silber (Flammazine) and Sulfadiazin-Silber, Kombinationen (Ialugen Plus) has a caution for use in patients with known or suspected G6PD deficiency.</p>
",1450815394.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for Sulfadiazin-Silber, Kombinationen (Ialugen Plus):</p>
<blockquote class=""blockquote"">
<p>Precautions
In patients with a proven or suspected deficiency of glucose-6-phosphate dehydrogenase, the preparation should be used with caution and under careful supervision due to possible hemolysis.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=38607&amp;highlight=Glucose-6-Phosphat-Dehydrogenase"" target=""_blank"">Sulfadiazin-Silber drug label</a> and <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=51722&amp;highlight=Glucose-6-Phosphat-Dehydrogenase"" target=""_blank"">Sulfadiazin-Silber, Kombinationen drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184392,Annotation of Swissmedic Label for tamoxifen and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103100, 'title': 'Swissmedic label for tamoxifen', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=39053', 'crossReferences': [{'id': 1450812061, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=39053', '_url': 'https://amiko.oddb.org/de/fi?gtin=39053'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451581', 'name': 'tamoxifen'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815403.0,"<p>The Swiss drug label for tamoxifen (Nolvadex) cautions about changes in efficacy in CYP2D6 poor metabolizers.</p>
",1450815404.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for tamoxifen (Nolvadex):</p>
<blockquote class=""blockquote"">
<p>Precautions
In published studies, the simultaneous use of CYP2D6 inhibitors reduced plasma concentrations of the active metabolite endoxifene, which may be associated with a loss of efficacy (see &quot;Interactions&quot;). According to a published study, the loss of efficacy of tamoxifen in combination with treatment with SSRI paroxetine increased mortality. Tamoxifen should therefore not be administered together with CYP2D6 inhibitors (e.g. SSRI antidepressants such as paroxetine or fluoxetine, cinacalcet, quinidine). Reduced endoxifen concentrations and thus reduced efficacy can also be expected in so-called poor metabolizers for CYP2D6 (see &quot;Pharmacokinetics&quot; and &quot;Properties/Effects&quot;).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=39053&amp;highlight=metabolisern"" target=""_blank"">tamoxifen drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184391,Annotation of Swissmedic Label for sulfasalazine and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103099, 'title': 'Swissmedic label for sulfasalazin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=15303', 'crossReferences': [{'id': 1450812060, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=15303', '_url': 'https://amiko.oddb.org/de/fi?gtin=15303'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451547', 'name': 'sulfasalazine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450815400.0,"<p>The Swiss drug label for sulfasalazine (Salazopyrin) states that the drug is contraindicated in patients with G6PD deficiency.</p>
",1450815401.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for sulfasalazine (Salazopyrin):</p>
<blockquote class=""blockquote"">
<p>Contraindications
Patients with glucose-6-phosphate dehydrogenase deficiency</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=15303&amp;highlight=Glucose-6-Phosphat-Dehydrogenase-Mangel"" target=""_blank"">sulfasalazine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184425,Annotation of Swissmedic Label for tolperisone and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103106, 'title': 'Swissmedic label for tolperison', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=32665', 'crossReferences': [{'id': 1450812067, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=32665', '_url': 'https://amiko.oddb.org/de/fi?gtin=32665'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166152940', 'name': 'tolperisone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815568.0,"<p>The Swiss drug label for tolperisone (Mydocalm) suggests that tolperisone exposure may be increased in CYP2D6 poor metabolizers.</p>
",1450815569.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for tolperisone (Mydocalm):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Since a genetic polymorphism exists for the cytochrome CYP2D6, an accumulation of the parent substance tolperisone and a reduced formation of the hydroxylated metabolite can be expected in the slow metabolisers (about 15% of the population).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=32665&amp;highlight=genetischer"" target=""_blank"">tolperisone drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184236,Annotation of Swissmedic Label for umeclidinium / vilanterol and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103114, 'title': 'Swissmedic label for Vilanterol und Umeclidinium bromid', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=63152', 'crossReferences': [{'id': 1450812075, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=63152', '_url': 'https://amiko.oddb.org/de/fi?gtin=63152'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184235', 'name': 'umeclidinium / vilanterol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450814451.0,"<p>The Swiss drug label for umeclidinium/vilanterol (Anoro® Ellipta®) states that umeclidinium exposure is not affected by CYP2D6 variants.</p>
",1450814452.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for umeclidinium/vilanterol (Anoro® Ellipta®):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
A population pharmacokinetic analysis showed that no dose adjustment of Umeclidinium or Vilanterol is required due to age, race, sex, use of inhaled corticosteroids or weight. A study with slow CYP2D6 metabolizers did not demonstrate any effect of CYP2D6 genetic polymorphism on systemic Umeclidinium exposure.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=63152&amp;highlight=genetischen"" target=""_blank"">umeclidinium/vilanterol drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184239,Annotation of Swissmedic Label for vortioxetine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103117, 'title': 'Swissmedic label for vortioxetin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65937', 'crossReferences': [{'id': 1450812078, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65937', '_url': 'https://amiko.oddb.org/de/fi?gtin=65937'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166122595', 'name': 'vortioxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450814460.0,"<p>The Swiss drug label for vortioxetine (Brintellix) states that plasma concentrations of vortioxetine are increased in CYP2D6 &quot;slow metabolizers&quot; compared to normal metabolizers.</p>
",1450814461.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for vortioxetine (Brintellix):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Slow metabolisers of CYP2D6: The plasma concentrations of vortioxetine were about twice as high in slow metabolisers of CYP2D6 as in extensive metabolisers. In the presence of strong CYP3A4/2C9 inhibitors, exposure may potentially be higher (see &quot;&quot;Interactions&quot;&quot;). As with all patients, dose adjustment should be considered depending on the individual response of the patient (see &quot;&quot;Dosage/Application&quot;&quot;).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65937&amp;highlight=Metabolisierer"" target=""_blank"">vortioxetine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184386,"Annotation of Swissmedic Label for letermovir and SLCO1B1, UGT1A1",False,False,[],False,[],False,[],True,"[{'id': 15103247, 'title': 'Swissmedic label for letermovir', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=66652', 'crossReferences': [{'id': 1450815337, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=66652', '_url': 'https://amiko.oddb.org/de/fi?gtin=66652'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166154547', 'symbol': 'rs2306283', 'name': 'rs2306283'}, {'objCls': 'Variant', 'id': 'PA166155721', 'symbol': 'rs4148323', 'name': 'rs4148323'}, {'objCls': 'Variant', 'id': 'PA166154575', 'symbol': 'rs4149032', 'name': 'rs4149032'}, {'objCls': 'Variant', 'id': 'PA166154579', 'symbol': 'rs4149056', 'name': 'rs4149056'}, {'objCls': 'Haplotype', 'id': 'PA166115842', 'symbol': 'UGT1A1*28', 'name': '*28'}]","[{'objCls': 'Chemical', 'id': 'PA166184379', 'name': 'letermovir'}]","[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}, {'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",Swissmedic,1450815382.0,"<p>The Swiss drug label for letermovir (Prevymis) gives information about variants in UGT1A1 and SLCO1B1 that were tested for association with letermovir pharmacokinetics although no clinically relevant effects were observed.</p>
",1450815383.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for letermovir (Prevymis):</p>
<blockquote class=""blockquote"">
<p>Properties/Effects:
Pharmacogenomics:
The effect of genetic variants in the OATP1B1 gene SLCO1B1 (rs4149056, rs2306283, rs4149032) and UGT1A1 (rs4148323 and promoter TA repeat variants) on the pharmacokinetics of Letermovir was evaluated in 299 study participants. There were no clinically relevant effects of these variants on Letermovir exposure.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=66652&amp;highlight=Pharmakogenomik"" target=""_blank"">letermovir drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166122967,Annotation of EMA Label for fesoterodine and CYP2D6,False,False,[],False,"[{'id': 1184513617, 'date': '2014-08-07T00:00:00-07:00', 'type': 'Create', 'version': 0}]",False,[],True,"[{'id': 15102986, 'title': 'Toviaz | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/toviaz', 'crossReferences': [{'id': 1450417094, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/toviaz', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/toviaz'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958376', 'name': 'fesoterodine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1447982127.0,"<p>The EMA European Public Assessment Report (EPAR) for fesoterodine (Toviaz) states that Cmax and AUC of the active metabolite are 1.7 and 2-fold higher, respectively, in CYP2D6 poor metabolizers as compared to extensive metabolizers.</p>
",1447982126.0,"<p>Excerpts from the fesoterodine (Toviaz) EPAR:</p>
<div class=""blockquote"">
<p>Following inhibition of CYP3A4 by co-administration of ketoconazole 200 mg twice daily, Cmax and AUC of the active metabolite of fesoterodine increased 2.0 and 2.3-fold in CYP2D6 extensive metabolisers and 2.1 and 2.5-fold in CYP2D6 poor metabolisers, respectively.</p>
</div>
<div class=""blockquote"">
<p>The interaction with CYP2D6 inhibitors was not tested clinically. Mean Cmax and AUC of the active metabolite are 1.7 and 2-fold higher, respectively, in CYP2D6 poor metabolisers as compared to extensive metabolisers. Co-administration of a potent CYP2D6 inhibitor may result in increased exposure and adverse events. A dose reduction to 4 mg may be needed.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Fesoterodine_06_21_19_EMA.pdf"">fesoterodine EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166286161,Annotation of HCSC Label for allopurinol and HLA-B,True,False,[],False,"[{'id': 1452503742, 'date': '2024-06-18T16:58:29.422-07:00', 'description': 'added Alternate Drug tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15159622, 'title': 'Drugs@HCSC: Drug Product ALLOPURINOL (allopurinol tablets), Pro Doc Ltee.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4724', 'crossReferences': [{'id': 1452503761, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4724', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4724'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165987831', 'symbol': 'HLA-B*58:01', 'name': '*58:01'}]","[{'objCls': 'Chemical', 'id': 'PA448320', 'name': 'allopurinol'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",HCSC,1451980200.0,"<p>The HCSC product monograph for allopurinol states that screening for HLA-B*5801 should be considered before starting treatment in patient subgroups where the allele frequency is known to be high.</p>
",1451980201.0,"<p>Excerpts from the <em><strong>Allopurinol</strong></em> (Allopurinol tablets) product monograph:</p>
<blockquote class=""blockquote"">
<p>The HLA-B*5801 allele has been shown to be associated with an increased risk of developing
allopurinol related serious hypersensitivity syndromes, including SJS and TEN. The frequency of the
HLA-B*5801 allele varies widely between ethnic populations: up to 20% in Han Chinese population, 8
to 15% in the Thai, about 12% in the Korean population and 1 to 2% in individuals of Japanese or
European origin. Screening for HLA-B*5801 should be considered before starting treatment with
allopurinol in patient subgroups where the prevalence of this allele is known to be high.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In case that no HLA-B*5801 genotyping is
available for patients with Han Chinese, Thai or Korean descent, the benefits should be thoroughly
assessed and considered to outweigh the possible higher risks before starting therapy. The use of
genotyping has not been established in other patient populations. If the patient is a known carrier of HLA-B*5801 (especially in those who are from Han Chinese, Thai or Korean descent), allopurinol should
not be started unless there are no other reasonable therapeutic options and the benefits are thought
to exceed risks. SJS/TEN can still occur in patients who are found to be negative for HLA-B*5801
irrespective of their ethnic origin.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Allopurinol_HSCS_2023_01_11.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Allopurinol_HSCS_2023_01_11.pdf""><em><strong>Allopurinol</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1451980202.0,"<p>Excerpts from the <em><strong>Allopurinol</strong></em> (Allopurinol tablets) product monograph:</p>
<blockquote class=""blockquote"">
<p>In case that no HLA-B*5801 genotyping is
available for patients with Han Chinese, Thai or Korean descent, the benefits should be thoroughly
assessed and considered to outweigh the possible higher risks before starting therapy. The use of
genotyping has not been established in other patient populations. If the patient is a known carrier of HLA-B*5801 (especially in those who are from Han Chinese, Thai or Korean descent), allopurinol should
not be started unless there are no other reasonable therapeutic options and the benefits are thought
to exceed risks. SJS/TEN can still occur in patients who are found to be negative for HLA-B*5801
irrespective of their ethnic origin.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184422,Annotation of Swissmedic Label for tetrabenazine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103103, 'title': 'Swissmedic label for tetrabenazin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=58375', 'crossReferences': [{'id': 1450812064, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=58375', '_url': 'https://amiko.oddb.org/de/fi?gtin=58375'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA140222719', 'name': 'tetrabenazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815554.0,"<p>The Swiss drug label for tetrabenazine (Xenazine) states that patients should be tested for CYP2D6 poor metabolizer status prior to receiving daily doses above 50 mg.</p>
",1450815555.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for tetrabenazine (Xenazine):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
The primary metabolites of tetrabenazine, a- and ß- dihydrotetrabenazines, are metabolized by cytochrome P450 2D6 (CYP2D6). In poor CYP2D6 metabolisers, exposure to these metabolites will be significantly higher. In addition, strong inhibitors of CYP2D6 (such as paroxetine and fluoxetine) lead to significantly increased exposure to these metabolites. Thus, a dose reduction of tetrabenazine may be necessary if patients already treated with tetrabenazine additionally receive strong CYP2D6 inhibitors.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Precautions:
QT interval extension: Tetrabenazine causes a slight dose-dependent increase (approx. 8 msec) of the corrected QT interval. Caution should therefore be exercised in the case of congenital QT syndrome and comedication with QT time prolonging and CYP2D6-inhibiting drugs. After starting such a comedication, ECG controls to monitor the QT interval are mandatory. These should be closely monitored during the first 2 weeks. A gene test for CYP2D6 metabolism should be performed prior to administration of daily doses above 50 mg to identify poor metabolizers with increased risk.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=58375&amp;highlight=Gentest"" target=""_blank"">tetrabenazin drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450815556.0,"<blockquote class=""blockquote"">
<p>A gene test for CYP2D6 metabolism should be performed prior to administration of daily doses above 50 mg to identify poor metabolizers with increased risk.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166122972,Annotation of FDA Label for fesoterodine and CYP2D6,False,False,[],False,"[{'id': 1184513752, 'date': '2014-08-08T00:00:00-07:00', 'description': 'Created', 'type': 'Create', 'version': 0}, {'id': 1448604462, 'date': '2017-03-15T10:48:49.234-07:00', 'type': 'Update', 'version': 0}, {'id': 1454040360, 'date': '2025-04-23T14:13:05.623-07:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15178202, 'title': 'Drugs@FDA: Drug Product Toviaz (fesoterodine fumarate), Pfizer Laboratories Div Pfizer Inc - NDA022030/SUPPL-23, 02/28/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022030', 'crossReferences': [{'id': 1454040316, 'resource': 'FDA Application', 'resourceId': 'NDA022030/SUPPL-23', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022030'}], 'objCls': 'Literature', 'pubDate': '2024-02-28T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101833, 'title': 'Drugs@FDA: Drug Product Toviaz (fesoterodine fumarate), NDA022030, Avera McKennan Hospital', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022030', 'crossReferences': [{'id': 1449754636, 'resource': 'FDA Application', 'resourceId': 'NDA022030', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022030'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958376', 'name': 'fesoterodine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450361435.0,"<p>The FDA-approved drug label for fesoterodine (TOVIAZ) notes that CYP2D6 poor metabolizers may have increased maximum plasma concentrations of the active metabolite of fesoterodine, as compared to CYP2D6 extensive metabolizers. However, the label does not comment on the clinical significance of these increased concentrations.</p>
",1450361436.0,"<p>Excerpts from the fesoterodine (TOVIAZ) drug label:</p>
<blockquote class=""blockquote"">
<p>After oral administration, fesoterodine is rapidly and extensively hydrolyzed to its active metabolite. The active metabolite is further metabolized in the liver to its carboxy, carboxy-N-desisopropyl, and N-desisopropyl metabolites via two major pathways involving CYP2D6 and CYP3A4. None of these metabolites contribute significantly to the antimuscarinic activity of fesoterodine.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A subset of individuals (approximately 7% of Caucasians and approximately 2% of African Americans) are poor metabolizers for CYP2D6. Cmax and AUC of the active metabolite are increased 1.7-and 2-fold, respectively, in CYP2D6 poor metabolizers, as compared to extensive metabolizers.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Fesoterodine_2025_04_23_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Fesoterodine_2025_04_23_FDA.pdf"">fesoterodine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1454040319.0,"<blockquote class=""blockquote"">
<p>Toviaz is indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25 kg.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166400362,Annotation of FDA Label for deuruxolitinib and CYP2C9,True,False,[],False,[],False,[],True,"[{'id': 15178902, 'title': 'Drugs@FDA: Drug Product LEQSELVI (deuruxolitinib), NDA217900/ORIG-1, 07/25/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217900', 'crossReferences': [{'id': 1454056780, 'resource': 'FDA Application', 'resourceId': 'NDA217900/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217900'}], 'objCls': 'Literature', 'pubDate': '2024-07-25T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166400021', 'name': 'deuruxolitinib'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1454056802.0,"<p>The FDA-approved drug label for deuruxolitinib (LEQSELVI) states that it is contraindicated in patients who are CYP2C9 poor metabolizers. Although the label also states that there is no FDA-approved test to detect CYP2C9 variants, determining the CYP2C9 genotype of patients is listed under &quot;recommended evaluations [...] prior to and during treatment&quot;.</p>
",1454056803.0,"<p>Excerpts from the deuruxolitinib (LEQSELVI) label:</p>
<blockquote class=""blockquote"">
<p>2.1 Recommended Evaluations and Immunizations Prior to and During Treatment</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Perform the following prior to treatment with LEQSELVI:</p>
<ul>
<li>CYP2C9 genotype determination: Test patients for CYP2C9 variants to determine CYP2C9 genotype. LEQSELVI is contraindicated in patients who are CYP2C9 poor metabolizers (patients with decreased cytochrome P450 (CYP) 2C9 function) [see Contraindications (4)]. An FDA-cleared or -approved test for the detection of CYP2C9 variants to direct the use of LEQSELVI is not currently available.</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Based on modeling, higher exposure of deuruxolitinib in patients who are CYP2C9 poor metabolizers is expected with concomitant use of LEQSELVI, which may increase the risk of LEQSELVI-associated serious adverse reactions. Before initiation of treatment with LEQSELVI, test patients to determine CYP2C9 genotype. An FDA-cleared or -approved test for the detection of CYP2C9 variants to direct the use of LEQSELVI is not currently available.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Deuruxolitinib is primarily metabolized by CYP2C9 (76%) and CYP3A4 (21%). CYP2C9 activity is reduced in patients with genetic variants in CYP2C9, such as the CYP2C9*2 and CYP2C9*3 alleles. The impact of CYP2C9 genetic variants on the pharmacokinetics of deuruxolitinib has not been directly evaluated. Based on drug-drug interaction modeling data, CYP2C9 poor metabolizers (e.g., *2/*3, *3/*3) may have up to 2-fold higher concentrations of deuruxolitinib, when compared to normal metabolizers [see Warnings and Precautions (5.6)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The pharmacokinetics of deuruxolitinib were not evaluated in individuals who are intermediate metabolizers (e.g., individuals with *1/*3 genotype).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The prevalence of the CYP2C9 poor metabolizer phenotype is approximately 2 to 3% in White populations, 0.5 to 4% in Asian populations, and &lt;1% in Black or African American populations. Other decreased or nonfunctional CYP2C9 alleles (e.g., *5, *6, *8, *11) are more prevalent in Black or African American populations.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Deuruxolitinib_2025_05_07_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Deuruxolitinib_2025_05_07_FDA.pdf"">deuruxolitinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1454056804.0,"<blockquote class=""blockquote"">
<p>LEQSELVI is contraindicated in patients who:</p>
<ul>
<li>Are CYP2C9 poor metabolizers [...]</li>
</ul>
</blockquote>
",,,,,,,
Label Annotation,PA166400401,Annotation of EMA Label for seladelpar and CYP2C9,False,False,[],False,[],False,[],True,"[{'id': 15178942, 'title': 'Lyvdelzi (previously Seladelpar Gilead) | European Medicines Agency (EMA)', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/lyvdelzi', 'crossReferences': [{'id': 1454057021, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/lyvdelzi', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/lyvdelzi'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166400041', 'name': 'seladelpar'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",EMA,1454057022.0,"<p>The EMA European Public Assessment Report (EPAR) for seladelpar (Lyvdelzi) states that plasma exposure to seladelpar was 18% higher in CYP2C9 intermediate metabolizers compared to CYP2C9 normal metabolizers, and that no conclusion could be made for CYP2C9 poor metabolizers due to limited data.</p>
",1454057023.0,"<p>Excerpts from the seladelpar (Lyvdelzi) EPAR:</p>
<blockquote class=""blockquote"">
<p>Seladelpar is primarily metabolised <em>in vitro</em> by CYP2C9 which is a polymorphic enzyme. Seladelpar plasma exposure (dose-normalised AUC0-inf) was 18% higher in CYP2C9 intermediate metabolisers (*1/*2, *1/*8, *1/*3, *2/*2, n=28) compared to CYP2C9 normal metabolisers (*1/*1, n=84) after a single dose of seladelpar 1 mg to 15 mg. No conclusion could be made for poor metabolisers due to only one identified subject with *2/*3 and no subjects with *3/*3 were identified</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Seladelpar is primarily metabolized by CYP2C9 and to a lesser extent by CYP2C8 and CYP3A4. M2 is a major metabolite observed in human plasma, accounting for 17.6% of the total plasma radioactivity in the mass balance study and approximately doubling the plasma exposure compared to seladelpar. M2 is not expected to have clinically relevant pharmacological effects.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Seladelpar_2025_05_08_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Seladelpar_2025_05_08_EMA.pdf"">seladelpar EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166104841,Annotation of EMA Label for clopidogrel and CYP2C19,False,False,[],False,"[{'id': 1184466989, 'date': '2013-10-25T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1452529862, 'date': '2024-07-17T17:09:53.743-07:00', 'description': 'updated label, added variants', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102918, 'title': 'Plavix | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/plavix', 'crossReferences': [{'id': 1450416941, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/plavix', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/plavix'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165980635', 'symbol': 'CYP2C19*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165980636', 'symbol': 'CYP2C19*3', 'name': '*3'}, {'objCls': 'Haplotype', 'id': 'PA165980637', 'symbol': 'CYP2C19*4', 'name': '*4'}, {'objCls': 'Haplotype', 'id': 'PA165980638', 'symbol': 'CYP2C19*5', 'name': '*5'}, {'objCls': 'Haplotype', 'id': 'PA165816522', 'symbol': 'CYP2C19*6', 'name': '*6'}, {'objCls': 'Haplotype', 'id': 'PA165816523', 'symbol': 'CYP2C19*7', 'name': '*7'}, {'objCls': 'Haplotype', 'id': 'PA165816524', 'symbol': 'CYP2C19*8', 'name': '*8'}]","[{'objCls': 'Chemical', 'id': 'PA449053', 'name': 'clopidogrel'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",EMA,1447981674.0,"<p>The EMA European Public Assessment Report (EPAR) for clopidogrel (Plavix) states that in patients who are CYP2C19 poor metabolizers, clopidogrel at recommended doses forms less of the active metabolite and has a smaller effect on platelet function. The EPAR also discusses literature on the effect of CYP2C19 metabolizer status on clopidogrel pharmacokinetics and antiplatelet response.</p>
",1447981673.0,"<p>Excerpts from the clopidogrel (Plavix) EPAR:</p>
<blockquote class=""blockquote"">
<p>In patients who are poor CYP2C19 metabolisers, clopidogrel at recommended doses forms less of the active metabolite of clopidogrel and has a smaller effect on platelet function. Tests are available to identify a patient's CYP2C19 genotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by <em>ex vivo</em> platelet aggregation assays, differ according to CYP2C19 genotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles are nonfunctional. The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers. Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5, *6, *7, and *8. A patient with poor metaboliser status will possess two loss-of-function alleles as defined above. Published frequencies for the poor CYP2C19 metaboliser genotypes are approximately 2% for Caucasians, 4% for Blacks and 14% for Chinese. Tests are available to determine a patient’s CYP2C19 genotype.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Clopidogrel_2024_07_15_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Clopidogrel_2024_07_15_EMA.pdf"">clopidogrel EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166127706,Annotation of HCSC Label for rabeprazole and CYP2C19,False,False,[],False,"[{'id': 1452535240, 'date': '2024-07-22T23:11:07.435-07:00', 'description': 'Changed label to a different product as Mylan-Rabeprazole is no longer marketed in Canada. Added label document and edited annotation text to fit template.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161542, 'title': 'Drugs@HCSC: Drug Product Pariet (rabeprazole), Janssen Inc', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67734', 'crossReferences': [{'id': 1452535200, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67734', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67734'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451216', 'name': 'rabeprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1447982345.0,"<p>The product monograph for rabeprazole states that individuals with CYP2C19 deficiency have reduced metabolism of rabeprazole.</p>
",1447982344.0,"<p>Excerpts from the rabeprazole (Pariet) product monograph:</p>
<blockquote class=""blockquote"">
<p>Rabeprazole is...metabolized in the liver by cytochromes P450 3A (CYP3A), to a sulphone metabolite, and cytochrome P450 2C19 (CYP2C19), to desmethyl rabeprazole. CYP2C19 exhibits a known genetic polymorphism due to its deficiency in some sub-populations (e.g., 3 to 5% of Caucasians and 17 to 20% of Asians). Rabeprazole metabolism is slow in these sub-populations; therefore, they are referred to as poor metabolizers of the drug.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Rabeprazole_2024_07_23_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Rabeprazole_2024_07_23_HCSC.pdf"">rabeprazole product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166122487,Annotation of EMA Label for propranolol and CYP2D6,False,False,[],False,"[{'id': 1184471866, 'date': '2014-06-26T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452702621, 'date': '2024-11-15T10:52:50.657-08:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102914, 'title': 'Hemangiol | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/hemangiol', 'crossReferences': [{'id': 1450663660, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/hemangiol', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/hemangiol'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451145', 'name': 'propranolol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1447982141.0,"<p>The EMA European Public Assessment Report (EPAR) for propranolol hydrochloride (Hemangiol) gives information regarding the metabolism of the drug by three different routes which varies between individuals, but that no difference in oral clearance or elimination is observed between CYP2D6 extensive and poor metabolizers.</p>
",1447982140.0,"<p>Excerpt from the propranolol hydrochloride (Hemangiol) EPAR:</p>
<div class=""blockquote"">
<p>Propranolol is metabolized through three primary routes: aromatic hydroxylation (mainly 4-hydroxylation), N-dealkylation followed by further side-chain oxidation, and direct glucuronidation. The percentage contributions of these routes to total metabolism are 42%, 41% and 17%, respectively, but with considerable variability between individuals. The four major final metabolites are propranolol glucuronide, naphthyloxylactic acid and glucuronic acid, and sulfate conjugates of 4-hydroxypropranolol. In vitro studies indicated that CYP2D6 (aromatic hydroxylation), CYP1A2 (chain oxidation) and to a less extent CYP2C19 were involved in propranolol metabolism. In healthy subjects, no difference was observed between CYP2D6 extensive metabolizers and poor metabolizers with respect to oral clearance or elimination half-life.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Propranolol_EMA_EPAR_May_22_2014.pdf"">propranolol EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",1452702620.0,"<blockquote class=""blockquote"">
<p>HEMANGIOL is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy:</p>
<ul>
<li>Life- or function-threatening haemangioma,</li>
<li>Ulcerated haemangioma with pain and/or lack of response to simple wound care measures,</li>
<li>Haemangioma with a risk of permanent scars or disfigurement.</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>It is to be initiated in infants aged 5 weeks to 5 months (see section 4.2).</p>
</blockquote>
",1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166127702,"Annotation of HCSC Label for primaquine and CYB5R1, CYB5R2, CYB5R3, CYB5R4, CYP2D6",False,False,[],False,"[{'id': 1452538201, 'date': '2024-07-24T23:19:55.361-07:00', 'description': 'Added Prescribing section, tags and label document', 'type': 'Update', 'version': 0}, {'id': 1452539600, 'date': '2024-07-25T16:54:57.732-07:00', 'description': 'updated label, split G6PD off to a new annotation, added CYP2D6 info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161882, 'title': 'Drugs@HCSC: Drug Product PRIMAQUINE (primaquine), sanofi-aventis Canada Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00057221.PDF', 'crossReferences': [{'id': 1452538180, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00057221.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00057221.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA134979668', 'symbol': 'CYB5R1', 'name': 'cytochrome b5 reductase 1'}, {'objCls': 'Gene', 'id': 'PA142672060', 'symbol': 'CYB5R2', 'name': 'cytochrome b5 reductase 2'}, {'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA134904907', 'symbol': 'CYB5R4', 'name': 'cytochrome b5 reductase 4'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451103', 'name': 'primaquine'}]","[{'objCls': 'Gene', 'id': 'PA134979668', 'symbol': 'CYB5R1', 'name': 'cytochrome b5 reductase 1'}, {'objCls': 'Gene', 'id': 'PA142672060', 'symbol': 'CYB5R2', 'name': 'cytochrome b5 reductase 2'}, {'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA134904907', 'symbol': 'CYB5R4', 'name': 'cytochrome b5 reductase 4'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982487.0,"<p>The product monograph for primaquine states that caution should be used in individuals with NADH methemoglobin reductase (<em>CYB5R1-4</em>) deficiency due to the risk of methemoglobinemia. In case of treatment failure, after checking patient’s compliance to treatment, it may be useful to assess the patient’s CYP2D6 status.</p>
",1447982486.0,"<p>Primaquine is an anti-malarial. Excerpts from the primaquine product monograph:</p>
<blockquote class=""blockquote"">
<p>Primaquine may cause transient increase in methemoglobin levels up to 10% in patients without risk factors (see ADVERSE REACTIONS). Methemoglobinemia may be severe in patients who are deficient in nicotinamide adenine dinucleotide (NADH) methemoglobin reductase or treated with methemoglobinemia-inducing drugs (such as dapsone, or sulfonamide, see DRUG INTERACTIONS). In these cases, close blood monitoring is required.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Based on non-clinical data, primaquine activity probably depends on the formation CYP2D6 metabolite(s). Therefore, CYP2D6 polymorphism may be associated with variability in clinical response to primaquine.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Limited clinical data reported more elevated treatment failure rates in patients with CYP2D6 poor or intermediate metabolizer status than in patients with normal/extensive metabolizer status (see ACTION AND CLINICAL PHARMACOLOGY).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In case of treatment failure, after checking patient’s compliance to treatment, it may be useful to reconsider potential concomitant use of CYP2D6 inhibitors (see DRUG INTERACTIONS) and to assess the patient’s CYP2D6 status if feasible. For poor CYP2D6 metabolizers, alternative treatment should be considered.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Primaquine_2024_07_25_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Primaquine_2024_07_25_HCSC.pdf"">primaquine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452538200.0,"<p>Excerpts from the primaquine product monograph:</p>
<blockquote class=""blockquote"">
<p>Methemoglobinemia may be severe in patients who are deficient in nicotinamide adenine dinucleotide (NADH) methemoglobin reductase [...]. In these cases, close blood monitoring is required.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In case of treatment failure, after checking patient’s compliance to treatment, it may be useful [...] to assess the patient’s CYP2D6 status if feasible. For poor CYP2D6 metabolizers, alternative treatment should be considered.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166104902,Annotation of FDA Label for sulfadiazine and G6PD,False,False,[],False,"[{'id': 1183681276, 'date': '2013-10-25T11:05:37.674-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101923, 'title': 'Drugs@FDA: Drug Product SILVADENE (silver sulfadiazine), NDA017381, Central Texas Community Health Centers', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017381', 'crossReferences': [{'id': 1449794232, 'resource': 'FDA Application', 'resourceId': 'NDA017381', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017381'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451539', 'name': 'sulfadiazine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981781.0,"<p>Sulfadiazine (SILVADENE) is an antimicrobial topical drug used to prevent and treat wound sepsis in second and third degree burns. A link between sulfadiazine-induced hemolytic anemia and G6PD deficiency is highlighted in the Warnings section of the label.</p>
",1447981780.0,"<p>Excerpt from the sulfadiazine (SILVADENE) drug label:</p>
<div class=""blockquote"">
<p>The use of SILVADENE Cream 1% (silver sulfadiazine) in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Sulfadiazine_02_27_19_FDA.pdf"">sulfadiazine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166127707,Annotation of HCSC Label for rasburicase and G6PD,True,False,[],False,"[{'id': 1452595183, 'date': '2024-09-19T09:48:58.313-07:00', 'description': 'updated label, added Pediatric tag and info, added Alternate Drug tag and info, changed PGx level to ""Testing Required"" based on the imperative ""screen patients at higher risk for G6PD deficiency..."" language', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15165942, 'title': 'Drugs@HCSC: Drug Product FASTURTEC (rasburicase), sanofi-aventis Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72766', 'crossReferences': [{'id': 1452595180, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72766', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72766'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA10176', 'name': 'rasburicase'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982341.0,"<p>The product monograph for rasburicase (FASTURTEC) states that patients at higher risk for G6PD deficiency (e.g. those of African or Mediterranean ancestry) be screened prior to starting treatment, due to the risk of severe hemolytic anemia.</p>
",1447982340.0,"<p>Excerpts from the rasburicase (FASTURTEC) product monograph:</p>
<blockquote class=""blockquote"">
<p>Fasturtec (rasburicase for injection) should not be administered to patients with a known history of [...] glucose-6-phosphate dehydrogenase deficiency (G6PD) or other cellular metabolic disorders known to cause hemolytic anemia</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Do not administer Fasturtec to patients with glucose-6phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue Fasturtec if hemolysis occurs. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Fasturtec therapy (see 7 WARNINGS AND PRECAUTIONS, Hematologic).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Fasturtec administered to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency can cause severe hemolysis. Therefore, Fasturtec is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD), in order to prevent hemolytic anemia in this patient population. It is recommended that patients at higher risk for G6PD deficiency (e.g. patients of African or Mediterranean ancestry) be screened prior to starting Fasturtec therapy.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Rasburicase_2024_09_18_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Rasburicase_2024_09_18_HCSC.pdf"">rasburicase product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452595182.0,"<blockquote class=""blockquote"">
<p><strong>Pediatrics (1 month – 18 years of age):</strong> Based on the data submitted and reviewed by Health Canada, the safety and efficacy of Fasturtec in pediatric patients have been established. Therefore, Health Canada has authorized an indication for pediatric use.</p>
</blockquote>
",1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1452595181.0,"<blockquote class=""blockquote"">
<p>Fasturtec (rasburicase for injection) is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD). Hydrogen peroxide is one of the major by-products of the conversion of uric acid to allantoin, and therefore, Fasturtec is contraindicated in patients with G6PD deficiency, in order to prevent hemolytic anemia in this patient population.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166104793,Annotation of FDA Label for risperidone and CYP2D6,False,False,[],False,"[{'id': 1183681450, 'date': '2013-10-25T11:38:49.104-07:00', 'type': 'Update', 'version': 0}, {'id': 1450821622, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1452212340, 'date': '2023-08-22T01:32:09.005-07:00', 'description': 'removed prescribing tag - label advocates not changing prescribing based on CYP2D6 genotype', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101893, 'title': 'Drugs@FDA: Drug Product PERSERIS (Risperidone), NDA210655, Indivior Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210655', 'crossReferences': [{'id': 1450369535, 'resource': 'FDA Application', 'resourceId': 'NDA210655', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210655'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451257', 'name': 'risperidone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981570.0,"<p>The FDA-approved drug label for risperidone (PERSERIS) states that exposure to the total active moiety is similar in CYP2D6 extensive, intermediate and poor metabolizers, supporting no need for dose adjustment based on CYP2D6 genotype.</p>
",1447981569.0,"<p>Excerpt from the risperidone (PERSERIS) drug label:</p>
<div class=""blockquote"">
<p>CYP2D6, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs. CYP2D6 is subject to genetic polymorphism (about 6 to 8% of Caucasians, and a very low percentage of Asians, have little or no activity and are “poor metabolizers”) and to inhibition by a variety of substrates and some non-substrates, notably quinidine. Extensive CYP2D6 metabolizers convert risperidone rapidly into 9-hydroxyrisperidone, whereas poor CYP2D6 metabolizers convert it much more slowly. Plasma exposure to total active moiety was similar in CYP2D6 extensive, intermediate and poor metabolizers following subcutaneous injection with PERSERIS, supporting no need for dose adjustment based on genotype of CYP2D6.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Risperidone_02_25_19_FDA.pdf"">risperidone drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104881,Annotation of FDA Label for glyburide and G6PD,True,False,[],False,"[{'id': 1183681372, 'date': '2013-10-25T11:27:01.052-07:00', 'type': 'Update', 'version': 0}, {'id': 1183704754, 'date': '2013-12-17T00:00:00-08:00', 'type': 'Update', 'version': 0}, {'id': 1452216549, 'date': '2023-08-25T00:37:34.839-07:00', 'description': 'Added ""Alternate Drug"" tag based on updated definition', 'type': 'Update', 'version': 0}, {'id': 1452583300, 'date': '2024-09-09T00:00:00-07:00', 'description': 'added FDA Biomarker List label, drug is listed under the glyburide synonym', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102045, 'title': 'Drugs@FDA: Drug Product Glynase (glyburide), NDA020051, Pharmacia and Upjohn Company LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020051', 'crossReferences': [{'id': 1449754731, 'resource': 'FDA Application', 'resourceId': 'NDA020051', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020051'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449782', 'name': 'glyburide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981747.0,"<p>The FDA-approved drug label for glibenclamide (glyburide; GLYNASE PresTab) notes that caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.</p>
",1447981746.0,"<p>Excerpt from the glibenclamide (GLYNASE PresTab) drug label:</p>
<div class=""blockquote"">
<p>Hemolytic Anemia: Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because GLYNASE PresTab belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. In post marketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Glyburide_01_24_19_FDA.pdf"">glibenclamide drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399093.0,"<p>Excerpt from the glibenclamide (GLYNASE PresTab) drug label:</p>
<blockquote class=""blockquote"">
<p>Because GLYNASE PresTab belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166127633,Annotation of HCSC Label for atomoxetine and CYP2D6,False,False,[],False,"[{'id': 1452721382, 'date': '2024-12-02T10:30:43.432-08:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171322, 'title': 'Drugs@HCSC: Drug Product JAMP Atomoxetine (atomoxetine), JAMP Pharma Corporation', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99616', 'crossReferences': [{'id': 1452721380, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99616', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99616'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA134688071', 'name': 'atomoxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982307.0,"<p>The product monograph for atomoxetine notes that CYP2D6 poor metabolizers (PMs) have a 10-fold higher area under the curve (AUC) and a 5-fold higher peak concentration of the drug as compared to extensive metabolizers (EM); this leads to a higher rate of some adverse events for PMs compared to EMs.</p>
",1447982306.0,"<p>Atomoxetine is indicated for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). Excerpts from the atomoxetine product monograph:</p>
<blockquote class=""blockquote"">
<p>Poor metabolizers (PMs) of CYP2D6 have a 10-fold higher AUC and a 5-fold higher peak concentration to a given dose of atomoxetine capsules compared with extensive metabolizers (EMs). Approximately 7% of a Caucasian population are PMs. Laboratory tests are available to identify CYP2D6 PMs. The blood levels in PMs are similar to those attained by taking strong inhibitors of CYP2D6. The higher blood levels in PMs lead to a higher rate of some adverse effects of atomoxetine capsules (see ADVERSE REACTIONS).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The following adverse events occurred in at least 2% of child and adolescent CYP2D6 PM patients and were statistically significantly more frequent in PM patients compared with CYP2D6 EM patients: appetite decreased (24% of PMs, 17% of EMs); insomnia and middle insomnia (14% of PMs, 7% of EMs); weight decreased (7% of PMs, 4% of EMs); constipation (7% of PMs, 4% of EMs); sedation (4% of PMs, 2% of EMs); depression and/or depressed mood (5% of PMs, 3% of EMs); abrasion (4% of PMs, 2% of EMs); tremor (5% of PMs, 1% of EMs); early morning awakening (2% of PMs, 1% of EMs); enuresis (3% of PMs, 1% of EMs); pruritus (3% of PMs, 1% of EMs); mydriasis (2% of PMs, 1% of EMs); conjunctivitis (3% of PMs, 1% of EMs); syncope (2% of PMs, 1% of EMs); animal bite (2% of PMs, 1% of EMs).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The following adverse events occurred in at least 2% of adult CYP2D6 poor metaboliser (PM) patients and were statistically significantly more frequent in PM patients compared to CYP2D6 extensive metaboliser (EM) patients: vision blurred (3.9% of PMs, 1.3% of EMs); dry mouth (34.5% of PMs, 17.4% of EMs); constipation (11.3% of PMs, 6.7% EMs); feeling jittery (4.9% PMs, 1.9% of EMs); decreased appetite (23.2% of PMs, 14.7% of EMs); tremor (5.4% of PMs, 1.2% of EMs); insomnia (19.2% of PMs, 11.3% of EMs); sleep disorder (6.9% of PMs, 3.4% of EMs); middle insomnia (5.4% of PMs, 2.7% of EMs); terminal insomnia (3.0% of PMs, 0.9% of EMs); urinary retention (5.9% of PMs, 1.2% of EMs); erectile dysfunction (20.9% of PMs, 8.9% of EMs); ejaculation disorder (6.1% of PMs, 2.2% of EMs); hyperhidrosis (14.8% of PMs, 6.8% of EMs); peripheral coldness (3.0% of PMs, 0.5% or EMs).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>There are two major phenotypes associated with CYP2D6: extensive metabolizers that comprise &gt; 90% of the population, and poor metabolizers. Approximately 7% of the Caucasian population and 2% of Black population are poor metabolizers of CYP2D6.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Atomoxetine_2024_11_22_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Atomoxetine_2024_11_22_HCSC.pdf"">atomoxetine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452721381.0,"<blockquote class=""blockquote"">
<p>JAMP Atomoxetine (atomoxetine hydrochloride) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children 6 years of age and over, adolescents, and adults.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166159707,Annotation of HCSC Label for atazanavir and CYP2C19,False,False,[],False,"[{'id': 1452488802, 'date': '2024-05-30T14:20:52.582-07:00', 'description': 'updated label, changed level to Actionable, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15158842, 'title': 'Drugs@HCSC: Drug Product JAMP Atazanavir (atazanavir), JAMP Pharma Corporation', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100234', 'crossReferences': [{'id': 1452488800, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100234', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100234'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10251', 'name': 'atazanavir'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1448124849.0,"<p>Atazanavir is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. The HCSC-approved product monograph for atazanavir contains pharmacogenetic information related to co-treatment with voriconazole and ritonavir. The use of voriconazole in patients with a functional CYP2C19 allele and receiving atazanavir with ritonavir is not recommended unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.</p>
",1448124848.0,"<p>Excerpts from the atazanavir (JAMP Atazanavir) product monograph:</p>
<blockquote class=""blockquote"">
<p>atazanavir capsules/ ritonavir in subjects with a functional CYP2C19 allele: Voriconazole should not be administered to patients receiving JAMP Atazanavir and ritonavir (100 mg once daily) unless an assessment of the benefit/risk to the patient justifies the use of voriconazole. Patients should be carefully monitored for voriconazole-associated adverse events and loss of either voriconazole or atazanavir efficacy during the co-administration of voriconazole and JAMP Atazanavir/ritonavir.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>atazanavir capsules/ ritonavir in subjects without a functional CYP2C19 allele: Co-administration of voriconazole with JAMP Atazanavir (without ritonavir) may increase atazanavir concentrations; however, no data are available. Co-administration of voriconazole with high-dose ritonavir (400 mg every 12 hours) is contraindicated due to a significant reduction in voriconazole plasma concentrations and possible loss of effect. Please see the NORVIR (ritonavir) and VFEND* (voriconazole) Product Monograph for additional information.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Atazanavir_2024_05_30_HSCS.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Atazanavir_2024_05_30_HSCS.pdf"">atazanavir product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452488801.0,"<blockquote class=""blockquote"">
<p>JAMP Atazanavir (atazanavir capsules) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients 6 years of age and older weighing at least 20 kg.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166115435,Annotation of EMA Label for timolol and CYP2D6,False,False,[],False,"[{'id': 1183702953, 'date': '2014-01-22T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1450933215, 'date': '2019-12-04T13:30:15.425-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452215422, 'date': '2023-08-24T16:09:27.779-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103659, 'title': 'Ganfort | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ganfort', 'crossReferences': [{'id': 1450932891, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ganfort', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ganfort'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451690', 'name': 'timolol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1447982073.0,"<p>The EMA EPAR for timolol contains information regarding potentiated beta-blockade when treatment is combined with CYP2D6 inhibitors. No pharmacogenetic information was found in the label.</p>
",1447982072.0,"<p>Excerpt from the timolol (Ganfort) EPAR:</p>
<blockquote class=""blockquote"">
<p>Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.</p>
</blockquote>
<p>This information is highlighted in the following sections: Interaction with other medicinal products and other forms of interaction.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Ganfort_EMA_EPAR_31_Oct_2013.pdf"">timolol (Ganfort) EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166114378,Annotation of EMA Label for telaprevir and IFNL3,False,False,[],False,"[{'id': 1184512684, 'date': '2013-10-28T00:00:00-07:00', 'type': 'Create', 'version': 0}]",False,[],True,"[{'id': 15102912, 'title': 'Incivo | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/incivo', 'crossReferences': [{'id': 1450806129, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/incivo', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/incivo'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958354', 'name': 'telaprevir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",EMA,1447981767.0,"<p>The EMA European Public Assessment Report (EPAR) for telaprevir (Incivo) contains a table showing higher SVR rates for patients with the IL28B (IFNL3) CC genotype compared to those with CT or TT when treated with the telaprevir, peginterferon alfa-2a and ribavirin drug combination, though this is not discussed further in the main text. <strong>Please note that as of September 2016 telaprevir (Incivo) has been <a rel=""noopener noreferrer"" href=""https://www.ema.europa.eu/en/medicines/human/EPAR/incivo"" target=""_blank"">withdrawn</a> from use in the European Union.</strong></p>
",1447981766.0,"<p><strong>Please note that as of September 2016 telaprevir (Incivo) has been <a rel=""noopener noreferrer"" href=""https://www.ema.europa.eu/en/medicines/human/EPAR/incivo"" target=""_blank"">withdrawn</a> from use in the European Union.</strong></p>
<p>Excerpt from the telaprevir (Incivo) EPAR:</p>
<div class=""blockquote"">
<p>Table 6 shows SVR rates by IL28B genotype and the stage of liver fibrosis at baseline.</p>
</div>
<div class=""blockquote"">
<p><em>Table 6: SVR rates for patient subgroups: Study C211</em></p>
</div>
<div class=""blockquote"">
<table class=""table"">
<thead>
<tr><th>Subgroup</th><th>T12(b.i.d.)/PR  N=369  %(n/N)</th><th>T12(q8h)/PR  N=371  %(n/N)</th></tr>
</thead>
<tbody>
<tr><td>IL28B genotype</td><td></td><td></td></tr>
<tr><td>CC</td><td>92% (97/105)</td><td>87% (92/106)</td></tr>
<tr><td>CT</td><td>67% (139/206)</td><td>68% (141/208)</td></tr>
<tr><td>TT</td><td>66% (38/58)</td><td>65% (37/57)</td></tr>
</tbody>
</table>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Incivo_EMA_EPAR_28_Oct_2013.pdf"">telaprevir EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166114913,Annotation of FDA Label for dabrafenib and G6PD,False,False,[],False,"[{'id': 1183704744, 'date': '2013-12-13T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1449037850, 'date': '2017-11-09T12:51:31.026-08:00', 'type': 'Update', 'version': 0}, {'id': 1452312460, 'date': '2023-11-30T00:00:00-08:00', 'description': 'Updated label and label source.', 'type': 'Update', 'version': 0}, {'id': 1452473361, 'date': '2024-05-14T13:47:23.502-07:00', 'description': 'added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1452817207, 'date': '2025-01-17T15:15:28.224-08:00', 'description': 'updated label; added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15173162, 'title': 'Drugs@FDA: Drug Product Tafinlar (dabrafenib), Novartis Pharmaceuticals Corporation - NDA202806/SUPPL-31, 07/11/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806', 'crossReferences': [{'id': 1452817193, 'resource': 'FDA Application', 'resourceId': 'NDA202806/SUPPL-31', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806'}], 'objCls': 'Literature', 'pubDate': '2024-07-11T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,True,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166114911', 'name': 'dabrafenib'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450342866.0,"<p>The drug label for dabrafenib (TAFINLAR) states that it is indicated, as a single agent or in combination with trametinib, for patients with certain types of cancer. The label also notes that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have a risk for developing hemolytic anemia, and that these patients should be closely observed when taking dabrafenib.</p>
",1450342867.0,"<p>Excerpt from the dabrafenib (TAFINLAR) drug label:</p>
<blockquote class=""blockquote"">
<p>TAFINLAR, which contains a sulfonamide moiety, confers a potential risk of hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Monitor patients with G6PD deficiency for signs of hemolytic anemia while taking TAFINLAR.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Dabrafenib_2025_01_17_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dabrafenib_2025_01_17_FDA.pdf"">dabrafenib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452817206.0,"<blockquote class=""blockquote"">
<p>TAFINLAR is indicated, in combination with trametinib, for: [...]</p>
<ul>
<li>the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (1.6, 2.1)</li>
<li>the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (1.7, 2.1)</li>
</ul>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452473360.0,"<p>Excerpt from the dabrafenib (TAFINLAR) drug label:</p>
<blockquote class=""blockquote"">
<p>TAFINLAR, which contains a sulfonamide moiety, confers a potential risk of hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.  Monitor patients with G6PD deficiency for signs of hemolytic anemia while taking TAFINLAR.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166122969,Annotation of EMA Label for vardenafil,False,False,[],False,"[{'id': 1184513632, 'date': '2014-08-07T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933217, 'date': '2019-12-04T13:31:05.622-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452220461, 'date': '2023-08-29T12:49:52.130-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103661, 'title': 'Levitra | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/levitra', 'crossReferences': [{'id': 1450932893, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/levitra', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/levitra'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10229', 'name': 'vardenafil'}]",[],EMA,1447982115.0,"<p>The EMA European Public Assessment Report (EPAR) for vardenafil (Levitra) contains genetic information regarding its contraindication in patients with hereditary retinal degenerative disorders. It also mentions that the drug is metabolized primarily by CYP3A4 and that concomitant use of potent CYP3A4 inhibitors is contraindicated, or dose adjustments should be made when prescribed with moderate CYP3A4 inhibitors.</p>
",1447982114.0,"<p>Vardenafil (Levitra) is contraindicated in patients with hereditary degenerative retinal disorders, such as retinitis pigmentosa. Variants in different genes can underlie these disorders (see <a rel=""noopener noreferrer"" href=""http://omim.org/entry/268000"" target=""_blank"">OMIM</a> for more information). The drug is also contraindicated in patients with hereditary fructose intolerance due to the presence of sorbitol in the tablet composition (fructose intolerance is caused by variants within the <em>ALDOB</em> gene - see <a rel=""noopener noreferrer"" href=""http://omim.org/entry/229600"" target=""_blank"">OMIM</a> for more information).</p>
<p>Excerpts from the vardenafil (Levitra) EPAR:</p>
<blockquote class=""blockquote"">
<p>The safety of vardenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated until further information is available:</p>
</blockquote>
<ul>
<li>severe hepatic impairment (Child-Pugh C),</li>
<li>end stage renal disease requiring dialysis,</li>
<li>hypotension (blood pressure &lt;90/50 mmHg),</li>
<li>recent history of stroke or myocardial infarction (within the last 6 months),</li>
<li>unstable angina, and known hereditary retinal degenerative disorders such as retinitis pigmentosa.</li>
</ul>
<blockquote class=""blockquote"">
<p>Concomitant use of vardenafil with the potent CYP3A4 inhibitors ketoconazole and itraconazole (oral form) is contraindicated in men older than 75 years.</p>
<p>Concomitant use of vardenafil with HIV protease inhibitors such as ritonavir and indinavir is contraindicated, as they are very potent inhibitors of CYP3A4 (see section 4.5).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/vardenafil_EMA_EPAR_Aug_6_2014.pdf"">vardenafil (Levitra) EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166122826,Annotation of EMA Label for voriconazole and CYP2C19,False,False,[],False,"[{'id': 1184512688, 'date': '2014-08-06T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933218, 'date': '2019-12-04T13:31:46.026-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452220520, 'date': '2023-08-29T12:56:08.385-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}, {'id': 1452725360, 'date': '2024-12-04T15:24:00.285-08:00', 'description': 'updated label, changed PGx level to Informative, removed CYP2C9, CYP3A4 genes', 'type': 'Update', 'version': 0}, {'id': 1452824221, 'date': '2025-01-24T11:45:52.751-08:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103662, 'title': 'Vfend | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vfend', 'crossReferences': [{'id': 1450932894, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vfend', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vfend'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10233', 'name': 'voriconazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",EMA,1447982137.0,"<p>The EMA European Public Assessment Report (EPAR) for voriconazole (VFEND) notes that CYP2C19 poor metabolizers have, on average, 4-fold higher exposure to the drug as compared to extensive metabolizers.</p>
",1447982136.0,"<p>Excerpts from the voriconazole (VFEND) EPAR:</p>
<blockquote class=""blockquote"">
<p><em>In vitro</em> studies showed that voriconazole is metabolised by the hepatic cytochrome P450 isoenzymes CYP2C19, CYP2C9 and CYP3A4.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>In vivo</em> studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 15-20% of Asian populations may be expected to be poor metabolisers. For Caucasians and Blacks the prevalence of poor metabolisers is 3-5%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolisers have, on average, 4-fold higher voriconazole exposure (AUCτ) than their homozygous extensive metaboliser counterparts. Subjects who are heterozygous extensive metabolisers have on average 2-fold higher voriconazole exposure than their homozygous extensive metaboliser counterparts.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Voriconazole_2024_12_04_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Voriconazole_2024_12_04_EMA.pdf"">voriconazole EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",1452824220.0,"<blockquote class=""blockquote"">
<p>VFEND, is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above [...]</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166127704,Annotation of HCSC Label for propafenone and CYP2D6,False,False,[],False,"[{'id': 1452702521, 'date': '2024-11-15T09:29:56.347-08:00', 'description': 'updated label, changed PGx level to No Clinical PGx', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15170202, 'title': 'Drugs@HCSC: Drug Product APO-PROPAFENONE (propafenone), APOTEX INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67227', 'crossReferences': [{'id': 1452702520, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67227', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67227'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451131', 'name': 'propafenone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982339.0,"<p>The product monograph for propafenone notes that individuals with reduced CYP2D6 activity may have higher plasma concentrations of the drug as compared to those who do not have reduced CYP2D6 activity, but despite these differences in pharmacokinetics, steady-state conditions are achieved after three to four days of dosing in both patient populations.</p>
",1447982338.0,"<p>Propafenone is indicated for the treatment of life-threatening ventricular arrhythmias. Excerpts from the propafenone product monograph:</p>
<blockquote class=""blockquote"">
<p>Due to a genetically determined presence or deficiency of one metabolizing pathway (CYP2D6), patients may be categorized into fast (over 90% of all patients) or slow metabolizers of propafenone hydrochloride, resulting in low or high plasma concentrations respectively. [...]</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Slow metabolizers had higher propafenone plasma concentrations which they required for suppression of arrhythmia since they did not produce the active metabolite 5-hydroxypropafenone (5-OHP). These higher propafenone plasma concentrations may lead to clinically evident beta-blockade.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Despite these differences in pharmacokinetics, steady-state conditions are achieved after three to four days of dosing in all patients (fast and slow metabolizers).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Propafenone_2024_11_15_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Propafenone_2024_11_15_HCSC.pdf"">propafenone product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166127701,Annotation of HCSC Label for phenytoin and HLA-B,True,False,[],False,"[{'id': 1452594162, 'date': '2024-09-18T12:00:09.399-07:00', 'description': 'updated label, added Pediatric tag and info, Alternate Drug tag and prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15165922, 'title': 'Drugs@HCSC: Drug Product DILANTIN (phenytoin), BGP Pharma ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1036', 'crossReferences': [{'id': 1452594122, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1036', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1036'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165954769', 'symbol': 'HLA-B*15:02', 'name': '*15:02'}]","[{'objCls': 'Chemical', 'id': 'PA450947', 'name': 'phenytoin'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",HCSC,1447982391.0,"<p>The product monograph for phenytoin (DILANTIN) notes that individuals with the HLA-B*15:02 allele have an increased risk of developing Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) when receiving the drug. It further notes that this allele is common in individuals of Asian ancestry, and HLA-B genotyping should be considered as a screening tool in these patients. The use of phenytoin should be avoided in patients who test positive for the HLA-B*15:02 allele.</p>
",1447982390.0,"<p>Excerpts from the phenytoin (DILANTIN) product monograph:</p>
<blockquote class=""blockquote"">
<p><strong>HLA-B*1502</strong>
In studies that included small samples of patients of Asian ancestry a strong association was found between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA-B gene. The HLA-B*1502 allele is found almost exclusively in individuals with ancestry across broad areas of Asia1. Results of these studies suggest that the presence of the HLA-B*1502 allele may be one of the risk factors for phenytoin-associated SJS/TEN in patients with Asian ancestry.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Therefore, physicians should consider HLA-B*1502 genotyping as a screening tool in these patients. Until further information is available, the use of phenytoin and other anti-epileptic drugs associated with SJS/TEN should also be avoided in patients who test positive for the HLA-B*1502 allele.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Important Limitations of HLA-B*1502 Genotyping</strong>
HLA-B*1502 genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management. Many HLA-B*1502-positive Asian patients treated with phenytoin will not develop SJS/TEN, and these reactions can still occur infrequently in HLA-B*1502-negative patients of any ethnicity. The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug (AED) dose, compliance, concomitant medications, co-morbidities, and the level of dermatologic monitoring have not been studied.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In addition, it should be kept in mind that the majority of phenytoin treated patients who will experience SJS/TEN have this reaction within the first few months of treatment. This information may be taken into consideration when deciding whether to screen genetically at-risk patients currently on phenytoin.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Should signs and symptoms suggest a severe skin reaction such as SJS or TEN, phenytoin should be withdrawn at once, under clinical supervision.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Phenytoin_2024_09_18_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Phenytoin_2024_09_18_HCSC.pdf"">phenytoin product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452594161.0,"<p>Phenytoin is HCSC-indicated for pediatric use. The product monograph contains information on recommended dose and dosage adjustments.</p>
<p>Excerpt from the phenytoin (DILANTIN) product monograph:</p>
<blockquote class=""blockquote"">
<p><strong>Pediatrics (&lt; 18 years of age)</strong>
Initially, 5 mg/kg/day in two or three equally divided doses, with subsequent dosage individualized to a maximum of 300 mg daily. A recommended daily maintenance dosage is usually 4 to 8 mg/kg. Children over 6 years old may require the minimum adult dose (300 mg/day). Pediatric dosage forms available include a 30 mg extended phenytoin sodium capsule, a 50 mg palatably flavoured chewable tablet, or an oral suspension form containing 30 mg of phenytoin in each 5 mL.</p>
</blockquote>
",1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1452594160.0,"<blockquote class=""blockquote"">
<p>Until further information is available, the use of phenytoin and other anti-epileptic drugs associated with SJS/TEN should also be avoided in patients who test positive for the HLA-B*1502 allele.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127635,Annotation of HCSC Label for azathioprine and TPMT,False,False,[],False,"[{'id': 1452530941, 'date': '2024-07-18T16:58:36.347-07:00', 'description': 'updated label, added Other Guidance tag and prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160862, 'title': 'Drugs@HCSC: Drug Product APO-AZATHIOPRINE (azathioprine), APOTEX INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66740', 'crossReferences': [{'id': 1452530920, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66740', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66740'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448515', 'name': 'azathioprine'}]","[{'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",HCSC,1447982319.0,"<p>The product monograph for azathioprine notes that individuals with an inherited deficiency of the thiopurine methyltransferase (TPMT) enzyme may be at risk for developing myelosuppression when treated with the drug, and that close monitoring of blood counts is necessary.</p>
",1447982318.0,"<p>Excerpts from the azathioprine (APO-AZATHIOPRINE) product monograph:</p>
<blockquote class=""blockquote"">
<p>There are individuals with an inherited deficiency of the enzyme thiopurine methyl-transferase (TPMT) who may be unusually sensitive to the myelosuppressive effect of azathioprine and prone to developing rapid bone marrow depression following the initiation of treatment with APO-AZATHIOPRINE. This problem could be exacerbated by coadministration with drugs that inhibit TPMT, such as olsalazine, mesalazine or sulphasalazine. Also a possible association between decreased TPMT activity and secondary leukemias and myelodysplasia has been reported in individuals receiving 6-mercaptopurine (the active metabolite of azathioprine) in combination with other cytotoxics. Some laboratories offer testing for TPMT deficiency, although these tests have not been shown to identify all patients at risk of severe toxicity. Therefore close monitoring of blood counts is still necessary.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Reduced thiopurine doses for patients who carry the NUDT15 variants may decrease their risk of toxicity. Therefore, genotypic analysis determining NUDT15 genotype should be determined for all patients, including paediatric patients, prior to initiating thiopurine treatment (see 4.2 Recommended Dose and Dosage Adjustment, Patients with NUDT15 variant). The prescribing physician is advised to establish whether dose reduction is required based on patient response to treatment as well as their genetic profile.
Patients with variants in both the NUDT15 and TPMT enzymes are significantly less tolerant of thiopurines than those with risk alleles in only one of these two genes.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Azathioprine_2024_07_18_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Azathioprine_2024_07_18_HCSC.pdf"">azathioprine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452530940.0,"<p>Excerpt from the azathioprine (APO-AZATHIOPRINE) product monograph:</p>
<blockquote class=""blockquote"">
<p>There are individuals with an inherited deficiency of the enzyme thiopurine methyl-transferase (TPMT) who may be unusually sensitive to the myelosuppressive effect of azathioprine and prone to developing rapid bone marrow depression following the initiation of treatment with APO-AZATHIOPRINE. [...] Some laboratories offer testing for TPMT deficiency, although these tests have not been shown to identify all patients at risk of severe toxicity. Therefore close monitoring of blood counts is still necessary.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127647,Annotation of HCSC Label for celecoxib and CYP2C9,False,False,[],True,"[{'id': 1452532041, 'date': '2024-07-19T10:33:20.245-07:00', 'description': 'updated label, added Dosing Info tag and text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161022, 'title': 'Drugs@HCSC: Drug Product pmsc-CELECOXIB (celecoxib), PHARMASCIENCE INC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100645', 'crossReferences': [{'id': 1452532020, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100645', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100645'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]","[{'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA448871', 'name': 'celecoxib'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",HCSC,1447982223.0,"<p>The product monograph for celecoxib (pmsc-CELECOXIB) notes that patients who are CYP2C9 poor metabolizers should be administered celecoxib with caution. It further states that the drug should be introduced at half the lowest recommended dose in these individuals, with a maximum recommended dose of 100 mg/day. However, the product monograph does not discuss CYP2C9 genotyping prior to treatment.</p>
",1447982222.0,"<p>Excerpts from the celecoxib (pmsc-CELECOXIB) product monograph:</p>
<blockquote class=""blockquote"">
<p>Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. These metabolites are inactive as COX-1 or COX-2 inhibitors. Cytochrome P450 2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*3 polymorphism. Patients who are known or suspected to be P450 2C9 poor metabolizers based on a previous history should be administered pmsc-CELECOXIB with caution as they may have abnormally high plasma levels due to reduced metabolic clearance. The maximum recommended dose in CYP2C9 poor metabolizers is 100 mg daily (see 7.1 Special Populations, CYP2C9 Poor Metabolizers and 9 DRUG INTERACTIONS).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In a pharmacokinetic study of celecoxib 200 mg administered once daily in healthy volunteers, genotyped as either CYP2C9*1/*1, CYP2C9*1/*3, or CYP2C9*3/*3, the median Cmax and AUC 0-24 of celecoxib on Day 7 were approximately 4-fold and 7-fold, respectively, in subjects genotyped as CYP2C9*3/*3 compared to other genotypes. In three separate single dose studies, involving a total of 5 subjects genotyped as CYP2C9*3/*3, single-dose AUC 0-24 increased by approximately 3-fold compared to normal metabolizers. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3 – 1.0% among different ethnic groups.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Celecoxib_2024_07_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Celecoxib_2024_07_19_HCSC.pdf"">celecoxib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452532040.0,"<blockquote class=""blockquote"">
<p>Patients who are known, or suspected to be CYP2C9 poor metabolizers based on previous history/experience with other CYP2C9 substrates should be administered pmsc-CELECOXIB with caution. pmsc-CELECOXIB should be introduced at half the lowest recommended dose in CYP2C9 poor metabolizers, with a maximum recommended dose of 100 mg daily (see 9 DRUG INTERACTIONS and 4 DOSAGE AND ADMINISTRATION).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127649,Annotation of HCSC Label for chlorpropamide and G6PD,True,False,[],False,"[{'id': 1452532281, 'date': '2024-07-19T13:52:23.684-07:00', 'description': 'label has ""dormant"" status; label annotation was retired', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161042, 'title': 'Drugs@HCSC: Drug Product APO-CHLORPROPAMIDE (chlorpropamide), APOTEX INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2658', 'crossReferences': [{'id': 1452532100, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2658', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2658'}], 'notes': 'Current status: Dormant', 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448966', 'name': 'chlorpropamide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982219.0,"<p>The product monograph for chlorpropamide notes that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.</p>
<p><strong>Please note that as of July 2024, the drug label for chlorpropamide (APO-CHLORPROPAMIDE) has the Status: Dormant on the HCSC database. As a result, this label annotation has been retired.</strong></p>
",1447982218.0,"<p>Excerpts from the chlorpropamide product monograph:</p>
<blockquote class=""blockquote"">
<p>Hemolytic anemia: Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because APO-CHLORPROPAMIDE belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. In post-marketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Chlorpropamide_HCSC_05_20_15.pdf"">chlorpropamide product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452532280.0,"<blockquote class=""blockquote"">
<p>Hemolytic anemia: Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because APO-CHLORPROPAMIDE belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. In post-marketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency.</p>
</blockquote>
",1451832060.0,Retirement Reason,[],Other,retirement:1451832060,True,
Label Annotation,PA166127650,Annotation of HCSC Label for citalopram and CYP2C19,False,False,[],True,"[{'id': 1452532361, 'date': '2024-07-19T14:57:19.370-07:00', 'description': 'updated label, added Dosing Info tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161102, 'title': 'Drugs@HCSC: Drug Product CELEXA (citalopram), Lundbeck Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63077', 'crossReferences': [{'id': 1452532340, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63077', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63077'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449015', 'name': 'citalopram'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1447982255.0,"<p>The product monograph for citalopram (CELEXA) recommends that patients who are CYP2C19 poor metabolizers receive an initial dose of 10 mg daily during the first two weeks of treatment, and should not receive a dose of greater than 20 mg/day. However, it makes no statements regarding genetic testing of CYP2C19 prior to treatment.</p>
",1447982254.0,"<p>Excerpts from the citalopram (CELEXA) product monograph:</p>
<blockquote class=""blockquote"">
<p>An initial dose of 10 mg daily during the first two weeks of treatment is recommended for patients who are known to be poor metabolisers of CYP2C19. The dose may be increased to a maximum of 20 mg daily depending on individual patient response (see 10.3 Pharmacokinetics, Metabolism). CELEXA 20 mg/day is also the maximum recommended dose for patients taking concomitant CYP2C19 inhibitors (e.g. cimetidine) because of the risk of QT prolongation.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In vitro studies indicated that the biotransformation of citalopram to its demethyl metabolites depends on both CYP2C19 and CYP3A4, with a small contribution from CYP2D6. An initial dose of 10 mg is recommended for known poor metabolisers of CYP2C19 (see 4.2 Recommended Dose and Dosage Adjustment, CYP2C19 Poor Metabolisers).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Citalopram_2024_07_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Citalopram_2024_07_19_HCSC.pdf"">citalopram product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452532360.0,"<blockquote class=""blockquote"">
<p>Reduced dosing: Use lower initial (10 mg) and maximum (20 mg) daily doses for [...]
CYP2C19 poor metabolizers, or those taking cimetidine, omeprazole or other CYP2C19 inhibitors, due to the risk of QT interval prolongation.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127705,Annotation of HCSC Label for quinine and G6PD,True,False,[],False,"[{'id': 1452533361, 'date': '2024-07-22T00:54:35.168-07:00', 'description': 'Added Prescribing section, tags and label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161263, 'title': 'Drugs@HCSC: Drug Product Teva Quinine (quinine), Teva Canada Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=651', 'crossReferences': [{'id': 1452533326, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=651', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=651'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451213', 'name': 'quinine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982229.0,"<p>The product monograph for quinine states that it is contraindicated in patients with G6PD deficiency. However, it makes no statements regarding testing for G6PD deficiency prior to treatment.</p>
",1447982228.0,"<p>Quinine is an antimalarial agent. Excerpts from the quinine product monograph:</p>
<blockquote class=""blockquote"">
<p>Contraindications...patients with G-6-PD deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients at risk for G-6-PD deficiency should not be breastfed until this disease can be ruled out.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Quinine_HCSC_06_04_15.pdf"">quinine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452533360.0,"<p>Excerpts from the quinine product monograph:</p>
<blockquote class=""blockquote"">
<p>Contraindications...patients with G-6-PD deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients at risk for G-6-PD deficiency should not be breastfed until this disease can be ruled out.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166105321,"Annotation of EMA Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5",False,False,[],False,"[{'id': 1184512676, 'date': '2013-10-27T00:00:00-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102963, 'title': 'Efient | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/efient', 'crossReferences': [{'id': 1450663659, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/efient', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/efient'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA154410481', 'name': 'prasugrel'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}, {'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA131', 'symbol': 'CYP3A5', 'name': 'cytochrome P450 family 3 subfamily A member 5'}]",EMA,1447982008.0,"<p>The EMA European Public Assessment Report (EPAR) for prasugrel (Efient) contains information regarding the lack of effect of genetic variants in the CYP3A5, CYP2B6, CYP2C9 and CYP2C19 genes on the pharmacokinetics of prasugrel or response.</p>
",1447982007.0,"<p>Excerpt from the prasugrel (Efient) EPAR:</p>
<div class=""blockquote"">
<p>In healthy subjects, patients with stable atherosclerosis, and patients with ACS receiving Efient, there was no relevant effect of genetic variation in CYP3A5, CYP2B6, CYP2C9, or CYP2C19 on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Prasugrel_EMA_EPAR_25July2013.pdf"">prasugrel EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166127646,Annotation of HCSC Label for carvedilol and CYP2D6,False,False,[],False,"[{'id': 1452531961, 'date': '2024-07-19T10:07:06.789-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161002, 'title': 'Drugs@HCSC: Drug Product APO-CARVEDILOL (carvedilol), APOTEX INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72243', 'crossReferences': [{'id': 1452531960, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72243', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72243'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448817', 'name': 'carvedilol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982413.0,"<p>The product monograph for carvedilol notes that CYP2D6 poor metabolizers exhibit 2- to 3-fold higher plasma concentrations of R( + )-carvedilol compared to extensive metabolizers. Plasma levels of S( - )-carvedilol are increased only about 20 - 25% in poor metabolizers.</p>
",1447982412.0,"<p>Carvedilol is indicated for treatment of congestive heart failure. Carvedilol is a racemic mixture and undergoes stereoselective first-pass metabolism.</p>
<p>Excerpts from the carvedilol (APO-CARVEDILOL) product monograph:</p>
<blockquote class=""blockquote"">
<p>Carvedilol is subject to genetic polymorphism with poor metabolizers of debrisoquin (deficient in CYP2D6) exhibiting 2- to 3-fold higher plasma concentrations of the R(+)-carvedilol compared to extensive metabolizers. In contrast, plasma levels of S(-)-carvedilol are increased only about 20% to 25% in poor metabolizers, indicating that the metabolism of this enantiomer is affected to a lesser extent by CYP2D6 than R(+)-carvedilol. The pharmacokinetics of carvedilol enantiomers do not appear to be different in poor metabolizers of S-mephenytoin, i.e., deficient in CYP2C19.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Carvedilol_2024_07_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Carvedilol_2024_07_19_HCSC.pdf"">carvedilol product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166127708,Annotation of HCSC Label for risperidone and CYP2D6,False,False,[],False,"[{'id': 1452725261, 'date': '2024-12-04T14:49:40.804-08:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171622, 'title': 'Drugs@HCSC: Drug Product RISPERIDONE, Sivem Pharmaceuticals ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102277', 'crossReferences': [{'id': 1452725260, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102277', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102277'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451257', 'name': 'risperidone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982351.0,"<p>The product monograph for risperidone notes that since CYP2D6 is responsible for the metabolism of risperidone to 9-hydroxyrisperidone, the levels of each differ between CYP2D6 poor and extensive metabolizers. However, the concentration of risperidone and 9-hydroxyrisperidone combined does not differ substantially between poor and extensive metabolizers.</p>
",1447982350.0,"<p>Risperidone is indicated for treatment of schizophrenia and related psychotic disorders. Excerpt from the risperidone product monograph:</p>
<blockquote class=""blockquote"">
<p>Risperidone is extensively metabolized in the liver by CYP 2D6 to a major active metabolite, 9-hydroxyrisperidone, which appears approximately equi-effective with risperidone with respect to receptor-binding activity. (A second minor pathway is N-dealkylation). Consequently, the clinical effect of the drug likely results from the combined concentrations of risperidone plus 9-hydroxyrisperidone. The hydroxylation of risperidone is dependent upon debrisoquine 4-hydroxylase, i.e. the metabolism of risperidone is sensitive to the debrisoquine hydroxylation type genetic polymorphism. Consequently, the concentrations of parent drug and active metabolite differ substantially in extensive and poor metabolizers. However, the concentration of risperidone and 9-hydroxyrisperidone combined, did not differ substantially between extensive and poor metabolizers, and elimination half-lives were similar in all subjects (approximately 20 to 24 hours).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Risperidone_2024_12_04_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Risperidone_2024_12_04_HCSC.pdf"">risperidone product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166104786,Annotation of FDA Label for chloroquine and G6PD,False,False,[],False,"[{'id': 1183681522, 'date': '2013-10-25T12:29:32.200-07:00', 'type': 'Update', 'version': 0}, {'id': 1450821550, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1450824507, 'date': '2019-10-24T06:49:01.952-07:00', 'description': 'Added prescribing info on monitoring.', 'type': 'Update', 'version': 0}, {'id': 1451091820, 'date': '2020-03-23T10:12:17.854-07:00', 'description': 'Added CDC link and text', 'type': 'Update', 'version': 0}, {'id': 1452250200, 'date': '2023-09-27T10:36:21.102-07:00', 'description': 'Removed broken links to CDC pages about chloroquine and COVID-19. Updated link for latest version of CDC Treatment ofMalaria.', 'type': 'Update', 'version': 0}, {'id': 1452250280, 'date': '2023-09-27T11:14:35.707-07:00', 'description': 'Put link to CDC resource into text not as source literature. Put FDA source literature.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101942, 'title': 'Drugs@FDA: Drug Product chloroquine (NDA006002)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=006002', 'crossReferences': [{'id': 1449895496, 'resource': 'FDA Application', 'resourceId': 'NDA006002', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=006002'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448948', 'name': 'chloroquine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450342785.0,"<p>The FDA-approved drug label for chloroquine (ARALAN) states that it may cause hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. However, CDC guidelines from 2019 recommend chloroquine for malaria prophylaxis in patients who cannot be treated with primaquine or tafenoquine due to G6PD deficiency.</p>
",1450342786.0,"<p>Excerpt from the chloroquine (ARALAN) drug label:</p>
<blockquote class=""blockquote"">
<p>Chloroquine may cause hemolysis in glucose-6 phosphate dehydrogenase (G-6-PD) deficiency. Blood monitoring may be needed as hemolytic anemia may occur, in particular in association with other drugs that cause hemolysis.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Chloroquine_01_08_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Chloroquine_01_08_19_FDA.pdf"">chloroquine drug label</a>.</p>
<p>Excerpt from the <a href=""/literature/15105122"">CDC Treatment of Malaria: Guidelines for Clinicians (United States)</a></p>
<blockquote class=""blockquote"">
<p>Patients with G6PD deficiency who are not expected to tolerate primaquine or tafenoquine should be put on chloroquine
prophylaxis (300 mg)</p>
</blockquote>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450824506.0,"<p>Excerpt from the chloroquine (ARALAN) drug label:</p>
<blockquote class=""blockquote"">
<p>Chloroquine may cause hemolysis in glucose-6 phosphate dehydrogenase (G-6-PD) deficiency. Blood monitoring may be needed as hemolytic anemia may occur, in particular in association with other drugs that cause hemolysis.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104887,Annotation of FDA Label for iloperidone and CYP2D6,False,False,[],True,"[{'id': 1183681662, 'date': '2013-10-25T14:17:43.077-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101819, 'title': 'Drugs@FDA: Drug Product FANAPT (Iloperidone), NDA022192, Avera McKennan Hospital', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022192', 'crossReferences': [{'id': 1449754758, 'resource': 'FDA Application', 'resourceId': 'NDA022192', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022192'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA161199368', 'name': 'iloperidone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981741.0,"<p>The FDA-approved drug label for iloperidone (FANAPT) states that CYP2D6 poor metabolizers have higher exposure to iloperidone compared with extensive metabolizers, and they should have their dose reduced by one half.</p>
",1447981740.0,"<p>Excerpts from the iloperidone drug label:</p>
<div class=""blockquote"">
<p>The iloperidone metabolite P95 represents 47.9% of the AUC of iloperidone and its metabolites in plasma at steady-state for extensive metabolizers (EM) and 25% for poor metabolizers (PM). The active metabolite P88 accounts for 19.5% and 34.0% of total plasma exposure in EM and PM, respectively. Approximately 7% - 10% of Caucasians and 3% - 8% of black/African Americans lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are intermediate, extensive or ultrarapid metabolizers.</p>
</div>
<div class=""blockquote"">
<p>Similarly, PMs of CYP2D6 have higher exposure to iloperidone compared with EMs and PMs should have their dose reduced by one-half. Laboratory tests are available to identify CYP2D6 PMs.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Iloperidone_02_05_19_FDA.pdf"">iloperidone drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399554.0,"<p>Excerpt from the iloperidone drug label:</p>
<blockquote class=""blockquote"">
<p>...PMs of CYP2D6 have higher exposure to iloperidone compared with EMs and PMs should have their dose reduced by one-half. Laboratory tests are available to identify CYP2D6 PMs.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104872,Annotation of EMA Label for boceprevir and IFNL3,False,False,[],False,"[{'id': 1184466973, 'date': '2013-10-25T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1452206300, 'date': '2023-08-14T11:19:19.025-07:00', 'description': 'Changed annotation from actionable to informative.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102971, 'title': 'Victrelis | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis', 'crossReferences': [{'id': 1450416961, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165948902', 'name': 'boceprevir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",EMA,1447981721.0,"<p>The EMA European Public Assessment Report (EPAR) for boceprevir (Victrelis) contains pharmacogenetic information regarding a genetic variant within the <em>IL28B</em> gene that is associated with response to treatment with peginterferon alfa-2b/ribavirin (drugs taken concomitantly with boceprevir), but highlight caveats in studies carried out so far and that the association with boceprevir is currently being investigated further. <strong>Please note that as of June 2018 boceprevir (Victrelis) has been <a rel=""noopener noreferrer"" href=""https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis"" target=""_blank"">withdrawn</a> from use in the European Union.</strong></p>
",1447981720.0,"<p><strong>Please note that as of June 2018 boceprevir (Victrelis) has been <a rel=""noopener noreferrer"" href=""https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis"" target=""_blank"">withdrawn</a> from use in the European Union.</strong></p>
<p>Excerpts from the boceprevir (Victrelis) EPAR:</p>
<div class=""blockquote"">
<p>Exploratory pharmacogenomic analysis of IL28B in phase 3 studies of Victrelis...A genetic variant near the gene encoding interferon-lambda-3 (IL28B <a href=""/variant/PA166155468"">rs12979860</a>, a C to T change) is a strong predictor of response to peginterferon alfa-2b/ribavirin. IL28B <a href=""/variant/PA166155468"">rs12979860</a> was genotyped in 653 of 1,048 (62%) subjects in SPRINT-2 (previously untreated) and 259 of 394 (66%) subjects in RESPOND-2 (previous treatment failure)...The results of this retrospective subgroup analysis should be viewed with caution because of the small sample size and potential differences of the sub-study population relative to the overall trial population.</p>
</div>
<div class=""blockquote"">
<p>The degree of added value of Victrelis on top of the bitherapy in C/C patients will depend on the likelihood of achieving SVR with the bitherapy only. In C/C patients receiving tritherapy 89% in treatment naive were HCV-RNA undetectable by TW 8 and eligible for shorter duration of therapy as compared to 52% in treatment naïve non C/C.</p>
</div>
<div class=""blockquote"">
<p>Whether on treatment early viral response and/or IL28B genotype could reliably identify those patients who are unlikely to retrieve significant benefit of boceprevir (higher SVR rates or short course treatment duration) on top of the bitherapy is currently under investigation.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Victrelis_EMA_EPAR_12_17_2012.pdf"">boceprevir EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166104835,Annotation of FDA Label for fluoxetine and CYP2D6,False,False,[],False,"[{'id': 1183681275, 'date': '2013-10-25T11:05:36.616-07:00', 'type': 'Update', 'version': 0}, {'id': 1452230981, 'date': '2023-09-07T21:43:59.385-07:00', 'description': 'updated label, level', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101897, 'title': 'Drugs@FDA: Drug Product Prozac Weekly (Fluoxetine hydrochloride), NDA021235, Eli Lilly and Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021235', 'crossReferences': [{'id': 1449754660, 'resource': 'FDA Application', 'resourceId': 'NDA021235', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021235'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449673', 'name': 'fluoxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450361450.0,"<p>Fluoxetine (PROZAC) is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder, obsessive compulsive disorder, bulimia nervosa, and panic disorder. Fluoxetine is primarily metabolized by CYP2D6.  It should be used used with caution in patients with congenital long QT syndrome; a previous history of QT prolongation and other conditions that predispose to QT prolongation and ventricular arrhythmia (which include conditions that predispose to increased fluoxetine exposure (overdose, hepatic impairment, use of CYP2D6 inhibitors, CYP2D6 poor metabolizer status, or use of other
highly protein-bound drugs).</p>
",1450361451.0,"<p>Excerpts from the fluoxetine (PROZAC) drug label:</p>
<blockquote class=""blockquote"">
<p>QT Prolongation: Post-marketing cases of QT interval prolongation and ventricular arrhythmia including Torsades de Pointes have been reported in patients treated with PROZAC. PROZAC should be used with caution in patients with congenital long QT syndrome; a previous history of QT prolongation; a family history of long QT syndrome or sudden cardiac death; and other conditions that predispose to QT prolongation and ventricular arrhythmia. Such conditions include concomitant use of drugs that prolong the QT interval; hypokalemia or hypomagnesemia; recent myocardial infarction, uncompensated heart failure, bradyarrhythmias, and other significant arrhythmias; and conditions that predispose to increased fluoxetine exposure (overdose, hepatic impairment, use of CYP2D6 inhibitors, CYP2D6 poor metabolizer status, or use of other
highly protein-bound drugs). PROZAC is primarily metabolized by CYP2D6.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Variability in Metabolism — A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme cytochrome P450 2D6 (CYP2D6). Such individuals are referred to as “poor metabolizers” of drugs such as debrisoquin, dextromethorphan, and the TCAs. In a study involving labeled and unlabeled enantiomers administered as a racemate, these individuals metabolized S- fluoxetine at a slower rate and thus achieved higher concentrations of S-fluoxetine. Consequently, concentrations of S-norfluoxetine at steady state were lower. The metabolism of R-fluoxetine in these poor metabolizers appears normal. When compared with normal metabolizers, the total sum at steady state of the plasma concentrations of the 4 active enantiomers was not significantly greater among poor metabolizers. Thus, the net pharmacodynamic activities were essentially the same. Alternative, nonsaturable pathways (non-2D6) also contribute to the metabolism of fluoxetine. This explains how fluoxetine achieves a steady-state concentration rather than increasing without limit.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""fluoxetine_FDA_20230907.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/fluoxetine_FDA_20230907.pdf"">fluoxetine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452230980.0,"<blockquote class=""blockquote"">
<p>QT Prolongation:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Post-marketing cases of QT interval prolongation and ventricular arrhythmia including Torsades de Pointes have been reported in patients treated with PROZAC. PROZAC should be used with caution in patients with congenital long QT syndrome; a previous history of QT prolongation; a family history of long QT syndrome or sudden cardiac death; and other conditions that predispose to QT prolongation and ventricular arrhythmia. Such conditions include concomitant use of drugs that prolong the QT interval; hypokalemia or hypomagnesemia; recent myocardial infarction, uncompensated heart failure, bradyarrhythmias, and other significant arrhythmias; and conditions that predispose to increased fluoxetine exposure (overdose, hepatic impairment, use of CYP2D6 inhibitors, CYP2D6 poor metabolizer status, or use of other
highly protein-bound drugs).</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104880,Annotation of FDA Label for nefazodone and CYP2D6,False,False,[],False,"[{'id': 1183681682, 'date': '2013-10-25T14:29:42.151-07:00', 'type': 'Update', 'version': 0}, {'id': 1452207481, 'date': '2023-08-15T12:42:45.736-07:00', 'description': 'prescribing tag taken off', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101818, 'title': 'Drugs@FDA: Drug Product Nefazodone Hydrochloride (Nefazodone Hydrochloride), ANDA076037, Preferred Pharmaceuticals Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=076037', 'crossReferences': [{'id': 1450368909, 'resource': 'FDA Application', 'resourceId': 'ANDA076037', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=076037'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450603', 'name': 'nefazodone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981745.0,"<p>The FDA-approved drug label for nefazodone states that treatment adjustment is not required based on CYP2D6 metabolizer status.</p>
",1447981744.0,"<p>Excerpt from the nefazodone label:</p>
<blockquote class=""blockquote"">
<p>A subset (3% to 10%) of the population has reduced activity of the drug-metabolizing enzyme CYP2D6. Such individuals are referred to commonly as &quot;poor metabolizers&quot; of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. The pharmacokinetics of nefazodone and its major metabolites are not altered in these &quot;poor metabolizers.&quot; Plasma concentrations of one minor metabolite (mCPP) are increased in this population; the adjustment of nefazodone dosage is not required when administered to &quot;poor metabolizers.&quot; Nefazodone and its metabolites have been shown <em>in vitro</em> to be extremely weak inhibitors of CYP2D6. Thus, it is not likely that nefazodone will decrease the metabolic clearance of drugs metabolized by this isozyme.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Nefazodone_08_10_2017_FDA.pdf"">nefazodone drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104782,"Annotation of FDA Label for azathioprine and NUDT15, TPMT",True,False,[],True,"[{'id': 1183681499, 'date': '2013-10-25T11:48:21.121-07:00', 'type': 'Update', 'version': 0}, {'id': 1450399517, 'date': '2019-05-09T10:00:37.562-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1451279860, 'date': '2020-10-15T00:00:00-07:00', 'description': 'Removing TPMT alleles and NUDT15 rsID because label does not specify them but rather refers to TPMT and NUDT15 deficiency', 'type': 'Update', 'version': 0}, {'id': 1452213600, 'date': '2023-08-22T22:18:58.560-07:00', 'description': 'Added Alternate Drug and Dosing Information tags because language such as ""consider"" now meets the criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101941, 'title': 'Drugs@FDA: Drug Product IMURAN (azathioprine), NDA016324, Sebela Pharmaceuticals Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016324', 'crossReferences': [{'id': 1449894210, 'resource': 'FDA Application', 'resourceId': 'NDA016324', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016324'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448515', 'name': 'azathioprine'}]","[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",FDA,1450044183.0,"<p>The FDA-approved drug label for azathioprine (IMURAN) states to consider genotyping or phenotyping patients for TPMT deficiency and genotyping for NUDT15 deficiency in patients with severe myelosuppression. Alternative therapy in patients with homozygous TPMT or NUDT15 deficiency and reduced dosages in patients with heterozygous deficiency should be considered.</p>
",1450044184.0,"<p>Excerpts from the azathioprine (IMURAN) drug label:</p>
<div class=""blockquote"">
<p>Patients with thiopurine S-methyl transferase (TPMT) or nucleotide diphosphatase (NUDT15) deficiency may be at an increased risk of severe and life-threatening myelotoxicity if receiving conventional doses of IMURAN...Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine. In patients with severe myelosuppression, consider evaluation for TPMT and NUDT15 deficiency...Consider alternative therapy in patients with homozygous TPMT or NUDT15 deficiency and reduced dosages in patients with heterozygous deficiency.</p>
</div>
<div class=""blockquote"">
<p>TPMT and NUDT15 Testing: Consider genotyping or phenotyping patients for TPMT deficiency and genotyping for NUDT15 deficiency in patients with severe myelosuppression. TPMT and NUDT15 testing cannot substitute for complete blood count (CBC) monitoring in patients receiving IMURAN. Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions.</p>
</div>
<div class=""blockquote"">
<p>Homozygous deficiency in either TPMT or NUDT15...Because of the risk of increased toxicity, consider alternative therapies for patients who are known to have TPMT or NUDT15 deficiency.</p>
</div>
<div class=""blockquote"">
<p>Heterozygous deficiency in TPMT and/or NUDT15...Because of the risk of increased toxicity, dosage reduction is recommended in patients known to have heterozygous deficiency of TPMT or NUDT15. Patients who are heterozygous for both TPMT and NUDT15 deficiency may require more substantial dosage reductions.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Azathioprine_05_10_19_FDA.pdf"">azathioprine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1450399516.0,"<p>Excerpts from the azathioprine (IMURAN) drug label:</p>
<blockquote class=""blockquote"">
<p>Consider alternative therapy in patients with homozygous TPMT or NUDT15 deficiency and reduced dosages in patients with heterozygous deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Because of the risk of increased toxicity, dosage reduction is recommended in patients known to have heterozygous deficiency of TPMT or NUDT15. Patients who are heterozygous for both TPMT and NUDT15 deficiency may require more substantial dosage reductions.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104830,Annotation of FDA Label for tiotropium and CYP2D6,False,False,[],False,"[{'id': 1183681251, 'date': '2013-10-25T11:01:17.364-07:00', 'type': 'Update', 'version': 0}, {'id': 1452217600, 'date': '2023-08-27T22:36:40.795-07:00', 'description': 'remove informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101813, 'title': 'Drugs@FDA: Drug Product Spiriva Respimat (tiotropium bromide inhalation spray), NDA021936, Boehringer Ingelheim Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021936', 'crossReferences': [{'id': 1449887878, 'resource': 'FDA Application', 'resourceId': 'NDA021936', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021936'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164769056', 'name': 'tiotropium'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981630.0,"<p>Tiotropium (SPIRIVA RESPIMAT) is an inhalation powder used daily for the treatment of bronchospasms associated with chronic obstructive pulmonary disease (COPD) and maintenance treatment of asthma. It is believed to be metabolized in part by CYP2D6.</p>
",1447981629.0,"<p>Excerpt from the tiotropium (SPIRIVA RESPIMAT) drug label:</p>
<div class=""blockquote"">
<p><em>In vitro</em> experiments with human liver microsomes and human hepatocytes suggest that a fraction of the administered dose (74% of an intravenous dose is excreted unchanged in the urine, leaving 25% for metabolism) is metabolized by cytochrome P450-dependent oxidation and subsequent glutathione conjugation to a variety of Phase II metabolites. This enzymatic pathway can be inhibited by CYP450 2D6 and 3A4 inhibitors, such as quinidine, ketoconazole, and gestodene. Thus, CYP450 2D6 and 3A4 are involved in the metabolic pathway that is responsible for the elimination of a small part of the administered dose. In vitro studies using human liver microsomes showed that tiotropium in supra-therapeutic concentrations did not inhibit CYP450 1A1, 1A2, 2B6, 2C9, 2C19, 2D6, 2E1, or 3A4.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tiotropium_08_30_2017_FDA.pdf"">tiotropium drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,Formerly on FDA Biomarker List
Label Annotation,PA166104822,Annotation of FDA Label for terbinafine and CYP2D6,False,False,[],False,"[{'id': 1183681491, 'date': '2013-10-25T11:43:32.933-07:00', 'type': 'Update', 'version': 0}, {'id': 1452215421, 'date': '2023-08-24T16:08:04.717-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101917, 'title': 'Drugs@FDA: Drug Product Lamisil (terbinafine hydrochloride), NDA020539, Novartis Pharmaceuticals Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020539', 'crossReferences': [{'id': 1449816786, 'resource': 'FDA Application', 'resourceId': 'NDA020539', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020539'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451614', 'name': 'terbinafine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981624.0,"<p>The FDA-approved drug label for terbinafine (LAMISIL) states that the drug is an inhibitor of the CYP2D6 enzyme, and therefore may convert CYP2D6 extensive metabolizers to poor metabolizers.</p>
",1447981623.0,"<p>Terbinafine is an antifungal drug used for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium).</p>
<p>Excerpt from the terbinafine (LAMISIL) drug label:</p>
<div class=""blockquote"">
<p>In vivo studies have shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme...Thus, terbinafine may convert extensive CYP2D6 metabolizers to poor metabolizer status.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Terbinafine_02_28_19_FDA.pdf"">terbinafine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,Formerly on FDA Biomarker List
Label Annotation,PA166104779,Annotation of EMA Label for indacaterol and UGT1A1,False,False,[],False,"[{'id': 1184467012, 'date': '2013-10-27T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1450933198, 'date': '2019-12-04T13:19:38.016-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452209880, 'date': '2023-08-18T10:49:01.138-07:00', 'description': 'changed gene from drug target ADRB2 to metabolizer UGT1A1', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103643, 'title': 'Hirobriz Breezhaler | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/hirobriz-breezhaler', 'crossReferences': [{'id': 1450932874, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/hirobriz-breezhaler', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/hirobriz-breezhaler'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958348', 'name': 'indacaterol'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",EMA,1447981540.0,"<p>The EMA European Public Assessment Report (EPAR) for indacaterol (Hirobriz Breezhaler) does not contain pharmacogenetic information, but does contain information regarding the pharmacodynamics of the drug as a beta2-adrenoceptor (ADRB2) agonist and also contains information regarding the pharmacokinetics of indacaterol involving UGT1A1, CYP3A4 and ABCB1.</p>
",1447981539.0,"<p>Excerpts from the indacaterol EPAR:</p>
<blockquote class=""blockquote"">
<p>Pharmacotherapeutic group: Long-acting beta2-adrenergic agonist.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>In vitro</em> investigations indicated that UGT1A1 is the only UGT isoform that metabolized indacaterol in the phenolic O-glucuronide. The oxidative metabolites were found in incubations with recombinant CYP1A1, CYP2D6, and CYP3A4. CYP3A4 is concluded to be the predominant isoenzyme responsible for hydroxylation of indacaterol. <em>In vitro</em> investigations further indicated that indacaterol is a low affinity substrate for the efflux pump P-gp.</p>
</blockquote>
<p>This information is highlighted in the following sections:</p>
<p>Special warnings and precautions for use, pharmacological properties, pharmacokinetic properties.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Indacaterol_EMA_EPAR_April18th2013.pdf"">indacaterol EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166104804,Annotation of FDA Label for tositumomab and MS4A1,False,True,[],False,"[{'id': 1183681249, 'date': '2013-10-25T11:00:46.846-07:00', 'type': 'Update', 'version': 0}, {'id': 1448604430, 'date': '2017-03-14T15:25:12.059-07:00', 'type': 'Update', 'version': 0}, {'id': 1451835107, 'date': '2022-07-29T12:10:25.226-07:00', 'description': 'Retiring annotation due to label withdrawal and drug no longer being manufactured', 'type': 'Update', 'version': 0}, {'id': 1452220420, 'date': '2023-08-29T12:31:52.959-07:00', 'description': 'removed the informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15153742, 'title': 'These highlights do not include all the information needed to use BEXXAR safely and effectively. See full prescribing information for BEXXAR.BEXXAR (tositumomab and iodine I 131 tositumomab)Injection, for intravenous infusionInitial U.S. Approval: 2003', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d706611-abab-42f1-ae8a-2097eb1be38d', 'crossReferences': [{'id': 827920784, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '0d706611-abab-42f1-ae8a-2097eb1be38d', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d706611-abab-42f1-ae8a-2097eb1be38d'}], 'notes': 'This is archived at dailymed.', 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164748364', 'name': 'tositumomab'}]","[{'objCls': 'Gene', 'id': 'PA31111', 'symbol': 'MS4A1', 'name': 'membrane spanning 4-domains A1'}]",FDA,1449713257.0,"<p>Tositumomab is used to treat patients with CD20-positive non-Hodgkin's lymphoma. The drug is a monoclonal antibody that targets the CD20 antigen, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label. <strong>Please note that as of August 2013, tositumomab (Bexxar) is <a rel=""noopener noreferrer"" href=""https://us.gsk.com/en-us/media/press-releases/2013/gsk-to-discontinue-manufacture-and-sale-of-the-bexxar-therapeutic-regimen-tositumomab-and-iodine-i-131-tositumomab/"" target=""_blank"">no longer being manufactured or sold</a>. Labels for this drug are no longer available on <a rel=""noopener noreferrer"" href=""https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm"" target=""_blank"">Drugs@FDA</a> or <a rel=""noopener noreferrer"" href=""https://dailymed.nlm.nih.gov/dailymed/index.cfm"" target=""_blank"">DailyMed</a>.</strong></p>
",1449713258.0,"<p>Tositumomab is an anti-neoplastic radiotherapeutic monoclonal antibody-based regimen targeted against the CD20 antigen.  CD20 is coded for by the gene MS4A1 and found on the surface of normal and malignant B lymphocytes. Tositumomab is used to treat CD-20 positive non-Hodgkins' lymphoma during or after rituximab therapy. <strong>Please note that as of August 2013, tositumomab (Bexxar) is <a rel=""noopener noreferrer"" href=""https://us.gsk.com/en-us/media/press-releases/2013/gsk-to-discontinue-manufacture-and-sale-of-the-bexxar-therapeutic-regimen-tositumomab-and-iodine-i-131-tositumomab/"" target=""_blank"">no longer being manufactured or sold</a>. Labels for this drug are no longer available on <a rel=""noopener noreferrer"" href=""https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm"" target=""_blank"">Drugs@FDA</a> or <a rel=""noopener noreferrer"" href=""https://dailymed.nlm.nih.gov/dailymed/index.cfm"" target=""_blank"">DailyMed</a>.</strong></p>
<p>Excerpt from the Tositumomab (Bexxar) drug label:</p>
<blockquote class=""blockquote"">
<p>Tositumomab binds specifically to the CD20 (human B-lymphocyte-restricted differentiation antigen, Bp 35 or B1) antigen. This antigen is a transmembrane phosphoprotein expressed on pre-B lymphocytes and at higher density on mature B lymphocytes. The antigen is also expressed on &gt;90% of B-cell non-Hodgkins lymphomas (NHL). The recognition epitope for Tositumomab is found within the extracellular domain of the CD20 antigen. CD20 does not shed from the cell surface and does not internalize following antibody binding.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tositumomab_10_15_13.pdf"">Tositumomab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,1451259820.0,Retirement Reason,[],Withdrawal,retirement:1451259820,True,Formerly on FDA Biomarker List
Label Annotation,PA166104869,Annotation of FDA Label for galantamine and CYP2D6,False,False,[],False,"[{'id': 1183681660, 'date': '2013-10-25T14:16:52.655-07:00', 'type': 'Update', 'version': 0}, {'id': 1452212360, 'date': '2023-08-22T01:34:06.899-07:00', 'description': 'removed prescribing tag - label advocates not changing prescribing based on CYP2D6 genotype', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101816, 'title': 'Drugs@FDA: Drug Product galantamine hydrobromide (galantamine hydrobromide), NDA021169, Patriot Pharmaceuticals, LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021169', 'crossReferences': [{'id': 1449754717, 'resource': 'FDA Application', 'resourceId': 'NDA021169', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021169'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449726', 'name': 'galantamine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981703.0,"<p>The FDA-approved drug label for galantamine (RAZADYNE) states dosage adjustment of galantamine is not necessary in patients identified as CYP2D6 poor metabolizers as the dose is individually titrated to tolerability.</p>
",1447981702.0,"<p>Excerpts from the galantamine (RAZADYNE) label:</p>
<div class=""blockquote"">
<p>CYP2D6 Poor Metabolizers...Approximately 7% of the normal population has a genetic variation that leads to reduced levels of activity of CYP2D6 isozyme. Such individuals have been referred to as poor metabolizers. After a single oral dose of 4 mg or 8 mg galantamine, CYP2D6 poor metabolizers demonstrated a similar Cmax and about 35% AUC8 increase of unchanged galantamine compared to extensive metabolizers.</p>
</div>
<div class=""blockquote"">
<p>A total of 356 patients with Alzheimer's disease enrolled in two Phase 3 studies were genotyped with respect to CYP2D6 (n=210 hetero-extensive metabolizers, 126 homo-extensive metabolizers, and 20 poor metabolizers). Population pharmacokinetic analysis indicated that there was a 25% decrease in median clearance in poor metabolizers compared to extensive metabolizers. Dosage adjustment is not necessary in patients identified as poor metabolizers as the dose of drug is individually titrated to tolerability.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Galantamine_07_27_2017_FDA.pdf"">galantamine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104850,Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2,False,False,[],False,"[{'id': 1183681739, 'date': '2013-10-25T15:00:07.297-07:00', 'type': 'Update', 'version': 0}, {'id': 1450822317, 'date': '2019-10-15T06:20:54.258-07:00', 'description': 'No changes to annotation text but label was updated at FDA, so new label attached with same PGx highlighted.', 'type': 'Update', 'version': 0}, {'id': 1452231461, 'date': '2023-09-08T14:24:01.985-07:00', 'description': 'changed label from informative to actionable', 'type': 'Update', 'version': 0}, {'id': 1452536341, 'date': '2024-07-23T13:47:18.854-07:00', 'description': 'updated label; marketing status: Discontinued', 'type': 'Update', 'version': 0}, {'id': 1452836040, 'date': '2025-02-05T10:03:24.684-08:00', 'description': 'note that newer drug label is available, although Marketing Status is still Discontinued', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161682, 'title': 'Drugs@FDA: Drug Product NDA050705/SUPPL-24, 12/08/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050705', 'crossReferences': [{'id': 1452536360, 'resource': 'FDA Application', 'resourceId': 'NDA050705/SUPPL-24', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050705'}], 'notes': 'Marketing Status: Discontinued (as of July 2024)', 'objCls': 'Literature', 'pubDate': '2023-12-08T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101815, 'title': 'Drugs@FDA: Drug Product Rifater (rifampin, isoniazid and pyrazinamide), NDA050705, sanofi-aventis U.S. LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050705', 'crossReferences': [{'id': 1449754777, 'resource': 'FDA Application', 'resourceId': 'NDA050705', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050705'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166176022', 'name': 'isoniazid / pyrazinamide / rifampin'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",FDA,1447981676.0,"<p>The FDA-approved drug label for rifampin, isoniazid and pyrazinamide (RIFATER) states that 'slow inactivators' of isoniazid may be more susceptible to drug toxicity due to higher blood concentrations of the drug in these individuals. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to inactivator or acetylator status.</p>
<p><strong>Note: As of July 2024, the Marketing Status of this drug combination is Discontinued, but the drug combination remains on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. A newer drug label with the Action Date 10/10/2024 is also available on the FDA website.</strong></p>
",1447981675.0,"<p>Excerpt from the rifampin, isoniazid and pyrazinamide (RIFATER) drug label:</p>
<blockquote class=""blockquote"">
<p>Isoniazid is metabolized in the liver mainly by acetylation and dehydrazination. The rate of acetylation is genetically determined. Approximately 50% of African Americans and Caucasians are “slow inactivators” and the rest are “rapid inactivators”; the majority of Eskimos and Asians are “rapid inactivators.” The rate of acetylation does not significantly alter the effectiveness of isoniazid. However, slow acetylation may lead to higher blood levels of the drug, and, thus, an increase in toxic reactions.</p>
</blockquote>
<p>Note that this drug combination appears on the <a rel=""noopener noreferrer"" href=""https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm"" target=""_blank"">FDA Biomarker List</a> with the biomarker stated as &quot;Nonspecific (NAT)&quot;.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Rifampin_isoniazid_pyrazinamide_2024_07_23_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Rifampin_isoniazid_pyrazinamide_2024_07_23_FDA.pdf"">rifampin, isoniazid and pyrazinamide drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104896,Annotation of EMA Label for abacavir and HLA-B,True,False,[],False,"[{'id': 1184466965, 'date': '2013-10-15T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1184512625, 'date': '2013-10-15T00:00:00-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102972, 'title': 'Ziagen | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen', 'crossReferences': [{'id': 1450416858, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165987830', 'symbol': 'HLA-B*57:01', 'name': '*57:01'}]","[{'objCls': 'Chemical', 'id': 'PA448004', 'name': 'abacavir'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",EMA,1447981769.0,"<p>The EMA European Public Assessment Report (EPAR) for abacavir (Ziagen) states that screening for the HLA-B*5701 allele should be performed in any HIV-infected patient, and that the drug should not be used in patient's with the HLA-B*57:01 allele.</p>
",1447981768.0,"<p>Excerpts from the abacavir (Ziagen) EPAR:</p>
<div class=""blockquote"">
<p>Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin(see section 4.4). Abacavir should not be used in patients known to carry the HLA-B*5701 allele</p>
</div>
<div class=""blockquote"">
<p>The risk for abacavir HSR to occur is high for patients who test positive for the HLA-B*5701 allele. However, abacavir HSRs have been reported at a lower frequency in patients who do not carry this allele.</p>
</div>
<div class=""blockquote"">
<p>HLA-B*5701 is the only identified pharmacogenetic marker that is consistently associated with clinical diagnosis of an ABC HSR reaction. However, some patients with a suspected ABC hypersensitivity reaction may not have the HLA-B*5701 allele.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Abacavir_06_18_19_EMA.pdf"">abacavir EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450416680.0,"<p>&quot;Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin...Abacavir should not be used in patients known to carry the HLA-B*5701 allele.&quot;</p>
",,,,,,,
Label Annotation,PA166104916,Annotation of FDA Label for codeine and CYP2D6,True,False,[],False,"[{'id': 1183681204, 'date': '2013-10-25T10:42:53.790-07:00', 'type': 'Update', 'version': 0}, {'id': 1448616068, 'date': '2017-05-01T16:59:35.747-07:00', 'type': 'Update', 'version': 0}, {'id': 1450385852, 'date': '2019-04-29T11:30:54.425-07:00', 'description': 'added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1451266132, 'date': '2020-09-18T14:48:37.373-07:00', 'description': 'add pediatric-specific  tag and text', 'type': 'Update', 'version': 0}, {'id': 1453103780, 'date': '2025-04-15T14:04:54.314-07:00', 'description': 'added CYP2D6*1xN and CYP2D6*2xN alleles', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101866, 'title': 'Drugs@FDA: Drug Product Codeine sulfate (codeine sulfate), NDA022402, West-Ward Pharmaceuticals Corp.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022402', 'crossReferences': [{'id': 1449754222, 'resource': 'FDA Application', 'resourceId': 'NDA022402', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022402'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]","[{'objCls': 'Haplotype', 'id': 'PA165988479', 'symbol': 'CYP2D6*1xN', 'name': '*1xN'}, {'objCls': 'Haplotype', 'id': 'PA165988480', 'symbol': 'CYP2D6*2xN', 'name': '*2xN'}]","[{'objCls': 'Chemical', 'id': 'PA449088', 'name': 'codeine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450342833.0,"<p>The FDA-approved drug label for codeine states in a black box warning that respiratory depression and death have occurred in children who received codeine following a tonsillectomy and/or adenoidectomy and who had evidence of being CYP2D6 ultra-rapid metabolizers. The label also states that individuals who are CYP2D6 ultra-rapid metabolizers should not use codeine.</p>
",1450342834.0,"<p><strong>On April 20th 2017, the FDA released a <a rel=""noopener noreferrer"" href=""https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery"" target=""_blank"">safety announcement</a> stating that they are restricting the use of codeine and tramadol in children, and recommending against the use of codeine and tramadol in breastfeeding mothers due to possible harm to their infants. Please refer to the link above for full details on the safety announcement.</strong></p>
<p>Codeine is an opioid analgesic pro-drug, typically used for pain relief.  It is metabolized by CYP2D6 into morphine, which is the active drug form.</p>
<p>Excerpts from the codeine drug label:</p>
<blockquote class=""blockquote"">
<p>Life-threatening respiratory depression and death have occurred in children who received codeine; most cases followed tonsillectomy and/or adenoidectomy and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to a CYP2D6 polymorphism.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Nursing Mothers...At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine. Breastfeeding is not recommended during treatment with Codeine Sulfate Tablets.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (e.g., gene duplications denoted as *1/*1xN or *1/*2xN). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 1 to 10% for Whites (European, North American), 3 to 4% for Blacks (African Americans), 1 to 2% for East Asians (Chinese, Japanese, Korean), and may be greater than 10% in certain racial/ethnic groups (i.e., Oceanian, Northern African, Middle Eastern, Ashkenazi Jews, Puerto Rican). These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing). Therefore, individuals who are ultra-rapid metabolizers should not use Codeine Sulfate Tablets.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Codeine_01_09_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Codeine_01_09_19_FDA.pdf"">codeine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1451266131.0,"<p>Excerpts from the codeine drug label:</p>
<blockquote class=""blockquote"">
<p>Adverse reaction:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-Threatening Respiratory Depression in Children (see Warnings and Precautions (5.4))</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pediatric Use:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The safety and effectiveness of Codeine Sulfate Tablets in pediatric patients have not been established. Life-threatening respiratory depression and death have occurred in children who received codeine (see Warnings and Precautions (5.4)). In most of the reported cases, these events followed tonsillectomy and/or adenoidectomy, and many of the children had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). Children with sleep apnea may be particularly sensitive to the
respiratory depressant effects of codeine. Because of the risk of life-threatening respiratory depression and death:
• Codeine Sulfate Tablets are contraindicated for all children younger than 12 years of age (see Contraindications (4)).
• Codeine Sulfate Tablets are contraindicated for post-operative management in pediatric patients younger than 18 years of age following tonsillectomy and/or adenoidectomy (see Contraindications (4)).
• Avoid the use of Codeine Sulfate Tablets in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine unless the benefits outweigh the risks. Risk factors include conditions associated with hypoventilation, such as postoperative status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, and concomitant use of other medications that cause respiratory depression.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Ultra-Rapid Codeine Metabolism of Codeine and Other Risk Factors for Life-Threatening Respiratory Depression in Children</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Advise caregivers that Codeine Sulfate Tablets are contraindicated in all children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. Advise caregivers of children 12 to 18 years of age receiving Codeine Sulfate Tablets to monitor for signs of respiratory depression (see Warnings and Precautions (5.4)).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Nursing Mothers:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine. Breastfeeding is not recommended during treatment with Codeine Sulfate Tablets (see Use in Specific Populations (8.2)).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Lactation:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Risk Summary: Codeine and its active metabolite, morphine, are present in human milk. There are published studies and cases that have reported excessive sedation, respiratory depression, and death in infants exposed to codeine via breast milk. Women who are ultra-rapid metabolizers of codeine achieve higher than expected serum levels of morphine, potentially leading to higher levels of morphine in breast milk that can be dangerous in their breastfed infants. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450385851.0,"<p>Excerpts from the codeine drug label:</p>
<blockquote class=""blockquote"">
<p>Life-threatening respiratory depression and death have occurred in children who received codeine; most cases followed tonsillectomy and/or adenoidectomy and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to a CYP2D6 polymorphism. Codeine Sulfate Tablets are contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>...individuals who are ultra-rapid metabolizers should not use Codeine Sulfate Tablets.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104922,Annotation of FDA Label for flurbiprofen and CYP2C9,False,False,[],True,"[{'id': 1183681653, 'date': '2013-10-25T14:13:23.026-07:00', 'type': 'Update', 'version': 0}, {'id': 1452833620, 'date': '2025-02-03T11:36:53.743-08:00', 'description': 'updated label to DailyMed generic', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15173942, 'title': 'DailyMed - FLURBIPROFEN tablet', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4670cf21-eb0e-4f5a-ab22-41af85733525', 'crossReferences': [{'id': 1452831100, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '4670cf21-eb0e-4f5a-ab22-41af85733525', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4670cf21-eb0e-4f5a-ab22-41af85733525'}], 'notes': 'ANDA074431, generic for ANSAID', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15102022, 'title': 'Drugs@FDA: Drug Product FLURBIPROFEN SODIUM (flurbiprofen sodium), NDA019404, Rebel Distributors Corp', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019404', 'crossReferences': [{'id': 1449754670, 'resource': 'FDA Application', 'resourceId': 'NDA019404', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019404'}], 'notes': 'OCUFEN', 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}, {'id': 15102343, 'title': 'Drugs@FDA: Drug Product flurbiprofen (NDA018766)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018766', 'crossReferences': [{'id': 1449754668, 'resource': 'FDA Application', 'resourceId': 'NDA018766', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018766'}], 'notes': 'ANSAID  \nMarketing Status: Discontinued', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449683', 'name': 'flurbiprofen'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1447981820.0,"<p>The FDA-approved drug label for flurbiprofen states that patients known or suspected to be CYP2C9 poor metabolizers should receive a reduced dose of flurbiprofen to avoid abnormally high plasma levels.</p>
",1447981819.0,"<p>Flurbiprofen (former brand name: ANSAID) is indicated for the relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis.</p>
<p>Excerpts from the flurbiprofen label:</p>
<blockquote class=""blockquote"">
<p>In patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin and phenytoin), reduce the dose of flurbiprofen to avoid abnormally high plasma levels due to reduced metabolic clearance.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In vitro studies have demonstrated that cytochrome CYP2C9 plays an important role in the metabolism of flurbiprofen to its major metabolite 4'-hydroxy-flurbiprofen. The 4'-
hydroxy-flurbiprofen metabolite showed little anti-inflammatory activity in animal models of inflammation. In vitro studies also demonstrated glucuronidation of both enantiomers of flurbiprofen and 4'-hydroxy-flurbiprofen. UGT2B7 is the predominant UGT isozyme responsible for the glucuronidation. Flurbiprofen does not induce enzymes that alter its metabolism.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Flurbiprofen_2025_01_31_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Flurbiprofen_2025_01_31_FDA.pdf"">flurbiprofen drug label</a>.</p>
<p>Note: Flurbiprofen (OCUFEN) is indicated for the inhibition of intraoperative miosis. The <a download=""Flurbiprofen_ophthalmic_2025_01_31_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Flurbiprofen_ophthalmic_2025_01_31_FDA.pdf"">ophthalmic flurbiprofen drug label</a> contains no information regarding CYP2C9 metabolizer status.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399549.0,"<p>Excerpt from the flurbiprofen label:</p>
<blockquote class=""blockquote"">
<p>In patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin and phenytoin), reduce the dose of flurbiprofen to avoid abnormally high plasma levels due to reduced metabolic clearance.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104825,Annotation of FDA Label for valproic acid and OTC,True,False,[],False,"[{'id': 1183681257, 'date': '2013-10-25T11:02:37.826-07:00', 'type': 'Update', 'version': 0}, {'id': 1447952386, 'date': '2016-03-21T14:25:50.450-07:00', 'type': 'Update', 'version': 0}, {'id': 1449140144, 'date': '2017-11-10T10:21:10.001-08:00', 'type': 'Update', 'version': 0}, {'id': 1449295752, 'date': '2018-04-18T10:18:34.127-07:00', 'type': 'Update', 'version': 0}, {'id': 1450821515, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1452011319, 'date': '2023-02-16T21:00:40.841-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101842, 'title': 'Drugs@FDA: Drug Product Depakene (Valproic Acid), NDA018081, REMEDYREPACK INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018081', 'crossReferences': [{'id': 1449891327, 'resource': 'FDA Application', 'resourceId': 'NDA018081', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018081'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA32840', 'symbol': 'OTC', 'name': 'ornithine transcarbamylase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451846', 'name': 'valproic acid'}]","[{'objCls': 'Gene', 'id': 'PA32840', 'symbol': 'OTC', 'name': 'ornithine transcarbamylase'}]",FDA,1447981608.0,"<p>The FDA-approved drug label for valproic acid (Depakene) notes that it is contraindicated in patients with known urea cycle disorders (UCDs), a group of uncommon genetic abnormalities, particularly ornithine transcarbamylase (OTC) deficiency.</p>
",1447981607.0,"<p>UCDs result from mutations in one of several genes, such as ornithine transcarbamylase (<em>OTC</em>).</p>
<p>Excerpts from the valproic acid (Depakene) drug label:</p>
<div class=""blockquote"">
<p>Depakene is contraindicated in patients with known urea cycle disorders (UCD).</p>
</div>
<div class=""blockquote"">
<p>Hyperammonemic  encephalopathy, sometimes fatal, has been reported following initiation of valproate therapy in patients with urea cycle disorders, a group of uncommon genetic abnormalities, particularly ornithine transcarbamylase deficiency.  Prior to the initiation of valproate therapy, evaluation for UCD should be considered in the following patients: 1) those with a history of unexplained encephalopathy, unexplained mental retardation, or history of elevated plasma ammonia or glutamine; 2) those with cyclical vomiting and lethargy, episodic extreme irritability, ataxia, low blood urea nitrogen (BUN), or protein avoidance; 3) those with a family history of UCD or a family history of unexplained infant deaths (particularly males); 4) those with other signs or symptoms of UCD.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Valproic_Acid_03_01_19_FDA.pdf"">valproic acid drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450384316.0,"<p>Excerpts from the valproic acid (Depakene) drug label:</p>
<blockquote class=""blockquote"">
<p>Depakene is contraindicated in patients with known urea cycle disorders (UCD)...Hyperammonemic  encephalopathy, sometimes fatal, has been reported following initiation of valproate therapy in patients with urea cycle disorders, a group of uncommon genetic abnormalities, particularly ornithine transcarbamylase deficiency...</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104805,Annotation of FDA Label for thioridazine and CYP2D6,True,False,[],False,"[{'id': 1183681187, 'date': '2013-10-25T10:25:03.161-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101807, 'title': 'Drugs@FDA: Drug Product Thioridazine Hydrochloride (thioridazine hydrochloride), ANDA088004, REMEDYREPACK INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=088004', 'crossReferences': [{'id': 1450369738, 'resource': 'FDA Application', 'resourceId': 'ANDA088004', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=088004'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451666', 'name': 'thioridazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981578.0,"<p>Thioridazine is used to treat schizophrenia, but has been associated with Torsades de pointes and sudden death.  Due to the potentially fatal side effects, it is typically reserved for patients who do not respond well to other anti-psychotics.  This drug is contraindicated in patients with reduced CYP2D6 activity.</p>
",1447981577.0,"<p>Excerpts from the thioridazine drug label:</p>
<div class=""blockquote"">
<p>Therefore, thioridazine is contraindicated with these drugs as well as in patients, comprising about 7% of the normal population, who are known to have a genetic defect leading to reduced levels of activity of P450 2D6.</p>
</div>
<div class=""blockquote"">
<p>Certain circumstances may increase the risk of Torsades de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including 1) bradycardia, 2) hypokalemia, 3) concomitant use of other drugs that prolong the QTc interval, 4) presence of congenital prolongation of the QT interval, and 5) for thioridazine in particular, its use in patients with reduced activity of P450 2D6 or its coadministration with drugs that may inhibit P450 2D6 or by some other mechanism interfere with the clearance of thioridazine.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Thioridazine_08_28_2017_FDA.pdf"">thioridazine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450383101.0,"<p>Excerpts from the thioridazine drug label:</p>
<blockquote class=""blockquote"">
<p>...thioridazine is contraindicated...in patients, comprising about 7% of the normal population, who are known to have a genetic defect leading to reduced levels of activity of P450 2D6.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104862,Annotation of FDA Label for desipramine and CYP2D6,False,False,[],False,"[{'id': 1183681222, 'date': '2013-10-25T10:46:41.141-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101920, 'title': 'Drugs@FDA: Drug Product Norpramin (desipramine), NDA014399/SUPPL-71, 11/09/2018', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=014399', 'crossReferences': [{'id': 1453106544, 'resource': 'FDA Application', 'resourceId': 'NDA014399/SUPPL-71', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=014399'}], 'objCls': 'Literature', 'pubDate': '2018-11-09T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449233', 'name': 'desipramine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981717.0,"<p>The FDA-approved drug label for desipramine (NORPRAMIN) notes that CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs), such as desipramine, when given typical doses. Additionally, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. It is therefore desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be a CYP2D6 inhibitor.</p>
",1450342938.0,"<p>Desipramine (NORPRAMIN) is an antidepressant drug belonging to the tricyclic antidepressants class.</p>
<p>Excerpt from the desipramine (NORPRAMIN) label:</p>
<div class=""blockquote"">
<p>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6...is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called &quot;poor metabolizers&quot;); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers...It is desirable to monitor TCA plasma levels whenever a TCA including is going to be co-administered with another drug known to be an inhibitor of P450 2D6.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Desipramine_01_11_19_FDA.pdf"">desipramine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104814,Annotation of FDA Label for drospirenone / ethinyl estradiol and CYP2C19,False,False,[],False,"[{'id': 1183681229, 'date': '2013-10-25T10:57:58.082-07:00', 'type': 'Update', 'version': 0}, {'id': 1183701077, 'date': '2013-12-17T09:12:39.964-08:00', 'description': 'FDA Table changed the pharmacogenomic biomarker from CYP2C19 to CYP2D6', 'type': 'Update', 'version': 0}, {'id': 1184483104, 'date': '2014-07-14T00:00:00-07:00', 'description': 'FDA Table changed the pharmacogenomic biomarker from CYP2D6 to CYP2C19', 'type': 'Update', 'version': 0}, {'id': 1452206940, 'date': '2023-08-15T07:14:44.001-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101808, 'title': 'Drugs@FDA: Drug Product Gianvi (Drospirenone and ethinyl estradiol), NDA021676, Teva Pharmaceuticals USA Inc', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021676', 'crossReferences': [{'id': 1449754511, 'resource': 'FDA Application', 'resourceId': 'NDA021676', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021676'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165290928', 'name': 'drospirenone / ethinyl estradiol'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1450361162.0,"<p>The FDA-approved drug label for drospirenone and ethinyl estradiol (Yaz) notes that drospirenone did not affect the clearance of omeprazole, suggesting that it does not inhibit the CYP2C19 enzyme.</p>
",1450361163.0,"<p>Drospirenone and ethinyl estradiol (Yaz) is a combined oral contraceptive drug.</p>
<p>Excerpts from the drospirenone and ethinyl estradiol (Yaz) drug label:</p>
<div class=""blockquote"">
<p>The potential effect of [drospirenone] on CYP2C19 activity was investigated in a clinical pharmacokinetic study using omeprazole as a marker substrate. In the study with 24 postmenopausal woman (including 12 women with homozygous (wild type) CYP2C19 genotype and 12 women with heterozygous CYP2C19 genotype) the daily oral administration of 3 mg [drospirenone] for 14 days did not affect the oral clearance of omeprazole (40 mg, single oral dose) and the CYP2C19 product 5-hydroxy omeprazole...These results demonstrate that [drospirenone] did not inhibit CYP2C19...<em>in vivo</em>...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Drospirenone_Ethinyl_Estradiol_01_15_19_FDA.pdf"">drospirenone and ethinyl estradiol drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104853,Annotation of FDA Label for cisplatin and TPMT,False,False,[],False,"[{'id': 1183681200, 'date': '2013-10-25T10:42:12.074-07:00', 'type': 'Update', 'version': 0}, {'id': 1452206743, 'date': '2023-08-15T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}, {'id': 1452540460, 'date': '2024-07-26T17:07:33.484-07:00', 'description': 'updated label, changed level to Actionable PGx', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162282, 'title': 'Drugs@FDA: Drug Product CISplatin (CISplatin), WG Critical Care, LLC - NDA018057/SUPPL-92, 03/24/2022', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018057', 'crossReferences': [{'id': 1452540441, 'resource': 'FDA Application', 'resourceId': 'NDA018057/SUPPL-92', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018057'}], 'objCls': 'Literature', 'pubDate': '2022-03-24T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449014', 'name': 'cisplatin'}]","[{'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",FDA,1450342813.0,"<p>The FDA-approved drug label for cisplatin states that genetic factors, such as variants in the TPMT gene, may contribute to cisplatin-induced ototoxicity. However, this association has not be consistent across populations and study designs.</p>
",1450342814.0,"<p>Excerpt from the cisplatin drug label:</p>
<blockquote class=""blockquote"">
<p>Genetic factors (e.g. variants in the thiopurine S-methyltransferase [TPMT] gene) may also contribute to the cisplatin-induced ototoxicity; although this association has not been consistent across populations and study designs.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Cisplatin_2024_07_26_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Cisplatin_2024_07_26_FDA.pdf"">cisplatin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104905,Annotation of EMA Label for capecitabine and DPYD,True,False,[],False,"[{'id': 1184466980, 'date': '2013-10-25T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1451794140, 'date': '2022-06-03T19:35:44.482-07:00', 'description': 'update with new PGx excerpts from updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132122, 'title': 'Capecitabine medac | European Medicines Agency.', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-medac', 'crossReferences': [{'id': 1451794160, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-medac', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-medac'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15132142, 'title': 'Capecitabine teva | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-teva', 'crossReferences': [{'id': 1451794180, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-teva', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-teva'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15102919, 'title': 'Xeloda | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/xeloda', 'crossReferences': [{'id': 1450416886, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/xeloda', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/xeloda'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]","[{'objCls': 'Haplotype', 'id': 'PA166171120', 'symbol': 'DPYD c.1129-5923C>G, c.1236G>A (HapB3)', 'name': 'c.1129-5923C>G, c.1236G>A (HapB3)'}, {'objCls': 'Haplotype', 'id': 'PA166171118', 'symbol': 'DPYD c.1679T>G (*13)', 'name': 'c.1679T>G (*13)'}, {'objCls': 'Haplotype', 'id': 'PA166171117', 'symbol': 'DPYD c.1905+1G>A (*2A)', 'name': 'c.1905+1G>A (*2A)'}, {'objCls': 'Haplotype', 'id': 'PA166171119', 'symbol': 'DPYD c.2846A>T', 'name': 'c.2846A>T'}]","[{'objCls': 'Chemical', 'id': 'PA448771', 'name': 'capecitabine'}]","[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",EMA,1447981787.0,"<p>The EMA European Public Assessment Report (EPAR) for capecitabine (Medac) states that it is contraindicated in patients with complete absence of DPD activity, and that genotyping for certain alleles is recommended to identify patients at increased risk for severe toxicity. It also states that a reduction in starting dose in patients with partial DPD deficiency should be considered to avoid serious toxicity.</p>
",1447981786.0,"<p>Excerpts from the capecitabine (Medac) EPAR:</p>
<blockquote class=""blockquote"">
<p>Contraindications...Known complete dihydropyrimidine dehydrogenase (DPD) deficiency</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Complete DPD deficiency:  Complete DPD deficiency is rare (0.01-0.5% of Caucasians). Patients with complete DPD deficiency are at high risk of life-threatening or fatal toxicity and must not be treated with Capecitabine medac.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Partial DPD deficiency: Patients with partial DPD deficiency are at increased risk of severe and potentially life-threatening toxicity. A reduced starting dose should be considered to limit this toxicity. DPD deficiency should be considered as a parameter to be taken into account in conjunction with other routine measures for dose reduction.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Testing for DPD deficiency: Phenotype and/or genotype testing prior to the initiation of treatment with Capecitabine medac is recommended despite uncertainties regarding optimal pre-treatment testing methodologies. Consideration should be given to applicable clinical guidelines.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genotypic characterisation of DPD deficiency: Pre-treatment testing for rare mutations of the DPYD gene can identify patients with DPD deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The four DPYD variants c.1905+1G&gt;A (also known as DPYD*2A), c.1679T&gt;G (DPYD*13), c.2846A&gt;T and c.1236G&gt;A/HapB3 can cause complete absence or reduction of DPD enzymatic activity. Other rare variants may also be associated with an increased risk of severe or life-threatening toxicity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Certain homozygous and compound heterozygous mutations in the DPYD gene locus (e.g. combinations of the four variants with at least one allele of c.1905+1G&gt;A or c.1679T&gt;G) are known to cause complete or near complete absence of DPD enzymatic activity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with certain heterozygous DPYD variants (including c.1905+1G&gt;A, c.1679T&gt;G, c.2846A&gt;T and c.1236G&gt;A/HapB3) have increased risk of severe toxicity when treated with fluoropyrimidines.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The frequency of the heterozygous c.1905+1G&gt;A genotype in the DPYD gene in Caucasian patients is around 1%, 1.1% for c.2846A&gt;T, 2.6-6.3% for c.1236G&gt;A/HapB3 variants and 0.07 to 0.1% for c.1679T&gt;G. Data on the frequency of the four DPYD variants in other populations than Caucasian is limited. At the present, the four DPYD variants (c.1905+1G&gt;A, c.1679T&gt;G, c.2846A&gt;T and c.1236G&gt;A/HapB3) are considered virtually absent in populations of African (-American) or Asian origin.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Capacitabine_medec_2022_06_03_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Capacitabine_medec_2022_06_03_EMA.pdf"">capecitabine EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1450416885.0,"<p>&quot;Contraindications...Known complete dihydropyrimidine dehydrogenase (DPD) deficiency&quot;</p>
<p>&quot;Partial DPD deficiency: Patients with partial DPD deficiency are at increased risk of severe and potentially life-threatening toxicity. A reduced starting dose should be considered to limit this toxicity. DPD deficiency should be considered as a parameter to be taken into account in conjunction with other routine measures for dose reduction.&quot;</p>
<p>&quot;Testing for DPD deficiency: Phenotype and/or genotype testing prior to the initiation of treatment with Capecitabine medac is recommended despite uncertainties regarding optimal pre-treatment testing methodologies. Consideration should be given to applicable clinical guidelines.&quot;</p>
",,,,,,,
Label Annotation,PA166104870,Annotation of FDA Label for pimozide and CYP2D6,False,False,[],True,"[{'id': 1183681336, 'date': '2013-10-25T11:20:32.124-07:00', 'type': 'Update', 'version': 0}, {'id': 1450382166, 'date': '2019-04-19T14:13:33.932-07:00', 'description': 'Added prescribing information', 'type': 'Update', 'version': 0}, {'id': 1452218600, 'date': '2023-08-28T10:31:42.118-07:00', 'description': 'Added pediatric tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101860, 'title': 'Drugs@FDA: Drug Product ORAP (Pimozide), NDA017473, Teva Select Brands', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017473', 'crossReferences': [{'id': 1449776466, 'resource': 'FDA Application', 'resourceId': 'NDA017473', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017473'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450965', 'name': 'pimozide'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981707.0,"<p>The FDA-approved drug label for pimozide (ORAP) states that CYP2D6 genotyping should be performed at doses above 0.05mg/kg/day in children or above 4 mg/day in adults. In poor CYP2D6 metabolizers, pimozide doses should not exceed 0.05mg/kg/day in children or 4 mg/day in adults and doses should not be increased earlier than 14 days.</p>
",1447981706.0,"<p>Excerpts from the pimozide (ORAP) drug label:</p>
<div class=""blockquote"">
<p>Individuals with genetic variations resulting in poor CYP2D6 metabolism (approximately 5 to 10% of the population) exhibit higher pimozide concentrations than extensive CYP2D6 metabolizers. The concentrations observed in poor CYP 2D6 metabolizers are similar to those seen with strong CYP2D6 inhibitors such as paroxetine. The time to achieve steady state pimozide concentrations is expected to be longer (approximately 2 weeks) in poor CYP2D6 metabolizers because of the prolonged half-life. Alternative dosing strategies are recommended in patients who are genetically poor CYP2D6 metabolizers.</p>
</div>
<div class=""blockquote"">
<p>In children: At doses above 0.05mg/kg/day, CYP2D6 genotyping should be performed. In poor CYP2D6 metabolizers, ORAP doses should not exceed 0.05mg/kg/day, and doses should not be increased earlier than 14 days.</p>
</div>
<div class=""blockquote"">
<p>In adults: At doses above 4 mg/day, CYP2D6 genotyping should be performed. In poor CYP2D6 metabolizers, ORAP doses should not exceed 4 mg/day, and doses should not be increased earlier than 14 days.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Pimozide_02_22_19_FDA.pdf"">pimozide drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450382165.0,"<p>Excerpts from the pimozide (ORAP) drug label:</p>
<blockquote class=""blockquote"">
<p>Children: At doses above 0.05 mg/kg/day, CYP 2D6 genotyping should be performed. In poor CYP 2D6 metabolizers, ORAP doses should not exceed 0.05 mg/kg/day, and doses should not be increased earlier than 14 days</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Adults: At doses above 4 mg/day, CYP 2D6 genotyping should be performed. In poor CYP 2D6 metabolizers, ORAP doses should not exceed 4 mg/day, and doses should not be increased earlier than 14 days</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104876,Annotation of FDA Label for primaquine and G6PD,True,False,[],False,"[{'id': 1183681281, 'date': '2013-10-25T11:07:23.755-07:00', 'type': 'Update', 'version': 0}, {'id': 1183704784, 'date': '2013-12-20T00:00:00-08:00', 'type': 'Update', 'version': 0}, {'id': 1448604781, 'date': '2017-03-16T12:45:00.833-07:00', 'description': 'Testing level changed from actionable to required', 'type': 'Update', 'version': 0}, {'id': 1449051108, 'date': '2017-11-09T14:53:58.316-08:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101840, 'title': 'Drugs@FDA: Drug Product Primaquine Phosphate (Primaquine Phosphate), NDA008316, PD-Rx Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008316', 'crossReferences': [{'id': 1449776486, 'resource': 'FDA Application', 'resourceId': 'NDA008316', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008316'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451103', 'name': 'primaquine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981727.0,"<p>The FDA-approved drug label for primaquine states that G6PD testing has to be performed before using the drug, and that it should not be prescribed for patients with severe G6PD deficiency.</p>
",1447981726.0,"<p>Primaquine is indicated for the radical cure (prevention of relapse) of vivax malaria. Excerpts from the primaquine drug label:</p>
<div class=""blockquote"">
<p>Due to the risk of hemolytic anemia in patients with G6PD deficiency, G6PD testing has to be performed before using primaquine. Due to the limitations of G6PD tests, physicians need to be aware of residual risk of hemolysis and adequate medical support and follow-up to manage hemolytic risk should be available.</p>
</div>
<div class=""blockquote"">
<p>Primaquine should not be prescribed for patients with severe G6PD deficiency.</p>
</div>
<div class=""blockquote"">
<p>In case of mild to moderate G6PD deficiency, a decision to prescribe primaquine must be based on an assessment of the risks and benefits...</p>
</div>
<div class=""blockquote"">
<p>When the G6PD status is unknown and G6PD testing is not available, a decision to prescribe primaquine must be based on an assessment of the risks and benefits...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Primaquine_08_16_2017_FDA.pdf"">primaquine drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450399721.0,"<p>Excerpts from the primaquine drug label:</p>
<blockquote class=""blockquote"">
<p>Primaquine should not be prescribed for patients with severe G6PD deficiency...In case of mild to moderate G6PD deficiency, a decision to prescribe primaquine must be based on an assessment of the risks and benefits...</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104898,Annotation of FDA Label for lansoprazole and CYP2C19,False,False,[],False,"[{'id': 1183681672, 'date': '2013-10-25T14:25:31.140-07:00', 'type': 'Update', 'version': 0}, {'id': 1452210120, 'date': '2023-08-18T14:43:23.067-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101901, 'title': 'Drugs@FDA: Drug Product Prevacid (lansoprazole), NDA020406, REMEDYREPACK INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020406', 'crossReferences': [{'id': 1449754828, 'resource': 'FDA Application', 'resourceId': 'NDA020406', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020406'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450180', 'name': 'lansoprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1447981773.0,"<p>The FDA-approved drug label for lansoprazole (PREVACID) states that it is metabolized mainly by CYP3A and CYP2C19 isozymes. Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19</p>
",1447981772.0,"<p>Excerpts from the lansoprazole (PREVACID) label:</p>
<div class=""blockquote"">
<p>Lansoprazole is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes.</p>
</div>
<div class=""blockquote"">
<p>Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Lansoprazole_02_06_19_FDA.pdf"">lansoprazole drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104899,Annotation of EMA Label for aripiprazole and CYP2D6,False,False,[],True,"[{'id': 1184466968, 'date': '2013-10-25T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1450933188, 'date': '2019-12-04T13:14:39.235-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452323260, 'date': '2023-12-11T00:00:00-08:00', 'description': 'Updated label source to show both formulations.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103632, 'title': 'Abilify Maintena | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena', 'crossReferences': [{'id': 1450932863, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15151762, 'title': 'Abilify | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/abilify', 'crossReferences': [{'id': 1452323242, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/abilify', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/abilify'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}, {'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",[],"[{'objCls': 'Chemical', 'id': 'PA10026', 'name': 'aripiprazole'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1447981775.0,"<p>The EMA European Public Assessment Report (EPAR) for aripiprazole (Abilify Maintena) states that the starting and maintenance dose should be 300 mg in known CYP2D6 poor metabolizers. The EMA EPAR for aripiprazole (ABILIFY) states that the mean elimination half-life for the drug is approximately 75 hours in CYP2D6 extensive metabolizers and 146 hours in CYP2D6 poor metabolizers, but does not provide any dosing advice based on CYP2D6 metabolizer status.</p>
",1447981774.0,"<p><strong>Excerpts from the aripiprazole (Abilify Maintena) EPAR:</strong></p>
<div class=""blockquote"">
<p>Known CYP2D6 poor metabolisers...In patients who are known to be CYP2D6 poor metabolisers, the starting and maintenance dose should be 300 mg. When used concomitantly with strong CYP3A4 inhibitors the dose should be reduced to 200 mg...</p>
</div>
<div class=""blockquote"">
<p>CYP2D6 poor metabolisers...Based on population pharmacokinetic evaluation of Abilify Maintena, the total body clearance of aripiprazole was 3.71 L/h in extensive metabolisers of CYP2D6 and approximately 1.88 L/h (approximately 50 % lower) in poor metabolisers of CYP2D6...</p>
</div>
<p><strong>Excerpt from aripiprazole (ABILIFY) EPAR:</strong></p>
<div class=""blockquote"">
<p>The mean elimination half-lives for aripiprazole are approximately 75 hours in extensive metabolisers of CYP2D6 and approximately 146 hours in poor metabolisers of CYP2D6.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Aripiprazole_ABILIFY_MAINTENA_06_18_19_EMA.pdf"">aripiprazole (Abilify Maintena) EPAR PDF</a> and <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Aripiprazole_ABILIFY_06_18_19_EMA.pdf"">aripiprazole (ABILIFY) EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450416694.0,"<p>Excerpt from aripiprazole (Abilify Maintena) EPAR:</p>
<p>&quot;Known CYP2D6 poor metabolisers...In patients who are known to be CYP2D6 poor metabolisers, the starting and maintenance dose should be 300 mg. When used concomitantly with strong CYP3A4 inhibitors the dose should be reduced to 200 mg...&quot;</p>
",,,,,,,
Label Annotation,PA166123048,Annotation of EMA Label for cabazitaxel and CYP3A4,False,False,[],False,"[{'id': 1184518968, 'date': '2014-08-21T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933190, 'date': '2019-12-04T13:16:57.623-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452206401, 'date': '2023-08-14T12:19:13.188-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103634, 'title': 'Jevtana | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana', 'crossReferences': [{'id': 1450932865, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/jevtana'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958401', 'name': 'cabazitaxel'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447982143.0,"<p>The EMA European Public Assessment Report (EPAR) for cabazitaxel (Jevtana) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A, and coadministration of strong CYP3A inhibitors or inducers should be avoided.</p>
",1447982142.0,"<p>The EMA-approved drug cabazitaxel (Jevtana) is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>Excerpt from the cabazitaxel (Jevtana) EPAR:</p>
<blockquote class=""blockquote"">
<p>Concomitant medicinal products that are strong inducers or strong inhibitors of CYP3A should be avoided. However, if patients require co-administration of a strong CYP3A inhibitor, a 25% cabazitaxel dose reduction should be considered (see sections 4.4 and 4.5).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/cabazitaxel_EMA_EPAR_Aug_6_2014_1.pdf"">cabazitaxel (Jevtana) EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166104832,Annotation of FDA Label for carisoprodol and CYP2C19,False,False,[],False,"[{'id': 1183681193, 'date': '2013-10-25T10:41:07.472-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101974, 'title': 'Drugs@FDA: Drug Product Soma (Carisoprodol), NDA011792, Rebel Distributors Corp', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=011792', 'crossReferences': [{'id': 1449895197, 'resource': 'FDA Application', 'resourceId': 'NDA011792', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=011792'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448809', 'name': 'carisoprodol'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1447981634.0,"<p>Carisoprodol (SOMA) should be used with caution in patients with reduced CYP2C19 activity. Published studies indicate that patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to carisoprodol and a 50% decreased exposure to meprobamate (a metabolite of carisoprodol) compared to normal CYP2C19 metabolizers.</p>
",1447981633.0,"<p>Carisoprodol (SOMA) is skeletal muscle relaxant. The FDA-approved drug label for carisoprodol (SOMA) highlights information regarding CYP2C19 poor metabolizers.</p>
<p>Excerpt from the carisoprodol drug label:</p>
<div class=""blockquote"">
<p>Patients with Reduced CYP2C19 Activity: SOMA should be used with caution in patients with reduced CYP2C19 activity. Published studies indicate that patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to carisoprodol, and concomitant 50% reduced exposure to meprobamate compared to normal CYP2C19 metabolizers. The prevalence of poor metabolizers in Caucasians and African Americans is approximately 3-5% and in Asians is approximately 15-20%.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Carisoprodol_01_07_19_FDA.pdf"">carisoprodol drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399542.0,"<p>Excerpt from the carisoprodol drug label:</p>
<blockquote class=""blockquote"">
<p>Patients with Reduced CYP2C19 Activity: SOMA should be used with caution in patients with reduced CYP2C19 activity.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104843,Annotation of FDA Label for celecoxib and CYP2C9,True,False,[],True,"[{'id': 1183681375, 'date': '2013-10-25T11:27:11.104-07:00', 'type': 'Update', 'version': 0}, {'id': 1450399443, 'date': '2019-05-08T08:19:29.155-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1451327040, 'date': '2021-02-05T13:21:19.998-08:00', 'description': 'updated annotation text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101949, 'title': 'Drugs@FDA: Drug Product CELEBREX (Celecoxib), NDA020998, Aphena Pharma Solutions - Tennessee, LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020998', 'crossReferences': [{'id': 1449895278, 'resource': 'FDA Application', 'resourceId': 'NDA020998', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020998'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]","[{'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA448871', 'name': 'celecoxib'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1450342774.0,"<p>The FDA-approved drug label for celecoxib (CELEBREX) states that in adult patients known or suspected to be poor CYP2C9 metabolizers, treatment should be initiated with half of the lowest recommended dose. In patients with juvenile rheumatoid arthritis (JRA) known or suspected to be poor CYP2C9 metabolizers, alternative treatments should be considered.</p>
",1450342775.0,"<p>Excerpts from the celecoxib (CELEBREX) drug label:</p>
<blockquote class=""blockquote"">
<p>Dosage and administration:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Poor Metabolizers of CYP2C9 Substrates:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In patients who are known or suspected to be poor CYP2C9 metabolizers (i.e., CYP2C9*3/*3), based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin, phenytoin) administer CELEBREX starting with half the lowest recommended dose. Alternative management should be considered in JRA patients identified to be CYP2C9 poor metabolizers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacogenomics: CYP2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*2 and CYP2C9*3 polymorphisms. Limited data from 4 published reports that included a total of 8 subjects with the homozygous CYP2C9*3/*3 genotype showed celecoxib systemic levels that were 3- to 7-fold higher in these subjects compared to subjects with CYP2C9*1/*1 or *I/*3 genotypes. The pharmacokinetics of celecoxib have not been evaluated in subjects with other CYP2C9 polymorphisms, such as *2, *5, *6, *9 and *11. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3% to 1.0% in various ethnic groups.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Celecoxib_01_08_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Celecoxib_01_08_19_FDA.pdf"">celecoxib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399442.0,"<p>Excerpts from the celecoxib (CELEBREX) drug label:</p>
<blockquote class=""blockquote"">
<p>Dosage and administration:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Poor Metabolizers of CYP2C9 Substrates:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In patients who are known or suspected to be poor CYP2C9 metabolizers (i.e., CYP2C9*3/*3), based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin, phenytoin) administer CELEBREX starting with half the lowest recommended dose. Alternative management should be considered in JRA patients identified to be CYP2C9 poor metabolizers.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104894,Annotation of EMA Label for rasburicase and G6PD,True,False,[],False,"[{'id': 1184512680, 'date': '2013-10-27T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1452016886, 'date': '2023-02-22T22:05:16.308-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102999, 'title': 'Fasturtec | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/fasturtec', 'crossReferences': [{'id': 1450663670, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/fasturtec', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/fasturtec'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA10176', 'name': 'rasburicase'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",EMA,1447981763.0,"<p>The EMA European Public Assessment Report (EPAR) for rasburicase (Fasturtec) states that it is contraindicated in patients with G6PD deficiency due to a risk of hemolytic anemia or methemoglobinemia. Testing or screening for G6PD deficiency is not mentioned.</p>
",1447981762.0,"<p>Excerpt from the rasburicase (Fasturtec) EPAR:</p>
<div class=""blockquote"">
<p>Contraindications...G6PD deficiency and other cellular metabolic disorders known to cause haemolytic anaemia.</p>
</div>
<div class=""blockquote"">
<p>In clinical trials, haematological disorders such as haemolysis, haemolytic anaemia and methaemoglobinaemia are uncommonly caused by Fasturtec. The enzymatic digestion of uric acid to allantoin by rasburicase produces hydrogen peroxide and haemolytic anaemia or methaemoglobinaemia have been observed in certain at risk populations such as those with G6PD deficiency.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Rasburicase_06_26_19_EMA.pdf"">rasburicase EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450663669.0,"<p>&quot;Contraindications...G6PD deficiency and other cellular metabolic disorders known to cause haemolytic anaemia.&quot;</p>
",,,,,,,
Label Annotation,PA166400441,Annotation of FDA Label for seladelpar and CYP2C9,False,False,[],False,[],False,[],True,"[{'id': 15178943, 'title': 'Drugs@FDA: Drug Product Livdelzi (SELADELPAR LYSINE), Gilead Sciences, Inc - NDA217899/ORIG-1, 08/14/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217899', 'crossReferences': [{'id': 1454057026, 'resource': 'FDA Application', 'resourceId': 'NDA217899/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217899'}], 'objCls': 'Literature', 'pubDate': '2024-08-14T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166400041', 'name': 'seladelpar'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1454057580.0,"<p>The FDA-approved drug label for seladelpar (LIVDELZI) notes that compared to CYP2C9 normal metabolizers, dose-normalized AUC0-inf was 48% higher in CYP2C9 poor metabolizers and 24% higher in CYP2C9 intermediate metabolizers. CYP2C9 poor metabolizers who receive a concomitant moderate to strong CYP3A4 inhibitor should be monitored more frequently for adverse reactions.</p>
",1454057581.0,"<p>Excerpts from the seladelpar (LIVDELZI) label:</p>
<blockquote class=""blockquote"">
<p>CYP2C9 activity is decreased in individuals with genetic variants such as CYP2C9*2 and CYP2C9*3. Compared to CYP2C9 normal metabolizers (*1/*1, n=84) after a single dose of seladelpar 1 mg to 15 mg, dose-normalized AUC0-inf was 48% higher in CYP2C9 poor metabolizers (*2/*3, n=2) and 24% higher in CYP2C9 intermediate metabolizers (*1/*2, *1/*8, *1/*3, *2/*2, n=28). Dose-normalized Cmax was similar for CYP2C9 normal, intermediate, and poor metabolizers. Seladelpar pharmacokinetics was not evaluated in patients who are CYP2C9 poor metabolizers with two no function alleles (e.g., *3/*3). CYP2C9 poor metabolizers may have increased AUC when seladelpar is used concomitantly with a moderate to strong CYP3A4 inhibitor [see Drug Interactions (7.1), Use in Specific Populations (8.8)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The prevalence of CYP2C9 poor metabolizers is approximately 2 to 3% in White populations, 0.5 to 4% in Asian populations, and &lt;1% in African American populations. Additional decreased or nonfunctional alleles (e.g., *5, *6, *11) are more prevalent in African American populations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Seladelpar is primarily metabolized in vitro by CYP2C9 and to a lesser extent by CYP2C8 and CYP3A4, resulting in the three major metabolites: seladelpar sulfoxide (M1), desethyl-seladelpar (M2), and desethyl-seladelpar sulfoxide (M3). The metabolite-to-parent AUC ratios were 0.36, 2.32 and 0.63 for M1, M2 and M3, respectively. Median Tmax for metabolites were 10 hours for M1 and 4 hours for M2 and M3. None of the major metabolites have pharmacological activity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Monitor CYP2C9 poor metabolizers who receive a concomitant moderate to strong CYP3A4 inhibitor more frequently for adverse reactions.
Seladelpar is a CYP2C9 and CYP3A4 substrate. Increased seladelpar AUC is expected in patients who are CYP2C9 poor metabolizers with concomitant use of a moderate to strong CYP3A4 inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.5)].</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Seladelpar_2025_05_08_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Seladelpar_2025_05_08_FDA.pdf"">seladelpar drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1454057582.0,"<blockquote class=""blockquote"">
<p>Monitor CYP2C9 poor metabolizers who receive a concomitant moderate to strong CYP3A4 inhibitor more frequently for adverse reactions.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166401161,Annotation of FDA Label for donanemab and APOE,False,False,[],False,[],False,[],True,"[{'id': 15179282, 'title': 'Drugs@FDA: Drug Product Kisunla (donanemab-azbt), Eli Lilly and Company - BLA761248/ORIG-1, 07/02/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761248', 'crossReferences': [{'id': 1454080522, 'resource': 'FDA Application', 'resourceId': 'BLA761248/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761248'}], 'objCls': 'Literature', 'pubDate': '2024-07-02T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166400001', 'name': 'donanemab'}]","[{'objCls': 'Gene', 'id': 'PA55', 'symbol': 'APOE', 'name': 'apolipoprotein E'}]",FDA,1454080541.0,"<p>The FDA label for donanemab includes warnings that the ApoE ε4 status of patients should be determined prior to initiation of treatment; individuals homozygous for the ApoE ε4 allele have increased risk for amyloid related imaging abnormalities (ARIA) when treated with donanemab.</p>
",1454080542.0,"<p>Excerpts from the donanemab-azbt (KISUNLA) label:</p>
<blockquote class=""blockquote"">
<p>ApoE ε4 Homozygotes
Patients who are apolipoprotein E ε4 (ApoE ε4) homozygotes (approximately 15% of Alzheimer's disease patients) treated with this class of medications, including KISUNLA, have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers [see Warnings and Precautions (5.1)]. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed, they can still be treated with KISUNLA; however, it cannot be determined if they are ApoE ε4 homozygotes and at higher risk for ARIA [see Warnings and Precautions (5.1)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>An FDA-authorized test for detection of ApoE ε4 alleles to identify patients at risk of ARIA if treated with KISUNLA is not currently available. Currently available tests used to identify ApoE ε4 alleles may vary in accuracy and design.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Donanemab-azbt_2025_05_15_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Donanemab-azbt_2025_05_15_FDA.pdf"">donanemab-azbt drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166401162,Annotation of EMA Label for donanemab,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166400001', 'name': 'donanemab'}]",[],EMA,,,1454080545.0,"<p>As of May 15, 2025, the EMA website (https://www.ema.europa.eu/en/medicines/human/EPAR/kisunla) states:</p>
<blockquote class=""blockquote"">
<p><strong>Update as of 10 April 2025</strong>
The company for Kisunla has requested a re-examination of EMA's March 2025 opinion.  Upon receipt of the grounds of this request, the Agency will re-examine its opinion and issue a final recommendation.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The European Medicines Agency has recommended the refusal of the marketing authorisation for Kisunla, a medicine intended for the treatment of early Alzheimer’s disease.</p>
</blockquote>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166119824,Annotation of EMA Label for belimumab and TNFSF13B,False,False,[],False,"[{'id': 1184174951, 'date': '2014-05-02T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933189, 'date': '2019-12-04T13:16:07.889-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452206141, 'date': '2023-08-14T10:14:43.610-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103633, 'title': 'Benlysta | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta', 'crossReferences': [{'id': 1450932864, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166114904', 'name': 'belimumab'}]","[{'objCls': 'Gene', 'id': 'PA434', 'symbol': 'TNFSF13B', 'name': 'TNF superfamily member 13b'}]",EMA,1447982147.0,"<p>The EMA European Public Assessment Report (EPAR) for belimumab (Benlysta) contains information regarding its mechanism of action for use in the treatment of systemuc lupus erythematosus (SLE). It is a human IgG1lambda that blocks binding of TNFSF13B to its receptor to inhibit B cell survival and reduce differentiation.</p>
",1447982146.0,"<p>Excerpt/s from the belimumab (Benlysta) EPAR:</p>
<blockquote class=""blockquote"">
<p>Benlysta is a human IgG1lamda monoclonal antibody specific for soluble human B Lymphocyte Stimulator protein (BLyS, also referred to as BAFF and TNFSF13B). Benlysta blocks the binding of soluble BLyS, a B cell survival factor, to its receptors on B cells. Benlysta does not bind B cells directly, but by binding BLyS, Benlysta inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.</p>
<p>BLyS levels are elevated in patients with SLE and other autoimmune diseases. There is an association between plasma BLyS levels and SLE disease activity. The relative contribution of BLyS levels to the pathophysiology of SLE is not fully understood.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Belimumab_EMA_EPAR_May_02_2014.pdf"">belimumab (Benlysta) EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166122488,Annotation of EMA Label for regorafenib and KRAS,False,True,[],False,"[{'id': 1184471881, 'date': '2014-06-26T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1451818140, 'date': '2022-07-05T00:00:00-07:00', 'description': 'Added most recent label.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102966, 'title': 'Stivarga | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga', 'crossReferences': [{'id': 1450806104, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166114943', 'name': 'regorafenib'}]","[{'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",EMA,1447982121.0,"<p>The EMA European Public Assessment Report (EPAR) for regorafenib (Stivarga) states that the hazard ratios for overall survival and progression-free survival were lower in patients with KRAS wild-type tumors as compared to KRAS mutant tumors. However, the EPAR does not comment on the significance of this difference.</p>
",1447982120.0,"<p>Excerpts from the regorafenib (Stivarga) EPAR:</p>
<blockquote class=""blockquote"">
<p>Stivarga is used to treat:</p>
<ul>
<li>colon or rectal cancer that has spread to other parts of the body in adult patients who have received other treatments or cannot be treated with other medicines (fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy)</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Subgroup analysis results by historical KRAS mutational status showed a treatment effect for OS in favour of regorafenib over placebo for patients with KRAS wild-type tumours whereas a numerically lower effect was reported in patients with KRAS mutant tumours; the treatment effect for PFS favouring regorafenib was observed regardless of KRAS mutational status. The hazard ratio (95% CI) of OS was 0.653 (0.476 to 0.895) for patients with KRAS wild-type tumours and 0.867 (0.670 to 1.123) for patients with KRAS mutant tumours, with no evidence of heterogeneity in treatment effect (non-significant interaction test). The hazard ratio (95% CI) of PFS was 0.475 (0.362 to 0.623) for patients with KRAS wild-type tumours and 0.525 (0.425 to 0.649) for patients with KRAS mutant tumours.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Regorafenib_EMA_2022_07_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Regorafenib_EMA_2022_07_05.pdf"">regorafenib EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166114382,Annotation of EMA Label for ticagrelor and CYP2C19,False,False,[],False,"[{'id': 1184512686, 'date': '2013-10-29T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452532080, 'date': '2024-07-19T10:57:54.474-07:00', 'description': 'Updated label PDF and removed non-PGx text from the main annotation', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103583, 'title': 'Brilique | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/brilique', 'crossReferences': [{'id': 1450931581, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/brilique', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/brilique'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165374673', 'name': 'ticagrelor'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",EMA,1447981594.0,"<p>The EMA European Public Assessment Report (EPAR) for ticagrelor (Brilique) contains information regarding a study in which CYP2C19 and ABCB1 genotyping was carried out (PLATO - platelet inhibition and patient outcomes). In patients with one or more CYP2C19 loss of function allele, non-coronary artery by-pass grafting (non-CABG) PLATO major bleeding was increased when treated with ticagrelor compared to clopidogrel, but was similar in patients with no loss of function alleles.</p>
",1447981593.0,"<p>Excerpt from the ticagrelor (Brilique) EPAR:</p>
<blockquote class=""blockquote"">
<p>CYP2C19 and ABCB1 genotyping of 10,285 patients in PLATO provided associations of genotype groups with PLATO outcomes. The superiority of ticagrelor over clopidogrel in reducing major CV events was not significantly affected by patient CYP2C19 or ABCB1 genotype. Similar to the overall PLATO study, total PLATO Major bleeding did not differ between ticagrelor and clopidogrel, regardless of CYP2C19 or ABCB1 genotype. Non-CABG PLATO Major bleeding was increased with ticagrelor compared clopidogrel in patients with one or more CYP2C19 loss of function alleles, but similar to clopidogrel in patients with no loss of function allele.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Ticagrelor_2024_07_19_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ticagrelor_2024_07_19_EMA.pdf"">ticagrelor (Brilique) EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166401241,Annotation of FDA Label for lazertinib and GSTM1,False,False,[],False,[],False,[],True,"[{'id': 15179342, 'title': 'Drugs@FDA: Drug Product LAZCLUZE (lazertinib), Janssen Biotech, Inc. - NDA219008/ORIG-1, 08/19/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=219008', 'crossReferences': [{'id': 1454080701, 'resource': 'FDA Application', 'resourceId': 'NDA219008/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=219008'}], 'objCls': 'Literature', 'pubDate': '2024-08-19T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166314341', 'name': 'lazertinib'}]","[{'objCls': 'Gene', 'id': 'PA182', 'symbol': 'GSTM1', 'name': 'glutathione S-transferase mu 1'}]",FDA,1454080740.0,"<p>Lazertinib (LAZCLUZE) is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. No clinically significant differences in safety or efficacy were observed as a function of a patient's GSTM1 genotype.</p>
",1454080741.0,"<p>Excerpts from the lazertinib (LAZCLUZE) label:</p>
<blockquote class=""blockquote"">
<p>Patients with at least one GSTM1 normal function allele have 44% lower systemic levels of lazertinib compared with those with the two GSTM1 no-function alleles (i.e., no enzyme activity). No clinically significant differences in safety or efficacy were observed as a function of GSTM1 genotype in patients receiving LAZCLUZE in combination with amivantamab.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Lazertinib is primarily metabolized by glutathione conjugation, either enzymatic via glutathioneS-transferase (GST) or non-enzymatic, as well as by CYP3A4.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Lazertinib_2025_05_15_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lazertinib_2025_05_15_FDA.pdf"">lazertinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166121251,"Annotation of EMA Label for mercaptopurine and NUDT15, TPMT",False,False,[],True,"[{'id': 1184512660, 'date': '2013-10-27T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1452537941, 'date': '2024-07-24T00:00:00-07:00', 'description': 'updated label, added Pediatric tag and info, added Dosing Info tag, changed level to Testing Recommended', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102968, 'title': 'Xaluprine (previously Mercaptopurine Nova Laboratories) | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/xaluprine-previously-mercaptopurine-nova-laboratories', 'crossReferences': [{'id': 1450622569, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/xaluprine-previously-mercaptopurine-nova-laboratories', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/xaluprine-previously-mercaptopurine-nova-laboratories'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]","[{'objCls': 'Variant', 'id': 'PA166154759', 'symbol': 'rs116855232', 'name': 'rs116855232'}]","[{'objCls': 'Chemical', 'id': 'PA450379', 'name': 'mercaptopurine'}]","[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",EMA,1447982119.0,"<p>The EMA European Public Assessment Report (EPAR) for mercaptopurine (Xaluprine) states that starting or target doses should be lower in patients with reduced or absent TPMT enzyme activity, and that patients with mutated NUDT15 gene also generally require a dose reduction.</p>
",1447982118.0,"<p>Excerpts from the mercaptopurine (Xaluprine) EPAR:</p>
<blockquote class=""blockquote"">
<p>Depending on phase of treatment, starting or target doses generally vary between 25-75 mg/m2 body surface area (BSA) per day, but should be lower in patients with reduced or absent Thiopurine Methyl Transferase (TPMT) enzyme activity (see section 4.4).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>6-mercaptopurine is metabolised by the polymorphic TPMT enzyme. Patients with little or no inherited TPMT activity are at increased risk for severe toxicity from conventional doses of mercaptopurine and generally require substantial dose reduction. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity. TPMT testing cannot substitute for haematological monitoring in patients receiving Xaluprine. The optimal starting dose for homozygous deficient patients has not been established (see section 4.4).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity, (see 4.4). These patients generally require dose reduction; particularly those being NUDT15 variant homozygotes (see 4.4). Genotypic testing of NUDT15 variants may be considered before initiating 6-mercaptopurine therapy. In any case, close monitoring of blood counts is necessary.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>There are individuals with an inherited deficiency of the TPMT enzyme activity who are very sensitive to the myelosuppressive effect of 6-mercaptopurine and prone to developing rapid bone marrow depression following the initiation of treatment with 6-mercaptopurine. This problem could be exacerbated by coadministration with active substances that inhibit TPMT, such as olsalazine, mesalazine or sulfasalazine. Some laboratories offer testing for TPMT deficiency, although these tests have not been shown to identify all patients at risk of severe toxicity. Therefore close monitoring of blood counts is necessary. Substantial dose reductions are generally required for homozygous-TPMT deficiency patients to avoid the development of life threatening bone marrow suppression.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy. They generally require dose reduction, particularly those being NUDT15 variant homozygotes (see 4.2). The frequency of NUDT15 c.415C&gt;T has an ethnic variability of approximately 10 % in East Asians, 4 % in Hispanics, 0.2 % in Europeans and 0 % in Africans. In any case, close monitoring of blood counts is necessary.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Mercaptopurine_2024_07_24_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Mercaptopurine_2024_07_24_EMA.pdf"">mercaptopurine EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",1452537940.0,"<blockquote class=""blockquote"">
<p>Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.</p>
</blockquote>
",1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1450622568.0,"<blockquote class=""blockquote"">
<p>Patients with little or no inherited TPMT activity are at increased risk for severe toxicity from conventional doses of mercaptopurine and generally require substantial dose reduction. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity. TPMT testing cannot substitute for haematological monitoring in patients receiving Xaluprine. The optimal starting dose for homozygous deficient patients has not been established (see section 4.4).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity, (see 4.4). These patients generally require dose reduction; particularly those being NUDT15 variant homozygotes (see 4.4). Genotypic testing of NUDT15 variants may be considered before initiating 6-mercaptopurine therapy. In any case, close monitoring of blood counts is necessary.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166401261,Annotation of EMA Label for lazertinib and GSTM1,False,False,[],False,[],False,[],True,"[{'id': 15179382, 'title': 'Lazcluze | European Medicines Agency (EMA)', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/lazcluze', 'crossReferences': [{'id': 1454080744, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/lazcluze', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/lazcluze'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166314341', 'name': 'lazertinib'}]","[{'objCls': 'Gene', 'id': 'PA182', 'symbol': 'GSTM1', 'name': 'glutathione S-transferase mu 1'}]",EMA,1454080780.0,"<p>Lazertinib (Lazcluze) is an irreversible EGFR tyrosine kinase inhibitor that is indicated in combination with amivantamab for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Before initiation of treatment, EGFR mutation-positive status in tumor tissue or plasma specimens must be established using a validated test method. The plasma exposure of lazertinib is affected by GSTM1-mediated metabolism, leading to lower exposure (less than 2-fold difference) in Non-null GSTM1 patients; however, no dose adjustment is required based on GSTM1 status.</p>
",1454080781.0,"<p>Excerpt from the lazertinib (Lazcluze) EPAR:</p>
<blockquote class=""blockquote"">
<p>Lazertinib is primarily metabolised by glutathione conjugation, either enzymatic via glutathione-S-transferase (GST) or non-enzymatic, as well as by CYP3A4. The most abundant metabolites are glutathione catabolites and considered clinically inactive. The plasma exposure of lazertinib was affected by GSTM1 mediated metabolism, leading to lower exposure (less than 2-fold difference) in Non-null GSTM1 patients. No dose adjustment is required based on GSTM1 status.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Lazertinib_2025_05_15_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lazertinib_2025_05_15_EMA.pdf"">lazertinib EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166401281,Annotation of EMA Label for arimoclomol,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166400062', 'name': 'arimoclomol'}]",[],EMA,,,1454080860.0,"<p>As of May 15, 2025, the EMA webpage for arimoclomol (https://www.ema.europa.eu/en/medicines/human/EPAR/miplyffa) has the &quot;Application withdrawn&quot; status and states:</p>
<blockquote class=""blockquote"">
<p>Orphazyme A/S withdrew its application for a marketing authorisation of Miplyffa for the treatment of Niemann-Pick disease type C (NPC) in patients aged 2 years and older in combination with miglustat (another medicine to treat NPC).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The company withdrew the application on 22 March 2022.</p>
</blockquote>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166151881,Annotation of FDA Label for rasburicase and G6PD,True,False,[],False,"[{'id': 1447952337, 'date': '2016-03-21T13:56:59.599-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101891, 'title': 'Drugs@FDA: Drug Product Elitek (rasburicase), BLA103946, sanofi-aventis U.S. LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103946', 'crossReferences': [{'id': 1449776546, 'resource': 'FDA Application', 'resourceId': 'BLA103946', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103946'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA10176', 'name': 'rasburicase'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447982323.0,"<p>The FDA-approved drug label for rasburicase (Elitek) states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency. The label also states that It is unclear whether patients with NADH cytochrome b5 reductase (<em>CYB5R1, 2, 3, 4</em>) deficiency are at risk for methemoglobinemia or hemolytic anemia.</p>
",1447982322.0,"<p>Excerpts from the rasburicase (Elitek) drug label:</p>
<div class=""blockquote"">
<p>Do not administer Elitek to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue Elitek in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek.</p>
</div>
<div class=""blockquote"">
<p>Elitek is contraindicated in patients with G6PD deficiency because hydrogen peroxide is one of the major by-products of the conversion of uric acid to allantoin. In clinical studies, hemolysis occurs in &lt;1% patients receiving Elitek; severe hemolytic reactions occurred within 2-4 days of the start of Elitek. Immediately and permanently discontinue Elitek administration in any patient developing hemolysis. Institute appropriate patient monitoring and support measures (e.g., transfusion support). Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Rasburicase_08_17_2017_FDA.pdf"">rasburicase drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450399724.0,"<p>Excerpt from the rasburicase (Elitek) drug label:</p>
<blockquote class=""blockquote"">
<p>Elitek is contraindicated in patients with G6PD deficiency because hydrogen peroxide is one of the major by-products of the conversion of uric acid to allantoin.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166185194,"Annotation of FDA Label for raloxifene and ESR1, ESR2",False,True,[],False,"[{'id': 1452214640, 'date': '2023-08-23T17:15:41.657-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452230583, 'date': '2023-09-07T11:31:17.905-07:00', 'description': 'added cancer genome tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103478, 'title': 'Drugs@FDA: Drug Product  raloxifene NDA 020815', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020815', 'crossReferences': [{'id': 1450826946, 'resource': 'FDA Application', 'resourceId': 'NDA020815', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020815'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451221', 'name': 'raloxifene'}]","[{'objCls': 'Gene', 'id': 'PA156', 'symbol': 'ESR1', 'name': 'estrogen receptor 1'}, {'objCls': 'Gene', 'id': 'PA27886', 'symbol': 'ESR2', 'name': 'estrogen receptor 2'}]",FDA,1450826943.0,"<p>The FDA label for raloxifene (EVISTA) states that EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women, for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. The label notes the percentages of patients in clinical studies who had estrogen receptor (ER) positive disease.</p>
",1450826944.0,"<p>Excerpts from the raloxifene (EVISTA) drug label:</p>
<div class=""blockquote"">
<p>Clinical studies:</p>
</div>
<div class=""blockquote"">
<p>Reduction in Risk of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis: CORE Trial:
The effect of EVISTA on the incidence of invasive breast cancer was evaluated for 4 additional years in a follow-up
study conducted in a subset of postmenopausal women originally enrolled in the MORE osteoporosis treatment trial.
Women were not re-randomized; the treatment assignment from the osteoporosis treatment trial was carried forward to
this study. EVISTA, 60 mg administered once daily, reduced the incidence of invasive breast cancer by 56%, compared
with placebo (ARR 3.0 per 1000 women-years); this was primarily due to a 63% reduction in the incidence of ER-positive
invasive breast cancer in the EVISTA group compared with placebo. There was no reduction in the incidence of ERnegative
breast cancer. In the osteoporosis treatment trial and the follow-up study, there was no difference in incidence of
noninvasive breast cancer between the EVISTA and placebo groups. Table 7 presents efficacy and selected safety
outcomes.</p>
</div>
<div class=""blockquote"">
<p>RUTH trial: EVISTA, 60 mg administered once daily, reduced the incidence of invasive breast cancer by 44% compared with
placebo [absolute risk reduction (ARR) 1.2 per 1000 women-years]; this was primarily due to a 55% reduction in estrogen
receptor (ER)-positive invasive breast cancer in the EVISTA group compared with placebo (ARR 1.2 per 1000 womenyears).
There was no reduction in ER-negative invasive breast cancer. Table 8 presents efficacy and selected safety
outcomes.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/raloxefene_11_05_2019_FDA.pdf"">raloxifene drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166160289,Annotation of HCSC Label for brivaracetam and CYP2C19,False,False,[],False,"[{'id': 1452527642, 'date': '2024-07-15T11:26:08.144-07:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160662, 'title': 'Drugs@HCSC: Drug Product BRIVLERA (brivaracetam), UCB Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93933', 'crossReferences': [{'id': 1452527640, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93933', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93933'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166153491', 'name': 'brivaracetam'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1448259040.0,"<p>The drug label for brivaracetam (BRIVLERA) states that individuals with ineffective mutations of CYP2C19 had decreased production of the hydroxy metabolite and increased concentrations of brivaracetam.</p>
",1448259039.0,"<p>Excerpt from the brivaracetam (BRIVLERA) product monograph:</p>
<blockquote class=""blockquote"">
<p><em>In vitro</em>, the hydroxylation pathway is mediated primarily by CYP2C19. <em>In vivo</em>, in human subjects possessing ineffective mutations of CYP2C19, production of the hydroxy metabolite is decreased 2- or 10-fold while brivaracetam itself is increased by 22% or 42% in individuals with one or both mutated alleles, respectively.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Brivaracetam_2024_07_15_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Brivaracetam_2024_07_15_HCSC.pdf"">brivaracetam product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452527641.0,"<blockquote class=""blockquote"">
<p>BRIVLERA (brivaracetam) is indicated as adjunctive therapy in the management of partial-onset seizures in patients 4 years of age and older with epilepsy who are not satisfactorily controlled with conventional therapy.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166159938,Annotation of HCSC Label for belimumab and TNFSF13B,False,False,[],False,"[{'id': 1452206180, 'date': '2023-08-14T10:41:08.797-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452782443, 'date': '2024-12-12T17:36:09.189-08:00', 'description': 'added label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171942, 'title': 'Drugs@HCSC: Drug Product BENLYSTA (belimumab), GlaxoSmithKline Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85508', 'crossReferences': [{'id': 1452782460, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85508', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85508'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166114904', 'name': 'belimumab'}]","[{'objCls': 'Gene', 'id': 'PA434', 'symbol': 'TNFSF13B', 'name': 'TNF superfamily member 13b'}]",HCSC,1448255761.0,"<p>Belimumab (BENLYSTA) is a human IgG1&lambda; monoclonal antibody, indicated for use in adults with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. It acts by blocking binding of soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B-cell survival factor, to its receptors on B cells.</p>
",1448255760.0,"<p>Excerpts from the belimumab (BENLYSTA) drug label:</p>
<blockquote class=""blockquote"">
<p>BENLYSTA (belimumab) is a fully human IgG1&lambda; monoclonal antibody specific for soluble human B Lymphocyte Stimulator protein (BLyS, also referred to as BAFF and TNFSF13B).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Belimumab is a B Lymphocyte Stimulator (BLyS)-specific inhibitor that blocks the binding of soluble BLyS, ... belimumab inhibits the survival of B-cells, including autoreactive B-cells, and reduces the differentiation of B-cells into immunoglobulin producing plasma cells.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Belimumab specifically binds to soluble B Lymphocyte Stimulator (BLyS) protein and blocks the binding of soluble BLyS to its receptors expressed on B cells.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Belimumbab_05_23_16.pdf"">belimumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166182726,Annotation of FDA Label for rivaroxaban and F5,False,False,[],False,"[{'id': 1452215220, 'date': '2023-08-24T15:04:47.097-07:00', 'description': 'remove informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102367, 'title': 'Drugs@FDA: Drug Product Xarelto (rivaroxaban), NDA022406, Janssen Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022406', 'crossReferences': [{'id': 1450399996, 'resource': 'FDA Application', 'resourceId': 'NDA022406', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022406'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958360', 'name': 'rivaroxaban'}]","[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}]",FDA,1450399993.0,"<p>Rivaroxaban (XARELTO) is an anticoagulant with several indications, including for the reduction of risk of recurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE). In a study of the efficacy of rivaroxaban in reducing the risk of recurrence of DVT or PE, mutations in F5 are mentioned as a risk factor for recurrence of DVT or PE.</p>
",1450399994.0,"<p>Excerpt from the rivaroxaban (XARELTO) drug label:</p>
<div class=""blockquote"">
<p>A total of 2275 patients were randomized and followed on study treatment for a mean of 290 days for the XARELTO and aspirin treatment groups. The mean age was approximately 59 years. The population was 56% male, 70% Caucasian, 14% Asian and 3% Black. In the EINSTEIN CHOICE study, 51% of patients had DVT only, 33% had PE only, and 16% had PE and DVT combined. Other risk factors included idiopathic VTE (43%), previous episode of DVT/PE (17%), recent surgery or trauma (12%), prolonged immobilization (10%), use of estrogen containing drugs (5%), known thrombophilic conditions (6%), Factor V Leiden gene mutation (4%), or active cancer (3%).</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Rivaroxaban_05_13_19_FDA.pdf"">rivaroxaban drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166160121,"Annotation of FDA Label for nivolumab and BRAF, ERBB2",False,True,[],False,"[{'id': 1448604428, 'date': '2017-03-14T15:24:11.474-07:00', 'type': 'Update', 'version': 0}, {'id': 1449005541, 'date': '2017-11-08T14:42:47.724-08:00', 'type': 'Update', 'version': 0}, {'id': 1449174531, 'date': '2018-02-27T10:42:49.708-08:00', 'description': 'Added the CD274 Biomarker ', 'type': 'Update', 'version': 0}, {'id': 1450378862, 'date': '2019-04-14T15:37:03.501-07:00', 'description': 'Added prescribing information', 'type': 'Update', 'version': 0}, {'id': 1450379898, 'date': '2019-04-16T11:52:22.959-07:00', 'description': ""Checked 'Alternate Drug' box"", 'type': 'Update', 'version': 0}, {'id': 1450379968, 'date': '2019-04-16T14:10:21.712-07:00', 'description': 'Added variant information', 'type': 'Update', 'version': 0}, {'id': 1450380880, 'date': '2019-04-18T14:58:27.692-07:00', 'description': 'Added cancer genome tag', 'type': 'Update', 'version': 0}, {'id': 1450824361, 'date': '2019-10-22T06:36:05.882-07:00', 'description': 'Updated to new label. Removed prescribing info. Updated annotation as BRAF indication has changed. Added annotation of ALK and EGFR. Changed from Testing required to Informational.', 'type': 'Update', 'version': 0}, {'id': 1451285121, 'date': '2020-10-28T17:24:51.769-07:00', 'description': 'moved PD-L1, EGFR, ALK to testing required based on label update', 'type': 'Update', 'version': 0}, {'id': 1451537000, 'date': '2021-10-14T12:47:57.071-07:00', 'description': 'Updated annotation based on updates to FDA label', 'type': 'Update', 'version': 0}, {'id': 1452209441, 'date': '2023-08-17T17:25:13.848-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452315220, 'date': '2023-12-04T00:00:00-08:00', 'description': 'Updated label.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101963, 'title': 'Drugs@FDA: Drug Product OPDIVO (nivolumab), BLA125554, E.R. Squibb & Sons, L.L.C.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125554', 'crossReferences': [{'id': 1452315240, 'resource': 'FDA Application', 'resourceId': 'BLA125554/SUPPL-121', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125554'}], 'objCls': 'Literature', 'pubDate': '2023-10-13T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166157522', 'symbol': 'rs113488022', 'name': 'rs113488022'}]","[{'objCls': 'Chemical', 'id': 'PA166129522', 'name': 'nivolumab'}]","[{'objCls': 'Gene', 'id': 'PA25408', 'symbol': 'BRAF', 'name': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'objCls': 'Gene', 'id': 'PA27844', 'symbol': 'ERBB2', 'name': 'erb-b2 receptor tyrosine kinase 2'}]",FDA,1448257891.0,"<p>The FDA-approved drug label for nivolumab (OPDIVO) previously stated that it is indicated for the treatment of patients with BRAF V600 wild-type or BRAF V600 mutation-positive unresectable or metastatic melanoma as a single agent, among other indications. The label now indicates for unresectable or metastatic melanoma and does not define by BRAF mutation, although there is discussion of BRAF in the different clinical studies. The label also mentions that patients with ERBB2 (HER2) positive cancers were excluded from some clinical studies of nivolumab.</p>
",1448257890.0,"<p>Excerpts from the nivolumab (OPDIVO) drug label:</p>
<blockquote class=""blockquote"">
<p>Clinical studies:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The safety of OPDIVO was evaluated in CHECKMATE-037, a randomized, open-label trial in 370 patients with unresectable or metastatic melanoma. Patients had documented disease progression following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The safety of OPDIVO was also evaluated in CHECKMATE-066, a randomized, double-blind,
active-controlled trial in 411 previously untreated patients with BRAF V600 wild-type
unresectable or metastatic melanoma.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The safety of OPDIVO in combination with chemotherapy was evaluated in CHECKMATE-649 [...]. The trial excluded patients who were known human epidermal growth factor receptor 2 (HER2) positive.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Nivolumab_FDA_2023_11_30.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Nivolumab_FDA_2023_11_30.pdf"">nivolumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182725,"Annotation of FDA Label for eribulin and ERBB2, ESR1, ESR2, PGR",False,True,[],False,"[{'id': 1450399965, 'date': '2019-05-14T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450805255, 'date': '2019-07-03T12:18:49.429-07:00', 'description': ""tagging with 'cancer genome'"", 'type': 'Update', 'version': 0}, {'id': 1452209242, 'date': '2023-08-17T14:13:58.592-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102366, 'title': 'Drugs@FDA: Drug Product Halaven (eribulin mesylate), NDA201532, Eisai Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201532', 'crossReferences': [{'id': 1450399966, 'resource': 'FDA Application', 'resourceId': 'NDA201532', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201532'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182723', 'name': 'eribulin'}]","[{'objCls': 'Gene', 'id': 'PA27844', 'symbol': 'ERBB2', 'name': 'erb-b2 receptor tyrosine kinase 2'}, {'objCls': 'Gene', 'id': 'PA156', 'symbol': 'ESR1', 'name': 'estrogen receptor 1'}, {'objCls': 'Gene', 'id': 'PA27886', 'symbol': 'ESR2', 'name': 'estrogen receptor 2'}, {'objCls': 'Gene', 'id': 'PA266', 'symbol': 'PGR', 'name': 'progesterone receptor'}]",FDA,1450399963.0,"<p>The FDA-approved label for eribulin (HALAVEN) states that it is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease and unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.</p>
",1450399964.0,"<p>Excerpt from the eribulin (HALAVEN) drug label:</p>
<p>Under 14 CLINICAL STUDIES, 14.1 Metastatic Breast Cancer</p>
<div class=""blockquote"">
<p>Patients were randomized (2:1) to receive HALAVEN (n=508) or a single agent therapy selected prior to randomization (control arm, n=254). Randomization was stratified by geographic region, HER2/neu status, and prior capecitabine exposure.</p>
</div>
<div class=""blockquote"">
<p>Tumor prognostic characteristics, including estrogen receptor status (positive: 67%, negative: 28%), progesterone receptor status (positive: 49%, negative: 39%), HER2/neu receptor status (positive: 16%, negative: 74%), triple negative status (ER-, PR-, HER2/neu -: 19%), presence of visceral disease (82%, including 60% liver and 38% lung) and bone disease (61%), and number of sites of metastases (greater than two: 50%), were also similar in the HALAVEN and control arms.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Eribulin_05_14_2019_FDA.pdf"">eribulin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182787,Annotation of FDA Label for tolbutamide and G6PD,True,False,[],False,"[{'id': 1452216660, 'date': '2023-08-25T00:54:22.510-07:00', 'description': 'Added ""Alternate Drug"" tag based on updated definition', 'type': 'Update', 'version': 0}, {'id': 1452640420, 'date': '2024-10-14T10:37:32.775-07:00', 'description': 'note that drug is discontinued', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102404, 'title': 'Drugs@FDA: Drug Product Tolbutamide (tolbutamide), ANDA086445, Mylan Pharmaceuticals Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=086445', 'crossReferences': [{'id': 1450401677, 'resource': 'FDA Application', 'resourceId': 'ANDA086445', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=086445'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451718', 'name': 'tolbutamide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450401674.0,"<p>The FDA-approved drug label for tolbutamide states that, due to the risk of hemolytic anemia, caution should be used when administering tolbutamide to patients with G6PD deficiency.</p>
<p><strong>Note: As of 10/14/2024, tolbutamide is shown as Discontinued and has no drug labels available on the FDA or DailyMed web sites. However, the drug is still included on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling.</strong></p>
",1450401675.0,"<p>Excerpt from the tolbutamide drug label:</p>
<div class=""blockquote"">
<p>Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because tolbutamide belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. In post-marketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tolbutamide_05_20_19_FDA.pdf"">tolbutamide drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450416018.0,"<p>Excerpt from the tolbutamide drug label:</p>
<blockquote class=""blockquote"">
<p>Because tolbutamide belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166182944,Annotation of EMA Label for duloxetine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15102929, 'title': 'Cymbalta | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/cymbalta', 'crossReferences': [{'id': 1450416970, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/cymbalta', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/cymbalta'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10066', 'name': 'duloxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1450416968.0,"<p>The EMA European Public Assessment Report (EPAR) for duloxetine (Cymbalta) states that the pharmacokinetics of the drug have large intersubject variability partly due to gender, age, smoking status and CYP2D6 metabolizer status. Limited data suggests that concentrations of duloxetine are higher in CYP2D6 poor metabolizers.</p>
",1450416969.0,"<p>Excerpts from the duloxetine (Cymbalta) EPAR:</p>
<div class=""blockquote"">
<p>Duloxetine is extensively metabolised by oxidative enzymes (CYP1A2 and the polymorphic CYP2D6), followed by conjugation. The pharmacokinetics of duloxetine demonstrate large intersubject variability (generally 50-60%), partly due to gender, age, smoking status and CYP2D6 metaboliser status.</p>
</div>
<div class=""blockquote"">
<p>The pharmacokinetics of duloxetine in patients who are poor metabolisers with respect to CYP2D6 has not been specifically investigated. Limited data suggest that the plasma levels of duloxetine are higher in these patients.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Duloxetine_06_20_19_EMA.pdf"">duloxetine EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166182943,Annotation of EMA Label for dolutegravir and UGT1A1,False,False,[],False,"[{'id': 1452849700, 'date': '2025-02-18T18:04:35.296-08:00', 'description': 'Juluca is a combination drug, added the missing rilpivirine in the Note', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102928, 'title': 'Tivicay | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay', 'crossReferences': [{'id': 1450806454, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166114961', 'name': 'dolutegravir'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",EMA,1450416964.0,"<p>The EMA European Public Assessment Report (EPAR) for dolutegravir (Tivicay) states that subjects with UGT1A1 genotypes that confer poor dolutegravir metabolism had a 32% lower clearance and 46% higher AUC as compared to subjects with UGT1A1 genotypes that confer normal dolutegravir metabolism.</p>
",1450416965.0,"<p>Excerpt from the dolutegravir (Tivicay) EPAR:</p>
<blockquote class=""blockquote"">
<p>Dolutegravir is primarily metabolized through glucuronidation via UGT1A1 with a minor CYP3A component.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>There is no evidence that common polymorphisms in drug metabolising enzymes alter dolutegravir pharmacokinetics to a clinically meaningful extent. In a meta-analysis using pharmacogenomics samples collected in clinical studies in healthy subjects, subjects with UGT1A1 (n=7) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with subjects with genotypes associated with normal metabolism via UGT1A1 (n=41).</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Dolutegravir_06_20_19_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dolutegravir_06_20_19_EMA.pdf"">dolutegravir EPAR PDF</a></p>
<p><strong>Note: The EPAR for <a rel=""noopener noreferrer"" href=""https://www.ema.europa.eu/en/medicines/human/EPAR/juluca"" target=""_blank"">dolutegravir and rilpivirine (Juluca)</a> notes that dolutegravir is metabolized by UGT1A1, but does not comment on differences in clearance or AUC between UGT1A1 poor or normal metabolizers.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166129528,Annotation of HCSC Label for sodium nitrite and G6PD,True,False,[],False,"[{'id': 1452533162, 'date': '2024-07-21T23:19:42.588-07:00', 'description': 'Added Prescribing section, tags and label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161202, 'title': 'Drugs@HCSC: Drug Product Sodium Nitrate Injection USP (sodium nitrate), Hope Pharmaceuticals Ltd', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92482', 'crossReferences': [{'id': 1452533160, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92482', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92482'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166115361', 'name': 'sodium nitrite'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982235.0,"<p>Sodium nitrite is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning judged to be life-threatening. Patients with G6PD deficiency are at increased risk for hemolytic crisis when administered sodium nitrite; the product monograph notes that alternative therapeutic approaches should be considered in these patients.</p>
",1447982234.0,"<p>Excerpt from the sodium nitrite product monograph:</p>
<blockquote class=""blockquote"">
<p>Because patients with G6PD deficiency are at increased risk of a hemolytic crisis with sodium nitrite administration, alternative therapeutic approaches should be considered in these patients. Patients with known or suspected G6PD deficiency should be monitored for an acute drop in hematocrit. Exchange transfusion may be needed for patients with G6PD deficiency who receive sodium nitrite.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Sodium_Nitrite_HCSC_10_23_15.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Sodium_Nitrite_HCSC_10_23_15.pdf"">sodium nitrite product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452533161.0,"<p>Excerpt from the sodium nitrite product monograph:</p>
<blockquote class=""blockquote"">
<p>Because patients with G6PD deficiency are at increased risk of a hemolytic crisis with sodium nitrite administration, alternative therapeutic approaches should be considered in these patients. Patients with known or suspected G6PD deficiency should be monitored for an acute drop in hematocrit. Exchange transfusion may be needed for patients with G6PD deficiency who receive sodium nitrite</p>
</blockquote>
",,,,,,,
Label Annotation,PA166183621,Annotation of Swissmedic Label for mefloquine and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15102940, 'title': 'Swissmedic label for mefloquine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=47385', 'crossReferences': [{'id': 1450811080, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=47385', '_url': 'https://amiko.oddb.org/de/fi?gtin=47385'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450348', 'name': 'mefloquine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450809053.0,"<p>The Swiss drug label for mefloquine (Mephaquin Lactab) states that there's no in vitro or in vivo evidence to suggest hemolysis to be associated with glucose-6-phosphate dehydrogenase deficiency in patients treated with mefloquine.</p>
",1450809057.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the mefloquine (Mephaquin Lactab) label:</p>
<div class=""blockquote"">
<p>Neither in vitro nor in vivo studies have suggested hemolysis associated with glucose-6-phosphate dehydrogenase deficiency.</p>
</div>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=47385&amp;highlight=Glucose-6-Phosphat-Dehydrogenase-Mangel"" target=""_blank"">mefloquine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166402161,Annotation of EMA Label for vanzacaftor / tezacaftor / deutivacaftor and CFTR,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166362502', 'name': 'vanzacaftor / tezacaftor / deutivacaftor'}]","[{'objCls': 'Gene', 'id': 'PA109', 'symbol': 'CFTR', 'name': 'CF transmembrane conductance regulator'}]",EMA,,,1454089880.0,"<p>As of May 21, 2025, the EMA has issued an opinion on this medicine:</p>
<blockquote class=""blockquote"">
<p>On 25 April 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Alyftrek, intended for the treatment of cystic fibrosis in people aged 6 years and older who have at least one non‑class I mutation in the cystic fibrosis transmembrane conductance regulator (<em>CFTR</em>) gene.</p>
</blockquote>
<p>See: https://www.ema.europa.eu/en/medicines/human/EPAR/alyftrek</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166402201,Annotation of HCSC Label for lazertinib and GSTM1,False,False,[],False,[],False,[],True,"[{'id': 15179862, 'title': 'Drugs@HCSC: Drug Product LAZCLUZE (lazertinib), Janssen Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468', 'crossReferences': [{'id': 1454090760, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166314341', 'name': 'lazertinib'}]","[{'objCls': 'Gene', 'id': 'PA182', 'symbol': 'GSTM1', 'name': 'glutathione S-transferase mu 1'}]",HCSC,1454090800.0,"<p>Lazertinib (LAZCLUZE) is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. No clinically significant differences in safety or efficacy were observed as a function of a patient's GSTM1 genotype.</p>
",1454090801.0,"<p>Excerpt from the lazertinib (LAZCLUZE) product monograph:</p>
<blockquote class=""blockquote"">
<p>Lazertinib is primarily metabolized by glutathione conjugation, either enzymatically via glutathione-S-transferase (GST) or non-enzymatically, as well as by CYP3A4 to a lesser extent. The most abundant metabolites are glutathione catabolites and considered clinically inactive. The plasma exposure of lazertinib was affected by GSTM1 mediated metabolism, leading to higher exposure (up to 2-fold difference) in null GSTM1 patients. No clinically significant differences in safety or efficacy were observed as a function of GSTM1 genotype in patients receiving LAZCLUZE in combination with amivantamab.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Lazertinib_2025_05_22_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lazertinib_2025_05_22_HCSC.pdf"">lazertinib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166183593,Annotation of Swissmedic Label for acenocoumarol and CYP2C9,False,False,[],False,[],False,[],True,"[{'id': 15103004, 'title': 'Swissmedic label for acenocoumarol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=21693', 'crossReferences': [{'id': 1450811082, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=21693', '_url': 'https://amiko.oddb.org/de/fi?gtin=21693'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA452632', 'name': 'acenocoumarol'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",Swissmedic,1450808829.0,"<p>The Swiss drug label for acenocoumarol (Sintrom) states that patients with the CYP2C9*2 or *3 variants have reduced clearance of acenocoumarol.</p>
",1450808830.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for acenocoumarol (Sintrom):</p>
<div class=""blockquote"">
<p>The genetic variability regarding CYP2C9 is responsible for 14% of the interindividual variability of the pharmacodynamic response of acenocoumarol.</p>
</div>
<div class=""blockquote"">
<p>CYP2C9 enzyme systems are expressed polymorphically and the frequency of their occurrence may vary. In Caucasians, CYP2C9*2 and CYP2C9*3 occur at 12% and 8%, respectively. In patients with one or more variants of the CYP2C9 allele the clearance of S-Acenocoumarol is reduced. In African patients, CYP2C9*2 and CYP2C9*3 have significantly lower allele frequencies of 1-4% and 0.5-2.3%, respectively, compared to Caucasians. Japanese patients also had lower allele frequencies of 0.1% for CYP2C9 * 2 and 1-6% for CYP2C9 * 3 compared to Caucasians.</p>
</div>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=21693&amp;highlight=CYP2C9"" target=""_blank"">acenocoumarol drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184238,Annotation of Swissmedic Label for voriconazole and CYP2C19,False,False,[],False,[],False,[],True,"[{'id': 15103116, 'title': 'Swissmedic label for voriconazol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55945', 'crossReferences': [{'id': 1450812077, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55945', '_url': 'https://amiko.oddb.org/de/fi?gtin=55945'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10233', 'name': 'voriconazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",Swissmedic,1450814457.0,"<p>The Swiss drug label for voriconazole (Vfend) states that voriconazole levels are increased in patients who are CYP2C19 intermediate or poor metabolizers.</p>
",1450814458.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for voriconazole (Vfend):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
In vivo studies have shown that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme shows a genetic polymorphism. It can be assumed that 15-20% of the Asian population metabolizes CYP2C19 substrates delayed (so-called Poor Metaboliser). In the white and black population, the prevalence of slow metabolism is 3-5%. Studies on healthy whites and Japanese show that homozygous Poor Metabolisers reach on average 4 times higher voriconazole levels (AUCt) than homozygous ones with fast metabolism. Heterozygote have on average 2 times higher voriconazole levels than homozygote with rapid metabolism.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=55945&amp;highlight=genetischenPolymorphismus"" target=""_blank"">voriconazole drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184404,"Annotation of Swissmedic Label for tamsulosin and CYP2D6, CYP3A4",False,False,[],False,[],False,[],True,"[{'id': 15103102, 'title': 'Swissmedic label for Tamsulosin und Dutasterid', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=60095', 'crossReferences': [{'id': 1450812063, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=60095', '_url': 'https://amiko.oddb.org/de/fi?gtin=60095'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103101, 'title': 'Swissmedic label for tamsulosin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=57160', 'crossReferences': [{'id': 1450812062, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=57160', '_url': 'https://amiko.oddb.org/de/fi?gtin=57160'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451583', 'name': 'tamsulosin'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}, {'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",Swissmedic,1450815468.0,"<p>The Swiss drug label for tamsulosin (Pradif) and tamsulosin and dutasteride (Duodart) states that since CYP3A4 inhibitors can significantly influence exposure to tamsulosin in CYP2D6 poor metabolizers, all tamsulosin treated patients should avoid strong CYP3A4 inhibitors.</p>
",1450815469.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug labels for tamsulosin (Pradif) and tamsulosin and dutasteride (Duodart):</p>
<blockquote class=""blockquote"">
<p>Precautions:
Simultaneous treatment with tamsulosin hydrochloride and CYP3A4 inhibitors may increase tamsulosin exposure (see &quot;Interactions&quot;). In particular, there is a risk of significantly increased tamsulosin exposure to CYP2D6 poor metabolizers treated simultaneously with strong CYP3A4 inhibitors. As the polymorphism for CYP2D6 is usually not known outside clinical studies, tamsulosin should not be used together with strong CYP3A4 inhibitors (e.g. itraconazole, voriconazole, clarithromycin, indinavir, nelfinavir, ritonavir, saquinavir).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=57160&amp;highlight=metabolisern"" target=""_blank"">tamsulosin drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160010,Annotation of FDA Label for dolutegravir and UGT1A1,False,False,[],False,[],False,[],True,"[{'id': 15101906, 'title': 'Drugs@FDA: Drug Product Tivicay (dolutegravir sodium), NDA204790, REMEDYREPACK INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204790', 'crossReferences': [{'id': 1449754481, 'resource': 'FDA Application', 'resourceId': 'NDA204790', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204790'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166114961', 'name': 'dolutegravir'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",FDA,1448257156.0,"<p>The FDA-approved drug label for TIVICAY (dolutegravir) states that subjects with <em>UGT1A1</em> genotypes that result in poor metabolism of the drug have decreased clearance and increased AUC as compared to those who have <em>UGT1A1</em> genotypes that result in normal dolutegravir metabolism. The label does not mention specific <em>UGT1A1</em> variants or genetic testing.</p>
",1448257079.0,"<p>Dolutegravir is indicated for the treatment of HIV-1 infection, in combination with other antiretroviral agents. Excerpts from the dolutegravir drug label:</p>
<div class=""blockquote"">
<p>Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A.</p>
</div>
<div class=""blockquote"">
<p>Polymorphisms in Drug-Metabolizing Enzymes: In a meta-analysis of healthy subject trials, subjects with UGT1A1 (n = 7) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with subjects with genotypes associated with normal metabolism via UGT1A1 (n = 41).</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Dolutegravir_01_14_19_FDA.pdf"">dolutegravir drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166151974,Annotation of HCSC Label for nilotinib and UGT1A1,False,False,[],False,"[{'id': 1452536802, 'date': '2024-07-23T23:06:05.731-07:00', 'description': 'Added Prescribing section, tags and label document', 'type': 'Update', 'version': 0}, {'id': 1452810901, 'date': '2025-01-15T16:19:06.438-08:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161742, 'title': 'Drugs@HCSC: Drug Product Tasigna (nilotinib), Novartis Pharmaceuticals Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85322', 'crossReferences': [{'id': 1452536800, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85322', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85322'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,True,True,"[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]","[{'objCls': 'Variant', 'id': 'PA166159020', 'symbol': 'rs8175347', 'name': 'rs8175347'}]","[{'objCls': 'Chemical', 'id': 'PA165958345', 'name': 'nilotinib'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",HCSC,1447981690.0,"<p>The product monograph for nilotinib (TASIGNA) notes that patients homozygous for the UGT1A1*28 allele (<a href=""/variant/PA166159020"">rs8175347</a>; (TA)7) may be at risk for hyperbilirubinemia when receiving nilotinib.  This drug is indicated for patients with Philadelphia chromosome positive (BCR-ABL1 fusion) chronic myeloid leukemia, though individuals with the BCR-ABL T315I mutation are highly resistant to the drug.</p>
",1447981689.0,"<p>Excerpt from the nilotinib (TASIGNA) product monograph:</p>
<blockquote class=""blockquote"">
<p><strong>Pharmacogenomics:</strong> Tasigna can lead to elevated bilirubin levels. A pharmacogenetic analysis of 101 imatinib-resistant or -intolerant Ph+ CML-CP and CML-AP patients was conducted to evaluate the polymorphisms of UGT1A1 and its potential association with hyperbilirubinemia during Tasigna treatment. In this study, the (TA)7/(TA)7 genotype was associated with a statistically significant increase in the risk of hyperbilirubinemia relative to the (TA)6/(TA)6 and (TA)6/(TA)7 genotypes. The largest increases in bilirubin were observed in patients with the (TA)7/(TA)7 genotype. Caution is recommended in patients with (TA)7/(TA)7 genotype.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Nilotinib_2024_08_09_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Nilotinib_2024_08_09_HCSC.pdf"">nilotinib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452810900.0,"<blockquote class=""blockquote"">
<p><strong>Pediatrics (2 to &lt; 18 years):</strong> The safety and efficacy of Tasigna in pediatric patients with Ph+ CML-CP from 2 to less than 18 years of age have been established (see 8 ADVERSE REACTIONS, 10 CLINICAL PHARMACOLOGY, and 14 CLINICAL TRIALS). There is no experience in pediatric patients below 2 years of age or in pediatric patients with Ph+ CML-AP or blast crisis (BC). The long-term effects of prolonged treatment with Tasigna in pediatric patients are unknown (see 7 WARNINGS AND PRECAUTIONS).</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452536801.0,"<p>Excerpt from the nilotinib (TASIGNA) product monograph:</p>
<blockquote class=""blockquote"">
<p>Tasigna can lead to elevated bilirubin levels. A pharmacogenetic analysis of 101 imatinib-resistant or -intolerant Ph+ CML-CP and CML-AP patients was conducted to evaluate the polymorphisms of UGT1A1 and its potential association with hyperbilirubinemia during Tasigna treatment. In this study, the (TA)7/(TA)7 genotype was associated with a statistically significant increase in the risk of hyperbilirubinemia relative to the (TA)6/(TA)6 and (TA)6/(TA)7 genotypes. The largest increases in bilirubin were observed in patients with the (TA)7/(TA)7 genotype. Caution is recommended in patients with (TA)7/(TA)7 genotype.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166183590,Annotation of Swissmedic Label for maraviroc and CYP3A5,False,False,[],False,[],False,[],True,"[{'id': 15103003, 'title': 'Swissmedic label for maraviroc', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=58197', 'crossReferences': [{'id': 1450811081, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=58197', '_url': 'https://amiko.oddb.org/de/fi?gtin=58197'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA166128213', 'symbol': 'CYP3A5*1', 'name': '*1'}]","[{'objCls': 'Chemical', 'id': 'PA164768835', 'name': 'maraviroc'}]","[{'objCls': 'Gene', 'id': 'PA131', 'symbol': 'CYP3A5', 'name': 'cytochrome P450 family 3 subfamily A member 5'}]",Swissmedic,1450808798.0,"<p>The Swiss drug label for maraviroc (Celsentri) states that CYP3A5 genotypes may affect the exposure to maraviroc.</p>
",1450808799.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the maraviroc (Celsentri) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacogenomics:
In a Phase 1 study in healthy volunteers, members of the black population whose CYP3A5 genotype is associated with a rapid Maraviroc metabolism (2 CYP3A5*1 alleles; n = 12) showed that 300 mg of Maraviroc 300 twice daily increased by 37% or 26% lower AUC than black (n = 11) and Caucasian (n = 12) participants whose CYP3A5 genotype is associated with slow Maraviroc metabolism (no CYP3A5*1 allele). Participants of the black population whose CYP3A5 genotype is associated with rapid (n = 12) or slow (n = 11) Maraviroc metabolism showed Maraviroc AUC decreased by 17% once daily in the presence of a strong CYP3A inhibitor (Darunavir/Cobicistat) under Maraviroc 150 mg.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=58197&amp;highlight=CYP3A5"" target=""_blank"">maraviroc drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166182949,Annotation of EMA Label for erlotinib and UGT1A1,False,False,[],False,"[{'id': 1452549241, 'date': '2024-08-06T15:21:08.620-07:00', 'description': 'added Other Guidance tag, Prescribing Info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102931, 'title': 'Tarceva | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva', 'crossReferences': [{'id': 1450417082, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA134687924', 'name': 'erlotinib'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",EMA,1450417083.0,"<p>The EMA European Public Assessment Report (EPAR) for erlotinib (Tarceva) states that patients with low expression levels of UGT1A1 or genetic glucuronidation disorders such as Gilbert's disease may have increased concentrations of bilirubin and should be treated with caution.</p>
",1450417084.0,"<p>Excerpt from the erlotinib (Tarceva) EPAR:</p>
<div class=""blockquote"">
<p>Patients with low expression levels of UGT1A1 or genetic glucuronidation disorders (e.g. Gilbert’s disease) may exhibit increased serum concentrations of bilirubin and must be treated with caution.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Erlotinib_06_21_19_EMA.pdf"">erlotinib EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452549240.0,"<blockquote class=""blockquote"">
<p>Patients with low expression levels of UGT1A1 or genetic glucuronidation disorders (e.g. Gilbert’s disease) may exhibit increased serum concentrations of bilirubin and must be treated with caution.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166183219,Annotation of EMA Label for mirabegron and CYP2D6,False,False,[],False,"[{'id': 1452207460, 'date': '2023-08-15T12:24:54.567-07:00', 'description': 'Prescribing tag taken off', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102936, 'title': 'Betmiga | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga', 'crossReferences': [{'id': 1450649210, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177513', 'name': 'mirabegron'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1450649206.0,"<p>The EMA European Public Assessment Report (EPAR) for mirabegron (Betmiga) states that CYP2D6 genetic polymporphisms have a minimal impact on exposure to mirabegron and no dose adjustment is needed when administered to patients who are CYP2D6 poor metabolizers.</p>
",1450649207.0,"<p>Excerpt from the mirabegron (Betmiga) EPAR:</p>
<div class=""blockquote"">
<p>In healthy subjects who are genotypically poor metabolisers of CYP2D6 substrates (used as a surrogate for CYP2D6 inhibition), mean Cmax and AUCinf of a single 160 mg dose of a mirabegron IR formulation were 14% and 19% higher than in extensive metabolisers, indicating that CYP2D6 genetic polymorphism has minimal impact on the mean plasma exposure to mirabegron. Interaction of mirabegron with a known CYP2D6 inhibitor is not expected and was not studied. No dose adjustment is needed for mirabegron when administered with CYP2D6 inhibitors or in patients who are CYP2D6 poor metabolisers.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Mirabegron_06_25_19_EMA.pdf"">mirabegron EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166183563,Annotation of Swissmedic Label for abacavir and HLA-B,True,False,[],False,"[{'id': 1452021765, 'date': '2023-02-28T13:05:13.784-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103118, 'title': 'Swissmedic label for Zidovudin, Lamivudin und Abacavir', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55537', 'crossReferences': [{'id': 1450812079, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55537', '_url': 'https://amiko.oddb.org/de/fi?gtin=55537'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15102961, 'title': 'Swissmedic label for abacavir', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55048', 'crossReferences': [{'id': 1450808460, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55048', '_url': 'https://amiko.oddb.org/de/fi?gtin=55048'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103263, 'title': 'Swissmedic label for dolutegravir, abacavir und lamivudine (Triumeq)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=63283', 'crossReferences': [{'id': 1450815647, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=63283', '_url': 'https://amiko.oddb.org/de/fi?gtin=63283'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103242, 'title': 'Swissmedic label for lamivudine and abacavir (Kivexa)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=56977', 'crossReferences': [{'id': 1450815333, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=56977', '_url': 'https://amiko.oddb.org/de/fi?gtin=56977'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165987830', 'symbol': 'HLA-B*57:01', 'name': '*57:01'}]","[{'objCls': 'Chemical', 'id': 'PA448004', 'name': 'abacavir'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",Swissmedic,1450808457.0,"<p>The Swiss drug label for abacavir (Ziagen) states that patients should be screened for the presence of HLA-B*57:01 prior to starting treatment with abacavir. Ziagen is contraindicated in carriers of the HLA-B*57:01 allele.</p>
",1450808458.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for abacavir (Ziagen):</p>
<div class=""blockquote"">
<p>Before starting treatment with abacavir, each HIV-infected patient should be screened for the presence of the HLA-B*5701 allele, regardless of ethnicity. Patients who are known to carry the HLA-B*5701 allele should not use abacavir unless no other treatment option is available for these patients based on treatment history and resistance test results (see sections &quot;Warnings and Precautions&quot; and &quot;Adverse Effects&quot;).</p>
</div>
<div class=""blockquote"">
<p>The use of Ziagen is contraindicated in patients with known hypersensitivity to abacavir or any other component of the tablets or solution and in carriers of the HLA-B*5701 allele.</p>
</div>
<div class=""blockquote"">
<p>In the prospective study CNA106030 (PREDICT-1), screening for the HLA-B*5701 allele prior to initiation of therapy, in conjunction with the discontinuation of abacavir in patients with this allele, led to a reduction in the incidence of clinical suspected cases of abacavir hypersensitivity reactions from 7,8% (66 of 847) to 3.4% (27 of 803) (p&lt;0.0001) and a reduction in the incidence of hypersensitivity responses confirmed by epicutaneous patch tests from 2.7% (23 of 842) to 0.0% (0 of 802) (p&lt;0.0001). Based on this study, it is estimated that 48% to 61% of HLA-B*5701 positive patients will develop a hypersensitivity response during abacavir treatment compared to 0% to 4% in patients not wearing the HLA-B*5701 allele.</p>
</div>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=55048&amp;highlight=HLA-B*5701"" target=""_blank"">abacavir drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450808459.0,"<blockquote class=""blockquote"">
<p>Patients who are known to carry the HLA-B*5701 allele should not use abacavir unless no other treatment option is available for these patients based on treatment history and resistance test results.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166161536,Annotation of PMDA Label for atazanavir and CYP2C19,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10251', 'name': 'atazanavir'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",PMDA,1448432467.0,"<p>The PMDA package insert for atazanavir (Reyataz) contains pharmacogenetic information related to co-treatment with voriconazole and ritonavir: atazanavir exposure is expected to be decreased and voriconazole exposure is expected to be increased in patients who are CYP2C19 poor metabolizers.</p>
",1448432466.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the atazanavir (Reyataz) package insert:</p>
<blockquote class=""blockquote"">
<p>In patients who hold more than one CYP2C19 active gene (Extensive Metabolizer: EM), the combination use of atazanavir/ritonavir (300mg/100mg once/day) and voriconazole (200mg twice/day) may potentially decrease plasma concentration of voriconazole and atazanavir. On the other hand, in patients who do not hold CYP2C19 active gene (Poor Metabolizer: PM), combination use of atazanavir/ritonavir (300mg/100mg once/day) and voriconazole (50mg twice/day) may potentially increase plasma concentration of voriconazole and decrease plasma concentration of atazanavir.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Atazanavir_PMDA_11_30_16.pdf"">atazanavir package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166183441,Annotation of EMA Label for umeclidinium and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103001, 'title': 'Incruse Ellipta (previously Incruse) | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/incruse-ellipta-previously-incruse', 'crossReferences': [{'id': 1450806429, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/incruse-ellipta-previously-incruse', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/incruse-ellipta-previously-incruse'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177519', 'name': 'umeclidinium'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1450806427.0,"<p>The EMA European Public Assessment Report (EPAR) for umeclidinium (Incruse Ellipta) states that there is no evidence of any clinically significant effect of CYP2D6 genetic polymorphism on systemic exposure to umeclidinium.</p>
",1450806428.0,"<p>Excerpt from the umeclidinium (Incruse Ellipta) EPAR:</p>
<div class=""blockquote"">
<p>The steady-state pharmacokinetics of umeclidinium bromide were assessed in healthy volunteers lacking CYP2D6 (poor metabolisers). No effect on umeclidinium AUC or Cmax was observed at a dose 4-fold higher than the therapeutic dose. An approximately 1.3-fold increase in umeclidinium bromide AUC was observed at an 8-fold higher dose with no effect on umeclidinium bromide Cmax. Based on the magnitude of these changes, no clinically relevant drug interaction is expected when umeclidinium is co-administered with CYP2D6 inhibitors or when administered to subjects genetically deficient in CYP2D6 activity (poor metabolisers).</p>
</div>
<div class=""blockquote"">
<p>A study in CYP2D6 poor metabolisers showed no evidence of a clinically significant effect of CYP2D6 genetic polymorphism on systemic exposure to umeclidinium bromide.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Umeclidinium_07_17_19_EMA.pdf"">umeclidinium EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166177479,Annotation of FDA Label for cariprazine and CYP2D6,False,False,[],False,"[{'id': 1452206741, 'date': '2023-08-15T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15101909, 'title': 'Drugs@FDA: Drug Product Vraylar (cariprazine), NDA204370, Allergan, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204370', 'crossReferences': [{'id': 1449895166, 'resource': 'FDA Application', 'resourceId': 'NDA204370', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204370'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177476', 'name': 'cariprazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1449169706.0,"<p>Cariprazine (VRAYLAR) is an atypical antipsychotic used for the treatment of schizophrenia and bipolar disorder. The label notes that CYP2D6 poor metabolizer status does not have a clinically relevant effect on cariprazine pharmacokinetics.</p>
",1449169705.0,"<p>Excerpt from the cariprazine (VRAYLAR) drug label:</p>
<blockquote class=""blockquote"">
<p>CYP2D6 Poor Metabolizers...CYP2D6 poor metabolizer status does not have clinically relevant effect on pharmacokinetics of cariprazine, DCAR, or DDCAR.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Cariprazine_FDA_02_12_18.pdf"">cariprazine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182932,Annotation of EMA Label for brivaracetam and CYP2C19,False,False,[],False,"[{'id': 1452527604, 'date': '2024-07-15T11:13:33.287-07:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102991, 'title': 'Briviact (in Italy: Nubriveo) | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo', 'crossReferences': [{'id': 1450416883, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166153491', 'name': 'brivaracetam'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",EMA,1450416881.0,"<p>The EMA European Public Assessment Report (EPAR) for brivaracetam (Briviact) states that individuals with ineffective mutations of CYP2C19 had decreased production of the hydroxy metabolite and increased concentrations of brivaracetam.</p>
",1450416882.0,"<p>Excerpt from the brivaracetam (Briviact) EPAR:</p>
<blockquote class=""blockquote"">
<p><em>In vitro</em>, the hydroxylation of brivaracetam is mediated primarily by CYP2C19. [...] <em>In vivo</em>, in human subjects possessing ineffective mutations of CYP2C19, production of the hydroxy metabolite is decreased 10-fold while brivaracetam itself is increased by 22 % or 42 % in individuals with one or both mutated alleles.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Brivaracetam_2024_07_15_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Brivaracetam_2024_07_15_EMA.pdf"">brivaracetam EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",1452527603.0,"<blockquote class=""blockquote"">
<p>Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166182766,"Annotation of FDA Label for fosphenytoin and CYP2C9, HLA-B",True,False,[],True,"[{'id': 1450401298, 'date': '2019-05-17T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1451530520, 'date': '2021-10-12T20:21:54.838-07:00', 'description': 'Updated annotation based on updates to FDA label', 'type': 'Update', 'version': 0}, {'id': 1452214501, 'date': '2023-08-23T14:54:28.082-07:00', 'description': 'Added Dosing Info and Alt Drug tags with new definitions', 'type': 'Update', 'version': 0}, {'id': 1452721942, 'date': '2024-12-02T14:33:43.915-08:00', 'description': 'removed CYP2C19 from the gene list (no prescribing info)', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102392, 'title': 'Drugs@FDA: Drug Product CEREBYX (Fosphenytoin Sodium), NDA020450, Pfizer Laboratories Div Pfizer Inc', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020450', 'crossReferences': [{'id': 1450401299, 'resource': 'FDA Application', 'resourceId': 'NDA020450', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020450'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}, {'objCls': 'Haplotype', 'id': 'PA165954769', 'symbol': 'HLA-B*15:02', 'name': '*15:02'}]","[{'objCls': 'Chemical', 'id': 'PA164746820', 'name': 'fosphenytoin'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",FDA,1450401295.0,"<p>The FDA label for fosphenytoin (CEREBYX) states that limited evidence suggests that the HLA-B*15:02 and CYP2C9*3 alleles may increase the risk of severe cutaneous adverse reactions in patients of Asian ancestry who are treated with phenytoin and that prescribers should consider avoiding fosphenytoin as an alternative to carbamazepine in these patients. It also notes that the phenytoin derived from fosphenytoin is metabolized by CYP2C9 and CYP2C19 and that patients who are known to be CYP2C9 intermediate or poor metabolizers may have lower fosphenytoin dose requirements.</p>
",1450401296.0,"<p>Excerpts from the FDA fosphenytoin (CEREBYX) label:</p>
<blockquote class=""blockquote"">
<p>Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. In addition, retrospective, case-control, genome-wide association studies in patients of southeast Asian ancestry have also identified an increased risk of SCARs in carriers of the decreased function CYP2C9*3 variant, which has also been associated with decreased clearance of phenytoin. Consider avoiding CEREBYX as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers. Should CEREBYX be utilized for CYP2C9*3 carriers, consider starting at the lower end of the dosage range</p>
<p>The use of HLA-B*1502 or CYP2C9 genotyping has important limitations and must never substitute for appropriate clinical vigilance and patient management. The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug (AED) dose, compliance, concomitant medications, comorbidities, and the level of dermatologic monitoring have not been studied.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Use in Patients with Decreased CYP2C9 Function</strong>
Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses to maintain similar steady-state concentrations compared to normal metabolizers. In patients who are known to be carriers of the decreased function CYP2C9*2 or *3 alleles (intermediate and poor metabolizers), consider starting at the low end of the dosage range and monitor serum concentrations to maintain total phenytoin concentrations of 10 to 20 mcg/mL. If early signs of dose-related central nervous system (CNS) toxicity develop, serum concentrations should be checked immediately.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Phenytoin derived from administration of CEREBYX is extensively metabolized in the liver by the cytochrome P450 enzyme CYP2C9 and to a lesser extent by CYP2C19.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Fospheytoin_FDA_10_12_21.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Fospheytoin_FDA_10_12_21.pdf"">fosphenytoin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450401297.0,"<p>Excerpts from the FDA fosphenytoin (CEREBYX) label:</p>
<blockquote class=""blockquote"">
<p>Consider avoiding CEREBYX as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers. Should CEREBYX be utilized for CYP2C9*3 carriers, consider starting at the lower end of the dosage range.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In patients who are known to be carriers of the decreased function CYP2C9*2 or *3 alleles (intermediate and poor metabolizers), consider starting at the low end of the dosage range and monitor serum concentrations to maintain total phenytoin concentrations of 10 to 20 mcg/mL.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166184917,Annotation of FDA Label for avatrombopag and CYP2C9,False,False,[],False,"[{'id': 1452206100, 'date': '2023-08-14T09:24:40.944-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452525660, 'date': '2024-07-11T17:32:57.079-07:00', 'description': 'updated label version and annotation', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160442, 'title': 'Drugs@FDA: Drug Product DOPTELET (avatrombopag maleate), AkaRx, Inc. - NDA210238/SUPPL-6, 10/14/2021', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210238', 'crossReferences': [{'id': 1452525641, 'resource': 'FDA Application', 'resourceId': 'NDA210238/SUPPL-6', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210238'}], 'objCls': 'Literature', 'pubDate': '2021-10-14T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA166179849', 'name': 'avatrombopag'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1450824501.0,"<p>The FDA-approved drug label for avatrombopag (DOPTELET) states that avatrombopag is primarily metabolized by CYP2C9 and CYP3A4, and that the CYP2C9*2 and CYP2C9*3 loss-of-function polymorphisms result in reduced CYP2C9 enzymatic activity and higher drug exposure in heterozygous and homozygous carriers.</p>
",1450824502.0,"<p>Excerpts from the avatrombopag (DOPTELET) label:</p>
<blockquote class=""blockquote"">
<p>Avatrombopag is primarily metabolized by cytochrome P450 CYP2C9 and CYP3A4.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The CYP2C9*2 and CYP2C9*3 loss-of-function polymorphisms result in reduced CYP2C9 enzymatic activity. In a pooled pharmacogenomic analysis of avatrombopag studies, subjects heterozygous for CYP2C9 loss-of-function polymorphisms (intermediate metabolizers [n=24]) had approximately 1.4-fold higher exposure and subjects homozygous for CYP2C9 loss-of-function polymorphisms (poor metabolizers [n=2]) had approximately 2-fold higher exposure compared to subjects wild-type for CYP2C9 (normal metabolizers [n=94]).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Avatrombopag_2024_07_11_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Avatrombopag_2024_07_11_FDA.pdf"">avatrombopag drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166160668,Annotation of PMDA Label for allopurinol and HLA-B,False,False,[],False,"[{'id': 1448525341, 'date': '2016-12-08T08:08:12.010-08:00', 'type': 'Approve', 'version': 0}]",False,[],True,[],False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165987831', 'symbol': 'HLA-B*58:01', 'name': '*58:01'}]","[{'objCls': 'Chemical', 'id': 'PA448320', 'name': 'allopurinol'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",PMDA,1448265210.0,"<p>The PMDA package insert for allopurinol (TEVA) notes that the <em>HLA-B*58:01</em> allele was present at a high frequency in patients with Stevens-Johnson syndrome or toxic epidermal necrolysis who came from Han Chinese, Japanese or European populations.</p>
",1448265209.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for allopurinol (TEVA):</p>
<blockquote class=""blockquote"">
<p>A retrospective study on Han-Chinese has revealed that as a result of HLA type analysis, all of 51 subjects who developed severe drug eruption such as mucocutaneous ocular syndrome (Stevens-Johnson syndrome) and toxic epidermal necrolysis (Lyell syndrome) due to allopurinol had <em>HLA-B*5801</em>. Separate study reported that, for the subjects who developed mucocutaneous ocular syndrome  and toxic epidermal necrolysis due to allopurinol in Japanese and European population, 4 cases out of 10 (40%), and 15 cases out of 27 (55%) had <em>HLA-B*5801</em> respectively. Prevalence of <em>HLA-B*5801</em> is 20-30% in Han-Chinese population, while only 1-2% in Japanese and European populations.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Allopurinol_PMDA_10_03_16.pdf"">allopurinol package insert</a> (in Japanese)</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166170937,Annotation of FDA Label for trametinib and G6PD,False,False,[],False,"[{'id': 1452220421, 'date': '2023-08-29T12:33:01.913-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}, {'id': 1452821241, 'date': '2025-01-21T14:25:49.004-08:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15173342, 'title': 'Drugs@FDA: Drug Product Mekinist (trametinib), Novartis Pharmaceuticals Corporation - NDA204114/SUPPL-27, 10/01/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114', 'crossReferences': [{'id': 1452821222, 'resource': 'FDA Application', 'resourceId': 'NDA204114/SUPPL-27', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114'}], 'objCls': 'Literature', 'pubDate': '2024-10-01T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101887, 'title': 'Drugs@FDA: Drug Product Mekinist (trametinib), NDA204114, Novartis Pharmaceuticals Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114', 'crossReferences': [{'id': 1449888917, 'resource': 'FDA Application', 'resourceId': 'NDA204114', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166115364', 'name': 'trametinib'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1449053514.0,"<p>Trametinib (MEKINIST) is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, or metastatic non-small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test. The label also notes that patients with a known history of G6PD deficiency were excluded from some clinical trials.</p>
",1449053513.0,"<p>Excerpt from the trametinib (MEKINIST) drug label:</p>
<blockquote class=""blockquote"">
<p><em>MEKINIST with Dabrafenib</em>  [...]
Both trials excluded patients with [...] known history of glucose-6-phosphate dehydrogenase deficiency [see Clinical Studies (14.1)].</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Trametinib_2025_01_17_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Trametinib_2025_01_17_FDA.pdf"">trametinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452821240.0,"<blockquote class=""blockquote"">
<p>MEKINIST is indicated, in combination with dabrafenib, for: [...]</p>
<ul>
<li>the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (1.5, 2.1)</li>
<li>the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (1.6, 2.1)</li>
</ul>
</blockquote>
",,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166159586,Annotation of HCSC Label for aliskiren and ABCB1,False,False,[],False,"[{'id': 1452205940, 'date': '2023-08-14T06:10:49.771-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452782361, 'date': '2024-12-12T15:23:53.827-08:00', 'description': 'retired label annotation; marketing status is Cancelled', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171902, 'title': 'Drugs@HCSC: Drug Product RASILEZ HCT (aliskiren)', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81838', 'crossReferences': [{'id': 1452782360, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81838', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81838'}], 'notes': 'Marketing Status: Cancelled Post Market', 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA143487910', 'name': 'aliskiren'}]","[{'objCls': 'Gene', 'id': 'PA267', 'symbol': 'ABCB1', 'name': 'ATP binding cassette subfamily B member 1'}]",HCSC,1448123226.0,"<p>The HCSC product monograph for aliskiren (Rasilez HCT) does not contain pharmacogenetic information. It contains information regarding the role of ABCB1 (Pgp, MDR1) in intestinal absorption of aliskiren, and concomitant use of aliskiren with potent P-gp inhibitors is contraindicated.</p>
<p><strong>As of December 12, 2024, all aliskiren drug products have a &quot;Cancelled Post Market&quot; or &quot;Cancelled Pre Market&quot; status on the HCSC website.</strong></p>
",1448123225.0,"<p>The HCSC product monograph states the importance of <em>ABCB1</em> (Pgp, MDR1) in absorption and drug interactions. Overexposure due to low MDR1 expression is a risk especially in the pediatric population.</p>
<p>Excerpts from the aliskiren (Rasilez HCT) HCSC product monograph:</p>
<blockquote class=""blockquote"">
<p>In vitro studies indicate that MDR1 (Pgp) is the major efflux transporter involved in absorption and disposition of aliskiren. The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The concomitant use of these potent PgP inhibitors, such as cyclosporine A and itraconazole, with aliskiren is not recommended</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>Pediatric patients:</em> Aliskiren is a P-glycoprotein (Pgp) substrate, and there is a potential for aliskiren overexposure in children with an immature Pgp drug transporter system. The age at which the transporter system is mature cannot be determined</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Aliskiren_HCSC_05.31.2016.PDF"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Aliskiren_HCSC_05.31.2016.PDF"">aliskiren HCSC drug label</a>.</p>
<p><strong>As of December 12, 2024, all aliskiren drug products have a &quot;Cancelled Post Market&quot; or &quot;Cancelled Pre Market&quot; status on the HCSC website.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,1451259820.0,Retirement Reason,[],Withdrawal,retirement:1451259820,True,
Label Annotation,PA166183784,Annotation of Swissmedic Label for amifampridine phosphate and NAT2,False,False,[],False,[],False,[],True,"[{'id': 15103028, 'title': 'Swissmedic label for amifampridine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=61853', 'crossReferences': [{'id': 1450811131, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=61853', '_url': 'https://amiko.oddb.org/de/fi?gtin=61853'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182002', 'name': 'amifampridine phosphate'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",Swissmedic,1450811132.0,"<p>The Swiss drug label for amifampridine (Firdapse) states that patients who are NAT2 slow acetylators may have higher exposure to the drug and more adverse effects as compared to fast acetylators</p>
",1450811133.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for amifampridine (Firdapse):</p>
<div class=""blockquote"">
<p>In a study in healthy volunteers, systemic exposure to amifampridine was influenced primarily by the metabolic acetylation activity of NAT enzymes as a whole and by the NAT2 genotype. The NAT genes are highly polymorphic and result in phenotypes with variable acetylation activity rates from slow to fast. In the study with healthy volunteers, rapidly acetylating volunteers were defined as those with a caffeine metabolism quotient of &gt;0.3 and slowly acetylating volunteers as those with a caffeine metabolism quotient of &lt;0.2. Exposure was significantly higher in the slowly acetylating volunteers than in the rapidly acetylating volunteers. With regard to the pharmacokinetic parameters C, AUC, ts and apparent clearance, statistically significant differences between the rapidly and slowly acetylating subjects were found for all dose strengths of amifampridine...Table 1: Mean Firdapse PK parameters of amifampridine in healthy volunteers after single dose of oral doses (5-30 mg) in slow and fast acetylating phenotypes...Table 2: PK parameters of amifampridine in healthy volunteers and patients with impaired renal function after a single dose (10mg) in slow and fast acetylator phenotypes...</p>
</div>
<div class=""blockquote"">
<p>Genetic variants...The pharmacokinetics and systemic amifampridine exposure is mainly influenced by the metabolic acetylation activity of polymorphic N-acetyl transferase (NAT) enzymes (acetylator phenotype) as a whole and by the NAT2 genotype...as could be shown in the study with healthy volunteers. In this study, slow acetylating volunteers had more adverse effects than fast acetylating volunteers. The safety profile in this study is consistent with adverse effects observed in patients treated with Firdapse.</p>
</div>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=61853&amp;highlight=NAT2-Genotyp"" target=""_blank"">amifampridine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166183782,Annotation of Swissmedic Label for aspirin and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103025, 'title': 'Swissmedic label for Aspirin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=49526', 'crossReferences': [{'id': 1450811121, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=49526', '_url': 'https://amiko.oddb.org/de/fi?gtin=49526'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103026, 'title': 'Swissmedic label for Aspirin Cardio 100/300', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=51795', 'crossReferences': [{'id': 1450811122, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=51795', '_url': 'https://amiko.oddb.org/de/fi?gtin=51795'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103024, 'title': 'Swissmedic label for Aspirin-C', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=33670', 'crossReferences': [{'id': 1450811120, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=33670', '_url': 'https://amiko.oddb.org/de/fi?gtin=33670'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448497', 'name': 'aspirin'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450811123.0,"<p>The Swiss drug label for aspirin (Aspirin Cardio 100/300, Aspirin, Aspirin-C) states that acetylsalicylic acid could induce hemolysis or hemolytic anemia in patients with G6PD deficiency.</p>
",1450811124.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for aspirin (Aspirin Cardio 100/300, Aspirin, Aspirin-C):</p>
<div class=""blockquote"">
<p>Warnings and Precautions...Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency because acetylsalicylic acid could induce hemolysis or hemolytic anemia. Factors that increase this risk include high doses, fever or acute infections.</p>
</div>
<div class=""blockquote"">
<p>Hemolysis and hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency has been reported.</p>
</div>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=51795&amp;highlight=Glucose-6-Phosphatdehydrogenase"" target=""_blank"">aspirin (Aspirin Cardio 100/300) drug label</a>, <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=49526&amp;highlight=Glucose-6-Phosphatdehydrogenase"" target=""_blank"">aspirin (Aspirin) drug label</a> or <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=33670&amp;highlight=Glucose-6-Phosphatdehydrogenase"" target=""_blank"">aspirin (Aspirin-C) drug label</a> (all in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184232,Annotation of Swissmedic Label for venlafaxine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103112, 'title': 'Swissmedic label for venlafaxin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=54168', 'crossReferences': [{'id': 1450812073, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=54168', '_url': 'https://amiko.oddb.org/de/fi?gtin=54168'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451866', 'name': 'venlafaxine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450814439.0,"<p>The Swiss drug label for venlafaxine (Efexor ER) states that CYP2D6 poor metabolizers experience a greater increase in the AUCs of venlafaxine and O-desmethylvenlafaxine when treated with concomitant ketoconazole compared to normal metabolizers.</p>
",1450814440.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for venlafaxine (Efexor ER):</p>
<blockquote class=""blockquote"">
<p>Interactions:
In a pharmacokinetic study, the administration of ketoconazole to CYP 2D6 extensive metabolizers (EM) and poor metabolizers (PM) resulted in an increased AUC of venlafaxine (70% and 21%, respectively, in subjects with CYP 2D6 PM and EM) and of O-desmethylvenlafaxine (33% and 23%, respectively, in subjects with CYP 2D6 PM and EM).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=54168&amp;highlight=Metabolisierern"" target=""_blank"">venlafaxine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166182788,Annotation of HCSC Label for tolbutamide and G6PD,True,False,[],False,"[{'id': 1452453125, 'date': '2024-04-24T12:54:03.711-07:00', 'description': 'Minor text edits to main annotation text', 'type': 'Update', 'version': 0}, {'id': 1452532182, 'date': '2024-07-19T00:00:00-07:00', 'description': 'Added text to Prescribing section', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161062, 'title': 'Drugs@HCSC: Drug Product Apo-Tolbutamide (tolbutamide), Apotex Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00009779.PDF', 'crossReferences': [{'id': 1452532180, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00009779.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00009779.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451718', 'name': 'tolbutamide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1450401708.0,"<p>The HCSC-approved product monograph for tolbutamide (APO-TOLBUTAMIDE) states that, due to the risk of hemolytic anemia, caution should be used when administering tolbutamide to patients with G6PD deficiency.</p>
<p><strong>Please note that as of July 2024, the drug label for tolbutamide (APO-TOLBUTAMIDE) is no longer available on the HCSC database. As a result, this label annotation has been retired.</strong></p>
",1450401709.0,"<p>Excerpt from the tolbutamide (APO-TOLBUTAMIDE) product monograph:</p>
<blockquote class=""blockquote"">
<p>Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because APO-TOLBUTAMIDE belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. In post marketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency.</p>
</blockquote>
<p><strong>Please note that as of July 2024, the drug label for tolbutamide (APO-TOLBUTAMIDE) is no longer available on the HCSC database. As a result, this label annotation has been retired.</strong></p>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Tolbutamide_05_13_19_HCSC.PDF"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Tolbutamide_05_13_19_HCSC.PDF"">tolbutamide product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452532181.0,"<p>Excerpt from the tolbutamide (APO-TOLBUTAMIDE) product monograph:</p>
<blockquote class=""blockquote"">
<p>Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because APO-TOLBUTAMIDE belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. In post marketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency.</p>
</blockquote>
",1451259820.0,Retirement Reason,[],Withdrawal,retirement:1451259820,True,
Label Annotation,PA166159584,Annotation of HCSC Label for obinutuzumab and MS4A1,False,True,[],False,"[{'id': 1452204940, 'date': '2023-08-11T00:00:00-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452204960, 'date': '2023-08-11T11:44:49.253-07:00', 'description': 'Checked cancer genome', 'type': 'Update', 'version': 0}, {'id': 1452782281, 'date': '2024-12-12T14:57:41.149-08:00', 'description': 'updated label, removed afutuzumab synonym', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171882, 'title': 'Drugs@HCSC: Drug Product GAZYVA (obinutuzumab), Hoffmann-La Roche Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91910', 'crossReferences': [{'id': 1452782280, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91910', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91910'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166122586', 'name': 'obinutuzumab'}]","[{'objCls': 'Gene', 'id': 'PA31111', 'symbol': 'MS4A1', 'name': 'membrane spanning 4-domains A1'}]",HCSC,1448123197.0,"<p>Obinutuzumab (GAZYVA) in combination with certain other drugs is indicated for treatment of patients with chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL). The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, <em>MS4A1</em>, and therefore no mention of genetic testing in the drug label.</p>
",1448123196.0,"<p>Obinutuzumab (GAZYVA) binds to the CD20 molecule, which is expressed on pre-B and mature B lymphocytes. Upon binding to CD20, it mediates B-cell lysis. CD20 is coded for by the <em>MS4A1</em> gene.</p>
<p>Excerpts from the obinutuzumab (GAZYVA) product monograph:</p>
<blockquote class=""blockquote"">
<p>GAZYVA (obinutuzumab) is a recombinant monoclonal humanized and glycoengineered Type II anti-CD20 antibody of the IgG1 isotype. It specifically targets the extracellular loop of the CD20 transmembrane antigen on the surface of non-malignant and malignant pre-B and mature B-lymphocytes, but not on haematopoietic stem cells, pro-B cells, normal plasma cells or other normal tissue. Glycoengineering of the Fc part of GAZYVA results in higher affinity for FcɣRIII receptors on immune effector cells such as natural killer (NK) cells, and macrophages and monocytes as compared to non-glycoengineered antibodies.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In nonclinical studies, GAZYVA induces direct cell death and mediates antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) through recruitment of FcɣRIII positive immune effector cells. In addition, GAZYVA mediates low degree of complement dependent cytotoxicity (CDC). In animal models, GAZYVA mediates potent B cell depletion and antitumour efficacy. Compared to Type I CD20 antibodies, GAZYVA, a Type II antibody, is characterized by an enhanced direct cell death induction with a concomitant reduction in CDC. Compared to non-glycoengineered CD20 antibodies, GAZYVA is characterized by enhanced antibody dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) as a consequence of the glycoengineering. This translates in superior B cell depletion and anti-tumour efficacy in animal models.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Obinutuzumab_2024_12_12_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Obinutuzumab_2024_12_12_HCSC.pdf"">obinutuzumab product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Health Canada and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166170930,"Annotation of FDA Label for dabrafenib and HRAS, KRAS, NRAS",True,True,[],False,"[{'id': 1451356480, 'date': '2021-03-16T13:44:10.923-07:00', 'description': 'Added cancer genome tag', 'type': 'Update', 'version': 0}, {'id': 1452229281, 'date': '2023-09-06T09:13:48.946-07:00', 'description': 'Changed to actionable.', 'type': 'Update', 'version': 0}, {'id': 1452312500, 'date': '2023-11-30T00:00:00-08:00', 'description': 'Updated label and label source.', 'type': 'Update', 'version': 0}, {'id': 1452817209, 'date': '2025-01-17T15:18:28.795-08:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15173162, 'title': 'Drugs@FDA: Drug Product Tafinlar (dabrafenib), Novartis Pharmaceuticals Corporation - NDA202806/SUPPL-31, 07/11/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806', 'crossReferences': [{'id': 1452817193, 'resource': 'FDA Application', 'resourceId': 'NDA202806/SUPPL-31', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806'}], 'objCls': 'Literature', 'pubDate': '2024-07-11T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,True,True,"[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166114911', 'name': 'dabrafenib'}]","[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",FDA,1450342870.0,"<p>The drug label for dabrafenib (TAFINLAR) states that it is indicated, as a single agent or in combination with trametinib, for patients with certain types of cancer. The label also notes that the drug may promote growth and development of malignancies with activation of RAS.</p>
",1449036741.0,"<p>Excerpt from the dabrafenib (TAFINLAR) drug label:</p>
<blockquote class=""blockquote"">
<p>Based on its mechanism of action, TAFINLAR may promote the growth and development of malignancies with activation of RAS through mutation or other mechanisms [...] Monitor patients receiving TAFINLAR for signs or symptoms of non-cutaneous malignancies. Permanently discontinue TAFINLAR for RAS mutation-positive non-cutaneous malignancies</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Dabrafenib_2025_01_17_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dabrafenib_2025_01_17_FDA.pdf"">dabrafenib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452817208.0,"<blockquote class=""blockquote"">
<p>TAFINLAR is indicated, in combination with trametinib, for: [...]</p>
<ul>
<li>the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (1.6, 2.1)</li>
<li>the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (1.7, 2.1)</li>
</ul>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452229280.0,"<p>Excerpt from the dabrafenib (TAFINLAR) drug label:</p>
<blockquote class=""blockquote"">
<p>Based on its mechanism of action, TAFINLAR may promote the growth and development of malignancies with activation of RAS through mutation or other mechanisms [...] Monitor patients receiving TAFINLAR for signs or symptoms of non-cutaneous malignancies. Permanently discontinue TAFINLAR for RAS mutation-positive non-cutaneous malignancies.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166183251,Annotation of EMA Label for raltegravir and UGT1A1,False,False,[],False,"[{'id': 1452214660, 'date': '2023-08-23T17:18:20.471-07:00', 'description': 'removed prescribing information since ""Dose adjustment is not considered necessary ...""', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102998, 'title': 'Isentress | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/isentress', 'crossReferences': [{'id': 1450663666, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/isentress', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/isentress'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164888966', 'name': 'raltegravir'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",EMA,1450663663.0,"<p>The EMA European Public Assessment Report (EPAR) for raltegravir (ISENTRESS) states that the geometric mean ratio of AUC was 1.41 in patients with the UGT1A1*28/*28 genotype and 1.91 in patients with the UGT1A1 wild-type genotype, and that dose adjustment is not necessary based on UGT1A1 genotype.</p>
",1450663664.0,"<p>Excerpts from the raltegravir (ISENTRESS) EPAR:</p>
<div class=""blockquote"">
<p>UGT1A1 Polymorphism...In a comparison of 30 subjects with *28/*28 genotype to 27 subjects with wild-type genotype, the geometric mean ratio (90 % CI) of AUC was 1.41 (0.96, 2.09) and the geometric mean ratio of C12 hr was 1.91 (1.43, 2.55). Dose adjustment is not considered necessary in subjects with reduced UGT1A1 activity due to genetic polymorphism.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Raltegravir_06_26_19_EMA.pdf"">raltegravir EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166183248,Annotation of EMA Label for palonosetron and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15102996, 'title': 'Aloxi | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/aloxi', 'crossReferences': [{'id': 1450663641, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/aloxi', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/aloxi'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10352', 'name': 'palonosetron'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1450663639.0,"<p>The EMA European Public Assessment Report (EPAR) for palonosetron (Aloxi) states that pharmacokinetic parameters are not significantly different between CYP2D6 poor and extensive metabolizers.</p>
",1450663640.0,"<p>Excerpt from the palonosetron (Aloxi) EPAR:</p>
<div class=""blockquote"">
<p>However, clinical pharmacokinetic parameters are not significantly different between poor and extensive metabolisers of CYP2D6 substrates.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Palonosetron_06_25_19_EMA.pdf"">palonosetron EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166169877,Annotation of FDA Label for avelumab and CD274,False,True,[],False,"[{'id': 1449005531, 'date': '2017-11-08T14:34:24.284-08:00', 'type': 'Update', 'version': 0}, {'id': 1451518380, 'date': '2021-10-08T10:31:21.022-07:00', 'description': 'changed level based on excerpt in label indication', 'type': 'Update', 'version': 0}, {'id': 1452225360, 'date': '2023-08-31T23:47:06.382-07:00', 'description': 'removed prescribing info and alternate drug tag and added indication tag', 'type': 'Update', 'version': 0}, {'id': 1452547381, 'date': '2024-08-05T10:39:43.895-07:00', 'description': 'removed Testing Required PGx level; testing is not mentioned; removed Indication tag', 'type': 'Update', 'version': 0}, {'id': 1452802503, 'date': '2025-01-09T11:07:57.505-08:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102004, 'title': 'Drugs@FDA: Drug Product BAVENCIO (avelumab), BLA761049, EMD Serono, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761049', 'crossReferences': [{'id': 1449894158, 'resource': 'FDA Application', 'resourceId': 'BLA761049', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761049'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166169875', 'name': 'avelumab'}]","[{'objCls': 'Gene', 'id': 'PA134915280', 'symbol': 'CD274', 'name': 'CD274 molecule'}]",FDA,1450043648.0,"<p>The FDA-approved drug label for avelumab (BAVENCIO) states that it is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of metastatic Merkel cell carcinoma and locally advanced or metastatic urothelial carcinoma. PD-L1 is encoded by the <em>CD274</em> gene.</p>
",1450043649.0,"<p>Excerpts from the avelumab (BAVENCIO) drug label:</p>
<blockquote class=""blockquote"">
<p>Indication and Usage:<br />
BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC)...Patients with locally advanced or metastatic urothelial carcinoma...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation, and cytokine production. Avelumab binds PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This interaction releases the inhibitory effects of PD-L1 on the immune response resulting in the restoration of immune responses, including anti-tumor immune responses. Avelumab has also been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. In syngeneic mouse tumor models, blocking PD-L1 activity resulted in decreased tumor growth.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Avelumab_11_29_18_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Avelumab_11_29_18_FDA.pdf"">avelumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452802502.0,"<blockquote class=""blockquote"">
<p>BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: [...]</p>
<ul>
<li>Adults and pediatric patients 12 years and older with metastatic MCC. (1.1, 14.1)</li>
</ul>
</blockquote>
",,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166183783,Annotation of Swissmedic Label for allopurinol and HLA-B,False,False,[],False,"[{'id': 1452021767, 'date': '2023-02-28T13:05:58.981-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103027, 'title': 'Swissmedic label for allopurinol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=32917', 'crossReferences': [{'id': 1450811126, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=32917', '_url': 'https://amiko.oddb.org/de/fi?gtin=32917'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165987831', 'symbol': 'HLA-B*58:01', 'name': '*58:01'}]","[{'objCls': 'Chemical', 'id': 'PA448320', 'name': 'allopurinol'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",Swissmedic,1450811127.0,"<p>The Swiss drug label for allopurinol (Zyloric) states that in patients with the HLA-B*58:01 allele, use of allopurinol may be considered if the benefits are considered greater than the risks. However, increased attention to signs of hypersensitivity reaction or SJS/TEN is required.</p>
",1450811128.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for allopurinol (Zyloric):</p>
<div class=""blockquote"">
<p>The allele HLA-B*5801 is a genetic risk factor for the occurrence of hypersensitivity syndrome and SJS/TEN associated with allopurinol. The frequency of the allele HLA-B*5801 varies widely in people with different ethnic backgrounds: up to 20% in certain Asian and African populations...and 1-2% in people of Japanese or European origin. The use of genotyping as a research method to decide on treatment with allopurinol has not been established. If it is known that the patient is a carrier of HLA-B*5801, the use of allopurinol may be considered if the benefits are considered greater than the risks. Increased attention for signs of hypersensitivity syndrome or SJS/TEN is required and the patient should be informed that treatment should be stopped immediately when symptoms first occur.</p>
</div>
<div class=""blockquote"">
<p>In retrospective pharmacogenetic case-control studies with patients of Han Chinese, Japanese and European descent, the allele HLA-B*5801 was identified as a genetic risk factor for the occurrence of SJS/TEN associated with allopurinol. Some Han Chinese, Thai, African and Indian populations have up to 20-30% carriers of the HLA-B*5801 allele, while Northern European, US European and Japanese patients have an estimated 1-2% carriers of HLA-B*5801. However, no genotyping procedures have yet been introduced as a screening tool for deciding on allopurinol therapy.</p>
</div>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=32917&amp;highlight=HLA-B*5801"" target=""_blank"">allopurinol drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450811129.0,"<blockquote class=""blockquote"">
<p>If it is known that the patient is a carrier of HLA-B*5801, the use of allopurinol may be considered if the benefits are considered greater than the risks. Increased attention for signs of hypersensitivity syndrome or SJS/TEN is required and the patient should be informed that treatment should be stopped immediately when symptoms first occur.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166183172,"Annotation of EMA Label for lapatinib and HLA-DQA1, HLA-DRB1",False,False,[],False,[],False,[],True,"[{'id': 15102917, 'title': 'Tyverb | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb', 'crossReferences': [{'id': 1450593235, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165951292', 'symbol': 'HLA-DQA1*02:01', 'name': '*02:01'}, {'objCls': 'Haplotype', 'id': 'PA165951644', 'symbol': 'HLA-DRB1*07:01', 'name': '*07:01'}]","[{'objCls': 'Chemical', 'id': 'PA152241907', 'name': 'lapatinib'}]","[{'objCls': 'Gene', 'id': 'PA35066', 'symbol': 'HLA-DQA1', 'name': 'major histocompatibility complex, class II, DQ alpha 1'}, {'objCls': 'Gene', 'id': 'PA35072', 'symbol': 'HLA-DRB1', 'name': 'major histocompatibility complex, class II, DR beta 1'}]",EMA,1450593236.0,"<p>The EMA European Public Assessment Report (EPAR) for lapatinib (Tyverb) states that patients with the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have an increased risk of hepatotoxicity.</p>
",1450593237.0,"<p>Excerpts from the lapatinib (Tyverb) EPAR:</p>
<div class=""blockquote"">
<p>Patients who carry the HLA alleles DQA1*02:01 and DRB1*07:01 have increased risk of Tyverb-associated hepatotoxicity.</p>
</div>
<div class=""blockquote"">
<p>In a large, randomised clinical trial of Tyverb monotherapy (n=1,194), the cumulative frequency of severe liver injury (ALT &gt;5 times the upper limit of normal, NCI CTCAE grade 3) at 1 year of treatment was 2.8% overall. The cumulative frequency in DQA1*02:01 and DRB1*07:01 allele carriers was 10.3% and in non-carriers was 0.5%. Carriage of the HLA risk alleles is common (15 to 25%) in Caucasian, Asian, African and Hispanic populations but lower (1%) in Japanese populations.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Lapatinib_06_25_19_EMA.pdf"">lapatinib EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166353003,Annotation of HCSC Label for bempedoic acid / ezetimibe,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166353821', 'name': 'bempedoic acid / ezetimibe'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166353023,Annotation of HCSC Label for mavorixafor,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166353004', 'name': 'mavorixafor'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166353022,Annotation of EMA Label for mavorixafor,False,False,[],False,"[{'id': 1452696640, 'date': '2024-11-11T11:36:07.708-08:00', 'description': 'removed gene; drug is not approved yet, no label available', 'type': 'Update', 'version': 0}]",False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166353004', 'name': 'mavorixafor'}]",[],EMA,,,1452610945.0,"<p>Mavorixafor has been granted orphan designation for the treatment of WHIM syndrome: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2183</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166353141,Annotation of HCSC Label for medroxyprogesterone,False,False,[],False,[],False,[],True,"[{'id': 15166402, 'title': 'Drugs@HCSC: Drug Product PROVERA (medroxyprogesterone acetate), Pfizer Canada ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13037', 'crossReferences': [{'id': 1452612063, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13037', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13037'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA450344', 'name': 'medroxyprogesterone'}]",[],HCSC,,,1452612100.0,"<p>Excerpts from the medroxyprogesterone (PROVERA) product monograph:</p>
<blockquote class=""blockquote"">
<p>PROVERA (Medroxyprogesterone acetate tablets USP) is indicated for: [...]</p>
<ul>
<li>Adjunctive and/or palliative treatment of hormonally-dependent, recurrent metastatic breast cancer in postmenopausal women.</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Serious Warnings and Precautions</strong> [...]
The <em>estrogen plus progestin</em> arm of the WHI trial (mean age 63.3 years) indicated an increased risk of <em>myocardial infarction</em> (MI), <em>stroke</em>, <em>invasive breast cancer</em>, <em>pulmonary emboli</em> and <em>deep vein thrombosis</em> in postmenopausal women receiving treatment with combined conjugated equine estrogens (CEE, 0.625 mg/day) and medroxyprogesterone acetate (MPA, 2.5 mg/day) for 5.2 years compared to those receiving placebo.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Medroxyprogesterone_2024_09_27_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Medroxyprogesterone_2024_09_27_HCSC.pdf"">medroxyprogesterone product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166353121,"Annotation of FDA Label for medroxyprogesterone and ESR1, ESR2",False,False,[],False,[],False,[],True,"[{'id': 15166382, 'title': 'Drugs@FDA: Drug Product medroxyprogesterone acetate (medroxyprogesterone acetate), Greenstone LLC - NDA011839/SUPPL-83, 02/15/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=011839', 'crossReferences': [{'id': 1452612040, 'resource': 'FDA Application', 'resourceId': 'NDA011839/SUPPL-83', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=011839'}], 'objCls': 'Literature', 'pubDate': '2024-02-15T00:00:00-08:00', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450344', 'name': 'medroxyprogesterone'}]","[{'objCls': 'Gene', 'id': 'PA156', 'symbol': 'ESR1', 'name': 'estrogen receptor 1'}, {'objCls': 'Gene', 'id': 'PA27886', 'symbol': 'ESR2', 'name': 'estrogen receptor 2'}]",FDA,1452612060.0,"<p>The FDA-approved drug label for medroxyprogesterone contains Boxed Warnings about the increased risk of invasive breast cancer in women who took daily oral conjugated estrogens combined with medroxyprogesterone acetate that was reported in the Women’s Health Initiative (WHI) estrogen plus progestin substudy. The FDA Table of Pharmacogenomic Biomarkers in Drug Labeling lists &quot;ESR (Hormone Receptor)&quot; as a biomarker.</p>
",1452612061.0,"<p>Excerpt from the medroxyprogesterone (PROVERA) label:</p>
<blockquote class=""blockquote"">
<p>After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer in women who took daily CE plus MPA. [...] Other prognostic factors such as histologic subtype, grade, and hormone receptor status did not differ between the groups.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Medroxyprogesterone_2024_09_27_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Medroxyprogesterone_2024_09_27_FDA.pdf"">medroxyprogesterone drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166353122,Annotation of EMA Label for medroxyprogesterone,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450344', 'name': 'medroxyprogesterone'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166353123,Annotation of HCSC Label for pitavastatin,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA142650384', 'name': 'pitavastatin'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166160153,Annotation of PMDA Label for celecoxib and CYP2C9,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448871', 'name': 'celecoxib'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",PMDA,1448258055.0,"<p>The PMDA package insert for celecoxib (Celecox) notes that individuals with the CYP2C9 *1/*3 or *3/*3 genotypes had increased AUC or Cmax of celecoxib as compared to those with the *1/*1 genotype.</p>
",1448258050.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for celecoxib (Celecox):</p>
<blockquote class=""blockquote"">
<p>Results from in vitro and in vivo studies have shown that the metabolism of the product is predominantly mediated via CYP2C9.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Effect of CYP2C9 polymorphisms (CYP2C9*3): Single or repeated dosing of celecoxib resulted in approximately 1.6-fold higher AUC in 15 healthy adults with the heterozygous CYP2C9 genotype (Ile359 --&gt; Leu359; CYP2C9*1/*3) compared to 137 healthy adults with the wild-type genotype (CYP2C9*1/*1). Following a single dose of 100 mg celecoxib in healthy adults, the AUC in 3 subjects with CYP2C9*3/*3 was approximately 3 times higher than that in 4 subjects with CYP2C9*1/*1 (data from non-Japanese subjects), and repeated once daily dosing of 200 mg celecoxib for 7 days resulted in approximately 4-fold higher Cmax and approximately 7-fold higher AUC in 3 subjects with CYP2C9*3/*3 compared to 7 subjects with CYP2C9*1/*1 (data from non-Japanese subjects).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Celecoxib_PMDA_08_18_16.pdf"">celecoxib package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160226,Annotation of PMDA Label for codeine and CYP2D6,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449088', 'name': 'codeine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",PMDA,1448258415.0,"<p>The PMDA package insert for codeine notes that CYP2D6 ultrarapid metabolizers are at increased risk of developing side effects due to high serum levels of morphine, and that they may also have higher morphine levels in breast milk.</p>
",1448258414.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the codeine package insert:</p>
<blockquote class=""blockquote"">
<p>In patients who are known to have high CYP2D6 activity (i.e., ultra-rapid metabolizers), use of this product may lead to higher morphine levels in breast milk.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients who are genetically known to have high CYP2D6 activity (i.e., ultra-rapid metabolizers) are at increased risk of developing side effects associated with higher than expected serum levels of the active metabolite of the product, morphine.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Codeine_PMDA_08_18_16.pdf"">codeine package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160683,Annotation of PMDA Label for dapsone and G6PD,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449211', 'name': 'dapsone'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",PMDA,1448265430.0,"<p>The PMDA package insert for dapsone (PROTOGEN) states that hemolysis may occur in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.</p>
",1448265429.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the package insert for dapsone (PROTOGEN):</p>
<blockquote class=""blockquote"">
<p>Patients with a glucose-6-phosphate dehydrogenase deficiency (hemolysis may occur).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Dapsone_PMDA_10_04_16.pdf"">dapsone package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160162,Annotation of PMDA Label for efavirenz and CYP2B6,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449441', 'name': 'efavirenz'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}]",PMDA,1448258098.0,"<p>The PMDA package insert for efavirenz (STOCRIN) notes that patients with the CYP2B6 rs3745274 TT genotype may have an increased AUC as compared to those with the GG genotype.</p>
",1448258097.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for efavirenz (STOCRIN):</p>
<blockquote class=""blockquote"">
<p>CYP3A4 and CYP2B6 are responsible for the metabolism of this product in humans.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A 516G &gt; T single nucleotide polymorphism (amino acid sequence: Gln172His) has been identified for CYP2B6. Once daily dosing of 600 mg with concomitant medications in HIV-infected patients resulted in approximately 3 times higher steady-state AUC in patients with the 516TT CYP2B6 genotype compared to those with 516GG. The frequency of the 516TT CYP2B6 genotype is reported to be 8.9% in Japanese populations.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Efavirenz_PMDA_08_18_16.pdf"">efavirenz package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160712,Annotation of PMDA Label for fesoterodine and CYP2D6,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958376', 'name': 'fesoterodine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",PMDA,1448265830.0,"<p>The PMDA package insert for fesoterodine (Toviaz) states that CYP2D6 poor metabolizers had increased Cmax and AUC of the active metabolite (5-HMT) as compared to extensive metabolizers.</p>
",1448265829.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the fesoterodine (Toviaz) package insert:</p>
<blockquote class=""blockquote"">
<p>In poor metabolizers (PMs) for CYP2D6, Cmax and AUC of 5-HMT increased 1.7- and 2-fold, respectively, compared to CYP2D6 extensive metabolizers (EMs).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Fesoterodine_PMDA_10_05_16.pdf"">fesoterodine package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160717,Annotation of PMDA Label for letrozole and CYP2A6,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450196', 'name': 'letrozole'}]","[{'objCls': 'Gene', 'id': 'PA121', 'symbol': 'CYP2A6', 'name': 'cytochrome P450 family 2 subfamily A member 6'}]",PMDA,1448265957.0,"<p>The PMDA package insert for letrozole notes that CYP2A6 slow metabolizers were found to have 2-fold higher mean plasma trough concentrations as compared to extensive metabolizers.</p>
",1448265956.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the letrozole package insert:</p>
<blockquote class=""blockquote"">
<p>Letrozole is metabolized to a pharmacologically-inactive carbinol metabolite, whose glucuronide conjugate is excreted renally, representing the major clearance pathway. In vitro, it has been indicated that letrozole is metabolized by CYP3A4 and CYP2A6 in human liver microsomes.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Following repeated dosing of letrozole 2.5 mg once daily in postmenopausal women with breast cancer, the plasma trough concentration reached a steady state after 4 to 8 weeks of dosing in slow metabolizers (SMs) who were deficient for CYP2A6, the enzyme responsible for drug metabolism, or had a combination of genotypes associated with reduced enzyme activity (CYP2A6*4, CYP2A6*7, CYP2A6*9 and CYP2A6*10) as well as in extensive metabolizers (EMs) who had wild-type genotypes, CYP2A6*1A or CYP2A6*1B; however, the mean plasma trough concentration was approximately 2-fold higher in SMs than in EMs.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Letrozole_PMDA_10_07_16.pdf"">letrozole package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160719,Annotation of PMDA Label for nalidixic acid and G6PD,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164746384', 'name': 'nalidixic acid'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",PMDA,1448265977.0,"<p>The PMDA package insert for nalidixic acid states that patients with G6PD deficiency are at increased risk of hemolytic anemia.</p>
",1448265976.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the package insert for nalidixic acid:</p>
<blockquote class=""blockquote"">
<p>Hemolytic anemia. It has been reported that patients with G-6PD deficiency are at increased risk.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Nalidixic_Acid_PMDA_10_07_16.pdf"">nalidixic acid package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160845,Annotation of PMDA Label for perphenazine and CYP2D6,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450882', 'name': 'perphenazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",PMDA,1448267013.0,"<p>The PMDA package insert for perphenazine states that individuals who are deficient in CYP2D6 may have higher serum levels of the drug.</p>
",1448267012.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the package insert for perphenazine:</p>
<blockquote class=""blockquote"">
<p>Serum Concentration...Non-Japanese Data...Perphenazine is metabolized by the drug-metabolizing enzyme CYP2D6 (a molecular species in the cytochrome P450 family), for which genetic polymorphisms are known. There is an anecdotal report of approximately 2-fold higher levels of perphenazine in patients genetically deficient in CYP2D6 compared to normal individuals. In this report, the steady-state serum perphenazine levels ranged from 0.5 to 12 nmol/L following oral dosing of 2 to 24 mg/kg in deficient and normal individuals.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Perphenazine_PMDA_10_18_16.pdf"">perphenazine package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160846,Annotation of PMDA Label for rabeprazole and CYP2C19,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451216', 'name': 'rabeprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",PMDA,1448267021.0,"<p>The PMDA package insert for rabeprazole states that CYP2C19 and CYP3A4 are involved in the metabolism of the drug, and provides data showing that CYP2C19 poor metabolizers have increased Cmax, AUC and half-life time as compared to extensive metabolizers.</p>
",1448267020.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the rabeprazole package insert:</p>
<blockquote class=""blockquote"">
<p>The primary metabolite detected in the plasma following oral dosing of 10 mg and 20 mg in healthy adult males was a thioether compound formed via nonenzymatic reduction. Other metabolites detected were a desmethyl compound produced via demethylation by the hepatic metabolizing enzyme cytochrome P450 2C19 (CYP2C19) and a sulfone compound produced via sulfonation by 3A4 (CYP3A4).</p>
</blockquote>
<p><strong>Plasma Pharmacokinetic Parameters of Rabeprazole Following Repeated Dosing (5 mg, 10 mg or 20 mg) in Healthy Male Adults</strong></p>
<table class=""table"">
<thead>
<tr><th>Dose</th><th>Phenotype</th><th>Cmax (ng/mL)</th><th>tmax (hr)</th><th>AUC0-t (ng*h/mL)</th><th>t1/2 (hr)</th></tr>
</thead>
<tbody>
<tr><td>5 mg</td><td>EM</td><td>146 +/- 56</td><td>3.0 (2.0-4.5)</td><td>236 +/- 97</td><td>1.8 +/- 0.9</td></tr>
<tr><td>5 mg</td><td>PM</td><td>252 +/- 55</td><td>2.5 (1.5-5.5)</td><td>585 +/- 137</td><td>4.2 +/- 0.5</td></tr>
<tr><td>10 mg</td><td>EM</td><td>383 +/- 83</td><td>3.3 (2.0-5.0)</td><td>539 +/- 200</td><td>1.5 +/- 0.4</td></tr>
<tr><td>10 mg</td><td>PM</td><td>509 +/- 64</td><td>2.8 (2.0-4.5)</td><td>1230 +/- 200</td><td>3.8 +/- 0.3</td></tr>
<tr><td>20 mg</td><td>EM</td><td>654 +/- 348</td><td>4.0 (2.5-8.0)</td><td>994 +/- 477</td><td>2.3 +/- 1.4</td></tr>
<tr><td>20 mg</td><td>PM</td><td>822 +/- 232</td><td>3.3 (3.0 - 6.0)</td><td>2331 +/- 633</td><td>3.7 +/- 0.3</td></tr>
</tbody>
</table>
<blockquote class=""blockquote"">
<p>(Mean ± S.D. except the tmax, which is the median (minimum-maximum); 16 EMs and 8 PMs). EM (extensive metabolizer): CYP2C19*1/*1, CYP2C19*1/*2 or CYP2C19*1/*3. PM (poor metabolizer): CYP2C19*2/*2, CYP2C19*2/*3 or CYP2C19*3/*3</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Rabeprazole_PMDA_10_18_16.pdf"">rabeprazole package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160847,Annotation of PMDA Label for sulfadiazine and G6PD,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451539', 'name': 'sulfadiazine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",PMDA,1448267041.0,"<p>The PMDA package insert for sulfadiazine (GEBEN) states that hemolysis may occur in patients with G6PD deficiency.</p>
",1448267040.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from sulfadiazine (GEBEN) package insert:</p>
<blockquote class=""blockquote"">
<p>Precautions...Patients with a glucose-6-phosphate dehydrogenase (G-6-PD) deficiency (hemolysis may occur).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Sulfadiazine_PMDA_10_18_16.pdf"">sulfadiazine package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160848,Annotation of PMDA Label for sulfamethoxazole / trimethoprim and G6PD,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10715', 'name': 'sulfamethoxazole / trimethoprim'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",PMDA,1448267048.0,"<p>The PMDA package insert for sulfamethoxazole and trimethoprim (DAIPHEN) states that hemolysis may occur in patients with G6PD deficiency.</p>
",1448267047.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from sulfamethoxazole and trimethoprim (DAIPHEN) package insert:</p>
<blockquote class=""blockquote"">
<p>Contraindications...Patients with a glucose-6-phosphate dehydrogenase (G-6-PD) deficiency (hemolysis may occur).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Sulfamethoxaole_Trimethoprim_PMDA_10_18_16.pdf"">sulfamethoxazole and trimethoprim package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160849,Annotation of PMDA Label for sulfasalazine and G6PD,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451547', 'name': 'sulfasalazine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",PMDA,1448267059.0,"<p>The PMDA package insert for sulfasalazine (Azulfidine) states that hemolysis may occur in patients with G6PD deficiency.</p>
",1448267058.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from sulfasalazine (Azulfidine) package insert:</p>
<blockquote class=""blockquote"">
<p>Precautions...Patients with a glucose-6-phosphate dehydrogenase (G-6-PD) deficiency (hemolysis may occur).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Sulfasalazine_PMDA_10_18_16.pdf"">sulfasalazine package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160850,Annotation of PMDA Label for tetrabenazine and CYP2D6,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA140222719', 'name': 'tetrabenazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",PMDA,1448267092.0,"<p>The PMDA package insert for tetrabenazine states that CYP2D6 poor metabolizers and intermediate metabolizer are at increased risk of developing side effects due to higher levels of the active metabolite, and that caution should be used in treating these patients.</p>
",1448267091.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the tetrabenazine package insert:</p>
<blockquote class=""blockquote"">
<p>Patients receiving CYP2D6 inhibitors, CYP2D6 poor metabolizers deficient in CYP2D6 activity and CYP2D6 intermediate metabolizers with reduced CYP2D6 activity are at increased risk of developing side effects due to higher levels of the active metabolites of this product. Caution and close monitoring should be used in treating these patients, and the dose should be increased gradually and only when it is tolerated.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The active metabolites of tetrabenazine, &alpha;-HTBZ and &beta;-HTBZ, are known substrates of CYP2D6. Following single oral dosing of 12.5, 25 or 50 mg of tetrabenazine in 17 healthy adult males under fasting condition, the Cmax and AUC0-inf were higher in CYP2D6 intermediate metabolizers (IM) compared to extensive metabolizers (EMs) for both &alpha;-HTBZ and &beta;-HTBZ, while the Cmax and AUC0-inf of 9-desmethyl-&beta;-HTBZ were lower in IMs than in EMs. These results indicate that plasma levels of &alpha;-HTBZ, &beta;-HTBZ and 9-desmethyl-&beta;-HTBZ were affected by CYP2D6 phenotypes.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tetrabenazine_PMDA_10_18_16.pdf"">tetrabenazine package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160854,Annotation of PMDA Label for moviprep and G6PD,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166163260', 'name': 'moviprep'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",PMDA,1448267144.0,"<p>MoviPrep, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy. Because it contains Vitamin C (ascorbic acid), the PMDA package insert warns that hemolytic reactions are possible in those with G6PD deficiency.</p>
",1448267143.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the MoviPrep package insert:</p>
<blockquote class=""blockquote"">
<p>Precautions...Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency (hemolysis may occur).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/MoviPrep_PMDA_10_19_16.pdf"">MoviPrep package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160856,Annotation of PMDA Label for voriconazole and CYP2C19,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10233', 'name': 'voriconazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",PMDA,1448267172.0,"<p>The PMDA package insert for voriconazole (VFEND) notes that it is metabolized by CYP2C19 (as well as CYP2C9 and CYP3A4) and provides tables showing the difference in pharmacokinetic metrics between extensive metabolizers (EM), intermediate metabolizers (also known as heterozygous extensive metabolizers (HEM)) and poor metabolizers (PM) in adults and pediatrics.</p>
",1448267171.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the voriconazole (VFEND) package insert:</p>
<blockquote class=""blockquote"">
<p>The product is metabolized by the hepatic metabolic enzymes CYP2C19, 2C9 and 3A4 and inhibits CYP2C19, 2C9 and 3A4 (in vitro).</p>
</blockquote>
<p><strong>Plasma concentrations in healthy adults following repeated dosing...Healthy Japanese male volunteers received loading doses of voriconazole 6 mg/kg IV twice on Day 1 and then repeated doses of 3 or 4 mg/kg IV twice daily for 10 days...</strong></p>
<table class=""table"">
<thead>
<tr><th>Dose</th><th>CYP2C19 Genotype</th><th>Number of Cases</th><th>Cinf (ug/mL)</th><th>AUC&tau; (ug*h/mL)</th><th>t1/2 (h)</th></tr>
</thead>
<tbody>
<tr><td>3 mg/kg</td><td>EM</td><td>2</td><td>2.83</td><td>11.42</td><td>6.6</td></tr>
<tr><td>3 mg/kg</td><td>HEM</td><td>2</td><td>3.86</td><td>28.83</td><td>6.3</td></tr>
<tr><td>3 mg/kg</td><td>PM</td><td>2</td><td>5.53</td><td>46.29</td><td>8.3</td></tr>
<tr><td>4 mg/kg</td><td>EM</td><td>2</td><td>4.52</td><td>18.86</td><td>6.1</td></tr>
<tr><td>4 mg/kg</td><td>HEM</td><td>4</td><td>5.70</td><td>37.34</td><td>5.3</td></tr>
</tbody>
</table>
<p><strong>Plasma concentrations in pediatric patients following repeated dosing...Japanese pediatric patients (aged 3-14 years, 20 cases) received loading doses of voriconazole 9 mg/kg IV twice on Day 1 and then repeated doses of 8 mg/kg IV twice daily for 6 days...</strong></p>
<table class=""table"">
<thead>
<tr><th>CYP2C19 Genotype</th><th>Number of Cases</th><th>Cmax (ug/mL)</th><th>AUC&tau; (ug*h/mL)</th></tr>
</thead>
<tbody>
<tr><td>EM</td><td>8</td><td>5.32 (2.32-8.31)</td><td>36 (14.2-70.0)</td></tr>
<tr><td>HEM</td><td>10</td><td>8.12 (4.62-12.5)</td><td>56.4 (23.0-103)</td></tr>
<tr><td>PM</td><td>2</td><td>15.7 (12.6, 19.6)</td><td>127.5 (91.8, 177)</td></tr>
</tbody>
</table>
<blockquote class=""blockquote"">
<p>The CYP2C19 genotype represents the patients’ phenotypes predicted based on their genotypes: EM: CYP2C19*1/*1 or CYP2C19*1/*17. HEM: CYP2C19*1/*2 or CYP2C19*1/*3. PM: CYP2C19*2/*2, CYP2C19*2/*3 or CYP2C19*3/*3</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Voriconazole_PMDA_10_19_16.pdf"">voriconazole package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160709,Annotation of PMDA Label for eliglustat and CYP2D6,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166123486', 'name': 'eliglustat'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",PMDA,1448265793.0,"<p>The PMDA package insert for eliglustat (CERDELGA) states that a patient's CYP2D6 genotype should be established prior to treatment, and that the drug is not recommended in CYP2D6 poor or ultrarapid metabolizers, or those who CYP2D6 metabolizer status cannot be determined.</p>
",1448265792.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the eliglustat (CERDELGA) drug label:</p>
<blockquote class=""blockquote"">
<p>Establish the patient’s CYP2D6 genotype prior to the initiation of this product...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The use of this product is not recommended in CYP2D6 PMs due to the risk of increased plasma concentrations. If treatment is necessary, the indication of dose is 100 mg once daily and should be administered with caution.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The use of this product is not recommended in patients who are CYP2D6 ultra-rapid metabolizers (URMs), as they may not achieve adequate plasma concentrations of the product to achieve a therapeutic effect.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The use of this product is not recommended in patients whose CYP2D6 metabolizer status cannot be determined by CYP2D6 genotyping.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>From the results of a population pharmacokinetics analysis in patients with Gaucher disease type 1, Cmax and AUC0-12h were estimated to be 9.3- and 11.2-fold higher in PMs compared to EMs, respectively, and 2.7- and 2.8 higher in IMs compared to EMs, respectively, following repeated doses of 100 mg eliglustat tartrate twice daily. In URMs, these values were both estimated to be about 47% of those in EMs.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Note: CYP2D6 genotypes. URM: CYP2D6*1/*1X2, CYP2D6*1/*2X2. EM: CYP2D6*1/*1, CYP2D6*1/*10, CYP2D6*1/*10X2, CYP2D6*1/*2, CYP2D6*1/*21, CYP2D6*1/*4, CYP2D6*1/*5, CYP2D6*2X2/*5, CYP2D6*2/*10, CYP2D6*2/*5. IM: CYP2D6*10/*10, CYP2D6*10/*10X2, CYP2D6*5/*10. PM: CYP2D6*5/*14.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Eliglustat_PMDA_10_05_16.pdf"">eliglustat package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166160710,Annotation of PMDA Label for erlotinib and EGFR,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA134687924', 'name': 'erlotinib'}]","[{'objCls': 'Gene', 'id': 'PA7360', 'symbol': 'EGFR', 'name': 'epidermal growth factor receptor'}]",PMDA,1448265805.0,"<p>The PMDA package insert for erlotinib states that it is indicated for recurrent and/or advanced inoperable non-small cell lung cancer that is positive for an EGFR gene mutation and has not been previously treated with chemotherapy.</p>
",1448265804.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for erlotinib:</p>
<blockquote class=""blockquote"">
<p>Recurrent and/or advanced inoperable non-small cell lung cancer that is positive for EGFR gene mutation and has not been previously treated with chemotherapy</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A phase II clinical trial (J022903) was conducted in Japan for monotherapy for the first line treatment of patients with advanced or recurrent non-small cell lung cancer containing EGFR gene mutations (exon 19 deletions or exon 21 L858R substitution mutations).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A phase III clinical trial (ML20650) was conducted to compare this product and a standard chemotherapyNote12) for the first line treatment of patients with advanced or recurrent non-small cell lung cancer containing EGFR gene mutations (exon 19 deletions or exon 21 L858R substitution mutations).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Erlotinib_PMDA_10_05_16.pdf"">erlotinib package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166160851,Annotation of PMDA Label for vemurafenib and BRAF,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165946873', 'name': 'vemurafenib'}]","[{'objCls': 'Gene', 'id': 'PA25408', 'symbol': 'BRAF', 'name': 'B-Raf proto-oncogene, serine/threonine kinase'}]",PMDA,1448267126.0,"<p>The PMDA package insert for vemurafenib (ZELBORAF) states that it is indicated for patients with unresectable, refractory melanoma with BRAF gene mutation.</p>
",1448267125.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the vemurafenib (ZELBORAF) package insert:</p>
<blockquote class=""blockquote"">
<p>Unresectable, refractory melanoma with BRAF gene mutation.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Vemurafenib appears to suppress the growth of tumors containing BRAF V600 mutations by inhibiting mutated forms of BRAF kinase, including BRAF V600 (V600E, V600D, V600R, V600K, V600G and V600M), which in turn inhibits phosphorylation of MEK and ERK by activated BRAF.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Vemurafenib_PMDA_10_19_16.pdf"">vemurafenib package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166160669,"Annotation of PMDA Label for escitalopram and CYP2C19, CYP2D6",False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10074', 'name': 'escitalopram'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",PMDA,1448265240.0,"<p>The PMDA package insert for escitalopram notes that the recommended maximum dose is 10 mg in patients with genetically absent CYP2C19 activity (poor metabolizers), due to an increased risk for developing QT prolongation and other side effects from the increased plasma concentrations.</p>
",1448265239.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for escitalopram:</p>
<blockquote class=""blockquote"">
<p>The recommended dose is 10 mg maximum in patients with hepatic impairment, elderly patients and those with genetically absent CYP2C19 activity (poor metabolizers) as these patients are at increased risk of developing QT prolongation and other side effects due to increased plasma concentrations of this product.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>After 21 days of dosing, Cmax, AUC and T1/2 were about 2-fold higher in the CYP2C19 PM group compared to the CYP2C19 EM group...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>After repeated oral dosing of 10 mg once daily for 21 days in healthy patients (5 CYP2C19 PMs and 5 EMs), the amount of escitalopram excreted in urine by 24 hours after final dosing was 17.4% of administered dosage in the CYP2C19 EM group and 30.7% in the CYP2C19 PM group...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 (Data from non-Japanese subjects). Oral or intravenous administration of the product in healthy adults resulted in a 1.2-fold increase in Cmax and a 1.3-fold increase in AUC compared to CYP2D6 EMs in 1 of 8 CYP2D6 PMs, but Cmax and AUC in the other 7 subjects were similar to those of CYP2D6 EMs.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Escitalopram_PMDA_10_03_16.pdf"">escitalopram package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166353162,Annotation of EMA Label for pitavastatin,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA142650384', 'name': 'pitavastatin'}]",[],EMA,,,1452612187.0,"<p>The EMA database contains periodic safety update report single assessment (PSUSA) and paediatric investigation plan (PIP) documents for pitavastatin.</p>
<p>https://www.ema.europa.eu/en/search?search_api_fulltext=pitavastatin</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166184460,Annotation of Swissmedic Label for haloperidol and CYP2D6,False,False,[],False,"[{'id': 1451832160, 'date': '2022-07-25T11:19:18.892-07:00', 'description': 'retired the label annotation due to updated text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103284, 'title': 'Swissmedic label for haloperidol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=26892', 'crossReferences': [{'id': 1450815669, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=26892', '_url': 'https://amiko.oddb.org/de/fi?gtin=26892'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449841', 'name': 'haloperidol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450820143.0,"<p>This label was updated after the collaboration between PharmGKB and PCRG concluded. The updated label does still contain pharmacogenomic information, but it's in German and the update falls outside of the scope of the collaboration. As a result, this annotation has been retired by PharmGKB.</p>
",1450820144.0,"<p><strong>This label was updated after the collaboration between PharmGKB and PCRG concluded. The updated label does still contain pharmacogenomic information, but it's in German and the update falls outside of the scope of the collaboration. As a result, this annotation has been retired by PharmGKB.</strong></p>
<p><strong>Annotation from September  2019:</strong></p>
<p>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</p>
<p>Excerpt from the drug label for haloperidol (Haldol):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
CYP2D6 polymorphism: Although in vitro the contribution of the enzyme CYP2D6 is limited, clinical studies have shown that the clearance of haloperidol and reduced haloperidol in patients with deep CYP2D6 capacity is about 30% lower compared to the so-called &quot;extensive metabolizers&quot;.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=26892&amp;highlight=Polymorphismus"" target=""_blank"">haloperidol drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,1451832060.0,Retirement Reason,[],Other,retirement:1451832060,True,
Label Annotation,PA166183881,Annotation of Swissmedic Label for mivacurium and BCHE,False,False,[],False,"[{'id': 1451941121, 'date': '2022-11-15T00:00:00-08:00', 'description': 'Moved tag from mivacurium chloride to mivacurium as redundant drug pages are consolidated.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103046, 'title': 'Swissmedic label for mivacurium chlorid', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=52290', 'crossReferences': [{'id': 1450811994, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=52290', '_url': 'https://amiko.oddb.org/de/fi?gtin=52290'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450528', 'name': 'mivacurium'}]","[{'objCls': 'Gene', 'id': 'PA25294', 'symbol': 'BCHE', 'name': 'butyrylcholinesterase'}]",Swissmedic,1450811995.0,"<p>The Swiss drug label for mivacurium chlorid (Mivacron) states that BCHE genotypes may affect the response to mivacurium chlorid.</p>
",1450811996.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the mivacurium chlorid (Mivacron) label:</p>
<blockquote class=""blockquote"">
<p>Precautions:
As with suxamethonium/succinylcholine, patients who are homozygous for the atypical plasmacholinesterase gene (1 in 2,500 patients) are very sensitive to the neuromuscular effect of mivacron. In 3 such patients, a small mivacurium dose of 0.03 mg/kg (about ED10-20 in genotypically normal patients) resulted in a complete block of 26-128 minutes. In patients heterozygous for the atypical plasmacholinesterase gene, the clinically effective duration of neuromuscular blockade by 0.15 mg mivacurium/kg is about 10 minutes longer than in control patients.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=52290"" target=""_blank"">mivacurium chlorid drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184130,Annotation of Swissmedic Label for dapoxetine and CYP2D6,False,False,[],True,[],False,[],True,"[{'id': 15103171, 'title': 'Swissmedic label for dapoxetine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=60470', 'crossReferences': [{'id': 1450813280, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=60470', '_url': 'https://amiko.oddb.org/de/fi?gtin=60470'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166151992', 'name': 'dapoxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450813705.0,"<p>The Swiss drug label for dapoxetine (Priligy) states that dapoxetine should be used with caution in CYP2D6 &quot;slow metabolizers&quot; and that the dose of dapoxetine should not be increased to 60mg in these patients.</p>
",1450813706.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for dapoxetine (Priligy):</p>
<blockquote class=""blockquote"">
<p>Dosage/Usage:
Caution should be exercised in patients known to be of the CYP2D6 slow metaboliser genotype or in patients treated with potent CYP2D6 inhibitors at the same time (see &quot;Warnings and Precautions&quot; and &quot;Interactions&quot;). An increase of the dose to 60 mg should not be applied to these patients.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Precautionary measures:
Caution should be exercised in patients taking potent CYP2D6 inhibitors or in patients of the genotype CYP2D6 slow metabolisers, as these may increase levels of activity, which may lead to an increased incidence and severity of dose-dependent side effects (see &quot;Dosage/Application&quot; and &quot;Interactions&quot;).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=60470&amp;highlight=Genotyp"" target=""_blank"">dapoxetine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813707.0,"<blockquote class=""blockquote"">
<p>Caution should be exercised in patients known to be of the CYP2D6 slow metaboliser genotype or in patients treated with potent CYP2D6 inhibitors at the same time (see &quot;Warnings and Precautions&quot; and &quot;Interactions&quot;). An increase of the dose to 60 mg should not be applied to these patients.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184115,Annotation of Swissmedic Label for carbamazepine and HLA-A,True,False,[],False,"[{'id': 1452021785, 'date': '2023-02-28T13:06:53.474-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103157, 'title': 'Swissmedic label for carbamazepine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=29789', 'crossReferences': [{'id': 1450813256, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=29789', '_url': 'https://amiko.oddb.org/de/fi?gtin=29789'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35055', 'symbol': 'HLA-A', 'name': 'major histocompatibility complex, class I, A'}]","[{'objCls': 'Haplotype', 'id': 'PA165954030', 'symbol': 'HLA-A*31:01', 'name': '*31:01'}]","[{'objCls': 'Chemical', 'id': 'PA448785', 'name': 'carbamazepine'}]","[{'objCls': 'Gene', 'id': 'PA35055', 'symbol': 'HLA-A', 'name': 'major histocompatibility complex, class I, A'}]",Swissmedic,1450813629.0,"<p>The Swiss drug label for carbamazepine (Tegretol) recommends that patients of certain ancestries be tested for the presence of the HLA-A*31:01 allele before beginning carbamazepine therapy. Carbamazepine should be avoided in patients carrying the HLA-A*31:01 allele unless the benefits clearly outweigh the risks.</p>
",1450813630.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for carbamazepine (Tegretol):</p>
<blockquote class=""blockquote"">
<p>Dosage/Usage:
Patients who are possible carriers of the HLA-A*3101 allele on the basis of their pedigree: Before starting treatment with Tegretol, it is recommended that patients whose ancestry represents a risk for the occurrence of certain adverse skin/hypersensitivity reactions be examined for the presence of the allele HLA-A*3101 for better risk assessment (see &quot;&quot;Warnings and Precautions&quot;&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Precautionary Measures:
There is increasing evidence that different HLA alleles in predisposed patients play a role in undesired immune responses.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Association with HLA-A*3101 allele: The human leukocyte antigen (HLA)-A*3101 may be a risk factor for the development of adverse skin reactions such as SJS/TEN, DRESS (Drug Rash with Eosinophilia and Systemic Symptoms), AGEP (Acute Generalized Exanthematic Pustulosis) and maculopapular rashes.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Retrospective genetic studies in the Japanese and Northern European populations showed an association between severe skin reactions (SJS/TEN, DRESS, AGEP) and maculopapular rashes associated with the use of carbamazepine and the presence of HLA-A*3101 allele.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Before starting treatment with Tegretol, it is recommended that patients whose ancestry poses a risk (e.g. patients from Japan, Caucasians) and the American indigenous population, patients of Spanish and Portuguese ancestry, as well as patients of South Indian and Arabic ancestry) be examined for the presence of the allele HLA-A*3101 (see &quot;&quot;Dosage/Application&quot;&quot;). In case of a positive result, treatment with Tegretol should be avoided unless the benefit is clearly greater than the risk. Screening for HLA-A*3101 is generally not recommended in patients who have been using Tegretol for some time, as SJS/TEN, AGEP, DRESS and maculopapular rashes usually occur only in the first months of therapy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>An association between the presence of the HLA-A*3101 allele and mild adverse reactions associated with the use of carbamazepine has been demonstrated. The HLA-A*3101 allele is thus a risk factor for developing severe hypersensitivity syndrome or mild maculopapular rash during carbamazepine treatment.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Undesired Effects:
Very rare: Stevens-Johnson syndrome (rarely reported in some Asian countries, see &quot;Warnings and precautions&quot;), Epidermolysis acuta toxica, photosensitivity reaction, Erythema multiforme et nodosum, changes in skin pigmentation, purpura, acne, hyperhidrosis, hair loss, hirsutism.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=29789&amp;highlight=HLA-A*3101"" target=""_blank"">carbamazepine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1450813631.0,"<blockquote class=""blockquote"">
<p>Before starting treatment with Tegretol, it is recommended that patients whose ancestry poses a risk (e.g. patients from Japan, Caucasians) and the American indigenous population, patients of Spanish and Portuguese ancestry, as well as patients of South Indian and Arabic ancestry) be examined for the presence of the allele HLA-A*3101 (see &quot;&quot;Dosage/Application&quot;&quot;). In case of a positive result, treatment with Tegretol should be avoided unless the benefit is clearly greater than the risk. Screening for HLA-A*3101 is generally not recommended in patients who have been using Tegretol for some time, as SJS/TEN, AGEP, DRESS and maculopapular rashes usually occur only in the first months of therapy.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184445,Annotation of Swissmedic Label for escitalopram and CYP2C19,False,False,[],True,"[{'id': 1452021844, 'date': '2023-02-28T13:09:21.888-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103269, 'title': 'Swissmedic label for escitalopram', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55961', 'crossReferences': [{'id': 1450815653, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55961', '_url': 'https://amiko.oddb.org/de/fi?gtin=55961'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",[],"[{'objCls': 'Chemical', 'id': 'PA10074', 'name': 'escitalopram'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",Swissmedic,1450815725.0,"<p>The Swiss drug label for escitalopram (Cipralex) states that care should be used in dosing in CYP2C19 metabolizers.</p>
",1450815726.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for escitalopram (Cipralex):</p>
<blockquote class=""blockquote"">
<p>Dosage/Application:
Slow metabolisers of CYP2C19. The dosage should be carried out carefully. An initial dose of 5 mg per day during the first 2 weeks is recommended.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Kinetics:
Polymorphism: In poor metabolisers with respect to CYP2C19, twice as high plasma levels of escitalopram were measured as in good metabolisers. No significant changes in plasma levels were measured in poor CYP2D6 metabolizers.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=55961&amp;highlight=Metabolisierer"" target=""_blank"">escitalopram drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450815727.0,"<blockquote class=""blockquote"">
<p>Slow metabolisers of CYP2C19. The dosage should be carried out carefully. An initial dose of 5 mg per day during the first 2 weeks is recommended.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184378,Annotation of Swissmedic Label for irinotecan and UGT1A1,False,False,[],True,"[{'id': 1452021967, 'date': '2023-02-28T14:30:23.538-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103239, 'title': 'Swissmedic label for irinotecan', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65994', 'crossReferences': [{'id': 1450815315, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65994', '_url': 'https://amiko.oddb.org/de/fi?gtin=65994'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]","[{'objCls': 'Haplotype', 'id': 'PA166115842', 'symbol': 'UGT1A1*28', 'name': '*28'}]","[{'objCls': 'Chemical', 'id': 'PA450085', 'name': 'irinotecan'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",Swissmedic,1450815326.0,"<p>The Swiss drug label for irinotecan (Onivyde) gives dosing changes for patients homozygous for UGT1A1*28.</p>
",1450815327.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for irinotecan (Onivyde):</p>
<blockquote class=""blockquote"">
<p>Dosage/Application:
Homozygous carriers of the UGT1A1*28 variant. In patients who are homozygous carriers of UGT1A1*28, the recommended initial dose of ONIVYDE (liposomal irinotecan) is 60 mg/m (see &quot;Warnings and Precautions&quot;). An increase in dose from ONIVYDE to 80 mg/m may be considered if tolerated for subsequent cycles.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Precautions:
Patients carrying the UGT1A1*28 variant (UGT1A1*28 allele homozygous) are at increased risk of neutropenia from non-liposomal irinotecan. Blood count and liver counts in these individuals should be closely monitored.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65994"" target=""_blank"">irinotecan drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450815328.0,"<blockquote class=""blockquote"">
<p>Dosage/Application:
Homozygous carriers of the UGT1A1*28 variant. In patients who are homozygous carriers of UGT1A1*28, the recommended initial dose of ONIVYDE (liposomal irinotecan) is 60 mg/m (see &quot;Warnings and Precautions&quot;). An increase in dose from ONIVYDE to 80 mg/m may be considered if tolerated for subsequent cycles.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166183901,Annotation of Swissmedic Label for moxifloxacin and G6PD,False,False,[],False,"[{'id': 1452021982, 'date': '2023-02-28T14:31:34.682-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103048, 'title': 'Swissmedic label for moxifloxacin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55213', 'crossReferences': [{'id': 1450812009, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55213', '_url': 'https://amiko.oddb.org/de/fi?gtin=55213'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450555', 'name': 'moxifloxacin'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450812220.0,"<p>The Swiss drug label for moxifloxacin (Avalox) states that moxifloxacin should be used with caution in patients with G6PD deficiency.
.</p>
",1450812221.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the moxifloxacin (Avalox) label:</p>
<blockquote class=""blockquote"">
<p>Precautions:
Glucose-6-phosphate dehydrogenase deficiency
Patients with present glucose-6-phosphate dehydrogenase deficiency or glucose-6-phosphate dehydrogenase deficiency in family history may develop hemolytic reactions under treatment with quinolones. Therefore, moxifloxacin should be used with caution in these patients.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=55213&amp;highlight=Glucose-6-phosphat-Dehydrogenase-Mangel"" target=""_blank"">moxifloxacin drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813289.0,"<p>&quot;Patients with present glucose-6-phosphate dehydrogenase deficiency or glucose-6-phosphate dehydrogenase deficiency in family history may develop hemolytic reactions under treatment with quinolones. Therefore, moxifloxacin should be used with caution in these patients.&quot;</p>
",,,,,,,
Label Annotation,PA166184082,Annotation of Swissmedic Label for nicorandil and G6PD,False,False,[],False,"[{'id': 1452021984, 'date': '2023-02-28T14:31:54.640-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103052, 'title': 'Swissmedic label for nicorandil', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=51593', 'crossReferences': [{'id': 1450812013, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=51593', '_url': 'https://amiko.oddb.org/de/fi?gtin=51593'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166184081', 'name': 'nicorandil'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450813320.0,"<p>The Swiss drug label for nicorendil (Dancor 10/20) states that patients with glucose-6-phosphate dehydrogenase deficiency should use Dancor with caution.</p>
",1450813321.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the nicorendil (Dancor 10/20) label:</p>
<blockquote class=""blockquote"">
<p>Precautions:
Glucose-6-phosphate dehydrogenase deficiency:
Dancor should be used with caution in patients with glucose-6-phosphate dehydrogenase deficiency. Nicorandil acts partly through its organic nitrate group. The metabolism of organic nitrates can lead to the formation of nitrites, which can cause methaemoglobinaemia in patients with glucose-6-phosphate dehydrogenase deficiency.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=51593&amp;highlight=Glucose-6-phosphat-Dehydrogenasemangel"" target=""_blank"">Dancor drug label</a> (in German)</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813322.0,"<blockquote class=""blockquote"">
<p>Dancor should be used with caution in patients with glucose-6-phosphate dehydrogenase deficiency. Nicorandil acts partly through its organic nitrate group. The metabolism of organic nitrates can lead to the formation of nitrites, which can cause methaemoglobinaemia in patients with glucose-6-phosphate dehydrogenase deficiency.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184128,Annotation of Swissmedic Label for acetaminophen / codeine and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103169, 'title': 'Swissmedic label for acetaminophen/codeine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=47353', 'crossReferences': [{'id': 1450813278, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=47353', '_url': 'https://amiko.oddb.org/de/fi?gtin=47353'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184061', 'name': 'acetaminophen / codeine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450813698.0,"<p>The Swiss drug label for acetaminophen/codeine (Co-Dafalgan) states that acetaminophen (paracetamol) should be used with caution in patients with G6PD deficiency.</p>
",1450813699.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for acetaminophen/codeine (Co-Dafalgan):</p>
<blockquote class=""blockquote"">
<p>Precautionary measures
Paracetamol should be used with caution in: Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) (may lead to hemolytic anaemia)</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=47353&amp;highlight=Metabolisiererin"" target=""_blank"">acetaminophen/codeine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184109,Annotation of Swissmedic Label for aripiprazole and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103150, 'title': 'Swissmedic label for aripiprazole', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=56209', 'crossReferences': [{'id': 1450813246, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=56209', '_url': 'https://amiko.oddb.org/de/fi?gtin=56209'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10026', 'name': 'aripiprazole'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450813579.0,"<p>The Swiss drug label for aripiprazole (Abilify) states that CYP2D6 poor metabolizers who take aripiprazole with a concomitant strong CYP3A4 inhibitor may have increased plasma concentrations of aripiprazole compared to CYP2D6 normal metabolizers.</p>
",1450813580.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for aripiprazole (Abilify):</p>
<blockquote class=""blockquote"">
<p>Dosage/Usage
When co-medicating Abilify with a strong CYP3A4 or CYP2D6 inhibitor, the aripiprazole dose should be reduced (see &quot;Interactions&quot;). After discontinuation of the CYP3A4 or CYP2D6 inhibitor, the Abilify dose should be increased. About 8% of the Caucasians are 'poor' metabolizers of CYP2D6 substrates (see &quot;Pharmacokinetics&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Interactions
In a clinical study with healthy volunteers, a highly effective inhibitor of CYP3A4 (ketoconazole) increased the AUC and Cmax of aripiprazole by 63 % and 37 %, respectively. The AUC and Cmax of dehydro-ripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 'poor' metabolizers, the combined use with highly potent inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to CYP2D6 extensive metabolizers. Considering the combined administration of ketoconazole or other highly potent CYP3A4 inhibitors with aripiprazole, the potential benefit should outweigh the potential risks to the patient. If ketoconazole is given together with aripiprazole, the aripiprazole dose should be reduced to approximately half the prescribed dose. Other highly potent inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors, are likely to have similar effects and therefore similar dose reductions should be applied.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Kinetics
Approximately 8% of Caucasians lack the ability to metabolize CYP2D6 substrates. These are classified as poor metabolizers (PM) with the remainder being extensive metabolizers (EM). PMs have about 80 % increased aripiprazole exposure and about 30 % decreased exposure of the active metabolite compared to EMs. This results in approximately 60% higher exposure of the entire active part of an administered dose of aripiprazole compared to EMs.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=56209&amp;highlight=Metabolisierer"" target=""_blank"">aripiprazole drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184119,Annotation of Swissmedic Label for celecoxib and CYP2C9,False,False,[],False,[],False,[],True,"[{'id': 15103161, 'title': 'Swissmedic label for celecoxib', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=54994', 'crossReferences': [{'id': 1450813268, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=54994', '_url': 'https://amiko.oddb.org/de/fi?gtin=54994'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165816542', 'symbol': 'CYP2C9*1', 'name': '*1'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA448871', 'name': 'celecoxib'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",Swissmedic,1450813647.0,"<p>The Swiss drug label for celecoxib (Celebrex) states that celecoxib should be used with caution in patients who are known or suspected to be CYP2C9 &quot;slow metabolizers&quot;.</p>
",1450813648.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<blockquote class=""blockquote"">
<p>Kinetics:
The activity of CYP2C9 is decreased in individuals with a genetic polymorphism leading to decreased enzyme activity (e.g. homozygous carriers of CYP2C9*3 polymorphism).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In a pharmacokinetic study, healthy subjects genotyped as either CYP2C9*1/*1, CYP2C9*1/*3, or CYP2C9*1/*3 received 200 mg celecoxib once daily. In individuals genotyped as CYP2C9*3/*3, median C and AUC of celecoxib on the seventh day were approximately 4-fold and 7-fold, respectively, of the other genotypes. In three different single-dose studies in a total of 5 individuals genotyped as CYP2C9*3/*3, AUC increased approximately 3-fold compared to individuals with normal metabolism.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The frequency of the homozygous genotype *3/*3 is probably between 0.3 and 1.0% for different ethnic groups.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Celecoxib should be used with caution in patients known from previous anamnesis or experience with other CYP2C9 substrates or suspected slow CYP2C9 metabolizers. It is recommended to start therapy at half the lowest recommended dose (see sections &quot;Dosage/Application&quot; and &quot;Interactions&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dosage/Usage:
Slow CYP2C9 metabolisers. Celecoxib should be used with caution in patients known to be (genotype or anamnesis/experience with other CYP2C9 substrates) or suspected slow CYP2C9 metabolizers. In these patients, consideration should be given to initiating therapy at half the lowest recommended dose (see sections &quot;&quot;Interactions&quot;&quot; and &quot;&quot;Pharmacokinetics&quot;&quot;).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=54994&amp;highlight=genetischenPolymorphismus"" target=""_blank"">celecoxib drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184131,Annotation of Swissmedic Label for darifenacin and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103172, 'title': 'Swissmedic label for darifenacin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=56871', 'crossReferences': [{'id': 1450813281, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=56871', '_url': 'https://amiko.oddb.org/de/fi?gtin=56871'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164774901', 'name': 'darifenacin'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450813709.0,"<p>The Swiss drug label for darifenacin (Emselex) states that CYP2D6 poor metabolizers who are taking darifenacin with a concomitant strong CYP3A4 inhibitor may have significantly increased exposure to darifenacin.</p>
",1450813710.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for darifenacin (Emselex):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Darifenacin is metabolized by CYP3A4 and CYP2D6. Due to genetic differences, the enzyme CYP2D6 is absent in about 7% of the Caucasian population, which are referred to as slow metabolizers (&quot;poor metabolisers&quot;). Conversely, a small part of the population shows increased CYP2D6 activity (so-called ultrafast metabolizers). The ratio between slow and ultrafast metabolizers for Cmax and AUC was 1.9 and 1.7, respectively, once daily in steady state after 15 mg of darifenacin. Unless otherwise stated, the following data refer to individuals with normal CYP2D6 activity (fast metabolizers).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 slow metabolisers: The metabolism of Darifenacin in slow CYP2D6 metabolisers is basically mediated by CYP3A4. In a pharmacokinetic study, steady state exposure was 164% and 99% higher during once-daily treatment with 7.5 mg and 15 mg, respectively, in slow metabolisers. However, a pharmacokinetic population analysis of Phase III data showed that steady state exposure was on average only 66% higher in slow metabolizers than in rapid metabolizers. There is a significant overlap of plasma levels between the two populations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Properties/Effects:
In a comparative study on n= 288 volunteers (20% poor metaboliser for CYP2D6) the effect of Darifenacin 15 mg and 75 mg on the QT duration compared to placebo and Moxifloxacin 400 mg as positive control was investigated. The duration of treatment was 4 weeks. No prolongation of QTcF was observed for either dose of Darifenacin.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Precautionary Measures:
Simultaneous treatment with Darifenacin and CYP3A4 inhibitors may increase Darifenacin exposure (see &quot;Interactions&quot;). In particular, there is a risk of significantly increased exposure to darifenacin in CYP2D6 poor metabolites treated simultaneously with potent CYP3A4 inhibitors. As the polymorphism of CYP2D6 is usually not known outside clinical trials, darifenacin should not be used in combination with strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, voriconazole, clarithrornycin, indinavir, nelfinavir, ritonavir, saquinavir).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=56871&amp;highlight=genetischer"" target=""_blank"">darifenacin drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184444,Annotation of Swissmedic Label for eletriptan and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103267, 'title': 'Swissmedic label for eletriptan', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55218', 'crossReferences': [{'id': 1450815651, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55218', '_url': 'https://amiko.oddb.org/de/fi?gtin=55218'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA134687947', 'name': 'eletriptan'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815719.0,"<p>The Swiss drug label for eletriptan (Relpax) states that CYP2D6 polymorphisms have no clinically relevant effect on eletriptan pharmacokinetics.</p>
",1450815720.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for eletriptan (Relpax):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
In vitro studies show that eletriptan is mainly metabolized by the hepatic cytochrome P-450 enzyme CYP3A4. This finding is supported by elevated eletriptan plasma levels after simultaneous administration of erythromycin, a known selective and potent CYP3A4 inhibitor. In vitro studies also suggest low involvement of CYP2D6, although clinical studies indicate that there is no clinically relevant effect of CYP2D6 polymorphism on the pharmacokinetics of eletriptan.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=55218&amp;highlight=Polymorphismus"" target=""_blank"">eletriptan drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184448,Annotation of Swissmedic Label for flucloxacillin and HLA-B,False,False,[],False,[],False,[],True,"[{'id': 15103272, 'title': 'Swissmedic label for flucloxacillin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=37404', 'crossReferences': [{'id': 1450815656, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=37404', '_url': 'https://amiko.oddb.org/de/fi?gtin=37404'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165987830', 'symbol': 'HLA-B*57:01', 'name': '*57:01'}]","[{'objCls': 'Chemical', 'id': 'PA164781042', 'name': 'flucloxacillin'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",Swissmedic,1450815735.0,"<p>The Swiss drug label for flucloxacillin (Floxapen) states that patients carrying the HLA-B*5701 allele have increased risk for drug-induced liver damage although routine testing is not required due to the low positive predictive value.</p>
",1450815736.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for flucloxacillin (Floxapen):</p>
<blockquote class=""blockquote"">
<p>Precautions:
There is evidence that the risk of flucloxacillin-induced liver damage is increased in patients carrying the HLA-B*5701 allele. Despite this clear correlation, only one in 500-1000 carriers will develop liver damage. Consequently, the positive prediction of tests on the HLA-B*5701 allele for liver damage is very low (0.12%) and routine testing for this allele is not recommended.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=37404&amp;highlight=HLA-B*5701"" target=""_blank"">flucloxacillin drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184108,Annotation of Swissmedic Label for fluorouracil / salicylic acid and DPYD,False,False,[],False,[],False,[],True,"[{'id': 15103149, 'title': 'Swissmedic label for fluorouracil/salacyclic acid (Actikerall)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=61467', 'crossReferences': [{'id': 1450813245, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=61467', '_url': 'https://amiko.oddb.org/de/fi?gtin=61467'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103213, 'title': 'Swissmedic label for fluorouracil/salacyclic acid (Verrumal)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=42695', 'crossReferences': [{'id': 1450814463, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=42695', '_url': 'https://amiko.oddb.org/de/fi?gtin=42695'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166183787', 'name': 'fluorouracil / salicylic acid'}]","[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",Swissmedic,1450813575.0,"<p>The Swiss drug labels for fluorouracil/salicylic acid (Actikerall and Verrumal) state that, where appropriate, DPYD activity levels should be determined prior to fluorouracil treatment.</p>
",1450813576.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for fluorouracil/salicylic acid (Actikerall):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
The absorbed portion of fluorouracil is rapidly metabolized in the liver by dihydropyrimidine dehydrogenase (DPD) and the metabolites are excreted via urine and breath. A genetic polymorphism is known for dihydropyrimidine dehydrogenase.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Precautionary Measures - DPD enzyme:
The enzyme dihydropyrimidine dehydrogenase (DPD) plays an important role in the degradation of fluorouracil. Inhibition, deficiency or decreased activity of this enzyme can lead to accumulation and increase of toxic effects of fluorouracil. Caution should therefore be exercised in patients with DPD deficiency. Although systemic exposure is low, DPD deficiency should be considered when systemic toxicity occurs. Where appropriate, determination of DPD enzyme activity is indicated prior to treatment with fluorouracil or other fluoropyrimidines.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with DPD deficiency who use Phenytoin and Actikerall at the same time should be regularly checked for elevated phenytoin plasma levels (see &quot;Interactions&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Interactions:
Where appropriate, determination of DPD enzyme activity is indicated prior to treatment with fluorouracil or other fluoropyrimidines.</p>
</blockquote>
<p>Excerpts from the drug label for fluorouracil/salicylic acid (Verrumal):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
The absorbed portion of fluorouracil is rapidly metabolized in the liver by dihydropyrimidine dehydrogenase (DPD) and the metabolites are excreted via urine and breath. A genetic polymorphism is known for dihydropyrimidine dehydrogenase.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Precautionary Measures:
Caution should therefore be exercised in patients with DPD deficiency. Although systemic exposure is low, DPD deficiency should be considered when systemic toxicity occurs. Where appropriate, determination of DPD enzyme activity before treatment with Verrumal is indicated.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Interactions:
Where appropriate, determination of DPD enzyme activity before treatment with Verrumal is indicated.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=61467&amp;highlight=DPD-Enzymaktivität"" target=""_blank"">Actikerall drug label</a> or the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=42695&amp;highlight=genetischer"" target=""_blank"">Verrumal drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,,,,,,,,,
Label Annotation,PA166184453,Annotation of Swissmedic Label for fluvoxamine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103278, 'title': 'Swissmedic label for fluvoxamine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=44603', 'crossReferences': [{'id': 1450815662, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=44603', '_url': 'https://amiko.oddb.org/de/fi?gtin=44603'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449690', 'name': 'fluvoxamine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815756.0,"<p>The Swiss drug label for fluvoxamine (Floxyfral) states that the pharmacological properties and relative proportions of metabolites of fluvoxamine are altered in CYP2D6 poor metabolizers.</p>
",1450815757.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for fluvoxamine (Floxyfral):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
In about 3 to 10% of the healthy population, a genetic defect leads to a reduction in the activity of the cytochrome-450 isozyme P4502D6. Such individuals are referred to as poor metabolizers of substances such as debrisoquine, dextromethorphan and tricyclic antidepressants. Many substances, including fluvoxamine and other selective serotonin reuptake inhibitors, are metabolized by this isoenzyme; therefore, the pharmacological properties and relative proportions of metabolites in poor metabolizers are altered.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=44603&amp;highlight=genetischen"" target=""_blank"">fluvoxamine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184458,Annotation of Swissmedic Label for glimepiride and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103283, 'title': 'Swissmedic label for glimepiride', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=53130', 'crossReferences': [{'id': 1450815668, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=53130', '_url': 'https://amiko.oddb.org/de/fi?gtin=53130'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449761', 'name': 'glimepiride'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450820136.0,"<p>The Swiss drug label for glimepiride (Amaryl) states that caution should be used when treating patients with G6PD deficiency with glimepiride as they are at increased risk for hemolytic anemia.</p>
",1450820137.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for glimepiride (Amaryl):</p>
<blockquote class=""blockquote"">
<p>Precautions:
Treatment of patients with glucose-6-phosphate dehydrogenase deficiency with sulfonylurea compounds may lead to hemolytic anemia. Glimepiride should be used with caution in patients with glucose-6-phosphate dehydrogenase deficiency because it belongs to the class of sulfonylureas. Treatment with a non-sulfonylurea substitute should also be considered.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=53130&amp;highlight=Glucose-6-Phosphat-Dehydrogenase-Mangel"" target=""_blank"">glimepiride drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184377,Annotation of Swissmedic Label for indacaterol and UGT1A1,False,False,[],False,[],False,[],True,"[{'id': 15103237, 'title': 'Swissmedic label for indacaterol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=60141', 'crossReferences': [{'id': 1450815313, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=60141', '_url': 'https://amiko.oddb.org/de/fi?gtin=60141'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103238, 'title': 'Swissmedic label for indacaterol and glycopyrronium bromide', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=63132', 'crossReferences': [{'id': 1450815314, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=63132', '_url': 'https://amiko.oddb.org/de/fi?gtin=63132'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA166115842', 'symbol': 'UGT1A1*28', 'name': '*28'}]","[{'objCls': 'Chemical', 'id': 'PA165958348', 'name': 'indacaterol'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",Swissmedic,1450815320.0,"<p>The Swiss drug labels for indacaterol (Onbrez Breezhaler) and  indacaterol and  glycopyrronium bromide (Ultibro Breezhaler) states that the UGT1A1 (TA)7(TA)7 genotype is associated with marginally increased exposure to indacaterol.</p>
",1450815321.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for indacaterol (Onbrez Breezhaler):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
The pharmacokinetics of indacaterol was investigated in two different UGT1A1 genotypes - the fully functional (TA)6(TA)6 genotype and the weakly active (TA)7(TA)7 genotype (Gilbert's syndrome genotype). The study showed that the AUC and Cmax values of indacaterol in steady state were 1.2 times higher in the presence of the (TA)7(TA)7 genotype, suggesting that systemic exposure of indacaterol is only marginally affected by this variant of the UGT1A1 genotype.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=60141&amp;highlight=UGT1A1&amp;anchor=section14"" target=""_blank"">indicaterol drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184382,Annotation of Swissmedic Label for lansoprazole and CYP2C19,False,False,[],False,[],False,[],True,"[{'id': 15103243, 'title': 'Swissmedic label for lansoprazole', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=51969', 'crossReferences': [{'id': 1450815334, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=51969', '_url': 'https://amiko.oddb.org/de/fi?gtin=51969'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450180', 'name': 'lansoprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",Swissmedic,1450815368.0,"<p>The Swiss drug label for lansoprazole (Agopton) states that CYP2C19 poor metabolizers have increased exposure to lansoprazole compared to normal metabolizers.</p>
",1450815369.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for lansoprazole (Agopton):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Poor CYP2C19 metabolisers:
CYP2C19 is subject to a genetic polymorphism and 2-6% of the population, so-called poor metabolisers (PMs), are homozygous for a mutant CYP2C19 allele and therefore have no functional CYP2C19 enzyme. Lansoprazole exposure is many times higher in PMs than in extensive metabolizers (EMs).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=51969"" target=""_blank"">lansoprazole drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184385,Annotation of Swissmedic Label for lesinurad and CYP2C9,False,False,[],False,[],False,[],True,"[{'id': 15103245, 'title': 'Swissmedic label for lesinurad', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65925', 'crossReferences': [{'id': 1450815336, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65925', '_url': 'https://amiko.oddb.org/de/fi?gtin=65925'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165816542', 'symbol': 'CYP2C9*1', 'name': '*1'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA166160006', 'name': 'lesinurad'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",Swissmedic,1450815377.0,"<p>The Swiss drug label for lesinurad (Zurampic) gives information about CYP2C9 slow metabolizers and pharmacokinetics.</p>
",1450815378.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for lesinurad (Zurampic):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Slow metabolisers for CYP2C9:
About half of an oral dose of Lesinurad is excreted via the CYP2C9 metabolism. The effects of the CYP2C9 genotype on the pharmacokinetics of lesinurad were studied in 8 healthy volunteers and 59 gout patients receiving between 200 and 600 mg of lesinurad per day with or without xanthine oxidase inhibitors. At the 400 mg dose, increased exposure to lesinuras (AUC increase of approximately 22%) was detected in individuals with intermediate CYP2C9 metabolism (CYP2C9 *1/*3, N=4) compared to individuals with extensive CYP2C9 metabolism (CYP2C9 *1/*1, N=41). This was also true for persons with poor CYP2C9 metabolism (CYP2C9 *3/*3, N=1, AUC increase of about 111 %). The AUC increase was accompanied by an increased excretion of the Lesinurad via the kidneys. However, the individual values were within the range observed in individuals with extensive metabolism.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65925&amp;highlight=Metabolisierer"" target=""_blank"">lesinurad drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166183790,Annotation of Swissmedic Label for metoprolol and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103033, 'title': 'Swissmedic label for Beloc ZOK 25, 50, 100, 200', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=52110', 'crossReferences': [{'id': 1450811191, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=52110', '_url': 'https://amiko.oddb.org/de/fi?gtin=52110'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103032, 'title': 'Swissmedic label for Logimax 5/50, 10/100', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=44917', 'crossReferences': [{'id': 1450811190, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=44917', '_url': 'https://amiko.oddb.org/de/fi?gtin=44917'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450480', 'name': 'metoprolol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450811192.0,"<p>The Swiss drug label for metoprolol (Beloc ZOK, Logimax) states that CYP2D6 genotypes may affect the plasma concentration of metoprolol.</p>
",1450811193.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the metoprolol (Beloc ZOK) label:</p>
<blockquote class=""blockquote"">
<p>Precausions:
Beloc ZOK can lead to an increased plasma concentration in genetically induced debrisoquin polymorphism in slow metabolizers.</p>
</blockquote>
<p>Excerpts from the metoprolol (Logimax) label:</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Genetically induced debrisoquine polymorphism (slow metabolisers) may result in elevated plasma levels of metoprolol.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Absorption
Metoprolol is mainly absorbed from the duodenum and the upper part of the jejunum. With retard formulations of metoprolol, maximum plasma concentrations are reached after about 4 - 5 h. The plasma concentration of metoprolol is reduced to a minimum. In the dosage range between 50 mg and 200 mg, the plasma concentration of metoprolol increases approximately proportionally to the dose.
Due to the strong first-pass effect in the liver, only about 50% of a single oral dose of metoprolol enters the systemic circulation. The pre-systemic elimination of metoprolol is individually and differently pronounced due to genetic differences in oxidative metabolism. Although the concentration profile in plasma shows large interindividual differences, it is reproducible in individual cases.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=52110"" target=""_blank"">Beloc ZOK drug label</a>; <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=44917"" target=""_blank"">Logimax drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166183810,Annotation of Swissmedic Label for mirabegron and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103037, 'title': 'Swissmedic label for mirabegron', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=62755&highlight=CYP2D6', 'crossReferences': [{'id': 1450811352, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=62755&highlight=CYP2D6', '_url': 'https://amiko.oddb.org/de/fi?gtin=62755&highlight=CYP2D6'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177513', 'name': 'mirabegron'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450811353.0,"<p>The Swiss drug label for mirabegron (Betmiga) states that CYP2D6 genetic polymorphism has minimal effect on mean plasma exposure to mirabegron.</p>
",1450811354.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the mirabegron (Betmiga) label:</p>
<blockquote class=""blockquote"">
<p>Interaction:
In healthy volunteers who were genotypically weak metabolizers of CYP2D6 substrates (and served as surrogates for CYP2D6 inhibition), the mean Cmax and AUCinf of a single dose of 160 mg of an immediate release Mirabegron formulation were 14% and 19%, respectively, higher than in extensive metabolizers. This suggests that CYP2D6 genetic polymorphism has a minimal effect on mean plasma exposure to mirabegron. An interaction of Mirabegron with a known CYP2D6 inhibitor is not expected and has not been investigated. When Betmiga is administered together with CYP2D6 inhibitors or to patients who are weak metabolizers of CYP2D6, no dose adjustment is required.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=62755&amp;highlight=CYP2D6"" target=""_blank"">mirabegron drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184118,Annotation of Swissmedic Label for carvedilol and CYP2D6,False,False,[],False,"[{'id': 1452206742, 'date': '2023-08-15T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15103160, 'title': 'Swissmedic label for carvedilol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=53162', 'crossReferences': [{'id': 1450813267, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=53162', '_url': 'https://amiko.oddb.org/de/fi?gtin=53162'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448817', 'name': 'carvedilol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450813643.0,"<p>The Swiss drug label for carvedilol (Dilatrend) states that CYP2D6 &quot;slow metabolizers&quot; have increased plasma concentrations of R- S-carvedilol. However, this is thought to be of limited clinical significance.</p>
",1450813644.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for carvedilol (Dilatrend):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Genetic polymorphism: The results of human clinical pharmacokinetic studies have shown that CYP2D6 plays an important role in the metabolism of R- and S-carvedilol. As a result, plasma concentrations of R- and S-carvedilol are elevated in slow CYP2D6 metabolizers. The importance of the CYP2D6 genotype for the pharmacokinetics of R- and S-carvedilol was confirmed in population pharmacokinetic studies, whereas other studies did not confirm this observation. It was concluded that CYP2D6 genetic polymorphism may have limited clinical significance.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=53162&amp;highlight=Genetischer"" target=""_blank"">carvedilol drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184127,Annotation of Swissmedic Label for acetaminophen / codeine and CYP2D6,True,False,[],False,"[{'id': 1452442580, 'date': '2024-04-15T04:17:59.408-07:00', 'description': 'Corrected typo in summary section', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103169, 'title': 'Swissmedic label for acetaminophen/codeine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=47353', 'crossReferences': [{'id': 1450813278, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=47353', '_url': 'https://amiko.oddb.org/de/fi?gtin=47353'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166184061', 'name': 'acetaminophen / codeine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450813694.0,"<p>The Swiss drug label for acetaminophen/codeine (Co-Dafalgan) states that CYP2D6 genotyping should be carried out in breastfeeding mothers prior to analgesic therapy as acetaminophen/codeine is contraindicated in patients with a CYP2D6 ultrarapid metabolizer phenotype. Patients with a CYP2D6 poor metabolizer phenotype do not experience an analgesic effect from codeine.</p>
",1450813695.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for acetaminophen/codeine (Co-Dafalgan):</p>
<div class=""blockquote"">
<p>Kinetics</p>
</div>
<div class=""blockquote"">
<p>Codeine phosphate is broken down in the liver. It is subject to O-demethylation. This reaction is mainly catalyzed by the enzyme CYP2D6, which follows a genetic polymorphism. The conversion to morphine takes place to varying degrees depending on the phenotype of the patient's O-demethylation. Metabolites are eliminated with urine in glucurone-conjugated form.</p>
</div>
<div class=""blockquote"">
<p>Contraindications</p>
</div>
<div class=""blockquote"">
<p>In patients known to be ultrafast metabolizers of the CYP2D6 phenotype.</p>
</div>
<div class=""blockquote"">
<p>Pregnancy</p>
</div>
<div class=""blockquote"">
<p>If the patient is an ultrafast metaboliser of CYP2D6, elevated levels of the active metabolite morphine may occur in breast milk. In very rare cases, symptoms of opioid poisoning of the child up to death may occur.</p>
</div>
<div class=""blockquote"">
<p>Precautionary measures</p>
</div>
<div class=""blockquote"">
<p>Respiratory effects: Opioids cause respiratory depression due to their dampening effect on the CNS. The risk of respiratory depression may be increased by the use of concomitant drugs and pharmacogenetic factors.</p>
</div>
<div class=""blockquote"">
<p>Ultrarapid codeine metabolisers: Codeine is converted into its active metabolite morphine by the hepatic isozymes CYP2D6, some of which are genetic polymorphisms. Patients with an &quot;ultra-rapid CYP2D6 metaboliser&quot; phenotype have a high CYP2D6 activity, so that toxic serum levels of morphine can develop even at low doses. These &quot;ultra-rapid metabolizers&quot; can show symptoms of overdose, such as dizziness, deep sedation, shortness of breath, nausea and vomiting, to respiratory and cardiac arrest.</p>
</div>
<div class=""blockquote"">
<p>Breastfeeding mothers who are &quot;ultra-rapid CYP2D6 metabolizers&quot; and receive codeine therapy are at high risk of overdose and death of the newborn due to high morphine serum concentrations. Ideally, CYP2D6 genotyping should be performed prior to analgesic therapy. When there are signs of opioid toxicity, close monitoring of patients is of enormous importance. For &quot;ultra-rapid CYP2D6 metabolizers&quot;, alternative analgesic therapy is recommended.</p>
</div>
<div class=""blockquote"">
<p>Poor codeine metabolizers: In patients with a weak CYP2D6 metaboliser phenotype, the formation of morphine from codeine is impaired. In these patients, no analgesic effect can be achieved by codeine therapy, but side effects may occur.</p>
</div>
<div class=""blockquote"">
<p>All children received codeine doses in the appropriate dose range. However, there was evidence that these children were either ultrafast metabolizers or pronounced metabolizers in terms of codeine and morphine metabolism.</p>
</div>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=47353&amp;highlight=Metabolisiererin"" target=""_blank"">acetaminophen/codeine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450813696.0,"<blockquote class=""blockquote"">
<p>Contraindications: In patients known to be ultrafast metabolizers of the CYP2D6 phenotype.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166182929,Annotation of EMA Label for binimetinib and UGT1A1,False,False,[],False,"[{'id': 1452206182, 'date': '2023-08-14T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102981, 'title': 'Mektovi | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi', 'crossReferences': [{'id': 1450416866, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166179867', 'name': 'binimetinib'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",EMA,1450416853.0,"<p>The EMA European Public Assessment Report (EPAR) for binimetinib (Mektovi) states that it is indicated in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The EPAR also states that there is no apparent relationship observed between binimetinib exposure and UGT1A1 mutation status.</p>
",1450416854.0,"<p>Excerpt from the binimetinib (Mektovi) EPAR:</p>
<div class=""blockquote"">
<p>Binimetinib is primarily metabolised through UGT1A1 mediated glucuronidation. In clinical study sub-analysis, however, there was no apparent relationship observed between binimetinib exposure and UGT1A1 mutation status.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Binimetinib_06_19_19_EMA.pdf"">binimetinib EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166353202,Annotation of HCSC Label for resmetirom,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166353181', 'name': 'resmetirom'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166184156,Annotation of Swissmedic Label for norfloxacin and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103054, 'title': 'Swissmedic label for norfloxacin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=54301', 'crossReferences': [{'id': 1450812015, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=54301', '_url': 'https://amiko.oddb.org/de/fi?gtin=54301'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450654', 'name': 'norfloxacin'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450813894.0,"<p>The Swiss drug label for norfloxacin (Norsol) states that patients with G6PD deficiency may experience hemolytic anemia.</p>
",1450813895.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for norfloxacin (Norsol):</p>
<blockquote class=""blockquote"">
<p>Precautions:
Patients with latent or existing defect of glucose-6-phosphate dehydrogenase activity treated with quinolone antibiotics including Norsol were rarely reported to have hemolytic reactions (see &quot;Adverse effects&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Adverse effects:
Rarely: Hemolytic anemia sometimes associated with glucose-6-phosphate dehydrogenase deficiency.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=54301&amp;highlight=Glucose-6-phosphat-Dehydrogenaseaktivität"" target=""_blank"">norfloxacin drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184459,Annotation of Swissmedic Label for nitroglycerin and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103286, 'title': 'Swissmedic label for glycerol trinitrate', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=45986', 'crossReferences': [{'id': 1450815671, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=45986', '_url': 'https://amiko.oddb.org/de/fi?gtin=45986'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450644', 'name': 'nitroglycerin'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450820139.0,"<p>The Swiss drug label for Glyceroltrinitrat (Deponit) states that caution should be used when treating patients with G6PD deficiency with glycerol trinitrate (also known as nitroglycerin) due to reduced metabolism.</p>
",1450820140.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for Glyceroltrinitrat (Deponit):</p>
<blockquote class=""blockquote"">
<p>Precautions:
Patients with anemic hypoxemia (including forms due to glucose-6-phosphate dehydrogenase deficiency) should be treated with caution as these patients have a reduced biotransformation of glycerol trinitrate.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=45986&amp;highlight=Glucose-6-Phosphat-Dehydrogenase-Mangel"" target=""_blank"">glycerol trinitrate drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184159,Annotation of Swissmedic Label for omeprazole and CYP2C19,False,False,[],False,[],False,[],True,"[{'id': 15103058, 'title': 'Swissmedic label for omeprazol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=54380', 'crossReferences': [{'id': 1450812019, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=54380', '_url': 'https://amiko.oddb.org/de/fi?gtin=54380'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450704', 'name': 'omeprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",Swissmedic,1450813907.0,"<p>The Swiss label for omeprazole (Antramups®, Tabletten) states that CYP2C19 is involved in the metabolism of the drug, and that slow metabolizers have a greater systemic exposure to omeprazole than that of fast metabolizers.</p>
",1450813908.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for omeprazole (Antramups®, Tabletten):</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
metabolism: Omeprazole is completely metabolized mainly in the liver via the cytochrome P450 enzyme system. The major part of the metabolism is metabolized via polymorphic, specific isoforms of CYP2C19 (S-mephenytoin hydroxylase). These are responsible for the formation of hydroxyomeprazole, the main metabolite in plasma. The remaining part of the metabolism depends on the specific isoenzyme CYP3A4, which is responsible for the formation of omeprazole sulfone.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Since CYP2C19 is competitively inhibited by omeprazole, there is a risk of metabolic interaction between omeprazole and other substances metabolized by CYP2C19 (see also chapter &quot;Interactions&quot;). This risk is increased in CYP2C19 slow metabolizers (&quot;mephenytoin polymorphism&quot;; 3-5% of Caucasians). Omeprazole has no potential to inhibit the metabolism of other CYP3A4 substrates as it has a weak affinity to CYP3A4.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Ethics in specific patient groups: About 3% of the Caucasian population and about 15-20% of the Asian population have a non-functional CYP2C19 enzyme and are therefore called slow metabolizers. In this group of patients the metabolism of omeprazole is mainly catalyzed by CYP3A4. After repeated, once daily administration of 20 mg omeprazole, the average AUC of slow metabolizers was 5-10 times higher than that of fast metabolizers. The average maximum plasma concentrations were approximately 3-5 times higher. The clinical relevance of this higher exposure is uncertain. However, there is no evidence that slow metabolizers are at increased risk of adverse effects due to higher omeprazole exposure.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=54380&amp;highlight=polymorphe"" target=""_blank"">omeprazole drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184222,Annotation of Swissmedic Label for pantoprazole and CYP2C19,False,False,[],False,[],False,[],True,"[{'id': 15103067, 'title': 'Swissmedic label for pantoprazol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=52710', 'crossReferences': [{'id': 1450812028, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=52710', '_url': 'https://amiko.oddb.org/de/fi?gtin=52710'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450774', 'name': 'pantoprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",Swissmedic,1450814361.0,"<p>The Swiss label for pantoprazole (Pantozol 20/40/- i.v.) states that individuals with CYP2C19 enzyme deficiency (poor metabolizers) may have increased pantoprazole concentration as compared to individuals with intact CYP2C19 enzyme activity (extensive metabolizers).</p>
",1450814362.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for pantoprazole (Pantozol® 20/40/- i.v.):</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics
About 3% of the European population has a functional CYP2C19 enzyme deficiency (poor metabolizers). In these individuals, pantoprazole is probably catalyzed mainly via CYP3A4. After a single dose of 40 mg pantoprazole, the mean AUC was about 6 times higher in poor metabolizers than in persons with intact CYP2C19 enzyme activity (extensive metabolizers). The mean maximum plasma concentration was increased by 60%. These results have no influence on the dosage of Pantoprazole.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=52710&amp;highlight=metabolizers"" target=""_blank"">pantoprazole drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166182930,Annotation of EMA Label for brexpiprazole and CYP2D6,False,False,[],True,[],False,[],True,"[{'id': 15102924, 'title': 'Rxulti | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti', 'crossReferences': [{'id': 1450416874, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}, {'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166160053', 'name': 'brexpiprazole'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1450416871.0,"<p>The EMA European Public Assessment Report (EPAR) for brexpiprazole (RXULTI) states that known CYP2D6 poor metabolizers should receive half the recommended dose, and known CYP2D6 poor metabolizers taking strong or moderate CYP3A4 inhibitors should receive a quarter of the recommended dose.</p>
",1450416872.0,"<p>Excerpts from the brexpiprazole (RXULTI) EPAR:</p>
<div class=""blockquote"">
<p>Dosing modifications to half the recommended doses is required for patients with known CYP2D6 poor metaboliser status. Further dosing modifications to a quarter of the recommended dose is required for known CYP2D6 poor metabolisers while taking strong or moderate CYP3A4 inhibitors...</p>
</div>
<div class=""blockquote"">
<p>Population pharmacokinetic evaluation shows that CYP2D6 poor metabolisers have 47% higher exposure to brexpiprazole compared to extensive metabolisers...</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Brexpiprazole_06_19_19_EMA.pdf"">brexpiprazole EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450416873.0,"<p>&quot;Dosing modifications to half the recommended doses is required for patients with known CYP2D6 poor metaboliser status. Further dosing modifications to a quarter of the recommended dose is required for known CYP2D6 poor metabolisers while taking strong or moderate CYP3A4 inhibitors...&quot;</p>
",,,,,,,
Label Annotation,PA166184402,Annotation of Swissmedic Label for ranolazine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103081, 'title': 'Swissmedic label for ranolazine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=60533', 'crossReferences': [{'id': 1450812042, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=60533', '_url': 'https://amiko.oddb.org/de/fi?gtin=60533'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164746007', 'name': 'ranolazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815439.0,"<p>The Swiss drug label for ranolazine (Ranexa) states that CYP2D6 poor metabolizers may have higher risk for adverse events.</p>
",1450815440.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the ranolazine (Ranexa) label:</p>
<blockquote class=""blockquote"">
<p>Precautions:
The risk of increased exposure to these subgroups leading to adverse events is higher in patients with no CYP2D6 activity (poor metabolizers, SM) than in those with the ability to metabolize CYP2D6 (extensive metabolizers, EM) (see section &quot;Pharmacokinetics&quot;). The above precautions are based on the risk in a CYP2D6-SM patient. These precautions are necessary when CYP2D6 status is unknown. Patients with CYP2D6 status &quot;EM&quot; require fewer precautions. If the patient's CYP2D6 status has been determined (e.g. by genotyping) or is known to be &quot;EM&quot;, Ranexa can be used with caution in these patients, even if they have a combination of several of the above risk factors.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Ranolazine is metabolized rapidly and comprehensively. In healthy young adults, ranolazine accounts for about 13% of plasma radioactivity after an orally administered 500 mg single dose of [14C]-Ranolazine. A large number of metabolites were identified in human plasma (47 metabolites), urine (&gt;100 metabolites) and faeces (25 metabolites). Fourteen primary metabolic pathways were identified, of which O-demethylation and N-dealkylation are the most important. In vitro studies with human liver microsomes indicate that Ranolazine is primarily metabolized by CYP3A4, but also by CYP2D6. At a dose of 500 mg twice daily, subjects with no CYP2D6 activity (poor metabolisers, SM) had a 62% higher AUC than subjects with CYP2D6 metabolic capacity (extensive metabolisers, EM). At the dosage of 1'000 mg twice daily the corresponding difference was 25%..</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=60533"" target=""_blank"">ranolazine drug label</a> (in German);</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450815441.0,"<blockquote class=""blockquote"">
<p>The risk of increased exposure to these subgroups leading to adverse events is higher in patients with no CYP2D6 activity (poor metabolizers, SM) than in those with the ability to metabolize CYP2D6 (extensive metabolizers, EM) (see section &quot;Pharmacokinetics&quot;). The above precautions are based on the risk in a CYP2D6-SM patient. These precautions are necessary when CYP2D6 status is unknown. Patients with CYP2D6 status &quot;EM&quot; require fewer precautions. If the patient's CYP2D6 status has been determined (e.g. by genotyping) or is known to be &quot;EM&quot;, Ranexa can be used with caution in these patients, even if they have a combination of several of the above risk factors.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184373,Annotation of Swissmedic Label for piroxicam and CYP2C9,False,False,[],False,[],False,[],True,"[{'id': 15103075, 'title': 'Swissmedic label for piroxicam', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=45452', 'crossReferences': [{'id': 1450812036, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=45452', '_url': 'https://amiko.oddb.org/de/fi?gtin=45452'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA450985', 'name': 'piroxicam'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",Swissmedic,1450815288.0,"<p>The Swiss label for piroxicam (Felden) states that CYP2C9 variants may impact the systemic exposure and elimination half-life of piroxicam.</p>
",1450815289.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the piroxicam (Felden) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
The activity of CYP2C9 is reduced in individuals with a genetic polymorphism such as CYP2C9*2 or CYP2C9*3 polymorphism. Limited information from two publications showed that after oral administration of a single dose in individuals with a heterozygous CYP2C9*1/*2 (n=9), a heterozygous CYP2C9*1/*3 (n=9) and a homozygous CYP2C9*3/*3 (n=1) genotype 1.7-, 1.7-, and 5.3-fold higher systemic Piroxicam levels were observed in individuals with a normal CYP2C9*1/*1 (n=17) metabolic genotype. The mean piroxicam elimination half-lives in CYP2C9*1/*2 (n=9) and CYP2C9*3/*3 (n=1) genotypes were 1.7 and 8.8 times longer, respectively, than in CYP2C9*1/*1 individuals.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=45452&amp;highlight=genetischen%20Polymorphismus"" target=""_blank"">piroxicam drug label</a> (in German)</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184381,Annotation of Swissmedic Label for prilocaine and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103241, 'title': 'Swissmedic label for prilocaine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=57659', 'crossReferences': [{'id': 1450815332, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=57659', '_url': 'https://amiko.oddb.org/de/fi?gtin=57659'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451101', 'name': 'prilocaine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450815348.0,"<p>The Swiss drug label for prilocaine (Oraqix) cautions that patients with G6PD may be at increased risk for methemoglobinemia.</p>
",1450815349.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for prilocaine (Oraqix)</p>
<blockquote class=""blockquote"">
<p>Precautions
Prilocaine can cause elevated methaemoglobin levels, especially in combination with methaemoglobin-inducing substances. Few cases of methemoglobinemia have also been reported in conjunction with lidocaine treatments. Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more prone to drug-induced methemoglobinemia. The signs and symptoms of methemoglobinemia may be delayed for several hours after drug exposure.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=57659&amp;highlight=Glucose-6-Phosphat-Dehydrogenase&amp;anchor=Section7250"" target=""_blank"">prilocaine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184234,Annotation of Swissmedic Label for vernakalant and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103113, 'title': 'Swissmedic label for vernakalant', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=61304', 'crossReferences': [{'id': 1450812074, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=61304', '_url': 'https://amiko.oddb.org/de/fi?gtin=61304'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184233', 'name': 'vernakalant'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450814446.0,"<p>The Swiss drug label for vernakalant (Brinavess) outlines the differences in venlafaxine metabolism and clearance between CYP2D6 normal metabolizers and &quot;weak metabolizers&quot; but states that these differences do not require a dose adjustment to be made.</p>
",1450814447.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for vernakalant (Brinavess):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Distribution: Vernacalant is widely and rapidly distributed in the body, the distribution volume is approximately 2 l/kg. A comparable distribution volume was observed in extensive (representing the majority of patients) and weak CYP2D6 metabolizers. The free fraction of vernacalant in human serum is 53-63% in a concentration range of 1-5 µg/ml.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Metabolism: In strong CYP2D6 metabolisers, vernacalant is metabolized predominantly by CYP2D6-mediated O-demethylation at position 4 and subsequent glucuronidation of the resulting O-demethylated metabolite. In weak CYP2D6 metabolisers, direct glucuronidation of vernacalant is a more important pathway. The main metabolites circulating in human plasma were the glucuronic acid conjugate of 4-O-demethylated vernacalant (in extensive metabolizers) and the glucuronic acid conjugate of vernacalant itself (in weak metabolizers), neither of which is pharmacologically active.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Elimination: After application of an intravenous dose of 240 mg (C)-labelled vernacalant in healthy volunteers, about 93% and 7% of the radioactivity administered to extensive metabolizers was excreted in urine and faeces, respectively. The recovery rate in weak metabolizers was 82% in urine (this slightly lower recovery rate is probably due to incomplete urine sample collection in one of the weak metabolizers) and 6% in faeces. The excretion of unmodified vernacalant in urine averaged about 8% in extensive CYP2D6 metabolizers and 23% in weak metabolizers. Extensive metabolizers had higher levels of 4-O-demethylated vernacalant in glucuronidated form in urine, whereas weak metabolizers had higher levels of vernacalant and glucuronidated vernacalant. Therefore, the elimination of vernacalant in extensive CYP2D6 metabolizers is predominantly by CYP2D6-mediated O-demethylation, whereas in weak metabolizers it is by direct glucuronidation and renal excretion.
In patients, the typical total clearance of vernacalant from the body was estimated to be 0.41 l/h/kg. The mean elimination half-life of vernakalant in patients was approximately 3 hours (extensive CYP2D6 metabolizer) and approximately 5.5 hours (weak metabolizer).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacokinetics of specific patient groups: A population kinetic analysis suggests that the CYP2D6 metabolisation status influences the clearance of vernacalant. Nevertheless, the acute exposure of vernacalant (AUC) to weak metabolizers at the recommended clinical dose is only 15.2% higher and the average plasma peak concentrations (C) only 8.1% higher than in extensive metabolizers. Therefore, dose adjustment is not necessary due to the CYP2D6 metabolisation status.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=61304&amp;highlight=Metabolisierer"" target=""_blank"">vernakalant drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184504,Annotation of Swissmedic Label for zidovudine / lamivudine / abacavir and HLA-B,False,False,[],False,"[{'id': 1452022066, 'date': '2023-02-28T14:38:33.533-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103118, 'title': 'Swissmedic label for Zidovudin, Lamivudin und Abacavir', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55537', 'crossReferences': [{'id': 1450812079, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55537', '_url': 'https://amiko.oddb.org/de/fi?gtin=55537'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165987830', 'symbol': 'HLA-B*57:01', 'name': '*57:01'}]","[{'objCls': 'Chemical', 'id': 'PA166184503', 'name': 'zidovudine / lamivudine / abacavir'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",Swissmedic,1450820454.0,"<p>The Swiss drug label for zidovudine / lamivudine / abacavir (Trizivir) states that patients should be screened for the presence of HLA-B*57:01 prior to starting treatment with abacavir. Trizivir is contraindicated in carriers of the HLA-B*57:01 allele.</p>
",1450820455.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for zidovudine / lamivudine / abacavir (Trizivir):</p>
<blockquote class=""blockquote"">
<p>Precautions:
Before initiating treatment with abacavir, HLA-B*5701 status should be determined if possible, and before resuming treatment with abacavir in patients with unknown HLA-B*5701 status who have previously tolerated abacavir.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Trizivir is contraindicated in carriers of the HLA-B*5701 allele or in patients who had suspected Abacavir HSR after treatment with another abacavir-containing drug (e.g. Ziagen, Kivexa, Triumeq), regardless of HLA-B*5701 status.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=55537&amp;highlight=HLA-B*5701-Allel"" target=""_blank"">zidovudine / lamivudine / abacavir drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450820456.0,"<blockquote class=""blockquote"">
<p>Before initiating treatment with abacavir, HLA-B*5701 status should be determined if possible, and before resuming treatment with abacavir in patients with unknown HLA-B*5701 status who have previously tolerated abacavir.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Trizivir is contraindicated in carriers of the HLA-B*5701 allele or in patients who had suspected Abacavir HSR after treatment with another abacavir-containing drug (e.g. Ziagen, Kivexa, Triumeq), regardless of HLA-B*5701 status.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184110,Annotation of Swissmedic Label for vitamin c and G6PD,False,False,[],True,"[{'id': 1452022062, 'date': '2023-02-28T14:38:09.925-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103177, 'title': 'Swissmedic label for vitamin C (CALLIMON)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=32209', 'crossReferences': [{'id': 1450813298, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=32209', '_url': 'https://amiko.oddb.org/de/fi?gtin=32209'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103178, 'title': 'Swissmedic label for vitamin C (REVITALOSE)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=53215', 'crossReferences': [{'id': 1450813299, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=53215', '_url': 'https://amiko.oddb.org/de/fi?gtin=53215'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103151, 'title': 'Swissmedic label for vitamin C (Streuli)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=25926', 'crossReferences': [{'id': 1450813247, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=25926', '_url': 'https://amiko.oddb.org/de/fi?gtin=25926'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451898', 'name': 'vitamin c'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450813592.0,"<p>The Swiss drug labels for vitamin C (Streuli, Callimon and Revitalose) state that high doses of vitamin C should be avoided in patients with G6PD deficiency.</p>
",1450813593.0,"<p><strong>Please note that the information contained within these drug label annotations are available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original labels in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for vitamin C (Streuli):</p>
<blockquote class=""blockquote"">
<p>Cautionary measures:
In individual cases of patients with erythrocytic glucose-6-phosphate dehydrogenase deficiency, severe hemolysis was observed when taking high doses of vitamin C (4 g daily). Exceeding the dose recommendations should therefore be avoided.</p>
</blockquote>
<p>Excerpt from the drug label for vitamin C (Callimon):</p>
<blockquote class=""blockquote"">
<p>Ascorbic acid overdose can lead to iron overload in patients with iron storage disorders (e.g. sideroblastic anemia, hemochromatosis) - see &quot;Contraindications&quot; - and cause hemolysis in patients with congenital erythrocyte glucose-6-phosphate dehydrogenase deficiency.</p>
</blockquote>
<p>Excerpt from the drug label for vitamin C (Revitalose):</p>
<blockquote class=""blockquote"">
<p>Contraindications:
Patients with glucose-6-phosphate dehydrogenase deficiency (risk of hemolysis) at doses of vitamin C higher than 1 g/24 h.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=25926&amp;highlight=Glucose-6-phosphat-Dehydrogenase-Mangel"" target=""_blank"">Streuli drug label</a>, the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=32209&amp;highlight=Glucose-6-Phosphat-Dehydrogenase-Mangel"" target=""_blank"">Callimon drug label</a> or the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=53215&amp;highlight=Glucose-6-Phosphat"" target=""_blank"">Revitalose drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813594.0,"<blockquote class=""blockquote"">
<p>Contraindications... Patients with glucose-6-phosphate dehydrogenase deficiency (risk of hemolysis) at doses of vitamin C higher than 1g/24 h.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Exceeding the dose recommendations should therefore be avoided.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184441,"Annotation of Swissmedic Label for dolutegravir and CYP3A4, CYP3A5, NR1I2, UGT1A1",False,False,[],False,"[{'id': 1452206923, 'date': '2023-08-15T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15103262, 'title': 'Swissmedic label for dolutegravir', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=66790', 'crossReferences': [{'id': 1450815645, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=66790', '_url': 'https://amiko.oddb.org/de/fi?gtin=66790'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103263, 'title': 'Swissmedic label for dolutegravir, abacavir und lamivudine (Triumeq)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=63283', 'crossReferences': [{'id': 1450815647, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=63283', '_url': 'https://amiko.oddb.org/de/fi?gtin=63283'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166114961', 'name': 'dolutegravir'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}, {'objCls': 'Gene', 'id': 'PA131', 'symbol': 'CYP3A5', 'name': 'cytochrome P450 family 3 subfamily A member 5'}, {'objCls': 'Gene', 'id': 'PA378', 'symbol': 'NR1I2', 'name': 'nuclear receptor subfamily 1 group I member 2'}, {'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",Swissmedic,1450815673.0,"<p>The Swiss drug label for dolutegravir (Julica) states that there is no evidence that gene variants of UGT1A1, CYP3A4, CYP3A5 and NR1I2 have clinically relevant effects.</p>
",1450815674.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for dolutegravir (Julica):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
There is no evidence that frequently occurring polymorphisms of drug metabolizing enzymes have a clinically relevant effect on the pharmacokinetics of dolutegravir. In a meta-analysis of data from healthy subjects sampled for pharmacogenomic studies in clinical trials, individuals with UGT1A1 genotypes causing slow dolutegravir metabolism (n = 7) had 32% lower dolutegravir clearance and 46% higher AUC than individuals with genotypes associated with normal UGT1A1 mediated metabolism (n = 41). Polymorphisms of CYP3A4, CYP3A5 and NR1I2 were not associated with differences in the pharmacokinetics of dolutegravir.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=66790&amp;highlight=Polymorphismen"" target=""_blank"">dolutegravir drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166182951,Annotation of EMA Label for glyburide and G6PD,True,False,[],False,"[{'id': 1452534920, 'date': '2024-07-22T14:14:39.686-07:00', 'description': 'added Other Guidance tag, info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102951, 'title': 'Amglidia | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/amglidia', 'crossReferences': [{'id': 1450417107, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/amglidia', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/amglidia'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449782', 'name': 'glyburide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",EMA,1450417104.0,"<p>The EMA European Public Assessment Report (EPAR) for glibenclamide (AMGLIDIA) states that it should not be prescribed in patients with G6PD deficiency, and that use of an alternative treatment is strongly recommended.</p>
",1450417105.0,"<p>Excerpts from the glibenclamide (AMGLIDIA) EPAR:</p>
<div class=""blockquote"">
<p>In patients carrying a G6PD enzyme deficiency, cases of acute haemolytic anaemia have been reported with glibenclamide. It should therefore not be prescribed for these patients, and the use of an alternative treatment is strongly recommended, if available. If there is no alternative, the decision for each patient must consider the danger of haemolysis and the potential benefit expected from the treatment. If it is necessary to prescribe this medicinal product, screening should be conducted for the occurrence of any haemolysis.</p>
</div>
<div class=""blockquote"">
<p>Warnings and precautions...G6PD is an enzyme evolved in sugar metabolism. If your child carries a G6PD enzyme deficiency, he/she may experiment an abnormal breakdown of red blood cells (acute haemolytic anaemia) after taking AMGLIDIA. Tell the doctor if you know that your child is affected by G6PD deficiency and contact him/her if you notice that your child is pale as compared to usually.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Glibenclamide_06_21_19_EMA.pdf"">glibenclamide EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450417106.0,"<blockquote class=""blockquote"">
<p>In patients carrying a G6PD enzyme deficiency, cases of acute haemolytic anaemia have been reported with glibenclamide. It should therefore not be prescribed for these patients, and the use of an alternative treatment is strongly recommended, if available.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>If it is necessary to prescribe this medicinal product, screening should be conducted for the occurrence of any haemolysis.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166183183,"Annotation of EMA Label for lidocaine / prilocaine and CYB5R3, G6PD",False,False,[],False,"[{'id': 1452536581, 'date': '2024-07-23T16:27:30.532-07:00', 'description': 'added CYB5R3 gene, Other Guidance tag and prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102978, 'title': 'Fortacin | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/fortacin', 'crossReferences': [{'id': 1450607985, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/fortacin', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/fortacin'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166176018', 'name': 'lidocaine / prilocaine'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",EMA,1450607983.0,"<p>The EMA European Public Assessment Report (EPAR) for lidocaine and prilocaine (Fortacin) states that patients or their partner with G6PD deficiency are more susceptible to methemoglobinemia, and caution should be exercised.</p>
",1450607984.0,"<p>Fortacin is a cutaneous spray indicated for the treatment of primary premature ejaculation in adult men. Excerpts from the lidocaine and prilocaine (Fortacin) EPAR:</p>
<blockquote class=""blockquote"">
<p>Patients or their partner with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methaemoglobinaemia are more susceptible to medicinal product-induced methaemoglobinaemia (see section 4.5).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Although the systemic availability of prilocaine by cutaneous absorption of Fortacin is low, caution should be exercised in patients with anaemia, congenital or acquired methaemoglobinaemia or patients on concomitant therapy known to produce such conditions.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Talk to your doctor or pharmacist before using Fortacin</p>
<ul>
<li>if you, or your partner, have been diagnosed with a genetic disease or other condition affecting your red blood cells (glucose-6-phosphate deficiency, anaemia or methaemoglobinaemia)</li>
</ul>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Lidocaine_prilocaine_2024_07_23_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lidocaine_prilocaine_2024_07_23_EMA.pdf"">lidocaine and prilocaine EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452536580.0,"<blockquote class=""blockquote"">
<p>Although the systemic availability of prilocaine by cutaneous absorption of Fortacin is low, caution should be exercised in patients with anaemia, congenital or acquired methaemoglobinaemia or patients on concomitant therapy known to produce such conditions.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166182950,Annotation of EMA Label for gefitinib and CYP2D6,False,False,[],False,"[{'id': 1452550207, 'date': '2024-08-07T10:29:06.999-07:00', 'description': 'added Other Guidance tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102977, 'title': 'Iressa | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/iressa', 'crossReferences': [{'id': 1450417098, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/iressa', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/iressa'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA131301952', 'name': 'gefitinib'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1450417099.0,"<p>The EMA European Public Assessment Report (EPAR) for gefitinib (IRESSA) states that no specific dose adjustment is recommended in patients with known CYP2D6 poor metabolizer genotype, but these patients should be closely monitored for adverse events. The EPAR also states that mean exposure to gefitinib was 2-fold higher in poor metabolizers as compared to extensive metabolizers, and that these higher exposures may be clinically relevant.</p>
",1450417100.0,"<p>Excerpts from the gefitinib (IRESSA) EPAR:</p>
<div class=""blockquote"">
<p>No specific dose adjustment is recommended in patients with known CYP2D6 poor metaboliser genotype, but these patients should be closely monitored for adverse events.</p>
</div>
<div class=""blockquote"">
<p>In individual patients with CYP2D6 poor metaboliser genotype, treatment with a potent CYP3A4 inhibitor might lead to increased plasma levels of gefitinib. At initiation of treatment with a CYP3A4 inhibitor, patients should be closely monitored for gefitinib adverse reactions.</p>
</div>
<div class=""blockquote"">
<p>The formation of O-desmethyl gefitinib has been shown, in vitro, to be via CYP2D6. The role of CYP2D6 in the metabolic clearance of gefitinib has been evaluated in a clinical trial in healthy volunteers genotyped for CYP2D6 status. In poor metabolisers no measurable levels of O-desmethyl gefitinib were produced. The levels of exposure to gefitinib achieved in both the extensive and the poor metaboliser groups were wide and overlapping but the mean exposure to gefitinib was 2-fold higher in the poor metaboliser group. The higher average exposures that could be achieved by individuals with no active CYP2D6 may be clinically relevant since adverse effects are related to dose and exposure.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Gefitinib_06_21_19_EMA.pdf"">gefitinib EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450417101.0,"<p>&quot;No specific dose adjustment is recommended in patients with known CYP2D6 poor metaboliser genotype, but these patients should be closely monitored for adverse events.&quot;</p>
",,,,,,,
Label Annotation,PA166182945,Annotation of EMA Label for efavirenz and CYP2B6,False,False,[],False,[],False,[],True,"[{'id': 15102930, 'title': 'Sustiva | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/sustiva', 'crossReferences': [{'id': 1450416974, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/sustiva', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/sustiva'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165818750', 'symbol': 'CYP2B6*1', 'name': '*1'}, {'objCls': 'Haplotype', 'id': 'PA165818762', 'symbol': 'CYP2B6*6', 'name': '*6'}, {'objCls': 'Variant', 'id': 'PA166155409', 'symbol': 'rs3745274', 'name': 'rs3745274'}]","[{'objCls': 'Chemical', 'id': 'PA449441', 'name': 'efavirenz'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}]",EMA,1450416972.0,"<p>The EMA European Public Assessment Report (EPAR) for efavirenz (Sustiva) states that patients with the CYP2B6*6/*6 genotype had higher Cmax as compared to patients with the CYP2B6*1/*1 genotype, and the mean QTc prolongation was 8.7 ms. The label also notes that plasma exposure may be increased in patients with the rs3745274 TT genotype (G516T).</p>
",1450416973.0,"<p>Excerpts from the efavirenz (Sustiva) EPAR:</p>
<div class=""blockquote"">
<p>The effect of efavirenz on the QTc interval was evaluated in an open-label, positive and placebo controlled, fixed single sequence 3-period, 3-treatment crossover QT study in 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean Cmax of efavirenz in subjects with CYP2B6 *6/*6 genotype following the administration of 600 mg daily dose for 14 days was 2.25-fold the mean Cmax observed in subjects with CYP2B6 *1/*1 genotype. A positive relationship between efavirenz concentration and QTc prolongation was observed. Based on the concentration-QTc relationship, the mean QTc prolongation and its upper bound 90% confidence interval are 8.7 ms and 11.3 ms in subjects with CYP2B6*6/*6 genotype following the administration of 600 mg daily dose for 14 days...</p>
</div>
<div class=""blockquote"">
<p>Efavirenz plasma exposure may be increased in patients with the homozygous G516T genetic variant of the CYP2B6 isoenzyme. The clinical implications of such an association are unknown; however, the potential for an increased frequency and severity of efavirenz-associated adverse events cannot be excluded.</p>
</div>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Efavirenz_06_20_19_EMA.pdf"">efavirenz EPAR PDF</a></p>
<p><strong>Note: The EPAR for <a rel=""noopener noreferrer"" href=""https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-teva"" target=""_blank"">efavirenz (Teva)</a> also contains information about the effect of the G516T variant on efavirenz plasma exposure. However, the label does not discuss the effect of CYP2B6*6 on Cmax or QTc prolongation.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166183171,Annotation of EMA Label for lacosamide and CYP2C19,False,False,[],False,"[{'id': 1452824081, 'date': '2025-01-24T10:05:16.924-08:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102955, 'title': 'Vimpat | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat', 'crossReferences': [{'id': 1450593230, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166160048', 'name': 'lacosamide'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",EMA,1450593228.0,"<p>The EMA European Public Assessment Report (EPAR) for lacosamide (Vimpat) states that no clinically relevant difference in lacosamide exposure was seen when comparing CYP2C19 extensive metabolizers and CYP2C19 poor metabolizers.</p>
",1450593229.0,"<p>Excerpt from the lacosamide (Vimpat) EPAR:</p>
<blockquote class=""blockquote"">
<p><em>In vitro</em> data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite but the main contributing isoenzyme has not been confirmed <em>in vivo</em>. No clinically relevant difference in lacosamide exposure was observed comparing its pharmacokinetics in extensive metabolisers (EMs, with a functional CYP2C19) and poor metabolisers (PMs, lacking a functional CYP2C19).</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Lacosamide_2025_01_24_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lacosamide_2025_01_24_EMA.pdf"">lacosamide EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",1452824080.0,"<blockquote class=""blockquote"">
<p>Vimpat is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Vimpat is indicated as adjunctive therapy</p>
<ul>
<li>in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.</li>
<li>in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.</li>
</ul>
</blockquote>
",1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166353201,Annotation of FDA Label for resmetirom and ABCG2,False,False,[],False,[],False,[],True,"[{'id': 15166442, 'title': 'Drugs@FDA: Drug Product REZDIFFRA (Resmetirom), Madrigal Pharmaceuticals, Inc. - NDA217785/ORIG-1, 03/14/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217785', 'crossReferences': [{'id': 1452612281, 'resource': 'FDA Application', 'resourceId': 'NDA217785/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217785'}], 'objCls': 'Literature', 'pubDate': '2024-03-14T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166156543', 'symbol': 'rs2231137', 'name': 'rs2231137'}, {'objCls': 'Variant', 'id': 'PA166156544', 'symbol': 'rs2231142', 'name': 'rs2231142'}]","[{'objCls': 'Chemical', 'id': 'PA166353181', 'name': 'resmetirom'}]","[{'objCls': 'Gene', 'id': 'PA390', 'symbol': 'ABCG2', 'name': 'ATP binding cassette subfamily G member 2 (JR blood group)'}]",FDA,1452612282.0,"<p>The FDA-approved drug label for resmetirom (REZDIFFRA) states that there were no clinically significant differences in the pharmacokinetics based on ABCG2 genotype.</p>
",1452612283.0,"<p>Excerpts from the resmetirom (REZDIFFRA) label:</p>
<blockquote class=""blockquote"">
<p>Resmetirom is metabolized by CYP2C8 and is not metabolized by other CYP enzymes in vitro.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>No clinically significant differences in the pharmacokinetics of resmetirom were observed based on age (18 to 83 years), sex, race (White, Black, or Asian), or ABCG2 genotype (BCRP p.Gln141Lys, p.Val12Met).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Resmetirom_2024_09_27_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Resmetirom_2024_09_27_FDA.pdf"">resmetirom drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166353203,Annotation of EMA Label for resmetirom,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166353181', 'name': 'resmetirom'}]",[],EMA,,,1452612287.0,"<p>As of October 4, 2024, the EMA website shows a &quot;paediatric investigation plan&quot; (PIP number EMEA-003087-PIP01-21) for resmetirom with a decision date of October 28, 2022.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166353242,Annotation of HCSC Label for tislelizumab,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166353221', 'name': 'tislelizumab'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166353281,Annotation of EMA Label for tovorafenib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166345561', 'name': 'tovorafenib'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166353282,Annotation of HCSC Label for tovorafenib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166345561', 'name': 'tovorafenib'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166283201,Annotation of HCSC Label for mivacurium and BCHE,True,False,[],False,"[{'id': 1452539262, 'date': '2024-07-25T11:34:23.070-07:00', 'description': 'retired annotation; drug is listed as cancelled post-market by HCSC', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162042, 'title': 'Drugs@HCSC: Drug Product MIVACRON (mivacurium), AbbVie Corporation', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00018113.PDF', 'crossReferences': [{'id': 1452539260, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00018113.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00018113.PDF'}], 'notes': 'Current status: Cancelled Post Market, Current status date: 2012-11-03', 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450528', 'name': 'mivacurium'}]","[{'objCls': 'Gene', 'id': 'PA25294', 'symbol': 'BCHE', 'name': 'butyrylcholinesterase'}]",HCSC,1451941123.0,"<p>The HCSC product monograph for Mivacurium contraindicates use in patients who are known or suspected to be homozygotes for the atypical plasma cholinesterase gene, <a href=""/gene/PA25294"">BCHE</a>.</p>
<p><strong>Please note that as of July 2024, mivacurium is listed as Cancelled Post Market on the HCSC database. As a result, this label annotation has been retired.</strong></p>
",1451941124.0,"<p>Excerpts from the Mivacurium (<em><strong>MIVACRON</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>MIVACRON is not recommended for patients who are known or suspected to be homozygotes for
the atypical plasma cholinesterase gene.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Hydrolysis by plasma cholinesterase is the primary mechanism for inactivation of mivacurium</p>
</blockquote>
<p><strong>Please note that as of July 2024, mivacurium is listed as Cancelled Post Market on the HCSC database. As a result, this label annotation has been retired.</strong></p>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Mivacurium_HCSC_2022_11_15.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Mivacurium_HCSC_2022_11_15.pdf""><em><strong>Mivacurium</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452539261.0,"<blockquote class=""blockquote"">
<p>MIVACRON is not recommended for patients who are known or suspected to be homozygotes for the atypical plasma cholinesterase gene.</p>
</blockquote>
",1451832060.0,Retirement Reason,[],Other,retirement:1451832060,True,
Label Annotation,PA166353781,Annotation of EMA Label for dextromethorphan hydrobromide / bupropion hydrochloride,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166278341', 'name': 'dextromethorphan hydrobromide / bupropion hydrochloride'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166353801,Annotation of HCSC Label for dextromethorphan hydrobromide / bupropion hydrochloride,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166278341', 'name': 'dextromethorphan hydrobromide / bupropion hydrochloride'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166353861,Annotation of FDA Label for xanomeline / trospium and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15166822, 'title': 'Drugs@FDA: Drug Product COBENFY (xanomeline and trospium chloride), NDA216158/ORIG-1, 09/26/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216158', 'crossReferences': [{'id': 1452623201, 'resource': 'FDA Application', 'resourceId': 'NDA216158/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216158'}], 'objCls': 'Literature', 'pubDate': '2024-09-26T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166353841', 'name': 'xanomeline / trospium'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1452623360.0,"<p>COBENFY is a combination of xanomeline and trospium chloride, both muscarinic antagonists, and is indicated for the treatment of schizophrenia in adults. The FDA-approved label states that CYP2D6 polymorphisms impact pharmacokinetic parameters of xanomeline.</p>
",1452623361.0,"<p>Excerpt from the xanomeline and trospium chloride (COBENFY) label:</p>
<blockquote class=""blockquote"">
<p>CYP2D6 is a significant contributor to the metabolism of xanomeline. The gene encoding CYP2D6 has polymorphisms that impact protein function. Based on a population pharmacokinetic analysis, compared to subjects with normal CYP2D6 function, the median Cmax and median AUC0-12h of xanomeline were estimated to increase by 28% and 15% in CYP2D6 intermediate metabolizers (N=84) and decrease by 43% in both parameters for ultrarapid metabolizers (N=12). The pharmacokinetics of xanomeline have not been adequately characterized in subjects who are poor metabolizers.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Xanomeline_and_trospium_chloride_2024_10_03_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Xanomeline_and_trospium_chloride_2024_10_03_FDA.pdf"">xanomeline and trospium chloride drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166284101,Annotation of HCSC Label for erdafitinib and CYP2C9,False,False,[],False,"[{'id': 1452549201, 'date': '2024-08-06T15:05:53.405-07:00', 'description': 'updated label, added Other Guidance tag', 'type': 'Update', 'version': 0}, {'id': 1452623520, 'date': '2024-10-03T17:26:18.952-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15163082, 'title': 'Drugs@HCSC: Drug Product BALVERSA (erdafitinib), Janssen Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'crossReferences': [{'id': 1452549200, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]","[{'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA166182720', 'name': 'erdafitinib'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",HCSC,1451952300.0,"<p>The HCSC product monograph for erdafitinib states that erdafitinib plasma concentrations were predicted to be higher in patients with the CYP2C9*3/*3 genotype and to monitor for increased adverse reactions in patients who are known to have CYP2C9*3/*3 genotype.</p>
",1451952301.0,"<p>Excerpts from the erdafitinib (BALVERSA) product monograph:</p>
<blockquote class=""blockquote"">
<p>Erdafitinib is primarily metabolized in humans by CYP2C9 and CYP3A4 to form the O-demethylated major metabolite. The contribution of CYP2C9 and CYP3A4 in the total clearance of erdafitinib is estimated to be 39% and 20% respectively.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Simulation suggested that the exposure of erdafitinib is predicted to increase in subjects of CYP2C9 *3/*3 genotype. Patients known to have this genotype should be monitored for increased adverse reactions.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Erdafitinib_2024_10_03_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Erdafitinib_2024_10_03_HCSC.pdf"">erdafitinib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451952320.0,"<p>Excerpt from the erdafitinib (BALVERSA) product monograph:</p>
<blockquote class=""blockquote"">
<p>Simulation suggested that the exposure of erdafitinib is predicted to increase in subjects of CYP2C9 *3/*3 genotype. Patients known to have this genotype should be monitored for increased adverse reactions.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166353941,Annotation of FDA Label for quinine and G6PD,True,False,[],False,[],False,[],True,"[{'id': 15101955, 'title': 'Drugs@FDA: Drug Product Quinine Sulfate (Quinine Sulfate), Sun Pharmaceutical Industries, Inc. - NDA021799/SUPPL-29, 06/19/2019', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021799', 'crossReferences': [{'id': 1452624400, 'resource': 'FDA Application', 'resourceId': 'NDA021799/SUPPL-29', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021799'}], 'notes': 'Listed as Marketing Status Discontinued as of 10/4/2024; however, an active DailyMed entry is available: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c44c8b7-8b38-4487-a8ba-a94f708d1f50', 'objCls': 'Literature', 'pubDate': '2019-06-19T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15167002, 'title': 'DailyMed - QUALAQUIN- quinine sulfate capsule', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c44c8b7-8b38-4487-a8ba-a94f708d1f50', 'crossReferences': [{'id': 1452624420, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '1c44c8b7-8b38-4487-a8ba-a94f708d1f50', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c44c8b7-8b38-4487-a8ba-a94f708d1f50'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15166982, 'title': 'DailyMed - QUININE SULFATE capsule (Lupin Pharmaceuticals Inc.)', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f32f05c-a215-40be-b951-e41a7b54a8a0', 'crossReferences': [{'id': 1452624360, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '1f32f05c-a215-40be-b951-e41a7b54a8a0', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f32f05c-a215-40be-b951-e41a7b54a8a0'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451213', 'name': 'quinine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1452624421.0,"<p>Quinine is an antimalarial indicated for treatment of uncomplicated <em>Plasmodium falciparum</em> malaria. G6PD is mentioned in the Warnings and Precautions section of the label. The information present on current drug labels differ; glucose-6-phosphate dehydrogenase (G6PD) deficiency as a contraindication was removed from the QUALAQUIN label in 6/2019, while it is present on the generic quinine sulfate label by Lupin Pharmaceuticals from 10/2023.</p>
",1452624422.0,"<p>Excerpts from the quinine sulfate (Lupin Pharmaceuticals Inc.) label:</p>
<blockquote class=""blockquote"">
<p>Quinine sulfate capsule USP is an antimalarial drug indicated only for treatment of uncomplicated <em>Plasmodium falciparum</em> malaria.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Quinine sulfate is contraindicated in patients with the following: [...]
Glucose-6-phosphate dehydrogenase (G6PD) deficiency [...]</p>
</blockquote>
<p>Excerpts from the quinine sulfate (QUALAQUIN) label:</p>
<blockquote class=""blockquote"">
<p>Contraindications, Glucose-6-phosphate dehydrogenase (G6PD) deficiency (4) Removed 6/2019</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Acute hemolytic anemia has been reported in patients receiving quinine for treatment of malaria, including patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The cause for the acute hemolytic anemia in quinine-treated patients with malaria and its potential relationship with G6PD deficiency has not been determined. Closely monitor hemoglobin and hematocrit during quinine treatment. Quinine should be discontinued if patients develop acute hemolytic anemia.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Quinine_2024_10_04_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Quinine_2024_10_04_FDA.pdf"">quinine sulfate drug label (Lupin Pharmaceuticals Inc.)</a> and the <a download=""quinine_sulfate_10_17_2019FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/quinine_sulfate_10_17_2019FDA.pdf"">quinine sulfate drug label (QUALAQUIN)</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452624423.0,"<p>Excerpt from the quinine sulfate (Lupin Pharmaceuticals Inc.) label:</p>
<blockquote class=""blockquote"">
<p>Quinine sulfate is contraindicated in patients with the following: [...]
Glucose-6-phosphate dehydrogenase (G6PD) deficiency [...]</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166357541,Annotation of HCSC Label for dronabinol,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449421', 'name': 'dronabinol'}]",[],HCSC,,,1452690980.0,"<p>As of November 2024, all dronabinol drug products have a &quot;Cancelled Post Market&quot; status on the HCSC website.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166357561,Annotation of HCSC Label for enasidenib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177484', 'name': 'enasidenib'}]",[],HCSC,,,1452691001.0,"<p>As of November 2024, all enasidenib drug products have a &quot;Cancelled Post Market&quot; status on the HCSC website.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166357681,Annotation of HCSC Label for desipramine,False,False,[],False,[],False,[],True,"[{'id': 15169242, 'title': 'Drugs@HCSC: Drug Product DESIPRAMINE (desipramine), AA PHARMA INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20014', 'crossReferences': [{'id': 1452690780, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20014', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20014'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA449233', 'name': 'desipramine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166357721,"Annotation of HCSC Label for doxepin and CYP2C19, CYP2D6",False,False,[],False,[],False,[],True,"[{'id': 15169302, 'title': 'Drugs@HCSC: Drug Product SILENOR (doxepin), Paladin Labs Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88319', 'crossReferences': [{'id': 1452690960, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88319', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88319'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449409', 'name': 'doxepin'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452693521.0,"<p>The HCSC-approved product monograph for doxepin (SILENOR) notes that CYP2D6 and CYP2C19 poor metabolizers may have higher doxepin plasma levels than normal metabolizers.</p>
",1452693522.0,"<p>Excerpts from the doxepin (SILENOR) product monograph:</p>
<blockquote class=""blockquote"">
<p><em>In vitro</em> studies have shown that CYP2C19 and CYP2D6 are the major enzymes involved in doxepin metabolism, and that CYP1A2 and CYP2C9 are involved to a lesser extent.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Poor metabolizers of CYP2C19 and CYP2D6 may have higher doxepin plasma levels than normal subjects.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Doxepin_2024_11_05_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Doxepin_2024_11_05_HCSC.pdf"">doxepin product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166357728,Annotation of HCSC Label for fluoxetine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15169402, 'title': 'Drugs@HCSC: Drug Product NRA-FLUOXETINE (fluoxetine), Nora Pharma Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99331', 'crossReferences': [{'id': 1452692020, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99331', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99331'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449673', 'name': 'fluoxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452693548.0,"<p>Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder, obsessive compulsive disorder, bulimia nervosa, and panic disorder. Fluoxetine is primarily metabolized by CYP2D6. Both the pharmacokinetic properties and relative proportion of metabolites of fluoxetine may be affected by a patient’s CYP2D6 pharmacogenetic phenotype, or by a number of different drugs known to inhibit the CYP2D6 enzyme.</p>
",1452693549.0,"<p>Excerpts from the fluoxetine product monograph:</p>
<blockquote class=""blockquote"">
<p>Both the pharmacokinetic properties and relative proportion of metabolites of fluoxetine may be affected by a patient’s CYP2D6 pharmacogenetic phenotype, or by a number of different drugs known to inhibit the CYP2D6 enzyme.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A double-blind, placebo-controlled, randomised, multiple dose study was performed in two cohorts of healthy adult subjects (CYP2D6 intermediate and extensive metabolizers). In the first cohort, subjects received once-daily oral dosing for 28 days with fluoxetine 20 mg (N = 12) or placebo (N = 4), whilst in the second cohort, subjects received once-daily oral dosing for 28 days with fluoxetine 40 mg (N = 12) or placebo (N = 4). Serial ECG assessments were performed at baseline and on days 1 and 28 of treatment. For the 40 mg fluoxetine treatment (N = 12), the maximal mean difference from placebo in change from time- averaged baseline in QTcF (QT/RR0.33) was 12.005 msec (90% CI 4.412, 19.598) on day 28. For the 20-mg treatment, the corresponding placebo-adjusted increase in the QTcF interval was 4.841 msec (90% CI -4.009, 13.69) (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular; 8.2 Clinical Trial Adverse Reactions, ECG Findings &amp; 8.5 Post-Market Adverse Reactions; 9 DRUG INTERACTIONS).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Fluoxetine_2024_11_06_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Fluoxetine_2024_11_06_HCSC.pdf"">fluoxetine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166357732,Annotation of HCSC Label for fluvoxamine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15169462, 'title': 'Drugs@HCSC: Drug Product TEVA-FLUVOXAMINE (fluvoxamine), Teva Canada Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74072', 'crossReferences': [{'id': 1452692100, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74072', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74072'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449690', 'name': 'fluvoxamine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452693561.0,"<p>The HCSC-approved product monograph for fluvoxamine states that it is mainly metabolized by CYP2D6, and that caution is indicated in patients with reduced levels of CYP2D6 activity.</p>
",1452693562.0,"<p>Excerpt from the fluvoxamine product monograph:</p>
<blockquote class=""blockquote"">
<p>Fluvoxamine is mainly metabolized by CYP2D6.
Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6. Such individuals have been referred to as &quot;poor metabolizers&quot; (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants. A study of fluvoxamine (100 mg) single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 &quot;extensive metabolizers&quot; (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine, buproprion, fluoxetine, paroxetine, cinacalcet).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Fluvoxamine_2024_11_06_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Fluvoxamine_2024_11_06_HCSC.pdf"">fluvoxamine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452693563.0,"<p>Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine, buproprion, fluoxetine, paroxetine, cinacalcet).</p>
",,,,,,,
Label Annotation,PA166357726,Annotation of HCSC Label for flibanserin and CYP2C19,False,False,[],False,[],False,[],True,"[{'id': 15169382, 'title': 'Drugs@HCSC: Drug Product ADDYI (flibanserin), Searchlight Pharma Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00059744.PDF', 'crossReferences': [{'id': 1452691986, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00059744.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00059744.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166153431', 'name': 'flibanserin'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1452693539.0,"<p>The product monograph for flibanserin (ADDYI) states that CYP2C19 poor metabolizers had increased exposure to the drug as compared to extensive metabolizers, which may increase risk of adverse reactions such as hypotension and syncope. The label states to increase monitoring for adverse reactions in patients who are CYP2C19 poor metabolizers.</p>
",1452693540.0,"<p>Excerpts from the flibanserin (ADDYI) product monograph:</p>
<blockquote class=""blockquote"">
<p>CYP2C19 poor metabolizers had increased flibanserin exposures compared to CYP2C19 extensive metabolizers (see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY). Therefore, increase monitoring for adverse reactions (e.g., hypotension and syncope) in patients who are CYP2C19 poor metabolizers (see WARNINGS AND PRECAUTIONS/Endocrine and Metabolism/Genetic Polymorphism).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genetic polymorphism: CYP2C19 poor metabolizers had increased flibanserin exposures compared to CYP2C19 extensive metabolizers. In a study with 9 subjects who were poor CYP2C19 metabolizers, syncope occurred in one subject (see DRUG INTERACTIONS; CLINICAL PHARMACOLOGY). Therefore, increase monitoring for adverse reactions (e.g., hypotension, dizziness, syncope, etc.) in patients who are CYP2C19 poor metabolizers. The frequencies of poor CYP2C19 metabolizers are approximately 2-5% among Caucasians and Africans and approximately 2–15% among Asians.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Special Populations and Conditions</strong></p>
<ul>
<li><strong>Genetic Polymorphism:</strong> Patients who are CYP2D6, CYP2C9 or CYP2C19 poor metabolizers are deficient in CYP2D6, CYP2C9 or CYP2C19 enzyme activity, respectively. Extensive metabolizers have normal functioning CYP enzymes. [...]
CYP2C19 Poor Metabolizers
A study comparing flibanserin exposure in CYP2C19 poor metabolizers to CYP2C19 extensive metabolizers was conducted in lieu of a drug interaction study with ADDYI and a strong CYP2C19 inhibitor. In 9 women who were CYP2C19 poor metabolizers, Cmax and AUC0-∞ of flibanserin 100 mg once daily increased 1.5-fold (1.1-2.1) and 1.3-fold (0.9-2.1), compared to exposures among 8 CYP2C19 extensive metabolizers. Flibanserin half-life was increased from 11.1 hours in the CYP2C19 extensive metabolizers to 13.5 hours in the CYP2C19 poor metabolizers. The frequencies of CYP2C19 poor metabolizers are approximately 2–5% among Caucasians and Africans and approximately 2–15% among Asians (see WARNINGS AND PRECAUTIONS/Endocrine and Metabolism).</li>
</ul>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Flibanserin_2024_11_06_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Flibanserin_2024_11_06_HCSC.pdf"">flibanserin product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452693541.0,"<blockquote class=""blockquote"">
<p>CYP2C19 poor metabolizers had increased flibanserin exposures compared to CYP2C19 extensive metabolizers [...]. Therefore, increase monitoring for adverse reactions (e.g., hypotension and syncope) in patients who are CYP2C19 poor metabolizers</p>
</blockquote>
",,,,,,,
Label Annotation,PA166357727,"Annotation of HCSC Label for flibanserin and CYP2C9, CYP2D6",False,False,[],False,[],False,[],True,"[{'id': 15169382, 'title': 'Drugs@HCSC: Drug Product ADDYI (flibanserin), Searchlight Pharma Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00059744.PDF', 'crossReferences': [{'id': 1452691986, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00059744.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00059744.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166153431', 'name': 'flibanserin'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452693544.0,"<p>The product monograph for flibanserin (ADDYI) notes the influence of CYP2D6 and CYP2C9 metabolizer phenotypes on flibanserin exposure.</p>
",1452693545.0,"<p>Excerpts from the flibanserin (ADDYI) product monograph:</p>
<blockquote class=""blockquote"">
<p><strong>Special Populations and Conditions</strong></p>
<ul>
<li><strong>Genetic Polymorphism:</strong> Patients who are CYP2D6, CYP2C9 or CYP2C19 poor metabolizers are deficient in CYP2D6, CYP2C9 or CYP2C19 enzyme activity, respectively. Extensive metabolizers have normal functioning CYP enzymes.</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 Poor Metabolizers
A study comparing flibanserin exposure in CYP2D6 poor metabolizers to CYP2D6 extensive metabolizers was conducted in addition to a drug interaction study with paroxetine, a strong CYP2D6 inhibitor. In 12 CYP2D6 poor metabolizers, steady state Cmax and AUC of flibanserin 50 mg twice daily was decreased by 4% and increased by 18%, respectively, compared to exposures among 19 CYP2D6 extensive metabolizers, intermediate metabolizers and ultra-rapid metabolizers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C9 Poor Metabolizers
A study comparing flibanserin exposure in CYP2C9 poor metabolizers to CYP2C9 extensive metabolizers was conducted in lieu of a drug interaction study with ADDYI and a strong CYP2C9 inhibitor. In 8 women who were CYP2C9 poor metabolizers, Cmax and AUC0-∞ of flibanserin 100 mg once daily decreased 23% and 18%, compared to exposures among 8 CYP2C9 extensive metabolizers.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Flibanserin_2024_11_06_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Flibanserin_2024_11_06_HCSC.pdf"">flibanserin product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166357729,Annotation of HCSC Label for flurbiprofen and CYP2C9,False,False,[],False,"[{'id': 1452833660, 'date': '2025-02-03T11:45:32.031-08:00', 'description': 'removed Dosing Info tag; dosage guidance is based on age, not CYP2C9 metabolizer phenotype', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15169422, 'title': 'Drugs@HCSC: Drug Product FLURBIPROFEN (flurbiprofen), AA PHARMA INC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11466', 'crossReferences': [{'id': 1452692060, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11466', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11466'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449683', 'name': 'flurbiprofen'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",HCSC,1452693552.0,"<p>The product monograph for flurbiprofen states that consideration should be given to reducing the starting dose in elderly patients; patients who are known or suspected to be poor CYP2C9 metabolizers should be administered flurbiprofen with caution as they may have abnormally high plasma levels due to reduced metabolic clearance.</p>
",1452693553.0,"<p>Excerpt from the flurbiprofen product monograph:</p>
<blockquote class=""blockquote"">
<p>Consideration should be given to reducing the starting dose in elderly patients. Flurbiprofen metabolism is predominantly mediated via cytochrome P450 CYP 2C9 in the liver. Patients who are known or suspected to be poor CYP2C9 metabolizers based on previous history/experience with other CYP2C9 substrates should be administered flurbiprofen with caution as they may have abnormally high plasma levels due to reduced metabolic clearance.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Flurbiprofen_2024_11_06_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Flurbiprofen_2024_11_06_HCSC.pdf"">flurbiprofen product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452693554.0,"<blockquote class=""blockquote"">
<p>Patients who are known or suspected to be poor CYP2C9 metabolizers based on previous history/experience with other CYP2C9 substrates should be administered flurbiprofen with caution as they may have abnormally high plasma levels due to reduced metabolic clearance.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166357682,Annotation of HCSC Label for desvenlafaxine,False,False,[],False,[],False,[],True,"[{'id': 15169262, 'title': 'Drugs@HCSC: Drug Product PRISTIQ (desvenlafaxine), Pfizer Canada ULC, Licensee', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80650', 'crossReferences': [{'id': 1452690860, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80650', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80650'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958374', 'name': 'desvenlafaxine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166357724,Annotation of HCSC Label for estradiol / progesterone,False,False,[],False,[],False,[],True,"[{'id': 15169362, 'title': 'Drugs@HCSC: Drug Product BIJUVA (estradiol/progesterone), Knight Therapeutics Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99458', 'crossReferences': [{'id': 1452691923, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99458', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99458'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA166190221', 'name': 'estradiol / progesterone'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166357730,Annotation of HCSC Label for flutamide,False,False,[],False,[],False,[],True,"[{'id': 15169442, 'title': 'Drugs@HCSC: Drug Product FLUTAMIDE (flutamide), AA PHARMA INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61987', 'crossReferences': [{'id': 1452692080, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61987', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61987'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA449685', 'name': 'flutamide'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166357701,"Annotation of HCSC Label for diazepam and CYP2C19, CYP3A4",False,False,[],False,[],False,[],True,"[{'id': 15169282, 'title': 'Drugs@HCSC: Drug Product DIASTAT (diazepam), Bausch Health, Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61553', 'crossReferences': [{'id': 1452690920, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61553', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61553'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15169283, 'title': 'Drugs@HCSC: Drug Product VALIUM (diazepam), Searchlight Pharma Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3178', 'crossReferences': [{'id': 1452690921, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3178', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3178'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449283', 'name': 'diazepam'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",HCSC,1452693500.0,"<p>The HCSC product monographs for diazepam (DIASTAT and VALIUM) note that the drug is metabolized by CYP2C19 and CYP3A4, and that inter-individual variation in clearance of the drug is likely attributable to genetic polymorphism of CYP2C19 and CYP3A4.</p>
",1452693501.0,"<p>Excerpts from the diazepam (DIASTAT) product monograph:</p>
<blockquote class=""blockquote"">
<p>DIASTAT (diazepam gel) is indicated for the management of selected, refractory, patients with epilepsy, on stable regimens of anti-epileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The metabolism of diazepam is primarily hepatic and involves demethylation (involving primarily CYP2C19 and CYP3A4) and 3-hydroxylation (involving primarily CYP3A4), followed by glucuronidation. The marked inter-individual variability in the clearance of diazepam reported in the literature is probably attributable to variability of CYP2C19 (which is known to exhibit genetic polymorphism; about 3-5% of Caucasians have little or no activity and are “poor metabolizers”) and CYP3A4.</p>
</blockquote>
<p>Excerpts from the diazepam (VALIUM) product monograph:</p>
<blockquote class=""blockquote"">
<p>VALIUM (diazepam) is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension, excitation, agitation, fear or aggressiveness, such as may occur in: psychoneurosis, anxiety reactions due to stress conditions and anxiety states with somatic expression.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Oxidation of diazepam is mediated by cytochrome P450 isozymes; formation of desmethyl-diazepam mainly by CYP2C19 and CYP3A and 3-hydroxy-diazepam (temazepam) and oxazepam by CYP3A. Because CYP2C19 is polymorphic, extensive metabolizers (EMs), and poor metabolizers (PMs) of diazepam can be distinguished. PMs of diazepam showed significantly lower clearance (12 vs 26 mL/min) and longer elimination half-life (88 vs 41 h) of diazepam than EMs after a single oral dose. Also, PMs had lower clearance, higher AUC and longer elimination half-life of desmethyl-diazepam.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Diazepam_2024_11_05_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Diazepam_2024_11_05_HCSC.pdf"">diazepam gel product monograph</a> and the <a download=""Diazepam_Valium_2024_11_05_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Diazepam_Valium_2024_11_05_HCSC.pdf"">diazepam (Valium) product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452693502.0,"<p>Excerpt from the diazepam (DIASTAT) product monograph:</p>
<blockquote class=""blockquote"">
<p>Clinical studies have not been conducted to establish the efficacy and safety of DIASTAT in children under 2 years of age. Prolonged CNS depression has been observed in neonates treated with diazepam, apparently due to an inability to biotransform diazepam into inactive metabolites. Therefore, Health Canada has not authorized an indication for pediatric use (&lt;2 years of age) (see 1.1 Pediatrics).</p>
</blockquote>
<p>Excerpt from the diazepam (VALIUM) product monograph:</p>
<blockquote class=""blockquote"">
<p>VALIUM is contraindicated in children under 6 months (see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION, Children).</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166357722,Annotation of HCSC Label for efavirenz and CYP2B6,False,False,[],False,[],False,[],True,"[{'id': 15169322, 'title': 'Drugs@HCSC: Drug Product MYLAN-EFAVIRENZ (efavirenz), Mylan Pharmaceuticals ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86737', 'crossReferences': [{'id': 1452690983, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86737', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86737'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165818762', 'symbol': 'CYP2B6*6', 'name': '*6'}]","[{'objCls': 'Chemical', 'id': 'PA449441', 'name': 'efavirenz'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}]",HCSC,1452693525.0,"<p>The HCSC-approved product monograph for efavirenz states that plasma exposure may be increased in patients with the homozygous G516T genetic variant of the CYP2B6 isozyme, and that the potential for an increased frequency and severity of efavirenz-associated adverse events cannot be excluded.</p>
",1452693526.0,"<p>Excerpts from the efavirenz (MYLAN-EFAVIRENZ) product monograph:</p>
<blockquote class=""blockquote"">
<p>The <em>in vitro</em> studies suggest that CYP3A4 and CYP2B6 are the major isozymes responsible for efavirenz metabolism.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Efavirenz plasma exposure may be increased in patients with the homozygous G516T genetic variant of the CYP2B6 isozyme. The clinical implications of such an association are unknown; however, the potential for an increased frequency and severity of efavirenz-associated adverse events cannot be excluded.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The effect of efavirenz on the QTc interval was evaluated in an open-label, positive and placebo controlled, fixed single sequence 3-period, 3-treatment crossover QT study in 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean Cmax of efavirenz in subjects with CYP2B6 *6/*6 genotype following the administration of 600 mg daily dose for 14 days was 2.25-fold the mean Cmax observed in subjects with CYP2B6*1/*1 genotype. A positive relationship between efavirenz concentration and QTc prolongation was observed. Based on the concentration-QTc relationship, the mean QTc prolongation and its upper bound 90% confidence interval are 8.7 ms and 11.3 ms in subjects with CYP2B6*6/*6 genotype following the administration of 600 mg daily dose for 14 days (see WARNINGS AND PRECAUTIONS).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Efavirenz_2024_11_05_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Efavirenz_2024_11_05_HCSC.pdf"">efavirenz product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452693527.0,"<blockquote class=""blockquote"">
<p>Pediatric Patients and Adolescents</p>
</blockquote>
<blockquote class=""blockquote"">
<p>It is recommended that Mylan-Efavirenz be taken on an empty stomach, preferably at bedtime. The recommended dosage of Mylan-Efavirenz for pediatric patients weighing greater than 40 kg is 600 mg, once daily. Mylan-Efavirenz tablets are not recommended for children weighing less than 40 kg because no appropriate dose adjustment can be made.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Information is based on one study, ACTG 382. Patients were administered efavirenz in combination with nelfinavir and NRTIs.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166357723,Annotation of HCSC Label for elagolix and SLCO1B1,False,False,[],False,[],False,[],True,"[{'id': 15169342, 'title': 'Drugs@HCSC: Drug Product ORILISSA (elagolix), AbbVie Corporation', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97182', 'crossReferences': [{'id': 1452691000, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97182', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97182'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166154579', 'symbol': 'rs4149056', 'name': 'rs4149056'}]","[{'objCls': 'Chemical', 'id': 'PA166182348', 'name': 'elagolix'}]","[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",HCSC,1452693530.0,"<p>The HCSC-approved product monograph for elagolix (ORILISSA) states that higher plasma concentrations of the drug can be expected in patients who have two reduced function alleles of the gene that encodes the OATP1B1 transporter (SLCO1B1 521T&gt;C, rs4149056 variant), but no dose adjustment is necessary.</p>
",1452693531.0,"<p>Excerpt from the elagolix (ORILISSA) product monograph:</p>
<blockquote class=""blockquote"">
<p>Disposition of elagolix involves the OATP1B1 transporter protein. Plasma concentrations of elagolix in patients who have 2 reduced function alleles of the gene that encodes OATP1B1 (SLCO1B1 521T&gt;C) are expected to be 78% higher than in patients without this genotype. The frequency of this SLCO1B1 521 C/C genotype is generally less than 5% in most racial/ethnic groups. No dose adjustment of ORILISSA is required based on OATP1B1 genotype status.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Elagolix_2024_11_05_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Elagolix_2024_11_05_HCSC.pdf"">elagolix product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166357761,Annotation of HCSC Label for hydralazine and NAT2,False,False,[],True,[],False,[],True,"[{'id': 15169522, 'title': 'Drugs@HCSC: Drug Product HYDRALAZINE (hydralazine hydrochloride), Sanis Health Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102854', 'crossReferences': [{'id': 1452693660, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102854', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102854'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449894', 'name': 'hydralazine'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",HCSC,1452693661.0,"<p>Hydralazine is partly metabolized by acetylation, and individuals who are slow acetylators generally have higher plasma levels of hydralazine and require lower doses to maintain control of blood pressure. Acetylator status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the product monograph never mentions any specific gene with regard to acetylator status.</p>
",1452693662.0,"<p>Excerpts from the hydralazine product monograph:</p>
<blockquote class=""blockquote"">
<p>Plasma levels of hydralazine vary widely among individuals. Orally administered hydralazine undergoes extensive, saturable first-pass metabolism (systemic availability: 26 - 55%), this first- pass effect being dependent on the individual's acetylator status. In response to the same oral dose, slow-acetylators show higher “apparent” plasma hydralazine levels than rapid acetylators and require lower doses to maintain control of blood pressure.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>After intravenous administration of hydralazine no first-pass effect occurs; acetylator status therefore has no influence on the plasma levels.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Hydralazine may provoke in a few patients a clinical picture simulating systemic lupus erythematosus (SLE) including glomerulonephritis. [...] The frequency of these untoward effects increases with dosage and duration of exposure to the drug and is higher in slow than in fast acetylators. When treated with the same dosage, slow acetylators have higher serum concentrations than fast acetylators. The lowest effective dosage should therefore be used for maintenance therapy. If 100 mg daily fails to elicit an adequate clinical effect, the patient's acetylator status should be evaluated.
Slow acetylators and women run a greater risk of developing this SLE-like syndrome. In such cases dosage should be kept below 100 mg daily and the patients carefully monitored for clinical signs and symptoms suggestive of this syndrome.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Hydralazine_2024_11_07_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Hydralazine_2024_11_07_HCSC.pdf"">hydralazine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452693663.0,"<blockquote class=""blockquote"">
<p>Orally administered hydralazine undergoes extensive, saturable first-pass metabolism (systemic availability: 26 - 55%), this first- pass effect being dependent on the individual's acetylator status. In response to the same oral dose, slow-acetylators show higher “apparent” plasma hydralazine levels than rapid acetylators and require lower doses to maintain control of blood pressure.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166357781,Annotation of HCSC Label for hydroxychloroquine and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15169542, 'title': 'Drugs@HCSC: Drug Product PLAQUENIL (hydroxychloroquine), sanofi-aventis Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14735', 'crossReferences': [{'id': 1452693680, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14735', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14735'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164777036', 'name': 'hydroxychloroquine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1452693681.0,"<p>The HCSC-approved product monograph for hydroxychloroquine (PLAQUENIL) states that hemolysis was reported in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency; patients should be monitored for hemolytic anemia.</p>
",1452693682.0,"<p>Excerpts from the hydroxychloroquine (PLAQUENIL) product monograph:</p>
<blockquote class=""blockquote"">
<p>Hemolysis has been reported in patients with glucose-6-phosphate dehydrogenase deficiency. Monitor for hemolytic anemia and observe caution in patients with blood disorders or glucose-6-phosphate dehydrogenase deficiency.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Hydroxychloroquine_2024_11_07_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Hydroxychloroquine_2024_11_07_HCSC.pdf"">hydroxychloroquine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452693683.0,"<blockquote class=""blockquote"">
<p>Hemolysis has been reported in patients with glucose-6-phosphate dehydrogenase deficiency. Monitor for hemolytic anemia and observe caution in patients with blood disorders or glucose-6-phosphate dehydrogenase deficiency.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166355241,Annotation of EMA Label for belinostat,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165971474', 'name': 'belinostat'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166355242,Annotation of HCSC Label for belinostat,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165971474', 'name': 'belinostat'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166357801,Annotation of HCSC Label for imipramine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15169562, 'title': 'Drugs@HCSC: Drug Product IMIPRAMINE (imipramine hydrochloride), AA PHARMA INC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2444', 'crossReferences': [{'id': 1452693720, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2444', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2444'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449969', 'name': 'imipramine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452693721.0,"<p>The HCSC-approved product monograph for imipramine states that CYP2D6 inhibitors make normal metabolizers resemble poor metabolizers, and that a given dose of tricyclic antidepressant (such as imipramine) may become abruptly toxic. Specific mention of CYP2D6 poor metabolizers only occurs in the Patient Medication Information section.</p>
",1452693722.0,"<p>Excerpts from the imipramine product monograph:</p>
<blockquote class=""blockquote"">
<p>Certain drugs that inhibit the activity of CYP2D6 make normal metabolizers resemble poor metabolizers. A given dose of tricyclic antidepressant may become abruptly toxic when a drug that inhibits CYP2D6 is introduced as concomitant therapy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>To help avoid side effects and ensure proper use, talk to your healthcare professional before you take IMIPRAMINE. Talk about any health conditions or problems you may have, including if you: [...]</p>
<ul>
<li>have been told you have enzymes that do not work well (such as “CYP2D6 poor metabolizer” or “CYP2C19 poor metabolizer”).</li>
</ul>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Imipramine_2024_11_07_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Imipramine_2024_11_07_HCSC.pdf"">imipramine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166355282,Annotation of HCSC Label for brexpiprazole and CYP2D6,False,False,[],True,[],False,[],True,"[{'id': 15167862, 'title': 'Drugs@HCSC: Drug Product REXULTI (brexpiprazole), Otsuka Pharmaceutical Co., Ltd.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94950', 'crossReferences': [{'id': 1452642024, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94950', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94950'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166160053', 'name': 'brexpiprazole'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452642025.0,"<p>The HCSC-approved product monograph for brexpiprazole (REXULTI) states that known CYP2D6 poor metabolizers should have the usual dosage reduced by half, and that known CYP2D6 poor metabolizers who are also taking strong/moderate CYP3A4 inhibitors should be administered a quarter of the usual dose.</p>
",1452642026.0,"<p>Excerpts from the brexpiprazole (REXULTI) product monograph:</p>
<blockquote class=""blockquote"">
<p>CYP isozymes: Dosage adjustments are recommended in patients who are known cytochrome P450 (CYP) 2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers (see Table 2).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em><strong>CYP2D6 Poor Metabolism Status:</strong></em> Based on the results of the population PK analysis CYP2D6 poor metabolizer subjects exhibited 47% higher exposure (AUCt) to brexpiprazole compared with CYP2D6 extensive metabolizer subjects (see 4.1 Dosing Considerations).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Brexpiprazole_2024_10_15_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Brexpiprazole_2024_10_15_HCSC.pdf"">brexpiprazole product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452642027.0,"<blockquote class=""blockquote"">
<p>Dosage adjustments are recommended in patients who are known cytochrome P450 (CYP) 2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers (see Table 2).</p>
</blockquote>
<p>Known CYP2D6 poor metabolizers: Administer half of the usual dose</p>
<p>Known CYP2D6 poor metabolizers taking strong/moderate CYP3A4 inhibitors: Administer a quarter of the usual dose</p>
",,,,,,,
Label Annotation,PA166357821,Annotation of HCSC Label for lacosamide and CYP2C19,False,False,[],False,[],False,[],True,"[{'id': 15169582, 'title': 'Drugs@HCSC: Drug Product VIMPAT (lacosamide), UCB Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84272', 'crossReferences': [{'id': 1452694280, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84272', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84272'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166160048', 'name': 'lacosamide'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1452694320.0,"<p>The product monograph for lacosamide (VIMPAT) states that plasma concentrations of the lacosamide O-desmethyl metabolite were reduced by approximately 70% in CYP2C19 poor metabolizers (PMs) as compared to extensive metabolizers (EMs), but that there are no clinically relevant differences in lacosamide pharmacokinetics between PMs and EMs.</p>
",1452694321.0,"<p>Excerpts from the lacosamide (VIMPAT) product monograph:</p>
<blockquote class=""blockquote"">
<p>CYP2C19, CYP2C9 and CYP3A4 are mainly responsible for the formation of the O-desmethyl metabolite. However, no clinically relevant difference in lacosamide exposure was observed comparing its pharmacokinetics in extensive metabolisers (EMs, with a functional CYP2C19) and poor metabolisers (PMs, lacking a functional CYP2C19). Furthermore, an interaction trial with omeprazole (CYP2C19-inhibitor) demonstrated no clinically relevant changes in lacosamide plasma concentrations indicating that the importance of this pathway is minor. No other enzymes have been identified to be involved in the metabolism of lacosamide.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Genetic Polymorphism:</strong> There are no clinically relevant differences in the pharmacokinetics of lacosamide between CYP2C19 poor metabolizers and extensive metabolizers. Results from a trial in poor metabolizers (PM) (N=4) and extensive metabolizers (EM) (N=8) of cytochrome P450 (CYP) 2C19 showed that lacosamide plasma concentrations were similar in PMs and EMs, but plasma concentrations and the amount excreted into urine of the O-desmethyl metabolite were about 70% reduced in PMs compared to EMs.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Lacosamide_2024_11_08_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lacosamide_2024_11_08_HCSC.pdf"">lacosamide product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166355301,Annotation of HCSC Label for carisoprodol,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448809', 'name': 'carisoprodol'}]",[],HCSC,,,1452642040.0,"<p>As of October 15, 2024, the Current status of carisoprodol on the HCSC website is Cancelled Post Market, with a Current status date of 2002-06-10.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166357822,Annotation of EMA Label for lecanemab,False,False,[],False,"[{'id': 1452804380, 'date': '2025-01-10T14:43:14.791-08:00', 'description': 'update: ""positive opinion"" on marketing authorization', 'type': 'Update', 'version': 0}]",False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166313301', 'name': 'lecanemab'}]",[],EMA,,,1452694324.0,"<p>&quot;On 14 November 2024, the Committee for Medicinal Products for Human Use (CHMP), following a re-examination procedure, adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Leqembi, intended for the treatment of early Alzheimer’s disease in apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes. The applicant for this medicinal product is Eisai GmbH.&quot;</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166355421,Annotation of HCSC Label for cisplatin,False,False,[],False,[],False,[],True,"[{'id': 15168022, 'title': 'Drugs@HCSC: Drug Product CISPLATIN INJECTION (cisplatin), Teva Canada Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88800', 'crossReferences': [{'id': 1452642860, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88800', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88800'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA449014', 'name': 'cisplatin'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166357841,"Annotation of HCSC Label for lidocaine / prilocaine and CYB5R3, G6PD",True,False,[],False,[],False,[],True,"[{'id': 15169602, 'title': 'Drugs@HCSC: Drug Product ORAQIX (lidocaine and prilocaine), DENTSPLY Canada Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81134', 'crossReferences': [{'id': 1452694420, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81134', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81134'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166176018', 'name': 'lidocaine / prilocaine'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1452694421.0,"<p>The HCSC-approved product monograph for lidocaine and prilocaine (ORAQIX) states that patients with G6PD deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia, and that ORAQIX should not be used in those patients with congenital or idiopathic methemoglobinemia.</p>
",1452694422.0,"<p>Excerpts from the lidocaine and prilocaine (ORAQIX) product monograph:</p>
<blockquote class=""blockquote"">
<p>ORAQIX® (Lidocaine and Prilocaine Periodontal Gel) is contraindicated: [...]</p>
<ul>
<li>in patients with congenital or idiopathic methemoglobinemia</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. ORAQIX® (Lidocaine and Prilocaine Periodontal Gel) should not be used in those patients with congenital or idiopathic methemoglobinemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Very young patients or patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced
methemoglobinemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>To minimize the risk of methemoglobinemai, BEFORE you use ORAQIX® talk to your dentist/dental hygienist if: [...]</p>
<ul>
<li>you have glucose 6-phosphate deficiencies.</li>
</ul>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Lidocaine_prilocaine_2024_11_08_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lidocaine_prilocaine_2024_11_08_HCSC.pdf"">lidocaine and prilocaine product monograph</a>.</p>
<p>NOTE: While the <em>CYB5R3</em> gene is not explicitly mentioned in the product monograph, variants in this gene are associated with congenital methemoglobinemia I and II.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452694423.0,"<blockquote class=""blockquote"">
<p>Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. ORAQIX® (Lidocaine and Prilocaine Periodontal Gel) should not be used in those patients with congenital or idiopathic methemoglobinemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>To minimize the risk of methemoglobinemai, BEFORE you use ORAQIX® talk to your dentist/dental hygienist if: [...]</p>
<ul>
<li>you have glucose 6-phosphate deficiencies.</li>
</ul>
</blockquote>
",,,,,,,
Label Annotation,PA166355442,Annotation of HCSC Label for clobazam and CYP2C19,False,False,[],True,[],False,[],True,"[{'id': 15168042, 'title': 'Drugs@HCSC: Drug Product TEVA-CLOBAZAM (clobazam), Teva Canada Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61740', 'crossReferences': [{'id': 1452642880, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61740', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61740'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10888', 'name': 'clobazam'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1452642884.0,"<p>In patients known to be CYP2C19 poor metabolizers, the product monograph states that the starting dose of clobazam should be the lowest initial recommended dose, and that dose titration should proceed slowly according to the age group, but to half the maximum dose described.</p>
",1452642885.0,"<p>Excerpts from the clobazam (TEVA-CLOBAZAM) product monograph:</p>
<blockquote class=""blockquote"">
<p>In CYP2C19 poor metabolizers, levels of N-desmethylclobazam, clobazam’s active metabolite, will be increased. Therefore, in patients known to be CYP2C19 poor metabolizers, the starting dose should be the lowest initial recommended dose and dose titration should proceed slowly, as tolerated according to the age group, but to half the maximum dose described. If necessary and based upon clinical response, an additional titration to the maximum dose (depending on the age group) may be started on day 21.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The polymorphic CYP2C19 is the main enzyme that metabolizes the pharmacologically active N-desmethylclobazam. Compared to CYP2C19 extensive metabolizers, N-desmethylclobazam AUC and Cmax are approximately 3-5 times higher in poor metabolizers (e.g., subjects with *2/*2 genotype) and 2 times higher in intermediate metabolizers (e.g., subjects with *1/*2 genotype). The prevalence of CYP2C19 poor metabolism differs, depending on racial/ethnic background. Dosage in patients who are known CYP2C19 poor metabolizers may need to be adjusted (see DOSAGE AND ADMINISTRATION section).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The systemic exposure of clobazam is similar for both CYP2C19 poor and extensive metabolizers.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Clobazam_2024_10_16_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Clobazam_2024_10_16_HCSC.pdf"">clobazam product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452642887.0,"<blockquote class=""blockquote"">
<p><strong>Recommended Dose and Dosage Adjustment</strong> [...]</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Children from 2 to 16 years:</strong> The initial dose in children should be 5 mg/day, which may be increased at 5-day intervals to a maximum of 40 mg/day.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Infants ≤ 2 years:</strong> In infants, the initial daily dose is 0.5-1 mg/kg/day.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452642886.0,"<blockquote class=""blockquote"">
<p>[...] in patients known to be CYP2C19 poor metabolizers, the starting dose should be the lowest initial recommended dose and dose titration should proceed slowly, as tolerated according to the age group, but to half the maximum dose described. If necessary and based upon clinical response, an additional titration to the maximum dose (depending on the age group) may be started on day 21.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166357861,"Annotation of HCSC Label for lidocaine and tetracaine and CYB5R3, G6PD",True,False,[],False,[],False,[],True,"[{'id': 15169622, 'title': 'Drugs@HCSC: Drug Product PLIAGLIS (lidocaine and tetracaine), CRESCITA SKIN SCIENCES INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88297', 'crossReferences': [{'id': 1452694440, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88297', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88297'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166182735', 'name': 'lidocaine and tetracaine'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1452694441.0,"<p>The HCSC-approved product monograph for lidocaine and tetracaine (PLIAGLIS) states that patients with G6PD deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia, and that PLIAGLIS is contraindicated in patients with congenital or idiopathic methemoglobinemia.</p>
",1452694442.0,"<p>Excerpts from the lidocaine and tetracaine (PLIAGLIS) product monograph:</p>
<blockquote class=""blockquote"">
<p>PLIAGLIS (lidocaine 7% and tetracaine 7%) cream is contraindicated in:</p>
<ul>
<li>patients with congenital or idiopathic methemoglobinemia</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Several local anaesthetics, including tetracaine, have been associated with methemoglobinemia. The risk of methemoglobinemia is greatest for patients with congenital or idiopathic methemoglobinemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>PLIAGLIS is contraindicated for patients with congenital or idiopathic methemoglobinemia (see also CONTRAINDICATIONS). Patients with glucose-6-phosphate dehydrogenase deficiency are more susceptible to drug-induced methemoglobinemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>BEFORE you use PLIAGLIS talk to your doctor or pharmacist if you: [...]</p>
<ul>
<li>have glucose-6-phosphate dehydrogenase deficiency</li>
</ul>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Lidocaine_tetracaine_2024_11_08_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lidocaine_tetracaine_2024_11_08_HCSC.pdf"">lidocaine and tetracaine product monograph</a>.</p>
<p>NOTE: While the <em>CYB5R3</em> gene is not explicitly mentioned in the product monograph, variants in this gene are associated with congenital methemoglobinemia I and II.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452694443.0,"<blockquote class=""blockquote"">
<p>PLIAGLIS is contraindicated for patients with congenital or idiopathic methemoglobinemia (see also CONTRAINDICATIONS). Patients with glucose-6-phosphate dehydrogenase deficiency are more susceptible to drug-induced methemoglobinemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>BEFORE you use PLIAGLIS talk to your doctor or pharmacist if you: [...]</p>
<ul>
<li>have glucose-6-phosphate dehydrogenase deficiency</li>
</ul>
</blockquote>
",,,,,,,
Label Annotation,PA166104884,Annotation of FDA Label for clobazam and CYP2C19,False,False,[],True,"[{'id': 1183681207, 'date': '2013-10-25T10:43:19.198-07:00', 'type': 'Update', 'version': 0}, {'id': 1450384196, 'date': '2019-04-23T21:35:22.852-07:00', 'description': 'added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1452642891, 'date': '2024-10-16T13:46:46.992-07:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101921, 'title': 'Drugs@FDA: Drug Product Onfi (clobazam), NDA202067, Lundbeck Pharmaceuticals LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202067', 'crossReferences': [{'id': 1449754203, 'resource': 'FDA Application', 'resourceId': 'NDA202067', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202067'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",[],"[{'objCls': 'Chemical', 'id': 'PA10888', 'name': 'clobazam'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1450342821.0,"<p>In patients known to be CYP2C19 poor metabolizers, the drug label states that the initial dose of clobazam (ONFI) should be 5 mg/day, and that dose titration should be proceed slowly according to weight.</p>
",1450342822.0,"<p>Clobazam (ONFI) is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age or older.</p>
<p>Excerpts from the clobazam (ONFI) label:</p>
<div class=""blockquote"">
<p>In CYP2C19 poor metabolizers, levels of N-desmethylclobazam, clobazam’s active metabolite, will be increased. Therefore, in patients known to be CYP2C19 poor metabolizers, the starting dose should be 5 mg/day and dose titration should proceed slowly according to weight, but to half the dose presented in Table 1, as tolerated. If necessary and based upon clinical response, an additional titration to the maximum dose (20 mg/day or 40 mg/day, depending on the weight group) may be started on day 21.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Clobazam_01_09_19_FDA.pdf"">clobazam drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452642890.0,"<blockquote class=""blockquote"">
<p>ONFI is a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450384195.0,"<p>Excerpt from the clobazam (ONFI) label:</p>
<blockquote class=""blockquote"">
<p>...in patients known to be CYP2C19 poor metabolizers, the starting dose should be 5 mg/day and dose titration should proceed slowly according to weight, but to half the dose presented in Table 1, as tolerated. If necessary and based upon clinical response, an additional titration to the maximum dose (20 mg/day or 40 mg/day, depending on the weight group) may be started on day 21.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166357881,"Annotation of EMA Label for lusutrombopag and F2, F5, PROC, PROS1, SERPINC1",False,False,[],False,[],False,[],True,"[{'id': 15169642, 'title': 'Mulpleo (previously Lusutrombopag Shionogi) | European Medicines Agency (EMA)', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/mulpleo', 'crossReferences': [{'id': 1452694480, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/mulpleo', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/mulpleo'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]","[{'objCls': 'Variant', 'id': 'PA166154336', 'symbol': 'rs1799963', 'name': 'rs1799963'}, {'objCls': 'Variant', 'id': 'PA166153554', 'symbol': 'rs6025', 'name': 'rs6025'}]","[{'objCls': 'Chemical', 'id': 'PA166182748', 'name': 'lusutrombopag'}]","[{'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",EMA,1452694500.0,"<p>The EMA-approved EPAR for lusutrombopag (Mulpleo) states that patients with congenital coagulopathy the risk for thrombosis or thromboembolism may increase. These patients should be clinically monitored when treated with lusutrombopag.</p>
<p>Although the EPAR does not mention specific genes, genetic prothrombotic conditions include Factor V Leiden (F5), Prothrombin 20210A (F2), Antithrombin deficiency (SERPINC1) or Protein C (PROC) or S (PROS1) deficiency.</p>
",1452694501.0,"<p>Excerpt from the lusutrombopag (Mulpleo) EPAR:</p>
<blockquote class=""blockquote"">
<p>In patients with thrombosis or thromboembolism, with a history of thrombosis or thromboembolism, with absence of hepatopetal blood flow in the main trunk of the portal vein, or patients with congenital coagulopathy the risk for thrombosis or thromboembolism may increase. These patients should be clinically monitored when treated with lusutrombopag.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Lusutrombopag_2024_11_08_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lusutrombopag_2024_11_08_EMA.pdf"">lusutrombopag EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452694502.0,"<blockquote class=""blockquote"">
<p>In patients with thrombosis or thromboembolism, with a history of thrombosis or thromboembolism, with absence of hepatopetal blood flow in the main trunk of the portal vein, or patients with congenital coagulopathy the risk for thrombosis or thromboembolism may increase. These patients should be clinically monitored when treated with lusutrombopag.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166355461,Annotation of HCSC Label for clozapine,False,False,[],False,[],False,[],True,"[{'id': 15168062, 'title': 'Drugs@HCSC: Drug Product CLOZARIL (clozapine), HLS Therapeutics Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11422', 'crossReferences': [{'id': 1452642900, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11422', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11422'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449061', 'name': 'clozapine'}]",[],HCSC,1452642920.0,"<p>The clozapine product monograph states that clozapine is a substrate for many CYP 450 isoenzymes, in particular 1A2 and 3A4.</p>
",1452642921.0,"<p>Excerpt from the clozapine (CLOZARIL) product monograph:</p>
<blockquote class=""blockquote"">
<p>Clozapine is almost completely metabolized prior to excretion. Clozapine is converted to norclozapine (desmethyl clozapine) by CYP1A2 and 3A4, and to clozapine-N-oxide by 3A4, and metabolized to some extent by CYP2C19 and 2D6. Recent studies suggest that there is a significant correlation between clozapine plasma levels and clinical response. The concentrations of clozapine, and its major metabolite norclozapine, were significantly higher in responders than in nonresponders although the mean doses of clozapine did not differ between the two groups. Of the main metabolites, only norclozapine was found to be active. In patients who responded to treatment, plasma clozapine levels reached at least 350 to 370 ng/mL.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Clozapine is a substrate for many CYP 450 isoenzymes, in particular 1A2 and 3A4. Caution is called for in patients receiving concomitant treatment with other drugs which are either inhibitors or inducers of these enzymes.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Clozapine_2024_10_16_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Clozapine_2024_10_16_HCSC.pdf"">clozapine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166355481,Annotation of HCSC Label for dextromethorphan / quinidine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166175998', 'name': 'dextromethorphan / quinidine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166355501,Annotation of HCSC Label for donepezil,False,False,[],False,[],False,[],True,"[{'id': 15168082, 'title': 'Drugs@HCSC: Drug Product Sandoz Donepezil (donepezil), Sandoz Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81417', 'crossReferences': [{'id': 1452642940, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81417', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81417'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449394', 'name': 'donepezil'}]",[],HCSC,1452642960.0,"<p>The HCSC-approved product monograph for donepezil states that it is metabolized by the CYP2D6 and CYP3A4 enzymes and undergoes glucuronidation.</p>
",1452642961.0,"<p>Excerpt from the donepezil (Sandoz® Donepezil) product monograph:</p>
<blockquote class=""blockquote"">
<p>Donepezil is metabolized by CYP 450 isoenzymes 2D6 and 3A4 and undergoes glucuronidation.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Donepezil_2024_10_16_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Donepezil_2024_10_16_HCSC.pdf"">donepezil product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166355801,Annotation of EMA Label for lonafarnib and CYP3A4,False,False,[],True,[],False,[],True,"[{'id': 15151022, 'title': 'Zokinvy | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zokinvy', 'crossReferences': [{'id': 1452304982, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zokinvy', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zokinvy'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,True,True,"[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166129466', 'name': 'lonafarnib'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1452644160.0,"<p>Lonafarnib is EMA-indicated for the treatment of patients with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy. Patients with a known dysfunctional polymorphism in CYP3A4 should start therapy at 50% of the indicated dose. QTc monitoring is necessary.</p>
",1452644161.0,"<p>Excerpts from the lonafarnib (Zokinvy) EPAR:</p>
<blockquote class=""blockquote"">
<p><em>Dose adjustment for patients with known dysfunctional polymorphisms in CYP3A4</em>
The patient’s daily dose of lonafarnib should be reduced by 50% and the reduced daily dose should be divided into two equal doses. Each dose should be rounded to the nearest 25 mg increment. The dosing regimen will be either 25 mg twice daily, 50 mg twice daily or 75 mg twice daily. Patients who have a reduced daily dose of 50 mg (25 mg twice daily) should mix the contents of a lonafarnib 50 mg capsule with 10 mL of orange juice to achieve the correct dose. Only half (5 mL) of the 10-mL mixture will be consumed (see section 6.6). QTc monitoring is recommended.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Subjects with a known dysfunctional polymorphism in CYP3A4 should start therapy at 50% of the indicated dose. QTc monitoring is necessary (see section 4.2 and 4.5).</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Lonafarnib_EMA_2023_10_11.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lonafarnib_EMA_2023_10_11.pdf"">lonafarnib EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",1452644163.0,"<blockquote class=""blockquote"">
<p>Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous <em>LMNA</em> mutation with progerin-like protein accumulation or a homozygous or compound heterozygous <em>ZMPSTE24</em> mutation.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452644162.0,"<blockquote class=""blockquote"">
<p>Subjects with a known dysfunctional polymorphism in CYP3A4 should start therapy at 50% of the indicated dose. QTc monitoring is necessary (see section 4.2 and 4.5).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166355321,Annotation of HCSC Label for ceftriaxone,False,False,[],False,[],False,[],True,"[{'id': 15167882, 'title': 'Drugs@HCSC: Drug Product cefTRIAXone Sodium for Injection BP (ceftriaxone), SteriMax Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81096', 'crossReferences': [{'id': 1452642060, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81096', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81096'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA448866', 'name': 'ceftriaxone'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166355882,Annotation of HCSC Label for duloxetine,False,False,[],False,[],False,[],True,"[{'id': 15168202, 'title': 'Drugs@HCSC: Drug Product DULOXETINE (duloxetine), Sanis Health Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98092', 'crossReferences': [{'id': 1452644384, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98092', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98092'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10066', 'name': 'duloxetine'}]",[],HCSC,1452644385.0,"<p>Duloxetine is metabolized by CYP2D6 and CYP1A2.</p>
",1452644386.0,"<p>Excerpt from the duloxetine product monograph:</p>
<blockquote class=""blockquote"">
<p>Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Duloxetine_2024_10_17_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Duloxetine_2024_10_17_HCSC.pdf"">duloxetine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166184123,"Annotation of Swissmedic Label for citalopram and CYP2C19, CYP2D6",False,False,[],True,"[{'id': 1452021840, 'date': '2023-02-28T13:08:39.808-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103165, 'title': 'Swissmedic label for citalopram', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=49970', 'crossReferences': [{'id': 1450813272, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=49970', '_url': 'https://amiko.oddb.org/de/fi?gtin=49970'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449015', 'name': 'citalopram'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450813677.0,"<p>The Swiss drug label for citalopram (Seropram) states that variants in both CYP2D6 and CYP2C19 can affect metabolism of citalopram. Patients who have reduced CYP2C19 metabolism should be given a reduced dose of citalopram.</p>
",1450813678.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for citalopram (Seropram):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
In vivo studies have shown that polymorphisms (branchine/debrisoquin oxidation (CYP2D6) and mephenytoin hydroxylation (CYP2C19)) contribute to the variability of pharmacokinetics in the metabolism of citalopram. The clinical significance is currently unclear. Dosage adjustment may be required (see also Dosage/Application).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dosage/Application:
Reduced metabolism via CYP2C19: For patients known to have reduced metabolism via CYP2C19, a starting dose of 10 mg daily is recommended in the first two weeks. Depending on the individual response of the patient, the dose may be increased to a maximum of 20 mg per day (see Pharmacokinetics).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=49970&amp;highlight=Polymorphismen"" target=""_blank"">citalopram drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813679.0,"<blockquote class=""blockquote"">
<p>For patients known to have reduced metabolism via CYP2C19, a starting dose of 10 mg daily is recommended in the first two weeks. Depending on the individual response of the patient, the dose may be increased to a maximum of 20 mg per day.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184345,"Annotation of Swissmedic Label for phenytoin and CYP2C9, HLA-B",False,False,[],True,"[{'id': 1452021990, 'date': '2023-02-28T14:34:57.361-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103074, 'title': 'Swissmedic label for phenytoin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=25930', 'crossReferences': [{'id': 1450812035, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=25930', '_url': 'https://amiko.oddb.org/de/fi?gtin=25930'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165954769', 'symbol': 'HLA-B*15:02', 'name': '*15:02'}]","[{'objCls': 'Chemical', 'id': 'PA450947', 'name': 'phenytoin'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",Swissmedic,1450815178.0,"<p>The Swiss drug label for phenytoin (Phenytoin-Gerot) states that HLA-B*1502 may be associated with an increased risk of Stevens-Johnson syndrome (SJS) in individuals of Thai or Han Chinese descent treated with phenytoin and the use of phenytoin should only be considered if the benefit is considered higher than the risks for these patients known to carry HLA-B*5102.</p>
",1450815179.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the phenytoin (Phenytoin-Gerot) label:</p>
<blockquote class=""blockquote"">
<p>Precautions:
HLA-B*1502 may be associated with an increased risk of Stevens-Johnson syndrome (SJS) in individuals of Thai or Han Chinese descent treated with phenytoin. If it is known that these patients have the gene variant HLA-B* 1502, the use of phenytoin should only be considered if the benefit is considered higher than the risks.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Metabolism: Phenytoin is more than 95% biotransformed in the liver (mostly via CYP2C9 and to a small extent via CYP2C19). The major metabolite is the glucuronide of p-hydroxy-diphenyl-hydantoin, which circulates in the enterohepatic cycle.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dosage / Application:
Patients with genetically determined slow hydroxylation may develop signs of overdose at moderate doses. Dose reduction under plasma concentration control is required.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=25930&amp;highlight=HLA-B*"" target=""_blank"">phenytoin drug label</a> (in German);</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450815180.0,"<blockquote class=""blockquote"">
<p>HLA-B*1502 may be associated with an increased risk of Stevens-Johnson syndrome (SJS) in individuals of Thai or Han Chinese descent treated with phenytoin. If it is known that these patients have the gene variant HLA-B* 1502, the use of phenytoin should only be considered if the benefit is considered higher than the risks.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with genetically determined slow hydroxylation may develop signs of overdose at moderate doses. Dose reduction under plasma concentration control is required.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184424,Annotation of Swissmedic Label for thioguanine and TPMT,False,False,[],True,"[{'id': 1452022060, 'date': '2023-02-28T14:37:48.011-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103105, 'title': 'Swissmedic label for tioguanin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=37890', 'crossReferences': [{'id': 1450812066, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=37890', '_url': 'https://amiko.oddb.org/de/fi?gtin=37890'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451663', 'name': 'thioguanine'}]","[{'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",Swissmedic,1450815563.0,"<p>The Swiss drug label for thioguanine (Lanvis) cautions about use in patients with a congenital deficiency of the enzyme thiopurine methyltransferase (TPMT).</p>
",1450815564.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for thioguanine (Lanvis):</p>
<blockquote class=""blockquote"">
<p>Precautions:
There are patients with a congenital deficiency of the enzyme thiopurine methyltransferase (TPMT) who are unusually sensitive to the myelosuppressive effect of thioguanine. These tend to develop a rapid myelosuppression after starting treatment with Lanvis (see &quot;Pharmacokinetics/Metabolism&quot; and &quot;Dosage/Application&quot;). This effect may be enhanced by simultaneous administration of drugs that inhibit TPMT (such as olsalazine, mesalazine or sulfasalazine) (see &quot;Interactions&quot;). Although some laboratories offer tests to determine TPMT activity, no evidence has been provided that these tests can detect all patients at risk of severe toxicity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dosage/Applications:
Patients with thiopurine methyltransferase (TMPT) deficiency: Patients with inherited low or no TMPT activity have an increased risk of thioguanine poisoning when administered the usual dosage and generally require a significant dose reduction. The optimal starting dose in homozygous TMPT deficient patients is not established (See &quot;Warnings and Precautions&quot; and &quot;Pharmacokinetics/Metabolism&quot;)Most patients with heterozygous TMPT deficiency tolerate the recommended dose, but some require dose reduction. Tests for the genotype and phenotype of TMPT are possible.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=37890&amp;highlight=TMPT-Mangel"" target=""_blank"">thioguanine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450815565.0,"<blockquote class=""blockquote"">
<p>Patients with inherited low or no TMPT activity have an increased risk of thioguanine poisoning when administered the usual dosage and generally require a significant dose reduction. The optimal starting dose in homozygous TMPT deficient patients is not established (See &quot;Warnings and Precautions&quot; and &quot;Pharmacokinetics/Metabolism&quot;) Most patients with heterozygous TMPT deficiency tolerate the recommended dose, but some require dose reduction.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166358301,Annotation of HCSC Label for methylene blue and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15169802, 'title': 'Drugs@HCSC: Drug Product Methylene Blue, Phebra Pty Ltd', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97817', 'crossReferences': [{'id': 1452698560, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97817', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97817'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450457', 'name': 'methylene blue'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1452698561.0,"<p>The HCSC-approved product monograph for methylene blue states that it should be used with caution in patients with glucose-6-phosphate dehydrogenase deficiency due to their increased susceptibility to hemolytic anemia.</p>
",1452698562.0,"<p>Excerpts from the methylene blue product monograph:</p>
<blockquote class=""blockquote"">
<p>Methylene Blue should be used with caution in the treatment of toxic methemoglobinemia; high doses can cause hemolytic anemia and patients with glucose-6-phosphate dehydrogenase (G6PD) deficiencies are particularly susceptible.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A rapid disappearance of cyanosis in response to Methylene Blue would be expected within one hour but might not occur if the patient has erythrocyte G6PD or NADPH-diaphorase deficiency or if methemoglobinemia is due to the ingestion of compounds such as aniline or dapsone.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Methylene Blue should be used with caution in patients with glucose-6-phosphate dehydrogenase deficiency.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Methylene_blue_2024_11_12_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Methylene_blue_2024_11_12_HCSC.pdf"">methylene blue product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452698563.0,"<blockquote class=""blockquote"">
<p>Methylene Blue should be used with caution in patients with glucose-6-phosphate dehydrogenase deficiency.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166356321,Annotation of FDA Label for hydralazine and NAT2,False,False,[],True,[],False,[],True,"[{'id': 15168542, 'title': 'Drugs@FDA: Drug Product Hydralazine Hydrochloride (Hydralazine Hydrochloride), American Regent, Inc. - ANDA040136/SUPPL-5, 04/26/2013', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=040136', 'crossReferences': [{'id': 1452648341, 'resource': 'FDA Application', 'resourceId': 'ANDA040136/SUPPL-5', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=040136'}], 'objCls': 'Literature', 'pubDate': '2013-04-26T00:00:00-07:00', 'terms': [], 'type': 'Drug Label'}, {'id': 15168543, 'title': 'DailyMed - HYDRALAZINE HYDROCHLORIDE tablet', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f9f56326-6d72-47d3-89ac-3625b8a6d713', 'crossReferences': [{'id': 1452648342, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': 'f9f56326-6d72-47d3-89ac-3625b8a6d713', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f9f56326-6d72-47d3-89ac-3625b8a6d713'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449894', 'name': 'hydralazine'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",FDA,1452648343.0,"<p>Hydralazine hydrochloride is partly metabolized by acetylation, and individuals who are slow acetylators generally have higher plasma levels of hydralazine and require lower doses to maintain control of blood pressure. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to acetylator status.</p>
",1452648344.0,"<p>Excerpt from the hydralazine hydrochloride label:</p>
<blockquote class=""blockquote"">
<p>Plasma levels of hydralazine vary widely among individuals. Hydralazine is subject to polymorphic acetylation; slow acetylators generally have higher plasma levels of hydralazine and require lower doses to maintain control of blood pressure.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Hydralazine_2024_10_21_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Hydralazine_2024_10_21_FDA.pdf"">hydralazine drug label</a>. The <a download=""Hydralazine_injection_2024_10_21_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Hydralazine_injection_2024_10_21_FDA.pdf"">injectable hydralazine drug label</a> does not contain language suggesting dose adjustment for slow acetylators.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452648345.0,"<blockquote class=""blockquote"">
<p>Hydralazine is subject to polymorphic acetylation; slow acetylators generally have higher plasma levels of hydralazine and require lower doses to maintain control of blood pressure.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166358581,Annotation of HCSC Label for modafinil and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15169822, 'title': 'Drugs@HCSC: Drug Product TEVA-MODAFINIL (modafinil), Teva Canada Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90485', 'crossReferences': [{'id': 1452699860, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90485', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90485'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450530', 'name': 'modafinil'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452699880.0,"<p>Modafinil, used to improve wakefulness, is metabolized by many cytochrome P450s. Patients that are poor metabolizers for CYP2D6 may need dose modifications for medications that have ancillary metabolism via CYP2C19, such as tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs).</p>
",1452699881.0,"<p>Excerpts from the modafinil (TEVA-MODAFINIL) product monograph:</p>
<blockquote class=""blockquote"">
<p>Modafinil has the potential to inhibit CYP2C19, suppress CYP2C9, and induce CYP3A4, CYP2B6, and CYP1A2.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In addition, in individuals deficient in the enzyme CYP2D6 (i.e., 7-10% of the Caucasian population; similar or lower in other populations), the levels of CYP2D6 substrates such as tricyclic antidepressants and selective serotonin reuptake inhibitors, which have ancillary routes of elimination through CYP2C19, may be increased by co-administration of modafinil. Dose adjustments may be necessary for patients being treated with these and similar medications.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Modafinil_2024_11_13_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Modafinil_2024_11_13_HCSC.pdf"">modafinil product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166104891,Annotation of FDA Label for nalidixic acid and G6PD,False,False,[],False,"[{'id': 1183681370, 'date': '2013-10-25T11:26:26.851-07:00', 'type': 'Update', 'version': 0}, {'id': 1183704774, 'date': '2013-12-18T00:00:00-08:00', 'type': 'Update', 'version': 0}, {'id': 1452700040, 'date': '2024-11-13T12:56:40.582-08:00', 'description': 'added note about discontinued marketing status', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101820, 'title': 'Drugs@FDA: Drug Product nalidixic acid (NDA014214)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=014214', 'crossReferences': [{'id': 1449763237, 'resource': 'FDA Application', 'resourceId': 'NDA014214', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=014214'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164746384', 'name': 'nalidixic acid'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981755.0,"<p>Nalidixic acid (NegGram) is used to treat urinary tract infections due to gram-negative bacteria.  Although the nalidixic acid drug label does not specifically mention genetic testing, the FDA highlight precaution prior to initiating treatment with nalidixic acid for G6PD deficient individuals due to an association with hemolytic anemia.</p>
<p><strong>November 2024: Please note that the marketing status of nalidixic acid is listed as discontinued by the FDA. However, this drug is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
",1447981754.0,"<p>Excerpt from the nalidixic acid (NegGram) drug label:</p>
<blockquote class=""blockquote"">
<p>Caution should be observed in patients with glucose-6-phosphate dehydrogenase deficiency. (See ADVERSE REACTIONS).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>ADVERSE REACTIONS...Other: Tendon disorders including tendon rupture, cholestasis, paresthesia, metabolic acidosis, thrombocytopenia, leukopenia, or hemolytic anemia, sometimes associated with glucose 6-phosphate dehydrogenase deficiency and peripheral neuropathy.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Nalidixic_Acid_12_15_17.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Nalidixic_Acid_12_15_17.pdf"">nalidixic acid drug label</a>.</p>
<p><strong>November 2024: Please note that the marketing status of nalidixic acid is listed as discontinued by the FDA. However, this drug is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399712.0,"<p>Excerpt from the nalidixic acid (NegGram) drug label:</p>
<blockquote class=""blockquote"">
<p>Caution should be observed in patients with glucose-6-phosphate dehydrogenase deficiency. (See ADVERSE REACTIONS).</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166358601,Annotation of HCSC Label for nateglinide,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450600', 'name': 'nateglinide'}]",[],HCSC,,,1452700080.0,"<p>As of November 2024, all nateglinide drug products have a &quot;Cancelled Post Market&quot; status on the HCSC website.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166358621,Annotation of HCSC Label for nebivolol and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15169842, 'title': 'Drugs@HCSC: Drug Product BYSTOLIC (nebivolol), AbbVie Corporation', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88390', 'crossReferences': [{'id': 1452700120, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88390', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88390'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA151958426', 'name': 'nebivolol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452700121.0,"<p>The HCSC-approved product monograph for nebivolol (BYSTOLIC) states that, though it is metabolized by CYP2D6, no dose adjustments are necessary for CYP2D6 poor metabolizers, as the clinical effect and safety profile was similar between poor and extensive metabolizers.</p>
<p>The product monograph also notes that the drug is contraindicated in patients with the rare hereditary conditions of Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, but no genes are mentioned.</p>
",1452700122.0,"<p>Excerpts from the nebivolol (BYSTOLIC) product monograph:</p>
<blockquote class=""blockquote"">
<p>No dose adjustments are necessary for patients who are CYP2D6 poor metabolizers. The clinical effect and safety profile observed in poor metabolizers were similar to those of extensive metabolizers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Nebivolol is predominantly (75%) metabolized by cytochrome P450 2D6 via direct glucuronidation and to a lesser extent, via N-dealkylation and oxidation of the parent
compound. Its stereospecific metabolites contribute to the pharmacologic activity. Nebivolol is also metabolized to a lesser extent by CYP3A4/5 (16-20%). <em>d</em>-Nebivolol, has an effective halflife of about 13 hours in CYP2D6 extensive metabolizers (EM, most people), and 22 hours in poor metabolizers (PM) and exposure to d-nebivolol is substantially increased in poor metabolizers. This may have less importance than usual, however, because the metabolites, including the hydroxyl metabolite and glucuronides (the predominant circulating metabolites), partially contribute to β-blocking activity of nebivolol.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>BYSTOLIC is contraindicated in patients with: [...]</p>
<ul>
<li>The rare hereditary conditions of Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption</li>
</ul>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Nebivolol_2024_11_13_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Nebivolol_2024_11_13_HCSC.pdf"">nebivolol product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166358701,Annotation of HCSC Label for palonosetron and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15170022, 'title': 'Drugs@HCSC: Drug Product ALOXI (palonosetron), Knight Therapeutics Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86757', 'crossReferences': [{'id': 1452701220, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86757', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86757'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10352', 'name': 'palonosetron'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452701260.0,"<p>The HCSC-approved product monograph for palonosetron (ALOXI) states that there is no significant difference in clinical pharmacokinetic parameters between CYP2D6 poor and extensive metabolizers.</p>
",1452701261.0,"<p>Excerpts from the palonosetron (ALOXI) product monograph:</p>
<blockquote class=""blockquote"">
<p><em>In vitro</em> metabolism studies have suggested that CYP2D6 and to a lesser extent, CYP3A4 and CYP1A2 are involved in the metabolism of palonosetron. However, clinical pharmacokinetic parameters are not significantly different between poor and extensive metabolizers of CYP2D6 substrates.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Palonosetron_2024_11_14_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Palonosetron_2024_11_14_HCSC.pdf"">palonosetron product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452701262.0,"<blockquote class=""blockquote"">
<p><strong>Pediatrics (2 to 17 years of age):</strong> The safety and efficacy of ALOXI injection has been established in pediatric patients aged 2 to 17 years undergoing moderately and highly emetogenic cancer chemotherapy. Data in patients aged 2 months to 2 years were limited. No data are available in children aged less than 2 months (see ADVERSE REACTIONS/Clinical Trial Adverse Reactions [Pediatrics]; CLINICAL TRIALS).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Safety and effectiveness of ALOXI capsules in patients below the age of 18 years have not been established.</p>
</blockquote>
",1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166358762,Annotation of HCSC Label for pantoprazole,False,False,[],False,[],False,[],True,"[{'id': 15170062, 'title': 'Drugs@HCSC: Drug Product M-PANTOPRAZOLE (pantoprazole), Mantra Pharma Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95575', 'crossReferences': [{'id': 1452701426, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95575', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95575'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450774', 'name': 'pantoprazole'}]",[],HCSC,1452701427.0,"<p>The HCSC-approved product monograph states that the main metabolic pathway for pantoprazole is demethylation by CYP2C19. Pantoprazole is not authorized for pediatric use by Health Canada.</p>
",1452701428.0,"<p>Excerpts from the pantoprazole (M-PANTOPRAZOLE) product monograph:</p>
<blockquote class=""blockquote"">
<p>Pantoprazole undergoes extensive hepatic metabolism via cytochrome P450-mediated oxidation. The main metabolic pathway is demethylation by CYP 2C19 and other metabolic pathways which include oxidation by CYP 3A4. This is followed by sulphate conjugation via a Phase II reaction (non-saturable, non-cytochrome P450 dependent).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Pantoprazole_2024_11_14_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Pantoprazole_2024_11_14_HCSC.pdf"">pantoprazole product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166358781,Annotation of HCSC Label for pazopanib and HLA-B,False,False,[],False,[],False,[],True,"[{'id': 15170102, 'title': 'Drugs@HCSC: Drug Product VOTRIENT (pazopanib), Novartis Pharmaceuticals Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83758', 'crossReferences': [{'id': 1452701540, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83758', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83758'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165956201', 'symbol': 'HLA-B*51:01', 'name': '*51:01'}]","[{'objCls': 'Chemical', 'id': 'PA165291492', 'name': 'pazopanib'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",HCSC,1452701541.0,"<p>The HCSC-approved product monograph for pazopanib states that patients who carry the HLA-B*57:01 allele have an increased risk of pazopanib-associated ALT elevations, and that a careful risk/benefit assessment should be made for patients known to be carrying the HLA-B*57:01 allele.</p>
",1452701542.0,"<p>Excerpts from the pazopanib (VOTRIENT) product monograph:</p>
<blockquote class=""blockquote"">
<p>Patients who carry the HLA-B*57:01 allele also have an increased risk of pazopanib-associated ALT elevations. Liver function should be monitored in all patients receiving pazopanib, regardless of genotype or age. A careful risk/benefit assessment should be made for patients known to be carrying the HLA-B*57:01 allele (see 10 CLINICAL PHARMACOLOGY, Pharmacogenomics).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In a pharmacogenetic meta-analysis of data from 31 clinical studies of pazopanib administered as either monotherapy or in combination with other agents, ALT &gt; 3 X ULN occurred in 32% of HLA-B*57:01 allele carriers and in 19% of non-carriers, and ALT &gt; 5 X ULN (NCI CTC Grade 3) occurred in 19% of HLA-B*57:01 allele carriers and in 10% of non-carriers. In this dataset, 133/2235 (6%) of the patients carried the HLA-B*57:01 allele (see 7 Warnings and Precautions).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pazopanib is a substrate of CYP3A4 and the multidrug efflux pump P-glycoprotein (PgP).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pazopanib is a potent in vitro inhibitor of proteins UDP glucuronsyltransferase 1 family, polypeptide A1 (UGT1A1) and the organic anion transporter polypeptide 1B1 (OATP1B1).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Pazopanib_2024_11_14_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Pazopanib_2024_11_14_HCSC.pdf"">pazopanib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452701543.0,"<blockquote class=""blockquote"">
<p>Patients who carry the HLA-B*57:01 allele also have an increased risk of pazopanib-associated ALT elevations. Liver function should be monitored in all patients receiving pazopanib, regardless of genotype or age. A careful risk/benefit assessment should be made for patients known to be carrying the HLA-B*57:01 allele</p>
</blockquote>
",,,,,,,
Label Annotation,PA166358801,Annotation of HCSC Label for pemetrexed,False,False,[],False,[],False,[],True,"[{'id': 15170122, 'title': 'Drugs@HCSC: Drug Product ALIMTA (pemetrexed), Eli Lilly Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79204', 'crossReferences': [{'id': 1452701740, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79204', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79204'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA10810', 'name': 'pemetrexed'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166358821,Annotation of HCSC Label for perphenazine,False,False,[],False,[],False,[],True,"[{'id': 15170142, 'title': 'Drugs@HCSC: Drug Product Perphenazine, AA Pharma Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2368', 'crossReferences': [{'id': 1452701760, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2368', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2368'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA450882', 'name': 'perphenazine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166358841,Annotation of HCSC Label for piroxicam,False,False,[],False,[],False,[],True,"[{'id': 15170162, 'title': 'Drugs@HCSC: Drug Product APO-PIROXICAM (piroxicam), APOTEX INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6714', 'crossReferences': [{'id': 1452701780, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6714', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6714'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA450985', 'name': 'piroxicam'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166358861,"Annotation of HCSC Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5",False,False,[],False,[],False,[],True,"[{'id': 15170182, 'title': 'Drugs@HCSC: Drug Product JAMP Prasugrel (prasugrel), JAMP Pharma Corporation', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99200', 'crossReferences': [{'id': 1452702460, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99200', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99200'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA154410481', 'name': 'prasugrel'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}, {'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA131', 'symbol': 'CYP3A5', 'name': 'cytochrome P450 family 3 subfamily A member 5'}]",HCSC,1452702461.0,"<p>The HCSC-approved product monograph for prasugrel contains information regarding a lack of effect of genetic variants in the CYP3A5, CYP2B6, CYP2C9 and CYP2C19 genes on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.</p>
",1452702462.0,"<p>Excerpts from the prasugrel (JAMP Prasugrel) product monograph:</p>
<blockquote class=""blockquote"">
<p>[Prasugrel] is rapidly hydrolyzed in the intestine to a thiolactone, which is then converted to the active metabolite by a single step of cytochrome P450 metabolism, primarily by CYP3A4 and CYP2B6 and to a lesser extent by CYP2C9 and CYP2C19. The active metabolite is further metabolized to two inactive compounds by S-methylation or conjugation with cysteine.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In healthy subjects, patients with stable atherosclerosis, and patients with ACS receiving prasugrel, there was no relevant effect of genetic variation in CYP3A5, CYP2B6, CYP2C9, or CYP2C19 on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Prasugrel_2024_11_15_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Prasugrel_2024_11_15_HCSC.pdf"">prasugrel product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166358881,Annotation of HCSC Label for propranolol and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15170222, 'title': 'Drugs@HCSC: Drug Product HEMANGIOL (propranolol), Pierre Fabre Dermo-Cosmetique Canada Inc', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94488', 'crossReferences': [{'id': 1452702600, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94488', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94488'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451145', 'name': 'propranolol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452702601.0,"<p>The product monograph for propranolol (HEMANGIOL) gives information regarding the metabolism of the drug by three different routes which varies between individuals, but that no difference in oral clearance or elimination half life is observed between CYP2D6 extensive and poor metabolizers.</p>
",1452702602.0,"<p>Excerpts from the propranolol (HEMANGIOL) product monograph:</p>
<blockquote class=""blockquote"">
<p>Propranolol is metabolized through three primary routes: aromatic hydroxylation (mainly 4-hydroxylation), N-dealkylation followed by further side-chain oxidation, and direct glucuronidation. The percentage contributions of these routes to total metabolism are 42%, 41% and 17%, respectively, but with considerable variability between individuals. The four major final metabolites are propranolol glucuronide, naphthyloxylactic acid and glucuronic acid, and sulfate conjugates of 4-hydroxy propranolol. <em>In vitro</em> studies indicated that CYP2D6 (aromatic hydroxylation), CYP1A2 (chain oxidation) and to a less extent CYP2C19 were involved in propranolol metabolism.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In healthy subjects, no difference was observed between CYP2D6 extensive metabolizers and poor metabolizers with respect to oral clearance or elimination half-life.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Propranolol_2024_11_15_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Propranolol_2024_11_15_HCSC.pdf"">propranolol product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452702603.0,"<blockquote class=""blockquote"">
<p>HEMANGIOL (propranolol oral solution) is indicated for:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The treatment of proliferating infantile hemangioma requiring systemic therapy:</p>
<ul>
<li>Life- or function-threatening hemangioma,</li>
<li>Ulcerated hemangioma with pain and/or lack of response to simple wound care measures,</li>
<li>Hemangioma with a risk of permanent scarring or disfigurement.</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Treatment should be initiated in infants aged 5 weeks to 5 months. Age for treatment initiation should be corrected in case of prematurity.</p>
</blockquote>
",1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166358901,Annotation of HCSC Label for raltegravir and UGT1A1,False,False,[],False,[],False,[],True,"[{'id': 15170242, 'title': 'Drugs@HCSC: Drug Product ISENTRESS (raltegravir), Merck Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87770', 'crossReferences': [{'id': 1452702640, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87770', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87770'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164888966', 'name': 'raltegravir'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",HCSC,1452702660.0,"<p>The product monograph for raltegravir (ISENTRESS) states that there is no evidence that common UGT1A1 polymorphisms alter raltegravir pharmacokinetics to a clinically meaningful extent, despite UGT1A1 being the primary enzyme involved in raltegravir elimination.</p>
",1452702661.0,"<p>Excerpts from the raltegravir (ISENTRESS) product monograph:</p>
<blockquote class=""blockquote"">
<p><strong>Genetic Polymorphism:</strong> There is no evidence that common UGT1A1 polymorphisms alter raltegravir pharmacokinetics to a clinically meaningful extent. In a comparison of 30 adult subjects with *28/*28 genotype (associated with reduced activity of UGT1A1) to 27 adult subjects with wild-type genotype, the geometric mean ratio (90% CI) of AUC was 1.41 (0.96, 2.09).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Based on <em>in vivo</em> and <em>in vitro</em> studies, raltegravir is eliminated mainly by metabolism via a UGT1A1-mediated glucuronidation pathway.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Raltegravir_2024_11_15_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Raltegravir_2024_11_15_HCSC.pdf"">raltegravir product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166358921,Annotation of HCSC Label for ramucirumab,False,False,[],False,[],False,[],True,"[{'id': 15170262, 'title': 'Drugs@HCSC: Drug Product CYRAMZA (ramucirumab), Eli Lilly Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92855', 'crossReferences': [{'id': 1452702720, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92855', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92855'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184558', 'name': 'ramucirumab'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166358961,Annotation of EMA Label for risperidone and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15170302, 'title': 'Okedi | European Medicines Agency (EMA)', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/okedi', 'crossReferences': [{'id': 1452702820, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/okedi', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/okedi'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451257', 'name': 'risperidone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1452702821.0,"<p>The EPAR for risperidone (OKEDI) states that the pharmacokinetics of the total active moiety is similar in CYP2D6 extensive and poor metabolizers.</p>
",1452702822.0,"<p>Excerpts from the risperidone (OKEDI) EPAR:</p>
<blockquote class=""blockquote"">
<p>Risperidone is metabolised by CYP2D6 to 9-hydroxy-risperidone, which has a similar pharmacological activity as risperidone. Risperidone plus 9-hydroxy-risperidone form the active moiety. CYP2D6 is subject to genetic polymorphism. Extensive CYP2D6 metabolisers convert risperidone rapidly into 9-hydroxy-risperidone, whereas poor CYP2D6 metabolisers convert it much more slowly. Although extensive metabolisers have lower risperidone and higher 9-hydroxy-risperidone concentrations than poor metabolisers, the pharmacokinetics of risperidone and 9-hydroxy-risperidone combined (i.e., the active moiety), after single and multiple doses, are similar in extensive and poor metabolisers of CYP2D6.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Risperidone_2024_11_15_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Risperidone_2024_11_15_EMA.pdf"">risperidone EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166358981,Annotation of HCSC Label for ropivacaine,False,False,[],False,[],False,[],True,"[{'id': 15170322, 'title': 'Drugs@HCSC: Drug Product NAROPIN (ropivacaine), Aspen Pharmacare Canada Inc', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47216', 'crossReferences': [{'id': 1452704220, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47216', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47216'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451271', 'name': 'ropivacaine'}]",[],HCSC,1452704240.0,"<p>The product monograph for ropivacaine (NAROPIN) contains no information about the risk of developing methemoglobinemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and congenital methemoglobinemia (associated with variants in CYB5R3).</p>
",1452704241.0,"<p>Excerpt from the ropivacaine (NAROPIN) product monograph:</p>
<blockquote class=""blockquote"">
<p>Ropivacaine is extensively metabolized in the liver predominantly to 3-hydroxy-ropivacaine by an aromatic hydroxylation process mediated by cytochrome P4501A2 and N-dealkylation to S-PPX mediated by CYP3A4.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Ropivacaine_2024_11_15_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ropivacaine_2024_11_15_HCSC.pdf"">ropivacaine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166359101,Annotation of HCSC Label for streptomycin,False,False,[],False,[],False,[],True,"[{'id': 15170522, 'title': 'Drugs@HCSC: Drug Product Streptomycin, SteriMax Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67590', 'crossReferences': [{'id': 1452706600, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67590', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67590'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA451512', 'name': 'streptomycin'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166359201,Annotation of HCSC Label for tamsulosin and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15170542, 'title': 'Drugs@HCSC: Drug Product TAMSULOSIN CR (tamsulosin), Sivem Pharmaceuticals ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91411', 'crossReferences': [{'id': 1452707180, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91411', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91411'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451583', 'name': 'tamsulosin'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452707181.0,"<p>The product monograph for tamsulosin states that an increase in exposure is expected in CYP2D6 poor metabolizers as compared to extensive metabolizers.</p>
",1452707182.0,"<p>Excerpts from the tamsulosin (TAMSULOSIN CR) product monograph:</p>
<blockquote class=""blockquote"">
<p>Tamsulosin is extensively metabolized by cytochrome P450 enzymes (CYP3A4 and CYP2D6) in the liver, followed by extensive glucuronide or sulfate conjugation of metabolites.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The effects of paroxetine (a strong inhibitor of CYP2D6) at 20 mg once daily for 9 days on the pharmacokinetics of a single tamsulosin hydrochloride sustained-release capsule 0.4 mg dose was investigated in 24 healthy volunteers (age range 23 to 47 years). Concomitant treatment with paroxetine resulted in an increase in the Cmax and AUC of tamsulosin by a factor of 1.3 and 1.6, respectively. A similar increase in exposure is expected in CYP2D6 poor metabolizers (PM) as compared to extensive metabolizers (EM).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Tamsulosin_2024_11_18_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Tamsulosin_2024_11_18_HCSC.pdf"">tamsulosin product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166293681,"Annotation of FDA Label for trastuzumab deruxtecan and ESR1, ESR2",False,True,[],False,"[{'id': 1452220423, 'date': '2023-08-29T12:35:53.457-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}, {'id': 1452253866, 'date': '2023-09-28T09:52:37.748-07:00', 'description': 'Fixed typo in label link.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15104822, 'title': 'Drugs@FDA: Drug Product  ENHERTU BLA761139', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761139', 'crossReferences': [{'id': 1450971162, 'resource': 'FDA Application', 'resourceId': 'BLA761139', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761139'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166190621', 'name': 'trastuzumab deruxtecan'}]","[{'objCls': 'Gene', 'id': 'PA156', 'symbol': 'ESR1', 'name': 'estrogen receptor 1'}, {'objCls': 'Gene', 'id': 'PA27886', 'symbol': 'ESR2', 'name': 'estrogen receptor 2'}]",FDA,1452041481.0,"<p>The FDA table lists ESR as biomarker for trastuzumab deruxtecan as hormone receptor status is mentioned in the label in the clinical studies section.</p>
",1452041482.0,"<p>Excerpts from the trastuzumab deruxtecan (<em><strong>ENHERTU</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>The efficacy of ENHERTU was evaluated in study DESTINY-Breast04 (NCT03734029), a randomized, multicenter, open-label study that enrolled 557 adult patients with unresectable or metastatic HER2-low breast cancer. The study included 2 cohorts: 494 hormone receptor-positive (HR+) patients and 63 hormone receptor-negative (HR-) patients. HER2-low expression was defined as IHC 1+ or IHC 2+/ISH-, as determined at a central laboratory using Ventana’s PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody assay.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""TrastuzumabDeruxtecan_FDA_2023_03_20.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/TrastuzumabDeruxtecan_FDA_2023_03_20.pdf""><em><strong>TrastuzumabDeruxtecan</strong></em> drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166163412,Annotation of FDA Label for ombitasvir / paritaprevir / ritonavir and IFNL3,False,False,[],False,"[{'id': 1450378268, 'date': '2019-04-11T16:36:53.902-07:00', 'description': 'Added variant information', 'type': 'Update', 'version': 0}, {'id': 1450379055, 'date': '2019-04-14T17:31:19.935-07:00', 'description': 'Updated label PDF', 'type': 'Update', 'version': 0}, {'id': 1452230510, 'date': '2023-09-07T11:17:45.572-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101907, 'title': 'Drugs@FDA: Drug Product Technivie (Ombitasvir and Paritaprevir and Ritonavir), NDA207931, AbbVie Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207931', 'crossReferences': [{'id': 1449767728, 'resource': 'FDA Application', 'resourceId': 'NDA207931', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207931'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166163408', 'name': 'ombitasvir / paritaprevir / ritonavir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",FDA,1448604817.0,"<p>Technivie (ombitasvir, paritaprevir and ritonavir) is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.</p>
",1448604816.0,"<p>Excerpts from the Technivie drug label:</p>
<blockquote class=""blockquote"">
<p>Clinical Trial Results in Adults with Chronic GT4 HCV Infection without Cirrhosis...79% had IL28B (rs12979860) non-CC genotype...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Clinical Trial Results in Adults with Chronic GT4 HCV Infection with Compensated Cirrhosis...86% had IL28B (rs12979860) non-CC genotype...</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Ombitasvir_Paritaprevir_Ritonavir_04_14_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ombitasvir_Paritaprevir_Ritonavir_04_14_19_FDA.pdf"">Technivie drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166163435,Annotation of FDA Label for olaratumab and PDGFRA,False,True,[],False,"[{'id': 1450380953, 'date': '2019-04-18T15:26:57.881-07:00', 'description': 'Added cancer genome tag', 'type': 'Update', 'version': 0}, {'id': 1452214240, 'date': '2023-08-23T10:19:54.142-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102003, 'title': 'Drugs@FDA: Drug Product LARTRUVO (olaratumab), BLA761038, Eli Lilly and Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761038', 'crossReferences': [{'id': 1449767725, 'resource': 'FDA Application', 'resourceId': 'BLA761038', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761038'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166163434', 'name': 'olaratumab'}]","[{'objCls': 'Gene', 'id': 'PA33147', 'symbol': 'PDGFRA', 'name': 'platelet derived growth factor receptor alpha'}]",FDA,1448605074.0,"<p>Olaratumab (LARTRUVO) is a platelet-derived growth factor receptor alpha (PDGFR-&alpha;) blocking antibody indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.</p>
",1448605073.0,"<p>Excerpts from the olaratumab (LARTRUVO) drug label:</p>
<div class=""blockquote"">
<p>LARTRUVO...is a platelet-derived growth factor receptor alpha (PDGFR-&alpha;) blocking antibody indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.</p>
</div>
<div class=""blockquote"">
<p>Olaratumab is a human IgG1 antibody that binds platelet-derived growth factor receptor alpha (PDGFR-&alpha;). PDGFR-&alpha; is a receptor tyrosine kinase expressed on cells of mesenchymal origin. Signaling through this receptor plays a role in cell growth, chemotaxis, and mesenchymal stem cell differentiation. The receptor has also been detected on some tumor and stromal cells, including sarcomas, where signaling can contribute to cancer cell proliferation, metastasis, and maintenance of the tumor microenvironment.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Olaratumab_08_11_2017_FDA.pdf"">olaratumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166359241,Annotation of HCSC Label for ticagrelor and CYP2C19,False,False,[],False,[],False,[],True,"[{'id': 15170582, 'title': 'Drugs@HCSC: Drug Product BRILINTA (ticagrelor), AstraZeneca Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94181', 'crossReferences': [{'id': 1452707340, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94181', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94181'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165374673', 'name': 'ticagrelor'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1452707341.0,"<p>Ticagrelor (BRILINTA) is a platelet inhibitor used to reduce the risk of thrombotic cardiovascular events for patients with acute coronary syndrome. The product monograph notes that major cardiovascular events and bleeding were not significantly affected by CYP2C19 genotype compared to clopidogrel in the PLATO substudy.</p>
",1452707342.0,"<p>Excerpts from the ticagrelor (BRILINTA) product monograph:</p>
<blockquote class=""blockquote"">
<p><strong>PLATO Genetic Substudy</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C19 genotyping of 10,285 patients in PLATO provided associations of genotype groups with the efficacy and safety outcomes. The effects of BRILINTA compared to clopidogrel on major CV events and bleeding were not significantly affected by CYP2C19 genotype. The efficacy and safety results of the substudy were consistent with the main PLATO study.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP3A is the major enzyme responsible for ticagrelor metabolism and the formation of the active metabolite and their interactions with other CYP3A substrates ranges from activation through to inhibition. Ticagrelor and the active metabolite are weak p-glycoprotein inhibitors. There is a complex interaction between ticagrelor and CYP3A4/5, depending on the substrate used.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Ticagrelor_2024_11_18_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ticagrelor_2024_11_18_HCSC.pdf"">ticagrelor product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166294981,Annotation of EMA Label for pemigatinib and FGFR2,False,True,[],False,[],False,[],True,"[{'id': 15142542, 'title': 'Drugs@EMA: Drug Product Pemazyre (pemigatinib), Incyte Biosciences Distribution B.V.', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre', 'crossReferences': [{'id': 1452047660, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre'}], 'objCls': 'Literature', 'pubDate': '2023-02-01T00:00:00-08:00', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166248041', 'name': 'pemigatinib'}]","[{'objCls': 'Gene', 'id': 'PA28128', 'symbol': 'FGFR2', 'name': 'fibroblast growth factor receptor 2'}]",EMA,1452047680.0,"<p>Pemigatinib is a kinase inhibitor indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.</p>
",1452047681.0,"<p>Excerpts from the pemigatinib (Pemazyre) EPAR:</p>
<blockquote class=""blockquote"">
<p>Pemigatinib is a kinase inhibitor of FGFR1, 2 and 3 which inhibits FGFR phosphorylation and signalling and decreases cell viability in cells expressing FGFR genetic alterations, including point mutations, amplifications, and fusions or rearrangements. FGFR2 fusions/rearrangements are strong oncogenic drivers and are the most common FGFR alteration occurring, almost exclusively, in 10-16 % of intrahepatic cholangiocarcinoma (CCA).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>FGFR 2 fusion positivity status must be known prior to initiation of Pemazyre therapy. Assessment for FGFR 2 fusion positivity in tumor specimen should be performed with an appropriate diagnostic test.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""pemigatinib_2023_03_16_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/pemigatinib_2023_03_16_EMA.pdf"">pemigatinib EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166295001,Annotation of HCSC Label for pemigatinib and FGFR2,False,True,[],False,[],False,[],True,"[{'id': 15142562, 'title': 'Drugs@HCSC: Drug Product PEMAZYRE (pemigatinib), Incyte Corporation', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100917', 'crossReferences': [{'id': 1452047720, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100917', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100917'}], 'objCls': 'Literature', 'pubDate': '2021-09-01T00:00:00-07:00', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166248041', 'name': 'pemigatinib'}]","[{'objCls': 'Gene', 'id': 'PA28128', 'symbol': 'FGFR2', 'name': 'fibroblast growth factor receptor 2'}]",HCSC,1452047740.0,"<p>PEMAZYRE™ (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.</p>
",1452047741.0,"<p>Excerpts from the pemigatinib (PEMAZYRE) product monograph:</p>
<blockquote class=""blockquote"">
<p>PEMAZYRE™ (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients must be selected for the treatment of locally advanced or metastatic cholangiocarcinoma with PEMAZYRE™ based on the confirmation of an FGFR2 fusion or rearrangement by a validated test.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Before taking PEMAZYRE™, patients must have confirmation of an FGFR2 fusion or other rearrangement by a validated test. In the FIGHT-202 clinical trial, qualifying in-frame fusions and other rearrangements were predicted to have a breakpoint within intron 17/exon 18 of the FGFR2 gene, leaving the FGFR2 kinase domain intact.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""pemigatinib_2023_03_16_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/pemigatinib_2023_03_16_HCSC.pdf"">pemigatinib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166104800,Annotation of FDA Label for indacaterol and UGT1A1,False,False,[],False,"[{'id': 1183681668, 'date': '2013-10-25T14:23:57.468-07:00', 'type': 'Update', 'version': 0}, {'id': 1452694140, 'date': '2024-11-08T09:50:12.060-08:00', 'description': 'add text about discontinued status of indacaterol', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102010, 'title': 'Drugs@FDA: Drug Product ARCAPTA NEOHALER (INDACATEROL MALEATE), NDA022383, Sunovion Pharmaceuticals Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022383', 'crossReferences': [{'id': 1449754767, 'resource': 'FDA Application', 'resourceId': 'NDA022383', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022383'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958348', 'name': 'indacaterol'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",FDA,1447981550.0,"<p>The FDA-approved drug label for indacaterol (ARCAPTA NEOHALER) states that steady-state AUC and Cmax of indacaterol were 1.2-fold higher in patients with the (TA)7/(TA)7 (*28/*28) genotype than in patients with the (TA)6/(TA)6 (*1/*1) genotype, suggesting no relevant effect of UGT1A1 genotype of indacaterol exposure.</p>
<p><strong>November 2024: Please note that indacaterol is listed as discontinued by the FDA. However, this drug is still listed on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
",1447981549.0,"<p>Excerpt from the indacaterol (ARCAPTA NEOHALER) label:</p>
<blockquote class=""blockquote"">
<p>The pharmacokinetics of indacaterol were prospectively investigated in subjects with the UGT1A1 (TA)7/(TA)7 genotype (low UGT1A1 expression; also referred to as *28) and the (TA)6, (TA)6 genotype. Steady-state AUC and Cmax of indacaterol were 1.2-fold higher in the [(TA)7, (TA)7] genotype, suggesting no relevant effect of UGT1A1 genotype of indacaterol exposure.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Indacaterol_07_31_2017_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Indacaterol_07_31_2017_FDA.pdf"">indacaterol drug label</a>.</p>
<p><strong>November 2024: Please note that indacaterol is listed as discontinued by the FDA. However, this drug is still listed on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104798,Annotation of FDA Label for propranolol and CYP2D6,False,False,[],False,"[{'id': 1183681390, 'date': '2013-10-25T11:33:02.886-07:00', 'type': 'Update', 'version': 0}, {'id': 1452702523, 'date': '2024-11-15T09:36:47.452-08:00', 'description': 'fixed typo', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101944, 'title': 'Drugs@FDA: Drug Product INDERAL XL (propranolol hydrochloride), NDA021438, Mist Pharmaceuticals, LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021438', 'crossReferences': [{'id': 1450369520, 'resource': 'FDA Application', 'resourceId': 'NDA021438', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021438'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451145', 'name': 'propranolol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981546.0,"<p>The FDA-approved drug label for propranolol (INNOPRAN XL) states that no difference in clearance of the drug was observed between CYP2D6 extensive and poor metabolizers.</p>
",1447981545.0,"<p>Excerpts from the propranolol (INNOPRAN XL) drug label:</p>
<blockquote class=""blockquote"">
<p>In healthy subjects, no difference was observed between CYP2D6 extensive metabolizers (EMs) and poor metabolizers (PMs) with respect to oral clearance or elimination half-life. Partial clearance to 4-hydroxy propranolol was significantly higher and to naphthyloxylactic acid was significantly lower in EMs than PMs.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Propranolol_02_25_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Propranolol_02_25_19_FDA.pdf"">propranolol drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104811,Annotation of FDA Label for quinidine and CYP2D6,False,False,[],False,"[{'id': 1183681392, 'date': '2013-10-25T11:33:49.052-07:00', 'type': 'Update', 'version': 0}, {'id': 1452230587, 'date': '2023-09-07T11:33:48.252-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102013, 'title': 'Drugs@FDA: Drug Product Quinidine Gluconate (Quinidine Gluconate), ANDA089338, Carilion Materials Management', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=089338', 'crossReferences': [{'id': 1449776512, 'resource': 'FDA Application', 'resourceId': 'ANDA089338', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=089338'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451209', 'name': 'quinidine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981600.0,"<p>The FDA-approved drug label for quinidine states that the drug inhibits the action of CYP2D6, effectively converting CYP2D6 extensive metabolizers into poor metabolizers. The drug label advises caution whenever quinidine is prescribed together with drugs metabolized by CYP2D6.</p>
",1447981599.0,"<p>Quinidine is a Class I antiarrhythmic medication</p>
<p>Excerpt from the quinidine drug label:</p>
<div class=""blockquote"">
<p>Quinidine is not metabolized by cytochrome P450IID6, but therapeutic serum levels of quinidine inhibit the action of cytochrome P450IID6, effectively converting extensive metabolizers into poor metabolizers. Caution must be exercised whenever quinidine is prescribed together with drugs metabolized by cytochrome P450IID6.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Quinidine_02_25_19_FDA.pdf"">quinidine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104845,Annotation of FDA Label for dapsone and CYB5R3,True,False,[],False,"[{'id': 1183681538, 'date': '2013-10-25T12:31:26.009-07:00', 'type': 'Update', 'version': 0}, {'id': 1450821531, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1450822530, 'date': '2019-10-15T09:35:14.558-07:00', 'description': 'Added link and text about CYB5R3 and congenital methemoglobinemia.', 'type': 'Update', 'version': 0}, {'id': 1452532461, 'date': '2024-07-19T15:52:43.257-07:00', 'description': 'split G6PD into a separate label annotation; added Alternate Drug and prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101977, 'title': 'Drugs@FDA: Drug Product DAPSONE (dapsone), Pacific Pharma, Inc. - NDA021794/SUPPL-16, 05/18/2018', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021794', 'crossReferences': [{'id': 1452532404, 'resource': 'FDA Application', 'resourceId': 'NDA021794/SUPPL-16', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021794'}], 'objCls': 'Literature', 'pubDate': '2018-05-18T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449211', 'name': 'dapsone'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}]",FDA,1450342871.0,"<p>The FDA-approved label for dapsone gel (ACZONE) states that some subjects with G6PD deficiency using ACZONE developed laboratory changes suggestive of hemolysis. The label states that dapsone gel (ACZONE) should be avoided in patients with congenital methemoglobinemia, which is associated with variants in CYB5R3.</p>
",1450342872.0,"<p>Dapsone (ACZONE) is indicated for the topical treatment of acne vulgaris.</p>
<p>Excerpt from the dapsone gel (ACZONE) drug label:</p>
<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia, with resultant hospitalization, have been reported postmarketing in association with ACZONE Gel, 5% treatment. Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. Avoid use of ACZONE Gel, 5% in those patients with congenital or idiopathic methemoglobinemia.</p>
</blockquote>
<p>NOTE: While the CYB5R3 gene is not explicitly stated in the drug label variants in this gene are associated with congenital methemoglobinemia I and II <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/250800"" target=""_blank"">OMIM 250800</a>.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the and <a download=""Dapsone_01_10_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dapsone_01_10_19_FDA.pdf"">dapsone drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452532460.0,"<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia, with resultant hospitalization, have been reported postmarketing in association with ACZONE Gel, 5% treatment. [...] Avoid use of ACZONE Gel, 5% in those patients with congenital or idiopathic methemoglobinemia.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166295822,Annotation of FDA Label for teclistamab,False,True,[],False,"[{'id': 1452215400, 'date': '2023-08-24T16:01:29.574-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15142782, 'title': 'Drugs@FDA: Drug Product TECVAYLI (teclistamab-cqyv), BLA 761291, Janssen Biotech', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761291', 'crossReferences': [{'id': 1452242821, 'resource': 'FDA Application', 'resourceId': 'BLA761291', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761291'}], 'objCls': 'Literature', 'pubDate': '2022-10-01T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166295601', 'name': 'teclistamab'}]",[],FDA,1452053382.0,"<p>Teclistamab is a bispecific B-cell maturation antigen-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.</p>
<p>The FDA biomarker table entries for teclistamab mention Chromosome 17p, Chromosome 4p;14q, and Chromosome 14q;16q.</p>
",1452053383.0,"<p>Excerpt from the Clinical Studies section of the teclistamab (TECVAYLI) label:</p>
<blockquote class=""blockquote"">
<p>The efficacy population included 110 patients.
High-risk cytogenetics (presence of del(17p), t(4;14) and t(14;16)) were present in 25% of patients.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""teclistamab-cqyv_2023_03_16_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/teclistamab-cqyv_2023_03_16_FDA.pdf"">teclistamab-cqyv drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104788,Annotation of FDA Label for fluoxetine / olanzapine and CYP2D6,False,False,[],False,"[{'id': 1183681712, 'date': '2013-10-25T14:46:46.360-07:00', 'type': 'Update', 'version': 0}, {'id': 1183701081, 'date': '2013-12-17T09:26:12.231-08:00', 'description': 'Removed from FDA Biomarker Table', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102036, 'title': 'Drugs@FDA: Drug Product Symbyax (Olanzapine and Fluoxetine hydrochloride), NDA021520, Eli Lilly and Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021520', 'crossReferences': [{'id': 1449754665, 'resource': 'FDA Application', 'resourceId': 'NDA021520', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021520'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166176027', 'name': 'fluoxetine / olanzapine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450361452.0,"<p>The FDA-approved drug label for fluoxetine and olanzapine (SYMBYAX) states that individuals who are CYP2D6 poor metabolizers metabolized S-fluoxetine at a slower rate and achieved higher concentrations.</p>
",1450361454.0,"<p>Excerpts from the fluoxetine and olanzapine (SYMBYAX) drug label:</p>
<div class=""blockquote"">
<p>A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme CYP2D6. Such individuals are referred to as &quot;poor metabolizers&quot; of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants (TCAs). In a study involving labeled and unlabeled enantiomers administered as a racemate, these individuals metabolized S-fluoxetine at a slower rate and thus achieved higher concentrations of S-fluoxetine. Consequently, concentrations of S-norfluoxetine at steady state were lower.</p>
</div>
<div class=""blockquote"">
<p>Because the metabolism of fluoxetine, like that of a number of other compounds including TCAs and other selective serotonin antidepressants, involves the CYP2D6 system, concomitant therapy with drugs also metabolized by this enzyme system (such as the TCAs) may lead to drug interactions.</p>
</div>
<div class=""blockquote"">
<p>Fluoxetine inhibits the activity of CYP2D6 and may make individuals with normal CYP2D6 metabolic activity resemble a poor metabolizer. Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6... should be approached with caution.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Fluoxetine_Olanzapine_08_11_2017_FDA.pdf"">fluoxetine and olanzapine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166104833,Annotation of FDA Label for abacavir and HLA-B,True,False,[],False,"[{'id': 1183681374, 'date': '2013-10-25T11:27:09.748-07:00', 'type': 'Update', 'version': 0}, {'id': 1450377490, 'date': '2019-04-10T06:25:05.615-07:00', 'description': 'Update to include haplotype.', 'type': 'Update', 'version': 0}, {'id': 1450399447, 'date': '2019-05-08T08:53:17.982-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101896, 'title': 'Drugs@FDA: Drug Product ZIAGEN (abacavir sulfate), NDA020977, ViiV Healthcare Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020977', 'crossReferences': [{'id': 1449893329, 'resource': 'FDA Application', 'resourceId': 'NDA020977', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020977'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165987830', 'symbol': 'HLA-B*57:01', 'name': '*57:01'}]","[{'objCls': 'Chemical', 'id': 'PA448004', 'name': 'abacavir'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",FDA,1450043400.0,"<p>The FDA-approved label for abacavir (ZIAGEN) states that genetic testing for the HLA-B*5701 allele is required prior to initiating or reinitiating treatment with abacavir in patients of unknown HLA-B*5701 status. Abacavir is contraindicated in patients with the HLA-B*5701 allele due to risk for abacavir hypersensitivity reactions.</p>
",1450042734.0,"<p>Excerpts from the abacavir (ZIAGEN) drug label:</p>
<blockquote class=""blockquote"">
<p>All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with ZIAGEN or reinitiation of therapy with ZIAGEN, unless patients have a previously documented HLA-B*5701 allele assessment.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>ZIAGEN is contraindicated in patients: who have the HLA-B*5701 allele.</p>
</blockquote>
<p>In the CNA106030 (PREDICT-1) study of 1650 HIV-infected adults, it was found that pre-screening for the HLA-B*5701 allele reduced the incidence of suspected hypersensitivity reactions from 7.8% to 3.4%. Based on this study, it is estimated that 61% of patients carrying the HLA-B*5701 allele will develop a hypersensitivity reaction to abacavir vs. 4% of patients who do not have this allele.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Abacavir_11_15_2018_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Abacavir_11_15_2018_FDA.pdf"">abacavir drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450399446.0,"<p>Excerpts from the abacavir (ZIAGEN) drug label:</p>
<blockquote class=""blockquote"">
<p>DOSAGE AND ADMINISTRATION: Before initiating ZIAGEN, screen for the HLA-B*5701 allele.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS: Presence of HLA-B*5701 allele.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104812,Annotation of FDA Label for protriptyline and CYP2D6,False,False,[],False,"[{'id': 1183681343, 'date': '2013-10-25T11:21:51.184-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101850, 'title': 'Drugs@FDA: Drug Product protriptyline (ANDA073644)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=073644', 'crossReferences': [{'id': 1449776505, 'resource': 'FDA Application', 'resourceId': 'ANDA073644', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=073644'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451168', 'name': 'protriptyline'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981584.0,"<p>Protriptyline hydrochloride is an antidepressant agent and belongs to the class of tricyclic antidepressants. CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.</p>
",1447981583.0,"<p>Excerpts from the protriptyline drug label:</p>
<div class=""blockquote"">
<p>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquine hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small or quite large (8 fold increase in plasma AUC of the TCA).</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Protriptyline_02_22_19_FDA.pdf"">protriptyline drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104806,Annotation of FDA Label for tolterodine and CYP2D6,False,False,[],False,"[{'id': 1183681247, 'date': '2013-10-25T11:00:19.845-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102037, 'title': 'Drugs@FDA: Drug Product Tolterodine Tartrate (Tolterodine Tartrate), NDA020771, REMEDYREPACK INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020771', 'crossReferences': [{'id': 1450369809, 'resource': 'FDA Application', 'resourceId': 'NDA020771', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020771'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164746757', 'name': 'tolterodine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981580.0,"<p>Tolterodine (DETROL) is used for the treatment of overactive bladder and is primarily metabolized by CYP2D6.  Poor metabolizers may have greater plasma concentrations of the drug which could possibly have an effect QT interval.</p>
",1447981579.0,"<p>Excerpts from the tolterodine (DETROL) drug label:</p>
<div class=""blockquote"">
<p>The primary metabolic route involves the oxidation of the 5-methyl group and is mediated by the cytochrome P450 2D6 (CYP2D6) and leads to the formation of a pharmacologically active 5-hydroxymethyl metabolite.</p>
</div>
<div class=""blockquote"">
<p>Pharmacokinetic studies revealed that tolterodine is metabolized at a slower rate in poor metabolizers than in extensive metabolizers; this results in significantly higher serum concentrations of tolterodine and in negligible concentrations of the 5-hydroxymethyl metabolite.</p>
</div>
<div class=""blockquote"">
<p>Tolterodine's effect on QT interval was found to correlate with plasma concentration of tolterodine. There appeared to be a greater QTc interval increase in CYP2D6 poor metabolizers than in CYP2D6 extensive metabolizers after tolterodine treatment in this study.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tolterodine_03_01_19_FDA.pdf"">tolterodine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104863,Annotation of FDA Label for dexlansoprazole and CYP2C19,False,False,[],False,"[{'id': 1183681225, 'date': '2013-10-25T10:57:11.337-07:00', 'type': 'Update', 'version': 0}, {'id': 1452823422, 'date': '2025-01-23T14:42:03.805-08:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101857, 'title': 'Drugs@FDA: Drug Product Dexilant (dexlansoprazole), Cardinal Health 107, LLC - NDA022287/SUPPL-30, 06/07/2018', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022287', 'crossReferences': [{'id': 1452823420, 'resource': 'FDA Application', 'resourceId': 'NDA022287/SUPPL-30', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022287'}], 'objCls': 'Literature', 'pubDate': '2018-06-07T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166110257', 'name': 'dexlansoprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1447981719.0,"<p>The FDA-approved drug label for dexlansoprazole (DEXILANT) notes that systemic exposure of the drug is generally higher in CYP2C19 intermediate and poor metabolizers, as compared to extensive metabolizers.</p>
",1447981718.0,"<p>The FDA-approved drug label for dexlansoprazole (DEXILANT) highlights information regarding CYP2C19 poor metabolizers, as well as information about concomitant administration of tacrolimus. Dexlansoprazole is a protein pump inhibitor, and the R-enantiomer of lansoprazole (a racemic mixture of R- and S-enantiomers). It is metabolized by CYP2C19, among other enzymes.</p>
<p>Excerpts from the dexlansoprazole (DEXILANT) label:</p>
<div class=""blockquote"">
<p>In male Japanese subjects who received a single dose of DEXILANT 30 mg or 60 mg (N=2 to 6 subjects/group), mean dexlansoprazole Cmax and AUC values were up to 2 times higher in intermediate compared to extensive metabolizers; in poor metabolizers, mean Cmax was up to 4 times higher and mean AUC was up to 12 times higher compared to extensive metabolizers. Though such study was not conducted in Caucasians and African Americans, it is expected dexlansoprazole exposure in these races will be affected by CYP2C19 phenotypes as well.</p>
</div>
<div class=""blockquote"">
<p>Concomitant administration of dexlansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Dexlansoprazole_01_11_19_FDA.pdf"">dexlansoprazole drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452823421.0,"<blockquote class=""blockquote"">
<p>The safety and effectiveness of DEXILANT have been established in pediatric patients 12 to 17 years of age for the healing of all grades of EE, the maintenance of healed EE and relief of heartburn, and treatment of heartburn associated with symptomatic non-erosive GERD.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104848,Annotation of FDA Label for rabeprazole and CYP2C19,False,False,[],False,"[{'id': 1183681417, 'date': '2013-10-25T11:34:54.159-07:00', 'type': 'Update', 'version': 0}, {'id': 1450821621, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1452824163, 'date': '2025-01-24T11:35:52.757-08:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101814, 'title': 'Drugs@FDA: Drug Product rabeprazole - NDA020973/SUPPL-39, 06/07/2018', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020973', 'crossReferences': [{'id': 1452824161, 'resource': 'FDA Application', 'resourceId': 'NDA020973/SUPPL-39', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020973'}], 'objCls': 'Literature', 'pubDate': '2018-06-07T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451216', 'name': 'rabeprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1447981668.0,"<p>The FDA-approved drug label for rabeprazole (ACIPHEX) provides evidence from a study showing that gastric acid suppression was higher in CYP2C19 poor metabolizers as compared to extensive metabolizers, possibly due to higher rabeprazole levels in poor metabolizers.</p>
",1447981667.0,"<p>Excerpts from the rabeprazole (ACIPHEX) drug label:</p>
<div class=""blockquote"">
<p>Pharmacogenomics...In a clinical study in evaluating ACIPHEX delayed-release tablets in Japanese adult patients categorized by CYP2C19 genotype (n=6 per genotype category), gastric acid suppression was higher in poor metabolizers as compared to extensive metabolizers. This could be due to higher rabeprazole plasma levels in poor metabolizers. The clinical relevance of this is not known. Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.</p>
</div>
<div class=""blockquote"">
<p>CYP2C19 exhibits a known genetic polymorphism due to its deficiency in some sub-populations (e.g., 3 to 5% of Caucasians and 17 to 20% of Asians). Rabeprazole metabolism is slow in these sub-populations, therefore, they are referred to as poor metabolizers of the drug.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Rabeprazole_02_25_19_FDA.pdf"">rabeprazole drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452824162.0,"<blockquote class=""blockquote"">
<p>ACIPHEX delayed-release tablets are indicated for the treatment of symptomatic GERD in adolescents 12 years of age and above for up to 8 weeks.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104831,Annotation of FDA Label for irinotecan and UGT1A1,False,False,[],True,"[{'id': 1183681670, 'date': '2013-10-25T14:24:48.880-07:00', 'type': 'Update', 'version': 0}, {'id': 1452260720, 'date': '2023-10-03T06:06:34.831-07:00', 'description': 'Updated excerpts, attached most recent label and changed to testing recommended based on sentence in section 5.3 ""Consider UGT1A1 genotype testing for the *28 and *6 alleles to determine UGT1A1 metabolizer status.""', 'type': 'Update', 'version': 0}, {'id': 1452489282, 'date': '2024-05-31T14:30:59.810-07:00', 'description': 'added the Onivyde label source and prescribing info', 'type': 'Update', 'version': 0}, {'id': 1452492640, 'date': '2024-06-04T16:43:09.564-07:00', 'description': 'added quote on other guidance from the CAMPTOSAR label to the Prescribing box', 'type': 'Update', 'version': 0}, {'id': 1452572183, 'date': '2024-08-30T12:07:18.707-07:00', 'description': 'updated Onivyde label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15164562, 'title': 'Drugs@FDA: Drug Product Onivyde (IRINOTECAN HYDROCHLORIDE), Ipsen Biopharmaceuticals, Inc. - NDA207793/SUPPL-16, 02/13/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207793', 'crossReferences': [{'id': 1452572182, 'resource': 'FDA Application', 'resourceId': 'NDA207793/SUPPL-16', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207793'}], 'objCls': 'Literature', 'pubDate': '2024-02-13T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15102015, 'title': 'Drugs@FDA: Drug Product Camptosar (irinotecan hydrochloride), Pharmacia & Upjohn Company LLC - NDA020571/SUPPL-53, 01/27/2022', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020571', 'crossReferences': [{'id': 1452624081, 'resource': 'FDA Application', 'resourceId': 'NDA020571/SUPPL-53', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020571'}], 'notes': 'CAMPTOSAR', 'objCls': 'Literature', 'pubDate': '2022-01-27T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]","[{'objCls': 'Haplotype', 'id': 'PA166115842', 'symbol': 'UGT1A1*28', 'name': '*28'}, {'objCls': 'Haplotype', 'id': 'PA166115858', 'symbol': 'UGT1A1*6', 'name': '*6'}]","[{'objCls': 'Chemical', 'id': 'PA450085', 'name': 'irinotecan'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",FDA,1447981632.0,"<p>The FDA-approved drug label for irinotecan (CAMPTOSAR) states that a reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele, the UGT1A1*6 allele or compound heterozygotes. The label recommends to consider UGT1A1 genotype testing for the *28 and *6 alleles to determine UGT1A1 metabolizer status. The FDA-approved drug label for irinotecan liposome injection (ONIVYDE) contains language regarding starting dose reduction in patients who are homozygous for the UGT1A1*28 allele, but does not have a genotype testing recommendation.</p>
",1447981631.0,"<p>Excerpts from the irinotecan (CAMPTOSAR) label:</p>
<blockquote class=""blockquote"">
<p>5.3 Increased Risk of Neutropenia in Patients With Reduced UGT1A1 Activity
Published studies have shown that individuals who are homozygous for either the UGT1A1*28 or *6 alleles (*28/*28, *6/*6) or who are compound or double heterozygous for the UGT1A1*28 and *6 alleles (*6/*28) are at increased risk for severe or life-threatening neutropenia during treatment with CAMPTOSAR. These individuals are UGT1A1 poor metabolizers and experience increased systemic exposure to SN-38, an active metabolite of irinotecan. Individuals who are heterozygous for either the UGT1A1*28 or *6 alleles (*1/*28, *1/*6) are intermediate metabolizers and may also have an increased risk of severe or life-threatening neutropenia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consider UGT1A1 genotype testing for the *28 and *6 alleles to determine UGT1A1 metabolizer status.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>When administering CAMPTOSAR, consider a reduction in the CAMPTOSAR starting dose by at least one level for patients known to be homozygous or compound heterozygous for the UGT1A1*28 and/or *6 alleles (*28/*28, *6/*6, *6/*28). Closely monitor patients with UGT1A1*28 or *6 alleles for neutropenia during and after treatment with CAMPTOSAR. The precise dosage reduction in this patient population is not known. Subsequent dosage modifications may be required based on individual patient tolerance to treatment</p>
</blockquote>
<blockquote class=""blockquote"">
<p>2.3 Dosage in Patients With Reduced UGT1A1 Activity
When administered in combination with other agents, or as a single-agent, consider a reduction in the starting dose by at least one level of CAMPTOSAR for patients known to be homozygous for the UGT1A1*28 or *6 alleles (*28/*28, *6/*6) or compound heterozygous for the UGT1A1*28 and *6 alleles (*6/*28). Subsequent dosage modifications may be required based on individual patient tolerance to treatment.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Irinotecan is subject to extensive metabolic conversion by various enzyme systems, including esterases that form an active metabolite SN-38, and UGT1A1 which mediates the glucuronidation of SN-38 to form an inactive metabolite. SN-38 glucuronide had 1/50 to 1/100 the activity of SN-38. Patients who are homozygous for either the UGT1A1*28 or *6 alleles, or who are compound heterozygous for these alleles, have higher SN-38 AUC than patients with the wild-type UGT1A1 alleles.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>12.5 Pharmacogenomics
The active metabolite SN-38 is further metabolized via UGT1A1. Genetic variants of the UGT1A1 gene such as the UGT1A1*28 (TA)7 and *6 alleles lead to reduced UGT1A1 enzyme expression or activity and decreased function to a similar extent. Individuals who are homozygous or compound (double) heterozygous for these alleles (e.g.,
*28/*28, *6/*6, *6/*28) are UGT1A1 poor metabolizers and are at increased risk for severe or life-threatening neutropenia from CAMPTOSAR due to elevated systemic exposure to SN-38. The UGT1A1*6/*6 genotype should not be confused with 6/6 genotype, which is sometimes used to represent the genotype of individuals who are wild type for UGT1A1*28. Individuals who are heterozygous for either the UGT1A1*28 or *6 alleles (*1/*6, *1/*28) are UGT1A1 intermediate metabolizers and may also have an increased risk of severe or life-threatening neutropenia.
Published studies have shown that individuals with UGT1A1*28 and *6 alleles may be at an increased risk of severe diarrhea. The risk evidence appears greater in UGT1A1*28 and *6 homozygous patients and in those taking irinotecan doses &gt; 125 mg/m2</p>
</blockquote>
<p>Excerpt from the irinotecan (ONIVYDE) drug label:</p>
<blockquote class=""blockquote"">
<p>In combination with fluorouracil and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy [...]</p>
<ul>
<li>The recommended dosage of ONIVYDE is 70 mg/m2 administered by intravenous infusion over 90 minutes every 2 weeks.</li>
<li>The recommended starting dose of ONIVYDE in patients known to be homozygous for the UGT1A1*28 allele is 50 mg/m2 administered by intravenous infusion over 90 minutes. Increase the dose of ONIVYDE to 70 mg/m2 as tolerated in subsequent cycles.</li>
</ul>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""irinotecan_FDA_2023_10_02.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/irinotecan_FDA_2023_10_02.pdf"">irinotecan (CAMPTOSAR) drug label</a> and the <a download=""Irinotecan_liposome_injection_2024_08_30_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Irinotecan_liposome_injection_2024_08_30_FDA.pdf"">irinotecan (ONIVYDE) drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1450399556.0,"<p>Excerpt from the irinotecan (CAMPTOSAR) label:</p>
<blockquote class=""blockquote"">
<p>2.3 Dosage in Patients With Reduced UGT1A1 Activity
When administered in combination with other agents, or as a single-agent, consider a reduction in the starting dose by at least one level of CAMPTOSAR for patients known to be homozygous for the UGT1A1*28 or *6 alleles (*28/*28, *6/*6) or compound heterozygous for the UGT1A1*28 and *6 alleles (*6/*28). Subsequent dosage modifications may be required based on individual patient tolerance to treatment.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Individuals who are heterozygous for either the UGT1A1*28 or *6 alleles (*1/*6, *1/*28) are UGT1A1 intermediate metabolizers and may also have an increased risk of severe or life-threatening neutropenia. Published studies have shown that individuals with UGT1A1*28 and *6 alleles may be at an increased risk of severe diarrhea.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Closely monitor patients with UGT1A1*28 or *6 alleles for neutropenia during and after treatment with CAMPTOSAR.</p>
</blockquote>
<p>Excerpt from the irinotecan (ONIVYDE) drug label:</p>
<blockquote class=""blockquote"">
<p>In combination with fluorouracil and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy [...]</p>
<ul>
<li>The recommended dosage of ONIVYDE is 70 mg/m2 administered by intravenous infusion over 90 minutes every 2 weeks.</li>
<li>The recommended starting dose of ONIVYDE in patients known to be homozygous for the UGT1A1*28 allele is 50 mg/m2 administered by intravenous infusion over 90 minutes. Increase the dose of ONIVYDE to 70 mg/m2 as tolerated in subsequent cycles.</li>
</ul>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104828,Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2,False,False,[],False,"[{'id': 1183681540, 'date': '2013-10-25T12:34:52.715-07:00', 'type': 'Update', 'version': 0}, {'id': 1450822040, 'date': '2019-10-14T11:53:10.420-07:00', 'description': 'No changes to annotation text but label was updated at FDA, so new label attached with same PGx and DDI highlighted.', 'type': 'Update', 'version': 0}, {'id': 1452231460, 'date': '2023-09-08T14:20:44.204-07:00', 'description': 'changed label from informative to actionable', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101812, 'title': 'Drugs@FDA: Drug Product isosorbide dinitrate and hydralazine hydrochloride (hydralazine hydrochloride and isosorbide dinitrate), Bryant Ranch Prepack - NDA020727/SUPPL-10, 03/12/2019', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020727', 'crossReferences': [{'id': 1452535822, 'resource': 'FDA Application', 'resourceId': 'NDA020727/SUPPL-10', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020727'}], 'objCls': 'Literature', 'pubDate': '2019-03-12T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166176017', 'name': 'hydralazine / isosorbide dinitrate'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",FDA,1447981626.0,"<p>Hydralazine hydrochloride and isosorbide dinitrate (BiDil) is metabolized by acetylation, and individuals who are 'fast acetylators' may have decreased exposure to the drug, whereas individuals who are 'slow acetylators' may have increased drug bioavailability. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to acetylator status.</p>
",1447981625.0,"<p>Hydralazine hydrochloride and isosorbide dinitrate (BiDil) is indicated for the treatment of heart failure in self-identified Black patients, as an adjunct therapy to standard therapy. The genetics behind the mode of efficacy related to this population of patients is to our knowledge currently unknown.</p>
<p>Excerpts from the hydralazine hydrochloride and isosorbide dinitrate (BiDil) drug label:</p>
<div class=""blockquote"">
<p>Hydralazine is metabolized by acetylation, ring oxidation and conjugation with endogenous compounds including pyruvic acid. Acetylation occurs predominantly during the first-pass after oral administration which explains the dependence of the absolute bioavailability on the acetylator phenotype. About 50% of patients are fast acetylators and have lower exposure.</p>
</div>
<div class=""blockquote"">
<p>In patients with heart failure, mean absolute bioavailability of a single oral dose of hydralazine 75 mg varies from 10 to 26%, with the higher percentages in slow acetylators.</p>
</div>
<p>Note that this drug combination appears on the <a rel=""noopener noreferrer"" href=""https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm"" target=""_blank"">FDA Biomarker List</a> with the biomarker stated as &quot;Nonspecific (NAT)&quot;.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/hydralazine_10_14_2019FDA.pdf"">hydralazine and isosorbide dinitrate drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104777,Annotation of FDA Label for clopidogrel and CYP2C19,True,False,[],False,"[{'id': 1183681214, 'date': '2013-10-25T10:44:47.616-07:00', 'type': 'Update', 'version': 0}, {'id': 1448265244, 'date': '2016-10-03T12:00:38.977-07:00', 'description': 'Corrected a typo in the P2RY12 gene symbol in the label description.', 'type': 'Update', 'version': 0}, {'id': 1452211480, 'date': '2023-08-21T15:28:21.828-07:00', 'description': 'Added ""Alt Drug"" tag because the definition has been changed to include labels that say \'consider\' or similar language', 'type': 'Update', 'version': 0}, {'id': 1452529840, 'date': '2024-07-17T16:54:37.975-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160742, 'title': 'Drugs@FDA: Drug Product Plavix (clopidogrel), sanofi-aventis U.S. LLC - NDA020839/SUPPL-78, 09/16/2022', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020839', 'crossReferences': [{'id': 1452529803, 'resource': 'FDA Application', 'resourceId': 'NDA020839/SUPPL-78', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020839'}], 'objCls': 'Literature', 'pubDate': '2022-09-16T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101940, 'title': 'Drugs@FDA: Drug Product Plavix (clopidogrel bisulfate), NDA020839, Rebel Distributors Corp', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020839', 'crossReferences': [{'id': 1449754209, 'resource': 'FDA Application', 'resourceId': 'NDA020839', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020839'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449053', 'name': 'clopidogrel'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1447981538.0,"<p>The FDA-approved drug label for clopidogrel (Plavix) states that in patients who are CYP2C19 poor metabolizers, clopidogrel at recommended doses has a reduced effect on platelet activity, and that use of another platelet P2Y12 inhibitor should be considered.</p>
",1447981537.0,"<p>Excerpts from the clopidogrel (Plavix) label:</p>
<blockquote class=""blockquote"">
<p>Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is achieved through an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 [see Boxed Warning].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The effectiveness of Plavix results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions (5.1), Clinical Pharmacology (12.3)]. Plavix at recommended doses forms less of the active metabolite and so has a reduced effect on platelet activity in patients who are homozygous for nonfunctional alleles of the CYP2C19 gene, (termed “CYP2C19 poor metabolizers”). Tests are
available to identify patients who are CYP2C19 poor metabolizers [see Clinical Pharmacology (12.5)]. Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by <em>ex vivo</em> platelet aggregation assays, differ according to CYP2C19 genotype. Patients who are homozygous for nonfunctional alleles of the CYP2C19 gene are termed “CYP2C19 poor metabolizers.” Approximately 2% of White and 4% of Black patients are poor metabolizers; the prevalence of poor metabolism is higher in Asian patients (e.g., 14% of Chinese). Tests are available to identify patients who are CYP2C19 poor metabolizers.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Clopidogrel_2024_07_15_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Clopidogrel_2024_07_15_FDA.pdf"">clopidogrel drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399539.0,"<p>Excerpt from the clopidogrel (Plavix) drug label:</p>
<blockquote class=""blockquote"">
<p>Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104813,Annotation of FDA Label for carvedilol and CYP2D6,False,False,[],False,"[{'id': 1183681245, 'date': '2013-10-25T11:00:10.660-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101946, 'title': 'Drugs@FDA: Drug Product COREG (carvedilol), NDA020297, GlaxoSmithKline LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020297', 'crossReferences': [{'id': 1449895240, 'resource': 'FDA Application', 'resourceId': 'NDA020297', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020297'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448817', 'name': 'carvedilol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450342771.0,"<p>The FDA-approved drug label for carvedilol (COREG) states that it is affected by the poor metabolizers of debrisoquin (a marker for cytochrome P450 2D6) resulting in higher plasma concentrations of R( + )-carvedilol. Additionally, CYP2D6 poor metabolizers had a higher rate of dizziness during up-titration.</p>
",1450342772.0,"<p>Carvedilol (COREG) is indicated for the treatment of mild-to-severe chronic heart failure, left ventricular dysfunction following myocardial infarction in clinically stable patients, and hypertension.</p>
<p>Excerpts from the carvedilol (COREG) drug label:</p>
<div class=""blockquote"">
<p>Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the &alpha;-blocking R(+) enantiomer.</p>
</div>
<div class=""blockquote"">
<p>Carvedilol is subject to the effects of genetic polymorphism with poor metabolizers of debrisoquin (a marker for cytochrome P450 2D6) exhibiting 2- to 3-fold higher plasma concentrations of R( + )-carvedilol compared to extensive metabolizers. In contrast, plasma levels of S( - )-carvedilol are increased only about 20% to 25% in poor metabolizers, indicating this enantiomer is metabolized to a lesser extent by cytochrome P450 2D6 than R(+)-carvedilol. The pharmacokinetics of carvedilol do not appear to be different in poor metabolizers of S-mephenytoin (patients deficient in cytochrome P450 2C19).</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Carvedilol_01_08_19_FDA.pdf"">carvedilol drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104851,Annotation of FDA Label for ticagrelor and CYP2C19,False,False,[],False,"[{'id': 1183681199, 'date': '2013-10-25T10:42:08.271-07:00', 'type': 'Update', 'version': 0}, {'id': 1448604784, 'date': '2017-03-16T12:50:57.649-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101855, 'title': 'Drugs@FDA: Drug Product BRILINTA (Ticagrelor), NDA022433, AstraZeneca Pharmaceuticals LP', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022433', 'crossReferences': [{'id': 1449818653, 'resource': 'FDA Application', 'resourceId': 'NDA022433', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022433'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165374673', 'name': 'ticagrelor'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1447981684.0,"<p>Ticagrelor (BRILINTA) is a platelet inhibitor used to reduce the risk of thrombotic cardiovascular events for patients with acute coronary syndrome. The FDA-approved drug label notes that thrombotic cardiovascular events did not depend on CYP2C19 loss of function status.</p>
",1447981683.0,"<p>Excerpts from the ticagrelor (BRILINTA) drug label:</p>
<div class=""blockquote"">
<p>Pharmacogenetics...In a genetic substudy cohort of PLATO, the rate of thrombotic CV events in the BRILINTA arm did not depend on CYP2C19 loss of function status.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Ticagrelor_08_28_2017_FDA.pdf"">ticagrelor drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104784,"Annotation of FDA Label for diazepam and CYP2C19, CYP3A4",False,False,[],False,"[{'id': 1183681227, 'date': '2013-10-25T10:57:41.398-07:00', 'type': 'Update', 'version': 0}, {'id': 1452322940, 'date': '2023-12-11T00:00:00-08:00', 'description': 'While there are newer labels available for both NDAs, the language around CYPs is the same.', 'type': 'Note', 'version': 0}, {'id': 1452823461, 'date': '2025-01-23T00:00:00-08:00', 'description': 'added Pediatric tag and info; CYP3A4', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101804, 'title': 'Drugs@FDA: Drug Product Diazepam (diazepam), Bryant Ranch Prepack - NDA020648/SUPPL-14, 12/16/2016', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020648', 'crossReferences': [{'id': 1452823443, 'resource': 'FDA Application', 'resourceId': 'NDA020648/SUPPL-14', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020648'}], 'notes': 'Diastat', 'objCls': 'Literature', 'pubDate': '2016-12-16T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101846, 'title': 'Drugs@FDA: Drug Product Valium (diazepam), NDA013263, Roche Laboratories Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=013263', 'crossReferences': [{'id': 1449754285, 'resource': 'FDA Application', 'resourceId': 'NDA013263', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=013263'}], 'notes': 'Valium', 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449283', 'name': 'diazepam'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",FDA,1450342995.0,"<p>The FDA-approved drug label for diazepam (Diastat) notes that the drug is metabolized by CYP2C19 and CYP3A4, and that inter-individual variation in clearance of the drug is likely attributable genetic polymorphism of CYP2C19 and CYP3A4.</p>
",1450342996.0,"<p>Diazepam (Diastat) is drug intended for treatment of breakthrough seizures.</p>
<p>Excerpt from the diazepam (Diastat) drug label:</p>
<div class=""blockquote"">
<p>The metabolism of diazepam...involves demethylation (involving primarily CYP2C19 and CYP3A4) and 3-hydroxylation (involving primarily CYP3A4), followed by glucuornidation. The marked inter-individual variability in the clearance of diazepam reported in the literature is probably attributable to variability of CYP2C19 (which is known to exhibit genetic polymorphism; about 3-5% of Caucasians have little or no activity and are &quot;poor metabolizers&quot;) and CYP3A4.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Diazepam_01_11_19_FDA.pdf"">diazepam drug label</a>.</p>
<p><strong>Note: Diazepam (Valium) is indicated for the management of anxiety disorders, among other indications. The drug label for diazepam (Valium) notes that the drug is metabolized by CYP2C19 and CYP3A4, but does not comment on genetic variability affecting clearance.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452823460.0,"<p>Excerpt from the diazepam (Diastat) drug label:</p>
<blockquote class=""blockquote"">
<p>The controlled trials demonstrating the effectiveness of Diazepam rectal gel included children two years of age and older. Clinical studies have not been conducted to establish the efficacy and safety of Diazepam rectal gel in children under two years of age.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104799,Annotation of FDA Label for tramadol and CYP2D6,True,False,[],False,"[{'id': 1183681485, 'date': '2013-10-25T11:42:15.747-07:00', 'type': 'Update', 'version': 0}, {'id': 1448616076, 'date': '2017-05-01T17:28:38.621-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101969, 'title': 'Drugs@FDA: Drug Product ULTRAM (tramadol hydrochloride), NDA020281, Janssen Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020281', 'crossReferences': [{'id': 1450369811, 'resource': 'FDA Application', 'resourceId': 'NDA020281', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020281'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451735', 'name': 'tramadol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981548.0,"<p>The FDA-approved label for tramadol (ULTRAM) states that individuals who are CYP2D6 ultra-rapid metabolizers convert tramadol into its active metabolite more rapidly than other people, and that even at labeled dosage regimens they may have life-threatening or fatal respiratory depression; these individuals should not use tramadol.</p>
",1447981547.0,"<p><strong>On April 20th 2017, the FDA released a <a rel=""noopener noreferrer"" href=""https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery"" target=""_blank"">safety announcement</a> stating that they are restricting the use of codeine and tramadol in children, and recommending against the use of codeine and tramadol in breastfeeding mothers due to possible harm to their infants. Please refer to the link above for full details on the safety announcement.</strong></p>
<p>Excerpts from the tramadol (ULTRAM) drug label:</p>
<div class=""blockquote"">
<p>ULTRA-RAPID METABOLISM OF TRAMADOL AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN. Life-threatening respiratory depression and death have occurred in children who received tramadol. Some of the reported cases following tonsillectomy and/or adenoidectomy; in at least one case, the child had evidence of being an ultra-rapid metabolizer of tramadol due to CYP2D6 polymorphism.</p>
</div>
<div class=""blockquote"">
<p>Approximately 7% of the population has reduced activity of the CYPD2D6 isoenzyme...Based on a population PK analysis...concentrations of tramadol were approximately 20% higher in &quot;poor metabolizers&quot; versus &quot;extensive metabolizers&quot;...</p>
</div>
<div class=""blockquote"">
<p>Tramadol is subject to the same polymorphic metabolism as codeine, with ultra-rapid metabolizers of CYP2D6 substrates being potentially exposed to life-threatening levels of the active metabolite O-desmethyltramadol (M1). At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine.</p>
</div>
<div class=""blockquote"">
<p>Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype...These individuals convert tramadol into its active metabolite, <em>O</em>-desmethyltramadol (M1), more rapidly and completely than other people. This rapid conversion results in higher than expected serum M1 levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression...Therefore, individuals who are ultra-rapid metabolizers should not use ULTRAM.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tramadol_03_01_19_FDA.pdf"">tramadol drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450383896.0,"<p>Excerpt from the tramadol (ULTRAM) drug label:</p>
<blockquote class=""blockquote"">
<p>...individuals who are ultra-rapid metabolizers should not use ULTRAM.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104816,Annotation of FDA Label for esomeprazole and CYP2C19,False,False,[],False,"[{'id': 1183681233, 'date': '2013-10-25T10:58:33.638-07:00', 'type': 'Update', 'version': 0}, {'id': 1452540283, 'date': '2024-07-26T14:04:35.819-07:00', 'description': 'updated label, added Pediatric tag and info, changed PGx level to Informative (change in exposure is not clinically meaningful)', 'type': 'Update', 'version': 0}, {'id': 1452785320, 'date': '2024-12-16T11:46:37.937-08:00', 'description': 'fixed typo', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162222, 'title': 'Drugs@FDA: Drug Product NEXIUM (Esomeprazole magnesium), AstraZeneca Pharmaceuticals LP - NDA022101/SUPPL-24, 07/18/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022101', 'crossReferences': [{'id': 1452540281, 'resource': 'FDA Application', 'resourceId': 'NDA022101/SUPPL-24', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022101'}], 'objCls': 'Literature', 'pubDate': '2023-07-18T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101851, 'title': 'Drugs@FDA: Drug Product NEXIUM (Esomeprazole magnesium), NDA021153, Rebel Distributors Corp', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021153', 'crossReferences': [{'id': 1449754610, 'resource': 'FDA Application', 'resourceId': 'NDA021153', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021153'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10075', 'name': 'esomeprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1447981592.0,"<p>The FDA-approved drug label for esomeprazole (NEXIUM) notes that individuals who are CYP2C19 poor metabolizers may have increased exposure to esomeprazole compared to extensive metabolizers. This change in exposure is not considered clinically meaningful.</p>
",1450361420.0,"<p>Esomeprazole (NEXIUM) is a proton pump inhibitor and enantiomer of omeprazole, and is metabolized in the liver by CYP2C19 and CYP3A4.</p>
<p>Excerpts from the esomeprazole (NEXIUM) drug label:</p>
<blockquote class=""blockquote"">
<p>CYP2C19, a polymorphic enzyme, is involved in the metabolism of esomeprazole. The CYP2C19*1 allele is fully functional while the CYP2C19*2 and *3 alleles are nonfunctional. There are other alleles associated with no or reduced enzymatic function. Patients carrying two fully functional alleles are extensive metabolizers and those carrying two loss-of-function alleles are poor metabolizers. The systemic exposure to esomeprazole varies with a patient’s metabolism status: poor metabolizers &gt; intermediate metabolizers &gt; extensive metabolizers. Approximately 3% of Caucasians and 15 to 20% of Asians are CYP2C19 poor metabolizers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Systemic esomeprazole exposures were modestly higher (approximately 17%) in CYP2C19 intermediate metabolizers (IM; n=6) compared to extensive metabolizers (EM; n=17) of CYP2C19. Similar pharmacokinetic differences were noted across these genotypes in a study of Chinese healthy subjects that included 7 EMs and 11 IMs. There is very limited pharmacokinetic information for poor metabolizers (PM) from these studies.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>At steady state following once daily administration of esomeprazole 40 mg, the ratio of AUC in poor metabolizers to AUC in the rest of the population (EMs) is approximately 1.5. This change in exposure is not considered clinically meaningful.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Esomeprazole_2024_07_26_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Esomeprazole_2024_07_26_FDA.pdf"">esomeprazole drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452540282.0,"<blockquote class=""blockquote"">
<p>NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the:</p>
<ul>
<li>Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. (1.1) [...]</li>
<li>Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. (1.3) [...]</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>NEXIUM for delayed-release oral suspension is indicated for the:</p>
<ul>
<li>Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. (1.1)</li>
<li>Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. (1.3)</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Use is not recommended for the treatment of symptomatic GERD in patients 1 month to less than 1 year of age; efficacy was not demonstrated. (8.4)</p>
</blockquote>
",1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104808,"Annotation of FDA Label for nelfinavir and CYP2C19, CYP3A4, CYP3A5",False,False,[],False,"[{'id': 1183681686, 'date': '2013-10-25T14:31:05.800-07:00', 'type': 'Update', 'version': 0}, {'id': 1452207482, 'date': '2023-08-15T12:45:12.886-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452570201, 'date': '2024-08-29T13:59:45.832-07:00', 'description': 'Removed ""CYP3A"" as that is no longer recognized by HGNC or NCBI; replaced with CYP3A4 and CYP3A5', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102012, 'title': 'Drugs@FDA: Drug Product VIRACEPT (nelfinavir mesylate), NDA020779, H.J. Harkins Company, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020779', 'crossReferences': [{'id': 1449763688, 'resource': 'FDA Application', 'resourceId': 'NDA020779', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020779'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450606', 'name': 'nelfinavir'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}, {'objCls': 'Gene', 'id': 'PA131', 'symbol': 'CYP3A5', 'name': 'cytochrome P450 family 3 subfamily A member 5'}]",FDA,1447981596.0,"<p>The FDA-approved drug label for nelfinavir (VIRACEPT) states that coadministration of nelfinavir and drugs that induce CYP3A or CYP2C19 may decrease nelfinavir plasma concentrations and reduce its therapeutic effect. Coadministration of nelfinavir and drugs that inhibit CYP3A or CYP2C19 may increase nelfinavir plasma concentrations.</p>
",1447981595.0,"<p>Nelfinavir is a protease inhibitor which is used in combination with other medications to treat human immunodeficiency virus (HIV) infection by slowing the spread of the infection within the body. It is metabolized by cytochrome P-450 enzymes, mainly CYP3A and CYP2C19.</p>
<p>Excerpts from the nelfinavir (VIRACEPT) drug label:</p>
<div class=""blockquote"">
<p>Nelfinavir is metabolized by CYP3A and CYP2C19. Coadministration of VIRACEPT and drugs that induce CYP3A or CYP2C19, such as rifampin, may decrease nelfinavir plasma concentrations and reduce its therapeutic effect. Coadministration of VIRACEPT and drugs that inhibit CYP3A or CYP2C19 may increase nelfinavir plasma concentrations.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Nelfinavir_12_07_2017_FDA.pdf"">nelfinavir drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,Formerly on FDA Biomarker List
Label Annotation,PA166104836,Annotation of FDA Label for metoprolol and CYP2D6,False,False,[],False,"[{'id': 1183681285, 'date': '2013-10-25T11:07:34.521-07:00', 'type': 'Update', 'version': 0}, {'id': 1452230742, 'date': '2023-09-07T12:28:56.527-07:00', 'description': 'annotated updated label, changed level to actionable', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101975, 'title': 'Drugs@FDA: Drug Product TOPROL XL (Metoprolol succinate), NDA019962, Aphena Pharma Solutions - Tennessee, LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019962', 'crossReferences': [{'id': 1449762103, 'resource': 'FDA Application', 'resourceId': 'NDA019962', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019962'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450480', 'name': 'metoprolol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981642.0,"<p>The FDA-approved drug label for metoprolol (TOPROL-XL) states that is metabolized predominantly by CYP2D6, and that poor metabolizers of CYP2D6 will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity.</p>
",1447981641.0,"<p>Metoprolol is a selective beta1-adrenoreceptor blocking agent used for the treatment of hypertension, angina pectoris, and acute myocardial infarction.</p>
<p>Excerpts from the metoprolol (TOPROL-XL) drug label:</p>
<blockquote class=""blockquote"">
<p>Metoprolol is metabolized predominantly by CYP2D6.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations. CYP2D6 can be inhibited by several drugs. Poor metabolizers of CYP2D6 will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Metoprolol_09_07_23_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Metoprolol_09_07_23_FDA.pdf"">metoprolol drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104820,"Annotation of FDA Label for doxepin and CYP2C19, CYP2D6",False,False,[],False,"[{'id': 1183681269, 'date': '2013-10-25T11:04:22.111-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101973, 'title': 'Drugs@FDA: Drug Product Doxepin Hydrochloride (Doxepin Hydrochloride), NDA020126, REMEDYREPACK INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020126', 'crossReferences': [{'id': 1450361150, 'resource': 'FDA Application', 'resourceId': 'NDA020126', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020126'}], 'notes': 'ZONALON', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101811, 'title': 'Drugs@FDA: Drug Product Silenor (doxepin hydrochloride), NDA022036, Pernix Therapeutics, LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022036', 'crossReferences': [{'id': 1450361147, 'resource': 'FDA Application', 'resourceId': 'NDA022036', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022036'}], 'notes': 'Silenor', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449409', 'name': 'doxepin'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450361157.0,"<p>The FDA-approved drug label for doxepin (Silenor) notes that CYP2D6 and CYP2C19 poor metabolizers have higher than expected plasma levels of the drug when given typical doses. The FDA-approved drug label for doxepin cream (ZONALON) notes the genetic variability of the CYP2D6 enzyme and its effect on tricyclic antidepressants (TCAs).</p>
",1450361160.0,"<p>Doxepin belongs to a class of agents known as tricyclic antidepressants (TCAs). Doxepin (Silenor) is indicated for the treatment of insomnia, while doxepin cream (ZONALON) is indicated for management of moderate pruritus in adults.</p>
<p><strong>Excerpts from the Silenor drug label:</strong></p>
<div class=""blockquote"">
<p>Silenor is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin.</p>
</div>
<div class=""blockquote"">
<p>Poor metabolizers of CYP2C19 and CYP2D6 may have higher doxepin plasma levels than normal subjects.</p>
</div>
<p><strong>Excerpt from the ZONALON drug label</strong>:</p>
<div class=""blockquote"">
<p>Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7- 10% of Caucasians are so-called &quot;poor metabolizers&quot;); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Doxepin_Silenor_07_17_2017_FDA.pdf"">doxepin (Silenor) drug label</a> and the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Doxepin_Zonalon_01_15_19_FDA.pdf"">doxepin (ZONALON) drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104854,Annotation of FDA Label for fluvoxamine and CYP2D6,False,False,[],False,"[{'id': 1183681656, 'date': '2013-10-25T14:15:03.488-07:00', 'type': 'Update', 'version': 0}, {'id': 1452534445, 'date': '2024-07-22T11:11:49.464-07:00', 'description': 'updated label, added Pediatric tag and info, Other Guidance tag and prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161442, 'title': 'DailyMed - FLUVOXAMINE MALEATE capsule, extended release', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9924422b-7c90-42bf-a680-ffd92063d5f0', 'crossReferences': [{'id': 1452534440, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '9924422b-7c90-42bf-a680-ffd92063d5f0', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9924422b-7c90-42bf-a680-ffd92063d5f0'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101856, 'title': 'Drugs@FDA: Drug Product fluvoxamine maleate (Fluvoxamine maleate), NDA021519, Bryant Ranch Prepack', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021519', 'crossReferences': [{'id': 1449754682, 'resource': 'FDA Application', 'resourceId': 'NDA021519', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021519'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,True,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449690', 'name': 'fluvoxamine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981692.0,"<p>The FDA-approved drug label for fluvoxamine (LUVOX) states that it appears to be metabolized, at least in part, by CYP2D6, and that caution should be used in treating patients with reduced CYP2D6 activity.</p>
",1447981691.0,"<p>Excerpts from the fluvoxamine drug label:</p>
<blockquote class=""blockquote"">
<p>Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6 enzyme. Such individuals have been referred to as “poor
metabolizers” (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an <em>in vivo</em> study of fluvoxamine single dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 “extensive metabolizers” (EM): mean C , AUC, and half life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6. Caution is indicated in patients known to have reduced levels of cytochrome P450 2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>In vitro</em> data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Fluvoxamine_2024_07_22_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Fluvoxamine_2024_07_22_FDA.pdf"">fluvoxamine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452534444.0,"<blockquote class=""blockquote"">
<p><strong>Fluvoxamine maleate extended-release capsules and other antidepressant medicines may increase suicidal thoughts or actions</strong> in some children, teenagers, or young adults within the <strong>first few months of treatment or when the dose is changed.</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<p>Fluvoxamine maleate extended-release capsules have not been evaluated in pediatric patients (see Boxed Warning). The efficacy of fluvoxamine maleate administered as
immediate-release tablets for the treatment of OCD was demonstrated in a 10-week multi-center placebo-controlled study with 120 outpatients ages 8 to 17. In addition, 99 of these outpatients continued open-label fluvoxamine maleate treatment for up to another one to three years, equivalent to 94 patient years. The adverse reaction profile observed in that study was generally similar to that observed in adult studies with immediate-release fluvoxamine maleate tablets [see Adverse Reactions (6.3)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The risks, if any, that may be associated with fluvoxamine’s extended use in children and adolescents with OCD have not been systematically assessed. The prescriber
should be mindful that the evidence relied upon to conclude that fluvoxamine is safe for use in children and adolescents derives from relatively short-term clinical studies and
from extrapolation of experience gained with adult patients. In particular, there are no studies that directly evaluate the effects of long-term fluvoxamine use on the growth,
cognitive behavioral development, and maturation of children and adolescents. Although there is no affirmative finding to suggest that fluvoxamine possesses a capacity to
adversely affect growth, development, or maturation, the absence of such findings is not compelling evidence of the absence of the potential of fluvoxamine to have adverse
effects in chronic use [see Warnings and Precautions- Clinical Worsening and Suicide Risk (5.1)] .</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Safety and effectiveness in the pediatric population other than pediatric patients with OCD have not been established [see Boxed Warning and Warnings and Precautions-
Clinical Worsening and Suicide Risk (5.1)]. Anyone considering the use of fluvoxamine maleate extended-release capsules in a child or adolescent must balance the potential
risks with the clinical need.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In pediatric patients (N = 57) treated with immediate-release fluvoxamine maleate tablets, the overall profile of adverse reactions was generally similar to that seen in adult
studies, as shown in Table 2. However, the following adverse reactions, not appearing in Table 2, were reported in two or more of the pediatric patients and were more frequent
with immediate-release fluvoxamine maleate tablets than with placebo: cough increase, dysmenorrhea, ecchymosis, emotional lability, epistaxis, hyperkinesia, manic reaction,
rash, sinusitis, and weight decrease.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452534443.0,"<blockquote class=""blockquote"">
<p>Caution is indicated in patients known to have reduced levels of cytochrome P450 2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104857,Annotation of FDA Label for trimipramine and CYP2D6,False,False,[],False,"[{'id': 1183681243, 'date': '2013-10-25T10:59:46.145-07:00', 'type': 'Update', 'version': 0}, {'id': 1452532220, 'date': '2024-07-19T11:55:22.983-07:00', 'description': 'Corrected typo', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101979, 'title': ""Drugs@FDA: Drug Product Surmontil (Trimipramine Maleate), NDA016792, Teva Women's Health, Inc."", '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016792', 'crossReferences': [{'id': 1449890803, 'resource': 'FDA Application', 'resourceId': 'NDA016792', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016792'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451791', 'name': 'trimipramine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981682.0,"<p>Trimipramine (SURMONTIL) is a tricyclic antidepressant used to treat depression.  Like many antidepressants, it has a black box warning for increased risk of suicidal thoughts and behavior.  Trimipramine is metabolized by CYP2D6 and poor metabolizers may experience higher plasma concentrations of the drug at typical doses.</p>
",1447981681.0,"<p>Excerpt from the Trimipramine (SURMONTIL) drug label:</p>
<div class=""blockquote"">
<p>Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).</p>
</div>
<div class=""blockquote"">
<p>Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Trimipramine_03_01_19_FDA.pdf"">trimipramine drug label</a>
*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104818,Annotation of FDA Label for voriconazole and CYP2C19,False,False,[],False,"[{'id': 1183681235, 'date': '2013-10-25T10:58:37.841-07:00', 'type': 'Update', 'version': 0}, {'id': 1452824241, 'date': '2025-01-24T11:48:29.760-08:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101809, 'title': 'Drugs@FDA: Drug Product Voriconazole (Voriconazole), NDA021266, Greenstone LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021266', 'crossReferences': [{'id': 1449891793, 'resource': 'FDA Application', 'resourceId': 'NDA021266', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021266'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10233', 'name': 'voriconazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1447981616.0,"<p>The FDA-approved drug label for voriconazole (VFEND) states that CYP2C19 poor metabolizers have, on average, 4-fold higher voriconazole exposure as compared to normal metabolizers, while intermediate metabolizers have 2-fold higher exposure as compared to normal metabolizers.</p>
",1447981615.0,"<p>Excerpt from the voriconazole (VFEND) drug label:</p>
<div class=""blockquote"">
<p>Pharmacogenomics...CYP2C19, significantly involved in the metabolism of voriconazole, exhibits genetic polymorphism. Approximately 15-20% of Asian populations may be expected to be poor metabolizers. For Caucasians and Blacks, the prevalence of poor metabolizers is 3-5%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolizers have, on average, 4-fold higher voriconazole exposure (AUC&tau;) than their homozygous extensive metabolizer counterparts. Subjects who are heterozygous extensive metabolizers have, on average, 2-fold higher voriconazole exposure than their homozygous extensive metabolizer counterparts.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Voriconazole_03_01_19_FDA.pdf"">voriconazole drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452824240.0,"<blockquote class=""blockquote"">
<p>VFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older [...]</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104802,Annotation of FDA Label for capecitabine and DPYD,True,False,[],False,"[{'id': 1183681518, 'date': '2013-10-25T12:25:22.795-07:00', 'type': 'Update', 'version': 0}, {'id': 1450399696, 'date': '2019-05-10T08:42:29.125-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1451968500, 'date': '2022-12-19T15:33:11.126-08:00', 'description': 'update label, PGx level', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101916, 'title': 'Drugs@FDA: Drug Product Xeloda (capecitabine), NDA020896, Genentech, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020896', 'crossReferences': [{'id': 1449894845, 'resource': 'FDA Application', 'resourceId': 'NDA020896', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020896'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448771', 'name': 'capecitabine'}]","[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",FDA,1450342104.0,"<p>The FDA-approved label for capecitabine (XELODA) notes that patients with certain homozygous or compound heterozygous variants in the DPYD gene are at increased risk for acute early-onset toxicity and serious, including fatal, adverse reactions due to XELODA. FDA states &quot;Consider testing for genetic variants of DPYD prior to initiating XELODA to reduce the risk of serious adverse reactions if the patient’s clinical status permits and based on clinical judgement&quot;.</p>
",1450342105.0,"<p>Capecitabine is a pro-drug of 5-fluorouracil used for the treatment of various types of neoplasms including colorectal and breast neoplasms. Variants in the DPYD gene (also known as dihydropyrimidine dehydrogenase and DPD) are associated with increased risk for adverse events. See the <a href=""http://www.pharmgkb.org/pathway/PA150653776"">Fluroropyrimidine Pathway</a> and <a href=""http://www.pharmgkb.org/vip/PA145"">DPYD VIP</a> for more information.</p>
<p>Excerpts from the capecitabine (XELODA) drug label:</p>
<blockquote class=""blockquote"">
<p>WARNINGS AND PRECAUTIONS: Serious Adverse Reactions from Dihydropyrimidine Dehydrogenase (DPD) Deficiency</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with certain homozygous or compound heterozygous variants in the DPYD gene known to result in complete or near complete absence of DPD activity (complete DPD deficiency) are at increased risk for acute early-onset toxicity and serious, including fatal, adverse reactions due to XELODA (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity). Patients with partial DPD activity (partial DPD deficiency) may also have increased risk of serious, including fatal, adverse reactions.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>XELODA is not recommended for use in patients known to have certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency.
Withhold or permanently discontinue XELODA based on clinical assessment of the onset, duration, and severity of the observed adverse reactions in patients with evidence of acute early- onset or unusually severe reactions, which may indicate complete DPD deficiency. No XELODA dose has been proven safe for patients with complete DPD deficiency. There are insufficient data to recommend a specific dose in patients with partial DPD deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consider testing for genetic variants of DPYD prior to initiating XELODA to reduce the risk of serious adverse reactions if the patient’s clinical status permits and based on clinical judgement. Serious adverse reactions may still occur even if no DPYD variants are identified.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>An FDA-authorized test for the detection of genetic variants of DPYD to identify patients at risk of serious adverse reactions due to increased systemic exposure to XELODA is not currently available. Currently available tests used to identify DPYD variants may vary in accuracy and design (e.g., which DPYD variant(s) they identify).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacogenomics: The DPYD gene encodes the enzyme DPD, which is responsible for the catabolism of &gt;80% of fluorouracil. Approximately 3-5% of White populations have partial DPD deficiency and 0.2% of White populations have complete DPD deficiency, which may be due to certain genetic no function or decreased function variants in DPYD resulting in partial to complete or near complete absence of enzyme activity. DPD deficiency is estimated to be more prevalent in Black or African American populations compared to White populations. Insufficient information is available to estimate the prevalence of DPD deficiency in other populations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients who are homozygous or compound heterozygous for no function DPYD variants (i.e., carry two no function DPYD variants) or are compound heterozygous for a no function DPYD variant plus a decreased function DPYD variant have complete DPD deficiency and are at increased risk for acute early-onset of toxicity and serious life-threatening, or fatal adverse reactions due to increased systemic exposure to XELODA. Partial DPD deficiency can result from the presence of either two decreased function DPYD variants or one normal function plus either a decreased function or a no function DPYD variant. Patients with partial DPD deficiency may also be at an increased risk for toxicity from XELODA.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Four DPYD variants have been associated with impaired DPD activity in White populations, especially when present as homozygous or compound heterozygous variants: c.1905+1G&gt;A (DPYD *2A), c.1679T&gt;G (DPYD *13), c.2846A&gt;T, and c.1129-5923C&gt;G (Haplotype B3). DPYD*2A and DPYD*13 are no function variants, and c.2846A&gt;T and c.1129-5923C&gt;G are decreased function variants. The decreased function DPYD variant c.557A&gt;G is observed in individuals of African ancestry. This is not a complete listing of all DPYD variants that may result in DPD deficiency.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""capecitabine_2022_12_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/capecitabine_2022_12_19_FDA.pdf"">capecitabine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1450399695.0,"<p>Excerpt from the capecitabine (XELODA) drug label:</p>
<blockquote class=""blockquote"">
<p>Patients with certain homozygous or compound heterozygous variants in the DPYD gene known to result in complete or near complete absence of DPD activity (complete DPD deficiency) are at increased risk for acute early-onset toxicity and serious, including fatal, adverse reactions due to XELODA (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity). Patients with partial DPD activity (partial DPD deficiency) may also have increased risk of serious, including fatal, adverse reactions.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>XELODA is not recommended for use in patients known to have certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency.
Withhold or permanently discontinue XELODA based on clinical assessment of the onset, duration, and severity of the observed adverse reactions in patients with evidence of acute early- onset or unusually severe reactions, which may indicate complete DPD deficiency. No XELODA dose has been proven safe for patients with complete DPD deficiency. There are insufficient data to recommend a specific dose in patients with partial DPD deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consider testing for genetic variants of DPYD prior to initiating XELODA to reduce the risk of serious adverse reactions if the patient’s clinical status permits and based on clinical judgement. Serious adverse reactions may still occur even if no DPYD variants are identified.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>An FDA-authorized test for the detection of genetic variants of DPYD to identify patients at risk of serious adverse reactions due to increased systemic exposure to XELODA is not currently available. Currently available tests used to identify DPYD variants may vary in accuracy and design (e.g., which DPYD variant(s) they identify).</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104815,Annotation of FDA Label for clozapine and CYP2D6,False,False,[],True,"[{'id': 1183681263, 'date': '2013-10-25T11:03:47.343-07:00', 'type': 'Update', 'version': 0}, {'id': 1452214466, 'date': '2023-08-23T14:52:20.688-07:00', 'description': 'Added Dosing Info tag with updated definition', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101971, 'title': 'Drugs@FDA: Drug Product Clozaril (clozapine), NDA019758, HLS Therapeutics (USA), Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019758', 'crossReferences': [{'id': 1449754212, 'resource': 'FDA Application', 'resourceId': 'NDA019758', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019758'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449061', 'name': 'clozapine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450342828.0,"<p>The FDA-approved drug label for clozapine (CLOZARIL) states that it may be necessary to reduce the dose in patients who are CYP2D6 poor metabolizers, as these individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.</p>
",1450342829.0,"<p>Clozapine (CLOZARIL) is an atypical antipsychotic drug. It is approved for the treatment of severely ill patients with schizophrenia who fail to show an acceptable response to standard antipsychotic drug treatment.</p>
<p>Excerpts from the clozapine (CLOZARIL) drug label:</p>
<div class=""blockquote"">
<p>It may be necessary to reduce the CLOZARIL dose in patients with significant renal or hepatic impairment, or in CYP2D6 poor metabolizers...</p>
</div>
<div class=""blockquote"">
<p>A subset (3%–10%) of the population has reduced activity of CYP2D6 (CYP2D6 poor metabolizers). These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Clozapine_01_09_19_FDA.pdf"">clozapine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399540.0,"<p>Excerpt from the clozapine (CLOZARIL) drug label:</p>
<blockquote class=""blockquote"">
<p>It may be necessary to reduce the CLOZARIL dose in patients with significant renal or hepatic impairment, or in CYP2D6 poor metabolizers...</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104810,"Annotation of FDA Label for mercaptopurine and NUDT15, TPMT",False,False,[],True,"[{'id': 1183681676, 'date': '2013-10-25T14:27:32.568-07:00', 'type': 'Update', 'version': 0}, {'id': 1452280420, 'date': '2023-10-24T18:10:12.897-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}, {'id': 1452495081, 'date': '2024-06-06T18:17:49.907-07:00', 'description': 'added second drug label, Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101945, 'title': 'Drugs@FDA: Drug Product PURINETHOL (Mercaptopurine), Quinn Pharmaceuticals - NDA009053/SUPPL-40, 12/29/2020', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009053', 'crossReferences': [{'id': 1452495063, 'resource': 'FDA Application', 'resourceId': 'NDA009053/SUPPL-40', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009053'}], 'objCls': 'Literature', 'pubDate': '2020-12-29T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15159242, 'title': 'Drugs@FDA: Drug Product PURIXAN (mercaptopurine), Nova Laboratories, Ltd - NDA205919/SUPPL-4, 04/07/2020', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205919', 'crossReferences': [{'id': 1452495061, 'resource': 'FDA Application', 'resourceId': 'NDA205919/SUPPL-4', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205919'}], 'objCls': 'Literature', 'pubDate': '2020-04-06T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]","[{'objCls': 'Haplotype', 'id': 'PA166131620', 'symbol': 'NUDT15*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA166131621', 'symbol': 'NUDT15*3', 'name': '*3'}, {'objCls': 'Haplotype', 'id': 'PA165819269', 'symbol': 'TPMT*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165819270', 'symbol': 'TPMT*3A', 'name': '*3A'}, {'objCls': 'Haplotype', 'id': 'PA165819272', 'symbol': 'TPMT*3C', 'name': '*3C'}]","[{'objCls': 'Chemical', 'id': 'PA450379', 'name': 'mercaptopurine'}]","[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",FDA,1447981602.0,"<p>The FDA-approved drug labels for mercaptopurine (PURIXAN and PURINETHOL) state that patients with severe myelosuppression should be evaluated for TPMT or NUDT15 deficiency, and that patients with homozygous TPMT or NUDT15 deficiency may require dose reductions.</p>
<p>The FDA Table of Pharmacogenomic Biomarkers in Drug Labeling lists two different labels for mercaptopurine, mercaptopurine oral suspension (PURIXAN) and mercaptopurine tablets (PURINETHOL).</p>
",1447981601.0,"<p>Mercaptopurine is indicated for the treatment of acute lymphoblastic leukemia (ALL). Excerpts from the mercaptopurine (PURIXAN) drug label:</p>
<blockquote class=""blockquote"">
<p>Evaluate thiopurine S-methyltransferase (TPMT) and nucleotide diphosphatase (NUDT15) status in patients in patients with severe myelosuppression or repeated episodes of myelosuppression</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dosage Modifications in Patients with TPMT and NUDT15 Deficiency</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consider testing for TPMT and NUDT15 deficiency in patients who experience severe myelosuppression or repeated episodes of myelosuppression</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Homozygous Deficiency in either TPMT or NUDT15: Patients with homozygous deficiency of either enzyme typically require 10% or less of the recommended dosage. Reduce the recommended starting dosage of PURIXAN in patients who are known to have homozygous TPMT or NUDT15 deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Heterozygous Deficiency in TPMT and/or NUDT15: Reduce the PURIXAN dosage based on tolerability. Most patients with heterozygous TPMT or NUDT15 deficiency tolerate recommended dosage, but some require dose reduction based on adverse reactions. Patients who are heterozygous for both TPMT and NUDT15 may require more substantial dose reductions.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consider testing for thiopurine S-methyltransferase (TPMT) or nucleotide diphosphatase (NUDT15) deficiency in patients with severe myelosuppression or repeated episodes of myelosuppression. TPMT genotyping or phenotyping (red blood cell TPMT activity) and NUDT15 genotyping can identify patients who have reduced activity of these enzymes. Patients with homozygous TPMT or NUDT15 deficiency may require a dose reduction</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacogenomics</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Several published studies indicate that patients with reduced TPMT or NUDT15 activity receiving usual doses of mercaptopurine, accumulate excessive cellular concentrations of active 6-TGNs, and are at higher risk for severe myelosuppression [see Warnings and Precautions (5.1)]. In a study of 1028 children with ALL, the approximate tolerated mercaptopurine dosage for patients with TPMT and/or NUDT15 deficiency on mercaptopurine maintenance therapy (as a percentage of the planned dosage) was as follows: heterozygous for either TPMT or NUDT15, 50-90%; heterozygous for both TPMT and NUDT15, 30-50%; homozygous for either TPMT or NUDT15, 5-10%.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Approximately 0.3% (1:300) of patients of European or African ancestry have two loss-of-function alleles of the TPMT gene and have little or no TMPT activity (homozygous deficient or poor metabolizers), and approximately 10% of patients have one loss-of-function TPMT allele leading to intermediate TPMT activity (heterozygous deficient or intermediate metabolizers). The TPMT*2, TPMT*3A, and TPMT*3C alleles account for about 95% of individuals with reduced levels of TPMT activity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>NUDT15 deficiency is detected in &lt;1% of patients of European or African ancestry. Among patients of East Asian ancestry (i.e., Chinese, Japanese, Vietnamese), 2% have two loss-of-function alleles of the NUDT15 gene, and approximately 21% have one loss-of-function allele. The p.R139C variant of NUDT15 (present on the *2 and *3 alleles) is the most commonly observed, but other less common loss-of-function NUDT15 alleles have been observed.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consider all clinical information when interpreting results from phenotypic testing used to determine the level of thiopurine nucleotides or TPMT activity in erythrocytes, since some coadministered drugs can influence measurement of TPMT activity in blood, and blood from recent transfusions will misrepresent a patient’s actual TPMT activity</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Mercaptopurine-PURIXAN_2024_06_06_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Mercaptopurine-PURIXAN_2024_06_06_FDA.pdf"">mercaptopurine (PURIXAN) drug label</a> or the <a download=""mercaptopurine_FDA_10242023.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/mercaptopurine_FDA_10242023.pdf"">mercaptopurine (PURINETHOL) drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452495080.0,"<blockquote class=""blockquote"">
<p>Safety and effectiveness of PURIXAN has been established in pediatric patients. Use of PURIXAN in pediatrics is supported by evidence from the published literature and clinical experience. Symptomatic hypoglycemia has been reported in pediatric patients with ALL receiving mercaptopurine. Reported cases were in pediatrics less than 6 years or with a low body mass index.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Wide inter individual variations in systemic exposure is observed. Following oral administration of 50 mg/m2
mercaptopurine in 10 children, median plasma concentrations 1 hour post dose was 0.35 (range 0.03 to 1.03) μM and median AUC1–5hours was 56 (range 23 to 65) μM·min. Tmax ranged from 1 to 3 hours.</p>
</blockquote>
",1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1450399706.0,"<p>Excerpts from the mercaptopurine (PURIXAN) drug label:</p>
<blockquote class=""blockquote"">
<p>Homozygous Deficiency in either TPMT or NUDT15:
Patients with homozygous deficiency of either enzyme typically require 10% or less of the recommended dosage. Reduce the recommended starting dosage of PURIXAN in patients who are known to have homozygous TPMT or NUDT15 deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Heterozygous Deficiency in TPMT and/or NUDT15:
Reduce the PURIXAN dosage based on tolerability. Most patients with heterozygous TPMT or NUDT15 deficiency tolerate recommended dosage, but some require dose reduction based on adverse reactions. Patients who are heterozygous for both TPMT and NUDT15 may require more substantial dose reductions.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104864,Annotation of FDA Label for paroxetine and CYP2D6,False,False,[],False,"[{'id': 1183681319, 'date': '2013-10-25T11:15:52.702-07:00', 'type': 'Update', 'version': 0}, {'id': 1452230581, 'date': '2023-09-07T11:24:42.078-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102019, 'title': 'Drugs@FDA: Drug Product PEXEVA (paroxetine mesylate), NDA021299, Sebela Pharmaceuticals Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021299', 'crossReferences': [{'id': 1449767788, 'resource': 'FDA Application', 'resourceId': 'NDA021299', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021299'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450801', 'name': 'paroxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981694.0,"<p>The FDA-approved drug label for paroxetine (PEXEVA) states that it is both metabolized by and an inhibitor of CYP2D6. It also notes that when CYP2D6 extensive metabolizers were given paroxetine in combination with atomoxetine, atomoxetine steady state levels were higher than when the drug was given alone.</p>
",1447981693.0,"<p>Excerpts from the paroxetine (PEXEVA) label:</p>
<div class=""blockquote"">
<p>The metabolism of paroxetine is accomplished in part by cytochrome CYP2D6.</p>
</div>
<div class=""blockquote"">
<p><em>In vitro</em> drug interaction studies reveal that paroxetine inhibits CYP2D6.</p>
</div>
<div class=""blockquote"">
<p>In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone. Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when it is given with paroxetine.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Paroxetine_02_20_19_FDA.pdf"">paroxetine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104855,Annotation of FDA Label for boceprevir and IFNL3,False,False,"[{'id': 1183629325, 'name': 'http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae879ebe-b620-4829-b6f8-74b58da1c771', 'resource': 'FDA Drug Label at DailyMed', 'resourceId': 'ae879ebe-b620-4829-b6f8-74b58da1c771', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae879ebe-b620-4829-b6f8-74b58da1c771'}]",False,"[{'id': 1183681501, 'date': '2013-10-25T12:04:21.255-07:00', 'type': 'Update', 'version': 0}, {'id': 1452540300, 'date': '2024-07-26T14:42:46.344-07:00', 'description': 'added note that drug has been discontinued', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101978, 'title': 'Drugs@FDA: Drug Product boceprevir (NDA202258)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202258', 'crossReferences': [{'id': 1449894466, 'resource': 'FDA Application', 'resourceId': 'NDA202258', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202258'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166155468', 'symbol': 'rs12979860', 'name': 'rs12979860'}]","[{'objCls': 'Chemical', 'id': 'PA165948902', 'name': 'boceprevir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",FDA,1447981678.0,"<p>The FDA-approved drug label for boceprevir (Victrelis) contains information regarding a genetic variant near the IFNL3 gene (IL28B, <a href=""/variant/PA166155468"">rs12979860</a>, a C to T change) which is a strong predictor of response to peginterferon alfa-2b (PegIntron) / ribavirin (Rebetol) treatment. Boceprevir must not be used as a monotherapy and should only be used in combination with these drugs for the treatment of chronic hepatitis C genotype 1.</p>
<p><strong>July 2024: Please note that boceprevir is listed as discontinued by the FDA. However, this drug is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
",1447981677.0,"<p>Excerpt from the boceprevir (<em>Victrelis</em>) drug label:</p>
<blockquote class=""blockquote"">
<p>&quot;A genetic variant near the gene encoding interferon-lambda-3 (IL28B <a href=""/variant/PA166155468"">rs12979860</a>, a C to T change) is a strong predictor of response to PegIntron/REBETOL. IL28B <a href=""/variant/PA166155468"">rs12979860</a> was genotyped in 653 of 1048 (62%) subjects in SPRINT-2 (previously untreated) and 259 of 394 (66%) subjects in RESPOND-2 (previous treatment failure)...Among subjects that received at least one dose of placebo or VICTRELIS (Modified-Intent-to-Treat population), SVR rates tended to be lower in subjects with the C/T and T/T genotypes compared to those with the C/C genotype, particularly among previously untreated subjects receiving 48 weeks of PegIntron and REBETOL (see Table 9). Among previous treatment failures, subjects of all genotypes appeared to have higher SVR rates with VICTRELIS-containing regimens. The results of this retrospective subgroup analysis should be viewed with caution because of the small sample size and potential differences in demographic or clinical characteristics of the substudy population relative to the overall trial population.&quot;</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Boceprevir_7_5_2017_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Boceprevir_7_5_2017_FDA.pdf"">boceprevir drug label </a></p>
<p><strong>July 2024: Please note that boceprevir is listed as discontinued by the FDA. However, this drug is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104783,"Annotation of FDA Label for rasburicase and CYB5R1, CYB5R2, CYB5R3, CYB5R4",False,False,[],False,"[{'id': 1183681441, 'date': '2013-10-25T11:35:42.986-07:00', 'type': 'Update', 'version': 0}, {'id': 1447952335, 'date': '2016-03-21T13:56:52.505-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101891, 'title': 'Drugs@FDA: Drug Product Elitek (rasburicase), BLA103946, sanofi-aventis U.S. LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103946', 'crossReferences': [{'id': 1449776546, 'resource': 'FDA Application', 'resourceId': 'BLA103946', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103946'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10176', 'name': 'rasburicase'}]","[{'objCls': 'Gene', 'id': 'PA134979668', 'symbol': 'CYB5R1', 'name': 'cytochrome b5 reductase 1'}, {'objCls': 'Gene', 'id': 'PA142672060', 'symbol': 'CYB5R2', 'name': 'cytochrome b5 reductase 2'}, {'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA134904907', 'symbol': 'CYB5R4', 'name': 'cytochrome b5 reductase 4'}]",FDA,1447981522.0,"<p>The FDA-approved drug label for rasburicase (Elitek) states that is unclear whether patients with NADH cytochrome b5 reductase (<em>CYB5R1, 2, 3, 4</em>) deficiency are at risk for methemoglobinemia or hemolytic anemia. It also states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency.</p>
",1447981521.0,"<p>Excerpt from the rasburicase (Elitek) drug label:</p>
<div class=""blockquote"">
<p>It is not known whether patients with deficiency of cytochrome b5 reductase (formerly known as methemoglobin reductase) or of other enzymes with antioxidant activity are at increased risk for methemoglobinemia or hemolytic anemia.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Rasburicase_08_17_2017_FDA.pdf"">rasburicase drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104803,Annotation of FDA Label for maraviroc and CCR5,False,False,[],False,"[{'id': 1183681588, 'date': '2013-10-25T12:46:34.715-07:00', 'type': 'Update', 'version': 0}, {'id': 1452210220, 'date': '2023-08-18T15:15:41.409-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101848, 'title': 'Drugs@FDA: Drug Product SELZENTRY (maraviroc), NDA208984, ViiV Healthcare Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208984', 'crossReferences': [{'id': 1449755486, 'resource': 'FDA Application', 'resourceId': 'NDA208984', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208984'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164768835', 'name': 'maraviroc'}]","[{'objCls': 'Gene', 'id': 'PA26170', 'symbol': 'CCR5', 'name': 'C-C motif chemokine receptor 5'}]",FDA,1447981556.0,"<p>The drug labeling for maraviroc (SELZENTRY) is not related to genetic testing of the patient, rather testing of the HIV-1 strain that has infected the patient. The FDA-approved label states that HIV tropism testing be carried out before treatment with maraviroc. This drug is indicated only for CCR5-tropic HIV-1 infection, and due to its mechanism of action, is not effective against CXCR4-tropic and dual-tropic HIV-1.</p>
",1447981555.0,"<p>Maraviroc (SELZENTRY) is a CCR5 antagonist, and works by preventing HIV-1 from entering cells via the CCR5 cell surface receptor. The drug labeling information demonstrates why a sensitive HIV tropism assay should be used to diagnose CCR5-tropic HIV-1, in order to avoid treating individuals with CXCR4- or Dual/ Mixed- tropic virus (discussed in section 14.3).</p>
<p>Excerpt from the maraviroc (SELZENTRY) drug label:</p>
<div class=""blockquote"">
<p>SELZENTRY, in combination with other antiretroviral agents, is indicated for adult patients infected with only CCR5-tropic HIV-1.</p>
</div>
<div class=""blockquote"">
<p>The following points should be considered when initiating therapy with SELZENTRY: Adult patients infected with only CCR5-tropic HIV-1 should use SELZENTRY...Tropism testing must be conducted with a highly sensitive tropism assay that has demonstrated the ability to identify patients appropriate for use of SELZENTRY. Outgrowth of pre-existing low-level CXCR4-or dual/mixed-tropic HIV-1 not detected by tropism testing at screening has been associated with virologic failure on SELZENTRY</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Maraviroc_08_04_2017_FDA.pdf"">maraviroc drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,Formerly on FDA Biomarker List
Label Annotation,PA166104868,Annotation of FDA Label for modafinil and CYP2D6,False,False,[],False,"[{'id': 1183681678, 'date': '2013-10-25T14:28:23.202-07:00', 'type': 'Update', 'version': 0}, {'id': 1452699884, 'date': '2024-11-13T10:39:24.059-08:00', 'description': 'removed Informative PGx level; label text is about drug interactions', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101980, 'title': 'Drugs@FDA: Drug Product modafinil (modafinil), NDA020717, Dispensing Solutions, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020717', 'crossReferences': [{'id': 1449762546, 'resource': 'FDA Application', 'resourceId': 'NDA020717', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020717'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450530', 'name': 'modafinil'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981705.0,"<p>Modafinil (PROVIGIL), used to improve wakefulness, is metabolized by many cytochrome P450s. Patients that are poor metabolizers for CYP2D6 may need dose modifications for medications that have ancillary metabolism via CYP2C19, such as tricyclic antidepressants (TCAs).</p>
",1447981704.0,"<p>Excerpts from the modafinil (PROVIGIL) label:</p>
<div class=""blockquote"">
<p>In individuals deficient in the CYP2D6 enzyme, the levels of CYP2D6 substrates which have ancillary routes of elimination through CYP2C19, such as tricyclic antidepressants and selective serotonin reuptake inhibitors, may be increased by co-administration of PROVIGIL.</p>
</div>
<div class=""blockquote"">
<p>In tricyclic-treated patients deficient in CYP2D6 (i.e., those who are poor metabolizers of debrisoquine; 7-10% of the Caucasian population; similar or lower in other populations), the amount of metabolism by CYP2C19 may be substantially increased. PROVIGIL may cause elevation of the levels of the tricyclics in this subset of patients...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Modafinil_08_10_2017_FDA.pdf"">modafinil drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104867,Annotation of FDA Label for telaprevir and IFNL3,False,False,[],False,"[{'id': 1183681487, 'date': '2013-10-25T11:42:26.255-07:00', 'type': 'Update', 'version': 0}, {'id': 1452707185, 'date': '2024-11-18T12:01:13.136-08:00', 'description': 'added the Discontinued FDA status', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101859, 'title': 'Drugs@FDA: Drug Product telaprevir (NDA201917)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201917', 'crossReferences': [{'id': 1449814515, 'resource': 'FDA Application', 'resourceId': 'NDA201917', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201917'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166155468', 'symbol': 'rs12979860', 'name': 'rs12979860'}]","[{'objCls': 'Chemical', 'id': 'PA165958354', 'name': 'telaprevir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",FDA,1447981701.0,"<p>Among both treatment-naïve and previous treatment failures patients with HCV genotype 1 infections, subjects of all IL28B genotypes appeared to have higher SVR rates with telaprevir (INCIVEK)-containing regimens compared to PEG-IFN alpha and RBV only. Patients with the favorable IFNL3 genotype (<a href=""/variant/PA166155468"">rs12979860</a> CC) tend to have higher response rates (SVR) as compared to patients with the CT or TT genotype with the protease inhibitor combination in treatment naïve patients.</p>
<p><strong>November 2024: Please note that telaprevir is shown as discontinued by the FDA. However, this drug is still listed on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
",1447981700.0,"<p>Excerpt from the telaprevir (INCIVEK) label:</p>
<blockquote class=""blockquote"">
<p>12.5 Pharmacogenomics</p>
<p>A genetic variant near the gene encoding interferon-lambda-3 (IL28B <a href=""/variant/PA166155468"">rs12979860</a>, a C to T change) is a strong predictor of response to peginterferon alfa and ribavirin (PR). <a href=""/variant/PA166155468"">rs12979860</a> was genotyped in 454 of 1088 subjects in Study Trial 108 (treatment-naïve) and 527 of 662 subjects in Trial C216 (previously treated) (see Clinical Studies (14.2 and 14.3) for trial descriptions). SVR rates tended to be lower in subjects with the CT and TT genotypes compared to those with the CC genotype, particularly among treatment-naïve subjects receiving PR48 (Table 9). Among both treatment-naïve and previous treatment failures, subjects of all IL28B genotypes appeared to have higher SVR rates with INCIVEK-containing regimens. The results of this retrospective subgroup analysis should be viewed with caution because of the small sample size and potential differences in demographic or clinical characteristics of the subtrial population relative to the overall trial population.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Telaprevir_12_14_17_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Telaprevir_12_14_17_FDA.pdf"">telaprevir drug label</a>.</p>
<p><strong>November 2024: Please note that telaprevir is shown as discontinued by the FDA. However, this drug is still listed on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166105213,Annotation of FDA Label for oxcarbazepine and HLA-B,True,False,[],False,"[{'id': 1448604587, 'date': '2017-03-15T10:58:39.065-07:00', 'type': 'Update', 'version': 0}, {'id': 1450380036, 'date': '2019-04-16T14:35:24.701-07:00', 'description': 'Added variant and prescribing information', 'type': 'Update', 'version': 0}, {'id': 1454142360, 'date': '2025-06-13T09:19:38.943-07:00', 'description': 'fixed HLA allele formal name', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102024, 'title': 'Drugs@FDA: Drug Product OXTELLAR XR (OXCARBAZEPINE), NDA202810, Supernus Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202810', 'crossReferences': [{'id': 1449767755, 'resource': 'FDA Application', 'resourceId': 'NDA202810', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202810'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165954769', 'symbol': 'HLA-B*15:02', 'name': '*15:02'}]","[{'objCls': 'Chemical', 'id': 'PA450732', 'name': 'oxcarbazepine'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",FDA,1447981848.0,"<p>The FDA-approved drug label for oxcarbazepine (OXTELLAR XR) states that testing for the presence of the HLA-B*15:02 allele should be considered in patients with ancestry in genetically at-risk populations prior to initiating treatment with the drug, due to the risk for Stevens-Johnson syndrome or toxic epidermal necrolysis.</p>
",1447981847.0,"<p>Excerpts from the oxcarbazepine (OXTELLAR XR) drug label:</p>
<div class=""blockquote"">
<p>Patients carrying the HLA-B*1502 allele may be at increased risk for SJS/TEN with oxcarbazepine treatment.</p>
</div>
<div class=""blockquote"">
<p>The frequency of the HLA-B*1502 allele ranges from 2 to 12% in Han Chinese populations, is about 8% in Thai populations, and above 15% in the Philippines and in some Malaysian populations. Allele frequencies up to about 2% and 6% have been reported in Korea and India, respectively. The frequency of the HLA-B*1502 allele is negligible in people from European descent, several African populations, indigenous peoples of the Americas, Hispanic populations, and in Japanese (&lt;1%).</p>
</div>
<div class=""blockquote"">
<p>Testing for the presence of the HLA-B*1502 allele should be considered in patients with ancestry in genetically at-risk populations, prior to initiating treatment with oxcarbazepine. The use of oxcarbazepine should be avoided in patients positive for HLA-B*1502 unless the benefits clearly outweigh the risks. Consideration should also be given to avoid the use of other drugs associated with SJS/TEN in HLA-B*1502 positive patients, when alternative therapies are otherwise equally available.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Oxcarbazepine_02_19_19_FDA.pdf"">oxcarbazepine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1450380035.0,"<p>Excerpt from the oxcarbazepine (OXTELLAR XR) drug label:</p>
<blockquote class=""blockquote"">
<p>The use of oxcarbazepine should be avoided in patients positive for HLA-B*1502 unless the benefits clearly outweigh the risks. Consideration should also be given to avoid the use of other drugs associated with SJS/TEN in HLA-B*1502 positive patients, when alternative therapies are otherwise equally available.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104906,Annotation of FDA Label for probenecid and G6PD,False,False,[],False,"[{'id': 1183681279, 'date': '2013-10-25T11:06:56.619-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101924, 'title': 'Drugs@FDA: Drug Product Probenecid (probenecid), ANDA084211, Carilion Materials Management', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=084211', 'crossReferences': [{'id': 1450369322, 'resource': 'FDA Application', 'resourceId': 'ANDA084211', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=084211'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451106', 'name': 'probenecid'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981789.0,"<p>Probenecid is used to treat chronic gouty arthritis.  An association between probenecid-induced hemolytic anemia and G6PD deficiency is highlighted in the Adverse Reactions section of the probenecid label.</p>
",1447981788.0,"<p>Excerpt from the probenecid drug label:</p>
<div class=""blockquote"">
<p>Adverse Reactions...Hematologic: aplastic anemia, leukopenia, hemolytic anemia which in some patients could be related to genetic deficiency of glucose-6-phosphate dehydrogenase in red blood cells, anemia.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Probenecid_02_22_19_FDA.pdf"">probenecid drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104877,Annotation of FDA Label for mycophenolic acid and HPRT1,True,False,[],False,"[{'id': 1183681680, 'date': '2013-10-25T14:29:05.494-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101951, 'title': 'Drugs@FDA: Drug Product Myfortic (mycophenolic acid), NDA050791, Novartis Pharmaceuticals Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050791', 'crossReferences': [{'id': 1449762715, 'resource': 'FDA Application', 'resourceId': 'NDA050791', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050791'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA29427', 'symbol': 'HPRT1', 'name': 'hypoxanthine phosphoribosyltransferase 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164748728', 'name': 'mycophenolic acid'}]","[{'objCls': 'Gene', 'id': 'PA29427', 'symbol': 'HPRT1', 'name': 'hypoxanthine phosphoribosyltransferase 1'}]",FDA,1447981729.0,"<p>Mycophenolic acid (Myfortic) is an IMPDH Inhibitor that should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.</p>
",1447981728.0,"<p>Excerpt from the mycophenolic acid (Myfortic) drug label:</p>
<blockquote class=""blockquote"">
<p>Myfortic is an inosine monophosphate dehydrogenase inhibitor (IMPDH Inhibitor). Myfortic should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes because it may cause an exacerbation of disease symptoms characterized by the overproduction and accumulation of uric acid leading to symptoms associated with gout such as acute arthritis, tophi, nephrolithiasis or urolithiasis and renal disease including renal failure.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Mycophenolic_acid_08_10_2017_FDA.pdf"">mycophenolic acid drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399711.0,"<p>Excerpt from the mycophenolic acid (Myfortic) drug label:</p>
<blockquote class=""blockquote"">
<p>Myfortic should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes because it may cause an exacerbation of disease symptoms characterized by the overproduction and accumulation of uric acid leading to symptoms associated with gout such as acute arthritis, tophi, nephrolithiasis or urolithiasis and renal disease including renal failure.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104917,"Annotation of FDA Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5",False,False,[],False,"[{'id': 1183681341, 'date': '2013-10-25T11:21:14.385-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101925, 'title': 'Drugs@FDA: Drug Product Effient (Prasugrel hydrochloride), NDA022307, Eli Lilly and Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022307', 'crossReferences': [{'id': 1449776476, 'resource': 'FDA Application', 'resourceId': 'NDA022307', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022307'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA154410481', 'name': 'prasugrel'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}, {'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA131', 'symbol': 'CYP3A5', 'name': 'cytochrome P450 family 3 subfamily A member 5'}]",FDA,1447981812.0,"<p>The FDA-approved drug label for prasugrel (Effient) contains information regarding a lack of effect of genetic variants on prasugrel pharmacokinetics.</p>
",1447981811.0,"<p>Excerpts from the prasugrel (Effient) label:</p>
<div class=""blockquote"">
<p>In healthy subjects, patients with stable atherosclerosis, and patients with ACS receiving prasugrel, there was no relevant effect of genetic variation in CYP2B6, CYP2C9, CYP2C19, or CYP3A5 on the pharmacokinetics of prasugrel's active metabolite or its inhibition of platelet aggregation.</p>
</div>
<div class=""blockquote"">
<p>There is no relevant effect of genetic variation in CYP2B6, CYP2C9, CYP2C19, or CYP3A5 on the pharmacokinetics of prasugrel's active metabolite or its inhibition of platelet aggregation.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Prasugrel_08_16_2017_FDA.pdf"">prasugrel drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104875,Annotation of FDA Label for clomipramine and CYP2D6,False,False,[],False,"[{'id': 1183681212, 'date': '2013-10-25T10:44:09.437-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102020, 'title': 'Drugs@FDA: Drug Product CLOMIPRAMINE HYDROCHLORIDE (clomipramine hydrochloride), SpecGx LLC - NDA019906/SUPPL-40, 05/24/2017', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019906', 'crossReferences': [{'id': 1453105786, 'resource': 'FDA Application', 'resourceId': 'NDA019906/SUPPL-40', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019906'}], 'objCls': 'Literature', 'pubDate': '2017-05-24T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449048', 'name': 'clomipramine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450342825.0,"<p>The FDA-approved drug label for clomipramine (Anafranil) notes that CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs), such as clomipramine, when given typical doses.</p>
",1450342826.0,"<p>Clomipramine (Anafranil) is an antiobsessional drug belonging to the tricyclic antidepressants class.</p>
<p>Excerpt from the clomipramine (Anafranil) label:</p>
<div class=""blockquote"">
<p>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6...is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called &quot;poor metabolizers&quot;); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers...It is desirable to monitor TCA plasma levels whenever an agent of the tricyclic antidepressant class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Clomipramine_01_09_19_FDA.pdf"">clomipramine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166105222,Annotation of FDA Label for piroxicam and CYP2C9,False,False,[],True,"[{'id': 1450382273, 'date': '2019-04-19T14:49:23.710-07:00', 'description': 'Added variant information', 'type': 'Update', 'version': 0}, {'id': 1452214484, 'date': '2023-08-23T15:01:20.104-07:00', 'description': 'Added Dosing Info tag with updated definition', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101870, 'title': 'Drugs@FDA: Drug Product Feldene (piroxicam), NDA018147, Pfizer Laboratories Div Pfizer Inc', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018147', 'crossReferences': [{'id': 1449776469, 'resource': 'FDA Application', 'resourceId': 'NDA018147', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018147'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450985', 'name': 'piroxicam'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1448604865.0,"<p>The FDA-approved drug label for piroxicam (FELDENE) states that CYP2C9 intermediate and poor metabolizers had higher systemic levels of piroxicam as compared to normal metabolizers, and that known or suspected CYP2C9 poor metabolizers should consider a dose reduction.</p>
",1448604864.0,"<p>Piroxicam (FELDENE) is a nonsteroidal anti-inflammatory drug indicated for osteoarthritis and rheumatoid arthritis.</p>
<p>Excerpts from the piroxicam (FELDENE) drug label:</p>
<div class=""blockquote"">
<p>In vitro studies indicate...CYP2C9...as the main enzyme involved in the formation to the 5'-hydroxy-piroxicam, the major metabolite.</p>
</div>
<div class=""blockquote"">
<p>Pharmacogenomics...CYP2C9 activity is reduced in individuals with genetic polymorphisms, such as the CYP2C9*2 and CYP2C9*3 polymorphisms. Limited data from two published reports showed that subjects with heterozygous CYP2C9*1/*2 (n=9), heterozygous CYP2C9*1/*3 (n=9), and homozygous CYP2C9*3/*3 (n=1) genotypes showed 1.7-, 1.7-, and 5.3-fold higher piroxicam systemic levels, respectively, than the subjects with CYP2C9*1/*1 (n=17, normal metabolizer genotype) following administration of a single oral dose. The mean elimination half-life values of piroxicam for subjects with CYP2C9*1/*3 (n=9) and CYP2C9*3/*3 (n=1) genotypes were 1.7- and 8.8-fold higher than subjects with CYP2C9*1/*1 (n=17). It is estimated that the frequency of the homozygous *3/*3 genotype is 0% to 1% in the population at large; however, frequencies as high as 5.7% have been reported in certain ethnic groups.</p>
</div>
<div class=""blockquote"">
<p><em>Poor Metabolizers of CYP2C9 Substrates:</em> In patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin and phenytoin) consider dose reduction as they may have abnormally high plasma levels due to reduced metabolic clearance.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Piroxicam_08_16_2017_FDA.pdf"">piroxicam drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399720.0,"<p>Excerpt from the piroxicam (FELDENE) drug label:</p>
<blockquote class=""blockquote"">
<p>In patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin and phenytoin) consider dose reduction as they may have abnormally high plasma levels due to reduced metabolic clearance.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166105023,Annotation of FDA Label for rosuvastatin and SLCO1B1,False,False,[],False,"[{'id': 1183704715, 'date': '2014-01-14T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1448604638, 'date': '2017-03-15T14:13:04.365-07:00', 'description': 'LDLR gene removed', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102023, 'title': 'Drugs@FDA: Drug Product CRESTOR (Rosuvastatin calcium), NDA021366, Carilion Materials Management', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021366', 'crossReferences': [{'id': 1449776556, 'resource': 'FDA Application', 'resourceId': 'NDA021366', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021366'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166154579', 'symbol': 'rs4149056', 'name': 'rs4149056'}]","[{'objCls': 'Chemical', 'id': 'PA134308647', 'name': 'rosuvastatin'}]","[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",FDA,1447981894.0,"<p>The FDA-approved drug label for rosuvastatin (CRESTOR) states that higher plasma concentrations of the drug have been seen in small groups of patients homozygous for the <em>SLCO1B1</em> rs4149056 variant.</p>
",1447981893.0,"<p>Excerpts from the rosuvastatin (CRESTOR) drug label:</p>
<div class=""blockquote"">
<p>Pharmacogenomics...Higher plasma concentrations of rosuvastatin have been reported in very small groups of patients (n=3 to 5) who have two reduced function alleles of the gene that encodes OATP1B1 (SLCO1B1 521T &gt; C). The frequency of this genotype (i.e., SLCO1B1 521 C/C) is generally lower than 5% in most racial/ethnic groups. The impact of this polymorphism on efficacy and/or safety of rosuvastatin has not been clearly established.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Rosuvastatin_02_25_19_FDA.pdf"">rosuvastatin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104893,Annotation of FDA Label for perphenazine and CYP2D6,False,False,[],False,"[{'id': 1183681323, 'date': '2013-10-25T11:17:02.266-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102046, 'title': 'Drugs@FDA: Drug Product perphenazine (NDA010775)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=010775', 'crossReferences': [{'id': 1449767805, 'resource': 'FDA Application', 'resourceId': 'NDA010775', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=010775'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450882', 'name': 'perphenazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981761.0,"<p>The FDA-approved drug label for perphenazine (TRILAFON) states that its metabolism is mediated by the CYP2D6 enzyme, and that CYP2D6 poor metabolizers will metabolize the drug more slowly and experience higher concentrations as compared with normal metabolizers. This may lead to greater side effects.</p>
",1447981760.0,"<p>Excerpts from the perphenazine (TRILAFON) label:</p>
<div class=""blockquote"">
<p>The pharmacokinetics of perphenazine covary with the hydroxylation of debrisoquine which is mediated by cytochrome P450 2D6 (CYP 2D6) and thus is subject to genetic polymorphism - ie, 7%-10% of Caucasians and a low percentage of Asians have little or no activity and are called “poor metabolizers.” Poor metabolizers of CYP 2D6 will metabolize perphenazine more slowly and will experience higher concentrations compared with normal or “extensive” metabolizers.</p>
</div>
<div class=""blockquote"">
<p>In one study of 45 elderly patients suffering from dementia treated with perphenazine, the 5 patients who were prospectively identified as poor P450 2D6 metabolizers had reported significantly greater side effects during the first 10 days of treatment than the 40 extensive metabolizers...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Perphenazine_02_21_19_FDA.pdf"">perphenazine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104921,Annotation of FDA Label for omeprazole and CYP2C19,False,False,[],False,"[{'id': 1183681291, 'date': '2013-10-25T11:08:47.151-07:00', 'type': 'Update', 'version': 0}, {'id': 1448604790, 'date': '2017-03-16T13:11:50.498-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101953, 'title': 'Drugs@FDA: Drug Product Prilosec (omeprazole magnesium), NDA022056, Covis Pharma', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022056', 'crossReferences': [{'id': 1449767736, 'resource': 'FDA Application', 'resourceId': 'NDA022056', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022056'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450704', 'name': 'omeprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1447981818.0,"<p>The FDA-approved drug label for omeprazole (PRILOSEC) notes that CYP2C19 is involved in the metabolism of the drug, and that poor metabolizers have a greater systemic exposure to omeprazole, followed by intermediate and then extensive metabolizers.</p>
",1447981817.0,"<p>Excerpts from the omeprazole (PRILOSEC) drug label:</p>
<div class=""blockquote"">
<p>Pharmacogenomics...CYP2C19...is involved in the metabolism of omeprazole. The CYP2C19*1 allele is fully functional while the CYP2C19*2 and *3 alleles are nonfunctional. There are other alleles associated with no or reduced enzymatic function. Patients carrying two fully functional alleles are extensive metabolizers and those carrying two loss-of-function alleles are poor metabolizers. In extensive metabolizers, omeprazole is primarily metabolized by CYP2C19. The systemic exposure to omeprazole varies with a patient’s metabolism status: poor metabolizers &gt; intermediate metabolizers &gt; extensive metabolizers. Approximately 3% of Caucasians and 15 to 20% of Asians are CYP2C19 poor metabolizers.In a pharmacokinetic study of single 20 mg omeprazole dose, the AUC of omeprazole in Asian subjects was approximately four-fold of that in Caucasians.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Omeprazole_02_19_19_FDA.pdf"">omeprazole drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166105178,"Annotation of FDA Label for lidocaine / prilocaine and CYB5R3, G6PD",False,False,[],False,"[{'id': 1448605696, 'date': '2017-03-29T13:08:50.097-07:00', 'type': 'Update', 'version': 0}, {'id': 1450821519, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1450822360, 'date': '2019-10-15T08:35:10.662-07:00', 'description': 'Added link and text about CYB5R3 and congenital methemoglobinemia.', 'type': 'Update', 'version': 0}, {'id': 1452264240, 'date': '2023-10-05T16:07:34.961-07:00', 'description': 'removed CYB5R3 as FDA biomarker table only list as ""Nonspecific (Congenital Methemoglobinemia)""', 'type': 'Update', 'version': 0}, {'id': 1452536503, 'date': '2024-07-23T00:00:00-07:00', 'description': 'added CYB5R3 gene, Other Guidance tag, prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102048, 'title': 'Drugs@FDA: Drug Product Oraqix (lidocaine and prilocaine), Dentsply Pharmaceutical - NDA021451/SUPPL-14, 11/02/2018', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021451', 'crossReferences': [{'id': 1452536480, 'resource': 'FDA Application', 'resourceId': 'NDA021451/SUPPL-14', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021451'}], 'objCls': 'Literature', 'pubDate': '2018-11-02T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166176018', 'name': 'lidocaine / prilocaine'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1448257416.0,"<p>The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
",1448257415.0,"<p>ORAQIX (lidocaine and prilocaine periodontal gel) is an amide local anesthetic. Excerpts from the ORAQIX drug label:</p>
<blockquote class=""blockquote"">
<p>Patients with glucose-6-phosphate dehydrogenase deficiencies, and patients taking oxidizing drugs such as antimalarials and sulfonamides are more susceptible to drug-induced methemoglobinemia. [See Warnings and Precautions (5.1)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
<p>NOTE: While the CYB5R3 gene is not explicitly stated in the drug label, variants in this gene are associated with congenital methemoglobinemia I and II <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/250800"" target=""_blank"">OMIM 250800</a>.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Lidocaine_Prilocaine_02_06_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lidocaine_Prilocaine_02_06_19_FDA.pdf"">lidocaine and prilocaine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452536502.0,"<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166105028,Annotation of FDA Label for nebivolol and CYP2D6,False,False,[],False,"[{'id': 1452207480, 'date': '2023-08-15T12:37:10.913-07:00', 'description': 'prescribing tag taken off', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101902, 'title': 'Drugs@FDA: Drug Product Bystolic (nebivolol hydrochloride), NDA021742, Carilion Materials Management', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021742', 'crossReferences': [{'id': 1449763361, 'resource': 'FDA Application', 'resourceId': 'NDA021742', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021742'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA151958426', 'name': 'nebivolol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1448604890.0,"<p>The FDA-approved drug label for nebivolol (BYSTOLIC) states that, though it is metabolized by CYP2D6, no dose adjustments are necessary for CYP2D6 poor metabolizers, as the clinical effect and safety profile was similar between poor and extensive metabolizers.</p>
",1448604889.0,"<p>Nebivolol (BYSTOLIC) is indicated for the treatment of hypertension.</p>
<p>Excerpts from the nebivolol (BYSTOLIC) drug label:</p>
<div class=""blockquote"">
<p>No dose adjustments are necessary for patients who are CYP2D6 poor metabolizers. The clinical effect and safety profile observed in poor metabolizers were similar to those of extensive metabolizers.</p>
</div>
<div class=""blockquote"">
<p>Nebivolol is metabolized by a number of routes, including glucuronidation and hydroxylation by CYP2D6. The active isomer (d-nebivolol) has an effective half-life of about 12 hours in CYP2D6 extensive metabolizers (most people), and 19 hours in poor metabolizers and exposure to d-nebivolol is substantially increased in poor metabolizers. This has less importance than usual, however, because the metabolites, including the hydroxyl metabolite and glucuronides (the predominant circulating metabolites), contribute to ß-blocking activity. Plasma levels of d–nebivolol increase in proportion to dose in EMs and PMs for doses up to 20mg. Exposure to l-nebivolol is higher than to d-nebivolol but l-nebivolol contributes little to the drug’s activity as d-nebivolol’s beta receptor affinity is &gt; 1000-fold higher than l-nebivolol. For the same dose, PMs attain a 5-fold higher Cmax and 10-fold higher AUC of d-nebivolol than do EMs. d-Nebivolol accumulates about 1.5-fold with repeated once-daily dosing in EMs.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Nebivolol_02_13_19_FDA.pdf"">nebivolol drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104901,Annotation of FDA Label for pantoprazole and CYP2C19,False,False,[],True,"[{'id': 1183681317, 'date': '2013-10-25T11:15:03.843-07:00', 'type': 'Update', 'version': 0}, {'id': 1452211520, 'date': '2023-08-21T15:44:52.310-07:00', 'description': 'Add ""Dosing"" tag because definition has been updated to include wording such as ""consider"".', 'type': 'Update', 'version': 0}, {'id': 1452824120, 'date': '2025-01-24T11:09:00.315-08:00', 'description': 'added CYP2C19 star allele', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101863, 'title': 'Drugs@FDA: Drug Product Protonix Delayed-Release (PANTOPRAZOLE SODIUM), NDA020987, Avera McKennan Hospital', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020987', 'crossReferences': [{'id': 1449767774, 'resource': 'FDA Application', 'resourceId': 'NDA020987', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020987'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]","[{'objCls': 'Haplotype', 'id': 'PA165980635', 'symbol': 'CYP2C19*2', 'name': '*2'}]","[{'objCls': 'Chemical', 'id': 'PA450774', 'name': 'pantoprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1447981779.0,"<p>The FDA-approved drug label for pantoprazole (PROTONIX) states that pediatric patients who are CYP2C19 poor metabolizers exhibited ~10-fold lower clearance of the drug as compared to extensive metabolizers, and that a dose reduction should be considered in these patients. No dosage adjustment is needed in adult CYP2C19 poor metabolizers.</p>
",1447981778.0,"<p>Pantoprazole is indicated for short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease, maintenance of healing of erosive esophagitis, and pathological hypersecretory conditions including Zollinger-Ellison Syndrome.</p>
<p>Excerpt from the pantoprazole (PROTONIX) label:</p>
<div class=""blockquote"">
<p>CYP2C19 displays a known genetic polymorphism due to its deficiency in some subpopulations (e.g., approximately 3% of Caucasians and African-Americans and
17% to 23% of Asians are poor metabolizers). Although these subpopulations of pantoprazole poor metabolizers have elimination half-life values of 3.5 to 10 hours in adults, they still have minimal accumulation (23% or less) with once-daily dosing. For adult patients who are CYP2C19 poor metabolizers, no dosage adjustment is needed. Similar to adults, pediatric patients who have the poor metabolizer genotype of CYP2C19 (CYP2C19 *2/*2) exhibited greater than a 6-fold increase in AUC compared to pediatric extensive (CYP2C19 *1/*1) and intermediate (CYP2C19 *1/*x) metabolizers. Poor metabolizers exhibited approximately 10-fold lower apparent oral clearance compared to extensive metabolizers. For known pediatric poor metabolizers, a dose reduction should be considered.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Pantoprazole_02_20_19_FDA.pdf"">pantoprazole drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1451306583.0,"<p>Excerpt from the pantoprazole (PROTONIX) label:</p>
<blockquote class=""blockquote"">
<p>For adult patients who are CYP2C19 poor metabolizers, no dosage adjustment is needed...For known pediatric poor metabolizers, a dose reduction should be considered.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399717.0,"<p>Excerpt from the pantoprazole (PROTONIX) label:</p>
<blockquote class=""blockquote"">
<p>For adult patients who are CYP2C19 poor metabolizers, no dosage adjustment is needed...For known pediatric poor metabolizers, a dose reduction should be considered.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104886,Annotation of FDA Label for dextromethorphan / quinidine and CYP2D6,False,False,[],False,"[{'id': 1183681194, 'date': '2013-10-25T10:41:12.257-07:00', 'type': 'Update', 'version': 0}, {'id': 1452219061, 'date': '2023-08-28T15:10:30.862-07:00', 'description': 'Added Prescribing Info because of language about considering testing', 'type': 'Update', 'version': 0}, {'id': 1452280480, 'date': '2023-10-24T18:33:20.730-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102021, 'title': 'Drugs@FDA: Drug Product Nuedexta (dextromethorphan hydrobromide and quinidine sulfate), Otsuka America Pharmaceutical, Inc - NDA021879/SUPPL-14, 06/11/2019', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021879', 'crossReferences': [{'id': 1453106661, 'resource': 'FDA Application', 'resourceId': 'NDA021879/SUPPL-14', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021879'}], 'objCls': 'Literature', 'pubDate': '2019-06-11T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166175998', 'name': 'dextromethorphan / quinidine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450342993.0,"<p>The quinidine component of NUEDEXTA is a CYP2D6 inhibitor used to increase the plasma availability of dextromethorphan, which is metabolized by CYP2D6. CYP2D6 poor metabolizers may be at risk of experiencing toxicity.</p>
",1450342992.0,"<p>NUEDEXTA is a combination of dextromethorphan and quinidine, used as a treatment for pseudobulbar affect (PBA). The quinidine component of NUEDEXTA is a CYP2D6 inhibitor used to increase the plasma availability of dextromethorphan.  Dextromethorphan is metabolized by CYP2D6, while quinidine is a CYP2D6 inhibitor that is metabolized by CYP3A4.</p>
<p>Excerpt from the dextromethorphan and quinidine (NUEDEXTA) label:</p>
<blockquote class=""blockquote"">
<p>The quinidine component of NUEDEXTA is intended to inhibit CYP2D6 so that higher exposure to dextromethorphan can be achieved compared to when dextromethorphan is given alone. Approximately 7-10% of Caucasians and 3-8% of African Americans generally lack the capacity to metabolize CYP2D6 substrates and are classified as PMs. The quinidine component of NUEDEXTA is not expected to contribute to the effectiveness of NUEDEXTA in PMs, but adverse events of the quinidine are still possible. In those patients who may be at risk of significant toxicity due to quinidine, genotyping to determine if they are PMs should be considered prior to making the decision to treat with NUEDEXTA.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Contraindications: Concomitant use with drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine or pimozide).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 substrates: Nuedexta inhibits CYP2D6. Accumulation of parent drug and/or failure of metabolite formation may decrease safety and/or ef
of concomitant CYP2D6 metabolized drugs. Adjust dose of CYP2D6 substrate or use alternative treatment when clinically indicated.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""NUEDEXTA_FDA_10242023.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/NUEDEXTA_FDA_10242023.pdf"">dextromethorphan and quinidine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1452219060.0,"<p>Excerpt from the dextromethorphan and quinidine (NUEDEXTA) label:</p>
<blockquote class=""blockquote"">
<p>The quinidine component of NUEDEXTA is intended to inhibit CYP2D6 so that higher exposure to dextromethorphan can be achieved compared to when dextromethorphan is given alone...The quinidine component of NUEDEXTA is not expected to contribute to the effectiveness of NUEDEXTA in PMs, but adverse events of the quinidine are still possible. In those patients who may be at risk of significant toxicity due to quinidine, genotyping to determine if they are PMs should be considered prior to making the decision to treat with NUEDEXTA.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104912,"Annotation of FDA Label for eltrombopag and F5, SERPINC1",False,False,[],False,"[{'id': 1183681231, 'date': '2013-10-25T10:58:15.902-07:00', 'type': 'Update', 'version': 0}, {'id': 1451277940, 'date': '2020-10-13T16:25:06.093-07:00', 'description': 'added text for chromosome 7, 13 based on update from biomarker table, updated label', 'type': 'Update', 'version': 0}, {'id': 1452532141, 'date': '2024-07-19T11:23:48.370-07:00', 'description': 'added prescribing info and tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101864, 'title': 'Drugs@FDA: Drug Product PROMACTA (eltrombopag olamine), NDA022291, Novartis Pharmaceuticals Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022291', 'crossReferences': [{'id': 1449754563, 'resource': 'FDA Application', 'resourceId': 'NDA022291', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022291'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}]",[],"[{'objCls': 'Chemical', 'id': 'PA165981594', 'name': 'eltrombopag'}]","[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",FDA,1450361358.0,"<p>The FDA-approved drug label for eltrombopag (PROMACTA) notes that patients taking the drug have an increased risk of thromboembolism if they have antithrombin III deficiency (SERPINC1) or Factor V Leiden (F5). The label also mentions that when patients were evaluated for cytogenetic abnormalities in PROMACTA D1-M6 cohort, some patients had loss of chromosome 7 or deletion of chromosome 13.</p>
",1447981792.0,"<p>Eltrombopag olamine (PROMACTA) is a thrombopoietin receptor agonist.</p>
<p>Excerpt from the eltrombopag (PROMACTA) drug label:</p>
<blockquote class=""blockquote"">
<p>Consider the potential for an increased risk of thromboembolism when administering PROMACTA to patients with known risk factors for thromboembolism (e.g., Factor V Leiden, ATIII deficiency, antiphospholipid syndrome, chronic liver disease)</p>
</blockquote>
<p>Note that Factor V Leiden is a polymorphism resulting in an Arg to Gln substitution at position 506 in the Factor V heavy chain (<a href=""/variant/PA166153554"">rs6025</a>)</p>
<blockquote class=""blockquote"">
<p>Cytogenetic Abnormalities:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In this trial, patients had bone marrow aspirates evaluated for cytogenetic abnormalities. Seven patients in the PROMACTA D1-M6 cohort had a new cytogenetic abnormality reported of which 4 had the loss of chromosome 7; these 4 occurred within 6.1 months. Across all cohorts, clonal cytogenetic evolution occurred in 15 out of 153 (10%) patients. Of the 15 patients who experienced a cytogenetic abnormality: 7 patients had the loss of chromosome 7, 6 of which occurred within 6.1 months; 4 patients had chromosomal aberrations which were of unclear significance; 3 patients had a deletion of chromosome 13; and 1 patient had a follow-up bone marrow assessment at 5 years with features of dysplasia with hypercellularity concerning for potential development of MDS. It is unclear whether these findings occurred due to the underlying disease, the immunosuppressive therapy, and/or treatment with PROMACTA.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""eltrombopag_FDA_10132020.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/eltrombopag_FDA_10132020.pdf"">eltrombopag drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452532140.0,"<p>Excerpt from the eltrombopag (PROMACTA) drug label:</p>
<blockquote class=""blockquote"">
<p>Consider the potential for an increased risk of thromboembolism when administering PROMACTA to patients with known risk factors for thromboembolism (e.g., Factor V Leiden, ATIII deficiency, antiphospholipid syndrome, chronic liver disease). To minimize the risk for thrombotic/thromboembolic complications, do not use PROMACTA in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain target platelet counts.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166114905,Annotation of FDA Label for belimumab and TNFSF13B,False,False,[],False,"[{'id': 1183704734, 'date': '2013-12-13T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1184513525, 'date': '2014-08-06T00:00:00-07:00', 'description': 'This drug-biomarker combination is no longer present on the FDA Biomarker table.', 'type': 'Update', 'version': 0}, {'id': 1452206140, 'date': '2023-08-14T10:11:39.549-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101927, 'title': 'Drugs@FDA: Drug Product BENLYSTA (belimumab), BLA125370, Human Genome Sciences, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125370', 'crossReferences': [{'id': 1449894259, 'resource': 'FDA Application', 'resourceId': 'BLA125370', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125370'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166114904', 'name': 'belimumab'}]","[{'objCls': 'Gene', 'id': 'PA434', 'symbol': 'TNFSF13B', 'name': 'TNF superfamily member 13b'}]",FDA,1447981942.0,"<p>Belimumab (BENLYSTA) is a human IgG1lambda monoclonal antibody, indicated for use in adults with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. It acts by blocking binding of soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B-cell survival factor, to its receptors on B cells.</p>
",1450044186.0,"<p>Excerpts from the belimumab (BENLYSTA) drug label:</p>
<div class=""blockquote"">
<p>BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy.</p>
</div>
<div class=""blockquote"">
<p>BENLYSTA (belimumab) is a human IGg1lambda monoclonal antibody specific for soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B).</p>
</div>
<div class=""blockquote"">
<p>BENLYSTA is a BLyS-specific inhibitor that blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells...by binding BLyS, BENLYSTA inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Belimumab_11_30_18_FDA.pdf"">belimumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,Formerly on FDA Biomarker List
Label Annotation,PA166104888,Annotation of FDA Label for nortriptyline and CYP2D6,False,False,[],False,"[{'id': 1183681287, 'date': '2013-10-25T11:08:10.735-07:00', 'type': 'Update', 'version': 0}, {'id': 1452536841, 'date': '2024-07-23T23:25:12.824-07:00', 'description': 'Removed excerpt about DDIs', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101982, 'title': 'Drugs@FDA: Drug Product PAMELOR (nortriptyline hydrochloride), NDA018013, SpecGx LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018013', 'crossReferences': [{'id': 1450369022, 'resource': 'FDA Application', 'resourceId': 'NDA018013', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018013'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450657', 'name': 'nortriptyline'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981751.0,"<p>The FDA-approved drug label for nortriptyline (Pamelor), a tricyclic antidepressant (TCA), states that CYP2D6 poor metabolizers have higher than expected plasma concentrations of TCAs when given usual doses.</p>
",1447981750.0,"<p>Nortriptyline (Pamelor) is indicated for the relief of symptoms of depression.</p>
<p>Excerpt from the nortriptyline (Pamelor) label:</p>
<blockquote class=""blockquote"">
<p>The biochemical activity of the drug metabolizing isozyme cytochrome P4502D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called 'poor metabolizers'); reliable estimates of the prevalence of reduced P4502D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Nortriptyline_08_10_2017_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Nortriptyline_08_10_2017_FDA.pdf"">nortriptyline drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104866,Annotation of FDA Label for pravastatin and APOE,False,False,[],False,"[{'id': 1183681386, 'date': '2013-10-25T11:31:19.129-07:00', 'type': 'Update', 'version': 0}, {'id': 1183701636, 'date': '2013-12-20T09:50:08.931-08:00', 'description': 'This drug-biomarker combination is no longer present on the FDA Biomarker table - the table now lists pravastatin with the LDLR gene.', 'type': 'Update', 'version': 0}, {'id': 1450382794, 'date': '2019-04-22T10:25:03.063-07:00', 'description': 'Markdown edit', 'type': 'Update', 'version': 0}, {'id': 1452230560, 'date': '2023-09-07T11:20:42.894-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101858, 'title': 'Drugs@FDA: Drug Product PRAVACHOL (PRAVASTATIN SODIUM), NDA019898, E.R. Squibb & Sons, L.L.C.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019898', 'crossReferences': [{'id': 1449776479, 'resource': 'FDA Application', 'resourceId': 'NDA019898', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019898'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451089', 'name': 'pravastatin'}]","[{'objCls': 'Gene', 'id': 'PA55', 'symbol': 'APOE', 'name': 'apolipoprotein E'}]",FDA,1447981696.0,"<p>The FDA-approved drug label for pravastatin (PRAVACHOL) contains pharmacogenetic information regarding response results in patients with APOE genotype E2/E2 and Fredrickson Type III dysbetalipoproteinemia.</p>
",1447981695.0,"<p>Excerpt from the pravastatin (PRAVACHOL) label:</p>
<div class=""blockquote"">
<p>14.5 Dysbetalipoproteinemia (Fredrickson Type III)...The response to pravastatin in two double-blind crossover studies of 46 patients with genotype E2/E2 and Fredrickson Type III dysbetalipoproteinemia is shown in Table 9.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Pravastatin_02_22_19_FDA.pdf"">pravastatin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,Formerly on FDA Biomarker List
Label Annotation,PA166104892,Annotation of FDA Label for sulfasalazine and G6PD,False,False,[],False,"[{'id': 1183681273, 'date': '2013-10-25T11:05:08.414-07:00', 'type': 'Update', 'version': 0}, {'id': 1448604595, 'date': '2017-03-15T11:02:25.575-07:00', 'type': 'Update', 'version': 0}, {'id': 1450821536, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1450824509, 'date': '2019-10-24T06:49:42.209-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1452557660, 'date': '2024-08-16T13:59:58.935-07:00', 'description': 'split NAT2 out to separate label annotation', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101983, 'title': 'Drugs@FDA: Drug Product Sulfasalazine (Sulfasalazine), NDA007073, REMEDYREPACK INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=007073', 'crossReferences': [{'id': 1449800626, 'resource': 'FDA Application', 'resourceId': 'NDA007073', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=007073'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451547', 'name': 'sulfasalazine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981759.0,"<p>Sulfasalazine (Azulfidine) is used to treat and prolong remission for ulcerative colitis. The label warns that people with glucose-6 phosphate dehydrogenase deficiency are susceptible to hemolytic anemia on this drug. The label also notes that acetylator status may affect metabolism of the drug and risk for adverse events; acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to inactivator or acetylator status.</p>
",1447981758.0,"<p>Excerpts from the sulfasalazine (Azulfidine) drug label:</p>
<div class=""blockquote"">
<p>Patients with glucose-6 phosphate dehydrogenase deficiency should be observed closely for signs of hemolytic anemia. This reaction is frequently dose related. If toxic or hypersensitivity reactions occur, the drug should be discontinued immediately.</p>
</div>
<div class=""blockquote"">
<p>Acetylator Status: The metabolism of SP to AcSP is mediated by polymorphic enzymes such that two distinct populations of slow and fast metabolizers exist. Approximately 60% of the Caucasian population can be classified as belonging to the slow acetylator phenotype. These subjects will display a prolonged plasma half-life for SP...and an accumulation of higher plasma levels of SP than fast acetylators. The clinical implication of this is unclear; however, in a small pharmacokinetic trial where acetylator status was determined, subjects who were slow acetylators of SP showed a higher incidence of adverse events.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Sulfasalazine_02_28_19_FDA.pdf"">sulfasalazine drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450824508.0,"<p>Excerpt from the sulfasalazine (Azulfidine) drug label:</p>
<blockquote class=""blockquote"">
<p>Patients with glucose-6 phosphate dehydrogenase deficiency should be observed closely for signs of hemolytic anemia. This reaction is frequently dose related. If toxic or hypersensitivity reactions occur, the drug should be discontinued immediately.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166177509,"Annotation of FDA Label for formoterol and CYP2C19, CYP2D6",False,False,[],False,"[{'id': 1452692101, 'date': '2024-11-06T14:30:45.569-08:00', 'description': 'removed ""No Clinical PGx"" level; does not meet criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102033, 'title': 'Drugs@FDA: Drug Product Perforomist (formoterol fumarate dihydrate), NDA022007, Mylan Specialty L.P.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022007', 'crossReferences': [{'id': 1449754709, 'resource': 'FDA Application', 'resourceId': 'NDA022007', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022007'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA134687907', 'name': 'formoterol'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1449169941.0,"<p>Formoterol (PERFOROMIST) is indicated in patients with chronic obstructive pulmonary disease (COPD). The label notes that the effect of patients with CYP2D6 or CYP2C19 deficiency on formoterol exposure has not been adequately explored.</p>
",1449169940.0,"<p>Excerpt from the formoterol (PERFOROMIST) drug label:</p>
<div class=""blockquote"">
<p>Some patients may be deficient in CYP2D6 or 2C19 or both. Whether a deficiency in one or both of these isozymes results in elevated systemic exposure to formoterol or systemic adverse effects has not been adequately explored.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Formoterol_FDA_02_12_18.pdf"">formoterol drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166163422,Annotation of FDA Label for dronabinol and CYP2C9,False,False,[],False,"[{'id': 1452830561, 'date': '2025-01-30T17:23:43.471-08:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15173902, 'title': 'Drugs@FDA: Drug Product SYNDROS (Dronabinol), Benuvia Operations, LLC - NDA205525/SUPPL-13, 05/17/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205525', 'crossReferences': [{'id': 1452830560, 'resource': 'FDA Application', 'resourceId': 'NDA205525/SUPPL-13', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205525'}], 'notes': 'As of January 2025, the Marketing Status of Syndros is listed as Discontinued on the FDA website.', 'objCls': 'Literature', 'pubDate': '2024-05-17T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15102002, 'title': 'Drugs@FDA: Drug Product SYNDROS (Dronabinol), NDA205525, Insys Therapeutics, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205525', 'crossReferences': [{'id': 1449754498, 'resource': 'FDA Application', 'resourceId': 'NDA205525', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205525'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449421', 'name': 'dronabinol'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1448604924.0,"<p>The FDA-approved drug label for dronabinol (SYNDROS) notes that patients who carry genetic variants that result in diminished CYP2C9 function may have a 2- to 3-fold higher dronabinol exposure.</p>
",1448604923.0,"<p>Excerpts from the dronabinol (SYNDROS) drug label:</p>
<blockquote class=""blockquote"">
<p>Published data suggest that systemic clearance of dronabinol may be reduced and concentrations may be increased in presence of CYP2C9 genetic polymorphism. Monitoring for increased adverse reactions is recommended in patients known to carry genetic variants associated with diminished CYP2C9 function [see Clinical Pharmacology (12.5)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Published <em>in vitro</em> data indicate that CYP2C9 and CYP3A4 are the primary enzymes in the metabolism of dronabinol. CYP2C9 appears to be the enzyme responsible for the formation of the primary active metabolite [see Clinical Pharmacology (12.5)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Published data indicate a 2- to 3-fold higher dronabinol exposure in individuals carrying genetic variants associated with diminished CYP2C9 function.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Dronabinol_2025_01_30_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dronabinol_2025_01_30_FDA.pdf"">dronabinol drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451139245.0,"<p>Excerpt from the dronabinol (SYNDROS) drug label:</p>
<blockquote class=""blockquote"">
<p>Monitoring for increased adverse reactions is recommended in patients known to carry genetic variants associated with diminished CYP2C9 function.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166182751,Annotation of FDA Label for mepivacaine and G6PD,False,False,[],False,"[{'id': 1450821522, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1450822437, 'date': '2019-10-15T08:49:36.351-07:00', 'description': 'Added link and text about CYB5R3 and congenital methemoglobinemia.', 'type': 'Update', 'version': 0}, {'id': 1450824515, 'date': '2019-10-24T07:20:48.201-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1452261660, 'date': '2023-10-03T19:47:36.517-07:00', 'description': 'removed CYB5R3 gene as FDA biomarker table lists as ""Nonspecific (Congenital Methemoglobinemia)""', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102385, 'title': 'Drugs@FDA: Drug Product Carbocaine (Mepivacaine Hydrochloride), NDA012250, Hospira, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=012250', 'crossReferences': [{'id': 1450400579, 'resource': 'FDA Application', 'resourceId': 'NDA012250', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=012250'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164748741', 'name': 'mepivacaine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450400576.0,"<p>The FDA-approved drug label for mepivacaine states that patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency and congenital methemoglobinemia may be more susceptible to developing clinical manifestations of methemoglobinemia. Close monitoring for symptoms and signs of methemoglobinemia is recommended in this subset of patients.</p>
",1450400577.0,"<p>Excerpt from the mepivacaine FDA drug label:</p>
<blockquote class=""blockquote"">
<p>Methemoglobinemia</p>
<p>Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all
patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency,
congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months
of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to
developing clinical manifestations of the condition. If local anesthetics must be used in these patients,
close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""mepivacaine_05_14_2019_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/mepivacaine_05_14_2019_FDA.pdf"">mepivacaine drug label</a>.</p>
<p>*Disclaimer: The contents of this page are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450824514.0,"<p>Excerpt from the mepivacaine FDA drug label:</p>
<blockquote class=""blockquote"">
<p>Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency,
congenital or idiopathic methemoglobinemia ... are more susceptible to
developing clinical manifestations of the condition. If local anesthetics must be used in these patients,
close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166179855,"Annotation of FDA Label for avatrombopag and F2, F5, PROC, PROS1, SERPINC1",False,False,[],False,"[{'id': 1450820822, 'date': '2019-10-07T10:26:04.464-07:00', 'description': 'Added CYP2C9 and excerpt as per FDA table.', 'type': 'Update', 'version': 0}, {'id': 1450824504, 'date': '2019-10-24T06:33:26.205-07:00', 'description': 'Moved CYP2C9 annotation to separate annotation as is Informational rather than Actionable.', 'type': 'Update', 'version': 0}, {'id': 1452525701, 'date': '2024-07-11T17:52:11.962-07:00', 'description': 'updated drug label version, added Other Guidance tag, prescribing info and genes', 'type': 'Update', 'version': 0}, {'id': 1452529720, 'date': '2024-07-17T15:07:36.665-07:00', 'description': 'added F2, F5 variants', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160442, 'title': 'Drugs@FDA: Drug Product DOPTELET (avatrombopag maleate), AkaRx, Inc. - NDA210238/SUPPL-6, 10/14/2021', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210238', 'crossReferences': [{'id': 1452525641, 'resource': 'FDA Application', 'resourceId': 'NDA210238/SUPPL-6', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210238'}], 'objCls': 'Literature', 'pubDate': '2021-10-14T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]","[{'objCls': 'Variant', 'id': 'PA166154336', 'symbol': 'rs1799963', 'name': 'rs1799963'}, {'objCls': 'Variant', 'id': 'PA166153554', 'symbol': 'rs6025', 'name': 'rs6025'}]","[{'objCls': 'Chemical', 'id': 'PA166179849', 'name': 'avatrombopag'}]","[{'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",FDA,1449713953.0,"<p>The FDA-approved drug label for avatrombopag (DOPTELET) states that the risk for thrombosis should be considered in patients with risk factors for thromboembolism, including genetic prothrombotic conditions such as Factor V Leiden (F5), Prothrombin 20210A (F2), Antithrombin deficiency (SERPINC1) or Protein C (PROC) or S (PROS1) deficiency.</p>
",1449713952.0,"<p>Excerpt from the avatrombopag (DOPTELET) drug label:</p>
<blockquote class=""blockquote"">
<p>Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (e.g., Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Avatrombopag_2024_07_11_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Avatrombopag_2024_07_11_FDA.pdf"">avatrombopag drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452525700.0,"<blockquote class=""blockquote"">
<p>Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (e.g., Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166170936,"Annotation of FDA Label for tamoxifen and F2, F5",False,False,[],False,[],False,[],True,"[{'id': 15101886, 'title': 'Drugs@FDA: Drug Product Soltamox (TAMOXIFEN CITRATE), NDA021807, Midatech Pharma US Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021807', 'crossReferences': [{'id': 1449814157, 'resource': 'FDA Application', 'resourceId': 'NDA021807', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021807'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451581', 'name': 'tamoxifen'}]","[{'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}]",FDA,1449052557.0,"<p>Tamoxifen (SOLTAMOX) is indicated for the treatment of breast cancer. A clinical trial showed no benefit of screening for Factor V Leiden (F5) or Prothrombin (F2) mutations when treating with tamoxifen.</p>
",1449052556.0,"<p>Excerpt from the tamoxifen (SOLTAMOX) drug label:</p>
<div class=""blockquote"">
<p>In a small substudy (N = 81) of the NSABP-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tamoxifen_02_28_19_FDA.pdf"">tamoxifen drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166153432,"Annotation of FDA Label for flibanserin and CYP2C9, CYP2D6",False,False,[],False,"[{'id': 1448604473, 'date': '2017-03-15T10:52:50.639-07:00', 'type': 'Update', 'version': 0}, {'id': 1452534276, 'date': '2024-07-22T09:33:16.211-07:00', 'description': 'updated label, removed CYP2C19 (new label annotation)', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161402, 'title': 'Drugs@FDA: Drug Product ADDYI (flibanserin), Sprout Pharmaceuticals, Inc. - NDA022526/SUPPL-10, 09/29/2021', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022526', 'crossReferences': [{'id': 1452534220, 'resource': 'FDA Application', 'resourceId': 'NDA022526/SUPPL-10', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022526'}], 'objCls': 'Literature', 'pubDate': '2021-09-29T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101959, 'title': 'Drugs@FDA: Drug Product ADDYI (flibanserin), NDA022526, Sprout Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022526', 'crossReferences': [{'id': 1449754639, 'resource': 'FDA Application', 'resourceId': 'NDA022526', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022526'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166153431', 'name': 'flibanserin'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447991011.0,"<p>The FDA-approved drug label for flibanserin (ADDYI) notes the influence of CYP2D6 and CYP2C9 metabolizer phenotypes on flibanserin exposure.</p>
",1447990093.0,"<p>Flibanserin (ADDYI) is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Excerpts from the FDA-approved drug label for flibanserin:</p>
<blockquote class=""blockquote"">
<p>A study comparing flibanserin exposure in CYP2D6 poor metabolizers to CYP2D6 extensive metabolizers was conducted in addition to a drug interaction study with paroxetine, a strong CYP2D6 inhibitor. In 12 poor metabolizers of CYP2D6, steady state Cmax and AUC of flibanserin 50 mg twice daily was decreased by 4% and increased by 18%, respectively, compared to exposures among 19 extensive metabolizers, intermediate metabolizers and ultra rapid metabolizers of CYP2D6.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A study comparing flibanserin exposure in CYP2C9 poor metabolizers to CYP2C9 extensive metabolizers was conducted in lieu of a drug interaction study with ADDYI and a strong CYP2C9 inhibitor. In 8 women who were poor metabolizers of CYP2C9, Cmax and AUC0-inf of flibanserin 100 mg once daily decreased 23% and 18%, compared to exposures among 8 extensive metabolizers of CYP2C9.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Flibanserin_2024_07_22_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Flibanserin_2024_07_22_FDA.pdf"">flibanserin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182765,Annotation of FDA Label for flutamide and G6PD,False,False,[],False,"[{'id': 1450401289, 'date': '2019-05-17T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452534362, 'date': '2024-07-22T10:01:14.288-07:00', 'description': 'updated label, added Other Guidance tag, prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161422, 'title': 'DailyMed - EULEXIN- flutamide capsule', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56b6ba36-9b49-4422-a2a4-7bfa0d941a5d', 'crossReferences': [{'id': 1452534360, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '56b6ba36-9b49-4422-a2a4-7bfa0d941a5d', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56b6ba36-9b49-4422-a2a4-7bfa0d941a5d'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15102391, 'title': 'Drugs@FDA: Drug Product flutamide (NDA018554)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018554', 'crossReferences': [{'id': 1450401290, 'resource': 'FDA Application', 'resourceId': 'NDA018554', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018554'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449685', 'name': 'flutamide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450401287.0,"<p>The FDA-approved drug label for flutamide (Eulexin) states that in patients susceptible to aniline toxicity (e.g. persons with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease and smokers), monitoring of methemoglobin levels should be considered.</p>
",1450401288.0,"<p>Excerpt from the flutamide (Eulexin) drug label:</p>
<blockquote class=""blockquote"">
<p>One metabolite of Eulexin™ is 4-nitro-3-fluoro-methylaniline. Several toxicities consistent with aniline exposure, including methemoglobinemia, hemolytic anemia and cholestatic jaundice have been observed in both animals and humans after Eulexin™ administration. In patients susceptible to aniline toxicity (e.g. persons with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease and smokers), monitoring of methemoglobin levels should be considered.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Flutamide_2024_07_22_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Flutamide_2024_07_22_FDA.pdf"">flutamide drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452534361.0,"<blockquote class=""blockquote"">
<p>In patients susceptible to aniline toxicity (e.g. persons with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease and smokers), monitoring of methemoglobin levels should be considered.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166180000,Annotation of FDA Label for meclizine and CYP2D6,False,False,[],False,"[{'id': 1450824103, 'date': '2019-10-21T07:00:43.803-07:00', 'description': 'Label update with no change to annotation.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102063, 'title': 'Drugs@FDA: Drug Product meclizine (NDA010721)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=010721', 'crossReferences': [{'id': 1449755992, 'resource': 'FDA Application', 'resourceId': 'NDA010721', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=010721'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450338', 'name': 'meclizine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1449714786.0,"<p>The FDA-approved drug label for meclizine (ANTIVERT) states that CYP2D6 is the dominant metabolizing enzyme and that genetic polymorphism of CYP2D6 could contribute to large variability in meclizine exposure</p>
",1449714785.0,"<p>Excerpt from the meclizine (ANTIVERT) drug label:</p>
<div class=""blockquote"">
<p>In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP2D6 was found to be the dominant enzyme for metabolism of meclizine. The genetic polymorphism of CYP2D6 that results in extensive-, poor-, intermediate- and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/meclizine_10_17_2019FDA.pdf"">meclizine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451139480.0,"<p>Excerpt from the meclizine (ANTIVERT) drug label:</p>
<blockquote class=""blockquote"">
<p>The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure. Therefore, when ANTIVERT® is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166181925,Annotation of FDA Label for tamoxifen and CYP2D6,False,False,[],False,"[{'id': 1450821494, 'date': '2019-10-09T14:37:39.867-07:00', 'description': 'Added tag for FDA biomarker list', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101886, 'title': 'Drugs@FDA: Drug Product Soltamox (TAMOXIFEN CITRATE), NDA021807, Midatech Pharma US Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021807', 'crossReferences': [{'id': 1449814157, 'resource': 'FDA Application', 'resourceId': 'NDA021807', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021807'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451581', 'name': 'tamoxifen'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450369804.0,"<p>The FDA-approved drug label for tamoxifen (SOLTAMOX) states that the impact of CYP2D6 polymorphisms on the efficacy of tamoxifen is not well established, but that CYP2D6 poor metabolizers have lower endoxifen concentrations are compared to intermediate, normal or ultrarapid metabolizers.</p>
",1450369805.0,"<p>Excerpt from the tamoxifen (SOLTAMOX) drug label:</p>
<div class=""blockquote"">
<p>Pharmacogenomics...The impact of CYP2D6 polymorphisms on the efficacy of tamoxifen is not well established. CYP2D6 poor metabolizers carrying two non-functional alleles exhibit significantly lower endoxifen plasma concentrations compared to patients carrying one or more fully functional alleles of CYP2D6. In patients with estrogen receptor-positive breast cancer who were participating in the WHEL (Women’s Health Eating and Living) Study (NCT00003787), the mean (SD) serum concentration of endoxifen was 22.8 (11.3), 15.9 (9.2), 8.1 (4.9) and 5.6 (3.8) ng/mL in 27 ultrarapid, 1,097 normal, 164 intermediate and 82 poor metabolizers (p&lt;0.001), respectively. This finding is consistent with other published studies that report lower endoxifen concentrations in poor metabolizers compared to normal metabolizers.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tamoxifen_02_28_19_FDA.pdf"">tamoxifen drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166129553,Annotation of FDA Label for belinostat and UGT1A1,False,False,[],True,"[{'id': 1450399519, 'date': '2019-05-09T10:04:06.358-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101995, 'title': 'Drugs@FDA: Drug Product Beleodaq (Belinostat), NDA206256, Spectrum Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206256', 'crossReferences': [{'id': 1449894305, 'resource': 'FDA Application', 'resourceId': 'NDA206256', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206256'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA165971474', 'name': 'belinostat'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",FDA,1450044190.0,"<p>The FDA-approved drug label for belinostat (BELEODAQ) states that the starting dose should be reduced to 750 mg/m<sup>2</sup> in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities. However, testing or screening for the *28 allele is not mentioned.</p>
",1450044191.0,"<p>The standard recommended dose of belinostat (BELEODAQ) is 1000 mg/m<sup>2</sup> administered over 30 minutes by intravenous infusion once daily on days 1-5 of a 21-day cycle. Excerpts from the belinostat (BELEODAQ) drug label:</p>
<blockquote class=""blockquote"">
<p>UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1*28 polymorphism. Approximately 20% of the black population, 10% of the white population, and 2% of the Asian population are homozygous for the UGT1A1*28 allele. Additional reduced function alleles may be more prevalent in specific populations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Because belinostat is primarily (80-90%) metabolized by UGT1A1, the clearance of belinostat could be decreased in patients with reduced UGT1A1 activity (<em>e.g.</em>, patients with UGT1A1*28 allele). Reduce the starting dose of Beleodaq to 750 mg/m<sup>2</sup> in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Belinostat_11_30_18_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Belinostat_11_30_18_FDA.pdf"">belinostat drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399518.0,"<p>Excerpt from the belinostat (BELEODAQ) drug label:</p>
<blockquote class=""blockquote"">
<p>Reduce the starting dose of Beleodaq to 750 mg/m<sup>2</sup> in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166127663,Annotation of FDA Label for divalproex sodium and POLG,True,False,[],False,"[{'id': 1452212282, 'date': '2023-08-22T00:33:16.034-07:00', 'description': ""added 'pediatric' tag"", 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101875, 'title': 'Drugs@FDA: Drug Product Divalproex Sodium Extended Release (Divalproex Sodium), NDA021168, Zydus Pharmaceuticals USA Inc', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021168', 'crossReferences': [{'id': 1449754301, 'resource': 'FDA Application', 'resourceId': 'NDA021168', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021168'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA33500', 'symbol': 'POLG', 'name': 'DNA polymerase gamma, catalytic subunit'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164783479', 'name': 'divalproex sodium'}]","[{'objCls': 'Gene', 'id': 'PA33500', 'symbol': 'POLG', 'name': 'DNA polymerase gamma, catalytic subunit'}]",FDA,1447982343.0,"<p>The FDA-approved drug label for divalproex states that it is contraindicated in individuals with known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and suspected POLG-related disorders in children under 2 years old.</p>
",1447982342.0,"<p>POLG is a mitochondrial DNA polymerase and mutations in this gene are associated with hereditary neurometabolic syndromes such as Alpers Huttenlocher Syndrome. Excerpts from the divalproex drug label:</p>
<div class=""blockquote"">
<p>There is an increased risk of valproate-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA Polymerase gamma (POLG) gene (e.g., Alpers Huttenlocher Syndrome). Divalproex sodium delayed-release capsules are contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under 2 years of age who are clinically suspected of having a mitochondrial disorder. In patients over 2 years of age who are clinically suspected of having a hereditary mitochondrial disease, divalproex sodium delayed-release capsules should only be used after other anticonvulsants have failed...POLG mutation screening should be performed in accordance with current clinical practice.</p>
</div>
<div class=""blockquote"">
<p>POLG mutation testing should be performed in accordance with current clinical practice for the diagnostic evaluation of such disorders. The A467T and W748S mutations are present in approximately 2/3 of patients with autosomal recessive POLG-related disorders.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Divalproex_Sodium_01_11_19_FDA.pdf"">divalproex drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450399544.0,"<p>Excerpt from the divalproex drug label:</p>
<blockquote class=""blockquote"">
<p>Divalproex sodium delayed-release capsules are contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under 2 years of age who are clinically suspected of having a mitochondrial disorder. In patients over 2 years of age who are clinically suspected of having a hereditary mitochondrial disease, divalproex sodium delayed-release capsules should only be used after other anticonvulsants have failed...</p>
</blockquote>
",,,,,,,Formerly on FDA Biomarker List
Label Annotation,PA166182739,Annotation of FDA Label for tafenoquine and G6PD,True,False,[],False,[],False,[],True,"[{'id': 15102372, 'title': 'Drugs@FDA: Drug Product Arakoda (Tafenoquine), NDA210607, 60 Degrees Pharmaceuticals, LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210607', 'crossReferences': [{'id': 1450400322, 'resource': 'FDA Application', 'resourceId': 'NDA210607', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210607'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166115580', 'name': 'tafenoquine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450400318.0,"<p>The FDA-approved drug label for tafenoquine states that G6PD testing must be performed before prescribing the drug, and that tafenoquine is contraindicated in patients with G6PD deficiency or of unknown G6PD status.</p>
",1450400319.0,"<p>Excerpts from the tafenoquine (ARAKODA) drug label:</p>
<div class=""blockquote"">
<p>All patients must be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency prior to
prescribing ARAKODA.</p>
</div>
<div class=""blockquote"">
<p>ARAKODA is contraindicated in:</p>
<ul>
<li>patients with G6PD deficiency or unknown G6PD status due to the risk of hemolytic anemia [see Warnings and Precautions (5.2)].</li>
<li>breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if the
G6PD status of the infant is unknown [see Warnings and Precautions (5.3), Use in Specific
Populations (8.2)].</li>
</ul>
</div>
<div class=""blockquote"">
<p><strong>Hemolytic Anemia</strong>
Due to the risk of hemolytic anemia in patients with G6PD deficiency, G6PD testing must be
performed before prescribing ARAKODA [see Contraindications (4)]. Due to the limitations
with G6PD tests, physicians need to be aware of residual risk of hemolysis and adequate medical
support and follow-up to manage hemolytic risk should be available. Treatment with
ARAKODA is contraindicated in patients with G6PD deficiency or unknown G6PD status [see
Contraindications (4)]. In clinical trials, declines in hemoglobin levels were reported in some
G6PD-normal patients [see Adverse Reactions (6.1)]. Monitor patients for clinical signs or
symptoms of hemolysis [see Warnings and Precautions (5.6)]. Advise patients to discontinue
ARAKODA and seek medical attention if signs of hemolysis occur.</p>
</div>
<div class=""blockquote"">
<p><strong>G6PD Deficiency in Pregnancy and Lactation</strong> .<br />
<em>Potential Harm to the Fetus</em>
The use of ARAKODA during pregnancy may cause hemolytic anemia in a G6PD-deficient
fetus. Even if a pregnant woman has normal levels of G6PD, the fetus could be G6PD deficient.
Advise females of reproductive potential that treatment with ARAKODA during pregnancy is
not recommended and to avoid pregnancy or use effective contraception during treatment and for
3 months after the last dose of ARAKODA. If a pregnancy is detected during ARAKODA use,
discontinue ARAKODA as soon as possible and switch to an alternative prophylactic drug for
malaria during pregnancy [see Use in Specific Populations (8.1 and 8.3)].<br />
<em>Potential Harm to the Breastfeeding Infant</em>
A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA
through breast milk. Infant G6PD status should be checked before breastfeeding begins.
ARAKODA is contraindicated in breastfeeding women when the infant is found to be G6PD
deficient or the G6PD status of the infant is unknown [see Contraindications (4)]. Advise the
woman with a G6PD-deficient infant or if the G6PD status of the infant is unknown not to
breastfeed during treatment with ARAKODA and for 3 months after the final dose [see Use in
Specific Populations (8.2)].</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tafenoquine_05_13_19_FDA.pdf"">tafenoquine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450400320.0,"<p>Excerpts from the tafenoquine (ARAKODA) drug label:</p>
<blockquote class=""blockquote"">
<p>ARAKODA is contraindicated in:...</p>
<ul>
<li>patients with G6PD deficiency or unknown G6PD status due to the risk of hemolytic anemia [see Warnings and Precautions (5.2)]...</li>
<li>breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if the G6PD status of the infant is unknown [see Warnings and Precautions (5.3), Use in Specific Populations (8.2)].</li>
</ul>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166160021,Annotation of FDA Label for cabozantinib and RET,False,True,[],False,"[{'id': 1452206740, 'date': '2023-08-15T06:46:11.620-07:00', 'description': 'Unchecked informative as no longer meets criteria. Checked Cancer genome.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101936, 'title': 'Drugs@FDA: Drug Product CABOMETYX (cabozantinib), NDA208692, Exelixis, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208692', 'crossReferences': [{'id': 1449894782, 'resource': 'FDA Application', 'resourceId': 'NDA208692', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208692'}], 'notes': 'CABOMETYX', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15102000, 'title': 'Drugs@FDA: Drug Product COMETRIQ (cabozantinib), NDA203756, Exelixis, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203756', 'crossReferences': [{'id': 1449894796, 'resource': 'FDA Application', 'resourceId': 'NDA203756', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203756'}], 'notes': 'COMETRIQ', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165906891', 'name': 'cabozantinib'}]","[{'objCls': 'Gene', 'id': 'PA34335', 'symbol': 'RET', 'name': 'ret proto-oncogene'}]",FDA,1450342099.0,"<p>The FDA-approved drug label for cabozantinib (COMETRIQ) states that RET mutation status was determined in clinical studies of the drug, and that the drug inhibits the activity of the RET protein.</p>
",1450342101.0,"<p>Cabozantinib (COMETRIQ) is a kinase inhibitor indicated for the treatment of progressive, metastatic medullary thyroid cancer. Excerpts from the cabozantinib (COMETRIQ) drug label:</p>
<div class=""blockquote"">
<p>In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2.</p>
</div>
<div class=""blockquote"">
<p>The safety and efficacy of COMETRIQ was assessed in an international, multi-center, randomized, double-blind, controlled trial (Study 1) of 330 patients with metastatic medullary thyroid carcinoma (MTC)...The <em>RET</em> mutation status determined by a research-use assay was positive in 51%, negative in 14%, and was unknown in 35%...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Cabozantinib_12_14_18_FDA.pdf"">cabozantinib (COMETRIQ) drug label</a>.</p>
<p><strong>Note: Cabozantinib (CABOMETYX) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). The drug label for cabozantinib (CABOMETYX) does not contain any information about determining RET mutation status in clinical studies. However, it does state that the drug inhibits the activity of the RET protein.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166177512,"Annotation of FDA Label for inotuzumab ozogamicin and ABL1, BCR",False,True,[],False,"[{'id': 1452209960, 'date': '2023-08-18T11:45:00.572-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101888, 'title': 'Drugs@FDA: Drug Product Besponsa (inotuzumab ozogamicin), BLA761040, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761040', 'crossReferences': [{'id': 1449754770, 'resource': 'FDA Application', 'resourceId': 'BLA761040', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761040'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177510', 'name': 'inotuzumab ozogamicin'}]","[{'objCls': 'Gene', 'id': 'PA24413', 'symbol': 'ABL1', 'name': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'objCls': 'Gene', 'id': 'PA25321', 'symbol': 'BCR', 'name': 'BCR activator of RhoGEF and GTPase'}]",FDA,1449169953.0,"<p>Inotuzumab ozogamicin (BESPONSA) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The label notes that clinical studies included patients with Philadelphia chromosome-negative or -positive ALL.</p>
",1449169952.0,"<p>Excerpt from the inotuzumab ozogamicin (BESPONSA) label:</p>
<div class=""blockquote"">
<p>CLINICAL STUDIES...Patients With Relapsed or Refractory ALL – INO-VATE ALL...Eligible patients were &gt;= 18 years of age with Philadelphia chromosome-negative or Philadelphia chromosome-positive relapsed or refractory B-cell precursor ALL...The median age was 47 years (range: 18-79 years), 276 patients (85%) had Philadelphia chromosome-negative ALL...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Inotuzumab_Ozogamicin_FDA_02_12_18.pdf"">inotuzumab ozogamicin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182729,Annotation of FDA Label for amoxapine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15102369, 'title': 'Drugs@FDA: Drug Product Amoxapine (Amoxapine), ANDA072691, Actavis Pharma, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=072691', 'crossReferences': [{'id': 1453103820, 'resource': 'FDA Application', 'resourceId': 'ANDA072691/SUPPL-36', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=072691'}], 'objCls': 'Literature', 'pubDate': '2014-07-17T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448405', 'name': 'amoxapine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450400079.0,"<p>The FDA-approved drug label for amoxapine contains information regarding the metabolism of tricyclic antidepressants by CYP2D6: CYP2D6 poor metabolizers may have higher plasma concentrations of tricyclic antidepressants, and the label suggests monitoring of plasma levels if this drug is co-administrered with a CYP2D6 inhibitor.</p>
",1450400080.0,"<p>Excerpt from the amoxapine drug label:</p>
<div class=""blockquote"">
<p>The biochemical activity of the drug metabolizing isozyme
cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a
subset of the caucasian population (about 7 to 10% of
caucasians are so called “poor metabolizers”); reliable estimates
of the prevalence of reduced P450 2D6 isozyme activity among
Asian, African and other populations are not yet available. Poor
metabolizers have higher than expected plasma concentrations
of tricyclic antidepressants (TCAs) when given usual doses.
Depending on the fraction of drug metabolized by P450 2D6, the
increase in plasma concentration may be small, or quite large (8
fold increase in plasma AUC of the TCA).</p>
</div>
<div class=""blockquote"">
<p>In addition, certain drugs inhibit the activity of this isozyme and
make normal metabolizers resemble poor metabolizers. An
individual who is stable on a given dose of TCA may become
abruptly toxic when given one of these inhibiting drugs as
concomitant therapy. The drugs that inhibit cytochrome
P450 2D6 include some that are not metabolized by the enzyme
(quinidine, cimetidine) and many that are substrates for
P450 2D6 (many other anti depressants, phenothiazines, and the
Type 1C antiarrhythmics propafenone and flecainide). While all
the selective serotonin reuptake inhibitors (SSRIs),
e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they
may vary in the extent of inhibition. The extent to which
SSRI-TCA interactions may pose clinical problems will depend
on the degree of inhibition and the pharmacokinetics of the SSRI
involved. Nevertheless, caution is indicated in the
co-administration of TCAs with any of the SSRIs and also in
switching from one class to the other. Of particular importance,
sufficient time must elapse before initiating TCA treatment in a
patient being withdrawn from fluoxetine, given the long half-life
of the parent and active metabolite (at least 5 weeks may be
necessary).</p>
</div>
<div class=""blockquote"">
<p>Concomitant use of tricyclic antidepressants with drugs that can
inhibit cytochrome P450 2D6 may require lower doses than
usually prescribed for either the tricyclic antidepressant or the
other drug. Furthermore, whenever one of these other drugs is
withdrawn from co-therapy, an increased dose of tricyclic
anti depressant may be required. It is desirable to monitor TCA
plasma levels whenever a TCA is going to be co-administered
with another drug known to be an inhibitor of P450 2D6.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/amoxapine_05_13_2019FDA.pdf"">amoxapine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166170957,"Annotation of FDA Label for vemurafenib and HRAS, KRAS, NRAS",False,True,[],False,"[{'id': 1452220480, 'date': '2023-08-29T12:50:47.166-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102006, 'title': 'Drugs@FDA: Drug Product ZELBORAF (Vemurafenib), NDA202429, Genentech, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202429', 'crossReferences': [{'id': 1449891622, 'resource': 'FDA Application', 'resourceId': 'NDA202429', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202429'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165946873', 'name': 'vemurafenib'}]","[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",FDA,1449140114.0,"<p>Vemurafenib (ZELBORAF) is a kinase inhibitor used to treat patients with unresectable or metastatic melanoma in cases where the BRAF V600E mutation is found by an FDA-approved test. The label notes that the drug may promote malignancies associated with activation of RAS (<em>HRAS</em>, <em>KRAS</em>, <em>NRAS</em>).</p>
",1449140113.0,"<p>Excerpts from the vemurafenib (ZELBORAF) drug label:</p>
<div class=""blockquote"">
<p>Based on mechanism of action, ZELBORAF may promote malignancies associated with activation of RAS through mutation or other mechanisms. Monitor patients receiving ZELBORAF closely for signs or symptoms of other malignancies.</p>
</div>
<div class=""blockquote"">
<p>Postmarketing Experience...<em>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</em>: Progression of pre-existing chronic myelomonocytic leukemia with NRAS mutation.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Vemurafenib_09_18_2017_FDA.pdf"">vemurafenib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166170932,Annotation of FDA Label for pembrolizumab and BRAF,False,True,[],False,"[{'id': 1450381670, 'date': '2019-04-19T11:17:19.101-07:00', 'description': 'Added variant information and cancer genome tag', 'type': 'Update', 'version': 0}, {'id': 1452214520, 'date': '2023-08-23T16:37:49.254-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452312581, 'date': '2023-11-30T00:00:00-08:00', 'description': 'Updated label and label source.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15151342, 'title': 'Drugs@FDA: Drug Product KEYTRUDA (pembrolizumab), Merck Sharp & Dohme LLC - BLA125514/SUPPL-143, 11/16/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514', 'crossReferences': [{'id': 1452312600, 'resource': 'FDA Application', 'resourceId': 'BLA125514/SUPPL-143', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514'}], 'objCls': 'Literature', 'pubDate': '2023-11-16T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166157522', 'symbol': 'rs113488022', 'name': 'rs113488022'}]","[{'objCls': 'Chemical', 'id': 'PA166124615', 'name': 'pembrolizumab'}]","[{'objCls': 'Gene', 'id': 'PA25408', 'symbol': 'BRAF', 'name': 'B-Raf proto-oncogene, serine/threonine kinase'}]",FDA,1449040599.0,"<p>The FDA-approved drug label for pembrolizumab (KEYTRUDA) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (CD274) as detected by an FDA-approved test. The label also mentions BRAF V600 mutations.</p>
",1449040598.0,"<p>Excerpts from the pembrolizumab (KEYTRUDA) drug label:</p>
<blockquote class=""blockquote"">
<p>Ipilimumab-Naive Melanoma...The study population characteristics were...36% with reported BRAF mutation-positive melanoma...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Ipilimumab-Refractory Melanoma...Randomization was stratified by ECOG performance status (0 vs. 1), LDH levels (normal vs. elevated (=110% ULN)) and BRAF V600 mutation status (wild-type (WT) or V600E)...</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Pembrolizumab_FDA_2023_11_30.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Pembrolizumab_FDA_2023_11_30.pdf"">pembrolizumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166153492,Annotation of FDA Label for brivaracetam and CYP2C19,False,False,[],True,"[{'id': 1448604458, 'date': '2017-03-15T10:43:59.383-07:00', 'type': 'Update', 'version': 0}, {'id': 1449005896, 'date': '2017-11-09T10:27:28.417-08:00', 'type': 'Update', 'version': 0}, {'id': 1452157560, 'date': '2023-07-18T22:01:20.845-07:00', 'description': 'added ""dosing info"" tag', 'type': 'Update', 'version': 0}, {'id': 1452527601, 'date': '2024-07-15T10:57:25.398-07:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160642, 'title': 'Drugs@FDA: Drug Product Briviact (brivaracetam), UCB, Inc. - NDA205836/SUPPL-14, 05/17/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205836', 'crossReferences': [{'id': 1452527580, 'resource': 'FDA Application', 'resourceId': 'NDA205836/SUPPL-14', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205836'}], 'objCls': 'Literature', 'pubDate': '2023-05-17T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101997, 'title': 'Drugs@FDA: Drug Product Briviact (brivaracetam), NDA205836, UCB, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205836', 'crossReferences': [{'id': 1449894677, 'resource': 'FDA Application', 'resourceId': 'NDA205836', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205836'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166153491', 'name': 'brivaracetam'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1447991035.0,"<p>The FDA-approved drug label for brivaracetam (BRIVIACT) states that CYP2C19 intermediate or poor metabolizers may have increased blood levels of brivaracetam, and that poor metabolizers may require a dose reduction.</p>
",1450342085.0,"<p>Brivaracetam (BRIVIACT) is indicated as an adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are 1 month and older. Excerpt from the FDA-approved drug label for brivaracetam:</p>
<blockquote class=""blockquote"">
<p>Brivaracetam is primarily metabolized by hydrolysis of the amide moiety to form the corresponding carboxylic acid metabolite, and secondarily by hydroxylation on the propyl side chain to form the hydroxy metabolite. [...] The hydroxylation pathway is mediated primarily by CYP2C19. In human subjects possessing genetic variations in CYP2C19, production of the hydroxy metabolite is decreased 2-fold or 10-fold, while the blood level of brivaracetam itself is increased by 22% or 42%, respectively, in individuals with one or both mutated alleles. CYP2C19 poor metabolizers and patients using inhibitors of CYP2C19 may require dose reduction.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Brivaracetam_2024_07_15_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Brivaracetam_2024_07_15_FDA.pdf"">brivaracetam drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452527600.0,"<blockquote class=""blockquote"">
<p>BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399533.0,"<p>Excerpt from the FDA-approved drug label for brivaracetam:</p>
<blockquote class=""blockquote"">
<p>CYP2C19 poor metabolizers and patients using inhibitors of CYP2C19 may require dose reduction.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166160061,Annotation of FDA Label for dinutuximab and MYCN,False,True,[],False,"[{'id': 1452206921, 'date': '2023-08-15T07:10:38.378-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101837, 'title': 'Drugs@FDA: Drug Product Unituxin (DINUTUXIMAB), BLA125516, United Therapeutics Corp.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125516', 'crossReferences': [{'id': 1449754293, 'resource': 'FDA Application', 'resourceId': 'BLA125516', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125516'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166160060', 'name': 'dinutuximab'}]","[{'objCls': 'Gene', 'id': 'PA31359', 'symbol': 'MYCN', 'name': 'MYCN proto-oncogene, bHLH transcription factor'}]",FDA,1448257567.0,"<p>The FDA-approved drug label for dinutuximab (UNITUXIN) provides information on the MYCN status of patients in a clinical study of the drug.</p>
",1448257566.0,"<p>Dinutuximab (UNITUXIN) is indicated, in combination with GM-CSF, IL-2 and 13-cis-retinoic acid, for treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent multimodality therapy. Amplification of <em>MYCN</em> gene is found in about 25 percent of neuroblastomas; amplification of the MYCN gene is associated with a more severe form of neuroblastoma (see <a rel=""noopener noreferrer"" href=""https://ghr.nlm.nih.gov/gene/MYCN#conditions"" target=""_blank"">Genetics Home Reference</a>). Excerpt from the dinutuximab drug label:</p>
<div class=""blockquote"">
<p>The safety and effectiveness of Unituxin was evaluated in a randomized, open-label, multicenter trial conducted in pediatric patients with high-risk neuroblastoma (Study 1)...Forty-six percent of patients had neuroblastoma that was not MYCN-amplified, 36% had tumors with known MYCN-amplification, and MYCN status was unknown or missing in 19% of patients.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Dinutuximab_07_17_2017_FDA.pdf"">dinutuximab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182760,"Annotation of FDA Label for docetaxel and ESR1, ESR2, PGR",False,True,[],False,"[{'id': 1452206922, 'date': '2023-08-15T07:11:26.558-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102503, 'title': 'Drugs@FDA: Drug Product Docetaxel (DOCETAXEL ANHYDROUS), NDA022234, Hospira, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022234', 'crossReferences': [{'id': 1450415975, 'resource': 'FDA Application', 'resourceId': 'NDA022234', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022234'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449383', 'name': 'docetaxel'}]","[{'objCls': 'Gene', 'id': 'PA156', 'symbol': 'ESR1', 'name': 'estrogen receptor 1'}, {'objCls': 'Gene', 'id': 'PA27886', 'symbol': 'ESR2', 'name': 'estrogen receptor 2'}, {'objCls': 'Gene', 'id': 'PA266', 'symbol': 'PGR', 'name': 'progesterone receptor'}]",FDA,1450401040.0,"<p>The FDA-approved drug label for docetaxel mentions subset analysis for Breast Cancer patients defined by positive estrogen and/or progesterone receptor status.</p>
",1450401041.0,"<p>Excerpt from the docetaxel drug label:</p>
<div class=""blockquote"">
<p>A multicenter, open-label, randomized trial (TAX316)...Docetaxel was administered as a 1-hour infusion; all other drugs
were given as intravenous bolus on day 1. In both arms, after the last cycle of chemotherapy, patients with
positive estrogen and/or progesterone receptors received tamoxifen 20 mg daily for up to 5 years.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Docetaxel_05_13_2019FDA.pdf"">docetaxel drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166115363,Annotation of FDA Label for succimer and G6PD,False,False,[],False,"[{'id': 1183704709, 'date': '2014-01-15T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1452215342, 'date': '2023-08-24T15:56:33.973-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101873, 'title': 'Drugs@FDA: Drug Product Chemet (succimer), NDA019998, RECORDATI RARE DISEASES, INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019998', 'crossReferences': [{'id': 1449788692, 'resource': 'FDA Application', 'resourceId': 'NDA019998', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019998'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451521', 'name': 'succimer'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447982043.0,"<p>Succimer (CHEMET) is used for treating lead poisoning in pediatric patients with blood lead levels greater than 45 mcg/dL. The drug label notes that succimer has been used to treat five patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency without any adverse reactions.</p>
",1447982042.0,"<p>Excerpt from the succimer (CHEMET) drug label:</p>
<div class=""blockquote"">
<p>Succimer has been used for the treatment of lead poisoning in one patient with sickle cell anemia and five patients with glucose-6-phosphodehydrogenase (G6PD) deficiency without adverse reactions.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Succimer_02_27_19_FDA.pdf"">succimer drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166163430,"Annotation of FDA Label for isosorbide dinitrate and CYB5R1, CYB5R2, CYB5R3, CYB5R4",False,False,[],False,"[{'id': 1452543020, 'date': '2024-07-30T10:56:38.701-07:00', 'description': 'updated label, changed PGx level to Actionable', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162482, 'title': 'DailyMed - ISOSORBIDE DINITRATE tablet', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b0db8af-bcf9-458f-b752-420130cba428', 'crossReferences': [{'id': 1452543000, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '5b0db8af-bcf9-458f-b752-420130cba428', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b0db8af-bcf9-458f-b752-420130cba428'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15102030, 'title': 'Drugs@FDA: Drug Product Dilatrate SR (Isosorbide Dinitrate), NDA019790, Endo Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019790', 'crossReferences': [{'id': 1449754781, 'resource': 'FDA Application', 'resourceId': 'NDA019790', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019790'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450125', 'name': 'isosorbide dinitrate'}]","[{'objCls': 'Gene', 'id': 'PA134979668', 'symbol': 'CYB5R1', 'name': 'cytochrome b5 reductase 1'}, {'objCls': 'Gene', 'id': 'PA142672060', 'symbol': 'CYB5R2', 'name': 'cytochrome b5 reductase 2'}, {'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA134904907', 'symbol': 'CYB5R4', 'name': 'cytochrome b5 reductase 4'}]",FDA,1448605029.0,"<p>Isosorbide dinitrate (dilatrate-SR) is indicated for the prevention of angina pectoris due to coronary artery disease. The FDA-approved drug label provides information about patients with cytochrome b5 reductase activity and risk for methemoglobinemia.</p>
",1448605028.0,"<p>NADH-cytochrome b5 reductase is encoded by the <em>CYB5R1</em>, <em>CYB5R2</em>, <em>CYB5R3</em> and <em>CYB5R4</em> genes.</p>
<p>Excerpts from the isosorbide dinitrate drug label:</p>
<blockquote class=""blockquote"">
<p>Nitrate ions liberated during metabolism of isosorbide dinitrate can oxidize hemoglobin into methemoglobin. Even in patients totally without cytochrome b reductase activity,
however, and even assuming that the nitrate moieties of isosorbide dinitrate are quantitatively applied to oxidation of hemoglobin, about 1 mg/kg of isosorbide dinitrate should be required before any of these patients manifests clinically significant (greater than or equal to 10%) methemoglobinemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Notwithstanding these observations, there are case reports of significant methemoglobinemia in association with moderate overdoses of organic nitrates. None of the affected patients had been thought to be unusually susceptible.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Isosorbide_dinitrate_2024_07_30_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Isosorbide_dinitrate_2024_07_30_FDA.pdf"">isosorbide dinitrate drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182724,"Annotation of FDA Label for ixabepilone and ERBB2, ESR1, ESR2, PGR",False,True,[],False,"[{'id': 1452210100, 'date': '2023-08-18T14:39:09.995-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102380, 'title': 'Drugs@FDA: Drug Product IXEMPRA (ixabepilone), NDA022065, R-Pharm US Operating, LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022065', 'crossReferences': [{'id': 1450399956, 'resource': 'FDA Application', 'resourceId': 'NDA022065', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022065'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165110439', 'name': 'ixabepilone'}]","[{'objCls': 'Gene', 'id': 'PA27844', 'symbol': 'ERBB2', 'name': 'erb-b2 receptor tyrosine kinase 2'}, {'objCls': 'Gene', 'id': 'PA156', 'symbol': 'ESR1', 'name': 'estrogen receptor 1'}, {'objCls': 'Gene', 'id': 'PA27886', 'symbol': 'ESR2', 'name': 'estrogen receptor 2'}, {'objCls': 'Gene', 'id': 'PA266', 'symbol': 'PGR', 'name': 'progesterone receptor'}]",FDA,1450399954.0,"<p>Ixabepilone (IXEMPRA) in combination with capecitabine is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane. IXEMPRA as monotherapy is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, and capecitabine. The label notes the percentages of patients in clinical studies who are hormone receptor positive or negative.</p>
",1450399955.0,"<p>Excerpts from the ixabepilone FDA drug label:</p>
<div class=""blockquote"">
<p>Clinical studies:
Sixty-seven percent of patients were White, 23% were Asian, and 3% were Black.
Both arms were evenly matched with regards to race, age (median 53 years), baseline
performance status (Karnofsky 70-100%), and receipt of prior adjuvant or neo-adjuvant
chemotherapy (75%). Tumors were ER-positive in 47% of patients, ER-negative in 43%,
HER2-positive in 15%, HER2-negative in 61%, and ER-negative, PR-negative, HER2
negative in 25%. The baseline disease characteristics and previous therapies for all
patients (n=752) are shown in Table 6.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/ixabepilone_05_13_2019_FDA.pdf"">ixabepilone drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166163417,Annotation of FDA Label for sofosbuvir / velpatasvir and IFNL3,False,False,[],False,"[{'id': 1452215341, 'date': '2023-08-24T15:50:47.347-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102056, 'title': 'Drugs@FDA: Drug Product Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir), NDA208341, Asegua Therapeutics LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208341', 'crossReferences': [{'id': 1449787897, 'resource': 'FDA Application', 'resourceId': 'NDA208341', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208341'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166155468', 'symbol': 'rs12979860', 'name': 'rs12979860'}]","[{'objCls': 'Chemical', 'id': 'PA166163416', 'name': 'sofosbuvir / velpatasvir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",FDA,1448604874.0,"<p>EPCLUSA (sofosbuvir and velpatasvir) is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ribavirin. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.</p>
",1448604873.0,"<p>Patients with the rs12979860 non-CC genotype may have lower response rates when treated with pegylated interferon and ribavirin combination therapy as compared to those with the CC genotype.</p>
<p>Excerpts from the EPCLUSA drug label:</p>
<div class=""blockquote"">
<p>Clinical Trials in Subjects without Cirrhosis and Subjects with Compensated Cirrhosis...Genotype 1, 2, 4, 5, and 6 HCV Infected Adults (ASTRAL-1)...69% had non-CC IL28B alleles (CT or TT)...</p>
</div>
<div class=""blockquote"">
<p>Clinical Trials in Subjects without Cirrhosis and Subjects with Compensated Cirrhosis...Genotype 2 HCV Infected Adults (ASTRAL-2)...62% had non-CC IL28B alleles (CT or TT)...</p>
</div>
<div class=""blockquote"">
<p>Clinical Trials in Subjects without Cirrhosis and Subjects with Compensated Cirrhosis...Genotype 3 HCV Infected Adults (ASTRAL-3)...61% had non-CC IL28B alleles (CT or TT)...</p>
</div>
<div class=""blockquote"">
<p>Clinical Trials in Subjects with Decompensated Cirrhosis...76% had non-CC IL28B alleles (CT or TT)...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Sofosbuvir_velpatasvir_08_25_2017_FDA.pdf"">EPCLUSA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166163420,"Annotation of FDA Label for venetoclax and FLT3, IDH1, IDH2, NPM1, TP53",False,True,[],False,"[{'id': 1450821514, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Note', 'version': 0}, {'id': 1452220481, 'date': '2023-08-29T12:52:44.529-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101881, 'title': 'Drugs@FDA: Drug Product Venclexta (Venetoclax), NDA208573, AbbVie Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208573', 'crossReferences': [{'id': 1449891719, 'resource': 'FDA Application', 'resourceId': 'NDA208573', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208573'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166153473', 'name': 'venetoclax'}]","[{'objCls': 'Gene', 'id': 'PA28181', 'symbol': 'FLT3', 'name': 'fms related receptor tyrosine kinase 3'}, {'objCls': 'Gene', 'id': 'PA29630', 'symbol': 'IDH1', 'name': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'objCls': 'Gene', 'id': 'PA29631', 'symbol': 'IDH2', 'name': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'objCls': 'Gene', 'id': 'PA31712', 'symbol': 'NPM1', 'name': 'nucleophosmin 1'}, {'objCls': 'Gene', 'id': 'PA36679', 'symbol': 'TP53', 'name': 'tumor protein p53'}]",FDA,1448604901.0,"<p>Venetoclax (VENCLEXTA) is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy. The label also notes whether mutation analyses detected mutations in the <em>TP53</em>, <em>IDH1</em>, <em>IDH2</em>, <em>FLT3</em> and <em>NPM1</em> genes. The label states that the 11q deletion was detected in 32% of patients in the MURANO study.</p>
",1448604900.0,"<p>Individuals with a 17p deletion have a missing portion of the short (petit) arm of chromosome 17.</p>
<p>Excerpts from the venetoclax (VENCLEXTA) drug label:</p>
<div class=""blockquote"">
<p>VENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia
(CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.</p>
</div>
<div class=""blockquote"">
<p>The efficacy of VENCLEXTA was established in study M13-982 (NCT01889186), an open- label, single-arm, multicenter clinical trial of 106 patients with CLL with 17p deletion who had received at least one prior therapy. In the study, 17p deletion was confirmed in peripheral blood specimens from patients using Vysis CLL FISH Probe Kit, which is FDA approved for selection of patients for VENCLEXTA treatment.</p>
</div>
<div class=""blockquote"">
<p>CLINICAL STUDIES...Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia...<em>MURANO</em>... A 17p deletion was detected in 24% of patients, TP53 mutations in 25%, 11q deletion in 32%, and unmutated IgVH in 63%.</p>
</div>
<div class=""blockquote"">
<p>Table 20. Baseline Patient Characteristics for Patients with AML Treated with VENCLEXTA in Combination with Azacitidine or Decitabine...Characteristic...Mutation analyses detected...<em>TP53</em>...<em>IDH1 or IDH2</em>...<em>FLT-3</em>...<em>NPM1</em>...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Venetoclax_05_10_19_FDA.pdf"">venetoclax drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166170931,"Annotation of FDA Label for midostaurin and KIT, NPM1",False,True,[],False,"[{'id': 1451356460, 'date': '2021-03-16T13:32:22.422-07:00', 'description': 'Added cancer genome tag', 'type': 'Update', 'version': 0}, {'id': 1452207423, 'date': '2023-08-15T12:06:29.467-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101883, 'title': 'Drugs@FDA: Drug Product RYDAPT (RYDAPT), NDA207997, Novartis Pharmaceuticals Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207997', 'crossReferences': [{'id': 1449762222, 'resource': 'FDA Application', 'resourceId': 'NDA207997', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207997'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166169917', 'name': 'midostaurin'}]","[{'objCls': 'Gene', 'id': 'PA30128', 'symbol': 'KIT', 'name': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'objCls': 'Gene', 'id': 'PA31712', 'symbol': 'NPM1', 'name': 'nucleophosmin 1'}]",FDA,1449038780.0,"<p>The FDA-approved label for midostaurin (RYDAPT) states that it is indicated for the treatment of adult patients with acute myeloid leukemia that is FLT3 mutation-positive as detected by an FDA-approved test. The label also notes the percentage of patients with an NPM1 mutation or KIT D816V mutation in clinical studies.</p>
",1449038779.0,"<p>Mutations in the FLT3, NPM1 and KIT genes are common in acute myeloid leukemia.</p>
<p>Excerpt from the midostaurin (RYDAPT) drug label:</p>
<blockquote class=""blockquote"">
<p>CLINICAL STUDIES...Acute Myeloid Leukemia...Of the 563 patients with NPM1 testing, 58% had an NPM1 mutation.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CLINICAL STUDIES...Systemic Mastocytosis...82% had the KIT D816V mutation detected at baseline...Confirmed major or partial responses occurred in 46 of 73 patients with a documented KIT D816V mutation, 7 of 16 with wild-type or unknown status with respect to KIT D816V mutation, and 21 of 32 having prior therapy for SM.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Midostaurin_08_30_17_FDA.pdf"">midostaurin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182757,Annotation of FDA Label for inotersen and TTR,False,False,[],False,"[{'id': 1450401014, 'date': '2019-05-16T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452209940, 'date': '2023-08-18T11:43:57.400-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102386, 'title': 'Drugs@FDA: Drug Product Tegsedi (inotersen), NDA211172, Akcea Therapeutics, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211172', 'crossReferences': [{'id': 1450401015, 'resource': 'FDA Application', 'resourceId': 'NDA211172', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211172'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182756', 'name': 'inotersen'}]","[{'objCls': 'Gene', 'id': 'PA37069', 'symbol': 'TTR', 'name': 'transthyretin'}]",FDA,1450401012.0,"<p>The FDA-approved drug label for inotersen (TEGSEDI) states that TEGSEDI is a transthyretin-directed antisense oligonucleotide indicated for treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.</p>
",1450401013.0,"<p>Excerpt from the inotersen (TEGSEDI) drug label:</p>
<div class=""blockquote"">
<p>Inotersen is an antisense oligonucleotide (ASO) inhibitor of human transthyretin (TTR) protein synthesis.</p>
</div>
<div class=""blockquote"">
<p>Inotersen is an antisense oligonucleotide that causes degradation of mutant and wild-type TTR mRNA through binding to the TTR mRNA, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Inotersen_05_14_2019_FDA.pdf"">inotersen drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166163428,Annotation of FDA Label for ledipasvir / sofosbuvir and IFNL3,False,False,[],False,"[{'id': 1452229227, 'date': '2023-09-06T08:54:07.042-07:00', 'description': 'removed informative PGx tag; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101964, 'title': 'Drugs@FDA: Drug Product Ledipasvir and Sofosbuvir (Ledipasvir and Sofosbuvir), NDA205834, Asegua Therapeutics LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205834', 'crossReferences': [{'id': 1449754842, 'resource': 'FDA Application', 'resourceId': 'NDA205834', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205834'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166163427', 'name': 'ledipasvir / sofosbuvir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",FDA,1448604994.0,"<p>HARVONI (ledipasvir and sofosbuvir) is indicated with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.</p>
",1448604998.0,"<p>Patients with the rs12979860 non-CC genotype may have lower response rates when treated with pegylated interferon and ribavirin combination therapy as compared to those with the CC genotype.</p>
<p>Excerpts from the HARVONI drug label:</p>
<div class=""blockquote"">
<p>Clinical Trials in Subjects with Genotype 1 HCV...73% had non-C/C IL28B alleles (CT or TT)...</p>
</div>
<div class=""blockquote"">
<p>Clinical Trials in Subjects Coinfected with HCV and HIV-1...76% had non-C/C IL28B alleles (CT or TT)...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Ledipasvir_Sofosbuvir_02_06_19_FDA.pdf"">ledipasvir and sofosbuvir drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166114944,Annotation of FDA Label for regorafenib and KRAS,False,True,[],False,"[{'id': 1183704717, 'date': '2013-12-13T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1183704718, 'date': '2014-01-14T00:00:00-08:00', 'description': 'no longer on FDA biomarker list', 'type': 'Update', 'version': 0}, {'id': 1450821060, 'date': '2019-10-08T08:57:53.598-07:00', 'description': 'This drug was restored to the FDA list (Biomarker = RAS) so changed the Biomarker list status.', 'type': 'Update', 'version': 0}, {'id': 1452214702, 'date': '2023-08-23T18:23:55.372-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452566040, 'date': '2024-08-26T14:18:18.323-07:00', 'description': 'removed EGFR, VEGFA genes that are not mentioned on the FDA Biomarker Table', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101871, 'title': 'Drugs@FDA: Drug Product Stivarga (regorafenib), NDA203085, Bayer HealthCare Pharmaceuticals Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203085', 'crossReferences': [{'id': 1449776542, 'resource': 'FDA Application', 'resourceId': 'NDA203085', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203085'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166114943', 'name': 'regorafenib'}]","[{'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",FDA,1447982047.0,"<p>The FDA-approved drug label for regorafenib (STIVARGA) states that it is intended for patients with metastatic colorectal cancer who were previously given fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if they were RAS wild type, an anti-EGFR therapy.</p>
",1447982046.0,"<p>Regorafenib is indicated for patients with various types of cancer.</p>
<p>Excerpts from the regorafenib (STIVARGA) drug label:</p>
<div class=""blockquote"">
<p>Stivarga(R) is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy.</p>
</div>
<div class=""blockquote"">
<p>Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions...In <em>in vitro</em> biochemical or cellular assays, regorafenib or its major human active metabolites M-2 and M-5 inhibited the activity of...VEGFR1, VEGFR2, VEGFR3...at concentrations of regorafenib that have been achieved clinically.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Regorafenib_08_17_2017_FDA.pdf"">regorafenib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166163421,Annotation of FDA Label for daclatasvir and IFNL3,False,False,[],False,"[{'id': 1452206840, 'date': '2023-08-15T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15102029, 'title': 'Drugs@FDA: Drug Product DAKLINZA (daclatasvir), NDA206843, E.R. Squibb & Sons, L.L.C.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206843', 'crossReferences': [{'id': 1449754240, 'resource': 'FDA Application', 'resourceId': 'NDA206843', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206843'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166128167', 'name': 'daclatasvir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",FDA,1448604917.0,"<p>Daclatasvir (DAKLINZA) is indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1 or 3 infection. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.</p>
",1448604916.0,"<p>Excerpts from daclatasvir (DAKLINZA) drug label:</p>
<div class=""blockquote"">
<p>Clinical Trials in HCV Genotype 3 (ALLY-3)...40% had the IL28B rs12979860 CC genotype...SVR12 rates were comparable regardless of HCV treatment history, age, gender, IL28B allele status, or baseline HCV RNA level.</p>
</div>
<div class=""blockquote"">
<p>Clinical Trials in HCV/HIV Coinfected Subjects (ALLY-2)...73% had IL28B rs12979860 non-CC genotype...SVR12 rates were comparable regardless of antiretroviral therapy, HCV treatment history, age, race, gender, IL28B allele status, HCV genotype 1 subtype, or baseline HCV RNA level.</p>
</div>
<div class=""blockquote"">
<p>Clinical Trials in Subjects with Child-Pugh A, B, or C Cirrhosis or with HCV Recurrence after Liver Transplantation (ALLY-1)...77% had IL28B rs12979860 non-CC genotype...SVR12 rates were comparable regardless of age, gender, IL28B allele status, or baseline HCV RNA level.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Daclatasvir_07_17_2017_FDA.pdf"">daclatasvir drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166269301,Annotation of FDA Label for maralixibat and JAG1,False,False,[],False,"[{'id': 1452210200, 'date': '2023-08-18T15:14:13.234-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}, {'id': 1452624160, 'date': '2024-10-04T10:27:38.967-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15166902, 'title': 'Drugs@FDA: Drug Product Livmarli (maralixibat chloride), Mirum Pharmaceuticals Inc. - NDA214662/SUPPL-10, 07/24/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214662', 'crossReferences': [{'id': 1452624141, 'resource': 'FDA Application', 'resourceId': 'NDA214662/SUPPL-10', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214662'}], 'objCls': 'Literature', 'pubDate': '2024-07-24T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15131202, 'title': 'Drugs@FDA: Drug Product Livmarli (maralixibat chloride), Mirum Pharmaceuticals Inc. - NDA214662/SUPPL-1, 04/01/2022', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214662', 'crossReferences': [{'id': 1452624121, 'resource': 'FDA Application', 'resourceId': 'NDA214662/SUPPL-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214662'}], 'objCls': 'Literature', 'pubDate': '2022-04-01T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166268803', 'name': 'maralixibat'}]","[{'objCls': 'Gene', 'id': 'PA29986', 'symbol': 'JAG1', 'name': 'jagged canonical Notch ligand 1'}]",FDA,1451749820.0,"<p>The FDA-approved drug label for maralixibat contains information about the JAG1 mutation status of pediatric clinical trial patients.</p>
",1451749821.0,"<p>Excerpt from the maralixibat (LIVMARLI) label:</p>
<blockquote class=""blockquote"">
<p>Thirty-one pediatric ALGS patients with cholestasis and pruritus were enrolled, with 90.3% of patients receiving at least one medication to treat pruritus at study entry. All patients had JAGGED1 mutation.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Maralixibat_2024_10_04_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Maralixibat_2024_10_04_FDA.pdf"">maralixibat drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1451749822.0,"<blockquote class=""blockquote"">
<p>LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor indicated for:</p>
<ul>
<li>the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS).</li>
<li>the treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC).</li>
</ul>
</blockquote>
",,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166238981,"Annotation of FDA Label for synthetic conjugated estrogens, A and PROC, PROS1, SERPINC1",True,False,[],False,[],False,[],True,"[{'id': 15119402, 'title': 'Drugs@FDA: Drug Product synthetic conjugated estrogens, A (NDA020992)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020992', 'crossReferences': [{'id': 1451412480, 'resource': 'FDA Application', 'resourceId': 'NDA020992', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020992'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166238763', 'name': 'synthetic conjugated estrogens, A'}]","[{'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",FDA,1451412460.0,"<p>The FDA-approved label for conjugated synthetic estrogens, A (CENESTIN) states that it is contraindicated for use in patients with protein C, protein S, or antithrombin deficiency. These proteins are encoded by <em>PROC</em>, <em>PROS1</em>, and <em>SERPINC1</em>, respectively.</p>
",1451412461.0,"<p>Excerpts from the synthetic conjugated estrogens, A drug label:</p>
<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS: Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""conjugated_synthetic_estrogens_a_04_09_21_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/conjugated_synthetic_estrogens_a_04_09_21_FDA.pdf"">conjugated synthetic estrogens, A label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451412462.0,"<p>Synthetic conjugated estrogens, A is contraindicated for use in patients with protein C, protein S, or antithrombin deficiency.</p>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166293421,"Annotation of FDA Label for pemigatinib and FGFR1, FGFR2",False,True,[],False,[],False,[],True,"[{'id': 15142082, 'title': 'Drugs@FDA: Drug Product PEMAZYRE (pemigatinib), NDA213736, Incyte Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213736', 'crossReferences': [{'id': 1452039180, 'resource': 'FDA Application', 'resourceId': 'NDA213736', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213736'}], 'objCls': 'Literature', 'pubDate': '2022-08-01T00:00:00-07:00', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166248041', 'name': 'pemigatinib'}]","[{'objCls': 'Gene', 'id': 'PA28127', 'symbol': 'FGFR1', 'name': 'fibroblast growth factor receptor 1'}, {'objCls': 'Gene', 'id': 'PA28128', 'symbol': 'FGFR2', 'name': 'fibroblast growth factor receptor 2'}]",FDA,1452039160.0,"<p>Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement or adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.</p>
",1452039161.0,"<p>Excerpts from the pemigatinib (PEMAZYRE) label:</p>
<blockquote class=""blockquote"">
<p>PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>PEMAZYRE is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Select patients for the treatment of locally advanced or metastatic cholangiocarcinoma with PEMAZYRE based on the presence of an FGFR2 fusion or rearrangement as detected by an FDA-approved test. Information on FDA-approved test(s) for the detection of an FGFR2 fusion or rearrangement in cholangiocarcinoma is available at http://www.fda.gov/CompanionDiagnostics.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Select patients for the treatment of relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement with PEMAZYRE based on the presence of an FGFR1 rearrangement. An FDA-approved test for detection of FGFR1 rearrangement in patients with relapsed or refractory myeloid/lymphoid neoplasm for selecting patients for treatment with PEMAZYRE is not available.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Concomitant use of PEMAZYRE with a strong or moderate CYP3A inducer decreases pemigatinib plasma concentrations, which may reduce the efficacy of PEMAZYRE. Avoid concomitant use of strong and moderate CYP3A inducers with PEMAZYRE.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Concomitant use of a strong or moderate CYP3A inhibitor with PEMAZYRE increases pemigatinib plasma concentrations, which may increase the incidence and severity of adverse reactions. Avoid concomitant use of strong and moderate CYP3A inhibitors with PEMAZYRE. Reduce PEMAZYRE dosage if concomitant use of strong and moderate CYP3A inhibitors cannot be avoided.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""pemigatinib_2023_03_16_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/pemigatinib_2023_03_16_FDA.pdf"">pemigatinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166190141,Annotation of FDA Label for enfortumab vedotin and NECTIN4,False,True,[],False,"[{'id': 1452209240, 'date': '2023-08-17T14:08:59.964-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15104502, 'title': 'Drugs@FDA: Drug Product  enfortumab BLA761137', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761137', 'crossReferences': [{'id': 1450966140, 'resource': 'FDA Application', 'resourceId': 'BLA761137', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761137'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166190121', 'name': 'enfortumab vedotin'}]","[{'objCls': 'Gene', 'id': 'PA134991624', 'symbol': 'NECTIN4', 'name': 'nectin cell adhesion molecule 4'}]",FDA,1450966120.0,"<p>Enfortumab vedotin-ejfv (PADCEV) is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. In clinical studies, an immunohistochemistry clinical trial assay was used to assess patients with tumor tissue available, and detected Nectin-4 expression in all patients tested.</p>
",1450966121.0,"<p>Excerpt from the enfortumab vedotin-ejfv (PADCEV) drug label:</p>
<div class=""blockquote"">
<p>Indication and usage:</p>
</div>
<div class=""blockquote"">
<p>PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.</p>
</div>
<div class=""blockquote"">
<p>Clinical Studies:</p>
</div>
<div class=""blockquote"">
<p>The efficacy of PADCEV was evaluated in EV-201 (NCT03219333), single-arm, multicenter trial that enrolled 125 patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy. Patients were excluded if they had active CNS metastases, ongoing sensory or motor neuropathy ≥ Grade 2, or uncontrolled diabetes defined as hemoglobin A1C (HbA1c) ≥8% or HbA1c ≥7% with associated diabetes symptoms. The median age was 69 years (range: 40 to 84 years), 70% were male, and 85% were Caucasian. All patients had a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 (32%) or 1 (68%). Ninety percent of patients had visceral metastases including 40% with liver metastases. Two-thirds of patients had pure
transitional cell carcinoma (TCC) histology; 33% had TCC with other histologic variants. An immunohistochemistry clinical trial assay was used to assess patients with tumor tissue available, and detected Nectin-4 expression in all patients tested (n=120). The median number of prior systemic therapies was 3 (range: 1 to 6). Forty-six percent of patients received prior PD-1 inhibitor, 42% received prior PD-L1 inhibitor, and an additional 13% received both PD-1 and PD-L1 inhibitors. Sixty-six percent of patients received prior cisplatinbased
regimens, 26% received prior carboplatin-based regimens, and an additional 8% received both cisplatin and carboplatin-based regimens.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/enfortumab_vedotin_02_13_2020_FDA.pdf"">enfortumab vedotin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,Formerly on FDA Biomarker List
Label Annotation,PA166185180,Annotation of FDA Label for nusinersen and SMN2,False,False,[],False,"[{'id': 1452209460, 'date': '2023-08-17T17:27:43.107-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103475, 'title': 'Drugs@FDA: Drug Product  nusinersen NDA 209531', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209531', 'crossReferences': [{'id': 1450826806, 'resource': 'FDA Application', 'resourceId': 'NDA209531', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209531'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182882', 'name': 'nusinersen'}]","[{'objCls': 'Gene', 'id': 'PA35967', 'symbol': 'SMN2', 'name': 'survival of motor neuron 2, centromeric'}]",FDA,1450826803.0,"<p>The FDA-approved drug label for nusinersen (SPINRAZA) states that nusinersen is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.</p>
",1450826804.0,"<p>Excerpts from the nusinersen (SPINRAZA) drug label:</p>
<div class=""blockquote"">
<p>Indications and usage: SPINRAZA is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.</p>
</div>
<div class=""blockquote"">
<p>Description: Nusinersen is a modified antisense oligonucleotide, where the 2’-hydroxy groups of the ribofuranosyl rings are replaced with 2’-O-2-methoxyethyl groups and the phosphate linkages are replaced with phosphorothioate linkages. Nusinersen binds to a specific sequence in the intron downstream of exon 7 of the SMN2 transcript.</p>
</div>
<div class=""blockquote"">
<p>Clinical pharmacology:</p>
</div>
<div class=""blockquote"">
<p>Mechanism of Action: SPINRAZA is an antisense oligonucleotide (ASO) designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Using in vitro assays and studies in transgenic animal models of SMA, SPINRAZA was shown to increase exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts and production of full-length SMN protein.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/nusinersen_11_04_2019_FDA.pdf"">nusinersen drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182769,Annotation of FDA Label for hydroxychloroquine and G6PD,False,False,[],False,"[{'id': 1450401313, 'date': '2019-05-17T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1451091860, 'date': '2020-03-23T11:31:46.399-07:00', 'description': 'Added links fo CDC', 'type': 'Update', 'version': 0}, {'id': 1451517540, 'date': '2021-10-07T12:15:29.766-07:00', 'description': 'updated text based on new label', 'type': 'Update', 'version': 0}, {'id': 1452250340, 'date': '2023-09-27T11:48:21.338-07:00', 'description': 'Removed outdated links to CDC COVID-19 information.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102394, 'title': 'Drugs@FDA: Drug Product Plaquenil (Hydroxychloroquine Sulfate), NDA009768, Carilion Materials Management', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009768', 'crossReferences': [{'id': 1450401314, 'resource': 'FDA Application', 'resourceId': 'NDA009768', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009768'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164777036', 'name': 'hydroxychloroquine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450401310.0,"<p>The FDA-approved drug label for hydroxychloroquine (PLAQUENIL) states that hemolysis was reported in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency and monitor for hemolytic anemia.</p>
",1450401311.0,"<p>Excerpts from the hydroxychloroquine (PLAQUENIL) drug label:</p>
<blockquote class=""blockquote"">
<p>Warnings and precautions:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Hemolytic Anemia Associated with G6PD Deficiency: Hemolysis has been reported in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Monitor for hemolytic anemia as this can occur, particularly in association with other drugs that cause hemolysis.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""hydroxychloroquine_10072021_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/hydroxychloroquine_10072021_FDA.pdf"">hydroxychloroquine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450401312.0,"<p>Excerpt from the hydroxychloroquine (PLAQUENIL) drug label:</p>
<blockquote class=""blockquote"">
<p>Warnings and precautions:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Hemolytic Anemia Associated with G6PD Deficiency: Hemolysis has been reported in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Monitor for hemolytic anemia as this can occur, particularly in association with other drugs that cause hemolysis.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166278281,Annotation of FDA Label for estradiol valerate,False,False,[],False,"[{'id': 1452209320, 'date': '2023-08-17T14:48:32.200-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15135502, 'title': 'Drugs@FDA: Drug Product DELESTROGEN (estradiol valerate), NDA 009402, Par Sterile Products', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009402', 'crossReferences': [{'id': 1451877143, 'resource': 'FDA Application', 'resourceId': 'NDA009402', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009402'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166278261', 'name': 'estradiol valerate'}]",[],FDA,1451877140.0,"<p>The FDA-approved label for estradiol valerate (DELESTROGEN) states that estradiol valerate is indicated for treatment of symptoms associated with menopause, treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and treatment of advanced androgen-dependent carcinoma of the prostate.</p>
",1451877141.0,"<p>Excerpts from the estradiol valerate (DELESTROGEN) label:</p>
<blockquote class=""blockquote"">
<p>INDICATIONS AND USAGE -- DELESTROGEN (estradiol valerate injection, USP) is indicated in the:</p>
</blockquote>
<ol>
<li>Treatment of moderate to severe vasomotor symptoms associated with the menopause.</li>
<li>Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with
the menopause. When prescribing solely for the treatment of symptoms of vulvar and
vaginal atrophy, topical vaginal products should be considered.</li>
<li>Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure.</li>
<li>Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).</li>
</ol>
<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS -- DELESTROGEN should not be used in women with any of the following conditions:</p>
</blockquote>
<ol>
<li>Undiagnosed abnormal genital bleeding.</li>
<li>Known, suspected, or history of cancer of the breast.</li>
<li>Known or suspected estrogen-dependent neoplasia.</li>
<li>Active deep vein thrombosis, pulmonary embolism or a history of these conditions.</li>
<li>Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke,
myocardial infarction).</li>
<li>Liver dysfunction or disease.</li>
<li>DELESTROGEN should not be used in patients with known hypersensitivity to its
ingredients.</li>
<li>Known or suspected pregnancy. There is no indication for DELESTROGEN in pregnancy.
There appears to be little or no increased risk of birth defects in children born to women
who have used estrogens and progestins from oral contraceptives inadvertently during early
pregnancy.</li>
</ol>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""estradiol_valerate_2022_09_07_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/estradiol_valerate_2022_09_07_FDA.pdf"">estradiol valerate drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166235441,"Annotation of FDA Label for bupivacaine and CYB5R3, G6PD",False,False,[],False,"[{'id': 1452531001, 'date': '2024-07-18T17:37:35.361-07:00', 'description': 'updated label, added Other Guidance tag and prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160882, 'title': 'Drugs@FDA: Drug Product Marcaine Spinal (Bupivacaine Hydrochloride in Dextrose), Hospira, Inc. - NDA018692/SUPPL-24, 09/28/2022', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018692', 'crossReferences': [{'id': 1452530981, 'resource': 'FDA Application', 'resourceId': 'NDA018692/SUPPL-24', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018692'}], 'objCls': 'Literature', 'pubDate': '2022-09-28T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA135057240', 'name': 'bupivacaine'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1451400080.0,"<p>The FDA-approved drug label for bupivacaine (MARCAINE SPINAL) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia; close monitoring for symptoms of methemoglobinemia is recommended.</p>
",1451400081.0,"<p>Excerpts from the bupivacaine (MARCAINE SPINAL) label:</p>
<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose 6 phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition [see Drug Interactions (7.2)]. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious CNS and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue MARCAINE SPINAL and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.</p>
</blockquote>
<p>NOTE: While the <em>CYB5R3</em> gene is not explicitly stated in the drug label, variants in this gene are associated with congenital methemoglobinemia I and II <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/250800"" target=""_blank"">OMIM 250800</a>.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Bupivacaine_2024_07_18_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Bupivacaine_2024_07_18_FDA.pdf"">bupivacaine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452531000.0,"<blockquote class=""blockquote"">
<p>Although all patients are at risk for methemoglobinemia, patients with glucose 6 phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia [...] are more susceptible to developing clinical manifestations of the condition [see Drug Interactions (7.2)]. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166225101,Annotation of FDA Label for sacituzumab govitecan and UGT1A1,False,False,[],False,"[{'id': 1452280240, 'date': '2023-10-24T14:30:17.580-07:00', 'description': 'new highlighted label and excerpts from 02/2023 version of the drug label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15114642, 'title': 'Drugs@FDA: Drug Product sacituzumab govitecan-hziy BLA761115', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761115', 'crossReferences': [{'id': 1451277824, 'resource': 'FDA Application', 'resourceId': 'BLA761115', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761115'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]","[{'objCls': 'Haplotype', 'id': 'PA166115842', 'symbol': 'UGT1A1*28', 'name': '*28'}]","[{'objCls': 'Chemical', 'id': 'PA166225061', 'name': 'sacituzumab govitecan'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",FDA,1451277820.0,"<p>The FDA label for sacituzumab govitecan-hziy (TRODELVY) states that patients who are homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia and other adverse reactions following initiation of TRODELVY treatment. Closely monitor patients with reduced UGT1A1 activity for adverse reactions.</p>
",1451277821.0,"<p>Excerpts from the sacituzumab govitecan-hziy (TRODELVY) drug label:</p>
<blockquote class=""blockquote"">
<p>Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia; and may be at increased risk for other adverse reactions when treated with TRODELVY.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 enzyme activity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>12.5 Pharmacogenomics</p>
</blockquote>
<blockquote class=""blockquote"">
<p>SN-38 is metabolized via UGT1A1 (see Clinical Pharmacology (12.3)). Genetic variants of the UGT1A1 gene such as the UGT1A1*28 allele lead to reduced UGT1A1 enzyme activity. Individuals who are homozygous or heterozygous for the UGT1A1*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia from TRODELVY compared to individuals who are wildtype (*1/*1) (see Warnings and Precautions (5.5)). Approximately 20% of the Black or African American population, 10% of the White population, and 2% of the East Asian population are homozygous for the UGT1A1*28 allele (*28/*28). Approximately 40% of the Black or African American population, 50% of the White population, and 25% of the East Asian population are heterozygous for the UGT1A1*28 allele (*1/*28). Decreased function alleles other than UGT1A1*28 may be present in certain populations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Metabolism:  No metabolism studies with sacituzumab govitecan-hziy have been conducted. SN-38 (the small molecule moiety of sacituzumab govitecan-hziy) is metabolized via UGT1A1. The glucuronide metabolite of SN-38 (SN-38G) was detectable in the serum of patients.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Effect of Other Drugs on TRODELVY</p>
</blockquote>
<blockquote class=""blockquote"">
<p>UGT1A1 Inhibitors: Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38 (see Warning and Precaution (5.5) and Clinical Pharmacology (12.3, 12.5)). Avoid administering UGT1A1 inhibitors with TRODELVY.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>UGT1A1 Inducers: Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers (see Warning and Precaution (5.5) and Clinical Pharmacology (12.3, 12.5)). Avoid administering UGT1A1 inducers with TRODELVY.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""sacituzumab_govitecan-hziy_2023_10_24_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/sacituzumab_govitecan-hziy_2023_10_24_FDA.pdf"">sacituzumab govitecan-hziy drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451277822.0,"<blockquote class=""blockquote"">
<p>Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia; and may be at increased risk for other adverse reactions when treated with TRODELVY.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 enzyme activity.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166182890,"Annotation of FDA Label for olaparib and ESR1, ESR2, PGR, PPP2R2A",False,True,[],False,"[{'id': 1451276200, 'date': '2020-10-09T21:54:45.849-07:00', 'description': 'Added PPP2R2A gene based on FDA biomarker table update', 'type': 'Update', 'version': 0}, {'id': 1452209522, 'date': '2023-08-17T17:41:50.630-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102487, 'title': 'Drugs@FDA: Drug Product Lynparza (olaparib), NDA208558, AstraZeneca Pharmaceuticals LP', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208558', 'crossReferences': [{'id': 1449767722, 'resource': 'FDA Application', 'resourceId': 'NDA208558', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208558'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164920420', 'name': 'olaparib'}]","[{'objCls': 'Gene', 'id': 'PA156', 'symbol': 'ESR1', 'name': 'estrogen receptor 1'}, {'objCls': 'Gene', 'id': 'PA27886', 'symbol': 'ESR2', 'name': 'estrogen receptor 2'}, {'objCls': 'Gene', 'id': 'PA266', 'symbol': 'PGR', 'name': 'progesterone receptor'}, {'objCls': 'Gene', 'id': 'PA33668', 'symbol': 'PPP2R2A', 'name': 'protein phosphatase 2 regulatory subunit Balpha'}]",FDA,1450415729.0,"<p>The FDA-approved drug label for olaparib (Lynparza) states that it is indicated for treatment of adult patients ovarian or breast cancer. The label also notes that patients with hormone receptor positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Although patients with PPP2R2A gene mutations were enrolled in the trial PROfound (NCT02987543), olaparib is not indicated for the treatment of patients with this gene mutation due to unfavorable risk-benefit.</p>
",1450415730.0,"<p>Excerpts from the olaparib (Lynparza) drug label:</p>
<blockquote class=""blockquote"">
<p>Breast cancer...in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients were divided into two cohorts based on HRR gene mutation status. Patients with mutations in either BRCA1, BRCA2, or ATM were randomized in Cohort A; patients with mutations among 12 other genes involved in the HRR pathway (BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, or RAD54L) were randomized in Cohort B; patients with co-mutations (BRCA1, BRCA2, or ATM plus a Cohort B gene) were assigned to Cohort A. Although patients with PPP2R2A gene mutations were enrolled in the trial, Lynparza is not indicated for the treatment of patients with this gene mutation due to unfavorable risk-benefit.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""olaparib_FDA_10092020.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/olaparib_FDA_10092020.pdf"">olaparib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166190761,Annotation of FDA Label for upadacitinib and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15104902, 'title': 'Drugs@FDA: Drug Product upadacitinib NDA211675', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211675', 'crossReferences': [{'id': 1450971524, 'resource': 'FDA Application', 'resourceId': 'NDA211675', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211675'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166189803', 'name': 'upadacitinib'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450971521.0,"<p>Upadacitinib (RINVOQ) is a Janus kinase (JAK) inhibitor indicated for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate. Upadacitinib is metabolized by CYP3A4 with a minor contribution from CYP2D6. However, CYP2D6 metabolic phenotype had not shown to have effect on upadacitinib pharmacokinetics.</p>
",1450971522.0,"<p>Excerpt from the Upadacitinib (RINVOQ) drug label:</p>
<div class=""blockquote"">
<p>Mechanism of Action:</p>
</div>
<div class=""blockquote"">
<p>Upadacitinib metabolism is mediated by mainly CYP3A4 with a potential minor contribution from CYP2D6. The pharmacologic activity of upadacitinib is attributed to the parent molecule. In a human radiolabeled study, unchanged upadacitinib accounted for 79% of the total
radioactivity in plasma while the main metabolite detected (product of monooxidation followed by glucuronidation) accounted for 13% of the total plasma radioactivity. No active metabolites have been identified for upadacitinib.</p>
</div>
<div class=""blockquote"">
<p>Drug interaction Studies:</p>
</div>
<div class=""blockquote"">
<p>Upadacitinib is metabolized in vitro by CYP3A4 with a minor contribution from CYP2D6. The effect of co-administered drugs on upadacitinib plasma exposures is provided in Table 3...CYP2D6 metabolic phenotype had no effect on upadacitinib pharmacokinetics (based on population pharmacokinetic analyses), indicating that inhibitors of CYP2D6 have no clinically relevant effect on upadacitinib exposures.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/upadacitinib_02_22_2020_FDA.pdf"">upadacitinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166185168,Annotation of FDA Label for pitolisant and CYP2D6,False,False,[],True,"[{'id': 1450964160, 'date': '2020-02-11T10:37:56.750-08:00', 'description': 'on FDA biomarker list 02/05/2020', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103462, 'title': 'Drugs@FDA: Drug Product  pitolisant NDA 211150', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211150', 'crossReferences': [{'id': 1450826724, 'resource': 'FDA Application', 'resourceId': 'NDA211150', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211150'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166185163', 'name': 'pitolisant'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450826720.0,"<p>The FDA-approved drug label for pitolisant (WAKIX) states that dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers because these patients have higher pitolisant concentrations than normal CYP2D6 metabolizers. The maximum recommended dosage is 17.8 mg once daily for poor metabolizers of CYP2D6.</p>
",1450826721.0,"<p>Excerpts from the pitolisant (WAKIX) drug label:</p>
<blockquote class=""blockquote"">
<p>Dosage and administration:</p>
<p>In patients known to be poor CYP2D6 metabolizers, initiate WAKIX at 8.9 mg once daily and titrate to a maximum dose of 17.8 mg once daily after 7 days [see Use in Specific Populations (8.8), Clinical Pharmacology (12.5)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Specific populations:</p>
<p>CYP2D6 Poor Metabolizers: Dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers because these patients have higher pitolisant concentrations than normal CYP2D6 metabolizers [see Dosage and Administration (2.5), Clinical Pharmacology (12.3, 12.5)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Clinical pharmacology:</p>
<p>Metabolism: Pitolisant is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4; these metabolites are further metabolized or conjugated with glycine or glucuronic acid. None of these metabolites are pharmacologically active.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 Poor Metabolizers: The pharmacokinetics of pitolisant were evaluated in 3 subjects who were CYP2D6 poor metabolizers (PMs) and 5 subjects who were CYP2D6 extensive metabolizers (EMs). All subjects received WAKIX 17.8 mg daily for 7 days. Exposure of pitolisant in CYP2D6 PMs are summarized in Figure 3.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/pitolisant_11_04_2019_FDA.pdf"">pitolisant drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450826722.0,"<p>Excerpts from the pitolisant (WAKIX) drug label:</p>
<blockquote class=""blockquote"">
<p>In patients known to be poor CYP2D6 metabolizers, initiate WAKIX at 8.9 mg once daily and titrate to a maximum dose of 17.8 mg once daily after 7 days [see Use in Specific Populations (8.8), Clinical Pharmacology (12.5)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 Poor Metabolizers:</p>
<p>Dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers because these patients have higher pitolisant concentrations than normal CYP2D6 metabolizers [see Dosage and Administration (2.5), Clinical Pharmacology (12.3, 12.5)].</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166127644,Annotation of HCSC Label for capecitabine and DPYD,True,False,[],False,"[{'id': 1452055281, 'date': '2023-03-31T17:38:10.808-07:00', 'description': 'updated text, level', 'type': 'Update', 'version': 0}, {'id': 1452593860, 'date': '2024-09-18T10:29:11.429-07:00', 'description': 'added label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15165883, 'title': 'Drugs@HCSC: Drug Product ACH-CAPECITABINE (capecitabine), Accord Healthcare Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91132', 'crossReferences': [{'id': 1452593830, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91132', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91132'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]","[{'objCls': 'Haplotype', 'id': 'PA166171117', 'symbol': 'DPYD c.1905+1G>A (*2A)', 'name': 'c.1905+1G>A (*2A)'}]","[{'objCls': 'Chemical', 'id': 'PA448771', 'name': 'capecitabine'}]","[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",HCSC,1447982265.0,"<p>The product monograph for capecitabine states that it is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Testing for DPD deficiency should be considered prior to treatment, based on the local availability and current guidelines.</p>
",1447982264.0,"<p>Excerpt from the capecitabine product monograph:</p>
<blockquote class=""blockquote"">
<p>Capecitabine is contraindicated in patients who have Complete absence of dihydropyrimidine dehydrogenase (DPD) activity. Testing for DPD deficiency should be considered prior to treatment, based on the local availability and current guidelines.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Severe toxicity (e.g. stomatitis, diarrhea, mucosal inflammation, neutropenia and neurotoxicity) associated with 5-fluorouracil has been attributed to a deficiency of
DPD activity, an enzyme involved in fluorouracil degradation. Fatalities have been reported. Testing for DPD deficiency should be considered prior to treatment, based on the local availability and current guidelines.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dihydropyrimidine dehydrogenase (DPD) deficiency: Patients with certain homozygous or certain compound heterozygous mutations in the DPYD gene locus that cause complete or near complete absence of DPD activity, are at the highest risk for severe, life-threatening or fatal adverse reactions caused by fluorouracil. These patients should not be treated with ACH-CAPECITABINE . No dose has been proven safe for patients with complete absence of DPD activity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with certain heterozygous DPYD variants (eg. DPYD*2A variant) that may cause partial DPD deficiency have been shown to have increased risk of severe toxicity when treated with capecitabine. For patients with partial DPD deficiency where the benefi ts of capecitabine are considered to outweigh the risks (taking into account the suitability of an alternative nonfluoropyrimidine chemotherapeutic regimen), these patients must be treated with extreme caution, initially with a substantial dose reduction and frequent subsequent monitoring and dose adjustment according to toxicity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Testing for DPD deficiency should be considered prior to treatment, based on the local availability and current guidelines.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In patients with unrecognised DPD deficiency treated with capecitabine as well as patients who test negative for specific DPYD variations, life-threatening toxicities manifesting as acute overdose may occur. In the event of grade 2-4 acute toxicity, treatment must be discontinued immediately. Permanent discontinuation should be considered based on clinical assessment of the onset, duration and severity of the observed toxicities.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Capecitabine_20230330_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Capecitabine_20230330_HCSC.pdf"">capecitabine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1452055280.0,"<blockquote class=""blockquote"">
<p>Capecitabine is contraindicated in patients who have Complete absence of dihydropyrimidine dehydrogenase (DPD) activity. Testing for DPD deficiency should be considered prior to treatment, based on the local availability and current guidelines.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166236001,Annotation of FDA Label for sodium oxybate and ALDH5A1,True,False,[],False,"[{'id': 1451760720, 'date': '2022-04-22T10:49:42.323-07:00', 'description': 'Changed drug to sodium oxybate', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15118762, 'title': 'Drugs@FDA: Drug Product Xyrem (sodium oxybate), NDA021196, Jazz Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021196', 'crossReferences': [{'id': 1451403325, 'resource': 'FDA Application', 'resourceId': 'NDA021196', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021196'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA24702', 'symbol': 'ALDH5A1', 'name': 'aldehyde dehydrogenase 5 family member A1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166236501', 'name': 'sodium oxybate'}]","[{'objCls': 'Gene', 'id': 'PA24702', 'symbol': 'ALDH5A1', 'name': 'aldehyde dehydrogenase 5 family member A1'}]",FDA,1451403320.0,"<p>The FDA-approved drug label for sodium oxybate (XYREM) states that it is a central nervous depressant indicated for treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy and that it is contraindicated for use in patients with succinic semialdehyde dehydrogenase deficiency.</p>
",1451403321.0,"<p>Excerpts from the sodium oxybate drug label:</p>
<blockquote class=""blockquote"">
<p>Xyrem is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS: Succinic semialdehyde dehydrogenase deficiency</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Do not take XYREM if you or your child:</p>
<p>has a rare problem called succinic semialdehyde dehydrogenase deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The primary pathway involves a cytosolic NADP+-linked enzyme, GHB dehydrogenase, that catalyzes the conversion of GHB to succinic semialdehyde, which is then biotransformed to succinic acid by the enzyme succinic semialdehyde dehydrogenase</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""sodium_oxybate_04_05_2021.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/sodium_oxybate_04_05_2021.pdf"">sodium oxybate drug label.</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1451403323.0,"<p>Excerpt from the sodium oxybate drug label:</p>
<blockquote class=""blockquote"">
<p>Xyrem is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Do not take XYREM if you or your child:</p>
<p>has a rare problem called succinic semialdehyde dehydrogenase deficiency.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451403322.0,"<p>Sodium oxybate is contraindicated for individuals with a deficiency of succinic semialdehyde dehydrogenase, an enzyme encoded by the gene <em>ALDH5A1</em>.</p>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166121327,Annotation of EMA Label for pegloticase and G6PD,True,False,[],False,"[{'id': 1184467702, 'date': '2014-06-05T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452055361, 'date': '2023-03-31T20:19:44.860-07:00', 'description': 'updated text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102942, 'title': 'Krystexxa | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/krystexxa', 'crossReferences': [{'id': 1450663648, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/krystexxa', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/krystexxa'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165963961', 'name': 'pegloticase'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",EMA,1447981972.0,"<p>The EMA European Public Assessment Report (EPAR) for pegloticase (Krystexxa) states that screening in patients at higher risk for G6PD deficiency should be carried out prior to pegloticase treatment. It is contraindicated in these patients due to a higher risk of hemolysis and methemoglobinemia. <strong>Please note that as of June 2016 pegloticase (Krystexxa) has been <a rel=""noopener noreferrer"" href=""https://www.ema.europa.eu/en/medicines/human/EPAR/krystexxa"" target=""_blank"">withdrawn</a> from use in the European Union.</strong></p>
",1447981971.0,"<p><strong>Please note that as of June 2016 pegloticase (Krystexxa) has been <a rel=""noopener noreferrer"" href=""https://www.ema.europa.eu/en/medicines/human/EPAR/krystexxa"" target=""_blank"">withdrawn</a> from use in the European Union.</strong></p>
<p>Excerpt from the pegloticase (Krystexxa) EPAR:</p>
<div class=""blockquote"">
<p>Glucose-6-phosphate dehydrogenase (G6PD) deficiency and other cellular metabolic disorders known to cause haemolysis and methemoglobinemia. All patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) should be screened for G6PD deficiency before starting KRYSTEXXA.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Pegloticase_EMA_EPAR_May_22_2014.pdf"">pegloticase EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1452055360.0,"<blockquote class=""blockquote"">
<p>Glucose-6-phosphate dehydrogenase (G6PD) deficiency and other cellular metabolic disorders known to cause haemolysis and methemoglobinemia. All patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) should be screened for G6PD deficiency before starting KRYSTEXXA.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166123390,Annotation of EMA Label for fampridine and SLC22A2,False,False,[],False,"[{'id': 1450933195, 'date': '2019-12-04T13:18:50.718-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452209360, 'date': '2023-08-17T16:29:08.979-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103640, 'title': 'Fampyra | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra', 'crossReferences': [{'id': 1450932871, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/fampyra'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166123389', 'name': 'fampridine'}]","[{'objCls': 'Gene', 'id': 'PA331', 'symbol': 'SLC22A2', 'name': 'solute carrier family 22 member 2'}]",EMA,1447982179.0,"<p>The EMA European Public Assessment Report (EPAR) for fampridine (Fampyra) does not contain pharmacogenetic information. It contains information regarding the role of OCT2 (SLC22A2) in the secretion of fampridine, and states that concomitant use of drugs that are inhibitors of OCT2 are contraindicated, and cautions the use of concomitant drugs that are substrates of OCT2.</p>
",1447982178.0,"<p>The EMA-approved drug fampridine (Fampyra) is tagged with OCT2 (encoded by the <em>SLC22A2</em> gene) in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>Excerpt from the fampridine (Fampyra) EPAR:</p>
<blockquote class=""blockquote"">
<p>Fampridine is eliminated mainly via kidneys with active renal secretion accounting for about 60% (see section 5.2). OCT2 is the transporter responsible for the active secretion of fampridine. Thus, the concomitant use of fampridine with medicinal products that are inhibitors of OCT2 for example, cimetidine are contraindicated (see section 4.3) and concomitant use of fampridine with medicinal products that are substrates of OCT2 for example, carvedilol, propanolol and metformin is cautioned (see section 4.4.)</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/fampridine_EMA_EPAR_Aug_6_2014.pdf"">fampridine EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166123412,Annotation of EMA Label for sunitinib and CYP3A4,False,False,[],False,"[{'id': 1184754419, 'date': '2014-09-16T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933213, 'date': '2019-12-04T13:28:08.840-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452215343, 'date': '2023-08-24T15:57:59.370-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103657, 'title': 'Sutent | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/sutent', 'crossReferences': [{'id': 1450932889, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/sutent', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/sutent'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA162372840', 'name': 'sunitinib'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447981654.0,"<p>The EMA European Public Assessment Report (EPAR) for sunitinib (SUTENT) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and that potent CYP3A4 inhibitors or inducers should be avoided as they may affect sunitinib plasma levels.</p>
",1447981653.0,"<p>The EMA-approved drug sunitinib is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/sunitinib_EMA_EPAR_Aug_6_2014_1.pdf"">sunitinib EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166123421,Annotation of EMA Label for atazanavir and CYP2C19,False,False,[],False,"[{'id': 1184754514, 'date': '2014-09-16T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452488861, 'date': '2024-05-30T14:34:33.815-07:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}, {'id': 1452539460, 'date': '2024-07-25T14:15:44.874-07:00', 'description': 'changed PGx level to Actionable PGx; CYP2C19 testing is only recommended when cotreatment with voriconazole is required', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102962, 'title': 'Reyataz | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz', 'crossReferences': [{'id': 1450416863, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10251', 'name': 'atazanavir'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",EMA,1447982207.0,"<p>The EMA European Public Assessment Report (EPAR) for atazanavir (REYATAZ) states that co-administration with voriconazole and ritonavir is not recommended, and that if voriconazole treatment is required a patient's CYP2C19 genotype should be performed if feasible. If the patient has at least one functional CYP2C19 allele, close clinical monitoring for a loss of voriconazole and atazanvir efficacy is recommended.</p>
",1447982206.0,"<p>Excerpts from the atazanavir (REYATAZ) EPAR:</p>
<div class=""blockquote"">
<p>In the majority of patients with at least one functional CYP2C19 allele, a reduction in both voriconazole and atazanavir exposures are expected.</p>
</div>
<div class=""blockquote"">
<p>Co-administration of voriconazole and REYATAZ with ritonavir is not recommended unless an assessment of the benefit/risk to the patient justifies the use of voriconazole...At the time voriconazole treatment is required, a patient's CYP2C19 genotype should be performed if feasible...if the combination is unavoidable, the following recommendations are made according to the CYP2C19 status...in patients with at least one functional CYP2C19 allele, close clinical monitoring for a loss of both voriconazole (clinical signs) and atazanavir (virologic response) efficacy is recommended...If genotyping is not feasible, full monitoring of safety and efficacy should be performed.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Atazanavir_06_17_19_EMA.pdf"">atazanavir EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",1452488860.0,"<blockquote class=""blockquote"">
<p>REYATAZ capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4.2).</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166123528,Annotation of PMDA Label for atomoxetine and CYP2D6,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA134688071', 'name': 'atomoxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",PMDA,1447982197.0,"<p>The PMDA package insert for atomoxetine (Strattera) states that individuals who are CYP2D6 poor metabolizers (PMs) and administered atomoxetine may have higher exposure to the drug and be at a greater risk of experiencing adverse events. The insert recommends dosing these patients with discretion.</p>
",1447982196.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for atomoxetine (Strattera):</p>
<blockquote class=""blockquote"">
<p>...[in] patients who are known to have CYP2D6 deficiency (Poor Metabolizer), the plasma concentration of atomoxetine may potentially increase and is likely to cause adverse effects. Therefore, administration of atomoxetine requires caution and constant observation of patient condition, and dose increase shall be done only when there is no problem found with tolerability.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Atomoxetine is mainly metabolized by drug metabolizing enzyme CYP2D6.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Atomoxetine_PMDA_11_14_14.pdf"">atomoxetine package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166123530,Annotation of PMDA Label for azathioprine and TPMT,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448515', 'name': 'azathioprine'}]","[{'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",PMDA,1447982211.0,"<p>The PMDA package insert for azathioprine notes that individuals with certain TPMT genetic variations may be at increased risk of developing myelotoxicity. The insert also notes that this myelotoxicity could be exacerbated by co-administration of drugs that inhibit TPMT, such as aminosalicylic acid derivatives.</p>
",1447982210.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for azathioprine (Imuran):</p>
<blockquote class=""blockquote"">
<p>It has been reported that patients with alterations in the TPMT gene are at increased risk of bone marrow suppression.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Bone suppression may be potentiated by concurrent use of TPMT inhibitors (e.g., aminosalicylate derivatives) and the product in patients who are genetically deficient in TPMT activity.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Azathioprine_PMDA_10_03_16.pdf"">azathioprine package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166123531,Annotation of PMDA Label for capecitabine and DPYD,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448771', 'name': 'capecitabine'}]","[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",PMDA,1447982217.0,"<p>The PMDA package insert for capecitabine states that severe adverse events have occurred in patients receiving the drug who are dihydropyrimidine dehydrogenase (DPD)-deficient. DPD is the enzyme responsible for the degradation of capecitabine and other fluoropyrimidines.</p>
",1447982216.0,"<p><strong>Please note that the information contained within this drug label annotation is sourced from <a href=""http://www.pharmgkb.org/pmid/23895776"">Shimazawa and Ikeda (2013)</a>, whose paper provided an unofficial translation of the pharmacogenetic information contained in the PMDA package insert for research purposes.</strong></p>
<p>Excerpt from the package insert for capecitabine:</p>
<blockquote class=""blockquote"">
<p>Rarely, there are patients with a deficiency of dihydropyrimidine dehydrogenase (DPD), which is a catabolic enzyme of fluorouracil. Severe adverse events (eg, stomatitis, diarrhea, blood dyscrasias and neurotoxicity) associated with fluorouracils in initial treatment have been reported in these patients.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Capecitabine_PMDA_11_14_14.pdf"">capecitabine package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166123535,Annotation of PMDA Label for clopidogrel and CYP2C19,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449053', 'name': 'clopidogrel'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",PMDA,1447982171.0,"<p>The PMDA package insert for clopidogrel states that in clinical pharmacological studies, CYP2C19 poor metabolizers had diminished inhibition of platelet aggregation.</p>
",1447982170.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the package insert for clopidogrel:</p>
<blockquote class=""blockquote"">
<p>In clinical pharmacological studies conducted overseas in healthy adults, the inhibition level of 5 µM ADP-induced platelet aggregation at 24 hours after an initial dose of 300 mg was 40 ± 21%, 39 ± 28%, 37 ± 21% and 24 ± 26% in ultrarapid metabolizers (UMs), extensive metabolizers (EMs), intermediate metabolizers (IMs) and poor metabolizers (PMs), respectively, by CYP2C19 metabolizer status. The initial dose was followed by 75 mg per day for 4 days, and this resulted in platelet aggregation inhibition of 56 ± 13%, 58 ± 19%, 60 ± 18% and 37 ± 23%, respectively, indicating diminished inhibition of platelet aggregation in PMs.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Clopidogrel_PMDA_10_04_16.pdf"">clopidogrel package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166123536,Annotation of PMDA Label for crizotinib and ALK,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165946122', 'name': 'crizotinib'}]","[{'objCls': 'Gene', 'id': 'PA24719', 'symbol': 'ALK', 'name': 'ALK receptor tyrosine kinase'}]",PMDA,1447982203.0,"<p>Crizotinib is indicated for the treatment of patients with non-small cell lung cancer. The PMDA package insert for crizotinib states positive confirmation of the ALK fusion gene is necessary prior to treatment.</p>
",1447982202.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for crizotinib:</p>
<blockquote class=""blockquote"">
<p>Confirmation of positive status for ALK fusion gene is necessary prior to therapy.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Crizotinib_PMDA_10_04_16.pdf"">crizotinib package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166123538,Annotation of PMDA Label for eltrombopag and SERPINC1,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165981594', 'name': 'eltrombopag'}]","[{'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",PMDA,1447982173.0,"<p>The PMDA package insert for eltrombopag notes that caution should be taken when administering the drug to patients with antithrombin III (AT III; <em>SERPINC1</em> gene) deficiency.</p>
",1447982172.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the package insert for eltrombopag:</p>
<blockquote class=""blockquote"">
<p>Careful administration (Use with caution in the following patients)...Antithrombin III deficiency</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Eltrombopag_PMDA_10_05_16.pdf"">eltrombopag package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166123539,Annotation of PMDA Label for fluorouracil and DPYD,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA128406956', 'name': 'fluorouracil'}]","[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",PMDA,1447982175.0,"<p>The PMDA package insert for fluorouracil states that severe adverse events have occurred in patients receiving the drug who are dihydropyrimidine dehydrogenase (DPD)-deficient. DPD is the enzyme responsible for the degradation of fluorouracil and other fluoropyrimidines.</p>
",1447982174.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the package insert for fluorouracil:</p>
<blockquote class=""blockquote"">
<p>In rare cases of deficiency in dihydropyrimidine dehydrogenase (DPD), a catabolic enzyme of fluorouracil, serious side effects (e.g., stomatitis, diarrhea, hematologic side effects, neurotoxicity) have been reported following administration of fluorouracil at an early phase of dosing.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Fluorouracil_PMDA_10_05_16.pdf"">fluorouracil package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166123543,Annotation of PMDA Label for indacaterol and UGT1A1,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958348', 'name': 'indacaterol'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",PMDA,1447982441.0,"<p>The PMDA package insert for indacaterol (Onbrez) states that individuals who have low UGT1A1 expression have increased steady-state area under the concentration-time curve (AUC) and maximum plasma concentration (Cmax) as compared to UGT1A1 wild-type individuals.</p>
",1447982440.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the package insert for indacaterol (Onbrez):</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics of indacaterol in patients with variant UGT1A1 genotypes. Following repeated inhalation of indacaterol in subjects with variant, low-activity UGT1A1 genotypes, the steady-state Cmax and AUC were both 1.2-fold higher compared to those with the wild-type genotype (non-Japanese data).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Indacaterol_PMDA_10_06_16.pdf"">indacaterol package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166123526,Annotation of PMDA Label for irinotecan and UGT1A1,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450085', 'name': 'irinotecan'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",PMDA,1447982191.0,"<p>The PMDA package insert for irinotecan states that it is for the treatment of refractory, inoperable pancreatic cancer and that patients should be selected for treatment based on their stage, general condition and UGT1A1 polymorphism.</p>
",1447982190.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for irinotecan:</p>
<blockquote class=""blockquote"">
<p>For the treatment of refractory, inoperable pancreatic cancer, select patients based upon thorough understanding of the efficacy and safety of the product by fully evaluating the patient’s stage, general condition and UGT1A1 polymorphism described in Clinical Study Results.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>It has been reported that patients who are singly homozygous (UGT1A1*6/*6 or UGT1A1*28/*28) or dually heterozygous (UGT1A1*6/*28) for two polymorphisms (UGT1A1*6 or UGT1A1*28) of UDP-glucuronosyltransferase (UGT), which is a major enzyme responsible for metabolism of the active metabolite of this product (SN-38), have delayed SN-38 metabolism due to reduced glucuronidation activity and thus are at increased risk for serious side effects (especially neutropenia). Therefore, use caution when administering the product to these patients...</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Irinotecan_PMDA_10_31_16.pdf"">irinotecan package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,,,,,,,,,
Label Annotation,PA166123546,Annotation of PMDA Label for mycophenolic acid and HPRT1,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164748728', 'name': 'mycophenolic acid'}]","[{'objCls': 'Gene', 'id': 'PA29427', 'symbol': 'HPRT1', 'name': 'hypoxanthine phosphoribosyltransferase 1'}]",PMDA,1447982425.0,"<p>The PMDA package insert for mycophenolic acid notes that caution should be used in patients with deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes, due to the risk for exacerbation of hyperuricemia.</p>
",1447982424.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the package insert for mycophenolic acid:</p>
<blockquote class=""blockquote"">
<p>Caution should be used in patients with deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), such as Lesch-Nyhan and Kelley-Seegmiller syndrome, as exacerbation of hyperuricemia may occur.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Mycophenolic_acid_PMDA_11_17_14.pdf"">mycophenolic acid package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166123547,Annotation of PMDA Label for panitumumab and KRAS,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA162373091', 'name': 'panitumumab'}]","[{'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",PMDA,1447982427.0,"<p>The PMDA package insert for panitumumab (Vectibix) states that it is indicated for patients with wild-type <em>KRAS</em> colorectal cancer, and that patients should be selected based on <em>RAS</em> (<em>KRAS</em> and <em>NRAS</em>) mutation status.</p>
",1447982426.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for panitumumab (Vectibix):</p>
<blockquote class=""blockquote"">
<p>Select patient based on <em>RAS</em> (<em>KRAS</em> and <em>NRAS</em>) gene mutation status.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>KRAS</em> mutations at codons 12 and 13 were assessed.
<em>KRAS</em> mutations at codons 12, 13, 61, 117 and 146 and NRAS mutations at codons 12, 13, 61, 117 and 146 were assessed.
<em>KRAS</em> mutations at codons 12, 13, 59, 61, 117 and 146 and NRAS mutations at codons 12, 13, 59, 61, 117 and 146 were assessed.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Panitumumab_PMDA_10_18_16.pdf"">panitumumab package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166123548,Annotation of PMDA Label for rasburicase and G6PD,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10176', 'name': 'rasburicase'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",PMDA,1447982463.0,"<p>The PMDA package insert for rasburicase notes that foreign clinical studies have shown that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency can have severe hemolytic reactions when administered rasburicase, and patients should be carefully screened for a family history of G6PD deficiency or other red blood cell enzyme defects.</p>
",1447982462.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for rasburicase:</p>
<blockquote class=""blockquote"">
<p>In overseas clinical studies, severe hemolytic anemia was reported in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients should be carefully screened for a family history of G6PD deficiency and other red blood cell enzyme defects.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Contraindication...Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or patients with other types of red blood cell enzyme defects that are known to cause hemolytic anemia.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Rasburicase_PMDA_10_18_16.pdf"">rasburicase package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166123550,Annotation of PMDA Label for trastuzumab and ERBB2,False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451743', 'name': 'trastuzumab'}]","[{'objCls': 'Gene', 'id': 'PA27844', 'symbol': 'ERBB2', 'name': 'erb-b2 receptor tyrosine kinase 2'}]",PMDA,1447982459.0,"<p>The PMDA package insert for trastuzumab states that it is indicated for patients with HER2-overexpressing breast or gastric cancers.</p>
",1447982458.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the package insert for trastuzumab:</p>
<blockquote class=""blockquote"">
<p>Indications...HER2-overexpressing breast cancer. HER2-overexpressing unresectable, advanced, recurrent gastric cancer.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Trastuzumab_PMDA_11_17_14.pdf"">trastuzumab package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166123537,"Annotation of PMDA Label for dasatinib and ABL1, BCR",False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA162372878', 'name': 'dasatinib'}]","[{'objCls': 'Gene', 'id': 'PA24413', 'symbol': 'ABL1', 'name': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'objCls': 'Gene', 'id': 'PA25321', 'symbol': 'BCR', 'name': 'BCR activator of RhoGEF and GTPase'}]",PMDA,1447982205.0,"<p>The PMDA package insert for dasatinib states that it is indicated for individuals with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).</p>
",1447982204.0,"<p><strong>Please note that the information contained within this drug label annotation is sourced from <a href=""http://www.pharmgkb.org/pmid/23895776"">Shimazawa and Ikeda (2013)</a>, whose paper provided an unofficial translation of the pharmacogenetic information contained in the PMDA package insert for research purposes.</strong></p>
<p>Excerpt from the package insert for dasatinib:</p>
<blockquote class=""blockquote"">
<p>Philadelphia chromosome-positive, recurrent or refractory acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Dasatinib_PMDA_11_17_14.pdf"">dasatinib package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166127721,Annotation of HCSC Label for tolterodine and CYP2D6,False,False,[],False,"[{'id': 1452540101, 'date': '2024-07-26T11:05:22.595-07:00', 'description': 'updated label, changed PGx level to Actionable', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162142, 'title': 'Drugs@HCSC: Drug Product DETROL (tolterodine), BGP Pharma ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62518', 'crossReferences': [{'id': 1452540100, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62518', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62518'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164746757', 'name': 'tolterodine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982353.0,"<p>The product monograph for tolterodine (DETROL) notes that the effect of tolterodine on QTc interval appeared to be greater in CYP2D6 poor metabolizers than in CYP2D6 extensive metabolizers.</p>
",1447982352.0,"<p>Tolterodine is converted to a pharmacologically active 5-hydroxymethyl metabolite (DD 01) by CYP2D6. Excerpts from the tolterodine (DETROL) product monograph:</p>
<blockquote class=""blockquote"">
<p>Approximately 7% of Caucasians are poor metabolizers of CYP2D6 substrates. A pharmacokinetic/pharmacodynamic model estimated that QTc interval increases in poor metabolizers treated with tolterodine 2 mg BID are comparable to those observed in extensive metabolizers receiving 4 mg BID.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Tolterodine is converted to a pharmacologically active 5-hydroxymethyl metabolite (DD 01) by the isozyme cytochrome P450 2D6 (debrisoquine hydroxylase). This metabolite exhibits an antimuscarinic profile similar to that of tolterodine, both <em>in vitro</em> and <em>in vivo</em>.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A subset (about 7%) of the population is devoid of the drug-metabolizing isoenzyme cytochrome P450 2D6, the enzyme responsible for the formation of DD 01. The identified pathway of metabolism for these individuals, referred to as “poor metabolizers” (PMs), is dealkylation via cytochrome P450 3A4 to N-dealkylated tolterodine. The remainder of the population is referred to as “extensive metabolizers” (EMs). Since tolterodine and DD 01 have similar antimuscarinic effects, the net activity of DETROL is expected to be similar in EMs and PMs (see DETAILED PHARMACOLOGY).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Tolterodine’s effect on QT interval was found to correlate with plasma concentration of tolterodine. The effect on QTc interval appeared to be greater in CYP2D6 poor metabolizers than in CYP2D6 extensive metabolizers. In this study, the point estimates of manual-read QTc interval increase were 2.1 msec in extensive metabolizers and 8.7 msec in poor metabolizers receiving tolterodine 2 mg BID treatment. However, this study was not designed to make direct statistical comparisons by CYP2D6 metabolizer status nor between drugs or dose levels. At both doses of tolterodine, no subject, irrespective of their metabolic profile (ie. poor/extensive metabolizers), exceeded 500 msec for absolute QTcF or 60 msec for change from baseline. The clinical relevance of these findings will depend on individual patient risk factors and susceptibilities present (see WARNINGS AND PRECAUTIONS, Cardiovascular).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Tolterodine_2024_07_26_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Tolterodine_2024_07_26_HCSC.pdf"">tolterodine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166123408,Annotation of EMA Label for vortioxetine and CYP2D6,False,False,[],True,"[{'id': 1184754365, 'date': '2014-09-15T00:00:00-07:00', 'type': 'Create', 'version': 0}]",False,[],True,"[{'id': 15102945, 'title': 'Brintellix | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix', 'crossReferences': [{'id': 1450806452, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166122595', 'name': 'vortioxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1447982185.0,"<p>The EMA European Public Assessment Report (EPAR) for vortioxetine (Brintellix) states that CYP2D6 poor metabolizers have higher concentrations of vortioxetine as compared to extensive metabolizers. Additionally, for CYP2D6 ultra-rapid metabolizers, a dose adjustment may be considered depending on individual patient response.</p>
",1447982184.0,"<p>Excerpt from the vortioxetine (Brintellix) EPAR:</p>
<div class=""blockquote"">
<p>CYP2D6 gene types...The plasma concentration of vortioxetine was approximately two times higher in CYP2D6 poor metabolisers than in extensive metabolisers. Co-administration of strong CYP3A4/2C9-inhibitors to CYP2D6 poor metabolisers could potentially result in higher exposure...In CYP2D6 ultra-rapid metabolisers, the plasma concentration of vortioxetine 10 mg/day were between those obtained in extensive metabolisers at 5 mg/day and 10 mg/day. Depending on individual patient response, a dose adjustment may be considered...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Vortioxetine_07_17_19_EMA.pdf"">Vortioxetine EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450806451.0,"<p>&quot;In CYP2D6 ultra-rapid metabolisers, the plasma concentration of vortioxetine 10 mg/day were between those obtained in extensive metabolisers at 5 mg/day and 10 mg/day. Depending on individual patient response, a dose adjustment may be considered...&quot;</p>
",,,,,,,
Label Annotation,PA166127730,Annotation of HCSC Label for voriconazole and CYP2C19,False,False,[],False,"[{'id': 1452725340, 'date': '2024-12-04T15:11:38.821-08:00', 'description': 'updated label', 'type': 'Update', 'version': 0}, {'id': 1452824223, 'date': '2025-01-24T11:50:20.648-08:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171642, 'title': 'Drugs@HCSC: Drug Product VFEND (voriconazole), Pfizer Canada ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74170', 'crossReferences': [{'id': 1452725320, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74170', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74170'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10233', 'name': 'voriconazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1447982479.0,"<p>The product monograph for voriconazole (VFEND) notes that CYP2C19 poor metabolizers have, on average, 4-fold higher exposure to the drug as compared to extensive metabolizers.</p>
",1447982478.0,"<p>Voriconazole is an antifungal medication. Excerpts from the voriconazole (VFEND) product monograph:</p>
<blockquote class=""blockquote"">
<p><em>In vitro</em> studies showed that voriconazole is metabolised by the hepatic cytochrome P450 isoenzymes, CYP2C19, CYP2C9 and CYP3A4.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>In vivo</em> studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 15-20% of Asian populations may be expected to be poor metabolisers. For Caucasians and Blacks, the prevalence of poor metabolisers is 3-5%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolisers have, on average, 4-fold higher voriconazole exposure (AUCtau) than their homozygous extensive metaboliser counterparts. Subjects who are heterozygous extensive metabolisers have, on average, 2-fold higher voriconazole exposure than their homozygous extensive metaboliser counterparts.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Voriconazole_2024_12_04_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Voriconazole_2024_12_04_HCSC.pdf"">voriconazole product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452824222.0,"<blockquote class=""blockquote"">
<p>Pediatrics (&lt;12 years of age). Based on the data submitted and reviewed by Health Canada, the safety and efficacy of VFEND in pediatric patients below 12 years of age have not been established; therefore, Health Canada has not authorized an indication for use in these patients.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166127732,"Annotation of HCSC Label for warfarin and CYP2C9, VKORC1",False,False,[],True,"[{'id': 1452711361, 'date': '2024-11-21T12:04:06.764-08:00', 'description': 'changed PGx level to Actionable, added Dosing Info tag, prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161082, 'title': 'Drugs@HCSC: Drug Product Apo-Warfarin (warfarin), Apotex Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66762', 'crossReferences': [{'id': 1452532241, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66762', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66762'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA133787052', 'symbol': 'VKORC1', 'name': 'vitamin K epoxide reductase complex subunit 1'}]","[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}, {'objCls': 'Variant', 'id': 'PA166155091', 'symbol': 'rs9923231', 'name': 'rs9923231'}]","[{'objCls': 'Chemical', 'id': 'PA451906', 'name': 'warfarin'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA133787052', 'symbol': 'VKORC1', 'name': 'vitamin K epoxide reductase complex subunit 1'}]",HCSC,1447982243.0,"<p>The product monograph for warfarin notes that patients carrying one or two copies of the CYP2C9*2 or *3 alleles may require a decreased mean daily warfarin dose, and have an increased bleeding risk, as compared to those homozygous for the CYP2C9*1 allele. Additionally, variations in the <em>VKORC1</em> gene, such as -1639G&gt;A, are also associated with changes in the dose requirement of warfarin.</p>
",1447982242.0,"<p>Warfarin is an anticoagulant. Excerpts from the warfarin product monograph:</p>
<blockquote class=""blockquote"">
<p>A meta-analysis of 9 qualified studies including 2775 patients (99% Caucasian)...suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles. Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In an observational study...in 219 Swedish patients...The relative risk of over anticoagulation as measured by INR &gt;3 during the first 2 weeks of therapy was approximately doubled for those patients classified as *2 or *3 compared to patients who were homozygous for the *1 allele.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined. About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs and indication for warfarin therapy in Caucasian patients. Similar observations have been reported in Asian patients.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Warfarin_2024_07_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Warfarin_2024_07_19_HCSC.pdf"">warfarin product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452711360.0,"<blockquote class=""blockquote"">
<p>It is recommended that APO-WARFARIN therapy be initiated with a dose of 2 to 5 mg per day with dosage adjustments based on the results of PT/INR determinations. The lower initiation doses should be considered for patients with certain genetic variations in CYP2C9 and VKORC1 enzymes [...]</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127729,Annotation of HCSC Label for moviprep and G6PD,False,False,[],False,"[{'id': 1452539361, 'date': '2024-07-25T13:10:52.844-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162062, 'title': 'Drugs@HCSC: Drug Product MOVIPREP (Macrogol 3350, Sodium sulphate anhydrous, Sodium chloride, Potassium chloride, Ascorbic acid, Sodium ascorbate), Aralez Pharmaceuticals Canada Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00062617.PDF', 'crossReferences': [{'id': 1452539360, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00062617.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00062617.PDF'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166163260', 'name': 'moviprep'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982469.0,"<p>MOVIPREP, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy. Because it contains Vitamin C (ascorbic acid), the label warns that hemolytic reactions are possible in those with G6PD deficiency.</p>
",1447982468.0,"<p>Excerpt from the MOVIPREP (polyethylene glycol 3350, sodium sulfate anhydrous, sodium chloride, potassium chloride, ascorbic acid, sodium ascorbate) product monograph:</p>
<blockquote class=""blockquote"">
<p><strong>Ascorbic acid:</strong> Patients with Glucose-6-phosphate dehydrogenase deficiency may be at risk of acute haemolysis due to the presence of ascorbate.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Before you use MOVIPREP, talk to your doctor or pharmacist if you have: [...]</p>
<ul>
<li>not enough glucose-6-phosphate dehydrogenase produced by your body.</li>
</ul>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Moviprep_2024_07_25_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Moviprep_2024_07_25_HCSC.pdf"">MOVIPREP product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166129515,"Annotation of FDA Label for desflurane and CACNA1S, RYR1",True,False,[],False,"[{'id': 1450398344, 'date': '2019-05-04T19:08:29.082-07:00', 'description': 'added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1450822021, 'date': '2019-10-14T11:06:37.432-07:00', 'description': 'No changes to annotation text but label was updated at FDA, so new label attached with same PGx and DDI highlighted.', 'type': 'Update', 'version': 0}, {'id': 1452016899, 'date': '2023-02-22T22:11:50.798-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452054920, 'date': '2023-03-31T14:03:33.608-07:00', 'description': 'updated text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101905, 'title': 'Drugs@FDA: Drug Product SUPRANE (desflurane), NDA020118, Baxter Healthcare Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020118', 'crossReferences': [{'id': 1449754259, 'resource': 'FDA Application', 'resourceId': 'NDA020118', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020118'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164749136', 'name': 'desflurane'}]","[{'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",FDA,1450342935.0,"<p>Desflurane (SUPRANE) is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia. The FDA-approved label warns that individuals with a genetic predisposition to malignant hyperthermia, or patients with Duchenne Muscular Dystrophy, are at greater risk of developing malignant hyperthermia, or hyperkaelemia, respectively, if administered desflurane.</p>
",1450342936.0,"<p>Specific variants in the <em>RYR1</em> and <em>CACNA1S</em> genes are associated with risk of malignant hyperthermia in individuals administered potent inhalational anesthetics, including desflurane.  The FDA-approved label for desflurane (SUPRANE) contraindicates it for individuals with known, or suspected, genetic predisposition to malignant hyperthermia.</p>
<p>Excerpts from the FDA-approved desflurane (SUPRANE) drug label:</p>
<blockquote class=""blockquote"">
<p>The use of SUPRANE is contraindicated in the following conditions...Malignant Hyperthermia: Malignant hyperthermia may occur, especially in individuals with known or suspected susceptibility based on genetic factors or family history. Discontinue triggering agents, administer intravenous dantrolene sodium, and apply supportive therapies.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In susceptible individuals, volatile anesthetic agents, including desflurane, may trigger malignant hyperthermia, a skeletal muscle hypermetabolic state leading to high oxygen demand. Fatal outcomes of malignant hyperthermia have been reported.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The risk of developing malignant hyperthermia increases with the concomitant administration of succinylcholine and volatile anesthetic agents. SUPRANE can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacogenomics: RYR1 and CACNA1S are polymorphic genes and multiple pathogenic variants have been associated with malignant hyperthermia susceptibility (MHS) in patients receiving volatile anesthetic agents, including SUPRANE. Case reports as well as exvivo studies have identified multiple variants in RYR1 and CACNA1S associated with
MHS. Variant pathogenicity should be assessed based on prior clinical experience, functional studies, prevalence information, or other evidence (see Contraindications (4),
Warnings and Precautions (5.1)).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Desflurane_20230330_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Desflurane_20230330_FDA.pdf"">desflurane drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450398343.0,"<p>Excerpt from the FDA-approved desflurane (SUPRANE) drug label:</p>
<blockquote class=""blockquote"">
<p>The use of SUPRANE is contraindicated in the following conditions...
Malignant Hyperthermia: Malignant hyperthermia may occur, especially in individuals with known or suspected susceptibility based on genetic factors or family history. Discontinue triggering agents, administer intravenous dantrolene sodium, and apply supportive therapies.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166129516,"Annotation of HCSC Label for desflurane and CACNA1S, RYR1",True,False,[],False,"[{'id': 1452055241, 'date': '2023-03-31T17:25:25.552-07:00', 'description': 'updated text', 'type': 'Update', 'version': 0}, {'id': 1452595304, 'date': '2024-09-19T11:59:24.444-07:00', 'description': 'replaced label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15165962, 'title': 'Drugs@HCSC: Drug Product SUPRANE (desflurane), Baxter Corporation', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43455', 'crossReferences': [{'id': 1452595320, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43455', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43455'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164749136', 'name': 'desflurane'}]","[{'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",HCSC,1447982381.0,"<p>Desflurane (SUPRANE) is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia. The HCSC-approved product monograph warns that individuals with a genetic predisposition to malignant hyperthermia, or patients with Duchenne Muscular Dystrophy, are at greater risk of developing malignant hyperthermia or hyperkaelemia, respectively, if administered desflurane.</p>
<p>Specific variants in the <em>RYR1</em> and <em>CACNA1S</em> genes are associated with risk of malignant hyperthermia in individuals administered potent inhalational anesthetics, such as desflurane. Although the product monograph for desflurane (SUPRANE) does not specifically mention genetic testing, it states that desflurane is contraindicated in individuals with a genetic predisposition to malignant hyperthermia.</p>
",1447982380.0,"<p>The HCSC product monograph warns that individuals with a genetic predisposition to malignant hyperthermia are at an elevated risk of developing malignant hyperthermia, and that patients with Duchenne's Muscular Dystrophy are at an elevated risk of developing hyperkaelemia if administered desflurane, or other potent inhalational anesthetics.</p>
<p>Excerpts from the desflurane (SUPRANE) product monograph:</p>
<blockquote class=""blockquote"">
<p><strong>CONTRAINDICATIONS</strong> [...]</p>
<ul>
<li>Known or suspected genetic susceptibility to malignant hyperthermia or in patients with a history of malignant hyperthermia</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>SUPRANE (desflurane) may trigger Malignant Hyperthermia in susceptible individuals and fatal outcomes have been reported</p>
</blockquote>
<blockquote class=""blockquote"">
<p>SUPRANE (desflurane) use may lead to Perioperative Hyperkalemia in patients with neuromuscular disorders</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Perioperative Hyperkalemia:</strong> Use of inhaled anesthetic agents, including desflurane, has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias, some fatal, in patients during the postoperative period. Patients with latent as well as overt muscular dystrophies, particularly Duchenne Muscular Dystrophy, appear to be most vulnerable.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Desflurane_2024_09_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Desflurane_2024_09_19_HCSC.pdf"">desflurane product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the HCSC and are the sole responsibility of PharmGKB.</p>
",1452595303.0,"<blockquote class=""blockquote"">
<p>SUPRANE (desflurane) is indicated as an inhalation agent for maintenance of general anesthesia following induction with agents other than SUPRANE (desflurane) and subsequent endotracheal intubation in pediatric patients.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452055240.0,"<blockquote class=""blockquote"">
<p><strong>SUPRANE (desflurane) anesthesia is contraindicated in subjects known to be susceptible to MH.</strong> In susceptible individuals, SUPRANE (desflurane) anesthesia may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia. [...] Fatal outcome of malignant hyperthermia has been reported with desflurane.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166129448,Annotation of EMA Label for ibrutinib,False,True,[],False,"[{'id': 1452550500, 'date': '2024-08-07T13:35:26.552-07:00', 'description': 'updated label, removed Testing Required PGx level', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102947, 'title': 'Imbruvica | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica', 'crossReferences': [{'id': 1450806459, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA36679', 'symbol': 'TP53', 'name': 'tumor protein p53'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166121346', 'name': 'ibrutinib'}]",[],EMA,1447982411.0,"<p>The EMA European Public Assessment Report (EPAR) for ibrutinib (IMBRUVICA) states that is indicated as a single or combination therapy for the treatment of adult patients with refractory mantle cell lymphoma, chronic lymphocytic leukemia, or Waldenström’s macroglobulinaemia.</p>
<p>Patients with 17p or 11q deletions are mentioned in the context of clinical trials.</p>
",1447982410.0,"<p>Excerpts from the ibrutinib (IMBRUVICA) drug label:</p>
<blockquote class=""blockquote"">
<p>IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Ibrutinib_2024_08_07_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ibrutinib_2024_08_07_EMA.pdf"">ibrutinib EPAR</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166127631,Annotation of HCSC Label for aripiprazole and CYP2D6,True,False,[],True,"[{'id': 1452603841, 'date': '2024-09-20T13:48:26.132-07:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}, {'id': 1453083201, 'date': '2025-03-28T11:16:27.659-07:00', 'description': 'added ABILIFY MAINTENA and ABILIFY ASIMTUFII label, annotation, Alternate Drug and Dosing Info tags', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15177022, 'title': 'Drugs@HCSC: Drug Product ABILIFY MAINTENA and ABILIFY ASIMTUFII (aripiprazole), Otsuka Pharmaceutical Co., Ltd.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104340', 'crossReferences': [{'id': 1453083180, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104340', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104340'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15166062, 'title': 'Drugs@HCSC: Drug Product Aripiprazole, Sivem Pharmaceuticals ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102326', 'crossReferences': [{'id': 1452603820, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102326', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102326'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA10026', 'name': 'aripiprazole'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982301.0,"<p>The product monograph for oral aripiprazole notes that CYP2D6 poor metabolizers have approximately an 80% increase in aripiprazole exposure and approximately a 30% decrease in exposure to the active metabolite compared to CYP2D6 extensive metabolizers (EMs), resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs.</p>
<p>The product monograph for the aripiprazole long-acting injectable formulations ABILIFY MAINTENA and ABILIFY ASIMTUFII provides guidance for patients who are CYP2D6 poor metabolizers (PMs). CYP2D6 PMs taking ABILIFY MAINTENA should have their dose reduced to 300 mg from the recommended dose of 400 mg; ABILIFY ASIMTUFII is contraindicated in CYP2D6 PMs.</p>
",1447982300.0,"<p>Aripiprazole is indicated for treatment of schizophrenia and related psychotic disorders and is available in oral and prolonged release injectable (ABILIFY MAINTENA and ABILIFY ASIMTUFII) formulations.</p>
<p>Excerpts from the oral aripiprazole product monograph:</p>
<blockquote class=""blockquote"">
<p>CYP2D6 poor metabolizers: Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM). CYP2D6 metabolizing capacity should be considered when aripiprazole is co-administered with drugs that inhibit CYP2D6 (see DRUG INTERACTIONS, Drug-Drug Interactions).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Aripiprazole is metabolized primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalyzed by CYP3A4. Aripiprazole is the predominant drug moiety in the systemic circulation. At steady state, dehydro-aripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma.
Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM). PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs. Co-administration of aripiprazole with known inhibitors of CYP2D6, like quinidine in EMs, results in a 112% increase in aripiprazole plasma exposure, and dose adjustment is needed (see DRUG INTERACTIONS, Drug-Drug Interactions). The mean elimination half-life for aripiprazole is about 75 hours in EMs and 146 hours in PMs. Aripiprazole does not inhibit or induce the CYP2D6 pathway.</p>
</blockquote>
<p>Excerpts from the prolonged release injectable aripiprazole (ABILIFY MAINTENA and ABILIFY ASIMTUFII) product monograph:</p>
<blockquote class=""blockquote"">
<p>Dosage reductions are recommended in patients who are known CYP2D6 poor metabolizers [...]</p>
</blockquote>
<blockquote class=""blockquote"">
<p>ABILIFY ASIMTUFII is contraindicated in patients who are known CYP2D6 poor metabolizers</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Aripiprazole_2024_09_20_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Aripiprazole_2024_09_20_HCSC.pdf"">oral aripiprazole product monograph</a> and the <a download=""Aripiprazole_AbilifyMaintenaAsimtufii_2025_03_28_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Aripiprazole_AbilifyMaintenaAsimtufii_2025_03_28_HCSC.pdf"">prolonged release injectable aripiprazole product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452603840.0,"<blockquote class=""blockquote"">
<p>ARIPIPRAZOLE is indicated for the treatment of schizophrenia in adolescents 15 to 17 years of age.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>ARIPIPRAZOLE is indicated for the acute treatment of manic or mixed episodes in bipolar I disorder as monotherapy in adolescent patients 13 to 17 years of age.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The safety and efficacy of ABILIFY MAINTENA and ABILIFY ASIMTUFII have not been established in patients under 18 years of age and their use in this population is not recommended.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1453083200.0,"<p>Excerpts from the aripiprazole (ABILIFY MAINTENA and ABILIFY ASIMTUFII) product monograph:</p>
<blockquote class=""blockquote"">
<p>ABILIFY ASIMTUFII is contraindicated in patients who are known CYP2D6 poor metabolizers.</p>
</blockquote>
<p>Dose Adjustments of ABILIFY MAINTENA (Table 1):</p>
<table class=""table"">
<thead>
<tr>
<th></th>
<th>Adjusted Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Known CYP2D6 Poor Metabolizers</td>
<td>One injection start: 300 mg as starting and maintenance dose; Two injection start: 2 separate injections of 300 mg at initiation; Maintenance dose: 300 mg</td>
</tr>
<tr>
<td>Known CYP2D6 Poor Metabolizers taking strong concomitant CYP3A4 inhibitors</td>
<td>One injection start: 200 mg as starting and maintenance dose; Do not use two injection start</td>
</tr>
</tbody>
</table>
<p>Dose Adjustments of ABILIFY ASIMTUFII (Table 3):</p>
<table class=""table"">
<thead>
<tr>
<th></th>
<th>Adjusted Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Known CYP2D6 Poor Metabolizers</td>
<td>ABILIFY ASIMTUFII should not be used in known CYP2D6 Poor Metabolizers (see 2 CONTRAINDICATIONS).</td>
</tr>
<tr>
<td>Known CYP2D6 Poor Metabolizers taking concomitant CYP3A4 inhibitors</td>
<td>Avoid use</td>
</tr>
</tbody>
</table>
",,,,,,,
Label Annotation,PA166123418,Annotation of EMA Label for posaconazole and CYP3A4,False,False,[],False,"[{'id': 1184754505, 'date': '2014-09-16T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933207, 'date': '2019-12-04T13:25:25.406-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452214560, 'date': '2023-08-23T16:45:04.168-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103651, 'title': 'Noxafil | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/noxafil', 'crossReferences': [{'id': 1450932883, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/noxafil', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/noxafil'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA151958574', 'name': 'posaconazole'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447982199.0,"<p>The EMA European Public Assessment Report (EPAR) for posaconazole (Noxafil) does not contain pharmacogenetic information. It contains information regarding metabolism drug-drug interactions with CYP3A4 substrates.</p>
",1447982198.0,"<p>The EMA-approved drug posaconazole is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/posaconazole_EMA_EPAR_Aug_6_2014_1.pdf"">posaconazole EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166123419,Annotation of EMA Label for indinavir and CYP3A4,False,False,[],False,"[{'id': 1184754508, 'date': '2014-09-16T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933199, 'date': '2019-12-04T13:20:07.477-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452209900, 'date': '2023-08-18T10:51:31.634-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103644, 'title': 'Crixivan | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/crixivan', 'crossReferences': [{'id': 1450932875, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/crixivan', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/crixivan'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449977', 'name': 'indinavir'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447982201.0,"<p>The EMA European Public Assessment Report (EPAR) for indinavir (Crixivan) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and contraindicates concomitant use of drugs that are CYP3A4 substrates.</p>
",1447982200.0,"<p>The EMA-approved drug indinavir is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/indinavir_EMA_EPAR_Aug_6_2014_1.pdf"">indinavir EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166123409,Annotation of EMA Label for aliskiren and ABCB1,False,False,[],False,"[{'id': 1184754373, 'date': '2014-09-15T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933187, 'date': '2019-12-04T13:13:52.026-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452205922, 'date': '2023-08-14T06:11:25.563-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452782300, 'date': '2024-12-12T15:15:25.625-08:00', 'description': 'retired label annotation; marketing authorization for the drug was withdrawn', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103631, 'title': 'Rasilez HCT | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez-hct', 'crossReferences': [{'id': 1450932862, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez-hct', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez-hct'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA143487910', 'name': 'aliskiren'}]","[{'objCls': 'Gene', 'id': 'PA267', 'symbol': 'ABCB1', 'name': 'ATP binding cassette subfamily B member 1'}]",EMA,1447982181.0,"<p>The EMA European Public Assessment Report (EPAR) for aliskiren (Rasilez HCT) does not contain pharmacogenetic information. It contains information regarding the role of ABCB1 (P-gp, MDR1) in intestinal absorption and biliary secretion of aliskiren, and concomitant use of aliskiren with potent P-gp inhibitors is contraindicated.</p>
<p><strong>As of December 12, 2024, the EMA website shows the following note: &quot;The marketing authorisation for Rasilez HCT has been withdrawn at the request of the marketing-authorisation holder.&quot;</strong></p>
",1447982180.0,"<p>Excerpt from the aliskiren (Rasilez HCT) EPAR:</p>
<blockquote class=""blockquote"">
<p><em>P-glycoprotein interactions:</em> MDR1/Mdr1a/1b (P-gp) was found to be the major efflux system involved in intestinal absorption and biliary excretion of aliskiren in preclinical studies. Rifampicin, which is an inducer of P-gp, reduced aliskiren bioavailability by approximately 50% in a clinical study. Other inducers of P-gp (St. John’s wort) might decrease the bioavailability of aliskiren. Although this has not been investigated for aliskiren, it is known that P-gp also controls tissue uptake of a variety of substrates and P-gp inhibitors can increase the tissue-to-plasma concentration ratios. Therefore, P-gp inhibitors may increase tissue levels more than plasma levels. The potential for drug interactions at the P-gp site will likely depend on the degree of inhibition of this transporter.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""aliskiren_EMA_EPAR_Aug_6_2014.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/aliskiren_EMA_EPAR_Aug_6_2014.pdf"">aliskiren EMA drug label</a>.</p>
<p><strong>As of December 12, 2024, the EMA website shows the following note: &quot;The marketing authorisation for Rasilez HCT has been withdrawn at the request of the marketing-authorisation holder.&quot;</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,1451259820.0,Retirement Reason,[],Withdrawal,retirement:1451259820,True,
Label Annotation,PA166127675,Annotation of HCSC Label for galantamine and CYP2D6,False,False,[],False,"[{'id': 1452209421, 'date': '2023-08-17T00:00:00-07:00', 'description': 'removed prescribing info', 'type': 'Update', 'version': 0}, {'id': 1452723560, 'date': '2024-12-03T14:50:17.142-08:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171502, 'title': 'Drugs@HCSC: Drug Product GALANTAMINE ER (galantamine), SANIS HEALTH INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92757', 'crossReferences': [{'id': 1452723540, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92757', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92757'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449726', 'name': 'galantamine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982283.0,"<p>The product monograph for galantamine notes that CYP2D6 poor metabolizers have decreased clearance and increased AUC of galantamine as compared to extensive metabolizers. However, it also states that dosage adjustment based on CYP2D6 genotype is not necessary since the drug is individually titrated to tolerability.</p>
",1447982282.0,"<p>Galantamine is indicated for treatment of Alzheimer's disease. Excerpts from the galantamine product monograph:</p>
<blockquote class=""blockquote"">
<p>Based on <em>in vitro</em> studies, CYP2D6 and CYP3A4 were the major enzymes involved in the metabolism of galantamine. CYP2D6 was involved in the formation of O-desmethyl-galantamine, whereas CYP3A4 mediated the formation of galantamine-N-oxide.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>O-demethylation, mediated by CYP2D6 is greater in extensive metabolizers of CYP2D6 than in poor metabolizers. In plasma from both poor and extensive metabolizers, however, unchanged galantamine and its glucuronide accounted for most of the sample radioactivity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>CYP2D6 Poor Metabolizers:</strong> Approximately 7% of the normal population has a genetic variation that leads to reduced levels of activity of the CYP2D6 isozyme. Such individuals have been referred to as poor metabolizers. After a single oral dose of 4 mg or 8 mg galantamine, CYP2D6 poor metabolizers demonstrated a similar Cmax and about 35% AUC∞ increase of unchanged galantamine compared to extensive metabolizers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A total of 356 patients with Alzheimer’s disease enrolled in two Phase III studies were genotyped with respect to CYP2D6 (n=210 hetero-extensive metabolizers, 126 homo-extensive metabolizers, and 20 poor metabolizers). Population pharmacokinetic analysis indicated that there was a 25% decrease in median clearance in poor metabolizers compared to extensive metabolizers. Dosage adjustment is not necessary in patients identified as poor metabolizers as the dose of drug is individually titrated to tolerability due to observed inter-patient variability.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Galantamine_2024_12_02_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Galantamine_2024_12_02_HCSC.pdf"">galantamine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166127657,Annotation of HCSC Label for dapsone and G6PD,False,False,[],False,"[{'id': 1452532522, 'date': '2024-07-19T16:12:23.098-07:00', 'description': 'updated label, changed level to Informative', 'type': 'Update', 'version': 0}, {'id': 1452716481, 'date': '2024-11-26T14:38:57.062-08:00', 'description': 'added dapsone tablet label, changed PGx level to Actionable/Other Guidance', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161142, 'title': 'Drugs@HCSC: Drug Product ACZONE (dapsone), Bausch Health, Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76674', 'crossReferences': [{'id': 1452532520, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76674', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76674'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15171062, 'title': 'Drugs@HCSC: Drug Product MAR-DAPSONE (dapsone tablets), Marcan Pharmaceuticals Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97168', 'crossReferences': [{'id': 1452716460, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97168', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97168'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,True,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449211', 'name': 'dapsone'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982415.0,"<p>Dapsone is available in an oral and a topical formulation. Dapsone tablets are indicated for the treatment of Leprosy, Dermatitis herpetiformis, and actinomycotic mycetoma. Dapsone gel (ACZONE) is indicated for the topical treatment of acne vulgaris.</p>
<p>The product monograph for dapsone tablets states that oral dapsone treatment can result in hemolytic anemia in patients who are glucose-6-phosphate dehydrogenase (G6PD)-deficient. Dapsone should be used with caution in these patients, and routine hematological analyses should be carried out. However, for the topical formulation of the drug, a study showed no clinically relevant cases of hemolysis or anemia in G6PD-deficient individuals.</p>
",1447982414.0,"<p>Excerpts from the oral dapsone (MAR-DAPSONE) product monograph:</p>
<blockquote class=""blockquote"">
<p>Mar-Dapsone should be used with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, cardiac, pulmonary, hepatic or renal disease. Routine
hematologic analyses should be carried out during long-term therapy with sulfones, because of the danger of hemolytic anemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The risk of methemoglobinemia and the hemolytic effect of sulfones such as dapsone may be exaggerated in glucose-6-phosphate dehydrogenase deficient individuals.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Varying degrees of dose-related hemolysis and methemoglobinemia may occur during treatment at therapeutic doses, but individuals with glucose-6-phosphate-dehydrogenase deficiency may be affected by dosages above 50 mg daily.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Dapsone_2024_11_26_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dapsone_2024_11_26_HCSC.pdf"">dapsone tablets product monograph</a>.</p>
<p>Excerpts from the topical dapsone (ACZONE) product monograph:</p>
<blockquote class=""blockquote"">
<p>Oral dapsone treatment has produced dose-related hemolysis and hemolytic anemia. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are more prone to hemolysis with the use of certain drugs. G6PD deficiency is most prevalent in populations of African, South Asian, Middle Eastern and Mediterranean ancestry. A sex-linked trait, G6PD deficiency is more common in males but does occur in females. G6PD-deficient persons are more sensitive to oxidative stress, and therefore may have a history of hematological abnormalities following drug exposure, infection, or a history of favism.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In patients treated with ACZONE, including patients who were G6PD deficient, there was no evidence of clinically relevant hemolysis or anemia. A randomized, double-blind, vehicle-controlled, cross-over clinical study was conducted in G6PD-deficient patients with acne vulgaris to evaluate the risk of hemolysis and/or hemolytic anemia with ACZONE treatment. In this study 56 safety-evaluable patients showed no evidence of clinically relevant hemolysis or anemia. Some subjects with G6PD deficiency using ACZONE developed laboratory changes suggestive of mild hemolysis. For further details on this study refer to the CLINICAL TRIALS section.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Dapsone_2024_07_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dapsone_2024_07_19_HCSC.pdf"">topical dapsone product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452532521.0,"<blockquote class=""blockquote"">
<p>ACZONE was studied in 578 12-15-year-old patients, demonstrating a similar safety and efficacy profile to the adult acne vulgaris patient population. ACZONE was not studied in patients less than 12 years of age thus ACZONE is not recommended for use in this age group.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452716480.0,"<blockquote class=""blockquote"">
<p>Mar-Dapsone should be used with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, cardiac, pulmonary, hepatic or renal disease. Routine
hematologic analyses should be carried out during long-term therapy with sulfones, because of the danger of hemolytic anemia.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127674,Annotation of HCSC Label for fluorouracil and DPYD,True,False,[],False,"[{'id': 1452454641, 'date': '2024-04-25T12:10:19.438-07:00', 'description': 'Increased the genetic testing level to ""testing recommended""; replaced the fluorouracil injection drug label with a newer label that contains more PGx information and added the topical fluorouracil label.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15157183, 'title': 'Drugs@HCSC: Drug Product fluorouracil cream (EFUDEX)', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2138', 'crossReferences': [{'id': 1452454820, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2138', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2138'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15157182, 'title': 'Drugs@HCSC: Drug Product fluorouracil injection', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96756', 'crossReferences': [{'id': 1452454840, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96756', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96756'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA128406956', 'name': 'fluorouracil'}]","[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",HCSC,1447982321.0,"<p>Fluorouracil injection is contraindicated in patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity. Testing for DPD deficiency should be considered prior to treatment, based on local availability and current guidelines.</p>
<p>Fluorouracil is available as both an injection and a topical cream. These two formulations have different indications. Both HCSC-approved labels contain information about the potential for severe toxicity in patients with DPD deficiency.</p>
",1447982320.0,"<p>Excerpt from the fluorouracil injection product monograph:</p>
<blockquote class=""blockquote"">
<p>FLUOROURACIL INJECTION is contraindicated in patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity. Testing for DPD deficiency should be considered prior to treatment, based on local availability and current guidelines (see WARNINGS and PRECAUTIONS, Laboratory Tests).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Severe toxicity (e.g., stomatitis, diarrhea, neutropenia, and neurotoxicity) associated with fluorouracil has been attributed to a deficiency of dihydropyrimidine dehydrogenase (DPD) activity. Fatal outcome has been reported in some cases. Absence of this catabolic enzyme appears to result in prolonged clearance of fluorouracil. Special attention should be given to DPD status when evaluating patients experiencing fluorouracil-related toxicities. No dose has been proven safe for patients with complete absence of DPD activity.</p>
</blockquote>
<p>Excerpt from the topical fluorouracil product monograph:</p>
<blockquote class=""blockquote"">
<p>The enzyme dihydropyrimidine dehydrogenase (DPD) plays an important role in the breakdown of fluorouracil. Inhibition, deficiency or decreased activity of this enzyme can result in accumulation of fluorouracil. EFUDEX must not be used on patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Life-threatening systemic toxicity has been reported with the topical use of fluorouracil a patient with DPD deficiency. Signs of fluorouracil toxicity may include nausea, vomiting, diarrhea, stomatitis, esophagopharyngitis, gastrointestinal ulceration and bleeding, hemorrhage from any site and bone marrow depression (thrombocytopenia and agranulocytosis). If toxicity is observed or suspected, immediately stop treatment, wash treated area with warm water and seek medical attention immediately.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""fluorouracil_injection_2024_04_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/fluorouracil_injection_2024_04_19_HCSC.pdf"">fluorouracil injection product monograph</a> and the <a download=""fluorouracil_topical_2024_04_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/fluorouracil_topical_2024_04_19_HCSC.pdf"">topical fluorouracil product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1452454640.0,"<p>Excerpt from the fluorouracil injection product monograph:</p>
<blockquote class=""blockquote"">
<p>FLUOROURACIL INJECTION is contraindicated in patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity. Testing for DPD deficiency should be considered prior to treatment, based on local availability and current guidelines (see WARNINGS and PRECAUTIONS, Laboratory Tests).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Special attention should be given to DPD status when evaluating patients experiencing fluorouracil-related toxicities. No dose has been proven safe for patients with complete absence of DPD activity.</p>
</blockquote>
<p>Excerpt from the topical fluorouracil product monograph:</p>
<blockquote class=""blockquote"">
<p>EFUDEX is contraindicated in patients with known dihydropyridine dehydrogenase (DPD) enzyme deficiency (see 7 WARNINGS AND PRECAUTIONS).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127628,"Annotation of HCSC Label for acetaminophen, tramadol and CYP2D6",False,False,[],False,"[{'id': 1452530500, 'date': '2024-07-18T10:17:48.171-07:00', 'description': 'updated label, annotation', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160782, 'title': 'Drugs@HCSC: Drug Product AURO-TRAMADOL/ACETAMINOPHEN (tramadol hydrochloride and acetaminophen), Auro Pharma Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92342', 'crossReferences': [{'id': 1452530480, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92342', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92342'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448015', 'name': 'acetaminophen'}, {'objCls': 'Chemical', 'id': 'PA451735', 'name': 'tramadol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982293.0,"<p>The product monograph for tramadol and acetaminophen (AURO-TRAMADOL/ACETAMINOPHEN) notes that patients who are CYP2D6 ultrarapid metabolizers convert tramadol more rapidly into its more potent opioid metabolite O-desmethyltramadol, which could result in higher than expected opioid-like side effects including life-threatening or fatal respiratory depression or signs of overdose.</p>
",1447982292.0,"<p>Excerpts from the tramadol and acetaminophen (AURO-TRAMADOL/ACETAMINOPHEN) product monograph:</p>
<blockquote class=""blockquote"">
<p>Tramadol is converted to the active M1 metabolite by CYP2D6, hence its safety and efficacy is controlled by CYP2D6 activity, which has a high degree of variability in humans (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Race). Levels of CYP2D6 activity have been associated with outcomes from tramadol administration that range from an absence of effect to responses with the potential of serious medical consequences (see WARNINGS AND PRECAUTIONS, Respiratory and DRUG INTERACTIONS, Overview).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Some individuals may be CYP2D6 ultra-rapid metabolizers. These individuals convert tramadol more rapidly than other people into its more potent opioid metabolite O-desmethyltramadol (M1). Even at labelled dosage regimens, this rapid conversion could result in higher than expected opioid-like side effects including life- threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing) (see OVERDOSAGE, Symptoms: Tramadol; WARNINGS AND PRECAUTIONS, Special Populations, Labour, Delivery and Nursing Women; DRUG INTERACTIONS, Overview). The prevalence of this CYP2D6 phenotype varies widely in the population (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Race).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Tramadol is subject to the same polymorphic metabolism as codeine, with ultra-rapid metabolizers of CYP2D6 substrates being potentially exposed to life-threatening levels of O-desmethyltramadol (M1). At least one death was reported in a breast-feeding infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine. A baby breast-feeding from an ultra-rapid metabolizer mother taking AURO-TRAMADOL/ACETAMINOPHEN could potentially be exposed to high levels of M1, and experience life-threatening respiratory depression. Therefore, maternal use of tramadol can lead to serious adverse reactions, including death in nursing infants (see WARNINGS AND PRECAUTIONS, Respiratory).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Following oral administration, tramadol is extensively metabolized by a number of pathways, including CYP2D6 and CYP3A4, as well as by conjugation of parent and metabolites. [...] Patients who are CYP2D6 ultra-rapid metabolizers convert tramadol to its active metabolite (M1) more rapidly and completely than other patients.
Conversely, some patients are CYP2D6 poor metabolizers of tramadol, or other drugs (e.g., debrisoquine, dextromethorphan, and tricyclic antidepressants) (see Special Populations and Conditions, Race). Based on a population PK analysis of Phase I studies in healthy subjects, concentrations of tramadol were approximately 20% higher in “CYP2D6 poor metabolizers” versus “extensive CYP2D6 metabolizers”, while M1 concentrations were 40% lower.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Some patients are CYP2D6 ultra-rapid metabolizers of tramadol due to a specific genotype. These individuals convert tramadol into its active metabolite, M1, more rapidly and completely than other people leading to higher-than-expected serum M1 levels. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese, Japanese and Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups (see WARNINGS AND PRECAUTIONS, Respiratory and Special Populations, Labor, De livery and Nursing Women). In contrast, some patients exhibit the CYP2D6 poor metabolizer phenotype and do not convert tramadol to the active M1 metabolite sufficiently to benefit from the analgesic effect of the drug (see DRUG INTERACTIONS, Overview). The prevalence of this CYP2D6 phenotype is about 5-10 percent in Caucasians and 1 percent of Asians.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Tramadol_Acetaminophen_2024_07_18_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Tramadol_Acetaminophen_2024_07_18_HCSC.pdf"">tramadol and acetaminophen product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166127627,Annotation of HCSC Label for abacavir and HLA-B,True,False,[],False,"[{'id': 1452373801, 'date': '2024-02-07T14:47:19.386-08:00', 'description': 'Adding alternate drug guidance to this annotation', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15157442, 'title': 'Drugs@HCSC: Drug Product ZIAGEN (abacavir sulfate), ViiV Healthcare ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63900', 'crossReferences': [{'id': 1452458220, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63900', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63900'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165987830', 'symbol': 'HLA-B*57:01', 'name': '*57:01'}]","[{'objCls': 'Chemical', 'id': 'PA448004', 'name': 'abacavir'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",HCSC,1447982387.0,"<p>The product monograph for abacavir (ZIAGEN) states that all patients should be screened for the HLA-B*5701 allele prior to initiating or re-initiating treatment with abacavir, due to the high risk of experiencing a hypersensitivity reaction (HSR) for patients carrying this allele.</p>
",1447982386.0,"<p>Abacavir (ZIAGEN) is used as part of antiretroviral combination therapy to treat human immunodeficiency virus (HIV) infection. Excerpts from the abacavir (ZIAGEN) product monograph:</p>
<blockquote class=""blockquote"">
<p>The risk for abacavir HSR to occur is significantly increased for patients who test positive for the HLA-B*5701 allele. However, abacavir HSRs have been reported at a lower frequency in patients who do not carry this allele.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>All patients should be screened for the HLA-B*5701 allele prior to initiating or re-initiating treatment with ZIAGEN. Do not use ZIAGEN in HLA-B*5701-positive patients or in patients with negative HLA-B*5701 status who had a suspected abacavir HSR on a previous abacavir-containing regimen.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Abacavir_03_02_16_HCSC.PDF"">abacavir product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1452373800.0,"<p>Excerpts from the abacavir (ZIAGEN) drug label:</p>
<blockquote class=""blockquote"">
<p>Do not use ZIAGEN in HLA-B*5701-positive patients or in patients with negative HLA-B*5701 status who had a suspected abacavir HSR on a previous abacavir-containing regimen.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127659,Annotation of HCSC Label for darifenacin and CYP2D6,False,False,[],False,"[{'id': 1452721581, 'date': '2024-12-02T11:52:47.366-08:00', 'description': 'updated label, changed PGx level to No Clinical PGx', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171382, 'title': 'Drugs@HCSC: Drug Product ENABLEX (darifenacin), Searchlight Pharma Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75871', 'crossReferences': [{'id': 1452721580, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75871', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75871'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164774901', 'name': 'darifenacin'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982455.0,"<p>The product monograph for darifenacin notes that CYP2D6 poor metabolizers may have higher levels of the drug as compared to extensive metabolizers. However, it also notes that there are no special dosing requirements for poor metabolizers.</p>
",1447982454.0,"<p>Darifenacin (ENABLEX) is indicated for the treatment of overactive bladder. Excerpt from the darifenacin product monograph:</p>
<blockquote class=""blockquote"">
<p>Darifenacin is extensively metabolized by the liver following oral dosing. Metabolism is mediated by cytochrome P450 enzymes CYP 2D6 and CYP 3A4. The three main metabolic routes are as follows: (i) monohydroxylation in the dihydrobenzofuran ring; (ii) dihydrobenzofuran ring opening; (iii) N-dealkylation of the pyrrolidine nitrogen.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Variability in metabolism: A subset of individuals are devoid of CYP 2D6 enzyme activity (i.e. approximately 7% of the Caucasian population). Therefore, the metabolism of darifenacin in these poor metabolizers (PMs) will be principally mediated via CYP 3A4. The darifenacin ratios (poor metabolizers: extensive metabolizers) for Cmax and AUC following darifenacin 15 mg once-daily at steady state were 1.9 and 1.7, respectively.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Population pharmacokinetic analyses of Phase 3 data indicated that on average PMs have 55% higher steady-state exposure than EMs. However, there is considerable overlap between the ranges of exposures seen in EM and PM populations and clinical experience confirms that there are no special dosing requirements for PMs.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Estimated darifenacin clearance is 40 L/h (11.1 mL/s) for EMs and 32 L/h (8.9 mL/s) for PMs.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Darifenacin_2024_12_02_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Darifenacin_2024_12_02_HCSC.pdf"">darifenacin product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166127661,Annotation of HCSC Label for dexlansoprazole and CYP2C19,False,False,[],False,"[{'id': 1452721702, 'date': '2024-12-02T13:20:27.199-08:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171402, 'title': 'Drugs@HCSC: Drug Product DEXILANT (dexlansoprazole), Takeda Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84014', 'crossReferences': [{'id': 1452721700, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84014', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84014'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166110257', 'name': 'dexlansoprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1447982421.0,"<p>The product monograph for dexlansoprazole (DEXILANT) notes that CYP2C19 intermediate and poor metabolizers generally have higher exposure to the drug as compared to extensive metabolizers.</p>
",1447982420.0,"<p>Excerpts from the dexlansoprazole (DEXILANT) product monograph:</p>
<blockquote class=""blockquote"">
<p>Dexlansoprazole is extensively metabolized in the liver by oxidation, reduction, and subsequent formation of sulfate, glucuronide and glutathione conjugates to inactive metabolites. Oxidative metabolites are formed by the cytochrome P450 (CYP) enzyme system including hydroxylation mainly by CYP2C19, and oxidation to the sulfone by CYP3A4.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C19 is a polymorphic liver enzyme which exhibits three phenotypes in the metabolism of CYP2C19 substrates; extensive metabolizers (*1/*1), intermediate metabolizers (*1/mutant) and poor metabolizers (mutant/mutant). Systemic exposure of dexlansoprazole is generally higher in intermediate and poor metabolizers. Dexlansoprazole is the major circulating component in plasma, regardless of CYP2C19 metabolizer status. In CYP2C19 intermediate and extensive metabolizers, the major plasma metabolites are 5-hydroxy dexlansoprazole and its glucuronide conjugate, while in CYP2C19 poor metabolizers dexlansoprazole sulfone is the major plasma metabolite.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Dexlansoprazole_2024_12_02_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dexlansoprazole_2024_12_02_HCSC.pdf"">dexlansoprazole product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452721701.0,"<blockquote class=""blockquote"">
<p>Based on the data submitted and reviewed by Health Canada, the safety and efficacy of DEXILANT in pediatric patients aged 12 to 17 years has been established. Therefore, Health Canada has authorized all indications for pediatric use in this age group.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166127717,Annotation of HCSC Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD,False,False,[],False,"[{'id': 1452538260, 'date': '2024-07-25T00:01:03.641-07:00', 'description': 'Retired annotation as the drug is listed as discontinued on HCSC', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161902, 'title': 'Drugs@HCSC: Drug Product Pediazole (erythromycin ethylsuccinate / sulfisoxazole acetyl), Amdipharm Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5294', 'crossReferences': [{'id': 1452538240, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5294', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5294'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166176008', 'name': 'erythromycin ethylsuccinate / sulfisoxazole acetyl'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982273.0,"<p>The product monograph for erythromycin and sulfisoxazole states that it is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, due to the risk for hemolysis. However, the monograph does not discuss testing for G6PD deficiency prior to treatment.</p>
<p><strong>Please note that as of July 2024, erythromycin and sulfisoxazole is listed as discontinued on the HCSC database. As a result, this label annotation has been retired.</strong></p>
",1447982272.0,"<p>Erythromycin and sulfisoxazole (PEDIAZOLE) is indicated for treatment of children with acute otitis media caused by strains of <em>Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes</em> or <em>Branhamella catarrhalis</em> susceptible to this combination. Excerpts from the erythromycin and sulfisoxazole product monograph:</p>
<blockquote class=""blockquote"">
<p>PEDIAZOLE(R) (erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension USP) is contraindicated in:</p>
<ul>
<li>Uremic patients, and patients with a deficiency of erythrocytic glucose-6-phosphate dehydrogenase (G-6-PD).</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Hemolysis may occur in glucose-6-phosphate dehydrogenase deficient individuals.</p>
</blockquote>
<p><strong>Please note that as of July 2024, erythromycin and sulfisoxazole is listed as discontinued on the HCSC database. As a result, this label annotation has been retired.</strong></p>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Erythromycin_and_sulfisoxazole_HCSC_06_05_15.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Erythromycin_and_sulfisoxazole_HCSC_06_05_15.pdf"">erythromycin and sulfisoxazole product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,1451259820.0,Retirement Reason,[],Withdrawal,retirement:1451259820,True,
Label Annotation,PA166127653,Annotation of HCSC Label for clopidogrel and CYP2C19,True,False,[],False,"[{'id': 1452529801, 'date': '2024-07-17T00:00:00-07:00', 'description': 'updated label, added Prescribing info, variants', 'type': 'Update', 'version': 1}]",False,[],True,"[{'id': 15160722, 'title': 'Drugs@HCSC: Drug Product PLAVIX (clopidogrel), sanofi-aventis Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62114', 'crossReferences': [{'id': 1452529600, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62114', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62114'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]","[{'objCls': 'Haplotype', 'id': 'PA165980635', 'symbol': 'CYP2C19*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165980636', 'symbol': 'CYP2C19*3', 'name': '*3'}, {'objCls': 'Haplotype', 'id': 'PA165980637', 'symbol': 'CYP2C19*4', 'name': '*4'}, {'objCls': 'Haplotype', 'id': 'PA165980638', 'symbol': 'CYP2C19*5', 'name': '*5'}, {'objCls': 'Haplotype', 'id': 'PA165816522', 'symbol': 'CYP2C19*6', 'name': '*6'}, {'objCls': 'Haplotype', 'id': 'PA165816523', 'symbol': 'CYP2C19*7', 'name': '*7'}, {'objCls': 'Haplotype', 'id': 'PA165816524', 'symbol': 'CYP2C19*8', 'name': '*8'}]","[{'objCls': 'Chemical', 'id': 'PA449053', 'name': 'clopidogrel'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1447982419.0,"<p>The product monograph for clopidogrel (PLAVIX) states that CYP2C19 poor metabolizers may be at increased risk for experiencing cardiovascular events when taking the drug at recommended doses as compared to normal CYP2C19 metabolizers, and that an alternative treatment or treatment strategies should be considered in these patients.</p>
",1447982418.0,"<p>Excerpts from the clopidogrel (PLAVIX) product monograph:</p>
<blockquote class=""blockquote"">
<p>PLAVIX is a pro-drug, which requires metabolism by the hepatic cytochrome CYP2C19 to form the active thiol metabolite. The function of this enzyme can be compromised, either through direct drug inhibition or dysfunctional genetic variants that lower enzyme activity, thus the effectiveness of PLAVIX could diminish correspondingly.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C19 poor metaboliser status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen in poor metaboliser healthy subjects increases antiplatelet response, an appropriate dose regimen for this patient population has not been established in clinical outcome trials (see 10 CLINICAL PHARMACOLOGY).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In patients who are CYP2C19 poor metabolisers, PLAVIX at recommended doses forms less of the active metabolite of clopidogrel and has a smaller effect on platelet function. Poor metabolisers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with PLAVIX at recommended doses may exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolisers (see 4 DOSAGE AND ADMINISTRATION and 10 CLINICAL PHARMACOLOGY).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles are nonfunctional. The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolisers. Other alleles associated with absent or reduced metabolism are less frequent and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metaboliser status will possess two loss-of-function alleles as defined above. Published frequencies for the poor CYP2C19 metaboliser genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Clopidogrel_2024_07_15_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Clopidogrel_2024_07_15_HCSC.pdf"">clopidogrel product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452529800.0,"<blockquote class=""blockquote"">
<p>Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolisers (see 4 DOSAGE AND ADMINISTRATION and 10 CLINICAL PHARMACOLOGY).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127667,Annotation of HCSC Label for efavirenz / emtricitabine / tenofovir disoproxil and CYP2B6,False,False,[],False,"[{'id': 1452721801, 'date': '2024-12-02T13:50:54.481-08:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171422, 'title': 'Drugs@HCSC: Drug Product JAMP Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate (efavirenz/emtricitabine/tenefovir disoproxil fumarate), JAMP Pharma Corporation', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100873', 'crossReferences': [{'id': 1452721800, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100873', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100873'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165818762', 'symbol': 'CYP2B6*6', 'name': '*6'}, {'objCls': 'Variant', 'id': 'PA166155409', 'symbol': 'rs3745274', 'name': 'rs3745274'}]","[{'objCls': 'Chemical', 'id': 'PA166176033', 'name': 'efavirenz / emtricitabine / tenofovir disoproxil'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}]",HCSC,1447982375.0,"<p>The product monograph for efavirenz, emtricitabine and tenofovir disoproxil fumarate states that patients homozygous for the G516T genetic variant in CYP2B6 may have increased plasma exposure of the drug. However, the effect of this increase on the occurrence of adverse events is unclear.</p>
",1447982374.0,"<p>Excerpts from the efavirenz, emtricitabine and tenofovir disoproxil fumarate product monograph:</p>
<blockquote class=""blockquote"">
<p>In vitro studies suggest CYP3A4 and CYP2B6 are the major isozymes responsible for EFV metabolism.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Efavirenz: The effect of EFV on the QTc interval was evaluated in an open-label, positive and placebo-controlled, fixed single sequence 3-period, 3-treatment crossover QT study in 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean Cmax of EFV in subjects with CYP2B6 *6/*6 genotype following the administration of 600 mg daily dose for 14 days was 2.25-fold the mean Cmax observed in subjects with CYP2B6 *1/*1 genotype. A positive relationship between EFV concentration and QTc prolongation was observed. Based on the concentration-QTc relationship, the mean QTc prolongation and its upper bound 90% confidence interval are 8.7 msec and 11.3 msec, respectively, in subjects with CYP2B6 *6/*6 genotype following the administration of 600 mg daily dose for 14 days (see WARNINGS AND PRECAUTIONS).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Efavirenz plasma exposure may be increased in patients with the homozygous G516T genetic variant of the CYP2B6 isozyme. The clinical implications of such an association are unknown; however, the potential for an increased frequency and severity of EFV-associated adverse events cannot be excluded.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Efavirenz_emtricitabine_tenofovir_2024_12_02_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Efavirenz_emtricitabine_tenofovir_2024_12_02_HCSC.pdf"">efavirenz, emtricitabine and tenofovir disoproxil fumarate product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166127654,Annotation of HCSC Label for codeine and CYP2D6,True,False,[],False,"[{'id': 1452532401, 'date': '2024-07-19T15:31:11.607-07:00', 'description': 'updated label, added Alternate Drug tag, prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161122, 'title': 'Drugs@HCSC: Drug Product codeine, LABORATOIRE RIVA INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16474', 'crossReferences': [{'id': 1452532380, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16474', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16474'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]","[{'objCls': 'Haplotype', 'id': 'PA166228161', 'symbol': 'CYP2D6*2x2', 'name': '*2x2'}]","[{'objCls': 'Chemical', 'id': 'PA449088', 'name': 'codeine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982471.0,"<p>The codeine (CODEINE 15, CODEINE 30) product monograph states that CYP2D6 ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing at normal dosing regimens of codeine. Mothers who are ultra-rapid metabolizers and breast-feeding have higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants.</p>
",1447982470.0,"<p>Codeine is an opioid analgesic pro-drug, typically used for pain relief. It is metabolized by CYP2D6 into morphine, which is the active drug form.</p>
<p>Excerpts from the codeine product monograph:</p>
<blockquote class=""blockquote"">
<p>Risk of Death in Ultra-Rapid Metabolizers of Codeine
Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6*2x2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labelled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. (See Special Populations, Labour, Delivery and Nursing Women).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and inform their patients about these risks and the signs of morphine overdose (see DOSAGE AND ADMINISTRATION, Dosing Considerations).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolisers of codeine (see CONTRAINDICATIONS, Ultra-Rapid Metabolisers of Codeine; and WARNINGS AND PRECAUTIONS, Risk of Death in Ultra-rapid Metabolizers of Codeine). These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breast-fed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death in nursing infants.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Since there is a risk of infant exposure to codeine and morphine through breast milk, CODEINE 15 and CODEINE 30 is contraindicated in breast-feeding. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about any use of codeine during breast-feeding.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Codeine_2024_07_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Codeine_2024_07_19_HCSC.pdf"">codeine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452532400.0,"<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS</p>
</blockquote>
<blockquote class=""blockquote"">
<p>-CYP2D6 ultra-rapid metabolizers who convert codeine into its active metabolite more rapidly and completely than other people (see WARNINGS AND PRECAUTIONS, Risk of Death in Ultra-Rapid Metabolizers of Codeine; and OVERDOSAGE, Symptoms and Treatment)</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Even at labelled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127673,Annotation of HCSC Label for fesoterodine and CYP2D6,False,False,[],False,"[{'id': 1452721901, 'date': '2024-12-02T14:16:33.116-08:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171442, 'title': 'Drugs@HCSC: Drug Product TOVIAZ (fesoterodine), Pfizer Canada ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86587', 'crossReferences': [{'id': 1452721900, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86587', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86587'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958376', 'name': 'fesoterodine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982285.0,"<p>The product monograph for fesoterodine (TOVIAZ) states that CYP2D6 poor metabolizers have increased levels of the active metabolite of the drug as compared to extensive metabolizers.</p>
",1447982284.0,"<p>Excerpts from the fesoterodine (TOVIAZ) product monograph:</p>
<blockquote class=""blockquote"">
<p>After oral administration, fesoterodine is rapidly and extensively hydrolyzed to its active metabolite 5-HMT. The active metabolite is further metabolized in the liver to its carboxy, carboxy-N-desisopropyl, and N-desisopropyl metabolites via two major pathways involving CYP2D6 and CYP3A4. None of these metabolites contribute significantly to the antimuscarinic activity of fesoterodine.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Variability in CYP2D6 Metabolism: A subset of individuals (approximately 7% of Caucasians and approximately 2% of African Americans) are poor metabolizers for CYP2D6. Cmax and AUC of the active metabolite are increased 1.7- and 2-fold, respectively, in CYP2D6 poor metabolizers as compared to extensive metabolizers.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Fesoterodine_2024_12_02_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Fesoterodine_2024_12_02_HCSC.pdf"">fesoterodine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166127677,Annotation of HCSC Label for glyburide and G6PD,True,False,[],False,"[{'id': 1452534882, 'date': '2024-07-22T13:59:29.453-07:00', 'description': 'updated label, added Alt Drug, Other Guidance tag and prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161502, 'title': 'Drugs@HCSC: Drug Product Glyburide, SANIS HEALTH INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83567', 'crossReferences': [{'id': 1452534880, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83567', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83567'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449782', 'name': 'glyburide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982473.0,"<p>Glyburide belongs to a class of drugs known as sulfonylurea agents. The product monograph for glyburide states that caution should be used when administering this drug to patients with G6PD deficiency due to the risk for hemolytic anemia, and that a nonsulfonylurea agent should be considered in these individuals.</p>
",1447982472.0,"<p>Glyburide is indicated for the lowering of blood glucose in adults with type 2 diabetes. Excerpt from the glyburide product monograph:</p>
<blockquote class=""blockquote"">
<p>Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD)-deficiency with sulfonylurea agents can lead to hemolytic anemia. Since GLYBURIDE belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a nonsulfonylurea alternative should be considered.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Glyburide_2024_07_22_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Glyburide_2024_07_22_HCSC.pdf"">glyburide product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452534881.0,"<blockquote class=""blockquote"">
<p>Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD)-deficiency with sulfonylurea agents can lead to hemolytic anemia. Since GLYBURIDE belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a nonsulfonylurea alternative should be considered.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127678,Annotation of HCSC Label for glimepiride and G6PD,True,False,[],False,"[{'id': 1452534961, 'date': '2024-07-22T14:31:42.983-07:00', 'description': 'updated label, added Alt drug, Other guidance tags and prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161522, 'title': 'Drugs@HCSC: Drug Product SANDOZ GLIMEPIRIDE (glimepiride), Sandoz Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75494', 'crossReferences': [{'id': 1452534940, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75494', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75494'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449761', 'name': 'glimepiride'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982475.0,"<p>Glimepiride belongs to a class of drugs known as sulfonylurea agents. The product monograph for glimepiride states that caution should be used when administering this drug to patients with G6PD deficiency due to the risk for hemolytic anemia, and that a nonsulfonylurea agent should be considered in these individuals.</p>
",1447982474.0,"<p>Glimepiride (AMARYL) is indicated for the lowering of blood glucose in patients with type 2 diabetes. Excerpt from the glimepiride (SANDOZ GLIMEPIRIDE) product monograph:</p>
<blockquote class=""blockquote"">
<p>Treatment of patients with G6PD-deficiency with sulfonylurea agents can lead to hemolytic anemia. Since glimepiride belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a nonsulfonylurea alternative should be considered.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Glimepiride_2024_07_22_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Glimepiride_2024_07_22_HCSC.pdf"">glimepiride product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452534960.0,"<blockquote class=""blockquote"">
<p>Treatment of patients with G6PD-deficiency with sulfonylurea agents can lead to hemolytic anemia. Since glimepiride belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a nonsulfonylurea alternative should be considered.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127670,Annotation of HCSC Label for esomeprazole and CYP2C19,False,False,[],False,"[{'id': 1452540261, 'date': '2024-07-26T13:42:00.312-07:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162202, 'title': 'Drugs@HCSC: Drug Product NEXIUM (esomeprazole), AstraZeneca Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68498', 'crossReferences': [{'id': 1452540240, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68498', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68498'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10075', 'name': 'esomeprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1447982325.0,"<p>The product monograph for esomeprazole (NEXIUM) states that CYP2C19 poor metabolizers have increased concentrations of the drug as compared to the rest of the population, but that dosage adjustment based on CYP2C19 genotype is not necessary.</p>
",1447982324.0,"<p>Excerpt from the esomeprazole (NEXIUM) product monograph:</p>
<blockquote class=""blockquote"">
<p>Esomeprazole undergoes first-pass metabolism and is completely metabolized by the cytochrome P-450 system, mainly in the liver via CYP 2C19 (S-mephenytoin hydroxylase) and CYP 3A4. The CYP 2C19 isozyme, which is involved in the metabolism of all available proton pump inhibitors, exhibits polymorphism and is less pronounced for esomeprazole than for omeprazole. Some 3% of Caucasians and 15-20% of Asians lack CYP 2C19 and are termed “poor metabolizers”. At steady state (40 mg for 5 days), the ratio of AUC in poor metabolizers to AUC in the rest of the population is approximately 2. Dosage adjustment of NEXIUM based on CYP 2C19 status is not necessary (see Endocrine and Metabolism, and Genetic Polymorphism).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Esomeprazole_2024_07_26_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Esomeprazole_2024_07_26_HCSC.pdf"">esomeprazole product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452540260.0,"<blockquote class=""blockquote"">
<p><strong>Pediatrics (1-17 years of age):</strong> The use of NEXIUM in pediatric patients for the short term treatment (up to 8 weeks) of GERD is supported by extrapolation of results already included in the currently approved labelling from a) adequate and well-controlled studies in adults that supported the approval of NEXIUM for adults, and additionally from b) safety and pharmacokinetic studies performed in pediatric patients (see 8.2.1 Clinical Trial Adverse Reactions – Pediatrics, 10.3 Pharmacokinetics, and In Pediatrics (1-17 years of age) - Study Results).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>No data is currently available in children (1-11 years of age) with hepatic insufficiency (see 4 DOSAGE AND ADMINISTRATION).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Pediatrics (&lt;1 years of age):</strong> The safety and effectiveness of NEXIUM have not yet been established.</p>
</blockquote>
",1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166127665,Annotation of HCSC Label for divalproex sodium and POLG,True,False,[],False,"[{'id': 1452585006, 'date': '2024-09-10T13:11:52.827-07:00', 'description': 'added Pediatric tag and info, Alternate Drug tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15165282, 'title': 'Drugs@HCSC: Drug Product MYLAN-DIVALPROEX (divalproex sodium), Mylan Pharmaceuticals ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94597', 'crossReferences': [{'id': 1452585040, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94597', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94597'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164783479', 'name': 'divalproex sodium'}]","[{'objCls': 'Gene', 'id': 'PA33500', 'symbol': 'POLG', 'name': 'DNA polymerase gamma, catalytic subunit'}]",HCSC,1447982313.0,"<p>The product monograph for divalproex states that it is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and in children under two years of age who are suspected of having a POLG-related disorder.</p>
",1447982312.0,"<p>Divalproex is indicated for epilepsy, as well as manic episodes associated with bipolar disorder. Excerpts from the divalproex product monograph:</p>
<blockquote class=""blockquote"">
<p>Mylan-divalproex (divalproex sodium) delayed-release tablets is contraindicated: in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG; e.g. Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>There is an increased risk of valproate-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA polymerase gamma (POLG) gene (e.g. Alpers Huttenlocher Syndrome)...POLG mutation screening should be performed in accordance with current clinical practice.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The A467T and W748S mutations are present in approximately 2/3 of patients with autosomal recessive POLG-related disorders.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Divalproex_HCSC_06_01_15.pdf"">divalproex product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452585005.0,"<blockquote class=""blockquote"">
<p>When divalproex sodium is used in children under the age of 2 years, it should be used with extreme caution and as a sole agent. Above the age of 2 years, experience in epilepsy has indicated that the incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups. For a brief discussion, see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics (&lt;18 years of age). The safety and effectiveness of divalproex sodium for the treatment of acute mania has not been studied in individuals below the age of 18 years.</p>
</blockquote>
",1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1452585004.0,"<blockquote class=""blockquote"">
<p>Mylan-divalproex (divalproex sodium) delayed-release tablets is contraindicated: in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG; e.g. Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166129518,"Annotation of HCSC Label for isoflurane and CACNA1S, RYR1",True,False,[],False,"[{'id': 1452055902, 'date': '2023-04-01T21:01:20.902-07:00', 'description': 'updated text', 'type': 'Update', 'version': 0}, {'id': 1452595308, 'date': '2024-09-19T12:08:05.143-07:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15165982, 'title': 'Drugs@HCSC: Drug Product Isoflurane USP (isoflurane), Fresenius Kabi Canada Ltd.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51381', 'crossReferences': [{'id': 1452595306, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51381', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51381'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450106', 'name': 'isoflurane'}]","[{'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",HCSC,1447982431.0,"<p>Isoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.  It is contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia, or with a history of malignant hyperthermia.</p>
",1447982430.0,"<p>The HCSC product monograph warns that individuals with a genetic predisposition to malignant hyperthermia are at an elevated risk of developing malignant hyperthermia, and that patients with Duchenne's Muscular Dystrophy are at an elevated risk of developing hyperkaelemia if administered isoflurane, or other potent inhalational anesthetics.</p>
<p>Specific variants in the <em>RYR1</em> and <em>CACNA1S</em> genes are associated with risk of malignant hyperthermia in individuals administered potent inhalational anesthetics, such as isoflurane. Although the product monograph for isoflurane does not specifically mention genetic testing, it states that isoflurane is contraindicated in individuals with known to have a genetic predisposition to malignant hyperthermia.</p>
<p>Excerpts from the isoflurane product monograph:</p>
<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS: Isoflurane is contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia, or with a history of malignant hyperthermia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In susceptible individuals, ISOFLURANE anesthesia may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""isoflurane_20230402_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/isoflurane_20230402_HCSC.pdf"">isoflurane product monograph</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the HCSC and are the sole responsibility of PharmGKB.</p>
",1452595307.0,"<blockquote class=""blockquote"">
<p><strong>INDICATIONS AND CLINICAL USE</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<p>Isoflurane is indicated for:</p>
<ul>
<li>induction and maintenance of general anesthesia. [...]</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Pediatrics (0 ‒ 16 years of age):</strong>
MAC values for children up to 5 years of age, including those for preterm neonates, are available. Isoflurane MAC decreases with increasing age, except for both term and preterm neonates, measured approximately at 1 month of age. See table in DOSAGE AND ADMINISTRATION.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452055901.0,"<blockquote class=""blockquote"">
<p>Isoflurane is contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia, or with a history of malignant hyperthermia.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166123416,Annotation of EMA Label for ivabradine and CYP3A4,False,False,[],False,"[{'id': 1184754486, 'date': '2014-09-16T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933200, 'date': '2019-12-04T13:20:23.870-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452210080, 'date': '2023-08-18T14:36:59.245-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103645, 'title': 'Corlentor | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/corlentor', 'crossReferences': [{'id': 1450932876, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/corlentor', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/corlentor'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166123415', 'name': 'ivabradine'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447981656.0,"<p>The EMA European Public Assessment Report (EPAR) for ivabradine (Corlentor) does not contain pharmacogenetic information. It contains information regarding metabolism of ivabradine by CYP3A4, and that concomitant use of potent CYP3A4 inhibitors is contraindicated.</p>
",1447981655.0,"<p>The EMA-approved drug ivabradine is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/ivabradine_EMA_EPAR_Aug_6_2014_2.pdf"">ivabradine EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166129447,Annotation of EMA Label for eliglustat and CYP2D6,True,False,[],True,"[{'id': 1454040141, 'date': '2025-04-23T10:58:39.675-07:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102948, 'title': 'Cerdelga | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga', 'crossReferences': [{'id': 1450417062, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166123486', 'name': 'eliglustat'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1447982303.0,"<p>The EMA European Public Assessment Report (EPAR) for eliglustat (Cerdelga) states that it is indicated for adults and paediatric patients older than 6 years and weighing ≥ 15 kg with Gaucher disease type 1. Before initiation of treatment, patients must be genotyped for CYP2D6 to determine the CYP2D6 metabolizer status. Dosing recommendations for CYP2D6 EMs, IMs and PMs are given. The label also notes that eliglustat should not be used in patients who are CYP2D6 ultra-rapid metabolizers or indeterminate metabolizers.</p>
",1447982302.0,"<p>Excerpts from the eliglustat (Cerdelga) EPAR:</p>
<blockquote class=""blockquote"">
<p>Before initiation of treatment with Cerdelga, patients must be genotyped for CYP2D6 to determine the CYP2D6 metaboliser status.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Eliglustat should not be used in patients who are CYP2D6 ultra-rapid metabolisers (URMs) or indeterminate metabolisers (see section 4.4).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Eliglustat is metabolised primarily by CYP2D6 and to a lesser extent by CYP3A4. Concomitant administration of substances affecting CYP2D6 or CYP3A4 activity may alter eliglustat plasma concentrations. Eliglustat is an inhibitor of P-gp and CYP2D6 <em>in vitro</em>; concomitant administration of eliglustat with P-gp or CYP2D6 substrate substances may increase the plasma concentration of those substances.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Eliglustat_2025_04_16_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Eliglustat_2025_04_16_EMA.pdf"">eliglustat EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",1454040140.0,"<blockquote class=""blockquote"">
<p>Cerdelga is indicated for paediatric patients with GD1 who are 6 years and older with a minimum body weight of 15 kg, who are stable on enzyme replacement therapy (ERT), and who are CYP2D6 PMs, IMs or EMs.</p>
</blockquote>
",1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450417061.0,"<blockquote class=""blockquote"">
<p>Before initiation of treatment with Cerdelga, patients must be genotyped for CYP2D6 to determine the CYP2D6 metaboliser status.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Eliglustat should not be used in patients who are CYP2D6 ultra-rapid metabolisers (URMs) or indeterminate metabolisers (see section 4.4).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>Adults</em>
The recommended dose is 84 mg eliglustat twice daily in CYP2D6 IMs and EMs.
The recommended dose is 84 mg eliglustat once daily in CYP2D6 PMs.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>Paediatric population (from 6 to &lt;18 years of age) weighing ≥ 15 kg</em></p>
</blockquote>
<blockquote class=""blockquote"">
<p>Weight: ≥ 50 kg; Dose, CYP2D6 EMs and IMs: 84 mg twice daily, Dose, CYP2D6 PMs: 84 mg once daily</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Weight: 25 to &lt; 50 kg; Dose, CYP2D6 EMs and IMs: 84 mg twice daily, Dose, CYP2D6 PMs: 42 mg once daily</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Weight: 15 to &lt; 25 kg; Dose, CYP2D6 EMs and IMs: 42 mg twice daily, Dose, CYP2D6 PMs: 21 mg once daily</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127714,Annotation of HCSC Label for sulfadiazine and G6PD,False,False,[],False,"[{'id': 1452533241, 'date': '2024-07-21T23:57:16.674-07:00', 'description': 'Added Prescribing section, tags and label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161223, 'title': 'Drugs@HCSC: Drug Product Flamazine (sulfadiazine), Smith & Nephew Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2146', 'crossReferences': [{'id': 1452533204, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2146', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2146'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451539', 'name': 'sulfadiazine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982357.0,"<p>The product monograph for sulfadiazine states that it should be used in caution in patients who are deficient for glucose-6-phosphate dehydrogenase (G6PD) due to the risk for hemolysis. However, the monograph makes no mention of testing for G6PD deficiency prior to treatment.</p>
",1447982356.0,"<p>Silver sulfadiazine is indicated as a topical antibacterial agent. Excerpt from the sulfadiazine product monograph:</p>
<blockquote class=""blockquote"">
<p>Silver sulfadiazine cream should be used with caution on patients with a history of glucose-6-phosphate dehydrogenase deficiency as hemolysis may occur.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Sulfadiazine_HCSC_06_05_15.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Sulfadiazine_HCSC_06_05_15.pdf"">sulfadiazine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452533240.0,"<p>Silver sulfadiazine is indicated as a topical antibacterial agent. Excerpt from the sulfadiazine product monograph:</p>
<blockquote class=""blockquote"">
<p>Silver sulfadiazine cream should be used with caution on patients with a history of glucose-6-phosphate dehydrogenase deficiency as hemolysis may occur.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127683,Annotation of HCSC Label for irinotecan and UGT1A1,False,False,[],True,"[{'id': 1452489341, 'date': '2024-05-30T17:00:00-07:00', 'description': 'updated to newer drug label, added Dosing Info tag, changed level to Testing Recommended based on ""UGT1A1 genotyping can be useful""', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15158902, 'title': 'Drugs@HCSC: Drug Product IRINOTECAN HYDROCHLORIDE INJECTION USP (Irinotecan), Pfizer Canada ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74343', 'crossReferences': [{'id': 1452489320, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74343', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74343'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA166115842', 'symbol': 'UGT1A1*28', 'name': '*28'}, {'objCls': 'Haplotype', 'id': 'PA166115858', 'symbol': 'UGT1A1*6', 'name': '*6'}]","[{'objCls': 'Chemical', 'id': 'PA450085', 'name': 'irinotecan'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",HCSC,1447982385.0,"<p>The HCSC-approved product monograph for irinotecan (IRINOTECAN HYDROCHLORIDE INJECTION USP) states that a reduction in the starting dose should be considered for patients known to be homozygous for UGT1A1*28 or *6 allele. It states that in order to identify patients at increased risk of experiencing neutropenia and diarrhea, UGT1A1 genotyping can be useful.</p>
",1447982384.0,"<p>Excerpts from the irinotecan (IRINOTECAN HYDROCHLORIDE INJECTION USP) product monograph:</p>
<blockquote class=""blockquote"">
<p>Patients with UGT1A1*28 or *6 variants (especially if homozygous) are at increased risk of experiencing adverse events such as neutropenia and diarrhea. A reduced irinotecan starting dose should be considered for homozygous patients (see 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment). In addition, *28 and *6 homozygous and heterozygous patients should be closely monitored for neutropenia and diarrhea. In order to identify patients at increased risk of experiencing neutropenia and diarrhea, UGT1A1 genotyping can be useful (see 7 WARNINGS AND PRECAUTIONS, Hematologic). More in detail, UGT1A1*28 genotyping can be useful in Caucasians, Africans and Latinos, UGT1A1*6 in East-Asians and combined UGT1A1*28 and *6 in Chinese and Japanese, since these are the populations in which these variants are more prevalent.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Individuals with certain polymorphs of UGT1A1, such as UGT1A1*28, may have reduced activity of this enzyme. Approximately 10% of the North American population is homozygous for the UGT1A1*28 allele (also referred to as UGT1A1 7/7 genotype).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In one study an increased risk of neutropenia was observed in patients homozygous for the UGT1A1*28 allele, who received single-agent irinotecan hydrochloride trihydrate at a dose of 350 mg/m2. Individuals with certain genetic polymorphisms in the UGT1A1 gene (e.g. UGT1A1 *28/*28 genotype) have reduced UGT1A1 activity, which in turn increases the concentration of SN-38, the active metabolite of irinotecan (see 10 CLINICAL PHARMACOLOGY, 10.3 Pharmacokinetics).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with the UGT1A1*28 allele, treated with combination regimens that deliver doses of irinotecan hydrochloride trihydrate in the range of 100-180 mg/m2, in combination with 5-FU/LV, the risk of grade 4 neutropenia was lower than in studies where irinotecan hydrochloride trihydrate was administered at doses of 300-350 mg/m2 as a single agent (see 8 ADVERSE REACTIONS, Hematology).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Another specific polymorphism of UGT1A1 gene (that reduces the activity of this enzyme) is a missense mutation known as UGT1A1*6 variant.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A reduced irinotecan starting dose should be considered for patients known to be homozygous for UGT1A1*28 or *6 allele, as well as for those who have experienced prior hematologic toxicity with previous treatment. The exact reduction in starting dose in this patient population has not been established and any subsequent dose modifications should be based on individual patient tolerance to treatment (see 4 DOSAGE AND ADMINISTRATION).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Irinotecan_2024_05_31_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Irinotecan_2024_05_31_HCSC.pdf"">irinotecan product monograph</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1452489340.0,"<blockquote class=""blockquote"">
<p>When administered in combination with other agents, or as a single-agent, a reduction in the starting dose should be considered for patients known to be homozygous for UGT1A1*28 or *6 allele, as well as for those who have experienced prior hematologic toxicity with previous treatment. The exact reduction in starting dose in this patient population has not been established and any subsequent dose modifications should be based on individual patient tolerance to treatment (see 7 WARNINGS AND PRECAUTIONS, Hematologic).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127696,Annotation of HCSC Label for norfloxacin and G6PD,False,False,[],False,"[{'id': 1452536844, 'date': '2024-07-23T23:43:33.174-07:00', 'description': 'Updated label PDF and annotation text. Added label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161782, 'title': 'Drugs@HCSC: Drug Product Norfloxacin (norfloxacin), AA Pharma Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47429', 'crossReferences': [{'id': 1452536843, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47429', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47429'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450654', 'name': 'norfloxacin'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982453.0,"<p>The product monograph for norfloxacin states that hemolytic reactions have occurred in patients with glucose-6-phosphate dehydrogenase deficiency.</p>
",1447982452.0,"<p>Norfloxacin is an antibacterial agent. Excerpt from the norfloxacin product monograph:</p>
<blockquote class=""blockquote"">
<p>Rarely, hemolytic reactions have been reported in patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity who take quinolone antibacterial agents, including norfloxacin (see ADVERSE REACTIONS).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Although the following adverse reactions were not observed in these clinical trials with norfloxacin, they have been reported following treatment with other quinolone antibacterial agents:</p>
<ul>
<li>hemolytic anemia in patients with latent or actual defects in glucose-6-phosphate dehydrogenase (G6PD) activity;</li>
</ul>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Norfloxacin_2024_07_24_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Norfloxacin_2024_07_24_HCSC.pdf"">norfloxacin product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166127694,Annotation of HCSC Label for nitrofurantoin and G6PD,True,False,[],False,"[{'id': 1452536822, 'date': '2024-07-23T23:22:01.035-07:00', 'description': 'Added Prescribing section, tags and label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161762, 'title': 'Drugs@HCSC: Drug Product TEVA-NITROFURANTOIN (nitrofurantoin), Teva Canada Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50295', 'crossReferences': [{'id': 1452536820, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50295', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50295'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450640', 'name': 'nitrofurantoin'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982271.0,"<p>The product monograph for nitrofurantoin states that individuals with a glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at risk for hemolytic anemia when receiving the drug, and that it should be discontinued if the patient exhibits signs of hemolysis.</p>
",1447982270.0,"<p>Excerpts from the nitrofurantoin product monograph:</p>
<blockquote class=""blockquote"">
<p>Cases of hemolytic anemia of the primaquine sensitivity type have been induced by nitrofurantoin. The hemolysis appears to be linked to a glucose-6-phosphate dehydrogenase deficiency in the red blood cells of the affected patients. This deficiency is found in 10% of blacks and a small percentage of ethnic groups of Mediterranean and Near-Eastern origin. Any sign of hemolysis is an indication to discontinue the drug. Hemolysis ceases when the drug is withdrawn.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Nitrofurantoin has been detected in trace amounts in breast milk. Caution should be exercised when nitrofurantoin is administered to a nursing woman, especially if the infant is known or suspected to have a glucose-6-phosphate dehydrogenase deficiency.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Nitrofurantoin_HCSC_06_03_15.pdf"">nitrofurantoin product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452536821.0,"<p>Excerpts from the nitrofurantoin product monograph:</p>
<blockquote class=""blockquote"">
<p>Cases of hemolytic anemia of the primaquine sensitivity type have been induced by nitrofurantoin. The hemolysis appears to be linked to a glucose-6-phosphate dehydrogenase deficiency in the red blood cells of the affected patients. This deficiency is found in 10% of blacks and a small percentage of ethnic groups of Mediterranean and Near-Eastern origin. Any sign of hemolysis is an indication to discontinue the drug. Hemolysis ceases when the drug is withdrawn.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Nitrofurantoin has been detected in trace amounts in breast milk. Caution should be exercised when nitrofurantoin is administered to a nursing woman, especially if the infant is known or suspected to have a glucose-6-phosphate dehydrogenase deficiency.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127715,Annotation of HCSC Label for sulfamethoxazole / trimethoprim and G6PD,False,False,[],False,"[{'id': 1452533320, 'date': '2024-07-22T00:26:49.823-07:00', 'description': 'Updated label PDF and added label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161242, 'title': 'Drugs@HCSC: Drug Product Sulfatrim (sulfamethoxazole/trimethoprim), AA Pharma Inc', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3678', 'crossReferences': [{'id': 1452533300, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3678', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3678'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10715', 'name': 'sulfamethoxazole / trimethoprim'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982359.0,"<p>The product monograph for sulfamethoxazole and trimethoprim (SULFATRIM) states that hemolysis may occur in individuals taking the drug who are deficient in glucose-6-phosphate dehydrogenase (G6PD). However, it does not make any statements regarding testing for G6PD deficiency prior to treatment.</p>
",1447982358.0,"<p>Sulfamethoxazole and trimethoprim (SULFATRIM) is an antibacterial agent. Excerpt from the sulfamethoxazole and trimethoprim (SULFATRIM) product monograph:</p>
<blockquote class=""blockquote"">
<p>In glucose-6-phosphate dehydrogenase-deficient individuals, hemolysis may occur. This reaction is frequently dose-related.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""sulfamethoxazole_trimethoprim_2024_07_22_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/sulfamethoxazole_trimethoprim_2024_07_22_HCSC.pdf"">sulfamethoxazole and trimethoprim product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166127690,"Annotation of HCSC Label for mercaptopurine and NUDT15, TPMT",False,False,[],True,"[{'id': 1452538882, 'date': '2024-07-25T09:25:25.771-07:00', 'description': 'updated label, added Pediatric tag and info, changed PGx level to Testing Recommended, added Dosing Info tag and prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161982, 'title': 'Drugs@HCSC: Drug Product PURINETHOL (mercaptopurine), Teva Canada Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=960', 'crossReferences': [{'id': 1452538840, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=960', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=960'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]","[{'objCls': 'Variant', 'id': 'PA166154759', 'symbol': 'rs116855232', 'name': 'rs116855232'}, {'objCls': 'Haplotype', 'id': 'PA165819269', 'symbol': 'TPMT*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165819270', 'symbol': 'TPMT*3A', 'name': '*3A'}, {'objCls': 'Haplotype', 'id': 'PA165819272', 'symbol': 'TPMT*3C', 'name': '*3C'}]","[{'objCls': 'Chemical', 'id': 'PA450379', 'name': 'mercaptopurine'}]","[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",HCSC,1447982395.0,"<p>The product monograph for mercaptopurine (PURINETHOL) states that individuals who are TPMT deficient are at risk of developing life-threatening bone marrow suppression when receiving the drug, and that substantial dose reductions are usually required for these individuals.</p>
",1447982394.0,"<p>Mercaptopurine (PURINETHOL) is indicated for treatment of acute lymphatic leukemia as part of a combination regimen. Excerpts from the mercaptopurine (PURINETHOL) product monograph:</p>
<blockquote class=""blockquote"">
<p><em>Patients with TPMT variant</em>
Mercaptopurine is primarily inactivated by metabolism through the enzyme thiopurine S-methyltransferase (TPMT), whose activity can be highly variable due to polymorphisms in the TPMT gene. Patients with low or intermediate TPMT activity accumulate higher concentrations of mercaptopurine cytotoxic metabolites than those with normal TPMT activity. Individuals who are homozygous for an inherited defect in the TPMT (thiopurine-Smethyltransferase) gene are unusually sensitive to the myelosuppressive effects of mercaptopurine and prone to developing rapid bone marrow suppression following the initiation of treatment. Laboratory tests are available, both genotypic and phenotypic, to determine the TPMT status. Substantial dose reductions are generally required for homozygous-TPMT deficiency patients (two non-functional alleles) to avoid the development of life threatening bone marrow suppression (See 10.3 Pharmacokinetics). Although heterozygous patients with intermediate TPMT activity may have increased mercaptopurine toxicity, this is variable, and the majority of patients tolerate normal doses of PURINETHOL. If a patient has clinical or laboratory evidence of severe toxicity, particularly myelosuppression, TPMT testing should be considered. In patients who exhibit excessive myelosuppression due to 6-mercaptopurine, it may be possible to adjust the mercaptopurine dose and administer the usual dosage of other myelosuppressive chemotherapy as required for treatment (see 4 DOSAGE AND ADMINISTRATION).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>Patients with NUDT15 variant</em>
Patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurinetoxicity, such as early leukopenia and alopecia, from conventional doses of
thiopurine therapy. They generally, require dose reduction, particularly those being NUDT15 variant homozygotes (see 4.2 Recommended Dose and Dosage Adjustment and 10.3 Pharmacokinetics). Close monitoring of blood count is necessary.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>If a patient has clinical or laboratory evidence of severe bone marrow toxicity, particularly myelosuppression, TPMT and NUDT15 testing should be considered.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Although available, phenotypic or genetic screening tests for TPMT deficiency are not currently uniform for patient care in Canada. Genotypic testing can determine the allelic pattern of a patient. Currently, 3 alleles—TPMT*2, TPMT*3A and TPMT*3C— account for about 95% of individuals with reduced levels of TPMT activity. Individuals homozygous for these alleles are TPMT deficient and those heterozygous for these alleles have variable TPMT (low or intermediate) activity. Phenotypic testing determines the level of thiopurine nucleotides or TPMT activity in erythrocytes and can also be informative. Caution must be used with phenotyping since some coadministered drugs can influence measurement of TPMT activity in blood, and recent blood transfusions will misrepresent a patient’s actual TPMT activity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Mercaptopurine is inactivated via two major pathways. One is thiol methylation, which is catalyzed by the polymorphic enzyme thiopurine Smethyltransferase (TPMT), to form the inactive metabolite methyl-6-MP. TPMT activity is highly variable in patients because of a genetic polymorphism in the TPMT gene.
For Caucasians and African Americans, approximately 0.3% (1:300) of patients have two non-functional alleles (homozygous-deficient) of the TPMT gene and have little or no detectable enzyme activity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Approximately 10% of patients have one TPMT non-functional allele (heterozygous) leading to low or intermediate TPMT activity and 90% of individuals have normal TPMT activity with two functional alleles. Homozygous-deficient patients (two non-functional alleles), if given usual doses of mercaptopurine, accumulate excessive cellular concentrations of active thioguanine nucleotides predisposing them to mercaptopurine toxicity. Heterozygous patients with low or intermediate TPMT activity accumulate higher concentrations of active thioguanine nucleotides than people with normal TPMT activity and are more likely to experience mercaptopurine toxicity. TPMT genotyping or phenotyping (red blood cell TPMT activity) can identify patients who are homozygous deficient or have low or intermediate TPMT activity (See 4.2 DOSAGE AND ADMINISTRATION).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Recent studies indicate that a strong association exists between the NUDT15 variant NUDT15 c.415C&gt;T [p.Arg139Cys] (also known as NUDT15 R139C [rs116855232]), which is thought to lead to a loss of function of the NUDT15 enzyme, and thiopurine-mediated toxicity such as leukopenia and alopecia. The frequency of NUDT15 c.415C&gt;T has an ethnic variability of 9.8 % in East Asians, 3.9 % in Hispanics, 0.2 % in Europeans and 0.0 % in Africans, indicating an increased risk for the Asian population. Patients who are NUDT15 variant homozygotes (NUDT15 T risk alleles) are at an excessive risk of thiopurine toxicity compared with the C homozygotes (See 4.2 DOSAGE AND ADMINISTRATION)</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Mercaptopurine_2024_07_24_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Mercaptopurine_2024_07_24_HCSC.pdf"">mercaptopurine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452538881.0,"<blockquote class=""blockquote"">
<p><strong>Pediatrics (&lt; 18 years of age)</strong>: Acute lymphatic leukemia occurring in children responds, in general, more favorably to mercaptopurine than the same disorder occurring in adults (see 7.1.3 Special Populations).</p>
</blockquote>
",1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1452538880.0,"<blockquote class=""blockquote"">
<p>Consider testing for TPMT and NUDT15 deficiency in patients who experience severe myelosuppression or repeated episodes of myelosuppression.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with inherited little or no thiopurine S-methyltransferase (TPMT) activity are at increased risk for severe PURINETHOL toxicity from conventional doses of mercaptopurine and generally require dose reduction (See 7 WARNINGS AND PRECUATIONS; Patients with NUDT15 variant). The optimal starting dose for homozygous deficient patients has not been established. (See 10 CLINICAL PHARMACOLOGY.)</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Most patients with heterozygous TPMT deficiency tolerated recommended PURINETHOL doses, but some require dose reduction. Genotypic and phenotypic testing of TPMT status are available. (See 10 CLINICAL PHARMACOLOGY)</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with inherited mutations in the NUDT15 gene are at an increased risk for severe mercaptopurine toxicity. These patients generally require dose reduction, particularly those being NUDT15 variant homozygotes (see 7 WARNINGS AND PRECAUTIONS, Hematologic). Genotypic testing of NUDT15 variants may be considered before initiating 6-mercaptopurine therapy. In any case, close monitoring of blood counts is necessary. The prescribing physician is advised to establish whether dose reduction is required based on patient response to treatment as well as their genetic profile.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127692,Annotation of HCSC Label for mycophenolic acid and HPRT1,True,False,[],False,"[{'id': 1452539421, 'date': '2024-07-25T13:28:03.371-07:00', 'description': 'updated label, added Alternate Drug tag and prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162082, 'title': 'Drugs@HCSC: Drug Product MYFORTIC (mycophenolic acid), Novartis Pharmaceuticals Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75000', 'crossReferences': [{'id': 1452539400, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75000', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75000'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA29427', 'symbol': 'HPRT1', 'name': 'hypoxanthine phosphoribosyltransferase 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164748728', 'name': 'mycophenolic acid'}]","[{'objCls': 'Gene', 'id': 'PA29427', 'symbol': 'HPRT1', 'name': 'hypoxanthine phosphoribosyltransferase 1'}]",HCSC,1447982245.0,"<p>The product monograph for mycophenolic acid (MYFORTIC) states that it should be avoided in patients with hereditary deficiencies of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT, encoded by <em>HPRT1</em>), such as Lesch-Nyhan and Kelley-Seegmiller syndrome.</p>
",1447982244.0,"<p>Mycophenolic acid (MYFORTIC) is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, in combination with cyclosporine and corticosteroids. Excerpt from the mycophenolic acid (MYFORTIC) product monograph:</p>
<blockquote class=""blockquote"">
<p>On theoretical grounds, because MYFORTIC is an IMPDH Inhibitor, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>To help avoid side effects and ensure proper use, talk to your healthcare professional before you take MYFORTIC. Talk about any health conditions or problems you may have, including if you:</p>
<ul>
<li>have a family history of a genetic disease known as Lesch-Nyhan or Kelley-Seegmiller syndrome;</li>
</ul>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Mycophenolic_acid_2024_07_25_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Mycophenolic_acid_2024_07_25_HCSC.pdf"">mycophenolic acid product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452539420.0,"<blockquote class=""blockquote"">
<p>On theoretical grounds, because MYFORTIC is an IMPDH Inhibitor, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127716,Annotation of HCSC Label for sulfasalazine and G6PD,False,False,[],False,"[{'id': 1452533324, 'date': '2024-07-22T00:38:53.855-07:00', 'description': 'Added Prescribing section, tags and label document', 'type': 'Update', 'version': 0}, {'id': 1452556540, 'date': '2024-08-14T16:15:43.529-07:00', 'description': 'added Other Guidance tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161262, 'title': 'Drugs@HCSC: Drug Product Salazopyrin (sulfasalazine), Pfizer Canada Inc', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17417', 'crossReferences': [{'id': 1452533322, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17417', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17417'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451547', 'name': 'sulfasalazine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1447982361.0,"<p>The product monograph for sulfasalazine (SALAZOPYRIN) notes that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency should be closely monitored for signs of hemolytic anemia when receiving the drug. However, no statement is made regarding testing for G6PD deficiency prior to treatment.</p>
",1447982360.0,"<p>Sulfasalazine (SALAZOPYRIN) is an anti-inflammatory drug. Excerpts from the sulfasalazine (SALAZOPYRIN) product monograph:</p>
<blockquote class=""blockquote"">
<p>Patients, especially those with glucose-6-phosphate dehydrogenase deficiency, should be observed closely for signs of hemolytic anemia. This reaction is frequently dose related. If toxic or hypersensitivity reactions occur, the drug should be discontinued immediately.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Caution should be used, particularly if breastfeeding premature infants or those deficient in Glucose-6-Phosphate Dehydrogenase (G-6-PD).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Sulfasalazine_HCSC_06_05_15.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Sulfasalazine_HCSC_06_05_15.pdf"">sulfasalazine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452533323.0,"<p>Excerpts from the sulfasalazine (SALAZOPYRIN) product monograph:</p>
<blockquote class=""blockquote"">
<p>Patients, especially those with glucose-6-phosphate dehydrogenase deficiency, should be observed closely for signs of hemolytic anemia. This reaction is frequently dose related. If toxic or hypersensitivity reactions occur, the drug should be discontinued immediately.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Caution should be used, particularly if breastfeeding premature infants or those deficient in Glucose-6-Phosphate Dehydrogenase (G-6-PD).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127697,Annotation of HCSC Label for nortriptyline and CYP2D6,False,False,[],False,"[{'id': 1452537744, 'date': '2024-07-24T12:58:42.555-07:00', 'description': 'Added label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161803, 'title': 'Drugs@HCSC: Drug Product Aventyl (nortriptyline), AA Pharm Inc', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15', 'crossReferences': [{'id': 1452537743, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450657', 'name': 'nortriptyline'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982327.0,"<p>The product monograph for nortriptyline notes that individuals who are CYP2D6 poor metabolizers may have higher than expected levels of tricyclic antidepressants (of which nortriptyline is a member) when given usual doses.</p>
",1447982326.0,"<p>Nortriptyline is a tricyclic antidepressant. Excerpt from the nortriptyline product monograph:</p>
<blockquote class=""blockquote"">
<p>A subset (3 to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as &quot;poor metabolizers&quot; of drugs such as debrisoquin, dextromethorphan and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given the usual doses.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Nortriptyline_HCSC_06_03_15.pdf"">nortriptyline product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166123423,Annotation of EMA Label for tipranavir and CYP3A4,False,False,[],False,"[{'id': 1184754740, 'date': '2014-09-17T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933216, 'date': '2019-12-04T13:30:29.400-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452217622, 'date': '2023-08-27T22:40:44.821-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103660, 'title': 'Aptivus | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/aptivus', 'crossReferences': [{'id': 1450932892, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/aptivus', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/aptivus'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA163522473', 'name': 'tipranavir'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447982195.0,"<p>The EMA European Public Assessment Report (EPAR) for tipranavir (Aptivus) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of tipranavir by CYP3A4, and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers.</p>
",1447982194.0,"<p>The EMA-approved drug tipranavir (Aptivus) is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/tipranavir_EMA_EPAR_Aug_6_2014.pdf"">tipranavir EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166182753,Annotation of FDA Label for meloxicam and CYP2C9,False,False,[],False,"[{'id': 1450964180, 'date': '2020-02-11T10:41:54.367-08:00', 'description': 'added to FDA biomarker table 02/05/2020', 'type': 'Update', 'version': 0}, {'id': 1452216281, 'date': '2023-08-24T23:16:58.610-07:00', 'description': ""Added 'Dosing Info' tag with updated definition"", 'type': 'Update', 'version': 0}, {'id': 1452698041, 'date': '2024-11-12T00:00:00-08:00', 'description': 'added Pediatric tag and info; changed Actionable to Informative PGx level and removed prescribing info - newer labels no longer contain these recommendations', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102505, 'title': 'Drugs@FDA: Drug Product Mobic (meloxicam), NDA020938/SUPPL-28, 04/28/2021, Boehringer Ingelheim', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020938', 'crossReferences': [{'id': 1452698080, 'resource': 'FDA Application', 'resourceId': 'NDA020938/SUPPL-28', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020938'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'pubDate': '2021-04-28T00:00:00-07:00', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}, {'id': 15102504, 'title': 'Drugs@FDA: Drug Product Vivlodex (meloxicam), NDA207233/SUPPL-4, 04/28/2021, Iceutica Operations', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207233', 'crossReferences': [{'id': 1452698062, 'resource': 'FDA Application', 'resourceId': 'NDA207233/SUPPL-4', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207233'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'pubDate': '2021-04-28T00:00:00-07:00', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}, {'id': 15102384, 'title': 'Drugs@FDA: Drug Product QMIIZ ODT (meloxicam), NDA211210, TerSera Therapeutics LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211210', 'crossReferences': [{'id': 1452698060, 'resource': 'FDA Application', 'resourceId': 'NDA211210/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211210'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'pubDate': '2018-10-19T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15169782, 'title': 'DailyMed - MELOXICAM tablet', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bd53770-7077-49c7-8215-73a17a20ea70', 'crossReferences': [{'id': 1452696900, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '8bd53770-7077-49c7-8215-73a17a20ea70', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bd53770-7077-49c7-8215-73a17a20ea70'}], 'notes': 'ANDA077920', 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450353', 'name': 'meloxicam'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1450400586.0,"<p>The FDA-approved drug label for meloxicam notes that CYP2C9 plays an important role in the metabolism of meloxicam, but as of November 2024, it no longer contains any statements about dose reductions and monitoring for adverse effects for patients who are known or suspected to be poor CYP2C9 metabolizers.</p>
<p><strong>As of November 12, 2024, the FDA Table of Pharmacogenetic Associations states that CYP2C9 poor metabolizer or *3 carriers status results in higher systemic concentrations, and to consider dose reductions in poor metabolizers and monitor patients for adverse reactions. However, the marketing status of the drug linked from the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling, QMIIZ ODT, is shown as Discontinued, and newer meloxicam labels do not contain any statements about CYP2C9 metabolizer status.</strong></p>
",1450400587.0,"<p>Meloxicam is a non-steroidal anti-inflammatory drug indicated for treatment of osteoarthritis and rheumatoid arthritis in adults, and juvenile rheumatoid arthritis in pediatric patients weighing greater than or equal to 60 kg.</p>
<p>Excerpt from the meloxicam drug label (ANDA077920):</p>
<blockquote class=""blockquote"">
<p><em>In vitro</em> studies indicate that CYP2C9 (cytochrome P450 metabolizing enzyme) plays an important role in this metabolic pathway with a minor contribution of the CYP3A4 isozyme.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Meloxicam_2024_11_11_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Meloxicam_2024_11_11_FDA.pdf"">meloxicam drug label</a>.</p>
<p><strong>Note: As of November 2024, all branded meloxicam products (MOBIC, VIVLODEX, QMIIZ ODT and ANJESO) are listed as discontinued on the FDA website. The drug labels for meloxicam (MOBIC) and meloxicam (VIVLODEX) did not contain information regarding dose reduction based on CYP2C9 metabolizer status.</strong></p>
<p>Excerpts from the meloxicam (QMIIZ ODT, <strong>discontinued</strong>) drug label:</p>
<blockquote class=""blockquote"">
<p>Poor Metabolizers of CYP2C9 Substrates
In patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or
previous history/experience with other CYP2C9 substrates (such as warfarin or phenytoin),
consider dose reduction, as these patients may have abnormally high plasma levels of meloxicam
due to reduced metabolic clearance. Monitor these patients for adverse effects.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacogenomics
CYP2C9 activity is reduced in individuals with genetic variants such as CYP2C9*2 and
CYP2C9*3 polymorphisms. Limited data from three published reports showed that meloxicam
AUC was substantially higher in individuals with reduced CYP2C9 activity, particularly in poor
metabolizers (e.g., *3/*3), compared to normal metabolizers (*1/*1). The frequency of CYP2C9
poor metabolizer genotypes varies based on racial/ethnic background but is generally present in
&lt;5% of the population.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""meloxicam_05_14_2019_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/meloxicam_05_14_2019_FDA.pdf"">meloxicam (QMIIZ ODT, <strong>discontinued</strong>) drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452698040.0,"<blockquote class=""blockquote"">
<p>The safety and effectiveness of meloxicam in pediatric JRA patients from 2 to 17 years of age has been evaluated in three clinical trials [see Dosage and Administration (2.3), Adverse Reactions (6.1) and Clinical Studies (14.2)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>For the treatment of juvenile rheumatoid arthritis, the recommended oral dose of meloxicam tablets is 7.5 mg once daily in children who weigh ≥60 kg. There was no additional benefit demonstrated by increasing the dose above 7.5 mg in clinical trials.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Meloxicam tablets should not be used in children who weigh &lt;60 kg.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166127719,Annotation of HCSC Label for tetrabenazine and CYP2D6,False,False,[],False,"[{'id': 1452531182, 'date': '2024-07-18T23:42:08.339-07:00', 'description': 'Added prescribing info and tagged as Other Guidance. Rewrote main annotation text to fit template and added label document.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160922, 'title': 'Drugs@HCSC: Drug Product Apo-Tetrabenazine (tetrabenazine), Apotex Inc', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89232', 'crossReferences': [{'id': 1452531180, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89232', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89232'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA140222719', 'name': 'tetrabenazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982355.0,"<p>The product monograph for tetrabenazine notes that the tetrabenazine active metabolite HTBZ is likely increased in CYP2D6 poor metabolizers as compared to extensive metabolizers, and that caution in dosing should be exercised.</p>
",1447982354.0,"<p>Excerpts from the tetrabenazine (Apo-Tetrabenazine) product monograph:</p>
<blockquote class=""blockquote"">
<p><strong>CYP2D6 Poor Metabolizers</strong> Although the pharmacokinetics of tetrabenazine and its metabolites in subjects who do not express the drug metabolizing enzyme CYP2D6 (poor metabolizers) have not been systematically evaluated, it is likely that the exposure to alpha-HTBZ and beta-HTBZ would be increased compared to subjects who express the enzyme (extensive metabolizers), with the AUC0-inf increases similar to those observed in patients taking strong CYP2D6 inhibitors (approximately 3.4-fold to 9.6-fold, respectively). Caution in dosing should be exercised.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Tetrabenazine_HCSC_06_05_15.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Tetrabenazine_HCSC_06_05_15.pdf"">tetrabenazine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452531181.0,"<blockquote class=""blockquote"">
<p><strong>CYP2D6 Poor Metabolizers</strong> [...] Caution in dosing should be exercised.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127720,"Annotation of HCSC Label for thioguanine and NUDT15, TPMT",False,False,[],True,"[{'id': 1452531302, 'date': '2024-07-19T00:50:10.713-07:00', 'description': 'Replaced label with current version from HCSC. Updated annotation to reflect content in new label.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160923, 'title': 'Drugs@HCSC: Drug Product Lanvis (thioguanine), Aspen Pharmacare Canada Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00073846.PDF', 'crossReferences': [{'id': 1452531183, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00073846.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00073846.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,True,True,"[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]","[{'objCls': 'Variant', 'id': 'PA166154759', 'symbol': 'rs116855232', 'name': 'rs116855232'}, {'objCls': 'Haplotype', 'id': 'PA165819269', 'symbol': 'TPMT*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165819270', 'symbol': 'TPMT*3A', 'name': '*3A'}, {'objCls': 'Haplotype', 'id': 'PA165819271', 'symbol': 'TPMT*3B', 'name': '*3B'}, {'objCls': 'Haplotype', 'id': 'PA165819272', 'symbol': 'TPMT*3C', 'name': '*3C'}, {'objCls': 'Haplotype', 'id': 'PA165819274', 'symbol': 'TPMT*4', 'name': '*4'}]","[{'objCls': 'Chemical', 'id': 'PA451663', 'name': 'thioguanine'}]","[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",HCSC,1447982237.0,"<p>The product monograph for thioguanine (LANVIS) recommends that patients undergo genotypic or phenotypic testing for TPMT and NUDT15 before beginning thioguanine treatment. Patients with reduced or no TPMT activity or carrying a NUDT15 variant should be given a dose reduction and their blood counts should be monitored.</p>
",1447982236.0,"<p>Excerpts from the thioguanine (Lanvis) product monograph:</p>
<blockquote class=""blockquote"">
<p><em><strong>Serious Warnings and Precautions</strong></em> [...] Myelosuppression including life-threatening infections and bleeding, especially in patients with thiopurine S-methyltransferase deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em><strong>Recommended Dose and Dosage Adjustment</strong></em> [...] <strong>Thiopurine S-methyltransferase-deficient Patients</strong>
Genotypic or phenotypic tests of thiopurine S-methyltransferase (TPMT) are recommended prior to
initiating LANVIS to identify high risk patients (see Hematologic and Monitoring and Laboratory Tests).
Patients with inherited little or no TPMT activity are at increased risk for severe thioguanine toxicity
(e.g., severe myelosuppression) from conventional doses of LANVIS and generally require substantial
dose reduction (see Table 1).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Table 1</p>
<table class=""table"">
<thead>
<tr>
<th><strong>TPMT Genotype and Phenotype</strong></th>
<th><strong>Dosing Recommendations for LANVIS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Homozygous wild-type or normal, high activity (two functional *1 alleles)</td>
<td>Start with normal starting dose. Adjust doses of LANVIS and of other myelosuppressive therapy without any special emphasis on LANVIS. Allow 2 weeks to reach steady state after each dose adjustment.</td>
</tr>
<tr>
<td>Heterozygote or intermediate activity (one functional allele - *1, plus one of the nonfunctional alleles - *2, *3A, *3B, *3C, or *4)</td>
<td>Reduce the starting dose by 30-50% and adjust doses of LANVIS based on degree of myelosuppression. Allow 2-4 weeks to reach steady state after each dose adjustment. In setting of myelosuppression, and depending on other therapy, emphasis should be on reducing LANVIS over other agents</td>
</tr>
<tr>
<td>Homozygous variant, mutant, or low/ deficient activity (two nonfunctional alleles - *2, *3A, *3B, *3C, or *4)</td>
<td>Reduce the starting dose of LANVIS by 10-fold and dose thrice weekly instead of daily and adjust doses of LANVIS based on degree of myelosuppression. Allow 4-6 weeks to reach steady state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing LANVIS over other agents.</td>
</tr>
</tbody>
</table>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>NUDT15 Variant Patients</strong> Genotypic and phenotypic testing of NUDT15 variants should be considered before initiating thiopurine therapy in all patients (including pediatric patients) to reduce the risk of thiopurine-related severe leukocytopenia and alopecia, especially in Asian populations patients (see Hematologic and Monitoring and Laboratory Tests).<br />
Patients with inherited mutated NUDT15 gene are at increased risk for severe thiopurine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy and require substantial dose reduction. Patients of Asian ethnicity are particularly at risk, due to the increased frequency of the mutation in this population. The optimal starting dose for heterozygous or homozygous deficient patients has not been established. Therefore, hematological parameters should be monitored during treatment with LANVIS.<br />
The prescribing physician is advised to establish whether dose reduction is required based on patient response to treatment as well as their genetic profile.<br />
Patients with variants in both the NUDT15 and TPMT enzymes are significantly less tolerant of thiopurines than those with risk alleles in only one of these two genes (see 10 CLINICAL PHARMACOLOGY).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em><strong>Warnings and Precuations</strong></em> [...] <strong>Thiopurine methyltransferase deficient patients:</strong> There are individuals with an inherited deficiency of the enzyme thiopurine methyltransferase (TPMT) who may be unusually sensitive to the myelosuppressive effect of thioguanine and prone to developing rapid and severe bone marrow depression following the initiation of treatment with LANVIS. This toxicity could be exacerbated by coadministration with drugs that inhibit TPMT, such as olsalazine, mesalazine or sulphasalazine.<br />
Genotypic or phenotypic tests of TPMT are recommended prior to initiating LANVIS as patients with TPMT deficiency may need significantly reduced starting dose (see 4 DOSAGE AND ADMINISTRATION). Close monitoring of blood counts is also necessary (see Monitoring and Laboratory Tests).<br />
<strong>NUDT15 variant patients:</strong> Case series and several published studies indicate that patients with inherited mutated nudix hydrolase 15 (NUDT15) gene are at increased risk for severe thiopurine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy and require substantial dose reduction. Patients of Asian ethnicity are particularly at risk, due to the increased frequency of the mutation in this population. The optimal starting dose for heterozygous or homozygous deficient patients has not been established.<br />
Genotypic and phenotypic testing of NUDT15 variants should be considered before initiating thiopurine therapy in all patients (including pediatric patients) to reduce the risk of thiopurine-related severe leukocytopenia and alopecia, especially in Asian populations (see 4 DOSAGE AND ADMINISTRATION and 10 CLINICAL PHARMACOLOGY).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genotypic and phenotypic tests of thiopurine methyltransferase (TPMT) and mutated nudix hydrolase 15 (NUDT15) gene are recommended prior to initiating LANVIS to identify patients with higher risk of
toxicity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em><strong>Metabolism</strong></em> [...] Individuals with an inherited deficiency of TPMT activity (i.e., with homozygous or heterozygous deficient alleles of TPMT) may experience higher exposures of thioguanine and the active thioguanine nucleotides (6-TGN). This could lead to higher sensitivity to standard dose of thioguanine and severe
myelosuppression (see Hematologic and Monitoring and Laboratory Tests). Recent studies indicate that a strong association exists between the NUDT15 variant NUDT15 c.415C&gt;T [p. Arg139Cys] (also known as NUDT15 R139C [rs116855232]), which is thought to lead to a loss of function of the NUDT15 enzyme, and thiopurine-mediated toxicity such as leukopenia and alopecia. The frequency of NUDT15 c.415C&gt;T has an ethnic variability of 9.8 % in East Asians, 3.9 % in Hispanics, 0.2 % in Europeans and 0.0 % in Africans, indicating an increased risk for the Asian population. Patients who are NUDT15 variant homozygotes (NUDT15 T risk alleles) are at an excessive risk of thiopurine toxicity compared with the C homozygotes (See Hematologic).<br />
Reduced thiopurine doses for patients who carry the NUDT15 variants may decrease their risk of toxicity (See 4 DOSAGE AND ADMINISTRATION).<br />
The precise mechanism of NUDT15-associated thiopurine-related toxicity is not fully established.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Thioguanine_2024_07_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Thioguanine_2024_07_19_HCSC.pdf"">thioguanine product monograph</a>.</p>
<p>The archived thioguanine product monograph can be accessed <a download=""Thioguanine_HCSC_06_05_15.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Thioguanine_HCSC_06_05_15.pdf"">here</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452531301.0,"<p>Excerpt from the thioguanine (Lanvis) product monograph:</p>
<blockquote class=""blockquote"">
<p>Genotypic and phenotypic testing of NUDT15 variants should be considered before initiating thiopurine therapy in all patients (including pediatric patients) to reduce the risk of thiopurine-related severe leukocytopenia and alopecia, especially in Asian populations patients (see Hematologic and Monitoring and Laboratory Tests).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>For children, similar dosages to those used in adults, with appropriate correction for body surface area, have been used.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Liver toxicity has been observed in a high proportion of children receiving thioguanine as part of maintenance therapy for acute lymphoblastic leukaemia and in other conditions associated with continuous use of thioguanine. LANVIS is not recommended for maintenance therapy or similar long-term continuous treatments due to the high risk of liver toxicity (see 4 DOSAGE AND ADMINISTRATION).</p>
</blockquote>
",1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1452531300.0,"<p>Excerpts from the thioguanine (Lanvis) label:</p>
<blockquote class=""blockquote"">
<p>Genotypic or phenotypic tests of thiopurine S-methyltransferase (TPMT) are recommended prior to initiating LANVIS to identify high risk patients (see Hematologic and Monitoring and Laboratory Tests). Patients with inherited little or no TPMT activity are at increased risk for severe thioguanine toxicity (e.g., severe myelosuppression) from conventional doses of LANVIS and generally require substantial dose reduction (see Table 1).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genotypic and phenotypic testing of NUDT15 variants should be considered before initiating thiopurine therapy in all patients (including pediatric patients) to reduce the risk of thiopurine-related severe leukocytopenia and alopecia [...] The optimal starting dose for heterozygous or homozygous deficient patients has not been established. Therefore, hematological parameters should be monitored during treatment with LANVIS.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The prescribing physician is advised to establish whether dose reduction is required based on patient response to treatment as well as their genetic profile.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166129520,"Annotation of HCSC Label for sevoflurane and CACNA1S, RYR1",True,False,[],False,"[{'id': 1452055841, 'date': '2023-04-01T20:21:25.498-07:00', 'description': 'updated text', 'type': 'Update', 'version': 0}, {'id': 1452598822, 'date': '2024-09-19T14:06:00.493-07:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15166022, 'title': 'Drugs@HCSC: Drug Product Sevoflurane, Baxter Corporation', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75141', 'crossReferences': [{'id': 1452598820, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75141', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75141'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451341', 'name': 'sevoflurane'}]","[{'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",HCSC,1447982393.0,"<p>Sevoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.</p>
",1447982392.0,"<p>The HCSC product monograph warns that individuals with a genetic predisposition to malignant hyperthermia are at an elevated risk of developing malignant hyperthermia, and that patients with Duchenne's Muscular Dystrophy are at an elevated risk of developing hyperkaelemia if administered sevoflurane, or other potent inhalational anesthetics.</p>
<p>Specific variants in the <em>RYR1</em> and <em>CACNA1S</em> genes are associated with risk of malignant hyperthermia in individuals administered potent inhalational anesthetics, such as sevoflurane. Although the product monograph for sevoflurane does not specifically mention genetic testing, it states that sevoflurane is contraindicated in individuals with known to have a genetic predisposition to malignant hyperthermia.</p>
<p>Excerpts from the sevoflurane product monograph:</p>
<blockquote class=""blockquote"">
<p>Contraindications SEVOFLURANE is contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia, or in patients with a known or suspected history of malignant hyperthermia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Malignant Hyperthermia: In susceptible individuals, potent inhalation anesthetic agents, including sevoflurane, may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""sevoflurane_20230402_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/sevoflurane_20230402_HCSC.pdf"">sevoflurane product monograph</a></p>
",1452598821.0,"<p>Sevoflurane is HCSC-indicated for pediatric use.</p>
<blockquote class=""blockquote"">
<p><strong>7.1.3 Pediatrics</strong>
The concentration of SEVOFLURANE required for maintenance of general anesthesia is age-dependent. See 4.2 Recommended Dose and Dosage Adjustment.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452055840.0,"<blockquote class=""blockquote"">
<p>SEVOFLURANE is contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia, or in patients with a known or suspected history of malignant hyperthermia.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166359261,Annotation of HCSC Label for tobramycin and MT-RNR1,True,False,[],False,[],False,[],True,"[{'id': 15170602, 'title': 'Drugs@HCSC: Drug Product TEVA-TOBRAMYCIN (tobramycin), Teva Canada Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87512', 'crossReferences': [{'id': 1452707440, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87512', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87512'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]","[{'objCls': 'Variant', 'id': 'PA166159181', 'symbol': 'rs267606617', 'name': 'rs267606617'}]","[{'objCls': 'Chemical', 'id': 'PA451704', 'name': 'tobramycin'}]","[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]",HCSC,1452707441.0,"<p>Tobramycin is an inhaled aminoglycoside antibacterial indicated for the management of cystic fibrosis patients with chronic pulmonary <em>Pseudomonas aeruginosa</em> infections.
The product monograph states that due to the risk of ototoxicity, alternative treatments other than aminoglycosides should be considered in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1).</p>
",1452707442.0,"<p>Excerpt from the tobramycin (TEVA-TOBRAMYCIN) product monograph:</p>
<blockquote class=""blockquote"">
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A&gt;G variant. These patients may be at increased risk for ototoxicity. Ototoxicity occurred in some patients even when their aminoglycoside serum levels were within the recommended range. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Tobramycin_2024_11_18_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Tobramycin_2024_11_18_HCSC.pdf"">tobramycin product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452707444.0,"<blockquote class=""blockquote"">
<p>Based on the data submitted and reviewed by Health Canada, the safety and efficacy of tobramycin inhalation solution in pediatric patients 6 years of age and older has been established. Therefore, Health Canada has authorized an indication for this patient population.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The safety and efficacy of tobramycin inhalation solution has not been studied in pediatric patients under 6 years of age. Therefore, Health Canada has not authorized an indication for this patient population.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452707443.0,"<blockquote class=""blockquote"">
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A&gt;G variant. These patients may be at increased risk for ototoxicity. [...] In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166359281,Annotation of HCSC Label for trimipramine,False,False,[],False,[],False,[],True,"[{'id': 15170622, 'title': 'Drugs@HCSC: Drug Product Trimipramine, AA Pharma Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8065', 'crossReferences': [{'id': 1452708320, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8065', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8065'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA451791', 'name': 'trimipramine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166359501,Annotation of HCSC Label for umeclidinium and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15170682, 'title': 'Drugs@HCSC: Drug Product INCRUSE ELLIPTA (umeclidinium), GlaxoSmithKline Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90830', 'crossReferences': [{'id': 1452709840, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90830', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90830'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177519', 'name': 'umeclidinium'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452709841.0,"<p>Umeclidinium (INCRUSE ELLIPTA) is indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD). The label notes that umeclidinium pharmacokinetics were not significantly affected in a population of CYP2D6 poor metabolizers.</p>
",1452709842.0,"<p>Excerpts from the umeclidinium (INCRUSE ELLIPTA) product monograph:</p>
<blockquote class=""blockquote"">
<p>Umeclidinium is a substrate of cytochrome P450 2D6 (CYP2D6); however umeclidinium pharmacokinetics were not significantly affected in a population of CYP2D6 poor metabolizers (see 10.3 Pharmacokinetics, Metabolism).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In vitro studies showed that umeclidinium is metabolized principally by the cytochrome P450 enzyme CYP2D6 and is a substrate for the P-gp transporter. The primary metabolic routes for umeclidinium are oxidative (hydroxylation, O-dealkylation) followed by conjugation (e.g., glucuronidation, etc.), resulting in a range of metabolites with either reduced pharmacological activity or for which the pharmacological activity has not been established. Systemic exposure to the metabolites is low.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Umeclidinium_2024_11_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Umeclidinium_2024_11_19_HCSC.pdf"">umeclidinium product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166359521,Annotation of HCSC Label for valbenazine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166170051', 'name': 'valbenazine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166114910,Annotation of FDA Label for chlorpropamide and G6PD,True,False,[],False,"[{'id': 1183704740, 'date': '2013-12-13T00:00:00-08:00', 'type': 'Update', 'version': 0}, {'id': 1450379957, 'date': '2019-04-16T14:06:11.500-07:00', 'description': 'added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1452216566, 'date': '2023-08-25T00:42:52.386-07:00', 'description': 'Added ""Alternate Drug"" tag based on updated definition', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101929, 'title': 'Drugs@FDA: Drug Product chlorpropamide (NDA011641)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=011641', 'crossReferences': [{'id': 1449895540, 'resource': 'FDA Application', 'resourceId': 'NDA011641', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=011641'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448966', 'name': 'chlorpropamide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450342789.0,"<p>The FDA-approved drug label for chlorpropamide (DIABINESE) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients.</p>
",1450342790.0,"<p>Chlorpropamide (DIABINESE) is a blood-glucose-lowering drug indicated for use in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.</p>
<p>Excerpt from the chlorpropamide (DIABINESE) drug label:</p>
<div class=""blockquote"">
<p>Hemolytic Anemia: Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because DIABINESE belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Chlorpropamide_07_13_2017_FDA.pdf"">chlorpropamide drug label</a>.</p>
<p>*Disclaimer: The contents of this page are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450379956.0,"<p>Excerpt from the chlorpropamide (DIABINESE) drug label:</p>
<blockquote class=""blockquote"">
<p>Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because DIABINESE belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104787,Annotation of FDA Label for cevimeline and CYP2D6,False,False,[],False,"[{'id': 1183681261, 'date': '2013-10-25T11:03:08.892-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101805, 'title': 'Drugs@FDA: Drug Product Cevimeline (Cevimeline), NDA020989, Sun Pharmaceutical Industries, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020989', 'crossReferences': [{'id': 1449895442, 'resource': 'FDA Application', 'resourceId': 'NDA020989', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020989'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164754754', 'name': 'cevimeline'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450342783.0,"<p>The FDA-approved drug label for cevimeline (EVOXAC) states that CYP2D6, CYP3A3 and CYP3A4 are responsible for the metabolism of cevimeline, and that cevimeline should be used with caution in individuals known or suspected to be CYP2D6 poor metabolizers, as they may be at a higher risk of adverse events.</p>
",1450342784.0,"<p>Cevimeline (EVOXAC) is indicated for the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome.</p>
<p>Excerpts from the cevimeline (EVOXAC) drug label:</p>
<div class=""blockquote"">
<p>Isozymes CYP2D6 and CYP3A3/4 are responsible for the metabolism of cevimeline.</p>
</div>
<div class=""blockquote"">
<p>Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline. Cevimeline should be used with caution in individuals known or suspected to be deficient in CYP2D6 activity, based on previous experience, as they may be at a higher risk of adverse events.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Cevimeline_07_13_2017_FDA.pdf"">cevimeline drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399537.0,"<p>Excerpt from the cevimeline (EVOXAC) drug label:</p>
<blockquote class=""blockquote"">
<p>Cevimeline should be used with caution in individuals known or suspected to be deficient in CYP2D6 activity, based on previous experience, as they may be at a higher risk of adverse events.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166359641,Annotation of HCSC Label for venlafaxine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15170722, 'title': 'Drugs@HCSC: Drug Product EFFEXOR XR (venlafaxine), BGP Pharma ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60600', 'crossReferences': [{'id': 1452710920, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60600', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60600'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451866', 'name': 'venlafaxine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452710960.0,"<p>The product monograph for venlafaxine (EFFEXOR XR) states that, although plasma concentrations of venlafaxine were higher in CYP2D6 poor metabolizers than extensive metabolizers, the total exposure of venlafaxine and its active metabolite was similar, and there is no need for different venlafaxine dosing regimens for these two groups.</p>
",1452710961.0,"<p>Excerpts from the venlafaxine (EFFEXOR® XR) product monograph:</p>
<blockquote class=""blockquote"">
<p>Following absorption, venlafaxine undergoes extensive presystemic metabolism in the liver. The absolute bioavailability of venlafaxine is approximately 45%. The primary metabolite of venlafaxine is ODV, which is an active metabolite. ODV peak plasma levels occur approximately 4 hours after dosing. Venlafaxine is also metabolized to N-desmethylvenlafaxine, N,O-didesmethylvenlafaxine, and other minor metabolites. In vitro studies indicate that the formation of ODV is catalysed by CYP2D6 and that the formation of N-desmethylvenlafaxine is catalysed by CYP3A3/4. The results of the in vitro studies have been confirmed in a clinical study with subjects who are CYP2D6 poor and extensive metabolizers. However, despite the metabolic differences between the CYP2D6 poor and extensive metabolizers, the total exposure to the sum of the two active species (venlafaxine and ODV, which have comparable activity) was similar in the two metabolizer groups.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Genetic Polymorphism:</strong> Plasma concentrations of venlafaxine were higher in CYP2D6 poor metabolizers than extensive metabolizers. Because the total exposure (AUC) of venlafaxine and ODV was similar in poor and extensive metabolizer groups, there is no need for different venlafaxine dosing regimens for these two groups.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Venlafaxine_2024_11_20_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Venlafaxine_2024_11_20_HCSC.pdf"">venlafaxine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166127731,Annotation of HCSC Label for vortioxetine and CYP2D6,False,False,[],False,"[{'id': 1452711240, 'date': '2024-11-21T11:12:54.952-08:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15170822, 'title': 'Drugs@HCSC: Drug Product TRINTELLIX (vortioxetine), Lundbeck Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91732', 'crossReferences': [{'id': 1452711202, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91732', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91732'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166122595', 'name': 'vortioxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982417.0,"<p>The product monograph for vortioxetine (TRINTELLIX) states that the plasma concentration of the drug is approximately 2 times higher in CYP2D6 poor metabolizers as compared to extensive metabolizers.</p>
",1447982416.0,"<p>Vortioxetine (TRINTELLIX) is indicated for the treatment of major depressive disorder. Excerpts from the vortioxetine (TRINTELLIX) product monograph:</p>
<blockquote class=""blockquote"">
<p><em>In vitro</em>, the cytochrome P450 isozymes CYP2D6, CYP3A4/5, CYP2C19, CYP2C9, CYP2A6, CYP2C8 and CYP2B6 are involved in the metabolism of vortioxetine. CYP2D6 is the primary enzyme catalyzing the metabolism of vortioxetine to its major, pharmacologically inactive, carboxylic acid metabolite.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Genetic Polymorphism (CYP2D6 Poor Metabolizers):</strong> The plasma concentration of vortioxetine was approximately two times higher in CYP2D6 poor metabolizers than in extensive metabolizers. In the presence of strong CYP3A4/2C9-inhibitors, the exposure could potentially be higher and a dosage adjustment may be required (see 9.4 Drug-Drug Interactions).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Vortioxetine_2024_11_21_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Vortioxetine_2024_11_21_HCSC.pdf"">vortioxetine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184423,Annotation of Swissmedic Label for antithrombotic agents and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103104, 'title': 'Swissmedic label for Thrombozytenaggregationshemmer, exkl. Heparin (DuoPlavin 75/100 mg)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=58696', 'crossReferences': [{'id': 1450812065, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=58696', '_url': 'https://amiko.oddb.org/de/fi?gtin=58696'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA452200', 'name': 'antithrombotic agents'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450815558.0,"<p>The Swiss drug label for Thrombozytenaggregationshemmer, exkl. Heparin (DuoPlavin 75/100 mg) cautions about use in patients with G6PD deficiency.</p>
",1450815559.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for Thrombozytenaggregationshemmer, exkl. Heparin (DuoPlavin 75/100 mg):</p>
<blockquote class=""blockquote"">
<p>Precautions
This medication should be used under strict medical supervision in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk of hemolysis (see &quot;Adverse effects&quot;).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=58696&amp;highlight=G6PD-Mangel"" target=""_blank"">antithrombotic drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184111,Annotation of Swissmedic Label for atomoxetine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103152, 'title': 'Swissmedic label for atomoxetine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=58245', 'crossReferences': [{'id': 1450813248, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=58245', '_url': 'https://amiko.oddb.org/de/fi?gtin=58245'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA134688071', 'name': 'atomoxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450813596.0,"<p>The Swiss drug label for atomoxetine (Srattera) states that caution should be exercised when CYP2D6 poor metabolizers take atomoxetine at the same time other cytochrome P450 inhibitors, as there is a risk of increasing the plasma concentrations of atomoxetine.</p>
",1450813597.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for atomoxetine (Srattera):</p>
<blockquote class=""blockquote"">
<p>Dosage/Usage
About 7% of all Caucasians have a genotype corresponding to a defective CYP2D6 enzyme (so-called CYP2D6 poor metabolisers). Patients with this genotype have an increased exposure to atomoxetine compared to patients with a functioning enzyme.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Kinetics
Atomoxetine is mainly metabolized by cytochrome P450 2D6 (CYP2D6). The main metabolite formed by oxidation is 4-hydroxyatomoxetine, which is rapidly glucuronidated. Persons with reduced activity of this metabolic pathway (&quot;poor metaboliser&quot;, PM) (about 7% of all Caucasians) have a higher atomoxetine plasma concentration compared to persons with normal activity of this metabolic pathway (&quot;extensive metabolisers&quot;, EM). The AUC for atomoxetine in PM's is about 10 times and the steady state levels (Css, max) are about 5 times higher compared to EM's. 4-Hydoxyatomoxetine has the same effect as atomoxetine, but is present in much lower plasma concentrations. Although 4-hydroxyatomoxetine is mainly produced by CYP2D6, 4-hydroxyatomoxetine can be produced by various other cytochrome P450 enzymes in individuals with no CYP2D6 activity, but more slowly. At therapeutic doses, atomoxetine does not inhibit or induce CYP2D6 activity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Interactions
CYP2D6 inhibitors (SSRI's (e.g. fluoxetine, paroxetine), quinidine, terbinafine): Atomoxetine is mainly metabolized by CYP2D6 to 4-hydroxyatomoxetine. In patients with strong metabolization by CYP2D6 (&quot;extensive metabolizer&quot;), selective CYP2D6 inhibitors may increase atomoxetine steady-state plasma concentration to a level similar to that observed in patients with weak metabolization by CYP2D6 (&quot;poor metabolizer&quot;). In patients with pronounced metabolism who are treated simultaneously with paroxetine or fluoxetine, both the AUC of atomoxetine (about 6 to 8 times) and the steady state levels (3 to 4 times) are elevated compared to patients who are treated only with atomoxetine. Slower titration of atomoxetine may be necessary in patients taking CYP2D6 inhibitors at the same time. If a CYP2D6 inhibitory substance is prescribed or discontinued after the maintenance dose of atomoxetine has been defined, clinical efficacy and tolerability should be reassessed and the dose adjusted for the patient if necessary.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Caution should be exercised when patients with poor metabolizers of CYP2D6 are taking atomoxetine at the same time as substances that can inhibit other cytochrome P450 enzymes in addition to CYP2D6, as there is a risk of increasing the concentration of atomoxetine plasma. In vivo data on this are not known.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=58245&amp;highlight=metabolizer"" target=""_blank"">atomoxetine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184456,Annotation of Swissmedic Label for glibenclamide and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103281, 'title': 'Swissmedic label for glibenclamide', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=35402', 'crossReferences': [{'id': 1450815665, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=35402', '_url': 'https://amiko.oddb.org/de/fi?gtin=35402'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449782', 'name': 'glyburide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450815772.0,"<p>The Swiss drug label for glibenclamide (Daonil) states that caution should be used when treating patients with G6PD deficiency with glibenclamide as they are at increased risk for hemolytic anemia.</p>
",1450815773.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for glibenclamide (Daonil):</p>
<blockquote class=""blockquote"">
<p>Precautions:
Treatment of patients with glucose-6-phosphate dehydrogenase deficiency with sulfonylurea compounds may lead to hemolytic anemia. Glibenclamide should be used with caution in patients with glucose-6-phosphate dehydrogenase deficiency because it belongs to the class of sulfonylureas. Treatment with a non-sulfonylurea substitute should also be considered.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=35402&amp;highlight=Glucose-6-Phosphat-Dehydrogenase-Mangel"" target=""_blank"">glibenclamide drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166104776,"Annotation of FDA Label for warfarin and CYP2C9, VKORC1",False,False,[],True,"[{'id': 1183681191, 'date': '2013-10-25T10:40:29.882-07:00', 'type': 'Update', 'version': 0}, {'id': 1184483106, 'date': '2014-07-14T00:00:00-07:00', 'description': 'FDA Table added the gene PROC', 'type': 'Update', 'version': 0}, {'id': 1451280400, 'date': '2020-10-16T17:59:39.889-07:00', 'description': 'Updated Prescribing Info section to be more specific about what is in Table 1.', 'type': 'Update', 'version': 0}, {'id': 1452324620, 'date': '2023-12-12T10:56:21.222-08:00', 'description': 'Added dosing info tag because the label provides genotype-based dosing guidance', 'type': 'Update', 'version': 0}, {'id': 1452711484, 'date': '2024-11-21T00:00:00-08:00', 'description': 'moved PROC, PROS1 genes to a separate label annotation', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101939, 'title': 'Drugs@FDA: Drug Product COUMADIN (warfarin sodium), NDA009218, Bristol-Myers Squibb Pharma Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009218', 'crossReferences': [{'id': 1449891982, 'resource': 'FDA Application', 'resourceId': 'NDA009218', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009218'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA133787052', 'symbol': 'VKORC1', 'name': 'vitamin K epoxide reductase complex subunit 1'}]","[{'objCls': 'Haplotype', 'id': 'PA165816542', 'symbol': 'CYP2C9*1', 'name': '*1'}, {'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}, {'objCls': 'Variant', 'id': 'PA166155091', 'symbol': 'rs9923231', 'name': 'rs9923231'}]","[{'objCls': 'Chemical', 'id': 'PA451906', 'name': 'warfarin'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA133787052', 'symbol': 'VKORC1', 'name': 'vitamin K epoxide reductase complex subunit 1'}]",FDA,1447981534.0,"<p>Warfarin (COUMADIN) is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillation and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. Pharmacogenomics-related dosing information for CYP2C9 and VKORC1 variants is provided within the label.</p>
",1447981533.0,"<p>The VKORC1:G-1639A polymorphism is associated with lower dose requirements for warfarin in Caucasian and Asian patients. Increased bleeding risk and lower initial warfarin dose requirements have been associated with the CYP2C9*2 and CYP2C9*3 alleles. Approximately 30% of the variance in warfarin dose could be attributed to genetic variation in VKORC1, and about 40% of dose variance could be explained taking into consideration both VKORC1 and CYP2C9 genetic polymorphisms. Accounting for genetic variation in both VKORC1 and CYP2C9, age, height, body weight, interacting drugs, and indication for warfarin therapy explained about 55% of the variability in warfarin dose.</p>
<p>Excerpts from the warfarin (COUMADIN) drug label:</p>
<div class=""blockquote"">
<p>Table 1 displays three ranges of expected maintenance COUMADIN doses observed in subgroups of patients having different combinations of CYP2C9 and VKORC1 gene variants...If the patient’s CYP2C9 and/or VKORC1 genotype are known, consider these ranges in choosing the initial dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3, and *3/*3 may require more prolonged time (&gt;2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen than patients without these CYP variants.</p>
</div>
<div class=""blockquote"">
<p>Known or suspected deficiency in protein C mediated anticoagulant response: Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Warfarin_03_01_19_FDA.pdf"">warfarin drug label</a>. Pharmacogenomics-related dosing information is found in Table 5 on page 27.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450384944.0,"<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and &quot;VKORC1−1639G&gt;A (rs9923231)&quot; genotypes.</p>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166184223,"Annotation of Swissmedic Label for Paracetamol, combinations excl. Psycholeptics (Vicks MediNait Sirup) and CYP2D6, G6PD",False,False,[],False,"[{'id': 1451753960, 'date': '2022-04-18T09:14:46.804-07:00', 'description': 'Removed broken link to one label, the Vicks MediNait Syrup label is still valid and remains.', 'type': 'Update', 'version': 0}, {'id': 1452021988, 'date': '2023-02-28T14:33:14.092-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103069, 'title': 'Swissmedic label for Paracetamol, Kombinationen exkl. Psycholeptika (Vicks MediNait Sirup)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=41799', 'crossReferences': [{'id': 1450812030, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=41799', '_url': 'https://amiko.oddb.org/de/fi?gtin=41799'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166184497', 'name': 'paracetamol, combinations excl. Psycholeptics (Vicks MediNait Sirup)'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450814366.0,"<p>The Swiss drug label for Paracetamol (acetaminophen), combinations excl. Psycholeptics (Vicks MediNait® Sirup) states that patients with Glucose-6-phosphate dehydrogenase deficiency may have risk for hemolytic anemia and patients with CYP2D6 deficiency may have altered drug metabolism.</p>
",1450814367.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for Paracetamol, Kombinationen exkl. Psycholeptika (Vicks MediNait® Sirup) :</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Metabolism and elimination are strongly delayed in patients with CYP2D6 deficiency. Due to a genetic polymorphism, 10 to 15% of the population belong to the so-called slow metabolizers (debrisoquin type). In the case of liver or kidney dysfunction, delayed elimination must also be expected.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Warnings and Precautions:
In the following cases a medical consultation is required before the start of treatment:
Glucose-6-phosphate dehydrogenase deficiency (may lead to hemolytic anemia)</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Overdose:
An overdose can occur directly (acutely), but also if considerably higher doses are taken for more than 3-4 days and if there is a delay in elimination (genetic or due to interactions).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the
<a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=41799&amp;highlight=genetisch"" target=""_blank"">Vicks MediNait® Sirup drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450821360.0,"<blockquote class=""blockquote"">
<p>Warnings and Precautions:
In the following cases a medical consultation is required before the start of treatment:
Glucose-6-phosphate dehydrogenase deficiency (may lead to hemolytic anemia)</p>
</blockquote>
",,,,,,,
Label Annotation,PA166359701,"Annotation of FDA Label for warfarin and PROC, PROS1",False,False,[],False,[],False,[],True,"[{'id': 15101939, 'title': 'Drugs@FDA: Drug Product COUMADIN (warfarin sodium), NDA009218, Bristol-Myers Squibb Pharma Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009218', 'crossReferences': [{'id': 1449891982, 'resource': 'FDA Application', 'resourceId': 'NDA009218', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009218'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451906', 'name': 'warfarin'}]","[{'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}]",FDA,1452711480.0,"<p>Warfarin (COUMADIN) is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillation and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. The drug label notes that deficiency in protein C (PROC) or protein S (PROS1) have been associated with tissue necrosis following warfarin administration.</p>
",1452711481.0,"<p>Excerpts from the warfarin (COUMADIN) label:</p>
<blockquote class=""blockquote"">
<p>Deficiency in protein C-mediated anticoagulant response: COUMADIN reduces the synthesis of the naturally occurring anticoagulants, protein C and protein S. Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Concomitant anticoagulation therapy with heparin for 5 to 7 days during initiation of therapy with COUMADIN may minimize the incidence of tissue necrosis in these patients.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Warfarin_03_01_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Warfarin_03_01_19_FDA.pdf"">warfarin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452711482.0,"<blockquote class=""blockquote"">
<p>Deficiency in protein C-mediated anticoagulant response: COUMADIN reduces the synthesis of the naturally occurring anticoagulants, protein C and protein S. Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Concomitant anticoagulation therapy with heparin for 5 to 7 days during initiation of therapy with COUMADIN may minimize the incidence of tissue necrosis in these patients.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166184428,Annotation of Swissmedic Label for sertindole and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103089, 'title': 'Swissmedic label for sertindol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=53845', 'crossReferences': [{'id': 1450812050, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=53845', '_url': 'https://amiko.oddb.org/de/fi?gtin=53845'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164784002', 'name': 'sertindole'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815588.0,"<p>The Swiss drug label for sertindole (Serdolect) states that sertindole is extensively metabolized by the CYP2D6 and CYP3A, and sertidole concentration may be affected in patients who are CYP2D6 poor metabolizers and in patients simultaneously taking drugs that are CYP2C6 or CYP3A inhibitors.</p>
",1450815589.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the sertindole (Serdolect) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
Sertindol is excreted via the liver with a mean terminal half-life of about 3 days. The clearance of Sertindol decreases with repeated administration to about 14 l/hour (in women the apparent clearance is about 20% lower than in men, although the clearance values corrected to lean body mass are comparable). Therefore, due to an increase in systemic bioavailability, the accumulation after repeated administration is higher than would be expected after extrapolation of single dose results. Nevertheless, in steady state clearance is dose-independent and plasma concentrations are dose-proportional. Due to the polymorphism of cytochrome P450 2D6 (CYP2D6) there is a moderate interindividual variability of the pharmacokinetics of Sertindol. The Sertindol clearance values of patients lacking this liver enzyme are only half or one third of those of good CYP2D6 metabolizers. In these poor metabolizers (up to 10% of the population) plasma levels will therefore be two to three times normal. Sertindol concentration is not a predictor of therapeutic efficacy in a single patient; individual dose settings are therefore best made by assessing therapeutic efficacy and tolerability.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Interaction:
Sertindol is extensively metabolized by the CYP2D6 and CYP3A isozymes of the cytochrome P450 system. CYP2D6 is polymorphic in the population. Both isoenzymes can be inhibited by a number of psychotropic and other drugs (see &quot;Warnings and Precautions&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6: In patients who simultaneously take fluoxetine or paroxetine (strong CYP2D6 inhibitors), the plasma concentration of sertindol is increased by a factor of 2-3. For this reason, Sertindol should be administered with great caution at the same time as these or other CYP2D6 inhibitors. A lower maintenance dose of Sertindol may be required, as may careful ECG monitoring before and after each dose adjustment of these drugs (see &quot;Warnings and Precautions&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP3A: Minor increases (&lt;25%) in sertindole plasma concentration have been detected for macrolide antibiotics (e.g. erythromycin, a CYP3A inhibitor) and calcium antagonists (diltiazem, verapamil). In slow CYP2D6 metabolizers, however, the effect may be more pronounced (since the metabolism of sertindole occurs via CYP2D6 as well as CYP3A). Since it is not possible to routinely detect slow CYP2D6 metabolizers, simultaneous administration of CYP3A inhibitors and sertindol is contraindicated as this may lead to significantly elevated sertindol levels (see &quot;Contraindications&quot;).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=53845&amp;highlight=polymorph"" target=""_blank"">sertindole drug label</a> (in German);</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184231,Annotation of Swissmedic Label for umeclidinium and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103277, 'title': 'Swissmedic label for fluticason furoat, umeclidinium, vilanterol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=66808', 'crossReferences': [{'id': 1450815661, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=66808', '_url': 'https://amiko.oddb.org/de/fi?gtin=66808'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103111, 'title': 'Swissmedic label for umeclidin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65091', 'crossReferences': [{'id': 1450812072, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65091', '_url': 'https://amiko.oddb.org/de/fi?gtin=65091'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177519', 'name': 'umeclidinium'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450814436.0,"<p>The Swiss drug label for umeclidinium (Incruse Ellipta) states that umeclidinium exposure is not affected by CYP2D6 genotype.</p>
",1450814437.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for umeclidinium (Incruse Ellipta):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
A population pharmacokinetic analysis showed that Umeclidinium bromide did not require dose adjustment due to age, race, sex, use of inhaled corticosteroids or weight. A study with slow CYP2D6 metabolizers did not demonstrate any effect of CYP2D6 genetic polymorphism on systemic Umeclidinium bromide exposure.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65091&amp;highlight=genetischen"" target=""_blank"">umeclidinium drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184237,Annotation of Swissmedic Label for Vitamin B-complex with vitamin C and G6PD,False,False,[],False,[],False,[],True,"[{'id': 15103115, 'title': 'Swissmedic label for vitamin-B-Komplex, andere Kombinationen', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=36327', 'crossReferences': [{'id': 1450812076, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=36327', '_url': 'https://amiko.oddb.org/de/fi?gtin=36327'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164713397', 'name': 'Vitamin B-complex with vitamin C'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450814454.0,"<p>The Swiss drug label for vitamin B complex with vitamin C (Begrocit) states that overdose of vitamin C can cause hemolysis in patients with G6PD deficiency.</p>
",1450814455.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for vitamin B complex (Begrocit):</p>
<blockquote class=""blockquote"">
<p>Overdose:
Ascorbic acid overdose can lead to iron overload in patients with iron storage disorders (e.g. sideroblastic anemia, hemochromatosis) - see &quot;Contraindications&quot; - and cause hemolysis in patients with congenital erythrocyte glucose-6-phosphate dehydrogenase deficiency.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=36327&amp;highlight=Glucose-6-Phosphat-Dehydrogenase-Mangel"" target=""_blank"">vitamin B complex with vitamin C drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166359741,Annotation of HCSC Label for amikacin,False,False,[],False,[],False,[],True,"[{'id': 15170862, 'title': 'Drugs@HCSC: Drug Product ERFA-AMIKACIN (amikacin), Searchlight Pharma Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97920', 'crossReferences': [{'id': 1452712380, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97920', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97920'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA164744372', 'name': 'amikacin'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166184490,Annotation of Swissmedic Label for zuclopenthixol and CYP2D6,False,False,[],False,"[{'id': 1452220505, 'date': '2023-08-29T13:02:46.187-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103119, 'title': 'Swissmedic label for zuclopenthixol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=44744', 'crossReferences': [{'id': 1450812080, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=44744', '_url': 'https://amiko.oddb.org/de/fi?gtin=44744'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA452629', 'name': 'zuclopenthixol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450820336.0,"<p>The Swiss drug label for zuclopenthixol (Clopixol) states that zuclopenthixol is metabolized by the polymorphic CYP2D6 but the clinical significance of poor metabolizer genotypes on metabolite production is not known.</p>
",1450820337.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for zuclopenthixol (Clopixol):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Zuclopenthixol is metabolized in three ways: by sulfoxidation, N-side chain dealkylation and glucuronic acid conjugation. The metabolites are pharmacologically inactive. Some of the metabolites of Zuclopenthixol are dependent on CYP2D6 and are subject to genetic polymorphism. The clinical significance of this polymorphism is unknown.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=44744&amp;highlight=genetischen%20Polymorphismus"" target=""_blank"">zuclopenthixol drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166184499,"Annotation of Swissmedic Label for rosuvastatin and ABCG2, SLCO1B1",False,False,[],True,"[{'id': 1452022040, 'date': '2023-02-28T14:36:35.748-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452555260, 'date': '2024-08-13T13:24:32.740-07:00', 'description': 'added Dosing Info tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103087, 'title': 'Swissmedic label for rosuvastatin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=56139', 'crossReferences': [{'id': 1450812048, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=56139', '_url': 'https://amiko.oddb.org/de/fi?gtin=56139'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA390', 'symbol': 'ABCG2', 'name': 'ATP binding cassette subfamily G member 2 (JR blood group)'}, {'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]","[{'objCls': 'Variant', 'id': 'PA166156544', 'symbol': 'rs2231142', 'name': 'rs2231142'}, {'objCls': 'Variant', 'id': 'PA166154579', 'symbol': 'rs4149056', 'name': 'rs4149056'}]","[{'objCls': 'Chemical', 'id': 'PA134308647', 'name': 'rosuvastatin'}]","[{'objCls': 'Gene', 'id': 'PA390', 'symbol': 'ABCG2', 'name': 'ATP binding cassette subfamily G member 2 (JR blood group)'}, {'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",Swissmedic,1450820423.0,"<p>The Swiss drug label for rosuvastatin (Crestor) states that genetic polymorphisms in SLCO1B1 and ABCG2  may lead to an increase in rosuvastatin exposure, a reduction in the dosage is recommended.</p>
",1450820424.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the rosuvastatin (Crestor) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
ethnicity: Pharmacokinetic studies conducted in Asia showed a 2-fold increase in mean AUC in Asians compared to Caucasians living in Asia or Europe. The involvement of environmental influences and genetic factors in these observed differences was not investigated. A pharmacokinetic analysis showed no clinically relevant differences between Caucasians, Hispanics and blacks or persons of Afro-Caribbean origin.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genetic polymorphisms: The availability of HMG-CoA reductase inhibitors such as rosuvastatin depends, among other things, on the transport proteins OATP1B1 and BCRP. Patients with different sequence variations of the SLCO1B1 gene (OATP1B1) and/or the ABCG2 gene (BCRP) are at risk of increased exposure to rosvastatin. The genotype variants SLCO1B1 c.521CC and ABCG2 c.421AA are associated with approximately 1.7-fold higher exposure to rosuvastatin (AUC) and 2.4-fold higher exposure respectively than the variants SLCO1B1 c.521TT and ABCG2 c.421CC.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dosage:
race: Increased plasma levels of rosuvastatin have been observed in Asians (see &quot;Warnings and Precautions&quot; and &quot;Pharmacokinetics&quot;). The recommended starting dose for Asians is 5 mg and the dose of 40 mg is contraindicated.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genetic polymorphisms: Specific types of genetic polymorphisms are known that may lead to an increase in rosuvastatin exposure (see &quot;Pharmacokinetics&quot;). In patients known to have such a polymorphism, a reduction in the dosage of Crestor is recommended.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=56139"" target=""_blank"">Crestor drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450820425.0,"<blockquote class=""blockquote"">
<p>Increased plasma levels of rosuvastatin have been observed in Asians (see &quot;Warnings and Precautions&quot; and &quot;Pharmacokinetics&quot;). The recommended starting dose for Asians is 5 mg and the dose of 40 mg is contraindicated.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genetic polymorphisms
Specific types of genetic polymorphisms are known that may lead to an increase in rosuvastatin exposure (see &quot;Pharmacokinetics&quot;). In patients known to have such a polymorphism, a reduction in the dosage of Crestor is recommended.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genetic polymorphisms
Specific types of genetic polymorphisms are known that may lead to an increase in rosuvastatin exposure (see &quot;Pharmacokinetics&quot;). In patients in whom such a polymorphism is known, a reduction in the dosage of ezetimib-rosuvastatin mepha is recommended.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166359761,"Annotation of HCSC Label for amitriptyline and CYP2C19, CYP2D6",False,False,[],True,[],False,[],True,"[{'id': 15170882, 'title': 'Drugs@HCSC: Drug Product AMITRIPTYLINE (amitriptyline), PRO DOC LTÉE.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2426', 'crossReferences': [{'id': 1452712440, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2426', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2426'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448385', 'name': 'amitriptyline'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452712441.0,"<p>The product monograph for amitriptyline states that CYP2D6 or CYP2C19 poor metabolizers may have higher plasma concentrations of amitriptyline, and that dosage adjustment should be considered..</p>
",1452712442.0,"<p>Excerpts from the amitriptyline product monograph:</p>
<blockquote class=""blockquote"">
<p><strong>Use in CYP2D6 or CYP2C19 poor metabolizers</strong> These patients may have higher plasma concentrations of amitriptyline (see 9.2 Drug Interactions Overview). Dosage adjustment should be considered.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Tricyclic antidepressants (TCA) including amitriptyline are primarily metabolized by the hepatic cytochrome P450 isozymes CYP2D6 and CYP2C19, which are polymorphic in the population.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The biochemical activity of the drug metabolizing isozyme CYP2D6 is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. The biochemical activity of the drug metabolizing isozyme CYP2C19 is also reduced in a subset of the population (CYP2C19 poor metabolizers). Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. For instance, in CYP2D6 poor metabolizers the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA), depending on the fraction of the drug metabolized by CYP2D6.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Other isozymes involved in the metabolism of amitriptyline are CYP3A4, CYP1A2 and CYP2C9.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Amitriptyline_2024_11_22_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Amitriptyline_2024_11_22_HCSC.pdf"">amitriptyline product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452712443.0,"<blockquote class=""blockquote"">
<p><strong>Use in CYP2D6 or CYP2C19 poor metabolizers</strong> These patients may have higher plasma concentrations of amitriptyline [...]. Dosage adjustment should be considered.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184434,"Annotation of Swissmedic Label for sofosbuvir and IFNL3, IFNL4",False,False,[],False,[],False,[],True,"[{'id': 15103093, 'title': 'Swissmedic label for sofosbuvir', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=63218', 'crossReferences': [{'id': 1450812054, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=63218', '_url': 'https://amiko.oddb.org/de/fi?gtin=63218'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}, {'objCls': 'Gene', 'id': 'PA166049147', 'symbol': 'IFNL4', 'name': 'interferon lambda 4 (gene/pseudogene)'}]","[{'objCls': 'Variant', 'id': 'PA166155468', 'symbol': 'rs12979860', 'name': 'rs12979860'}]","[{'objCls': 'Chemical', 'id': 'PA166122593', 'name': 'sofosbuvir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}, {'objCls': 'Gene', 'id': 'PA166049147', 'symbol': 'IFNL4', 'name': 'interferon lambda 4 (gene/pseudogene)'}]",Swissmedic,1450815607.0,"<p>The Swiss drug label for sofosbuvir (Sovaldi) states that &quot;consideration should be given to possibly extending the duration of therapy beyond 12 weeks up to 24 weeks, in particular for subgroups with one or more of the previously identified negative predictive factors associated in the past with lower response rates to interferon-containing therapies (e.g. advanced fibrosis/cirrhosis, high initial viral load, black skin, IL28B-Non-CC genotype, earlier non-response to peginterferon alfa and ribavirin).&quot;</p>
",1450815608.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the sofosbuvir (Sovaldi) label:</p>
<blockquote class=""blockquote"">
<p>Dosage:
Consideration should be given to possibly extending the duration of therapy beyond 12 weeks up to 24 weeks, in particular for subgroups with one or more of the previously identified negative predictive factors associated in the past with lower response rates to interferon-containing therapies (e.g. advanced fibrosis/cirrhosis, high initial viral load, black skin, IL28B-Non-CC genotype, earlier non-response to peginterferon alfa and ribavirin).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Properties / Effects:
SVR12 rates were similarly high (202/232 (87%)) among patients with the C/C allele of the IL28B gene at baseline (94/95 (99%)) and other alleles (C/T or T/T).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=63218&amp;highlight=Allelen"" target=""_blank"">sofosbuvir drug label</a> (in German);</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450815609.0,"<blockquote class=""blockquote"">
<p>Consideration should be given to possibly extending the duration of therapy beyond 12 weeks up to 24 weeks, in particular for subgroups with one or more of the previously identified negative predictive factors associated in the past with lower response rates to interferon-containing therapies (e.g. advanced fibrosis/cirrhosis, high initial viral load, black skin, IL28B-Non-CC genotype, earlier non-response to peginterferon alfa and ribavirin).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166223861,Annotation of FDA Label for bupropion and CYP2D6,False,False,[],False,"[{'id': 1452206400, 'date': '2023-08-14T12:17:51.553-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15114262, 'title': 'Drugs@FDA: Drug Product Wellbutrin (bupropion), NDA018644/SUPPL-54, 11/05/2019', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018644', 'crossReferences': [{'id': 1453104064, 'resource': 'FDA Application', 'resourceId': 'NDA018644/SUPPL-54', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018644'}], 'objCls': 'Literature', 'pubDate': '2019-11-05T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448687', 'name': 'bupropion'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1451265320.0,"<p>The FDA-approved drug label for bupropion (WELLBUTRIN) states that bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants, antipsychotics, beta-blockers, and Type 1C antiarrhythmics.</p>
",1451265321.0,"<p>Excerpts from the bupropion (WELLBUTRIN) drug label:</p>
<blockquote class=""blockquote"">
<p>Drugs Metabolized by CYP2D6</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include certain antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone and flecainide). When used concomitantly with WELLBUTRIN, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Drugs that require metabolic activation by CYP2D6 to be effective (e.g., tamoxifen) theoretically could have reduced efficacy when administered concomitantly with inhibitors of CYP2D6 such as bupropion. Patients treated concomitantly with WELLBUTRIN and such drugs may require increased doses of the drug</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""bupropion_FDA_label_08232020.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/bupropion_FDA_label_08232020.pdf"">bupropion drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166224061,Annotation of HCSC Label for oxcarbazepine and HLA-B,True,False,[],False,"[{'id': 1452021762, 'date': '2023-02-28T13:04:29.943-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452540061, 'date': '2024-07-26T09:46:31.851-07:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162122, 'title': 'Drugs@HCSC: Drug Product APO-OXCARBAZEPINE (oxcarbazepine), APOTEX INC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76987', 'crossReferences': [{'id': 1452540020, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76987', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76987'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165954769', 'symbol': 'HLA-B*15:02', 'name': '*15:02'}]","[{'objCls': 'Chemical', 'id': 'PA450732', 'name': 'oxcarbazepine'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",HCSC,1451266940.0,"<p>The product monograph for oxcarbazepine (APO-OXCARBAZEPINE) states that based on studies, the presence of HLA-B*1502 allele may be one of the risk factors for oxcarbazepine-associated SJS/TEN in patients with Asian ancestry. HLA-B*1502 genotyping should be considered in these patients, and use of oxcarbazepine should be avoided in patients who test positive for the HLA-B*1502 allele unless the benefits clearly outweigh the risks.</p>
",1451266941.0,"<p>Excerpts from the oxcarbazepine (APO-OXCARBAZEPINE) product monograph:</p>
<blockquote class=""blockquote"">
<p>Human Leukocyte Antigens (HLA)-A*3101 and HLA-B*1502 may be risk factors for the development of serious cutaneous adverse drug reactions.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In studies that included small samples of carbamazepine treated patients of Han Chinese ancestry a strong association was found between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA-B gene. The HLA- B*1502 allele is found almost exclusively in individuals with ancestry across broad areas of Asia. Results of these studies suggest that the presence of the HLA-B*1502 allele may be one of the risk factors for oxcarbazepine-associated SJS/TEN in patients with Asian ancestry. Therefore, physicians should consider HLA-B*1502 genotyping as a screening tool in these patients. Until further information is available, the use of APO-OXCARBAZEPINE and other anti-epileptic drugs associated with SJS/TEN should also be avoided in patients who test positive for the HLA-B*1502 allele unless the benefits clearly outweigh the risks. Screening is not generally recommended in patients from populations in which the prevalence of HLA-B*1502 is low or in current oxcarbazepine users, as the risk of SJS/TEN is largely confined to the first few months of therapy, regardless of HLA-B*1502 status.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>HLA-B*1502 and HLA-A*3101 genotyping as screening tools have important limitations and must never substitute for appropriate clinical vigilance and patient management. Many HLA-B*1502-positive Asian patients treated with oxcarbazepine will not develop SJS/TEN, and these reactions can still occur infrequently in HLA-B*1502-negative patients of any ethnicity. Similarly, many patients positive for HLA-A*3101 and treated with oxcarbazepine will not develop SJS, TEN, DRESS, AGEP or maculopapular rash and patients negative for HLA-A*3101 of any ethnicity can still develop these severe cutaneous adverse reactions. The role of other possible factors in the development of, and morbidity from, these severe cutaneous adverse reactions, such as antiepileptic drug (AED) dose, compliance, concomitant medications, co-morbidities, and the level of dermatologic monitoring have not been studied.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In addition, it should be kept in mind that oxcarbazepine treated patients who will experience SJS/TEN have this reaction within the first few months of treatment. This information may be taken into consideration when deciding whether to screen genetically at-risk patients currently on oxcarbazepine.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The identification of subjects carrying the HLA-B*1502 allele and the avoidance of carbamazepine therapy in these subjects has been shown to decrease the incidence of carbamazepine-induced SJS/TEN.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Oxcarbazepine_2024_07_26_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Oxcarbazepine_2024_07_26_HCSC.pdf"">oxcarbazepine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452540060.0,"<p>APO-OXCARBAZEPINE (oxcarbazepine) is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children ages 6 to 16.</p>
",1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1451266942.0,"<p>Excerpt from the oxcarbazepine (APO-OXCARBAZEPINE) product monograph:</p>
<blockquote class=""blockquote"">
<p>Results of these studies suggest that the presence of the HLA-B*1502 allele may be one of the risk factors for oxcarbazepine-associated SJS/TEN in patients with Asian ancestry. Therefore, physicians should consider HLA-B*1502 genotyping as a screening tool in these patients. Until further information is available, the use of APO-OXCARBAZEPINE and other anti-epileptic drugs associated with SJS/TEN should also be avoided in patients who test positive for the HLA-B*1502 allele unless the benefits clearly outweigh the risks. Screening is not generally recommended in patients from populations in which the prevalence of HLA-B*1502 is low or in current oxcarbazepine users, as the risk of SJS/TEN is largely confined to the first few months of therapy, regardless of HLA-B*1502 status.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166359721,"Annotation of HCSC Label for warfarin and PROC, PROS1",False,False,[],False,[],False,[],True,"[{'id': 15161082, 'title': 'Drugs@HCSC: Drug Product Apo-Warfarin (warfarin), Apotex Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66762', 'crossReferences': [{'id': 1452532241, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66762', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66762'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451906', 'name': 'warfarin'}]","[{'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}]",HCSC,1452711520.0,"<p>Warfarin is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillation and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. The drug label notes that hereditary or acquired deficiencies in protein C (PROC) or protein S (PROS1) have been associated with tissue necrosis following warfarin administration, but that the risk associated with these conditions is difficult to evaluate. Decisions about testing and therapy must be made on an individual basis. Concomitant anticoagulation therapy with heparin for 5 to 7 days during initiation of therapy with warfarin may minimize the incidence of tissue necrosis.</p>
",1452711521.0,"<p>Excerpts from the warfarin (APO-WARFARIN) product monograph:</p>
<blockquote class=""blockquote"">
<p>Deficiency in protein C–mediated anticoagulant response: APO-WARFARIN reduces the synthesis of the naturally occurring anticoagulants, protein C and protein S. Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Not all patients with these conditions develop necrosis, and tissue necrosis occurs in patients without these deficiencies. Inherited resistance to activated protein C has been described in many patients with venous thromboembolic disorders but has not yet been evaluated as a risk factor for tissue necrosis. The risk associated with these conditions, both for recurrent thrombosis and for adverse reactions, is difficult to evaluate since it does not appear to be the same for everyone. Decisions about testing and therapy must be made on an individual basis. It has been reported that concomitant anticoagulation therapy with heparin for 5 to 7 days during initiation of therapy with warfarin may minimize the incidence of tissue necrosis. Warfarin therapy should be discontinued when warfarin is suspected to be the cause of developing necrosis and heparin therapy may be considered for anticoagulation.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Warfarin_2024_07_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Warfarin_2024_07_19_HCSC.pdf"">warfarin product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452716280.0,"<blockquote class=""blockquote"">
<p>Deficiency in protein C–mediated anticoagulant response: APO-WARFARIN reduces the synthesis of the naturally occurring anticoagulants, protein C and protein S. Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. [...] It has been reported that concomitant anticoagulation therapy with heparin for 5 to 7 days during initiation of therapy with warfarin may minimize the incidence of tissue necrosis.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166224121,Annotation of FDA Label for escitalopram and CYP2D6,False,False,[],False,"[{'id': 1452280160, 'date': '2023-10-24T14:13:18.137-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}, {'id': 1452823561, 'date': '2025-01-23T17:53:22.964-08:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15173382, 'title': 'Drugs@FDA: Drug Product Lexapro (ESCITALOPRAM), Allergan, Inc. - NDA021323/SUPPL-58, 04/19/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021323', 'crossReferences': [{'id': 1452823520, 'resource': 'FDA Application', 'resourceId': 'NDA021323/SUPPL-58', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021323'}], 'objCls': 'Literature', 'pubDate': '2024-04-19T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15102047, 'title': 'Drugs@FDA: Drug Product Lexapro (ESCITALOPRAM OXALATE), NDA021323, Allergan, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021323', 'crossReferences': [{'id': 1449754597, 'resource': 'FDA Application', 'resourceId': 'NDA021323', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021323'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10074', 'name': 'escitalopram'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1451267760.0,"<p>The FDA-approved drug label for escitalopram (Lexapro) notes information about possible drug-drug interaction through CYP2D6.</p>
",1451267761.0,"<p>Excerpt from the escitalopram (Lexapro) drug label:</p>
<blockquote class=""blockquote"">
<p><strong>Drugs Metabolized by CYP2D6</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>Clinical Impact:</em> Coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>Intervention:</em> The clinical significance of this finding is unknown. Exercise caution during coadministration of escitalopram and drugs metabolized by CYP2D6.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Escitalopram_2025_01_23_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Escitalopram_2025_01_23_FDA.pdf"">escitalopram drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452823560.0,"<blockquote class=""blockquote"">
<p>Lexapro is a selective serotonin reuptake inhibitor (SSRI) indicated for the:</p>
<ul>
<li>treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older (1)</li>
<li>treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years and older (1)</li>
</ul>
</blockquote>
",,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166224101,Annotation of FDA Label for citalopram and CYP2D6,False,False,[],False,"[{'id': 1452206744, 'date': '2023-08-15T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15101950, 'title': 'Drugs@FDA: Drug Product Celexa (citalopram), NDA020822, Allergan, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020822', 'crossReferences': [{'id': 1449754196, 'resource': 'FDA Application', 'resourceId': 'NDA020822', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020822'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449015', 'name': 'citalopram'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1451267720.0,"<p>The FDA-approved drug label for citalopram (CELEXA) states that citalopram steady state levels were not significantly different between CYP2D6 poor and extensive metabolizers.</p>
",1451267721.0,"<p>Citalopram (CELEXA) is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.</p>
<p>Excerpts from the citalopram (CELEXA) drug label:</p>
<blockquote class=""blockquote"">
<p>CYP2D6 poor metabolizers - Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Citalopram_01_09_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Citalopram_01_09_19_FDA.pdf"">citalopram drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166224962,Annotation of FDA Label for isatuximab,False,True,[],False,"[{'id': 1452209980, 'date': '2023-08-18T11:56:14.633-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15114562, 'title': 'Drugs@FDA: Drug Product  isatuximab BLA761113', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761113', 'crossReferences': [{'id': 1451276489, 'resource': 'FDA Application', 'resourceId': 'BLA761113', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761113'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166224941', 'name': 'isatuximab'}]",[],FDA,1451276486.0,"<p>The FDA label for isatuximab-irfc (SARCLISA) states that it is a CD38-directed cytolytic antibody indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma. The label also notes in the clinical studies that the efficacy and safety of SARCLISA was evaluated in ICARIA-MM trial where 20% of patients had high-risk chromosomal abnormalities at study entry; del(17p), t(4;14) and t(14;16) were present in 12%, 8% and 2% of patients, respectively.</p>
",1451276487.0,"<p>Excerpts from the isatuximab-irfc (SARCLISA) drug label:</p>
<blockquote class=""blockquote"">
<p>Clinical studies:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>14.1 Multiple Myeloma: ICARIA-MM</p>
</blockquote>
<blockquote class=""blockquote"">
<p>... Overall, 20% of patients had high-risk chromosomal abnormalities at study entry; del(17p), t(4;14) and t(14;16) were present in 12%, 8% and 2% of patients, respectively.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""isatuximab_FDA_10092020.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/isatuximab_FDA_10092020.pdf"">isatuximab-irfc drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166225161,Annotation of FDA Label for oliceridine and CYP2D6,False,False,[],True,"[{'id': 1452245320, 'date': '2023-09-25T12:37:38.552-07:00', 'description': 'added Dosing Info tag', 'type': 'Update', 'version': 0}, {'id': 1452583241, 'date': '2024-09-09T16:37:36.644-07:00', 'description': 'added FDA Biomarker List status', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15114703, 'title': 'Drugs@FDA: Drug Product OLINVYK (OLICERIDINE), NDA210730, Trevena, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210730', 'crossReferences': [{'id': 1451278165, 'resource': 'FDA Application', 'resourceId': 'NDA210730', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210730'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166223601', 'name': 'oliceridine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1451278161.0,"<p>The FDA-approved drug label for oliceridine (OLINVYK) states that CYP2D6 poor metabolizers have increased plasma concentrations of olicerdine and may require less frequent dosing.</p>
",1451278162.0,"<p>Excerpts from the oliceridine (OLINVYK) FDA drug label:</p>
<blockquote class=""blockquote"">
<p>Increased plasma concentrations of oliceridine, which may result in prolonged opioid adverse reactions and exacerbated respiratory depression, may occur when OLINVYK is used under the following conditions:</p>
<ul>
<li>In patients with decreased Cytochrome P450 (CYP) 2D6 function (poor metabolizers of CYP2D6 or normal metabolizers taking moderate or strong CYP2D6 inhibitors)</li>
<li>In patients taking a moderate or strong CYP3A4 Inhibitor</li>
<li>In patients with decreased CYP2D6 function who are also receiving a moderate or strong CYP3A4 inhibitor</li>
<li>Discontinuation of a CYP3A4 inducer</li>
</ul>
<p>These patients may require less frequent dosing of OLINVYK. Closely monitor these patients for respiratory depression and sedation at frequent intervals and base subsequent doses of OLINVYK on the patient’s severity of pain and response to treatment.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In healthy subjects who are CYP2D6 poor metabolizers, the AUC0‐inf of oliceridine was approximately 2-fold higher than in subjects who are nonpoor CYP2D6 metabolizers.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""oliceridine_10_14_2020FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/oliceridine_10_14_2020FDA.pdf"">oliceridine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451278163.0,"<p>Excerpts from the oliceridine (OLINVYK) FDA drug label:</p>
<blockquote class=""blockquote"">
<p>Increased plasma concentrations of oliceridine, which may result in prolonged opioid adverse reactions and exacerbated respiratory depression, may occur when OLINVYK is used under the following conditions:</p>
<ul>
<li>In patients with decreased Cytochrome P450 (CYP) 2D6 function (poor metabolizers of CYP2D6 or normal metabolizers taking moderate or strong CYP2D6 inhibitors)</li>
<li>In patients taking a moderate or strong CYP3A4 Inhibitor</li>
<li>In patients with decreased CYP2D6 function who are also receiving a moderate or strong CYP3A4 inhibitor</li>
<li>Discontinuation of a CYP3A4 inducer</li>
</ul>
<p>These patients may require less frequent dosing of OLINVYK. Closely monitor these patients for respiratory depression and sedation at frequent intervals and base subsequent doses of OLINVYK on the patient’s severity of pain and response to treatment.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166224441,Annotation of FDA Label for ibrutinib and MYD88,False,True,[],False,"[{'id': 1452209860, 'date': '2023-08-18T10:38:49.470-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101933, 'title': 'Drugs@FDA: Drug Product Imbruvica (Ibrutinib), NDA205552, Pharmacyclics LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205552', 'crossReferences': [{'id': 1449754755, 'resource': 'FDA Application', 'resourceId': 'NDA205552', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205552'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166224421', 'symbol': 'rs387907272', 'name': 'rs387907272'}]","[{'objCls': 'Chemical', 'id': 'PA166121346', 'name': 'ibrutinib'}]","[{'objCls': 'Gene', 'id': 'PA31361', 'symbol': 'MYD88', 'name': 'MYD88 innate immune signal transduction adaptor'}]",FDA,1451271440.0,"<p>Ibrutinib (IMBRUVICA) is a kinase inhibitor indicated for patients with multiple different cancer types, including those with chronic lymphocytic leukemia with 17p deletion. The FDA label also mentions that MYD88 L265P mutations were present in 77% of patients from the INNOVATE study under the Clinical studies section.</p>
",1451271441.0,"<p>Excerpts from the ibrutinib (IMBRUVICA) drug label:</p>
<blockquote class=""blockquote"">
<p>Clinical studies:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>INNOVATE</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The INNOVATE study (A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination with Rituximab in Subjects with Waldenström’s Macroglobulinemia) (NCT02165397) was conducted in treatment naïve or previously treated patients with WM. Patients (n = 150) were randomized 1:1 to receive either IMBRUVICA 420 mg daily or placebo in combination with rituximab until disease progression or unacceptable toxicity. Rituximab was administered weekly at a dose of 375 mg/m2 for 4 consecutive weeks (weeks 1-4) followed by a second course of weekly rituximab for 4 consecutive weeks (weeks 17-20). The major efficacy outcome measure is progression-free survival (PFS) assessed by an IRC with additional efficacy measure of response rate.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>At baseline, the median serum IgM value was 3.2 g/dL (range, 0.6 to 8.3 g/dL), and MYD88 L265P mutations were present in 77% of patients, absent in 13% of patients, and 9% of patients were not evaluable for mutation status.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""ibrutinib_FDA_09292020.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/ibrutinib_FDA_09292020.pdf"">ibrutinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166227321,Annotation of HCSC Label for amifampridine phosphate and NAT2,False,False,[],True,[],False,[],True,"[{'id': 15115782, 'title': 'Drugs@HCSC: Drug Product FIRDAPSE (amifampridine phosphate), Kye Pharmaceuticals Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99250', 'crossReferences': [{'id': 1451300582, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99250', '_url': 'https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99250'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166182002', 'name': 'amifampridine phosphate'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",HCSC,1451300600.0,"<p>The product monograph for amifampridine phosphate states that if a patient is known to be a NAT2 fast acetylator, the starting dose can be increased from 15 mg to 30 mg daily.</p>
",1451300601.0,"<p>Excerpts from the amifampridine phosphate product monograph:</p>
<blockquote class=""blockquote"">
<p>The recommended starting dose is 15 mg daily, taken orally in divided doses (3 times daily). If the patient is known to be N acetyltransferase 2 (NAT2) fast acetylators the starting dose can be 30 mg.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genetic variants in the N-acetyltransferase gene 2 (NAT2) affect the rate and extent of FIRDAPSE metabolism. Poor acetylators, also referred to as “slow acetylators” (i.e., carriers of two reduced function alleles), have 3.5-to 4.5-fold higher Cmax, and 5.6-to 9 fold higher AUC than fast acetylators (i.e., carriers of two normal function alleles). Therefore, when initiating FIRDAPSE, known NAT2 poor acetylators should be closely monitored for adverse reactions. In the general population, the NAT2 poor acetylator phenotype prevalence is 40–60% in the White and African American populations, and is 10–30% in Asian ethnic populations (individuals of Japanese, Chinese, or Korean descent).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>At any given dose, the systemic exposure (Cmax and AUC) depends on the N-acetyltransferase (NAT) phenotype. Individuals who are fast (or rapid) acetylators have an approximately 3.5-to 4.5-fold lower mean peak concentration (Cmax) and 5.6-to 9-fold lower AUC of amifampridine when compared to slow acetylators.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The effect of hepatic impairment on the pharmacokinetics of FIRDAPSE has not been studied. FIRDAPSE is extensively metabolized by N-acetyltransferase 2 (NAT2) and hepatic impairment may cause an increase in exposure.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Amifampridine_phosphate_12_07_20_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Amifampridine_phosphate_12_07_20_HCSC.pdf"">amifampridine_phosphate product monograph.</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451300602.0,"<blockquote class=""blockquote"">
<p>The recommended starting dose is 15 mg daily, taken orally in divided doses (3 times daily). If the patient is known to be N acetyltransferase 2 (NAT2) fast acetylators the starting dose can be 30 mg.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Known N-acetyltransferase 2 (NAT2) Slow Acetylators: Exposure of FIRDAPSE is increased in patients who are N-acetyltransferase (NAT2) slow acetylators. Therefore, when initiating FIRDAPSE, known NAT2 poor acetylators should be closely monitored for adverse reactions.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>FIRDAPSE can cause QTc interval prolongation in N-acetyltransferase 2 slow acetylators. Caution should be observed if FIRDAPSE is administered to patients who have risk factors for torsade de pointes.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166227161,Annotation of EMA Label for ramucirumab and KRAS,False,True,[],False,"[{'id': 1452214680, 'date': '2023-08-23T18:14:32.123-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15115702, 'title': 'Cyramza | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza', 'crossReferences': [{'id': 1451299900, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184558', 'name': 'ramucirumab'}]","[{'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",EMA,1451299960.0,"<p>The EMA European Public Assessment Report (EPAR) for ramucirumab states that tumor KRAS status testing was used to stratify patients in the RAISE (NCT01183780) clinical trial of ramucirumab in metastatic colorectal cancer.</p>
",1451299961.0,"<p>Excerpt from the ramucirumab EPAR:</p>
<blockquote class=""blockquote"">
<p>Randomisation was stratified by geographic region, tumour KRAS status (mutant or wild-type), and time to disease progression (TTP) after commencing first-line treatment (&lt;6 months versus ≥6 months). Demographic and baseline characteristics for the ITT population were similar between treatment arms. Median age was 62 years and 40% of patients were ≥65 years; 57% of patients were male; 76% were White and 20% Asian; 49% had ECOG PS 0; 49% of patients had KRAS mutant tumours; and 24% of patients had TTP &lt;6 months after commencing first-line treatment.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The HR of OS was 0.82 (95% CI: 0.67 to 1.0) in patients with a KRAS wild type tumour, and 0.89 (95% CI: 0.73 to 1.09) in patients with a KRAS mutant tumour.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Ramucirumab_12_04_20_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ramucirumab_12_04_20_EMA.pdf"">ramucirumab EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166227221,Annotation of EMA Label for amifampridine phosphate and NAT2,False,False,[],False,[],False,[],True,"[{'id': 15115762, 'title': 'Firdapse | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse', 'crossReferences': [{'id': 1451300480, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182002', 'name': 'amifampridine phosphate'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",EMA,1451300481.0,"<p>The EMA European Public Assessment Report (EPAR) for states that the clearance of amifampridine phosphate (Firdapse) is predominantly due to metabolism by N-acetylation and NAT2 acetylator phenotype has a greater effect on metabolism and elimination than renal function. In a clinical study, slow acetylators experienced more adverse reactions than the fast acetylators.</p>
",1451300482.0,"<p>Excerpts from the amifampridine phosphate (Firdapse) EPAR:</p>
<blockquote class=""blockquote"">
<p>In a study of healthy volunteers, systemic exposure of amifampridine was notably influenced by the
overall metabolic acetylation activity of NAT enzymes and NAT2 genotype. The NAT genes are
highly polymorphic and result in phenotypes with variable acetylation activity rates ranging from slow to fast. In the healthy volunteer study, fast acetylators were defined by having a caffeine metabolite
ratio &gt;0.3 and slow acetylators with a caffeine metabolite ratio &lt;0.2 . There was significantly higher
exposure to amifampridine in slow acetylators compared to fast acetylators. Statistically significant
differences in amifampridine PK parameters Cmax, AUC0-∞, t1/2 and apparent clearance was observed between fast and slow acetylators at all dose levels. In this study, slow acetylators experienced more adverse reactions than the fast acetylators. The safety profile in this study is
consistent with adverse reactions observed with patients on amifampridine.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The overall clearance of amifampridine is predominantly due to metabolism by N-acetylation and
acetylator phenotype has a greater effect on an individual’s metabolism and elimination of
amifampridine than does elimination by renal function.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Exposure of amifampridine was generally higher in subjects with renal impairment than in subjects
with normal renal function; however, NAT2 phenotype had a greater effect on an individual’s
exposure to amifampridine than renal function status (See Table 4). Amifampridine exposure by
AUC0–∞ was up to 2-fold higher in slow acetylators and up to 3-fold higher in fast acetylators with
severe renal impairment compared to subjects with normal renal function. Exposure by Cmax was
marginally affected by renal impairment regardless of acetylation status.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Amifampridine_phosphate_12_07_20_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Amifampridine_phosphate_12_07_20_EMA.pdf"">amifampridine phosphate EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166160054,Annotation of FDA Label for brexpiprazole and CYP2D6,False,False,[],True,"[{'id': 1450396272, 'date': '2019-05-01T07:45:59.167-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102028, 'title': 'Drugs@FDA: Drug Product REXULTI (brexpiprazole), NDA205422, Otsuka America Pharmaceutical, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205422', 'crossReferences': [{'id': 1449894585, 'resource': 'FDA Application', 'resourceId': 'NDA205422', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205422'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166160053', 'name': 'brexpiprazole'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1448257481.0,"<p>The FDA-approved drug label for brexpiprazole (REXULTI) states that known CYP2D6 poor metabolizers should have their usual dosage reduced by half, and that known CYP2D6 poor metabolizers who are also taking strong/moderate CYP3A4 inhibitors should be administered a quarter of the usual dose. However, the label does not mention genetic testing.</p>
",1450320977.0,"<p>Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) and for the treatment of schizophrenia. Excerpts from the brexpiprazole (REXULTI) drug label:</p>
<div class=""blockquote"">
<p>Known CYP2D6 Poor Metabolizers: Reduce the usual dosage by half</p>
</div>
<div class=""blockquote"">
<p>Known CYP2D6 Poor Metabolizers taking strong/moderate CYP3A4 inhibitors...Administer a quarter of usual dose</p>
</div>
<div class=""blockquote"">
<p>Dosage adjustment is recommended in known CYP2D6 poor metabolizers, because these patients have higher brexpiprazole concentrations than normal metabolizers of CYP2D6. Approximately 8% of Caucasians and 3–8% of Black/African Americans cannot metabolize CYP2D6 substrates and are classified as poor metabolizers (PM).</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Brexpiprazole_12_13_18_FDA.pdf"">brexpiprazole drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450396271.0,"<p>Excerpt from the brexpiprazole (REXULTI) drug label:</p>
<blockquote class=""blockquote"">
<p>Table 1: Dosage Adjustments of REXULTI for CYP2D6 Poor Metabolizers and for Concomitant Use with CYP3A4 and CYP2D6 Inhibitors and/or CYP3A4 Inducers</p>
<table class=""table"">
<thead>
<tr>
<th>Factors</th>
<th>Adjusted REXULTI Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2D6 poor metabolizers</td>
<td>Administer half of the usual dose</td>
</tr>
<tr>
<td>Known CYP2D6 poor metabolizers taking strong/moderate CYP3A4 inhibitors</td>
<td>Administer a quarter of the usual dose</td>
</tr>
</tbody>
</table>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166234761,Annotation of FDA Label for simvastatin and SLCO1B1,False,False,[],False,"[{'id': 1452215303, 'date': '2023-08-24T15:39:27.954-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101889, 'title': 'Drugs@FDA: Drug Product ZOCOR (SIMVASTATIN), NDA019766, Merck Sharp & Dohme Corp.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019766', 'crossReferences': [{'id': 1452245801, 'resource': 'FDA Application', 'resourceId': 'NDA019766', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019766'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451363', 'name': 'simvastatin'}]","[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",FDA,1451391700.0,"<p>The FDA-approved label for simvastatin (ZOCOR) states that simvastatin acid is a substrate of the transport protein OATP1B1 (SLCO1B1) and concomitant administration of medicinal products that are inhibitors of the transport protein OATP1B1 may lead to increased plasma concentrations of simvastatin acid and an increased risk of myopathy.</p>
",1451391701.0,"<p>Excerpts from the simvastatin (ZOCOR) drug label:</p>
<blockquote class=""blockquote"">
<p>Simvastatin acid is a substrate of the transport protein OATP1B1. Concomitant administration of medicinal products that are inhibitors of the transport protein OATP1B1 may lead to increased plasma concentrations of simvastatin acid and an increased risk of myopathy. For example, cyclosporine has been shown to increase the AUC of statins; although the mechanism is not fully understood, the increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4 and/or OATP1B1.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""simvastatin_FDA_032021.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/simvastatin_FDA_032021.pdf"">simvastatin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166184430,"Annotation of Swissmedic Label for fenofibrate, simvastatin and SLCO1B1",False,False,[],False,[],False,[],True,"[{'id': 15103092, 'title': 'Swissmedic label for Simvastatin und Fenofibrat', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65222', 'crossReferences': [{'id': 1450812053, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65222', '_url': 'https://amiko.oddb.org/de/fi?gtin=65222'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166154579', 'symbol': 'rs4149056', 'name': 'rs4149056'}]","[{'objCls': 'Chemical', 'id': 'PA449594', 'name': 'fenofibrate'}, {'objCls': 'Chemical', 'id': 'PA451363', 'name': 'simvastatin'}]","[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",Swissmedic,1450815598.0,"<p>The Swiss drug label for Simvastatin and Fenofibrate (Cholib) states that the decreased function of hepatic OATP transport proteins may increase systemic simvastatin exposure and the risk for myopathy and rhabdomyolysis.</p>
",1450815599.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the simavastatin and fenofibrate (Cholib) label:</p>
<blockquote class=""blockquote"">
<p>Precautions:
Reduced transport protein function:
The decreased function of hepatic OATP transport proteins may increase systemic simvastatin exposure and the risk for myopathy and rhabdomyolysis. Decreased function may result from inhibition by interacting drugs (e.g., ciclosporin) or occur in patients carrying the SLCO1B1 c.521T&gt;C genotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In patients carrying the SLCO1B1 gene (c.521T&gt;C) coding for a less active OATP1B1 protein, systemic exposure to simvastatin and the risk of myopathy are increased. The risk of myopathy caused by high-dose simvastatin (80 mg) is generally 1% without genetic testing. Based on the results of the SEARCH study, carriers of the homozygous C allele (also called CC) treated with 80 mg have a 15% risk of myopathy within one year, while carriers of the heterozygous C allele (CT) have a 1.5% risk. The corresponding risk for patients with the most frequent genotype (TT) is 0.3% (see &quot;Pharmacokinetics&quot;).</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65222&amp;highlight=SLCO1B1"" target=""_blank"">Cholib drug label</a> (in German);</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184158,"Annotation of Swissmedic Label for ombitasvir / paritaprevir / ritonavir and IFNL3, IFNL4",False,False,[],False,[],False,[],True,"[{'id': 15103057, 'title': 'Swissmedic label for Ombitasvir, Paritaprevir, Ritonavir', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65301', 'crossReferences': [{'id': 1450812018, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65301', '_url': 'https://amiko.oddb.org/de/fi?gtin=65301'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166155468', 'symbol': 'rs12979860', 'name': 'rs12979860'}]","[{'objCls': 'Chemical', 'id': 'PA166163408', 'name': 'ombitasvir / paritaprevir / ritonavir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}, {'objCls': 'Gene', 'id': 'PA166049147', 'symbol': 'IFNL4', 'name': 'interferon lambda 4 (gene/pseudogene)'}]",Swissmedic,1450813901.0,"<p>The Swiss drug label for Ombitasvir/Paritaprevir/Ritonavir (Viekirax) states that IFNL3/4 (previously known as IL28B) genotypes may affect the efficacy of Viekirax.</p>
",1450813902.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for Ombitasvir/Paritaprevir/Ritonavir (Viekirax):</p>
<blockquote class=""blockquote"">
<p>Properties / Effects:
Host factors: Response to pegIFN/RBV pretreatment, sex, ethnicity, age, IL28B allele, body mass index at baseline, depression or bipolar disorder in history, fibrosis stage.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In the group Exviera and Viekirax without ribavirin, patients with IL28B not CC genotype showed a statistically lower SVR12 rate than patients with IL28B CC genotype. A lower SVR12 rate was also shown in this group in patients with fibrosis stage F2 or higher.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>All studies report prevalence of IL28B non-CC genotype.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65301&amp;highlight=ethnische"" target=""_blank"">Ombitasvir/Paritaprevir/Ritonavir drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166184394,"Annotation of Swissmedic Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5",False,False,[],False,[],False,[],True,"[{'id': 15103077, 'title': 'Swissmedic label for prasugrel', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=59136', 'crossReferences': [{'id': 1450812038, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=59136', '_url': 'https://amiko.oddb.org/de/fi?gtin=59136'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA154410481', 'name': 'prasugrel'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}, {'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA131', 'symbol': 'CYP3A5', 'name': 'cytochrome P450 family 3 subfamily A member 5'}]",Swissmedic,1450815420.0,"<p>The Swiss drug label for prasugrel (Efient) states that genetic variations of CYP3A5, CYP2B6, CYP2C9 or CYP2C19 have no relevant effect on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.</p>
",1450815421.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the prasugrel (Efient) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacokinetics:
In healthy volunteers, patients and patients with ACS who received Efient, no relevant effect of genetic variations of CYP3A5, CYP2B6, CYP2C9 or CYP2C19 on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation was observed.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=59136&amp;highlight=genetischer"" target=""_blank"">prasugrel drug label</a> (in German);</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166160718,"Annotation of PMDA Label for methylene blue and BLVRB, G6PD",False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450457', 'name': 'methylene blue'}]","[{'objCls': 'Gene', 'id': 'PA25374', 'symbol': 'BLVRB', 'name': 'biliverdin reductase B'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",PMDA,1448265968.0,"<p>The PMDA package insert for methylene blue states that patients with glucose-6-phosphate dehydrogenase (<em>G6PD</em>) deficiency or <a rel=""noopener noreferrer"" href=""http://www.omim.org/entry/250700"" target=""_blank"">NADPH reductase (<em>BLVRB</em>) deficiency</a> may have exacerbation of methemoglobinemia or hemolysis following administration.</p>
",1448265967.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the methylene blue package insert:</p>
<blockquote class=""blockquote"">
<p>Patients with known glucose-6-phosphate dehydrogenase deficiency: Exacerbation of methemoglobinemia and hemolysis may occur.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with known NADPH reductase deficiency: Exacerbation of methemoglobinemia and hemolysis may occur.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>When exacerbation of methemoglobinemia or hemolysis occurs following the administration of this product, glucose-6-phosphate dehydrogenase deficiency, NADPH reductase deficiency or overdosing is suspected. Monitor patients closely, and consider discontinuation of the product or switch to different therapies if these signs develop.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Methylene_Blue_PMDA_10_07_16.pdf"">methylene blue package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166160274,"Annotation of PMDA Label for cetuximab and EGFR, KRAS",False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10040', 'name': 'cetuximab'}]","[{'objCls': 'Gene', 'id': 'PA7360', 'symbol': 'EGFR', 'name': 'epidermal growth factor receptor'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",PMDA,1448258753.0,"<p>The PMDA package insert for cetuximab (ERBITUX) states that it is indicated for individuals with epidermal growth factor receptor (EGFR)-positive, progressive or recurrent colorectal cancer that is refractory and inoperable. It also notes that <em>K-Ras</em> mutational status should be considered when selecting patients.</p>
",1448258756.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the cetuximab (ERBITUX) drug label:</p>
<blockquote class=""blockquote"">
<p>When using the product for EGFR-positive, progressive or recurrent colorectal cancer that is refractory and inoperable, patients should be selected based on the presence or absence of <em>K-Ras</em> mutation.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Post-hoc analysis results stratified by <em>K-Ras</em> mutation status are presented below (1063 cases with valid data).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Post-hoc analysis results stratified by <em>K-Ras</em> mutation status are presented below (394 cases with valid data).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Post-hoc analysis results stratified by <em>K-Ras</em> mutation status are presented below (300 cases with valid data).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Cetuximab_PMDA_08_22_16.pdf"">cetuximab package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166160711,"Annotation of PMDA Label for everolimus and ERBB2, ESR1, ESR2",False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164746311', 'name': 'everolimus'}]","[{'objCls': 'Gene', 'id': 'PA27844', 'symbol': 'ERBB2', 'name': 'erb-b2 receptor tyrosine kinase 2'}, {'objCls': 'Gene', 'id': 'PA156', 'symbol': 'ESR1', 'name': 'estrogen receptor 1'}, {'objCls': 'Gene', 'id': 'PA27886', 'symbol': 'ESR2', 'name': 'estrogen receptor 2'}]",PMDA,1448265825.0,"<p>The PMDA package insert for everolimus (AFINITOR) states that it is indicated for patients with locally advanced or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer after failure of treatment with letrozole or anastrozole.</p>
",1448265824.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the everolimus (AFINITOR) package insert:</p>
<blockquote class=""blockquote"">
<p>Select patients based upon thorough understanding of the efficacy and safety of the product by fully evaluating the hormone receptor status and HER2 expression status described in Clinical Study Results in patients included in the clinical studies.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In an international multi-center phase III clinical trial in postmenopausal patients with locally advanced or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer after failure of treatment with letrozole or anastrozole...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>After failure of treatment with letrozole or anastrozole, postmenopausal patients with locally advanced or metastatic ER-positive, HER2-negative breast cancer received 10 mg of the product or placebo once daily after meal in combination with exemestane.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Everolimus_PMDA_10_05_16.pdf"">everolimus package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166184426,"Annotation of Swissmedic Label for tolterodine and CYP2D6, CYP3A4",False,False,[],False,[],False,[],True,"[{'id': 15103107, 'title': 'Swissmedic label for tolterodin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55581', 'crossReferences': [{'id': 1450812068, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55581', '_url': 'https://amiko.oddb.org/de/fi?gtin=55581'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164746757', 'name': 'tolterodine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}, {'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",Swissmedic,1450815571.0,"<p>The Swiss drug label for tolterodine (Detrusitol) gives information on pharmacokinetic changes in CYP2D6 poor metabolizers. This did not result in any changes in safety or tolerability alone but was notable in patients receiving CYP3A4 inhibitors.</p>
",1450815572.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for tolterodine (Detrusitol):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Tolterodine is metabolized mainly by the polymorphic enzyme CYP2D6 in about 90-95% of the Caucasian population, resulting in the formation of the pharmacologically active 5-hydroxymethyl metabolite (DD01). In poor metabolisers (those with a deficit of CYP2D6), tolterodine is dealkylated via the CYP3A isozymes to produce N-dealkylated tolterodine. This metabolite does not contribute to the clinical effect. The systemic clearance of tolterodine is approx. 30 l/h. The half-life for tolterodine and the 5-hydroxymethyl metabolite is approx. 6 hours. With poor metabolisers, the half-life of tolterodine is extended (11 hours) and clearance is reduced. In these patients, concentrations of tolterodine were found to increase about 7-fold, combined with undetectable concentrations of the 5-hydroxymethyl metabolite. This did not result in any differences with regard to safety and tolerability.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Simultaneous treatment with ketokonazole (200 mg/d), a potent CYP3A4 inhibitor, leads to an increase in AUC of tolterodine, especially when CYP2D6 activity is reduced. In a study of poor metabolizers for CYP2D6 (which account for approximately 5-10% of the Caucasian population), the AUC of tolterodine increased 2.2-fold. Patients receiving CYP3A4 inhibitors such as macrolide antibiotics (e.g. erythromycin and clarythromycin) or antimycotics (e.g. ketokonazole, itrakonazole and miconazole) at the same time should therefore not exceed 2 mg daily.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=55581&amp;highlight=Metabolisierern"" target=""_blank"">tolteridine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166120287,"Annotation of EMA Label for ethinyl estradiol / norelgestromin and F5, PROC, PROS1, SERPINC1",True,False,[],False,"[{'id': 1184233796, 'date': '2014-05-08T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452011201, 'date': '2023-02-16T20:39:08.295-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102941, 'title': 'Evra | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/evra', 'crossReferences': [{'id': 1450417091, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/evra', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/evra'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA165290929', 'name': 'ethinyl estradiol / norelgestromin'}]","[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",EMA,1447982083.0,"<p>The EMA European Public Assessment Report (EPAR) for norelgestromin and ethinyl estradiol (EVRA) states that it is contraindicated in patients with known hereditary or acquired predisposition for venous thromboembolism, including Factor 5 Leiden (<em>F5</em>), antithrombin-III deficiency (<em>SERPINC1</em>), protein C deficiency (<em>PROC</em>) and protein S deficiency (<em>PROS</em>).</p>
",1447982082.0,"<p>Excerpt from the norelgestromin and ethinyl estradiol (EVRA) EPAR:</p>
<div class=""blockquote"">
<p>Contraindications...Known hereditary or acquired predisposition for venous thromboembolism, such as APC-resistance, (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Ethinyl_Estradiol_Norelgestrom_06_21_19_EMA.pdf"">norelgestromin and ethinyl estradiol EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450417090.0,"<p>&quot;Contraindications...Known hereditary or acquired predisposition for venous thromboembolism, such as APC-resistance, (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency...&quot;</p>
",,,,,,,
Label Annotation,PA166104915,"Annotation of EMA Label for olanzapine and CYP1A2, CYP2D6",False,False,[],False,"[{'id': 1184512668, 'date': '2013-10-27T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1450933206, 'date': '2019-12-04T13:25:00.239-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452209540, 'date': '2023-08-17T17:37:24.880-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103650, 'title': 'Zalasta | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zalasta', 'crossReferences': [{'id': 1450932882, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zalasta', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zalasta'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450688', 'name': 'olanzapine'}]","[{'objCls': 'Gene', 'id': 'PA27093', 'symbol': 'CYP1A2', 'name': 'cytochrome P450 family 1 subfamily A member 2'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1447981801.0,"<p>The EMA European Public Assessment Report (EPAR) for olanzapine (Zalasta) contains information regarding the metabolism of the drug by the enzymes CYP1A2 and CYP2D6: factors that induce or inhibit CYP1A2 may alter the concentration of olanzapine and thus may require dosage monitoring. The EPAR does not mention pharmacogenetics or testing of genetic variants in these genes.</p>
",1447981800.0,"<p>The CYP2D6 inhibitor fluoxetine is noted not to have a significant effect on olanzapine pharmacokinetics.</p>
<p>Excerpts from the olanzapine (Zalasta) EPAR:</p>
<blockquote class=""blockquote"">
<p>Fluvoxamine, a specific CYP 1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine. The mean increase in olanzapine Cmax following fluvoxamine was 54% in female non-smokers and 77% in male smokers. The mean increase in olanzapine AUC was 52% and 108% respectively. A lower starting dose of olanzapine should be considered in patients who are using fluvoxamine or any other CYP1A2 inhibitors, such as ciprofloxacin. A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP 1A2 is initiated.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been found to significantly affect the pharmacokinetics of olanzapine.</p>
</blockquote>
<p>This information is highlighted in the following sections:</p>
<p>Interaction with other medicinal products and other forms of interaction, pharmacokinetic properties.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Zalasta_EMA_EPAR_Jan_09_2012.pdf"">olanzapine EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166104907,"Annotation of EMA Label for eltrombopag and F5, SERPINC1",False,False,[],False,"[{'id': 1184512645, 'date': '2013-01-02T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1184466997, 'date': '2013-10-25T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1452011188, 'date': '2023-02-16T20:38:05.075-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452556320, 'date': '2024-08-14T13:30:36.993-07:00', 'description': 'added Other Guidance tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102974, 'title': 'Revolade | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/revolade', 'crossReferences': [{'id': 1450417072, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/revolade', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/revolade'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA165981594', 'name': 'eltrombopag'}]","[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",EMA,1447981791.0,"<p>The EMA European Public Assessment Report (EPAR) states that caution should be taken when administering eltrombopag in patients with known risk factors for thromboembolism, including Factor V Leiden (F5 gene) and ATIII deficiency (SERPINC1 gene).</p>
",1447981790.0,"<p>Excerpt from the eltrombopag (Revolade) EPAR:</p>
<div class=""blockquote"">
<p>Thrombotic/Thromboembolic complications may occur in patients with ITP. Platelet counts above the normal range present a theoretical risk of thrombotic/thromboembolic complications. In eltrombopag clinical trials in ITP thromboembolic events were observed at low and normal platelet counts. Caution should be used when administering eltrombopag to patients with known risk factors for thromboembolism including but not limited to inherited (e.g. Factor V Leiden) or acquired risk factors (e.g. ATIII deficiency, antiphospholipid syndrome), advanced age, patients with prolonged periods of immobilisation, malignancies, contraceptives and hormone replacement therapy, surgery/trauma, obesity and smoking. Platelet counts should be closely monitored and consideration given to reducing the dose or discontinuing eltrombopag treatment if the platelet count exceeds the target levels...The risk-benefit balance should be considered in patients at risk of thromboembolic events (TEEs) of any aetiology.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Eltrombopag_06_21_19_EMA.pdf"">eltrombopag EPAR PFF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450417071.0,"<p>&quot;Caution should be used when administering eltrombopag to patients with known risk factors for thromboembolism including but not limited to inherited (e.g. Factor V Leiden) or acquired risk factors (e.g. ATIII deficiency, antiphospholipid syndrome)...&quot;</p>
",,,,,,,
Label Annotation,PA166120370,"Annotation of EMA Label for glimepiride, pioglitazone and G6PD",True,False,[],False,"[{'id': 1184467007, 'date': '2014-05-09T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452011261, 'date': '2023-02-16T20:41:33.411-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452534980, 'date': '2024-07-22T14:42:49.769-07:00', 'description': 'added Alt drug and Other guidance tags', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102952, 'title': 'Tandemact | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tandemact', 'crossReferences': [{'id': 1450417110, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tandemact', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tandemact'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449761', 'name': 'glimepiride'}, {'objCls': 'Chemical', 'id': 'PA450970', 'name': 'pioglitazone'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",EMA,1447982105.0,"<p>The EMA European Public Assessment Report (EPAR) for pioglitazone and glimepiride (Tandemact) states that caution should be taken in patients with G6PD deficiency as glimepiride is a sulfonylurea agent and a non-sulfonylurea alternative should be considered.</p>
",1447982104.0,"<p>Excerpt from the pioglitazone and glimepiride (Tandemact) EPAR:</p>
<div class=""blockquote"">
<p>Treatment of patients with G6PD-deficiency with sulfonylurea agents can lead to haemolytic anaemia. Since glimepiride belongs to the chemical class of sulfonylurea medicinal products, caution should be used in patients with G6PD-deficiency and a non-sulfonylurea alternative should be considered.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Glimepiride_Pioglitazone_06_21_19_EMA.pdf"">pioglitazone and glimepiride EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450417109.0,"<p>&quot;Since glimepiride belongs to the chemical class of sulfonylurea medicinal products, caution should be used in patients with G6PD-deficiency and a non-sulfonylurea alternative should be considered.&quot;</p>
",,,,,,,
Label Annotation,PA166127645,"Annotation of HCSC Label for carbamazepine and HLA-A, HLA-B",True,False,[],False,"[{'id': 1452594005, 'date': '2024-09-18T11:19:27.527-07:00', 'description': 'updated label, added Pediatric tag and info, added Alternate Drug tag and prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15165902, 'title': 'Drugs@HCSC: Drug Product TEGRETOL (carbamazepine), Novartis Pharmaceuticals Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=777', 'crossReferences': [{'id': 1452594042, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=777', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=777'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA35055', 'symbol': 'HLA-A', 'name': 'major histocompatibility complex, class I, A'}, {'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165954030', 'symbol': 'HLA-A*31:01', 'name': '*31:01'}, {'objCls': 'Haplotype', 'id': 'PA165954769', 'symbol': 'HLA-B*15:02', 'name': '*15:02'}]","[{'objCls': 'Chemical', 'id': 'PA448785', 'name': 'carbamazepine'}]","[{'objCls': 'Gene', 'id': 'PA35055', 'symbol': 'HLA-A', 'name': 'major histocompatibility complex, class I, A'}, {'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",HCSC,1447982485.0,"<p>The product monograph for carbamazepine (TEGETROL) states that the individuals with the <em>HLA-A*31:01</em> and <em>HLA-B*15:02</em> alleles are at risk of developing serious cutaneous adverse drug reactions when receiving the drug, and it is recommended that physicians consider <em>HLA-A*31:01</em> and <em>HLA-B*15:02</em> genotyping as a screening tool in genetically at-risk populations. Use of carbamazepine should be avoided in patients who test positive for the <em>HLA-A*31:01</em> or <em>HLA-B*15:02</em> alleles.</p>
",1447982484.0,"<p>Excerpts from the carbamazepine (TEGETROL) product monograph:</p>
<blockquote class=""blockquote"">
<p>There is growing evidence of the role of different HLA alleles in predisposing patients to immune-mediated adverse reactions.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Testing for the presence of HLA-A*3101 allele should be considered in patients with ancestry in genetically at-risk populations (for example, patients of the Japanese and Caucasian populations, patients who belong to the indigenous populations of the Americas, Hispanic populations, people of southern India, and people of Arabic descent), prior to initiating treatment with TEGRETOL (see 7 WARNINGS AND PRECAUTIONS, Important Limitations of HLA-A and HLA-B Genotyping). The use of TEGRETOL should be avoided in patients who are found to be positive for HLA-A*3101, unless the benefits clearly outweigh the risks. Screening is generally not recommended for any current TEGRETOL users, as the risk of SJS/TEN, AGEP, DRESS and maculopapular rash is largely confined to the first few months of therapy, regardless of HLA-A*3101 status.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In addition to being associated with severe adverse cutaneous reactions (see 7 WARNINGS AND PRECAUTIONS, Hypersensitivity), the HLA-A*3101 allele has been found to be associated with less severe adverse cutaneous reactions from carbamazepine, and may predict the risk of such reactions as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption). However, the HLA-B*1502 allele has not been found to predict the risk of these aforementioned skin reactions (see 7 WARNINGS AND PRECAUTIONS, Pharmacogenomics, Ancestry and Allelic Variation in the HLA-A Gene).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>[...] Results of these studies suggest that the presence of the HLA-B*1502 allele may be one of the risk factors for carbamazepine-associated SJS/TEN in patients with Asian ancestry. Therefore, physicians should consider HLA-B*1502 genotyping as a screening tool in these patients. Until further information is available, the use of TEGRETOL and other anti-epileptic drugs associated with SJS/TEN should also be avoided in patients who test positive for the HLA-B*1502 allele.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Carbamazepine_2024_09_18_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Carbamazepine_2024_09_18_HCSC.pdf"">carbamazepine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452594004.0,"<blockquote class=""blockquote"">
<p><strong>Epilepsy:</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Pediatrics (≥ 6 years of age):</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<p>TEGRETOL is indicated for use as an anticonvulsant drug either alone or in combination with other anticonvulsant drugs</p>
</blockquote>
",1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1452594003.0,"<blockquote class=""blockquote"">
<p>Until further information is available, the use of TEGRETOL and other anti-epileptic drugs associated with SJS/TEN should be avoided in patients who test positive for the HLA-A*3101 or HLA-B*1502 alleles</p>
</blockquote>
",,,,,,,
Label Annotation,PA166170938,"Annotation of FDA Label for trametinib and HRAS, KRAS, NRAS",False,True,[],False,"[{'id': 1452220422, 'date': '2023-08-29T12:33:33.876-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}, {'id': 1452821227, 'date': '2025-01-21T14:24:49.640-08:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15173342, 'title': 'Drugs@FDA: Drug Product Mekinist (trametinib), Novartis Pharmaceuticals Corporation - NDA204114/SUPPL-27, 10/01/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114', 'crossReferences': [{'id': 1452821222, 'resource': 'FDA Application', 'resourceId': 'NDA204114/SUPPL-27', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114'}], 'objCls': 'Literature', 'pubDate': '2024-10-01T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101887, 'title': 'Drugs@FDA: Drug Product Mekinist (trametinib), NDA204114, Novartis Pharmaceuticals Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114', 'crossReferences': [{'id': 1449888917, 'resource': 'FDA Application', 'resourceId': 'NDA204114', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166115364', 'name': 'trametinib'}]","[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",FDA,1449053850.0,"<p>Trametinib (MEKINIST) is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, or metastatic non-small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test. The label also notes that dabrafenib, the drug given in combination with trametinib for certain indications, may promote growth and development of malignancies with activitation of RAS (<em>HRAS</em>, <em>KRAS</em>, <em>NRAS</em>).</p>
",1449053849.0,"<p>Excerpt from the trametinib (MEKINIST) drug label:</p>
<blockquote class=""blockquote"">
<p>Based on its mechanism of action, dabrafenib may promote growth and development of malignancies with activation of RAS through mutation or other mechanisms; refer to the prescribing information for dabrafenib.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Trametinib_2025_01_17_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Trametinib_2025_01_17_FDA.pdf"">trametinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452821226.0,"<blockquote class=""blockquote"">
<p>MEKINIST is indicated, in combination with dabrafenib, for: [...]</p>
<ul>
<li>the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (1.5, 2.1)</li>
<li>the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (1.6, 2.1)</li>
</ul>
</blockquote>
",,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166184224,"Annotation of Swissmedic Label for acetaminophen, acetaminophen / tramadol and G6PD",False,False,[],False,"[{'id': 1452021781, 'date': '2023-02-28T13:05:37.367-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103070, 'title': 'Swissmedic label for Paracetamol, Tramadol hydrochlorid (Tramadol plus Spirig HC)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=63013', 'crossReferences': [{'id': 1450812031, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=63013', '_url': 'https://amiko.oddb.org/de/fi?gtin=63013'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103109, 'title': 'Swissmedic label for Tramadol, Kombinationen', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=55811', 'crossReferences': [{'id': 1450812070, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=55811', '_url': 'https://amiko.oddb.org/de/fi?gtin=55811'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103068, 'title': 'Swissmedic label for paracetamol', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=46344', 'crossReferences': [{'id': 1450812029, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=46344', '_url': 'https://amiko.oddb.org/de/fi?gtin=46344'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448015', 'name': 'acetaminophen'}, {'objCls': 'Chemical', 'id': 'PA166184496', 'name': 'acetaminophen / tramadol'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450814369.0,"<p>The Swiss drug label for Paracetamol, Tramadol hydrochlorid (Tramadol plus Spirig HC) states that patients with Glucose-6-phosphate dehydrogenase deficiency may have risk for hemolytic anemia.</p>
",1450814370.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for acetaminophen (paracetamol, Panadol) :</p>
<blockquote class=""blockquote"">
<p>Precautionary measures:
Hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency</p>
</blockquote>
<p>Excerpt from the drug label for Paracetamol, Tramadol hydrochlorid (Tramadol plus Spirig HC)</p>
<blockquote class=""blockquote"">
<p>Precautionary measures:
Hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency (genetic);</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=63013&amp;highlight=Glucose-6-Phosphat-Dehydrogenase-Mangel"" target=""_blank"">Tramadol plus Spirig HC drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450814371.0,"<blockquote class=""blockquote"">
<p>Precautionary measures:
Hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency (genetic).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166105232,Annotation of FDA Label for quinine and CYP2D6,False,False,[],False,"[{'id': 1183704720, 'date': '2013-12-20T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1450824202, 'date': '2019-10-21T10:16:18.075-07:00', 'description': 'Update to label and annotation, G6PD was removed from contraindications, changed text of annotation to reflect this change. Also removed alternate drug tag and prescribing info. .', 'type': 'Update', 'version': 0}, {'id': 1450824521, 'date': '2019-10-24T07:38:33.709-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1452219080, 'date': '2023-08-28T16:49:22.216-07:00', 'description': 'Removed Prescribing Info section since monitoring patients is not genotype dependent', 'type': 'Update', 'version': 0}, {'id': 1452429005, 'date': '2024-04-02T09:52:36.047-07:00', 'description': 'Changed PGx Level to Criteria Not Met. Although G6PD and CYP2D6 are still listed on the FDA Biomarker Table with reference to this drug/label, there are no actionable recommendations given based on variation in either G6PD or CYP2D6', 'type': 'Update', 'version': 0}, {'id': 1452624425, 'date': '2024-10-04T14:53:25.021-07:00', 'description': 'separated G6PD to a different label annotation', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101955, 'title': 'Drugs@FDA: Drug Product Quinine Sulfate (Quinine Sulfate), Sun Pharmaceutical Industries, Inc. - NDA021799/SUPPL-29, 06/19/2019', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021799', 'crossReferences': [{'id': 1452624400, 'resource': 'FDA Application', 'resourceId': 'NDA021799/SUPPL-29', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021799'}], 'notes': 'Listed as Marketing Status Discontinued as of 10/4/2024; however, an active DailyMed entry is available: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c44c8b7-8b38-4487-a8ba-a94f708d1f50', 'objCls': 'Literature', 'pubDate': '2019-06-19T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15167002, 'title': 'DailyMed - QUALAQUIN- quinine sulfate capsule', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c44c8b7-8b38-4487-a8ba-a94f708d1f50', 'crossReferences': [{'id': 1452624420, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '1c44c8b7-8b38-4487-a8ba-a94f708d1f50', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c44c8b7-8b38-4487-a8ba-a94f708d1f50'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15166982, 'title': 'DailyMed - QUININE SULFATE capsule (Lupin Pharmaceuticals Inc.)', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f32f05c-a215-40be-b951-e41a7b54a8a0', 'crossReferences': [{'id': 1452624360, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '1f32f05c-a215-40be-b951-e41a7b54a8a0', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f32f05c-a215-40be-b951-e41a7b54a8a0'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451213', 'name': 'quinine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1452429020.0,"<p>Quinine (QUALAQUIN) is an antimalarial indicated for treatment of uncomplicated <em>Plasmodium falciparum</em> malaria. CYP2D6 is mentioned in the Drug Interactions and Clinical Pharmacology sections.</p>
",1447981921.0,"<p>Excerpts from the quinine (QUALAQUIN) drug label:</p>
<blockquote class=""blockquote"">
<p><em><strong>Desipramine (CYP2D6 substrate)</strong></em> Quinine (750 mg/day for 2 days) decreased the metabolism of desipramine in patients who were extensive CYP2D6 metabolizers, but had no effect in patients who were poor CYP2D6 metabolizers.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""quinine_sulfate_10_17_2019FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/quinine_sulfate_10_17_2019FDA.pdf"">quinine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166123527,"Annotation of PMDA Label for arsenic trioxide and PML, RARA",False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448486', 'name': 'arsenic trioxide'}]","[{'objCls': 'Gene', 'id': 'PA33439', 'symbol': 'PML', 'name': 'PML nuclear body scaffold'}, {'objCls': 'Gene', 'id': 'PA34225', 'symbol': 'RARA', 'name': 'retinoic acid receptor alpha'}]",PMDA,1447982165.0,"<p>Arsenic trioxide is indicated for treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). The PMDA package insert for arsenic trioxide states that patients with APL should be characterized by presence of the t(15;17) translocation or PML/RAR-alpha gene expression.</p>
",1447982164.0,"<p><strong>Please note that the information contained within this drug label annotation is sourced from <a href=""http://www.pharmgkb.org/pmid/23895776"">Shimazawa and Ikeda (2013)</a>, whose paper provided an unofficial translation of the pharmacogenetic information contained in the PMDA package insert for research purposes.</strong></p>
<p>Excerpt from the package insert for arsenic trioxide:</p>
<blockquote class=""blockquote"">
<p>Precautions for indications: Patients with APL should be characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Arsenic_Trioxide_PMDA_11_14_14.pdf"">arsenic trioxide package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166123532,"Annotation of PMDA Label for carbamazepine and HLA-A, HLA-B",False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448785', 'name': 'carbamazepine'}]","[{'objCls': 'Gene', 'id': 'PA35055', 'symbol': 'HLA-A', 'name': 'major histocompatibility complex, class I, A'}, {'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",PMDA,1447982167.0,"<p>The PMDA package insert for carbamazepine notes that the <em>HLA-A*3101</em> allele appeared at a high frequency in Japanese patients who developed a serious drug rash when taking carbamazepine. The insert also notes that the <em>HLA-B*1502</em> allele appeared in nearly all of a group of Han Chinese patients who developed Stevens-Johnson syndrome or toxic epidermal necrolysis when taking carbamazepine.</p>
",1447982166.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for carbamazepine:</p>
<blockquote class=""blockquote"">
<p>In a retrospective genome-wide association study in a Japanese population, the <em>HLA-A*3101</em> allele was carried by 58% (45/77) of patients who developed a serious drug rash including mucocutaneous ocular syndrome, toxic epidermal necrolysis and hypersensitivity syndrome, while 13% (54/420) of patients who did not develop a drug rash had the <em>HLA-A*3101</em> allele. The frequency of the <em>HLA-A*3101</em> allele is reported to range from 0.071 to 0.120 in Japanese population.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In studies in patients of Han Chinese ancestry, the <em>HLA-B*1502</em> allele was carried by nearly all patients who developed mucocutaneous ocular syndrome and toxic epidermal necrolysis. The association between developing severe drug rash and the presence of <em>HLA-B*1502</em> was not established in the study with Japanese patients. The reported frequencies of the <em>HLA-B*1502</em> allele are 0.019 – 0.124 in Han Chinese ancestry and 0.001 in Japanese ancestry.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Carbamazepine_PMDA_10_03_16.pdf"">carbamazepine package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166123540,"Annotation of PMDA Label for fulvestrant and ESR1, ESR2",False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164747170', 'name': 'fulvestrant'}]","[{'objCls': 'Gene', 'id': 'PA156', 'symbol': 'ESR1', 'name': 'estrogen receptor 1'}, {'objCls': 'Gene', 'id': 'PA27886', 'symbol': 'ESR2', 'name': 'estrogen receptor 2'}]",PMDA,1447982483.0,"<p>The PMDA package insert for fulvestrant states that it is indicated for postmenopausal women with hormone-receptor positive breast cancer, and that fulvestrant should not be used in women negative for hormone receptor.</p>
",1447982482.0,"<p><strong>Please note that the information contained within this drug label annotation is sourced from <a href=""http://www.pharmgkb.org/pmid/23895776"">Shimazawa and Ikeda (2013)</a>, whose paper provided an unofficial translation of the pharmacogenetic information contained in the PMDA package insert for research purposes.</strong></p>
<p>Excerpt from the package insert for fulvestrant:</p>
<blockquote class=""blockquote"">
<p>Postmenopausal women with breast cancer. <em>Precautions for indications:</em> Expression of hormone receptor should be detected prior to the start of therapy and not be used in patients negative for hormone receptor.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Fulvestrant_PMDA_11_17_14.pdf"">fulvestrant package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166123541,"Annotation of PMDA Label for gefitinib and CYP2D6, EGFR",False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA131301952', 'name': 'gefitinib'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}, {'objCls': 'Gene', 'id': 'PA7360', 'symbol': 'EGFR', 'name': 'epidermal growth factor receptor'}]",PMDA,1447982439.0,"<p>The PMDA package insert for gefitinib (Iressa) states that patients should be tested for EGFR gene mutations prior to administration. It also discusses the role of CYP2D6 is the metabolism of gefitinib.</p>
",1447982438.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Gefitinib is indicated for patients with EGFR activating mutation positive non-small cell lung cancer (NSCLC).</p>
<p>Excerpt from the package insert for gefitinib (Iressa):</p>
<blockquote class=""blockquote"">
<p>Patients should be tested for EGFR gene mutations. The Lung Cancer Practice Guideline of the Japan Lung Cancer Society and other latest information should be consulted before administration of this product for selection of patients with or without known EGFR gene mutation status.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 metabolizes gefitinib to O-desmethyl gefitinib, and plasma O-desmethyl gefitinib was not measurable in healthy CYP2D6 poor metabolizers, who were CYP2D6 deficient (n = 15).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Gefitinib_PMDA_10_06_16.pdf"">gefitinib package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166123542,"Annotation of PMDA Label for imatinib and ABL1, BCR",False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10804', 'name': 'imatinib'}]","[{'objCls': 'Gene', 'id': 'PA24413', 'symbol': 'ABL1', 'name': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'objCls': 'Gene', 'id': 'PA25321', 'symbol': 'BCR', 'name': 'BCR activator of RhoGEF and GTPase'}]",PMDA,1447982447.0,"<p>Imatinib is an inhibitor of the BCR-ABL tyrosine kinase that is created by the Philadelphia chromosome rearrangement. The PMDA package insert for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with Philadelphia chromosome positive (BCR-ABL) acute lymphoblastic leukemia.</p>
",1447982446.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the package insert for imatinib (Glivec):</p>
<blockquote class=""blockquote"">
<p>Imatinib inhibited growth of BCR-ABL transfected cells and BCR-ABL-expressing cells derived from patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL). Imatinib induced apoptosis in BCR-ABL-positive cells <em>in vitro</em> and selectively inhibited colony formation in assays using <em>ex vivo</em> peripheral blood and bone marrow samples from CML and ALL patients.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Imatinib_PMDA_11_17_14.pdf"">imatinib package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166123544,"Annotation of PMDA Label for lapatinib and ERBB2, HLA-DQA1, HLA-DRB1",False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA152241907', 'name': 'lapatinib'}]","[{'objCls': 'Gene', 'id': 'PA27844', 'symbol': 'ERBB2', 'name': 'erb-b2 receptor tyrosine kinase 2'}, {'objCls': 'Gene', 'id': 'PA35066', 'symbol': 'HLA-DQA1', 'name': 'major histocompatibility complex, class II, DQ alpha 1'}, {'objCls': 'Gene', 'id': 'PA35072', 'symbol': 'HLA-DRB1', 'name': 'major histocompatibility complex, class II, DR beta 1'}]",PMDA,1447982289.0,"<p>The PMDA package insert for lapatinib states that it is indicated for individuals with breast cancer whose tumors overexpress HER2. It also contains information about the risk of severe liver injury in patients with the HLA-DQA1*02:01 or HLA-DRB1*07:01 variants.</p>
",1447982288.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpts from the package insert for lapatinib:</p>
<blockquote class=""blockquote"">
<p>Only administer to patients with overexpression of HER2 that has been confirmed by experienced pathologists or accredited laboratories.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In a randomized placebo-controlled trial of monotherapy with this product conducted overseas, the reported incidence of severe liver injury (ALT &gt; 5.0 times ULN) among HLA-DQA1*02:01 and DRB1*07:01 allele carriers was 7.7% (19/247 and 19/247, respectively) versus 0.5% in non-carriers (4/855 and 4/857, respectively). It has been reported that these HLA alleles are present in approximately 15-30% of Caucasian, Asian, African and other populations and in less than 2% of Japanese populations.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Lapatinib_PMDA_10_07_16.pdf"">lapatinib package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,
Label Annotation,PA166123552,"Annotation of PMDA Label for valproic acid and CPS1, OTC",False,False,[],False,[],False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451846', 'name': 'valproic acid'}]","[{'objCls': 'Gene', 'id': 'PA26840', 'symbol': 'CPS1', 'name': 'carbamoyl-phosphate synthase 1'}, {'objCls': 'Gene', 'id': 'PA32840', 'symbol': 'OTC', 'name': 'ornithine transcarbamylase'}]",PMDA,1447982277.0,"<p>The PMDA package insert for valproic acid states that it is contraindicated in patients with known urea cycle disorders (UCDs), due to a risk for severe hyperammonemia. UCDs result from mutations in one of several genes, including ornithine transcarbamylase (OTC) deficiency and carbamoyl-phosphate synthetase 1 (CPS1) deficiency.</p>
",1447982276.0,"<p><strong>Please note that the information contained within this drug label annotation is sourced from <a href=""http://www.pharmgkb.org/pmid/23895776"">Shimazawa and Ikeda (2013)</a>, whose paper provided an unofficial translation of the pharmacogenetic information contained in the PMDA package insert for research purposes.</strong></p>
<p>Excerpt from the package insert for valproic acid:</p>
<blockquote class=""blockquote"">
<p>Contraindications: Patients with known urea cycle disorders (there is the risk of severe hyperammonemia).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Valproic_acid_PMDA_11_17_14.pdf"">valproic acid package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,,,,,,,,,
Label Annotation,PA166104823,"Annotation of EMA Label for methylene blue and BLVRB, G6PD",True,False,[],False,"[{'id': 1184512662, 'date': '2013-10-27T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1452016853, 'date': '2023-02-22T22:00:54.588-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452698600, 'date': '2024-11-12T17:15:39.495-08:00', 'description': 'removed CYB5R3 as a prescribing gene; it is not listed as a contraindication', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102957, 'title': 'Methylthioninium chloride Proveblue | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/methylthioninium-chloride-proveblue', 'crossReferences': [{'id': 1450624250, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/methylthioninium-chloride-proveblue', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/methylthioninium-chloride-proveblue'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA25374', 'symbol': 'BLVRB', 'name': 'biliverdin reductase B'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450457', 'name': 'methylene blue'}]","[{'objCls': 'Gene', 'id': 'PA25374', 'symbol': 'BLVRB', 'name': 'biliverdin reductase B'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",EMA,1447981604.0,"<p>The EMA European Public Assessment Report (EPAR) for methylthioninium chloride Proveblue (also known as methylene blue) states that the drug is contraindicated in patients with G6PD deficiency due to risk of hemolytic anemia, and in patients with a deficiency in NADPH reductase (encoded by the <em>BLVRB</em> gene). The label also states that failure to respond to the drug may indicate a deficiency in cytochrome b5 reductase (CYB5R3) or G6PD.</p>
",1447981603.0,"<p>Excerpts from the  methylthioninium chloride Proveblue (methylene blue) EPAR:</p>
<blockquote class=""blockquote"">
<p>Contraindications [...]</p>
<ul>
<li>Patients with Glucose-6-phosphate dehydrogenase deficiency (G6PD) due to the risk of haemolytic anaemia [...]</li>
<li>Deficiency on NADPH (nicotinamide adenine dinucleotide phosphate) reductase</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Failure to respond to methylthioninium chloride suggests cytochrome b5 reductase deficiency, glucose-6-phosphate dehydrogenase deficiency or sulfhaemoglobinemia. Alternative treatment options should be considered.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Methylene_Blue_06_25_19_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Methylene_Blue_06_25_19_EMA.pdf"">methylene blue EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450624249.0,"<blockquote class=""blockquote"">
<p>&quot;Contraindications [...]</p>
<ul>
<li>Patients with Glucose-6-phosphate dehydrogenase deficiency (G6PD) due to the risk of haemolytic anaemia [...]</li>
<li>Deficiency on NADPH (nicotinamide adenine dinucleotide phosphate) reductase&quot;</li>
</ul>
</blockquote>
<p>&quot;Failure to respond to methylthioninium chloride suggests cytochrome b5 reductase deficiency, glucose-6-phosphate dehydrogenase deficiency or sulfhaemoglobinemia. Alternative treatment options should be considered.&quot;</p>
",,,,,,,
Label Annotation,PA166183781,"Annotation of Swissmedic Label for mercaptopurine and NUDT15, TPMT",False,False,[],False,[],False,[],True,"[{'id': 15103022, 'title': 'Swissmedic label for mercaptopurine (Puri-Nethol)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=21713&highlight=TPMT', 'crossReferences': [{'id': 1450811118, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=21713&highlight=TPMT', '_url': 'https://amiko.oddb.org/de/fi?gtin=21713&highlight=TPMT'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15103023, 'title': 'Swissmedic label for mercaptopurine (Xalupine)', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65371', 'crossReferences': [{'id': 1450811119, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65371', '_url': 'https://amiko.oddb.org/de/fi?gtin=65371'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]","[{'objCls': 'Haplotype', 'id': 'PA165819269', 'symbol': 'TPMT*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165819270', 'symbol': 'TPMT*3A', 'name': '*3A'}, {'objCls': 'Haplotype', 'id': 'PA165819272', 'symbol': 'TPMT*3C', 'name': '*3C'}]","[{'objCls': 'Chemical', 'id': 'PA450379', 'name': 'mercaptopurine'}]","[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",Swissmedic,1450811113.0,"<p>The Swiss drug label for mercaptopurine (Puri-Nethol, Xaluprine) states that patients with TPMT and/or NUDT15 variant genotype may have higher risk of severe adverse effects when treated with 6-mercaptopurine. Treatment should be cautious and patients should be carefully monitored for side effects.</p>
",1450811114.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the mercaptopurine (Puri-Nethol) label:</p>
<blockquote class=""blockquote"">
<p>Dosage/applications:
Patients with thiopurine methyltransferase (TPMT) deficiency: Patients with homozygous TPMT deficiency are at high risk of severe adverse effects when treated with 6-mercaptopurine. Treatment should be cautious, possibly with reduced doses (the optimal initial dose was not determined), and these patients should be carefully monitored for side effects (see also &quot;Warnings and Precautions&quot; and &quot;Interactions&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Precautions:
There are patients with a congenital deficiency of the enzyme thiopurine methyltransferase (TPMT) who are unusually sensitive to the myelosuppressive effect of 6-mercaptopurine. These tend to develop rapid myelosuppression after treatment with Puri-Nethol (see &quot;Pharmacokinetics/Metabolism&quot; and &quot;Dosage/Application&quot;). This effect may be enhanced by simultaneous administration of drugs that inhibit TPMT (such as olsalazine, mesalazine or sulfasalazine) (see &quot;Interactions&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Properties / Effects:
There is a TPMT polymorphism (alleles TPMT*2, TPMT*3A and TPMT*3C). A homozygous deficiency (0.3% of the white population) leads to low to non-measurable enzyme activity. A heterozygous deficiency (10% of the white population) leads to low to moderate enzyme activity. In addition to determining the TMPT genotype, the phenotype can also be determined by determining the nucleotide metabolites or the TMPT activity in the erythrocytes.</p>
</blockquote>
<p>Excerpts from the mercaptopurine (Xaluprine) label:</p>
<blockquote class=""blockquote"">
<p>Dosage/applications:
Patients with thiopurine methyltransferase (TPMT) deficiency: Patients with homozygous TPMT deficiency have a high risk of severe adverse effects when treated with 6-mercaptopurine. Treatment should be cautious, possibly at reduced doses (the optimal initial dose was not determined), and these patients should be carefully monitored for side effects (see also &quot;Warnings and Precautions&quot; and &quot;Interactions&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with the NUDT15 variant: Patients with congenital mutant NUDT15 gene have an increased risk of severe 6-mercaptopurine toxicity. In these patients, dose reduction is generally required, especially in patients carrying a homozygous NUDT15 variant. Therefore, genotyping to determine the NUDT15 variant may be considered before starting treatment with 6-mercaptopurine. Close monitoring of blood values is required in all cases (see &quot;Warnings and Precautions&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Precautions:
Although some laboratories offer tests to determine TPMT activity, no evidence has been provided to date that these tests can detect all patients at risk of severe toxicity. Therefore, close monitoring of blood levels continues to be necessary.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Properties / Effects:
There is a TPMT polymorphism (alleles TPMT*2, TPMT*3A and TPMT*3C). A homozygous deficiency (0.3% of the white population) leads to low to non-measurable enzyme activity. A heterozygous deficiency (10% of the white population) leads to low to moderate enzyme activity. In addition to determining the TMPT genotype, the phenotype can also be determined by determining the nucleotide metabolites or the TMPT activity in the erythrocytes.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=21713&amp;highlight=TPMT"" target=""_blank"">Puri-Nethol drug label</a> (in German);
<a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65371&amp;highlight=NUDT15"" target=""_blank"">Xaluprine drug label</a>(in German)</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813287.0,"<blockquote class=""blockquote"">
<p>Patients with thiopurine methyltransferase (TPMT) deficiency: Patients with homozygous TPMT deficiency are at high risk of severe adverse effects when treated with 6-mercaptopurine. Treatment should be cautious, possibly with reduced doses (the optimal initial dose was not determined), and these patients should be carefully monitored for side effects (see also &quot;Warnings and Precautions&quot; and &quot;Interactions&quot;).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with the NUDT15 variant: Patients with congenital mutant NUDT15 gene have an increased risk of severe 6-mercaptopurine toxicity. In these patients, dose reduction is generally required, especially in patients carrying a homozygous NUDT15 variant. Therefore, genotyping to determine the NUDT15 variant may be considered before starting treatment with 6-mercaptopurine. Close monitoring of blood values is required in all cases (see &quot;Warnings and Precautions&quot;).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127668,"Annotation of HCSC Label for eltrombopag and F5, SERPINC1",False,False,[],False,"[{'id': 1452532001, 'date': '2024-07-19T10:08:36.799-07:00', 'description': 'added newer label and prescribing info, updated text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160982, 'title': 'Drugs@HCSC: Drug Product REVOLADE (Eltrombopag), Novartis Pharmaceuticals Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84687', 'crossReferences': [{'id': 1452531920, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84687', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84687'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}]","[{'objCls': 'Variant', 'id': 'PA166153554', 'symbol': 'rs6025', 'name': 'rs6025'}]","[{'objCls': 'Chemical', 'id': 'PA165981594', 'name': 'eltrombopag'}]","[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",HCSC,1447982377.0,"<p>The product monograph for eltrombopag (REVOLADE) states caution should be used in patients with known risk factors for thromboembolism including but not limited to inherited (e.g. Factor V Leiden) or acquired risk factors (e.g. ATIII deficiency, antiphospholipid syndrome and systemic lupus erythematosus).</p>
",1447982376.0,"<p>The product monograph notes that caution should be used in patients with known risk factors for thromboembolism including but not limited to inherited (e.g. Factor V Leiden) or acquired risk factors (e.g. ATIII deficiency, antiphospholipid syndrome and systemic lupus erythematosus).</p>
<p>Excerpt from the eltrombopag product monograph:</p>
<blockquote class=""blockquote"">
<p>Caution should be used when administering REVOLADE to patients with known risk factors for thromboembolism including but not limited to inherited (e.g. Factor V Leiden) or acquired risk factors (e.g. ATIII deficiency, antiphospholipid syndrome and systemic lupus erythematosus), advanced age, patients with prolonged periods of immobilisation, malignancies, contraceptives and hormone replacement therapy, surgery/trauma, obesity and smoking. Platelet counts should be closely monitored and consideration given to reducing the dose or discontinuing REVOLADE if the platelet count exceeds the target levels. The risk-benefit balance should be considered in patients at risk of TEEs of any aetiology.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Eltrombopag_HCSC_11_03_21.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Eltrombopag_HCSC_11_03_21.pdf"">eltrombopag product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452532000.0,"<p>Excerpt from the eltrombopag product monograph:</p>
<blockquote class=""blockquote"">
<p>Caution should be used when administering REVOLADE to patients with known risk factors for thromboembolism including but not limited to inherited (e.g. Factor V Leiden) or acquired risk factors (e.g. ATIII deficiency, antiphospholipid syndrome and systemic lupus erythematosus), advanced age, patients with prolonged periods of immobilisation, malignancies, contraceptives and hormone replacement therapy, surgery/trauma, obesity and smoking. Platelet counts should be closely monitored and consideration given to reducing the dose or discontinuing REVOLADE if the platelet count exceeds the target levels. The risk-benefit balance should be considered in patients at risk of TEEs of any aetiology.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166185190,"Annotation of FDA Label for ospemifene and CYP2B6, CYP2C9",False,False,[],False,"[{'id': 1452214300, 'date': '2023-08-23T10:41:03.638-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103477, 'title': 'Drugs@FDA: Drug Product  ospemifene NDA 203505', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203505', 'crossReferences': [{'id': 1450826929, 'resource': 'FDA Application', 'resourceId': 'NDA203505', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203505'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182883', 'name': 'ospemifene'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}, {'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1450826926.0,"<p>The FDA-approved drug label for ospemifene (OSPHENA) states that ospemifene is metabolized primarily by CYP3A4 and CYP2C9, and ospemifene was also suggested to be a weak inhibitor for CYP2B6, CYP2C9, CYP2C19, CYP2C8, CYP2D6 and CYP3A4 in in vitro studies.</p>
",1450826927.0,"<p>Excerpts from the ospemifene (OSPHENA) drug label:</p>
<div class=""blockquote"">
<p>Clinical pharmacology:</p>
</div>
<div class=""blockquote"">
<p>Metabolism: In vitro experiments with human liver microsomes indicated that ospemifene primarily undergoes metabolism via CYP3A4, CYP2C9 and CYP2C19. The major metabolite was 4-hydroxyospemifene. The apparent total body clearance is 9.16 L/hr using a population approach.</p>
</div>
<div class=""blockquote"">
<p>Drug Interactions: Ospemifene is metabolized primarily by CYP3A4 and CYP2C9. CYP2C19 and other pathways contribute to the metabolism of ospemifene. In order of decreasing potency, ospemifene was suggested to be a weak inhibitor for CYP2B6, CYP2C9, CYP2C19, CYP2C8, CYP2D6 and CYP3A4 in in vitro studies. Ospemifene is not a significant P-glycoprotein substrate in vitro; no in vivo transporter study was conducted.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/ospemifene_11_05_2019_FDA.pdf"">ospemifene drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166127666,"Annotation of HCSC Label for drospirenone / ethinyl estradiol and F5, PROC, PROS1, SERPINC1",True,False,[],False,"[{'id': 1452530681, 'date': '2024-07-18T00:00:00-07:00', 'description': 'added text in prescribing field, added alternate drug tag, added label document, attached label from 2017', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160842, 'title': 'Drugs@HCSC: Drug Product YAZ (drospirenone/ethinyl estradiol), \u200bBayer Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80656', 'crossReferences': [{'id': 1452530660, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80656', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80656'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}]","[{'objCls': 'Variant', 'id': 'PA166153554', 'symbol': 'rs6025', 'name': 'rs6025'}]","[{'objCls': 'Chemical', 'id': 'PA165290928', 'name': 'drospirenone / ethinyl estradiol'}]","[{'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",HCSC,1447982373.0,"<p>The product monograph for drospirenone and ethinyl estradiol (YAZ) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency and protein S deficiency (among other contraindications), due to the risk for arterial or venous thrombosis.</p>
",1447982372.0,"<p>YAZ is indicated for conception control and treatment of moderate acne vulgaris. It is contraindicated in women who have a hereditary or acquired predisposition for venous or arterial thrombosis. One such predisposition is Factor V Leiden mutation - <a href=""/variant/PA166153554"">rs6025</a> within the <em>F5</em> gene. Others are antithrombin III, protein C or protein S deficiency. These three proteins are encoded by the <em>SERPINC1</em>, <em>PROC</em> and <em>PROS1</em> genes, respectively. Each of these predispositions and oral contraceptives themselves are known to independently increase the risk for thrombosis; together they may have a cumulative effect on thrombosis risk.</p>
<blockquote class=""blockquote"">
<p>YAZ should not be used in women with: presence of severe or multiple risk factor(s) for arterial or venous thrombosis: hereditary or acquired predisposition for venous or arterial thrombosis, such as Factor V Leiden mutation and activated protein C (APC-) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia and antiphospholipid-antibodies (anticardiolipin antibodies, lupus anticoagulant).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Drospirenone_and_ethinyl_estradiol_HCSC_03_02_2017.PDF"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Drospirenone_and_ethinyl_estradiol_HCSC_03_02_2017.PDF"">drospirenone and ethinyl estradiol product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452530680.0,"<p>The product monograph for drospirenone and ethinyl estradiol (YAZ) states:</p>
<blockquote class=""blockquote"">
<p>YAZ should not be used in women with: presence of severe or multiple risk factor(s) for arterial or venous thrombosis: hereditary or acquired predisposition for venous or arterial thrombosis, such as Factor V Leiden mutation and activated protein C (APC-) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia and antiphospholipid-antibodies (anticardiolipin antibodies, lupus anticoagulant).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166127726,"Annotation of HCSC Label for valproic acid and OTC, POLG",True,False,[],False,"[{'id': 1451813903, 'date': '2022-06-29T00:00:00-07:00', 'description': 'Updated to latest label. Fixed format on block quotes.', 'type': 'Update', 'version': 0}, {'id': 1452532202, 'date': '2024-07-19T11:52:21.051-07:00', 'description': 'Added excerpts to Prescribing section', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132722, 'title': 'Drugs@HCSC: Drug Product valproic acid', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00063621.PDF', 'crossReferences': [{'id': 1451813880, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00063621.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00063621.PDF'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA32840', 'symbol': 'OTC', 'name': 'ornithine transcarbamylase'}, {'objCls': 'Gene', 'id': 'PA33500', 'symbol': 'POLG', 'name': 'DNA polymerase gamma, catalytic subunit'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451846', 'name': 'valproic acid'}]","[{'objCls': 'Gene', 'id': 'PA32840', 'symbol': 'OTC', 'name': 'ornithine transcarbamylase'}, {'objCls': 'Gene', 'id': 'PA33500', 'symbol': 'POLG', 'name': 'DNA polymerase gamma, catalytic subunit'}]",HCSC,1447982239.0,"<p>The HCSC product monograph for valproic acid states that it is contraindicated in patients with mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG) or in patients with known urea cycle disorders, particularly ornithine transcarbamylase (OTC) deficiency.</p>
",1447982238.0,"<p>Excerpts from the valproic acid (DEPAKENE) product monograph:</p>
<blockquote class=""blockquote"">
<p>DEPAKENE® (valproic acid) is contraindicated in:</p>
<ul>
<li>Patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA
polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who
are suspected of having a POLG-related disorder (see 7 WARNINGS AND PRECAUTIONS,
Hepatic/Biliary/Pancreatic).</li>
<li>Patients with known urea cycle disorders</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Valproic acid is contraindicated in patients with known urea cycle disorders. Hyperammonemic encephalopathy, sometimes fatal, has been reported following initiation of valproic acid therapy in patients with urea cycle disorders, a group of uncommon genetic abnormalities, particularly ornithine transcarbamylase deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Valproate induced acute liver failure and liver-related deaths have been reported in patients with hereditary neurometabolic syndromes caused by mutations in the gene for mitochondrial DNA polymerase gamma (POLG) (e.g., Alpers-Huttenlocher Syndrome) at a higher rate than those without these syndromes...The A467T and W748S mutations are present in approximately 2/3 of patients with autosomal recessive POLG-related disorders.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Valproic_Acid_HCSC_2022_06_28.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Valproic_Acid_HCSC_2022_06_28.pdf"">valproic acid product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452532201.0,"<p>Excerpts from the valproic acid (DEPAKENE) product monograph:</p>
<blockquote class=""blockquote"">
<p>DEPAKENE® (valproic acid) is contraindicated in:</p>
<ul>
<li>Patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA
polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who
are suspected of having a POLG-related disorder (see 7 WARNINGS AND PRECAUTIONS,
Hepatic/Biliary/Pancreatic).</li>
<li>Patients with known urea cycle disorders</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Valproic acid is contraindicated in patients with known urea cycle disorders. Hyperammonemic encephalopathy, sometimes fatal, has been reported following initiation of valproic acid therapy in patients with urea cycle disorders, a group of uncommon genetic abnormalities, particularly ornithine transcarbamylase deficiency.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166182759,"Annotation of FDA Label for chloroprocaine and CYB5R3, G6PD",False,False,[],False,"[{'id': 1450821530, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1450822519, 'date': '2019-10-15T09:27:26.510-07:00', 'description': 'Added link and text about CYB5R3 and congenital methemoglobinemia.', 'type': 'Update', 'version': 0}, {'id': 1452532061, 'date': '2024-07-19T10:48:27.903-07:00', 'description': 'added Other Guidance tag, prescribing info', 'type': 'Update', 'version': 0}, {'id': 1452536500, 'date': '2024-07-23T15:44:20.918-07:00', 'description': 'fixed typo', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102388, 'title': 'Drugs@FDA: Drug Product CHLOROPROCAINE HCI (CHLOROPROCAINE HCI), HF Acquisition Co LLC, DBA HealthFirst - NDA009435/SUPPL-44, 11/02/2018', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009435', 'crossReferences': [{'id': 1452532045, 'resource': 'FDA Application', 'resourceId': 'NDA009435/SUPPL-44', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009435'}], 'notes': 'Nesacaine', 'objCls': 'Literature', 'pubDate': '2018-11-02T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15102502, 'title': 'Drugs@FDA: Drug Product Clorotekal (CHLOROPROCAINE HYDROCHLORIDE), NDA208791, B. Braun Medical Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208791', 'crossReferences': [{'id': 1450415970, 'resource': 'FDA Application', 'resourceId': 'NDA208791', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208791'}], 'notes': 'CLOROTEKAL', 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA448946', 'name': 'chloroprocaine'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450401034.0,"<p>The FDA-approved drug label for chloroprocaine (Nesacaine) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.</p>
",1450401035.0,"<p>Chloroprocaine (Nesacaine) is a non-pyrogenic local anesthetic.</p>
<p>Excerpt from the chloroprocaine (Nesacaine) drug label:</p>
<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
<p>NOTE: While the CYB5R3 gene is not explicitly stated in the drug label variants in this gene are associated with congenital methemoglobinemia I and II <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/250800"" target=""_blank"">OMIM 250800</a>.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Chloroprocaine_05_13_2019FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Chloroprocaine_05_13_2019FDA.pdf"">chloroprocaine drug label</a>.</p>
<p><strong>Note: Chloroprocaine (CLOROTEKAL) is indicated for intrathecal injection in adults for the production of subarachnoid block (spinal anesthesia). The drug label for chloroprocaine (CLOROTEKAL) contains no information regarding G6PD deficiency and methemoglobinemia.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452532060.0,"<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166129517,"Annotation of FDA Label for isoflurane and CACNA1S, RYR1",True,False,[],False,"[{'id': 1448604544, 'date': '2017-03-15T10:54:55.985-07:00', 'type': 'Update', 'version': 0}, {'id': 1450821533, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1452011309, 'date': '2023-02-16T20:52:10.561-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452055900, 'date': '2023-04-01T20:54:53.047-07:00', 'description': 'updated text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101993, 'title': 'Drugs@FDA: Drug Product FORANE (isoflurane), NDA017624, Baxter Healthcare Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017624', 'crossReferences': [{'id': 1449754774, 'resource': 'FDA Application', 'resourceId': 'NDA017624', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017624'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450106', 'name': 'isoflurane'}]","[{'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",FDA,1447982449.0,"<p>The FDA-approved drug label for isoflurane (FORANE) warns that individuals with a genetic predisposition to malignant hyperthermia.</p>
",1447982448.0,"<p>Isoflurane (FORANE) is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia. Specific variants in the <em>RYR1</em> and <em>CACNA1S</em> genes are associated with risk of malignant hyperthermia in individuals administered potent inhalational anesthetics, including isoflurane. Although the isoflurane drug label does not specifically mention genetic testing, the FDA-approved label for isoflurane contraindicates it for individuals with known, or suspected, genetic predisposition to malignant hyperthermia.</p>
<p>Excerpts from the isoflurane (FORANE) drug label:</p>
<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS...with known or suspected genetic susceptibility to malignant hyperthermia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Malignant Hyperthermia: In susceptible individuals, volatile anesthetic agents, including isoflurane, may trigger malignant hyperthermia, a skeletal muscle hypermetabolic state leading to high oxygen demand. Fatal outcomes of malignant hyperthermia have been reported. The risk of developing malignant hyperthermia increases with the concomitant administration of succinylcholine and volatile anesthetic agents. FORANE can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacogenomics: RYR1 and CACNA1S are polymorphic genes, and multiple pathogenic variants have been associated with malignant hyperthermia susceptibility (MHS) in patients receiving volatile anesthetic agents, including FORANE. Case reports as well as ex-vivo studies have identified multiple variants in RYR1 and CACNA1S associated with MHS. Variant pathogenicity should be assessed based on prior clinical experience, functional studies, prevalence information, or other evidence.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""isoflurane_20230402_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/isoflurane_20230402_FDA.pdf"">isoflurane drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399557.0,"<p>Excerpts from the isoflurane (FORANE) drug label:</p>
<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS...with known or suspected genetic susceptibility to malignant hyperthermia.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166123410,"Annotation of EMA Label for ritonavir and CYP2D6, CYP3A4",False,False,[],False,"[{'id': 1184754377, 'date': '2014-09-15T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933208, 'date': '2019-12-04T13:26:13.576-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452213500, 'date': '2023-08-22T21:09:14.499-07:00', 'description': ""removed informative PGx level as it doesn't fit new criteria"", 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103652, 'title': 'Norvir | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/norvir', 'crossReferences': [{'id': 1450932884, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/norvir', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/norvir'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451260', 'name': 'ritonavir'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}, {'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447982183.0,"<p>The EMA European Public Assessment Report (EPAR) for ritonavir (Norvir) does not contain pharmacogenetic information. It contains information regarding use of ritonavir as a pharmacokinetic enhancer for certain drugs to prolong their therapeutic effects. It is a potent inhibitor of CYP3A and CYP2D6-mediated biotransformation, and the EPAR provides a list of drugs contraindicated for concomitant use with ritonavir.</p>
",1447982182.0,"<p>The EMA-approved drug ritonavir (Norvir) is tagged with CYP3A4 and CYP2D6 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>Excerpts from the ritonavir (Norvir) EPAR:</p>
<blockquote class=""blockquote"">
<p><em>Ritonavir dosed as a pharmacokinetic enhancer</em></p>
<p>Pharmacokinetic enhancement by ritonavir is based on ritonavir’s activity as a potent inhibitor of CYP3A- mediated metabolism. The degree of enhancement is related to the metabolic pathway of the co-administered protease inhibitor and the impact of the co-administered protease inhibitor on the metabolism of ritonavir.</p>
<p>Ritonavir has a high affinity for several cytochrome P450 (CYP) isoforms and may inhibit oxidation with the following ranked order: CYP3A4 &gt; CYP2D6. Co-administration of Norvir and medicinal products primarily metabolised by CYP3A may result in increased plasma concentrations of the other medicinal product, which could increase or prolong its therapeutic and adverse effects. For select medicinal products (e.g. alprazolam) the inhibitory effects of ritonavir on CYP3A4 may decrease over time.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/ritonavir_EMA_EPAR_Aug_6_2014_1.pdf"">ritonavir EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166127695,"Annotation of HCSC Label for ethinyl estradiol / norelgestromin and F2, F5, MTHFR, PROC, PROS1, SERPINC1",True,False,[],False,"[{'id': 1452538341, 'date': '2024-07-25T00:00:00-07:00', 'description': 'Added variants, Prescribing section, tags and label document. Updated label PDF as previous one was discontinued.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161922, 'title': 'Drugs@HCSC: Drug Product Evra (ethinyl estradiol / norelgestromin), Searchlight Pharma Inc', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72637', 'crossReferences': [{'id': 1452538320, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72637', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72637'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA245', 'symbol': 'MTHFR', 'name': 'methylenetetrahydrofolate reductase'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]","[{'objCls': 'Variant', 'id': 'PA166154336', 'symbol': 'rs1799963', 'name': 'rs1799963'}, {'objCls': 'Variant', 'id': 'PA166153643', 'symbol': 'rs1801131', 'name': 'rs1801131'}, {'objCls': 'Variant', 'id': 'PA166153644', 'symbol': 'rs1801133', 'name': 'rs1801133'}]","[{'objCls': 'Chemical', 'id': 'PA165290929', 'name': 'ethinyl estradiol / norelgestromin'}]","[{'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA245', 'symbol': 'MTHFR', 'name': 'methylenetetrahydrofolate reductase'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",HCSC,1447982451.0,"<p>The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the <em>MTHFR</em> gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.</p>
",1447982450.0,"<p>EVRA(R) is a hormonal contraceptive. It is contraindicated in women who have a hereditary or acquired predisposition for venous or arterial thrombosis. One such predisposition is Factor V Leiden mutation - <a href=""/variant/PA166153554"">rs6025</a> within the F5 gene. Others are antithrombin III (<em>SERPINC1</em>), protein C (<em>PROC</em>) or protein S (<em>PROS</em>) deficiency, as well as hyperhomocysteinaemia due to the mutations C677T (<a href=""/variant/PA166153644"">rs1801133</a>) and A1298C (<a href=""/variant/PA166153643"">rs1801131</a>) in the <em>MTHFR</em> gene, and the G20210A mutation in the prothrombin gene (<em>F2</em>) (<a href=""/variant/PA166154336"">rs1799963</a>). Each of these predispositions and oral contraceptives themselves are known to independently increase the risk for thrombosis; together they may have a cumulative effect on thrombosis risk.</p>
<p>Excerpt from the product monograph:</p>
<blockquote class=""blockquote"">
<p>Contraindications. The EVRA(R) (norelgestromin and ethinyl estradiol) transdermal system should not be used in women with: presence of severe or multiple risk factor(s) for arterial or venous thrombosis such as:</p>
<ul>
<li>hereditary or acquired predisposition for venous or arterial thrombosis, such as Factor V Leiden mutation and activated protein C (APC-) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia (e.g., due to MTHFR C677T, A1298 mutations), prothrombin mutation G20210A, and antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant)</li>
</ul>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""ethinyl_estradiol_norelgestromin_2024_07_25_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/ethinyl_estradiol_norelgestromin_2024_07_25_HCSC.pdf"">norelgestromin and ethinyl estradiol product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452538340.0,"<p>Excerpt from the product monograph:</p>
<blockquote class=""blockquote"">
<p>Contraindications. The EVRA(R) (norelgestromin and ethinyl estradiol) transdermal system should not be used in women with: presence of severe or multiple risk factor(s) for arterial or venous thrombosis such as:</p>
<ul>
<li>hereditary or acquired predisposition for venous or arterial thrombosis, such as Factor V Leiden mutation and activated protein C (APC-) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia (e.g., due to MTHFR C677T, A1298 mutations), prothrombin mutation G20210A, and antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant)</li>
</ul>
</blockquote>
",,,,,,,
Label Annotation,PA166123422,Annotation of EMA Label for efavirenz / emtricitabine / tenofovir disoproxil and CYP2B6,False,False,[],False,"[{'id': 1184754519, 'date': '2014-09-16T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452721740, 'date': '2024-12-02T13:34:56.122-08:00', 'description': 'update with marketing authorization status ""Withdrawn""', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102946, 'title': 'Atripla | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/atripla', 'crossReferences': [{'id': 1450416976, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/atripla', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/atripla'}], 'notes': 'Marketing authorization: Withdrawn', 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165818762', 'symbol': 'CYP2B6*6', 'name': '*6'}, {'objCls': 'Variant', 'id': 'PA166155409', 'symbol': 'rs3745274', 'name': 'rs3745274'}]","[{'objCls': 'Chemical', 'id': 'PA166176033', 'name': 'efavirenz / emtricitabine / tenofovir disoproxil'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}]",EMA,1447982157.0,"<p>The EMA European Public Assessment Report (EPAR) for efavirenz, emtricitabine and tenofovir disoproxil (Atripla) states that patients with the CYP2B6*6/*6 genotype had higher Cmax as compared to patients with the CYP2B6*1/*1 genotype, and the mean QTc prolongation was 8.7 ms. The label also notes that plasma exposure may be increased in patients with the rs3745274 TT genotype (G516T).</p>
<p>As of December 2, 2024, the EMA website shows that &quot;The marketing authorisation for Atripla has been withdrawn at the request of the marketing-authorisation holder.&quot;</p>
",1447982156.0,"<p>Excerpts from the efavirenz, emtricitabine and tenofovir disoproxil (Atripla) EPAR:</p>
<blockquote class=""blockquote"">
<p>The effect of efavirenz on the QTc interval was evaluated in an open-label, positive and placebo controlled, fixed single sequence 3-period, 3-treatment crossover QT study in 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean Cmax of efavirenz in subjects with CYP2B6 *6/*6 genotype following the administration of 600 mg daily dose for 14 days was 2.25-fold the mean Cmax observed in subjects with CYP2B6 *1/*1 genotype. A positive relationship between efavirenz concentration and QTc prolongation was observed. Based on the concentration-QTc relationship, the mean QTc prolongation and its upper bound 90% confidence interval are 8.7 ms and 11.3 ms in subjects with CYP2B6*6/*6 genotype following the administration of 600 mg daily dose for 14 days...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Efavirenz plasma exposure may be increased in patients with the homozygous G516T genetic variant of the CYP2B6 isoenzyme. The clinical implications of such an association are unknown; however, the potential for an increased frequency and severity of efavirenz-associated adverse events cannot be excluded.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Efavirenz_Emtricitabine_Tenofovir_06_20_19_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Efavirenz_Emtricitabine_Tenofovir_06_20_19_EMA.pdf"">efavirenz, emtricitabine and tenofovir disproxil EPAR PDF</a></p>
<p>As of December 2, 2024, the EMA website shows that &quot;The marketing authorisation for Atripla has been withdrawn at the request of the marketing-authorisation holder.&quot;</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166240301,"Annotation of EMA Label for avatrombopag and CYP2C9, F2, F5, PROC, PROS1, SERPINC1",False,False,[],False,"[{'id': 1452526261, 'date': '2024-07-12T15:43:00.054-07:00', 'description': 'updated label, added Other Guidance annotation', 'type': 'Update', 'version': 0}, {'id': 1452529721, 'date': '2024-07-17T15:10:11.818-07:00', 'description': 'added F2, F5 variants', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15119602, 'title': 'Doptelet | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/doptelet', 'crossReferences': [{'id': 1451417131, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/doptelet', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/doptelet'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]","[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}, {'objCls': 'Variant', 'id': 'PA166154336', 'symbol': 'rs1799963', 'name': 'rs1799963'}, {'objCls': 'Variant', 'id': 'PA166153554', 'symbol': 'rs6025', 'name': 'rs6025'}]","[{'objCls': 'Chemical', 'id': 'PA166179849', 'name': 'avatrombopag'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",EMA,1451417160.0,"<p>The EMA European Public Assessment Report (EPAR) for avatrombopag (Doptelet) states that avatrombopag exposure may increase in patients with <em>CYP2C9*2</em> and/or <em>CYP2C9*3</em> alleles, and that increased exposure may increase the risk of clinically-relevant QTc prolongation. The label also states that potential increased thrombotic risk should be considered in patients with deficiency in Factor V Leiden (<em>F5</em>), prothrombin 20210A (<em>F2</em>), antithrombin (<em>SERPINC1</em>), protein C (<em>PROC</em>), or protein S (<em>PROS1</em>).</p>
",1451417161.0,"<p>Excerpts from the avatrombopag EPAR:</p>
<blockquote class=""blockquote"">
<p>CYP2C9 loss-of-function polymorphisms: Avatrombopag exposure may increase in patients with CYP2C9*2 and CYP2C9*3 loss-of-function polymorphisms. Healthy subjects (n=2) who were homozygous for these mutations (poor metabolizers) had approximately 2-fold higher exposure compared to subjects with wild-type CYP2C9.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>At exposures similar to that achieved at the 40 mg and 60 mg dose, Doptelet did not prolong the QT interval to any clinically relevant extent. Mean QTc prolongation effects &gt; 20 ms are not anticipated with the highest recommended therapeutic dosing regimen based on analysis of data from the pooled clinical trials in patients with chronic liver disease. [...] Caution must also be exercised in patients with loss-of-function polymorphisms of CYP2C9, as these can increase avatrombopag exposure.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Doptelet was not studied in patients with prior thromboembolic events. Consider the potential increased thrombotic risk when administering Doptelet to patients with known risk factors for thromboembolism, including but not limited to genetic prothrombotic conditions (e.g. Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency), acquired risk factors (e.g. antiphospholipid syndrome), advanced age, patients with prolonged periods of immobilisation, malignancies, contraceptives and hormone replacement therapy, surgery/trauma, obesity and smoking.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Avatrombopag_2024_07_11_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Avatrombopag_2024_07_11_EMA.pdf"">avatrombopag EPAR</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452526260.0,"<blockquote class=""blockquote"">
<p>Caution must also be exercised in patients with loss-of-function polymorphisms of CYP2C9, as these can increase avatrombopag exposure.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consider the potential increased thrombotic risk when administering Doptelet to patients with known risk factors for thromboembolism, including but not limited to genetic prothrombotic conditions (e.g. Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency), [...]</p>
</blockquote>
",,,,,,,
Label Annotation,PA166252901,"Annotation of FDA Label for tepotinib and ALK, EGFR",False,True,[],False,"[{'id': 1452215440, 'date': '2023-08-24T16:06:57.189-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15124482, 'title': 'tepotinib FDA label NDA214096', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214096', 'crossReferences': [{'id': 1451549320, 'resource': 'FDA Application', 'resourceId': 'NDA214096', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214096'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166211181', 'name': 'tepotinib'}]","[{'objCls': 'Gene', 'id': 'PA24719', 'symbol': 'ALK', 'name': 'ALK receptor tyrosine kinase'}, {'objCls': 'Gene', 'id': 'PA7360', 'symbol': 'EGFR', 'name': 'epidermal growth factor receptor'}]",FDA,1451549284.0,"<p>The FDA-approved drug label for tepotinib stated that it is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal- epithelial transition (MET) exon 14 skipping alterations. Eligible patients in the tepotinib clinical study were required to have advanced or metastatic NSCLC harboring METex14 skipping alterations, epidermal growth factor receptor (EGFR) wild-type and anaplastic lymphoma kinase (ALK) negative status.</p>
",1451549285.0,"<p>Excerpts from the tepotinib drug label:</p>
<blockquote class=""blockquote"">
<p>CLINICAL STUDIES:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The efficacy of TEPMETKO was evaluated in a single-arm, open-label, multicenter, non-randomized, multicohort study (VISION, NCT02864992). Eligible patients were required to have advanced or metastatic NSCLC harboring METex14 skipping alterations, epidermal growth factor receptor (EGFR) wild-type and anaplastic lymphoma kinase (ALK) negative status, at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. Patients with symptomatic CNS metastases, clinically significant uncontrolled cardiac disease, or who received treatment with any MET or hepatocyte growth factor (HGF) inhibitor were not eligible for the study</p>
</blockquote>
<blockquote class=""blockquote"">
<p>INDICATIONS AND USAGE:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>DOSAGE AND ADMINISTRATION:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patient Selection for METex14 Skipping Alterations: Select patients for treatment with TEPMETKO based on the presence of MET exon 14 skipping alterations in plasma or tumor specimens. Testing for the presence of MET exon 14 skipping alterations in plasma specimens is recommended only in patients for whom a tumor biopsy cannot be obtained. If an alteration is not detected in a plasma specimen, re-evaluate the feasibility of biopsy for tumor tissue testing. An FDA-approved test for detection of MET exon 14 skipping alterations in NSCLC for selecting patients for treatment with TEPMETKO is not available.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CLINICAL PHARMACOLOGY:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Mechanism of action: Tepotinib is a kinase inhibitor that targets MET, including variants with exon 14 skipping alterations. Tepotinib inhibits hepatocyte growth factor (HGF)-dependent and -independent MET phosphorylation and MET-dependent downstream signaling pathways. Tepotinib also inhibited melatonin 2 and imidazoline 1 receptors at clinically achievable concentrations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Metabolism: Tepotinib is primarily metabolized by CYP3A4 and CYP2C8. One major circulating plasma metabolite (M506) has been identified.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""tepotinib_10192021_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/tepotinib_10192021_FDA.pdf"">tepotinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166127698,Annotation of HCSC Label for omeprazole and CYP2C19,False,False,[],False,"[{'id': 1452723760, 'date': '2024-12-03T17:48:15.523-08:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171522, 'title': 'Drugs@HCSC: Drug Product LOSEC (omeprazole), CHEPLAPHARM Arzneimittel GmbH', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9823', 'crossReferences': [{'id': 1452723680, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9823', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9823'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450704', 'name': 'omeprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1447982225.0,"<p>The product monograph for omeprazole (LOSEC) states that CYP2C19 poor metabolizers have higher plasma concentrations of the drug as compared to extensive metabolizers. However, the monograph also notes that this has no implication on dosing of omeprazole.</p>
",1447982224.0,"<p>Excerpts from the omeprazole (LOSEC) product monograph:</p>
<blockquote class=""blockquote"">
<p>Omeprazole undergoes first-pass metabolism, and is completely metabolized by the cytochrome P-450 system (CYP), mainly in the liver. The major part of its metabolism is dependent upon the polymorphically expressed, specific isoform, CYP 2C19 (S-mephenytoin hydroxylase). The remaining part is dependent on another specific isoform, CYP 3A4, responsible for the formation of omeprazole sulphone. As a consequence of high affinity of omeprazole to CYP 2C19, there is a potential for competitive inhibition and metabolic drug-drug interactions with other substrates for CYP 2C19. However, due to low affinity to CYP 3A4, omeprazole has no potential to inhibit the metabolism of other CYP 3A4 substrates.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Poor metabolizers: Approximately 3% of the Caucasian population and 15-20% of Asian populations lack a functional CYP 2C19 enzyme and are called poor metabolizers. In such individuals, the metabolism of omeprazole is expected to be catalyzed by CYP 3A4. After repeated once-daily administration of 20 mg omeprazole, the mean AUC was 5 to 10 times higher in poor metabolizers than in subjects having a functional CYP 2C19 enzyme (extensive metabolizers). Mean peak plasma concentrations were also higher, by 3 to 5 times. However, these findings have no implication on dosing of LOSEC.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genetic Polymorphism &amp; Ethnic Origin: CYP 450 2C19 is a polymorphic enzyme. This heterogeneity is more pronounced in the Asian population where the proportion of slow metabolizers is higher than in Caucasians. In pharmacokinetic studies of single 20 mg omeprazole doses, an increase in AUC of approximately four-fold was noted in Asian subjects compared to Caucasians. The half-life of omeprazole in slow metabolizers is about 2.5 hours as compared to approximately 1 hour for rapid metabolizers. It is recommended that Asian populations be closely followed-up, particularly when doses are higher than 20 mg and/or there is concomitant hepatic disease.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Omeprazole_2024_12_03_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Omeprazole_2024_12_03_HCSC.pdf"">omeprazole product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166225042,Annotation of FDA Label for rimegepant and CYP2C9,False,False,[],False,"[{'id': 1452406940, 'date': '2024-03-13T09:12:44.833-07:00', 'description': 'Updated label with highlights.', 'type': 'Update', 'version': 0}, {'id': 1452725240, 'date': '2024-12-04T14:29:59.013-08:00', 'description': 'fixed typo', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15114622, 'title': 'Drugs@FDA: Drug Product NURTEC ODT (rimegepant sulfate), Pfizer Laboratories Div Pfizer Inc - NDA212728/SUPPL-9, 04/11/2022', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212728', 'crossReferences': [{'id': 1452406980, 'resource': 'FDA Application', 'resourceId': 'NDA212728/SUPPL-9', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212728'}], 'objCls': 'Literature', 'pubDate': '2022-04-11T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166225041', 'name': 'rimegepant'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1451277742.0,"<p>The FDA label for rimegepant (NURTEC ODT) states that it is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. The contribution of CYP2C9 to rimegepant metabolism is considered minor, and CYP2C9 polymorphism is not expected to significantly affect its exposure.</p>
",1451277743.0,"<p>Excerpts from the rimegepant (NURTEC ODT) drug label:</p>
<blockquote class=""blockquote"">
<p>12.5 Pharmacogenomics</p>
<p>CYP2C9 activity is reduced in individuals with genetic variants such as the CYP2C9*2 and CYP2C9*3 alleles. Rimegepant Cmax and AUC0-inf were similar in CYP2C9 intermediate metabolizers (i.e., *1/*2, *2/*2, *1/*3, n=43) as compared to normal metabolizers (i.e., *1/*1, N=72). Adequate PK data are not available from CYP2C9 poor metabolizers (i.e., *2/*3). Since the contribution of CYP2C9 to rimegepant metabolism is considered minor, CYP2C9 polymorphism is not expected to significantly affect its exposure.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C9 Inhibitors In a dedicated drug interaction study, concomitant administration of 75 mg rimegepant (single dose) with fluconazole, a combined moderate CYP3A4 and CYP2C9 inhibitor, resulted in increased exposures of rimegepant (AUC by 1.8-fold) with no relevant effect on Cmax. Rimegepant is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9. Increase in the exposure of rimegepant can be attributed to combined inhibition of CYP2C9 and CYP3A4 with fluconazole administration suggesting a minor contribution from CYP2C9. Thus, CYP2C9 inhibition alone is not expected to significantly affect rimegepant exposures.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Other Specific Populations: No clinically significant differences in the pharmacokinetics of rimegepant were observed based on age, sex, race/ethnicity, body weight, or CYP2C9 genotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Drug Interaction Studies: In Vitro Studies</p>
<p>Rimegepant is a substrate of CYP3A4 and CYP2C9 (see In Vivo Studies). Rimegepant is not an inhibitor of CYP1A2, 2B6, 2C9, 2C19, 2D6, or UGT1A1 at clinically relevant concentrations. However, rimegepant is a weak inhibitor of CYP3A4 with time-dependent inhibition. Rimegepant is not an inducer of CYP1A2, CYP2B6, or CYP3A4 at clinically relevant concentrations.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Rimegepant_FDA_2024_03_13.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Rimegepant_FDA_2024_03_13.pdf"">rimegepant drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166269081,Annotation of FDA Label for glycerol phenylbutyrate and NAGS,False,False,[],False,"[{'id': 1452209541, 'date': '2023-08-17T17:41:40.700-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15131162, 'title': 'FDA label for glycerol phenylbutyrate', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203284', 'crossReferences': [{'id': 1451747514, 'resource': 'FDA Application', 'resourceId': 'NDA203284', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203284'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166268801', 'name': 'glycerol phenylbutyrate'}]","[{'objCls': 'Gene', 'id': 'PA134968729', 'symbol': 'NAGS', 'name': 'N-acetylglutamate synthase'}]",FDA,1451747560.0,"<p>Glycerol phenylbutyrate (RAVICTI) is a nitrogen-binding agent indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. The FDA label states that the safety and efficacy for treatment of N-acetylglutamate synthase (NAGS)
deficiency has not been established for glycerol phenylbutyrate.</p>
",1451747561.0,"<p>Excerpts from the glycerol phenylbutyrate (RAVICTI) drug label:</p>
<blockquote class=""blockquote"">
<p>RAVICTI is a nitrogen-binding agent indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Limitations of use: Safety and efficacy for treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Glycerol_Phenylbutyrate_2022_04_05_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Glycerol_Phenylbutyrate_2022_04_05_FDA.pdf"">glycerol phenylbutyrate drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166269121,Annotation of FDA Label for nateglinide and CYP2C9,False,False,[],False,"[{'id': 1452536181, 'date': '2024-07-23T12:24:35.779-07:00', 'description': 'Added Prescribing section, tags and new label document. Noted that original FDA label is now discontinued.', 'type': 'Update', 'version': 0}, {'id': 1452540380, 'date': '2024-07-26T15:23:25.101-07:00', 'description': 'removed prescribing info, tag (DDI)', 'type': 'Update', 'version': 0}, {'id': 1452568620, 'date': '2024-08-28T14:34:55.557-07:00', 'description': 'added information about differences between drug label and FDA table', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161602, 'title': 'DailyMed - NATEGLINIDE tablet, coated', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c678b772-acba-4b59-a0b2-d70d84283425', 'crossReferences': [{'id': 1452536140, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': 'c678b772-acba-4b59-a0b2-d70d84283425', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c678b772-acba-4b59-a0b2-d70d84283425'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15131182, 'title': 'FDA label for nateglinide', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021204', 'crossReferences': [{'id': 1451747680, 'resource': 'FDA Application', 'resourceId': 'NDA021204', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021204'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450600', 'name': 'nateglinide'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1451747660.0,"<p>Nateglinide is a glinide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In a table of clinically significant drug interactions with nateglinide, the FDA label states that in patients who are known to be CYP2C9 poor metabolizers, alcohol may increase both the blood-glucose-lowering effect of nateglinide and susceptibility to hypoglycemia. Dose reductions and increased frequency of glucose monitoring may therefore be required.</p>
",1451747661.0,"<p>Excerpts from the nateglinide drug label:</p>
<blockquote class=""blockquote"">
<p><em>In vitro</em> drug metabolism studies indicate that nateglinide tablets are predominantly metabolized by the cytochrome P450 isozyme CYP2C9 (70%) and to a lesser extent CYP3A4 (30%).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Table 2: Clinically Significant Drug Interactions with Nateglinide</strong><br />
Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia:<br />
Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g. methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid, and inhibitors of CYP2C9 (e.g. amiodarone, fluconazole, voriconazole, sulfinpyrazone), or in patients known to be poor metabolizers of CYP2C9 substrates, alcohol.
Intervention: Dose reductions and increased frequency of glucose monitoring may be required when nateglinide tablets are coadministered with these
drugs.</p>
</blockquote>
<p>Note that while the FDA-approved nateglinide drug label only refers to CYP2C9 poor metabolizers in the context of drug-drug interactions (specifically with alcohol), the FDA Table of Pharmacogenetic Associations entry for nateglinide does not mention drug-drug interactions.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Nateglinide_2024_07_23_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Nateglinide_2024_07_23_FDA.pdf"">nateglinide drug label</a>.</p>
<p>This annotation was originally on the nateglinide (Starlix) label, which has now been discontinued. The PDF of the Starlix label is available <a download=""nateglinide_2022_04_05_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/nateglinide_2022_04_05_FDA.pdf"">here</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166268923,Annotation of FDA Label for ropeginterferon alfa-2b and JAK2,False,True,[],False,"[{'id': 1451818860, 'date': '2022-07-06T08:55:22.447-07:00', 'description': 'Added Cancer Genome tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15131044, 'title': 'Drugs@FDA: Drug Product BESREMi (ROPEGINTERFERON ALFA-2B), BLA761166, PharmaEssentia USA', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761166', 'crossReferences': [{'id': 1451741346, 'resource': 'FDA Application', 'resourceId': 'BLA761166', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761166'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166268922', 'symbol': 'rs77375493', 'name': 'rs77375493'}]","[{'objCls': 'Chemical', 'id': 'PA166268921', 'name': 'ropeginterferon alfa-2b'}]","[{'objCls': 'Gene', 'id': 'PA29989', 'symbol': 'JAK2', 'name': 'Janus kinase 2'}]",FDA,1451741291.0,"<p>The FDA label for ropeginterferon alfa-2b (BESREMi) states that the presence or absence of the JAK2 V617F (rs77375493) variant does not have a clinically significant effect on the pharmacokinetics of ropeginterferon alfa-2b</p>
",1451741292.0,"<p>Excerpts from the ropeginterferon alfa-2b (BESREMi) label:</p>
<blockquote class=""blockquote"">
<p>Specific Populations:<br />
No clinically significant differences in the pharmacokinetics of BESREMi were observed based on age, sex, body surface area, and JAK2V617F mutation.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Clinical Studies</strong><br />
The efficacy and safety of BESREMi were evaluated in the PEGINVERA study, [...] All patients had the JAK2V617F mutation.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Ropeginterferon_04_04_22_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ropeginterferon_04_04_22_FDA.pdf"">ropeginterferon alfa-2b drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166170052,Annotation of FDA Label for valbenazine and CYP2D6,False,False,[],True,"[{'id': 1451748680, 'date': '2022-04-12T10:21:54.060-07:00', 'description': 'update', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102005, 'title': 'Drugs@FDA: Drug Product INGREZZA (Valbenazine), NDA209241, Neurocrine Biosciences, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209241', 'crossReferences': [{'id': 1449891003, 'resource': 'FDA Application', 'resourceId': 'NDA209241', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209241'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166170051', 'name': 'valbenazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1448993494.0,"<p>The FDA-approved drug label for valbenazine (INGREZZA) states that dosage reduction of INGREZZA is recommended for known CYP2D6 poor metabolizers and the recommended dosage for known CYP2D6 poor metabolizers is 40 mg once daily.</p>
",1448993493.0,"<p>Excerpts from the valbenazine (INGREZZA) drug label:</p>
<blockquote class=""blockquote"">
<p>Dosage Recommendations for Known CYP2D6 Poor Metabolizers:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The recommended dosage for known CYP2D6 poor metabolizers is INGREZZA 40 mg once daily.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 Poor Metabolizers: Dosage reduction of INGREZZA is recommended for known CYP2D6 poor metabolizers. Increased exposure (Cmax and AUC) to valbenazine’s active metabolite is anticipated in CYP2D6 poor metabolizers. Increased exposure of active metabolite may increase the risk of exposure-related adverse reactions.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""valbenazine_2022_04_12_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/valbenazine_2022_04_12_FDA.pdf"">valbenazine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450384074.0,"<p>Excerpt from the valbenazine (INGREZZA) drug label:</p>
<blockquote class=""blockquote"">
<p>Dosage Recommendations for Known CYP2D6 Poor Metabolizers:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The recommended dosage for known CYP2D6 poor metabolizers is INGREZZA 40 mg once daily.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166234701,Annotation of FDA Label for allopurinol and HLA-B,True,False,[],False,"[{'id': 1452212400, 'date': '2023-08-22T01:39:40.922-07:00', 'description': 'added tag for on FDA biomarker list', 'type': 'Update', 'version': 0}, {'id': 1452260260, 'date': '2023-10-02T21:04:25.076-07:00', 'description': 'update text', 'type': 'Update', 'version': 0}, {'id': 1452482100, 'date': '2024-05-23T11:47:52.502-07:00', 'description': 'fixed typo', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15118302, 'title': 'Drugs@FDA: Drug Product ALOPRIM (allopurinol), NDA020298, Mylan', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020298', 'crossReferences': [{'id': 1451391622, 'resource': 'FDA Application', 'resourceId': 'NDA020298', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020298'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165987831', 'symbol': 'HLA-B*58:01', 'name': '*58:01'}]","[{'objCls': 'Chemical', 'id': 'PA448320', 'name': 'allopurinol'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",FDA,1451391601.0,"<p>The FDA-approved label for allopurinol (ALOPRIM) states that patients who carry the HLA-B*58:01 allele, found at a higher frequency in individuals of African, Asian (e.g., Han Chinese, Korean, Thai), and Native Hawaiian/Pacific Islander ancestry, are at a higher risk of allopurinol hypersensitivity syndrome (AHS). The label recommends testing for HLA-B*58:01 in genetically at-risk populations and states that ALOPRIM is not recommended in HLA-B*58:01 positive patients unless the benefits outweigh the risks.</p>
",1451391602.0,"<p>Excerpt from the allopurinol (ALOPRIM) drug label:</p>
<blockquote class=""blockquote"">
<p>The HLA-B*58:01 allele is a genetic marker for severe skin reactions indicative of
hypersensitivity to allopurinol. Patients who carry the HLA-B*58:01 allele are at a higher risk of
allopurinol hypersensitivity syndrome (AHS), but hypersensitivity reactions have been reported
in patients who do not carry this allele. The frequency of this allele is higher in individuals of
African, Asian (e.g., Han Chinese, Korean, Thai), and Native Hawaiian/Pacific Islander ancestry.
Prior to starting ALOPRIM, consider testing for the HLA-B*58:01 allele in genetically at-risk
populations. The use of ALOPRIM is not recommended in HLA-B*58:01 positive patients
unless the benefits clearly outweigh the risks.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Prior to starting ALOPRIM, consider testing for the HLA-B*58:01 allele in genetically at-risk populations. Screening is generally not recommended in patients from populations in which the prevalence of HLA-B*58:01 is low, or in current allopurinol users, as the risk of SJS/TEN/DRESS is largely confined to the first few months of therapy, regardless of HLA­ B*58:01 status.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>12.5 Pharmacogenomics:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The HLA-B*58:01 allele is a genetic marker for severe skin reactions indicative of hypersensitivity to allopurinol (see Warnings and Precautions (5.1)). The frequency of the HLA­ B*58:01 allele ranges from 8 to 10% in Han Chinese populations, about 8% in Thai populations, and about 6% in Korean populations based upon published literature and available databases. The frequency of the HLA-B*58:01 allele is about 4% in Blacks, about 1-2 % in indigenous peoples of the Americas and Hispanic populations, and &lt;1% in people from European descent and Japanese.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""allopurinol_FDA_10022023.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/allopurinol_FDA_10022023.pdf"">allopurinol drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1451391603.0,"<p>Excerpt from the allopurinol (ALOPRIM) drug label:</p>
<blockquote class=""blockquote"">
<p>Prior to starting ALOPRIM, consider testing for the HLA-B*58:01 allele in genetically at-risk populations. Screening is generally not recommended in patients from populations in which the prevalence of HLA-B*58:01 is low, or in current allopurinol users, as the risk of SJS/TEN/DRESS is largely confined to the first few months of therapy, regardless of HLA­ B*58:01 status.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166122592,Annotation of FDA Label for simeprevir and IFNL3,False,False,[],False,"[{'id': 1184483143, 'date': '2014-07-14T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452215320, 'date': '2023-08-24T15:37:05.993-07:00', 'description': 'change level to actionable PGx', 'type': 'Update', 'version': 0}, {'id': 1452221600, 'date': '2023-08-30T13:40:47.963-07:00', 'description': 'changed to informative PGx based on ""subjects of all _IL28B_ genotypes had the highest SVR rates with OLYSIO-containing regimens.""', 'type': 'Update', 'version': 0}, {'id': 1452540180, 'date': '2024-07-26T11:46:10.768-07:00', 'description': 'updated PGx level to Actionable; drug has been discontinued', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162182, 'title': 'Drugs@FDA: Drug Product NDA205123/SUPPL-14, 11/09/2017', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205123', 'crossReferences': [{'id': 1452540164, 'resource': 'FDA Application', 'resourceId': 'NDA205123/SUPPL-14', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205123'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'pubDate': '2017-11-09T00:00:00-08:00', 'terms': [], 'type': 'Drug Label'}, {'id': 15101930, 'title': 'Drugs@FDA: Drug Product simeprevir (NDA205123)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205123', 'crossReferences': [{'id': 1449776657, 'resource': 'FDA Application', 'resourceId': 'NDA205123', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205123'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166155468', 'symbol': 'rs12979860', 'name': 'rs12979860'}]","[{'objCls': 'Chemical', 'id': 'PA166122590', 'name': 'simeprevir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",FDA,1447982135.0,"<p>The FDA-approved drug label for simeprevir (OLYSIO) contains information regarding a genetic variant near the <em>IFNL3</em> gene (<em>IL28B</em>, <a href=""/variant/PA166155468"">rs12979860</a>, a C to T change) which is a strong predictor of response to peginterferon alfa and ribavirin treatment. Simeprevir must not be used as a monotherapy, and should be administered in combination with both peginterferon alfa and ribavirin for treatment of chronic hepatitis C genotype 1.</p>
<p><strong>July 2024: Please note that simeprevir is listed as discontinued by the FDA. However, this drug is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
",1447982134.0,"<p>Excerpt from the simeprevir (OLYSIO) drug label:</p>
<blockquote class=""blockquote"">
<p>A genetic variant near the gene encoding interferon-lambda-3 (<em>IL28B</em> <a href=""/variant/PA166155468"">rs12979860</a>, a C to T change) is a strong predictor of response to pegintereferon alfa and ribavirin (PR). In the Phase 3 trials, <em>IL28B</em> genotype was a stratification factor. Overall, SVR rates were lower in subjects with the CT and TT genotypes compared to those with the CC genotype. Among both treatment-naive subjects and those who experienced previous treatment failure, subjects of all <em>IL28B</em> genotypes had the highest SVR rates with OLYSIO-containing regimens.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Simeprevir_04_18_2019_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Simeprevir_04_18_2019_FDA.pdf"">simeprevir drug label </a></p>
<p><strong>July 2024: Please note that simeprevir is listed as discontinued by the FDA. However, this drug is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166127710,Annotation of HCSC Label for simeprevir and IFNL3,False,False,[],False,"[{'id': 1452215321, 'date': '2023-08-24T15:37:47.304-07:00', 'description': 'changed level to actionable PGx', 'type': 'Update', 'version': 0}, {'id': 1452221582, 'date': '2023-08-30T13:44:37.858-07:00', 'description': 'changed to informative PGx', 'type': 'Update', 'version': 0}, {'id': 1452540160, 'date': '2024-07-26T11:36:34.168-07:00', 'description': 'updated PGx level to Actionable, but marketing status is Cancelled Post Market', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162162, 'title': 'Drugs@HCSC: Drug Product GALEXOS (simeprevir), Janssen Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00040229.PDF', 'crossReferences': [{'id': 1452540140, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00040229.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00040229.PDF'}], 'notes': 'Current status: Cancelled Post Market\nCurrent status date: 2018-03-31', 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166155468', 'symbol': 'rs12979860', 'name': 'rs12979860'}]","[{'objCls': 'Chemical', 'id': 'PA166122590', 'name': 'simeprevir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",HCSC,1447982233.0,"<p>The product monograph for simeprevir (GALEXOS) contains information regarding a genetic variant near the IFNL3 gene (<em>IL28B</em>, <a href=""/variant/PA166155468"">rs12979860</a>) which is a strong predictor of response to peginterferon alfa (PegIFN-alfa) and ribavirin (RBV) treatment. Simeprevir is only indicated in combination with PegIFN-alfa and RBV or with sofosbuvir, it is not indicated as a monotherapy.</p>
<p><strong>Please note that as of July 2024, the HCSC database lists the marketing status of simeprevir as &quot;Cancelled Post Market&quot;.</strong></p>
",1447982232.0,"<p>Excerpts from the simeprevir (GALEXOS) product monograph:</p>
<blockquote class=""blockquote"">
<p>A genetic variant near the gene encoding interferon-lambda-3 (IL28B rs12979860, a C to T change) is a strong predictor of response to PegIFN-alfa and RBV.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In the Phase 3 studies, IL28B genotype was a stratification factor; hence IL28B genotype was determined in all patients.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Overall, [sustained virological response] rates were lower in subjects with the CT and TT genotypes compared to those with the CC genotype (Table 43 and Table 44). In studies C208, C216 and HPC3007, among both treatment-naïve and previous treatment failures, subjects of all IL28B genotypes had higher SVR rates with GALEXOS®-containing regimens (Table 43).</p>
</blockquote>
<p><strong>Please note that as of July 2024, the HCSC database lists the marketing status of simeprevir as &quot;Cancelled Post Market&quot;.</strong></p>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Simeprevir_2024_07_26_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Simeprevir_2024_07_26_HCSC.pdf"">simeprevir product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166122607,Annotation of FDA Label for vortioxetine and CYP2D6,False,False,[],True,"[{'id': 1184483980, 'date': '2014-07-16T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452204420, 'date': '2023-08-10T16:02:21.711-07:00', 'description': 'Fixed typo in drug trade name Trintellix', 'type': 'Correction', 'version': 0}]",False,[],True,"[{'id': 15101958, 'title': 'Drugs@FDA: Drug Product Trintellix (vortioxetine), NDA204447, Cardinal Health', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204447', 'crossReferences': [{'id': 1449891928, 'resource': 'FDA Application', 'resourceId': 'NDA204447', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204447'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166122595', 'name': 'vortioxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447982109.0,"<p>Vortioxetine (TRINTELLIX) is indicated as a treatment for major depressive disorder. The FDA-approved drug label for vortioxetine notes that the maximum recommended dose in patients who are known CYP2D6 poor metabolizers is 10 mg/day.</p>
",1447982108.0,"<p>Excerpts from the vortioxetine (TRINTELLIX) drug label:</p>
<blockquote class=""blockquote"">
<p>The maximum recommended dose of TRINTELLIX is 10 mg/day in known CYP2D6 poor metabolizers. Reduce the dose of TRINTELLIX by one half when patients are receiving a CYP2D6 strong inhibitor (e.g. bupropion, fluoxetine, paroxetine, or quinidine) concomitantly.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 is the primary enzyme catalyzing the metabolism of vortioxetine into its major, pharmacologicially inactive, carboxylic acid metabolite, and poor metabolizers of CYP2D6 have approximately twice the vortioxetine plasma concentration of extensive metabolizers.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Vortioxetine_09_26_2017_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Vortioxetine_09_26_2017_FDA.pdf"">vortioxetine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450384796.0,"<p>Excerpt from the vortioxetine (TRINTELLIX) drug label:</p>
<blockquote class=""blockquote"">
<p>The maximum recommended dose of TRINTELLIX is 10 mg/day in known CYP2D6 poor metabolizers.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166278361,Annotation of FDA Label for dextromethorphan hydrobromide / bupropion hydrochloride and CYP2D6,False,False,[],True,"[{'id': 1452622422, 'date': '2024-10-02T17:56:59.886-07:00', 'description': 'drug was added to the FDA biomarker table; updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15166802, 'title': 'Drugs@FDA: Drug Product AUVELITY (dextromethorphan hydrobromide, bupropion hydrochloride), Axsome Therapeutics, Inc. - NDA215430/SUPPL-8, 05/07/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215430', 'crossReferences': [{'id': 1452622421, 'resource': 'FDA Application', 'resourceId': 'NDA215430/SUPPL-8', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215430'}], 'objCls': 'Literature', 'pubDate': '2024-05-07T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15135602, 'title': 'Drugs@FDA Drug Product: AUVELITY (dextromethorphan hydrobromide / bupropion hydrochloride)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215430', 'crossReferences': [{'id': 1451880184, 'resource': 'FDA Application', 'resourceId': 'NDA215430', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215430'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166278341', 'name': 'dextromethorphan hydrobromide / bupropion hydrochloride'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1451880180.0,"<p>The FDA-approved drug label for dextromethorphan hydrobromide and bupropion hydrochloride (AUVELITY) states that it is indicated for the treatment of major depressive disorder in adults. Dextromethorphan is a CYP2D6 substrate and bupropion is an aminoketone and CYP450 2D6 inhibitor. The recommended dosage for patients known to be poor CYP2D6 metabolizers is one tablet once daily in the morning, because these patients have higher dextromethorphan concentrations than extensive/intermediate CYP2D6 metabolizers.</p>
",1451880181.0,"<p>Excerpts from the AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride) label:</p>
<blockquote class=""blockquote"">
<p>AUVELITY is a combination of dextromethorphan, an uncompetitive N-methyl D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, and bupropion, an aminoketone and CYP450 2D6 inhibitor, indicated for the treatment of major depressive disorder (MDD) in adults.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dosage adjustment is recommended in patients known to be poor CYP2D6 metabolizers because these patients have higher dextromethorphan concentrations than extensive/intermediate CYP2D6 metabolizers [see Dosage and Administration (2.5), Clinical Pharmacology (12.3)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The recommended dosage for patients known to be poor CYP2D6 metabolizers is one tablet once daily in the morning [see Use in Specific Populations (8.8), Clinical Pharmacology (12.3)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>AUVELITY is a combination of dextromethorphan and bupropion. Bupropion inhibits the metabolism of dextromethorphan via CYP2D6.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dextromethorphan is primarily metabolized by CYP2D6 to dextrorphan. Bupropion is extensively metabolized with three active metabolites: hydroxybupropion, which is formed via hydroxylation of the tert-butyl group of bupropion, and the amino-alcohol isomers, threohydroxybupropion and erythrohydroxybupropion, which are formed via reduction of the carbonyl group. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydroxybupropion.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In CYP2D6 extensive metabolizers, approximately 37-52% of the orally administered dose of dextromethorphan is recovered in the urine. Less than 2% of the administered dose is excreted as unchanged parent drug in the urine. In CYP2D6 poor metabolizers, approximately 45-83% of the administered dose is recovered in the urine. Approximately 26% of the administered dose is excreted as unchanged parent drug in the urine.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Dextromethorphan_hydrobromide_and_bupropion_hydrochloride_2024_10_02_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dextromethorphan_hydrobromide_and_bupropion_hydrochloride_2024_10_02_FDA.pdf"">Dextromethorphan hydrobromide and bupropion hydrochloride drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451880182.0,"<p>Excerpts from the AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride) drug label:</p>
<blockquote class=""blockquote"">
<p>Dosage adjustment is recommended in patients known to be poor CYP2D6 metabolizers because these patients have higher dextromethorphan concentrations than extensive/intermediate CYP2D6 metabolizers [see Dosage and Administration (2.5), Clinical Pharmacology (12.3)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The recommended dosage for patients known to be poor CYP2D6 metabolizers is one tablet once daily in the morning [see Use in Specific Populations (8.8), Clinical Pharmacology (12.3)].</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104807,Annotation of FDA Label for fluorouracil and DPYD,True,False,[],False,"[{'id': 1183681706, 'date': '2013-10-25T14:45:05.740-07:00', 'type': 'Update', 'version': 0}, {'id': 1448616977, 'date': '2017-05-04T12:14:46.001-07:00', 'type': 'Update', 'version': 0}, {'id': 1452259940, 'date': '2023-10-02T00:00:00-07:00', 'description': 'Attached most recent label for Carac. Unable to find a more recent FDA label for fluorouracil injection at drugs@FDA.', 'type': 'Update', 'version': 1}, {'id': 1452259780, 'date': '2023-10-02T10:17:12.697-07:00', 'description': 'Changed the order of information to list fluorouracil injection first and topical fluorouracil second. Clarified prescribing section to include instructions for both formulations.', 'type': 'Update', 'version': 0}, {'id': 1452448480, 'date': '2024-04-19T14:26:08.741-07:00', 'description': 'Increased the genetic testing level to ""testing recommended"" and replaced the fluorouracil injection drug label with a newer label that contains more PGx information.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15167202, 'title': 'Drugs@FDA: Drug Product FLUOROURACIL (FLUOROURACIL), Eugia US LLC - ANDA202669/SUPPL-9, 03/21/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202669', 'crossReferences': [{'id': 1452626944, 'resource': 'FDA Application', 'resourceId': 'ANDA202669/SUPPL-9', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202669'}], 'objCls': 'Literature', 'pubDate': '2024-03-21T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15158762, 'title': 'Drugs@FDA: Drug Product Fluorouracil (Fluorouracil), BluePoint Laboratories - ANDA210124/SUPPL-9, 03/21/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210124', 'crossReferences': [{'id': 1452487722, 'resource': 'FDA Application', 'resourceId': 'ANDA210124/SUPPL-9', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210124'}], 'objCls': 'Literature', 'pubDate': '2024-03-21T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15102038, 'title': 'Drugs@FDA: Drug Product Carac (fluorouracil), Bausch Health US, LLC - NDA020985/SUPPL-19, 05/26/2022', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020985', 'crossReferences': [{'id': 1452623543, 'resource': 'FDA Application', 'resourceId': 'NDA020985/SUPPL-19', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020985'}], 'objCls': 'Literature', 'pubDate': '2022-05-26T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15156942, 'title': 'DailyMed - FLUOROURACIL injection, solution', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ea3497db-23b9-4ace-9a6f-b54853d04a82', 'crossReferences': [{'id': 1452448500, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': 'ea3497db-23b9-4ace-9a6f-b54853d04a82', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ea3497db-23b9-4ace-9a6f-b54853d04a82'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA128406956', 'name': 'fluorouracil'}]","[{'objCls': 'Gene', 'id': 'PA145', 'symbol': 'DPYD', 'name': 'dihydropyrimidine dehydrogenase'}]",FDA,1450361445.0,"<p>Fluorouracil is not recommended for use in patients known to have certain homozygous or compound heterozygous DPYD variants that result in complete dihydropyrimidine dehydrogenase (DPD) deficiency. Prescribers should consider testing for genetic variants of DPYD prior to initiating fluorouracil. Fluorouracil is available as both an injection and a topical cream (CARAC). These two formulations have different indications. Both FDA-approved labels contain information about the potential for severe toxicity in patients with DPD deficiency.</p>
",1450361447.0,"<p>There are two label indications for fluroruracil linked from the FDA table of Pharmacogenomic Biomarkers in Drug Labeling: Fluorouracil injection is used in oncology for the treatment of various types of neoplasms, including colorectal neoplasms;  Fluorouracil cream (CARAC) is used in dermatology to treat multiple actinic or solar keratoses of the face and anterior scalp.</p>
<p>Excerpts from the fluorouracil injection drug label:</p>
<blockquote class=""blockquote"">
<p>Serious Adverse Reactions from Dihydropyrimidine Dehydrogenase (DPD) Deficiency</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients with certain homozygous or compound heterozygous variants in the DPYD gene known to result in complete or near complete absence of DPD activity (complete
DPD deficiency) are at increased risk for acute early-onset toxicity and serious, including fatal, adverse reactions due to fluorouracil (e.g., mucositis, diarrhea, neutropenia, and
neurotoxicity). Patients with partial DPD activity (partial DPD deficiency) may also have increased risk of serious, including fatal, adverse reactions.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Fluorouracil is not recommended for use in patients known to have certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Withhold or permanently discontinue fluorouracil based on clinical assessment of the onset, duration, and severity of the observed adverse events in patients with evidence of acute early-onset or unusually severe reactions, which may indicate complete DPD deficiency. No fluorouracil dose has been proven safe for patients with complete DPD deficiency. There are insufficient data to recommend a specific dose in patients with partial DPD deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consider testing for genetic variants of DPYD prior to initiating fluorouracil to reduce the risk of serious adverse reactions if the patient’s clinical status permits and based on
clinical judgement. Serious adverse reactions may still occur even if no DPYD variants are identified.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>An FDA-authorized test for the detection of genetic variants of DPYD to identify patients at risk of serious adverse reactions due to increased systemic exposure to fluorouracil is not currently available. Currently available tests used to identify DPYD variants may vary in accuracy and design (e.g., which DPYD variant(s) they identify).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The DPYD gene encodes the enzyme DPD, which is responsible for the catabolism of &gt;80% of fluorouracil. Approximately 3-5% of White populations have partial DPD
deficiency and 0.2% of White populations have complete DPD deficiency, which may be due to certain genetic no function or decreased function variants in DPYD resulting in
partial to complete or near complete absence of enzyme activity. DPD deficiency is estimated to be more prevalent in Black or African American populations compared to
White populations. Insufficient information is available to estimate the prevalence of DPD deficiency in other populations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients who are homozygous or compound heterozygous for no function DPYD variants (i.e., carry two no function DPYD variants) or are compound heterozygous for a no function DPYD variant plus a decreased function DPYD variant have complete DPD deficiency and are at increased risk for acute early-onset of toxicity and serious life-threatening, or fatal adverse reactions due to increased systemic exposure to fluorouracil. Partial DPD deficiency can result from the presence of either two decreased function DPYD variants or one normal function plus either a decreased function or a no function DPYD variant. Patients with partial DPD deficiency may also be at an increased risk for toxicity from fluorouracil.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Four DPYD variants have been associated with impaired DPD activity in White populations, especially when present as homozygous or compound heterozygous variants: c.1905+1G&gt;A (DPYD *2A), c.1679T&gt;G (DPYD *13), c.2846A&gt;T, and c.1129-5923C&gt;G (Haplotype B3). DPYD*2A and DPYD*13 are no function variants, and c.2846A&gt;T and c.1129-5923C&gt;G are decreased function variants. The decreased function DPYD variant c.557A&gt;G is observed in individuals of African ancestry. This is not a complete listing of all DPYD variants that may result in DPD deficiency.</p>
</blockquote>
<p>Excerpts from the fluorouracil cream (CARAC) drug label:</p>
<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS...Carac should not be used in patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>One case of life-threatening systemic toxicity has been reported with the topical use of 5% fluorouracil in a patient with a complete absence of DPD enzyme activity... Although this case was observed with 5% fluorouracil cream, it is unknown whether patients with profound DPD enzyme deficiency would develop systemic toxicity with lower concentrations of topically applied fluorouracil.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""fluorouracil_2024_04_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/fluorouracil_2024_04_19_FDA.pdf"">fluorouracil injection drug label</a> and the <a download=""fluorouracil_carac_FDA_2023_10_02.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/fluorouracil_carac_FDA_2023_10_02.pdf"">fluorouracil cream drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1450397806.0,"<p>Excerpt from the fluorouracil injection drug label:</p>
<blockquote class=""blockquote"">
<p>Withhold or permanently discontinue fluorouracil based on clinical assessment of the onset, duration, and severity of the observed adverse events in patients with evidence of acute early-onset or unusually severe reactions, which may indicate complete DPD deficiency. No fluorouracil dose has been proven safe for patients with complete DPD deficiency. There are insufficient data to recommend a specific dose in patients with partial DPD deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consider testing for genetic variants of DPYD prior to initiating fluorouracil to reduce the risk of serious adverse reactions if the patient’s clinical status permits and based on clinical judgement. Serious adverse reactions may still occur even if no DPYD variants are identified.</p>
</blockquote>
<p>Excerpt from the topical fluorouracil (<em>CARAC</em>) drug label:</p>
<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS...Carac should not be used in patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency...</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166182741,"Annotation of FDA Label for articaine / epinephrine and CYB5R3, G6PD",False,False,[],False,"[{'id': 1450401544, 'date': '2019-05-20T00:00:00-07:00', 'description': 'Attached to drug combination page instead of single drug page.', 'type': 'Correction', 'version': 0}, {'id': 1450821532, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1450822532, 'date': '2019-10-15T09:36:37.265-07:00', 'description': 'Added link and text about CYB5R3 and congenital methemoglobinemia.', 'type': 'Update', 'version': 0}, {'id': 1450824511, 'date': '2019-10-24T07:03:23.919-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102402, 'title': 'Drugs@FDA: Drug Product Articaine HCl and Epinephrine (articaine hydrochloride and epinephrine bitartrate), NDA022466, Safco Dental Supply Co.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022466', 'crossReferences': [{'id': 1450400399, 'resource': 'FDA Application', 'resourceId': 'NDA022466', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022466'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166182783', 'name': 'articaine / epinephrine'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450400397.0,"<p>The FDA-approved drug label for articaine and epinephrine (ORABLOC) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.</p>
",1450400398.0,"<p>Excerpt from the articaine and epinephrine (ORABLOC) drug label:</p>
<div class=""blockquote"">
<p>Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</div>
<p>NOTE: While the CYB5R3 gene is not explicitly stated in the drug label variants in this gene are associated with congenital methemoglobinemia I and II <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/250800"" target=""_blank"">OMIM 250800</a>.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/ArticaineAndEpinephrine_05_13_2019FDA.pdf"">articaine and epinephrine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450824510.0,"<p>Excerpt from the articaine and epinephrine (ORABLOC) drug label:</p>
<blockquote class=""blockquote"">
<p>Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia,...are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166170929,Annotation of FDA Label for gefitinib and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15101847, 'title': 'Drugs@FDA: Drug Product IRESSA (Gefitinib), NDA206995, AstraZeneca Pharmaceuticals LP', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206995', 'crossReferences': [{'id': 1449754724, 'resource': 'FDA Application', 'resourceId': 'NDA206995', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206995'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA131301952', 'name': 'gefitinib'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1449035658.0,"<p>The FDA-approved drug label for gefinitib (IRESSA) states that it is indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. The label also notes the potential clinical importance of considering CYP2D6 phenotype, though CYP2D6 testing is not mentioned.</p>
",1449035657.0,"<p>Excerpt from the gefitinib (IRESSA) drug label:</p>
<div class=""blockquote"">
<p>CYP2D6 metabolizes gefitinib to O-desmethyl gefitinib <em>in vitro</em>. In healthy CYP2D6 poor metabolizers, O-desmethyl gefitinib concentration was not measurable and the mean exposure to gefitinib was 2-fold higher as compared to extensive metabolizers. This increase in exposure in CYP2D6 poor metabolizers may be clinically important because some adverse reactions are related to higher exposure of gefitinib. No dose adjustment is recommended in patients with a known CYP2D6 poor metabolizer genotype, but these patients should be closely monitored for adverse reactions.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Gefitinib_07_27_2017_FDA.pdf"">gefitinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399552.0,"<p>Excerpt from the gefitinib (IRESSA) drug label:</p>
<blockquote class=""blockquote"">
<p>No dose adjustment is recommended in patients with a known CYP2D6 poor metabolizer genotype, but these patients should be closely monitored for adverse reactions.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104780,Annotation of FDA Label for carbamazepine and HLA-B,True,False,[],False,"[{'id': 1183681520, 'date': '2013-10-25T12:27:08.052-07:00', 'type': 'Update', 'version': 0}, {'id': 1447952365, 'date': '2016-03-21T14:11:49.614-07:00', 'type': 'Update', 'version': 0}, {'id': 1452264020, 'date': '2023-10-05T14:54:50.427-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}, {'id': 1452455740, 'date': '2024-04-26T14:30:24.605-07:00', 'description': 'fixed typo', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101913, 'title': 'Drugs@FDA: Drug Product Tegretol (carbamazepine), NDA016608, REMEDYREPACK INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016608', 'crossReferences': [{'id': 1449894948, 'resource': 'FDA Application', 'resourceId': 'NDA016608', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016608'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165954769', 'symbol': 'HLA-B*15:02', 'name': '*15:02'}]","[{'objCls': 'Chemical', 'id': 'PA448785', 'name': 'carbamazepine'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",FDA,1450342364.0,"<p>The FDA-approved label for carbamazepine (TEGRETOL) states that screening of patients with ancestry in genetically at-risk populations (patients of Asian descent) for the presence of the HLA-B*1502 allele should be carried out prior to treatment due to a high risk of serious and sometimes fatal dermatologic reactions. It also notes that a moderate association has been found between HLA-A*3101 and the risk of developing hypersensitivity reactions to carbamazepine, though it does not mention testing for this allele.</p>
",1450342365.0,"<p>Excerpts from the carbamazepine (TEGRETOL) drug label:</p>
<blockquote class=""blockquote"">
<p>Warnings:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE</p>
</blockquote>
<blockquote class=""blockquote"">
<p>SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH TEGRETOL. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH TEGRETOL. PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH TEGRETOL UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK (SEE WARNINGS AND PRECAUTIONS, LABORATORY TESTS).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>SJS/TEN and HLA-B*1502 Allele</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Retrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*1502. The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Across Asian populations, notable variation exists in the prevalence of HLA-B*1502. Greater than 15% of the population is reported positive in Hong Kong, Thailand, Malaysia, and parts of the Philippines, compared to about 10% in Taiwan and 4% in North China. South Asians, including Indians, appear to have intermediate prevalence of HLA-B*1502, averaging 2% to 4%, but higher in some groups. HLA-B*1502 is present in less than 1% of the population in Japan and Korea.
HLA-B*1502 is largely absent in individuals not of Asian origin (e.g., Caucasians, African-Americans, Hispanics, and Native Americans).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Prior to initiating Tegretol therapy, testing for HLA-B*1502 should be performed in patients with ancestry in populations in which HLA-B*1502 may be present. In deciding which patients to screen, the rates provided above for the prevalence of HLA-B*1502 may offer a rough guide, keeping in mind the limitations of these figures due to wide variability in rates even within ethnic groups, the difficulty in ascertaining ethnic ancestry, and the likelihood of mixed ancestry. Tegretol should not be used in patients positive for HLA-B*1502 unless the benefits clearly outweigh the risks. Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN (see BOXED WARNING and PRECAUTIONS, Laboratory Tests).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Over 90% of Tegretol treated patients who will experience SJS/TEN have this reaction within the first few months of treatment. This information may be taken into consideration in determining the need for screening of genetically at-risk patients currently on Tegretol.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The HLA-B*1502 allele has not been found to predict risk of less severe adverse cutaneous reactions from Tegretol, such as maculopapular eruption (MPE) or to predict Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consideration should be given to avoiding use of other drugs associated with SJS/TEN in HLA-B*1502 positive patients, when alternative therapies are otherwise equally acceptable.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Laboratory test: For genetically at-risk patients (see WARNINGS), high-resolution ‘HLA-B*1502 typing’ is recommended. The test is positive if either one or two HLA-B*1502 alleles are detected and negative if no HLA-B*1502 alleles are detected.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""carbamazepine_FDA_20231005.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/carbamazepine_FDA_20231005.pdf"">carbamazepine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450399534.0,"<p>Excerpt from the carbamazepine (TEGRETOL) drug label:</p>
<blockquote class=""blockquote"">
<p>SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH TEGRETOL. PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH TEGRETOL UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104839,Annotation of FDA Label for aripiprazole and CYP2D6,False,False,[],True,"[{'id': 1183681413, 'date': '2013-10-25T11:33:52.494-07:00', 'type': 'Update', 'version': 0}, {'id': 1450399508, 'date': '2019-05-09T09:04:20.296-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1453083082, 'date': '2025-03-28T10:06:38.292-07:00', 'description': 'added Pediatric tag and info; added ABILIFY ASIMTUFII drug label and info, Other Guidance tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15177002, 'title': 'Drugs@FDA: Drug Product Abilify Asimtufii (Aripiprazole), Otsuka America Pharmaceutical, Inc - NDA217006/SUPPL-2, 01/22/2025', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217006', 'crossReferences': [{'id': 1453083080, 'resource': 'FDA Application', 'resourceId': 'NDA217006/SUPPL-2', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217006'}], 'notes': 'ABILIFY ASIMTUFII', 'objCls': 'Literature', 'pubDate': '2025-01-22T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101976, 'title': 'Drugs@FDA: Drug Product ABILIFY (ARIPIPRAZOLE), NDA021436, Rebel Distributors Corp.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021436', 'crossReferences': [{'id': 1450043446, 'resource': 'FDA Application', 'resourceId': 'NDA021436', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021436'}], 'notes': 'ABILIFY', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101948, 'title': 'Drugs@FDA: Drug Product ABILIFY MAINTENA (aripiprazole), NDA202971, Otsuka America Pharmaceutical, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202971', 'crossReferences': [{'id': 1450043473, 'resource': 'FDA Application', 'resourceId': 'NDA202971', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202971'}], 'notes': 'ABILIFY MAINTENA', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,True,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA10026', 'name': 'aripiprazole'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450043484.0,"<p>The FDA-approved drug labels for aripiprazole (ABILIFY, ABILIFY MAINTENA and ABILIFY ASIMTUFII) provide dosage adjustments for patients who are CYP2D6 poor metabolizers (PMs). CYP2D6 PMs taking ABILIFY should receive half the usual dose; CYP2D6 PMs taking ABILIFY MAINTENA should have their dose reduced to 300 mg from the recommended dose of 400 mg; CYP2D6 PMs taking ABILIFY ASIMTUFII should have their dose reduced to 720 mg from the recommended dose of 960 mg. Also, CYP2D6 PMs taking concomitant CYP3A4 inhibitors should not be given ABILIFY ASIMTUFII.</p>
",1450043487.0,"<p>Aripiprazole (ABILIFY, ABILIFY MAINTENA and ABILIFY ASIMTUFII) is an atypical antipsychotic medication. ABILIFY formulations include tablet, solution, orally disintegrating tablet and injection. ABILIFY MAINTENA and ABILIFY ASIMTUFII are extended-release injectable suspensions for intramuscular use.</p>
<p>Excerpts from the ABILIFY (aripiprazole) drug label:</p>
<blockquote class=""blockquote"">
<p>Known CYP2D6 Poor Metabolizers...Administer half of usual dose...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dosage adjustment is recommended in known CYP2D6 poor metabolizers due to high aripiprazole concentrations. Approximately 8% of Caucasians and 3–8% of Black/African Americans cannot metabolize CYP2D6 substrates and are classified as poor metabolizers (PM) [...]</p>
</blockquote>
<p>Excerpt from the ABILIFY MAINTENA (aripiprazole) drug label:</p>
<blockquote class=""blockquote"">
<p>Known CYP2D6 poor metabolizers: Recommended starting and maintenance dose is 300 mg administered monthly as a single injection.</p>
</blockquote>
<p>Excerpt from the ABILIFY ASIMTUFII (aripiprazole) drug label:</p>
<blockquote class=""blockquote"">
<p>Known CYP2D6 poor metabolizers: Recommended dosage is 720 mg administered once every 2 months as a single injection</p>
</blockquote>
<p>For the complete drug label texts with sections containing pharmacogenetic information highlighted, see the <a download=""Aripiprazole_Abilify_01_17_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Aripiprazole_Abilify_01_17_19_FDA.pdf"">aripiprazole (ABILIFY) drug label</a>, the <a download=""Aripiprazole_Abilify_Maintena_11_28_18_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Aripiprazole_Abilify_Maintena_11_28_18_FDA.pdf"">aripiprazole (ABILIFY MAINTENA) drug label</a> and the <a download=""Aripiprazole_AbilifyAsimtufii_2025_03_21_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Aripiprazole_AbilifyAsimtufii_2025_03_21_FDA.pdf"">aripiprazole (ABILIFY ASIMTUFII) drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1453083081.0,"<p>Excerpts from the ABILIFY (aripiprazole) drug label:</p>
<blockquote class=""blockquote"">
<p><strong>Irritability Associated with Autistic Disorder</strong>
<strong>Pediatric Patients (6 to 17 years)</strong>
The recommended dosage range for the treatment of pediatric patients with irritability associated with autistic disorder is 5 to 15 mg/day.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Tourette’s Disorder</strong>
<strong>Pediatric Patients (6 to 18 years)</strong>
The recommended dosage range for Tourette’s Disorder is 5 to 20 mg/day.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Safety and effectiveness in pediatric patients with major depressive disorder or agitation associated with schizophrenia or bipolar mania have not been established.</p>
</blockquote>
<p>Excerpt from the ABILIFY MAINTENA (aripiprazole) drug label:</p>
<blockquote class=""blockquote"">
<p>ABILIFY MAINTENA has not been studied in children 18 years of age or younger.</p>
</blockquote>
<p>Excerpt from the ABILIFY ASIMTUFII (aripiprazole) drug label:</p>
<blockquote class=""blockquote"">
<p>Safety and effectiveness of ABILIFY ASIMTUFII in pediatric patients have not been established.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399507.0,"<p>Excerpt from the ABILIFY drug label:</p>
<table class=""table"">
<thead>
<tr>
<th>Factors</th>
<th>Dosage Adjustments for ABILIFY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Known CYP2D6 Poor Metabolizers</td>
<td>Administer half of usual dose</td>
</tr>
<tr>
<td>Known CYP2D6 Poor Metabolizers taking concomitant strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin)</td>
<td>Administer a quarter of usual dose</td>
</tr>
</tbody>
</table>
<p>Excerpt from the ABILIFY MAINTENA drug label (Table 1):</p>
<table class=""table"">
<thead>
<tr>
<th>Factors</th>
<th>Adjusted Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Known CYP2D6 Poor Metabolizers</td>
<td>300mg</td>
</tr>
<tr>
<td>Known CYP2D6 Poor Metabolizers taking concomitant CYP3A4 inhibitors</td>
<td>200 mg</td>
</tr>
</tbody>
</table>
<p>Excerpt from the ABILIFY ASIMTUFII drug label (Table 1):</p>
<table class=""table"">
<thead>
<tr>
<th>Factors</th>
<th>Dosage Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Known CYP2D6 Poor Metabolizers</td>
<td>720 mg once every 2 months</td>
</tr>
<tr>
<td>Known CYP2D6 Poor Metabolizers taking concomitant CYP3A4 inhibitors</td>
<td>Avoid use</td>
</tr>
</tbody>
</table>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166246301,Annotation of FDA Label for acetaminophen / caffeine / dihydrocodeine and CYP2D6,True,False,[],False,[],False,[],True,"[{'id': 15121262, 'title': 'Drugs@FDA: Drug Product Acetaminophen, Caffeine, Dihydrocodeine Bitartrate (Acetaminophen, Caffeine, Dihydrocodeine Bitartrate), ANDA204785, Xspire Pharma, Llc', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204785', 'crossReferences': [{'id': 1451470020, 'resource': 'FDA Application', 'resourceId': 'ANDA204785', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204785'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166246281', 'name': 'acetaminophen / caffeine / dihydrocodeine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1451470000.0,"<p>The FDA-approved drug label for acetaminophen/caffeine/dihydrocodeine (TREZIX) states that respiratory depression and death have occurred in children who received codeine following a tonsillectomy and/or adenoidectomy and who had evidence of being CYP2D6 ultra-rapid metabolizers. The label also states that CYP2D6 ultrarapid metabolizers should not use codeine.</p>
",1451470001.0,"<p>Excerpts from the acetaminophen/caffeine/dihydrocodeine label:</p>
<blockquote class=""blockquote"">
<p>Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-threatening Respiratory Depression in Children.<br />
Life-threatening respiratory depression and death have occurred in children who received codeine. Most of the reported cases occurred following tonsillectomy and/or adenoidectomy, and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to CYP2D6 polymorphism [see WARNINGS and PRECAUTIONS].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-threatening Respiratory Depression in Children.<br />
Life-threatening respiratory depression and death have occurred in children who received codeine. Codeine is subject to
variability in metabolism based upon CYP2D6 genotype (described below), which can lead to an increased exposure to the
active metabolite morphine. Based upon post-marketing reports, children less than 12 years old appear to be more susceptible
to the respiratory depressant effects of codeine, particularly if there are risk factors for respiratory depression. For example,
many reported cases of death occurred in the post-operative period following tonsillectomy and/or adenoidectomy, and many
of the children had evidence of being ultra-rapid metabolizers of codeine. Furthermore, children with obstructive sleep apnea
who are treated with codeine for post-tonsillectomy and/or adenoidectomy pain may be particularly sensitive to its respiratory
depressant effect.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Nursing Mothers.<br />
At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the
mother was an ultra-rapid metabolizer of codeine. Breastfeeding is not recommended during treatment with TREZIX™ [see
PRECAUTIONS; Nursing Mothers].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dihydrocodeine bitartrate and its active metabolite, morphine, are present in human milk. There are published studies and
cases that have reported excessive sedation, respiratory depression, and death in infants exposed to codeine via breast milk.
Women who are ultra-rapid metabolizers of dihydrocodeine achieve higher than expected serum levels of morphine,
potentially leading to higher levels of morphine in breast milk that can be dangerous in their breastfed infants. In women with
normal dihydrocodeine metabolism (normal CYP2D6 activity), the amount of dihydrocodeine secreted into human milk is low
and dose-dependent.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 Genetic Variability: Ultra-rapid metabolizer.<br />
Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (e.g., gene duplications denoted as
*1/*1xN or *1/*2xN). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 1 to 10% for Whites
(European, North American), 3 to 4% for Blacks (African Americans), 1 to 2% for East Asians (Chinese, Japanese, Korean),
and may be greater than 10% in certain ethnic groups (i.e., Oceanian, Northern African, Middle Eastern, Ashkenazi Jews,
Puerto Rican). These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other
people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens,
individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of
overdose (such as extreme sleepiness, confusion, or shallow breathing) [see OVERDOSAGE]. Therefore, individuals who are
ultra-rapid metabolizers should not use codeine.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Acetaminophen_Caffeine_Dihydrocodeine_07_12_21_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Acetaminophen_Caffeine_Dihydrocodeine_07_12_21_FDA.pdf"">acetaminophen/caffeine/dihydrocodeine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1451470003.0,"<p>Excerpts from the acetaminophen/caffeine/dihydrocodeine label:</p>
<blockquote class=""blockquote"">
<p>Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-threatening Respiratory Depression in Children
Life-threatening respiratory depression and death have occurred in children who received codeine. Codeine is subject to
variability in metabolism based upon CYP2D6 genotype (described below), which can lead to an increased exposure to the
active metabolite morphine. Based upon post-marketing reports, children less than 12 years old appear to be more susceptible
to the respiratory depressant effects of codeine, particularly if there are risk factors for respiratory depression. For example,
many reported cases of death occurred in the post-operative period following tonsillectomy and/or adenoidectomy, and many
of the children had evidence of being ultra-rapid metabolizers of codeine. Furthermore, children with obstructive sleep apnea
who are treated with codeine for post-tonsillectomy and/or adenoidectomy pain may be particularly sensitive to its respiratory
depressant effect. Because of the risk of life-threatening respiratory depression and death:<br />
• TREZIX™ is contraindicated for all children younger than 12 years of age [see CONTRAINDICATIONS].<br />
• TREZIX™ is contraindicated for post-operative management in pediatric patients younger than 18 years of age following
tonsillectomy and/or adenoidectomy [see CONTRAINDICATIONS].<br />
• Avoid the use of TREZIX™ in adolescents 12 to 18 years of age who have other risk factors that may increase their
sensitivity to the respiratory depressant effects of codeine unless the benefits outweigh the risks. Risk factors include
conditions associated with hypoventilation, such as postoperative status, obstructive sleep apnea, obesity, severe pulmonary
disease, neuromuscular disease, and concomitant use of other medications that cause respiratory depression.<br />
• As with adults, when prescribing codeine for adolescents, healthcare providers should choose the lowest effective dose for
the shortest period of time and inform patients and caregivers about these risks and the signs of morphine overdose [see
OVERDOSAGE].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Nursing Mothers:
At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the
mother was an ultra-rapid metabolizer of codeine. Breastfeeding is not recommended during treatment with TREZIX™ [see
PRECAUTIONS; Nursing Mothers].</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451470002.0,"<p>Excerpts from the acetaminophen/caffeine/dihydrocodeine label:</p>
<blockquote class=""blockquote"">
<p>Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (e.g., gene duplications denoted as
*1/*1xN or *1/*2xN). (...) These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other
people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens,
individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of
overdose (such as extreme sleepiness, confusion, or shallow breathing) (see OVERDOSAGE). Therefore, individuals who are
ultra-rapid metabolizers should not use codeine.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166104838,"Annotation of FDA Label for thioguanine and NUDT15, TPMT",False,False,[],True,"[{'id': 1183681495, 'date': '2013-10-25T11:45:18.839-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101919, 'title': 'Drugs@FDA: Drug Product TABLOID (thioguanine), NDA012429, Aspen Global Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=012429', 'crossReferences': [{'id': 1449817188, 'resource': 'FDA Application', 'resourceId': 'NDA012429', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=012429'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451663', 'name': 'thioguanine'}]","[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}, {'objCls': 'Gene', 'id': 'PA356', 'symbol': 'TPMT', 'name': 'thiopurine S-methyltransferase'}]",FDA,1447981646.0,"<p>The FDA-approved drug label for thioguanine (TABLOID) says to consider testing for TPMT and NUDT15 deficiency in patients who experience severe bone marrow toxicities or repeated episodes of myelosuppression. It also says to reduce initial dosage in patients known to have homozygous TPMT or NUDT15 deficiency.</p>
",1447981645.0,"<p>Thioguanine (TABLOID) is indicated for the treatment of acute nonlymphocytic leukemias. Excerpts from the thioguanine (TABLOID) drug label:</p>
<div class=""blockquote"">
<p>Consider testing for TPMT and NUDT15 deficiency in patients who experience severe bone marrow toxicities or repeated episodes of myelosuppression.</p>
</div>
<div class=""blockquote"">
<p>Patients with homozygous deficiency of either TPMT or NUDT15 enzyme typically require 10% or less of the standard thioguanine dosage. Reduce initial dosage in patients who are known to have homozygous TPMT or NUDT15 deficiency. Most patients with heterozygous TPMT or NUDT15 deficiency tolerate recommended thioguanine doses, but some require dose reduction based on toxicities. Patients who are heterozygous for both TPMT and NUDT15 may require more substantial dosage reductions. Reduce the dosage based on tolerability.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Thioguanine_08_09_18_FDA.pdf"">thioguanine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672077.0,Genetic Testing Level,[],Testing Recommended,geneTestLevel:1183672077,True,1450399732.0,"<p>Excerpt from the thioguanine (TABLOID) drug label:</p>
<blockquote class=""blockquote"">
<p>Patients with homozygous deficiency of either TPMT or NUDT15 enzyme typically require 10% or less of the standard thioguanine dosage. Reduce initial dosage in patients who are known to have homozygous TPMT or NUDT15 deficiency. Most patients with heterozygous TPMT or NUDT15 deficiency tolerate recommended thioguanine doses, but some require dose reduction based on toxicities. Patients who are heterozygous for both TPMT and NUDT15 may require more substantial dosage reductions. Reduce the dosage based on tolerability.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104801,Annotation of FDA Label for peginterferon alfa-2b and IFNL3,False,False,[],False,"[{'id': 1183681321, 'date': '2013-10-25T11:16:31.338-07:00', 'type': 'Update', 'version': 0}, {'id': 1448604593, 'date': '2017-03-15T11:00:59.260-07:00', 'type': 'Update', 'version': 0}, {'id': 1450381598, 'date': '2019-04-19T10:35:22.838-07:00', 'description': 'Added variant information', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102011, 'title': 'Drugs@FDA: Drug Product PEGINTRON (Peginterferon alfa-2b), BLA103949, Merck Sharp & Dohme Corp.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103949', 'crossReferences': [{'id': 1449767794, 'resource': 'FDA Application', 'resourceId': 'BLA103949', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103949'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166155468', 'symbol': 'rs12979860', 'name': 'rs12979860'}]","[{'objCls': 'Chemical', 'id': 'PA164784024', 'name': 'peginterferon alfa-2b'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",FDA,1447981552.0,"<p>The FDA-approved drug label for peginterferon alfa-2b (PEGINTRON) states that a single nucleotide polymorphism near the gene encoding interferon-lambda-3 (IL28B <a href=""/variant/PA166155468"">rs12979860</a>) was associated with variable sustained viral response (SVR) rates. SVR rates by <a href=""/variant/PA166155468"">rs12979860</a> genotype were as follows: CC 66% vs. CT 30% vs. TT 22%.</p>
",1447981551.0,"<p>Peginterferon alfa-2b (PEGINTRON) is an antiviral used for treatment of chronic hepatitis C infection in patients with compensated liver disease.</p>
<p>Excerpt from the peginterferon alfa-2b (PEGINTRON) drug label:</p>
<div class=""blockquote"">
<p>A retrospective genome-wide association analysis of 1671 subjects...was performed to identify human genetic contributions to anti-HCV treatment response in previously untreated HCV genotype 1 subjects. A single nucleotide polymorphism near the gene encoding interferon-lambda-3 (IL28B rs12979860) was associated with variable SVR rates. The rs12979860 genotype was categorized as CC, CT and TT. In the pooled analysis of Caucasian, African-American, and Hispanic subjects from these trials (n=1587), SVR rates by rs12979860 genotype were as follows: CC 66% vs. CT 30% vs. TT 22%. The genotype frequencies differed depending on racial/ethnic background, but the relationship of SVR to IL28B genotype was consistent across various racial/ethnic groups...Other variants near the IL28B gene (e.g., rs8099917 and rs8103142) have been identified; however, they have not been shown to independently influence SVR rates during treatment with pegylated interferon alpha therapies combined with ribavirin.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Peginterferon_02_21_19_FDA.pdf"">peginterferon alfa-2b drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166170935,"Annotation of FDA Label for rucaparib and CYP1A2, CYP2D6",False,False,[],False,"[{'id': 1451285321, 'date': '2020-10-28T19:53:07.436-07:00', 'description': 'update label pdf', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101838, 'title': 'Drugs@FDA: Drug Product Rubraca (rucaparib), NDA209115, Clovis Oncology, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209115', 'crossReferences': [{'id': 1449776559, 'resource': 'FDA Application', 'resourceId': 'NDA209115', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209115'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166163418', 'name': 'rucaparib'}]","[{'objCls': 'Gene', 'id': 'PA27093', 'symbol': 'CYP1A2', 'name': 'cytochrome P450 family 1 subfamily A member 2'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1449051826.0,"<p>Rucaparib (RUBRACA) is indicated for the treatment of patients with deleterious BRCA mutation-associated epithelial ovarian, fallopian tube or primary peritoneal cancer. The label notes that rucaparib concentrations did not differ significantly based on CYP2D6 or CYP1A2 genotypes.</p>
",1449051825.0,"<p>Excerpts from the rucaparib (RUBRACA) drug label:</p>
<blockquote class=""blockquote"">
<p>In vitro, rucaparib was metabolized primarily by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Based on population pharmacokinetic analyses, steady-state concentrations following rucaparib 600 mg twice daily did not differ significantly across CYP2D6 or CYP1A2 genotype subgroups.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""rucaparib_FDA_10282020.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/rucaparib_FDA_10282020.pdf"">rucaparib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166178750,Annotation of FDA Label for metoclopramide and CYP2D6,False,False,[],True,[],False,[],True,"[{'id': 15101844, 'title': 'Drugs@FDA: Drug Product Reglan (Metoclopramide Hydrochloride), ANI Pharmaceuticals, Inc. - NDA017854/SUPPL-62, 08/29/2017', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017854', 'crossReferences': [{'id': 1452538961, 'resource': 'FDA Application', 'resourceId': 'NDA017854/SUPPL-62', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017854'}], 'objCls': 'Literature', 'pubDate': '2017-08-29T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450475', 'name': 'metoclopramide'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1449310782.0,"<p>Metoclopramide (REGLAN) is indicated as a short-term treatment for adults with gastroesophageal reflux who fail to respond to conventional therapy. The label for metoclopramide notes that elimination of the drug may be slowed in CYP2D6 poor metabolizers, potentially increasing the risk for adverse reactions, and that these patients should receive a reduced dose of the drug.</p>
",1449310781.0,"<p>Excerpts from the metoclopramide (REGLAN) drug label:</p>
<div class=""blockquote"">
<p>Metoclopramide is a substrate of CYP2D6. The elimination of metoclopramide may be slowed in patients who are CYP2D6 poor metabolizers (compared to patients who are CYP2D6 intermediate, extensive, or ultra-rapid metabolizers); possibly increasing the risk of dystonic and other adverse reactions to Reglan...Reduce the Reglan dosage in patients who are poor CYP2D6 metabolizers.</p>
</div>
<div class=""blockquote"">
<p>Table 1. Recommended Reglan Tablet Dosage in Patients with Gastroesophageal Reflux...CYP2D6 poor metabolizers...Recommended Dosage...5 mg four times daily (thirty minutes before each meal and at bedtime), or 10 mg taken three times daily...Maximum Recommended Daily Dosage...30 mg.</p>
</div>
<div class=""blockquote"">
<p>Table 2. Recommended Reglan Tablet Dosage in Patients with Acute and Recurrent Diabetic Gastroparesis...CYP2D6 poor metabolizers...Recommended Dosage...5 mg four times daily (thirty minutes before each meal and at bedtime)...Maximum Recommended Daily Dosage...20 mg.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Metoclopramide_FDA_05_03_18.pdf"">metoclopramide drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399708.0,"<p>Excerpt from the metoclopramide (REGLAN) drug label:</p>
<blockquote class=""blockquote"">
<p>Reduce the Reglan dosage in patients who are poor CYP2D6 metabolizers.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166179887,Annotation of FDA Label for raltegravir and UGT1A1,False,False,[],False,"[{'id': 1450383788, 'date': '2019-04-23T10:24:02.549-07:00', 'description': 'Added variant information', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101966, 'title': 'Drugs@FDA: Drug Product ISENTRESS (RALTEGRAVIR), NDA022145, NuCare Pharmaceuticals,Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022145', 'crossReferences': [{'id': 1449776529, 'resource': 'FDA Application', 'resourceId': 'NDA022145', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022145'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA166115842', 'symbol': 'UGT1A1*28', 'name': '*28'}]","[{'objCls': 'Chemical', 'id': 'PA164888966', 'name': 'raltegravir'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",FDA,1449714168.0,"<p>The FDA-approved drug label for raltegravir (ISENTRESS) states that there is no evidence that common UGT1A1 polymorphisms alter raltegravir pharmacokinetics to a clinically meaningful extent, despite UGT1A1 being the primary enzyme involved in raltegravir elimination. However, the label notes that UGT1A1 activity is negligible at birth and provides dosing information based on neonatal age that takes into account increasing UGT1A1 activity.</p>
",1449714167.0,"<p>Raltegravir is indicated for the treatment of HIV-1 infection. Excerpts from the raltegravir (ISENTRESS) drug label:</p>
<div class=""blockquote"">
<p>Pharmacogenomics...UGT1A1 Polymorphism...There is no evidence that common UGT1A1 polymorphisms alter raltegravir pharmacokinetics to a
clinically meaningful extent. In a comparison of 30 adult subjects with *28/*28 genotype (associated with reduced activity of UGT1A1) to 27 adult subjects with wild-type genotype, the geometric mean ratio (90% CI) of AUC was 1.41 (0.96, 2.09)...In the neonatal study IMPAACT P1110, there was no association between apparent clearance (CL/F) of raltegravir and UGT1A1 genotype polymorphisms.</p>
</div>
<div class=""blockquote"">
<p>Elimination of raltegravir in vivo in human is primarily through the UGT1A1-mediated glucuronidation pathway. UGT1A1 catalytic activity is negligible at birth and matures after birth. The dose recommended for neonates less than 4 weeks of age takes into consideration the rapidly increasing UGT1A1 activity and drug clearance from birth to 4 weeks of age...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Raltegravir_08_08_18_FDA.pdf"">raltegravir drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166129519,"Annotation of FDA Label for sevoflurane and CACNA1S, RYR1",True,False,[],False,"[{'id': 1452011330, 'date': '2023-02-16T20:58:22.876-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452055800, 'date': '2023-04-01T20:09:13.558-07:00', 'description': 'updated text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101994, 'title': 'Drugs@FDA: Drug Product Ultane (Sevoflurane), NDA020478, AbbVie Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020478', 'crossReferences': [{'id': 1449776654, 'resource': 'FDA Application', 'resourceId': 'NDA020478', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020478'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451341', 'name': 'sevoflurane'}]","[{'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",FDA,1447982407.0,"<p>The FDA-approved drug label for sevoflurane (ULTANE) states that it should not be used in patients with known or suspected susceptibility to malignant hyperthermia. Specific variants in the <em>RYR1</em> and <em>CACNA1S</em> genes are associated with risk of malignant hyperthermia in individuals administered potent inhalational anesthetics, including sevoflurane. The label does not mention genetic testing.</p>
",1447982406.0,"<p>Sevoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia. In addition to commenting on the risk for malignant hyperthermia in patients with genetic susceptibility, the label also notes that patients with Duchenne muscular dystrophy are vulnerable to increases in serum potassium levels; Duchenne muscular dystrophy is caused by mutations in the <em>DMD</em> gene. Excerpts from the FDA-approved sevoflurane (ULTANE) drug label:</p>
<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS: Known or suspected genetic susceptibility to malignant hyperthermia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The risk of developing malignant hyperthermia increases with the concomitant administration of succinylcholine and volatile anesthetic agents. ULTANE can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacogenomics: RYR1 and CACNA1S are polymorphic genes, and multiple pathogenic variants have been associated with malignant hyperthermia susceptibility (MHS) in patients receiving volatile anesthetic agents, including sevoflurane. Case reports as well as ex-vivo studies have identified multiple variants in RYR1 and CACNA1S associated with MHS. Variant pathogenicity should be assessed based on prior clinical experience, functional studies, prevalence information, or other evidence.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable. Concomitant use of succinylcholine has been associated with most, but not all, of these cases.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""sevoflurane_20230402_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/sevoflurane_20230402_FDA.pdf"">sevoflurane drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399727.0,"<p>Excerpt from the sevoflurane (ULTANE) drug label:</p>
<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS: Known or suspected genetic susceptibility to malignant hyperthermia.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104829,Annotation of FDA Label for tetrabenazine and CYP2D6,False,False,[],True,"[{'id': 1183681493, 'date': '2013-10-25T11:44:34.121-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101852, 'title': 'Drugs@FDA: Drug Product tetrabenazine (tetrabenazine), NDA021894, Oceanside Pharmaceuticals', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021894', 'crossReferences': [{'id': 1449817062, 'resource': 'FDA Application', 'resourceId': 'NDA021894', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021894'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA140222719', 'name': 'tetrabenazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981628.0,"<p>The FDA-approved drug label for tetrabenazine (XENAZINE) states that patients requiring doses above 50 mg per day should be genotyped for the drug metabolizing enzyme CYP2D6 to determine if the patient is a poor metabolizer (PM) or an extensive metabolizer (EM). People with CYP2D6 poor metabolizer genotypes should be treated with lower doses.</p>
",1447981627.0,"<p>Tetrabenazine is used to treat Huntington's Disease chorea.</p>
<p>Excerpts from the tetrabenazine drug label:</p>
<div class=""blockquote"">
<p>Patients requiring doses above 50 mg per day should be genotyped for the drug metabolizing enzyme CYP2D6 to determine if the patient is a poor metabolizer (PM) or an extensive metabolizer (EM).</p>
<p>The maximum daily dose in PMs is 50 mg with a maximum single dose of 25 mg.</p>
<p>The maximum daily dose in EMs and intermediate metabolizers (IMs) 100 mg with a maximum single dose of 37.5 mg.</p>
</div>
<div class=""blockquote"">
<p>Before patients are given a daily dose of greater than 50 mg, they should be tested for the CYP2D6 gene to determine whether they are poor metabolizers (PMs) or extensive or intermediate metabolizers (EMs or IMs). When a dose of tetrabenazine is given to PMs, exposure will be substantially higher (about 3-fold for a-HTBZ and 9-fold for b-HTBZ) than it would be in EMs. The dosage should therefore be adjusted according to a patient's CYP2D6 metabolizer status by limiting the dose to 50 mg in patients who are CYP2D6 poor metabolizers.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tetrabenazine_04_22_19_FDA.pdf"">tetrabenazine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450383072.0,"<p>Excerpts from the tetrabenazine drug label:</p>
<blockquote class=""blockquote"">
<p>The maximum daily dose in PMs is 50 mg with a maximum single dose of 25 mg.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The maximum daily dose in EMs and intermediate metabolizers (IMs) 100 mg with a maximum single dose of 37.5 mg.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104827,Annotation of FDA Label for atomoxetine and CYP2D6,False,False,[],True,"[{'id': 1183681479, 'date': '2013-10-25T11:40:49.890-07:00', 'type': 'Update', 'version': 0}, {'id': 1450399515, 'date': '2019-05-09T09:35:04.312-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102040, 'title': 'Drugs@FDA: Drug Product Strattera (Atomoxetine hydrochloride), NDA021411, Eli Lilly and Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021411', 'crossReferences': [{'id': 1449893987, 'resource': 'FDA Application', 'resourceId': 'NDA021411', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021411'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA134688071', 'name': 'atomoxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450043627.0,"<p>The FDA-approved drug label for atomoxetine (STRATTERA) recommends a dose adjustment in children or adolescents who are CYP2D6 poor metabolizers, or who are administered strong CYP2D6 inhibitors. Additionally, the label notes a number of adverse events that occurred more frequently in CYP2D6 poor metabolizers than extensive metabolizers in clinical trials. Laboratory tests are available to identify CYP2D6 poor metabolizers.</p>
",1450043628.0,"<p>Atomoxetine (STRATERRA) is a selective noradrenaline reuptake inhibitor. It is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder.</p>
<p>Excerpts from the atomoxetine (STRATERRA) drug label:</p>
<div class=""blockquote"">
<p>In children and adolescents up to 70 kg body weight administered strong CYP2D6 inhibitors...or in patients who are known to be CYP2D6 PMs, STRATTERA should be initiated at 0.5 mg/kg/day and only increased to the usual target dose of 1.2 mg/kg/day if symptoms fail to improve after 4 weeks and the initial dose is well tolerated.</p>
</div>
<div class=""blockquote"">
<p>In children and adolescents over 70 kg body weight and adults administered strong CYP2D6 inhibitors...STRATTERA should be initiated at 40 mg/day and only increased to the usual target dose of 80 mg/day if symptoms fail to improve after 4 weeks and the initial dose is well tolerated.</p>
</div>
<div class=""blockquote"">
<p>The following adverse reactions occurred in at least 2% of child and adolescent CYP2D6 PM patients and were statistically significantly more frequent in PM patients compared with CYP2D6 EM patients: insomnia (11% of PMs, 6% of EMs); weight decreased (7% of PMs, 4% of EMs); constipation (7% of PMs, 4% of EMs); depression (7% of PMs, 4% of EMs); tremor (5% of PMs, 1% of EMs); excoriation (4% of PMs, 2% of EMs); middle insomnia (3% of PMs, 1% of EMs);
conjunctivitis (3% of PMs, 1% of EMs); syncope (3% of PMs, 1% of EMs); early morning awakening (2% of PMs, 1% of
EMs); mydriasis (2% of PMs, 1% of EMs); sedation (4% of PMs, 2% of EMs).</p>
</div>
<div class=""blockquote"">
<p>The following adverse events occurred in at least 2% of adult CYP2D6 poor metaboliser (PM) patients and were statistically significantly more frequent in PM patients compared to CYP2D6 extensive metaboliser (EM) patients: vision blurred (4% of PMs, 1% of EMs); dry mouth (35% of PMs, 17% of EMs); constipation (11% of PMs, 7% of EMs); feeling jittery (5% of PMs, 2% of EMs); decreased appetite (23% of PMs, 15% of EMs); tremor (5% of PMs, 1% of EMs); insomnia (19% of PMs, 11% of EMs); sleep disorder (7% of PMs, 3% of EMs); middle insomnia (5% of PMs, 3% of EMs); terminal insomnia (3% of PMs, 1% of EMs); urinary retention (6% of PMs, 1% of EMs); erectile dysfunction (21% of PMs, 9% of EMs); ejaculation disorder (6% of PMs, 2% of EMs); hyperhidrosis (15% of PMs, 7% of EMs); peripheral coldness (3% of PMs, 1% of EMs).</p>
</div>
<div class=""blockquote"">
<p>Laboratory tests are available to identify CYP2D6 PMs.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Atomoxetine_07_04_2017_FDA.pdf"">atomoxetine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399514.0,"<p>Excerpt from the atomoxetine (STRATERRA) drug label:</p>
<blockquote class=""blockquote"">
<p>In children and adolescents up to 70kg body weight administered strong CYP2D6 inhibitors, e.g.,paroxetine, fluoxetine, and quinidine, or in patients who are known to be CYP2D6 PMs, STRATTERA should be initiated at 0.5mg/kg/day and only increased to the usual target dose of 1.2mg/kg/day if symptoms fail to improve after 4weeks and the initial dose is well tolerated.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104856,Annotation of FDA Label for amitriptyline and CYP2D6,False,False,[],False,"[{'id': 1183681489, 'date': '2013-10-25T11:43:05.640-07:00', 'type': 'Update', 'version': 0}, {'id': 1183704791, 'date': '2013-12-16T00:00:00-08:00', 'type': 'Update', 'version': 0}, {'id': 1452530642, 'date': '2024-07-18T11:56:20.806-07:00', 'description': 'updated label to DailyMed, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160822, 'title': 'DailyMed - AMITRIPTYLINE HYDROCHLORIDE tablet', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=19b0c015-c07f-63b7-e063-6394a90a6060', 'crossReferences': [{'id': 1452530640, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '19b0c015-c07f-63b7-e063-6394a90a6060', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=19b0c015-c07f-63b7-e063-6394a90a6060'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448385', 'name': 'amitriptyline'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450043424.0,"<p>The FDA-approved drug label for amitriptyline contains information regarding the metabolism of tricyclic antidepressants by CYP2D6. CYP2D6 poor metabolizers may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses.</p>
",1450043427.0,"<p>Excerpt from the amitriptyline label:</p>
<blockquote class=""blockquote"">
<p>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7 to
10% of Caucasians are so called &quot;poor metabolizers&quot;); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Amitriptyline_2024_07_18_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Amitriptyline_2024_07_18_FDA.pdf"">amitriptyline drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452530641.0,"<blockquote class=""blockquote"">
<p>In view of the lack of experience with the use of this drug in pediatric patients, it is not recommended at the present time for patients under 12 years of age.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Safety and effectiveness in the pediatric population have not been established (see BOX WARNING and WARNINGS: Clinical Worsening and Suicide Risk ). Anyone
considering the use of amitriptyline hydrochloride in a child or adolescent must balance the potential risks with the clinical need.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104874,"Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD, NAT2",False,False,[],False,"[{'id': 1183681267, 'date': '2013-10-25T11:04:16.524-07:00', 'type': 'Update', 'version': 0}, {'id': 1183704786, 'date': '2014-01-15T00:00:00-08:00', 'type': 'Update', 'version': 0}, {'id': 1448993450, 'date': '2017-09-07T00:00:00-07:00', 'type': 'Update', 'version': 1}, {'id': 1450821535, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101817, 'title': 'Drugs@FDA: Drug Product Bactrim (sulfamethoxazole and Trimethoprim), NDA017377, Sun Pharmaceutical Industries, Inc', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017377', 'crossReferences': [{'id': 1449799277, 'resource': 'FDA Application', 'resourceId': 'NDA017377', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017377'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10715', 'name': 'sulfamethoxazole / trimethoprim'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}, {'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",FDA,1447981723.0,"<p>Sulfamethoxazole and trimethoprim (BACTRIM) is used to prevent and treat infections caused by certain bacteria. The label warns that hemolysis may occur in G6PD deficient individuals. It also notes that patients who are &quot;slow acetylators&quot; may be more prone to idiosyncratic reactions to sulfonamides. Acetylation status of an individual can be determined by examining variants in the <em>NAT2</em> gene. However, the label never mentions any specific gene with regard to acetylator status.</p>
",1447981722.0,"<p>Excerpts from the sulfamethoxazole and trimethoprim (BACTRIM) drug label:</p>
<div class=""blockquote"">
<p>In glucose-6-phosphate dehydrogenase-deficient individuals, hemolysis may occur. This reaction is frequently dose-related (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).</p>
</div>
<div class=""blockquote"">
<p>During treatment, adequate fluid intake and urinary output should be ensured to prevent crystalluria. Patients who are “slow acetylators” may be more prone to idiosyncratic reactions to sulfonamides.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Sulfamethoxazole_Trimethoprim_02_27_19_FDA.pdf"">sulfamethoxazole and trimethoprim drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166273021,Annotation of FDA Label for mavacamten and CYP2C19,False,False,[],False,"[{'id': 1452195100, 'date': '2023-07-28T17:15:12.665-07:00', 'description': 'fixed typo', 'type': 'Update', 'version': 0}, {'id': 1452268540, 'date': '2023-10-11T09:55:44.041-07:00', 'description': 'Uploaded 2023 label. There were no changes to CYP2C19 information.', 'type': 'Update', 'version': 0}, {'id': 1452269503, 'date': '2023-10-12T08:42:44.676-07:00', 'description': 'On FDA Biomarker list tag added. Tags for CYP2C19*2 and CYP2C19*3 added.', 'type': 'Update', 'version': 0}, {'id': 1452336121, 'date': '2023-12-20T05:42:03.402-08:00', 'description': 'Changed from Informative to Actionable since the label has specific information on PK changes for different variants.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15133182, 'title': 'Drugs@FDA: Drug Product CAMZYOS (mavacamten), NDA214998, Myokardia, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214998', 'crossReferences': [{'id': 1451820723, 'resource': 'FDA Application', 'resourceId': 'NDA214998', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214998'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165980635', 'symbol': 'CYP2C19*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165980636', 'symbol': 'CYP2C19*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA166272922', 'name': 'mavacamten'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1451820720.0,"<p>The FDA label for mavacamten gives information on pharmacokinetic differences in CYP2C19 poor metabolizers (PM) compared to normal metabolizers (NM), but does not give information on testing for alleles associated with PM or dose adjustments.</p>
",1451820721.0,"<p>Excerpts from the <em><strong>Mavacamten</strong></em> (<em><strong>CAMZYOS</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacogenomics
Mavacamten AUCinf increased by 241% and Cmax increased by 47% in CYP2C19 poor
metabolizers (PMs) compared to normal metabolizers (NMs) following a single dose of 15 mg
mavacamten. Mean half-life is prolonged in CYP2C19 PMs compared to NMs (23 days vs. 6 to
9 days, respectively).
Polymorphic CYP2C19 is the main enzyme involved in the metabolism of CAMZYOS. An
individual carrying two normal function alleles is a NM (e.g., *1/*1). An individual carrying two
no function alleles is a PM (e.g., *2/*2, *2/*3, *3/*3).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Weak CYP2C19 Inhibitors: Concomitant use of mavacamten (15 mg) with omeprazole (20 mg)
once daily increased mavacamten AUCinf by 48% with no effect on Cmax in healthy CYP2C19
NMs and rapid metabolizers (RMs; e.g., *1/*17).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Moderate CYP3A4 Inhibitors: Concomitant use of mavacamten (25 mg) with verapamil
sustained release (240 mg) increased mavacamten AUCinf by 15% and Cmax by 52% in
intermediate metabolizers (IMs; e.g., *1/*2, *1/*3, *2/*17, *3/*17) and NMs of CYP2C19.
Concomitant use of mavacamten with diltiazem in CYP2C19 PMs is predicted to increase
mavacamten AUC0-24h and Cmax up to 55% and 42%, respectively.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Strong CYP2C19 and CYP3A4 Inducers: Concomitant use of mavacamten (a single 15 mg dose)
with a strong CYP2C19 and CYP3A4 inducer (rifampin 600 mg daily dose) is predicted to
decrease mavacamten AUC0-inf and Cmax by 87% and 22%, respectively, in CYP2C19 NMs, and
by 69% and 4%, respectively, in CYP2C19 PMs.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP3A4 Substrates: Concomitant use of a 16-day course of mavacamten (25 mg on days 1 and
2, followed by 15 mg for 14 days) resulted in a 13% and 7% decrease in midazolam AUCinf and
Cmax, respectively, in healthy CYP2C19 NMs. Following coadministration of mavacamten once
daily in HCM patients, midazolam AUCinf and Cmax are predicted to decrease by 21 to 64% and
13 to 48%, respectively, depending on the dose of mavacamten and CYP2C19 phenotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C8 Substrates: Concomitant use of mavacamten once daily in HCM patients is predicted to
decrease AUC and Cmax of repaglinide, a CYP2C8 and CYP3A substrate, by 12 to 39%,
depending on the dose of mavacamten and CYP2C19 phenotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C9 Substrates: Concomitant use of mavacamten once daily in HCM patients is predicted to
decrease AUC and Cmax of tolbutamide, a CYP2C9 substrate, by 33 to 65%, depending on the
dose of mavacamten and CYP2C19 phenotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C19 Substrates: Concomitant use of mavacamten once daily in HCM patients is predicted
to decrease AUC and Cmax of omeprazole, a CYP2C19 substrate, by 48 to 67%, depending on the
dose of mavacamten and CYP2C19 phenotype.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Mavacamten_FDA_2023_10_11.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Mavacamten_FDA_2023_10_11.pdf""><em><strong>Mavacamten</strong></em> drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104879,Annotation of FDA Label for imipramine and CYP2D6,False,False,[],False,"[{'id': 1183681666, 'date': '2013-10-25T14:21:45.380-07:00', 'type': 'Update', 'version': 0}, {'id': 1452535881, 'date': '2024-07-23T09:28:49.575-07:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161582, 'title': 'DailyMed - IMIPRAMINE PAMOATE capsule', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1dde497-1889-4424-af18-da7ca6459cf3', 'crossReferences': [{'id': 1452535860, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': 'd1dde497-1889-4424-af18-da7ca6459cf3', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1dde497-1889-4424-af18-da7ca6459cf3'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101899, 'title': 'Drugs@FDA: Drug Product imipramine (NDA017090)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017090', 'crossReferences': [{'id': 1449754764, 'resource': 'FDA Application', 'resourceId': 'NDA017090', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017090'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449969', 'name': 'imipramine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981743.0,"<p>The FDA-approved drug label for imipramine states that CYP2D6 poor metabolizers have higher than expected plasma concentrations of TCAs when given usual doses.</p>
",1447981742.0,"<p>Excerpt from the imipramine pamoate drug label:</p>
<blockquote class=""blockquote"">
<p>Drugs Metabolized by P450 2D6 - The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called &quot;poor metabolizers&quot;); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Imipramine_2024_07_23_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Imipramine_2024_07_23_FDA.pdf"">imipramine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452535880.0,"<blockquote class=""blockquote"">
<p><strong>Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<p>Safety and effectiveness in the pediatric population have not been established (see BOX WARNING and WARNINGS, Clinical Worsening and Suicide Risk).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>It is generally recommended that imipramine pamoate should not be used in children because of the increased potential for acute overdosage due to the high unit potency (75 mg, 100 mg, 125 mg, and 150 mg). Each capsule contains imipramine pamoate equivalent to 75 mg, 100 mg, 125 mg, or 150 mg imipramine hydrochloride. Anyone considering the use of imipramine pamoate in a child or adolescent must balance the potential risks with the clinical need.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104885,Annotation of FDA Label for norfloxacin and G6PD,False,False,[],False,"[{'id': 1183681293, 'date': '2013-10-25T11:09:00.350-07:00', 'type': 'Update', 'version': 0}, {'id': 1450378915, 'date': '2019-04-14T16:17:36.337-07:00', 'description': 'Updated label PDF', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101981, 'title': 'Drugs@FDA: Drug Product norfloxacin (NDA019384)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019384', 'crossReferences': [{'id': 1449765684, 'resource': 'FDA Application', 'resourceId': 'NDA019384', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019384'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450654', 'name': 'norfloxacin'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981737.0,"<p>Norfloxacin (NOROXIN) is used to treat urinary tract infections, sexually transmitted diseases and prostatitis caused by certain microorganisms.  The label reports hemolytic reactions have been seen in G6PD deficient individuals in association with this drug.</p>
",1447981736.0,"<p>Excerpt from the norfloxacin (NOROXIN) drug label:</p>
<div class=""blockquote"">
<p>Rarely, hemolytic reactions have been reported in patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity who take quinolone antibacterial agents, including norfloxacin (see ADVERSE REACTIONS).</p>
</div>
<div class=""blockquote"">
<p>Adverse Reactions...Hematologic: Neutropenia; leukopenia; agranulocytosis; hemolytic anemia, sometimes associated with glucose-6-phosphate dehydrogenase deficiency; thrombocytopenia.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Norfloxacin_4_14_19_FDA.pdf"">norfloxacin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166104895,Annotation of FDA Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD,False,False,[],False,"[{'id': 1183681271, 'date': '2013-10-25T11:04:46.773-07:00', 'type': 'Update', 'version': 0}, {'id': 1448604908, 'date': '2017-03-17T13:54:58.013-07:00', 'type': 'Update', 'version': 0}, {'id': 1452538220, 'date': '2024-07-24T23:32:06.129-07:00', 'description': 'Retired annotation as the drug is listed as discontinued on FDA', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101952, 'title': 'Drugs@FDA: Drug Product ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL (ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL), ANDA062759, Rebel Distributors Corp', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=062759', 'crossReferences': [{'id': 1450361370, 'resource': 'FDA Application', 'resourceId': 'ANDA062759', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=062759'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166176008', 'name': 'erythromycin ethylsuccinate / sulfisoxazole acetyl'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981765.0,"<p>Erythromycin ethylsuccinate and sulfisoxazole acetyl is used to treat acute otitis media in children caused by certain strains of <em>Haemophilus influenzae</em>.  The label warns that hemolysis may occur in G6PD deficient patients on this drug.</p>
<p><strong>July 2024: Please note that erythromycin ethylsuccinate / sulfisoxazole acetyl is listed as discontinued by the FDA. However, this drug combination is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug combination is removed from the FDA Biomarker table.</strong></p>
",1450361373.0,"<p>Excerpt from the erythromycin ethylsuccinate and sulfisoxazole acetyl drug label:</p>
<blockquote class=""blockquote"">
<p>In glucose-6-phosphate dehydrogenase-deficient individuals, hemolysis may occur; this reaction is frequently dose related.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Erythromycin_ethylsuccinate_sulfisoxazole_acetyl_01_16_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Erythromycin_ethylsuccinate_sulfisoxazole_acetyl_01_16_19_FDA.pdf"">erythromycin ethylsuccinate and sulfisoxazole acetyl drug label</a>.</p>
<p><strong>July 2024: Please note that erythromycin ethylsuccinate / sulfisoxazole acetyl is listed as discontinued by the FDA. However, this drug combination is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug combination is removed from the FDA Biomarker table.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104795,"Annotation of FDA Label for busulfan and ABL1, BCR",False,True,[],False,"[{'id': 1183681512, 'date': '2013-10-25T12:22:38.254-07:00', 'type': 'Update', 'version': 0}, {'id': 1450399694, 'date': '2019-05-10T08:37:05.382-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1452322960, 'date': '2023-12-11T00:00:00-08:00', 'description': 'While there is a newer label available for BUSULFEX, the language on Philadelphia chromosome is still lacking. Label for MYLERAN is current.', 'type': 'Note', 'version': 0}, {'id': 1452369440, 'date': '2024-02-03T22:47:20.712-08:00', 'description': 'removed prescribing section and genes as does not meet the current criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102009, 'title': 'Drugs@FDA: Drug Product BUSULFEX (busulfan), NDA020954, Otsuka America Pharmaceutical, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020954', 'crossReferences': [{'id': 1449894746, 'resource': 'FDA Application', 'resourceId': 'NDA020954', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020954'}], 'notes': 'BUSULFEX', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101806, 'title': 'Drugs@FDA: Drug Product MYLERAN (busulfan), NDA009386, Aspen Global Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009386', 'crossReferences': [{'id': 1449894737, 'resource': 'FDA Application', 'resourceId': 'NDA009386', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009386'}], 'notes': 'MYLERAN', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448691', 'name': 'busulfan'}]","[{'objCls': 'Gene', 'id': 'PA24413', 'symbol': 'ABL1', 'name': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'objCls': 'Gene', 'id': 'PA25321', 'symbol': 'BCR', 'name': 'BCR activator of RhoGEF and GTPase'}]",FDA,1450342095.0,"<p>The FDA-approved drug label for busulfan (MYLERAN) states it is less effective in patients with chronic myelogenous leukemia who lack the Philadelphia chromosome.</p>
",1450342098.0,"<p>Busulfan (MYLERAN) is indicated for palliative treatment of patients with chronic myelogenous leukemia.</p>
<p>Excerpt from the busulfan (MYLERAN) drug label:</p>
<div class=""blockquote"">
<p>Busulfan is clearly less effective in patients with chronic myelogenous leukemia who lack the Philadelphia (Ph1) chromosome. Also, the so-called &quot;juvenile&quot; type of chronic myelogenous leukemia, typically occurring in young children and associated with the absence of a Philadelphia chromosome, responds poorly to busulfan.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Busulfan_06_07_2017_FDA.pdf"">busulfan (MYLERAN) drug label</a>.</p>
<p><strong>Note: Busulfan (BUSULFEX) is indicated in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. The drug label for busulfan (BUSULFEX) contains no information regarding the Philadelphia chromosome.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166114926,Annotation of FDA Label for mafenide and G6PD,False,False,[],False,"[{'id': 1183704760, 'date': '2013-12-17T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1452537802, 'date': '2024-07-24T15:00:25.476-07:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101904, 'title': 'Drugs@FDA: Drug Product Sulfamylon (mafenide acetate), NDA019832, Mylan Institutional Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019832', 'crossReferences': [{'id': 1452537820, 'resource': 'FDA Application', 'resourceId': 'NDA019832/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019832'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'pubDate': '1998-06-05T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15161822, 'title': 'DailyMed - MAFENIDE ACETATE powder, for solution', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f397e17-d14d-4a8d-a44c-6f81cd9a7abd', 'crossReferences': [{'id': 1452537800, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '3f397e17-d14d-4a8d-a44c-6f81cd9a7abd', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f397e17-d14d-4a8d-a44c-6f81cd9a7abd'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166114925', 'name': 'mafenide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447982149.0,"<p>The FDA-approved drug label for mafenide acetate mentions that fatal hemolytic anemia with disseminated intravascular coagulation has been reported following treatment with mafedine acetate, possibly related to a glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency is a condition caused by variants in the <em>G6PD</em> gene which can be determined by enzymatic or genetic tests. However, the drug label does not specifically mention testing.</p>
",1447982148.0,"<p>Mafenide Acetate 5% Topical Solution is a synthetic antimicrobial agent used as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.</p>
<p>Excerpt from the mafenide acetate drug label:</p>
<blockquote class=""blockquote"">
<p>Fatal hemolytic anemia with disseminated intravascular coagulation, presumably related to a glucose-6-phosphate dehydrogenase deficiency, has been reported following therapy with Mafenide Acetate.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Mafenide_2024_07_24_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Mafenide_2024_07_24_FDA.pdf"">mafenide drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452537801.0,"<blockquote class=""blockquote"">
<p>The safety and effectiveness of Mafenide Acetate for 5% Topical Solution have been established in the age groups 3 months to 16 years.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104878,Annotation of FDA Label for methylene blue and G6PD,True,False,[],False,"[{'id': 1183704762, 'date': '2013-12-17T00:00:00-08:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102044, 'title': 'Drugs@FDA: Drug Product PROVAYBLUE (methylene blue), NDA204630, American Regent, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204630', 'crossReferences': [{'id': 1449758763, 'resource': 'FDA Application', 'resourceId': 'NDA204630', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204630'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450457', 'name': 'methylene blue'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981731.0,"<p>The FDA-approved drug label for methylene blue (PROVAYBLUE) states that it is contraindicated in patients with G6PD deficiency due to the risks of hemolytic anemia.</p>
",1447981730.0,"<p>Excerpt from the methylene blue (PROVAYBLUE) drug label:</p>
<div class=""blockquote"">
<p>Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency with PROVAYBLUE(R) may result in severe hemolysis and severe anemia. PROVAYBLUE(R) is contraindicated for use in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Methylene_Blue_02_07_19_FDA.pdf"">methylene blue drug label</a>.</p>
<p>*Disclaimer: The contents of this page are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399707.0,"<p>Excerpt from the methylene blue (PROVAYBLUE) drug label:</p>
<blockquote class=""blockquote"">
<p>PROVAYBLUE(R) is contraindicated for use in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166182728,"Annotation of FDA Label for ropivacaine and CYB5R3, G6PD",False,False,[],False,"[{'id': 1450821518, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1450823377, 'date': '2019-10-17T05:48:53.618-07:00', 'description': 'Added link and text about CYB5R3 and congenital methemoglobinemia.', 'type': 'Update', 'version': 0}, {'id': 1452704245, 'date': '2024-11-15T15:12:12.717-08:00', 'description': 'changed PGx level to Actionable/Other Guidance and added quote from the label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102368, 'title': 'Drugs@FDA: Drug Product NAROPIN (ropivacaine hydrochloride), NDA020533, General Injectables & Vaccines, Inc', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020533', 'crossReferences': [{'id': 1450400064, 'resource': 'FDA Application', 'resourceId': 'NDA020533', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020533'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451271', 'name': 'ropivacaine'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450400061.0,"<p>The FDA-approved drug label for ropivacaine (NAROPIN) states that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and congenital methemoglobinemia (associated with variants in CYB5R3) are more susceptible to developing methemoglobinemia in association with use of local anesthetics.</p>
",1450400062.0,"<p>Excerpt from the ropivacaine (NAROPIN) drug label:</p>
<blockquote class=""blockquote"">
<p>Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, [...] are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
<p>NOTE: While the CYB5R3 gene is not explicitly stated in the drug label variants in this gene are associated with congenital methemoglobinemia I and II <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/250800"" target=""_blank"">OMIM 250800</a>.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Ropivacaine_05_13_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ropivacaine_05_13_19_FDA.pdf"">ropivacaine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452704244.0,"<blockquote class=""blockquote"">
<p>Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia[...] are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166105058,"Annotation of FDA Label for pazopanib and HLA-B, UGT1A1",False,False,[],False,"[{'id': 1183704809, 'date': '2014-02-12T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1183704810, 'date': '2014-02-15T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1448604625, 'date': '2017-03-15T13:31:49.522-07:00', 'type': 'Update', 'version': 0}, {'id': 1450381456, 'date': '2019-04-19T09:57:02.115-07:00', 'description': 'Added variant information', 'type': 'Update', 'version': 0}, {'id': 1450381457, 'date': '2019-04-19T10:02:31.665-07:00', 'description': 'Updated label PDF', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101825, 'title': 'Drugs@FDA: Drug Product VOTRIENT (pazopanib hydrochloride), NDA022465, Novartis Pharmaceuticals Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022465', 'crossReferences': [{'id': 1449767791, 'resource': 'FDA Application', 'resourceId': 'NDA022465', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022465'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165987830', 'symbol': 'HLA-B*57:01', 'name': '*57:01'}, {'objCls': 'Haplotype', 'id': 'PA166115842', 'symbol': 'UGT1A1*28', 'name': '*28'}]","[{'objCls': 'Chemical', 'id': 'PA165291492', 'name': 'pazopanib'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}, {'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",FDA,1447981896.0,"<p>The FDA-approved drug label for pazopanib (VOTRIENT) states that patients with the UGT1A1 *28/*28 genotype had a significantly increased incidence of hyperbilirubinemia when taking pazopanib, as compared to those with the *1/*1 or *1/*28 genotype. Additionally, ALT &gt; 3 x ULN and ALT &gt; 5 x ULN both occurred more often in carriers of the HLA-B*57:01 allele as compared to non-carriers.</p>
",1447981895.0,"<p>Pazopanib (VOTRIENT) is a kinase inhibitor indicated for patients with advanced renal cell carcinoma or patients with advanced soft tissue sarcoma who have received prior chemotherapy.</p>
<p>Excerpts from the pazopanib (VOTRIENT) drug label:</p>
<div class=""blockquote"">
<p>Pazopanib can increase serum total bilirubin levels...In vitro studies showed that pazopanib inhibits UGT1A1, which glucuronidates bilirubin for elimination. [In] a pooled pharmacogenetic analysis...the (TA)7/(TA)7 genotype (UGT1A1*28/*28) (underlying genetic susceptibility to Gilbert's syndrome) was associated with a statistically significant increase in the incidence of hyperbilirubinemia relative to the (TA)6/(TA)6 and (TA)6/(TA)7 genotypes.</p>
</div>
<div class=""blockquote"">
<p>In a pooled pharmacogenetic analysis of data from 31 clinical studies of pazopanib administered as either monotherapy or in combination with other agents, ALT &gt; 3 X ULN (NCI CTC Grade 2) occurred in 32% (42/133) of HLA-B*57:01 allele carriers and in 19% (397/2101) of non-carriers and ALT &gt; 5 X ULN (NCI CTC Grade 3) occurred in 19% (25/133) of HLA-B*57:01 allele carriers and in 10% (213/2101) of non- carriers. In this dataset, 6% (133/2234) of the patients carried the HLA-B*57:01 allele.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Pazopanib_04_19_19_FDA.pdf"">pazopanib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166122971,Annotation of FDA Label for darifenacin and CYP2D6,False,False,[],False,"[{'id': 1184513747, 'date': '2014-08-08T00:00:00-07:00', 'description': 'Created', 'type': 'Create', 'version': 0}, {'id': 1448604460, 'date': '2017-03-15T10:46:07.317-07:00', 'type': 'Update', 'version': 0}, {'id': 1452532600, 'date': '2024-07-19T16:54:52.688-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161162, 'title': 'DailyMed - DARIFENACIN tablet, film coated, extended release', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28ed5b58-46dd-4140-a877-4b422f780a94', 'crossReferences': [{'id': 1452532580, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '28ed5b58-46dd-4140-a877-4b422f780a94', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28ed5b58-46dd-4140-a877-4b422f780a94'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101832, 'title': 'Drugs@FDA: Drug Product Enablex (darifenacin), NDA021513, Allergan, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021513', 'crossReferences': [{'id': 1449754243, 'resource': 'FDA Application', 'resourceId': 'NDA021513', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021513'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164774901', 'name': 'darifenacin'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450342901.0,"<p>The FDA-approved drug label for darifenacin notes that CYP2D6 poor metabolizers may have increased maximum plasma concentrations of darifenacin, as compared to CYP2D6 extensive metabolizers. However, the label does not comment on the clinical significance of these increased concentrations.</p>
",1450342902.0,"<p>Excerpts from the darifenacin drug label:</p>
<blockquote class=""blockquote"">
<p>Metabolism is mediated by cytochrome P450 enzymes CYP2D6 and CYP3A4.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A subset of individuals (approximately 7% Caucasians and 2% African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs. Individuals with normal CYP2D6 activity are referred to as extensive metabolizers (EMs). The metabolism of darifenacin in PMs will be principally mediated via CYP3A4. The darifenacin ratios (PM versus EM) for Cmax and AUC following darifenacin 15 mg once daily at steady-state were 1.9 and 1.7, respectively.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Darifenacin_2024_07_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Darifenacin_2024_07_19_FDA.pdf"">darifenacin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166160052,Annotation of FDA Label for palonosetron and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15102027, 'title': 'Drugs@FDA: Drug Product palonosetron hydrochloride (palonosetron hydrochloride), NDA021372, Cipla USA Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021372', 'crossReferences': [{'id': 1449767765, 'resource': 'FDA Application', 'resourceId': 'NDA021372', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021372'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10352', 'name': 'palonosetron'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1448257457.0,"<p>The FDA-approved drug label for palonosetron (ALOXI) states that there is no significant difference in clinical pharmacokinetic parameters between CYP2D6 poor and extensive metabolizers.</p>
",1448257456.0,"<p>Palonosetron is an antiemetic.</p>
<p>Excerpt from the palonosetron (ALOXI) drug label:</p>
<div class=""blockquote"">
<p>In vitro metabolism studies have suggested that CYP2D6 and to a lesser extent, CYP3A4 and CYP1A2 are involved in the metabolism of palonosetron. However, clinical pharmacokinetic parameters are not significantly different between poor and extensive metabolizers of CYP2D6 substrates.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Palonosetron_FDA_08_11_2017_FDA.pdf"">palonosetron drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166185151,Annotation of FDA Label for amifampridine and NAT2,False,False,[],True,"[{'id': 1452469501, 'date': '2024-05-10T17:03:52.046-07:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}, {'id': 1452622000, 'date': '2024-10-02T11:53:13.166-07:00', 'description': 'drug was removed from FDA biomarker list; added text about conversion to a tentative approval by the FDA', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103442, 'title': 'Drugs@FDA: Drug Product RUZURGI (amifampridine) NDA 209321', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209321', 'crossReferences': [{'id': 1450826580, 'resource': 'FDA Application', 'resourceId': 'NDA209321', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209321'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166185150', 'name': 'amifampridine'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",FDA,1450826576.0,"<p>The drug label for amifampridine (RUZURGI) states that NAT2 poor metabolizers have higher concentrations of the drug as compared to normal metabolizers, and that the drug should be initiated at the lowest recommended starting dosage in these patients.</p>
<p>On 2/1/2022, the FDA converted the final approval of NDA209321/Original 1 to a tentative approval, and a drug label is no longer available on the FDA website.</p>
",1450826577.0,"<p>Amifampridine (RUZURGI) is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.</p>
<p>Excerpts from the amifampridine (RUZURGI) drug label:</p>
<div class=""blockquote"">
<p>The recommended oral dosage for pediatric patients 6 to less than 17 years of age is dependent on body weight and is included in Table 1. Dosage should be increased based on clinical response and tolerability.</p>
</div>
<div class=""blockquote"">
<p>Known N-acetyltransferase 2 (NAT2) Poor Metabolizers</p>
</div>
<div class=""blockquote"">
<p>The recommended starting dosage of RUZURGI in pediatric patients weighing 45 kg or more who are known N-acetyltransferase 2 (NAT2) poor metabolizers is 15 mg daily taken orally in divided doses. The recommended starting dosage in pediatric patients weighing less than 45 kg who are known NAT2 poor metabolizers is 7.5 mg daily taken orally in divided doses</p>
</div>
<div class=""blockquote"">
<p>Use in specific populations:
NAT2 Poor Metabolizers: Exposure of RUZURGI is increased in patients who are N-acetyltransferase (NAT2) poor metabolizers [see Clinical Pharmacology (12.5)]. Therefore, initiate RUZURGI in patients who are known NAT2 poor metabolizers at the lowest recommended starting dosage and monitor for adverse reactions [see Dosage and Administration (2.5)]. Consider dosage modification of RUZURGI for patients who are known NAT2 poor metabolizers as needed based on clinical effect and tolerability.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/amifampridine_11_01_19_FDA.pdf"">amifampridine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452469500.0,"<blockquote class=""blockquote"">
<p>RUZURGI is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450826578.0,"<p>Excerpts from the amifampridine (RUZURGI) drug label:</p>
<blockquote class=""blockquote"">
<p>Dosage and administration:
Known N-acetyltransferase 2 (NAT2) Poor Metabolizers.
The recommended starting dosage of RUZURGI in pediatric patients weighing 45 kg or more who are known N-acetyltransferase 2 (NAT2) poor metabolizers is 15 mg daily taken orally in divided doses. The recommended starting dosage in pediatric patients weighing less than 45 kg who are known NAT2 poor metabolizers is 7.5 mg daily taken orally in divided doses</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Use in specific populations:
NAT2 Poor Metabolizers: Exposure of RUZURGI is increased in patients who are N-acetyltransferase (NAT2) poor metabolizers [see Clinical Pharmacology (12.5)]. Therefore, initiate RUZURGI in patients who are known NAT2 poor metabolizers at the lowest recommended starting dosage and monitor for adverse reactions [see Dosage and Administration (2.5)]. Consider dosage modification of RUZURGI for patients who are known NAT2 poor metabolizers as needed based on clinical effect and tolerability.</p>
</blockquote>
",,,,,,,Formerly on FDA Biomarker List
Label Annotation,PA166105195,"Annotation of FDA Label for metoclopramide and CYB5R1, CYB5R2, CYB5R3, CYB5R4, G6PD",False,False,[],False,"[{'id': 1183704765, 'date': '2013-12-18T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1450823378, 'date': '2019-10-17T06:26:25.974-07:00', 'description': 'Added link and text about G6PD', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101844, 'title': 'Drugs@FDA: Drug Product Reglan (Metoclopramide Hydrochloride), ANI Pharmaceuticals, Inc. - NDA017854/SUPPL-62, 08/29/2017', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017854', 'crossReferences': [{'id': 1452538961, 'resource': 'FDA Application', 'resourceId': 'NDA017854/SUPPL-62', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017854'}], 'objCls': 'Literature', 'pubDate': '2017-08-29T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450475', 'name': 'metoclopramide'}]","[{'objCls': 'Gene', 'id': 'PA134979668', 'symbol': 'CYB5R1', 'name': 'cytochrome b5 reductase 1'}, {'objCls': 'Gene', 'id': 'PA142672060', 'symbol': 'CYB5R2', 'name': 'cytochrome b5 reductase 2'}, {'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA134904907', 'symbol': 'CYB5R4', 'name': 'cytochrome b5 reductase 4'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981916.0,"<p>Metoclopramide (reglan) is indicated as a short-term treatment for adults with gastroesophageal reflux who fail to respond to conventional therapy. The FDA-approved drug label for metoclopramide notes that patients with NADH-cytochrome b5 reductase deficiency have an increased risk of developing methemglobinemia and/or sulfhemoglobinemia when treated with metoclopramide. The label and FDA table also mention G6PD;  patients with G6PD deficiency experiencing metoclopramide-induced methemoglobinemia should not be given methylene blue.</p>
",1447981915.0,"<p>The drug label for metoclopramide (reglan) states that adults with NADH-cytochrome b5 reductase deficiency are more susceptible to developing methemoglobinemia and/or sulfhemoglobinemia when treated with the drug. Additionally, neonates have reduced levels of NADH-cytochrome b5 reductase and prolonged drug clearance, and therefore are also more susceptible to methemoglobinemia. NADH-cytochrome b5 reductase is encoded by the <em>CYB5R1</em>, <em>CYB5R2</em>, <em>CYB5R3</em> and <em>CYB5R4</em> genes.</p>
<p>Excerpts from the metoclopramide (reglan) drug label:</p>
<blockquote class=""blockquote"">
<p>Patients with NADH-cytochrome b5 reductase deficiency are at an increased risk of developing methemoglobinemia and/or sulfhemoglobinemia when metoclopramide is administered.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>...neonates have reduced levels of NADH-cytochrome b5 reductase which, in combination with the aforementioned pharmacokinetic factors, make neonates more susceptible to methemoglobinemia</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In patients with G6PD deficiency who experienced metoclopramide-induced methemoglobinemia, methylene blue treatment is not recommended.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Metoclopramide_FDA_05_03_18.pdf"">metoclopramide drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166170933,"Annotation of FDA Label for pertuzumab and ESR1, ESR2, PGR",False,True,[],False,"[{'id': 1450381747, 'date': '2019-04-19T12:48:48.727-07:00', 'description': 'Added cancer genome tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101862, 'title': 'Drugs@FDA: Drug Product PERJETA (Pertuzumab), BLA125409, Genentech, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125409', 'crossReferences': [{'id': 1449767808, 'resource': 'FDA Application', 'resourceId': 'BLA125409', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125409'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165290933', 'name': 'pertuzumab'}]","[{'objCls': 'Gene', 'id': 'PA156', 'symbol': 'ESR1', 'name': 'estrogen receptor 1'}, {'objCls': 'Gene', 'id': 'PA27886', 'symbol': 'ESR2', 'name': 'estrogen receptor 2'}, {'objCls': 'Gene', 'id': 'PA266', 'symbol': 'PGR', 'name': 'progesterone receptor'}]",FDA,1449041383.0,"<p>Pertuzumab (PERJETA) is a targeted antibody drug designed to bind to ERBB2 (HER2). The drug label notes that the pathological complete response rate was lower in patients with hormone receptor-positive tumors compared with hormone receptor-negative tumors.</p>
",1449041382.0,"<p>Excerpts from the pertuzumab (PERJETA) label:</p>
<div class=""blockquote"">
<p>The pCR rates and magnitude of improvement with PERJETA were lower in the subgroup of patients with hormone receptor-positive tumors compared to patients with hormone receptor-negative tumors.</p>
</div>
<div class=""blockquote"">
<p>In the subgroup of patients with hormone receptor-negative disease (n=408), the hazard ratio was 0.55 (95% CI: 0.42, 0.72). In the subgroup of patients with hormone receptor-positive disease (n=388), the hazard ratio was 0.72 (95% CI: 0.55, 0.95).</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Pertuzumab_08_16_2017_FDA.pdf"">pertuzumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182749,"Annotation of FDA Label for lusutrombopag and F2, F5, PROC, PROS1, SERPINC1",False,False,[],False,"[{'id': 1452537292, 'date': '2024-07-24T10:05:16.468-07:00', 'description': 'added Other Guidance tag, prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102383, 'title': 'Drugs@FDA: Drug Product Mulpleta (Lusutrombopag), SHIONOGI INC. - NDA210923/ORIG-1, 07/31/2018', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210923', 'crossReferences': [{'id': 1452536640, 'resource': 'FDA Application', 'resourceId': 'NDA210923/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210923'}], 'objCls': 'Literature', 'pubDate': '2018-07-31T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]","[{'objCls': 'Variant', 'id': 'PA166154336', 'symbol': 'rs1799963', 'name': 'rs1799963'}, {'objCls': 'Variant', 'id': 'PA166153554', 'symbol': 'rs6025', 'name': 'rs6025'}]","[{'objCls': 'Chemical', 'id': 'PA166182748', 'name': 'lusutrombopag'}]","[{'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",FDA,1450400565.0,"<p>The FDA-approved drug label for lusutrombopag (MULPLETA) states that the potential increased risk for thrombosis should be considered in patients with risk factors for thromboembolism, including genetic prothrombotic conditions such as Factor V Leiden (F5), Prothrombin 20210A (F2), Antithrombin deficiency (SERPINC1) or Protein C (PROC) or S (PROS1) deficiency.</p>
",1450400566.0,"<p>Excerpts from the lusutrombopag (MULPLETA) FDA drug label:</p>
<blockquote class=""blockquote"">
<p>MULPLETA is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>MULPLETA is a thrombopoietin (TPO) receptor agonist, and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. Portal vein thrombosis was reported in 1% (2 of 171) of MULPLETA-treated patients and 1% (2 of 170) of placebo-treated patients in 3 randomized, double-blind trials and was identified post-procedure in protocol-specified imaging. The thromboses were not associated with a marked increase in platelet count.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consider the potential increased thrombotic risk when administering MULPLETA to patients with known risk factors for thromboembolism, including genetic pro-thrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, or Protein C or S deficiency). In patients with ongoing or prior thrombosis or absence of hepatopetal blood flow, MULPLETA should only be used if the potential benefit to the patient justifies the potential risk.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""lusutrombopag_05_14_2019_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/lusutrombopag_05_14_2019_FDA.pdf"">lusutrombopag drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452537291.0,"<blockquote class=""blockquote"">
<p>Consider the potential increased thrombotic risk when administering MULPLETA to patients with known risk factors for thromboembolism, including genetic pro-thrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, or Protein C or S deficiency).</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166182737,Annotation of FDA Label for lidocaine and tetracaine and G6PD,False,False,[],False,"[{'id': 1450821521, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1450822423, 'date': '2019-10-15T08:46:40.774-07:00', 'description': 'Added link and text about CYB5R3 and congenital methemoglobinemia.', 'type': 'Update', 'version': 0}, {'id': 1452264260, 'date': '2023-10-05T16:08:53.079-07:00', 'description': 'removed CYB5R3 as FDA biomarker table only list as ""Nonspecific (Congenital Methemoglobinemia)""', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102379, 'title': 'Drugs@FDA: Drug Product Synera (lidocaine and tetracaine), NDA021623, Galen US Incorporated', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021623', 'crossReferences': [{'id': 1450400235, 'resource': 'FDA Application', 'resourceId': 'NDA021623', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021623'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166182735', 'name': 'lidocaine and tetracaine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450400232.0,"<p>The FDA-approved drug label for lidocaine and tetracaine (SYNERA) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for methemoglobinemia. Close monitoring for symptoms and signs of methemoglobinemia is recommended in this subset of patients.</p>
",1450400233.0,"<p>Lidocaine and tetracaine (SYNERA) is a combination amide and ester local anesthetic indicated for use on intact skin to provide local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodessication and shave biopsy of skin lesions.</p>
<p>Excerpt from the Lidocaine and tetracaine (SYNERA) drug label:</p>
<blockquote class=""blockquote"">
<p>Warnings and precautions:</p>
<p>Methemoglobinemia:
Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all
patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency,
congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months
of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to
developing clinical manifestations of the condition. If local anesthetics must be used in these patients,
close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""lidocaine_and_tetracaine_05_14_2019_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/lidocaine_and_tetracaine_05_14_2019_FDA.pdf"">Lidocaine and tetracaine drug label</a>.</p>
<p>*Disclaimer: The contents of this page are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450400234.0,"<p>Excerpt from the Lidocaine and tetracaine (SYNERA) drug label:</p>
<blockquote class=""blockquote"">
<p>Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166161219,Annotation of FDA Label for aripiprazole lauroxil and CYP2D6,True,False,[],True,[],False,[],True,"[{'id': 15101879, 'title': 'Drugs@FDA: Drug Product ARISTADA (aripiprazole lauroxil), NDA207533, Alkermes, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207533', 'crossReferences': [{'id': 1450043490, 'resource': 'FDA Application', 'resourceId': 'NDA207533', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207533'}], 'notes': 'ARISTADA', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15102054, 'title': 'Drugs@FDA: Drug Product ARISTADA INITIO (aripiprazole lauroxil), NDA209830, Alkermes, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209830', 'crossReferences': [{'id': 1450043501, 'resource': 'FDA Application', 'resourceId': 'NDA209830', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209830'}], 'notes': 'ARISTADA INITIO', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166161216', 'name': 'aripiprazole lauroxil'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450043504.0,"<p>The FDA-approved drug labels for aripiprazole lauroxil (ARISTADA and ARISTADA INITIO) provide dosing guidance for CYP2D6 poor metabolizers (PMs). CYP2D6 PMs taking ARISTADA who are taking a concomitant medicine that is a strong CYP3A4 inhibitor should have their dose reduced to 441 mg. ARISTADA INITIO should be avoided in CYP2D6 poor metabolizers.</p>
",1450043505.0,"<p>Aripiprazole lauroxil (ARISTADA and ARISTADA INITIO) is an atypical antipsychotic medication. ARISTADA INITIO is only available at a single strength, to be used as a single dose and not for repeated dosing.</p>
<p><strong>Excerpts from the ARISTADA drug label:</strong></p>
<div class=""blockquote"">
<p>Concomitant Medicine...Strong CYP3A4 Inhibitor...Dose Change for ARISTADA...For patients known to be poor metabolizers of CYP2D6: Reduce dose to 441 mg from 662 mg, 882 mg, or 1064 mg. No dosage adjustment is necessary in patients taking 441 mg ARISTADA, if tolerated.</p>
</div>
<div class=""blockquote"">
<p>Dosage adjustment is recommended in known CYP2D6 poor metabolizers due to high aripiprazole concentrations. Approximately 8% of Caucasians and 3-8% of Black/African Americans cannot metabolize CYP2D6 substrates and are classified as poor metabolizers (PM).</p>
</div>
<p><strong>Excerpts from the ARISTADA INITIO drug label:</strong></p>
<div class=""blockquote"">
<p>ARISTADA INITIO is only available at a single strength as a single-dose pre-filled syringe, so dosage adjustments are not possible. Therefore, avoid use in patients who are known CYP2D6 poor metabolizers.</p>
</div>
<p>For the complete drug label texts with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Aripiprazole_Lauroxil_11_28_18_FDA.pdf"">aripiprazole lauroxil (ARISTADA) drug label</a> and the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Aripiprazole_Lauroxil_Initio_11_28_18_FDA.pdf"">aripiprazole lauroxil (ARISTADA INITIO) drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399530.0,"<p>Excerpt from the ARISTADA label:</p>
<blockquote class=""blockquote"">
<p>Concomitant Medicine...Strong CYP3A4 Inhibitor...Dose Change for ARISTADA...For patients known to be poor metabolizers of CYP2D6: Reduce dose to 441 mg from 662 mg, 882 mg, or 1064 mg. No dosage adjustment is necessary in patients taking 441 mg ARISTADA, if tolerated.</p>
</blockquote>
<p>Excerpt from the ARISTADA INITIO label:</p>
<blockquote class=""blockquote"">
<p>ARISTADA INITIO is only available at a single strength as a single-dose pre-filled syringe, so dosage adjustments are not possible. Therefore, avoid use in patients who are known CYP2D6 poor metabolizers.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166182746,"Annotation of FDA Label for ceftriaxone and CYB5R3, G6PD",False,False,[],False,"[{'id': 1450821529, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1450822518, 'date': '2019-10-15T09:25:56.380-07:00', 'description': 'Added link and text about CYB5R3 and congenital methemoglobinemia.', 'type': 'Update', 'version': 0}, {'id': 1450824513, 'date': '2019-10-24T07:05:36.581-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1452642081, 'date': '2024-10-15T16:00:52.781-07:00', 'description': 'added Pediatric tag and info, newer DailyMed label', 'type': 'Update', 'version': 0}, {'id': 1452642120, 'date': '2024-10-15T16:11:15.003-07:00', 'description': 'added local anesthetic context to quote, removed Actionable PGx testing level and Other Guidance tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102375, 'title': 'Drugs@FDA: Drug Product ROCEPHIN (ceftriaxone) - NDA050585/SUPPL-68, 07/12/2018', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050585', 'crossReferences': [{'id': 1452644261, 'resource': 'FDA Application', 'resourceId': 'NDA050585/SUPPL-68', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050585'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'pubDate': '2018-07-12T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15167883, 'title': 'DailyMed - CEFTRIAXONE- ceftriaxone sodium injection, solution', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c5c2d3f-5038-41a1-a2fe-4dcd048dbac1', 'crossReferences': [{'id': 1452642062, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '4c5c2d3f-5038-41a1-a2fe-4dcd048dbac1', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c5c2d3f-5038-41a1-a2fe-4dcd048dbac1'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448866', 'name': 'ceftriaxone'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450400476.0,"<p>The FDA-approved drug label for ceftriaxone (ROCEPHIN) states that, in the context of coadministration with local anesthetics (e.g. lidocaine), individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia due to exposure to the anesthetic.</p>
<p><strong>Note that a newer FDA-approved drug label no longer mentions either G6PD deficiency or congenital methemoglobinemia. However, as of October 15, 2024, the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling still lists G6PD and Congenital Methemoglobinemia. The marketing status of the linked drug, Rocephin, as well as the &quot;Rocephin Kit&quot; version that also contained lidocaine, is shown as Discontinued.</strong></p>
",1450400477.0,"<p>Excerpt from the ceftriaxone (ROCEPHIN) drug label:</p>
<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia have been reported in association with local anesthetic use (e.g. lidocaine). Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
<p>NOTE: While the CYB5R3 gene is not explicitly stated in the drug label variants in this gene are associated with congenital methemoglobinemia I and II <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/250800"" target=""_blank"">OMIM 250800</a>.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Ceftriaxone_05_13_2019FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ceftriaxone_05_13_2019FDA.pdf"">ceftriaxone drug label</a>. A newer <a download=""Ceftriaxone_2024_10_15_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ceftriaxone_2024_10_15_FDA.pdf"">ceftriaxone (DailyMed) drug label</a> no longer mentions glucose-6-phosphate dehydrogenase deficiency or congenital methemoglobinemia.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452642080.0,"<blockquote class=""blockquote"">
<p>Safety and effectiveness of Ceftriaxone Injection in neonates, infants and pediatric patients have been established for the dosages described in the DOSAGE AND ADMINISTRATION section. In vitro studies have shown that ceftriaxone, like some other cephalosporins, can displace bilirubin from serum albumin. Ceftriaxone Injection should not be administered to hyperbilirubinemic neonates, especially prematures (see CONTRAINDICATIONS).</p>
</blockquote>
",,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104837,Annotation of FDA Label for propafenone and CYP2D6,False,False,[],False,"[{'id': 1183681388, 'date': '2013-10-25T11:32:19.843-07:00', 'type': 'Update', 'version': 0}, {'id': 1452011326, 'date': '2023-02-16T20:57:17.163-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452245000, 'date': '2023-09-25T10:31:30.956-07:00', 'description': 'changed PGx level to informative - no prescribing action required based on genotype', 'type': 'Update', 'version': 0}, {'id': 1452543124, 'date': '2024-07-30T11:36:35.163-07:00', 'description': 'added newer DailyMed label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101853, 'title': 'Drugs@FDA: Drug Product RYTHMOL SR (propafenone hydrochloride), NDA021416, GlaxoSmithKline LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021416', 'crossReferences': [{'id': 1452543060, 'resource': 'FDA Application', 'resourceId': 'NDA021416/SUPPL-15', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021416'}], 'objCls': 'Literature', 'pubDate': '2018-11-02T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15162502, 'title': 'DailyMed - PROPAFENONE HYDROCHLORIDE capsule, extended release', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fc0800c-c063-48f8-ab4e-9aa9a4c3841f', 'crossReferences': [{'id': 1452543140, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '3fc0800c-c063-48f8-ab4e-9aa9a4c3841f', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fc0800c-c063-48f8-ab4e-9aa9a4c3841f'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451131', 'name': 'propafenone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981644.0,"<p>The FDA-approved drug label for propafenone (RYTHMOL SR) states that administration of the drug to CYP2D6 slow and extensive metabolizers resulted in significant differences in plasma concentrations. However, the recommended dosing regimen of the drug is the same for all patients.</p>
",1447981643.0,"<p>Excerpts from the propafenone (RYTHMOL SR) drug label:</p>
<div class=""blockquote"">
<p>...administration of RYTHMOL SR to slow and extensive metabolizers results in significant differences in plasma concentrations of propafenone, with slow metabolizers achieving concentrations about twice those of extensive metabolizers at daily doses of 850 mg/day. At low doses the differences are greater, with slow metabolizers attaining concentrations about 3 to 4 times higher than extensive metabolizers...Because the difference decreases at high doses and is mitigated by the lack of the active 5-hydroxymetabolite in the slow metabolizers, and because steady-state conditions are achieved after 4 to 5 days of dosing in all patients, the recommended dosing regimen of RYTHMOL SR is the same for all patients.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Propafenone_02_22_19_FDA.pdf"">propafenone drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166177514,Annotation of FDA Label for mirabegron and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15101938, 'title': 'Drugs@FDA: Drug Product Myrbetriq (mirabegron), NDA202611, Astellas Pharma US, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202611', 'crossReferences': [{'id': 1449762458, 'resource': 'FDA Application', 'resourceId': 'NDA202611', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202611'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177513', 'name': 'mirabegron'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1449169959.0,"<p>Mirabegron (MYRBETRIQ) is indicated for the treatment of overactive bladder. The label notes that CYP2D6 poor metabolizers had increased concentrations of the drug as compared to CYP2D6 extensive metabolizers.</p>
",1449169958.0,"<p>Excerpt from the mirabegron (MYRBETRIQ) label:</p>
<div class=""blockquote"">
<p>In healthy subjects who are genotypically poor metabolizers of CYP2D6, mean Cmax and AUCtau were approximately 16% and 17% higher than in extensive metabolizers of CYP2D6, respectively.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Mirabegron_FDA_02_12_18.pdf"">mirabegron drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104903,Annotation of FDA Label for nitrofurantoin and G6PD,True,False,[],False,"[{'id': 1183681295, 'date': '2013-10-25T11:09:24.060-07:00', 'type': 'Update', 'version': 0}, {'id': 1183704776, 'date': '2013-12-18T00:00:00-08:00', 'type': 'Update', 'version': 0}, {'id': 1452536805, 'date': '2024-07-23T23:13:31.177-07:00', 'description': 'Added Prescribing section and tags', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101821, 'title': 'Drugs@FDA: Drug Product Furadantin (Nitrofurantoin), NDA009175, Casper Pharma LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009175', 'crossReferences': [{'id': 1449765663, 'resource': 'FDA Application', 'resourceId': 'NDA009175', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009175'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450640', 'name': 'nitrofurantoin'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981783.0,"<p>Nitrofurantion (Furadantin) is used to treat urinary tract infections caused by certain strains of bacteria.  A link between nitrofurantoin-induced hemolytic anemia and G6PD deficiency is highlighted in the Warnings section.</p>
",1447981782.0,"<p>Excerpt from the nitrofurantoin (Furadantin) drug label:</p>
<div class=""blockquote"">
<p>Cases of hemolytic anemia of the primaquine-sensitivity type have been induced by nitrofurantoin. Hemolysis appears to be linked to a glucose-6-phosphate dehydrogenase deficiency in the red blood cells of the affected patients. This deficiency is found in 10 percent of Blacks and a small percentage of ethnic groups of Mediterranean and Near-Eastern origin. Hemolysis is an indication for discontinuing Furadantin; hemolysis ceases when the drug is withdrawn.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Nitrofurantoin_02_14_19_FDA.pdf"">nitrofurantoin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452536804.0,"<p>Excerpt from the nitrofurantoin (Furadantin) drug label:</p>
<blockquote class=""blockquote"">
<p>Cases of hemolytic anemia of the primaquine-sensitivity type have been induced by nitrofurantoin. Hemolysis appears to be linked to a glucose-6-phosphate dehydrogenase deficiency in the red blood cells of the affected patients. This deficiency is found in 10 percent of Blacks and a small percentage of ethnic groups of Mediterranean and Near-Eastern origin. Hemolysis is an indication for discontinuing Furadantin; hemolysis ceases when the drug is withdrawn.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166169912,Annotation of FDA Label for enflurane,False,False,[],False,"[{'id': 1450821534, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1450964120, 'date': '2020-02-11T10:18:08.945-08:00', 'description': 'This is taken off the FDA biomarker list 02/05/2010', 'type': 'Update', 'version': 0}, {'id': 1452011283, 'date': '2023-02-16T20:46:38.217-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452312920, 'date': '2023-11-30T00:00:00-08:00', 'description': 'removed prescribing information and genes since the label doesn\'t include genes, level set to ""Criteria not met""', 'type': 'Update', 'version': 0}, {'id': 1452312960, 'date': '2023-11-30T17:44:05.854-08:00', 'description': 'added wording that enflurane is no longer commonly used.', 'type': 'Update', 'version': 0}, {'id': 1452691886, 'date': '2024-11-06T10:10:09.654-08:00', 'description': 'Enflurane is labeled as Discontinued on the FDA website, and no drug labels are available.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102059, 'title': 'Drugs@FDA: Drug Product enflurane (NDA017087)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017087', 'crossReferences': [{'id': 1449754580, 'resource': 'FDA Application', 'resourceId': 'NDA017087', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017087'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449461', 'name': 'enflurane'}]",[],FDA,1450361361.0,"<p>Enflurane (ETHRANE) is an inhalational anesthetic. The FDA-approved label warns that individuals with known or suspected genetic predisposition to malignant hyperthermia, or patients with Duchenne Muscular Dystrophy, are at greater risk of developing malignant hyperthermia, or hyperkaelemia, respectively.</p>
",1450361362.0,"<p>The enflurane drug label does not specifically mention genetic testing or genes, the FDA-approved label for enflurane contraindicates it for individuals with known, or suspected, genetic predisposition to malignant hyperthermia. Note that enflurane is no longer commonly used and is no longer listed in the FDA PGx biomarker table.</p>
<p>Excerpts from the enflurane (ETHRANE) drug label:</p>
<blockquote class=""blockquote"">
<p>CONTRAINDICATIONS...Known or suspected genetic susceptibility to malignant hyperthermia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In susceptible individuals, enflurane anesthesia may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable. Concomitant use of succinylcholine has been associated with most, but not all, of these cases.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Enflurane_08_30_17_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Enflurane_08_30_17_FDA.pdf"">enflurane drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,1451259820.0,Retirement Reason,[],Withdrawal,retirement:1451259820,True,Formerly on FDA Biomarker List
Label Annotation,PA166160672,Annotation of FDA Label for tamsulosin and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15102053, 'title': 'Drugs@FDA: Drug Product Flomax (tamsulosin hydrochloride), NDA020579, REMEDYREPACK INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020579', 'crossReferences': [{'id': 1449814391, 'resource': 'FDA Application', 'resourceId': 'NDA020579', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020579'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451583', 'name': 'tamsulosin'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1448265298.0,"<p>The FDA-approved drug label for tamsulosin (FLOMAX) states that it should be used with caution in CYP2D6 poor metabolizers, particularly at doses higher than 0.4 mg, due to the potential for a significant increase in exposure of the drug.</p>
",1448265297.0,"<p>Excerpts from the tamsulosin (FLOMAX) drug label:</p>
<div class=""blockquote"">
<p>Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6.</p>
</div>
<div class=""blockquote"">
<p>FLOMAX capsules should be used with caution...in patients known to be CYP2D6 poor metabolizers particularly at a dose higher than 0.4 mg (e.g., 0.8 mg).</p>
</div>
<div class=""blockquote"">
<p>The effects of paroxetine (a strong inhibitor of CYP2D6) at 20 mg once daily for 9 days on the pharmacokinetics of a single FLOMAX capsule 0.4 mg dose was investigated in 24 healthy volunteers (age range 23 to 47 years). Concomitant treatment with paroxetine resulted in an increase in the Cmax and AUC of tamsulosin by a factor of 1.3 and 1.6, respectively...A similar increase in exposure is expected in CYP2D6 poor metabolizers (PM) as compared to extensive metabolizers (EM). A fraction of the population (about 7% of Caucasians and 2% of African Americans) are CYP2D6 PMs. Since CYP2D6 PMs cannot be readily identified and the potential for significant increase in tamsulosin exposure exists when FLOMAX 0.4 mg is co-administered with strong CYP3A4 inhibitors in CYP2D6 PMs, FLOMAX 0.4 mg capsules should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole).</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tamsulosin_02_28_19_FDA.pdf"">tamsulosin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399731.0,"<p>Excerpt from the tamsulosin (FLOMAX) drug label:</p>
<blockquote class=""blockquote"">
<p>FLOMAX capsules should be used with caution...in patients known to be CYP2D6 poor metabolizers particularly at a dose higher than 0.4 mg (e.g., 0.8 mg).</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166105117,Annotation of FDA Label for efavirenz and CYP2B6,False,False,[],False,"[{'id': 1452531080, 'date': '2024-07-18T18:18:17.516-07:00', 'description': 'added updated label and updated text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160902, 'title': 'Drugs@FDA: Drug Product NDA020972/SUPPL-59, 11/08/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020972', 'crossReferences': [{'id': 1452531046, 'resource': 'FDA Application', 'resourceId': 'NDA020972/SUPPL-59', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020972'}], 'objCls': 'Literature', 'pubDate': '2023-11-08T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15101867, 'title': 'Drugs@FDA: Drug Product SUSTIVA (Efavirenz), NDA020972, Bristol-Myers Squibb Pharma Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020972', 'crossReferences': [{'id': 1449754541, 'resource': 'FDA Application', 'resourceId': 'NDA020972', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020972'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165818762', 'symbol': 'CYP2B6*6', 'name': '*6'}]","[{'objCls': 'Chemical', 'id': 'PA449441', 'name': 'efavirenz'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}]",FDA,1448604895.0,"<p>The FDA-approved drug label for efavirenz (SUSTIVA) states that efavirenz concentrations were higher in patients with the CYP2B6*6/*6 genotype as compared to the *1/*1 genotype, and that a positive relationship between increased efavirenz concentrations and QTc prologation has been observed. Some events of late-onset neurotoxicity have occurred in patients with CYP2B6 genetic polymorphisms which are associated with increased efavirenz levels despite standard dosing of SUSTIVA.</p>
",1448604894.0,"<p>Excerpts from the efavirenz (SUSTIVA) drug label:</p>
<blockquote class=""blockquote"">
<p>Some events of late-onset neurotoxicity have occurred in patients with CYP2B6 genetic polymorphisms which are associated with increased efavirenz levels despite standard dosing of SUSTIVA. Patients presenting with signs and symptoms of serious neurologic adverse experiences should be evaluated promptly to assess the possibility that these events may be related to efavirenz use, and whether discontinuation of SUSTIVA is warranted.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The effect of SUSTIVA on the QTc interval was evaluated in an open-label, positive and placebo controlled, fixed single sequence 3-period, 3-treatment crossover QT study in 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean Cmax of efavirenz in subjects with CYP2B6 *6/*6 genotype following the administration of 600 mg daily dose for 14 days was 2.25-fold the mean Cmax observed in subjects with CYP2B6 *1/*1 genotype. A positive relationship between efavirenz concentration and QTc prolongation was observed. Based on the concentration-QTc relationship, the mean QTc prolongation and its upper bound 90% confidence interval are 8.7 ms and 11.3 ms in subjects with CYP2B6*6/*6 genotype following the administration of 600 mg daily dose for 14 days.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The in vitro studies suggest that CYP3A and CYP2B6 are the major isozymes responsible for efavirenz metabolism.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Efavirenz_07_19_24_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Efavirenz_07_19_24_FDA.pdf"">efavirenz drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166177521,Annotation of FDA Label for umeclidinium and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15102034, 'title': 'Drugs@FDA: Drug Product Incruse Ellipta (umeclidinium), NDA205382, GlaxoSmithKline LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205382', 'crossReferences': [{'id': 1449890865, 'resource': 'FDA Application', 'resourceId': 'NDA205382', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205382'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177519', 'name': 'umeclidinium'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1449169984.0,"<p>Umeclidinium (INCRUSE ELLIPTA) is indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD). The label notes that there was no clinically meaningful difference in exposure to the drug between patients who were CYP2D6 poor metabolizers and those who were CYP2D6 intermediate, extensive and ultrarapid metabolizers.</p>
",1449169983.0,"<p>Excerpt from the umeclidinium (INCRUSE ELLIPTA) drug label:</p>
<blockquote class=""blockquote"">
<p>Umeclidinium and Cytochrome P450 2D6: In vitro metabolism of umeclidinium is mediated primarily by CYP2D6. However, no clinically meaningful difference in systemic exposure to umeclidinium (500 mcg) (8 times the approved dose) was observed following repeat daily inhaled dosing to normal (ultrarapid, extensive, and intermediate metabolizers) and CYP2D6 poor metabolizer subjects.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Umeclidinium_FDA_02_12_18.pdf"">umeclidinium drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182747,Annotation of FDA Label for lorlatinib and ROS1,False,True,[],False,"[{'id': 1452318060, 'date': '2023-12-05T05:48:24.842-08:00', 'description': 'Updated label, label source and third quote.', 'type': 'Update', 'version': 0}, {'id': 1452543008, 'date': '2024-07-30T11:08:03.257-07:00', 'description': 'fixed typo', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102382, 'title': 'Drugs@FDA: Drug Product Lorbrena (lorlatinib), NDA210868, Pfizer Laboratories Div Pfizer Inc', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210868', 'crossReferences': [{'id': 1452318062, 'resource': 'FDA Application', 'resourceId': 'NDA210868/SUPPL-4', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210868'}], 'objCls': 'Literature', 'pubDate': '2021-03-03T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182743', 'name': 'lorlatinib'}]","[{'objCls': 'Gene', 'id': 'PA34633', 'symbol': 'ROS1', 'name': 'ROS proto-oncogene 1, receptor tyrosine kinase'}]",FDA,1450400556.0,"<p>The FDA-approved drug label for lorlatinib (LORBRENA) states that it is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Lorlatinib has in vitro activity against ALK and ROS1 and adverse reactions observed in clinical trials consist of patients with ALK-positive or ROS1-positive metastatic NSCLC who received LORBRENA.</p>
",1450400557.0,"<p>Excerpts from the lorlatinib (LORBRENA) FDA label:</p>
<blockquote class=""blockquote"">
<p>LORBRENA® is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on: crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Lorlatinib is a kinase inhibitor with in vitro activity against ALK and ROS1 as well as TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, and ACK. Lorlatinib demonstrated in vitro activity against multiple mutant forms of the ALK enzyme, including some mutations detected in tumors at the time of disease progression on crizotinib and other ALK inhibitors.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Previously Treated ALK-Positive Metastatic NSCLC
The data described below reflect exposure to LORBRENA in 295 patients with ALK-positive or ROS1-positive metastatic NSCLC who received LORBRENA 100 mg orally once daily in Study B7461001, a multi-cohort, non-comparative trial (see Clinical Studies 14). The median duration of exposure to LORBRENA was
12.5 months (1 day to 35 months) and 52% received LORBRENA for ≥12 months. Patient characteristics were: median age of 53 years (19 to 85 years), age ≥65 years (18%), female (58%), White (49%), Asian (37%), and ECOG performance status 0 or 1 (96%).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Loratinib_FDA_2023_12_04.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Loratinib_FDA_2023_12_04.pdf"">lorlatinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104847,Annotation of FDA Label for venlafaxine and CYP2D6,False,False,[],False,"[{'id': 1183681253, 'date': '2013-10-25T11:01:36.606-07:00', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102302, 'title': 'Effexor XR Extended-Release (venlafaxine hydrochloride), NDA020699, Aphena Pharma Solutions - Tennessee, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020699', 'crossReferences': [{'id': 1450370391, 'resource': 'FDA Application', 'resourceId': 'NDA020699', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020699'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451866', 'name': 'venlafaxine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447981666.0,"<p>The FDA-approved drug label for venlafaxine (Effexor XR) states that CYP2D6 poor metabolizers had increased levels of venlafaxine as compared to CYP2D6 extensive metabolizers.</p>
",1447981665.0,"<p>Excerpt from the Venlafaxine (Effexor XR) drug label:</p>
<div class=""blockquote"">
<p>In vitro studies indicate that the formation of ODV is catalyzed by CYP2D6; this has been confirmed in a clinical study showing that patients with low CYP2D6 levels (poor metabolizers) had increased levels of venlafaxine and reduced levels of ODV compared to people with normal CYP2D6 levels (extensive metabolizers).</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Venlafaxine_03_01_19_FDA.pdf"">venlafaxine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166160007,Annotation of FDA Label for lesinurad and CYP2C9,False,False,[],False,"[{'id': 1452694380, 'date': '2024-11-08T11:58:16.093-08:00', 'description': 'added notice of drug discontinuation', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101935, 'title': 'Drugs@FDA: Drug Product Zurampic (lesinurad), NDA207988, Ironwood Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207988', 'crossReferences': [{'id': 1449754848, 'resource': 'FDA Application', 'resourceId': 'NDA207988', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207988'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166160006', 'name': 'lesinurad'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1448257045.0,"<p>The FDA-approved drug label for lesinurad (ZURAMPIC) states that exposure to the drug is increased in CYP2C9 poor metabolizers, and that caution should be used in these patients.</p>
<p><strong>November 2024: Please note that lesinurad is listed as discontinued by the FDA. However, this drug is still listed on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
",1448257044.0,"<p>Lesinurad (ZURAMPIC) is indicated for the treatment of hyperuricemia associated with gout.</p>
<p>Excerpts from the lesinurad (ZURAMPIC) drug label:</p>
<blockquote class=""blockquote"">
<p>Lesinurad exposure is increased when ZURAMPIC is co-administered with inhibitors of CYP2C9, and in CYP2C9 poor metabolizers. ZURAMPIC should be used with caution in patients taking moderate inhibitors of CYP2C9 (eg, fluconazole, amiodarone), and in CYP2C9 poor metabolizers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A cross-study pharmacogenomic analysis assessed the association between CYP2C9 polymorphism and lesinurad exposure in patients receiving single or multiple doses of lesinurad at 200 mg, 400 mg or 600 mg. At the 400 mg dose, ZURAMPIC exposure was approximately 1.8-fold higher in CYP2C9 poor metabolizers (i.e., subjects with CYP2C9 *2/*2 (N=1), and *3/*3 (N=1) genotype) compared to CYP2C9 extensive metabolizers (i.e., CYP2C9 *1/*1 (N=41) genotype).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Lesinurad_08_03_2017_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lesinurad_08_03_2017_FDA.pdf"">lesinurad drug label</a>.</p>
<p><strong>November 2024: Please note that lesinurad is listed as discontinued by the FDA. However, this drug is still listed on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399704.0,"<p>Excerpt from the lesinurad (ZURAMPIC) drug label:</p>
<blockquote class=""blockquote"">
<p>ZURAMPIC should be used with caution in patients taking moderate inhibitors of CYP2C9 (eg, fluconazole, amiodarone), and in CYP2C9 poor metabolizers.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166185156,Annotation of FDA Label for mivacurium and BCHE,True,False,[],False,"[{'id': 1451941120, 'date': '2022-11-15T11:27:15.253-08:00', 'description': 'Moved tag from mivacurium chloride to mivacurium as redundant drug pages are consolidated.', 'type': 'Update', 'version': 0}, {'id': 1452539265, 'date': '2024-07-25T11:44:07.064-07:00', 'description': 'added note on drug discontinuation', 'type': 'Update', 'version': 0}, {'id': 1452556482, 'date': '2024-08-14T15:59:58.297-07:00', 'description': 'added Alternate Drug, Other Guidance tags', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103444, 'title': 'Drugs@FDA: Drug Product MIVACRON (mivacurium), NDA020098/SUPPL-19, 07/26/2018', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020098', 'crossReferences': [{'id': 1452539264, 'resource': 'FDA Application', 'resourceId': 'NDA020098/SUPPL-19', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020098'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'pubDate': '2018-07-26T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA25294', 'symbol': 'BCHE', 'name': 'butyrylcholinesterase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450528', 'name': 'mivacurium'}]","[{'objCls': 'Gene', 'id': 'PA25294', 'symbol': 'BCHE', 'name': 'butyrylcholinesterase'}]",FDA,1450826618.0,"<p>The FDA drug label for mivacurium chloride (MIVACRON) states that MIVACRON should be used with great caution, if at all, in patients known or suspected of being homozygous for the atypical plasma cholinesterase gene (BCHE), due to risk of prolonged neuromuscular block following administration of MIVACRON.</p>
<p><strong>July 2024: Please note that mivacurium chloride is listed as discontinued by the FDA. However, this drug is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
",1450826619.0,"<p>Excerpts from the mivacurium chloride (MIVACRON) drug label:</p>
<blockquote class=""blockquote"">
<p>Precautions:</p>
<p>Reduced Plasma Cholinesterase Activity.
The possibility of prolonged neuromuscular block following administration of MIVACRON must be considered in patients with reduced plasma cholinesterase (pseudocholinesterase) activity. MIVACRON should be used with great caution, if at all, in patients known or suspected of being homozygous for the atypical plasma cholinesterase gene (see WARNINGS). Doses of 0.03 mg/kg produced complete neuromuscular block for 26 to 128 minutes in three such patients; thus initial doses greater than 0.03 mg/kg are not recommended in homozygous patients.
Infusions of MIVACRON are not recommended in homozygous patients.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>MIVACRON has been used safely in patients heterozygous for the atypical plasma cholinesterase gene and in genotypically normal patients with reduced plasma cholinesterase activity. After an initial dose of 0.15 mg/kg MIVACRON, the clinically effective duration of block in heterozygous patients may be approximately 10 minutes longer than in patients with normal genotype and normal plasma cholinesterase activity. Lower infusion rates of MIVACRON are recommended in these patients (see PRECAUTIONS - Reduced Plasma
Cholinesterase Activity).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Metabolism: Enzymatic hydrolysis by plasma cholinesterase is the primary mechanism for inactivation of mivacurium and yields a quaternary alcohol and a quaternary monoester metabolite. Tests in which these two metabolites were administered to cats and dogs suggest that each metabolite is unlikely to produce clinically significant neuromuscular, autonomic, or cardiovascular effects following administration of MIVACRON.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""mivacurium_11_01_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/mivacurium_11_01_19_FDA.pdf"">mivacurium drug label</a>.</p>
<p><strong>July 2024: Please note that mivacurium chloride is listed as discontinued by the FDA. However, this drug is still on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. PharmGKB has therefore decided to keep this annotation active until the drug is removed from the FDA Biomarker table.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450826620.0,"<p>Excerpts from the mivacurium chloride (MIVACRON) drug label:</p>
<blockquote class=""blockquote"">
<p>Precautions:</p>
<p>Reduced Plasma Cholinesterase Activity.
The possibility of prolonged neuromuscular block following administration of MIVACRON must be considered in patients with reduced plasma cholinesterase (pseudocholinesterase) activity. MIVACRON should be used with great caution, if at all, in patients known or suspected of being homozygous for the atypical plasma cholinesterase gene (see WARNINGS). Doses of 0.03 mg/kg produced complete neuromuscular block for 26 to 128 minutes in three such patients; thus initial doses greater than 0.03 mg/kg are not recommended in homozygous patients.
Infusions of MIVACRON are not recommended in homozygous patients.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>MIVACRON has been used safely in patients heterozygous for the atypical plasma cholinesterase gene and in genotypically normal patients with reduced plasma cholinesterase activity. After an initial dose of 0.15 mg/kg MIVACRON, the clinically effective duration of block in heterozygous patients may be approximately 10 minutes longer than in patients with normal genotype and normal plasma cholinesterase activity. Lower infusion rates of MIVACRON are recommended in these patients (see PRECAUTIONS - Reduced Plasma
Cholinesterase Activity).</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104897,Annotation of FDA Label for moviprep and G6PD,False,False,[],False,"[{'id': 1183681265, 'date': '2013-10-25T11:03:55.059-07:00', 'type': 'Update', 'version': 0}, {'id': 1183704779, 'date': '2013-12-18T00:00:00-08:00', 'type': 'Update', 'version': 0}, {'id': 1452583320, 'date': '2024-09-09T16:56:22.741-07:00', 'description': 'added FDA Biomarker List label back (listed under the ingredient combination: Ascorbic Acid, PEG-3350, Potassium Chloride, Sodium Ascorbate, Sodium Chloride, and Sodium Sulfate)', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101922, 'title': 'Drugs@FDA: Drug Product MoviPrep (POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, ASCORBIC ACID, SODIUM ASCORBATE), NDA021881, Salix Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021881', 'crossReferences': [{'id': 1449762627, 'resource': 'FDA Application', 'resourceId': 'NDA021881', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021881'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166163260', 'name': 'moviprep'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981771.0,"<p>MoviPrep, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy.  Because it contains Vitamin C (ascorbic acid), the label warns that hemolytic reactions are possible in those with G6PD deficiency.</p>
",1447981770.0,"<p>Although the MoviPrep (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, ascorbic acid, sodium ascorbate) drug label does not specifically mention genetic testing, the FDA highlight information regarding G6PD deficient individuals within the <em>Warnings and Precautions</em> section.</p>
<p>Excerpt from the MoviPrep drug label:</p>
<div class=""blockquote"">
<p><strong>Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.</strong> Since MoviPrep contains sodium ascorbate and ascorbic acid, MoviPrep should be used with caution in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency, especially G-6-PD deficiency patients with an active infection, with a history of hemolysis, or taking concomitant medications known to precipitate hemolytic reactions.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Moviprep_08_10_2017_FDA.pdf"">moviprep drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399710.0,"<p>Excerpt from the MoviPrep drug label:</p>
<blockquote class=""blockquote"">
<p>Since MoviPrep contains sodium ascorbate and ascorbic acid, MoviPrep should be used with caution in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency, especially G-6-PD deficiency patients with an active infection, with a history of hemolysis, or taking concomitant medications known to precipitate hemolytic reactions.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166224341,"Annotation of FDA Label for encorafenib and HRAS, KRAS, NRAS",True,True,[],False,"[{'id': 1452011282, 'date': '2023-02-16T20:45:44.996-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452281205, 'date': '2023-10-25T11:28:11.052-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}, {'id': 1452556340, 'date': '2024-08-14T13:34:56.545-07:00', 'description': 'added Alternate Drug tag', 'type': 'Update', 'version': 0}, {'id': 1452817333, 'date': '2025-01-17T15:42:40.004-08:00', 'description': 'added Other Guidance tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101845, 'title': 'Drugs@FDA: Drug Product BRAFTOVI (Encorafenib), NDA210496, Array BioPharma Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496', 'crossReferences': [{'id': 1449754577, 'resource': 'FDA Application', 'resourceId': 'NDA210496', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166179872', 'name': 'encorafenib'}]","[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",FDA,1451271180.0,"<p>The FDA-approved drug label for encorafenib (BRAFTOVI) states that BRAFTOVI may promote malignancies associated with activation of RAS through mutation or other mechanisms. FDA recommends monitor patients receiving BRAFTOVI for signs and symptoms of non-cutaneous malignancies and discontinue BRAFTOVI for RAS mutation-positive non-cutaneous malignancies.</p>
",1451271181.0,"<p>Excerpts from the encorafenib (BRAFTOVI) drug label:</p>
<blockquote class=""blockquote"">
<p>Dosage and Administration (2.5)</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Table 3: Recommended Dosage Modifications for BRAFTOVI for Adverse Reactions:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Non-Cutaneous RAS Mutation-positive Malignancies,  Permanently discontinue BRAFTOVI.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Warnings and precautions:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Non-Cutaneous Malignancies
Based on its mechanism of action, BRAFTOVI may promote malignancies associated with activation of RAS through mutation or other mechanisms (see Warnings and Precautions (5.2)). Monitor patients receiving BRAFTOVI for signs and symptoms of non-cutaneous malignancies. Discontinue BRAFTOVI for RAS mutation-positive non-cutaneous malignancies (see Dosage and Administration (2.5)).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""encorafenib_FDA_10252023.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/encorafenib_FDA_10252023.pdf"">encorafenib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451271182.0,"<p>Excerpt from the encorafenib (BRAFTOVI) drug label:</p>
<blockquote class=""blockquote"">
<p>Based on its mechanism of action, BRAFTOVI may promote malignancies associated with activation of RAS through mutation or other mechanisms [...]. Monitor patients receiving BRAFTOVI for signs and symptoms of non-cutaneous malignancies. Discontinue BRAFTOVI for RAS mutation-positive non-cutaneous malignancies .</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166160049,Annotation of FDA Label for lacosamide and CYP2C19,False,False,[],False,"[{'id': 1452824061, 'date': '2025-01-24T09:56:34.721-08:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102052, 'title': 'Drugs@FDA: Drug Product Vimpat (lacosamide), UCB, Inc. - NDA022253/SUPPL-41, 01/09/2019', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022253', 'crossReferences': [{'id': 1452694201, 'resource': 'FDA Application', 'resourceId': 'NDA022253/SUPPL-41', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022253'}], 'objCls': 'Literature', 'pubDate': '2019-01-09T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166160048', 'name': 'lacosamide'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1448257435.0,"<p>The FDA-approved drug label for lacosamide (VIMPAT) states that plasma concentrations of the lacosamide O-desmethyl metabolite were reduced by approximately 70% in CYP2C19 poor metabolizers (PMs) as compared to extensive metabolizers (EMs), but that there are no clinically relevant differences in lacosamide pharmacokinetics between PMs and EMs.</p>
",1448257434.0,"<p>Lacosamide is indicated for patients with partial-onset seizures.</p>
<p>Excerpts from the lacosamide (VIMPAT) drug label:</p>
<div class=""blockquote"">
<p>The CYP isoforms mainly responsible for the formation of the major metabolite (O-desmethyl) are CYP3A4, CYP2C9, and CYP2C19.</p>
</div>
<div class=""blockquote"">
<p>There are no clinically relevant differences in the pharmacokinetics of lacosamide between CYP2C19 poor metabolizers and extensive metabolizers. Results from a trial in poor metabolizers (PM) (N=4) and extensive metabolizers (EM) (N=8) of cytochrome P450 (CYP) 2C19 showed that lacosamide plasma concentrations were similar in PMs and EMs, but plasma concentrations and the amount excreted into urine of the O-desmethyl metabolite were about 70% reduced in PMs compared to EMs.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Lacosamide_02_06_19_FDA.pdf"">lacosamide drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452824060.0,"<blockquote class=""blockquote"">
<p>VIMPAT is indicated for the treatment of partial-onset seizures inpatients 4 years of age and older.</p>
</blockquote>
",1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166151882,Annotation of FDA Label for carbamazepine and HLA-A,False,False,[],False,"[{'id': 1447952369, 'date': '2016-03-21T14:12:01.787-07:00', 'type': 'Update', 'version': 0}, {'id': 1452264040, 'date': '2023-10-05T14:59:17.858-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}, {'id': 1452264061, 'date': '2023-10-05T15:04:31.501-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101913, 'title': 'Drugs@FDA: Drug Product Tegretol (carbamazepine), NDA016608, REMEDYREPACK INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016608', 'crossReferences': [{'id': 1449894948, 'resource': 'FDA Application', 'resourceId': 'NDA016608', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016608'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA35055', 'symbol': 'HLA-A', 'name': 'major histocompatibility complex, class I, A'}]","[{'objCls': 'Haplotype', 'id': 'PA165954030', 'symbol': 'HLA-A*31:01', 'name': '*31:01'}]","[{'objCls': 'Chemical', 'id': 'PA448785', 'name': 'carbamazepine'}]","[{'objCls': 'Gene', 'id': 'PA35055', 'symbol': 'HLA-A', 'name': 'major histocompatibility complex, class I, A'}]",FDA,1450342366.0,"<p>The FDA-approved label for carbamazepine (TEGRETOL) states that a moderate association has been found between HLA-A*3101 and the risk of developing hypersensitivity reactions to carbamazepine, and the risks and benefits of Tegretol therapy should be weighed before considering Tegretol in patients known to be positive for HLA-A*3101. The label also states that screening of patients with ancestry in genetically at-risk populations (patients of Asian descent) for the presence of the HLA-B*1502 allele should be carried out prior to treatment due to a high risk of serious and possibly fatal dermatologic reactions.</p>
",1450342367.0,"<p>Excerpt from the carbamazepine (TEGRETOL) drug label:</p>
<blockquote class=""blockquote"">
<p>Hypersensitivity Reactions and HLA-A*3101 Allele</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Retrospective case-control studies in patients of European, Korean, and Japanese ancestry have found a moderate association between the risk of developing hypersensitivity reactions and the presence of HLAA*3101, an inherited allelic variant of the HLA-A gene, in patients using carbamazepine. These hypersensitivity reactions include SJS/TEN, maculopapular eruptions, and Drug Reaction with Eosinophilia and Systemic Symptoms (see DRESS/Multiorgan hypersensitivity below).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>HLA-A*3101 is expected to be carried by more than 15% of patients of Japanese, Native American, Southern Indian (for example, Tamil Nadu), and some Arabic ancestry; up to about 10% in patients of Han Chinese, Korean, European, Latin American, and other Indian ancestry; and up to about 5% in African-Americans and patients of Thai, Taiwanese, and Chinese (Hong Kong) ancestry.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The risks and benefits of Tegretol therapy should be weighed before considering Tegretol in patients known to be positive for HLA-A*3101.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Application of HLA genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management. Many HLA-B*1502-positive and HLA-A*3101-positive patients treated with Tegretol will not develop SJS/TEN or other hypersensitivity reactions, and these reactions can still occur infrequently in HLA-B*1502-negative and HLA-A*3101-negative patients of any ethnicity. The role of other possible factors in the development of, and morbidity from, SJS/TEN and other hypersensitivity reactions, such as antiepileptic drug (AED) dose, compliance, concomitant medications, comorbidities, and the level of dermatologic monitoring, have not been studied.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""carbamazepine_FDA_20231005.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/carbamazepine_FDA_20231005.pdf"">carbamazepine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452264060.0,"<blockquote class=""blockquote"">
<p>The risks and benefits of Tegretol therapy should be weighed before considering Tegretol in patients known to be positive for HLA-A*3101.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Retrospective case-control studies in patients of European, Korean, and Japanese ancestry have found a moderate association between the risk of developing hypersensitivity reactions and the presence of HLA-A*3101, an inherited allelic variant of the HLA-A gene, in patients using carbamazepine. These hypersensitivity reactions include SJS/TEN, maculopapular eruptions, and Drug Reaction with Eosinophilia and Systemic Symptoms (see DRESS/Multiorgan hypersensitivity below).</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166170934,"Annotation of FDA Label for primaquine and CYB5R1, CYB5R2, CYB5R3, CYB5R4",False,False,[],False,"[{'id': 1452538161, 'date': '2024-07-24T23:07:41.404-07:00', 'description': 'Added Prescribing section and tags', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101840, 'title': 'Drugs@FDA: Drug Product Primaquine Phosphate (Primaquine Phosphate), NDA008316, PD-Rx Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008316', 'crossReferences': [{'id': 1449776486, 'resource': 'FDA Application', 'resourceId': 'NDA008316', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008316'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA134979668', 'symbol': 'CYB5R1', 'name': 'cytochrome b5 reductase 1'}, {'objCls': 'Gene', 'id': 'PA142672060', 'symbol': 'CYB5R2', 'name': 'cytochrome b5 reductase 2'}, {'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA134904907', 'symbol': 'CYB5R4', 'name': 'cytochrome b5 reductase 4'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451103', 'name': 'primaquine'}]","[{'objCls': 'Gene', 'id': 'PA134979668', 'symbol': 'CYB5R1', 'name': 'cytochrome b5 reductase 1'}, {'objCls': 'Gene', 'id': 'PA142672060', 'symbol': 'CYB5R2', 'name': 'cytochrome b5 reductase 2'}, {'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA134904907', 'symbol': 'CYB5R4', 'name': 'cytochrome b5 reductase 4'}]",FDA,1449051093.0,"<p>The FDA-approved drug label for primaquine states that G6PD testing has to be performed before using the drug, and that it should not be prescribed for patients with severe G6PD deficiency. The label also notes that individuals with a family or personal history of nicotinamide adenine dinucleotide (NADH) methemoglobin reductase (<em>CYB5R1-4</em>) deficiency should be observed closely.</p>
",1449051091.0,"<p>Primaquine is indicated for the radical cure (prevention of relapse) of vivax malaria. Excerpt from the primaquine drug label:</p>
<div class=""blockquote"">
<p>...an individual with a family or personal history of hemolytic anemia or nicotinamide adenine dinucleotide (NADH) methemoglobin reductase deficiency, the person should be observed closely.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Primaquine_08_16_2017_FDA.pdf"">primaquine drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452538160.0,"<p>Excerpt from the primaquine drug label:</p>
<blockquote class=""blockquote"">
<p>...an individual with a family or personal history of hemolytic anemia or nicotinamide adenine dinucleotide (NADH) methemoglobin reductase deficiency, the person should be observed closely.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166122970,"Annotation of FDA Label for succinylcholine and BCHE, CACNA1S, RYR1",True,False,[],False,"[{'id': 1452011314, 'date': '2023-02-16T20:59:08.558-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}, {'id': 1452055860, 'date': '2023-04-01T20:34:46.580-07:00', 'description': 'updated text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101932, 'title': 'Drugs@FDA: Drug Product Anectine (Succinylcholine Chloride), NDA008453, Sandoz Inc', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008453', 'crossReferences': [{'id': 1449790301, 'resource': 'FDA Application', 'resourceId': 'NDA008453', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008453'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA25294', 'symbol': 'BCHE', 'name': 'butyrylcholinesterase'}, {'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451522', 'name': 'succinylcholine'}]","[{'objCls': 'Gene', 'id': 'PA25294', 'symbol': 'BCHE', 'name': 'butyrylcholinesterase'}, {'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",FDA,1447982091.0,"<p>Succinylcholine (QUELICIN) is rapid acting, depolarizing skeletal muscle relaxant indicated as an adjunct to general anesthesia. The label warns that individuals who are carriers of the atypical variant of the plasma cholinesterase gene (<em>BCHE</em>) are at risk of prolonged apnea if administered succinylcholine. The label also notes the risk for malignant hyperthermia.</p>
",1447982090.0,"<p>Specific variants in the <em>RYR1</em> and <em>CACNA1S</em> genes are associated with risk of malignant hyperthermia in individuals administered succinylcholine.</p>
<p>Excerpts from the succinylcholine chloride (QUELICIN) drug label:</p>
<blockquote class=""blockquote"">
<p>Succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies, and known hypersensitivity to the drug.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>WARNINGS...Succinylcholine is metabolized by plasma cholinesterase and should be used with caution, if at all, in patients known to be or suspected of being homozygous for the atypical plasma cholinesterase gene.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients homozygous for atypical plasma cholinesterase gene (1 in 2500 patients) are extremely sensitive to the neuromuscular blocking effect of succinylcholine. In these patients, a 5- to 10-mg test dose of succinylcholine may be administered to evaluate sensitivity to succinylcholine, or neuromuscular blockade may be produced by the cautious administration of a 1-mg/mL solution of succinylcholine by slow IV infusion. Apnea or prolonged muscle paralysis should be treated with controlled respiration.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The risk of developing malignant hyperthermia increases with the concomitant administration of succinylcholine and volatile anesthetic agents. Anectine can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacogenomics: RYR1 and CACNA1S are polymorphic genes, and multiple pathogenic variants have been associated with malignant hyperthermia susceptibility (MHS) in patients receiving succinylcholine, including Anectine. Case reports as well as ex-vivo studies have identified multiple variants in RYR1 and CACNA1S associated with MHS. Variant pathogenicity should be assessed based on prior clinical experience, functional studies, prevalence information, or other evidence.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Succinylcholine_20230402_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Succinylcholine_20230402_FDA.pdf"">succinylcholine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399729.0,"<p>Excerpts from the succinylcholine chloride (QUELICIN) drug label:</p>
<blockquote class=""blockquote"">
<p>Succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies, and known hypersensitivity to the drug.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Succinylcholine is metabolized by plasma cholinesterase and should be used with caution, if at all, in patients known to be or suspected of being homozygous for the atypical plasma cholinesterase gene.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166105211,Annotation of FDA Label for ondansetron and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15102049, 'title': 'Drugs@FDA: Drug Product ZOFRAN (ondansetron hydrochloride), NDA020103, Novartis Pharmaceuticals Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020103', 'crossReferences': [{'id': 1449767741, 'resource': 'FDA Application', 'resourceId': 'NDA020103', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020103'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450705', 'name': 'ondansetron'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1448605005.0,"<p>The FDA-approved drug label for ondansetron (ZOFRAN) states that the drug is a substrate for CYP2D6 (among other CYP enzymes), but is likely that CYP2D6 genetic deficiency will result in little change in the rate of ondansetron elimination.</p>
",1448605004.0,"<p>Excerpts from the ondansetron (ZOFRAN) drug label:</p>
<div class=""blockquote"">
<p>In vitro metabolism studies have shown that ondansetron is a substrate for human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4. In terms of overall ondansetron turnover, CYP3A4 played the predominant role. Because of the multiplicity of metabolic enzymes capable of metabolizing ondansetron, it is likely that inhibition or loss of one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by others and may result in little change in overall rates of ondansetron elimination.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Ondansetron_02_19_19_FDA.pdf"">ondansetron drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166115362,"Annotation of FDA Label for sodium nitrite and CYB5R3, G6PD",True,False,[],False,"[{'id': 1183704711, 'date': '2014-01-14T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1450821517, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1450823003, 'date': '2019-10-16T08:05:14.579-07:00', 'description': 'Added link and text about CYB5R3 and congenital methemoglobinemia. Updated to new label.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101872, 'title': 'Drugs@FDA: Drug Product Sodium Nitrite (Sodium Nitrite), NDA203922, Hope Pharmaceuticals', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203922', 'crossReferences': [{'id': 1449776665, 'resource': 'FDA Application', 'resourceId': 'NDA203922', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203922'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166115361', 'name': 'sodium nitrite'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447982117.0,"<p>Sodium nitrite is intended for sequential use with sodium thiosulfate, in order to treat acute and life-threatening cyanide poisoning. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency who are treated with sodium nitrite are at risk for a hemolytic crisis. Consideration should also be given for patients at increased risk for methemoglobinemia such as those with variants in CYB5R3.</p>
",1447982116.0,"<p>Excerpts from the sodium nitrite drug label:</p>
<div class=""blockquote"">
<p>Because patients with G6PD deficiency are at increased risk of a hemolytic crisis with sodium nitrite administration, alternative therapeutic approaches should be considered in these patients. Patients with known or suspected G6PD deficiency should be monitored for an acute drop in hematocrit. Exchange transfusion may be needed for patients with G6PD deficiency who receive sodium nitrite.</p>
</div>
<div class=""blockquote"">
<p>special consideration should be given to administration of sodium nitrite if the patient is known or suspected to have diminished oxygen or cardiovascular reserve (e.g., smoke inhalation victims, pre-existing anemia, substantial blood loss, cardiac or respiratory compromise) or to be at higher risk of developing methemoglobinemia (e.g., congenital methemoglobin reductase deficiency).</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/sodium_nitrite_10_15_2019FDA.pdf"">sodium nitrite drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399728.0,"<p>Excerpt from the sodium nitrite drug label:</p>
<blockquote class=""blockquote"">
<p>Because patients with G6PD deficiency are at increased risk of a hemolytic crisis with sodium nitrite administration, alternative therapeutic approaches should be considered in these patients.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166179848,Annotation of FDA Label for lofexidine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15101910, 'title': 'Drugs@FDA: Drug Product Lucemyra (lofexidine hydrochloride), NDA209229, US WorldMeds, LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209229', 'crossReferences': [{'id': 1449754861, 'resource': 'FDA Application', 'resourceId': 'NDA209229', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209229'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164744510', 'name': 'lofexidine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1449713902.0,"<p>The FDA-approved drug label for lofexidine (LUCEMYRA) states that although the pharmacokinetics of the drug have not been systematically evaluated in patients who do not express CYP2D6, it is likely that exposure to the drug would be increased in these patients.</p>
",1449713901.0,"<p>Lofexidine is indicated for mitigation of opioid withdrawal symptoms.</p>
<p>Excerpts from the lofexidine (LUCEMYRA) drug label:</p>
<div class=""blockquote"">
<p>Although the pharmacokinetics of LUCEMYRA have not been systematically evaluated in patients who do not express the drug metabolizing enzyme CYP2D6, it is likely that the exposure to LUCEMYRA would be increased similarly to taking strong CYP2D6 inhibitors (approximately 28%). Monitor adverse events such as orthostatic hypotension and bradycardia in known CYP2D6 poor metabolizers. Approximately 8% of Caucasians and 3–8% of Black/African Americans cannot metabolize CYP2D6 substrates and are classified as poor metabolizers (PM).</p>
</div>
<div class=""blockquote"">
<p>...the major contributor to the hepatic metabolism of LUCEMYRA is CYP2D6, with CYP1A2 and CYP2C19 also capable of metabolizing LUCEMYRA.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Lofexidine_08_08_18_FDA.pdf"">lofexidine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451139262.0,"<p>Excerpts from the lofexidine (LUCEMYRA) drug label:</p>
<blockquote class=""blockquote"">
<p>Monitor adverse events such as orthostatic hypotension and bradycardia in known CYP2D6 poor metabolizers.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166105147,Annotation of FDA Label for glimepiride and G6PD,True,False,[],False,"[{'id': 1183704746, 'date': '2013-12-17T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1452216548, 'date': '2023-08-25T00:00:00-07:00', 'description': 'Added ""Alternate Drug"" tab based on updated definition', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101926, 'title': 'Drugs@FDA: Drug Product AMARYL (glimepiride), NDA020496, Sanofi-Aventis U.S. LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020496', 'crossReferences': [{'id': 1449754736, 'resource': 'FDA Application', 'resourceId': 'NDA020496', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020496'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449761', 'name': 'glimepiride'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981912.0,"<p>The FDA-approved drug label for glimepiride (AMARYL) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the <em>G6PD</em> gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.</p>
",1447981911.0,"<p>Glimepiride (AMARYL) is a blood-glucose-lowering drug indicated for use in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.</p>
<p>Excerpt from the glimepiride (AMARYL) drug label:</p>
<div class=""blockquote"">
<p>Hemolytic Anemia: Sulfonylureas can cause hemolytic anemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. Because AMARYL is a sulfonylurea, use caution in patients with G6PD deficiency and consider the use of a non-sulfonylurea alternative.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Glimepiride_01_25_19_FDA.pdf"">glimepiride drug label</a>.</p>
<p>*Disclaimer: The contents of this page are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399553.0,"<p>Excerpt from the glimepiride (AMARYL) drug label:</p>
<blockquote class=""blockquote"">
<p>Because AMARYL is a sulfonylurea, use caution in patients with G6PD deficiency and consider the use of a non-sulfonylurea alternative.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166184637,"Annotation of FDA Label for oxymetazoline and tetracaine and BCHE, CYB5R3, G6PD",False,False,[],False,"[{'id': 1450822455, 'date': '2019-10-15T08:53:58.838-07:00', 'description': 'Added link and text about CYB5R3 and congenital methemoglobinemia.', 'type': 'Update', 'version': 0}, {'id': 1450824517, 'date': '2019-10-24T07:21:56.655-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15148582, 'title': 'Drugs@FDA: Drug Product oxymetazoline and tetracaine (NDA208032)', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208032', 'crossReferences': [{'id': 1452242620, 'resource': 'FDA Application', 'resourceId': 'NDA208032', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208032'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA25294', 'symbol': 'BCHE', 'name': 'butyrylcholinesterase'}, {'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166182885', 'name': 'oxymetazoline and tetracaine'}]","[{'objCls': 'Gene', 'id': 'PA25294', 'symbol': 'BCHE', 'name': 'butyrylcholinesterase'}, {'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450821526.0,"<p>The FDA-approved drug label for Oxymetazoline and Tetracaine (KOVANAZE) states that patients with G6PD deficiency or congenital methemoglobinemia may be at increased risk for methemoglobinemia when treated with this drug. There is also a warning for pseudocholinesterase deficiency (BCHE) and risk for toxicity which is not listed on the FDA biomarker table.</p>
",1450821527.0,"<p>Excerpts from the Oxymetazoline and Tetracaine (KOVANAZE) FDA drug label:</p>
<blockquote class=""blockquote"">
<p>Methemoglobinemia</p>
<p>Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients
are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or
idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and
concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical
manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for
symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pseudocholinesterase Deficiency</p>
<p>Because of an inability to metabolize local anesthetics, those patients with pseudocholinesterase deficiency may
be at a greater risk of developing toxic plasma concentrations of tetracaine. Monitor patients with
pseudocholinesterase deficiency for signs of local anesthetic toxicity.</p>
</blockquote>
<p>NOTE: While the CYB5R3 gene is not explicitly stated in the drug label variants in this gene are associated with congenital methemoglobinemia I and II <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/250800"" target=""_blank"">OMIM 250800</a>:</p>
<p>NOTE: While the BCHE gene is not explicitly stated in the drug label there is a warning for pseudocholinesterase deficiency which is associated with variants in BCHE.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/OxymetazolineTetracaine_10_10_2019FDA.pdf"">Kovanaze drug label</a>.</p>
<p>*Disclaimer: The contents of this page are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450824516.0,"<p>Excerpts from the Oxymetazoline and Tetracaine (KOVANAZE) FDA drug label:</p>
<blockquote class=""blockquote"">
<p>Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia ... are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Because of an inability to metabolize local anesthetics, those patients with pseudocholinesterase deficiency may
be at a greater risk of developing toxic plasma concentrations of tetracaine. Monitor patients with
pseudocholinesterase deficiency for signs of local anesthetic toxicity.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104852,Annotation of FDA Label for citalopram and CYP2C19,False,False,[],True,"[{'id': 1183681203, 'date': '2013-10-25T10:42:48.988-07:00', 'type': 'Update', 'version': 0}, {'id': 1450380200, 'date': '2019-04-16T18:02:18.344-07:00', 'description': 'added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1451267700, 'date': '2020-09-22T14:09:08.685-07:00', 'description': 'removed 2D6 to create an informative label annotation', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101950, 'title': 'Drugs@FDA: Drug Product Celexa (citalopram), NDA020822, Allergan, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020822', 'crossReferences': [{'id': 1449754196, 'resource': 'FDA Application', 'resourceId': 'NDA020822', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020822'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449015', 'name': 'citalopram'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1450342818.0,"<p>The FDA-approved drug label for citalopram (CELEXA) recommends a maximum dose of 20 mg/day of citalopram in patients who are CYP2C19 poor metabolizers, due to the risk for QT prolongation.</p>
",1450342817.0,"<p>Citalopram (CELEXA) is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.</p>
<p>Excerpts from the citalopram (CELEXA) drug label:</p>
<blockquote class=""blockquote"">
<p>In CYP2C19 poor metabolizers, citalopram steady state Cmax and AUC was increased by 68% and 107%, respectively. Celexa 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The maximum dose should be limited to 20 mg/day in patients who are CYP2C19 poor metabolizers...</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Citalopram_01_09_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Citalopram_01_09_19_FDA.pdf"">citalopram drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450380199.0,"<p>Excerpt from the citalopram (CELEXA) drug label:</p>
<blockquote class=""blockquote"">
<p>In CYP2C19 poor metabolizers, citalopram steady state Cmax and AUC was increased by 68% and 107%, respectively. Celexa 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166278181,"Annotation of FDA Label for azacitidine and CBL, KRAS, NRAS, PTPN11",False,True,[],False,"[{'id': 1452206102, 'date': '2023-08-14T09:33:05.700-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452247405, 'date': '2023-09-26T06:51:06.414-07:00', 'description': 'Added indication tag.', 'type': 'Update', 'version': 0}, {'id': 1452547401, 'date': '2024-08-05T10:45:04.730-07:00', 'description': 'removed Indication tag (clinical studies only)', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15135422, 'title': 'Drugs@FDA: Drug Product Azacitidine (azacitidine), NDA050794, Sandoz Inc', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050794', 'crossReferences': [{'id': 1451876423, 'resource': 'FDA Application', 'resourceId': 'NDA050794', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050794'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451996', 'name': 'azacitidine'}]","[{'objCls': 'Gene', 'id': 'PA26115', 'symbol': 'CBL', 'name': 'Cbl proto-oncogene'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA33986', 'symbol': 'PTPN11', 'name': 'protein tyrosine phosphatase non-receptor type 11'}]",FDA,1451876420.0,"<p>The FDA label for azacitidine includes mention of the genes CBL, PTPN11, NRAS, and KRAS when discussing the clinical studies of Juvenile Myelomonocytic Leukemia.</p>
",1451876421.0,"<p>Excerpts from the azacitidine (<em><strong>VIDAZA</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>Patients with newly diagnosed JMML were included if they met the following criteria: diagnosis
confirmed in peripheral blood and bone marrow, and had one of the following: somatic mutation
in PTPN11, KRAS, or NRAS and HbF % &gt; 5 x normal value for age, or clinical diagnosis of
neurofibromatosis Type 1 (NF-1). Additionally, patients included had no CNS involvement,
isolated extramedullary disease, or germline molecular aberrations in CBL, PTPN11, NRAS, or
KRAS.
Eighteen patients with JMML (13 PTPN11, 3 NRAS, 1 KRAS somatic mutations and 1 clinical
diagnosis of neurofibromatosis type 1 were enrolled.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Azacitidine_FDA_2022_09_06.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Azacitidine_FDA_2022_09_06.pdf"">azacitidine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166278121,"Annotation of FDA Label for nivolumab / relatlimab and BRAF, CD274, LAG3",False,True,[],False,"[{'id': 1452208360, 'date': '2023-08-16T10:58:10.074-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452803041, 'date': '2025-01-09T15:50:50.855-08:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15135382, 'title': 'Drugs@FDA: Drug Product OPDUALAG (nivolumab and relatlimab-rmbw), BLA761234, E.R. Squibb & Sons, L.L.C.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761234', 'crossReferences': [{'id': 1451876263, 'resource': 'FDA Application', 'resourceId': 'BLA761234', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761234'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],"[{'objCls': 'Variant', 'id': 'PA166157522', 'symbol': 'rs113488022', 'name': 'rs113488022'}]","[{'objCls': 'Chemical', 'id': 'PA166277902', 'name': 'nivolumab / relatlimab'}]","[{'objCls': 'Gene', 'id': 'PA25408', 'symbol': 'BRAF', 'name': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'objCls': 'Gene', 'id': 'PA134915280', 'symbol': 'CD274', 'name': 'CD274 molecule'}, {'objCls': 'Gene', 'id': 'PA30265', 'symbol': 'LAG3', 'name': 'lymphocyte activating 3'}]",FDA,1451876260.0,"<p>The combination therapy of nivolumab, an antibody against CD274 (PD-L1) and relatlimab, an antibody against LAG3 is FDA approved for unresectable or metastatic melanoma. The label also mentions BRAF status for patients in one of the clinical studies but testing is not discussed or required as part of the indication.</p>
",1451876261.0,"<p>Excerpts from the nivolumab and relatlimab-rmbw (OPDUALAG) label:</p>
<blockquote class=""blockquote"">
<p>OPDUALAG is a combination of nivolumab, a programmed death receptor-1
(PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3
(LAG-3) blocking antibody, indicated for the treatment of adult and pediatric
patients 12 years of age or older with unresectable or metastatic melanoma.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Randomization was stratified by tumor PD-L1 expression
(≥1% vs. &lt;1%) using PD-L1 IHC 28-8 pharmDx test, LAG-3 expression (≥1% vs. &lt;1%) using a
clinical trial assay, BRAF V600 mutation status (V600 mutation positive vs. wild type),</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""nivolumabRelatlimab_FDA_2022_08_31.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/nivolumabRelatlimab_FDA_2022_08_31.pdf"">nivolumab / relatlimab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452803040.0,"<blockquote class=""blockquote"">
<p>OPDUALAG is a combination of nivolumab, a programmed death receptor-1
(PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3
(LAG-3) blocking antibody, indicated for the treatment of adult and pediatric
patients 12 years of age or older with unresectable or metastatic melanoma.</p>
</blockquote>
",,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166296361,Annotation of FDA Label for pemetrexed and CD274,False,True,[],False,"[{'id': 1452214540, 'date': '2023-08-23T16:40:37.161-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452230582, 'date': '2023-09-07T11:27:05.198-07:00', 'description': 'added cancer genome tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15142922, 'title': 'Drugs@FDA: Drug Product Alimta (Pemetrexed disodium), Eli Lilly and Company - NDA021462/SUPPL-55, 08/31/2022', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021462', 'crossReferences': [{'id': 1452701744, 'resource': 'FDA Application', 'resourceId': 'NDA021462/SUPPL-55', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021462'}], 'objCls': 'Literature', 'pubDate': '2022-08-31T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10810', 'name': 'pemetrexed'}]","[{'objCls': 'Gene', 'id': 'PA134915280', 'symbol': 'CD274', 'name': 'CD274 molecule'}]",FDA,1452055460.0,"<p>The FDA label for Pemetrexed (ALIMTA) states that it is a folate analog metabolic inhibitor indicated in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. The efficacy of ALIMTA was examined in Study KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in patients with metastatic non-squamous NSCLC, regardless of PD-L1 tumor expression status, who had not previously received systemic therapy for metastatic disease and in whom there were no EGFR or ALK genomic tumor aberrations.</p>
",1452055461.0,"<p>Excerpts from the Pemetrexed (ALIMTA) label:</p>
<blockquote class=""blockquote"">
<p>ALIMTA is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Initial Treatment in Combination with Pembrolizumab and Platinum The efficacy of ALIMTA in combination with pembrolizumab and platinum chemotherapy was investigated in Study KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in patients with metastatic non-squamous NSCLC, regardless of PD-L1 tumor expression status, who had not previously received systemic therapy for metastatic disease and in whom there were no EGFR or ALK genomic tumor aberrations.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Pemetrexed_20230331_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Pemetrexed_20230331_FDA.pdf""><em><strong>Pemetrexed</strong></em> drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166234723,Annotation of FDA Label for atorvastatin and SLCO1B1,False,False,[],False,"[{'id': 1452206980, 'date': '2023-08-15T00:00:00-07:00', 'description': 'Checked slightly newer label on FDA site (2022) to see if genotyping for SLCO1B1 was added and did not find any. Did not download and highlight newer label since still only has PK/DDI information.', 'type': 'Note', 'version': 0}, {'id': 1452206960, 'date': '2023-08-15T07:29:00.561-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452315341, 'date': '2023-12-04T09:34:38.395-08:00', 'description': 'Updated label and label source.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101967, 'title': 'Drugs@FDA: Drug Product ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM), NDA020702, Legacy Pharmaceutical Packaging, LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020702', 'crossReferences': [{'id': 1452315342, 'resource': 'FDA Application', 'resourceId': 'NDA020702/SUPPL-79', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020702'}], 'objCls': 'Literature', 'pubDate': '2022-12-07T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448500', 'name': 'atorvastatin'}]","[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",FDA,1451391669.0,"<p>The FDA-approved label for atorvastatin (LIPITOR) states that atorvastatin exposure may be increased by drug interactions due to inhibition of CYP3A4 and/or transporters (e.g., breast cancer resistant protein (BCRP), organic anion-transporting polypeptide (OATP1B1 (SLCO1B1)/OATP1B3) and P-glycoprotein (P-gp (ABCB1))), resulting in an increased risk of myopathy and rhabdomyolysis.</p>
",1451391670.0,"<p>Excerpts from the atorvastatin (LIPITOR) drug label:</p>
<blockquote class=""blockquote"">
<p>Warnings and precautions:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>LIPITOR exposure may be increased by drug interactions due to inhibition of cytochrome P450 enzyme 3A4 (CYP3A4) and/or transporters (e.g., breast cancer resistant protein (BCRP), organic anion-transporting polypeptide (OATP1B1/OATP1B3) and P-glycoprotein (P-gp)), resulting in an increased risk of myopathy and rhabdomyolysis.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>DRUG INTERACTIONS:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Drug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis with LIPITOR: LIPITOR is a substrate of CYP3A4 and transporters (e.g., OATP1B1/1B3, P-gp, or BCRP). LIPITOR plasma levels can be significantly increased with concomitant administration of inhibitors of CYP3A4 and transporters.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Atorvastatin plasma levels were significantly increased with concomitant administration of LIPITOR and cyclosporine, an inhibitor of CYP3A4 and OATP1B1</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Atorvastatin plasma levels were significantly increased with concomitant administration of LIPITOR with many anti-viral medications, which are inhibitors of CYP3A4 and/or transporters (e.g., BCRP, OATP1B1/1B3, P-gp, MRP2, and/or OAT2) . Cases of myopathy and rhabdomyolysis have been reported with concomitant use of ledipasvir plus sofosbuvir with LIPITOR.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Concomitant administration of LIPITOR with rifampin, an inducer of cytochrome P450 3A4 and inhibitor of OATP1B1, can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Atorvastatin is a substrate of the hepatic transporters, OATP1B1 and OATP1B3 transporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the efflux transporter BCRP, which may limit the intestinal absorption and biliary clearance of atorvastatin.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Atorvastatin_FDA_2023_12_04.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Atorvastatin_FDA_2023_12_04.pdf"">atorvastatin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166234801,"Annotation of FDA Label for tacrolimus and CYP3A4, CYP3A5",False,False,[],False,"[{'id': 1452215360, 'date': '2023-08-24T00:00:00-07:00', 'description': 'removed informative PGx tag. Drug-drug interaction information doesn\'t fit current PGx level criteria for ""informative PGx"", ""actionable PGx"", ""testing recommended"", and ""testing required"".', 'type': 'Update', 'version': 1}, {'id': 1452570198, 'date': '2024-08-29T13:58:29.430-07:00', 'description': 'Removed ""CYP3A"" as that is no longer recognized by the HGNC and NCBI; replaced with CYP3A4', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15118382, 'title': 'Drugs@FDA: Drug Product Prograf (Tacrolimus), NDA050708, Astellas Pharma US, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050708', 'crossReferences': [{'id': 1451397160, 'resource': 'FDA Application', 'resourceId': 'NDA050708', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050708'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451578', 'name': 'tacrolimus'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}, {'objCls': 'Gene', 'id': 'PA131', 'symbol': 'CYP3A5', 'name': 'cytochrome P450 family 3 subfamily A member 5'}]",FDA,1451397140.0,"<p>The FDA drug label for tacrolimus (PROGRAF) contains guidance on concomitant use with CYP3A inducers or inhibitors. The label states that tacrolimus blood concentrations are altered by CYP3A inhibitors and/or inducers, the risk of nephrotoxicity is increased with concomitant use of CYP3A inhibitors, and the risk of QT interval prolongation is increased by concomitant use of CYP3A4 substrates and/or inhibitors.</p>
",1451397141.0,"<p>Excerpts from the tacrolimus drug label:</p>
<blockquote class=""blockquote"">
<p>Tacrolimus is extensively metabolized by the mixed-function oxidase system, primarily the cytochrome P-450 system (CYP3A).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The risk for nephrotoxicity may increase when PROGRAF is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors)</p>
</blockquote>
<blockquote class=""blockquote"">
<p>When co-administering PROGRAF with strong CYP3A4 inhibitors (e.g., telaprevir, boceprevir, ritonavir, ketoconazole, itraconazole, voriconazole, clarithromycin) and strong inducers (e.g., rifampin, rifabutin), adjustments in the dosing regimen of PROGRAF and subsequent frequent monitoring of tacrolimus whole blood trough concentrations and tacrolimus-associated adverse reactions are recommended.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A rapid, sharp rise in tacrolimus levels has been reported after co-administration with a strong CYP3A4 inhibitor, clarithromycin, despite an initial reduction of tacrolimus dose. Early and frequent monitoring of tacrolimus whole blood trough levels is recommended.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>When co-administering PROGRAF with other substrates and/or inhibitors of CYP3A4 that also have the potential to prolong the QT interval, a reduction in PROGRAF dose, frequent monitoring of tacrolimus whole blood concentrations, and monitoring for QT prolongation is recommended.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""tacrolimus_prograf_02_11_21_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/tacrolimus_prograf_02_11_21_FDA.pdf"">tacrolimus drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166272961,Annotation of FDA Label for abrocitinib and CYP2C19,False,False,[],True,"[{'id': 1452074589, 'date': '2023-04-20T05:55:28.755-07:00', 'description': 'Modified text of summary to be clearer.', 'type': 'Update', 'version': 0}, {'id': 1452211600, 'date': '2023-08-21T15:59:54.495-07:00', 'description': 'This drug is on the FDA Biomarker List so added the Biomarker tag.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15133142, 'title': 'Drugs@FDA: Drug Product Cibinqo (abrocitinib), NDA213871, Pfizer Laboratories Div Pfizer Inc', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213871', 'crossReferences': [{'id': 1451820544, 'resource': 'FDA Application', 'resourceId': 'NDA213871', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213871'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166272921', 'name': 'abrocitinib'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1451820540.0,"<p>The FDA label for abrocitinib gives dosing modifications for CYP2C19 poor metabolizers. It does not describe which CYP2C19 variants or tests can be used to define poor metabolizers.</p>
",1451820541.0,"<p>Excerpts from the <em><strong>abrocitinib</strong></em> (<em><strong>CIBINQO</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>Recommended Dosage in CYP2C19 Poor Metabolizers
In patients who are known or suspected to be CYP2C19 poor metabolizers, the recommended dosage of CIBINQO is 50 mg once daily ... If an adequate response is not achieved with CIBINQO 50 mg orally daily after 12 weeks, consider increasing dosage to 100 mgorally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 100 mg once daily.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C19 Poor Metabolizers
In patients who are CYP2C19 poor metabolizers, the AUC of abrocitinib is increased compared to CYP2C19 normal metabolizers due to reduced metabolic clearance. Dosage reduction of CIBINQO is recommended in patients who are known or suspected to be CYP2C19 poor metabolizers based on genotype or previous history/experience with other CYP2C19 substrates.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Abrocitinib_FDA_2022_07_08.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Abrocitinib_FDA_2022_07_08.pdf""><em><strong>abrocitinib</strong></em> drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451820542.0,"<blockquote class=""blockquote"">
<p>Recommended Dosage in CYP2C19 Poor Metabolizers
In patients who are known or suspected to be CYP2C19 poor metabolizers, the recommended dosage of CIBINQO is 50 mg once daily ... If an adequate response is not achieved with CIBINQO 50 mg orally daily after 12 weeks, consider increasing dosage to 100 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 100 mg once daily.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166179871,Annotation of FDA Label for binimetinib and UGT1A1,False,False,[],False,"[{'id': 1452206181, 'date': '2023-08-14T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Update', 'version': 0}, {'id': 1452281204, 'date': '2023-10-25T11:21:52.670-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101911, 'title': 'Drugs@FDA: Drug Product MEKTOVI (BINIMETINIB), NDA210498, Array BioPharma Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498', 'crossReferences': [{'id': 1449894346, 'resource': 'FDA Application', 'resourceId': 'NDA210498', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166179867', 'name': 'binimetinib'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",FDA,1449714068.0,"<p>Binimetinib (MEKTOVI) states is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, or for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. The FDA-approved drug label also states that UGT1A1 genotype does not have a clinically important effect on binimetinib exposure.</p>
",1449714067.0,"<p>Excerpt from the binimetinib (MEKTOVI) drug label:</p>
<blockquote class=""blockquote"">
<p>UGT1A1 genotype and smoking (UGT1A1 inducer) do not have a clinically important effect on binimetinib exposure.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""binimetinib_FDA_10252023.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/binimetinib_FDA_10252023.pdf"">binimetinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166277681,Annotation of FDA Label for anifrolumab and IFNAR1,False,False,[],False,"[{'id': 1452205960, 'date': '2023-08-14T07:06:26.621-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15135102, 'title': 'Drugs@FDA: Drug Product SAPHNELO (Anifrolumab), BLA761123, AstraZeneca Pharmaceuticals LP', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761123', 'crossReferences': [{'id': 1451871863, 'resource': 'FDA Application', 'resourceId': 'BLA761123', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761123'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166277641', 'name': 'anifrolumab'}]","[{'objCls': 'Gene', 'id': 'PA29670', 'symbol': 'IFNAR1', 'name': 'interferon alpha and beta receptor subunit 1'}]",FDA,1451871860.0,"<p>Anifrolumab a monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1) and inhibits type I IFN signaling. Blockade of receptor mediated type I IFN signaling inhibits IFN responsive gene expression (gene signature) as well as downstream inflammatory and immunological processes.</p>
",1451871861.0,"<p>Excerpts from the <em><strong>Anifrolumab</strong></em> (<em><strong>SAPHNELO</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>Mechanism of Action
Anifrolumab-fnia is a human IgG1κ monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR) with high specificity and affinity. This binding inhibits type I IFN signaling, thereby blocking the biologic activity oftype I IFNs. Anifrolumab-fnia also induces the internalization of IFNAR1, thereby reducing the levels of cell surface IFNAR1 available for receptor assembly. Blockade of receptor mediated type I IFN signaling inhibits IFN responsive gene expression as well as downstream inflammatory and immunological processes. Inhibition of type I IFN blocks plasma cell differentiation and normalizes peripheral T-cell subsets.
Type I IFNs play a role in the pathogenesis of SLE. Approximately 60-80% of adult patients with active SLE express elevated levels of type I IFN inducible genes.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Anifrolumab_FDA_2022_08_30.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Anifrolumab_FDA_2022_08_30.pdf""><em><strong>Anifrolumab</strong></em> drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104860,"Annotation of FDA Label for phenytoin and CYP2C9, HLA-B",True,False,[],True,"[{'id': 1183681327, 'date': '2013-10-25T11:18:36.288-07:00', 'type': 'Update', 'version': 0}, {'id': 1450381754, 'date': '2019-04-19T13:00:30.995-07:00', 'description': 'Added variant information', 'type': 'Update', 'version': 0}, {'id': 1451527124, 'date': '2021-10-12T15:01:13.422-07:00', 'description': 'Updated annotation based on updates to FDA label', 'type': 'Update', 'version': 0}, {'id': 1452194340, 'date': '2023-07-27T06:28:34.615-07:00', 'description': 'Removed ""limited evidence"" and ""in Asian patients"" from the summary as this is outdated.', 'type': 'Update', 'version': 0}, {'id': 1452214483, 'date': '2023-08-23T14:59:18.843-07:00', 'description': 'Added Dosing Info and Alt Drug tags with updated definitions', 'type': 'Update', 'version': 0}, {'id': 1452594285, 'date': '2024-09-18T15:48:01.015-07:00', 'description': 'split CYP2C19 out to separate annotation, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15123822, 'title': 'Drugs@FDA Drug Product: DILANTIN (phenytoin), NDA008762, Upjohn', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008762', 'crossReferences': [{'id': 1449776459, 'resource': 'FDA Application', 'resourceId': 'NDA008762', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008762'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]","[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}, {'objCls': 'Haplotype', 'id': 'PA165954769', 'symbol': 'HLA-B*15:02', 'name': '*15:02'}]","[{'objCls': 'Chemical', 'id': 'PA450947', 'name': 'phenytoin'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",FDA,1447981713.0,"<p>The FDA-approved drug label for phenytoin (DILANTIN) states that the HLA-B*15:02 and CYP2C9*3 alleles may increase the risk of severe cutaneous adverse reactions in patients who are treated with phenytoin and that prescribers should consider avoiding phenytoin as an alternative to carbamazepine in these patients. It also notes that the drug is metabolized by CYP2C9 and CYP2C19 and that patients who are known to be CYP2C9 intermediate or poor metabolizers may have lower phenytoin dose requirements.</p>
",1447981712.0,"<p>Excerpts from the phenytoin (DILANTIN) drug label:</p>
<blockquote class=""blockquote"">
<p>Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. In addition, retrospective, case-control, genome-wide association studies in patients of southeast Asian ancestry have also identified an increased risk of SCARs in carriers of the decreased function CYP2C9*3 variant, which has also been associated with decreased clearance of phenytoin. Consider avoiding DILANTIN as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.</p>
<p>The use of HLA-B*1502 or CYP2C9 genotyping has important limitations and must never substitute for appropriate clinical vigilance and patient management. The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug (AED) dose, compliance, concomitant medications, comorbidities, and the level of dermatologic monitoring have not been studied.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Use in Patients with Decreased CYP2C9 Function</strong>
Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses of phenytoin to maintain similar steady-state concentrations compared to normal metabolizers. If early signs of dose-related central nervous system (CNS) toxicity develop, serum concentrations should be checked immediately.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Metabolism...Phenytoin is primarily metabolized by the hepatic cytochrome P450 enzyme CYP2C9 and to a lesser extent by CYP2C19.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Phenytoin_FDA_10_12_21.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Phenytoin_FDA_10_12_21.pdf"">phenytoin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452594284.0,"<p>Phenytoin is FDA-approved for pediatric use. The label gives information on dosing.</p>
<p>Excerpt from the phenytoin (DILANTIN) drug label:</p>
<blockquote class=""blockquote"">
<p>The recommended starting dosage for pediatric patients is 5 mg/kg/day by mouth in two or three equally divided doses, with subsequent dosage individualized to a maximum of 300 mg daily in divided doses. A recommended daily maintenance dosage is usually 4 to 8 mg/kg/day in equally divided doses. Children over 6 years and adolescents may require the minimum adult dosage (300 mg/day).</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399719.0,"<p>Excerpts from the phenytoin (DILANTIN) drug label:</p>
<blockquote class=""blockquote"">
<p>Consider avoiding DILANTIN as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients who are intermediate or poor metabolizers of CYP2C9 substrates (e.g., *1/*3, *2/*2, *3/*3) may exhibit increased phenytoin serum concentrations compared to patients who are normal metabolizers (e.g., *1/*1). Thus, patients who are known to be intermediate or poor metabolizers may ultimately require lower doses of phenytoin to maintain similar steady-state concentrations compared to normal metabolizers.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166184561,Annotation of FDA Label for ramucirumab and KRAS,False,True,[],False,"[{'id': 1452214700, 'date': '2023-08-23T18:16:35.713-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452318122, 'date': '2023-12-05T06:42:18.233-08:00', 'description': 'Updated label.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103359, 'title': 'Drugs@FDA: Drug Product CYRAMZA (ramucirumab), Eli Lilly and Company - BLA125477/SUPPL-42, 03/22/2022', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125477', 'crossReferences': [{'id': 1452318121, 'resource': 'FDA Application', 'resourceId': 'BLA125477/SUPPL-42', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125477'}], 'objCls': 'Literature', 'pubDate': '2022-03-22T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184558', 'name': 'ramucirumab'}]","[{'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",FDA,1450821056.0,"<p>The FDA-approved drug label for ramucirumab (CYRAMZA) states that KRAS status testing was used to stratify patients in the RAISE (NCT01183780) clinical trial of ramucirumab in metastatic colorectal cancer.</p>
",1450821057.0,"<p>Excerpt from the ramucirumab drug label:</p>
<blockquote class=""blockquote"">
<p>Randomization was stratified by
geographic region, tumor KRAS status, and time to disease progression after beginning first-line treatment (&lt;6 months
versus =6 months). The major efficacy outcome measure was OS. An additional efficacy outcome measure was PFS.
A total of 1072 patients were randomized, 536 to the CYRAMZA-treatment group and 536 to the placebo-treatment group.
Baseline demographics and disease characteristics were similar between treatment arms. The median age was 62 years
(range 21-87); 57% were men; 76% were White and 20% were Asian; 49% had ECOG PS 0; 49% had KRAS mutant
tumors; and 24% had &lt;6 months from time to disease progression after beginning first-line treatment. The treatment effect
was consistent across the pre-specified stratification factors.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Ramucirumab_FDA_2023_12_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ramucirumab_FDA_2023_12_05.pdf"">ramucirumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166170958,Annotation of FDA Label for valproic acid and POLG,True,False,[],False,"[{'id': 1449140194, 'date': '2017-11-10T11:10:42.866-08:00', 'type': 'Update', 'version': 0}, {'id': 1450821516, 'date': '2019-10-10T00:00:00-07:00', 'description': 'Checked per updated FDA table, no changes necessary.', 'type': 'Update', 'version': 0}, {'id': 1452212283, 'date': '2023-08-22T00:34:56.792-07:00', 'description': ""added 'pediatric' tag"", 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101842, 'title': 'Drugs@FDA: Drug Product Depakene (Valproic Acid), NDA018081, REMEDYREPACK INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018081', 'crossReferences': [{'id': 1449891327, 'resource': 'FDA Application', 'resourceId': 'NDA018081', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018081'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA33500', 'symbol': 'POLG', 'name': 'DNA polymerase gamma, catalytic subunit'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451846', 'name': 'valproic acid'}]","[{'objCls': 'Gene', 'id': 'PA33500', 'symbol': 'POLG', 'name': 'DNA polymerase gamma, catalytic subunit'}]",FDA,1449140148.0,"<p>The FDA-approved drug label for valproic acid (Depakene) states that it is contraindicated in individuals with known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and suspected POLG-related disorders in children under 2 years old.</p>
",1449140147.0,"<p>POLG is a mitochondrial DNA polymerase and mutations in this gene are associated with hereditary neurometabolic syndromes such as Alpers Huttenlocher Syndrome.</p>
<p>Excerpts from the valproic acid (Depakene) drug label:</p>
<div class=""blockquote"">
<p>There is an increased risk of valproate-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA Polymerase &gamma; (POLG) gene (e.g. Alpers Huttenlocher Syndrome). Depakene is contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under two years of age who are clinically suspected of having a mitochondrial disorder...POLG mutation screening should be performed in accordance with current clinical practice.</p>
</div>
<div class=""blockquote"">
<p>POLG mutation testing should be performed in accordance with current clinical practice for the diagnostic evaluation of such disorders. The A467T and W748S mutations are present in approximately 2/3 of patients with autosomal recessive POLG-related disorders.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Valproic_Acid_03_01_19_FDA.pdf"">valproic acid drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450384317.0,"<p>Excerpts from the valproic acid (Depakene) drug label:</p>
<blockquote class=""blockquote"">
<p>Depakene is contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under two years of age who are clinically suspected of having a mitochondrial disorder...POLG mutation screening should be performed in accordance with current clinical practice.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166184565,Annotation of FDA Label for tafamidis and TTR,False,False,[],False,"[{'id': 1452215361, 'date': '2023-08-24T15:59:32.961-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103358, 'title': 'Drugs@FDA: Drug Product Vyndaqel (tafamidis meglumine), NDA211996, Pfizer Laboratories Div Pfizer Inc', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211996', 'crossReferences': [{'id': 1450821091, 'resource': 'FDA Application', 'resourceId': 'NDA211996', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211996'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184562', 'name': 'tafamidis'}]","[{'objCls': 'Gene', 'id': 'PA37069', 'symbol': 'TTR', 'name': 'transthyretin'}]",FDA,1450821087.0,"<p>The FDA label for tafamidis (VYNDAQEL) and (VYNDAMAX) states is it indicated for the treatment of the cardiomyopathy of wild type or
hereditary transthyretin-mediated amyloidosis (ATTR-CM).</p>
",1450821088.0,"<p>Excerpts from the tafamidis (VYNDAQEL) and (VYNDAMAX) label:</p>
<div class=""blockquote"">
<p>VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or
hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and
cardiovascular-related hospitalization.</p>
</div>
<div class=""blockquote"">
<p>VYNDAQEL stabilized both the wild type TTR tetramer and the tetramers of 14 TTR variants tested clinically after once-daily dosing. Tafamidis also stabilized the TTR tetramer for 25 variants tested ex vivo.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/tafamidis_10_8_2019FDA.pdf"">tafamidis drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182786,Annotation of FDA Label for tolazamide and G6PD,True,False,[],False,"[{'id': 1452216640, 'date': '2023-08-25T00:53:26.048-07:00', 'description': 'Added ""Alternate Drug"" tag based on updated definition', 'type': 'Update', 'version': 0}, {'id': 1452640580, 'date': '2024-10-14T11:52:35.146-07:00', 'description': 'added drug discontinued notice', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102403, 'title': 'Drugs@FDA: Drug Product Tolazamide (tolazamide), ANDA070259, PD-Rx Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=070259', 'crossReferences': [{'id': 1450401643, 'resource': 'FDA Application', 'resourceId': 'ANDA070259', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=070259'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164774902', 'name': 'tolazamide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1450401640.0,"<p>The FDA-approved drug label for tolazamide states that, due to the risk of hemolytic anemia, caution should be used when administering tolazamide to patients with G6PD deficiency.</p>
<p><strong>Note: As of 10/14/2024, tolazamide is shown as Discontinued on the FDA web site. However, the drug is still included on the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling.</strong></p>
",1450401641.0,"<p>Excerpt from the tolazamide drug label:</p>
<div class=""blockquote"">
<p>Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea
agents can lead to hemolytic anemia. Because tolazamide belongs to the class of sulfonylurea agents,
caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be
considered. In post-marketing reports, hemolytic anemia has also been reported in patients who did not
have known G6PD deficiency.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tolazamide_05_20_19_FDA.pdf"">tolazamide drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450416017.0,"<p>Excerpt from the tolazamide drug label:</p>
<blockquote class=""blockquote"">
<p>Because tolazamide belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166127662,"Annotation of FDA Label for arformoterol and CYP2D6, UGT1A1",False,False,[],False,[],False,[],True,"[{'id': 15101874, 'title': 'Drugs@FDA: Drug Product Brovana (arformoterol tartrate), NDA021912, Sunovion Pharmaceuticals Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021912', 'crossReferences': [{'id': 1449893794, 'resource': 'FDA Application', 'resourceId': 'NDA021912', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021912'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164743977', 'name': 'arformoterol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}, {'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",FDA,1447982457.0,"<p>The FDA-approved label for arformoterol (BROVANA) states those with reduced CYP2D6 and/or UGT1A1 activity do not show changes in their systemic exposure to the drug compared to those with normal CYP2D6 and/or UGT1A1 enzymatic activities.</p>
",1450043442.0,"<p>Arformoterol (BROVANA) is indicated for treatment of chronic obstructive pulmonary disease. Excerpts from the arformoterol (BROVANA) drug label:</p>
<div class=""blockquote"">
<p>...arformoterol is primarily metabolized by...glucuronidation...and secondarily by O-demethylation. At least five human...UGT...isozymes catalyze arformoterol glucuronidation <em>in vitro</em>. Two cytochrome P450 isozymes (CYP2D6 and secondarily CYP2C19) catalyze the O-demethylation of arformoterol.</p>
</div>
<div class=""blockquote"">
<p>Pharmacogenomics. Arformoterol is eliminated through the action of multiple drug metabolizing enzymes...In otherwise healthy subjects with reduced CYP2D6 and/or UGT1A1 enzyme activity, there was no impact on systemic exposure to arformoterol compared to subjects with normal CYP2D6 and/or UGT1A1 enzyme activities.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Arformoterol_06_23_2017_FDA.pdf"">arformoterol drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166105010,Annotation of FDA Label for duloxetine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15101986, 'title': 'Drugs@FDA: Drug Product Cymbalta (Duloxetine hydrochloride), NDA021427, Carilion Materials Management', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021427', 'crossReferences': [{'id': 1449754522, 'resource': 'FDA Application', 'resourceId': 'NDA021427', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021427'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10066', 'name': 'duloxetine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1448604912.0,"<p>Duloxetine (CYMBALTA) is metabolized by CYP2D6 and CYP1A2. The FDA-approved drug label notes that concomitant administration of duloxetine and fluvoxamine (a potent CYP1A2 inhibitor) to CYP2D6 poor metabolizers resulted in a 6-fold increase in duloxetine AUC and Cmax.</p>
",1448604911.0,"<p>Excerpts from duloxetine (CYMBALTA) drug label:</p>
<div class=""blockquote"">
<p>Both CYP1A2 and CYP2D6 are responsible for CYMBALTA metabolism.</p>
</div>
<div class=""blockquote"">
<p>Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and Cmax.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Duloxetine_07_19_2017_FDA.pdf"">duloxetine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166122589,Annotation of FDA Label for obinutuzumab and MS4A1,False,True,[],False,"[{'id': 1184483118, 'date': '2014-07-14T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1449005525, 'date': '2017-11-08T14:29:53.143-08:00', 'type': 'Update', 'version': 0}, {'id': 1449156746, 'date': '2017-12-07T12:20:37.355-08:00', 'type': 'Update', 'version': 0}, {'id': 1452205920, 'date': '2023-08-14T00:00:00-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452583260, 'date': '2024-09-09T16:44:35.656-07:00', 'description': 'added FDA Biomarker List label back (listed under synonym obinutuzumab)', 'type': 'Update', 'version': 0}, {'id': 1452782241, 'date': '2024-12-12T14:42:08.613-08:00', 'description': 'updated label, removed afutuzumab synonym', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171862, 'title': 'Drugs@FDA: Drug Product Gazyva (obinutuzumab), Genentech, Inc. - BLA125486/SUPPL-34, 07/27/2022', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125486', 'crossReferences': [{'id': 1452782221, 'resource': 'FDA Application', 'resourceId': 'BLA125486/SUPPL-34', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125486'}], 'objCls': 'Literature', 'pubDate': '2022-07-27T00:00:00-07:00', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166122586', 'name': 'obinutuzumab'}]","[{'objCls': 'Gene', 'id': 'PA31111', 'symbol': 'MS4A1', 'name': 'membrane spanning 4-domains A1'}]",FDA,1447981958.0,"<p>Obinutuzumab (GAZYVA) in combination with certain other drugs is indicated for treatment of patients with chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL). The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, <em>MS4A1</em>, and therefore no mention of genetic testing in the drug label.</p>
",1447981957.0,"<p>Obinutuzumab (GAZYVA) binds to the CD20 molecule, which is expressed on pre-B and mature B lymphocytes. Upon binding to CD20, it mediates B-cell lysis. CD20 is coded for by the <em>MS4A1</em> gene.</p>
<p>Excerpts from the obinutuzumab (GAZYVA) drug label:</p>
<blockquote class=""blockquote"">
<p>Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B cells.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Obinutuzumab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes. Upon binding to CD20, obinutuzumab mediates B-cell lysis through (1) engagement of immune effector cells, (2) by directly activating intracellular death signaling pathways (direct cell death), and/or (3) activation of the complement cascade. The immune effector cell mechanisms include antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>As an antibody with reduced fucose content, obinutuzumab induces greater ADCC activity than rituximab in vitro using human cancer cell lines. Obinutuzumab also demonstrated an increased ability to induce direct cell death when compared to rituximab. Obinutuzumab binds to FcγRIII using purified proteins with a higher affinity than rituximab. Obinutuzumab and rituximab bind with similar affinity to overlapping epitopes on CD20.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Obinutuzumab_2024_12_12_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Obinutuzumab_2024_12_12_FDA.pdf"">obinutuzumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182755,"Annotation of FDA Label for vincristine and ABL1, BCR",False,True,[],False,"[{'id': 1452224682, 'date': '2023-08-31T21:24:04.610-07:00', 'description': 'removed prescribing info and alternate drug tag and added indication tag', 'type': 'Update', 'version': 0}, {'id': 1452711060, 'date': '2024-11-21T00:00:00-08:00', 'description': 'removed Testing Required PGx level, Indication tag; new label no longer mentions the indication', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102377, 'title': 'Drugs@FDA: Drug Product Marqibo (vincristine sulfate), Talon Therapeutics, Inc., NDA202497/ORIG-1, 08/09/2012', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202497', 'crossReferences': [{'id': 1452711081, 'resource': 'FDA Application', 'resourceId': 'NDA202497/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202497'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'pubDate': '2012-08-09T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15170742, 'title': 'DailyMed - VINCRISTINE SULFATE injection, solution', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b22e4c8e-dbe1-4d4b-a026-e1812974071c', 'crossReferences': [{'id': 1452711040, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': 'b22e4c8e-dbe1-4d4b-a026-e1812974071c', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b22e4c8e-dbe1-4d4b-a026-e1812974071c'}], 'notes': 'ANDA071484', 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451879', 'name': 'vincristine'}]","[{'objCls': 'Gene', 'id': 'PA24413', 'symbol': 'ABL1', 'name': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'objCls': 'Gene', 'id': 'PA25321', 'symbol': 'BCR', 'name': 'BCR activator of RhoGEF and GTPase'}]",FDA,1450400707.0,"<p>The FDA-approved drug label for vincristine states that it is indicated for the treatment of acute leukemia.</p>
<p><strong>November 2024: Please note that the marketing status of vincristine (MARQIBO) on the FDA website is Discontinued. However, a generic drug is available; the drug labels on the DailyMed website no longer mention a specific indication for the treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia.</strong></p>
<p>The FDA-approved drug label for vincristine (MARQIBO) states that it is indicated for the treatment of Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.</p>
",1450400708.0,"<p>Excerpts from the vincristine drug label:</p>
<blockquote class=""blockquote"">
<p>Vincristine Sulfate Injection is indicated in acute leukemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas,
rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The metabolism of vinca alkaloids has been shown to be mediated by hepatic cytochrome P450 isoenzymes in the CYP 3A subfamily.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Vincristine_2024_11_21_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Vincristine_2024_11_21_FDA.pdf"">vincristine drug label</a>.</p>
<p><strong>November 2024: Please note that the marketing status of vincristine (MARQIBO) on the FDA website is Discontinued. However, a generic drug is available; the drug labels on the DailyMed website no longer mention a specific indication for the treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia.</strong></p>
<p>Excerpt from the vincristine (MARQIBO, discontinued) drug label:</p>
<blockquote class=""blockquote"">
<p>Marqibo is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Vincristine_05_14_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Vincristine_05_14_19_FDA.pdf"">vincristine (MARQIBO, discontinued) drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166177518,Annotation of FDA Label for sofosbuvir / velpatasvir / voxilaprevir and IFNL3,False,False,[],False,"[{'id': 1452215323, 'date': '2023-08-24T15:51:32.761-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101965, 'title': 'Drugs@FDA: Drug Product Vosevi (SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR), NDA209195, Gilead Sciences, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209195', 'crossReferences': [{'id': 1449788155, 'resource': 'FDA Application', 'resourceId': 'NDA209195', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209195'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177517', 'name': 'sofosbuvir / velpatasvir / voxilaprevir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",FDA,1449169977.0,"<p>VOSEVI (sofosbuvir, velpatasvir and voxilaprevir) is indicated for treatment of adult patients with chronic hepatitis C virus (HCV) infection. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.</p>
",1449169976.0,"<p>Patients with the rs12979860 non-CC genotype may have lower response rates when treated with pegylated interferon and ribavirin combination therapy as compared to those with the CC genotype.</p>
<p>Excerpt from the VOSEVI drug label:</p>
<div class=""blockquote"">
<p>CLINICAL STUDIES...Clinical Trials in HCV DAA-Experienced Subjects...NS5A Inhibitor-Experienced Adults Without Cirrhosis or With Compensated Cirrhosis (POLARIS-1)...82% had a non-CC IL28B genotype (CT or TT)...DAA-Experienced Adults Without Cirrhosis or With Compensated Cirrhosis Who Had Not Received An NS5A Inhibitor (POLARIS-4)...81% had non-CC IL28B genotypes (CT or TT)...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Sofosbuvir_Velpatasvir_Voxilaprevir_FDA_02_12_18.pdf"">Vosevi drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182762,Annotation of FDA Label for elagolix and SLCO1B1,False,False,[],False,"[{'id': 1452138901, 'date': '2023-06-23T09:54:16.510-07:00', 'description': 'Fixed prescribing info box to show annotation on SLCO1B1', 'type': 'Update', 'version': 0}, {'id': 1452211620, 'date': '2023-08-21T18:03:41.279-07:00', 'description': 'Removed the Prescribing Information section since there is no suggested potential action to take based on SLCO1B1', 'type': 'Update', 'version': 0}, {'id': 1452531820, 'date': '2024-07-19T09:27:14.220-07:00', 'description': 'added newer label and updated the text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160962, 'title': 'Drugs@FDA: Drug Product Orilissa (Elagolix), AbbVie Inc. - NDA210450/SUPPL-9, 06/05/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210450', 'crossReferences': [{'id': 1452531780, 'resource': 'FDA Application', 'resourceId': 'NDA210450/SUPPL-9', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210450'}], 'objCls': 'Literature', 'pubDate': '2023-06-05T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15102389, 'title': 'Drugs@FDA: Drug Product Orilissa (Elagolix), NDA210450, AbbVie Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210450', 'crossReferences': [{'id': 1450401048, 'resource': 'FDA Application', 'resourceId': 'NDA210450', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210450'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166154579', 'symbol': 'rs4149056', 'name': 'rs4149056'}]","[{'objCls': 'Chemical', 'id': 'PA166182348', 'name': 'elagolix'}]","[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",FDA,1450401046.0,"<p>The FDA-approved drug label for elagolix (ORILISSA) states that higher plasma concentrations of the drug have been observed in patients who have two reduced function alleles of the gene that encodes OATP 1B1 (SLCO1B1 521T&gt;C, rs4149056 variant).</p>
",1450401047.0,"<p>Excerpt from the elagolix (ORILISSA) drug label:</p>
<blockquote class=""blockquote"">
<p>Hepatic uptake of elagolix involves the OATP 1B1 transporter protein. Higher plasma concentrations of elagolix have been observed in patients who have two reduced function alleles of the gene that encodes OATP 1B1 (SLCO1B1 521T&gt;C) (these patients are likely to have reduced hepatic uptake of elagolix and thus, higher plasma elagolix concentrations). The frequency of this SLCO1B1 521 C/C genotype is generally less than 5% in most racial/ethnic groups. Subjects with this genotype are expected to have a 78% mean increase in elagolix concentrations compared to subjects with normal transporter function (i.e., SLCO1B1 521T/T genotype). Adverse effects of elagolix have not been fully evaluated in subjects who have two reduced function alleles of the gene that encodes OATP1B1 (SLCO1B1 521T&gt;C).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Elagolix_06_05_2023_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Elagolix_06_05_2023_FDA.pdf"">elagolix drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166163439,Annotation of FDA Label for elbasvir / grazoprevir and IFNL3,False,False,[],False,"[{'id': 1452229220, 'date': '2023-09-06T08:46:50.229-07:00', 'description': 'remove informative PGx tag; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102031, 'title': 'Drugs@FDA: Drug Product ZEPATIER (elbasvir and grazoprevir), NDA208261, Merck Sharp & Dohme Corp.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208261', 'crossReferences': [{'id': 1449754548, 'resource': 'FDA Application', 'resourceId': 'NDA208261', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208261'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166163438', 'name': 'elbasvir / grazoprevir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",FDA,1450361336.0,"<p>Elbasvir and grazoprevir (ZEPATIER) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adults. It is indicated for use with ribavirin in certain patient populations. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.</p>
",1450361337.0,"<p>Patients with the rs12979860 non-CC genotype may have lower response rates when treated with pegylated interferon and ribavirin combination therapy as compared to those with the CC genotype.</p>
<p>Excerpts from the elbasvir and grazoprevir (ZEPATIER) drug label:</p>
<div class=""blockquote"">
<p>Clinical Trials in Treatment-Experienced Subjects with Genotype 1 HCV...79% had non-C/C IL28B alleles (CT or TT)...</p>
</div>
<div class=""blockquote"">
<p>Clinical Trial in Subjects with Genotype 1 HCV and Severe Renal Impairment Including Subjects on Hemodialysis (C-SURFER)...72% had non-C/C IL28B alleles (CT or TT)...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Elbasvir_and_Grazoprevir_03_21_17_FDA.pdf"">elbasvir and grazoprevir drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166160005,Annotation of FDA Label for dasabuvir / ombitasvir / paritaprevir / ritonavir and IFNL3,False,False,[],False,"[{'id': 1448604648, 'date': '2017-03-15T14:42:54.896-07:00', 'type': 'Update', 'version': 0}, {'id': 1452229300, 'date': '2023-09-06T09:17:14.105-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101999, 'title': 'Drugs@FDA: Drug Product Viekira Pak (Dasabuvir and Ombitasvir and Paritaprevir and Ritonavir), NDA206619, AbbVie Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206619', 'crossReferences': [{'id': 1449754246, 'resource': 'FDA Application', 'resourceId': 'NDA206619', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206619'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166160002', 'name': 'dasabuvir / ombitasvir / paritaprevir / ritonavir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",FDA,1448257020.0,"<p>The FDA-approved drug label for VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir, and dasabuvir) notes the percentage of subjects in clinical studies that carried the IL28B rs12979860 non-CC genotype. However, the label does not discuss the effect of this variant or genetic testing.</p>
",1448257019.0,"<p>Excerpts from the VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir and dasabuvir) drug label:</p>
<div class=""blockquote"">
<p>14.2 Clinical Trial Results in Adults with Chronic HCV Genotype 1a and 1b Infection without Cirrhosis...Subjects with Chronic HCV GT1a Infection without Cirrhosis...72% had IL28B (rs12979860) non-CC genotype...</p>
</div>
<div class=""blockquote"">
<p>14.2 Clinical Trial Results in Adults with Chronic HCV Genotype 1a and 1b Infection without Cirrhosis...Subjects with Chronic HCV GT1b Infection without Cirrhosis...83% had IL28B (rs12979860) non- CC genotype...</p>
</div>
<div class=""blockquote"">
<p>14.3 Clinical Trial Results in Adults with Chronic HCV Genotype 1a and 1b Infection and Compensated Cirrhosis...TURQUOISE-II...82% had IL28B (rs12979860) non-CC genotype...</p>
</div>
<div class=""blockquote"">
<p>14.3 Clinical Trial Results in Adults with Chronic HCV Genotype 1a and 1b Infection and Compensated Cirrhosis...TURQUOISE-III...83% had IL28B (rs12979860) non-CC genotype...</p>
</div>
<div class=""blockquote"">
<p>14.6 Clinical Trial in Subjects with HCV/HIV-1 Co-infection (TURQUOISE-I)...81% of subjects had IL28B (rs12979860) non-CC genotype...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Dasabuvir_Ombitasvir_Paritaprevir_Ritonavir_1_11_19_FDA.pdf"">Viekira Pak drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166251501,Annotation of FDA Label for cabotegravir / rilpivirine and UGT1A1,False,False,[],False,"[{'id': 1452206440, 'date': '2023-08-14T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}, {'id': 1452318160, 'date': '2023-12-05T07:27:40.548-08:00', 'description': 'Updated label and label source.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15148662, 'title': 'Drugs@FDA: Drug Product Cabenuva (cabotegravir and rilpivirine), NDA212888, ViiV Healthcare Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212888', 'crossReferences': [{'id': 1452318162, 'resource': 'FDA Application', 'resourceId': 'NDA212888/SUPPL-8', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212888'}], 'objCls': 'Literature', 'pubDate': '2023-02-27T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166251381', 'name': 'cabotegravir / rilpivirine'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",FDA,1451524561.0,"<p>The FDA label for cabotegravir / rilpivirine (CABENUVA) describes that cabotegravir is primarily metabolized by UGT1A1 but states that UGT1A1 polymorphisms did not have significant clinical effects on its pharmacokinetics.</p>
",1451524562.0,"<p>Cabotegravir / rilpivirine (CABENUVA) is an injectable extended-release combination of antiviral drugs for the treatment of <a href=""/disease/PA447230"">HIV</a>.</p>
<p>Excerpts from the FDA label</p>
<blockquote class=""blockquote"">
<p>No clinically significant differences in the pharmacokinetics of cabotegravir or rilpivirine were observed
based on age, sex, race/ethnicity, body mass index, or UGT1A1 polymorphisms.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Cabotegravir is primarily metabolized by UGT1A1 with some contribution from UGT1A9. Drugs that
are strong inducers of UGT1A1 or 1A9 are expected to decrease cabotegravir plasma concentrations and
may result in loss of virologic response; therefore, coadministration of CABENUVA with these drugs is
contraindicated</p>
</blockquote>
<p>For the complete drug label texts with sections containing pharmacogenetic information highlighted, see the <a download=""CabotegravirRilpivirine_FDA_2023_12_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/CabotegravirRilpivirine_FDA_2023_12_05.pdf"">cabotegravir / rilpivirine (CABENUVA) drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182738,Annotation of FDA Label for siponimod and CYP2C9,True,False,[],True,"[{'id': 1450821061, 'date': '2019-10-08T00:00:00-07:00', 'description': 'Checked and no update necessary.', 'type': 'Note', 'version': 0}, {'id': 1450821493, 'date': '2019-10-09T14:36:31.670-07:00', 'description': 'Added tag for FDA biomarker list', 'type': 'Update', 'version': 0}, {'id': 1451231120, 'date': '2020-07-21T00:00:00-07:00', 'description': 'Added PGx section text', 'type': 'Update', 'version': 1}, {'id': 1452031040, 'date': '2023-03-07T00:00:00-08:00', 'description': 'update with new PGx information including CYP2C9*5, *6, *8, *11', 'type': 'Update', 'version': 0}, {'id': 1452400860, 'date': '2024-03-07T10:47:47.245-08:00', 'description': 'corrected typo', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102371, 'title': 'Drugs@FDA: Drug Product MAYZENT (siponimod), NDA209884, Novartis Pharmaceuticals Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209884', 'crossReferences': [{'id': 1450400242, 'resource': 'FDA Application', 'resourceId': 'NDA209884', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209884'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]","[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA166182736', 'name': 'siponimod'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1450400238.0,"<p>The FDA-approved drug label for siponimod (MAYZENT) states that it is indicated for treatment of relapsing forms of multiple sclerosis (MS). Siponimod is contraindicated in patients with the CYP2C9*3/*3 genotype. Patients with the CYP2C9*1/*1, *1/*2 or *2/*2 genotypes should be given a daily maintenance dose of 2mg starting on Day 6 of treatment, while patients with the *1/*3 or *2/*3 genotypes should be given a daily maintenance dose of 1mg starting on Day 5 of treatment.</p>
",1450400239.0,"<p>Excerpts from the siponimod drug label:</p>
<blockquote class=""blockquote"">
<p>Test patients for CYP2C9 variants to determine CYP2C9 genotype (see Dosage and Administration (2.2, 2.3),
Contraindications (4), and Use in Specific Populations (8.6)). An FDA-cleared or -approved test for the detection of CYP2C9 variants to direct the use of siponimod is not currently available.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Recommended Dosage in Patients With CYP2C9 Genotypes *1/*1, *1/*2, or *2/*2</strong>
<em>Maintenance Dosage</em>
After treatment titration (see Treatment Initiation), the recommended maintenance dosage of MAYZENT is 2 mg taken orally once daily starting on Day 6. Dosage adjustment is required in patients with a CYP2C9 *1/*3 or *2/*3 genotype (see Dosage and Administration (2.3)).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>Treatment Initiation</em>
Initiate MAYZENT with a 5-day titration, as shown in Table 1 (see Warnings and Precautions (5.3)). A starter pack should be used for patients who will be titrated to the 2-mg maintenance dosage (see How Supplied/Storage and Handling (16.1, 16.2)).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Recommended Dosage in Patients With CYP2C9 Genotypes *1/*3 or *2/*3</strong> .<br />
<em>Maintenance Dosage</em> In patients with a CYP2C9 *1/*3 or *2/*3 genotype, after treatment titration (see Treatment Initiation), the recommended maintenance dosage of MAYZENT is 1 mg taken orally once daily starting on Day 5.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>Treatment Initiation</em> Initiate MAYZENT with a 4-day titration, as shown in Table 2 (see Warnings and Precautions (5.3) and Use in Specific Populations (8.6)). Do not use the starter pack for patients who will be titrated to the 1-mg maintenance dosage.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>MAYZENT is contraindicated in patients who have:</p>
<ul>
<li>A CYP2C9*3/*3 genotype (see Use in Specific Populations (8.6) and Clinical Pharmacology (12.5))</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p><em>CYP2C9 genotype</em>:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Before initiation of treatment with MAYZENT, test patients to determine CYP2C9 genotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>MAYZENT is contraindicated in patients homozygous for CYP2C9*3 (i.e., CYP2C9*3/*3 genotype) because of substantially elevated siponimod plasma levels. The *3/*3 genotype is present in approximately 0.5% of white patients and 1% of Asian patients, and is less prevalent in other racial/ethnic groups.
MAYZENT dosage adjustment is recommended in patients with CYP2C9*1/*3 or *2/*3 genotype because of an increase in exposure to siponimod (see Dosage and Administration (2.3) and Clinical Pharmacology (12.5)). The *1/*3 or *2/*3 genotypes are present in 2% to 20% of the population depending on ancestry.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>There are other less frequently occurring polymorphisms in CYP2C9. Some polymorphisms, such as *5, *6, *8, and *11, are associated with decreased or loss of enzyme function. The impact of variants other than *2 and *3 on the pharmacokinetics of siponimod has not been evaluated. It is anticipated that variants that result in loss of CYP2C9 function (e.g., *6) will have similar effects on siponimod pharmacokinetics as the *3 variant (see Dosage and Administration (2.3) and Clinical Pharmacology (12.5)).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>12.5 Pharmacogenomics</em></p>
</blockquote>
<blockquote class=""blockquote"">
<p>The CYP2C9 genotype has a significant impact on siponimod metabolism. After a single dose of 0.25 mg siponimod, AUCinf and AUClast was approximately 2-and 4-fold higher in subjects with the CYP2C9*2/*3 and CYP2C9*3/*3 genotypes, respectively, while there was only a minor increase of Cmax by 21% and 16%, respectively, compared to extensive metabolizers (CYP2C9*1/*1). Mean half-life is prolonged in CYP2C9*2/*3 and CYP2C9*3/*3 carriers (51 hours and 126 hours, respectively).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>An apparent systemic clearance (CL/F) of about 3.11 L/h was estimated in CYP2C9 extensive metabolizer (CYP2C9*1/*1 and CYP2C9*1/*2) MS patients after multiple oral administrations of siponimod. Cl/F is 2.5, 1.9, 1.6, and 0.9 L/h in subjects with the CYP2C9*2/*2, CYP2C9*1/*3, CYP2C9*2/*3, and CYP2C9*3/*3 genotypes respectively. The resultant increase in siponimod AUC was approximatively 25, 61, 91, and 285% higher in CYP2C9*2/*2, CYP2C9*1/*3, CYP2C9*2/*3, and CYP2C9*3/*3 subjects, respectively, as compared to CYP2C9*1/*1 subjects (see Dosage and Administration (2.1, 2.3) and Contraindications (4)). As the apparent clearance estimated for CYP2C9*1*2 subjects is comparable to that of CYP2C9*1/*1 subjects, similar siponimod exposure is expected for both genotypes.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Variants other than *2 and *3 may also lead to decreased or loss of CYP2C9 function (e.g., *5, *6, *8, *11) and may have substrate-specific effects. The frequency of certain CYP2C9 variants differs based on ancestry. The *2 and *3 variants are more prevalent in patients of European or Asian ancestry, while *5, *6, *8, and *11 are more prevalent in individuals of African ancestry (see Use in Specific Populations (8.6)).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Siponimod_20230307_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Siponimod_20230307_FDA.pdf"">siponimod drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450400240.0,"<p>Excerpts from the siponimod drug label:</p>
<blockquote class=""blockquote"">
<p>MAYZENT is contraindicated in patients who have:</p>
<ul>
<li>A CYP2C9*3/*3 genotype (see Use in Specific Populations (8.6) and Clinical Pharmacology (12.5))</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Recommended Dosage in Patients With CYP2C9 Genotypes *1/*1, *1/*2, or *2/*2</strong>
<em>Maintenance Dosage</em>
After treatment titration (see Treatment Initiation), the recommended maintenance dosage of MAYZENT is 2 mg taken orally once daily starting on Day 6. Dosage adjustment is required in patients with a CYP2C9 *1/*3 or *2/*3 genotype (see Dosage and Administration (2.3)).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>Treatment Initiation</em>
Initiate MAYZENT with a 5-day titration, as shown in Table 1 (see Warnings and Precautions (5.3)). A starter pack should be used for patients who will be titrated to the 2-mg maintenance dosage (see How Supplied/Storage and Handling (16.1, 16.2)).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Recommended Dosage in Patients With CYP2C9 Genotypes *1/*3 or *2/*3</strong> .<br />
<em>Maintenance Dosage</em> In patients with a CYP2C9 *1/*3 or *2/*3 genotype, after treatment titration (see Treatment Initiation), the recommended maintenance dosage of MAYZENT is 1 mg taken orally once daily starting on Day 5.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>Treatment Initiation</em> Initiate MAYZENT with a 4-day titration, as shown in Table 2 (see Warnings and Precautions (5.3) and Use in Specific Populations (8.6)). Do not use the starter pack for patients who will be titrated to the 1-mg maintenance dosage.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166178724,"Annotation of FDA Label for neratinib and ESR1, ESR2, PGR",False,True,[],False,"[{'id': 1452207484, 'date': '2023-08-15T12:49:08.474-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101843, 'title': 'Drugs@FDA: Drug Product Nerlynx (neratinib), NDA208051, Puma Biotechnology, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208051', 'crossReferences': [{'id': 1449763693, 'resource': 'FDA Application', 'resourceId': 'NDA208051', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208051'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165291472', 'name': 'neratinib'}]","[{'objCls': 'Gene', 'id': 'PA156', 'symbol': 'ESR1', 'name': 'estrogen receptor 1'}, {'objCls': 'Gene', 'id': 'PA27886', 'symbol': 'ESR2', 'name': 'estrogen receptor 2'}, {'objCls': 'Gene', 'id': 'PA266', 'symbol': 'PGR', 'name': 'progesterone receptor'}]",FDA,1449310277.0,"<p>Neratinib (NERLYNX) is indicated for the treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer. The label notes the percentages of patients in clinical studies who had hormone receptor positive disease.</p>
",1449310276.0,"<p>Excerpt from the neratinib (NERLYNX) drug label:</p>
<blockquote class=""blockquote"">
<p>CLINICAL STUDIES...Extended Adjuvant Treatment in Breast Cancer...Fifty-seven percent (57%) had hormone receptor positive disease (defined as ER-positive and/or PgR-positive)...</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Neratinib_FDA_02_12_18.pdf"">neratinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182764,"Annotation of FDA Label for emapalumab and PRF1, RAB27A, SH2D1A, STX11, STXBP2, UNC13D, XIAP",False,False,[],False,"[{'id': 1452209200, 'date': '2023-08-17T13:47:57.604-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102390, 'title': 'Drugs@FDA: Drug Product GAMIFANT ((emapalumab-lzsg)), BLA761107, NovImmune SA', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761107', 'crossReferences': [{'id': 1450401056, 'resource': 'FDA Application', 'resourceId': 'BLA761107', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761107'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182763', 'name': 'emapalumab'}]","[{'objCls': 'Gene', 'id': 'PA33732', 'symbol': 'PRF1', 'name': 'perforin 1'}, {'objCls': 'Gene', 'id': 'PA34117', 'symbol': 'RAB27A', 'name': 'RAB27A, member RAS oncogene family'}, {'objCls': 'Gene', 'id': 'PA35728', 'symbol': 'SH2D1A', 'name': 'SH2 domain containing 1A'}, {'objCls': 'Gene', 'id': 'PA36229', 'symbol': 'STX11', 'name': 'syntaxin 11'}, {'objCls': 'Gene', 'id': 'PA36242', 'symbol': 'STXBP2', 'name': 'syntaxin binding protein 2'}, {'objCls': 'Gene', 'id': 'PA134919958', 'symbol': 'UNC13D', 'name': 'unc-13 homolog D'}, {'objCls': 'Gene', 'id': 'PA25361', 'symbol': 'XIAP', 'name': 'X-linked inhibitor of apoptosis'}]",FDA,1450401054.0,"<p>Emapalumab (GAMIFANT) is indicated for hemophagocytic lymphohistiocytosis (HLH): the FDA label lists some of the genes associated with HLH in patients in the NI-0501-04 clinical study.</p>
",1450401055.0,"<p>Excerpt from the emapalumab (GAMIFANT) drug label:</p>
<div class=""blockquote"">
<p>A genetic mutation known to cause HLH was present in 82% of patients. The most frequent causative mutations were FHL3-UNC13D (MUNC 13-4) (26%), FHL2-PRF1 (19%), and Griscelli Syndrome type 2 (19%).</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Emapalumab_05_13_2019FDA.pdf"">emapalumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166163431,"Annotation of FDA Label for isosorbide mononitrate and CYB5R1, CYB5R2, CYB5R3, CYB5R4",False,False,[],False,"[{'id': 1452543040, 'date': '2024-07-30T11:04:02.764-07:00', 'description': 'changed PGx level to Actionable', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101908, 'title': 'Drugs@FDA: Drug Product isosorbide mononitrate (isosorbide mononitrate), Lannett Company, Inc. - NDA020215/SUPPL-24, 10/02/2014', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020215', 'crossReferences': [{'id': 1452543006, 'resource': 'FDA Application', 'resourceId': 'NDA020215/SUPPL-24', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020215'}], 'objCls': 'Literature', 'pubDate': '2014-10-02T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450126', 'name': 'isosorbide mononitrate'}]","[{'objCls': 'Gene', 'id': 'PA134979668', 'symbol': 'CYB5R1', 'name': 'cytochrome b5 reductase 1'}, {'objCls': 'Gene', 'id': 'PA142672060', 'symbol': 'CYB5R2', 'name': 'cytochrome b5 reductase 2'}, {'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA134904907', 'symbol': 'CYB5R4', 'name': 'cytochrome b5 reductase 4'}]",FDA,1448605046.0,"<p>Isosorbide mononitrate (monoket) is indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The FDA-approved drug label provides information about patients with cytochrome b5 reductase activity and risk for methemoglobinemia.</p>
",1448605045.0,"<p>NADH-cytochrome b5 reductase is encoded by the <em>CYB5R1</em>, <em>CYB5R2</em>, <em>CYB5R3</em> and <em>CYB5R4</em> genes.</p>
<p>Excerpts from the isosorbide mononitrate (monoket) drug label:</p>
<blockquote class=""blockquote"">
<p>Methemoglobinemia has been reported in patients receiving other organic nitrates, and it probably could also occur as a side effect of isosorbide mononitrate. Certainly nitrate ions liberated during metabolism of isosorbide mononitrate can oxidize hemoglobin into methemoglobin. Even in patients totally without cytochrome b5 reductase activity, however, and even assuming that the nitrate moiety of isosorbide mononitrate is quantitatively applied to oxidation of hemoglobin, about 2 mg/kg of isosorbide mononitrate should be required before any of these patients manifests clinically significant (&gt;=10%) methemoglobinemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Notwithstanding these observations, there are case reports of significant methemoglobinemia in association with moderate overdoses of organic nitrates. None of the affected patients had been thought to be unusually susceptible.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Isosorbide_Mononitrate_08_02_2017_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Isosorbide_Mononitrate_08_02_2017_FDA.pdf"">isosorbide mononitrate drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182730,Annotation of FDA Label for amphetamine and CYP2D6,False,False,[],False,"[{'id': 1452488748, 'date': '2024-05-30T11:46:15.777-07:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}, {'id': 1452540402, 'date': '2024-07-26T16:46:49.014-07:00', 'description': 'updated label, changed level to Actionable PGx', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102370, 'title': 'Drugs@FDA: Drug Product Adzenys ER (Amphetamine), NDA204325, Neos Therapeutics, LP', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204325', 'crossReferences': [{'id': 1452540401, 'resource': 'FDA Application', 'resourceId': 'NDA204325/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204325'}], 'notes': 'Marketing Status: Discontinued', 'objCls': 'Literature', 'pubDate': '2017-09-15T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15162262, 'title': 'DailyMed - ADZENYS XR-ODT- amphetamine tablet, orally disintegrating', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c1179269-00b5-48ea-972d-31e614e99b7e', 'crossReferences': [{'id': 1452540400, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': 'c1179269-00b5-48ea-972d-31e614e99b7e', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c1179269-00b5-48ea-972d-31e614e99b7e'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448408', 'name': 'amphetamine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450400085.0,"<p>The FDA-approved drug label for amphetamine (ADZENYS XR-ODT) states that CYP2D6 is known to be involved with formation of 4-hydroxy-amphetamine. Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a possibility.</p>
",1450400086.0,"<p>Excerpts from the amphetamine (ADZENYS XR-ODT) drug label:</p>
<blockquote class=""blockquote"">
<p>Although the enzymes involved in amphetamine metabolism have not been clearly defined, CYP2D6 is known to be involved with formation of 4-hydroxy-amphetamine.
Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a possibility.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Amphetamine is known to inhibit monoamine oxidase, whereas the ability of amphetamine and its metabolites to inhibit various P450 isozymes and other enzymes has not been adequately elucidated. <em>In vitro</em> experiments with human microsomes indicate minor inhibition of CYP2D6 by amphetamine and minor inhibition of CYP1A2, 2D6, and 3A4 by one or more metabolites. However, due to the probability of autoinhibition and the lack of information on the concentration of these metabolites relative to <em>in vivo</em> concentrations, no predications regarding the potential for amphetamine or its metabolites to inhibit the metabolism of other drugs by CYP isozymes <em>in vivo</em> can be made.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Amphetamine_2024_07_26_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Amphetamine_2024_07_26_FDA.pdf"">amphetamine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452488747.0,"<blockquote class=""blockquote"">
<p>ADZENYS XR-ODT is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166184539,Annotation of FDA Label for paliperidone and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15103360, 'title': 'Drugs@FDA: Drug Product INVEGA (paliperidone), NDA021999, TYA Pharmaceuticals', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021999', 'crossReferences': [{'id': 1450821097, 'resource': 'FDA Application', 'resourceId': 'NDA021999', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021999'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA163518919', 'name': 'paliperidone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1450820879.0,"<p>The FDA-approved drug label for paliperidone (INVEGA) states that population pharmacokinetic analyses found no difference in exposure or clearance of paliperidone between extensive metabolizers and poor metabolizers of CYP2D6 substrates.</p>
",1450820880.0,"<p>Excerpts from the paliperidone (INVEGA) drug label:</p>
<div class=""blockquote"">
<p>Population pharmacokinetic analyses found no difference in exposure or clearance of paliperidone between extensive metabolizers and poor metabolizers of CYP2D6 substrates.</p>
</div>
<div class=""blockquote"">
<p>Paliperidone is metabolized to a limited extent by CYP2D6 (see Clinical Pharmacology 12.3). In an interaction study in healthy subjects in which a single 3 mg dose of INVEGA® was administered concomitantly with 20 mg per day of paroxetine (a potent CYP2D6 inhibitor), paliperidone exposures were on average 16% (90% CI: 4, 30) higher in CYP2D6 extensive metabolizers. Higher doses of paroxetine have not been studied. The clinical relevance is unknown</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Paliperidone_10_7_2019FDA.pdf"">paliperidone drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166104778,Annotation of FDA Label for brentuximab vedotin and ALK,False,True,[],False,"[{'id': 1183681507, 'date': '2013-10-25T12:19:23.197-07:00', 'type': 'Update', 'version': 0}, {'id': 1452057680, 'date': '2023-04-03T15:27:25.277-07:00', 'description': 'updated text', 'type': 'Update', 'version': 0}, {'id': 1452206360, 'date': '2023-08-14T12:10:43.313-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452230940, 'date': '2023-09-07T20:59:08.286-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101912, 'title': 'Drugs@FDA: Drug Product ADCETRIS (brentuximab vedotin), SEAGEN INC. - BLA125388/SUPPL-107, 06/14/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125388', 'crossReferences': [{'id': 1452566201, 'resource': 'FDA Application', 'resourceId': 'BLA125388/SUPPL-107', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125388'}], 'objCls': 'Literature', 'pubDate': '2023-06-14T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165948903', 'name': 'brentuximab vedotin'}]","[{'objCls': 'Gene', 'id': 'PA24719', 'symbol': 'ALK', 'name': 'ALK receptor tyrosine kinase'}]",FDA,1450320963.0,"<p>Brentuximab vedotin (ADCETRIS) is a CD30-directed antibody-drug conjugate indicated for treatment of patients with various lymphomas. The Clinical Studies section of the label notes the percentage of patients who were anaplastic lymphoma kinase (ALK) negative and positive in certain trials.</p>
",1450320964.0,"<p>Excerpts from the brentuximab vedotin (ADCETRIS) drug label:</p>
<blockquote class=""blockquote"">
<p>Use in specific population:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Newly Diagnosed ALK+ ALCL: The safety and effectiveness of ADCETRIS in combination with alternating chemotherapy Courses A (dexamethasone, ifosfamide, methotrexate, etoposide, cytarabine) and B (dexamethasone, methotrexate, cyclophosphamide, doxorubicin) administered every 21 days for a total of 6 cycles was assessed but have not been established based on a study (NCT01979536) in 67 patients, which included 61 pediatric patients age 2 to less than 17 with newly diagnosed ALK+ ALCL. No new safety signals were identified in this study.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Randomized Clinical Trial in Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas (Study 6: ECHELON-2, NCT01777152)...Of the 452 patients enrolled, the disease subtypes included patients with systemic ALCL (70%; 48% anaplastic lymphoma kinase (ALK) negative and 22% ALK positive)...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Clinical Trial in Relapsed sALCL (Study 2, NCT00866047)...Seventy-two percent (72%) were anaplastic lymphoma kinase (ALK)-negative...</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""BRENTUXIMAB_VEDOTIN_FDA_20230907.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/BRENTUXIMAB_VEDOTIN_FDA_20230907.pdf"">brentuximab vedotin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166105012,Annotation of FDA Label for escitalopram and CYP2C19,False,False,[],False,"[{'id': 1451267740, 'date': '2020-09-22T14:24:19.408-07:00', 'description': 'removed 2D6 to create an informative label annotation for 2D6', 'type': 'Update', 'version': 0}, {'id': 1452280180, 'date': '2023-10-24T14:15:42.074-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}, {'id': 1452823541, 'date': '2025-01-23T17:52:08.101-08:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15173382, 'title': 'Drugs@FDA: Drug Product Lexapro (ESCITALOPRAM), Allergan, Inc. - NDA021323/SUPPL-58, 04/19/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021323', 'crossReferences': [{'id': 1452823520, 'resource': 'FDA Application', 'resourceId': 'NDA021323/SUPPL-58', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021323'}], 'objCls': 'Literature', 'pubDate': '2024-04-19T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15102047, 'title': 'Drugs@FDA: Drug Product Lexapro (ESCITALOPRAM OXALATE), NDA021323, Allergan, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021323', 'crossReferences': [{'id': 1449754597, 'resource': 'FDA Application', 'resourceId': 'NDA021323', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021323'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10074', 'name': 'escitalopram'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1448257610.0,"<p>The FDA-approved drug label for escitalopram (Lexapro) notes that escitalopram exposure under a supratherapeutic 30 mg dose is similar to the steady state concentrations expected in CYP2C19 poor metabolizers following a therapeutic dose of 20 mg.</p>
",1450361374.0,"<p>Excerpts from the escitalopram (Lexapro) drug label:</p>
<blockquote class=""blockquote"">
<p>The exposure under supratherapeutic 30 mg dose is similar to the steady state concentrations expected in CYP2C19 poor metabolizers following a therapeutic dose of 20 mg.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>In vitro</em> studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of escitalopram.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Escitalopram_2025_01_23_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Escitalopram_2025_01_23_FDA.pdf"">escitalopram drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452823540.0,"<blockquote class=""blockquote"">
<p>Lexapro is a selective serotonin reuptake inhibitor (SSRI) indicated for the:</p>
<ul>
<li>treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older (1)</li>
<li>treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years and older (1)</li>
</ul>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166169882,Annotation of FDA Label for deutetrabenazine and CYP2D6,False,False,[],True,"[{'id': 1450399263, 'date': '2019-05-07T14:48:22.337-07:00', 'description': 'added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1452230960, 'date': '2023-09-07T21:18:12.895-07:00', 'description': 'updated label, text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101937, 'title': 'Drugs@FDA: Drug Product Austedo (Deutetrabenazine), NDA208082, Teva Neuroscience, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208082', 'crossReferences': [{'id': 1449754269, 'resource': 'FDA Application', 'resourceId': 'NDA208082', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208082'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166169881', 'name': 'deutetrabenazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1448821088.0,"<p>Deutetrabenazine (AUSTEDO) is indicated for treatment of chorea associated with Huntington's disease. The maximum recommended dosage in poor CYP2D6 metabolizers is 36 mg per day (i.e. 18 mg twice daily).</p>
",1448821087.0,"<p>Excerpts from the deutetrabenazine (AUSTEDO) drug label:</p>
<blockquote class=""blockquote"">
<p>Dosage Adjustment with Strong CYP2D6 Inhibitors: In patients receiving strong CYP2D6 inhibitors (e.g., quinidine, antidepressants such as paroxetine, fluoxetine, and bupropion), the total daily dosage of AUSTEDO should not exceed 36 mg (maximum single dose of 18 mg)</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dosage Adjustment in Poor CYP2D6 Metabolizers: In patients who are poor CYP2D6 metabolizers, the total daily dosage of AUSTEDO should not
exceed 36 mg (maximum single dose of 18 mg) (see Use in Specific Populations).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Poor CYP2D6 Metabolizers: Although the pharmacokinetics of deutetrabenazine and its metabolites have not been systematically evaluated in patients who do not express the drug metabolizing enzyme, it is likely that the exposure to α-HTBZ and β-HTBZ would be increased similarly to taking a strong CYP2D6 inhibitor (approximately 3-fold). In patients who are CYP2D6 poor metabolizers, the daily dose of AUSTEDO should not exceed 36 mg (maximum single dose of 18 mg).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Cardiac Electrophysiology: At the maximum recommended dose, AUSTEDO does not prolong the QT interval to any clinically relevant extent. An exposure-response analysis on QTc prolongation from a study in extensive or intermediate (EM) and poor CYP2D6 metabolizers (PM) showed that a clinicallyrelevant effect can be excluded at exposures following single doses of 24 and 48 mg of AUSTEDO.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""deutetrabenazine_FDA_20230907.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/deutetrabenazine_FDA_20230907.pdf"">deutetrabenazine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399262.0,"<p>Excerpts from the deutetrabenazine (AUSTEDO) drug label:</p>
<blockquote class=""blockquote"">
<p>In patients who are poor CYP2D6 metabolizers, the total daily dosage of AUSTEDO should not exceed 36 mg (maximum single dose of 18 mg).</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166104900,Annotation of FDA Label for pegloticase and G6PD,True,False,[],False,"[{'id': 1183681289, 'date': '2013-10-25T11:08:35.039-07:00', 'type': 'Update', 'version': 0}, {'id': 1183704781, 'date': '2013-12-18T00:00:00-08:00', 'type': 'Update', 'version': 0}, {'id': 1448604778, 'date': '2017-03-16T11:43:38.465-07:00', 'description': 'Testing level changed from recommended to required', 'type': 'Update', 'version': 0}, {'id': 1452055320, 'date': '2023-03-31T20:17:52.577-07:00', 'description': 'updated text', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101984, 'title': 'Drugs@FDA: Drug Product Krystexxa (pegloticase), BLA125293, Horizon Pharma Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125293', 'crossReferences': [{'id': 1449767797, 'resource': 'FDA Application', 'resourceId': 'BLA125293', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125293'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA165963961', 'name': 'pegloticase'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981777.0,"<p>The FDA-approved drug label for pegloticase (KRYSTEXXA) states that patients at risk for G6PD deficiency should be screened prior to starting treatment, and that the drug should not be administered to patients with G6PD deficiency.</p>
",1447981776.0,"<p>Patients deficient in G6PD have reduced ability to reduce the hydrogen peroxide formed as a major byproduct of the pegloticase-catalyzed oxidation of uric acid to allantoin.  Excerpts from the pegloticase (KRYSTEXXA) drug label:</p>
<blockquote class=""blockquote"">
<p>Screen patients at risk for G6PD deficiency prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. KRYSTEXXAis contraindicated inpatients with G6PD deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>G6PD Deficiency Associated Hemolysis and Methemoglobinemia: Screen patients at risk for G6PD deficiency. Do not administer KRYSTEXXA to patients with G6PD deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Life threatening hemolytic reactions and methemoglobinemia have been reported with KRYSTEXXA in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency...Screen patients at risk for G6PD deficiency prior to starting KRYSTEXXA. For example, patients of African, Mediterranean (including Southern European and Middle Eastern), and Southern Asian ancestry are at increased risk for G6PD deficiency.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Pegloticase_20230330_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Pegloticase_20230330_FDA.pdf"">pegloticase drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450399718.0,"<p>Excerpt from the pegloticase (KRYSTEXXA) drug label:</p>
<blockquote class=""blockquote"">
<p>Screen patients at risk for G6PD deficiency prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. KRYSTEXXAis contraindicated inpatients with G6PD deficiency.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>G6PD Deficiency Associated Hemolysis and Methemoglobinemia: Screen patients at risk for G6PD deficiency. Do not administer KRYSTEXXA to patients with G6PD deficiency.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166182961,Annotation of FDA Label for duvelisib,False,True,[],False,"[{'id': 1452206942, 'date': '2023-08-15T07:16:36.681-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102582, 'title': 'Drugs@FDA: Drug Product Copiktra (duvelisib), NDA211155, Verastem, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211155', 'crossReferences': [{'id': 1450417154, 'resource': 'FDA Application', 'resourceId': 'NDA211155', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211155'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182761', 'name': 'duvelisib'}]",[],FDA,1450417152.0,"<p>Duvelisib (COPIKTRA) is indicated for various leukemia types and the FDA label mentions that some patients had the 17p chromosomal deletion.</p>
",1450417153.0,"<p>Excerpt from the duvelisib (COPIKTRA) drug label:</p>
<div class=""blockquote"">
<p>At baseline, 52% of patients had at least one tumor = 5 cm, and 22% of patients had a documented 17p deletion.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Duvelisib_05_13_2019FDA.pdf"">duvelisib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166184636,"Annotation of FDA Label for tipiracil / trifluridine and ERBB2, KRAS",False,True,[],False,"[{'id': 1450824523, 'date': '2019-10-24T07:40:25.233-07:00', 'description': 'Added prescribing info', 'type': 'Update', 'version': 0}, {'id': 1451305360, 'date': '2020-12-30T12:48:31.810-08:00', 'description': 'changed PGx level from testing required to informative PGx, the testing is for previous therapies', 'type': 'Update', 'version': 0}, {'id': 1452217601, 'date': '2023-08-27T22:38:34.181-07:00', 'description': 'remove informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15148602, 'title': 'Drugs@FDA: Drug Product LONSURF (trifluridine and tipiracil), NDA207981, Taiho Pharmaceutical Co., Ltd.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207981', 'crossReferences': [{'id': 1452242641, 'resource': 'FDA Application', 'resourceId': 'NDA207981', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207981'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184566', 'name': 'tipiracil / trifluridine'}]","[{'objCls': 'Gene', 'id': 'PA27844', 'symbol': 'ERBB2', 'name': 'erb-b2 receptor tyrosine kinase 2'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",FDA,1450821511.0,"<p>The FDA-approved drug label for tipiracil / trifluridine (Lonsurf) states that it is indicated for patients who have failed other targeted therapies including those for KRAS negative metastatic colorectal cancer and HER2 positive (ERBB2) metastatic gastric or gastroesophageal junction cancers. Therefore testing was required for those prior therapies.</p>
",1450821512.0,"<p>Excerpts from the LONSURF drug label:</p>
<blockquote class=""blockquote"">
<p>LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor,
and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment
of adult patients with:</p>
<p>• metastatic colorectal cancer who have been previously treated with
fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an
anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR
therapy.</p>
<p>• metastatic gastric or gastroesophageal junction adenocarcinoma
previously treated with at least two prior lines of chemotherapy that
included a fluoropyrimidine, a platinum, either a taxane or irinotecan,
and if appropriate, HER2/neu-targeted therapy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The efficacy of LONSURF was evaluated in RECOURSE (NCT01607957) ... Randomization was stratified by KRAS status (wild-type vs. mutant),</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The efficacy of LONSURF was evaluated in TAGS (NCT02500043) ...Patients with HER2/neu-positive tumors must have
received prior HER2/neu-targeted therapy, if available.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/tipiracilTrifluridine_10_8_2019FDA.pdf"">Lonsurf drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166163414,"Annotation of FDA Label for ustekinumab and IL12A, IL12B, IL23A",False,False,[],False,"[{'id': 1451286240, 'date': '2020-10-30T14:02:22.539-07:00', 'description': 'set PGx tag from actionable to informative', 'type': 'Update', 'version': 0}, {'id': 1452220460, 'date': '2023-08-29T12:48:44.456-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102055, 'title': 'Drugs@FDA: Drug Product Stelara (ustekinumab), BLA761044, Janssen Biotech, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761044', 'crossReferences': [{'id': 1449890948, 'resource': 'FDA Application', 'resourceId': 'BLA761044', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761044'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166048654', 'name': 'ustekinumab'}]","[{'objCls': 'Gene', 'id': 'PA29784', 'symbol': 'IL12A', 'name': 'interleukin 12A'}, {'objCls': 'Gene', 'id': 'PA29785', 'symbol': 'IL12B', 'name': 'interleukin 12B'}, {'objCls': 'Gene', 'id': 'PA29824', 'symbol': 'IL23A', 'name': 'interleukin 23 subunit alpha'}]",FDA,1448604854.0,"<p>The FDA-approved drug label for ustekinumab (STELARA) states that serious infections from mycobacteria, salmonella and BCG vaccinations have been reported in patients who are genetically deficient in IL-12/IL-23, and that diagnostic tests for these infections should be considered as dictated by clinical circumstances.</p>
",1448604853.0,"<p>Ustekinumab (STELARA) is a human interleukin-12 and -23 antagonist indicated for the treatment of adult patients with plaque psoriasis, psoriatic arthritis or Crohn's disease.</p>
<p>Excerpt from the ustekinumab (STELARA) drug label:</p>
<div class=""blockquote"">
<p>Theoretical Risk for Vulnerability to Particular Infections...Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria (including nontuberculous, environmental mycobacteria), salmonella (including nontyphi strains), and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and fatal outcomes have been reported in such patients. It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with STELARA may be susceptible to these types of infections. Appropriate diagnostic testing should be considered, e.g., tissue culture, stool culture, as dictated by clinical circumstances.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Ustekinumab_08_31_2017_FDA.pdf"">ustekinumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166123487,Annotation of FDA Label for eliglustat and CYP2D6,False,False,[],True,"[{'id': 1452218540, 'date': '2023-08-28T09:21:50.345-07:00', 'description': 'Added Alternate Drug tag because drug is not indicated for UMs', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101990, 'title': 'Drugs@FDA: Drug Product Cerdelga (eliglustat), Genzyme Corporation - NDA205494/SUPPL-3, 08/29/2018', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205494', 'crossReferences': [{'id': 1452460340, 'resource': 'FDA Application', 'resourceId': 'NDA205494/SUPPL-3', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205494'}], 'objCls': 'Literature', 'pubDate': '2018-08-29T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166123486', 'name': 'eliglustat'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1447982161.0,"<p>The FDA-approved drug label for eliglustat (CERDELGA) states that it is indicated for patients with Gaucher disease type 1. CYP2D6 intermediate and extensive metabolizers have a recommended dose of 84 mg twice daily, while poor metabolizers have a recommended dose of 84 mg once daily. The label notes that CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of eliglustat to achieve a therapeutic effect.</p>
",1450361340.0,"<p>Eliglustat (CERDELGA) is a glucosylceramide synthase inhibitor used for the long-term treatment of adult patients with Gaucher disease type 1.</p>
<p>Excerpts from the eliglustat (CERDELGA) drug label:</p>
<blockquote class=""blockquote"">
<p>CERDELGA is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs) or poor metabolizers (PMs) as detected by an FDA-cleared test...<strong>CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of CERDELGA to achieve a therapeutic effect.</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<p>Select patients with Gaucher disease type 1 based on their CYP2D6 metabolizer status. It is recommended patient genotypes be established using an FDA-cleared test for determining CYP2D6 genotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A specific dosage cannot be recommended for CYP2D6 indeterminate metabolizers...<strong>CYP2D6 EMs or IMs: 84 mg orally twice daily...CYP2D6 PMs: 84 mg orally once daily.</strong></p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Eliglustat_01_16_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Eliglustat_01_16_19_FDA.pdf"">eliglustat drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1450378812.0,"<p>Excerpts from the eliglustat (CERDELGA) drug label:</p>
<blockquote class=""blockquote"">
<p>CERDELGA is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs) or poor metabolizers (PMs) as detected by an FDA-cleared test...CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of CERDELGA to achieve a therapeutic effect.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A specific dosage cannot be recommended for CYP2D6 indeterminate metabolizers...<strong>CYP2D6 EMs or IMs: 84 mg orally twice daily...CYP2D6 PMs: 84 mg orally once daily.</strong></p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166177483,Annotation of FDA Label for desvenlafaxine and CYP2D6,False,False,[],False,"[{'id': 1452206920, 'date': '2023-08-15T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15102008, 'title': 'Drugs@FDA: Drug Product Pristiq Extended-Release (desvenlafaxine succinate), NDA021992, PD-Rx Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021992', 'crossReferences': [{'id': 1449754266, 'resource': 'FDA Application', 'resourceId': 'NDA021992', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021992'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165958374', 'name': 'desvenlafaxine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1449169734.0,"<p>Desvenlafaxine (PRISTIQ) is indicated for the treatment of adults with major depressive disorder. The label notes that the pharmacokinetics of the drug are similar in CYP2D6 poor metabolizers and CYP2D6 extensive metabolizers.</p>
",1449169733.0,"<p>Excerpt from the desvenlafaxine (PRISTIQ) drug label:</p>
<blockquote class=""blockquote"">
<p>The pharmacokinetics of desvenlafaxine was similar in subjects with CYP2D6 poor and extensive metabolizer phenotype.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Desvenlafaxine_FDA_02_12_18.pdf"">desvenlafaxine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166151878,"Annotation of FDA Label for lapatinib and HLA-DQA1, HLA-DRB1",False,False,[],False,"[{'id': 1447952303, 'date': '2016-03-21T13:37:30.470-07:00', 'type': 'Update', 'version': 0}, {'id': 1451254040, 'date': '2020-08-24T05:15:55.011-07:00', 'description': 'Tagged variants.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101934, 'title': 'Drugs@FDA: Drug Product TYKERB (lapatinib), NDA022059, Novartis Pharmaceuticals Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022059', 'crossReferences': [{'id': 1449754837, 'resource': 'FDA Application', 'resourceId': 'NDA022059', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022059'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165951292', 'symbol': 'HLA-DQA1*02:01', 'name': '*02:01'}, {'objCls': 'Haplotype', 'id': 'PA165951644', 'symbol': 'HLA-DRB1*07:01', 'name': '*07:01'}]","[{'objCls': 'Chemical', 'id': 'PA152241907', 'name': 'lapatinib'}]","[{'objCls': 'Gene', 'id': 'PA35066', 'symbol': 'HLA-DQA1', 'name': 'major histocompatibility complex, class II, DQ alpha 1'}, {'objCls': 'Gene', 'id': 'PA35072', 'symbol': 'HLA-DRB1', 'name': 'major histocompatibility complex, class II, DR beta 1'}]",FDA,1447982437.0,"<p>Lapatinib (TYKERB) is indicated for patients with breast cancer whose tumors overexpress HER2 (<em>ERBB2</em>). The FDA-approved drug label for lapatinib notes that the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have been associated with hepatotoxicity in individuals received the drug, but does not discuss genetic testing for these alleles.</p>
",1447982436.0,"<p>Excerpts from the lapatinib (TYKERB) drug label:</p>
<div class=""blockquote"">
<p>Pharmacogenomics. The HLA alleles DQA1*02:01 and DRB1*07:01 were associated with hepatotoxicity reactions in a genetic substudy of a monotherapy trial with TYKERB (n = 1,194). Severe liver injury (ALT &gt;5 times the upper limit of normal, NCI CTCAE Grade 3) occurred in 2% of patients overall; the incidence of severe liver injury among DQA1*02:01 or DRB1*07:01 allele carriers was 8% versus 0.5% in non-carriers. These HLA alleles are present in approximately 15% to 25% of Caucasian, Asian, African, and Hispanic populations and 1% in Japanese populations. Liver function should be monitored in all patients receiving therapy with TYKERB regardless of genotype.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Lapatinib_08_03_2017_FDA.pdf"">lapatinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166160040,Annotation of FDA Label for Parathyroid Hormones And Analogues and CASR,False,False,[],False,"[{'id': 1452214380, 'date': '2023-08-23T12:49:35.322-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101877, 'title': 'Drugs@FDA: Drug Product NATPARA (parathyroid hormone) (PARATHYROID HORMONE), BLA125511, Shire-NPS Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125511', 'crossReferences': [{'id': 1449767783, 'resource': 'FDA Application', 'resourceId': 'BLA125511', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125511'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164713150', 'name': 'Parathyroid Hormones And Analogues'}]","[{'objCls': 'Gene', 'id': 'PA26097', 'symbol': 'CASR', 'name': 'calcium sensing receptor'}]",FDA,1448257345.0,"<p>The FDA-approved drug label for parathyroid hormone (NATPARA) states that it was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor (<em>CASR</em>) mutations.</p>
",1448257344.0,"<p>Parathyroid hormone (NATPARA) is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.</p>
<p>Excerpts from the parathyroid hormone (NATPARA) drug label:</p>
<div class=""blockquote"">
<p>NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations.</p>
</div>
<div class=""blockquote"">
<p>The efficacy of NATPARA was evaluated in a 24-week, randomized, double-blind, placebo-controlled, multicenter trial...Patients with hypoparathyroidism due to calcium-sensing receptor mutations were excluded from the trial...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Parathyroid_Hormone_02_20_19_FDA.pdf"">parathyroid hormone drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166122594,Annotation of FDA Label for sofosbuvir and IFNL3,False,False,[],False,"[{'id': 1184483239, 'date': '2014-07-14T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452215304, 'date': '2023-08-24T15:52:53.161-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101931, 'title': 'Drugs@FDA: Drug Product Sovaldi (SOFOSBUVIR), NDA204671, Gilead Sciences, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204671', 'crossReferences': [{'id': 1449776678, 'resource': 'FDA Application', 'resourceId': 'NDA204671', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204671'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166155468', 'symbol': 'rs12979860', 'name': 'rs12979860'}]","[{'objCls': 'Chemical', 'id': 'PA166122593', 'name': 'sofosbuvir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",FDA,1447982107.0,"<p>Sofosbuvir (SOVALDI) is indicated for the treatment of chronic hepatitis C in combination with ribavirin and/or peg-interferon alfa. The FDA-approved drug label for sofosbuvir contains information regarding a genetic variant near the IFNL3 gene (IL28B, <a href=""/variant/PA166155468"">rs12979860</a>, a C to T change). Though the sofosbuvir label itself does not discuss why this variant is relevant, literature evidence has shown that this variant is a strong predictor of response to peginterferon alfa and ribavirin treatment.</p>
",1447982106.0,"<p>Excerpt from the sofosbuvir (SOVALDI) drug label:</p>
<div class=""blockquote"">
<p>Clinical Trials in Subject with Genotype 1 or 4 HCV...Treatment-Naive Adults - NEUTRINO (Study 110)...SVR12 rates were 99% (89/90) in subjects with genotype 1 or 4 HCV and baseline IL28B C/C allele and 87% (200/230) in subjects with genotype 1 or 4 HCV and baseline IL28B non-C/C alleles.s..</p>
</div>
<div class=""blockquote"">
<p>Clinical Trials in Adult Subjects Coinfected with HCV and HIV-1...SVR12 rates in subjects with HCV genotype 1 infection were 80% (24/30) in subjects with baseline IL28B C/C allele and 75% (62/83) in subjects with baseline IL28B non-C/C alleles...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Sofosbuvir_02_26_19_FDA.pdf"">sofosbuvir drug label </a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166105148,Annotation of FDA Label for glipizide and G6PD,True,False,[],False,"[{'id': 1183704748, 'date': '2013-12-17T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1452216562, 'date': '2023-08-25T00:39:15.988-07:00', 'description': 'Added ""Alternate Drug"" tag based on updated definition', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101868, 'title': 'Drugs@FDA: Drug Product Glucotrol (glipizide), NDA017783, Roerig', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017783', 'crossReferences': [{'id': 1449754739, 'resource': 'FDA Application', 'resourceId': 'NDA017783', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017783'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449762', 'name': 'glipizide'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1447981914.0,"<p>The FDA-approved drug label for glipizide (GLUCOTROL) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the <em>G6PD</em> gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.</p>
",1447981913.0,"<p>Glipizide (GLUCOTROL) is a blood-glucose-lowering drug indicated for use in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.</p>
<p>Excerpt from the glipizide (GLUCOTROL) drug label:</p>
<div class=""blockquote"">
<p>Hemolytic Anemia: Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because GLUCOTROL belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Glipizide_02_05_19_FDA.pdf"">glipizide drug label</a>.</p>
<p>*Disclaimer: The contents of this page are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450399215.0,"<p>Excerpt from the glipizide (GLUCOTROL) drug label:</p>
<blockquote class=""blockquote"">
<p>Because GLUCOTROL belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166105113,Annotation of FDA Label for donepezil and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15101827, 'title': 'Drugs@FDA: Drug Product Aricept (donepezil hydrochloride), Eisai Inc. - NDA020690/SUPPL-42, 12/18/2018', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020690', 'crossReferences': [{'id': 1453106712, 'resource': 'FDA Application', 'resourceId': 'NDA020690/SUPPL-42', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020690'}], 'objCls': 'Literature', 'pubDate': '2018-12-18T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449394', 'name': 'donepezil'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1448603832.0,"<p>The FDA-approved drug label for donepezil (ARICEPT) states that it is metabolized by the CYP2D6 and CYP3A4 enzymes, and that there are differences in clearance values among CYP2D6 poor, extensive and ultra-rapid metabolizers.</p>
",1450361146.0,"<p>Donepezil (ARICEPT) is indicated for the treatment of dementia of the Alzheimer's type.</p>
<p>Excerpts from the donepezil (ARICEPT) drug label:</p>
<div class=""blockquote"">
<p>Donepezil is metabolized by CYP 450 isoenzymes 2D6 and 3A4 and undergoes glucuronidation.</p>
</div>
<div class=""blockquote"">
<p>Examination of the effect of CYP2D6 genotype in Alzheimer's patients showed differences in clearance values among CYP2D6 genotype subgroups. When compared to the extensive metabolizers, poor metabolizer had a 31.5% slower clearance and ultra-rapid metabolizers had a 24% faster clearance.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Donepezil_01_15_19_FDA.pdf"">donepezil drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182021,Annotation of FDA Label for amifampridine phosphate and NAT2,False,False,[],True,"[{'id': 1450820726, 'date': '2019-10-04T00:00:00-07:00', 'description': 'Checked with no changes.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102109, 'title': 'Drugs@FDA: Drug Product Firdapse (amifampridine phosphate), NDA208078, Catalyst Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208078', 'crossReferences': [{'id': 1450371540, 'resource': 'FDA Application', 'resourceId': 'NDA208078', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208078'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166182002', 'name': 'amifampridine phosphate'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",FDA,1450371537.0,"<p>The FDA-approved drug label for amifampridine phosphate (FIRDAPSE) states that NAT2 poor metabolizers have higher concentrations of the drug as compared to normal metabolizers, and that the drug should be initiated at the lowest recommended starting dosage in these patients.</p>
",1450371538.0,"<p>Amifampridine phosphate (FIRDAPSE) is indicated for the treatment of Lambert-Eaton myasthenic syndrome.</p>
<p>Excerpts from the amifampridine phosphate (FIRDAPSE) drug label:</p>
<div class=""blockquote"">
<p>The recommended starting dosage of FIRDAPSE in known N-acetyltransferase 2 (NAT2) poor metabolizers is 15 mg daily, taken orally in 3 divided doses.</p>
</div>
<div class=""blockquote"">
<p>Genetic variants in the N-acetyltransferase gene 2 (NAT2) affect the rate and extent of FIRDAPSE metabolism. Poor metabolizers, also referred to as “slow acetylators” (i.e., carriers of two reduced function alleles), have 3.5- to 4.5-fold higher Cmax, and 5.6- to 9­ fold higher AUC than normal metabolizers, also referred to as “fast/rapid acetylators” (i.e., carriers of two normal function alleles). Therefore, FIRDAPSE should be initiated at the lowest recommended starting dosage (15 mg/day) in known NAT2 poor metabolizers, and such patients should be closely monitored for adverse reactions...In the general population, the NAT2 poor metabolizer phenotype prevalence is 40–60% in the White and African American populations, and in 10–30% in Asian ethnic populations (individuals of Japanese, Chinese, or Korean descent).</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Amifampridine_03_14_19_FDA.pdf"">amifampridine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450371543.0,"<p>Excerpt from the amifampridine phosphate (FIRDAPSE) drug label:</p>
<blockquote class=""blockquote"">
<p>The recommended starting dosage of FIRDAPSE in known N-acetyltransferase 2 (NAT2) poor metabolizers is 15 mg daily, taken orally in 3 divided doses.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166170939,"Annotation of FDA Label for trastuzumab and ESR1, ESR2, PGR",False,True,[],False,"[{'id': 1452220440, 'date': '2023-08-29T12:37:30.022-07:00', 'description': 'removed actionable PGx level tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101841, 'title': 'Drugs@FDA: Drug Product Herceptin (Trastuzumab), BLA103792, Genentech, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792', 'crossReferences': [{'id': 1449889041, 'resource': 'FDA Application', 'resourceId': 'BLA103792', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103792'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451743', 'name': 'trastuzumab'}]","[{'objCls': 'Gene', 'id': 'PA156', 'symbol': 'ESR1', 'name': 'estrogen receptor 1'}, {'objCls': 'Gene', 'id': 'PA27886', 'symbol': 'ESR2', 'name': 'estrogen receptor 2'}, {'objCls': 'Gene', 'id': 'PA266', 'symbol': 'PGR', 'name': 'progesterone receptor'}]",FDA,1449055521.0,"<p>Trastuzumab (Herceptin) is used for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The label also notes overall survival hazard ratios based on whether patients had hormone receptor-positive disease or hormone receptor-negative disease.</p>
",1449055520.0,"<p>Excerpt from the trastuzumab (Herceptin) drug label:</p>
<div class=""blockquote"">
<p>In the subgroup of patients with hormone receptor-positive disease (ER-positive and/or PR-positive) (n = 2223), the hazard ratio for OS was 0.63 (95% CI: 0.51, 0.78). In the subgroup of patients with hormone receptor-negative disease (ER-negative and PR-negative) (n = 1830), the hazard ratio for OS was 0.64 (95% CI: 0.52, 0.80)</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Trastuzumab_08_31_2017_FDA.pdf"">trastuzumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166313381,"Annotation of FDA Label for polatuzumab vedotin and BCL2, BCL6, MYC",False,True,[],False,[],False,[],True,"[{'id': 15147942, 'title': 'Drugs@FDA: Drug Product POLIVY (polatuzumab vedotin), BLA761121, Genentech, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761121', 'crossReferences': [{'id': 1452230700, 'resource': 'FDA Application', 'resourceId': 'BLA761121', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761121'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166313341', 'name': 'polatuzumab vedotin'}]","[{'objCls': 'Gene', 'id': 'PA25302', 'symbol': 'BCL2', 'name': 'BCL2 apoptosis regulator'}, {'objCls': 'Gene', 'id': 'PA25312', 'symbol': 'BCL6', 'name': 'BCL6 transcription repressor'}, {'objCls': 'Gene', 'id': 'PA31353', 'symbol': 'MYC', 'name': 'MYC proto-oncogene, bHLH transcription factor'}]",FDA,1452230680.0,"<p>The FDA label for polatuzumab vedotin discusses a study where some patients had MYC, BCL2 and/or BCL6 rearrangements.</p>
",1452230660.0,"<p>Excerpt from the <em><strong>polatuzumab vedotin-piiq</strong></em> (<em><strong>POLIVY</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>The majority of patients had DLBCL, NOS (84%; n = 740), 11% (n = 93) had HGBL with MYC and BCL2 and/or BCL6 rearrangements or HGBL, NOS, and 5% had other large B-cell lymphomas.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""polatuzumab_FDA_2023_09_07.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/polatuzumab_FDA_2023_09_07.pdf""><em><strong>Polatuzumab</strong></em> drug label</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166314003,"Annotation of FDA Label for odevixibat and JAG1, NOTCH2",False,False,[],False,[],False,[],True,"[{'id': 15131043, 'title': 'Drugs@FDA: Drug Product Bylvay (odevixibat), Ipsen Biopharmaceuticals, Inc. - NDA215498/SUPPL-3, 06/13/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215498', 'crossReferences': [{'id': 1452557721, 'resource': 'FDA Application', 'resourceId': 'NDA215498/SUPPL-3', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215498'}], 'objCls': 'Literature', 'pubDate': '2023-06-13T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166268805', 'name': 'odevixibat'}]","[{'objCls': 'Gene', 'id': 'PA29986', 'symbol': 'JAG1', 'name': 'jagged canonical Notch ligand 1'}, {'objCls': 'Gene', 'id': 'PA31684', 'symbol': 'NOTCH2', 'name': 'notch receptor 2'}]",FDA,1452237124.0,"<p>The FDA label for odevixibat (Bylvay) states that BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). JAG1 and NOTCH2 mutations implicated in ALGS are mentioned in the clinical studies section.</p>
",1452237125.0,"<p>Excerpts from the odevixibat (Bylvay) label:</p>
<blockquote class=""blockquote"">
<p>Indications and usage:</p>
<p>BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for:</p>
<p>Progressive Familial Intrahepatic Cholestasis (PFIC)• the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).</p>
<p>Alagille Syndrome (ALGS): BYLVAY is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with ALGS.</p>
<p>Clinical Studies: Alagille Syndrome (ALGS): : 92% of patients had the JAG1 mutation and 8% had the NOTCH2 mutation.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""odevixibat_FDA_20230913.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/odevixibat_FDA_20230913.pdf"">odevixibat drug label</a>.</p>
</blockquote>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166182722,Annotation of FDA Label for erdafitinib and CYP2C9,False,False,[],False,"[{'id': 1450399948, 'date': '2019-05-14T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450821495, 'date': '2019-10-09T14:38:41.944-07:00', 'description': 'Added tag for FDA biomarker list', 'type': 'Update', 'version': 0}, {'id': 1452623500, 'date': '2024-10-03T17:21:24.301-07:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15166882, 'title': 'Drugs@FDA: Drug Product BALVERSA (Erdafitinib), Janssen Products LP - NDA212018/SUPPL-9, 01/19/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212018', 'crossReferences': [{'id': 1452623461, 'resource': 'FDA Application', 'resourceId': 'NDA212018/SUPPL-9', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212018'}], 'objCls': 'Literature', 'pubDate': '2024-01-19T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]","[{'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA166182720', 'name': 'erdafitinib'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1450399945.0,"<p>The FDA-approved label for erdafitinib (BALVERSA) states that it is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations and whose disease has progressed on or after at least one line of prior systemic therapy. The label further states that erdafitinib plasma concentrations were predicted to be higher in patients with the CYP2C9*3/*3 genotype and to monitor for increased adverse reactions in patients who are known or suspected to have CYP2C9*3/*3 genotype.</p>
",1450399946.0,"<p>Excerpt from the erdafitinib (BALVERSA) drug label:</p>
<blockquote class=""blockquote"">
<p><strong>CYP2C9 Poor Metabolizers</strong>
<em>CYP2C9*3/*3 Genotype:</em> Erdafitinib plasma concentrations are predicted to be higher in patients with the CYP2C9*3/*3 genotype. Monitor for increased adverse reactions in patients who are known or suspected to have CYP2C9*3/*3 genotype [see Pharmacogenomics (12.5)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C9 activity is reduced in individuals with genetic variants, such as the CYP2C9*2 and CYP2C9*3 polymorphisms. Erdafitinib exposure was similar in subjects with CYP2C9*1/*2 and *1/*3 genotypes relative to subjects with CYP2C9*1/*1 genotype (wild type). No data are available in subjects characterized by other genotypes (e.g., *2/*2, *2/*3, *3/*3). Simulation suggested no clinically meaningful differences in erdafitinib exposure in subjects with CYP2C9*2/*2 and *2/*3 genotypes. The exposure of erdafitinib is predicted to be 50% higher in subjects with the CYP2C9*3/*3 genotype, estimated to be present in 0.4% to 3% of the population among various ethnic groups.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Erdafitinib_2024_10_03_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Erdafitinib_2024_10_03_FDA.pdf"">erdafitinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451139260.0,"<p>Excerpt from the erdafitinib (BALVERSA) drug label:</p>
<blockquote class=""blockquote"">
<p>Monitor for increased adverse reactions in patients who are known or suspected to have CYP2C9*3/*3 genotype.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166316281,Annotation of FDA Label for trofinetide and MECP2,False,False,[],False,[],False,[],True,"[{'id': 15148882, 'title': 'Drugs@FDA: Drug Product Daybue (trofinetide), NDA217026, Acadia Pharmaceuticals Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217026', 'crossReferences': [{'id': 1452250460, 'resource': 'FDA Application', 'resourceId': 'NDA217026', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217026'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166313324', 'name': 'trofinetide'}]","[{'objCls': 'Gene', 'id': 'PA30729', 'symbol': 'MECP2', 'name': 'methyl-CpG binding protein 2'}]",FDA,1452250440.0,"<p>Trofinetide (DAYBUE) is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. Clinical studies were performed in patients with a diagnosis of typical Rett syndrome according to the Rett Syndrome Diagnostic Criteria with a documented disease-causing mutation in the MECP2 gene.</p>
",1452250441.0,"<p>Excerpts from the trofinetide (DAYBUE) label:</p>
<blockquote class=""blockquote"">
<p>DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Trofinetide is not significantly metabolized by CYP450 enzymes.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""trofinetide_2023_09_27_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/trofinetide_2023_09_27_FDA.pdf"">trofinetide drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166316301,Annotation of FDA Label for plazomicin and MT-RNR1,True,False,[],False,[],False,[],True,"[{'id': 15148902, 'title': 'Drugs@FDA: Drug Product Zemdri (plazomicin) (Plazomicin), Achaogen, Inc. - NDA210303/SUPPL-7, 02/10/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210303', 'crossReferences': [{'id': 1452495642, 'resource': 'FDA Application', 'resourceId': 'NDA210303/SUPPL-7', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210303'}], 'objCls': 'Literature', 'pubDate': '2023-02-10T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]","[{'objCls': 'Variant', 'id': 'PA166159181', 'symbol': 'rs267606617', 'name': 'rs267606617'}]","[{'objCls': 'Chemical', 'id': 'PA166228921', 'name': 'plazomicin'}]","[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]",FDA,1452252280.0,"<p>Plazomicin (ZEMDRI) is an aminoglycoside antibacterial indicated for the treatment of patients 18 years of age or older with Complicated Urinary Tract Infections (cUTI) including Pyelonephritis.</p>
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A&gt;G variant. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
",1452252281.0,"<p>Excerpts from the plazomicin (ZEMDRI) label:</p>
<blockquote class=""blockquote"">
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A&gt;G variant. Ototoxicity occurred in some patients even when their aminoglycoside serum levels were within the recommended range. Mitochondrial DNA variants are present in less than 1% of the general US population, and the proportion of the variant carriers who may develop ototoxicity as well as the severity of ototoxicity is unknown. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""plazomicin_2023_09_27_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/plazomicin_2023_09_27_FDA.pdf"">plazomicin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452252282.0,"<blockquote class=""blockquote"">
<p>In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166316321,Annotation of FDA Label for amikacin and MT-RNR1,True,False,[],False,[],False,[],True,"[{'id': 15148922, 'title': 'Drugs@FDA: Drug Product ARIKAYCE (Amikacin), NDA207356, Insmed Incorporated', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207356', 'crossReferences': [{'id': 1452495640, 'resource': 'FDA Application', 'resourceId': 'NDA207356/SUPPL-12', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207356'}], 'objCls': 'Literature', 'pubDate': '2023-02-10T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]","[{'objCls': 'Variant', 'id': 'PA166159181', 'symbol': 'rs267606617', 'name': 'rs267606617'}]","[{'objCls': 'Chemical', 'id': 'PA164744372', 'name': 'amikacin'}]","[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]",FDA,1452252460.0,"<p>Amikacin (ARIKAYCE) is an aminoglycoside antibacterial indicated in adults who have limited or no alternative treatment options, for the treatment of <em>Mycobacterium avium</em> complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy.</p>
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A&gt;G variant. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
",1452252461.0,"<p>Excerpt from the amikacin (ARIKAYCE) label:</p>
<blockquote class=""blockquote"">
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A&gt;G variant. Ototoxicity occurred in some patients even when their aminoglycoside serum levels were within the recommended range. Mitochondrial DNA variants are present in less than 1% of the general US population, and the proportion of the variant carriers who may develop ototoxicity as well as the severity of ototoxicity is unknown. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""amikacin_2023_09_27_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/amikacin_2023_09_27_FDA.pdf"">amikacin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452252462.0,"<blockquote class=""blockquote"">
<p>In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166316341,Annotation of FDA Label for tobramycin and MT-RNR1,True,False,[],False,[],False,[],True,"[{'id': 15148942, 'title': 'Drugs@FDA: Drug Product BETHKIS (tobramycin), NDA201820, Chiesi USA, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201820', 'crossReferences': [{'id': 1452495643, 'resource': 'FDA Application', 'resourceId': 'NDA201820/SUPPL-6', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201820'}], 'objCls': 'Literature', 'pubDate': '2023-02-10T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]","[{'objCls': 'Variant', 'id': 'PA166159181', 'symbol': 'rs267606617', 'name': 'rs267606617'}]","[{'objCls': 'Chemical', 'id': 'PA451704', 'name': 'tobramycin'}]","[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]",FDA,1452252520.0,"<p>Tobramycin (BETHKIS) is an inhaled aminoglycoside antibacterial indicated for the management of cystic fibrosis patients with <em>Pseudomonas aeruginosa</em>.</p>
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A&gt;G variant. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
",1452252521.0,"<p>Excerpt from the tobramycin (BETHKIS) label:</p>
<blockquote class=""blockquote"">
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A&gt;G variant. Ototoxicity occurred in some patients even when their aminoglycoside serum levels were within the recommended range. Mitochondrial DNA variants are present in less than 1% of the general US population, and the proportion of the variant carriers who may develop ototoxicity as well as the severity of ototoxicity is unknown. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""tobramycin_2023_09_27_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/tobramycin_2023_09_27_FDA.pdf"">tobramycin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452252522.0,"<blockquote class=""blockquote"">
<p>In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166317742,Annotation of EMA Label for margetuximab,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166235241', 'name': 'margetuximab'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166190261,"Annotation of FDA Label for estradiol / progesterone and PROC, PROS1, SERPINC1",True,False,[],False,[],False,[],True,"[{'id': 15104542, 'title': 'Drugs@FDA: Drug Product  estradiol and progesterone NDA210132', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210132', 'crossReferences': [{'id': 1452245720, 'resource': 'FDA Application', 'resourceId': 'NDA210132', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210132'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166190221', 'name': 'estradiol / progesterone'}]","[{'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",FDA,1450968460.0,"<p>Estradiol / progesterone (BIJUVA) is a combination of an estrogen and progesterone indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause. It is contraindicated in patients with known protein C (PROC), protein S (PROS1), or antithrombin (SERPINC1) deficiency, or other known thrombophilic disorders.</p>
",1450968461.0,"<p>Excerpt from the estradiol / progesterone (BIJUVA) drug label:</p>
<blockquote class=""blockquote"">
<p>Contraindication:</p>
<p>Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/estradiol_progesterone_02_14_2020_FDA.pdf"">estradiol/progesterone drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450968462.0,"<p>Excerpt from the estradiol / progesterone (BIJUVA) drug label:</p>
<blockquote class=""blockquote"">
<p>Contraindication:</p>
<p>Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166251621,Annotation of FDA Label for viloxazine and SLCO1B1,False,False,[],False,"[{'id': 1452220500, 'date': '2023-08-29T12:55:17.633-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15123802, 'title': 'Drugs@FDA: Drug Product  QELBREE (VILOXAZINE HYDROCHLORIDE), NDA211964, SUPERNUS PHARMS', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211964', 'crossReferences': [{'id': 1452245662, 'resource': 'FDA Application', 'resourceId': 'NDA211964', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211964'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166251581', 'name': 'viloxazine'}]","[{'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",FDA,1451526170.0,"<p>The viloxazine FDA label mentions that it is not an inhibitor or a substrate of &quot;OATP1B1*1a&quot;. OATP1B1 is encoded by <a href=""/gene/PA134865839"">SLCO1B1</a> and likely OATP1B1*1a refers to the protein formed by the reference sequence of SLCO1B1, however this is not explained in the label.</p>
",1451526171.0,"<p>Excerpt from the FDA label:</p>
<blockquote class=""blockquote"">
<p>Viloxazine is not a inhibitor of P-gp, BCRP, MATE2-K,OATP1B1*1a, and OATP1B3 transporters. Viloxazine appears to be a weak inhibitor of the MATE1. Viloxazine is not a substrate of either OATP1B1*1a or OATP1B3 transporters.</p>
</blockquote>
<p>Note that OATP1B1 is encoded by <a href=""/gene/PA134865839"">SLCO1B1</a> and likely OATP1B1*1a refers to the protein formed by the reference sequence of SLCO1B1 (SLCO1B1), however this is not explained in the label.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""viloxazine_10_12_2021_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/viloxazine_10_12_2021_FDA.pdf"">viloxazine (Qelbree) drug label.</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166251522,Annotation of FDA Label for cabotegravir / rilpivirine and HLA-B,False,False,[],False,"[{'id': 1452206420, 'date': '2023-08-14T12:21:14.909-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452318161, 'date': '2023-12-05T07:28:08.272-08:00', 'description': 'Updated label.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15148662, 'title': 'Drugs@FDA: Drug Product Cabenuva (cabotegravir and rilpivirine), NDA212888, ViiV Healthcare Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212888', 'crossReferences': [{'id': 1452318162, 'resource': 'FDA Application', 'resourceId': 'NDA212888/SUPPL-8', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212888'}], 'objCls': 'Literature', 'pubDate': '2023-02-27T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166251381', 'name': 'cabotegravir / rilpivirine'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",FDA,1451524766.0,"<p>Cabotegravir and Rilpivirine is listed with HLA-B in the Table of Pharmacogenomic Biomarkers in Drug Labeling however the only mention of HLA-B in the label is in conjunction with the FLAIR clinical trial which avoided abacavir in subjects that were HLA-B*5701.</p>
",1451524767.0,"<p>Cabotegravir and Rilpivirine is listed with HLA-B in the Table of Pharmacogenomic Biomarkers in Drug Labeling however the only mention of HLA-B in the label is in conjunction with the FLAIR clinical trial which avoided abacavir in subjects that were HLA-B*5701. The label does have warnings about hypersensitivity but it is not gene or variant specific.</p>
<p>Excerpts from the label:</p>
<blockquote class=""blockquote"">
<p>Hypersensitivity reactions have been reported with rilpivirine-containing
regimens and in association with other integrase inhibitors.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The efficacy of CABENUVA has been evaluated in two Phase 3 randomized, multicenter, activecontrolled,
parallel-arm, open-label, non-inferiority trials:
• Trial 201584 (FLAIR, NCT02938520), (n = 629): HIV-1–infected, antiretroviral treatment (ART)-
naive subjects received a dolutegravir INSTI-containing regimen for 20 weeks (either
dolutegravir/abacavir/lamivudine or dolutegravir plus 2 other NRTIs if subjects were HLA-B*5701
positive). Subjects who were virologically suppressed (HIV-1 RNA less than 50 copies/mL, n = 566)
were then randomized (1:1) to receive either a cabotegravir plus rilpivirine regimen or remain on the
current antiretroviral regimen. Subjects randomized to receive cabotegravir plus rilpivirine initiated
treatment with daily oral lead-in dosing with one 30-mg VOCABRIA (cabotegravir) tablet plus one
25-mg EDURANT (rilpivirine) tablet for at least 4 weeks followed by monthly injections with
CABENUVA for an additional 44 weeks.</p>
</blockquote>
<p>For the complete drug label texts with sections containing pharmacogenetic information highlighted, see the <a download=""CabotegravirRilpivirine_FDA_2023_12_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/CabotegravirRilpivirine_FDA_2023_12_05.pdf"">cabotegravir / rilpivirine (CABENUVA) drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166268882,"Annotation of FDA Label for belzutifan and CYP2C19, UGT2B17",False,False,[],False,"[{'id': 1451835021, 'date': '2022-07-29T11:03:09.076-07:00', 'description': 'Add prescribing information', 'type': 'Update', 'version': 0}, {'id': 1451874180, 'date': '2022-09-01T16:58:27.664-07:00', 'description': 'fix source literature', 'type': 'Update', 'version': 0}, {'id': 1452253021, 'date': '2023-09-28T00:00:00-07:00', 'description': 'The wrong NDA was linked. Attached NDA215383', 'type': 'Correction', 'version': 0}]",False,[],True,"[{'id': 15131022, 'title': 'Drugs@FDA: Drug Product WELIREG (belzutifan), NDA215383, Merck Sharp & Dohme Corp.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215383', 'crossReferences': [{'id': 1451741244, 'resource': 'FDA Application', 'resourceId': 'NDA215383', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215383'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA37189', 'symbol': 'UGT2B17', 'name': 'UDP glucuronosyltransferase family 2 member B17'}]","[{'objCls': 'Haplotype', 'id': 'PA165980635', 'symbol': 'CYP2C19*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165980636', 'symbol': 'CYP2C19*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA166268761', 'name': 'belzutifan'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA37189', 'symbol': 'UGT2B17', 'name': 'UDP glucuronosyltransferase family 2 member B17'}]",FDA,1451741260.0,"<p>The FDA label for belzutifan has warnings that dual UGT2B17 and CYP2C19 Poor Metabolizers may be at increased risk for side effects such as anemia.</p>
",1451741247.0,"<p>Excerpts from the belzutifan (<em><strong>WELIREG</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>Monitor for anemia before initiation of, and periodically throughout, treatment with WELIREG. Closely monitor patients who are dual UGT2B17 and CYP2C19 poor metabolizers due to potential increases in exposure that may increase the incidence or severity of anemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Coadministration of WELIREG with inhibitors of UGT2B17 or CYP2C19 increases plasma exposure of belzutifan, which may increase the incidence and severity of adverse reactions of WELIREG. Monitor for anemia and hypoxia and reduce the dosage of WELIREG as recommended</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacogenomics
Patients who are UGT2B17, CYP2C19, or dual UGT2B17 and CYP2C19 poor metabolizers have 2-, 1.6-, or 3.2-fold higher belzutifan steady state AUC0-24h (respectively) compared to patients who are UGT2B17 normal (extensive) metabolizers and CYP2C19 non-poor (ultrarapid, rapid, normal, and intermediate) metabolizers.
UGT2B17 poor metabolizers who are homozygous for the UGT2B17*2 allele have no UGT2B17 enzyme activity. CYP2C19 poor metabolizers (such as *2/*2, *3/*3, *2/*3) have significantly reduced or absent CYP2C19 enzyme activity. Approximately 15% of White, 6% of Black or African American, and up to 77% of certain Asian populations are UGT2B17 poor metabolizers. Approximately 2% of White, 5% of Black or African American, and up to 19% of certain Asian populations are CYP2C19 poor metabolizers. Approximately 0.4% of White, 0.3% of Black or African American, and up to 15% of certain Asian populations are dual UGT2B17 and CYP2C19 poor metabolizers.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Belzutifan_FDA_04052022.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Belzutifan_FDA_04052022.pdf"">belzutifan drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1451835020.0,"<p>Excerpts from the belzutifan (<em><strong>WELIREG</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>Closely monitor patients who are dual UGT2B17 and CYP2C19 poor metabolizers due to potential increases in exposure that may increase the incidence or severity of anemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Coadministration of WELIREG with inhibitors of UGT2B17 or CYP2C19 increases plasma exposure of belzutifan, which may increase the incidence and severity of adverse reactions of WELIREG. Monitor for anemia and hypoxia and reduce the dosage of WELIREG as recommended</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166316381,Annotation of FDA Label for gentamicin and MT-RNR1,True,False,[],False,[],False,[],True,"[{'id': 15148982, 'title': 'Drugs@FDA: Drug Product Gentamicin Sulfate in Sodium Chloride (Gentamicin Sulfate), ANDA062373, Baxter Healthcare Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=062373', 'crossReferences': [{'id': 1452495644, 'resource': 'FDA Application', 'resourceId': 'ANDA062373/SUPPL-44', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=062373'}], 'objCls': 'Literature', 'pubDate': '2023-02-10T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15159262, 'title': 'DailyMed - GENTAMICIN SULFATE IN SODIUM CHLORIDE- gentamicin sulfate injection, solution', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=449c9a41-d61e-49fd-b5e3-d76f74b92acf', 'crossReferences': [{'id': 1452495645, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '449c9a41-d61e-49fd-b5e3-d76f74b92acf', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=449c9a41-d61e-49fd-b5e3-d76f74b92acf'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]","[{'objCls': 'Variant', 'id': 'PA166159181', 'symbol': 'rs267606617', 'name': 'rs267606617'}]","[{'objCls': 'Chemical', 'id': 'PA449753', 'name': 'gentamicin'}]","[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]",FDA,1452254360.0,"<p>Gentamicin is a water soluble antibiotic of the aminoglycoside group derived from <em>Micromonospora purpurea</em>.</p>
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A&gt;G variant. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
",1452254361.0,"<p>Excerpt from the gentamicin label:</p>
<blockquote class=""blockquote"">
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the
m.1555A&gt;G variant. Ototoxicity occurred in some patients even when their aminoglycoside serum levels were within the recommended range. Mitochondrial DNA variants are present in less than 1% of the general US population, and the proportion of the variant carriers who may develop ototoxicity as well as the severity of ototoxicity is unknown. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""gentamicin_2023_09_28_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/gentamicin_2023_09_28_FDA.pdf"">gentamicin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452254362.0,"<blockquote class=""blockquote"">
<p>In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166316361,Annotation of FDA Label for streptomycin and MT-RNR1,True,False,[],False,[],False,[],True,"[{'id': 15148962, 'title': 'Drugs@FDA: Drug Product Streptomycin (Streptomycin), ANDA064210, XGen Pharmaceuticals DJB, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=064210', 'crossReferences': [{'id': 1452495660, 'resource': 'FDA Application', 'resourceId': 'ANDA064210/SUPPL-16', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=064210'}], 'objCls': 'Literature', 'pubDate': '2023-02-10T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15159282, 'title': 'DailyMed - STREPTOMYCIN injection, powder, lyophilized, for solution', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e', 'crossReferences': [{'id': 827921183, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': 'abd1f64e-4283-4370-aae8-3666316aa36e', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]","[{'objCls': 'Variant', 'id': 'PA166159181', 'symbol': 'rs267606617', 'name': 'rs267606617'}]","[{'objCls': 'Chemical', 'id': 'PA451512', 'name': 'streptomycin'}]","[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]",FDA,1452254240.0,"<p>Streptomycin is a bactericidal aminoglycoside antibiotic derived from <em>Streptomyces griseus</em>.</p>
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A&gt;G variant. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
",1452254241.0,"<p>Excerpts from the streptomycin label:</p>
<blockquote class=""blockquote"">
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene ( MT-RNR1), particularly the
m.1555A&gt;G variant. Ototoxicity occurred in some patients even when their aminoglycoside serum levels were within the recommended range. Mitochondrial DNA variants are present in less than 1% of the general US population, and the proportion of the variant carriers who may develop ototoxicity as well as the severity of ototoxicity is unknown. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""streptomycin_2023_09_28_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/streptomycin_2023_09_28_FDA.pdf"">streptomycin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452254242.0,"<blockquote class=""blockquote"">
<p>In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166317641,Annotation of EMA Label for mavacamten and CYP2C19,False,False,[],True,"[{'id': 1452537881, 'date': '2024-07-24T15:36:24.408-07:00', 'description': 'added Dosing Info tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161862, 'title': 'Camzyos | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/camzyos', 'crossReferences': [{'id': 1452537860, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/camzyos', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/camzyos'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]","[{'objCls': 'Haplotype', 'id': 'PA165980634', 'symbol': 'CYP2C19*1', 'name': '*1'}, {'objCls': 'Haplotype', 'id': 'PA165980635', 'symbol': 'CYP2C19*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165980636', 'symbol': 'CYP2C19*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA166272922', 'name': 'mavacamten'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",EMA,1452268520.0,"<p>Mavacamten is indicated for the treatment of obstructive hypertrophic cardiomyopathy. The EMA label requires CYP2C19 genotyping and gives dosing adjustments for metabolizer phenotypes. The label states that if genotyping results have not yet been returned that patients should follow dosing instructions for poor metabolisers.</p>
",1452268521.0,"<p>Excerpts from the <em><strong>Mavacamten</strong></em> (<em><strong>CAMZYOS</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>Patients should be genotyped for Cytochrome P450 (CYP) 2C19 (CYP2C19) in order to determine appropriate mavacamten dose. Patients with CYP2C19 poor metabolizer phenotype may have increased mavacamten exposures (up to 3 times) that can lead to increased risk of systolic dysfunction compared to normal metabolizers (see section 4.4 and 5.2). If treatment initiation occurs prior to determination of CYP2C19 phenotype, patients should follow dosing instructions for poor metabolisers (see figure 1 and table 1) until CYP2C19 phenotype is determined.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C19 poor metaboliser phenotype
The recommended starting dose is 2.5 mg orally once daily. The maximum dose is 5 mg once daily. The patient should be assessed for early clinical response by left ventricular outflow tract (LVOT) gradient with Valsalva manoeuvre 4 and 8 weeks after treatment initiation (see figure 1).
CYP2C19 intermediate, normal, rapid and ultra-rapid metaboliser phenotype
The recommended starting dose is 5 mg orally once daily. The maximum dose is 15 mg once daily. The patient should be assessed for early clinical response by LVOT gradient with Valsalva manoeuvre 4 and 8 weeks after treatment initiation (see figure 2).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C19 phenotype
Polymorphic CYP2C19 is the main enzyme involved in the metabolism of mavacamten. An individual carrying two normal function alleles is a CYP2C19 normal metaboliser (e.g., *1/*1). An individual carrying two non-functional alleles is a CYP2C19 poor metaboliser (e.g., *2/*2, *2/*3, *3/*3).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In CYP2C19 intermediate, normal, rapid and ultra-rapid metabolisers, mavacamten is primarily metabolised by CYP2C19 and to a lesser extent by CYP3A4. In CYP2C19 poor metabolisers, metabolism is mostly by CYP3A4 (see section 5.2). CYP2C19 inhibitors/inducers and CYP3A4 inhibitors/inducers may thus affect the clearance of mavacamten and increase/decrease mavacamten plasma concentration, and this will depend on the CYP2C19 phenotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>All clinical drug-drug interaction studies mainly enrolled CYP2C19 normal metabolisers and no CYP2C19 poor metabolisers were included in the assessment of the drug-drug interaction and therefore the effect of co-administration of CYP2C19 and CYP3A4 inhibitors with mavacamten in CYP2C19 poor metabolisers is not completely certain.
Recommendations for dose modification and/or additional monitoring of patients initiating or discontinuing treatment with, or changing the dose of, concomitant medicinal products that are inhibitors of CYP2C19 or CYP3A4 or inducers of CYP2C19 or CYP3A4 are provided in table 2.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Women of childbearing potential must use effective contraception during treatment and for 6 months after discontinuation of CAMZYOS, since it takes approximately 5 half-lives (approximately 45 days for CYP2C19 normal metabolisers and 115 days for CYP2C19 poor metabolisers) to eliminate mavacamten from the body after treatment discontinuation</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Mavacamten_EMA_2023_10_11.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Mavacamten_EMA_2023_10_11.pdf""><em><strong>Mavacamten</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1452268522.0,"<p>Excerpts from the <em><strong>Mavacamten</strong></em> (<em><strong>CAMZYOS</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>CYP2C19 poor metaboliser phenotype
The recommended starting dose is 2.5 mg orally once daily. The maximum dose is 5 mg once daily. The patient should be assessed for early clinical response by left ventricular outflow tract (LVOT) gradient with Valsalva manoeuvre 4 and 8 weeks after treatment initiation (see figure 1).
CYP2C19 intermediate, normal, rapid and ultra-rapid metaboliser phenotype
The recommended starting dose is 5 mg orally once daily. The maximum dose is 15 mg once daily. The patient should be assessed for early clinical response by LVOT gradient with Valsalva manoeuvre 4 and 8 weeks after treatment initiation (see figure 2).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166313401,Annotation of FDA Label for lecanemab and APOE,False,False,[],False,"[{'id': 1452296500, 'date': '2023-11-13T05:45:32.455-08:00', 'description': 'Removed alternate drug tag as there is no language contraindicating or alternate drug suggested. Added definition of ARIA to the prescribing section not just summary section.', 'type': 'Update', 'version': 0}, {'id': 1452557820, 'date': '2024-08-16T16:57:19.939-07:00', 'description': 'removed Prescribing info; covered by the Testing Required PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15148643, 'title': 'Drugs@FDA: Drug Product LEQEMBI (lecanemab), BLA761269, Eisai Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761269', 'crossReferences': [{'id': 1452242763, 'resource': 'FDA Application', 'resourceId': 'BLA761269', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761269'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166155351', 'symbol': 'rs429358', 'name': 'rs429358'}, {'objCls': 'Variant', 'id': 'PA166155341', 'symbol': 'rs7412', 'name': 'rs7412'}]","[{'objCls': 'Chemical', 'id': 'PA166313301', 'name': 'lecanemab'}]","[{'objCls': 'Gene', 'id': 'PA55', 'symbol': 'APOE', 'name': 'apolipoprotein E'}]",FDA,1452231280.0,"<p>The FDA label for lecanemab includes warnings that testing should be performed for ApoE E4/E4 as individuals with ApoE E4/E4 have increased risk for amyloid related imaging abnormalities (ARIA) when treated with lecanemab. The label does not give details on the E4/E4 allele.</p>
",1452230740.0,"<p>Excerpts from the <em><strong>lecanemab-irmb</strong></em> (<em><strong>LEQEMBI</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>ApoE ε4 Homozygotes
Patients treated with this class of medications, including LEQEMBI,
who are ApoE ε4 homozygotes have a higher incidence of ARIA,
including symptomatic and serious ARIA, compared to
heterozygotes and noncarriers. Testing for ApoE ε4 status should
be performed prior to initiation of treatment to inform the risk of
developing ARIA. Prior to testing, prescribers should discuss with
patients the risk of ARIA across genotypes and the implications of
genetic testing results.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Inform patients that although ARIA can occur in any patient treated with LEQEMBI, there is an increased risk
in patients who are ApoE ε4 homozygotes and that testing for ApoE ε4 status should be performed prior to
initiation of treatment to inform the risk of developing ARIA. Prior to testing, discuss with patients the risk of
ARIA across genotypes and the implications of genetic testing results. Inform patients that if testing is not
performed, it cannot be determined if they are ApoE ε4 homozygotes and at a higher risk for ARIA.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The risk of
ARIA, including symptomatic and serious ARIA, is increased in apolipoprotein E ε4 (ApoE ε4) homozygotes.
In addition to ARIA, intracerebral hemorrhages greater than 1 cm in diameter have occurred in patients treated
with LEQEMBI.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Approximately 15% of Alzheimer’s disease patients are ApoE ε4 homozygotes. In Study 2, 16% (141/898) of
patients in the LEQEMBI arm were ApoE ε4 homozygotes, 53% (479/898) were heterozygotes, and 31%
(278/898) were noncarriers. The incidence of ARIA was higher in ApoE ε4 homozygotes (45% on LEQEMBI
vs. 22% on placebo) than in heterozygotes (19% on LEQEMBI vs 9% on placebo) and noncarriers (13% on
LEQEMBI vs 4% on placebo). Among patients treated with LEQEMBI, symptomatic ARIA-E occurred in 9%
of ApoE ε4 homozygotes compared with 2% of heterozygotes and 1% noncarriers. Serious events of ARIA
occurred in 3% of ApoE ε4 homozygotes, and approximately 1% of heterozygotes and noncarriers. The
recommendations on management of ARIA do not differ between ApoE ε4 carriers and noncarriers [see Dosage
and Administration (2.3)]. Testing for ApoE ε4 status should be performed prior to initiation of treatment to
inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA
across genotypes and the implications of genetic testing results. Prescribers should inform patients that if
genotype testing is not performed they can still be treated with LEQEMBI; however, it cannot be determined if
they are ApoE ε4 homozygotes and at higher risk for ARIA. An FDA-authorized test for the detection of ApoE
ε4 alleles to identify patients at risk of ARIA if treated with LEQEMBI is not currently available. Currently
available tests used to identify ApoE ε4 alleles may vary in accuracy and design.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""lecanemab_FDA_2023_09_07.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/lecanemab_FDA_2023_09_07.pdf""><em><strong>lecanemab</strong></em> drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166251601,Annotation of FDA Label for viloxazine and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15123802, 'title': 'Drugs@FDA: Drug Product  QELBREE (VILOXAZINE HYDROCHLORIDE), NDA211964, SUPERNUS PHARMS', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211964', 'crossReferences': [{'id': 1452245662, 'resource': 'FDA Application', 'resourceId': 'NDA211964', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211964'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166251581', 'name': 'viloxazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",FDA,1451525040.0,"<p>The FDA label for viloxazine mentions pharmacokinetic differences between CYP2D6 poor metabolizers and extensive metabolizers but does not state if this is clinically significant nor which genotypes were affected.</p>
",1451525041.0,"<p>The FDA label for viloxazine mentions pharmacokinetic differences between CYP2D6 poor metabolizers and extensive metabolizers but does not state if this is clinically significant nor which genotypes were affected.</p>
<p>Excerpts from the FDA label:</p>
<blockquote class=""blockquote"">
<p>Viloxazine is primarily metabolized by CYP2D6, UGT1A9, and UGT2B15. The major metabolite detected in plasma is 5-hydroxy-viloxazine glucuronide.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2D6 Metabolism
A multiple-dose study was conducted with Qelbree 900 mg once-daily in healthy volunteers to compare the effect of CYP2D6 poor metabolizers (PMs) and extensive metabolizers (EMs) on the PK of viloxazine. At steady state, viloxazine geometric means for Cmax and AUC0-24 were 21% and 26%, respectively, higher in CYP2D6 PMs compared to EMs.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""viloxazine_10_12_2021_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/viloxazine_10_12_2021_FDA.pdf"">viloxazine (Qelbree) drug label.</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166184754,Annotation of FDA Label for procainamide and NAT2,False,False,[],False,"[{'id': 1452211880, 'date': '2023-08-21T20:55:06.274-07:00', 'description': 'Removed Prescribing Information section as there is no specified action based on genotype or phenotype, or specific gene mentioned.', 'type': 'Update', 'version': 0}, {'id': 1452230580, 'date': '2023-09-07T11:22:00.546-07:00', 'description': 'Changed to actionable based on level criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15150042, 'title': 'DailyMed procainamide', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7cb1594-61cf-41c4-9007-1ee28aa69c50', 'crossReferences': [{'id': 1452282140, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': 'd7cb1594-61cf-41c4-9007-1ee28aa69c50', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7cb1594-61cf-41c4-9007-1ee28aa69c50'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}, {'id': 15148862, 'title': 'Drugs@FDA: Drug Product Procainamide Hydrochloride (Procainamide Hydrochloride), ANDA088636, International Medication Systems, Limited', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=088636', 'crossReferences': [{'id': 1452250220, 'resource': 'FDA Application', 'resourceId': 'ANDA088636', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=088636'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451108', 'name': 'procainamide'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",FDA,1450822656.0,"<p>The FDA label for procainamide states that it is metabolized by acetylation, and differences in exposure may occur between fast and slow acetylators. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to acetylator status.</p>
",1450822657.0,"<p>Excerpts from the FDA label for procainamide:</p>
<div class=""blockquote"">
<p>A significant fraction of the circulating PA may be metabolized in hepatocytes to N-acetylprocainamide
(NAPA), ranging from 16 to 21 percent of an administered dose in “slow acetylators” to 24 to 33
percent in “fast-acetylators”. Since NAPA also has significant antiarrhythmic activity and somewhat
slower renal clearance than PA, both hepatic acetylation rate capability and renal function, as well as
age, have significant effects on the effective biologic half-time of therapeutic action of administered
PA and the NAPA derivative.</p>
</div>
<div class=""blockquote"">
<p>If facilities are available for measurement of plasma PA and NAPA, or acetylation
capability, individual dose adjustment for optimal therapeutic levels may be easier, but close
observation of clinical effectiveness is the most important criterion.</p>
</div>
<div class=""blockquote"">
<p>A lupus erythematosus-like syndrome of arthralgia, pleural or abdominal pain, and
sometimes arthritis, pleural effusion, pericarditis, fever, chills, myalgia, and possibly related
hematologic or skin lesions (see below) is fairly common after prolonged PA administration, perhaps
more often in patients who are slow acetylators (See Boxed Warning and PRECAUTIONS).</p>
</div>
<p>NOTE: Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to acetylator status.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/procainamide_10_15_2019FDA.pdf"">procainamide drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166235901,"Annotation of FDA Label for margetuximab and FCGR2A, FCGR2B, FCGR3A",False,False,[],False,[],False,[],True,"[{'id': 15118482, 'title': 'Drugs@FDA:Drug MARGENZA (Margetuximab) BLA761150', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761150', 'crossReferences': [{'id': 1451402905, 'resource': 'FDA Application', 'resourceId': 'BLA761150', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761150'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166235241', 'name': 'margetuximab'}]","[{'objCls': 'Gene', 'id': 'PA28063', 'symbol': 'FCGR2A', 'name': 'Fc gamma receptor IIa'}, {'objCls': 'Gene', 'id': 'PA28064', 'symbol': 'FCGR2B', 'name': 'Fc gamma receptor IIb'}, {'objCls': 'Gene', 'id': 'PA28065', 'symbol': 'FCGR3A', 'name': 'Fc gamma receptor IIIa'}]",FDA,1451402942.0,"<p>The FDA label for margetuximab mentions that there may be interactions between the drug and FCGR3A (CD16A) and FCGR2B (CD32B) but that unspecified variant genotypes of FCGR3A (CD16A), FCGR2A (CD32A) and FCGR2B (CD32B) have no impact on clinical pharmacokinetics.</p>
",1451402940.0,"<p>Excerpt from the margetuximab (MARGENZA) drug label:</p>
<blockquote class=""blockquote"">
<p>No clinically significant differences in margetuximab-cmkb PK were observed based on ... FCGR3A (CD16A), FCGR2A (CD32A) and FCGR2B (CD32B) genotype, ...</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In vitro, the modified Fc region of margetuximab-cmkb increases binding to activating Fc receptor FCGR3A (CD16A) and decreases binding to inhibitory Fc receptor FCGR2B (CD32B). These changes lead to greater in vitro ADCC and NK cell activation.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Margetuximab_03_30_21_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Margetuximab_03_30_21_FDA.pdf"">margetuximab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166317741,Annotation of EMA Label for infigratinib,False,False,[],False,"[{'id': 1452726769, 'date': '2024-12-05T09:55:33.278-08:00', 'description': 'update to note that the application was withdrawn', 'type': 'Update', 'version': 0}]",False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166252061', 'name': 'infigratinib'}]",[],EMA,,,1452726768.0,"<p>As of December 5, 2024, the EMA website shows that the application for marketing authorization for infigratinib has been withdrawn.</p>
<p>https://www.ema.europa.eu/en/medicines/human/EPAR/febseltiq</p>
<blockquote class=""blockquote"">
<p>Helsinn Birex Pharmaceuticals Ltd withdrew its application for a marketing authorisation of Febseltiq for the treatment of cholangiocarcinoma (cancer of the bile ducts).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The company withdrew the application on 11 October 2022.</p>
</blockquote>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166317442,"Annotation of EMA Label for Ascorbic acid (vitamin C), plain",False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164712516', 'name': 'Ascorbic acid (vitamin C), plain'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317443,Annotation of EMA Label for desmopressin,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449237', 'name': 'desmopressin'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317444,Annotation of EMA Label for levothyroxine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450221', 'name': 'levothyroxine'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317445,Annotation of EMA Label for olutasidenib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166293881', 'name': 'olutasidenib'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317481,Annotation of EMA Label for desflurane,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164749136', 'name': 'desflurane'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317482,Annotation of EMA Label for isoflurane,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450106', 'name': 'isoflurane'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317483,Annotation of EMA Label for belzutifan,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166268761', 'name': 'belzutifan'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317501,Annotation of EMA Label for sevoflurane,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451341', 'name': 'sevoflurane'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317502,Annotation of EMA Label for succinylcholine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451522', 'name': 'succinylcholine'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317503,Annotation of EMA Label for escitalopram,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10074', 'name': 'escitalopram'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317504,Annotation of EMA Label for estradiol valerate,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166278261', 'name': 'estradiol valerate'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317721,Annotation of EMA Label for casimersen,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166251541', 'name': 'casimersen'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317701,Annotation of EMA Label for golodirsen,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166190721', 'name': 'golodirsen'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317663,Annotation of EMA Label for fosphenytoin,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164746820', 'name': 'fosphenytoin'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317662,Annotation of EMA Label for enflurane,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449461', 'name': 'enflurane'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317761,Annotation of EMA Label for metoclopramide,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450475', 'name': 'metoclopramide'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317762,Annotation of EMA Label for mivacurium,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450528', 'name': 'mivacurium'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317782,Annotation of EMA Label for oliceridine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166223601', 'name': 'oliceridine'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317783,Annotation of EMA Label for oxymetazoline and tetracaine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182885', 'name': 'oxymetazoline and tetracaine'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317781,Annotation of EMA Label for mobocertinib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166268804', 'name': 'mobocertinib'}]",[],EMA,,,1452552520.0,"<p>The company withdrew the application on 20 July 2022.
https://www.ema.europa.eu/en/medicines/human/EPAR/exkivity</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166317784,Annotation of EMA Label for phenytoin,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450947', 'name': 'phenytoin'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317801,Annotation of EMA Label for procainamide,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451108', 'name': 'procainamide'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317821,Annotation of EMA Label for tretinoin,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451746', 'name': 'tretinoin'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317841,Annotation of EMA Label for valproic acid,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451846', 'name': 'valproic acid'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317822,Annotation of EMA Label for viloxazine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166251581', 'name': 'viloxazine'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317842,Annotation of EMA Label for viltolarsen,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166236421', 'name': 'viltolarsen'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317901,Annotation of HCSC Label for adagrasib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166246421', 'name': 'adagrasib'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317882,Annotation of HCSC Label for futibatinib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166293381', 'name': 'futibatinib'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317903,Annotation of HCSC Label for mirvetuximab soravtansine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166293721', 'name': 'mirvetuximab soravtansine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317904,Annotation of HCSC Label for olutasidenib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166293881', 'name': 'olutasidenib'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317905,Annotation of HCSC Label for pegloticase,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165963961', 'name': 'pegloticase'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317906,Annotation of HCSC Label for ganaxolone,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166278301', 'name': 'ganaxolone'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317883,Annotation of HCSC Label for mitapivat,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166278021', 'name': 'mitapivat'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317884,Annotation of HCSC Label for casimersen,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166251541', 'name': 'casimersen'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317908,Annotation of HCSC Label for crizanlizumab-tmca,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166189801', 'name': 'crizanlizumab-tmca'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317941,Annotation of HCSC Label for lonafarnib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166129466', 'name': 'lonafarnib'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317942,Annotation of HCSC Label for margetuximab,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166235241', 'name': 'margetuximab'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317961,Annotation of HCSC Label for mobocertinib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166268804', 'name': 'mobocertinib'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317947,Annotation of HCSC Label for procainamide,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451108', 'name': 'procainamide'}]",[],HCSC,,,1452702466.0,"<p>As of November 15, 2024, the HCSC website contains this information:</p>
<p>Current status: Marketed</p>
<p>Current status date: 2005-09-27</p>
<p>DIN: 02184486 Electronic product monograph is not available</p>
<p>Company: SANDOZ CANADA INCORPORATED</p>
<p>https://health-products.canada.ca/dpd-bdpp/info?lang=eng&amp;code=19357</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166317962,Annotation of HCSC Label for ropeginterferon alfa-2b,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166268921', 'name': 'ropeginterferon alfa-2b'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317963,Annotation of HCSC Label for rucaparib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166163418', 'name': 'rucaparib'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317949,Annotation of HCSC Label for viloxazine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166251581', 'name': 'viloxazine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317964,Annotation of HCSC Label for viltolarsen,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166236421', 'name': 'viltolarsen'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317950,Annotation of HCSC Label for voxelotor,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166189802', 'name': 'voxelotor'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166319021,"Annotation of FDA Label for mepolizumab and FIP1L1, PDGFRA",False,False,[],False,[],False,[],True,"[{'id': 15149982, 'title': 'Drugs@FDA: Drug Product Nucala (mepolizumab), BLA125526, GlaxoSmithKline LLC', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125526', 'crossReferences': [{'id': 1452281100, 'resource': 'FDA Application', 'resourceId': 'BLA125526', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125526'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166313323', 'name': 'mepolizumab'}]","[{'objCls': 'Gene', 'id': 'PA134875694', 'symbol': 'FIP1L1', 'name': 'factor interacting with PAPOLA and CPSF1'}, {'objCls': 'Gene', 'id': 'PA33147', 'symbol': 'PDGFRA', 'name': 'platelet derived growth factor receptor alpha'}]",FDA,1452280380.0,"<p>Mepolizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa). FIP1L1 and PDGFRA are listed in the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling in the Adverse Reactions and Clinical Studies section.</p>
",1452280381.0,"<p>Excerpt from the mepolizumab (NUCALA) label:</p>
<blockquote class=""blockquote"">
<p>A total of 108 adult and adolescent patients aged 12 years and older with HES were evaluated in a randomized, placebo-controlled, multicenter, 32-week treatment trial. Patients with non-hematologic secondary HES or FIP1L1-PDGFRα kinase-positive HES were excluded from the trial.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""mepolizumab_2023_10_24_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/mepolizumab_2023_10_24_FDA.pdf"">mepolizumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166317948,Annotation of HCSC Label for rimegepant and CYP2C9,False,False,[],False,"[{'id': 1452406943, 'date': '2024-03-13T09:33:09.977-07:00', 'description': 'Updated now that approved and label available.', 'type': 'Update', 'version': 0}, {'id': 1452725203, 'date': '2024-12-04T14:26:31.081-08:00', 'description': 'added label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15171602, 'title': 'Drugs@HCSC: Drug Product NURTEC ODT (rimegepant), Pfizer Canada ULC', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00073578.PDF', 'crossReferences': [{'id': 1452725220, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00073578.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00073578.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA166225041', 'name': 'rimegepant'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",HCSC,1452406941.0,"<p>Rimegepant is a CGRP antagonist approved for acute treatment of migraine with or without aura in adults. The pharmacogenomics section gives information on variants of CYP2C9, but these are not expected to have clinical impact.</p>
",1452406942.0,"<p>Excerpts from the <em><strong>Rimegepant</strong></em> (<em><strong>NURTEC ODT</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>10.3 Pharmacokinetics</p>
<p>CYP2C9 polymorphism</p>
<p>Rimegepant Cmax and AUC0-inf were similar in CYP2C9 intermediate metabolizers (i.e., *1/*2, *2/*2,
*1/*3, n=43) as compared to normal metabolizers (i.e., *1/*1, n=72). Adequate PK data are not
available from CYP2C9 poor metabolizers (i.e., *2/*3, n=2). Since the contribution of CYP2C9 to
rimegepant metabolism is considered minor, CYP2C9 polymorphism is not expected to significantly
affect its exposure.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Rimegepant is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Rimegepant_HCSC_2024_03_13.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Rimegepant_HCSC_2024_03_13.pdf""><em><strong>Rimegepant</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166294083,Annotation of HCSC Label for durvalumab and CD274,False,True,[],False,"[{'id': 1452206941, 'date': '2023-08-15T07:15:51.488-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15159602, 'title': 'Drugs@HCSC: Drug Product IMFINZI (durvalumab), AstraZeneca Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736', 'crossReferences': [{'id': 1452503740, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166169883', 'name': 'durvalumab'}]","[{'objCls': 'Gene', 'id': 'PA134915280', 'symbol': 'CD274', 'name': 'CD274 molecule'}]",HCSC,1452043353.0,"<p>Durvalumab is HCSC indicated for NSCLC, extensive-stage small cell lung cancer, and biliary tract cancer but does not discuss biomarker status. The product monograph has information about PD-L1 (<a href=""/gene/PA134915280"">CD274</a>) in the mechanism of action section.</p>
",1452043354.0,"<p>Excerpts from the Durvalumab (<em><strong>IMFINZI</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>Mechanism of Action</p>
<p>Expression of programmed cell death ligand-1 (PD-L1) protein is an adaptive immune
response that helps tumours evade detection and elimination by the immune system. PD-L1
expression can be induced by inflammatory signals (e.g., IFN-gamma) and can be expressed
on both tumour cells and tumour-associated immune cells present in the tumour
microenvironment. Through its interactions with PD-1 and CD80, PD-L1 reduces
cytotoxic T-cell activity, proliferation, and cytokine production. IMFINZI (durvalumab) is a fully human, high affinity, immunoglobulin G1 kappa (IgG1κ)
monoclonal antibody that selectively blocks the interaction of PD-L1 with PD-1 and CD80 while leaving PD-1/PD-L2 interaction intact.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Durvalumab_HCSC_2023_03_21.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Durvalumab_HCSC_2023_03_21.pdf""><em><strong>Durvalumab</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166317902,"Annotation of HCSC Label for Ascorbic acid (vitamin C), plain",False,False,[],False,"[{'id': 1452804301, 'date': '2025-01-10T14:12:53.863-08:00', 'description': 'added label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15172842, 'title': 'Drugs@HCSC: Ascor L500 (ascorbic acid injection), McGuff Pharmaceuticals Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84117', 'crossReferences': [{'id': 1452804300, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84117', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84117'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA164712516', 'name': 'Ascorbic acid (vitamin C), plain'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166319001,"Annotation of FDA Label for sacituzumab govitecan and BRCA1, BRCA2",False,False,[],False,[],False,[],True,"[{'id': 15114642, 'title': 'Drugs@FDA: Drug Product sacituzumab govitecan-hziy BLA761115', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761115', 'crossReferences': [{'id': 1451277824, 'resource': 'FDA Application', 'resourceId': 'BLA761115', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761115'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166225061', 'name': 'sacituzumab govitecan'}]","[{'objCls': 'Gene', 'id': 'PA25411', 'symbol': 'BRCA1', 'name': 'BRCA1 DNA repair associated'}, {'objCls': 'Gene', 'id': 'PA25412', 'symbol': 'BRCA2', 'name': 'BRCA2 DNA repair associated'}]",FDA,1452280340.0,"<p>Sacituzumab govitecan-hziy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate used in the treatment of certain cancers. BRCA is listed in the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling in the Clinical Studies section.</p>
",1452280341.0,"<p>Excerpt from the sacituzumab govitecan-hziy (TRODELVY) label:</p>
<blockquote class=""blockquote"">
<p>The median age of patients in the full population (n = 529) was 54 years (range: 27 to 82 years); 99.6% were female; 79% were White, 12% were Black/African American; and 81% of patients were &lt; 65 years of age. All patients had an ECOG performance status of 0 (43%) or 1 (57%). Forty-two percent of patients had hepatic metastases, 9% were BRCA1/BRCA2 mutational status positive, and 70% were TNBC at diagnosis. Twelve percent had baseline brain metastases previously treated and stable (n=61; 32 on TRODELVY arm and 29 on single agent chemotherapy arm).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""sacituzumab_govitecan-hziy_2023_10_24_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/sacituzumab_govitecan-hziy_2023_10_24_FDA.pdf"">sacituzumab govitecan-hziy drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166293282,"Annotation of FDA Label for Ascorbic acid (vitamin C), combinations, Ascorbic acid (vitamin C), plain, sodium ascorbate and G6PD",False,False,[],True,"[{'id': 1452107740, 'date': '2023-05-23T11:59:37.709-07:00', 'description': 'Changed from Informative to Actionable. Fixed broken link to label.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15141962, 'title': 'Drugs@FDA: Drug Product Ascor (Ascorbic Acid), NDA209112, McGuff Pharmaceuticals, Inc.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209112', 'crossReferences': [{'id': 1452037486, 'resource': 'FDA Application', 'resourceId': 'NDA209112', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209112'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164712515', 'name': 'Ascorbic acid (vitamin C), combinations'}, {'objCls': 'Chemical', 'id': 'PA164712516', 'name': 'Ascorbic acid (vitamin C), plain'}, {'objCls': 'Chemical', 'id': 'PA166163262', 'name': 'sodium ascorbate'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1452037482.0,"<p>The FDA label for Ascorbic acid recommends that patients with G6PD deficiency do not exceed the recommended dietary allowance or daily intake due to risk of hemolysis.</p>
",1452037483.0,"<p>Excerpts from the Ascorbic acid (<em><strong>ASCOR</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>Dosage Reductions in Specific Populations
Women who are pregnant or lactating and patients with
glucose-6-dehydrogenase deficiency should not exceed the
U.S. Recommended Dietary Allowance (RDA) or daily Adequate Intake (AI) level for ascorbic acid for their age
group and condition</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Hemolysis in Patients with Glucose-6-PhosphateDehydrogenase Deficiency
Hemolysis has been reported with administration of ascorbic acid in patients with glucose-6-phosphate dehydrogenase
deficiency. Patients with glucose-6-phosphate dehydrogenase deficiency may be at increased risk for severe hemolysis during treatment with ascorbic acid. Monitor hemoglobin and blood count and use a reduced dose of ASCOR in patients with glucose-6-phosphate dehydrogenase deficiency</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""AscorbicAcid_FDA_2023_03_15.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/AscorbicAcid_FDA_2023_03_15.pdf""><em><strong>Ascorbic acid</strong></em> drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452037484.0,"<p>Excerpts from the Ascorbic acid (<em><strong>ASCOR</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>Dosage Reductions in Specific Populations
Women who are pregnant or lactating and patients with
glucose-6-dehydrogenase deficiency should not exceed the
U.S. Recommended Dietary Allowance (RDA) or daily Adequate Intake (AI) level for ascorbic acid for their age
group and condition</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166318021,Annotation of HCSC Label for tremelimumab,False,False,[],False,[],False,[],True,"[{'id': 15153482, 'title': 'Drugs@HCSC: Drug Product IMJUDO (tremelimumab), AstraZeneca Canada Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00074397.PDF', 'crossReferences': [{'id': 1452373740, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00074397.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00074397.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA166293321', 'name': 'tremelimumab'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317981,Annotation of HCSC Label for mavacamten and CYP2C19,False,False,[],False,"[{'id': 1452336120, 'date': '2023-12-20T05:41:29.826-08:00', 'description': 'Changed from Informative to Actionable since the label has specific information on PK changes for different variants.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161842, 'title': 'Drugs@HCSC: Drug Product CAMZYOS (mavacamten), Bristol-Myers Squibb Canada', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102157', 'crossReferences': [{'id': 1452537840, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102157', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102157'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166272922', 'name': 'mavacamten'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",HCSC,1452269500.0,"<p>The HCSC label for mavacamten gives information on pharmacokinetic differences in CYP2C19 poor metabolizers (PM) compared to normal metabolizers (NM), but does not give information on testing for alleles associated with PM or dose adjustments.</p>
",1452269501.0,"<p>Excerpts from the <em><strong>Mavacamten</strong></em> (<em><strong>CAMZYOS</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>Genetic Polymorphism
CYP 2C19 Poor Metabolizers (PMs): After a single dose of 15 mg mavacamten, Cmax and AUCinf
increased by 47% and 241%, respectively, in CYP 2C19 PMs compared to normal metabolizers
(NMs). Mean half-life is prolonged in CYP 2C19 PMs compared to NMs (23 days vs 6-9 days,
respectively)</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacokinetics
Mavacamten has a variable terminal t1/2 that depends on CYP 2C19 metabolic status (6-9 days in normal
metabolizers (NMs) and 23 days in poor metabolizers (PMs)). Exposure to mavacamten increased
approximately dose proportionally between 2 mg and 48 mg. The geometric mean accumulation was
approximately 7-fold for AUC0-24h and 2 to 2.6-fold for Cmax after multiple once-daily dosing of
mavacamten</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Elimination: Mavacamten is cleared from plasma primarily by metabolism through cytochrome P450
enzymes. Terminal half-life is 6-9 days in CYP 2C19 NMs or 23 days in PMs, depending on CYP 2C19
metabolic status. Drug accumulation occurs with an accumulation ratio about 2-fold for Cmax and about
7-fold for AUC in CYP 2C19 NMs. The accumulation depends on the metabolism status for CYP 2C19
with the largest accumulation observed in CYP 2C19 PMs. At steady-state, the peak-to-trough plasma
concentration ratio with once daily dosing is approximately 1.5. Intersubject PK variability is moderate,
with a coefficient of variation for exposure in of approximately 30 to 50% for Cmax and AUC.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, <a download=""Mavacamten_HCSC_2023_10_12.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Mavacamten_HCSC_2023_10_12.pdf"">Mavacamten product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184454,Annotation of Swissmedic Label for galantamine and CYP2D6,False,False,[],False,"[{'id': 1452221560, 'date': '2023-08-30T13:11:58.459-07:00', 'description': 'updated the level to informative PGx', 'type': 'Update', 'version': 0}, {'id': 1452297540, 'date': '2023-11-13T14:50:30.207-08:00', 'description': 'fixed typo', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103279, 'title': 'Swissmedic label for galantamine', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=56754', 'crossReferences': [{'id': 1450815663, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=56754', '_url': 'https://amiko.oddb.org/de/fi?gtin=56754'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA449726', 'name': 'galantamine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",Swissmedic,1450815759.0,"<p>The Swiss drug label for galantamine (Reminyl) states that CYP2D6 is involved in the metabolism of galantamine but there were limited differences between CYP2D6 extensive and poor metabolizers.</p>
",1450815760.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the drug label for galantamine (Reminyl):</p>
<blockquote class=""blockquote"">
<p>Kinetics:
The active substance is metabolized mainly by N-oxidation, N-demethylation, O-demethylation, glucuronidation and epimerization. O-demethylation was much more pronounced in individuals with extensive CYP2D6 metabolism. After ingestion of radioactively labelled galantamine, total radioactivity excretion in urine and faeces was not different in weak and strong metabolizers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>None of the active metabolites of galantamine (norgalantamine, O-desmethylgalantamine and O-desmethylnorgalantamine) could be detected after a single dose in its unconjugated form in plasma of weak or strong metabolizers.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=56754&amp;highlight=Metabolisierern"" target=""_blank"">galantamine drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166182719,Annotation of FDA Label for ipilimumab and HLA-A,False,False,[],False,"[{'id': 1450399931, 'date': '2019-05-14T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452315442, 'date': '2023-12-04T10:55:14.346-08:00', 'description': 'Updated label and label source. Edited summary to explain the gene-drug pair annotated.', 'type': 'Update', 'version': 0}, {'id': 1452802981, 'date': '2025-01-09T15:03:21.653-08:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102364, 'title': 'Drugs@FDA: Drug Product YERVOY (ipilimumab), E.R. Squibb & Sons, L.L.C. - BLA125377/SUPPL-129, 02/15/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125377', 'crossReferences': [{'id': 1452315441, 'resource': 'FDA Application', 'resourceId': 'BLA125377/SUPPL-129', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125377'}], 'objCls': 'Literature', 'pubDate': '2023-02-15T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],"[{'objCls': 'Haplotype', 'id': 'PA166123427', 'symbol': 'HLA-A*02:01', 'name': '*02:01'}]","[{'objCls': 'Chemical', 'id': 'PA166182718', 'name': 'ipilimumab'}]","[{'objCls': 'Gene', 'id': 'PA35055', 'symbol': 'HLA-A', 'name': 'major histocompatibility complex, class I, A'}]",FDA,1450399929.0,"<p>Ipilimumab (Yervoy) is a human cytotoxic T-lymphocyte antigen 4-blocking antibody indicated for several cancer types. The label mentions a clinical trial which selected patients with a particular HLA-A variant.</p>
",1450399930.0,"<p>Excerpts from the ipilimumab (Yervoy) drug label:</p>
<blockquote class=""blockquote"">
<p>14 Clinical studies, 14.1 Unresectable or metastatic melanoma...The safety and efficacy of YERVOY were investigated in a randomized (3:1:1), double- blind, double-dummy trial (MDX010-20, NCT00094653) that included 676 randomized patients with unresectable or metastatic melanoma previously treated with one or more of the following: aldesleukin, dacarbazine, temozolomide, fotemustine, or carboplatin. Of these 676 patients, 403 were randomized to receive YERVOY at 3 mg/kg in combination with an investigational peptide vaccine with incomplete Freund’s adjuvant (gp100), 137 were randomized to receive YERVOY at 3 mg/kg, and 136 were randomized to receive gp100 as a single agent. <strong>The trial enrolled only patients with HLA-A2*0201 genotype; this HLA genotype facilitates the immune presentation of the investigational peptide vaccine</strong>.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Ipilimumab_FDA_2023_12_04.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ipilimumab_FDA_2023_12_04.pdf"">ipilimumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452802980.0,"<blockquote class=""blockquote"">
<p>YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for:</p>
<ul>
<li>Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) [...]</li>
<li>Treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1.4)</li>
</ul>
</blockquote>
",1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166362201,Annotation of EMA Label for pemetrexed,False,False,[],False,[],False,[],True,"[{'id': 15172702, 'title': 'Alimta | European Medicines Agency (EMA)', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/alimta', 'crossReferences': [{'id': 1452803100, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/alimta', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/alimta'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA10810', 'name': 'pemetrexed'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166362261,Annotation of HCSC Label for ofatumumab and MS4A1,False,False,[],False,[],False,[],True,"[{'id': 15172782, 'title': 'Drugs@HCSC: Drug Product KESIMPTA (ofatumumab), Novartis Pharmaceuticals Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100057', 'crossReferences': [{'id': 1452804000, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100057', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100057'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165291493', 'name': 'ofatumumab'}]","[{'objCls': 'Gene', 'id': 'PA31111', 'symbol': 'MS4A1', 'name': 'membrane spanning 4-domains A1'}]",HCSC,1452804020.0,"<p>Ofatumumab (KESIMPTA) is used to treat adult patients with relapsing remitting multiple sclerosis. The drug is a CD20 (<em>MS4A1</em>)-directed cytolytic monoclonal antibody.</p>
<p>Ofatumumab (ARZERRA) was indicated as an antineoplastic; as of January 2025, its status on the HCSC website is &quot;Cancelled Post Market&quot;.
https://health-products.canada.ca/dpd-bdpp/info?lang=eng&amp;code=86740</p>
",1452804021.0,"<p>Excerpts from the ofatumumab (KESIMPTA) product monograph:</p>
<blockquote class=""blockquote"">
<p>KESIMPTA® (ofatumumab injection) is indicated for:</p>
<ul>
<li>the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features (see 14 CLINICAL TRIALS).</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>B-cells play an important role in MS pathogenesis due to production of pro-inflammatory cytokines, release of auto-reactive antibodies and activation of pathogenic T cells. Ofatumumab is a human monoclonal antibody (IgG1κ) that binds specifically to a distinct epitope encompassing both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the pre-B to mature B lymphocyte stage. The CD20 molecule is also expressed on a small fraction of activated T cells.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The binding of ofatumumab to CD20 induces lysis of CD20+ B-cells primarily through complement-dependent cytotoxicity (CDC) and to a lesser extent, through antibody-dependent cell-mediated cytotoxicity (ADCC). Ofatumumab has also been shown to induce cell lysis in both high and low CD20-expressing cells. CD20-expressing T cells are also depleted by ofatumumab.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Ofatumumab_2025_01_10_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ofatumumab_2025_01_10_HCSC.pdf"">ofatumumab product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166105059,Annotation of FDA Label for ofatumumab and MS4A1,False,True,[],False,"[{'id': 1183704724, 'date': '2013-12-18T00:00:00-08:00', 'type': 'Create', 'version': 0}, {'id': 1450380951, 'date': '2019-04-18T15:25:40.155-07:00', 'description': 'Added cancer genome tag', 'type': 'Update', 'version': 0}, {'id': 1452209521, 'date': '2023-08-17T17:34:39.078-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452804200, 'date': '2025-01-10T13:37:15.183-08:00', 'description': 'added Kesimpta label and annotation', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15172822, 'title': 'Drugs@FDA: Drug Product KESIMPTA (ofatumumab), Novartis Pharmaceuticals Corporation - BLA125326/SUPPL-79, 04/12/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125326', 'crossReferences': [{'id': 1452804160, 'resource': 'FDA Application', 'resourceId': 'BLA125326/SUPPL-79', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125326'}], 'objCls': 'Literature', 'pubDate': '2024-04-12T00:00:00-07:00', 'terms': [], 'type': 'Drug Label'}, {'id': 15101826, 'title': 'Drugs@FDA: Drug Product ARZERRA (ofatumumab), BLA125326, Novartis Pharmaceuticals Corporation', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125326', 'crossReferences': [{'id': 1449767716, 'resource': 'FDA Application', 'resourceId': 'BLA125326', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125326'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165291493', 'name': 'ofatumumab'}]","[{'objCls': 'Gene', 'id': 'PA31111', 'symbol': 'MS4A1', 'name': 'membrane spanning 4-domains A1'}]",FDA,1447981898.0,"<p>There are two FDA-approved ofatumumab products, ARZERRA and KESIMPTA. ARZERRA is used to treat patients with chronic lymphocytic leukemia, while KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis. Ofatumumab is a CD20 (<em>MS4A1</em>)-directed cytolytic monoclonal antibody.</p>
",1447981897.0,"<p>Ofatumumab binds to the CD20 molecule, which is expressed on pre-B and mature B lymphocytes. CD20 is coded for by the <em>MS4A1</em> gene.</p>
<p>Excerpts from the ofatumumab (ARZERRA) drug label:</p>
<blockquote class=""blockquote"">
<p>ARZERRA (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Ofatumumab binds specifically to both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B- to mature B-lymphocyte) and on B-cell CLL...The Fab domain of ofatumumab binds to the CD20 molecule and the Fc domain mediates immune effector functions to result in B-cell lysis in vitro.</p>
</blockquote>
<p>Excerpts from the ofatumumab (KESIMPTA) drug label:</p>
<blockquote class=""blockquote"">
<p>KESIMPTA is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The precise mechanism by which ofatumumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ofatumumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Ofatumumab_08_11_2017_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ofatumumab_08_11_2017_FDA.pdf"">ofatumumab (ARZERRA) drug label</a> and the <a download=""Ofatumumab_Kesimpta_2025_01_10_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ofatumumab_Kesimpta_2025_01_10_FDA.pdf"">ofatumumab (KESIMPTA) drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,Formerly on FDA Biomarker List
Label Annotation,PA166122968,Annotation of EMA Label for sildenafil,False,False,[],False,"[{'id': 1184513626, 'date': '2014-08-07T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933211, 'date': '2019-12-04T13:27:30.565-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452215302, 'date': '2023-08-24T15:34:12.559-07:00', 'description': 'remove informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103655, 'title': 'Viagra | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/viagra', 'crossReferences': [{'id': 1450932887, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/viagra', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/viagra'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451346', 'name': 'sildenafil'}]",[],EMA,1447982059.0,"<p>The EMA European Public Assessment Report (EPAR) for sildenafil (Viagra) contains genetic information regarding its contraindication in patients with hereditary degenerative retinal disorders. It also mentions that the drug is metabolized by CYP3A4 and CYP2C9, and that a lower dose of silenafil should be considered in patients taking CYP3A4 inhibitors concomitantly.</p>
",1447982058.0,"<p>Sildenafil (Viagra) is contraindicated in patients with hereditary degenerative retinal disorders, such as retinitis pigmentosa. Variants in different genes can underlie these disorders - see <a rel=""noopener noreferrer"" href=""http://omim.org/entry/268000"" target=""_blank"">OMIM</a> for more information.</p>
<p>Excerpts from the sildenafil (Viagra) EPAR:</p>
<blockquote class=""blockquote"">
<p>The safety of sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated: severe hepatic impairment, hypotension (blood pressure &lt;90/50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders such as retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>With the exception of ritonavir for which co-administration with sildenafil is not advised (see section 4.4) a starting dose of 25 mg should be considered in patients receiving concomitant treatment with CYP3A4 inhibitors (see section 4.5).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Sildenafil_EMA_EPAR_Aug_6_2014.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Sildenafil_EMA_EPAR_Aug_6_2014.pdf"">sildenafil (Viagra) EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166123388,Annotation of EMA Label for ruxolitinib and CYP3A4,False,False,[],False,"[{'id': 1184754032, 'date': '2014-09-12T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933210, 'date': '2019-12-04T13:26:45.033-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452215240, 'date': '2023-08-24T15:29:27.765-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103654, 'title': 'Jakavi | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi', 'crossReferences': [{'id': 1450932886, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166123386', 'name': 'ruxolitinib'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447982177.0,"<p>The EMA European Public Assessment Report (EPAR) for ruxolitinib (Jakavi) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and CYP2C9, and suggests dosing adjustments and more frequent monitoring of hematology parameters if co-administered with strong CYP3A4 inhibitors or inducers, or dual inhibitors of CYP3A4 and CYP2C9.</p>
",1447982176.0,"<p>The EMA-approved drug ruxolitinib (Jakavi) is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>Excerpt from the ruxolitinib (Jakavi) EPAR:</p>
<blockquote class=""blockquote"">
<p>When Jakavi is administered with strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole) the unit dose of Jakavi should be reduced by approximately 50%, to be administered twice daily (see section 4.5).</p>
<p>More frequent monitoring (e.g. twice a week) of haematology parameters and of clinical signs and symptoms of Jakavi-related adverse drug reactions is recommended while on strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 enzymes.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/ruxolitinib_EMA_EPAR_Aug_6_2014.pdf"">ruxolitinib (Jakavi) EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166123411,Annotation of EMA Label for sirolimus and CYP3A4,False,False,[],False,"[{'id': 1184754382, 'date': '2014-09-15T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933212, 'date': '2019-12-04T13:27:54.056-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452215340, 'date': '2023-08-24T15:48:29.415-07:00', 'description': 'remove informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103656, 'title': 'Rapamune | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rapamune', 'crossReferences': [{'id': 1450932888, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rapamune', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rapamune'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451365', 'name': 'sirolimus'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447981652.0,"<p>The EMA European Public Assessment Report (EPAR) for sirolimus (Rapamune) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and recommends therapeutic monitoring and dose adjustments when coadministrated with strong CYP3A inhibitors or inducers.</p>
",1447981651.0,"<p>The EMA-approved drug sirolimus (Rapamune) is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/sirolimus_EMA_EPAR_Aug_6_2014.pdf"">sirolimus EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166123413,Annotation of EMA Label for zonisamide and CYP3A4,False,False,[],False,"[{'id': 1184754426, 'date': '2014-09-16T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933219, 'date': '2019-12-04T13:32:23.277-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452220504, 'date': '2023-08-29T13:01:23.157-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103663, 'title': 'Zonegran | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zonegran', 'crossReferences': [{'id': 1450932895, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zonegran', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zonegran'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451978', 'name': 'zonisamide'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447982215.0,"<p>The EMA European Public Assessment Report (EPAR) for zonisamide (Zonegran) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and recommends dose adjustments if CYP3A4 inducers are taken concomitantly.</p>
",1447982214.0,"<p>The EMA-approved drug zonisamide is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/zonisamide_EMA_EPAR_Aug_6_2014_1.pdf"">zonisamide EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166123417,Annotation of EMA Label for telithromycin and CYP3A4,False,False,[],False,"[{'id': 1184754489, 'date': '2014-09-16T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933214, 'date': '2019-12-04T00:00:00-08:00', 'description': 'Added source literature and edited summary to show that medication has been withdrawn from EU', 'type': 'Update', 'version': 0}, {'id': 1452215420, 'date': '2023-08-24T16:02:13.007-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103658, 'title': 'Ketek | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ketek', 'crossReferences': [{'id': 1450932890, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ketek', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ketek'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10202', 'name': 'telithromycin'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447982187.0,"<p><strong>Note: this medication has been withdrawn from use in the European Union.</strong></p>
<p>The EMA European Public Assessment Report (EPAR) for telithromycin (Ketek) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and contains information regarding use of concomitant drugs that are CYP3A4 substrates, inhibitors or inducers.</p>
",1447982186.0,"<p>The EMA-approved drug telithromycin is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/telithromycin_EMA_EPAR_Aug_6_2014_1.pdf"">telithromycin EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166123420,Annotation of EMA Label for fosamprenavir and CYP3A4,False,False,[],False,"[{'id': 1184754511, 'date': '2014-09-16T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933196, 'date': '2019-12-04T13:19:05.964-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452209380, 'date': '2023-08-17T16:57:03.201-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103641, 'title': 'Telzir | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/telzir', 'crossReferences': [{'id': 1450932872, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/telzir', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/telzir'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10084', 'name': 'fosamprenavir'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447982189.0,"<p>The EMA European Public Assessment Report (EPAR) for fosamprenavir (Telzir) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. Concomitant use of drugs with a narrow therapeutic window that are substrates of CYP3A4 or CYP2D6 is contraindicated.</p>
",1447982188.0,"<p>Fosamprenavir is rapidly hydrolysed to amprenavir, which is metabolized primarily by CYP3A4. The EMA-approved drug fosamprenavir is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/fosamprenavir_EMA_EPAR_Aug_6_2014_1.pdf"">fosamprenavir EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166121252,Annotation of EMA Label for ofatumumab and MS4A1,False,False,[],False,"[{'id': 1184466964, 'date': '2014-05-29T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933205, 'date': '2019-12-04T13:24:42.837-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452209483, 'date': '2023-08-17T17:32:05.867-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452804041, 'date': '2025-01-10T11:43:07.909-08:00', 'description': 'added Kesimpta label and annotation, removed Arzerra text (withdrawn), removed Cancer Genome tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103649, 'title': 'Arzerra | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra', 'crossReferences': [{'id': 1450932881, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}, {'id': 15172802, 'title': 'Kesimpta | European Medicines Agency (EMA)', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta', 'crossReferences': [{'id': 1452804040, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165291493', 'name': 'ofatumumab'}]","[{'objCls': 'Gene', 'id': 'PA31111', 'symbol': 'MS4A1', 'name': 'membrane spanning 4-domains A1'}]",EMA,1447982097.0,"<p>Ofatumumab (Kesimpta) is used to treat adult patients with relapsing remitting multiple sclerosis. The drug is a CD20 (MS4A1)-directed cytolytic monoclonal antibody.</p>
<p>Ofatumumab (Arzerra) was indicated as an antineoplastic; as of January 2025, its marketing status on the EMA website is &quot;Withdrawn&quot;.
https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra</p>
",1447982096.0,"<p>Excerpts from the ofatumumab (Kesimpta) EPAR:</p>
<blockquote class=""blockquote"">
<p>Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features (see section 5.1).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Ofatumumab is a fully human anti-CD20 monoclonal immunoglobulin G1 (IgG1) antibody with a theoretical average molecular weight of 145kDa. The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the pre-B to mature B lymphocyte stage. The CD20 molecule is also expressed on a small fraction of activated T cells. A subcutaneous route of administration of ofatumumab and subsequent release/absorption from the tissue allows a gradual interaction with B cells.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The binding of ofatumumab to CD20 induces lysis of CD20+ B cells primarily through complement-dependent cytotoxicity (CDC) and, to a lesser extent, through antibody-dependent cell-mediated cytotoxicity (ADCC). Ofatumumab has also been shown to induce cell lysis in both high and low CD20 expressing cells. CD20-expressing T cells are also depleted by ofatumumab.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Ofatumumab_2025_01_10_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ofatumumab_2025_01_10_EMA.pdf"">ofatumumab (Kesimpta) EPAR</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166123424,Annotation of EMA Label for darunavir and CYP3A4,False,False,[],False,"[{'id': 1184754762, 'date': '2014-09-17T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933192, 'date': '2019-12-04T13:17:57.154-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452206880, 'date': '2023-08-15T07:06:00.679-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103637, 'title': 'Prezista | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/prezista', 'crossReferences': [{'id': 1450932868, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/prezista', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/prezista'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA163522472', 'name': 'darunavir'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447982209.0,"<p>The EMA European Public Assessment Report (EPAR) for darunavir (PREZISTA) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of darunavir by CYP3A and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers.</p>
",1447982208.0,"<p>The EMA-approved drug darunavir is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/darunavir_EMA_EPAR_Aug_6_2014.pdf"">darunavir EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166317885,Annotation of HCSC Label for fosdenopterin,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166252761', 'name': 'fosdenopterin'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317945,Annotation of HCSC Label for oliceridine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166223601', 'name': 'oliceridine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317921,Annotation of HCSC Label for golodirsen,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166190721', 'name': 'golodirsen'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166317946,Annotation of HCSC Label for oxymetazoline and tetracaine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182885', 'name': 'oxymetazoline and tetracaine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166104882,Annotation of EMA Label for desloratadine,False,False,[],False,"[{'id': 1184466995, 'date': '2013-10-25T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1450933193, 'date': '2019-12-04T13:18:14.238-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452229320, 'date': '2023-09-06T09:19:50.429-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103638, 'title': 'Aerinaze | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/aerinaze', 'crossReferences': [{'id': 1450932869, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/aerinaze', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/aerinaze'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164776964', 'name': 'desloratadine'}]",[],EMA,1447981749.0,"<p>The EMA European Public Assessment Report (EPAR) highlights information regarding variation in the metabolism of desloratadine in different individuals, but does not mention pharmacogenetics or genetic testing. The genes/ enzymes involved are not known.</p>
",1447981748.0,"<p>Excerpt from the Desloratadine and Pseudoephedrine (Aerinaze)  EPAR:</p>
<blockquote class=""blockquote"">
<p>&quot;In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine. The prevalence of this poor metabolizer phenotype was greater among Blacks adults than Caucasians adults (18 % vs. 2 %) however the safety profile of these subjects was not different from that of the general population. In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine. These subjects had a Cmax concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours.&quot;</p>
</blockquote>
<p>This information is highlighted in the following sections:</p>
<p>Pharmacokinetic properties.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Aerinaze_EMA_EPAR_12_17_2012.pdf"">Desloratadine and Pseudoephedrine EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166105315,Annotation of EMA Label for nelfinavir and CYP3A4,False,False,[],False,"[{'id': 1184512664, 'date': '2013-10-27T00:00:00-07:00', 'type': 'Update', 'version': 0}, {'id': 1450933203, 'date': '2019-12-04T00:00:00-08:00', 'description': 'Added source literature and edited summary to show that medication has been withdrawn from the EU.', 'type': 'Update', 'version': 0}, {'id': 1452207483, 'date': '2023-08-15T12:46:18.360-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103648, 'title': 'Viracept | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/viracept', 'crossReferences': [{'id': 1450932879, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/viracept', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/viracept'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450606', 'name': 'nelfinavir'}]","[{'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447981984.0,"<p><strong>Note: this medication has been withdrawn from use in the European Union</strong></p>
<p>The EMA European Public Assessment Report (EPAR) for nelfinavir (Viracept) contains information regarding the metabolism of the drug by CYP3A4, CYP2C19 and CYP2D6, and that concomitant use of CYP3A4 substrates or inducers is contraindicated. No genetic information is included.</p>
",1447981983.0,"<p>Excerpt from the nelfinavir (Viracept) EPAR:</p>
<blockquote class=""blockquote"">
<p>Potent inducers of CYP3A4 (e.g., rifampicin, pehnobarbital and carbamazepine) may reduce nelfianvir plasma concentrations and their coadministration is contraindicated (see section 4.3). Caution should be used when co-administering other agents that induce CYP3A4.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Co-administration of nelfinavir with inhibitors of CYP2C19 (e.g., fluconazole, fluoxetine, paroxetine, lansoprazole, imipramine, amitriptyline and diazepam) may be expected to reduce the conversion of nelfinavir to its major active metabolite M8 (tert-butyl hydroxy nelfinavir) with a concomitant increase in plasma nelfinavir levels (see section 5.2). Limited clinical trial data from patients receiving one or more of these medicinal products with nelfinavir indicated that a clinically significant effect on safety and efficacy is not expected. However, such an effect cannot be ruled out.</p>
</blockquote>
<p>This information is highlighted in the following sections:</p>
<p>Contraindications, interaction with other medicinal products and other forms of interaction, pharmacodynamic properties.</p>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Viracept_EMA_EPAR_25July2013.pdf"">nelfinavir (Viracept) EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166123549,Annotation of PMDA Label for tolterodine and CYP2D6,False,False,[],False,"[{'id': 1452206021, 'date': '2023-08-14T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164746757', 'name': 'tolterodine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",PMDA,1447982465.0,"<p>Tolterodine is metabolized by CYP2D6 into the pharmacologically active and equipotent 5-hydroxymethyl metabolite (DD01). The PMDA package insert for tolterodine (Detrusitol) notes that CYP2D6 poor metabolizers have negligible concentrations of the 5-hydroxymethyl metabolite and significantly increased concentrations of tolterodine, as compared to extensive metabolizers.</p>
",1447982464.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the package insert for tolterodine (Detrusitol):</p>
<blockquote class=""blockquote"">
<p>Tolterodine undergoes oxidation of the 5-methyl group on the phenyl ring by CYP2D6 resulting in the formation of DD01. Tolterodine and DD01 are dealkylated by CYP3A4...In PMs (individuals with deficient or low CYP2D6 activity), N-dealkylation via CYP3A4 has been identified as the major pathway of metabolism. In CYP2D6 PMs, negligible concentrations of DD01 are detected in the serum, while serum concentrations of tolterodine are higher compared to EMs (individuals with normal CYP2D6 activity). As DD01 exhibits a pharmacological activity similar to that of tolterodine, the pharmacological activity of the product is likely determined by the sum of unbound serum concentrations of tolterodine and DD01 (unbound active moiety concentration). Due to different protein-binding rates of tolterodine and DD01, the major fraction of the unbound active moiety is DD01 in EMs and tolterodine in PMs. Following dosing of the sustained-release or immediate-release products, the AUC of unbound tolterodine in PMs was similar to the sum of AUCs of unbound tolterodine and DD01 in EMs.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The effect of 4 days of repeated dosing of 4 mg/day (2 mg BID) and 8 mg/day (4 mg BID) of immediate-release tolterodine on the QT interval was evaluated in a crossover, double-blind placebo- and active-controlled (moxifloxacin 400 mg/day) study in 48 healthy male and female volunteers (aged 18-55 years, approximately equal representation of males and females as well as CYP2D6 EMs and PMs)...There appeared to be a greater QT interval increase in PMs than in EMs.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Tolterodine_PMDA_11_17_14.pdf"">tolterodine package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166123553,Annotation of PMDA Label for abacavir and HLA-B,False,False,[],False,"[{'id': 1452205980, 'date': '2023-08-14T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448004', 'name': 'abacavir'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",PMDA,1447982461.0,"<p>The <em>HLA-B*57:01</em> allele is associated with a high risk of experiencing a hypersensitivity reaction to abacavir in multiple populations, including Caucasians and African-Americans. However, the PMDA package insert for abacavir notes that the association between <em>HLA-B*57:01</em> and risk of an abacavir hypersensitivity reaction is unknown in Japanese patients, and that the <em>*57:01</em> allele has a reported prevalence of only 0.1% in the Japanese population.</p>
",1447982460.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the package insert for abacavir:</p>
<blockquote class=""blockquote"">
<p>The association of HLA-B*5701 and hypersensitivity in Japanese population is unknown.  There is a report claiming that prevalence of HLA-B*5701 is 5 to 8% in Caucasians, and 0.1% in Japanese.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Abacavir_PMDA_11_17_14.pdf"">abacavir package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166120286,Annotation of EMA Label for esomeprazole and CYP2C19,False,False,[],False,"[{'id': 1184233748, 'date': '2014-05-08T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452209300, 'date': '2023-08-17T00:00:00-07:00', 'description': 'removed prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102909, 'title': 'Nexium Control | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/nexium-control', 'crossReferences': [{'id': 1450417087, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/nexium-control', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/nexium-control'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10075', 'name': 'esomeprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",EMA,1447981842.0,"<p>The EMA European Public Assessment Report (EPAR) for esomeprazole (Nexium Control) notes that CYP2C19 poor metabolizers have higher plasma concentrations of the drug compared to extensive metabolizers, but there are no implications for dosing.</p>
",1447981841.0,"<p>Excerpt from the esomeprazole (Nexium Control) EPAR:</p>
<div class=""blockquote"">
<p>Approximately 2.9±1.5% of the population lack a functional CYP2C19 enzyme and are called poor metabolisers. In these individuals the metabolism of esomeprazole is probably mainly catalysed by CYP3A4. After repeated once-daily administration of 40 mg esomeprazole, the mean area under the plasma concentration-time curve was approximately 100% higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were 60% higher. These findings have no implications for the posology of esomeprazole.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Esomeprazole_06_21_19_EMA.pdf"">esomeprazole EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166127640,Annotation of HCSC Label for boceprevir and IFNL3,False,False,[],False,"[{'id': 1452540340, 'date': '2024-07-26T14:49:49.522-07:00', 'description': 'added note of current marketing status Cancelled Post Market', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162242, 'title': 'Drugs@HCSC: Drug Product VICTRELIS (boceprevir), Merck Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85593', 'crossReferences': [{'id': 1452540302, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85593', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85593'}], 'notes': 'Current status: Cancelled Post Market\nCurrent status date: 2017-01-10', 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA165948902', 'name': 'boceprevir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",HCSC,1447982331.0,"<p>The product monograph for boceprevir (VICTRELIS) contains information regarding a genetic variant near the IFNL3 gene (<em>IL28B</em>, <a href=""/variant/PA166155468"">rs12979860</a>, a C to T change) which is a strong predictor of response to peginterferon alfa-2b/ribavirin treatment.</p>
<p><strong>Please note that as of July 2024, the marketing status of boceprevir at HCSC is Cancelled Post Market.</strong></p>
",1447982330.0,"<p>Boceprevir (BOC; VICTRELIS) is indicated for treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alpha (PegIFNalpha)/ribavirin (RBV). Boceprevir must not be used as a monotherapy but only in combination with PegIFNalpha/RBV. Excerpts from the boceprevir (VICTRELIS) product monograph:</p>
<blockquote class=""blockquote"">
<p>Genetic variance near the gene encoding interferon-lambda-3 (<em>IL28B <a href=""/variant/PA166155468"">rs12979860</a></em>, C to T change) has been demonstrated to be a strong predictor of response to PegIFNalpha2b/RBV.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Overall, among the patients that received at least one dose of placebo or BOC (Modified-Intent-to-Treat population) plus PegIFNalpha2B/RBV for 48-weeks, the SVR rates tended to be lower in patients with the C/T and T/T genotypes when compared to the C/C genotype of both Previously untreated Patients and Previous Treatment Failures. The results of this retrospective subgroup analysis should be viewed with caution because of the small sample size and potential differences in demographic or clinical characteristics of the sub-study population relative to the overall trial population.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Boceprevir_HCSC_05_05_15.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Boceprevir_HCSC_05_05_15.pdf"">boceprevir product monograph</a>.</p>
<p><strong>Please note that as of July 2024, the marketing status of boceprevir at HCSC is Cancelled Post Market.</strong></p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166123414,"Annotation of EMA Label for dronedarone and CYP2D6, CYP3A4",False,False,[],False,"[{'id': 1184754428, 'date': '2014-09-16T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1450933194, 'date': '2019-12-04T13:18:31.879-08:00', 'description': 'Added source literature', 'type': 'Update', 'version': 0}, {'id': 1452206924, 'date': '2023-08-15T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15103639, 'title': 'Multaq | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0', 'crossReferences': [{'id': 1450932870, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA153619853', 'name': 'dronedarone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}, {'objCls': 'Gene', 'id': 'PA130', 'symbol': 'CYP3A4', 'name': 'cytochrome P450 family 3 subfamily A member 4'}]",EMA,1447982193.0,"<p>The EMA European Public Assessment Report (EPAR) for dronedarone (MULTAQ) states that it is a mild inhibitor of CYP2D6, and that the effect on metoprolol and propranol exposure is much below the difference seen between poor and extensive CYP2D6 metabolisers. It also contains information regarding metabolism of by dronedarone CYP3A4, and that concomitant drugs that are potent CYP3A4 inhibitors are contraindicated and potent CYP3A4 inducers are not recommended.</p>
",1447982192.0,"<p>The EMA-approved drug dronedarone is tagged with CYP3A4 in [Article:<a href=""/pmid/24433361"">24433361</a>].</p>
<p>Excerpt from the dronedarone EPAR:</p>
<blockquote class=""blockquote"">
<p>Dronedarone 800 mg daily increased metoprolol exposure by 1.6-fold and propranolol exposure by 1.3-fold (i.e. much below the 6-fold differences observed between poor and extensive CYP 2D6 metabolisers)</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/dronedarone_EMA_EPAR_Aug_6_2014_1.pdf"">dronedarone EMA drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166123387,"Annotation of EMA Label for axitinib and CYP2C19, UGT1A1",False,False,[],False,"[{'id': 1184754001, 'date': '2014-09-12T00:00:00-07:00', 'type': 'Create', 'version': 0}, {'id': 1452206101, 'date': '2023-08-14T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15102944, 'title': 'Inlyta | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta', 'crossReferences': [{'id': 1450416865, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164924493', 'name': 'axitinib'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",EMA,1447982213.0,"<p>The EMA European Public Assessment Report (EPAR) for axitinib (Inlyta) states that population pharmacokinetic analyses show no clinically relevant effects of UGT1A1 or CYP2C19 genotype.</p>
",1447982212.0,"<p>Excerpt from the axitinib (Inlyta) EPAR:</p>
<div class=""blockquote"">
<p>Population pharmacokinetic analyses in patients with advanced cancer (including advanced RCC) and healthy volunteers indicate that there are no clinically relevant effects of age, gender, body weight, race, renal function, UGT1A1 genotype, or CYP2C19 genotype.</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Axitinib_06_19_19_EMA.pdf"">axitinib EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166127691,Annotation of HCSC Label for metoprolol and CYP2D6,False,False,[],False,"[{'id': 1452209400, 'date': '2023-08-17T17:06:17.695-07:00', 'description': 'changed level to informative because of ""little or no effect on safety or tolerability of the drug"" in wording', 'type': 'Update', 'version': 0}, {'id': 1452539200, 'date': '2024-07-25T11:01:24.599-07:00', 'description': 'updated label; the language "" little or no effect on safety or tolerability of the drug"" no longer appears in the label; return to ""Actionable PGx""', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15162022, 'title': 'Drugs@HCSC: Drug Product METOPROLOL (metoprolol), PRO DOC LTÉE.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78208', 'crossReferences': [{'id': 1452539160, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78208', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78208'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450480', 'name': 'metoprolol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1447982409.0,"<p>The product monograph for metoprolol notes that CYP2D6 poor metabolizers exhibit higher plasma concentrations of the drug as compared to extensive metabolizers, which are associated with higher intensity of therapeutic effects, an increase in duration of action and an increase in the occurrence and severity of adverse events as compared to extensive metabolizers.</p>
",1447982408.0,"<p>Metoprolol is a beta-adrenergic receptor-blocking agent. Excerpts from the metoprolol product monograph:</p>
<blockquote class=""blockquote"">
<p>Metoprolol is not a significant P-glycoprotein substrate but is extensively metabolised by enzymes of the cytochrome P450 system in the liver. The oxidative metabolism of metoprolol is under genetic control with a major contribution of the polymorphic cytochrome P450 isoform 2D6 (CYP2D6), which causes inter-individual variability in pharmacokinetics and pharmacodynamics of metoprolol.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Indeed, the accumulation of metoprolol leads to high levels of the drug in plasma in poor metabolizers (PMs), which are associated with higher intensity of therapeutic effects, an increase in duration of action and an increase in the occurrence and severity of AEs as compared to extensive metabolizers (EMs).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Elimination is mainly by biotransformation in the liver, and the plasma half-life averages 3.5 hours (range: 1 [in EMs] to 9 hours [in PMs]). [...] Following single oral administration of 100 mg metoprolol the median clearance were 31, 168, and 367 L/h in poor metabolizers, extensive metabolizers, and ultrarapid metabolizers, respectively.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Ethnic Origin (Ethnic sensitivity):</strong> The oxidative metabolism of metoprolol is under genetic control with a major contribution of the polymorphic cytochrome P450 isoform 2D6 (CYP2D6). There are marked ethnic differences in the prevalence of the poor metabolizers (PM) phenotype. Approximately 7% of Caucasians and less than 1% Orientals are PMs. CYP2D6 poor metabolizers exhibit 5-fold higher plasma concentrations of metoprolol than extensive metabolizers with normal CYP2D6 activity.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Metoprolol_2024_07_25_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Metoprolol_2024_07_25_HCSC.pdf"">metoprolol product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166160720,Annotation of PMDA Label for omeprazole and CYP2C19,False,False,[],False,"[{'id': 1452206020, 'date': '2023-08-14T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450704', 'name': 'omeprazole'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",PMDA,1448265982.0,"<p>The PMDA package insert for omeprazole states that the slower metabolism of the drug in CYP2C19 poor metabolizers is similar to that observed with other proton-pump inhibitors.</p>
",1448265981.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the Japanese Society of Pharmacogenomics, who provided a translation of the pharmacogenetic information contained in the PMDA package insert.</strong></p>
<p>Excerpt from the omeprazole package insert:</p>
<blockquote class=""blockquote"">
<p>Data from non-Japanese populations have shown that the major plasma metabolites following oral dosing of omeprazole in healthy adults are omeprazole sulfone and hydroxyomeprazole, which have very little or no gastric antisecretory activity. In vitro assays using human liver microsomes indicated that the hydroxy and sulfone derivatives of omeprazole are metabolized by CYP2C19 and CYP3A4, respectively, and the metabolic clearance of omeprazole as hydroxyl is 4-fold greater than as sulfone. Genetic polymorphisms are known for CYP2C19, and the reported frequency of genetically CYP2C19 poor metabolizers (PMs) who are deficient in functional CYP2C19 is 13-20% in Mongolian descent, which includes Japanese, and 3-4% in Caucasians. The slower metabolism of omeprazole in PMs is similar to those observed with other proton-pump inhibitors.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Omeprazole_PMDA_10_07_16.pdf"">omeprazole package insert</a> (in Japanese).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166161087,Annotation of PMDA Label for isoniazid and NAT2,False,False,[],False,"[{'id': 1452206002, 'date': '2023-08-14T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450112', 'name': 'isoniazid'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",PMDA,1448308348.0,"<p>The PMDA package insert for isoniazid (ISCOTIN) notes that acetylation rate of isoniazid differs between individuals, and that about 10% of Japanese are slow acetylators.</p>
",1448308347.0,"<p>Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene (see <a href=""http://www.pharmgkb.org/vip/PA18"">NAT2 VIP summary</a>).</p>
<p>Excerpt from isoniazid (ISCOTIN) package insert:</p>
<blockquote class=""blockquote"">
<p>Metabolizing speed for N-acetylation is varied among individuals...about 10% of Japanese are slow acetylators.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Isoniazid_PMDA_11_01_16.pdf"">isoniazid package insert</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166183789,Annotation of Swissmedic Label for metabutethamine and G6PD,False,False,[],False,"[{'id': 1452021981, 'date': '2023-02-28T14:31:13.185-08:00', 'description': 'added prescribing genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15103030, 'title': 'Swissmedic label for metabutethamin', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=48447', 'crossReferences': [{'id': 1450811182, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=48447', '_url': 'https://amiko.oddb.org/de/fi?gtin=48447'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166183788', 'name': 'metabutethamine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",Swissmedic,1450811183.0,"<p>The Swiss drug label for metabutethamin (Alcacyl® 500 Instant-Pulver) states that patients with G6PD deficiency may have increased risk of adverse events to metabutethamin and caution is advised.</p>
",1450811184.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpts from the Metabutethamin (Alcacyl® 500 Instant-Pulver) label:</p>
<div class=""blockquote"">
<p>Caution is advised: Kidney and/or liver failure, chronic or recurrent stomach or duodenal pain, bronchial asthma or general tendency to hypersensitivity, nasal mucous membrane polyps, genetic glucose-6-phosphate dehydrogenase deficiency, concomitant therapy with anticoagulant drugs, conditions with increased risk of bleeding (e.g. injuries, dysmenorrhea).</p>
</div>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=48447&amp;highlight=Glucose-6-Phosphatdehydrogenase"" target=""_blank"">Metabutethamin drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1450813288.0,"<blockquote class=""blockquote"">
<p>Caution is advised: Kidney and/or liver failure, chronic or recurrent stomach or duodenal pain, bronchial asthma or general tendency to hypersensitivity, nasal mucous membrane polyps, genetic glucose-6-phosphate dehydrogenase deficiency, concomitant therapy with anticoagulant drugs, conditions with increased risk of bleeding (e.g. injuries, dysmenorrhea).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166184129,Annotation of Swissmedic Label for daclatasvir and IFNL3,False,False,[],False,"[{'id': 1452206860, 'date': '2023-08-15T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15103170, 'title': 'Swissmedic label for daclatasvir', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65332', 'crossReferences': [{'id': 1450813279, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65332', '_url': 'https://amiko.oddb.org/de/fi?gtin=65332'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166128167', 'name': 'daclatasvir'}]","[{'objCls': 'Gene', 'id': 'PA134952671', 'symbol': 'IFNL3', 'name': 'interferon lambda 3'}]",Swissmedic,1450813702.0,"<p>The Swiss drug label for daclatasvir (Daklinza) states that response to daclatasvir is not dependent on IFNL3 (IL28B) genotype.</p>
",1450813703.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for daclatasvir (Daklinza):</p>
<blockquote class=""blockquote"">
<p>Properties and Effects:
In the studies, SVR (=sustained virologic response) 12 was not dependent on the IL28B genotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Daclatasvir in combination with Sofosbuvir: The treatment duration was 12 weeks for 82 therapeutic patients with HCV genotype 1 and 24 weeks for the other 85 patients with HCV genotype 1 and 18 patients with HCV genotype 3. The 211 patients in the study were on average (median) 54 years old (range: 20 to 70); 83% were Caucasians, 12% African-American, 2% Asian and 20% Hispanic-American or Latin-American. The mean score in the FibroTest (a validated non-invasive diagnostic test method) was 0.460 (range: 0.03 to 0.89). The conversion of the FibroTest score to the corresponding METAVIR score suggests that 35% of all patients (49% of patients with failure under previous protase inhibitor treatment) had liver fibrosis grade =F3 Most of the patients in this study (71%, including 98% with failure under prior protease inhibitor treatment) had IL28B rs12979860 non-CC genotypes.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>SVR12 was achieved by 99% of patients with HCV genotype 1 and 89% of patients with HCV genotype 3 (see also Tables 7 and 8 below). Response to treatment was rapid (virus load at week 4 showed that 98% of patients responded to treatment) and was not dependent on HCV-GT1 subtype (1a/1b), IL28B genotype or ribavirin use. In the therapeutic patients with HCV RNA results in the two follow-up weeks 12 and 24, agreement between SVR12 and SVR24 was 99.2%, regardless of treatment duration.
...
Most patients (71% had a high baseline viral load (HCV RNA level =800,000 I.E./ml). 21% of patients had compensated cirrhosis. Most patients (61%) had IL28B rs12979860 non-CC genotypes.
...
Patients received daclatasvir 60 mg 1× daily (n = 82) or placebo (n = 42) plus pegIFN/RBV for 24 weeks. Patients in the daclatasvir treatment arm who did not achieve both week 4 and week 12 nondetectable HCV RNA titers and all patients in the placebo treatment arm were treated with pegIFN/RBV for a further 24 weeks. The median age of the patients treated was 49 years (range: 20 to 71); 77% were Caucasians, 19% Afro-American, and 4% Hispanic or Latin American. 10% of the patients had compensated cirrhosis and 75% of the patients had IL28B rs12979860 non-CC genotypes. The results of the AI444042 study are presented in Table 13. Response to treatment was rapid (91% of patients treated with daclatasvir at week 4 had HCV RNA &lt; LLOQ). SVR12 rates were higher in patients with the IL28B CC genotype than in patients with non-CC genotypes and higher in patients with an HCV initial load below 800,000 i.U./ml. In all subgroups, SVR 12 rates were higher in patients treated with daclatasvir than in patients treated with placebo.</p>
</blockquote>
<p>For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65332&amp;highlight=Genotyp"" target=""_blank"">daclatasvir drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166184380,"Annotation of Swissmedic Label for brivaracetam and CYP2C19, CYP2C9",False,False,[],False,[],False,[],True,"[{'id': 15103240, 'title': 'Swissmedic label for brivaracetam', '_sameAs': 'https://amiko.oddb.org/de/fi?gtin=65830', 'crossReferences': [{'id': 1450815316, 'resource': 'URL', 'resourceId': 'https://amiko.oddb.org/de/fi?gtin=65830', '_url': 'https://amiko.oddb.org/de/fi?gtin=65830'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166153491', 'name': 'brivaracetam'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",Swissmedic,1450815344.0,"<p>The Swiss drug label for brivaracetam (Briviact) discusses metabolism of brivaracetam by CYP2C19 and CYP2C9 and changes in pharmacokinetics in CYP2C19 poor metabolizers.</p>
",1450815345.0,"<p><strong>Please note that the information contained within this drug label annotation is available through a collaboration with the <a rel=""noopener noreferrer"" href=""http://www.pharmacare.unibas.ch"" target=""_blank"">Pharmaceutical Care Research Group (PCRG), Department of Pharmaceutical Sciences, University of Basel</a>, who provided a translation of the pharmacogenetic information contained in the Swiss drug labels. The original label in German can be accessed using the link under &quot;Source&quot; below.</strong></p>
<p>Excerpt from the drug label for brivaracetam (Briviact)</p>
<blockquote class=""blockquote"">
<p>Kinetics:
Brivaracetam is converted primarily by hydrolysis of the amide group to form the corresponding carboxylic acid and secondarily by hydroxylation at the propyl side chain. The hydrolysis of the amide group leading to the carboxylic acid metabolite is supported by hepatic and extrahepatic amidase (EC3.5.1.4). In vitro, the hydroxylation of brivaracetam is mediated mainly by CYP2C19. In vivo, the production of the hydroxy metabolite in human volunteers with ineffective CYP2C19 mutations is reduced by two or ten times, with Brivaracetam AUC increased by 22% and 42%, respectively, in volunteers with one or both alleles with loss of function compared to volunteers with wild-type enzymes. Therefore, CYP2C19 inhibitors are unlikely to have a significant effect on the pharmacokinetics of brivaracetam. Another metabolite (the hydroxy acid metabolite) is produced predominantly by hydroxylation of the propyl side chain of the carboxylic acid metabolite (mainly by CYP2C9). The AUC of the hydroxy, acid and hydroxy acid metabolites correspond to 10%, 8% and 2% respectively of the parent substance. The 3 metabolites are pharmacologically inactive.</p>
</blockquote>
<p>Given the sentence about the lack of impact of CYP2C19 inhibitors it may be assumed there is also no clinical impact of poor metabolizer phenotype and so categorized as informative PGx.
For the complete drug label text with pharmacogenetic information highlighted, see the <a rel=""noopener noreferrer"" href=""https://amiko.oddb.org/de/fi?gtin=65830"" target=""_blank"">brivaracetam drug label</a> (in German).</p>
<p>*Disclaimer: The contents of this page have not been endorsed by Swissmedic and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166272161,"Annotation of EMA Label for venetoclax and FLT3, IDH1, IDH2, NPM1, TP53",False,True,[],False,"[{'id': 1452220482, 'date': '2023-08-29T12:53:10.572-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132622, 'title': 'Venetoclax | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto', 'crossReferences': [{'id': 1451813160, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166153473', 'name': 'venetoclax'}]","[{'objCls': 'Gene', 'id': 'PA28181', 'symbol': 'FLT3', 'name': 'fms related receptor tyrosine kinase 3'}, {'objCls': 'Gene', 'id': 'PA29630', 'symbol': 'IDH1', 'name': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'objCls': 'Gene', 'id': 'PA29631', 'symbol': 'IDH2', 'name': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'objCls': 'Gene', 'id': 'PA31712', 'symbol': 'NPM1', 'name': 'nucleophosmin 1'}, {'objCls': 'Gene', 'id': 'PA36679', 'symbol': 'TP53', 'name': 'tumor protein p53'}]",EMA,1451813520.0,"<p>Venetoclax (Venclyxto) is EMA approved for certain patients with <a href=""/disease/PA446169"">CLL</a> or <a href=""/disease/PA444760"">AML</a> particularly those with 17p chromosome deletion or TP53 mutations. The label also notes whether mutation analyses detected mutations in the IDH1, IDH2, FLT3 and NPM1 genes.</p>
",1451813521.0,"<p>Excerpts from the Venetoclax (Venclyxto) EPAR:</p>
<blockquote class=""blockquote"">
<p>Venclyxto monotherapy is indicated for the treatment of CLL: in the presence of 17p deletion or TP53 mutation in adult patients</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The following mutations were identified: TP53 mutations in 21% (52/249), IDH1 and/or IDH2 mutation in 24% (89/372), 9% (34/372) with IDH1, 16% (58/372) with IDH2, 16% (51/314) with FLT3, and 18% (44/249) with NPM1.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Venetoclax_EMA_2022_06_28.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Venetoclax_EMA_2022_06_28.pdf"">Venetoclax EPAR pdf</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166272181,Annotation of EMA Label for upadacitinib and CYP2D6,False,False,[],False,"[{'id': 1452220424, 'date': '2023-08-29T12:43:43.161-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132642, 'title': 'Upadacitinib | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq', 'crossReferences': [{'id': 1451813560, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166189803', 'name': 'upadacitinib'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1451813580.0,"<p>Upadacitinib (Rinvoq) is indicated for moderate to severe active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis or moderate to severe atopic dermatitis in adult patients. Upadacitinib is metabolized by CYP3A4 with a minor contribution from CYP2D6. There is no information on the label about the impact of CYP2D6 variants.</p>
",1451813581.0,"<p>Excerpts from the Upadacitinib (Rinvoq) EPAR:</p>
<blockquote class=""blockquote"">
<p>Upadacitinib metabolism is mediated by CYP3A4 with a potential minor contribution from CYP2D6.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Upadacitinib has no relevant effects on plasma exposures of ethinylestradiol, levonorgestrel,
methotrexate, or medicinal products that are substrates for metabolism by CYP1A2, CYP2B6,
CYP2C9, CYP2C19, or CYP2D6.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Upadacitinib_EMA_2022_06_28.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Upadacitinib_EMA_2022_06_28.pdf"">Upadacitinib EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166272261,"Annotation of HCSC Label for venetoclax and FLT3, IDH1, IDH2, NPM1, TP53",False,True,[],False,"[{'id': 1451820620, 'date': '2022-07-08T08:46:07.856-07:00', 'description': 'Tagged Cancer genome', 'type': 'Correction', 'version': 0}, {'id': 1452220483, 'date': '2023-08-29T12:53:35.702-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132742, 'title': 'Drugs@HCSC: Drug Product Venetoclax', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00065382.PDF', 'crossReferences': [{'id': 1451813905, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00065382.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00065382.PDF'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166153473', 'name': 'venetoclax'}]","[{'objCls': 'Gene', 'id': 'PA28181', 'symbol': 'FLT3', 'name': 'fms related receptor tyrosine kinase 3'}, {'objCls': 'Gene', 'id': 'PA29630', 'symbol': 'IDH1', 'name': 'isocitrate dehydrogenase (NADP(+)) 1'}, {'objCls': 'Gene', 'id': 'PA29631', 'symbol': 'IDH2', 'name': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'objCls': 'Gene', 'id': 'PA31712', 'symbol': 'NPM1', 'name': 'nucleophosmin 1'}, {'objCls': 'Gene', 'id': 'PA36679', 'symbol': 'TP53', 'name': 'tumor protein p53'}]",HCSC,1451813960.0,"<p>Venetoclax (VENCLEXTA) is HCSC approved for certain patients with CLL or AML including those with 17p chromosome deletion. The label also notes whether mutation analyses detected mutations in the IDH1, IDH2, FLT3, NPM1, and TP53 genes.</p>
",1451813961.0,"<p>Excerpts from the Venetoclax (VENCLEXTA) product monograph:</p>
<blockquote class=""blockquote"">
<p>Mutation analyses detected ...
IDH1 or IDH2 ... IDH1 ...
IDH2 ...
FLT3 ...
NPM1 ...
TP53</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Venetoclax_HCSC_2022_06_28.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Venetoclax_HCSC_2022_06_28.pdf"">Venetoclax  product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166272621,Annotation of EMA Label for tafamidis and TTR,False,False,[],False,"[{'id': 1452215380, 'date': '2023-08-24T16:00:25.063-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132883, 'title': 'Tafamidis | European Medicines Agency.', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel', 'crossReferences': [{'id': 1451815721, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184562', 'name': 'tafamidis'}]","[{'objCls': 'Gene', 'id': 'PA37069', 'symbol': 'TTR', 'name': 'transthyretin'}]",EMA,1451815840.0,"<p>Tafamidis is EMA indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult
patients with cardiomyopathy (ATTR-CM).</p>
",1451815841.0,"<p>Excerpts from the tafamidis (Vyndaqel) EPAR:</p>
<blockquote class=""blockquote"">
<p>Vyndaqel is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult
patients with cardiomyopathy (ATTR-CM).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Tafamidis is a selective stabiliser of TTR. Tafamidis binds to TTR at the thyroxine binding sites,
stabilising the tetramer and slowing dissociation into monomers, the rate-limiting step in the
amyloidogenic process.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Tafamidis stabilised both the wild-type TTR tetramer and the tetramers of 14 TTR variants tested
clinically after once-daily dosing with tafamidis. Tafamidis also stabilised the TTR tetramer for
25 variants tested ex vivo, thus demonstrating TTR stabilisation of 40 amyloidogenic TTR genotypes.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Tafamidis_EMA_2022_07_01.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Tafamidis_EMA_2022_07_01.pdf""><em><strong>Tafamidis</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166272681,"Annotation of EMA Label for tipiracil / trifluridine and ERBB2, KRAS",False,True,[],False,"[{'id': 1452217621, 'date': '2023-08-27T22:39:29.322-07:00', 'description': 'removed informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15132862, 'title': 'Tipiracil and Trifluridine | European Medicines Agency.', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf', 'crossReferences': [{'id': 1451815700, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166184566', 'name': 'tipiracil / trifluridine'}]","[{'objCls': 'Gene', 'id': 'PA27844', 'symbol': 'ERBB2', 'name': 'erb-b2 receptor tyrosine kinase 2'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",EMA,1451817720.0,"<p>Tipiracil / trifluridine (Lonsurf) is EMA indicated for patients with metastatic colorectal cancer or metastatic gastric cancer who have failed other targeted therapies including those for KRAS negative metastatic colorectal cancer and HER2 positive (ERBB2) metastatic gastric or gastroesophageal junction cancers. Therefore testing was required for those prior therapies.</p>
",1451817721.0,"<p>Excerpts from the tipiracil / trifluridine (Lonsurf) EPAR:</p>
<blockquote class=""blockquote"">
<p>Therapeutic indications
Colorectal cancer
Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.
Gastric cancer
Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The clinical efficacy and safety of Lonsurf were evaluated in an international, randomised, double-blind, placebo-controlled Phase III study (RECOURSE) in patients with previously treated metastatic colorectal cancer....The primary site of disease was colon (62%) or rectum (38%). KRAS status was wild (49%) or mutant (51%) at study entry.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The clinical efficacy and safety of Lonsurf were evaluated in an international, randomised, double-blind, placebo-controlled Phase III study (TAGS) in patients with previously treated metastatic gastric cancer (including adenocarcinoma of the gastroesophageal junction), who had been previously treated with at least two prior systemic treatment regimens for advanced disease, including fluoropyrimidine-, platinum-, and either taxane- or irinotecan-based chemotherapy, plus if appropriate human epidermal growth factor receptor 2 (HER2) -targeted therapy.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Tipiracil_Trifluridine_EMA_2022_07_01.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Tipiracil_Trifluridine_EMA_2022_07_01.pdf"">tipiracil / trifluridine EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166272741,Annotation of EMA Label for ropeginterferon alfa-2b and JAK2,False,True,[],False,"[{'id': 1452215222, 'date': '2023-08-24T15:23:49.491-07:00', 'description': 'remove informative PGx tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15133002, 'title': 'Ropeginterferon Alfa2b | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/besremi', 'crossReferences': [{'id': 1451817860, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/besremi', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/besremi'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166268922', 'symbol': 'rs77375493', 'name': 'rs77375493'}]","[{'objCls': 'Chemical', 'id': 'PA166268921', 'name': 'ropeginterferon alfa-2b'}]","[{'objCls': 'Gene', 'id': 'PA29989', 'symbol': 'JAK2', 'name': 'Janus kinase 2'}]",EMA,1451818760.0,"<p>Ropeginterferon Alfa-2b is used as monotherapy for the treatment of polycythaemia vera in adults. Polycythaemia vera is a type of cancer in which the bone marrow produces too many red blood cells, white blood cells and platelets. Ropeginterferon Alfa-2b decreased the mutated JAK2V617F allele burden in patients with polycythaemia vera (a V617F point mutation, rs77375493G&gt;T, in the JAK2 kinase is a hallmark of polycythaemia vera and is present in approximately 95% of patients).</p>
",1451818761.0,"<p>Excerpts from the Ropeginterferon Alfa-2b (Besremi) EPAR:</p>
<blockquote class=""blockquote"">
<p>Mechanism of action
Interferon alfa belongs to the class of type I interferons which exhibit their cellular effects by binding to a transmembrane receptor termed interferon alfa receptor (IFNAR). Binding to IFNAR initiates a downstream signalling cascade through the activation of kinases, particularly Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) and signal transducer and activator of transcription (STAT) proteins...Further, it was demonstrated that interferon alfa is able to decrease the mutated JAK2V617F allele burden in patients with polycythaemia vera (a V617F point mutation in the JAK2 kinase is a hallmark of polycythaemia vera and is present in approximately 95% of patients).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients showed a statistically significant difference in the JAK2V617F allele burden (19.7%) and JAK2V617F allele change from baseline (-22.9%).</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""RopeginterferonAlfa2B_EMA_2022_07_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/RopeginterferonAlfa2B_EMA_2022_07_05.pdf""><em><strong>Ropeginterferon Alfa-2b</strong></em> EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166278501,Annotation of EMA Label for duvelisib,False,True,[],False,"[{'id': 1452206943, 'date': '2023-08-15T07:17:39.741-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15135902, 'title': 'Drugs@EMA: Drug Product Copiktra (duvelisib), Secura Bio Limited', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra', 'crossReferences': [{'id': 1451884281, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182761', 'name': 'duvelisib'}]",[],EMA,1451884640.0,"<p>The EMA drug label states that duvelisib monotherapy is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies and follicular lymphoma (FL) that is refractory to at least two prior systemic therapies.</p>
<p>The label mentions that some patients had a documented 17p deletion and/or TP53 mutation, and others had a documented 11q deletion.</p>
",1451884641.0,"<p>Excerpts from the duvelisib (Copiktra) EPAR:</p>
<blockquote class=""blockquote"">
<p>Mechanism of action: Duvelisib is a dual inhibitor of phosphatidylinositol 3-kinase p110δ (PI3K-δ) and PI3K-γ. PI3K-δ inhibition directly reduces proliferation and survival of malignant B-cell lines and primary CLL tumour cells, while PI3K-γ inhibition reduces the activity of CD4+ T cells and macrophages in the tumor microenvironment to support the malignant B cells. At 25 mg BID, the plasma levels of duvelisib may not be high enough to cause sustained inhibition of PI3K-γ, and the contribution of PI3K-γ inhibition to the efficacy may be limited.</p>
</blockquote>
<p>For the overall study population of a randomised, multicenter, open-label trial (Study IPI-145-07), the label states:</p>
<blockquote class=""blockquote"">
<p>At baseline, 46% of patients had at least one tumour ≥ 5 cm, 24% of patients had a documented 17p deletion, 32% of patients had a documented 17p deletion and/or TP53 mutation, and 23% had a documented 11q deletion.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""duvelisib_2022_09_16_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/duvelisib_2022_09_16_EMA.pdf"">duvelisib EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166282861,Annotation of HCSC Label for nusinersen and SMN2,False,False,[],False,"[{'id': 1452209481, 'date': '2023-08-17T17:28:58.392-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15151303, 'title': 'Drugs@HCSC: Drug Product SPINRAZA (nusinersen), Biogen Canada Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00074831.PDF', 'crossReferences': [{'id': 1452487740, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00074831.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00074831.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182882', 'name': 'nusinersen'}]","[{'objCls': 'Gene', 'id': 'PA35967', 'symbol': 'SMN2', 'name': 'survival of motor neuron 2, centromeric'}]",HCSC,1451934380.0,"<p>Nusinersen is an antisense oligonucleotide that increases the expression of SMN2 to treat SMA, an autosomal recessive progressive neuromuscular disease.</p>
",1451934381.0,"<p>Excerpts from the Nusinersen (<em><strong>SPINRAZA</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) specifically designed to treat SMA, an autosomal recessive progressive neuromuscular disease, caused by mutations in the chromosome 5q. These mutations lead to loss of function of the survival motor neuron 1 (SMN1) gene, resulting in deficiency of SMN protein. The SMN2 gene also produces SMN protein but at low levels. In patients with SMA, fewer SMN2 gene copies are associated with earlier age of onset and increased severity of symptoms.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>SPINRAZA binds to a specific site in the SMN2 pre-messenger ribonucleic acid (pre-mRNA) to increase the proportion of exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts made, which can be translated into the functional full length SMN protein.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""nusinersen_HCSC_2022_11_08.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/nusinersen_HCSC_2022_11_08.pdf""><em><strong>Nusinersen</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166283261,Annotation of HCSC Label for isatuximab,False,True,[],False,"[{'id': 1452210000, 'date': '2023-08-18T11:57:19.442-07:00', 'description': 'taking informative PGx tag off; no longer meets criteria', 'type': 'Update', 'version': 0}, {'id': 1452783100, 'date': '2024-12-13T10:20:42.833-08:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15172022, 'title': 'Drugs@HCSC: Drug Product SARCLISA (isatuximab), sanofi-aventis Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98801', 'crossReferences': [{'id': 1452783040, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98801', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98801'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166224941', 'name': 'isatuximab'}]",[],HCSC,1451941880.0,"<p>Isatuximab is listed on the FDA table with the biomarkers Chromosome 17p, 4p, 14q, 16q. The HCSC product monograph for isatuximab mentions clinical studies where patients had high-risk chromosomal abnormalities at study entry; del(17p), t(4;14) and t(14;16) but do not discuss testing or impact of these variants.</p>
",1451941881.0,"<p>Excerpts from the isatuximab (SARCLISA) product monograph:</p>
<blockquote class=""blockquote"">
<p>Study ICARIA-MM (EFC14335) [...] Overall, 19.5% of patients had high-risk chromosomal abnormalities at study entry; del(17p), t(4;14) and t(14;16) were present in 12.1%, 8.5% and 1.6% of patients, respectively.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Study IKEMA (EFC15246) [...] Overall, 24.2% of patients had high-risk chromosomal abnormalities at study entry; del(17p), t(4;14), t(14;16) were present in 11.3%, 13.9% and 2.0% of patients, respectively. In addition, gain(1q21) was present in 42.1% of patients.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Isatuximab_2024_12_13_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Isatuximab_2024_12_13_HCSC.pdf"">isatuximab product monograph</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166277721,Annotation of HCSC Label for anifrolumab and IFNAR1,False,False,[],False,"[{'id': 1452205961, 'date': '2023-08-14T07:07:50.097-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15135142, 'title': 'Drugs@HCSC: Drug Product Anifrolumab (SAPHNELO)', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101194', 'crossReferences': [{'id': 1452488463, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101194', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101194'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166277641', 'name': 'anifrolumab'}]","[{'objCls': 'Gene', 'id': 'PA29670', 'symbol': 'IFNAR1', 'name': 'interferon alpha and beta receptor subunit 1'}]",HCSC,1451871900.0,"<p>Anifrolumab a monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1) and inhibits type I IFN signaling. Blockade of receptor mediated type I IFN signaling inhibits IFN responsive gene expression (gene signature) as well as downstream inflammatory and immunological processes.</p>
",1451871901.0,"<p>Excerpts from the Anifrolumab (<em><strong>SAPHNELO</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>Mechanism of Action
Anifrolumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1) with high specificity and affinity. This binding inhibits type I IFN signalling thereby blocking the biologic activity of type I IFNs. Anifrolumab also induces the internalization of IFNAR1, thereby reducing the levels of cell surface IFNAR1 available for receptor assembly. Blockade of receptor mediated type I IFN signalling inhibits IFN responsive gene expression as well as downstream inflammatory and immunological processes.
Type I IFNs play an important role in the pathogenesis of SLE. Most adult patients with SLE (approximately 60-80%) express elevated levels of type I IFN inducible genes, which are associated with increased disease activity and severity.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In adult patients with SLE, administration of anifrolumab at doses ≥ 300 mg, via IV infusion every 4 weeks, demonstrated consistent neutralization (≥ 80%) of a 21 gene type I interferon pharmacodynamic (PD) signature in blood.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""anifrolumab_HCSC_2022_08_30.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/anifrolumab_HCSC_2022_08_30.pdf"">___Anifrolumab ___ product monograph</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166284661,Annotation of HCSC Label for pembrolizumab and BRAF,False,True,[],False,"[{'id': 1452214521, 'date': '2023-08-23T16:38:28.487-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15158802, 'title': 'Drugs@HCSC: Drug Product KEYTRUDA (pembrolizumab), Merck Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'crossReferences': [{'id': 1452488400, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166157522', 'symbol': 'rs113488022', 'name': 'rs113488022'}]","[{'objCls': 'Chemical', 'id': 'PA166124615', 'name': 'pembrolizumab'}]","[{'objCls': 'Gene', 'id': 'PA25408', 'symbol': 'BRAF', 'name': 'B-Raf proto-oncogene, serine/threonine kinase'}]",HCSC,1451957240.0,"<p>Pembrolizumab is an anti-PD-L1 (CD274) antibody HCSC indicated for a number of cancers including melanoma. BRAF V600 mutation status is mentioned in the context of prior therapies.</p>
",1451957241.0,"<p>Excerpts from the Pembrolizumab (<em><strong>KEYTRUDA</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>KEYTRUDA®, indicated for the</p>
<ul>
<li>Treatment of adult patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy.</li>
<li>Treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.</li>
</ul>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Pembrolizumab_HCSC_2022_12_06.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Pembrolizumab_HCSC_2022_12_06.pdf""><em><strong>Pembrolizumab</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166284701,Annotation of HCSC Label for regorafenib and KRAS,False,True,[],False,"[{'id': 1452214720, 'date': '2023-08-23T18:25:24.118-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452566061, 'date': '2024-08-26T14:27:14.262-07:00', 'description': 'removed EGFR, VEGFA genes', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15164422, 'title': 'Drugs@HCSC: Drug Product STIVARGA (regorafenib), Bayer Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00055344.PDF', 'crossReferences': [{'id': 1452566060, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00055344.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00055344.PDF'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166114943', 'name': 'regorafenib'}]","[{'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",HCSC,1451957740.0,"<p>Regorafenib is HCSC indicated for colon or rectal cancer that has
spread to other parts of the body in patients who have already
received other treatments (fluoropyrimidine-based
chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy,
and, if RAS wild type, an anti-EGFR therapy).</p>
",1451957741.0,"<p>Excerpts from the Regorafenib (<em><strong>STIVARGA</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>STIVARGA is used to treat colon or rectal cancer that has spread to other parts of the body in patients who have already received other treatments (fluoropyrimidine-based
chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Mechanism of Action
Regorafenib is an inhibitor of multiple protein kinases (IC50s &lt;300 nM), including kinases involved in tumor angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1,
BRAF, BRAFV600E), metastasis (VEGFR3, PDGFR, FGFR), and tumor immunity (CSF1R). Major human metabolites (M-2 and M-5) exhibited similar efficacies compared to regorafenib.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Serious cases of artery dissection have been reported in patients using VEGFR TKIs, including STIVARGA, with or without hypertension.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Regorafenib_HCSC_2022_09_22.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Regorafenib_HCSC_2022_09_22.pdf""><em><strong>Regorafenib</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166272981,"Annotation of EMA Label for abrocitinib and CYP2C19, CYP2C9",False,False,[],False,"[{'id': 1451820641, 'date': '2022-07-08T08:55:14.155-07:00', 'description': 'Added CYP2C9 since this is also specified in the sentence about genotypes', 'type': 'Update', 'version': 0}, {'id': 1452204920, 'date': '2023-08-11T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15133122, 'title': 'Abrocitinib | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo', 'crossReferences': [{'id': 1451820440, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166272921', 'name': 'abrocitinib'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",EMA,1451820580.0,"<p>The EMA product information for abrocitinib states that CYP2C19 or CYP2C9 genotype does not have a clinically significant effect on abrocitinib exposure. There is clinical dosing information about CYP2C19 drug-drug interactions.</p>
",1451820581.0,"<p>Excerpts from the <em><strong>abrocitinib</strong></em> (<em><strong>Cibinqo</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>Body weight, gender, CYP2C19/2C9 genotype, race and age did not have a clinically meaningful effect on abrocitinib exposure</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Abrocitinib_EMA_2022_07_08.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Abrocitinib_EMA_2022_07_08.pdf""><em><strong>Abrocitinib</strong></em> EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166273001,"Annotation of HCSC Label for abrocitinib and CYP2C19, CYP2C9",False,False,[],False,"[{'id': 1452204921, 'date': '2023-08-11T00:00:00-07:00', 'description': 'Checked and this meets new criteria for Informative.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15133162, 'title': 'Drugs@HCSC: Drug Product Abrocitinib (CIBINQO)', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101760', 'crossReferences': [{'id': 1452488482, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101760', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101760'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166272921', 'name': 'abrocitinib'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",HCSC,1451820660.0,"<p>The HCSC product monograph for abrocitinib states that CYP2C19 or CYP2C9 genotype does not have a clinically significant effect on abrocitinib exposure. There is clinical dosing information about drug-drug interactions.</p>
",1451820661.0,"<p>Excerpts from the <em><strong>Abrocitinib</strong></em> (<em><strong>CIBINQO</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>Body weight, gender, CYP2C19/2C9 genotype, race, and age did not have a clinically meaningful effect on CIBINQO exposure.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Abrocitinib_HCSC_2022_07_08.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Abrocitinib_HCSC_2022_07_08.pdf""><em><strong>Abrocitinib</strong></em> product monograph</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166273321,"Annotation of EMA Label for niraparib and BRCA1, BRCA2",False,True,[],False,"[{'id': 1452231380, 'date': '2023-09-08T00:00:00-07:00', 'description': 'updated literature source, set level to actionable', 'type': 'Update', 'version': 0}, {'id': 1452231340, 'date': '2023-09-08T00:00:00-07:00', 'description': 'The wrong label was attached (wrong drug). A new label has been downloaded. New excerpts have been added. The new level will be discussed and updated.', 'type': 'Note', 'version': 0}]",False,[],True,"[{'id': 15133322, 'title': 'Niraparib | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zejula', 'crossReferences': [{'id': 1451824901, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zejula', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/zejula'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166131610', 'name': 'niraparib'}]","[{'objCls': 'Gene', 'id': 'PA25411', 'symbol': 'BRCA1', 'name': 'BRCA1 DNA repair associated'}, {'objCls': 'Gene', 'id': 'PA25412', 'symbol': 'BRCA2', 'name': 'BRCA2 DNA repair associated'}]",EMA,1451825040.0,"<p>BRCA1 and BRCA2 status is discussed in some of the trials documented in the EMA product information for niraparib but it is not required as part of the indication. In the NOVA study patients with mutated BRCA genes (gBRCAmut) had improved progression-free survival and overall survival than non-gBRCAmut.</p>
",1451825041.0,"<p>Excerpts from the <em><strong>Niraparib</strong></em> (<em><strong>Zejula</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>At the final analysis, the median PFS2 in the gBRCAmut cohort was 29.9 months for patients treated with niraparib compared to 22.7 months for patients on placebo (HR = 0.70; 95% CI: 0.50, 0.97). The median PFS2 in the non-gBRCAmut cohort was 19.5 months for patients treated with niraparib compared to 16.1 months for patients on placebo (HR = 0.80; 95% CI: 0.63, 1.02).
At the final analysis of overall survival, the median OS in the gBRCAmut cohort (n = 203) was 40.9 months for patients treated with niraparib compared with 38.1 months for patients on placebo (HR = 0.85; 95% CI: 0.61, 1.20). The cohort maturity for the gBRCAmut cohort was 76%. The median OS in the non-gBRCAmut cohort (n = 350) was 31.0 months for patients treated with niraparib compared with 34.8 months for patients on placebo (HR = 1.06; 95% CI: 0.81, 1.37). The cohort maturity for the non-gBRCAmut cohort was 79%.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Increased niraparib-induced cytotoxicity was
observed in tumour cell lines with or without deficiencies in the BReast CAncer (BRCA) 1 and 2
tumour suppressor genes. In orthotopic high-grade serous ovarian cancer patient-derived xenograft
tumours (PDX) grown in mice, niraparib has been shown to reduce tumour growth in BRCA 1 and 2
mutant, BRCA wild-type but homologous recombination (HR) deficient, and in tumours that are BRCA
wild-type and without detectable HR deficiency.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Niraparib_EMA_2023_09_07.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Niraparib_EMA_2023_09_07.pdf""><em><strong>Niraparib</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166183424,"Annotation of EMA Label for rucaparib and CYP1A2, CYP2D6",False,False,[],False,"[{'id': 1452318220, 'date': '2023-12-05T00:00:00-08:00', 'description': 'Updated label to match that used for Annotation of EMA Label for rucaparib and BRCA1, BRCA2.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102983, 'title': 'Rubraca | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rubraca', 'crossReferences': [{'id': 1450806115, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rubraca', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/rubraca'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166163418', 'name': 'rucaparib'}]","[{'objCls': 'Gene', 'id': 'PA27093', 'symbol': 'CYP1A2', 'name': 'cytochrome P450 family 1 subfamily A member 2'}, {'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1450806117.0,"<p>The EMA European Public Assessment Report (EPAR) for rucaparib (Rubraca) states that no clinically relevant pharmacokinetic differences were observed among patients with different CYP2D6 or CYP1A2 phenotypes.</p>
",1450806118.0,"<p>Excerpt from the rucaparib (Rubraca) EPAR:</p>
<blockquote class=""blockquote"">
<p>In vitro, rucaparib is metabolised primarily by CYP2D6, and to a lesser extent by CYP1A2, and CYP3A4. In a population PK analysis, no clinically relevant PK differences were observed among patients with different CYP2D6 phenotypes (including poor metabolizers, n=9; intermediate metabolizers, n=71; normal metabolizers, n=76; and ultra-rapid metabolizers, n=4) or patients with different CYP1A2 phenotypes (including normal metabolizers, n=28; hyperinducers, n=136).</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Rucaparib_EMA_2022_07_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Rucaparib_EMA_2022_07_05.pdf"">rucaparib EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166127713,"Annotation of HCSC Label for succinylcholine and BCHE, CACNA1S, RYR1",True,False,[],False,"[{'id': 1452055863, 'date': '2023-04-01T20:44:44.604-07:00', 'description': 'updated text', 'type': 'Update', 'version': 0}, {'id': 1452599120, 'date': '2024-09-19T14:14:30.798-07:00', 'description': 'added label document, Other Guidance tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15166042, 'title': 'Drugs@HCSC: Drug Product Succinylcholine Chloride Injection USP, Hikma Canada Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90702', 'crossReferences': [{'id': 1452599080, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90702', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90702'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA25294', 'symbol': 'BCHE', 'name': 'butyrylcholinesterase'}, {'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451522', 'name': 'succinylcholine'}]","[{'objCls': 'Gene', 'id': 'PA25294', 'symbol': 'BCHE', 'name': 'butyrylcholinesterase'}, {'objCls': 'Gene', 'id': 'PA85', 'symbol': 'CACNA1S', 'name': 'calcium voltage-gated channel subunit alpha1 S'}, {'objCls': 'Gene', 'id': 'PA34896', 'symbol': 'RYR1', 'name': 'ryanodine receptor 1'}]",HCSC,1447982349.0,"<p>The product monograph for succinylcholine notes that it should be used with caution, if at all, in patients know or suspected of being homozygous for the atypical plasma cholinesterase gene (<em>BCHE</em>), due to the risk for prolonged muscle paralysis. It is also contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies, and known hypersensitivity to the drug.</p>
",1447982348.0,"<p>Succinylcholine is a neuromuscular blocking agent indicated as an adjunct to general anesthesia. Specific variants in the RYR1 and CACNA1S genes are associated with risk of malignant hyperthermia in individuals administered potent inhalational anesthetics, such as succinylcholine. Although the product monograph for succinylcholine does not specifically mention genetic testing, it states that succinylcholine is contraindicated in individuals with known to have a genetic predisposition to malignant hyperthermia.</p>
<p>Excerpts from the succinylcholine product monograph:</p>
<blockquote class=""blockquote"">
<p>Succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies, and known hypersensitivity to the drug.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Succinylcholine administration has been associated with acute onset of malignant hyperthermia, a potentially fatal hypermetabolic state of skeletal muscle. The risk of developing malignant hyperthermia following succinylcholine administration increases with the concomitant administration of volatile anesthetics. Malignant hyperthermia frequently presents as intractable spasm of the jaw muscles (masseter spasm) which may progress to generalized rigidity, increased oxygen demand, tachycardia, tachypnea and profound hyperpyrexia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Succinylcholine is metabolized by plasma cholinesterase and should be used with caution, if at all, in patients known to be or suspected of being homozygous for the atypical plasma cholinesterase gene.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Patients homozygous for atypical plasma cholinesterase gene (1 in 2500 patients) are extremely sensitive to the neuromuscular blocking effect of succinylcholine. In these patients, a 5 to 10 mg test dose of succinylcholine may be administered, or neuromuscular blockade may be produced by the cautious administration of a 1 mg/mL solution of succinylcholine by intravenous drip. Apnea or prolonged muscle paralysis should be treated with controlled respiration.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""succinylcholine_20230402_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/succinylcholine_20230402_HCSC.pdf"">succinylcholine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452055862.0,"<blockquote class=""blockquote"">
<p>Succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies, and known hypersensitivity to the drug.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Succinylcholine is metabolized by plasma cholinesterase and should be used with caution, if at all, in patients known to be or suspected of being homozygous for the atypical plasma cholinesterase gene.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166283181,Annotation of HCSC Label for meloxicam and CYP2C9,False,False,[],False,"[{'id': 1452207380, 'date': '2023-08-15T11:47:27.707-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452783160, 'date': '2024-12-13T10:40:13.189-08:00', 'description': 'updated label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15172042, 'title': 'Drugs@HCSC: Drug Product Auro-Meloxicam (meloxicam), Auro Pharma Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87627', 'crossReferences': [{'id': 1452783140, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87627', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87627'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450353', 'name': 'meloxicam'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",HCSC,1451940980.0,"<p>The product monograph for meloxicam discusses metabolism by CYP2C9 and drug-drug interactions, but does not discuss CYP2C9 variants or metabolizer status.</p>
",1451940981.0,"<p>Excerpts from the meloxicam (Auro-Meloxicam) product monograph:</p>
<blockquote class=""blockquote"">
<p>Meloxicam is eliminated almost entirely by hepatic metabolism, of which approximately two thirds are mediated by cytochrome (CYP) P450 enzymes (CYP 2C9 major pathway and CYP 3A4 minor pathway) and one-third by other pathways, such as peroxidase oxidation. The potential for a pharmacokinetic interaction should be taken into account when meloxicam and drugs known to inhibit, or to be metabolised by, CYP 2C9 and/or CYP 3A4 are administered concurrently.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Meloxicam is almost completely metabolized to four pharmacologically inactive metabolites. The major metabolite, 5'-carboxy meloxicam (60% of dose), from P-450 mediated metabolism was formed by oxidation of an intermediate metabolite 5'-hydroxymethyl meloxicam which is also excreted to a lesser extent (9% of dose). <em>In vitro</em> studies indicate that cytochrome P-450 2C9 plays an important role in this metabolic pathway with a minor contribution of the CYP 3A4 isozyme. Patients’ peroxidase activity is probably responsible for the other two metabolites which account for 16% and 4% of the administered dose, respectively.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Meloxicam_2024_12_13_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Meloxicam_2024_12_13_HCSC.pdf"">meloxicam product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166281781,"Annotation of HCSC Label for ospemifene and CYP2B6, CYP2C9",False,False,[],False,"[{'id': 1452214301, 'date': '2023-08-23T10:42:59.801-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}, {'id': 1452783240, 'date': '2024-12-13T11:30:34.085-08:00', 'description': 'added label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15172062, 'title': 'Drugs@HCSC: Drug Product OSPHENA (ospemifene), Duchesnay Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00062157.PDF', 'crossReferences': [{'id': 1452783202, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00062157.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00062157.PDF'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182883', 'name': 'ospemifene'}]","[{'objCls': 'Gene', 'id': 'PA123', 'symbol': 'CYP2B6', 'name': 'cytochrome P450 family 2 subfamily B member 6'}, {'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",HCSC,1451926163.0,"<p>The HCSC product monograph for ospemifene (OSPHENA) states that ospemifene is metabolized primarily by CYP3A4 and CYP2C9, and ospemifene was also suggested to be a weak inhibitor for CYP2B6, CYP2C9, CYP2C19, CYP2C8, CYP2D6 and CYP3A4 in in vitro studies. No details are given about the effects of poor metabolizer status or variants of these enzymes.</p>
",1451926160.0,"<p>Excerpts from the ospemifene (<em><strong>Osphena</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>Osphena is primarily metabolized by CYP3A4 and CYP2C9. CYP2C19 and other pathways contribute to the metabolism of ospemifene. In order of decreasing potency, ospemifene was suggested to be a weak inhibitor for CYP2B6, CYP2C9, CYP2C19, CYP2C8, CYP2D6 and CYP3A4 in in vitro studies.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Co-administration of Osphena with drugs such as rifampin which induce CYP3A4, CYP2C9 and/or CYP2C19 inducer activity would be expected to decrease the systemic exposure of ospemifene, which may decrease the clinical effect.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Ospemifene_HCSC_2022_10_31.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ospemifene_HCSC_2022_10_31.pdf""><em><strong>ospemifene</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166284741,Annotation of HCSC Label for nivolumab and BRAF,False,True,[],False,"[{'id': 1452230534, 'date': '2023-09-07T11:15:41.603-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15163502, 'title': 'Drugs@HCSC: Drug Product OPDIVO (nivolumab), Bristol-Myers Squibb Canada', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'crossReferences': [{'id': 1452552680, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166157522', 'symbol': 'rs113488022', 'name': 'rs113488022'}]","[{'objCls': 'Chemical', 'id': 'PA166129522', 'name': 'nivolumab'}]","[{'objCls': 'Gene', 'id': 'PA25408', 'symbol': 'BRAF', 'name': 'B-Raf proto-oncogene, serine/threonine kinase'}]",HCSC,1451958640.0,"<p>The HCSC product monograph for nivolumab (OPDIVO) notes that nivolumab is indicated for the treatment of unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.  The product monograph has information about BRAF V600 variants in clinical trials and which prior drugs may have been used as part of the indication for metastatic melanoma.</p>
",1451958641.0,"<p>Excerpts from the nivolumab (OPDIVO) product monograph:</p>
<blockquote class=""blockquote"">
<p>OPDIVO is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In CHECKMATE-037 [...] Patients were required to have progression of disease on or following ipilimumab treatment and, if BRAF V600 mutation positive, a BRAF inhibitor.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>There were objective responses in patients with and without BRAF V600 mutation-positive melanoma.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Efficacy by BRAF status:</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<p>The ORRs in the BRAF mutation-positive subgroup were 17% (n = 59; 95% CI: 8.4, 29.0) for OPDIVO and 11% (n= 27; 95% CI: 2.4, 29.2) for chemotherapy, and in the BRAF wild-type subgroup were 30% (n = 213; 95% CI: 24.0, 36.7) and 9% (n =106; 95% CI: 4.6, 16.7), respectively.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The OS HR for OPDIVO (n= 59) versus chemotherapy (n = 27) was 1.32 (95% CI: 0.75, 2.32) for BRAF mutation-positive patients. The OS HR for OPDIVO (n= 213) versus chemotherapy (n = 106) was 0.83 (95% CI: 0.62, 1.11) for BRAF wild-type patients.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Nivolumab_2024_08_09_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Nivolumab_2024_08_09_HCSC.pdf"">nivolumab product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166362721,Annotation of EMA Label for busulfan,False,False,[],False,[],False,[],True,"[{'id': 15173102, 'title': 'Busulfan Fresenius Kabi | European Medicines Agency (EMA)', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/busulfan-fresenius-kabi', 'crossReferences': [{'id': 1452810260, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/busulfan-fresenius-kabi', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/busulfan-fresenius-kabi'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA448691', 'name': 'busulfan'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166362741,Annotation of HCSC Label for busulfan,False,False,[],False,[],False,[],True,"[{'id': 15173122, 'title': 'Drugs@HCSC: Drug Product MYLERAN (busulfan), Aspen Pharmacare Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=959', 'crossReferences': [{'id': 1452810280, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=959', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=959'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA448691', 'name': 'busulfan'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166151853,Annotation of FDA Label for nilotinib and UGT1A1,False,False,[],False,"[{'id': 1452810821, 'date': '2025-01-15T15:53:05.758-08:00', 'description': 'updated label, added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15173142, 'title': 'Drugs@FDA: Drug Product Tasigna (nilotinib), Novartis Pharmaceuticals Corporation - NDA022068/SUPPL-41, 02/08/2024', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022068', 'crossReferences': [{'id': 1452810801, 'resource': 'FDA Application', 'resourceId': 'NDA022068/SUPPL-41', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022068'}], 'objCls': 'Literature', 'pubDate': '2024-02-08T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],"[{'objCls': 'Variant', 'id': 'PA166159020', 'symbol': 'rs8175347', 'name': 'rs8175347'}]","[{'objCls': 'Chemical', 'id': 'PA165958345', 'name': 'nilotinib'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",FDA,1447982397.0,"<p>Nilotinib (Tasigna) is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action. Individuals with the UGT1A1*28 genotype (TA)7/(TA)7 (<a href=""/variant/PA166159020"">rs8175347</a>) are at an increased risk of hyperbilirubinemia when taking nilotinib.</p>
",1447982396.0,"<p>Excerpt from the nilotinib (Tasigna) drug label:</p>
<blockquote class=""blockquote"">
<p>Tasigna can increase bilirubin levels. The (TA)7/(TA)7 genotype of UGT1A1 was associated with a statistically significant increase in the risk of hyperbilirubinemia relative to the (TA)6/(TA)6 and (TA)6/(TA)7 genotypes. However, the largest increases in bilirubin were observed in the (TA)7/(TA)7 genotype (UGT1A1*28) patients
[see Warnings and Precautions (5.6)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Nilotinib is primarily metabolized via CYP3A4-mediated oxidation and to a minor extent by CYP2C8.</p>
</blockquote>
<p>For the complete drug label text with sections containing this pharmacogenetic information highlighted, see the <a download=""Nilotinib_2025_01_15_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Nilotinib_2025_01_15_FDA.pdf"">nilotinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452810820.0,"<blockquote class=""blockquote"">
<p>Tasigna is a kinase inhibitor indicated for the treatment of:</p>
<ul>
<li>Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (1.1) [...]</li>
<li>Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. (1.3)</li>
</ul>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166329481,Annotation of EMA Label for fruquintinib and KRAS,False,True,[],False,[],False,[],True,"[{'id': 15169482, 'title': 'Fruzaqla | European Medicines Agency (EMA)', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/fruzaqla', 'crossReferences': [{'id': 1452692140, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/fruzaqla', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/fruzaqla'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328842', 'name': 'fruquintinib'}]","[{'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",EMA,1452693566.0,"<p>Fruquintinib (FRUZAQLA) is a vascular endothelial growth factor receptor inhibitor indicated for adults with metastatic colorectal cancer who have been previously treated with available standard therapies. The EPAR for fruquintinib discusses RAS status only in the context of prior treatments of patients with anti-EGFR therapy if their RAS status was wild-type.</p>
",1452693567.0,"<p>Excerpt from the fruquintinib (FRUZAQLA) EPAR:</p>
<blockquote class=""blockquote"">
<p>The clinical efficacy and safety of fruquintinib were evaluated in a global, randomised, double-blind, placebo-controlled, multicentre, phase III study (FRESCO-2) in 691 patients with mCRC who had been previously treated with standard approved therapies including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF biological therapy; an anti-EGFR therapy if RAS wild-type, and have progressed on or had intolerance to trifluridine/tipiracil and/or regorafenib.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Fruquintinib_2024_11_06_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Fruquintinib_2024_11_06_EMA.pdf"">fruqintinib EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166329281,Annotation of EMA Label for repotrectinib,False,False,[],False,"[{'id': 1452624561, 'date': '2024-10-04T16:59:00.713-07:00', 'description': 'added PIP info', 'type': 'Update', 'version': 0}, {'id': 1452804321, 'date': '2025-01-10T14:27:47.332-08:00', 'description': 'conditional marketing authorization', 'type': 'Update', 'version': 0}]",False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328881', 'name': 'repotrectinib'}]",[],EMA,,,1452624560.0,"<p>&quot;On 14 November 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Augtyro, intended for the treatment of patients whose solid tumours have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, or patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).&quot;</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166329501,Annotation of HCSC Label for fruquintinib and KRAS,False,True,[],False,"[{'id': 1452692161, 'date': '2024-11-06T14:54:51.333-08:00', 'description': 'add text to show marketing status is now approved', 'type': 'Update', 'version': 0}, {'id': 1452799641, 'date': '2025-01-07T00:00:00-08:00', 'description': 'added label and annotation; drug is now marketed in Canada', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15172662, 'title': 'Drugs@HCSC: Drug Product FRUZAQLA (fruquintinib), Takeda Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104019', 'crossReferences': [{'id': 1452799624, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104019', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104019'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328842', 'name': 'fruquintinib'}]","[{'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",HCSC,1452799640.0,"<p>Fruquintinib is a vascular endothelial growth factor receptor inhibitor indicated for adults with metastatic colorectal cancer that have previously been reated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. The product monograph for fruquintinib discusses RAS status in the context of which prior treatments a patient may have received and RAS status of patients in clinical trials.</p>
",1452692160.0,"<p>Excerpts from the fruquintinib (FRUZAQLA) product monograph:</p>
<blockquote class=""blockquote"">
<p>FRUZAQLA (fruquintinib capsules) is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, an anti-EGFR agent (if RAS wild-type), and either trifluridine-tipiracil or regorafenib.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>FRESCO Study</strong> [...] Randomisation was stratified by prior use of VEGF inhibitor (yes vs. no) and K RAS gene status (wild type vs. mutant).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Fruquintinib_2025_01_07_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Fruquintinib_2025_01_07_HCSC.pdf"">fruquintinib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166329001,Annotation of EMA Label for eflornithine,False,False,[],False,[],False,[],True,"[{'id': 15154823, 'title': 'Vaniqa | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vaniqa', 'crossReferences': [{'id': 1452396985, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vaniqa', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/vaniqa'}], 'notes': 'This is for a different indication, there is no label for oncology. This label is for a topical formulation of eflornithine for the treatment of facial hirsutism in women.', 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328781', 'name': 'eflornithine'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166329021,Annotation of HCSC Label for eflornithine,False,False,[],False,[],False,[],True,"[{'id': 15154842, 'title': 'Product information', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/search-fast-recherche-rapide?lang=eng&no=0143801001', 'crossReferences': [{'id': 1452397040, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/search-fast-recherche-rapide?lang=eng&no=0143801001', '_url': 'https://health-products.canada.ca/dpd-bdpp/search-fast-recherche-rapide?lang=eng&no=0143801001'}], 'notes': 'This is for a different indication, there is no label for oncology. This label is for a topical formulation of eflornithine for slowing of the growth of unwanted facial hair in women.', 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328781', 'name': 'eflornithine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166329061,Annotation of EMA Label for elranatamab,False,False,[],False,[],False,[],True,"[{'id': 15154882, 'title': 'Elrexfio | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/elrexfio', 'crossReferences': [{'id': 1452397123, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/elrexfio', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/elrexfio'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328801', 'name': 'elranatamab'}]",[],EMA,1452397120.0,"<p>Elranatamab is EMA indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies. The label mentions high risk cytogenetics results for patients including Chromosome 17p. Chromosome 4p;14q and Chromosome 14q;16q.</p>
",1452397121.0,"<p>Excerpts from the <em><strong>Elranatamab</strong></em> (<em><strong>TRADE NAME</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>High-risk cytogenetics, t(4;14), t(14;16), or del(17p), were present in 25.2% of patients. 31.7% of patients had extramedullary disease (presence of any plasmacytoma, extramedullary and/or paramedullary, with a soft-tissue component, by blinded independent central review (BICR) at baseline.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Elranatamab_EMA_2024_03_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Elranatamab_EMA_2024_03_05.pdf""><em><strong>Elranatamab</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166329043,Annotation of HCSC Label for elranatamab,False,True,[],False,[],False,[],True,"[{'id': 15154863, 'title': 'Product information', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103201', 'crossReferences': [{'id': 1452397090, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103201', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103201'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328801', 'name': 'elranatamab'}]",[],HCSC,1452397087.0,"<p>Elranatamab is HCSC the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy. The Clinical Trials section mentions high risk cytogenetics including Chromosome 17p. Chromosome 4p;14q and Chromosome 14q;16q.</p>
",1452397088.0,"<p>Excerpts from the <em><strong>Elranatamab</strong></em> (<em><strong>Elrexfio</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>High-risk cytogenetics, t(4;14), t(14;16),or del(17p), were present in 25.2% of patients</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Elranatamab_HCSC_2024_03_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Elranatamab_HCSC_2024_03_05.pdf""><em><strong>Elranatamab</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166329041,Annotation of FDA Label for elranatamab,False,True,[],False,[],False,[],True,"[{'id': 15154862, 'title': 'Drugs@FDA: Drug Product Elrexfio (elranatamab-bcmm), Pfizer Laboratories Div Pfizer Inc - BLA761345/ORIG-1, 08/14/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761345', 'crossReferences': [{'id': 1452397084, 'resource': 'FDA Application', 'resourceId': 'BLA761345/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761345'}], 'objCls': 'Literature', 'pubDate': '2023-08-14T00:00:00-07:00', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328801', 'name': 'elranatamab'}]",[],FDA,1452397080.0,"<p>Elranatamab is FDA indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. The Clinical Studies section mentions high risk cytogenetics results for patients including Chromosome 17p. Chromosome 4p;14q and Chromosome 14q;16q.</p>
",1452397081.0,"<p>Excerpts from the <em><strong>Elranatamab</strong></em> (<em><strong>ELREXFIO</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>CLINICAL STUDIES...High-risk cytogenetics, t(4;14), t(14;16), or del(17p), were present in 22.7% of patients. 34.0% of patients
had extramedullary disease at baseline by BICR.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Elranatamab_FDA_2024_03_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Elranatamab_FDA_2024_03_05.pdf""><em><strong>Elranatamab</strong></em> drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166329141,Annotation of HCSC Label for quizartinib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328862', 'name': 'quizartinib'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166329301,Annotation of HCSC Label for repotrectinib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328881', 'name': 'repotrectinib'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166329341,"Annotation of FDA Label for pirtobrutinib and BTK, IGH, TP53",False,True,[],False,[],False,[],True,"[{'id': 15155042, 'title': 'Drugs@FDA: Drug Product JAYPIRCA (pirtobrutinib), Eli Lilly and Company - NDA216059/SUPPL-1, 12/01/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216059', 'crossReferences': [{'id': 1452399084, 'resource': 'FDA Application', 'resourceId': 'NDA216059/SUPPL-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216059'}], 'objCls': 'Literature', 'pubDate': '2023-12-01T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328845', 'name': 'pirtobrutinib'}]","[{'objCls': 'Gene', 'id': 'PA25454', 'symbol': 'BTK', 'name': 'Bruton tyrosine kinase'}, {'objCls': 'Gene', 'id': 'PA35106', 'symbol': 'IGH', 'name': 'immunoglobulin heavy locus'}, {'objCls': 'Gene', 'id': 'PA36679', 'symbol': 'TP53', 'name': 'tumor protein p53'}]",FDA,1452399080.0,"<p>The FDA label for pirtobrutinib (JAYPIRCA) states that it is a a kinase inhibitor indicated for the treatment of Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor; and also Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. Under clinical studies, mutation status in BTK, TP53, IGHV and deletions in chromosome 11q and 17q were mentioned in patients treated with JAYPIRCA.</p>
",1452399081.0,"<p>Excerpts from the pirtobrutinib  (JAYPIRCA) label:</p>
<blockquote class=""blockquote"">
<p><em><strong>Clinical studies: Baseline ECOG performance status was 0 or 1 in 91% of patients and
48% of patients had Rai stage III or IV disease. Among those patients with central testing available, 42% (37 of 88
patients) had a C481 BTK mutation, 54% (43 of 79 patients) had 17p deletion and/or TP53 mutation, 93% (77 of 83
patients) had unmutated IGHV, and 22% (16 of 72 patients) had 11q deletion.</strong></em></p>
</blockquote>
<blockquote class=""blockquote"">
<p><em><strong>Mechanism of action: Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor
(BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell
proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK and BTK harboring C481
mutations, leading to inhibition of BTK kinase activity. In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell
CD69 expression and inhibited malignant B-cell proliferation. Pirtobrutinib showed dose-dependent anti-tumor activities in
BTK wild type and BTK C481S mutant mouse xenograft models</strong></em></p>
</blockquote>
<blockquote class=""blockquote"">
<p><em><strong>Dosage Modifications for Concomitant Use with Strong CYP3A Inhibitors
Avoid concomitant use of strong CYP3A inhibitors with JAYPIRCA [see Drug Interactions (7.1), Clinical
Pharmacology (12.3)]. If concomitant use of a strong CYP3A inhibitor is unavoidable, reduce the JAYPIRCA dose by
50 mg. If the current dosage is 50 mg once daily, interrupt JAYPIRCA treatment for the duration of strong CYP3A inhibitor
use. After discontinuation of a strong CYP3A inhibitor for 5 half-lives, resume the JAYPIRCA dose that was taken prior to
initiating the strong CYP3A inhibitor.</strong></em></p>
</blockquote>
<blockquote class=""blockquote"">
<p><em><strong>Dosage Modifications for Concomitant Use with CYP3A Inducers
Avoid concomitant use of strong or moderate CYP3A inducers with JAYPIRCA [see Drug Interactions (7.1), Clinical
Pharmacology (12.3)]. If concomitant use with moderate CYP3A inducers is unavoidable and the current dosage of
JAYPIRCA is 200 mg once daily, increase the dose to 300 mg. If the current dosage is 50 mg or 100 mg once daily,
increase the dose by 50 mg.</strong></em></p>
</blockquote>
<blockquote class=""blockquote"">
<p><em><strong>Drug-drug interaction: Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use is unavoidable, reduce the JAYPIRCA dose. (2.4, 7.1)
•Strong or Moderate CYP3A Inducers: Avoid concomitant use. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dose. (2.5, 7.1)
•Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: For substrates where minimal concentration changes may increase the risk of adverse reactions, follow recommendations for co- administration with CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP inhibitors provided in their approved product labeling.</strong></em></p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""pirtobrutinib_FDA_20240305.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/pirtobrutinib_FDA_20240305.pdf"">pirtobrutinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166329441,Annotation of EMA Label for pirtobrutinib and BTK,False,True,[],False,[],False,[],True,"[{'id': 15155082, 'title': 'Jaypirca | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca', 'crossReferences': [{'id': 1452400760, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328845', 'name': 'pirtobrutinib'}]","[{'objCls': 'Gene', 'id': 'PA25454', 'symbol': 'BTK', 'name': 'Bruton tyrosine kinase'}]",EMA,1452400220.0,"<p>The EMA label for pirtobrutinib (Jaypirca) states that Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory
mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor.</p>
",1452400221.0,"<p>Excerpts from the pirtobrutinib (Jaypirca) EPAR:</p>
<blockquote class=""blockquote"">
<p><em><strong>Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor</strong></em></p>
</blockquote>
<blockquote class=""blockquote"">
<p><em><strong>Mechanism of action: Pirtobrutinib is a reversible, noncovalent inhibitor of BTK. BTK is a signalling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK as well as BTK harboring C481 mutations leading to inhibition of BTK kinase activity.</strong></em></p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""jaypirca_EMA_20240305.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/jaypirca_EMA_20240305.pdf"">pirtobrutinib EPAR pdf</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166329525,Annotation of FDA Label for fruquintinib and KRAS,False,True,[],False,[],False,[],True,"[{'id': 15155062, 'title': 'Drugs@FDA: Drug Product Fruzaqla (fruquintinib), Takeda Pharmaceuticals America, Inc. - NDA217564/ORIG-1, 11/08/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217564', 'crossReferences': [{'id': 1452400721, 'resource': 'FDA Application', 'resourceId': 'NDA217564/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217564'}], 'objCls': 'Literature', 'pubDate': '2023-11-08T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328842', 'name': 'fruquintinib'}]","[{'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}]",FDA,1452400668.0,"<p>Fruquintinib is a vascular endothelial growth factor receptor inhibitor indicated for adults with metastatic colorectal cancer that have previously been reated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. The FDA label for fruquintinib discusses RAS status in the context of which prior treatments a patient may have received and RAS status of patients in clinical trials.</p>
",1452400669.0,"<p>Excerpts from the <em><strong>Fruquintinib</strong></em> (<em><strong>TRADE NAME</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>INDICATIONS AND USAGE</p>
<p>FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>FRESCO Study...Randomization was stratified by prior use of VEGF inhibitors (yes vs. no) and K-RAS status (wild type vs. mutant).</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Fruquintinib_FDA_2024_03_07.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Fruquintinib_FDA_2024_03_07.pdf""><em><strong>Fruquintinib</strong></em> drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166328981,Annotation of FDA Label for eflornithine and MYCN,False,True,[],False,[],False,[],True,"[{'id': 15154822, 'title': 'Drugs@FDA: Drug Product iwilfin (EFLORNITHINE HYDROCHLORIDE), USWM, LLC - NDA215500/ORIG-1, 12/13/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215500', 'crossReferences': [{'id': 1452396984, 'resource': 'FDA Application', 'resourceId': 'NDA215500/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215500'}], 'objCls': 'Literature', 'pubDate': '2023-12-13T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328781', 'name': 'eflornithine'}]","[{'objCls': 'Gene', 'id': 'PA31359', 'symbol': 'MYCN', 'name': 'MYCN proto-oncogene, bHLH transcription factor'}]",FDA,1452396980.0,"<p>Eflornithine is FDA indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma. It acts by inhibiting the enzyme ornithine decarboxylase (ODC), a transcriptional target of MYCN.</p>
",1452396981.0,"<p>Excerpts from the <em><strong>Eflornithine</strong></em> (<em><strong>IWILFIN</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>Eflornithine is an irreversible inhibitor of the enzyme ornithine decarboxylase (ODC), the first and rate-limiting enzyme in the biosynthesis of polyamines and a transcriptional target of MYCN. Polyamines are involved in differentiation and proliferation of mammalian cells and are important for neoplastic transformation. Inhibition of polyamine synthesis by eflornithine restored the balance of the LIN28/Let-7 metabolic pathway, which is involved in regulation of cancer stem cells and glycolytic metabolism, by decreasing expression of the oncogenic drivers MYCN and LIN28B in MYCN-amplified neuroblastoma. In vitro, eflornithine induced senescence and suppressed neurosphere formation in MYCN-amplified and MYCN non-amplified neuroblastoma cells, indicating a cytostatic effect. Treatment with eflornithine prevented or delayed tumor formation in mice injected with limiting dilutions of MYCN-amplified neuroblastoma cells.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>IWILFIN (eflornithine) is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Clinical Trials Experience... The median age of patients who received IWILFIN was 4 years (range: 1 to 17); 59% male; 85% White, 7% Black, 1% Asian, 8% Hispanic or Latino; 87% had International Neuroblastoma Staging System Stage 4 disease; 47% had neuroblastoma with known MYCN-amplification.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Eflornithine_FDA_2024_03_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Eflornithine_FDA_2024_03_05.pdf""><em><strong>Eflornithine</strong></em> drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166330081,Annotation of EMA Label for nirogacestat,False,False,[],False,"[{'id': 1452804341, 'date': '2025-01-10T14:35:35.051-08:00', 'description': 'removed genes, added orphan designation note', 'type': 'Update', 'version': 0}]",False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328844', 'name': 'nirogacestat'}]",[],EMA,,,1452804340.0,"<p>&quot;On 17 October 2019, orphan designation EU/3/19/2214 was granted by the European Commission to Voisin Consulting S.A.R.L., France, for nirogacestat for the treatment of soft tissue sarcoma.&quot;</p>
<p>&quot;In October 2021, Voisin Consulting S.A.R.L. changed name to Voisin Consulting Life Sciences.&quot;</p>
<p>https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2214</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166278001,"Annotation of HCSC Label for belzutifan and CYP2C19, UGT2B17",False,False,[],False,"[{'id': 1452821303, 'date': '2025-01-21T15:36:38.241-08:00', 'description': 'updated label, changed Informative PGx to Actionable PGx level', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15135302, 'title': 'Drugs@HCSC: Drug Product WELIREG (belzutifan), Merck Canada Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00078051.PDF', 'crossReferences': [{'id': 1452821320, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00078051.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00078051.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA37189', 'symbol': 'UGT2B17', 'name': 'UDP glucuronosyltransferase family 2 member B17'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166268761', 'name': 'belzutifan'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA37189', 'symbol': 'UGT2B17', 'name': 'UDP glucuronosyltransferase family 2 member B17'}]",HCSC,1451874160.0,"<p>The HCSC label for belzutifan mentions that UGT2B17 and CYP2C19 polymorphisms may affect belzutifan exposure. Although no dose adjustment is recommended, patients who are either UGT2B17 poor metabolizers or dual UGT2B17 and CYP2C19 poor metabolizers should be closely monitored for adverse reactions.</p>
",1451874161.0,"<p>Excerpts from the belzutifan (WELIREG) product monograph:</p>
<p>&lt; <strong>UGT2B17 and CYP2C19 Genetic Polymorphism:</strong> No dose adjustment is recommended for patients who are dual UGT2B17 and CYP2C19 poor metabolizers (see 7 WARNINGS AND PRECAUTIONS, 10 CLINICAL PHARMACOLOGY).</p>
<blockquote class=""blockquote"">
<p>WELIREG® is primarily metabolized by UGT2B17 and CYP2C19. Individuals who are UGT2B17 poor metabolizers are projected to have 2.7-fold higher WELIREG® exposures (steady state AUC0-24hr) compared to a UGT2B17 extensive metabolizer and CYP2C19 extensive/intermediate metabolizer. Individuals who are dual UGT2B17 and CYP2C19 poor metabolizers are projected to have 3.3-fold higher WELIREG® exposures (steady state AUC0-24hr) compared to a UGT2B17 extensive metabolizer and CYP2C19 extensive/intermediate metabolizer, for the recommended dose. No dose adjustment is recommended, however, close monitoring is recommended. (see 7.1.5 UGT2B17 and CYP2C19 Poor Metabolizers and 10.3 Pharmacokinetics).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Based on publicly available pharmacogenomic databases, Asians had the highest estimated frequency for UGT2B17 poor metabolizers and dual UGT2B17 and CYP2C19 poor metabolizers compared to other racial groups.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Based on publicly available pharmacogenomic databases, the estimated frequencies of CYP2C19 and UGT2B17 poor metabolizers in certain populations are listed below:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>UGT2B17 poor metabolizers: 15% of Caucasians, 11% of Latinos, 6% of African Americans, 38% of South Asians, and 70% of East Asians</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C19 poor metabolizers: 2% of Caucasians, 1% of Latinos, 5% of African Americans, 8% of South Asians, and 13% of East Asians</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Dual UGT2B17 and CYP2C19 poor metabolizers: 0.3% of Caucasians, 0.1% of Latinos, 0.3% of African Americans, 3% of South Asians, and 9% of East Asians</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Belzutifan_2025_01_21_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Belzutifan_2025_01_21_HCSC.pdf"">belzutifan product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452821302.0,"<blockquote class=""blockquote"">
<p>Closely monitor for adverse reactions in patients who are either UGT2B17 poor metabolizers or dual UGT2B17 and CYP2C19 poor metabolizers</p>
</blockquote>
",,,,,,,
Label Annotation,PA166330041,Annotation of EMA Label for nedosiran and AGXT,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328843', 'name': 'nedosiran'}]","[{'objCls': 'Gene', 'id': 'PA24633', 'symbol': 'AGXT', 'name': 'alanine--glyoxylate aminotransferase'}]",EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166330042,Annotation of HCSC Label for nedosiran and AGXT,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328843', 'name': 'nedosiran'}]","[{'objCls': 'Gene', 'id': 'PA24633', 'symbol': 'AGXT', 'name': 'alanine--glyoxylate aminotransferase'}]",HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166330082,"Annotation of HCSC Label for nirogacestat and APC, CTNNB1",False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328844', 'name': 'nirogacestat'}]","[{'objCls': 'Gene', 'id': 'PA24875', 'symbol': 'APC', 'name': 'APC regulator of WNT signaling pathway'}, {'objCls': 'Gene', 'id': 'PA27013', 'symbol': 'CTNNB1', 'name': 'catenin beta 1'}]",HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166330101,"Annotation of FDA Label for nirogacestat and APC, CTNNB1",False,False,[],False,[],False,[],True,"[{'id': 15155422, 'title': 'Drugs@FDA: Drug Product OGSIVEO (nirogacestat), SpringWorks Therapeutics, Inc. - NDA217677/ORIG-1, 11/27/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217677', 'crossReferences': [{'id': 1452408921, 'resource': 'FDA Application', 'resourceId': 'NDA217677/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=217677'}], 'objCls': 'Literature', 'pubDate': '2023-11-27T00:00:00-08:00', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166328844', 'name': 'nirogacestat'}]","[{'objCls': 'Gene', 'id': 'PA24875', 'symbol': 'APC', 'name': 'APC regulator of WNT signaling pathway'}, {'objCls': 'Gene', 'id': 'PA27013', 'symbol': 'CTNNB1', 'name': 'catenin beta 1'}]",FDA,1452414003.0,"<p>Nirogacestat is indicated for the treatment of progressing desmoid tumors in adult patients who require systemic treatment. <em>APC</em> and <em>CTNNB1</em> are mentioned in the Clinical Studies section of the label.</p>
",1452408900.0,"<p>Excerpts from the nirogacestat (OGSIVEO) label:</p>
<blockquote class=""blockquote"">
<p>The efficacy of OGSIVEO was evaluated in DeFi (NCT03785964), an international, multicenter, randomized (1:1), double-blind, placebo-controlled trial in 142 adult patients with progressing desmoid tumors not amenable to surgery. [...] Of 105 patients with known tumor mutation status, 81% had a CTNNB1 mutation and 21% had an APC mutation.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Nirogacestat_2024_03_12_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Nirogacestat_2024_03_12_FDA.pdf"">nirogacestat drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166277701,Annotation of EMA Label for anifrolumab and IFNAR1,False,False,[],False,"[{'id': 1452205962, 'date': '2023-08-14T07:08:40.179-07:00', 'description': 'Unchecked informative as no longer meets criteria.', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15135122, 'title': 'Anifrolumab | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/saphnelo', 'crossReferences': [{'id': 1451871940, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/saphnelo', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/saphnelo'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166277641', 'name': 'anifrolumab'}]","[{'objCls': 'Gene', 'id': 'PA29670', 'symbol': 'IFNAR1', 'name': 'interferon alpha and beta receptor subunit 1'}]",EMA,1451871880.0,"<p>Anifrolumab a monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1) and inhibits type I IFN signaling. Blockade of receptor mediated type I IFN signaling inhibits IFN responsive gene expression (gene signature) as well as downstream inflammatory and immunological processes.</p>
",1451871881.0,"<p>Excerpts from the Anifrolumab (SAPHNELO) EPAR:</p>
<blockquote class=""blockquote"">
<p>Mechanism of action
Anifrolumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to subunit 1 of the
type I interferon receptor (IFNAR1) with high specificity and affinity. This binding inhibits type I IFN
signalling thereby blocking the biologic activity of type I IFNs. Anifrolumab also induces the
internalisation of IFNAR1, thereby reducing the levels of cell surface IFNAR1 available for receptor
assembly. Blockade of receptor mediated type I IFN signalling inhibits IFN responsive gene
expression as well as downstream inflammatory and immunological processes. Inhibition of type I
IFN blocks plasma cell differentiation and normalises peripheral T-cell subsets, restoring the balance
between adaptive and innate immunity that is dysregulated in SLE.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pharmacodynamic effects
In adult patients with SLE, administration of anifrolumab at doses ≥300 mg, via intravenous infusion
every 4 weeks, demonstrated consistent neutralisation (≥80%) of a 21 gene type I interferon
pharmacodynamic (PD) signature in blood.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""anifrolumab_EMA_2022_08_30.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/anifrolumab_EMA_2022_08_30.pdf""><em><strong>Anifrolumab</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166329261,Annotation of EMA Label for etrasimod and CYP2C9,True,False,[],False,"[{'id': 1452538384, 'date': '2024-07-25T00:42:31.448-07:00', 'description': 'Added Prescribing section and tags', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15155002, 'title': 'Velsipity | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/velsipity', 'crossReferences': [{'id': 1452397945, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/velsipity', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/velsipity'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166328841', 'name': 'etrasimod'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",EMA,1452397942.0,"<p>The EMA label for etrasimod has contraindications for patients who are known or suspected to be CYP2C9 poor metabolisers (&lt; 5% of the population) and who take medicinal products that are moderate or strong inhibitors of CYP2C8 and/or CYP3A4.</p>
",1452397943.0,"<p>Excerpts from the <em><strong>Etrasimod</strong></em> (<em><strong>Velsipity</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>The use of etrasimod is not recommended in patients who are known or suspected to be CYP2C9 poor metabolisers (&lt; 5% of the population) and who take medicinal products that are moderate or strong inhibitors of CYP2C8 and/or CYP3A4 due to the risk of increased exposure of etrasimod.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Effect of CYP2C9 polymorphism
Due to the potential for increased exposure of etrasimod, co-administration of etrasimod in patients who are known or suspected to be CYP2C9 poor metabolisers (&lt; 5% of the population) and who take medicinal products that are moderate or strong inhibitors of CYP2C8 and/or CYP3A4 is not recommended</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Etrasimod_EMA_2024_03_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Etrasimod_EMA_2024_03_05.pdf""><em><strong>Etrasimod</strong></em> EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452538383.0,"<p>Excerpt from the <em><strong>Etrasimod</strong></em> (<em><strong>Velsipity</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>The use of etrasimod is not recommended in patients who are known or suspected to be CYP2C9 poor metabolisers (&lt; 5% of the population) and who take medicinal products that are moderate or strong inhibitors of CYP2C8 and/or CYP3A4 due to the risk of increased exposure of etrasimod.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166329181,Annotation of HCSC Label for etrasimod and CYP2C9,False,False,[],False,"[{'id': 1452538388, 'date': '2024-07-25T00:48:17.546-07:00', 'description': 'Added Prescribing section, tags and label document', 'type': 'Update', 'version': 0}, {'id': 1452568580, 'date': '2024-08-28T14:14:39.800-07:00', 'description': 'removed Prescribing section, Other Guidance tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15161942, 'title': 'Drugs@HCSC: Drug Product Velsipity (etrasimod), Pfizer Canada UFC', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00074415.PDF', 'crossReferences': [{'id': 1452538386, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00074415.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00074415.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166328841', 'name': 'etrasimod'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",HCSC,1452397652.0,"<p>The HCSC label for etrasimod has some recommendations to avoid drug-drug interactions in CYP2C9 poor metabolizers.</p>
",1452397653.0,"<p>Excerpts from the <em><strong>Etrasimod</strong></em> (<em><strong>VELSIPITY</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>CYP2C9 Polymorphisms</p>
<p>In patients who are suspected, or known to be, poor CYP2C9 metabolizers, coadministration of etrasimod with strong CYP2C8 inhibitors or strong CYP3A4 inhibitors is not recommended due to the potential of clinically significant elevated etrasimod exposures.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Metabolism:
Etrasimod is metabolized by oxidation and dehydrogenation mediated primarily by CYP2C8 (38%), CYP2C9 (37%), and CYP3A4 (22%), with minor contributions of CYP2C19 and CYP2J2. In addition, etrasimod undergoes glucuronidation and sulfation mediated by UGTs and sulfotransferases. Unchanged etrasimod is the major circulating component in plasma.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Etrasimod_HCSC_2024_03_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Etrasimod_HCSC_2024_03_05.pdf""><em><strong>Etrasimod</strong></em> product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166329161,Annotation of FDA Label for etrasimod and CYP2C9,False,False,[],False,"[{'id': 1452538381, 'date': '2024-07-25T00:40:46.161-07:00', 'description': 'Added Prescribing section and tags', 'type': 'Update', 'version': 0}, {'id': 1452540360, 'date': '2024-07-26T00:00:00-07:00', 'description': 'removed prescribing section (DDI), tag', 'type': 'Update', 'version': 0}, {'id': 1452583302, 'date': '2024-09-09T16:52:47.336-07:00', 'description': 'added FDA Biomarker List label', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15154942, 'title': 'Drugs@FDA: Drug Product Velsipity (etrasimod), U.S. Pharmaceuticals - NDA216956/ORIG-1, 10/12/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216956', 'crossReferences': [{'id': 1452397490, 'resource': 'FDA Application', 'resourceId': 'NDA216956/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216956'}], 'objCls': 'Literature', 'pubDate': '2023-10-12T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA166328841', 'name': 'etrasimod'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",FDA,1452397476.0,"<p>The FDA label for etrasimod (VELSIPIDY) states that the impact of CYP2C9 genetic variants on the pharmacokinetics of etrasimod has not been directly evaluated. The label has a Pharmacogenomics section with information that can be used for possible drug-drug interactions in CYP2C9 poor metabolizers.</p>
",1452397477.0,"<p>Excerpts from the <em><strong>Etrasimod</strong></em> (<em><strong>VELSIPITY</strong></em>) label:</p>
<blockquote class=""blockquote"">
<p>Pharmacogenomics</p>
<p>CYP2C9 activity is decreased in individuals with genetic variants such as CYP2C9*2 and CYP2C9*3 alleles. The impact of CYP2C9 genetic variants on the pharmacokinetics of etrasimod has not been directly evaluated.</p>
<p>CYP2C9 poor metabolizers (e.g., *2/*3, *3/*3) may have decreased clearance of etrasimod when VELSIPITY is used concomitantly with moderate to strong inhibitors of CYP2C8 or CYP3A4.</p>
<p>CYP2C9 intermediate metabolizers (e.g., *1/*2, *1/*3, *2/*2) may have decreased clearance of etrasimod when VELSIPITY is used concomitantly with moderate to strong inhibitors of CYP2C8 or CYP3A4; however, the effect on VELSIPITY exposure in CYP2C9 intermediate metabolizers with concomitant CYP2C8 or CYP3A4 inhibitors is not known.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The prevalence of the CYP2C9 poor metabolizer phenotype is approximately 2 to 3% in White populations, 0.5 to 4% in Asian populations, and &lt;1% in African-American populations. Other decreased or nonfunctional CYP2C9 alleles (e.g., *5, *6, *8, *11) are more prevalent in African-American populations.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Etrasimod is primarily metabolized by CYP2C8, CYP2C9, and CYP3A4.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The effect of concomitant use of VELSIPITY with a combination of separate drugs that are moderate to strong inhibitors or inducers of either CYP2C8, CYP2C9, or CYP3A4 is unknown. However, based on the information below, a similar clinically significant change in exposure cannot be ruled out when two or more metabolic pathways are affected.</p>
</blockquote>
<h5 id=""cyp2c9-poor-metabolizers-using-moderate-to-strong-inhibitors-of-cyp2c8-or-cyp3a4"">CYP2C9 Poor Metabolizers Using Moderate to Strong Inhibitors of CYP2C8 or CYP3A4</h5>
<table class=""table"">
<tbody>
<tr>
<td>Clinical Impact</td>
<td>Increased exposure of etrasimod in patients who are CYP2C9 poor metabolizers is expected with concomitant use of moderate to strong inhibitors of CYP2C8 or CYP3A4.</td>
</tr>
<tr>
<td>Prevention or Management</td>
<td>Concomitant use not recommended.</td>
</tr>
</tbody>
</table>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Etrasimod_FDA_2024_03_05.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Etrasimod_FDA_2024_03_05.pdf""><em><strong>Etrasimod</strong></em> drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166278581,Annotation of HCSC Label for siponimod and CYP2C9,True,False,[],True,"[{'id': 1452592286, 'date': '2024-09-17T11:48:11.581-07:00', 'description': 'added label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15165762, 'title': 'Drugs@HCSC: Drug Product MAYZENT (siponimod), Novartis Pharmaceuticals Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98630', 'crossReferences': [{'id': 1452592305, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98630', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98630'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]","[{'objCls': 'Haplotype', 'id': 'PA165816542', 'symbol': 'CYP2C9*1', 'name': '*1'}, {'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA166182736', 'name': 'siponimod'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",HCSC,1451887783.0,"<p>The HCSC product monograph indicates siponimod for the treatment of patients with secondary progressive multiple sclerosis. Siponimod is contraindicated in patients with CYP2C9*3/*3 genotype and gives a dose adjustment table for other genotypes involving CYP2C9*1, CYP2C9*2 and CYP2C9*3.</p>
",1451887780.0,"<p>Excerpts from the Siponimod (<em><strong>MAYZENT</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<blockquote class=""blockquote"">
<p>Prior to initiating treatment with MAYZENT the following assessments should be done to guide patient selection and treatment:
CYP2C9 genotype. The CYP2C9 genotype has a significant impact on siponimod metabolism.</p>
</blockquote>
<ul>
<li>Determine the CYP2C9 genotype of the patient to establish CYP2C9 metabolizer status. CYP2C9 genotyping prior to initiating treatment with siponimod will be offered by the manufacturer through its Patient Support Program.</li>
<li>MAYZENT is contraindicated in patients with a CYP2C9*3*3 genotype.</li>
<li>Dose adjustments are recommended for patients with CYP2C9*1*3 or a CYP2C9*2*3 genotype.</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Table 2 - Recommended MAYZENT maintenance doses by CYP2C9 genotype</p>
</blockquote>
<table class=""table"">
<thead>
<tr>
<th>CYP2C9 Genotype</th>
<th>Recommended maintenance dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extensive metabolizers</td>
<td></td>
</tr>
<tr>
<td>CYP2C9*1*1</td>
<td>2 mg</td>
</tr>
<tr>
<td>CYP2C9*1*2</td>
<td>2 mg</td>
</tr>
<tr>
<td>Intermediate metabolizers</td>
<td></td>
</tr>
<tr>
<td>CYP2C9*2*2</td>
<td>2 mg</td>
</tr>
<tr>
<td>CYP2C9*1*3</td>
<td>1 mg</td>
</tr>
<tr>
<td>Poor metabolizers</td>
<td></td>
</tr>
<tr>
<td>CYP2C9*2*3</td>
<td>1 mg</td>
</tr>
<tr>
<td>CYP2C9*3*3</td>
<td>Treatment is contraindicated</td>
</tr>
</tbody>
</table>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Siponimod_HCSC_2022_09_20.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Siponimod_HCSC_2022_09_20.pdf"">Siponimod product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1451887781.0,"<p>Excerpts from the Siponimod (<em><strong>MAYZENT</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p>Prior to initiating treatment with MAYZENT the following assessments should be done to guide patient selection and treatment:
CYP2C9 genotype. The CYP2C9 genotype has a significant impact on siponimod metabolism.</p>
<ul>
<li>Determine the CYP2C9 genotype of the patient to establish CYP2C9 metabolizer status. CYP2C9 genotyping prior to initiating treatment with siponimod will be offered by the manufacturer through its Patient Support Program.</li>
<li>MAYZENT is contraindicated in patients with a CYP2C9*3*3 genotype.</li>
<li>Dose adjustments are recommended for patients with CYP2C9*1*3 or a CYP2C9*2*3 genotype.</li>
</ul>
</blockquote>
",,,,,,,
Label Annotation,PA166334981,Annotation of EMA Label for fluorouracil,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA128406956', 'name': 'fluorouracil'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166335921,Annotation of HCSC Label for vincristine,False,False,[],False,[],False,[],True,"[{'id': 15157242, 'title': 'Drugs@HCSC: Drug Product vincristine', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19756', 'crossReferences': [{'id': 1452455822, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19756', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19756'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA451879', 'name': 'vincristine'}]",[],HCSC,,,1452455820.0,"<p>Excerpts from the vincristine product monograph:</p>
<blockquote class=""blockquote"">
<p>VINCRISTINE SULFATE INJECTION is indicated in the treatment of acute leukemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>It has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, soft-tissue sarcoma, bony-tissue sarcoma, sarcomas of specialized structures, breast cancer, small cell cancer of the lung, cancer of the uterine cervix, malignant melanoma, colorectal cancer, non-Hodgkin's lymphoma and Wilms' tumor.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Vincristine_2024_04_26_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Vincristine_2024_04_26_HCSC.pdf"">vincristine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166335941,Annotation of EMA Label for vincristine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451879', 'name': 'vincristine'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166336642,Annotation of HCSC Label for eliglustat and CYP2D6,True,False,[],True,[],False,[],True,"[{'id': 15157542, 'title': 'Drugs@HCSC: Drug Product CERDELGA (eliglustat), sanofi-aventis Canada Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00075274.PDF', 'crossReferences': [{'id': 1452460386, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00075274.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00075274.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166123486', 'name': 'eliglustat'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452460382.0,"<p>The HCSC-approved drug label for eliglustat (CERDELGA) states that it is indicated for patients with Gaucher disease type 1. Before initiation of treatment with eliglustat, patients must be genotyped for CYP2D6 to determine their CYP2D6 metabolizer status (predicted phenotype). Eliglustat should not be used in patients genotyped as CYP2D6 ultrarapid or indeterminate metabolizers. CYP2D6 intermediate and extensive metabolizers have a recommended dose of 84 mg twice daily, while poor metabolizers have a recommended dose of 84 mg once daily.</p>
",1452460383.0,"<p>Excerpts from the eliglustat (CERDELGA) product monograph:</p>
<blockquote class=""blockquote"">
<p>Before initiation of treatment with CERDELGA, patients must be genotyped for CYP2D6 to determine the CYP2D6 metabolizer status (predicted phenotype). CERDELGA is indicated for patients who are CYP2D6 PMs, IMs or EMs, as determined by CYP2D6 genotype testing.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CERDELGA should not be used in patients genotyped as CYP2D6 ultra-rapid metabolizers (URMs) as these patients may not achieve adequate concentrations of CERDELGA to achieve a therapeutic effect (or) CYP2D6 indeterminate metabolizers as a specific dosage cannot be recommended for these patients.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Eliglustat_2024_05_01_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Eliglustat_2024_05_01_HCSC.pdf"">eliglustat product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1452460384.0,"<blockquote class=""blockquote"">
<p>CERDELGA should not be used in patients who are CYP2D6 URMs or indeterminate metabolizers.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The recommended dose of CERDELGA depends on CYP2D6 metabolizer status, as follows:</p>
</blockquote>
<blockquote class=""blockquote"">
<p>• CYP2D6 Extensive metabolizer (EM): CERDELGA dosage is 84 mg twice daily</p>
</blockquote>
<blockquote class=""blockquote"">
<p>• CYP2D6 Intermediate metabolizer (IM): CERDELGA dosage is 84 mg twice daily</p>
</blockquote>
<blockquote class=""blockquote"">
<p>• CYP2D6 Poor metabolizer (PM): CERDELGA dosage is 84 mg once daily</p>
</blockquote>
",,,,,,,
Label Annotation,PA166336761,Annotation of EMA Label for tafenoquine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166115580', 'name': 'tafenoquine'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166335081,"Annotation of HCSC Label for lapatinib and HLA-DQA1, HLA-DRB1",False,False,[],False,[],False,[],True,"[{'id': 15161702, 'title': 'Drugs@HCSC: Drug Product TYKERB (lapatinib), Novartis Pharmaceuticals Canada Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00064944.PDF', 'crossReferences': [{'id': 1452536400, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00064944.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00064944.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165951292', 'symbol': 'HLA-DQA1*02:01', 'name': '*02:01'}, {'objCls': 'Haplotype', 'id': 'PA165951644', 'symbol': 'HLA-DRB1*07:01', 'name': '*07:01'}]","[{'objCls': 'Chemical', 'id': 'PA152241907', 'name': 'lapatinib'}]","[{'objCls': 'Gene', 'id': 'PA35066', 'symbol': 'HLA-DQA1', 'name': 'major histocompatibility complex, class II, DQ alpha 1'}, {'objCls': 'Gene', 'id': 'PA35072', 'symbol': 'HLA-DRB1', 'name': 'major histocompatibility complex, class II, DR beta 1'}]",HCSC,1452450480.0,"<p>The product monograph for lapatinib (TYKERB) states that patients with the HLA-DQA1*02:01 or HLA-DRB1*07:01 alleles have an increased risk of lapatinib-associated hepatotoxicity. The product monograph does not comment on genotyping for these HLA alleles.</p>
",1452450481.0,"<p>Excerpt from the lapatinib (TYKERB) product monograph:</p>
<blockquote class=""blockquote"">
<p>Patients who carry the HLA alleles DQA1*02:01 and DRB1*07:01 have increased risk of TYKERB(R)-associated hepatotoxicity. In a large, randomised clinical trial of TYKERB(R) monotherapy (n=1,194), the overall risk of severe liver injury (ALT &gt;5 times the upper limit of normal, NCI CTCAE grade 3) was 2% (1:50), the risk in DQA1*02:01 and DRB1*07:01 allele carriers was 8% (1:12) and the risk in non-carriers was 0.5% (1:200). Carriage of the HLA risk alleles is common (15 to 25%) in Caucasian, Asian, African and Hispanic populations but lower (1%) in Japanese populations.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Lapatinib_2024_04_22_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Lapatinib_2024_04_22_HCSC.pdf"">lapatinib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166336762,Annotation of HCSC Label for tafenoquine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166115580', 'name': 'tafenoquine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166336801,Annotation of EMA Label for allopurinol,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448320', 'name': 'allopurinol'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166337881,"Annotation of HCSC Label for avapritinib and KIT, PDGFRA",False,True,[],False,"[{'id': 1452641963, 'date': '2024-10-15T14:49:51.049-07:00', 'description': 'drug has been approved by HCSC', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15167842, 'title': 'Drugs@HCSC: Drug Product AYVAKYT (avapritinib), Blueprint Medicines Corporation', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104048', 'crossReferences': [{'id': 1452641960, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104048', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104048'}], 'notes': 'Current status: Approved\nCurrent status date: 2024-09-18', 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166223903', 'name': 'avapritinib'}]","[{'objCls': 'Gene', 'id': 'PA30128', 'symbol': 'KIT', 'name': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'objCls': 'Gene', 'id': 'PA33147', 'symbol': 'PDGFRA', 'name': 'platelet derived growth factor receptor alpha'}]",HCSC,1452641961.0,"<p>Avapritinib (AYVAKYT) is HCSC-indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia. Specific KIT and PDGRFA mutations are mentioned in the Mechanism of Action section of the product monograph.</p>
<p>Note that as of October 15, 2024, the current status of the drug on the HCSC website is Approved with a Current status date of 2024-09-18.</p>
",1452641962.0,"<p>Excerpts from the avapritinib (AYVAKYT) product monograph:</p>
<blockquote class=""blockquote"">
<p><strong>10.1 Mechanism of Action</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<p>Avapritinib is a tyrosine kinase inhibitor that targets KIT D816V, PDGFRA, and PDGFRA D842 mutants as well as multiple KIT exon 11, KIT exon 11/17, and KIT exon 17 mutants with half maximal inhibitory concentrations (IC50) below 28 nM in biochemical assays. Constitutive activation of KIT and PDGFRA receptor tyrosine kinases have been implicated in the pathogenesis of a number of oncology malignancies and rare hematologic diseases.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In cellular assays, avapritinib inhibited the autophosphorylation of KIT D816V and PDGFRA D842V with IC50 of 4 nM and 30 nM, respectively, and was less potent against wild-type KIT. Further, avapritinib inhibited the proliferation in KIT mutant cell lines, including a murine mastocytoma cell line and a human mast cell leukemia cell line.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Avapritinib also showed growth inhibitory activity in a xenograft model of murine mastocytoma with KIT exon 17 mutation.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Avapritinib_2024_10_15_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Avapritinib_2024_10_15_HCSC.pdf"">avapritinib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166339061,Annotation of HCSC Label for binimetinib and UGT1A1,False,False,[],False,"[{'id': 1452721441, 'date': '2024-12-02T10:54:08.995-08:00', 'description': 'added label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15165205, 'title': 'Drugs@HCSC: Drug Product MEKTOVI (binimetinib), Pfizer Canada ULC', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00060288.PDF', 'crossReferences': [{'id': 1452584904, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00060288.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00060288.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166179867', 'name': 'binimetinib'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",HCSC,1452479700.0,"<p>The binimetinib (MEKTOVI) product monograph states is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by a validated test. It also states that UGT1A1 genotype and smoking does not have a clinically important effect on binimetinib exposure.</p>
",1452479701.0,"<p>Excerpt from the binimetinib (MEKTOVI) product monograph:</p>
<blockquote class=""blockquote"">
<p>UGT1A1 genotype and smoking (UGT1A1 inducer) do not have a clinically important effect on binimetinib exposure. Based on PBPK simulations, a low potential for clinically significant drug interaction between binimetinib and atazanavir (UGT1A1 inhibitor) is expected. However, as this has not been evaluated in a formal clinical study, UGT1A1 inducers or inhibitors should be administered with caution.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Binimetinib_2024_05_21_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Binimetinib_2024_05_21_HCSC.pdf"">binimetinib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166336781,Annotation of EMA Label for obinutuzumab and MS4A1,False,True,[],False,"[{'id': 1452782200, 'date': '2024-12-12T14:23:54.809-08:00', 'description': 'removed afutuzumab synonym', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15157582, 'title': 'Gazyvaro | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro', 'crossReferences': [{'id': 1452462003, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166122586', 'name': 'obinutuzumab'}]","[{'objCls': 'Gene', 'id': 'PA31111', 'symbol': 'MS4A1', 'name': 'membrane spanning 4-domains A1'}]",EMA,1452462000.0,"<p>Obinutuzumab (Gazyvaro) in combination with certain other drugs is indicated for treatment of patients with chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL). The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, <em>MS4A1</em>, and therefore no mention of genetic testing in the drug label.</p>
",1452462001.0,"<p>Obinutuzumab (Gazyvaro) binds to the CD20 molecule, which is expressed on pre-B and mature B lymphocytes. Upon binding to CD20, it mediates B-cell lysis. CD20 is encoded by the <em>MS4A1</em> gene.</p>
<p>Excerpts from the obinutuzumab (Gazyvaro) EPAR:</p>
<blockquote class=""blockquote"">
<p>Obinutuzumab is a recombinant monoclonal humanised and glycoengineered Type II anti-CD20 antibody of the IgG1 isotype. It specifically targets the extracellular loop of the CD20 transmembrane antigen on the surface of non-malignant and malignant pre-B and mature B-lymphocytes, but not on haematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissue.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated CLL and with comorbidities making them unsuitable for full-dose fludarabine based therapy.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced FL.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Obinutuzumab_2024_05_03_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Obinutuzumab_2024_05_03_EMA.pdf"">obinutuzumab EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166337902,Annotation of EMA Label for avelumab and CD274,False,True,[],False,"[{'id': 1452802505, 'date': '2025-01-09T11:09:28.317-08:00', 'description': 'added Cancer Genome tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15157982, 'title': 'Bavencio | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio', 'crossReferences': [{'id': 1452469100, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166169875', 'name': 'avelumab'}]","[{'objCls': 'Gene', 'id': 'PA134915280', 'symbol': 'CD274', 'name': 'CD274 molecule'}]",EMA,1452469089.0,"<p>The EMA-approved drug label for avelumab (Bavencio) states that it is a human monoclonal IgG1 antibody directed against the immunomodulatory cell surface ligand protein programmed death-ligand 1 (PD-L1). PD-L1 is encoded by the <em>CD274</em> gene.</p>
<p>Avelumab is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma, as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy, and in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma.</p>
",1452469090.0,"<p>Excerpts from the avelumab (Bavencio) EPAR:</p>
<blockquote class=""blockquote"">
<p>Mechanism of action: Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against programmed death ligand 1 (PD-L1). Avelumab binds PD-L1 and blocks the interaction between PD-L1 and the programmed death 1 (PD-1) and B7.1 receptors. This removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, resulting in the restoration of anti-tumour T-cell responses. Avelumab has also shown to induce natural killer (NK) cell-mediated direct tumour cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC).</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Avelumab_2024_05_09_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Avelumab_2024_05_09_EMA.pdf"">avelumab EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166337901,Annotation of HCSC Label for avelumab and CD274,False,True,[],False,"[{'id': 1452802506, 'date': '2025-01-09T11:10:18.171-08:00', 'description': 'added Cancer Genome tag', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15157962, 'title': 'Drugs@HCSC: Drug Product BAVENCIO (avelumab), EMD Serono', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95856', 'crossReferences': [{'id': 1452469083, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95856', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95856'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166169875', 'name': 'avelumab'}]","[{'objCls': 'Gene', 'id': 'PA134915280', 'symbol': 'CD274', 'name': 'CD274 molecule'}]",HCSC,1452469080.0,"<p>The HCSC-approved drug label for avelumab (BAVENCIO) states that it is a programmed death ligand 1 (PD-L1) blocking antibody indicated for the treatment of unresectable locally advanced or metastatic urothelial carcinoma whose disease has not progressed following first-line platinum-based chemotherapy, metastatic Merkel cell carcinoma, and locally advanced or metastatic urothelial carcinoma. PD-L1 is encoded by the <em>CD274</em> gene.</p>
",1452469081.0,"<p>Excerpts from the avelumab (BAVENCIO) product monograph:</p>
<blockquote class=""blockquote"">
<p>Mechanism of Action: PD-L1 may be expressed on tumour cells and/or tumour-infiltrating immune cells and can contribute to the inhibition of the anti-tumour immune response in the tumour microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Avelumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody directed against programmed death ligand 1 (PD-L1). Avelumab binds PD-L1 and blocks the interaction between PD-L1 and the programmed death 1 (PD-1) and B7.1 receptors. This removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, resulting in the restoration of anti-tumour T-cell responses. In syngeneic mouse tumour models, blocking PD-L1 activity resulted in decreased tumour growth.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>As a fully human IgG1, avelumab retains FCƴ receptor binding and has shown to induce natural killer (NK) cell-mediated direct tumour cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Avelumab_2024_05_09_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Avelumab_2024_05_09_HCSC.pdf"">avelumab product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166337821,Annotation of HCSC Label for duvelisib,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166182761', 'name': 'duvelisib'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166337941,Annotation of EMA Label for amifampridine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166185150', 'name': 'amifampridine'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166339301,Annotation of HCSC Label for elacestrant,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166313327', 'name': 'elacestrant'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166337961,Annotation of FDA Label for atazanavir and CYP2C19,False,False,[],False,[],False,[],True,"[{'id': 15158002, 'title': 'DailyMed - REYATAZ- atazanavir capsule, gelatin coated REYATAZ- atazanavir powder', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=165cff62-b284-4a27-a65d-9ec8a5bfcdd8', 'crossReferences': [{'id': 1452469564, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '165cff62-b284-4a27-a65d-9ec8a5bfcdd8', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=165cff62-b284-4a27-a65d-9ec8a5bfcdd8'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA10251', 'name': 'atazanavir'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1452469560.0,"<p>Atazanavir (REYATAZ) is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. The FDA-approved drug label for atazanavir contains pharmacogenetic information related to co-treatment with voriconazole and ritonavir. The use of voriconazole in patients with a functional CYP2C19 allele and receiving atazanavir with ritonavir is not recommended unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.</p>
",1452469561.0,"<p>Excerpts from the atazanavir (REYATAZ) label:</p>
<blockquote class=""blockquote"">
<p>REYATAZ with ritonavir in subjects with a functional CYP2C19 allele:
The use of voriconazole in patients receiving REYATAZ with ritonavir is not recommended unless an assessment of the benefit/risk to the patient justifies the use of voriconazole. Patients should be carefully monitored for voriconazole-associated adverse reactions and loss of either voriconazole or atazanavir efficacy during the coadministration of voriconazole and REYATAZ with ritonavir.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>REYATAZ with ritonavir in subjects without a functional CYP2C19 allele:
Coadministration of voriconazole with REYATAZ (without ritonavir) may affect atazanavir concentrations; however, no data are available.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Atazanavir_2024_05_10_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Atazanavir_2024_05_10_FDA.pdf"">atazanavir drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452469562.0,"<blockquote class=""blockquote"">
<p>REYATAZ is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 3 months and older weighing at least 5 kg.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166340121,Annotation of EMA Label for amphetamine,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA448408', 'name': 'amphetamine'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166336561,Annotation of EMA Label for teclistamab,False,False,[],False,[],False,[],True,"[{'id': 15157522, 'title': 'Tecvayli | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli', 'crossReferences': [{'id': 1452459720, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA166295601', 'name': 'teclistamab'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166336562,Annotation of HCSC Label for teclistamab,False,False,[],False,[],False,[],True,"[{'id': 15157502, 'title': 'Drugs@HCSC: Drug Product TECVAYLI (teclistamab)', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102849', 'crossReferences': [{'id': 1452459700, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102849', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102849'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA166295601', 'name': 'teclistamab'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166340161,"Annotation of FDA Label for axitinib and CYP2C19, UGT1A1",False,False,[],False,[],False,[],True,"[{'id': 15158862, 'title': 'Drugs@FDA: Drug Product INLYTA (axitinib), Pfizer Laboratories Div Pfizer Inc - NDA202324/SUPPL-14, 09/22/2022', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202324', 'crossReferences': [{'id': 1452488881, 'resource': 'FDA Application', 'resourceId': 'NDA202324/SUPPL-14', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202324'}], 'objCls': 'Literature', 'pubDate': '2022-09-22T00:00:00-07:00', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164924493', 'name': 'axitinib'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",FDA,1452488882.0,"<p>The FDA-approved drug label for axitinib (INLYTA) states that population pharmacokinetic analyses show no clinically relevant effects of UGT1A1 or CYP2C19 genotype on the clearance of axitinib.</p>
",1452488883.0,"<p>Excerpt from the axitinib (INLYTA) label:</p>
<blockquote class=""blockquote"">
<p>Population pharmacokinetic analyses indicate that there are no clinically relevant effects of age, gender, race, body weight, body surface area, UGT1A1 genotype, or CYP2C19 genotype on the clearance of axitinib.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Axitinib_2024_05_30_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Axitinib_2024_05_30_FDA.pdf"">axitinib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166340181,"Annotation of HCSC Label for axitinib and CYP2C19, UGT1A1",False,False,[],False,[],False,[],True,"[{'id': 15158922, 'title': 'Drugs@HCSC: Drug Product INLYTA (axitinib), Pfizer Products ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87513', 'crossReferences': [{'id': 1452489380, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87513', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87513'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164924493', 'name': 'axitinib'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}, {'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",HCSC,1452489400.0,"<p>The HCSC-approved product monograph for axitinib (INLYTA) states that population pharmacokinetic analyses show no clinically relevant effects of UGT1A1 or CYP2C19 genotype.</p>
",1452489401.0,"<p>Excerpt from the axitinib (INLYTA) product monograph:</p>
<blockquote class=""blockquote"">
<p>Population pharmacokinetic analyses from patients with metastatic cancer (including metastatic RCC) and healthy volunteers indicate that there are no clinically relevant effects of age, gender, body weight, race, renal function, UGT1A1 genotype, or CYP2C19 genotype.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Axitinib_2024_05_30_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Axitinib_2024_05_30_HCSC.pdf"">axitinib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166344801,Annotation of FDA Label for dapsone and G6PD,False,False,[],False,"[{'id': 1452532560, 'date': '2024-07-19T16:26:04.711-07:00', 'description': 'changed level to Informative', 'type': 'Update', 'version': 0}, {'id': 1452716402, 'date': '2024-11-26T14:14:50.115-08:00', 'description': 'added oral formulation label, changed PGx level to Actionable/Other Guidance; added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15101977, 'title': 'Drugs@FDA: Drug Product DAPSONE (dapsone), Pacific Pharma, Inc. - NDA021794/SUPPL-16, 05/18/2018', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021794', 'crossReferences': [{'id': 1452532404, 'resource': 'FDA Application', 'resourceId': 'NDA021794/SUPPL-16', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021794'}], 'objCls': 'Literature', 'pubDate': '2018-05-18T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}, {'id': 15171042, 'title': 'DailyMed - DAPSONE 25 MG- dapsone tablets tablet DAPSONE 100 MG- dapsone tablets tablet', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d026bb6-05da-e9cf-e063-6394a90a2485', 'crossReferences': [{'id': 1452716380, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': '1d026bb6-05da-e9cf-e063-6394a90a2485', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d026bb6-05da-e9cf-e063-6394a90a2485'}], 'notes': 'ANDA086841, ANDA086842\nEverest Life Sciences, LLC', 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,True,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449211', 'name': 'dapsone'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",FDA,1452532440.0,"<p>Dapsone is available in an oral and a topical formulation. Dapsone tablets are a primary treatment for Dermatitis herpetiformis and are an antibacterial drug for susceptible cases of leprosy. Dapsone gel (ACZONE) is indicated for the topical treatment of acne vulgaris.</p>
<p>The FDA-approved label for dapsone tablets states that oral dapsone treatment can result in hemolysis, hemolytic anemia and hyperbilirubinemia, particularly in patients who are glucose-6-phosphate dehydrogenase (G6PD)-deficient. Dapsone should be given with caution to these patients, and monitoring of liver function is recommended. However, for the topical formulation of the drug, a study showed no clinically relevant cases of hemolysis or anemia in G6PD-deficient individuals.</p>
",1452532441.0,"<p>Excerpts from the dapsone (DAPSONE tablets) drug label:</p>
<blockquote class=""blockquote"">
<p>Hemolysis and Heinz body formation may be exaggerated in individuals with a glucose-6-phosphate dehydrogenase (G6PD) deficiency, or methemoglobin reductase
deficiency, or hemoglobin M. This reaction is frequently dose-related. Dapsone should be given with caution to these patients or if the patient is exposed to other agents or
conditions such as infection or diabetic ketosis capable of producing hemolysis. Drugs or chemicals which have produced significant hemolysis in G6PD or methemoglobin
reductase deficient patients include Dapsone, sulfanil amide, nitrite, aniline, phenylhydrazine, napthalene, niridazole, nitro-furantoin and 8-amino-antimalarials such as primaquine.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Toxic hepatitis and cholestatic jaundice have been reported early in therapy. Hyperbilirubinemia may occur more often in G6PD deficient patients. When feasible, baseline and subsequent monitoring of liver function is recommended; if abnormal, Dapsone should be discontinued until the source of the abnormality is established.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Hematologic Effects: Dose-related hemolysis is the most common adverse effect and is seen in patients with or without G6PD deficiency. Almost all patients demonstrate the inter-related changes of a loss of 1-2g of hemoglobin, an increase in the reticulocytes (2-12%), a shortened red cell life span and a rise in methemoglobin. G6PD deficient
patients have greater responses.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the and <a download=""Dapsone_2024_11_26_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dapsone_2024_11_26_FDA.pdf"">dapsone tablet drug label</a></p>
<p>Excerpts from the dapsone gel (ACZONE) drug label:</p>
<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia, with resultant hospitalization, have been reported postmarketing in association with ACZONE Gel, 5% treatment. Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. Avoid use of ACZONE Gel, 5% in those patients with congenital or idiopathic methemoglobinemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Oral dapsone treatment has produced dose-related hemolysis and hemolytic anemia. Individuals with glucose-6­ phosphate dehydrogenase (G6PD) deficiency are more prone to hemolysis with the use of certain drugs. G6PD deficiency is most prevalent in populations of African, South Asian, Middle Eastern, and Mediterranean ancestry [...] Some subjects with G6PD deficiency using ACZONE Gel developed laboratory changes suggestive of hemolysis. There was no evidence of clinically relevant hemolysis or anemia in patients treated with ACZONE Gel, 5%, including patients who were G6PD deficient.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Orally administered dapsone appears in human milk and could result in hemolytic anemia and hyperbilirubinemia especially in infants with G6PD deficiency.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the and <a download=""Dapsone_01_10_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dapsone_01_10_19_FDA.pdf"">dapsone gel drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452716401.0,"<p>Excerpt from the dapsone (DAPSONE tablets) drug label:</p>
<blockquote class=""blockquote"">
<p>Pediatric patients are treated on the same schedule as adults but with correspondingly smaller doses. Dapsone is generally not considered to have an effect on the later growth, development and functional development of the pediatric patient.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452716400.0,"<blockquote class=""blockquote"">
<p>Hemolysis and Heinz body formation may be exaggerated in individuals with a glucose-6-phosphate dehydrogenase (G6PD) deficiency, or methemoglobin reductase
deficiency, or hemoglobin M. This reaction is frequently dose-related. Dapsone should be given with caution to these patients [...]</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Toxic hepatitis and cholestatic jaundice have been reported early in therapy. Hyperbilirubinemia may occur more often in G6PD deficient patients. When feasible, baseline and subsequent monitoring of liver function is recommended; if abnormal, Dapsone should be discontinued until the source of the abnormality is established.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166343901,"Annotation of HCSC Label for avatrombopag and CYP2C9, F2, F5, PROC, PROS1, SERPINC1",False,False,[],False,"[{'id': 1452529761, 'date': '2024-07-17T15:11:26.066-07:00', 'description': 'added F2, F5 variants', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15160462, 'title': 'Drugs@HCSC: Drug Product DOPTELET (avatrombopag), Swedish Orphan Biovitrum AB (publ)', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00073257.PDF', 'crossReferences': [{'id': 1452526280, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00073257.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00073257.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]","[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}, {'objCls': 'Variant', 'id': 'PA166154336', 'symbol': 'rs1799963', 'name': 'rs1799963'}, {'objCls': 'Variant', 'id': 'PA166153554', 'symbol': 'rs6025', 'name': 'rs6025'}]","[{'objCls': 'Chemical', 'id': 'PA166179849', 'name': 'avatrombopag'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}, {'objCls': 'Gene', 'id': 'PA157', 'symbol': 'F2', 'name': 'coagulation factor II, thrombin'}, {'objCls': 'Gene', 'id': 'PA159', 'symbol': 'F5', 'name': 'coagulation factor V'}, {'objCls': 'Gene', 'id': 'PA33799', 'symbol': 'PROC', 'name': 'protein C, inactivator of coagulation factors Va and VIIIa'}, {'objCls': 'Gene', 'id': 'PA33809', 'symbol': 'PROS1', 'name': 'protein S'}, {'objCls': 'Gene', 'id': 'PA35026', 'symbol': 'SERPINC1', 'name': 'serpin family C member 1'}]",HCSC,1452526300.0,"<p>The HCSC-approved product monograph for avatrombopag (DOPTELET) states that avatrombopag exposure may increase in patients with CYP2C9*2 and/or CYP2C9*3 alleles, and that increased exposure may increase the risk of clinically-relevant QTc prolongation. The label also states that potential increased thrombotic risk should be considered in patients with deficiency in Factor V Leiden (F5), prothrombin 20210A (F2), antithrombin (SERPINC1), protein C (PROC), or protein S (PROS1).</p>
",1452526301.0,"<p>Excerpts from the avatrombopag (DOPTELET) product monograph:</p>
<blockquote class=""blockquote"">
<p>Avatrombopag is primarily metabolized by CYP2C9 and CYP3A4 enzymes.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The CYP2C9*2 and CYP2C9*3 loss-of-function polymorphisms result in reduced CYP2C9 enzymatic activity. In a pooled pharmacogenomic analysis of avatrombopag studies, subjects heterozygous for CYP2C9 loss-of-function polymorphisms (intermediate metabolizers [n=24]) had approximately 1.4-fold higher exposure and subjects homozygous for CYP2C9 loss-of-function polymorphisms (poor metabolizers [n=2]) had approximately 2-fold higher exposure compared to subjects wild-type for CYP2C9 (normal metabolizers [n=94]).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>QTc prolongation: At mean Cmax exposures similar to that achieved at the 40 mg dose, avatrombopag did not prolong the QT interval to any clinically relevant extent. Mean QTc prolongation effects &gt; 20 ms are not anticipated with the highest recommended therapeutic dosing regimen based on analysis of data from the pooled clinical trials in patients with chronic liver disease. [...] Caution must also be exercised in patients with loss-of-function polymorphisms of CYP2C9, as these can increase avatrombopag exposure.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including but not limited to advanced age, patients with prolonged periods of immobilization, malignancies, use of contraceptives or hormone replacement therapy, surgery/trauma, obesity, smoking, and genetic prothrombotic conditions (e.g., Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Avatrombopag_2024_07_11_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Avatrombopag_2024_07_11_HCSC.pdf"">avatrombopag product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452526302.0,"<blockquote class=""blockquote"">
<p>Caution must also be exercised in patients with loss-of-function polymorphisms of CYP2C9, as these can increase avatrombopag exposure.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including but not limited to [...] genetic prothrombotic conditions (e.g., Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).</p>
</blockquote>
",,,,,,,
Label Annotation,PA166344821,Annotation of HCSC Label for dapsone and CYB5R3,True,False,[],False,[],False,[],True,"[{'id': 15161142, 'title': 'Drugs@HCSC: Drug Product ACZONE (dapsone), Bausch Health, Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76674', 'crossReferences': [{'id': 1452532520, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76674', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76674'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}]",[],"[{'objCls': 'Chemical', 'id': 'PA449211', 'name': 'dapsone'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}]",HCSC,1452532540.0,"<p>The product monograph for dapsone gel (ACZONE) states that dapsone should be avoided in patients with congenital methemoglobinemia, which is associated with variants in CYB5R3.</p>
",1452532541.0,"<p>Excerpt from the dapsone (ACZONE) product monograph:</p>
<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia, with resultant hospitalization, have been reported post marketing in association with twice daily dapsone gel, 5%, treatment. Patients with glucose-6-phosphate dehydrogenase deficiency, or with congenital or idiopathic methemoglobinemia, are more susceptible to drug-induced methemoglobinemia. Avoid use of ACZONE Gel, 5%, in those patients with congenital or idiopathic methemoglobinemia.</p>
</blockquote>
<p>NOTE: While the CYB5R3 gene is not explicitly stated in the drug label, variants in this gene are associated with congenital methemoglobinemia I and II <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/250800"" target=""_blank"">OMIM 250800</a>.</p>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Dapsone_2024_07_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dapsone_2024_07_19_HCSC.pdf"">dapsone product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452532543.0,"<blockquote class=""blockquote"">
<p>ACZONE was studied in 578 12-15-year-old patients, demonstrating a similar safety and efficacy profile to the adult acne vulgaris patient population. ACZONE was not studied in patients less than 12 years of age thus ACZONE is not recommended for use in this age group.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452532542.0,"<blockquote class=""blockquote"">
<p>Cases of methemoglobinemia, with resultant hospitalization, have been reported post marketing in association with twice daily dapsone gel, 5%, treatment. [...] Avoid use of ACZONE Gel, 5%, in those patients with congenital or idiopathic methemoglobinemia.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166344841,Annotation of HCSC Label for dolutegravir and UGT1A1,False,False,[],False,[],False,[],True,"[{'id': 15161182, 'title': 'Drugs@HCSC: Drug Product TIVICAY (dolutegravir), ViiV Healthcare ULC', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89957', 'crossReferences': [{'id': 1452532620, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89957', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89957'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166114961', 'name': 'dolutegravir'}]","[{'objCls': 'Gene', 'id': 'PA420', 'symbol': 'UGT1A1', 'name': 'UDP glucuronosyltransferase 1 family, polypeptide A1'}]",HCSC,1452532621.0,"<p>The product monograph for dolutegravir (TIVICAY) states that subjects with UGT1A1 genotypes that result in poor metabolism of the drug have decreased clearance and increased AUC as compared to those who have UGT1A1 genotypes that result in normal dolutegravir metabolism.</p>
",1452532622.0,"<p>Excerpts from the dolutegravir (TIVICAY) product monograph:</p>
<blockquote class=""blockquote"">
<p>Dolutegravir is primarily metabolized via UGT1A1 with some contribution from CYP3A.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Polymorphisms in Drug Metabolizing Enzymes: In a meta-analysis using pharmacogenomics samples collected in clinical studies in healthy subjects, subjects with UGT1A1 (n=7) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with subjects with genotypes associated with normal metabolism via UGT1A1 (n=41).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Dolutegravir_2024_07_19_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dolutegravir_2024_07_19_HCSC.pdf"">dolutegravir product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452532623.0,"<blockquote class=""blockquote"">
<p>TIVICAY, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adults and in INSTI-naïve pediatric patients aged 4 weeks and older and weighing at least 3 kg.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Safety and efficacy of TIVICAY have not been established in children aged less than 4 weeks or weighing less than 3 kg or who are INSTI-experienced with documented or clinical suspected resistance to other INSTIs.</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166344641,Annotation of HCSC Label for azathioprine and NUDT15,False,False,[],True,[],False,[],True,"[{'id': 15160862, 'title': 'Drugs@HCSC: Drug Product APO-AZATHIOPRINE (azathioprine), APOTEX INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66740', 'crossReferences': [{'id': 1452530920, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66740', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66740'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}]","[{'objCls': 'Variant', 'id': 'PA166154759', 'symbol': 'rs116855232', 'name': 'rs116855232'}]","[{'objCls': 'Chemical', 'id': 'PA448515', 'name': 'azathioprine'}]","[{'objCls': 'Gene', 'id': 'PA134963132', 'symbol': 'NUDT15', 'name': 'nudix hydrolase 15'}]",HCSC,1452530942.0,"<p>The product monograph for azathioprine notes that patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity and generally require dose reduction. Therefore, genotypic analysis of the NUDT15 genotype should be performed for all patients, including paediatric patients, prior to initiating thiopurine treatment.</p>
",1452530943.0,"<p>Excerpts from the azathioprine (APO-AZATHIOPRINE) product monograph:</p>
<blockquote class=""blockquote"">
<p>Patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy. They generally, require dose reduction, particularly those being NUDT15 variant homozygotes (see 4.2 Recommended Dose and Dosage Adjustment).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The frequency of NUDT15 c.415C&gt;T has an ethnic variability of approximately 10 % in East Asians, 4 % in Hispanics, 0.2 % in Europeans and 0 % in Africans. In any case, close monitoring of blood count is necessary.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Recent studies indicate that a strong association exists between the NUDT15 variant NUDT15 c.415C&gt;T [p.Arg139Cys] (also known as NUDT15 R139C [rs116855232]), which is thought to lead to a loss of function of the NUDT15 enzyme, and thiopurine-mediated toxicity such as leukopenia and alopecia. The frequency of NUDT15 c.415C&gt;T has an ethnic variability of 9.8 % in East Asians, 3.9 % in Hispanics, 0.2 % in Europeans and 0.0 % in Africans, indicating an increased risk for the Asian population. Patients who are NUDT15 variant homozygotes (NUDT15 T risk alleles) are at an excessive risk of thiopurine toxicity compared with the C homozygotes.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Reduced thiopurine doses for patients who carry the NUDT15 variants may decrease their risk of toxicity. Therefore, genotypic analysis determining NUDT15 genotype should be determined for all patients, including paediatric patients, prior to initiating thiopurine treatment (see 4.2 Recommended Dose and Dosage Adjustment, Patients with NUDT15 variant). The prescribing physician is advised to establish whether dose reduction is required based on patient response to treatment as well as their genetic profile.
Patients with variants in both the NUDT15 and TPMT enzymes are significantly less tolerant of thiopurines than those with risk alleles in only one of these two genes.
The precise mechanism of NUDT15-associated thiopurine-related toxicity is not understood.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Azathioprine_2024_07_18_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Azathioprine_2024_07_18_HCSC.pdf"">azathioprine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1452530944.0,"<blockquote class=""blockquote"">
<p>Patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity (See 7 WARNINGS AND PRECAUTIONS, Patients with NUDT15 variant). These patients generally require dose reduction; particularly those being NUDT15 variant homozygotes (See 7 WARNINGS AND PRECAUTIONS, Patients with NUDT15 variant). Genotypic testing of NUDT15 variants may be considered before initiating 6-mercaptopurine therapy. In any case, close monitoring of blood counts is necessary.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166278381,"Annotation of EMA Label for bupivacaine and CYB5R3, G6PD",False,False,[],False,"[{'id': 1452531041, 'date': '2024-07-18T17:44:56.653-07:00', 'description': 'added Other Guidance tag, prescribing info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15135662, 'title': 'Drugs@EMA: Drug Product EXPAREL (bupivacaine), EMEA/H/C/004586, Pacira Ireland Limited', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/exparel-liposomal', 'crossReferences': [{'id': 1451880920, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/exparel-liposomal', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/exparel-liposomal'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",True,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA135057240', 'name': 'bupivacaine'}]","[{'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",EMA,1451880921.0,"<p>The EMA-approved drug label for bupivacaine (EXPAREL) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia and recommends close monitoring for symptoms in these patients.</p>
",1451880922.0,"<p>Excerpt from the bupivacaine (EXPAREL) EPAR:</p>
<blockquote class=""blockquote"">
<p>Cases of methaemoglobinaemia have been reported in association with local anaesthetic use. Although all patients are at risk for methaemoglobinaemia, infants under 6 months of age and patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methaemoglobinaemia, cardiac or pulmonary compromise, or concurrent exposure to oxidizing agents or their metabolites (see section 4.5) are more susceptible to developing clinical manifestations of the condition. If local anaesthetics must be used in these patients, close monitoring for symptoms and signs of methaemoglobinaemia is recommended.</p>
</blockquote>
<p>NOTE: While the CYB5R3 gene is not explicitly stated in the drug label, variants in this gene are associated with congenital methemoglobinemia I and II <a rel=""noopener noreferrer"" href=""https://www.omim.org/entry/250800"" target=""_blank"">OMIM 250800</a>.</p>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Bupivacaine_2022_09_12_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Bupivacaine_2022_09_12_EMA.pdf"">bupivacaine EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452531040.0,"<blockquote class=""blockquote"">
<p>Cases of methaemoglobinaemia have been reported in association with local anaesthetic use. Although all patients are at risk for methaemoglobinaemia, infants under 6 months of age and patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methaemoglobinaemia, cardiac or pulmonary compromise, or concurrent exposure to oxidizing agents or their metabolites (see section 4.5) are more susceptible to developing clinical manifestations of the condition. If local anaesthetics must be used in these patients, close monitoring for symptoms and signs of methaemoglobinaemia is recommended.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166344721,Annotation of HCSC Label for bupivacaine,False,False,[],False,[],False,[],True,"[{'id': 15160942, 'title': 'Drugs@HCSC: Drug Product BUPIVACAINE HYDROCHLORIDE INJECTION, USP (bupivacaine), Baxter Corporation', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97900', 'crossReferences': [{'id': 1452531680, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97900', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97900'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA135057240', 'name': 'bupivacaine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166345022,Annotation of FDA Label for flibanserin and CYP2C19,False,False,[],False,[],False,[],True,"[{'id': 15161402, 'title': 'Drugs@FDA: Drug Product ADDYI (flibanserin), Sprout Pharmaceuticals, Inc. - NDA022526/SUPPL-10, 09/29/2021', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022526', 'crossReferences': [{'id': 1452534220, 'resource': 'FDA Application', 'resourceId': 'NDA022526/SUPPL-10', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022526'}], 'objCls': 'Literature', 'pubDate': '2021-09-29T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166153431', 'name': 'flibanserin'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1452534263.0,"<p>The FDA-approved drug label for flibanserin (ADDYI) states that CYP2C19 poor metabolizers had increased exposure to the drug as compared to extensive metabolizers,  which may increase risk of hypotension, syncope, and CNS depression. The label states to increase monitoring for adverse reactions (e.g., hypotension) in patients who are CYP2C19 poor metabolizers.</p>
",1452534264.0,"<p>Excerpts from the flibanserin (ADDYI) label:</p>
<blockquote class=""blockquote"">
<p>CYP2C19 Poor Metabolizers: Increases flibanserin exposure which may increase risk of hypotension, syncope, and CNS depression (8.7)</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In a pharmacogenomic study of 100 mg ADDYI in subjects who were poor or extensive CYP2C19 metabolizers, syncope occurred in 1/9 (11%) subjects who were CYP2C19 poor metabolizers (this subject had a 3.2 fold higher flibanserin exposure compared to CYP2C19 extensive metabolizers) compared to no such adverse reactions in subjects who were CYP2C19 extensive metabolizers [see Drug Interactions (7), Use in Specific Populations (8.7) and Clinical Pharmacology (12.5)].</p>
</blockquote>
<blockquote class=""blockquote"">
<p>CYP2C19 poor metabolizers had increased flibanserin exposures compared to CYP2C19 extensive metabolizers. Additionally, syncope occurred in a subject who was a CYP2C19 poor metabolizer [see Adverse Reactions (6.1) and Clinical Pharmacology (12.5)]. Therefore, increase monitoring for adverse reactions (e.g., hypotension) in patients who are CYP2C19 poor metabolizers. The frequencies of poor CYP2C19 metabolizers are approximately 2–5% among Caucasians and Africans and approximately 2–15% among Asians.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>A study comparing flibanserin exposure in CYP2C19 poor metabolizers to CYP2C19 extensive metabolizers was conducted in lieu of a drug interaction study with ADDYI and a strong CYP2C19 inhibitor. In 9 women who were poor metabolizers of CYP2C19, Cmax and AUC0-inf of flibanserin 100 mg once daily increased 1.5-fold (1.1-2.1) and 1.3-fold (0.9-2.1), compared to exposures among 8 extensive metabolizers of CYP2C19. Flibanserin half-life was increased from 11.1 hours in the extensive metabolizers of CYP2C19 to
13.5 hours in the poor metabolizers of CYP2C19 [see Adverse Reactions (6.1) and Use in Specific Populations (8.7)].</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Flibanserin_2024_07_22_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Flibanserin_2024_07_22_FDA.pdf"">flibanserin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452534265.0,"<blockquote class=""blockquote"">
<p>CYP2C19 poor metabolizers had increased flibanserin exposures compared to CYP2C19 extensive metabolizers. Additionally, syncope occurred in a subject who was a CYP2C19 poor metabolizer [see Adverse Reactions (6.1) and Clinical Pharmacology (12.5)]. Therefore, increase monitoring for adverse reactions (e.g., hypotension) in patients who are CYP2C19 poor metabolizers.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166345321,Annotation of HCSC Label for glyburide and CYP2C9,False,False,[],True,[],False,[],True,"[{'id': 15161502, 'title': 'Drugs@HCSC: Drug Product Glyburide, SANIS HEALTH INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83567', 'crossReferences': [{'id': 1452534880, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83567', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83567'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]","[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA449782', 'name': 'glyburide'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",HCSC,1452534900.0,"<p>The product monograph for glyburide states that genetic polymorphisms of CYP2C9 may be associated with an increased response to glyburide, and that a lower dose regimen in poor metabolizers (CYP2C9*3 variant) should be considered.</p>
",1452534884.0,"<p>Excerpts from the glyburide product monograph:</p>
<blockquote class=""blockquote"">
<p>Glyburide is mainly metabolized by CYP2C9 and by CYP3A4. [...] Genetic polymorphisms of CYP2C9 may decrease oral clearance of glyburide (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Based on published literature, genetic polymorphisms of CYP2C9 may be associated with an increased response to glyburide. A lower dose regimen in poor metaboliser (CYP2C9*3 variant) should be considered, however an appropriate dose regimen for this patient population has not been established in clinical outcome trials (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genetic polymorphisms may reduce the metabolic capability of 2C9. Some clinical studies in a limited number of subjects have shown that genetic polymorphisms of CYP2C9 affect the pharmacokinetics of glyburide and that the carriers of CYP2C9*3 variant (3-8.5% of Caucasians) have lower (30-57%) oral clearance and 1 to 3-fold higher exposure (AUC(0-∞)) of glyburide. Individuals expressing this variant genotype may therefore be predisposed to have an increased response to glyburide. Moreover, the CYP2C9*3/*3 and *2/*3 genotypes may have an increased risk of hypoglycemia.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Glyburide_2024_07_22_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Glyburide_2024_07_22_HCSC.pdf"">glyburide product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452534885.0,"<blockquote class=""blockquote"">
<p>Based on published literature, genetic polymorphisms of CYP2C9 may be associated with an increased response to glyburide. A lower dose regimen in poor metaboliser (CYP2C9*3 variant) should be considered, however an appropriate dose regimen for this patient population has not been established in clinical outcome trials</p>
</blockquote>
",,,,,,,
Label Annotation,PA166345341,Annotation of HCSC Label for glimepiride and CYP2C9,False,False,[],True,[],False,[],True,"[{'id': 15161522, 'title': 'Drugs@HCSC: Drug Product SANDOZ GLIMEPIRIDE (glimepiride), Sandoz Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75494', 'crossReferences': [{'id': 1452534940, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75494', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75494'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]","[{'objCls': 'Haplotype', 'id': 'PA165816543', 'symbol': 'CYP2C9*2', 'name': '*2'}, {'objCls': 'Haplotype', 'id': 'PA165816544', 'symbol': 'CYP2C9*3', 'name': '*3'}]","[{'objCls': 'Chemical', 'id': 'PA449761', 'name': 'glimepiride'}]","[{'objCls': 'Gene', 'id': 'PA126', 'symbol': 'CYP2C9', 'name': 'cytochrome P450 family 2 subfamily C member 9'}]",HCSC,1452534941.0,"<p>The product monograph for glimepiride states that genetic polymorphisms of CYP2C9 may be associated with an increased response to glimepiride, and that a lower dose regimen in poor metabolizers (CYP2C9*3 variant) should be considered.</p>
",1452534942.0,"<p>Excerpts from the glimepiride (SANDOZ GLIMEPIRIDE) product monograph:</p>
<blockquote class=""blockquote"">
<p>Glimepiride is metabolized by cytochrome P450 2C9 (CYP2C9). This should be taken into account when glimepiride is coadministered with inducers (e.g. rifampicin) or inhibitors (e.g. fluconazole) of CYP 2C9. Genetic polymorphisms of CYP2C9 may decrease oral clearance of glimepiride (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Based on published literature, genetic polymorphisms of CYP2C9 may be associated with an increased response to glimepiride. A lower dose regimen in poor metaboliser (CYP2C9*3 variant) should be considered, however an appropriate dose regimen for this patient population has not been established in clinical outcome trials (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Genetic polymorphisms may reduce the metabolic capability of 2C9. Some clinical studies in a limited number of subjects have shown that genetic polymorphisms of CYP2C9 affect the pharmacokinetics of glimepiride and that the carriers of CYP2C9*3 variant (3-8.5% of Caucasians) may have lower (18-75%) oral clearance and 1.3 to 5.2-fold higher exposure (AUC(0-∞)) of glimepiride. Individuals expressing this variant genotype may therefore be predisposed to have an increased response to glimepiride. Moreover, the CYP2C9 *3/*3 and *2/*3 genotypes may have an increased risk of hypoglycemia.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Glimepiride_2024_07_22_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Glimepiride_2024_07_22_HCSC.pdf"">glimepiride product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452534943.0,"<blockquote class=""blockquote"">
<p>Based on published literature, genetic polymorphisms of CYP2C9 may be associated with an increased response to glimepiride. A lower dose regimen in poor metaboliser (CYP2C9*3 variant) should be considered, however an appropriate dose regimen for this patient population has not been established in clinical outcome trials</p>
</blockquote>
",,,,,,,
Label Annotation,PA166122947,Annotation of EMA Label for ranolazine and CYP2D6,True,False,[],True,"[{'id': 1452535261, 'date': '2024-07-22T23:34:05.773-07:00', 'description': 'Added Prescribing section, tags and label document', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15102939, 'title': 'Ranexa (previously Latixa) | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ranexa-previously-latixa', 'crossReferences': [{'id': 1450663668, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ranexa-previously-latixa', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/ranexa-previously-latixa'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA164746007', 'name': 'ranolazine'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1447982153.0,"<p>The EMA European Public Assessment Report (EPAR) for ranolazine (Ranexa) states that CYP2D6 poor metabolizers (PMs) had higher AUC as compared to extensive metabolizers (EMs), and that the risk for increased exposure leading to adverse events is higher in PMs than EMs.</p>
",1447982152.0,"<p>Excerpts from the ranolazine (Ranexa) EPAR:</p>
<blockquote class=""blockquote"">
<p>Caution should be exercised when prescribing or uptitrating ranolazine to patients in whom an increased exposure is expected:</p>
<ul>
<li>Concomitant administration of moderate CYP3A4 inhibitors [...].</li>
<li>Concomitant administration of P-gp inhibitors [...].</li>
<li>Mild hepatic impairment [...].</li>
<li>Mild to moderate renal impairment (creatinine clearance 30–80 ml/min) [...].</li>
<li>Elderly [...].</li>
<li>Patients with low weight (≤ 60 kg) [...].</li>
<li>Patients with moderate to severe CHF (NYHA Class III–IV) [...].</li>
</ul>
<p>In patients with a combination of these factors, additional exposure increases are expected. Dose dependent side effects are likely to occur. If Ranexa is used in patients with a combination of several of these factors, monitoring of adverse events should be frequent, the dose reduced, and treatment
discontinued, if needed.</p>
<p>The risk for increased exposure leading to adverse events in these different subgroups is higher in patients lacking CYP2D6 activity (poor metabolisers, PM) than subjects with CYP2D6 metabolising capacity (extensive metabolisers, EM) (see section 5.2). The above precautions are based on the risk in a CYP2D6 PM patient, and are needed when the CYP2D6 status is unknown. There is a lower need for precautions in patients with CYP2D6 EM status. If the CYP2D6 status of the patient has been determined (e.g. by genotyping) or is previously known to be EM, Ranexa can be used with caution in these patients when they have a combination of several of the above risk factors.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>At 500 mg twice daily, subjects lacking CYP2D6 activity (poor metabolisers, PM) had 62% higher AUC than subjects with CYP2D6 metabolising capacity (extensive metabolisers, EM). The corresponding difference at the 1000 mg twice-daily dose was 25%.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Ranolazine_2024_07_23_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Ranolazine_2024_07_23_EMA.pdf"">ranolazine EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452535260.0,"<p>Excerpt from the ranolazine (Ranexa) EPAR:</p>
<blockquote class=""blockquote"">
<p>Caution should be exercised when prescribing or uptitrating ranolazine to patients in whom an increased exposure is expected:</p>
<ul>
<li>Concomitant administration of moderate CYP3A4 inhibitors [...].</li>
<li>Concomitant administration of P-gp inhibitors [...].</li>
<li>Mild hepatic impairment [...].</li>
<li>Mild to moderate renal impairment (creatinine clearance 30–80 ml/min) [...].</li>
<li>Elderly [...].</li>
<li>Patients with low weight (≤ 60 kg) [...].</li>
<li>Patients with moderate to severe CHF (NYHA Class III–IV) [...].</li>
</ul>
<p>In patients with a combination of these factors, additional exposure increases are expected. Dose dependent side effects are likely to occur. If Ranexa is used in patients with a combination of several of these factors, monitoring of adverse events should be frequent, the dose reduced, and treatment
discontinued, if needed.</p>
<p>The risk for increased exposure leading to adverse events in these different subgroups is higher in patients lacking CYP2D6 activity (poor metabolisers, PM) than subjects with CYP2D6 metabolising capacity (extensive metabolisers, EM) (see section 5.2). The above precautions are based on the risk in a CYP2D6 PM patient, and are needed when the CYP2D6 status is unknown. There is a lower need for precautions in patients with CYP2D6 EM status. If the CYP2D6 status of the patient has been determined (e.g. by genotyping) or is previously known to be EM, Ranexa can be used with caution in these patients when they have a combination of several of the above risk factors.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166345301,"Annotation of HCSC Label for rosuvastatin and ABCG2, SLCO1B1",False,False,[],True,[],False,[],True,"[{'id': 15161462, 'title': 'Drugs@HCSC: Drug Product ACH-Rosuvastatin (rosuvastatin), Accord Healthcare Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92329', 'crossReferences': [{'id': 1452534800, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92329', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92329'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,"[{'objCls': 'Gene', 'id': 'PA390', 'symbol': 'ABCG2', 'name': 'ATP binding cassette subfamily G member 2 (JR blood group)'}, {'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]","[{'objCls': 'Variant', 'id': 'PA166156544', 'symbol': 'rs2231142', 'name': 'rs2231142'}, {'objCls': 'Variant', 'id': 'PA166154579', 'symbol': 'rs4149056', 'name': 'rs4149056'}]","[{'objCls': 'Chemical', 'id': 'PA134308647', 'name': 'rosuvastatin'}]","[{'objCls': 'Gene', 'id': 'PA390', 'symbol': 'ABCG2', 'name': 'ATP binding cassette subfamily G member 2 (JR blood group)'}, {'objCls': 'Gene', 'id': 'PA134865839', 'symbol': 'SLCO1B1', 'name': 'solute carrier organic anion transporter family member 1B1'}]",HCSC,1452534801.0,"<p>The product monograph for rosuvastatin states that genetic variants in SLCO1B1 (OATP1B1) and ABCG2 (BCRP) have been shown to be associated with an increase in rosuvastatin exposure. For patients known to have the SLCO1B1 c.521CC or ABCG2 c.421AA genotype, a maximum once daily dose of 20 mg of ACH-Rosuvastatin is recommended.</p>
",1452534802.0,"<p>Excerpts from the <em><strong>rosuvastatin</strong></em> (<em><strong>ACH-ROSUVASTATIN</strong></em>) product monograph:</p>
<blockquote class=""blockquote"">
<p><em><strong>Genetic Polymorphisms: Genotypes of SLCO1B1 (OATP1B1) c.521CC and ABCG2 (BCRP) c.421AA have been shown to be associated with an increase in rosuvastatin exposure (AUC) compared to SLCO1B1 c.521TT and ABCG2 c.421CC. For patients known to have the c.521CC or c.421AA genotype, a maximum once daily dose of 20 mg of ACH-Rosuvastatin is recommended.</strong></em></p>
</blockquote>
<blockquote class=""blockquote"">
<p><em><strong>Genetic Polymorphism: Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and BCRP transporter proteins. In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure. Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with an approximate 1.7- fold higher rosuvastatin exposure (AUC) or 2.4-fold higher exposure, respectively, compared to the SLCO1B1 c.521TT or ABCG2 c.421CC genotypes.</strong></em></p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""rosuvastatin_20240721_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/rosuvastatin_20240721_HCSC.pdf"">rosuvastatin product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452534804.0,"<blockquote class=""blockquote"">
<p>Pediatrics (10 to &lt;18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of rosuvastatin calcium in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use as an adjunct to diet to reduce elevated total cholesterol (Total-C), LDL-C and ApoB in boys and girls who are at least one year post- menarche with heterozygous familial hypercholesterolemia (see 14 CLINICAL TRIALS), when response to diet alone has been inadequate.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Pediatrics (&lt;10 years of age): No data are available to Health Canada for pediatric patients under the age of 10; therefore, Health Canada has not authorized an indication for pediatric use in this age range.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452534803.0,"<p>Genetic Polymorphisms: Genotypes of SLCO1B1 (OATP1B1) c.521CC and ABCG2 (BCRP) c.421AA have been shown to be associated with an increase in rosuvastatin exposure (AUC) compared to SLCO1B1 c.521TT and ABCG2 c.421CC. For patients known to have the c.521CC or c.421AA genotype, a maximum once daily dose of 20 mg of ACH-Rosuvastatin is recommended.</p>
",,,,,,,
Label Annotation,PA166344521,Annotation of HCSC Label for tramadol and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15160802, 'title': 'Drugs@HCSC: Drug Product Auro-Tramadol (tramadol), Auro Pharma Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97034', 'crossReferences': [{'id': 1452530511, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97034', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97034'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451735', 'name': 'tramadol'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452530560.0,"<p>The product monograph for tramadol (Auro-Tramadol) notes that patients who are CYP2D6 ultrarapid metabolizers convert tramadol more rapidly into its more potent opioid metabolite O-desmethyltramadol, which could result in higher than expected opioid-like side effects including life-threatening or fatal respiratory depression or signs of overdose.</p>
",1452530561.0,"<p>Excerpts from the tramadol (Auro-Tramadol) product monograph:</p>
<blockquote class=""blockquote"">
<p>Some individuals may be CYP2D6 ultra-rapid metabolizers. These individuals convert tramadol more rapidly than other people into its more potent opioid metabolite O-desmethyltramadol (M1). Even at labelled dosage regimens, this rapid conversion could result in higher than expected opioid-like side effects including life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing) (see OVERDOSAGE, Symptoms; WARNINGS
AND PRECAUTIONS, Special Populations, Labour, Delivery and Nursing Women; DRUG INTERACTIONS, Overview). The prevalence of this CYP2D6 phenotype varies widely in the population (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Race).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Tramadol is subject to the same polymorphic metabolism as codeine, with ultra-rapid metabolizers of CYP2D6 substrates being potentially exposed to life-threatening levels of O-desmethyltramadol (M1). At least one death was reported in a breast-feeding infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine. A baby breast-feeding from an ultra-rapid metabolizer mother taking tramadol could potentially be exposed to high levels of M1, and experience life-threatening respiratory depression. Therefore, maternal use of tramadol can lead to serious adverse reactions, including death in nursing infants (see WARNINGS AND PRECAUTIONS, Respiratory).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Approximately 7% of the population has reduced activity of the CYP2D6 isoenzyme of cytochrome P450. These individuals are “poor metabolizers” of debrisoquine, dextromethorphan, and tricyclic antidepressants, among other drugs. Based on a population PK analysis of Phase I studies in healthy subjects, concentrations of tramadol were approximately 20% higher in “poor metabolizers” versus “extensive metabolizers”, while M1 concentrations were 40% lower.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Some patients are CYP2D6 ultra-rapid metabolizers of tramadol due to a specific genotype. These individuals convert tramadol into its active metabolite, M1, more rapidly and completely than other people leading to higher-than-expected serum M1 levels. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese, Japanese and Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups (see WARNINGS AND PRECAUTIONS, Respiratory and Special Populations, Labour, Delivery and Nursing Women). In contrast, some patients exhibit the CYP2D6 poor metabolizer phenotype and do not convert tramadol to the active M1 metabolite sufficiently to benefit from the analgesic effect of the drug (see DRUG INTERACTIONS, Overview). The prevalence of this CYP2D6 phenotype is about 5-10 percent in Caucasians and 1 percent of Asians.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Tramadol_2024_07_18_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Tramadol_2024_07_18_HCSC.pdf"">tramadol product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166345781,Annotation of HCSC Label for metoclopramide and CYP2D6,False,False,[],True,[],False,[],True,"[{'id': 15162002, 'title': 'Drugs@HCSC: Drug Product pms-METOCLOPRAMIDE TABLETS (metoclopramide), PHARMASCIENCE INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49332', 'crossReferences': [{'id': 1452539003, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49332', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49332'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,"[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",[],"[{'objCls': 'Chemical', 'id': 'PA450475', 'name': 'metoclopramide'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452539040.0,"<p>The product monograph for metoclopramide notes that elimination of the drug may be slowed in CYP2D6 poor metabolizers, potentially increasing the risk for adverse reactions, and that these patients should receive a reduced dose of the drug.</p>
",1452539041.0,"<p>Excerpts from the metoclopramide (pms-METOCLOPRAMIDE TABLETS) product monograph:</p>
<blockquote class=""blockquote"">
<p>Metoclopramide undergoes enzymatic metabolism via oxidation as well as glucuronide and sulfate conjugation reactions in the liver. Monodeethylmetoclopramide, a major oxidative metabolite, is formed primarily by CYP2D6, an enzyme subject to genetic variability.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Metoclopramide is a substrate of CYP2D6. The elimination of metoclopramide may be slowed in patients who are CYP2D6 poor metabolizers (compared to patients who are CYP2D6 intermediate, extensive, or ultra-rapid metabolizers); possibly increasing the risk of dystonic and other adverse reactions to pms-METOCLOPRAMIDE (see 10.3 Pharmacokinetics, Special Populations and Conditions). The dose of pms-METOCLOPRAMIDE should be reduced in patients who are poor CYP2D6 metabolizers.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Metoclopramide_2024_07_25_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Metoclopramide_2024_07_25_HCSC.pdf"">metoclopramide product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452539042.0,"<blockquote class=""blockquote"">
<p>The dose of pms-METOCLOPRAMIDE should be reduced in patients who are poor CYP2D6 metabolizers.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166345921,Annotation of HCSC Label for primaquine and G6PD,True,False,[],True,[],False,[],True,"[{'id': 15161882, 'title': 'Drugs@HCSC: Drug Product PRIMAQUINE (primaquine), sanofi-aventis Canada Inc.', '_sameAs': 'https://pdf.hres.ca/dpd_pm/00057221.PDF', 'crossReferences': [{'id': 1452538180, 'resource': 'URL', 'resourceId': 'https://pdf.hres.ca/dpd_pm/00057221.PDF', '_url': 'https://pdf.hres.ca/dpd_pm/00057221.PDF'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,True,True,"[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA451103', 'name': 'primaquine'}]","[{'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1452539602.0,"<p>The product monograph for primaquine states that due to the risk of hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD) deficient patients, G6PD testing has to be performed before using primaquine. Primaquine is contraindicated in patients with severe G6PD deficiency; in case of mild to moderate G6PD deficiency, a decision to prescribe primaquine must be based on an assessment of the risks and benefits of using primaquine.</p>
",1452539603.0,"<p>Primaquine is an anti-malarial. Excerpts from the primaquine (PRIMAQUINE) product monograph:</p>
<blockquote class=""blockquote"">
<p>PRIMAQUINE is contraindicated:</p>
<ul>
<li>In patients with severe glucose-6-phosphate dehydrogenase (G6PD) deficiency.</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>The G6PD status of patients should be used to guide administration of primaquine for preventing relapse.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Due to the risk of hemolytic anemia in G6PD deficient patients, G6PD testing has to be performed before using primaquine. Before initiating treatment, it is advisable to check the patients for clinical signs of severe anemia or test hemoglobin level. In case of severe anemia, the G6PD testing and primaquine treatment should be postponed until recovery of anemia, in order to avoid false diagnosis due to reticulocytosis.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Baseline hematocrit and hemoglobin must be checked before treatment and close hematological monitoring (e.g. at day 3 and 8) is required. Due to the limitations of G6PD tests, physicians need to be aware of residual risk of hemolysis and adequate medical support and follow-up to manage hemolytic risk should be available. Observe particular caution in individuals with a personal or family history of hemolytic anemia.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In case of mild to moderate G6PD deficiency, a decision to prescribe primaquine must be based on an assessment of the risks and benefits of using primaquine; if primaquine administration is considered, the dosage regimen should be adapted accordingly (see DOSAGE AND ADMINISTRATION) and close hematological monitoring is required.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Adverse Reaction Overview</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<ul>
<li>In patients with G6PD deficiency, hemolytic anemia occurs very commonly and may be severe or fatal in patients with severe G6PD deficiency (see CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS).</li>
</ul>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Primaquine_2024_07_25_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Primaquine_2024_07_25_HCSC.pdf"">primaquine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452539605.0,"<blockquote class=""blockquote"">
<p><strong>Pediatric patients without G6PD deficiency (≥ 30 kg</strong> body weight <strong>and</strong> able to swallow tablets): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of primaquine in pediatric patients <strong>without</strong> G6PD deficiency, weighing <strong>30 kg</strong> or above <strong>and</strong> able to swallow tablets has been established; therefore, Health Canada has authorized an indication for pediatric use (see DOSAGE AND ADMINISTRATION).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Pediatric patients with mild-to-moderate G6PD deficiency (≥ 20 kg</strong> body weight <strong>and</strong> able to swallow tablets): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of primaquine in pediatric patients <strong>with mild-to-moderate</strong> G6PD deficiency, weighing <strong>20 kg</strong> or above <strong>and</strong> able to swallow tablets has been established; therefore, Health Canada has authorized an indication for pediatric use (see DOSAGE AND ADMINISTRATION).</p>
</blockquote>
",1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,1452539604.0,"<p>Excerpt from the primaquine product monograph:</p>
<blockquote class=""blockquote"">
<p>PRIMAQUINE is contraindicated:</p>
<ul>
<li>In patients with severe glucose-6-phosphate dehydrogenase (G6PD) deficiency.</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Recommended Dose and Dosage Adjustment</strong>
<em>Adult patients with mild to moderate G6PD deficiency:</em></p>
<ul>
<li>0.75 mg/kg of primaquine base once a week for 8 weeks (see WARNINGS AND PRECAUTIONS), not exceeding a 45 mg unit dose.</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p><em>Pediatric patients with mild to moderate G6PD deficiency:</em></p>
<ul>
<li>0.75 mg/kg of primaquine base once a week for 8 weeks (see WARNINGS AND PRECAUTIONS), not exceeding a 45 mg unit dose (see table below).</li>
<li>PRIMAQUINE is not suited for children weighing less than 20 kg or not able to swallow tablets.</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>In case of mild to moderate G6PD deficiency, a decision to prescribe primaquine must be based on an assessment of the risks and benefits of using primaquine; if primaquine administration is considered, the dosage regimen should be adapted accordingly (see DOSAGE AND ADMINISTRATION) and close hematological monitoring is required.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166346941,"Annotation of HCSC Label for dabrafenib and HRAS, KRAS, NRAS",False,False,[],False,"[{'id': 1452817301, 'date': '2025-01-17T15:25:39.462-08:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15158142, 'title': 'Drugs@HCSC: Drug Product TAFINLAR (dabrafinib), Novartis Pharmaceuticals Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'crossReferences': [{'id': 1452473460, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,True,True,"[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166114911', 'name': 'dabrafenib'}]","[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",HCSC,1452548623.0,"<p>The product monograph for dabrafenib (TAFINLAR) states that it is indicated, as a single agent or in combination with trametinib, for adult patients with certain types of cancer. The label also notes that the drug may promote growth and development of malignancies with activation of RAS.</p>
",1452548624.0,"<p>Excerpts from the dabrafenib (TAFINLAR) product monograph:</p>
<blockquote class=""blockquote"">
<p>The paradoxical activation of MAP-kinase signalling in BRAF wild-type cells exposed to BRAF inhibitors may lead to increased risk of non-cutaneous malignancies, including those with RAS mutations, in patients treated with TAFINLAR. In clinical trials, cases of RAS-associated malignancies have been reported including colorectal adenocarcinoma, bile duct adenocarcinoma and pancreatic adenocarcinoma, which have resulted in discontinuation of TAFINLAR.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Evaluate patients for symptoms or clinical signs of non-cutaneous malignancies before initiation of treatment, periodically during treatment, or as clinically indicated. Consider the benefits and risks before continuing treatment with TAFINLAR in patients with a non-cutaneous malignancy that has a RAS mutation. No dose modification of trametinib is required when taken in combination with TAFINLAR.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Dabrafenib_2024_05_14_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dabrafenib_2024_05_14_HCSC.pdf"">dabrafenib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",1452817300.0,"<p>Excerpts from the dabrafenib (TAFINLAR) product monograph:</p>
<blockquote class=""blockquote"">
<p>TAFINLAR (dabrafenib mesylate), in combination with trametinib, is indicated for:
• the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.
• the treatment of pediatric patients 1 year of age and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The safety and efficacy of TAFINLAR in combination with trametinib in pediatric patients 1 year of age and older with low-grade glioma are supported by evidence from the randomized LGG cohort of the G2201 study (N=73).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The safety and efficacy of TAFINLAR in combination with trametinib in pediatric patients 1 year of age and older with high-grade glioma are supported by evidence from the single-arm HGG cohort of the G2201 study (N=41).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The warnings applicable to adults are also relevant to pediatric use.</p>
</blockquote>
",1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452548625.0,"<blockquote class=""blockquote"">
<p>Evaluate patients for symptoms or clinical signs of non-cutaneous malignancies before initiation of treatment, periodically during treatment, or as clinically indicated. Consider the benefits and risks before continuing treatment with TAFINLAR in patients with a non-cutaneous malignancy that has a RAS mutation. No dose modification of trametinib is required when taken in combination with TAFINLAR.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166346641,Annotation of EMA Label for letrozole,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450196', 'name': 'letrozole'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166346802,Annotation of HCSC Label for azacitidine,False,False,[],False,[],False,[],True,"[{'id': 15162862, 'title': 'Drugs@HCSC: Drug Product VIDAZA (azacitidine), Bristol-Myers Squibb Canada', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82233', 'crossReferences': [{'id': 1452547454, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82233', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82233'}], 'objCls': 'Literature', 'terms': [{'id': 1452267781, 'resource': 'PharmGKB Tags', 'term': 'Has No PGx', 'termId': 'pgkbTags:1452267781'}], 'type': 'Drug Label'}]",False,False,False,[],[],"[{'objCls': 'Chemical', 'id': 'PA451996', 'name': 'azacitidine'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166338381,"Annotation of EMA Label for dabrafenib and HRAS, KRAS, NRAS",False,True,[],False,[],False,[],True,"[{'id': 15102965, 'title': 'Tafinlar | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar', 'crossReferences': [{'id': 1450416950, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",True,False,True,"[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",[],"[{'objCls': 'Chemical', 'id': 'PA166114911', 'name': 'dabrafenib'}]","[{'objCls': 'Gene', 'id': 'PA29444', 'symbol': 'HRAS', 'name': 'HRas proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA30196', 'symbol': 'KRAS', 'name': 'KRAS proto-oncogene, GTPase'}, {'objCls': 'Gene', 'id': 'PA31768', 'symbol': 'NRAS', 'name': 'NRAS proto-oncogene, GTPase'}]",EMA,1452473440.0,"<p>The drug label for dabrafenib (Tafinlar) states that it is indicated, as a single agent or in combination with trametinib, for adult patients with certain types of cancer. The label also notes that the drug may promote growth and development of malignancies with activation of RAS.</p>
",1452473441.0,"<p>Excerpts from the dabrafenib (Tafinlar) EPAR:</p>
<blockquote class=""blockquote"">
<p>In vitro experiments have demonstrated paradoxical activation of mitogen-activated protein kinase (MAP kinase) signalling in BRAF wild-type cells with RAS mutations when exposed to BRAF inhibitors. This may lead to increased risk of non-cutaneous malignancies with dabrafenib exposure when RAS mutations are present. RAS-associated malignancies have been reported in clinical trials, both with another BRAF inhibitor (chronic myelomonocytic leukaemia and non-cutaneous SCC of the head and neck) as well as with dabrafenib monotherapy (pancreatic adenocarcinoma, bile duct adenocarcinoma) and with dabrafenib in combination with the MEK inhibitor, trametinib (colorectal cancer, pancreatic cancer).</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The benefits and risks should be considered before administering dabrafenib in patients with a prior or concurrent cancer associated with RAS mutations. No dose modification of trametinib is required when taken in combination with dabrafenib.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Dabrafenib_2024_05_14_EMA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Dabrafenib_2024_05_14_EMA.pdf"">dabrafenib EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452473442.0,"<p>Excerpt from the dabrafenib (Tafinlar) EPAR:</p>
<blockquote class=""blockquote"">
<p>The benefits and risks should be considered before continuing treatment with dabrafenib in patients with a non-cutaneous malignancy that has a RAS mutation. No dose modification of trametinib is required when taken in combination with dabrafenib.</p>
</blockquote>
",,,,,,,
Label Annotation,PA166346981,Annotation of EMA Label for denileukin diftitox,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164750594', 'name': 'denileukin diftitox'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166347001,Annotation of HCSC Label for denileukin diftitox,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164750594', 'name': 'denileukin diftitox'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166347101,Annotation of EMA Label for eteplirsen,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166163432', 'name': 'eteplirsen'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166347121,Annotation of HCSC Label for eteplirsen,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166163432', 'name': 'eteplirsen'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166347141,Annotation of FDA Label for abemaciclib and MKI67,False,True,[],False,[],False,[],True,"[{'id': 15102007, 'title': 'Drugs@FDA: Drug Product Verzenio (abemaciclib), NDA208716, Eli Lilly and Company', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208716', 'crossReferences': [{'id': 1449893412, 'resource': 'FDA Application', 'resourceId': 'NDA208716', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208716'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166153471', 'name': 'abemaciclib'}]","[{'objCls': 'Gene', 'id': 'PA30825', 'symbol': 'MKI67', 'name': 'marker of proliferation Ki-67'}]",FDA,1452549521.0,"<p>Abemaciclib (VERZENIO) is indicated in combination with other medications or as a monotherapy for the treatment of women with hormone receptor-positive, HER2-negative breast cancer. KI-67 is mentioned in the clinical studies section.</p>
",1452549522.0,"<p>Excerpt from the abemaciclib (VERZENIO) drug label:</p>
<blockquote class=""blockquote"">
<p>Clinical Studies: Patients enrolled in cohort 2 could not have met the eligibility criteria for cohort 1. To be enrolled in cohort 2, patients had to have 1-3 pALN and Ki-67 score ≥20%. Breast tumor samples were tested at central sites using the Ki-67 IHC MIB-1 pharmDx (Dako Omnis) assay to establish if the Ki-67 score was ≥20%. The Ki-67 test is an antigen test for a biomarker coded for by MKI67.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""abemaciclib_FDA_20230911.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/abemaciclib_FDA_20230911.pdf"">abemaciclib drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166347181,Annotation of FDA Label for tremelimumab and CD274,False,True,[],False,[],False,[],True,"[{'id': 15142103, 'title': 'Drugs@FDA: Drug Product IMJUDO (tremelimumab), BLA761270/ORIG-1, 11/10/2022', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761270', 'crossReferences': [{'id': 1452318123, 'resource': 'FDA Application', 'resourceId': 'BLA761270/ORIG-1', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761270'}], 'objCls': 'Literature', 'pubDate': '2022-11-10T00:00:00-08:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166293321', 'name': 'tremelimumab'}]","[{'objCls': 'Gene', 'id': 'PA134915280', 'symbol': 'CD274', 'name': 'CD274 molecule'}]",FDA,1452549641.0,"<p>Tremelimumab-actl is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC), and in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.</p>
<p>Durvalumab is a PD-L1 inhibitor; PD-L1 (CD274) is also mentioned in the FDA pharmacogenomics biomarker table.</p>
",1452549642.0,"<p>Excerpts from the tremelimumab-actl (IMJUDO) label:</p>
<blockquote class=""blockquote"">
<p>IMJUDO, in combination with durvalumab and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""tremelimumab-actl_2023_03_15_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/tremelimumab-actl_2023_03_15_FDA.pdf"">tremelimumab-actl drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166345821,"Annotation of HCSC Label for metoclopramide and CYB5R1, CYB5R2, CYB5R3, CYB5R4, G6PD",False,False,[],False,[],False,[],True,"[{'id': 15162002, 'title': 'Drugs@HCSC: Drug Product pms-METOCLOPRAMIDE TABLETS (metoclopramide), PHARMASCIENCE INC.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49332', 'crossReferences': [{'id': 1452539003, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49332', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49332'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450475', 'name': 'metoclopramide'}]","[{'objCls': 'Gene', 'id': 'PA134979668', 'symbol': 'CYB5R1', 'name': 'cytochrome b5 reductase 1'}, {'objCls': 'Gene', 'id': 'PA142672060', 'symbol': 'CYB5R2', 'name': 'cytochrome b5 reductase 2'}, {'objCls': 'Gene', 'id': 'PA27331', 'symbol': 'CYB5R3', 'name': 'cytochrome b5 reductase 3'}, {'objCls': 'Gene', 'id': 'PA134904907', 'symbol': 'CYB5R4', 'name': 'cytochrome b5 reductase 4'}, {'objCls': 'Gene', 'id': 'PA28469', 'symbol': 'G6PD', 'name': 'glucose-6-phosphate dehydrogenase'}]",HCSC,1452539080.0,"<p>The product monograph for metoclopramide notes that patients with NADH-cytochrome b5 reductase deficiency have an increased risk of developing methemglobinemia and/or sulfhemoglobinemia when treated with metoclopramide. The label also mentions G6PD; patients with G6PD deficiency experiencing metoclopramide-induced methemoglobinemia should not be given methylene blue.</p>
",1452539081.0,"<p>Excerpt from the metoclopramide (pms-METOCLOPRAMIDE TABLETS) product monograph:</p>
<blockquote class=""blockquote"">
<p>Metoclopramide-treated patients with NADH-cytochrome b5 reductase deficiency are at an increased risk of developing methemoglobinemia and/or sulfhemoglobinemia. For patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency with metoclopramide-induced methemoglobinemia, methylene blue treatment is not recommended. Methylene blue may cause hemolytic anemia in patients with G6PD deficiency, which may be fatal.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Metoclopramide_2024_07_25_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Metoclopramide_2024_07_25_HCSC.pdf"">metoclopramide product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166345861,Annotation of HCSC Label for mirabegron and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15162102, 'title': 'Drugs@HCSC: Drug Product MYRBETRIQ (mirabegron), Astellas Pharma Canada, Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88770', 'crossReferences': [{'id': 1452539540, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88770', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88770'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166177513', 'name': 'mirabegron'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452539541.0,"<p>Mirabegron (MYRBETRIQ) is indicated for the treatment of overactive bladder. The label notes that CYP2D6 poor metabolizers had increased concentrations of the drug as compared to CYP2D6 extensive metabolizers, but that no dose adjustment is needed for mirabegron when administered in patients who are CYP2D6 poor metabolizers.</p>
",1452539542.0,"<p>Excerpt from the mirabegron (MYRBETRIQ) product monograph:</p>
<blockquote class=""blockquote"">
<p>In healthy subjects who are genotypically poor metabolizers of CYP2D6 substrates (used as a surrogate for CYP2D6 inhibition), mean Cmax and AUCinf of a single 160 mg dose of a mirabegron immediate-release oral formulation were 14% and 19% higher than in extensive metabolizers, indicating that CYP2D6 genetic polymorphism has minimal impact on the mean plasma exposure to mirabegron. Interaction of mirabegron with a known CYP2D6 inhibitor is not expected and was not studied. No dose adjustment is needed for mirabegron when administered with CYP2D6 inhibitors or in patients who are CYP2D6 poor metabolizers.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Mirabegron_2024_07_25_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Mirabegron_2024_07_25_HCSC.pdf"">mirabegron product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166347361,Annotation of HCSC Label for gefitinib and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15163102, 'title': 'Drugs@HCSC: Drug Product IRESSA (gefitinib), AstraZeneca Canada Inc.', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040', 'crossReferences': [{'id': 1452550200, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA131301952', 'name': 'gefitinib'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452550201.0,"<p>The product monograph for gefinitib (IRESSA) states that it is indicated for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer who have activating mutations of the EGFR-TK as assessed by a well-validated test. The label also notes the potential clinical importance of considering CYP2D6 phenotype.</p>
",1452550202.0,"<p>Excerpts from the gefitinib (IRESSA) product monograph:</p>
<blockquote class=""blockquote"">
<p>In a clinical trial of healthy volunteers, CYP2D6 poor metabolisers achieved a 2-fold higher mean exposure to gefitinib than in extensive metabolisers. The higher average gefitinib exposures achieved by individuals with no active CYP2D6 may be clinically relevant since adverse experiences are related to dose and exposure (see 9 Drug Interactions).</p>
</blockquote>
<blockquote class=""blockquote"">
<p><em>In vitro</em> data indicate that CYP3A4 is the major P450 isozyme involved in the oxidative metabolism of gefitinib.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The production of O-desmethyl gefitinib has also been shown, <em>in vitro</em>, to be via CYP2D6. The role of CYP2D6 in the metabolic clearance of gefitinib has been evaluated in a clinical trial in healthy volunteers genotyped for CYP2D6 status. In poor metabolisers (devoid of CYP2D6) no measurable levels of O-desmethyl gefitinib were produced. The range of gefitinib exposures achieved in both the extensive and the poor metaboliser groups were wide and overlapping but the mean exposure to gefitinib was 2-fold higher in the poor metaboliser group. The higher average exposures that could be achieved by individuals with no active CYP2D6 may be clinically relevant since adverse experiences are related to dose and exposure.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Gefitinib_2024_08_07_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Gefitinib_2024_08_07_HCSC.pdf"">gefitinib product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166347901,Annotation of FDA Label for panitumumab and EGFR,False,False,[],False,[],False,[],True,"[{'id': 15163702, 'title': 'Drugs@FDA: Drug Product Vectibix (panitumumab), Amgen Inc - BLA125147/SUPPL-210, 08/25/2021', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125147', 'crossReferences': [{'id': 1452554457, 'resource': 'FDA Application', 'resourceId': 'BLA125147/SUPPL-210', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125147'}], 'objCls': 'Literature', 'pubDate': '2021-08-25T00:00:00-07:00', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA162373091', 'name': 'panitumumab'}]","[{'objCls': 'Gene', 'id': 'PA7360', 'symbol': 'EGFR', 'name': 'epidermal growth factor receptor'}]",FDA,1452554560.0,"<p>The FDA-approved drug label for panitumumab (Vectibix) states that it is an EGFR antagonist indicated for the treatment of wild-type <em>RAS</em> (defined as wild-type in both <em>KRAS</em> and <em>NRAS</em>) metastatic colorectal cancer. The absence of  a <em>RAS</em> mutation needs to be confirmed prior to initiation of treatment with panitumumab.</p>
",1452554561.0,"<p>Excerpts from the panitumumab (Vectibix) label:</p>
<blockquote class=""blockquote"">
<p>Panitumumab is an epidermal growth factor receptor (EGFR) antagonist for intravenous use. [...] EGFR is overexpressed in certain human cancers, including colon and rectum cancers. Interaction of EGFR with its normal ligands (e.g., EGF, transforming growth factor-alpha) leads to phosphorylation and activation of a series of intracellular proteins, which in turn regulate transcription of genes involved with cellular growth and survival, motility, and proliferation. <em>KRAS</em> (Kirsten rat sarcoma 2 viral oncogene homologue) and <em>NRAS</em> (Neuroblastoma RAS viral oncogene homologue) are highly related members of the <em>RAS</em> oncogene family. Signal transduction through the EGFR can result in activation of the wild-type KRAS and NRAS proteins; however, in cells with activating <em>RAS</em> somatic mutations, the RAS-mutant proteins are continuously active and appear independent of EGFR regulation.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Panitumumab_2024_08_12_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Panitumumab_2024_08_12_FDA.pdf"">panitumumab drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,,,,,,,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166347941,Annotation of HCSC Label for toremifene,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451731', 'name': 'toremifene'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166273241,Annotation of EMA Label for paliperidone and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15133242, 'title': 'Paliperidone (Byannli) | European Medicines Agency.', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/byannli-previously-paliperidone-janssen-cilag-international', 'crossReferences': [{'id': 1451823880, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/byannli-previously-paliperidone-janssen-cilag-international', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/byannli-previously-paliperidone-janssen-cilag-international'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA163518919', 'name': 'paliperidone'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1451823940.0,"<p>The EMA product information for paliperidone states there no difference between CYP2D6 extensive metabolisers and poor metabolisers
and paliperidone clearance.</p>
",1451823941.0,"<p>Excerpts from the paliperidone (<em><strong>BYANNLI</strong></em>) EPAR:</p>
<blockquote class=""blockquote"">
<p>Although in vitro studies suggested a
role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, there is no evidence in vivo that
these isozymes play a significant role in the metabolism of paliperidone. Population pharmacokinetics
analyses indicated no discernible difference on the apparent clearance of paliperidone after
administration of oral paliperidone between extensive metabolisers and poor metabolisers of CYP2D6
substrates.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone
metabolism, but there are no indications in vitro nor in vivo that these isozymes play a significant role
in the metabolism of paliperidone. Concomitant administration of oral paliperidone with paroxetine, a
potent CYP2D6 inhibitor, showed no clinically significant effect on the pharmacokinetics of
paliperidone.</p>
</blockquote>
<p>For the complete EPAR text with sections containing pharmacogenetic information highlighted, see the <a download=""Paliperidone_EMA_2022_07_12.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Paliperidone_EMA_2022_07_12.pdf""><em><strong>Paliperidone</strong></em> EPAR PDF</a></p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1452529540.0,Genetic Testing Level,[],No Clinical PGx,geneTestLevel:1452529540,True,,,,,,,,,
Label Annotation,PA166122966,Annotation of EMA Label for darifenacin and CYP2D6,False,False,[],False,"[{'id': 1184513611, 'date': '2014-08-07T00:00:00-07:00', 'type': 'Create', 'version': 0}]",False,[],True,"[{'id': 15102967, 'title': 'Emselex | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/emselex', 'crossReferences': [{'id': 1450416958, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/emselex', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/emselex'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA164774901', 'name': 'darifenacin'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",EMA,1447982057.0,"<p>The EMA European Public Assessment Report (EPAR) for darifenacin (Emselex) states that a population pharmacokinetic analysis of Phase III data showed that steady-state exposure was 66% higher in CYP2D6 poor metabolizers as compared to extensive metabolizers.</p>
",1447982056.0,"<p>Excerpts from the darifenacin (Emselex) EPAR:</p>
<div class=""blockquote"">
<p>Darifenacin is metabolised by CYP3A4 and CYP2D6. Due to genetic differences, about 7% of the Caucasians lack the CYP2D6 enzyme and are said to be poor metabolisers. A few percent of the population have increased CYP2D6 enzyme levels (ultrafast metabolisers). The information below applies to subjects who have normal CYP2D6 activity (extensive metabolisers) unless otherwise stated...</p>
</div>
<div class=""blockquote"">
<p>The metabolism of darifenacin in CYP2D6 poor metabolisers is principally mediated by CYP3A4. In one pharmacokinetic study the steady-state exposure in poor metabolisers was 164% and 99% higher during treatment with 7.5 mg and 15 mg once daily, respectively. However, a population pharmacokinetic analyses of Phase III data indicated that on average steady-state exposure is 66% higher in poor metabolisers than in extensive metabolisers. There was considerable overlap between the ranges of exposures seen in these two populations...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Darifenacin_06_20_19_EMA.pdf"">darifenacin EPAR PDF</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166121326,Annotation of EMA Label for pazopanib and HLA-B,False,False,[],False,"[{'id': 1184467692, 'date': '2014-06-05T00:00:00-07:00', 'type': 'Create', 'version': 0}]",False,[],True,"[{'id': 15102913, 'title': 'Votrient | European Medicines Agency', '_sameAs': 'https://www.ema.europa.eu/en/medicines/human/EPAR/votrient', 'crossReferences': [{'id': 1450663647, 'resource': 'URL', 'resourceId': 'https://www.ema.europa.eu/en/medicines/human/EPAR/votrient', '_url': 'https://www.ema.europa.eu/en/medicines/human/EPAR/votrient'}], 'objCls': 'Literature', 'terms': [], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Haplotype', 'id': 'PA165987830', 'symbol': 'HLA-B*57:01', 'name': '*57:01'}]","[{'objCls': 'Chemical', 'id': 'PA165291492', 'name': 'pazopanib'}]","[{'objCls': 'Gene', 'id': 'PA35056', 'symbol': 'HLA-B', 'name': 'major histocompatibility complex, class I, B'}]",EMA,1447982113.0,"<p>The EMA European Public Assessment Report (EPAR) for pazopanib (Votrient) states that patients who carry the HLA-B*57:01 allele have an increased risk of pazopanib-associated ALT elevations.</p>
",1447982112.0,"<p>Excerpts from the pazopanib (Votrient) EPAR:</p>
<div class=""blockquote"">
<p>Patients who carry the HLA-B*57:01 allele have an increased risk of pazopanib-associated ALT elevations. Liver function should be monitored in all subjects receiving pazopanib, regardless of genotype or age...</p>
</div>
<div class=""blockquote"">
<p>In a pharmacogenetic meta-analysis of data from 31 clinical studies of pazopanib administered either as monotherapy or in combination with other agents, ALT &gt;5 x ULN (NCI CTC Grade 3) occurred in 19% of HLA-B*57:01 allele carriers and in 10% of non-carriers. In this dataset, 133/2235 (6%) of the patients carried the HLA-B*57:01 allele...</p>
</div>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Pazopanib_06_26_19_EMA.pdf"">pazopanib EPAR PDF</a>.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166347921,Annotation of HCSC Label for tamoxifen and CYP2D6,False,False,[],False,[],False,[],True,"[{'id': 15163842, 'title': 'Drugs@HCSC: Drug Product TEVA-TAMOXIFEN (tamoxifen), Teva Canada Limited', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10790', 'crossReferences': [{'id': 1452556160, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10790', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10790'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451581', 'name': 'tamoxifen'}]","[{'objCls': 'Gene', 'id': 'PA128', 'symbol': 'CYP2D6', 'name': 'cytochrome P450 family 2 subfamily D member 6'}]",HCSC,1452556162.0,"<p>The product monograph for tamoxifen states that it is indicated for treatment of early breast cancer in women with estrogen receptor positive tumors and the treatment of women with hormone responsive locally advanced / metastatic breast cancer. It also notes that individuals with low CYP2D6 activity (or using CYP2D6 inhibitors) may have reductions in plasma concentrations of the active metabolite of tamoxifen.</p>
",1452556163.0,"<p>Excerpts from the tamoxifen (TEVA-TAMOXIFEN) product monograph:</p>
<blockquote class=""blockquote"">
<p>TEVA-TAMOXIFEN (tamoxifen citrate) is indicated for:</p>
<ul>
<li>the adjuvant treatment of early breast cancer in women with estrogen receptor positive tumours.</li>
<li>the treatment of women with hormone responsive locally advanced / metastatic breast cancer.</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p>Estrogen and progesterone receptors status should be determined by a laboratory using a validated test.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>TEVA-TAMOXIFEN is a pro-drug requiring metabolic activation by CYP2D6. Low CYP2D6 activity that occurs in patients harbouring certain CYP2D6 alleles (i.e. *4) or from the chronic use of CYP2D6 inhibitors can lead to persistent reductions in plasma concentrations of an active metabolite of tamoxifen citrate (endoxifen). Reduced efficacy on tamoxifen citrate has been reported with concomitant usage of some selective serotonin reuptake inhibitor (SSRI) antidepressants (e.g. paroxetine, a known CYP2D6 inhibitor). Concurrent chronic use of CYP2D6 inhibitors that may affect tamoxifen citrate efficacy should be avoided if possible (see 7 WARNINGS AND PRECAUTIONS).</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Tamoxifen_2024_08_14_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Tamoxifen_2024_08_14_HCSC.pdf"">tamoxifen product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166347961,Annotation of FDA Label for sulfasalazine and NAT2,False,False,[],False,[],False,[],True,"[{'id': 15101983, 'title': 'Drugs@FDA: Drug Product Sulfasalazine (Sulfasalazine), NDA007073, REMEDYREPACK INC.', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=007073', 'crossReferences': [{'id': 1449800626, 'resource': 'FDA Application', 'resourceId': 'NDA007073', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=007073'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451547', 'name': 'sulfasalazine'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",FDA,1452557620.0,"<p>Sulfasalazine (Azulfidine) is used to treat and prolong remission for ulcerative colitis. The label warns that people with G6PD are susceptible to hemolytic anemia on this drug. The label also notes that acetylator status may affect metabolism of the drug and risk for adverse events; acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to inactivator or acetylator status.</p>
",1452557621.0,"<p>Excerpts from the sulfasalazine (Azulfidine) label:</p>
<blockquote class=""blockquote"">
<p>Acetylator Status: The metabolism of SP to AcSP is mediated by polymorphic enzymes such that two distinct populations of slow and fast metabolizers exist. Approximately 60% of the Caucasian population can be classified as belonging to the slow acetylator phenotype. These subjects will display a prolonged plasma half-life for SP (14.8 hours vs
10.4 hours) and an accumulation of higher plasma levels of SP than fast acetylators. The clinical implication of this is unclear; however, in a small pharmacokinetic trial where acetylator status was determined, subjects who were slow acetylators of SP showed a higher incidence of adverse events.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Sulfasalazine_02_28_19_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Sulfasalazine_02_28_19_FDA.pdf"">sulfasalazine drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166347981,Annotation of HCSC Label for sulfasalazine and NAT2,False,False,[],False,[],False,[],True,"[{'id': 15161262, 'title': 'Drugs@HCSC: Drug Product Salazopyrin (sulfasalazine), Pfizer Canada Inc', '_sameAs': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17417', 'crossReferences': [{'id': 1452533322, 'resource': 'URL', 'resourceId': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17417', '_url': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17417'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA451547', 'name': 'sulfasalazine'}]","[{'objCls': 'Gene', 'id': 'PA18', 'symbol': 'NAT2', 'name': 'N-acetyltransferase 2'}]",HCSC,1452557662.0,"<p>The product monograph for sulfasalazine (SALAZOPYRIN) notes that patients with glucose-6-phosphate dehydrogenase deficiency should be closely monitored for signs of hemolytic anemia when receiving the drug. The label also notes that acetylator status may affect metabolism of the drug and risk for adverse events; acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to acetylator status.</p>
",1452557663.0,"<p>Excerpts from the sulfasalazine (SALAZOPYRIN) product monograph:</p>
<blockquote class=""blockquote"">
<p>In patients who are slow acetylators, the serum concentration of free sulfapyridine is higher than that in fast acetylators.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Adverse reactions with sulfasalazine may be more frequent and more severe in patients who are slow acetylators.</p>
</blockquote>
<p>For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the <a download=""Sulfasalazine_2024_08_16_HCSC.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Sulfasalazine_2024_08_16_HCSC.pdf"">sulfasalazine product monograph</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.</p>
",,,1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,
Label Annotation,PA166350561,Annotation of EMA Label for triheptanoin,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166350462', 'name': 'triheptanoin'}]",[],EMA,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166350641,Annotation of FDA Label for neomycin and MT-RNR1,True,False,[],False,[],False,[],True,"[{'id': 15165042, 'title': 'DailyMed - NEOMYCIN SULFATE tablet', '_sameAs': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f430c5d9-ae82-3314-e053-2a95a90af04c', 'crossReferences': [{'id': 1452583000, 'resource': 'FDA Drug Label at DailyMed', 'resourceId': 'f430c5d9-ae82-3314-e053-2a95a90af04c', '_url': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f430c5d9-ae82-3314-e053-2a95a90af04c'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166159181', 'symbol': 'rs267606617', 'name': 'rs267606617'}]","[{'objCls': 'Chemical', 'id': 'PA450608', 'name': 'neomycin'}]","[{'objCls': 'Gene', 'id': 'PA31274', 'symbol': 'MT-RNR1', 'name': 'mitochondrially encoded 12S RNA'}]",FDA,1452583001.0,"<p>Neomycin is an aminoglycoside antibiotic obtained from the metabolic products of the actinomycete <em>Streptomyces fradiae</em>.</p>
<p>Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (<em>MT-RNR1</em>), particularly the m.1555A&gt;G variant. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
",1452583002.0,"<p>Excerpt from the neomycin label:</p>
<blockquote class=""blockquote"">
<p><strong>Risk of Ototoxicity Due to Mitochondrial DNA Variants</strong>
Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene ( MT-RNR1), particularly the
m.1555A&gt;G variant. Ototoxicity occurred in some patients even when their aminoglycoside serum levels were within the recommended range. Mitochondrial DNA variants are present in less than 1% of the general US population, and the proportion of the variant carriers who may develop ototoxicity as well as the severity of ototoxicity is unknown. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Neomycin_2024_09_09_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Neomycin_2024_09_09_FDA.pdf"">neomycin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672111.0,Genetic Testing Level,[],Actionable PGx,geneTestLevel:1183672111,True,1452583003.0,"<blockquote class=""blockquote"">
<p>In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.</p>
</blockquote>
",,,,,,,On FDA Biomarker List
Label Annotation,PA166350721,Annotation of FDA Label for aducanumab and APOE,False,False,[],False,[],False,[],True,"[{'id': 15165122, 'title': 'Drugs@FDA: Drug Product Aduhelm (Aducanumab), Biogen Inc. - BLA761178/SUPPL-11, 08/30/2023', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761178', 'crossReferences': [{'id': 1452583221, 'resource': 'FDA Application', 'resourceId': 'BLA761178/SUPPL-11', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761178'}], 'objCls': 'Literature', 'pubDate': '2023-08-30T00:00:00-07:00', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,False,True,[],"[{'objCls': 'Variant', 'id': 'PA166155351', 'symbol': 'rs429358', 'name': 'rs429358'}, {'objCls': 'Variant', 'id': 'PA166155341', 'symbol': 'rs7412', 'name': 'rs7412'}]","[{'objCls': 'Chemical', 'id': 'PA166350685', 'name': 'aducanumab'}]","[{'objCls': 'Gene', 'id': 'PA55', 'symbol': 'APOE', 'name': 'apolipoprotein E'}]",FDA,1452583222.0,"<p>The FDA label for aducanumab includes warnings that testing should be performed for ApoE ε4/ε4 as individuals with ApoE ε4/ε4 have increased risk for amyloid related imaging abnormalities (ARIA) when treated with aducanumab. The label does not give details on the ApoE ε4 allele.</p>
",1452583223.0,"<p>Excerpts from the aducanumab-avwa (ADUHELM) label:</p>
<blockquote class=""blockquote"">
<p>Patients treated with this class of medications, including ADUHELM, who are ApoE ε4 homozygotes have a higher incidence of ARIA, including symptomatic and serious ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>Amyloid Related Imaging Abnormalities (ARIA): Enhanced clinical vigilance for ARIA is recommended during the first 8 doses of treatment with ADUHELM, particularly during titration. Risk of ARIA, including symptomatic ARIA, was increased in apolipoprotein E ε4 homozygotes compared to heterozygotes and noncarriers. If a patient experiences
symptoms which could be suggestive of ARIA, clinical evaluation should be performed, including MRI testing if indicated.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>ApoE ε4 Carrier Status and Risk of ARIA. Approximately 15% of Alzheimer’s disease patients are ApoE ε4 homozygotes. In Studies 1 and 2, among patients with a known ApoE ε4 genotype, 17% (182/1103) of patients in the ADUHELM group were ApoE ε4 homozygotes, 51% (564/1103) were heterozygotes, and 32% (357/1103) were noncarriers. The incidence of symptomatic ARIA was higher in ApoE ε4 homozygotes (16%) than in heterozygotes (11%) and noncarriers (5%) among patients treated with ADUHELM. However, the incidence of serious adverse reactions with ARIA-E, including risk of death, persistent or significant disability or incapacity, hospitalization, or other medically important event that may require intervention to prevent serious outcomes, was similar for ApoE ε4 carriers and noncarriers (2% in homozygotes, 1% in heterozygotes, 2% in noncarriers). The recommendations on management of ARIA do not differ between ApoE ε4 carriers and noncarriers [see Dosage and Administration (2.3)]. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed they can still be treated with ADUHELM; however, it cannot be determined if they are ApoE ε4 homozygotes and at a higher risk for ARIA. An FDA-authorized test for detection of ApoE ε4 alleles to identify patients at risk of ARIA if treated with ADUHELM is not currently available. Currently available tests used to identify ApoE ε4 alleles may vary in accurary and design.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The presence of an ApoE ε4 allele is also associated with cerebral amyloid angiopathy which has an increased risk for intracerebral hemorrhage.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Aducanumab-avwa_2024_09_09_FDA.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Aducanumab-avwa_2024_09_09_FDA.pdf"">aducanumab-avwa drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",,,1183672041.0,Genetic Testing Level,[],Testing Required,geneTestLevel:1183672041,True,,,,,,,,,On FDA Biomarker List
Label Annotation,PA166350741,Annotation of HCSC Label for aducanumab,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166350685', 'name': 'aducanumab'}]",[],HCSC,,,,,,,,,,,,,,,,,,,,,
Label Annotation,PA166350722,Annotation of EMA Label for aducanumab,False,False,[],False,[],False,[],False,[],False,False,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA166350685', 'name': 'aducanumab'}]",[],EMA,,,1452621970.0,"<p>The EMA website shows that the application for marketing authorization was withdrawn:</p>
<blockquote class=""blockquote"">
<p>Biogen Netherlands B.V. withdrew its application for a marketing authorisation of Aduhelm for the treatment of Alzheimer’s disease.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>The company withdrew the application on 20 April 2022.</p>
</blockquote>
<p>https://www.ema.europa.eu/en/medicines/human/EPAR/aduhelm</p>
",,,,,,,,,,,,,,,,,
Label Annotation,PA166351741,Annotation of FDA Label for phenytoin and CYP2C19,False,False,[],False,"[{'id': 1452594287, 'date': '2024-09-18T15:48:35.696-07:00', 'description': 'added Pediatric tag and info', 'type': 'Update', 'version': 0}]",False,[],True,"[{'id': 15123822, 'title': 'Drugs@FDA Drug Product: DILANTIN (phenytoin), NDA008762, Upjohn', '_sameAs': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008762', 'crossReferences': [{'id': 1449776459, 'resource': 'FDA Application', 'resourceId': 'NDA008762', '_url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008762'}], 'objCls': 'Literature', 'terms': [{'id': 1452267780, 'resource': 'PharmGKB Tags', 'term': 'Has PGx', 'termId': 'pgkbTags:1452267780'}], 'type': 'Drug Label'}]",False,True,True,[],[],"[{'objCls': 'Chemical', 'id': 'PA450947', 'name': 'phenytoin'}]","[{'objCls': 'Gene', 'id': 'PA124', 'symbol': 'CYP2C19', 'name': 'cytochrome P450 family 2 subfamily C member 19'}]",FDA,1452594280.0,"<p>The FDA-approved drug label for phenytoin (DILANTIN) states that the drug is metabolized to some extent by CYP2C19 and that unusually high levels may result from variant CYP2C19 alleles, among other things.</p>
",1452594281.0,"<p>Excerpts from the phenytoin (DILANTIN) label:</p>
<blockquote class=""blockquote"">
<p>Phenytoin is primarily metabolized by the hepatic cytochrome P450 enzyme CYP2C9 and to a lesser extent by CYP2C19.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>In most patients maintained at a steady dosage, stable phenytoin serum levels are achieved. There may be wide interpatient variability in phenytoin serum levels with equivalent dosages. Patients with unusually low levels may be noncompliant or hypermetabolizers of phenytoin. Unusually high levels result from liver disease, variant CYP2C9 and CYP2C19 alleles, or drug interactions which result in metabolic interference.</p>
</blockquote>
<p>For the complete drug label text with sections containing pharmacogenetic information highlighted, see the <a download=""Phenytoin_FDA_10_12_21.pdf"" href=""https://api.pharmgkb.org/v1/download/file/attachment/Phenytoin_FDA_10_12_21.pdf"">phenytoin drug label</a>.</p>
<p>*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.</p>
",1452594286.0,"<p>Phenytoin is FDA-approved for pediatric use. The label gives information on dosing.</p>
<p>Excerpt from the phenytoin (DILANTIN) drug label:</p>
<blockquote class=""blockquote"">
<p>The recommended starting dosage for pediatric patients is 5 mg/kg/day by mouth in two or three equally divided doses, with subsequent dosage individualized to a maximum of 300 mg daily in divided doses. A recommended daily maintenance dosage is usually 4 to 8 mg/kg/day in equally divided doses. Children over 6 years and adolescents may require the minimum adult dosage (300 mg/day).</p>
</blockquote>
",1183672141.0,Genetic Testing Level,[],Informative PGx,geneTestLevel:1183672141,True,,,,,,,,,On FDA Biomarker List
